<SEC-DOCUMENT>0001558370-21-002715.txt : 20210310
<SEC-HEADER>0001558370-21-002715.hdr.sgml : 20210310
<ACCEPTANCE-DATETIME>20210310163103
ACCESSION NUMBER:		0001558370-21-002715
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		105
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210310
DATE AS OF CHANGE:		20210310

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protagonist Therapeutics, Inc
		CENTRAL INDEX KEY:			0001377121
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				980505495
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37852
		FILM NUMBER:		21730186

	BUSINESS ADDRESS:	
		STREET 1:		7707 GATEWAY BLVD., SUITE 140
		CITY:			NEWARK
		STATE:			CA
		ZIP:			94560-1160
		BUSINESS PHONE:		(510) 474-0170

	MAIL ADDRESS:	
		STREET 1:		7707 GATEWAY BLVD., SUITE 140
		CITY:			NEWARK
		STATE:			CA
		ZIP:			94560-1160

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Protagonist Therapeutics Inc
		DATE OF NAME CHANGE:	20130605

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Protagonist Inc
		DATE OF NAME CHANGE:	20061002
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>ptgx-20201231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.7713.40453 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 3/10/2021 9:28:51 PM -->
      <!-- iXBRL Library version: 1.0.7713.40461 -->
      <!-- iXBRL Service Job ID: c7e1f6ec-0978-4736-908b-bf36195b3f7b -->

  <html xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ptgx="http://www.protagonist-inc.com/20201231" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" xs:nil="true" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" name="us-gaap:CommitmentsAndContingencies" id="Hidden_0OM1DusEFUmqbPoDuT7X_Q"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" xs:nil="true" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" name="us-gaap:CommitmentsAndContingencies" id="Hidden_wm3XtSRd8kOC2xAeypDG3w"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" id="Hidden_vRN-MNGrlkCdyrjuSkYNyw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" id="Hidden_EjGcvmCxpEiSI52QmVUDEA">0</ix:nonFraction><ix:nonNumeric contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="Hidden_AQ9zi8pi-EaxuyzCo-xXWQ">us-gaap:OperatingLeaseRightOfUseAsset</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="Hidden_wWgcpLSf2kWkjdeeAc953A">us-gaap:OperatingLeaseLiabilityCurrent</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="Hidden_hlbRDx7p30CKaUxxFEW_Yg">us-gaap:OperatingLeaseLiabilityNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" name="us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" id="Hidden_ovgfxS-wnkODM924xAwfoA">us-gaap:OperatingLeaseLiabilityCurrent us-gaap:OperatingLeaseLiabilityNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="dei:EntityCentralIndexKey" id="Tc_6wgYli4F9EO94vNoCiMkFQ_2_1">0001377121</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="dei:CurrentFiscalYearEndDate" id="Tc_abAF5-1xEUSzl_47R_5xCw_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="dei:DocumentFiscalYearFocus" id="Tc_ZEaUUkUOo0y2Vg_yhrL01A_4_1">2020</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="dei:DocumentFiscalPeriodFocus" id="Tc_W4bVqBaK9Ui9OupcVEc1ig_5_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="dei:AmendmentFlag" id="Tc__7Z0SxMeukO7PZqqN1lIVw_6_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" xs:nil="true" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" name="us-gaap:PreferredStockValue" id="Hidden_kE3TOWjbKkC77ExmcLKTfQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" xs:nil="true" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" name="us-gaap:PreferredStockValue" id="Hidden_KKfUiE90KUuaywhloS9gMQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_zGKgQSrOrEauSny-uH-IKw">27217649</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_E8kndXbr3EajcZS50zXaqQ">43745465</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" xs:nil="true" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" name="us-gaap:CommonStockValue" id="Hidden_B2SDxtiWdkCPUjOMj_8kQA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" xs:nil="true" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" name="us-gaap:CommonStockValue" id="Hidden_xVeETI8KxU-fJOYA-X9IVg"></ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_aheLDwWGAUeZQPwvqQVzZA" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Hidden_MwXrAUuc4UmOUGbm0YW9XQ">P3Y</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" name="us-gaap:SubleaseIncome" id="Hidden_lqQvOls2gkKPXAv7NbH0Aw">0</ix:nonFraction><ix:nonNumeric contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="Hidden_zm9XCbYtdUWCFJoLceZSNQ">us-gaap:OperatingLeaseRightOfUseAsset</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="Hidden_NUnmw_5Jc0GQOhDxxgb5HA">us-gaap:OperatingLeaseLiabilityCurrent</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="Hidden_ffN_Bd0u6EuABPUHJggLOw">us-gaap:OperatingLeaseLiabilityNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" name="us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" id="Hidden_yNAOiRCkP0mEzcqrTZongA">us-gaap:OperatingLeaseLiabilityCurrent us-gaap:OperatingLeaseLiabilityNoncurrent</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="ptgx-20201231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_8i0o-skGv0azxibqP5J0Sw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_gRii_fhTDk-huJXJ4UdCVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_l4fVgIKvNUamq8cgrPWShQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_1odXtzTk20OYdf78bv-6Bg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:AtMarketingOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_fuC6tZWyUkSX0CU0In2zWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:AtMarketingOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_yGP8DkufmUSzKSdAVZGGrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:AtMarketingOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_yOGBS9pihEKHtHPrOQel3w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:AtMarketingOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_pKAkXlxvhUWymzMXd4z0KQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:AtMarketingOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_g3Hzv49Z9UGzLyh7mHry3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:AtMarketingOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0ejK20BXz0WlKLitqx2O8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2020_To_5_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_4Kh5pBSECkypUOYucapGkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2020_To_5_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GUwt944WL0uotoTy8UvAVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_8hhxYFRmo0SmVd81EZvSIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:AtMarketingOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YoX0pmi6v0e7iaLUqL8YHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_s2huIh7nUE-p0G6YC_4NhQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:AtMarketingOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2018_To_8_31_2018_srt_CounterpartyNameAxis_ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_j6JfV1HdAU2VL5Av0thXjA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:SecuritiesPurchaseAgreementWithAccreditedInvestorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2018-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_DzfKu3ClMU-xwF3bQXP75g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:AtMarketingOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dCBVr6oE30ePiiOHcTfKVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kO1ACPpowkmGPJDGZK-oJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Snnu9PZVQ0SEUhYgRyxRiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__O0aR-_h3kehqx2ICyExMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_PlWiT4oT-U-bNw8fFk2KMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_uLTlN99bs0KmTjmkSZDZtQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Ju5ZnA-BP0-NMMz3dq161g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8FClLya93E-DGTAwVTTPLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_XXYc_qkz7EiiqGkSkihtnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jUszAT7WFEGWt9BqEE93VQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2yPAw-zRyEu3cnkGbo1BJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_xs61-k8jCUqUc6YQqT9vow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_SBZjOH40VUWH7eyCsHOxeQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_hOb9HKro90mY6okLdtMCHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_kre8MFx27UW7IW8Z8ld4mw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_PlanNameAxis_ptgx_EmployeeStockPurchasePlan2016Member_GMhjmWwDW0OtNx4nu-iZpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:EmployeeStockPurchasePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_ptgx_EquityIncentivePlan2016Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_PrincipalOwnerMember_ExSFV52WIEW8KwIeap4Bxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:EquityIncentivePlan2016Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:PrincipalOwnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_ptgx_EquityIncentivePlan2016Member_uoGvCjLpdkK2StizIEWf5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ptgx:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_PlanNameAxis_ptgx_EquityIncentivePlan2016Member_F6df0QQhrU6i9GJCdhqPDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_PlanNameAxis_ptgx_EmployeeStockPurchasePlan2016Member_C-KW8xTQ90aKeamFtuPrNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:EmployeeStockPurchasePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_31_2016_us-gaap_PlanNameAxis_ptgx_StockOptionAndIncentivePlanAsAmendedAndRestated2007Member_Q8ASK54YZEa5T6ejJrDeJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:StockOptionAndIncentivePlanAsAmendedAndRestated2007Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2018_us-gaap_PlanNameAxis_ptgx_InducementStockPlanMember_3YM3Ufo1cE24pa1he7vSAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:InducementStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_31_2016_us-gaap_PlanNameAxis_ptgx_EquityIncentivePlan2016Member_X9g55Fo86EaIMiverpOurg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_31_2016_us-gaap_PlanNameAxis_ptgx_EmployeeStockPurchasePlan2016Member_nIsT07dVFEyHghpDxZtPUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:EmployeeStockPurchasePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PlanNameAxis_ptgx_EmployeeStockPurchasePlan2016Member_U56QTHCCKEa3NKcZoAUUQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:EmployeeStockPurchasePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_JMFKex3X3ESe5V_o92xQHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_H_jddmjI8U639x1Gtx8lig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zQrIRwTjBUOg--pd-u3-dg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_gc3icTBxzk6z-01YFoMDcQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_jA3zrw10lUyty-qrneby5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_K2QYwOvGJUmiUg9ZTS1GqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_pgiKOe1_8Ey6gxPzOimNvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ZbXixFzUcUGHwVYHkj-L5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_5o84alY-YEe58-Qyx7km0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_-b9HV2D17EWHTYX42MHUeg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_ptgx_StockOptionAndIncentivePlanAsAmendedAndRestated2007Member_jktel6yu6kK7pWrzaSuY2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ptgx:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:StockOptionAndIncentivePlanAsAmendedAndRestated2007Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_ptgx_EquityIncentivePlan2016Member_eF2snCub_Eahp8p8BWAONg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ptgx:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PlanNameAxis_ptgx_InducementStockPlanMember_KE5aREx68U2i_cgMV6Pj_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:InducementStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_PlanNameAxis_ptgx_InducementStockPlanMember_uV2sRVuEEkSt7OepkbYJpA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:InducementStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_ptgx_InducementStockPlanMember_yAEykxLHsUSSNG0CUEUjkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:InducementStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_ptgx_NonemployeeDirectorAnnualRefresherStockOptionsMember_us-gaap_PlanNameAxis_ptgx_EquityIncentivePlan2016Member_ZyLhj6L8U0eoAkYv_BvxHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ptgx:NonemployeeDirectorAnnualRefresherStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_ptgx_StockOptionAndIncentivePlanAsAmendedAndRestated2007Member_9U0z6hszwEGi_P9hNkxE5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ptgx:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:StockOptionAndIncentivePlanAsAmendedAndRestated2007Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_ptgx_NonEmployeeDirectorInitialStockOptionsMember_us-gaap_PlanNameAxis_ptgx_EquityIncentivePlan2016Member_jCMUIflu30Chq-y0-NBBeQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ptgx:NonEmployeeDirectorInitialStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2016_To_7_31_2016_us-gaap_PlanNameAxis_ptgx_EquityIncentivePlan2016Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_Pl5aD902hUizaGvF0_Ag0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:EquityIncentivePlan2016Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-07-01</xbrli:startDate><xbrli:endDate>2016-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2017_zWxDm9xYR0y9NPetyRPWMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_y_lWVCdXEkurpTEfNZLamw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_62ZwKcYzp0eJm6qW-U5FhA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_eremZ34RS0u0oYjA1BqUtA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_LicenseAndCollaborativeRevenueMember_us-gaap_TypeOfArrangementAxis_ptgx_PhaseTwoClinicalTrialMember_BryyTsUuxEmwlP3YXd1gUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:LicenseAndCollaborativeRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:PhaseTwoClinicalTrialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_FinancialServiceOtherMember_NBguqYBUHku6qOzTYn42VQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:FinancialServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_FinancialServiceOtherMember_mIs-a5_M8Ey3l6XrIQVjEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:FinancialServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_srt_ProductOrServiceAxis_us-gaap_FinancialServiceOtherMember_us-gaap_TypeOfArrangementAxis_ptgx_PhaseTwoClinicalTrialMember_lxJPPTHjz0OKFor2aG-yUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:FinancialServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:PhaseTwoClinicalTrialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_vfjwayMYI0exJuQhXetAgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_TypeOfArrangementAxis_ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member_D025L8JB50ySUyUf-9SxEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_us-gaap_TypeOfArrangementAxis_ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member__cZnEeVU-k2FtUN8yE2uXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_aheLDwWGAUeZQPwvqQVzZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_R76-sonyg0uleRlU84c1jA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_srt_StatementGeographicalAxis_country_AU_xtyNGWRadEizaBfhvBzeOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_srt_StatementGeographicalAxis_country_AU_NLZm2dhYp0akSbHnuso5uQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_srt_StatementGeographicalAxis_country_AU_J8ZYPbFagkiWnbQOuxYMlQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_th9MyYrG-kOe4hdG7OWBYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ptgx_LaboratoryEquipmentMember_mEJwmnq980i_X0P_Pcmk2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ptgx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ptgx_FurnitureAndComputerEquipmentMember_exDGgu7H0EeD4_dWpv6kGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ptgx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_XC_R2C90rU2vG1oQ__VR5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ptgx_LaboratoryEquipmentMember_nelsuh6t-0G0_6xLI9TWow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ptgx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ptgx_FurnitureAndComputerEquipmentMember_NDe2QtR56ES1v6jXmD0-nw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ptgx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_agJoJQfoR0S_u2bStgWXxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2020_To_5_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_SalesAgreementFrom2017Member_tZp0EkKbX0KKXBjYlmFbBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:SalesAgreementFrom2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_SalesAgreementFrom2017Member_4-Top2Z7HEGnoubmcpaUQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:SalesAgreementFrom2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember_jKn-PPj_GUaOCF64euSSCg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:CommonStockPreferredStockDebtSecuritiesAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_SalesAgreementFrom2017Member_qkNym65oekWLKJu7qHfcDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:SalesAgreementFrom2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_NzJb7MJr5kOz1KdJ49FjiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a0-ROxHHoku-VkXZ66GSxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DrgcQsWLEUegsx9gQx7K3w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_U65aTwB6ukC7yChGSORF8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_hYnmxupXL0yNnBeGNa_apA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_8neM6oYNfUCXGVbkjiKc6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_hM1ehx9ooUyOxNDleNQQrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_e0vNep3u2EaW55wxjoopSw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_ZealandPharmaMember_EFYZYS2pyEi6iqunSu7VTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:ZealandPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_srt_CounterpartyNameAxis_ptgx_ZealandPharmaMember_Z1DSgl1avkK9ttj7siMlow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:ZealandPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_ptgx_OverseasFindingsMember_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_Ni5ZAEOX-UqebOcqRpBGAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">ptgx:OverseasFindingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_IncomeTaxAuthorityAxis_ptgx_OverseasFindingsMember_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_-NKTzbOHOE-9ja3vgdH8Wg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">ptgx:OverseasFindingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_GicVha9PoUm3BEgizkKmRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ptgx:RevenueSourceAxis">ptgx:SmallBusinessInnovationResearchGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_Ug74VWMPT0WLeBk_hPZxCg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ptgx:RevenueSourceAxis">ptgx:SmallBusinessInnovationResearchGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2020_To_6_30_2020_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_jtE4FD5lLEuVCNA6A73V0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptgx:TermLoanCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_s0YO-nVtg0inq7Ue9XzaAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_N8l2Scu7LECQV05gQhBpcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:AtMarketingOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_BalanceSheetLocationAxis_ptgx_AccruedLiabilitiesAndOtherPayablesMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_YMLB38vu2U6BmlQp_T1TCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ptgx:AccruedLiabilitiesAndOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_BalanceSheetLocationAxis_ptgx_AccruedLiabilitiesAndOtherPayablesMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_nqaO_sxQyESRu9HD_l6AJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ptgx:AccruedLiabilitiesAndOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_cqtN9FUFIUSxqCPfOydBcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptgx:TermLoanCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_3_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_LicenseAndCollaborativeRevenueMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendmentMember_OXDfxfH58kqhheU3GQGUvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:LicenseAndCollaborativeRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_MilestonePaymentsMember_us-gaap_TypeOfArrangementAxis_ptgx_SecondGenerationDevelopmentCompoundMember_sAqgbJv3QkOF-0V4dOsnIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:MilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:SecondGenerationDevelopmentCompoundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_LicenseAndCollaborativeRevenueMember_TvNWwGu2eEC6vYE7HcfZ-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:LicenseAndCollaborativeRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendmentMember_GtedaLqT9E2-CCUloPfAtw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2019_To_6_30_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_LicenseAndCollaborativeRevenueMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendmentMember_XvMY8HCh9EOEQkePbHrEeg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:LicenseAndCollaborativeRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_LicenseAndCollaborativeRevenueMember_3QxHrdZZck25Pg-JQIj-nw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:LicenseAndCollaborativeRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_LicenseAndCollaborativeRevenueMember_KsXkSwmdJk6E8sIAWg2nyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:LicenseAndCollaborativeRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_13_2017_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_UpfrontCashPaymentMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_8ZzG4TogRUeK22l7bZWg6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:UpfrontCashPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-07-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_LicenseAndCollaborativeRevenueMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendmentMember_y5i3Re06f0iiRKOUUagPDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:LicenseAndCollaborativeRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendmentMember_0gY4oTF5r0WEXzTC15E-FQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_X-3f2T5tzkO0bujYt1VHYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_Iek_4R-H0EOc28_Wvd-Hnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_dyHYhh53okOYGwIKFCa5Ag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_E5rQEhmdCkiUzPRvbbp87g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_CPGeoM_E_U2hv7Q6-PEH9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ZQ8gS7l_jUWwlHn2F0NYhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ruvLYZdTr0WCWpXD9VpjZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_ptgx_JanssenLicenseAndCollaborationAgreement26May2017Member_C_BnSjKn10WVjRwNMh3ISQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:JanssenLicenseAndCollaborationAgreement26May2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_srt_CounterpartyNameAxis_ptgx_BiotechnologyValueFundL.pMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_ptgx_ExchangeAgreementMember_Ik7tchK9-Ue8oyRnGIgm_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:BiotechnologyValueFundL.pMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:ExchangeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_6_2018_srt_CounterpartyNameAxis_ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_z3QoxAuYuUKbQDm_MCaYpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:SecuritiesPurchaseAgreementWithAccreditedInvestorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_21_2018_srt_CounterpartyNameAxis_ptgx_BiotechnologyValueFundL.pMember_us-gaap_TypeOfArrangementAxis_ptgx_ExchangeAgreementMember_BJDxU0LhGkitpW7AZKjqUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:BiotechnologyValueFundL.pMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:ExchangeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_6_2018_us-gaap_ClassOfWarrantOrRightAxis_ptgx_WarrantsPurchaseAmountPerSharePriceTwoMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_GKATHoBzkEKJSJRivO9SBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ptgx:WarrantsPurchaseAmountPerSharePriceTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_6_2018_us-gaap_ClassOfWarrantOrRightAxis_ptgx_WarrantsPurchaseAmountPerSharePriceOneMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_186kOF-nN0ak3sZ7B7mYIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ptgx:WarrantsPurchaseAmountPerSharePriceOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2017_uBPncpspM02T8SbWW1EWfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_rK3dysi-wkKgewxxLVB-Eg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_Py5g_H7ZS0mto91KY61Pqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember_RcUZPhnZn0yecR06vLTPmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_uVbhr5AkeEyXPse4j8Vtdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">ptgx:UsTreasuryAndAgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_5KKCr5eHQEygdYItDdw9RQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_uzJVCv1ct0mqY9ZIAM4vDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_o8lJ8OmQqUuIzV1asN5-7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember_5sHQft-r50evFl5UcMy5tw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_GPbqzeyzuEyJ1N6rb_ntwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">ptgx:UsTreasuryAndAgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_K9-l4NAY-kmFaLEyWQ4rSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_pDkR-5RKjEyn9NkwkBrP6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember__UoGf4iXl0-vwHR1RxDl_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_XbTJJV-aUUKkYoe9CCHwlg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember_9p8nfsfW6EKn9p_BdoPZZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_wRs9ZU4Bekq5XgF2kvDBig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">ptgx:UsTreasuryAndAgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_FOvlkFRNTEmtTcC9nd5x6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_WRekQb2CvU25FJAvTO5BBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_wEd8XK0sFEmZYH9nDuBq9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember_LaPN7nYw4E2V8LpCkDOHiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_EE8cQuRZ_UmapNGf-h67ng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">ptgx:UsTreasuryAndAgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_z50eFBlU2Ee-Syluh-tL9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_aNicgv3ij0eMkeM8EWdR-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wuEhdkxUmkStpEwG9Rhsew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_j8Vx4K3ol0uyTIToUJMT7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_NoteWarrantMember_Dh7N5o3ASEqLQ1SQSZ-iVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:NoteWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_EAbWdmtN8E-9JmN6JhqI_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember_NJHZZccCf0a0YBEfSxOf_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_YwszWFT2W0SpYFDZtJaxqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_NoteWarrantMember_hBQwDx7S2ku26XmUy_6zMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:NoteWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_ooH8n7lz1E2xsje_V6E6Pg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember_bPuHxQjxo0m7NoN0XMxgBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_Ncd5mq0QL0CQQWUc-ElGVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_NoteWarrantMember_Ho8wL7fGKESaYVujfGx0mg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:NoteWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_WaiBERwpsUS_GxNwwF2grw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember_kEHM0bCdFEWZb0Y5aC4cvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_xH_J2AHGC0KEIm_y_jQVKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_4LOUmK3YM0qXjTWQBtwesw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_S8RyftvJ9k2sDQkwn9INpg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_hCAO4XqfOUC_Xr8C0zgyIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_5KLlildJr02InYyNq32knQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_5l8l7REXdEuTVwF8ShcykQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NemxNYQEjkS5VxdYCUEGfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_enQYGgNfqUCc5y0GKYBXkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_ptgx_BiotechnologyValueFundL.pMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_ptgx_ExchangeAgreementMember_cUqXG1yQX0uQTBHVoh090Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:BiotechnologyValueFundL.pMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:ExchangeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bsxNEJcruUKB7husbni8Lw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2018_To_12_31_2018_srt_CounterpartyNameAxis_ptgx_BiotechnologyValueFundL.pMember_us-gaap_TypeOfArrangementAxis_ptgx_ExchangeAgreementMember_JivbDCfMDUKimc02lEUXQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:BiotechnologyValueFundL.pMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:ExchangeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iSQxa82RA0epFzR7vgagyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YxGs3yboJkG0guGsknqgmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_ptgx_EquityIncentivePlan2016Member_Q2OzhxYJoE2GLzRZOait5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_ptgx_EmployeeStockPurchasePlan2016Member_4XSs44uQyEamm2z9D2PFFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:EmployeeStockPurchasePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_SubsidiarySaleOfStockAxis_ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember_p8qynIyKyk-zMkGoWZcW3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:CommonStockPreferredStockDebtSecuritiesAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_AtMarketOfferingMember_iy5bZi35C0SnS_cAS0HmXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2019_To_10_31_2019_srt_CounterpartyNameAxis_ptgx_AtMarketOfferingMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember_yaqgEgG5X0iZ4CZKQUqb8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:AtMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:CommonStockPreferredStockDebtSecuritiesAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2019_To_10_31_2019_us-gaap_SubsidiarySaleOfStockAxis_ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember_2WMpGtC9OEOlBeqopXrQRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:CommonStockPreferredStockDebtSecuritiesAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2017_To_9_30_2017_srt_CounterpartyNameAxis_ptgx_AtMarketOfferingMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_SalesAgreementFrom2017Member__YoSlLwDmEWFZ2JYQBWSFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:AtMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:SalesAgreementFrom2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2017_To_9_30_2017_us-gaap_SubsidiarySaleOfStockAxis_ptgx_CommonStockPreferredStockAndCertainDebtSecuritiesMember_zx3lVa2z8kOfh7KC7iZGpg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:CommonStockPreferredStockAndCertainDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2018_To_9_30_2018_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_uaChjCsyD0SFXSDtolYQ1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ptgx:RevenueSourceAxis">ptgx:SmallBusinessInnovationResearchGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2017_To_5_31_2017_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_yYD_ZbiKRkiaHuGwQjinPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ptgx:RevenueSourceAxis">ptgx:SmallBusinessInnovationResearchGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_g6Lfapz3kUapxhOM2FxjaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_qd1j0yCx90GcZk8LgZ8W2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ptgx:RevenueSourceAxis">ptgx:SmallBusinessInnovationResearchGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_3n6ishFs0EuWYpP4sr_RiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_tYZjiAg9zECpkNJndjRsBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ptgx:RevenueSourceAxis">ptgx:SmallBusinessInnovationResearchGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember__jiivLyteUW8NPb8U-43uw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_IH_M_FrIX0SJO0xc0LNU4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ptgx:RevenueSourceAxis">ptgx:SmallBusinessInnovationResearchGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_srt_CounterpartyNameAxis_ptgx_ZealandPharmaMember_srt_StatementScenarioAxis_ptgx_SuccessfullyDevelopAndCommercializeRusfertideComponentWithOutPartnerMember_zvHiCT5gZESB6MhV_EqkXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:ZealandPharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ptgx:SuccessfullyDevelopAndCommercializeRusfertideComponentWithOutPartnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_5_7_2019_To_5_7_2019_srt_ProductOrServiceAxis_ptgx_DevelopmentRegulatoryAndSalesMilestonePaymentsMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendmentMember_nG2wMUofPkqcS4glTe3R0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:DevelopmentRegulatoryAndSalesMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-07</xbrli:startDate><xbrli:endDate>2019-05-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_7_2020_To_3_7_2020_OZuW7QpORUGdPGLaaZ6w3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-07</xbrli:startDate><xbrli:endDate>2020-03-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_1DfwcEBf-ECRIZv8PZ8Rdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_KjsvtwPBSUeomIS3nTcYHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_srt_CounterpartyNameAxis_ptgx_BiotechnologyValueFundL.pMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_ptgx_ExchangeAgreementMember_mgjJN8kSnkmKkWqgSyHErQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:BiotechnologyValueFundL.pMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:ExchangeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2017_To_3_31_2017_srt_StatementGeographicalAxis_stpr_CA__NT8mR3K4kK7AM6iJIYK3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-03-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_us-gaap_PlanNameAxis_ptgx_InducementStockPlanMember_1aFOsX_HY0KODJxVov4uuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:InducementStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_27_2020_To_3_27_2020_d48ZoY7v8UOWrUfq_VZsYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-27</xbrli:startDate><xbrli:endDate>2020-03-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_cKfYUU8Sf0-u1ytV-rCvdg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptgx:TermLoanCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_29P04bh0akmybtKqt9iLyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptgx:TermLoanCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2019_To_10_31_2019_srt_StatementScenarioAxis_ptgx_DebtInstrumentRepaymentOnOrBeforeFirstAnniversaryMember_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_-UR7DvCLZkiYmYD5NsiohA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ptgx:DebtInstrumentRepaymentOnOrBeforeFirstAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptgx:TermLoanCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2019_To_10_31_2019_srt_StatementScenarioAxis_ptgx_DebtInstrumentRepaymentBetweenFirstAndSecondAnniversaryMember_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_0-kZriq9PE--kjrBZbtCWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ptgx:DebtInstrumentRepaymentBetweenFirstAndSecondAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptgx:TermLoanCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2019_To_10_31_2019_srt_StatementScenarioAxis_ptgx_DebtInstrumentRepaymentAfterSecondAnniversaryMember_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_yTz9fr8XpUmkKw5s-q0s6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ptgx:DebtInstrumentRepaymentAfterSecondAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptgx:TermLoanCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_31_2019_To_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_AItPGKFJaUGXTtctj0S3sw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptgx:TermLoanCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-31</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2019_To_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember_irqRQWto80mZoPOcLzfEEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptgx:TermLoanCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2019_To_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember__7GvdZr7Sk-sWaDylYb_nQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptgx:TermLoanCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_OTlJVqmnGkadZNc3gOI6uA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_H-NgQaNu50uhdMckH4xw9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_7_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendmentMember_9gK_kOJw_ESqRE-bsagxFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_7_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_Ptg200Phase3CdClinicalTrialPrimaryClinicalEndpointMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendmentMember_Bn4vSCBoGEOTDsfBtOVnNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:Ptg200Phase3CdClinicalTrialPrimaryClinicalEndpointMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_7_2019_srt_ProductOrServiceAxis_ptgx_DevelopmentRegulatoryAndSalesMilestonePaymentsMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendmentMember_PNZUEJ__x0m4Tx70AGON6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:DevelopmentRegulatoryAndSalesMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember_us-gaap_TypeOfArrangementAxis_ptgx_CollaborationAgreementTrancheThreeMember_tvpE-SkS6k2HRTzbxgh_wg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:CollaborationAgreementTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember_us-gaap_TypeOfArrangementAxis_ptgx_CollaborationAgreementTrancheFourMember_bqQIT5Ulw0CqIqPYWi81Yw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:CollaborationAgreementTrancheFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember_us-gaap_TypeOfArrangementAxis_ptgx_CollaborationAgreementTrancheFiveMember_zUOiK1ho7EWtoDBGEsNNOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:CollaborationAgreementTrancheFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember_d9hGXjKIFEOZdcykv_sYsw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_ptgx_SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember_mwtEbZMbFUWPqDXv33EobA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_ptgx_SecondGenerationAnalogPhase2CdClinicalTrialPrimaryClinicalEndpointMember_JacSAA95dUyCrU6tGgPPmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:SecondGenerationAnalogPhase2CdClinicalTrialPrimaryClinicalEndpointMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_ptgx_LicenseAndCollaborativeRevenueMember_8kLGBjtrT0WDvA027jn2RQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:LicenseAndCollaborativeRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_UpfrontCashPaymentMember_us-gaap_TypeOfArrangementAxis_ptgx_AmendedSecondOptInMember_cppdcoBeEkOHH_mebXmIVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:UpfrontCashPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:AmendedSecondOptInMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_UpfrontCashPaymentMember_us-gaap_TypeOfArrangementAxis_ptgx_AmendedCollaborationAgreementTrancheOneMember_c9va82PLx0uSFetk0cbloQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:UpfrontCashPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:AmendedCollaborationAgreementTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_SecondGenerationPhase2bMilestonePaymentMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendmentMember_H5wv-w3AKUSR5s2BPJL4Kg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:SecondGenerationPhase2bMilestonePaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_MilestonePaymentsMember_us-gaap_TypeOfArrangementAxis_ptgx_CollaborationAgreementTrancheThreeMember_2JbTuvZF1E6as5O_Zhxubg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:MilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:CollaborationAgreementTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_LicenseAndCollaborativeRevenueMember_us-gaap_TypeOfArrangementAxis_ptgx_EstimatedVariableConsiderationMember_arxMJ0T-00eGdw9zoeZApA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:LicenseAndCollaborativeRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:EstimatedVariableConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_ptgx_SecondGenerationDevelopmentCompoundMember_P6e595XTnUiY7TVn8K6bmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:SecondGenerationDevelopmentCompoundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2019_To_6_30_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_MilestonePaymentsMember_srt_StatementScenarioAxis_srt_ProFormaMember_cUCCwM3epUW2i97GGepUZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:MilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ProFormaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2019_To_6_30_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_LicenseAndCollaborativeRevenueMember_srt_StatementScenarioAxis_srt_ProFormaMember_D0E1ttaBzUyFCH2yOPFdiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:LicenseAndCollaborativeRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ProFormaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_LicenseAndCollaborativeRevenueMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendmentMember_t7Zx6qmuv02vXASmqBWLvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:LicenseAndCollaborativeRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_12_21_2018_To_12_21_2018_srt_CounterpartyNameAxis_ptgx_BiotechnologyValueFundL.pMember_us-gaap_TypeOfArrangementAxis_ptgx_ExchangeAgreementMember_vOU5zedUDk2RWTFaLEzOWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:BiotechnologyValueFundL.pMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:ExchangeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-21</xbrli:startDate><xbrli:endDate>2018-12-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_1lnDMEXB70mrHe1LD59Ocw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_WIiZJQ_HGE6FfcxqDuIIGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_poqDHHPT202Brw2nGTuPeA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_eDAghYO6dkquiKdNvv7gGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">ptgx:UsTreasuryAndAgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_b5xheGic50m0BOMQi6R-nw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_NCJa5a9fSEq4urrjZGFZCg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_E4MJhmAIOEC2XR0v8l-IgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_gb9tp0RYKkSz5MvwQ_K0Hg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">ptgx:UsTreasuryAndAgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_6_29_2020_To_6_29_2020_UccmW4dFl06gNFN5lNnw9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-06-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_6_2018_srt_CounterpartyNameAxis_ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VeE0MBURAUmr6KszgYXA8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:SecuritiesPurchaseAgreementWithAccreditedInvestorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member_ui-WhgpxI0OwEii6l0-3yQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_srt_ProductOrServiceAxis_ptgx_PhaseTwoBClinicalTrailOfPtg300Member_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_ptgx_EntityRequiredToContinueToMakePaymentsMember_us-gaap_TypeOfArrangementAxis_ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member_lKJ-7ATDp0CLQ8bWUlojWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:PhaseTwoBClinicalTrailOfPtg300Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ptgx:EntityRequiredToContinueToMakePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_srt_ProductOrServiceAxis_ptgx_PhaseTwoBClinicalTrailOfPtg300Member_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_ptgx_EntityRequiredToContinueToMakePaymentsMember_us-gaap_TypeOfArrangementAxis_ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member_GeOAJmLB2U-rVK1O1SLjzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:PhaseTwoBClinicalTrailOfPtg300Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ptgx:EntityRequiredToContinueToMakePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_srt_ProductOrServiceAxis_ptgx_PhaseThreeClinicalTrailOfPtg300Member_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_ptgx_EntityRequiredToContinueToMakePaymentsMember_us-gaap_TypeOfArrangementAxis_ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member_Mg3iwj6jfU-W-XYzhf-LYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:PhaseThreeClinicalTrailOfPtg300Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ptgx:EntityRequiredToContinueToMakePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_srt_ProductOrServiceAxis_ptgx_PhaseThreeClinicalTrailOfPtg300Member_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_ptgx_EntityRequiredToContinueToMakePaymentsMember_us-gaap_TypeOfArrangementAxis_ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member_NW5Hup9pVUGA-2WwTWjPHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:PhaseThreeClinicalTrailOfPtg300Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ptgx:EntityRequiredToContinueToMakePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_PsWEw3NZiEeVLOnWFnbiGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_26_2021_n-kaUE9lQUKHL57qjKx1HQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-02-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Institution_l_EWsumXIkS46w5G4NlRGw"><xbrli:measure>ptgx:Institution</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_hG9CfJX4lUefEcY3aN9DsQ"><xbrli:measure>ptgx:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_installment_pPbBqyhnckSax7ouQFoPyQ"><xbrli:measure>ptgx:installment</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_lease_62oZzE0uRUioB8CqY7th5A"><xbrli:measure>ptgx:lease</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_AUD_SNsUSUMs1k6MNx0ouGjszw"><xbrli:measure>iso4217:AUD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;min-height:5.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:9.2pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 2pt 0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_c13c9edc_4dc3_4733_b725_51f7693da3da"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 2pt 0pt;"><b style="font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 2pt 0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:2pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;text-indent:0pt;margin:0pt 0pt 2pt 0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="dei:DocumentType" id="Narr_NpJxfLDNaUGJVNrUYebpPA"><b style="font-weight:bold;">10-K</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:2pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"><a id="_791bc0e5_4de5_4e8d_9e64_b1f9f1d2a432"></a><a id="Tc_P64lv-pAskSoAq9TE8LlJA_1_1"></a></div></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:4.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:95.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 2pt 0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="dei:DocumentAnnualReport" id="Tc_E62Of-astEW0P8g_yfF7rQ_1_0"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:95.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt 0pt 2pt 0pt;"><b style="font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 2pt 0pt;"><b style="font-size:8pt;font-weight:bold;">For the fiscal&#160;year ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="dei:DocumentPeriodEndDate" id="Narr_tyPXJd1zqEWXE_0e8Nz-ow"><b style="font-size:8pt;font-weight:bold;">December 31, 2020</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 2pt 0pt;"><b style="font-weight:bold;">or</b></p><a id="_67c9a4aa_e602_479b_87a3_89f79ad01876"></a><a id="Tc_0gkGuJVdj0mxwy4FZGf1_g_1_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:4.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:95.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:4.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 2pt 0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="dei:DocumentTransitionReport" id="Tc_60V8cW3R2Um-mMVRMz740w_1_0"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:95.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt 0pt 2pt 0pt;"><b style="font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 2pt 0pt;"><b style="font-size:8pt;font-weight:bold;">Commission File No.&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="dei:EntityFileNumber" id="Narr_W0g2mvwkeke4b-v95KXLAA"><b style="font-size:8pt;font-weight:bold;">001-37852</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:2pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;text-indent:0pt;margin:0pt 0pt 2pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="dei:EntityRegistrantName" id="Narr_Zo41dg7Jjk-GiL2qambHyQ"><b style="font-weight:bold;">PROTAGONIST THERAPEUTICS,&#160;INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 2pt 0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:2pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"><a id="_4b85b7f4_2649_4dd0_9e6d_6ad312782e19"></a><a id="Tc_XxYfEti0FkmwfqEvXvHxTA_2_0"></a><a id="Tc_xikmvKKLr02hah-0bb0MRQ_2_1"></a><a id="Tc_ntKB1edRmkm3ck-pueVmkg_3_0"></a><a id="Tc_xA_yqVawHU2geOHXAUVPlg_3_1"></a><a id="Tc_-t_ZlnMnxUOz84Zvj3A4ug_4_0"></a><a id="Tc__XEwJkIlMEK-hV3vBVkyuQ_4_1"></a></div></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50.16%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:49.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="dei:EntityIncorporationStateCountryCode" id="Tc_zZy58tZmtUSxMtSVyvUsoA_1_0"><b style="font-size:8pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50.16%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="dei:EntityTaxIdentificationNumber" id="Tc_599Dvm2hZEmeqM6ZHNMpIQ_1_1"><b style="font-size:8pt;font-weight:bold;">98-0505495</b></ix:nonNumeric></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction of<br />incorporation or organization)</b></p></td><td style="vertical-align:bottom;width:50.16%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(I.R.S.&#160;Employer<br />Identification No.)</b></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="dei:EntityAddressAddressLine1" id="Narr_VWNqYqpfxke_MBO9PY-AFA"><b style="font-size:8pt;font-weight:bold;">7707 Gateway Boulevard, Suite 140</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;"><br /></b><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="dei:EntityAddressCityOrTown" id="Narr_-rf3Y893F0auiQSKM9aaEQ"><b style="font-size:8pt;font-weight:bold;">Newark</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, </b><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="dei:EntityAddressStateOrProvince" id="Narr_FcrIsBCbUkGeWZMI9OLVXw"><b style="font-size:8pt;font-weight:bold;">California</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="dei:EntityAddressPostalZipCode" id="Narr_N1GyRUTaq0i5TNC_TGwe5w"><b style="font-size:8pt;font-weight:bold;">94560</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:50.16%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9pt;text-align:center;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="dei:CityAreaCode" id="Narr_q4o-kNPDQUub7lyXHAiVWw"><b style="font-size:8pt;font-weight:bold;">510</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="dei:LocalPhoneNumber" id="Narr_Z3sQhc3B6E-YHsrM42JHBQ"><b style="font-size:8pt;font-weight:bold;">474-0170</b></ix:nonNumeric></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Address, including zip code, of registrant&#8217;s<br />principal executive offices)</b></p></td><td style="vertical-align:bottom;width:50.16%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Telephone&#160;number,&#160;including&#160;area&#160;code,&#160;of&#160;registrant&#8217;s<br />principal executive offices)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b) of the Act:</b></p><a id="_3a0ff2a9_cc4f_45ed_b294_cc777519773f"></a><a id="Tc_f5CZXtIo2UC9zh93aipg-w_1_0"></a><a id="Tc_Jdo7i9eFlUeCpqKroB7fkQ_1_1"></a><a id="Tc_HeP45vIPUkmZXUuEOan--w_1_2"></a><a id="Tc_R7FpA-K3PUyC_1drAreuDQ_2_2"></a><a id="Tc_WSHs1GdwekiRhtUOxy1HYg_3_0"></a><a id="Tc_OkS35oSAgUKLYxQm0wvIwg_4_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:33.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:33.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Title of each class</b></p></td><td style="vertical-align:bottom;width:33.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Trading Symbol</b></p></td><td style="vertical-align:bottom;width:33.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Name of each exchange on which registered</b></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:33.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="dei:Security12bTitle" id="Tc_n-dDfRx-70KZpk7Hwkmiyw_2_0"><b style="font-size:8pt;font-weight:bold;">Common Stock, $0.00001 par value</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:33.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="dei:TradingSymbol" id="Tc_nfH7JUevT0q2snJf7Pk2mQ_2_1"><b style="font-size:8pt;font-weight:bold;">PTGX</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:33.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9pt;text-align:center;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">The </b><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="dei:SecurityExchangeName" id="Narr__L6S9JCx-U-pErz-kzUV_Q"><b style="font-size:8pt;font-weight:bold;">Nasdaq</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;"> Global Market</b></p></td></tr><tr style="height:1pt;"><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section 12(g) of the Act:</b></p></td></tr><tr style="height:1pt;"><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">None</b></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:2pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 2pt 0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. &#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_DYoTeRRRdEqU3htVv7hy7w"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-size:8pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 2pt 0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Act. &#160;&#160;Yes&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-size:8pt;">&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="dei:EntityVoluntaryFilers" id="Narr_zR_v7fskJUa9-FNBU_UUWg"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 2pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. &#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="dei:EntityCurrentReportingStatus" id="Narr_O9h9qN17BkO3F61BkMG8aQ"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-size:8pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 2pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). &#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="dei:EntityInteractiveDataCurrent" id="Narr_ko1UGJiniUqWx7aL9zN4vw"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-size:8pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:18pt;margin:0pt 0pt 2pt 0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p><a id="_152e9630_b3cb_4b77_9a3f_e5c449f3af02"></a><a id="Tc_YU911B-O10eym7sQOt2ASQ_2_0"></a><a id="Tc_20yEApSgT02kCLrMGDq80A_2_1"></a><a id="Tc_XG8GIFPQIkGeDYKzjvWNpA_2_2"></a><a id="Tc_G7u9GF2X-UW-C-1rjfFBlg_2_3"></a><a id="Tc_MbLp2YSwE0uRTtyRSmLeZA_3_1"></a><a id="Tc_AW-6PRHIskOBL9xMOldQSg_3_2"></a><a id="Tc_tKuZ3MlByU-FsIvH-0oD3A_4_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:20.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:47.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:23.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:20.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:9pt;text-indent:0pt;margin:0pt;">Large&#160;accelerated&#160;filer</p></td><td style="vertical-align:bottom;width:47.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:9pt;text-indent:0pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:bottom;width:23.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:9pt;text-indent:0pt;margin:0pt;">Accelerated&#160;filer</p></td><td style="vertical-align:bottom;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:9pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="dei:EntityFilerCategory" id="Tc_t4ihd17nnEiP1XtrBBrjUQ_3_0"><span style="font-size:8pt;">Non-accelerated filer</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:47.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:9pt;text-indent:0pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9746;</span></p></td><td style="vertical-align:bottom;width:23.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:9pt;text-indent:0pt;margin:0pt;">Smaller&#160;reporting&#160;company</p></td><td style="vertical-align:bottom;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9pt;text-align:right;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="dei:EntitySmallBusiness" id="Tc_7pv7lOHq6UisnzQ6KeXHEw_3_3"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:20.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9pt;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9pt;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:9pt;text-indent:0pt;margin:0pt;">Emerging growth&#160;company</p></td><td style="vertical-align:bottom;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9pt;text-align:right;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="dei:EntityEmergingGrowthCompany" id="Tc_o1KmtdoQdEikoHx9ewbPiA_4_3"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 2pt 0pt;"><span style="font-size:8pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. &#160;&#160;Yes&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="dei:EntityExTransitionPeriod" id="Narr_lW6ffmkFL0yTcaxQiGAz1A"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 2pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="dei:IcfrAuditorAttestationFlag" id="Narr_15tPIRbhPEeRa4KtskVXpw"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 2pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act of 1934). &#160;&#160;Yes&#160;&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="dei:EntityShellCompany" id="Narr_0JU_GDIIhEuuK63Am2qBGw"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:18pt;margin:0pt 0pt 2pt 0pt;">The aggregate market value of the voting stock held by non-affiliates of the registrant was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" format="ixt:numdotdecimal" scale="6" contextRef="As_Of_6_30_2020_PsWEw3NZiEeVLOnWFnbiGw" decimals="-5" name="dei:EntityPublicFloat" id="Narr_laadgjm7-ECvMv9lZVFzDA">640.7</ix:nonFraction> million as of June&#160;30, 2020, based upon the closing sale price on The Nasdaq Global Market reported on June&#160;30, 2020. Excludes an aggregate of 522,160 shares of the registrant&#8217;s common stock held by officers, directors and affiliated stockholders. For purposes of determining whether a stockholder was an affiliate of the registrant at June&#160;30, 2020, the registrant assumed that a stockholder was an affiliate of the registrant at June&#160;30, 2020 if such stockholder (i)&#160;beneficially owned 10% or more of the registrant&#8217;s common stock, as determined based on public filings and/or (ii)&#160;was an executive officer or director or was affiliated with an executive officer or director of the registrant at June&#160;30, 2020. Exclusion of such shares should not be construed to indicate that any such person possesses the power, direct or indirect, to direct or cause the direction of the management or policies of the registrant or that such person is controlled by or under common control with the registrant. </p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:18pt;margin:0pt 0pt 2pt 0pt;">There were <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_2_26_2021_n-kaUE9lQUKHL57qjKx1HQ" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_wvMAE897REui6YvLB0QIjw">43,808,308</ix:nonFraction> shares of registrant&#8217;s Common Stock, par value $0.00001 per share, outstanding as of February&#160;26, 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 2pt 0pt;"><b style="font-weight:bold;">DOCUMENTS INCORPORATED BY REFERENCE: </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:18pt;margin:0pt 0pt 2pt 0pt;">Portions of the registrant&#8217;s definitive Proxy Statement for the registrant&#8217;s 2021 Annual Meeting of Stockholders, to be filed subsequent to the date hereof with the Securities and Exchange Commission (&#8220;SEC&#8221;), are incorporated by reference into Part&#160;III of this report. Such proxy statement will be filed with the SEC not later than 120&#160;days after the end of the registrant&#8217;s fiscal&#160;year ended December&#160;31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><a id="_2be962c6_cc08_40ba_9ac8_3a08a486fd12"></a></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">PROTAGONIST THERAPEUTICS,&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">2020 FORM&#160;10-K ANNUAL REPORT</b></p><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:83.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.48%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#PARTI_838451"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">PART&#160;I</span></a></p></td><td style="vertical-align:bottom;width:83.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:83.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item1Business_611152"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;1.</span></a></p></td><td style="vertical-align:bottom;width:83.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item1Business_611152"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Business</span></a></p></td><td style="vertical-align:bottom;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">4</p></td></tr><tr><td style="vertical-align:top;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item1ARiskFactors_756902"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;1A.</span></a></p></td><td style="vertical-align:bottom;width:83.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item1ARiskFactors_756902"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Risk Factors</span></a></p></td><td style="vertical-align:bottom;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">29</p></td></tr><tr><td style="vertical-align:top;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item1BUnresolvedStaffComments_95714"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;1B.</span></a></p></td><td style="vertical-align:bottom;width:83.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item1BUnresolvedStaffComments_95714"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Unresolved Staff Comments</span></a></p></td><td style="vertical-align:bottom;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">52</p></td></tr><tr><td style="vertical-align:top;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item2Properties_349128"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;2.</span></a></p></td><td style="vertical-align:bottom;width:83.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item2Properties_349128"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Properties</span></a></p></td><td style="vertical-align:bottom;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">52</p></td></tr><tr><td style="vertical-align:top;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item3LegalProceedings_994436"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;3.</span></a></p></td><td style="vertical-align:bottom;width:83.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item3LegalProceedings_994436"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Legal Proceedings</span></a></p></td><td style="vertical-align:bottom;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">52</p></td></tr><tr><td style="vertical-align:top;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_51645"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;4.</span></a></p></td><td style="vertical-align:bottom;width:83.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_51645"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:bottom;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">52</p></td></tr><tr><td style="vertical-align:top;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:83.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#PARTII_909557"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">PART&#160;II</span></a></p></td><td style="vertical-align:bottom;width:83.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:83.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item5MarketforRegistrants_334448"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;5.</span></a></p></td><td style="vertical-align:bottom;width:83.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item5MarketforRegistrants_334448"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td><td style="vertical-align:bottom;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">53</p></td></tr><tr><td style="vertical-align:top;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item6SelectedFinancialData_924114"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 6.</span></a></p></td><td style="vertical-align:bottom;width:83.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item6SelectedFinancialData_924114"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Selected Financial Data</span></a></p></td><td style="vertical-align:bottom;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">55</p></td></tr><tr><td style="vertical-align:top;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item7ManagementsDiscussionandAnalysis_85"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;7.</span></a></p></td><td style="vertical-align:bottom;width:83.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item7ManagementsDiscussionandAnalysis_85"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:bottom;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">55</p></td></tr><tr><td style="vertical-align:top;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item7AQuantitativeandQualitative_863327"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;7A.</span></a></p></td><td style="vertical-align:bottom;width:83.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item7AQuantitativeandQualitative_863327"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Quantitative and Qualitative Disclosures about Market Risk</span></a></p></td><td style="vertical-align:bottom;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">73</p></td></tr><tr><td style="vertical-align:top;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item8FinancialStatements_472680"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;8.</span></a></p></td><td style="vertical-align:bottom;width:83.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item8FinancialStatements_472680"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Financial Statements and Supplementary Data</span></a></p></td><td style="vertical-align:bottom;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">74</p></td></tr><tr><td style="vertical-align:top;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item9ChangesinandDisagreementswithAccoun"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;9.</span></a></p></td><td style="vertical-align:bottom;width:83.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item9ChangesinandDisagreementswithAccoun"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td><td style="vertical-align:bottom;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">110</p></td></tr><tr><td style="vertical-align:top;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#ControlsandProcedures_351029"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;9A.</span></a></p></td><td style="vertical-align:bottom;width:83.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#ControlsandProcedures_351029"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Controls and Procedures</span></a></p></td><td style="vertical-align:bottom;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">110</p></td></tr><tr><td style="vertical-align:top;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#OtherInformation_301461"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;9B.</span></a></p></td><td style="vertical-align:bottom;width:83.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#OtherInformation_301461"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Other Information</span></a></p></td><td style="vertical-align:bottom;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">110</p></td></tr><tr><td style="vertical-align:top;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:83.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#PARTIII_634690"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">PART&#160;III</span></a></p></td><td style="vertical-align:bottom;width:83.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:83.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item10DirectorsExecutiveOfficers_302483"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;10.</span></a></p></td><td style="vertical-align:bottom;width:83.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item10DirectorsExecutiveOfficers_302483"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Directors, Executive Officers, and Corporate Governance</span></a></p></td><td style="vertical-align:bottom;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">111</p></td></tr><tr><td style="vertical-align:top;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item11ExecutiveCompensation_184435"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;11.</span></a></p></td><td style="vertical-align:bottom;width:83.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item11ExecutiveCompensation_184435"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Executive Compensation</span></a></p></td><td style="vertical-align:bottom;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">111</p></td></tr><tr><td style="vertical-align:top;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item12SecurityOwnership_537465"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;12.</span></a></p></td><td style="vertical-align:bottom;width:83.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item12SecurityOwnership_537465"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td><td style="vertical-align:bottom;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">111</p></td></tr><tr><td style="vertical-align:top;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item13CertainRelationships_158382"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;13.</span></a></p></td><td style="vertical-align:bottom;width:83.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item13CertainRelationships_158382"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td><td style="vertical-align:bottom;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">111</p></td></tr><tr><td style="vertical-align:top;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item14PrincipalAccountantFees_983878"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;14.</span></a></p></td><td style="vertical-align:bottom;width:83.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item14PrincipalAccountantFees_983878"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Principal Accounting Fees and Services</span></a></p></td><td style="vertical-align:bottom;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">111</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#PARTIV_305182"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">PART&#160;IV</span></a></p></td><td style="vertical-align:bottom;width:83.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:83.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item15ExhibitsandFinancial_120427"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;15.</span></a></p></td><td style="vertical-align:bottom;width:83.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item15ExhibitsandFinancial_120427"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Exhibits, Financial Statement Schedules</span></a></p></td><td style="vertical-align:bottom;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">112</p></td></tr><tr><td style="vertical-align:top;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item16Form10KSummary_140453"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item 16.</span></a></p></td><td style="vertical-align:bottom;width:83.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item16Form10KSummary_140453"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form 10-K Summary</span></a></p></td><td style="vertical-align:bottom;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">116</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:94.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#SIGNATURES_83339"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">SIGNATURES</span></a></p></td><td style="vertical-align:bottom;width:5.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">117</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><a id="_63532739_1147_4ee9_b5e5_33a38476c04c"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="PARTI_838451"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;I</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Statements made in this Annual Report on Form&#160;10-K contain certain forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are identified by words such as &#8220;believe,&#8221; &#8220;will,&#8221; &#8220;may,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;should,&#8221; &#8220;plan,&#8221; &#8220;expect,&#8221; &#8220;predict,&#8221; &#8220;could,&#8221; &#8220;potentially&#8221; or the negative of these terms or similar expressions. You should read these statements carefully because they discuss future expectations, contain projections of future results of operations or financial condition, or state other &#8220;forward-looking&#8221; information. These statements relate to our future plans, objectives, expectations, intentions and financial performance and the assumptions that underlie these statements. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed in this report below, in &#8220;Item&#160;1A. Risk Factors&#8221; and elsewhere in this Annual Report. In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.</i> <i style="font-style:italic;">Forward-looking statements are based on our management&#8217;s beliefs and assumptions and on information currently available to our management. These statements, like all statements in this report, speak only as of their date, and we undertake no obligation to update or revise these statements in light of future developments. We caution investors that our business and financial performance are subject to substantial risks and uncertainties. </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Summary of Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="background-color:#ffffff;font-style:italic;">Below is a summary of the principal factors that make an investment in our common stock speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, can be found below under the heading &#8220;Item 1A. Risk Factors&#8221; and should be carefully considered, together with other information in this Annual Report on Form&#160;</i><i style="font-style:italic;">10-K</i><i style="background-color:#ffffff;font-style:italic;">&#160;and our other filings with the SEC, before making an investment decision regarding our common stock.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Under &#8220;<b style="font-weight:bold;">Risks Related to the COVID-19 Pandemic</b>&#8221; we describe risks to our business arising from the COVID-19 pandemic. The pandemic has and could continue to adversely impact our business, including our ongoing and planned clinical trials and preclinical and discovery research. The impacts on our business include, among others, delays to some of our ongoing clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Under &#8220;<b style="font-weight:bold;">Risks Related to Clinical Development</b>&#8221; we describe risks related to on our ongoing clinical development efforts. They include, among others, the following: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:23.75pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">We have no approved products and no historical product revenue, which makes it difficult to assess our future prospects and financial results.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:23.75pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">We are heavily dependent on the success of our product candidates in clinical development. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:23.75pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Clinical development is a lengthy and expensive process with an uncertain outcome, and failure can occur at any stage of clinical development.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:23.75pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Our product candidates may cause undesirable side effects or have other properties adversely impacting safety that delay or prevent their regulatory approval, restrict their approved labeling, or otherwise limit their commercial opportunity.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Under &#8220;<b style="font-weight:bold;">Risks Related to Financial Position and Capital Requirements</b>&#8221; we describe risks associated with our financial position and future capital requirements. They include, among others, the following: <span style="font-style:italic;font-weight:bold;"> </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">We have incurred significant losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">We have never generated any revenue from product sales and may never be profitable.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">We expect to require substantial additional funding. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Raising additional capital may cause dilution to our existing stockholders. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under &#8220;<b style="font-weight:bold;">Risks Related to Our Reliance on Third Parties</b>&#8221;<b style="font-weight:bold;"> </b><span style="white-space:pre-wrap;">we describe risks related to our reliance on third parties.  They include, among others, the following:</span><b style="font-weight:bold;"> </b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">We rely on Janssen Biotech, Inc. (&#8220;Janssen&#8221;) to continue the development of product candidates subject to our license and collaboration with Janssen, and to successfully commercialize any resulting products.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Our existing or future collaborations with third parties may not be successful.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">We rely on third parties to conduct our pre-clinical studies and clinical trials and are subject to risks associated with their businesses and performance of their obligations to us.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">We rely on third party contract manufacturers to manufacture our drug substance and clinical drug product.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under &#8220;<b style="font-weight:bold;">Risks Related to Regulatory Approval</b>&#8221; we describe risks related to the potential regulatory approval required to market our product candidates in the United States or other jurisdictions. If we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under &#8220;<b style="font-weight:bold;">Risks Related to Commercialization of our Product Candidates</b>&#8221; we describe risks related to the commercialization of any our product candidates that are eventually approved for marketing. We have no marketing and sales organization and may not be able to effectively market and sell any products or generate product revenue if any of our product candidates are approved for marketing. Also, if we commercialize our product candidates abroad, we will be subject to the risks of doing business outside of the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under &#8220;<b style="font-weight:bold;">Risks Related to Our Business and Industry</b><span style="white-space:pre-wrap;">&#8221; we describe risks related to our business in general, and to our company in the biotechnology and pharmaceutical industry.  They include, among others, the following: </span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">We</span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:left;"> </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">face significant competition from other biotechnology and pharmaceutical companies. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Our success depends on our ability to attract, retain and motivate qualified executives and other personnel.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">We may experience difficulties in managing the growth of our organization.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">We are subject to risks associated with information technology systems or breaches of data security.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Any misconduct by our employees, independent contractors, principal investigators, consultants and vendors could have a material adverse effect on our business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Our headquarters is located near known earthquake fault zones. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under &#8220;<b style="font-weight:bold;">Risks Related to Our Intellectual Property</b>&#8221;<b style="font-weight:bold;"> </b>we describe risks related to the intellectual property that is critical to the success of our business. They include, among others, the following:<b style="font-weight:bold;"> </b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">If we are unable to obtain or protect intellectual property rights related to our product candidates and technologies, we may not be able to compete effectively in our markets.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">We may be involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time consuming and ultimately unsuccessful.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Patents covering our product candidates could be found invalid or unenforceable.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Third party claims of intellectual property infringement may prevent or delay our drug discovery and development efforts.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under &#8220;<b style="font-weight:bold;">Risks Related to Ownership of our Common Stock</b><span style="white-space:pre-wrap;">&#8221; we describe risks associated with owning our common stock.  They include, among others, the following:</span><b style="font-weight:bold;"> </b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Our stock price has been and will likely continue to be volatile and may decline, regardless of our operating performance.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Any failure to maintain the adequacy of internal controls may adversely affect investor confidence in our company and, as a result, the value of our common stock.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Some provisions of our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, or make it difficult </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">for stockholders to replace members of our board of directors</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:left;"> </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:217.5pt;"><a id="Item1Business_611152"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item&#160;1.</b></span>Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We are a clinical-stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based drugs to address significant unmet medical needs and transform existing treatment paradigms for patients. We have multiple clinical assets derived from this platform in development for multiple indications. Our clinical programs fall into two broad categories of diseases; (i) hematology and blood disorders, and (ii) inflammatory and immunomodulatory diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Figure 1: Our Product Pipeline </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="ptgx-20201231x10k006.jpg" alt="Graphic" style="display:inline-block;height:217.45pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:485.3pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt 0pt 0pt 288pt;"><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">*Subject to Covid-19 related delays</sup><span style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:italic;margin-bottom:12pt;margin-left:0pt;vertical-align:top;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">Our most advanced clinical asset, rusfertide (generic name for PTG-300) is an injectable hepcidin mimetic in development for the potential treatment of erythrocytosis, iron overload and other blood disorders. Hepcidin is a key hormone in regulating iron equilibrium and is critical to the proper development of red blood cells. Rusfertide mimics the effect of the natural hormone hepcidin, but with greater potency, solubility and stability. We initiated Phase&#160;2 proof of concept (&#8220;POC&#8221;) studies in the blood disorders polycythemia vera (&#8220;PV&#8221;) in the third quarter of 2019 and hereditary hemochromatosis (&#8220;HH&#8221;) in January&#160;2020. In December 2020, we presented four posters and one oral presentation relating to rusfertide at the American Society for Hematology&#8217;s virtual annual meeting, including updated interim Phase&#160;2 results for rusfertide in PV. We believe these interim results provide evidence regarding the potential of rusfertide to eliminate the need for phlebotomy by controlling hematocrit levels below 45% on an individual patient basis. Rusfertide has a unique mechanism of action in the potential treatment of PV, which may enable it to decrease and maintain hematocrit levels within the range of recommended clinical guidelines without causing the iron deficiency that may occur with frequent phlebotomy. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">We selected PV as our first indication for potential pivotal study in rusfertide and expect to complete patient enrollment in the ongoing Phase 2 clinical trial by mid-2021. We are consulting with regulatory authorities in the first half of 2021 to discuss the registrational clinical development plan. In June&#160;2020, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) granted orphan drug designation for rusfertide for the treatment of PV. In October&#160;2020, the European Medicines Agency granted orphan drug designation for rusfertide for the treatment of PV. In December&#160;2020, the FDA granted Fast Track designation for rusfertide for the treatment of PV. In addition, we expect to disclose preliminary data from our Phase 2 POC study in HH, our second indication, in the second half of 2021. We discontinued development of rusfertide for anemia associated with beta-thalassemia and myelodysplastic syndromes during the first half of 2020. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Our clinical assets PTG-943 and PTG-200 are orally delivered investigational drugs currently in development for inflammatory bowel disease (&#8220;IBD&#8221;), a gastrointestinal (&#8220;GI&#8221;) disease consisting primarily of ulcerative colitis (&#8220;UC&#8221;) and Crohn&#8217;s disease (&#8220;CD&#8221;), that are designed to block biological pathways currently targeted by marketed injectable antibody drugs. Our orally stable peptide approach may offer targeted delivery to the GI tissue compartment. We believe that, compared to antibody drugs, these product candidates have the potential to provide improved safety due to minimal exposure in the blood, increased convenience and compliance due to oral delivery, and the opportunity for the earlier introduction of targeted oral therapy. As a result, if successfully developed and approved, we believe they may transform the existing treatment paradigm for IBD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">PN-943 is an investigational, orally delivered, gut-restricted alpha-4-beta-7 (&#8220;&#945;4&#946;7&#8221;) specific integrin antagonist. We developed PN-943 as a potentially more potent orally delivered, gut-restricted &#945;4&#946;7 backup compound to PTG-100, our first-generation orally delivered gut-restricted &#945;4&#946;7 inhibitor that was being developed for treatment of IBD. In 2019, we completed a Phase&#160;1 single ascending dose (&#8220;SAD&#8221;) and multiple ascending dose (&#8220;MAD&#8221;) clinical study of PN-943 in healthy volunteers to evaluate safety, pharmacokinetics and pharmacodynamics. The pharmacodynamic results indicated that the administration of PN-943 was well tolerated and showed results of target engagement that were suggestive of higher potency for PN-943 as compared to PTG-100. We submitted a U.S. Investigational New Drug application (&#8220;IND&#8221;) with the FDA for PN-943 in December&#160;2019, which took effect in January&#160;2020, and we initiated a Phase&#160;2 POC study in UC in the second quarter of 2020 which is expected to be completed in 2022, subject to delays related to the COVID-19 pandemic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">PTG-200 (also referenced as JNJ-67864238) is an investigational, orally delivered, gut-restricted Interleukin-23 receptor (&#8220;IL-23R&#8221;) antagonist for the treatment of IBD. In May&#160;2017, we entered into a worldwide license and collaboration agreement with Janssen Biotech, Inc. (&#8220;Janssen&#8221;), a Johnson &amp; Johnson company, to co-develop and co-detail PTG-200 and certain related compounds for all indications, including IBD. The agreement with Janssen was amended in May&#160;2019 to expand the collaboration by supporting efforts towards second-generation IL-&#160;23R antagonists, triggering a $25.0&#160;million milestone payment to us. In January&#160;2020, as part of the expanded research collaboration, we announced the identification and nomination of an orally delivered IL-23R antagonist peptide as a second-generation development candidate, triggering a $5.0&#160;million milestone payment to us. Janssen initiated a global Phase&#160;2 POC clinical study for PTG-200 in moderate-to-severe CD in the fourth quarter of 2019. Due to the uncertain effect on the timing of clinical trials caused by the COVID-19 pandemic, we have suspended guidance on a timeline for completion of the PTG-200 Phase&#160;2 study. In October&#160;2020, we announced the selection of two second-generation IL-R antagonists for advancement into clinical development, PN-235 (also referenced as JNJ-77242113) and PN-232 (also referenced as JNJ-75105186). A Phase 1 study was initiated for PN-235 in December 2020 and is expected to be completed in 2021. PN-232 is in the late preclinical stage and we expect to initiate and complete a Phase 1 study for PN-232 in 2021. The advancement of three different oral co-development candidates provides us with several strategic options for development in multiple indications. We are also continuing our joint research efforts to identify additional IL-23R antagonists.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Our clinical assets are all derived from our proprietary discovery platform. Our platform enables us to engineer novel, structurally constrained peptides that are designed to retain key advantages of both orally delivered small molecules and injectable antibody drugs in an effort to overcome many of their limitations as therapeutic agents. Importantly, constrained peptides can be designed to potentially alleviate the fundamental instability inherent in traditional peptides to allow different delivery forms, such as oral, subcutaneous, intravenous, and rectal. We continue to use our peptide technology platform to discover product candidates against targets in disease areas with significant unmet medical needs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:12pt 0pt 0pt 0pt;">RUSFERTIDE: AN INJECTABLE HEPCIDIN MIMETIC </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">Rusfertide, an injectable hepcidin mimetic, was discovered through our peptide technology platform. Hepcidin is a natural hormone that regulates iron metabolism. We are developing rusfertide for the treatment of certain disorders characterized by excessive red blood cells, iron overload or imbalance. In healthy individuals, hepcidin regulates iron levels by limiting release of iron from macrophages and inhibiting iron absorption from the GI tract. In diseases of excessive red blood cells (&#8220;RBCs&#8221;), such as PV, the body consumes iron in the production of cells, leading to iron </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">deficiency which can be exacerbated by phlebotomy. In diseases of iron overload, such as HH, there may be insufficient hepcidin to maintain appropriate iron levels. In other disorders, iron imbalance can benefit from increased levels of hepcidin-like activity to restore proper balance. Because of stability issues, complexity of synthesis and solubility limitations, direct replacement with native hepcidin is not a practical therapeutic approach. We developed rusfertide as a more potent, stable, soluble, and more readily manufactured injectable hepcidin mimetic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:2pt 0pt 0pt 0pt;">Mechanism of Action and Rationale</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The molecular target of the hormone hepcidin is the cellular trans-membrane protein ferroportin, which functions as the major export channel for intracellular iron in macrophages, liver hepatocytes, and duodenal enterocytes. By binding to the extracellular domain of ferroportin, hepcidin redistributes iron by reducing the export of iron from inside the enterocytes and macrophages to the systemic circulation. As a hepcidin mimetic, rusfertide can downregulate ferroportin and normalize red blood cell production by controlling the supply of iron from the macrophages and other stores to the bone marrow. In addition, by limiting the release of iron into the blood, rusfertide may inhibit the damage caused by excessive absorption of iron by vital organs such as the liver and heart. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Iron Disorders Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:22.5pt;margin:0pt;"><span style="font-weight:normal;text-decoration:underline;text-decoration-color:#000000;">Polycythemia vera (&#8220;PV&#8221;) </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">PV is a rare myeloproliferative neoplasm characterized primarily by the overproduction of red blood cells. PV is typically caused by a form of Janus Kinase 2 (&#8220;JAK2&#8221;) mutation. PV is a serious chronic condition as the increased red blood cell count causes the blood to thicken and puts patients at higher risk of cardiovascular and thrombotic events such as heart attack and stroke. Patients are typically stratified as low or high risk based on age and medical history. Regardless of risk categorization, treatment guidelines for PV are consistent: to control the patient&#8217;s hematocrit (red blood cells as a percentage of whole blood) below 45% in order to reduce the risk of further cardiovascular or thrombotic events. PV may progress to myelofibrosis or leukemia.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">Currently patients are typically treated with low dose aspirin and phlebotomy alone or hydroxyurea alone or in combination with phlebotomy. At later stages, patients may receive interferons or ruxolitinib, marketed as Jakafi&#174;. Jakafi&#174; is currently the only branded product in the United States for PV and the only FDA-approved treatment for PV in the past 12 years. Cytoreductive therapies such as hydroxyurea, interferons and ruxolitinib can have challenging side effect profiles as they reduce all cell types, not just red blood cells. Current treatments are effective in some patients but have limitations. We believe there are substantial PV patient groups that could benefit from a new non-cytoreductive therapeutic option which focuses on red blood cells. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">PV Market Overview </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">PV is a rare disease affecting approximately 160,000 patients living in the United States, with a similar prevalence in Europe, representing an estimated market opportunity of approximately $1.0 billion to $2.0 billion. Approximately 14,000 new patients have been diagnosed each year since 2017. Patients are typically diagnosed between the age of 50 and 70 and median survival is approximately 20 years. Recent analysis of a large medical claims database, representing approximately 90% of U.S. lives, indicates that the current treatment paradigm <span style="background-color:#ffffff;">consists primarily&#160;of&#160;therapeutic phlebotomy, hydroxyurea, or&#160;a&#160;combination&#160;of&#160;hydroxyurea&#160;and&#160;phlebotomy.&#160;&#160;The predominant&#160;treatment is phlebotomy for&#160;both low-risk and high-risk patients, and&#160;combination&#160;therapy is commonly used to control&#160;hematocrit.&#160;According to this database analysis, current therapies</span> do not offer adequate hematocrit control below 45%. In fact, less than 25% of patients in the data set had all hematocrit test results under 45% as recommended in National Comprehensive Cancer Network (&#8220;NCCN&#8221;), indicating that as many as 70,000 patients in the United States alone may be at elevated risk of cardiovascular and thrombotic events.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">We believe that rusfertide has the potential to provide substantial benefit to patients by providing a tool focused entirely on managing hematocrit in a consistent and predictable manner and dramatically decrease the need for therapeutic phlebotomy. rusfertide is a non-cytoreductive mimetic of the natural hormone hepcidin, the master regulator of iron homeostasis in the body. Rusfertide has a unique iron regulatory mechanism which, per early results from our </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Phase 2 study in PV, allows for persistent control of hematocrit without causing iron deficiency that is caused by excessive red blood cell production and exacerbated by frequent phlebotomy. Rusfertide acts by redistributing iron away from the bone marrow where iron is in high demand and essential for red blood cell production, thereby limiting excess red blood cell production in patients with PV while still providing sufficient iron levels to support other normal cellular and organ functions requiring iron.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Hereditary Hemochromatosis (&#8220;HH&#8221;) </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:23.75pt;margin:0pt;">HH is a blood disorder caused by genetic mutations that increase iron uptake from the diet and alter its distribution in the body, leading to iron buildup in the body&#8217;s tissues and organs, particularly in the skin, heart, liver, pancreas and joint tissues. Excess iron in these organs and tissues can be toxic and over time lead to cirrhosis, liver cancer, heart problems, joint pain and diabetes. Current treatments for HH are limited, the most common being therapeutic phlebotomy, which can be a significant burden to patients. The treatment goal in HH is to bring ferritin levels into a range of 50-150ng/ml. There are currently no pharmaceutical interventions for HH, although iron chelators may be used off-label in certain cases. Rusfertide, if approved, could potentially reduce the need for phlebotomy and offer new solution for management of the disease. The genetic defects that cause most HH are present in approximately five to seven million patients in the United States and European Union (&#8220;EU&#8221;). HH affects approximately one million people in the United States.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt;">In January 2020, we initiated a Phase 2 study of rusfertide in HH. This study is an open label, multicenter study designed to evaluate the effects of rusfertide in up to 20 adult patients over 24 weeks of treatment. Guidelines for HH focus on controlling baseline transferrin saturation (&#8220;TSAT&#8221;) and ferritin to prevent long-term complications. Given the TSAT reductions from rusfertide observed to date in both healthy volunteers and beta-thalassemia and PV patients, as well as regulation of organ iron content in a mouse model of HH, we believe that a significant reduction in phlebotomy may be possible with rusfertide. The endpoints of this POC study include change in TSAT and serum iron levels, reductions in phlebotomy requirements and an assessment of participant-reported outcomes. We expect to report preliminary data from this Phase 2 study in 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Rusfertide&#8217;s Clinical Development Program </i></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt;">In 2018, we successfully filed an IND for in the United States and related clinical trial applications outside the United States. In the first quarter of 2019, we began dosing patients in a global Phase 2 study of rusfertide in beta-thalassemia called TRANSCEND. Beta-thalassemia is a rare genetic blood disorder that is characterized by impaired red blood cell production. The study was a single-arm, open label, MAD design that evaluates safety, POC and dose finding in adolescent and adult patients with anemia associated with non-transfusion dependent (&#8220;NTD&#8221;) or transfusion dependent (&#8220;TD&#8221;) beta-thalassemia. NTD patients received 12 weeks treatment with rusfertide in escalating dose cohorts. The primary efficacy endpoint in NTD patients was a change in hemoglobin from baseline. TD patients received 16 weeks treatment with rusfertide in escalating dose cohorts. The primary efficacy endpoint in TD patients was a change in transfusion burden from baseline. The primary objectives of this study were to evaluate the safety, tolerability and preliminary efficacy of rusfertide and identify an appropriate starting dose and titration regimen for registration studies. </p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Preliminary results from the Phase 2 study in beta-thalassemia patients showed dose-related drug exposure reductions from TSAT and serum iron levels, with significant reductions at the 40 mg and 80 mg weekly doses and significant and sustained reductions at the 40 mg twice weekly doses. These early results suggested the potential of finding an appropriate dose of rusfertide for continued development in the treatment of beta-thalassemia. While we have observed clinical responders in the study based on the pre-specified criteria of reductions in transfusion burden, continued evaluation at higher doses would be required to evaluate the rate and durability of these effects in order to reach definitive conclusions. We discontinued development of rusfertide for anemia associated with beta-thalassemia and myelodysplastic syndromes, a group of disorders in which blood cells do not mature properly in the bone marrow, during the first half of 2020. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:183.57pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Figure 2: Phase 2 Study of Rusfertide in PV Clinical Design</b></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"><img src="ptgx-20201231x10k007.jpg" alt="Graphic" style="display:inline-block;height:179.13pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:482.4pt;" /></b></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt;">In the fourth quarter of 2019, we initiated a Phase 2 study of rusfertide in PV designed to evaluate safety and preliminary efficacy in patients requiring phlebotomy (Figure 2). The Phase 2 study in PV is expected to enroll approximately 50 patients and consists of a 16-week open-label dose finding stage every 4 weeks from 10 mg to 80 mg and a 12-week maintenance period at doses which generate desired hematocrit levels, followed by a 12-week randomized and blinded withdrawal stage. The study has an open-label extension for up to one year to monitor long term safety and benefits of the drug. The endpoints of this clinical POC study include measurement of blood parameters (hematocrit and hemoglobin levels), reductions or delay in phlebotomy requirements, and improvements in quality-of-life symptoms.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt;">In December 2020, we presented four posters and one oral presentation relating to rusfertide at the American Society for Hematology&#8217;s virtual annual meeting, including updated interim Phase&#160;2 results for rusfertide in PV as shown below. These preliminary results from the Phase 2 study of rusfertide in PV demonstrated dramatic decreases in the need for therapeutic phlebotomy in patients with PV, while maintaining control over blood hematocrit levels. </p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Figure 3: </b><b style="font-weight:bold;">Rusfertide Controlled HCT &lt;45% and Decreased RBC Count in PV Patients</b></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">                (Interim Data as of November 18, 2020)</b></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"><img src="ptgx-20201231x10k008.jpg" alt="Graphic" style="display:inline-block;height:183.57pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:482.4pt;" /></b></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:231.65pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Figure 4: Rusfertide Leads to Reversals in Iron Deficiency Markers</b></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">               (Interim Data as of November 18, 2020)</b></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ptgx-20201231x10k009.jpg" alt="Graphic" style="display:inline-block;height:231.65pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:485.3pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt;">Of the 18 PV patients treated with rusfertide, the vast majority were able to eliminate therapeutic phlebotomies and maintain a target hematocrit level of less than 45 percent. (Figure 3). Treatment with rusfertide was also shown to reverse iron deficiency, a serious side effect of regular therapeutic phlebotomies as a treatment for PV (Figure 4). Early observations suggest a decreased symptom burden over time, including overall burden (MPN-TSS), as well as measurements specific to mental function, fatigue and itching. </p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Figure 5. Adverse Events (&#8220;AE&#8217;s&#8221;) in Ongoing Rusfertide Phase 2 Study in PV</b></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">                (Interim Data as of November 18, 2020)</b></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ptgx-20201231x10k010.jpg" alt="Graphic" style="display:inline-block;height:210.6pt;width:489.6pt;" /></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt;">Administration of rusfertide was well tolerated, with injection site reactions and bruise as the only observed adverse events (&#8220;AEs&#8221;); no significant adverse events (&#8220;SAEs&#8221;) were observed (Figure 5). </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.5pt;margin:0pt;">We selected PV as our first indication for potential pivotal study in rusfertide and expect to complete patient enrollment in the ongoing Phase 2 clinical trial by mid-2021. We are consulting with regulatory authorities in the first half of 2021 to discuss the registrational clinical development plan. Rusfertide has received orphan drug designation from the FDA and EU regulatory authorities, and Fast Track designation from the FDA for the treatment of PV. <span style="background-color:#ffffff;">Fast Track&#160;designation&#160;is an expedited review to facilitate development of investigational drugs which treat a serious or life-threatening condition and fill an unmet medical need.&#160;</span><span style="background-color:#ffffff;">During the first quarter of 2021, we initiated a Phase 2 study for rusfertide in up to 20 patients diagnosed with PV and with routinely elevated hematocrit levels (&gt;48%).</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">OVERVIEW OF INFLAMMATORY BOWEL DISEASE </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">IBD is a group of chronic autoimmune and inflammatory conditions of the colon and small intestine, consisting primarily of UC and CD.&#160;In UC, inflammation may be limited to part of the colon or extend through its entirety. UC is primarily characterized by ulceration of the intestinal surface, accompanied by rectal bleeding and frequent, urgent bowel movements. CD occurs anywhere along the GI tract, commonly affecting the small intestine and the proximal large intestine. CD complications may include strictures and fistula, which penetrate all layers of the intestine. UC is usually diagnosed earlier than CD due to bleeding symptoms. Patients with CD may initially present with abdominal pain, fatigue and anorexia, which can be misdiagnosed. Both diseases&#8217; peak diagnosis years are in young adulthood and are found about equally in both males and females. Management is lifelong and affects school attendance, graduation rates, childbearing and work productivity. IBD prevalence is increasing worldwide and is correlated with the adoption of western diets and lifestyle, as well as genetic factors (5 to 20% of affected patients have a first degree relative with the disease). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Market Overview </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">According to the Crohn&#8217;s &amp; Colitis Foundation of America, there are more than 1.6 million IBD patients in the United States alone, an increase of approximately 200,000 patients since 2011. As many as 70,000 new cases of IBD are diagnosed in the United States each year, and there may be as many as 80,000 children in the United States with IBD. In 2019, GlobalData estimated that the UC market was approximately $6.7 billion across seven major markets: United States, France, Germany, Italy, Spain, United Kingdom and Japan. This is expected to increase at a compound annual growth rate of approximately 6.1% to $12.1 billion by 2029. In 2016, GlobalData estimated that the CD market reached approximately $7.3 billion across those same seven major markets and is expected to grow approximately 5.5% per year to $12.4 billion by 2029.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">For many years, tumor necrosis factor-alpha (&#8220;TNF-&#945;&#8221;) antibody drugs were the primary treatment for moderate-to-severe IBD. Humira&#174;<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> </sup>and Remicade&#174; are injectable and infused, respectively. Approximately one third of IBD patients do not respond to TNF-&#945; antibody drugs and approximately another 30% to 40% become refractory within the first year of treatment. Additionally, TNF-&#945; antibody drugs may predispose patients to an increased risk of serious infection and the development of anti-drug antibodies, which over time can cause loss of drug response. More recently, antibody products focused on potentially safer mechanisms of action have been gaining market share. One such product is Takeda Pharmaceuticals&#8217; Entyvio&#174;, which targets the &#945;4&#946;7 integrin pathway. Takada Pharmaceuticals reported 2020 sales of Entyvio&#174; of approximately $3.9 billion. Similarly, Johnson &amp; Johnson&#8217;s Stelara&#174;, which targets the Interleukin 12 (&#8220;IL-12&#8221;) and Interleukin 23 (&#8220;IL-23&#8221;) pathways, has gained significant traction. Johnson &amp; Johnson global sales of Stelara&#174; (approved for psoriasis, psoriatic arthritis, moderate-to-severe CD and UC) exceeded $7.7 billion in 2020. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:2pt 0pt 0pt 0pt;">Current Standard of Care in IBD </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">In recent years, treatment of IBD has evolved from a focus on successful symptom management to an emphasis on modifying the underlying disease to achieve long-term remission. While available treatments exist for moderate-to-severe IBD, there continues to be a significant medical need for novel, efficacious, safe and convenient treatments. New technologies and outcome measures have been developed to improve staging definitions and assessments of treatment benefit. Nonetheless, halting or reversing IBD progression has not yet been achieved with any single agent therapy, and attaining and maintaining long-term remission in most patients remains a significant unmet medical need. Across </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">therapeutic classes, 15% to 31% rates of clinical remission represent the current ceiling in patients with moderate-to-severely active disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Biosimilar infliximab and other tumor necrosis factor (&#8220;TNF&#8221;) inhibitors are the first line standard of care in moderate-to-severe IBD. Anti-TNFs bind to and neutralize a central pro-inflammatory cytokine in the gut via systemic immunosuppression. As a result, they can be associated with infection and malignancy risk. Although the magnitude of these risks is relatively low, they are significant for the young IBD population who must continue on lifelong treatment. In addition, more than 10% of patients treated with anti-TNF agents lose response with each year of treatment. In 2014, a novel anti-trafficking mechanism launched with vedolizumab, marketed as Entyvio&#174;, which blocks migration of leukocytes into the gut via &#945;4&#946;7 integrins. This mechanism remains the only true &#8220;gut selective&#8221; approach in the IBD market today, although formulation technologies can limit systemic exposure from orally delivered agents. Entyvio&#174; has shown an excellent safety profile, although it requires intravenous administration. Entyvio&#174; was followed by the launch of ustekinumab, marketed as Stelara&#174;, in CD in 2016, which blocks inflammation produced through the IL-12 and IL-23 pathways, and tofacitinib, marketed as Xeljanz&#174;, an orally delivered pan-Janus kinase (JAK) inhibitor approved in UC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">A head-to-head trial called VARSITY comparing the long-term safety and efficacy of an anti-integrin and anti-TNFs has been completed. Entyvio&#174; demonstrated superior rates of clinical remission and endoscopic improvement compared with Humira&#174;, the market leader in the TNF inhibitor class. The first formal combination trials in IBD were initiated in the last year, adding new mechanisms such as integrin inhibitors or IL-23 inhibitors to anti-TNFs. Most IBD experts now believe that combining treatment classes with additive or synergistic mechanisms of action will be required to attain the disease-modifying effects and lasting remissions in a larger group of patients documented in other areas of immunology, such as psoriasis or rheumatoid arthritis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We believe the development of new, potent and targeted orally delivered therapies for IBD may offer safer and more effective treatment options, alone or in combination, for moderate-to-severe IBD patients. In addition, many clinicians continue to advocate for earlier introduction of targeted therapeutics in mild-to-moderate IBD in order to prevent disease progression and irreversible gastrointestinal damage. Our orally delivered, GI-restricted, peptide drugs PTG-200, PN-235, PN-232 and PN-943 work on the same specific validated targets as FDA-approved injectable antibodies and have the potential to offer improved safety and compliance and to minimize the risk of immunogenicity associated with antibodies. We believe that our product candidates, if approved, have the potential to be used more broadly, including treatment of mild-to-moderate IBD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Our IBD Solution: Orally Delivered, GI-Restricted Peptides as Targeted Therapies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.5pt;margin:0pt 0pt 12pt 0pt;">For the IBD targets of interest, the size and nature of our peptides are carefully selected and modified so as to acquire the desired potency and specificity, and also to largely restrict their presence to the GI tissue compartment when administered orally. These features translate to orally delivered, GI-restricted, selective and potent peptide drug candidates with specific advantages compared to antibody drugs:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;text-align:left;">Oral administration</i><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">. We are developing our peptide therapeutics in a convenient capsule or tablet form intended for oral administration. We believe oral administration may reduce many of the problems and limitations associated with injections or infusions, including injection site pain and local reactions, inconvenience, anxiety, high rates of immunogenicity and potential safety risks.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;text-align:left;">Potential for improved safety and tolerability compared to antibody drugs</i><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;text-align:left;">Oral and GI-restricted delivery minimizes systemic exposure in the blood.</i><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> Oral and GI-restricted delivery results in lower drug levels in the blood that may provide the potential for an enhanced safety profile over antibody drugs.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;text-align:left;">Peptides can be cleared more quickly from systemic circulation.</i><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> Small molecules and peptides below a size threshold can be rapidly cleared from blood circulation by kidney filtration and excretion. Rapid clearance may be beneficial especially if patients need to discontinue therapy. In contrast, antibody </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">drugs, because of their long plasma half-life, may take&#160;months to clear from blood circulation, leaving patients exposed to continued or increased safety risk.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;text-align:left;">The likelihood of much lower immunogenicity of small stable peptides compared to antibody drugs reduces the risk of loss of response.</i><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> We believe that anti-drug antibodies are less likely to be elicited against constrained peptides, due to their small size, lack of epitope density, resistance to proteolysis, oral tolerance, and minimal systemic absorption.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;text-align:left;">Potential for localized delivery to site of disease.</i><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;"> We believe oral dosing of GI-restricted peptides results in substantially higher drug concentrations in the diseased GI tissue compartment compared to injectable antibody drugs. This targeted delivery to the site of action may lead to more immediate and significant target engagement at the site of active disease in the GI tissue compartment with the potential for improved efficacy.  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;text-align:left;">Cost-effective and less complex manufacturing</i><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">. Because of their size and stability, we believe that our orally delivered, GI-restricted peptide product candidates can be produced, stored and shipped in a more cost-effective manner than many antibody drugs.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">In chronic GI diseases such as IBD, we believe that our orally delivered, GI-restricted peptide product candidates may offer improved delivery, the potential for improved safety and tolerability, and cost efficiencies that may provide an overall benefit to patients, payors, and physicians.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:-4.5pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PN-943: AN ORALLY DELIVERED &#945;4&#946;7 INTEGRIN ANTAGONIST </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:25.2pt;margin:0pt 0pt 13.19pt 0pt;">PN-943, a second-generation, orally delivered, gut-restricted &#945;4&#946;7 specific integrin antagonist, was discovered through our peptide technology platform and is being developed initially for patients with moderate-to-severe UC. &#945;4&#946;7 integrin is considered to be one of the most GI-specific biological targets for IBD due to its binding to MAdCAM-1, an extracellular protein that resides mostly in the GI vasculature. Like Entyvio&#174;, which is dosed as an infusion and as an injectable antibody drug, PN-943 specifically inhibits &#945;4&#946;7 integrin. We have leveraged the development and regulatory path of Entyvio&#174; and other approved antibody drugs for IBD to help inform the design of our clinical development studies. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:2pt 0pt 0pt 0pt;">Mechanism of Action and Rationale</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Integrins, such as &#945;4&#946;7, are transmembrane proteins that regulate cellular movement into extravascular tissue and play an important role in modulating the inflammatory reaction in the gut. The &#945;4&#946;7 integrin is expressed on the surface of T cells, immune cells that help defend against foreign and potentially harmful substances that enter the body. The development of IBD is driven by the migration of &#945;4&#946;7 T cells into the GI tissue compartment and their subsequent activation within the GI tissue compartment. The entry of &#945;4&#946;7&#160;T&#160;cells into the GI&#160;tissue compartment is facilitated by the protein-protein interactions between the &#945;4&#946;7 integrin and its corresponding ligand, MAdCAM-1, which is primarily expressed in the GI tissue compartment. Hence, the binding of &#945;4&#946;7 to MAdCAM-1 can be categorized as a GI-specific interaction and has been identified as an IBD-specific targeted therapeutic approach. By blocking the binding of &#945;4&#946;7 integrin to MAdCAM-1, PN-943 may prevent trafficking and activation of T cells, thereby reducing the inflammation that leads to the clinical manifestations and long-term implications of UC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">&#945;4&#946;7 for IBD is targeted by Entyvio&#174;, which has demonstrated safety and efficacy in patients with moderate-to-severe UC and CD. Since PN-943 targets the same biological pathway as Entyvio&#174;, we utilized similar PD-based POC in our pre-clinical studies and Phase 1 clinical trial to inform and guide our Phase 2 development program. We sourced these PD biomarker assays from public scientific publications and do not maintain any contractual arrangement providing access to this information with the makers of these marketed products.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:244.92pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;">PN-943 Pre-Clinical Proof-of-Concept Studies<span style="font-style:normal;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">We have completed extensive pre-clinical studies of PN-943 in which we established pharmacodynamic target engagement POC, including effects on receptor occupancy, T cell trafficking and mucosal healing in rodents and monkeys. Pre-clinical data indicated that PN-943 may be a more potent &#945;4&#946;7 integrin antagonist compound than PTG-100 without sacrificing its other positive attributes, such as selectivity and tolerability. PTG-100 is our first generation &#945;4&#946;7 inhibitor that shares the same &#945;4&#946;7 integrin target as Entyvio&#174; for the treatment of moderate-to-severe UC and CD. We completed extensive pre-clinical studies of PTG-100 in which we established pharmacological POC and completed a Phase 1 clinical trial in Australia in 2016. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:2pt 0pt 0pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:2pt 0pt 0pt 0pt;">PN-943&#8217;s Phase 1 Clinical Trial Overview </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt;">We completed a Phase 1 randomized, double-blind, placebo-controlled clinical trial of PN-943 in&#160;<span style="white-space:pre-wrap;">normal healthy male volunteers in Australia in 2019. The Phase 1 SAD and MAD components were conducted with a solution-based liquid formulation. In addition to determining the safety and tolerability and pharmacokinetics of PN-943, the SAD and MAD components of the trial evaluated PD-based POC through the assessment of &#945;4&#946;7 receptor occupancy and &#945;4&#946;7 target expression that indicate target engagement on peripheral blood memory T cells similar to what was done in the pre-clinical studies and in the Phase 1 trial with PTG-100. In the clinical trial, dose escalation proceeded from 100 mg up to 1,400 mg for the SAD portion and 1,000 mg for the MAD portion.  </span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:25.3pt;margin:0pt 0pt 13.19pt 0pt;">We reported results of the SAD part of the study during the second quarter of 2019 and the MAD part of the study during the third quarter of 2019. The pharmacodynamic results of target engagement were supportive of the three-fold higher potency of PN-943 as compared to PTG-100 and saturation at 1000 mg. This is consistent with data from pre-clinical studies and confirmed by this Phase 1 pharmacodynamic data. We believe this links PN-943 to greater probability of success in a Phase 2 trial based on signs of clinical efficacy of PTG-100 in the Phase 2 PROPEL trial in UC patients. The administration of PN-943 was well-tolerated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">PN-943 Phase 2 Clinical Trial Overview</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Figure 6. PN-943 Phase 2 in UC IDEAL Study Design</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;"><img src="ptgx-20201231x10k011.jpg" alt="Graphic" style="display:inline-block;height:244.92pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:482.4pt;" /></b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:27pt;margin:0pt;"><span style="font-weight:normal;">We submitted a U.S. IND with the FDA for PN-943 in December&#160;2019, which took effect in January&#160;2020. During the second quarter of 2020, we initiated a global, randomized, double-blind placebo-controlled study called IDEAL evaluating the safety, tolerability and efficacy of PN-943 in approximately 150 patients with moderate-to-severe UC (Figure 6). This Phase 2 study is expected to be completed in 2022, subject to delays related to the COVID-19 pandemic.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:12pt 0pt 0pt 0pt;">PTG-200, PN-235 &amp; PN-232: ORALLY DELIVERED IL-23R ANTAGONISTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">PTG-200, an orally delivered, gut-restricted IL-23R specific antagonist for the treatment of IBD, was discovered through our peptide technology platform. IL-23, a member of the IL-12 family of pro-inflammatory cytokines, is a protein that regulates inflammatory and immune function and plays a key role in the development of IBD. By blocking IL-23R with PTG-200 in the GI tissue compartment, we hope to improve disease symptoms and reduce bowel wall damage while potentially minimizing the risk of systemic side effects due to its GI-restricted nature. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:2pt 0pt 0pt 0pt;">Mechanism of Action and Rationale</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">IL-23 is a member of the IL-12 family of cytokines with pro-inflammatory and autoimmune properties. Cytokines are cell signaling proteins that are released by cells and affect the behavior of other cells. Binding of the IL-23 ligand to the IL-23R receptor leads to an expression of pro-inflammatory cytokines involved in the mucosal autocrine cascade that is an important pathway of many inflammatory diseases, including IBD. Furthermore, genetic analyses of IBD patients have implicated IL-23R mutations as a risk factor associated with susceptibility to IBD. The infused antibody drug Stelara&#174; (marketed for psoriasis, psoriatic arthritis, UC and moderate-to-severe CD) is a p40 antagonist antibody that inhibits both the IL-23 and IL-12 pathways. Next-generation IBD antibody drugs, such as guselkumab, target the p19 subunit of the IL-23 ligand and are specific to the IL-23 pathway, which is believed to be an important driver of local IBD pathology, while not blockading the IL-12 pathway. IL-12 is believed to be important in immune surveillance against the development of infections and malignancies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We believe that the orally delivered, GI-restricted nature of PTG-200 may allow PTG-200 to be a potent inhibitor of the IL-23 pathway for the treatment of IBD. By targeting IL-23R with our orally delivered GI-restricted IL-23R antagonist PTG-200, we believe PTG-200 may restore proper immune function in the GI tissue compartment where there is active disease while minimizing the risk of systemic side effects. Several key cell types that reside in gut-associated lymphoid tissue (&#8220;GALT&#8221;), including T cells, innate lymphoid cells, and natural killer cells, increase their expression of IL-23R during the progression of IBD. Therefore, the high concentrations of PTG-200 in GALT will facilitate access and binding to IL-23R expressed in the same tissue with the potential for concomitant efficacy benefits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:2pt 0pt 0pt 0pt;">PTG-200&#8217;s Phase 1 Clinical Study</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We completed a Phase 1 clinical trial of PTG-200 in Australia during the fourth quarter of 2018. The Phase 1 study was a randomized, double-blind, placebo-controlled, SAD and MAD-escalation trial in 80 normal healthy volunteers. The primary endpoint was safety and tolerability. Secondary endpoints included the identification of the maximally tolerated dose and the evaluation of pharmacokinetic parameters. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Results of the Phase 1 study demonstrated that administration of PTG-200 was well-tolerated. No serious adverse events or dose-limiting toxicities were observed. The pharmacokinetic and pharmacodynamic parameters were consistent with the GI-restricted design of PTG-200. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">PTG-200&#8217;s Clinical Development Plan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">We have a worldwide license and collaboration agreement with Janssen to co-develop and co-detail PTG-200 and any second-generation compounds for all indications, including IBD. The agreement was amended in May 2019 to expand the collaboration by supporting efforts towards second-generation IL-23R antagonists, triggering a $25.0 million milestone payment to the Company. In January 2020, we announced the identification and nomination of an orally delivered, gut-restricted IL-23R antagonist peptide as a second-generation development candidate under our license and collaboration agreement with Janssen, advancing the collaboration and triggering a $5.0 million milestone payment to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">us. See &#8220;Item 7. Management&#8217;s Discussion and Analysis &#8211; Overview&#8221; and Note 3 to the Consolidated Financial Statements included elsewhere in this Annual Report on Form 10-K for additional information. Janssen submitted an IND for PTG-200 in CD during the second quarter of 2019, which took effect in July 2019. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Janssen initiated a Phase 2 clinical study of PTG-200 in CD called PRISM in the fourth quarter of 2019. The global, randomized, double blind, placebo-controlled, Phase 2 study is evaluating the efficacy of oral administration of PTG-200 in 90 patients with moderate-to-severe CD. The study will assess the effect of twice-daily dosing of PTG-200 on change from baseline in Crohn&#39;s Disease Activity Index score at week 12 as the primary endpoint. The study will also assess change from baseline in simple endoscopic score for CD rates of clinical response and remission, endoscopic response and remission, and patient-reported outcome-2 remission.&#160;Because of the COVID-19 pandemic, we have suspended guidance on a timeline for PTG-200 Phase&#160;2 study completion. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Second Generation IL23-R Antagonists PN-235 and PN-232</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.5pt;margin:0pt 0pt 12pt 0pt;">In October&#160;2020, we announced the selection of two second-generation IL-R antagonists for advancement into clinical development, PN-235 (also referenced as JNJ-77242113) and PN-232 (also referenced as JNJ-75105186), and a Phase 1 study was initiated for PN-235 in December 2020. The Phase 1 for PN-235 study is designed to determine the safety, tolerability and pharmacokinetics of PN-235 in approximately 100 healthy volunteers. The study will be conducted in three parts: a SAD component, an MAD component, and a randomized, crossover solid dose comparison component. The primary endpoint is safety as measured by number and severity of adverse events. Secondary outcomes include pharmacokinetics measurements of peak concentration and area under the curve. We expect results from the Phase 1 study for PN-235 in 2021. PN-232 is in the late preclinical stage and we expect to initiate and complete a Phase 1 study for PN-232 in 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The advancement of three different oral co-development candidates provides us with several strategic options for development in multiple indications. We are also continuing our joint research efforts to identify additional IL-23R antagonists.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:12pt 0pt 0pt 0pt;">OUR PEPTIDE TECHNOLOGY PLATFORM </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_Hlk34237856"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Our proprietary technology platform is purposefully built to exploit the advantages of constrained peptides, which are much smaller than antibody-based drugs and may be delivered orally but are big enough to bind and block the difficult targets that antibodies bind and modulate. The platform has been successfully applied to a diverse set of biological targets that has led to several pre-clinical and clinical stage peptide-based new chemical entities, including our clinical stage product candidates, for a variety of clinical indications. Our platform is comprised of a series of tools and methods, including a combination of molecular design, phage display, stability assays, medicinal chemistry, biomarker, formulations<i style="font-style:italic;">, in vitro</i> biochemical, cell and tissue-based assays, and <i style="font-style:italic;">in vivo</i> pharmacology and pharmacokinetic approaches. We apply this platform to the discovery and development of constrained peptides to develop new drug candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">The platform is used to develop potential drug candidates (agonists and antagonists): (i)&#160;using the structure of a target, when available, (ii)&#160;<i style="font-style:italic;">de novo</i> when no target structure exists, or (iii)&#160;from publicly disclosed peptide starting points. In a structure-based approach, our proprietary molecular design software and structural database of several thousand constrained peptides, termed Vectrix&#8482;, are screened to identify suitable scaffolds. The scaffolds identified form the basis of designing and constructing the first set of phage or chemical libraries. The initial hits are identified by either panning or screening such libraries, respectively. When structural information is unavailable for a target, hits are identified by panning a set of 34 proprietary cluster-based phage libraries consisting of millions of constrained peptides. Once the hits are identified, they are optimized using a set of peptide, peptide mimetic and medicinal chemistry techniques that include the incorporation of new or manipulation of existing cyclization-constraints, as well as natural or unnatural amino acids and chemical conjugation or acylation techniques. These techniques are applied to optimize potency, selectivity, stability, exposure and ultimately efficacy. For rusfertide, hit discovery and optimization relied exclusively on medicinal and computational chemistry, with no phage display, to develop potent and selective injectable candidates with enhanced stability and exposure in blood. For injectable products, stability in blood is determined using <i style="font-style:italic;">in vitro</i> assay techniques to identify chemical and biological sites of degradation, which are then optimized while still </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">maintaining potency and selectivity. Conjugation strategies are used to optimize the exposure of the injected peptide. For PN-943, PTG-200, PN-235 and PN-232, phage display is tightly coupled to medicinal chemistry, structural biology and oral stability techniques to develop potent, selective and orally delivered molecules that are GI-restricted. Oral stability is profiled in a series of <i style="font-style:italic;">in vitro</i> and <i style="font-style:italic;">ex vivo</i><span style="white-space:pre-wrap;"> assays that portray the chemical and metabolic barriers a peptide will encounter as it transits the GI tract.  These metabolically labile spots in the peptides are optimized using medicinal chemistry-based approaches to engineer oral stability whilst maintaining selectivity and potency.&#160;Various </span><i style="font-style:italic;">in vivo</i> pharmacology tools are then used to quantify peptide exposure in relevant GI organs and tissues. This data can be used to optimize required GI exposure over the required time frame to achieve <i style="font-style:italic;">in vivo</i> efficacy. This is complemented by formulation technologies to enhance GI and systemic exposure by exploiting the intrinsic stability of our oral peptides. Finally, various biomarkers are also developed to correlate exposure with efficacy to guide candidate selection, dose selection and provide preliminary proof-of-concept of target engagement in clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:2pt 0pt 0pt 0pt;">Future Applications of our Platform</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We believe we have built a versatile, well-validated and unique discovery platform. For example, this peptide technology platform has been used to develop product candidates for diverse target classes including G-protein-coupled receptors, ion channels, transporters, cytokines and their receptors for a variety of therapeutic areas. In the future we may tackle other GI and blood disorders and expand our delivery techniques to include other organ/tissue systems, such as the lung and eye, which will provide potential opportunities to pursue a wider variety of diseases. In addition, the gut may communicate with the immune, central nervous, and endocrine systems, providing the potential of our GI-restricted approach to treat metabolic, cancer and cardiovascular diseases. Lastly, we intend to progress our platform to achieve systemic bioavailability and activity with oral peptides, macrocycles and peptidomimetics, thereby enabling us to address systemic diseases. An example of this approach is our preclinical stage program to identify an orally active hepcidin mimetic as was recently reported at the American Society for Hematology&#8217;s virtual annual meeting in December 2020. We believe this will be complementary to the injectable rusfertide for offering the best treatment options for polycythemia vera, hereditary hemochromatosis and other potential erythropoietic and iron imbalance disorders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">COVID-19 Business Update</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We are continuing to closely monitor the impact of the ongoing global COVID-19 pandemic on our business and have taken and continue to take proactive efforts designed to protect the health and safety of our patients, study investigators, clinical research staff and employees, and to maintain business continuity. Following guidance from federal, state and local authorities, we transitioned to a fully remote working environment for a portion of 2020.&#160; As a result, our laboratories and office locations were closed for approximately two weeks. Our facility partially re-opened in April 2020 for laboratory personnel and a small number of critical personnel to resume limited operations. We have experienced relatively minor impacts on productivity overall, which were experienced primarily in as our personnel adjusted to working remotely in the early stages of the COVID-19 pandemic. Enrollment in certain of our clinical studies has been adversely affected by the pandemic. It is possible the pandemic will have a more significant negative impact on our business in the future, depending on the depth of the effects and the duration of the crisis. We cannot predict whether these trends will continue or be exacerbated, or when we will return to a normal working model. For information regarding the current and potential impacts of the effects of the COVID-19 pandemic on our business, see Part II, Item 7, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Overview&#8221; and elsewhere in this Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:12pt 0pt 0pt 0pt;">Material Agreements </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Janssen License and Collaboration Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">In May 2017, we and Janssen entered into an exclusive license and collaboration agreement for the clinical development, manufacture and potential commercialization of PTG-200 and certain related compounds worldwide for the treatment of CD and UC (the &#8220;Janssen License and Collaboration Agreement&#8221;). The Janssen License and Collaboration Agreement became effective on July 13, 2017 and was subsequently amended effective May 2019 (the &#8220;First Amendment&#8221;). The First Amendment expands the original collaboration by supporting efforts towards research and development of second-generation IL-23R antagonists. During the third quarter of 2017, we received a non-</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">refundable, upfront cash payment of $50.0 million from Janssen. During the second quarter of 2019, we received a non-refundable cash payment of $25.0 million upon execution of the First Amendment. During the first quarter of 2020, we received a milestone payment of $5.0 million triggered by the identification and nomination of a second-generation development candidate. See &#8220;Item 7. Management&#8217;s Discussion and Analysis &#8211; Overview&#8221; and Note 3 to the Consolidated Financial Statements included elsewhere in this Annual Report on Form 10-K for additional information. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;">Research Collaboration and License Agreement with Zealand Pharma A/S<span style="font-weight:bold;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">In June&#160;2012, we entered into a Research Collaboration and License Agreement with Zealand Pharma A/S (&#8220;Zealand&#8221;) to identify, optimize and develop novel disulfide-rich peptides to discover a hepcidin mimetic. We amended this agreement on February 28, 2014, at which point Protagonist assumed responsibility for the development program. See &#8220;Item 3. Legal Proceedings&#8221;, &#8220;Item 7. Management&#8217;s Discussion and Analysis &#8211; Contractual Obligations and Other Commitments&#8221; and Note 7 and Note 11 to the Consolidated Financial Statements included elsewhere in this Annual Report on Form 10-K for additional information. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Competition </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt 0pt 12pt 0pt;">The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. While we believe that our product candidates, technology, knowledge and experience provide us with certain competitive advantages, we face competition from established and emerging pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions, among others. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Ruxolitinib, marketed as Jakafi&#174;, is currently the only branded product in the United States approved for PV. O<span style="background-color:#ffffff;color:#121212;">n June 4, 2020, the FDA accepted a Biologics License Application for ropeginterferon alfa-2b for use in treatment for patients with PV in the absence of symptomatic splenomegaly from PharmaEssentia Corporation, the manufacturer of the novel pegylated interferon. A decision from the FDA on this application is expected in early 2021.</span><span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">There are currently no approved orally delivered peptide-based &#945;4&#946;7 or IL-23R products for IBD. We believe our principal competition in the treatment of IBD will come from companies with injectable agents in the anti-integrin class that are or will be approved by 2028, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:65.5pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Takeda&#8217;s vedolizumab (Entyvio&#174;) IV and SC; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:65.5pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Abbvie&#8217;s risankizumab (Skyrizi&#174;) SC (UC and CD Phase 3).</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In addition, orally delivered agents with novel mechanisms of action are approved or in development and may be approved for UC and/or CD prior to the launch of our product candidates. These include JAK inhibitors, pan-JAK tofacitinib (Xeljanz&#174;) approved in UC and next-generation JAK1 inhibitors filgotinib and upadacitinib, as well as S1P inhibitors, ozanimod, amiselmod and etrasimod. The anti-IL-23 antibodies are also demonstrating positive data in IBD. Our assets PTG-200, PN-235 and PN-232, if approved, will compete as the only orally delivered IL-23R antagonists.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Intellectual Property </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We strive to protect and enhance the proprietary technology, inventions, and improvements that are commercially important to the development of our business, including seeking, maintaining, and defending patent rights, whether developed internally or licensed from third parties. We also rely on trade secrets relating to our proprietary technology platform and on know-how, and continuing technological innovation to develop, strengthen, and maintain our proprietary position in the field of peptide-based therapeutics that may be important for the development of our business. We will also take advantage of regulatory protection afforded through data exclusivity, market exclusivity and patent term extensions where available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">Our commercial success may depend in part on our ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions and know-how related to our business; defend and enforce </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">our patents; preserve the confidentiality of our trade secrets; and operate without infringing the valid enforceable patents and proprietary rights of third parties. Our ability to stop third parties from making, using, selling, offering to sell or importing our products may depend on the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities. We cannot be sure that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications filed by us in the future, nor can we be sure that any of our existing patents or any patents that may be granted to us in the future will be commercially useful in protecting our commercial products and methods of manufacturing the same. For more information, please see &#8220;Item&#160;1A. Risk Factors&#8212;Risks Related to Our Intellectual Property.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We own or co-own 20 issued U.S. patents, over 35 granted ex-U.S. patents, and numerous U.S. and ex-U.S. patent applications related to our clinical assets. We possess substantial know-how and trade secrets relating to the development and commercialization of peptide based therapeutic products. Our proprietary intellectual property, including patent and non-patent intellectual property, is generally directed to, for example, peptide-based therapeutic compositions, methods of using these peptide-based therapeutic compositions to treat or prevent disease, methods of manufacturing peptide-based therapeutic compositions, and other proprietary technologies and processes related to our lead product development candidates. Specific patents and patent applications are directed to compositions of &#945;<i style="font-style:italic;">4</i>&#946;7 integrin peptides, IL-23R antagonist peptides, and hepcidin and enkephalin mimetics peptides, as well as methods of synthesizing and using these peptides to treat inflammatory disorders. Applications are currently pending in the United States and other major jurisdictions, including Australia, Canada, China, Japan, and Europe. We expect our patents and patent applications, if issued, and if the appropriate maintenance, renewal, annuity, or other governmental fees are paid, to expire from October&#160;2033 to July 2041 (excluding possible patent term extensions).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Our objective is to continue to expand our portfolio of patents and patent applications in order to protect our clinical assets and related peptide-based drug technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We also license patents and patent applications directed to processes and methods related to our technology platform. These patents have issued in the United States and other major jurisdictions, including Australia and Europe. Some licensed patents are expired, and others are expected to expire before or by February 2023. Material aspects of our technology platform are protected by trade secrets and confidentiality agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">In addition to the above, we have established expertise and development capabilities focused in the areas of pre-clinical research and development, manufacturing and manufacturing process scale-up, quality control, quality assurance, regulatory affairs and clinical trial design and implementation. We believe that our focus and expertise will help us develop products based on our proprietary intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, the patent term is 20&#160;years from the date of filing the non-provisional application. In the United States, a patent&#8217;s term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the U.S. Patent and Trademark Office in granting a patent or may be shortened if a patent is terminally disclaimed over an earlier-filed patent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The term of a patent that covers an FDA approved drug may also be eligible for patent term extension, which permits patent term restoration of a U.S. patent as compensation for the patent term lost during the FDA regulatory review process. The Hatch-Waxman Act permits a patent term extension of up to five&#160;years beyond the expiration of the patent. The length of the patent term extension is related to the length of time the drug is under regulatory review. A patent term extension cannot extend the remaining term of a patent beyond a total of 14&#160;years from the date of product approval and only one patent applicable to an approved drug may be extended. Moreover, a patent can only be extended once, and thus, if a single patent is applicable to multiple products, it can only be extended based on one product. Similar provisions are available in Europe and other foreign jurisdictions to extend the term of a patent that covers an approved drug. When possible, we expect to apply for patent term extensions for patents covering our product candidates and their methods of use.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Trade Secrets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We rely on trade secrets to protect certain aspects of our technology, particularly in relation to our technology platform. However, trade secrets can be difficult to protect. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our consultants, contractors or collaborators use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions. For more information, please see &#8220;Item&#160;1A. Risk Factors&#8212;Risks Related to Our Intellectual Property.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:2pt 0pt 0pt 0pt;"><b style="font-style:normal;font-weight:bold;">Manufacturing </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We contract with third parties for the manufacturing of our product candidates for pre-clinical and clinical studies and eventually for commercial supplies, and intend to continue to do so in the future. We do not own or operate any manufacturing facilities and we have no plans to build any owned clinical or commercial scale manufacturing capabilities. We believe that the use of contract manufacturing organizations (&#8220;CMOs&#8221;) eliminates the need for us to directly invest in manufacturing facilities, equipment and additional staff. We have established a global supply chain for raw material, active pharmaceutical ingredients (&#8220;API&#8221;), drug product manufacturing and distribution. We work with contract manufacturers in the United States, Europe and Asia. Although we rely on contract manufacturers, our personnel and consultants have extensive manufacturing and quality control experience overseeing CMOs. We regularly consider second source or back-up manufacturers for both API and drug product manufacturing. To date, our third-party manufacturers have met the manufacturing requirements for our product candidates. We expect third-party manufacturers to be capable of providing needed quantities of our product candidates to meet anticipated full-scale commercial demands, and we have selected CMOs that can manufacture our product candidates for our ongoing and planned clinical trials as well as commercial supplies. We currently engage CMOs on a &#8220;fee for services&#8221; basis for our current development and clinical supplies. We believe there are alternate sources of manufacturing that have been and could be engaged and enabled to satisfy our clinical and commercial requirements, however we cannot guarantee that identifying and establishing alternative relationships with such sources will be successful, cost effective, or completed on a timely basis without significant delay in the development or commercialization of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:2pt 0pt 0pt 0pt;"><b style="font-style:normal;font-weight:bold;">Government Regulation</b><span style="font-weight:bold;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The FDA and comparable regulatory authorities in state and local jurisdictions and in other countries impose substantial requirements upon companies involved in the clinical development, manufacture, marketing and distribution of drugs, such as those we are developing. These agencies and other federal, state and local entities regulate, among other things, the research and development, testing, manufacture, quality control, safety, effectiveness, labeling, storage, record keeping, approval, advertising and promotion, distribution, post-approval monitoring and reporting, sampling and export and import of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:2pt 0pt 0pt 0pt;">U.S. Government Regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;) and its implementing regulations. The process of obtaining regulatory approvals and the compliance with applicable federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA&#8217;s refusal to approve pending new drug applications (&#8220;NDAs&#8221;), withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The process required by the FDA before a drug may be marketed in the United States generally involves the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">completion of pre-clinical laboratory tests, animal studies and formulation studies in compliance with the FDA&#8217;s good laboratory practices regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">submission to the FDA of an IND application, which must become effective before human clinical trials may begin;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">approval by an independent institutional review board (&#8220;IRB&#8221;) at each clinical site before each trial may be initiated;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">performance of adequate and well-controlled human clinical trials in accordance with good clinical practice (&#8220;GCP&#8221;) requirements to establish the safety and efficacy of the proposed drug product for each indication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">submission to the FDA of an NDA (or Biologics License Application (&#8220;BLA&#8221;) for a biologic product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">satisfactory completion of an FDA advisory committee review, if applicable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with current good manufacturing practices (&#8220;cGMP&#8221;) requirements and to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">satisfactory completion of an FDA inspection of one or more clinical trial sites to assure compliance with GCP requirements and the clinical protocol; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">FDA review and approval of the NDA.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:2pt 0pt 0pt 0pt;">Pre-clinical Studies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Pre-clinical studies include laboratory evaluation of product chemistry, toxicity and formulation, as well as animal studies to assess potential safety and efficacy. An IND sponsor must submit the results of the pre-clinical tests, together with manufacturing information, analytical data and any available clinical data or literature, among other things, to the FDA as part of an IND. Some pre-clinical testing may continue even after the IND is submitted. An IND automatically becomes effective 30&#160;days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:2pt 0pt 0pt 0pt;">Clinical Trials</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Clinical trials involve the administration of the investigational new drug to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent in writing before their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND (or equivalent submission ex-US). In addition, an IRB or ethics committee (&#8220;EC&#8221;) must review and approve the plan for any clinical trial at each institution participating in the clinical trial before it commences at that site. Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health (&#8220;NIH&#8221;) for public dissemination on their www.clinicaltrials.gov website.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Phase 1: The drug is initially introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Phase 2: The drug is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the investigational drug product for specific targeted diseases and to determine dosage tolerance and optimal dosage.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Phase 3: The drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate labeling information (labeling) for the safe and efficacious administration for the labeling of the product.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB or EC can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:2pt 0pt 0pt 0pt;">Marketing Approval</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Assuming successful completion of the required clinical testing, the results of the pre-clinical and clinical studies, together with detailed information relating to the product&#8217;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the product for one or more indications. In most cases, the submission of an NDA is subject to a substantial application user fee. Under the Prescription Drug User Fee Act (&#8220;PDUFA&#8221;) guidelines that are currently in effect, the FDA has a goal of ten&#160;months from the date of &#8220;filing&#8221; of a standard NDA for a new molecular entity to review and act on the submission. This review typically takes twelve&#160;months from the date the NDA is submitted to FDA because the FDA has approximately two&#160;months to make a &#8220;filing&#8221; decision.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">In addition, under the Pediatric Research Equity Act of 2003 (&#8220;PREA&#8221;), as amended and reauthorized, certain NDAs or supplements to an NDA must contain data that are adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The FDA also may require submission of a risk evaluation and mitigation strategy (&#8220;REMS&#8221;) plan to ensure that the benefits of the drug outweigh its risks. The REMS plan could include medication guides, physician communication plans, assessment plans, and/or elements to assure safe use, such as restricted distribution methods, patient registries, or other risk minimization tools.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">The FDA conducts a preliminary review of all NDAs within the first 60&#160;days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA reviews an NDA to determine, among other things, whether the drug is safe and effective and whether the facility in which it is </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">manufactured, processed, packaged or held meets standards designed to assure the product&#8217;s continued safety, quality and purity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">After evaluating the NDA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a complete response letter. A complete response letter generally contains a statement of specific conditions that must be met in order to secure final approval of the NDA and may require additional clinical or pre-clinical testing in order for FDA to reconsider the application. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#8217;s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Even if the FDA approves a product, it may limit the approved indications for use of the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess a drug&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Fast Track Designation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt;">The FDA has various programs, including fast track designation, which are intended to expedite or simplify the process for the development and FDA review of drugs that are intended for the treatment of serious or life threatening diseases or conditions and demonstrate the potential to address unmet medical needs. The purpose of these programs is to provide important new drugs to patients earlier than under standard FDA review procedures. Under the fast track program, the sponsor of a new drug candidate may request that the FDA designate the drug candidate for a specific indication as a fast track drug concurrent with, or after, the filing of the IND for the drug candidate. To be eligible for a fast track designation, the FDA must determine, based on the request of a sponsor, that a product is intended to treat a serious or life threatening disease or condition and demonstrates the potential to address an unmet medical need. The FDA will determine that a product will fill an unmet medical need if it will provide a therapy where none exists or provide a therapy that may be potentially superior to existing therapy based on efficacy or safety factors. Fast track designation provides additional opportunities for interaction with the FDA&#8217;s review team and may allow for rolling review of NDA components before the completed application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA. However, the FDA&#8217;s time period goal for reviewing an application does not begin until the last section of the NDA is submitted. The FDA may decide to rescind the fast track designation if it determines that the qualifying criteria no longer apply.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:2pt 0pt 0pt 0pt;">Orphan Designation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The FDA may grant orphan designation to drugs or biologics intended to treat a rare disease or condition that affects fewer than 200,000 individuals in the United States, or if it affects more than 200,000 individuals in the United States, and there is no reasonable expectation that the cost of developing and marketing the product for this type of disease or condition will be recovered from sales in the United States.&#160;Orphan designation must be requested before submitting an NDA or BLA. After the FDA grants orphan designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">In the United States, orphan designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. In addition, if a product receives the first FDA approval for the indication for which it has orphan designation, the product is entitled to orphan exclusivity, which means the FDA may not approve any other application to market the same product for the same indication for a period of seven&#160;years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity or where the manufacturer with orphan exclusivity is unable to assure sufficient quantities of the approved orphan designated product. Competitors, however, may receive approval of different products for the indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication for which the orphan product has exclusivity. Orphan product exclusivity also could block the approval of one of our products for seven&#160;years if a competitor obtains approval of the same product as defined by the FDA or if our product candidate is determined to be contained within the competitor&#8217;s product for the same indication or disease. If a drug or biological product designated as an orphan product receives marketing approval for an indication broader than what is designated, it may not be entitled to orphan product exclusivity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:2pt 0pt 0pt 0pt;">Post-Approval Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual program user fee requirements for any marketed products, as well as application fees for supplemental applications with clinical data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">risks; or imposition of distribution or other restrictions under an REMS program. Other potential consequences include, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">fines, warning letters or holds on post-approval clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">product seizure or detention, or refusal to permit the import or export of products; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved prescribing information. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:2pt 0pt 0pt 0pt;">Coverage and Reimbursement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Sales of our product candidates, if approved, will depend, in part, on the extent to which the cost of such products will be covered and adequately reimbursed by third-party payors, such as government healthcare programs, commercial insurance and managed health care organizations. These third-party payors are increasingly limiting coverage and/or reducing reimbursements for medical products and services by challenging the prices and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. If these third-party payors do not consider our products to be cost-effective compared to other therapies, they may not cover our products after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our products on a profitable basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:23.75pt;margin:0pt;">There is no uniform policy requirement for coverage and reimbursement for drug products among third-party payors in the United States. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor.&#160;The coverage determination process can be a time-consuming and costly process that may require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained or applied consistently. Even if reimbursement is provided, market acceptance of our products may be adversely affected if the amount of payment for our products proves to be unprofitable for health care providers or less profitable than alternative treatments, or if administrative burdens make our products less desirable to use.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:23.75pt;margin:0pt;">In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products.&#160;Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net revenue and results. Decreases in third-party reimbursement for our product candidates or a decision by a third-party payor to not cover our product candidates could reduce physician usage of our products candidates, once approved, and have a material adverse effect on our sales, results of operations and financial condition.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, collectively referred to as the ACA, enacted in March&#160;2010, has had and is expected to continue to have a significant impact on the health care industry. The ACA, among other things, imposes a significant annual fee on certain companies that manufacture or import branded prescription drug products. The ACA also increased the Medicaid rebate rate and expanded the rebate program to include Medicaid managed care organizations. It also contains substantial new </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">provisions intended to broaden access to health insurance, reduce or constrain the growth of health care spending, enhance remedies against health care fraud and abuse, add new transparency requirements for the health care industry, impose new taxes and fees on pharmaceutical manufacturers, and impose additional health policy reforms, any or all of which may affect our business. </p><a id="_Hlk63619061"></a><a id="_Hlk63412788"></a><a id="_Hlk64231966"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">There have been executive, judicial and Congressional challenges to certain aspects of the ACA. For example, President Trump signed several Executive Orders and other directives designed to delay the implementation of certain requirements mandated by the ACA or otherwise circumvent some of the requirements for health insurance mandated by the ACA. Concurrently, Congress considered legislation to repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, several bills affecting the implementation of certain taxes under the ACA have been enacted. The Tax Cuts and Jobs Act of 2017, or the Tax Act, included a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year. Additionally, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the ACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and the medical device tax and, effective January 1, 2021, also eliminated the health insurance tax. Further, the Bipartisan Budget Act of 2018, or the BBA, among other things, amends the ACA, effective January 1, 2019, to close the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole&#8221;, and increase from 50% to 70% the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in the Medicare Part D program. On December 14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress as part of the Tax Act. Additionally, on December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. The U.S. Supreme Court is currently reviewing this case, but it is unclear when a decision will be made. Although the U.S. Supreme Court has not yet ruled on the constitutionality of the ACA, on January 28, 2021, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021 through May 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructs certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how the Supreme Court ruling, other such legislation and the healthcare reform measures of the Biden administration will impact the ACA and our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. These changes included aggregate reductions to Medicare payments to providers of 2% per fiscal year, which went into effect in April 2013 and, due to subsequent legislative amendments to the statute, including the BBA, will remain in effect through 2030 unless additional action is taken by Congress. However, COVID-19 relief legislation suspended the 2% Medicare sequester from May 1, 2020 through March 31, 2021. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers and increased the statute of limitations period in which the government may recover overpayments to providers from three to five years. New laws may result in additional reductions in Medicare and other health care funding.</p><a id="_Hlk64229735"></a><a id="_Hlk64470271"></a><a id="_Hlk64540183"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">Further, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products. Such scrutiny has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For example, on July 24, 2020 and September 13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that attempt to implement several of the administration&#8217;s proposals The FDA also released a final rule, effective November 30, 2020, implementing a portion of the importation executive order providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November&#160;20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part&#160;D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January 1, 2022 to January 1, 2023 in </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed pending review by the Biden administration until March 22, 2021. On November 20, 2020, the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) issued an interim final rule implementing President Trump&#8217;s Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. On December 28, 2020, the United States District Court in Northern California issued a nationwide preliminary injunction against implementation of the interim final rule. At the state level, legislatures have become increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We expect that additional state and federal healthcare reform measures will be adopted in the future, particularly in light of the new presidential administration, any of which could limit the amounts that federal and state governments will pay for healthcare therapies. Further, it is possible that additional governmental action is taken in response to the COVID-19 pandemic. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">It is uncertain whether and how future legislation, whether domestic or foreign, could affect prospects for our product candidates or what actions foreign, federal, state, or private payors for health care treatment and services may take in response to any such health care reform proposals or legislation. Adoption of price controls and other cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures reforms may prevent or limit our ability to generate revenue, attain profitability or commercialize our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:2pt 0pt 0pt 0pt;">Other Health Care Laws and Compliance Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We will also be subject to health care regulation and enforcement by the federal government and the states and foreign governments in which we will conduct our business once our products are approved. The laws that may affect our ability to operate include, but are not limited to, the federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), as amended by the Health Information Technology for Economic and Clinical Health Act, which governs the conduct of certain electronic health care transactions and protects the security and privacy of protected health information; the criminal health care fraud statutes under HIPAA also prohibits persons and entities from knowingly and willfully executing a scheme to defraud any health care benefit program, including private payors, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for health care benefits, items or services; the federal health care programs&#8217; Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal health care programs such as the Medicare and Medicaid programs; federal false claims laws and civil monetary penalties laws that prohibit, among other things, any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to have a false claim paid; and the Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid, or Children&#8217;s Health Insurance Program to report annually to the HHS information related to payments and other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, and ownership and investment interests held by physicians and their immediate family members and, beginning in 2022, applicable manufacturers also will be required to report such information regarding payments and transfers of value provided during the previous year to physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified nurse anesthetists and certified nurse-midwives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">The majority of states also have statutes or regulations similar to the aforementioned federal anti-kickback and false claims laws, which apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor. We may be subject to state laws governing the privacy and security of health </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. In addition, we may be subject to reporting requirements under state transparency laws, as well as state laws that require pharmaceutical companies to comply with the industry&#8217;s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government that otherwise restricts certain payments that may be made to health care providers and entities. In addition, certain states and local jurisdictions require the registration of pharmaceutical sales representatives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Because of the breadth of these laws and the narrowness of available statutory and regulatory exceptions, it is possible that some of our business activities could be subject to challenge under one or more of such laws. If we or our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including significant administrative, civil and criminal penalties, damages, fines, imprisonment, disgorgement, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, exclusion of products from reimbursement under U.S. federal or state health care programs, and the curtailment or restructuring of our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:2pt 0pt 0pt 0pt;">Government Regulation Outside of the United States </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">In addition to regulations in the United States, we will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical studies and any commercial sales and distribution of our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical studies or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission and approval of a clinical trial application much like the IND but specific to a clinical trial prior to the commencement of the human clinical study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The requirements and process governing the conduct of clinical studies, the protection of personal data, product licensing, pricing and reimbursement vary from country to country. If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:12pt 0pt 0pt 0pt;">Human Capital </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2020, we had 79 full-time equivalent employees, 59 of whom were in research and development, of which one holds an M.D. and 19 hold Ph.D. degrees. The remaining 20 employees worked in finance, legal, business development, human resources and administrative support, of which three hold a Ph.D. 72 of our full-time equivalent employees are located in the United States and seven are located in Australia. None of our employees are represented by a labor union or covered by a collective bargaining agreement. We consider our relationship with our employees to be good. We track and report internally on key talent metrics including workforce demographics, diversity data and the status of open positions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Attracting, developing and retaining talented employees to support the growth of our business is an integral part of our human capital strategy and critical to our success. We continue to seek additions to our staff, although the competition in our industry and in the San Francisco Bay Area where our headquarters is located is significant. We have a performance development review process in which managers provide regular feedback to assist with the development of our employees, including the use of individual plans to assist with career development. The principal purpose of our equity incentive and annual bonus programs is to attract, retain and motivate personnel through the granting of stock-based compensation awards and cash-based performance bonus awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.5pt;margin:0pt;">Safeguarding the health and safety of our employees is our top priority. We are committed to providing a safe working environment for all of our employees. In response to the COVID-19 pandemic, we implemented significant changes that we determined were in the best interest of our employees, as well as the communities in which we operate, and which comply with government regulations. This includes having our non-laboratory employees work remotely at </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">least part-time, while implementing additional safety measures for laboratory and other employees continuing critical on-site work. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:12pt 0pt 0pt 0pt;">Corporate and Other Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Protagonist Pty Limited (&#8220;Protagonist Australia&#8221;) was incorporated in Australia in September&#160;2001. We were incorporated as a Delaware corporation in 2006, under the name Protagonist Therapeutics,&#160;Inc., and became the parent of Protagonist Australia pursuant to a transaction in which all of the issued and outstanding capital stock of Protagonist Australia was exchanged for shares of our common stock and Series&#160;A preferred stock. Our principal executive offices are located at 7707 Gateway Boulevard, Suite 140, Newark, California 94560. Our telephone number is (510)&#160;474-0170. Our website address is www.protagonist-inc.com. References to our website address do not constitute incorporation by reference of the information contained on the website, and the information contained on the website is not part of this document.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We make available, free of charge on our corporate website, copies of our Annual Reports on Form&#160;10-K, Quarterly Reports on Form&#160;10-Q, Current Reports on Form&#160;8-K, Proxy Statements, and all amendments to these reports, as soon as reasonably practicable after such material is electronically filed with or furnished to the Securities and Exchange Commission (&#8220;SEC&#8221;) pursuant to Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934, as amended (&#8220;Exchange Act&#8221;). We also show detail about stock trading by corporate insiders by providing access to SEC Forms 3, 4 and 5. This information may also be obtained from the SEC&#8217;s on-line database, which is located at www.sec.gov. Our common stock is traded on the Nasdaq Stock Market under the symbol &#8220;PTGX.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012. As such, we are eligible for exemptions from various reporting requirements applicable to other public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002 and reduced disclosure obligations regarding executive compensation. We will remain an emerging growth company until December&#160;31, 2021. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_801dd19d_50e6_4995_b682_3f6308f00669"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Item1ARiskFactors_756902"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> </span><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item&#160;1A.</b></span>Risk Factors </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We have identified the following risks and uncertainties that may have a material adverse effect on our business, financial condition or results of operations. Investors should carefully consider the risks described below before making an investment decision. Our business faces significant risks and the risks described below may not be the only risks we face. If any of these risks occur, our business, results of operations or financial condition could suffer, and the market price of our common stock could decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to the COVID-19 Pandemic </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The COVID-19 pandemic has and could continue to adversely impact our business, including our ongoing and planned clinical trials and preclinical and discovery research.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The extent to which the COVID-19 pandemic will continue to impact our business is uncertain and cannot be predicted.  The pandemic&#8217;s impact on our business will depend on a variety of factors, including the timing, extent, effectiveness and durability of vaccine programs or other treatments, new or continuing travel and other restrictions public health measures,&#160;such as social distancing, business closures or disruptions. The effectiveness of actions taken in the United States and other countries to contain, ameliorate the impact of and treat the disease and to address its impact, is not yet known. A number of jurisdictions, including California and other jurisdictions in the United States, have at various times begun re-opening only to return to restrictions in the face of increases in new COVID-19 cases. As the COVID-19 pandemic continues, we could experience additional disruptions or increased expenses that may adversely impact our business, including: </span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">delays or difficulties in enrolling patients in our ongoing clinical trials and our future clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff, or maintaining ongoing operations at such sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others or interruption of clinical trial subject visits and study procedures, which may impact the integrity of subject data and clinical study endpoints;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">limitations in resources, including our employees, that would otherwise be focused on the conduct of our business or our current or planned clinical trials or preclinical research, including because of sickness, the desire to avoid contact with large groups of people or restrictions on movement or access to our facility as a result of government-imposed &#8220;shelter-in-place&#8221; or similar working restrictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">interruptions or delays in the operations of the U.S. Food and Drug Administration (&#8220;FDA&#8221;) or other regulatory authorities, which may impact review and approval timelines;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">delays in manufacturing, receiving the supplies, materials and services needed to conduct clinical trials and preclinical research;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">changes in regulations as part of a response to the COVID-19 pandemic which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs or require us to discontinue the clinical trial altogether; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">delays in necessary interactions with regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or furloughs of government or contractor personnel. </span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In addition, since March 2020, Alameda County, California, where our headquarters are located, has been subject to various &#8220;shelter-in-place&#8221; regulations and guidance related to the pandemic.  Our laboratory facilities currently remain open for research activities that cannot be conducted remotely, with heightened safety </span>measures designed to minimize occupational exposure and reduce transmission of COVID-19 within our workplace. Our non-laboratory employees telecommute at least part-time, which may impact certain of our operations over the near term and long term. In addition, we may in the future resume a more restrictive remote work model due to the pandemic. These disruptions in our operations could negatively impact our business, operating results and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Further, we may be required to develop and implement additional clinical study policies and procedures designed to help protect study participants from the COVID-19 virus, which may include using telemedicine visits, remote monitoring of patients and clinical sites, shipping drug product directly to patients rather than clinical sites, and measures to ensure that clinical data are collected pursuant to the study protocol and consistent with good clinical practices (GCPs). Patients who miss scheduled appointments, any interruption in study drug supply, or other consequence that may result in incomplete data being generated during a study as a result of the pandemic must be adequately documented and justified in accordance with FDA guidance. These additional requirements may be difficult to fulfill and may result in an incomplete data set, which could negatively impact the study results. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">While the extent of the impact of the COVID-19 pandemic on our business and financial results is uncertain, a continued and prolonged public health crisis such as the COVID-19 pandemic could have a material negative impact on our business, financial condition, and operating results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Clinical Development </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are a clinical-stage biopharmaceutical company with no approved products and no historical product revenue, which makes it difficult to assess our future prospects and financial results.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We are a clinical-stage biopharmaceutical company with a limited operating history as a publicly traded company. Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of uncertainty. Our operations to date have been limited to developing our technology, undertaking pre-clinical studies and Phase 1 and Phase 2 clinical trials of our pipeline candidates and conducting research to identify additional product candidates. We are planning to discuss our pivotal registration program for rusfertide for PV with regulatory agencies in the first half of 2021. However, we have not yet successfully developed an approved product or generated revenue from product sales or successfully conducted a pivotal registration trial for one of our product candidates. Consequently, the ability to accurately assess our future operating results or business prospects is significantly more limited than if we had a longer operating history or approved products on the market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We expect that our financial condition and operating results will fluctuate significantly from period to period due to a variety of factors, many of which are beyond our control, including the success of our programs, decisions by regulatory bodies, actions taken by competitors and other factors identified in these risk factors. Accordingly, the likelihood of our success must be evaluated in light of many potential challenges and variables associated with a clinical-stage biopharmaceutical company, many of which are outside of our control, and past results, including operating or financial results, should not be relied on as an indication of future results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are heavily dependent on the success of our product candidates in clinical development, and if any of these products fail to receive regulatory approval or are not successfully commercialized, our business would be adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">We currently have no product candidates that are in registrational or pivotal clinical trials or are approved for commercial sale, and we may never develop a marketable product. We expect that a substantial portion of our efforts and expenditures over the next few years will be devoted to our current product candidates and the development of other product candidates. We cannot be certain that our product candidates will receive regulatory approval or, if approved, be successfully commercialized. The research, testing, manufacturing, labeling, approval, sale, marketing and distribution of our product candidates will be subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries. In addition, even if approved, our pricing and reimbursement will be subject to further </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">review and discussions with payors. We are not permitted to market any product candidate in the United States until after approval of a new drug application (&#8220;NDA&#8221;) from the FDA, or in any foreign countries until approval by corresponding regulatory authorities. We will need to conduct larger, more extensive clinical trials in the target patient populations to support a potential application for regulatory approval by the FDA or corresponding regulatory authorities. Those trials, for rusfertide for PV or subsequent late-stage product candidates, may not demonstrate the safety and efficacy of our product candidates to support a marketing approval in the United States or other jurisdictions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Our product candidates require additional clinical development, regulatory approval and secure sources of commercial manufacturing supply. We cannot assure you that our clinical trials for our product candidates will be initiated or completed in a timely manner or successfully, or at all. Further we cannot be certain that we plan to advance any other product candidates into clinical trials. Moreover, any delay or setback in the development of any product candidate would be expected to adversely affect our business and cause our stock price to fall. For example, the announcement of the premature discontinuation of the global Phase 2 clinical trial of PTG-100 for the treatment of moderate-to-severe UC in March 2018 due to the interim analysis meeting futility criteria on the primary endpoint of clinical remission (that was subsequently confirmed to be due to human error in endoscopy reads by the original vendor) significantly depressed our stock price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Clinical development is a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results. Clinical failure can occur at any stage of clinical development.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical development process. The results of pre-clinical studies and early clinical trials of our product candidates and studies and trials of other products may not be predictive of the results of later-stage clinical trials. Any hypothesis formed from pre-clinical or early clinical observations for any of our product candidates may prove to be incorrect, and the data generated in animal models or observed in limited patient populations may be of limited value and may not be applicable in clinical trials conducted under the controlled conditions required by applicable regulatory requirements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">In addition to our planned pre-clinical studies and clinical trials, we expect to have to complete one or more large scale, well-controlled clinical trials to demonstrate substantial evidence of efficacy and safety for each product candidate we intend to commercialize. Further, given the patient populations for which we are developing therapeutics, we expect to have to evaluate long-term exposure to establish the safety of our therapeutics in a chronic-dose setting. We have never conducted a Phase 3 clinical trial or submitted an NDA. As a result, we have no history or track record to rely on when entering these phases of the development cycle. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through pre-clinical studies and initial clinical trials. Clinical trial failures may result from a multitude of factors including, but not limited to, flaws in trial design, dose selection, placebo effect, patient enrollment criteria and failure to demonstrate favorable safety and/or efficacy traits of the product candidate. Based upon negative or inconclusive results, we may decide, or regulators may require us, to conduct additional clinical trials or pre-clinical studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We may experience delays in ongoing clinical trials, and we do not know whether planned clinical trials will begin on time, need to be redesigned, enroll patients on time or be completed on schedule, if at all. Clinical trials can be delayed for a variety of reasons, including if a clinical trial is modified, suspended or terminated by us, by the IRBs or ECs of the institutions in which such clinical trials are being conducted, by a Data Safety Monitoring Board, for such trial or by the FDA or other regulatory authorities. Such authorities may impose a modification, suspension or termination due to a number of factors. In addition, there are a significant number of global clinical trials in IBD and in hematologic disorders that are currently ongoing, especially in Phases 2 and 3, making it highly competitive and challenging to recruit subjects. Furthermore, any negative results we may report in clinical trials of our product candidates, such as the premature termination of our Phase 2 clinical trial of PTG-100 for the treatment of moderate-to-severe UC, may make it difficult or impossible to recruit and retain patients in other clinical trials of that same product candidate. Delays or failures in planned patient enrollment or retention may result in increased costs, program delays or both. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">If we experience material delays in the completion of any clinical trial, the reduction in remaining patent term would harm the commercial prospects for that product candidate and our ability to generate product revenue from any of these product candidates will be delayed. Any of these occurrences may harm our business, financial condition and prospects significantly. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">All of our product candidates other than rusfertide, PTG-200, PN-235, PN-943 and PTG-100 are in research or pre-clinical development and have not entered into clinical trials. If we are unable to develop, test and commercialize our product candidates, our business will be adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">As part of our strategy, we seek to discover, develop and commercialize new product candidates in addition to rusfertide, PTG-200, PN-235, PN-943 and PTG-100. Research programs to identify appropriate biological targets, pathways and product candidates require substantial scientific, technical, financial and human resources, whether or not any product candidates are ultimately identified. Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for many reasons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our proprietary peptide platform may not result in any products of commercial value.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">We have developed a proprietary peptide technology platform to enable the identification, testing, design and development of new product candidates. Our peptide platform may not yield additional product candidates that enter clinical development and, ultimately, become commercially valuable. Although we expect to continue to enhance the capabilities of our platform by developing and integrating existing and new research technologies, our enhancement and development efforts may not succeed.  As a result, we may not be able to advance our drug discovery capabilities as quickly as we expect or identify as many potential drug candidates as we desire.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our product candidates may cause undesirable side effects or have other properties adversely impacting safety that delay or prevent their regulatory approval, restrict their approved labeling, or otherwise limit their commercial opportunity.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">If undesirable side effects or adverse events are caused by our product candidates or by other companies&#8217; similar approved drugs or product candidates, then we may elect to, or be required by an independent data monitoring committee or regulatory authorities to, delay or halt our clinical trials. If such side effects or adverse events are sufficiently severe or prevalent, the FDA or comparable foreign regulatory authorities could order us to suspend or cease altogether further development of our product candidates. Even if our product candidates are approved, side effects or adverse events could result in significant delay in or denial of, regulatory approval, restrictive labeling, or potential product liability claims. Moreover, since our product candidate PN-943 and the product candidates under development in our collaboration with Janssen are in development for indications for which injectable antibody drugs have been approved, clinical trials for those product candidates may need to show a risk/benefit profile that is competitive with those existing products in order to obtain regulatory approval or, if approved, a product label that is favorable for commercialization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have focused our limited resources to pursue particular product candidates and indications, and consequently, we may fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Because we have limited financial and managerial resources, we have focused on research programs and product candidates mainly on the development of rusfertide, PN-943 and the product candidates developed in our Janssen collaboration. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration partnerships, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Financial Position and Capital Requirements </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have incurred significant losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future. We have never generated any revenue from product sales and may never be profitable.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">We have incurred significant operating losses every year since inception and expect to continue to incur operating losses for the foreseeable future. As of December 31, 2020, we had an accumulated deficit of $283.8 million.  We expect to continue to incur significant research, development and other expenses related to our ongoing operations and product development. As a result, we expect to continue to incur losses in the future as we continue our development of, and seek regulatory approvals for, our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We do not anticipate generating revenue from sales of products for at least several years, if ever, and we do not yet have any product candidates in registration or pivotal clinical trials. If any of our product candidates fail in clinical trials or do not gain regulatory approval or fail to achieve market acceptance, we may never become profitable. Revenue we generate from our collaboration with Janssen and any future collaboration arrangements may not be sufficient to sustain our operations. Failure to become and remain profitable may adversely affect the market price of our common stock and our ability to raise capital and continue operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We expect to require substantial additional funding, which may not be available to us on acceptable terms, or at all. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Our operations have consumed substantial amounts of cash since inception. Developing pharmaceutical product candidates, including conducting pre-clinical studies and clinical trials, is expensive. We expect to require substantial additional future capital in order to complete clinical development and, if we are successful, to commercialize any of our current product candidates. Further, in the event our Janssen License and Collaboration Agreement is terminated, we may not receive any additional fees or milestone payments under that agreement. Absent the funding support from this agreement, our further development of the collaboration product candidates would require significant additional capital from us, or the establishment of alternative collaborations with third parties, which may not be possible.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2020, we had cash, cash equivalents and marketable securities of $307.8 million. Based upon our current operating plan and expected expenditures, we believe that our existing cash, cash equivalents, and marketable securities and proceeds from our debt facility will be sufficient to fund our operations for at least the next 12 months. However, we expect that we will need to have access substantial additional funds in the future in order to complete clinical development or commercialize our product candidates to a point where we can operate profitability. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our product candidates or technologies. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We may seek additional funding through a combination of equity offerings, debt financings, collaborations and/or licensing arrangements. Additional funding may not be available to us on acceptable terms, or at all. Our ability to raise additional capital may be adversely impacted by adverse economic conditions and market volatility. The incurrence of indebtedness and/or the issuance of certain equity securities could result in fixed payment obligations and could also result in certain additional restrictive covenants, such as limitations on our ability to incur debt and/or issue additional equity, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. In addition, the issuance of additional equity securities by us, or the possibility of such issuance, may cause the market price of our common stock to decline. In the event that we enter into collaborations and/or licensing arrangements in order to raise capital, we may be required to accept unfavorable terms, including relinquishing or licensing to a third party on unfavorable terms our rights to our proprietary technology platform or product candidates. To the extent that we raise additional capital through the sale of equity securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. If we issue common stock or securities convertible into common stock, our common stockholders would experience additional dilution and, as a result, our stock price may decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Covenants in our credit and security agreement restrict our business and operations in many ways and if we do not effectively manage our covenants, our financial condition and results of operations could be adversely affected. </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">In October 2019, we entered into a credit and security agreement (the &#8220;Credit Agreement&#8221;) pursuant to which $20.0 million remains available. All of our assets, except for intellectual property and certain other customary excluded property, are pledged collateral under the Credit Agreement. The Credit Agreement contains numerous affirmative and negative covenants, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, prepayment of other indebtedness and dividends and other distributions, any of which could restrict our business and operations, particularly our ability to respond to changes in our business or to take specified actions to take advantage of certain business opportunities that may be presented to us. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Our failure to comply with any of the covenants could result in a default under the Credit Agreement, which would permit the lenders to declare all or part of any outstanding borrowings to be immediately due and payable, or to refuse to permit additional borrowings under the loan and security agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Reliance on Third Parties </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If Janssen does not elect to continue the development of product candidates subject to our Janssen collaboration, our business and business prospects would be adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The product candidates in development pursuant to our Janssen collaboration may prove to have undesirable or unintended side effects or other characteristics adversely affecting their safety, efficacy or cost effectiveness that could prevent or limit their approval for marketing and successful commercial use, or that could delay or prevent the commencement and/or completion of clinical trials. Under the terms of the Janssen License and Collaboration Agreement, Janssen may terminate the agreement for convenience and without cause on written notice of a certain period. In addition, prior to any termination of the agreement, Janssen will generally have control over the further clinical development of PN-232, PN-235, PTG-200 and any other second-generation compounds. Janssen&#8217;s decisions with respect to such development will affect the timing and availability of potential future payments under the agreement, if any. If the research program or the Janssen License and Collaboration Agreement are terminated early, or if Janssen&#8217;s development activities are terminated early or suspended for an extended period of time, or are otherwise unsuccessful, our business and business prospects would be materially adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may have disagreements with Janssen during the term of the Janssen License and Collaboration Agreement, and if they are not settled amicably or in the favor of Protagonist, the result may harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We are subject to the risk of possible disagreements with Janssen regarding the development of our Janssen collaboration compounds or other matters under the Janssen License and Collaboration Agreement, such as interpretation of the agreement or ownership of proprietary rights. Also, after the period of collaborative development ends under the agreement, Janssen will have sole decision-making authority for product candidates resulting from the collaboration, which could lead to disputes with Janssen. Disagreements with Janssen could lead to litigation or arbitration, which would be expensive and would be time-consuming for our management and employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not be successful in obtaining or maintaining development and commercialization collaborations, any collaboration arrangements we enter into in the future may not be successful.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Other than our Janssen License and Collaboration Agreement, we have no active collaborations for any of our product candidates. Even if we establish other collaboration arrangements, any such collaboration may not ultimately be successful, which could have a negative impact on our business, results of operations, financial condition and growth prospects. If we enter into collaborations limited to certain territories, we may not maintain significant rights or control of future development and commercialization of any product candidate subject to the collaboration and potential disputes could develop in the future over the terms of the collaboration and the respective rights of the parties, such as our ongoing dispute with Zealand Pharma related to our collaboration that ended in 2014. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We rely on third parties to conduct our pre-clinical studies and clinical trials. If these third parties do not successfully carry out their contractual obligations or do not meet regulatory requirements or expected deadlines, we may not be able to obtain timely regulatory approval for or commercialize our product candidates and our business could be substantially harmed.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We have relied upon and plan to continue to rely upon third party CROs to execute, monitor and manage clinical trials and collect data for our pre-clinical studies and clinical programs. We control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that their conduct meets regulatory requirements and that each of our studies and trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards. We and our CROs are required to comply with good clinical practices (&#8220;GCPs&#8221;), which are regulations and guidelines promulgated by the FDA, the EMA and comparable foreign regulatory authorities for all of our product candidates in clinical development. If we or any of our CROs fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, EMA or comparable foreign regulatory authorities may not accept the data or require us to perform additional clinical trials before considering our filing for regulatory approval or approving our marketing application. In addition, significant portions of the clinical studies for our product candidates are expected to be conducted outside of the United States, which will make it more difficult for us to monitor CROs and perform visits of our clinical trial sites (particularly during the ongoing pandemic) and will force us to rely heavily on CROs to ensure the proper and timely conduct of our clinical trials and compliance with applicable regulations, including GCPs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">If any of our relationships with these third party CROs terminate, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase substantially and our ability to generate revenue could be delayed significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We face a variety of manufacturing risks and rely on third parties to manufacture our drug substance and clinical drug product and we intend to rely on third parties to produce commercial supplies of any approved product candidate.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">We rely on contract manufacturers to manufacture and provide product for us that meets applicable regulatory requirements. We do not currently have, nor do we plan to develop, the infrastructure or capability internally to manufacture our drug supplies and we expect to continue to depend on contract manufacturers for the foreseeable future. As we proceed with the development and potential commercialization of our product candidates, we will need to increase the scale at which the drug is manufactured which will require the development of new manufacturing processes to potentially reduce the cost of goods. We will rely on our internal process research and development efforts and those of contract manufacturers to develop the GMP manufacturing processes required for cost-effective, large-scale production. If we and our contract manufacturers are not successful in converting to commercial-scale manufacturing, then our product costs may not be competitive and the development and/or commercialization of our product candidates would be materially adversely affected. Moreover, our contract manufacturers are the sole source of supply for our clinical product candidates. If we were to experience an unexpected loss of supply for any reason, whether as a result of manufacturing, supply or storage issues, natural disasters, the ongoing COVID-19 pandemic or otherwise, we could experience delays, disruptions, suspensions or termination of our clinical study and planned development program, or be required to restart or repeat, any ongoing clinical trials.   </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We also rely on our contract manufacturers to purchase from third party suppliers the materials necessary to produce our product candidates for our clinical trials. There are a limited number of suppliers for raw materials that our vendors use to manufacture our drugs and there may be a need to assess alternate suppliers to prevent a possible disruption of the manufacture of the materials necessary to produce our product candidates for our clinical trials, and if approved, for commercial sale. Moreover, we currently do not have any agreements for the commercial production of these raw materials. Although we generally do not begin a clinical trial unless we believe we have a sufficient supply of a product candidate to complete the clinical trial, any significant delay in the supply of a product candidate, or the raw material components thereof, for an ongoing clinical trial due to the need to replace a contract manufacturer or other third party manufacturer could considerably delay completion of our clinical trials, product testing and potential regulatory approval of our product candidates. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Regulatory Approval</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy and time consuming , and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Our business is substantially dependent on our ability to successfully develop, obtain regulatory approval for and then successfully commercialize our product candidates. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the FDA, the EMA or any other foreign regulatory authority, and we may never receive such regulatory approval for any of our product candidates. The time required to obtain approval by the FDA and comparable foreign authorities is difficult to predict, typically takes many years following the commencement of clinical trials and depends upon numerous factors. Approval policies, regulations and the types and amount of clinical and manufacturing data necessary to gain approval may change during the course of clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate and it is possible that none of our existing product candidates or any product candidates we have in development or may seek to develop in the future will ever obtain regulatory approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Our product candidates could fail to receive regulatory approval for many reasons, including the following: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the results of clinical trials may fail to achieve the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data submitted in support of regulatory approval;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the data collected from pre-clinical studies and clinical trials of our product candidates may not be sufficient to support the submission of an NDA, supplemental NDA, or other regulatory submissions necessary to obtain regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">we or our contractors may not meet the GMP and other applicable requirements for manufacturing processes, procedures, documentation and facilities necessary for approval by the FDA or comparable foreign regulatory authorities; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">changes to the approval policies or regulations of the FDA or comparable foreign regulatory authorities with respect to our product candidates may result in our clinical data becoming insufficient for approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">In addition, even if we were to obtain regulatory approval, regulatory authorities may approve our product candidates for fewer or more limited indications than what we requested approval for, may include safety warnings or other restrictions that may negatively impact the commercial viability of our product candidates, including the potential for a favorable price or reimbursement at a level that we would otherwise intend to charge for our products. Likewise, regulatory authorities may grant approval contingent on the performance of costly post-marketing clinical trials or the conduct of an expensive risk-evaluation and mitigation system, which could significantly reduce the potential for commercial success or viability of our product candidates. Any of the foregoing possibilities could materially harm the prospects for our product candidates and business and operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may fail to obtain orphan drug designations from the FDA and/or EU for our product candidates, as applicable, and even if we obtain such designations, we may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Our strategy includes filing for orphan drug designation where available for our product candidates. Rusfertide has received orphan drug designation for the treatment of patients with PV from the FDA and the EU. Despite this designation, we may be unable to maintain the benefits associated with orphan drug status, including market exclusivity. We may not be the first to obtain regulatory approval of a product candidate for a given orphan-designated indication. In addition, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective or if we are unable to assure sufficient quantities of the product to meet patient needs. Further, even if we obtain orphan drug designation exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different active moieties may receive and be approved for the same condition, and only the first applicant to receive approval for a given active ingredient will receive the benefits of marketing exclusivity. Even after an orphan-designated product is approved, the FDA can subsequently approve a later drug with the same active moiety for the same condition if the FDA concludes that the later drug is clinically superior if it is shown to be safer, more effective or makes a major contribution to patient care. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Commercialization of our Product Candidates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We currently have no marketing and sales organization. To the extent any of our product candidates for which we maintain commercial rights is approved for marketing, if we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, we may not be able to effectively market and sell any products or generate product revenue.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We currently do not have a marketing or sales organization for the marketing, sales and distribution of pharmaceutical products. In order to commercialize any of our product candidates that receive marketing approval, we will have to build marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so. In the event of successful development of any of our product candidates, we may elect to build a targeted specialty sales force which will be expensive and time consuming. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. With respect to our product candidates, we may choose to partner with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems, and in the case of the Janssen License and Collaboration Agreement, we may elect to exercise our Co-Detailing Option (allows us to elect to provide up to 30% of the selling effort in the United States for PTG-200 and/or any second-generation compounds approved for commercial sale), which would require us to establish a U.S. sales team. If we are not successful in commercializing our product candidates, either on our own or through collaborations with one or more third parties, our future revenue will be materially and adversely impacted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">In the United States and some foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could, among other things, prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">For example, in the United States in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively, the ACA, was enacted to increase access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for health care and the health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. The law has continued the downward pressure on </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">pharmaceutical pricing, especially under the Medicare program, and increased the industry&#8217;s regulatory burdens and operating costs. </p><a id="_cp_text_2_41"></a><a id="_cp_text_1_42"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">There have been executive, judicial and Congressional challenges to certain aspects of the ACA. For example, President Trump signed Executive Orders and other directives designed to delay the implementation of certain provisions of the ACA or otherwise circumvent some of the requirements for health insurance mandated by the ACA. Concurrently, Congress considered legislation to repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, several bills affecting the implementation of certain taxes under the ACA have been enacted. The Tax Cuts and Jobs Act of 2017 (the &#8220;Tax Act&#8221;) included a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year. Additionally, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the ACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and the medical device tax and, effective January 1, 2021, also eliminated the health insurance tax. Further, the Bipartisan Budget Act of 2018 (the &#8220;BBA&#8221;) among other things, amends the ACA, effective January 1, 2019, to close the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole.&#8221; Congress may consider other legislation to repeal or replace other elements of the ACA. On December 14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress as part of the Tax Act. Additionally, on December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. The U.S. Supreme Court is currently reviewing this case, but it is unclear when a decision will be made. Although the U.S. Supreme Court has not yet ruled on the constitutionality of the ACA, on January 28, 2021, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021 through May 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructs certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how the Supreme Court ruling, other such litigation and the healthcare reform measures of the Biden administration will impact the ACA and our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. These changes included aggregate reductions to Medicare payments to providers of 2% per fiscal year, which went into effect in April 2013 and, due to subsequent legislative amendments to the statute, including the BBA, will remain in effect through 2030 unless additional action is taken by Congress. COVID-19 relief legislation suspended the 2% Medicare sequester from May 1, 2020 through March 31, 2021. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers and increased the statute of limitations period in which the government may recover overpayments to providers from three to five years. </p><a id="_Hlk63689237"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">Further, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products. Such scrutiny has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For example, on July 24, 2020 and September 13, 2020, the Trump administration announced four executive orders related to prescription drug pricing that attempt to implement several of the administration&#8217;s proposals. The FDA also released a final rule, effective November 30, 2020, implementing a portion of the importation executive order providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November&#160;20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part&#160;D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">which have also been delayed pending review by the Biden administration until March 22, 2021. On November 20, 2020, CMS issued an interim final rule implementing President Trump&#8217;s Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. On December 28, 2020, the United States District Court in Northern California issued a nationwide preliminary injunction against implementation of the interim final rule. At the state level, legislatures have become increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates, if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We expect that additional state and federal healthcare reform measures will be adopted in the future, particularly in light of the new presidential administration, any of which could limit the amounts that federal and state governments will pay for healthcare therapies, which could result in reduced demand for our product candidates or additional pricing pressures. Further, it is possible that additional governmental action is taken in response to the COVID-19 pandemic. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Legislative and regulatory proposals have also been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We currently conduct, and intend to continue to conduct, a substantial portion of the clinical trials for our product candidates outside of the United States. If approved, we may commercialize our product candidates abroad. We will thus be subject to the risks of doing business outside of the United States.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We currently conduct, and intend to continue to conduct, a substantial portion of our clinical trials outside of the United States and, if approved, we intend to also market our product candidates outside of the United States. We are thus subject to risks associated with doing business outside of the United States. Our business and financial results in the future could be adversely affected due to a variety of factors associated with conducting development and marketing of our product candidates, if approved, outside of the United States, including varying medical standards and practices, geopolitical risks, uncertainty around intellectual property protection, and regulatory risks, such as compliance with the Foreign Corrupt Practices Act. If we are unable to anticipate and address these risks properly, our business and financial results will be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Business and Industry</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. We have competitors worldwide, including major multinational pharmaceutical companies, biotechnology companies, specialty pharmaceutical and generic pharmaceutical companies as well as universities and other research institutions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">Many of our competitors have substantially greater financial, technical and other resources, such as larger research and development staff, and experienced marketing and manufacturing organizations. As a result, these companies may obtain regulatory approval more rapidly than we are able and may be more effective in selling and marketing their products. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Competition may increase further as a result of advances in the commercial applicability of newer technologies and greater availability of capital for investment in these industries. Our competitors may succeed in developing, acquiring or licensing, on an exclusive basis, pharmaceutical </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">products that are easier to develop, more effective or less costly than any product candidates that we are currently developing or that we may develop. If approved, our product candidates are expected to face competition from commercially available drugs as well as drugs that are in the development pipelines of our competitors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Pharmaceutical companies may invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make our product candidates less competitive. In addition, any new product that competes with an approved product must demonstrate advantages in efficacy, convenience, tolerability or safety in order to overcome price competition and to be commercially successful. If our competitors succeed in obtaining FDA, EMA or other regulatory approval or discovering, developing and commercializing drugs before we do, there would be a material adverse impact on the future prospects for our product candidates and business. For example, in June <span style="background-color:#ffffff;color:#121212;white-space:pre-wrap;">2020, the FDA accepted a Biologics License Application for ropeginterferon alfa-2b for use in treatment for patients with PV in the absence of symptomatic splenomegaly from PharmaEssentia Corporation, the manufacturer of the novel pegylated interferon. A decision from the FDA on this application is expected in early 2021.  We also face competition in certain instances from the existing standards of care, which may be significantly less expensive than our expected drug prices. For example, one widely used treatment for PV and HH patients is phlebotomy and/or chelation therapy. While patients may not like therapies that involve frequent blood draws, these therapies are inexpensive and may present pricing challenges for us if our drug candidates are successfully developed and approved. </span><span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we fail to comply with state and federal healthcare regulatory laws, we could face substantial penalties, damages, fines, disgorgement, integrity oversight and reporting obligations, exclusion from participation in governmental healthcare programs, and the curtailment of our operations, any of which could adversely affect our business, operations, and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Healthcare providers, including physicians, and third-party payors will play a primary role in the recommendation and prescription of any future product candidates we may develop or any product candidates for which we obtain marketing approval. Our arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may affect the business or financial arrangements and relationships through which we would market, sell and distribute our products. Even though we do not and will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, federal and state healthcare laws and regulations pertaining to fraud and abuse and patients&#8217; rights are and will be applicable to our business. The laws that may affect our ability to operate include, but are not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the federal Anti-Kickback Statute;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the federal false claims laws, including the False Claims Act;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and their implementing regulations, which also imposes obligations, including mandatory contractual terms, on HIPAA-covered entities, their business associates as well as their covered subcontractors with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the federal civil monetary penalties statute;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the federal Physician Payments Sunshine Act; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Further, the ACA, among other things, amended the intent requirements of the federal Anti-Kickback Statute and certain criminal statutes governing healthcare fraud. Any violations of these laws, or any action against us for violation of these laws, even if we successfully defend against it, could result in a material adverse effect on our reputation, business, results of operations and financial condition.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We have entered into consulting and scientific advisory board arrangements with physicians and other healthcare providers, including some who could influence the use of our product candidates, if approved. While we have worked to structure our arrangements to comply with applicable laws, because of the complex and far-reaching nature of these laws, regulatory agencies may view these transactions as prohibited arrangements that must be restructured, or discontinued, or for which we could be subject to other significant penalties. We could be adversely affected if regulatory agencies interpret our financial relationships with providers who may influence the ordering of and use our product candidates, if approved, to be in violation of applicable laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform. Federal and state enforcement bodies have continued to increase their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of significant investigations, prosecutions, convictions and settlements in the healthcare industry. Additionally, as a result of these investigations, healthcare providers and entities may have to agree to additional onerous compliance and reporting requirements as part of a consent decree or corporate integrity agreement. Any such investigation or settlement could significantly increase our costs or otherwise have an adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">If our operations are found to be in violation of any of these laws or any other governmental laws and regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, integrity oversight and reporting obligations, exclusion from government funded healthcare programs, such as Medicare and Medicaid, disgorgement, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations. If, and to the extent that, Janssen or we are unable to comply with these regulations, our ability to earn potential royalties from worldwide net sales of Janssen collaboration product candidates would be materially and adversely impacted. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. The imposition of any of these penalties or other commercial limitations could negatively impact our collaboration with Janssen or cause Janssen to terminate the Janssen License and Collaboration Agreement, either of which would materially and adversely affect our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our future success depends on our ability to retain our executive officers and to attract, retain and motivate qualified personnel. If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Our ability to compete in the highly competitive biotechnology and pharmaceuticals industries depends upon our ability to attract and retain highly qualified managerial, scientific, medical and regulatory personnel. We are highly dependent on our existing senior management team. The loss of the services of any of our executive officers or other key employees and our inability to find suitable replacements would harm our research and development efforts, our collaboration efforts, as well as our business, financial condition and prospects. Our success also depends on our ability to continue to attract, retain and motivate highly skilled and experienced personnel with scientific, medical, regulatory, manufacturing, marketing, sales, general and administrative and management training and skills.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We may not be able to attract or retain qualified personnel in the future due to the intense competition for a limited number of qualified personnel among biopharmaceutical, biotechnology, pharmaceutical and other businesses. Many of the other biopharmaceutical and pharmaceutical companies that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. Many are located in areas of the country with lower costs of living. Any or all of these factors may limit our ability to continue to attract and retain high quality personnel, which could negatively affect our ability to successfully develop and commercialize product candidates and to grow our business and operations as currently contemplated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We expect to expand the size of our organization, and we may experience difficulties in managing this growth.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">As of December 31, 2020, we had 79 full-time equivalent employees, including 59 full-time equivalent employees engaged in research and development. As our development and commercialization plans and strategies develop and we continue to operate as a public company, we expect to need additional managerial, operational, scientific, sales, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">marketing, research, development, regulatory, manufacturing, financial and other resources. In addition, as our operations expand, we expect that we will need to manage relationships with strategic collaborators, CROs, contract manufacturers, suppliers, vendors and other third parties. Our future financial performance and our ability to develop and commercialize our product candidates and to compete effectively will depend, in part, on our ability to manage any future growth effectively. We may not be successful in accomplishing these tasks in growing our company, and our failure to accomplish any of them could adversely affect our business and operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Significant disruptions of information technology systems or breaches of data security could adversely affect our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Our business is increasingly dependent on critical, complex and interdependent information technology systems, including Internet-based systems, to support business processes as well as internal and external communications. The size and complexity of our internal computer systems and those of our CROs, contract manufacturers, collaboration partner, and other third parties on which we rely may make them potentially vulnerable to breakdown, telecommunications and electrical failures, malicious intrusion such as ransomware and computer viruses that may result in the impairment of key business processes. Those systems and processes require appropriate training and adherence to security protocols by our personnel and third parties personnel. In addition, our systems are potentially vulnerable to data security breaches, by employees or others, that may expose sensitive data to unauthorized persons. Such data security breaches could lead to the loss of trade secrets or other intellectual property or could lead to the public exposure of personally identifiable information (including sensitive personal information) of our employees, collaborators, clinical trial patients, and others. A malicious intrusion, data security breach or privacy violation that leads to disclosure or modification of or prevents access to patient information, including personally identifiable information or protected health information, could harm our reputation, compel us to comply with federal and/or state breach notification laws, subject us to mandatory corrective action, require us to verify the correctness of database contents and otherwise subject us to liability under laws and regulations that protect personal data, resulting in increased costs or loss of revenue. If we are unable to prevent such data security breaches or privacy violations or implement satisfactory remedial measures, our operations could be disrupted, and we may suffer loss of reputation, financial loss and other regulatory penalties. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials, and produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our employees, independent contractors, principal investigators, consultants and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We are exposed to the risk that our employees, independent contractors, principal investigators, consultants or vendors may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violates: (i) FDA laws and regulations or those of comparable foreign regulatory authorities, (ii) manufacturing standards, (iii) federal and state data privacy, security, fraud and abuse and other healthcare laws and regulations established and enforced by comparable foreign regulatory authorities, or (iv) laws that require the true, complete and accurate reporting of financial information or data. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant fines or other sanctions.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and a breach of warranties. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to stop development or, if approved, limit commercialization of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Our inability to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the development or commercialization of our product candidates. We currently carry clinical trial liability insurance for our clinical trials. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our headquarters is located near known earthquake fault zones. The occurrence of an earthquake, fire or any other catastrophic event could disrupt our operations or the operations of third parties who provide vital support functions to us, which could have a material adverse effect on our business and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We and some of the third-party service providers on which we depend for various support functions are vulnerable to damage from catastrophic events, such as power loss, natural disasters, terrorism, pandemics and similar unforeseen events beyond our control. Our corporate headquarters, including our laboratory facilities, are located in the San Francisco Bay Area, which in the past has experienced severe earthquakes and fires. We do not carry earthquake insurance. Earthquakes or other natural disasters could severely disrupt our operations, and have a material adverse effect on our business, results of operations, financial condition and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The insurance coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for our product candidates could limit our ability to generate revenue.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The availability and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford medications and therapies. Sales of any of our product candidates that receive marketing approval will depend substantially, both in the United States and internationally, on the extent to which the costs of our product candidates will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain adequate pricing that will allow us to realize a sufficient return on our investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, the principal decisions about reimbursement for new products are typically made by the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;). CMS decides whether and to what extent a new product will be covered and reimbursed under Medicare. Private payors tend to follow CMS to a substantial degree, but also have their own methods and approval process. Therefore, coverage and reimbursement can differ significantly from payor to payor. It is difficult to predict what CMS will decide with respect to reimbursement for novel products such as ours since there is no body of established practices and precedents for these new products.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe, Canada and other countries may cause us to price our product candidates on less favorable terms than we currently anticipate. In many countries, particularly the countries of the European Union, the prices of medical products are subject to varying price control mechanisms as part of national health systems. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidates to other available therapies. In general, the prices of products under such systems are substantially lower than in the United States. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenues and profits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Moreover, increasing efforts by governmental and third-party payors, in the United States and internationally, to cap or reduce healthcare costs may cause such organizations to limit both coverage and level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for our product candidates. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products into the healthcare market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Intellectual Property </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to obtain or protect intellectual property rights related to our product candidates and technologies, we may not be able to compete effectively in our markets.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We rely upon a combination of patent protection, trade secret protection and confidentiality agreements to protect the intellectual property related to our product candidates and technologies. The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. We may or may not file or prosecute all necessary or desirable patent applications. The patent applications that we own or license may fail to result in issued patents in the United States or in other foreign countries, or they may fail to result in issued patents with claims that cover our product candidates or technologies in the United States or in other foreign countries. Any failure to identify relevant prior art relating to a patent or patent applications can invalidate a patent or prevent a patent from issuing. Even if patents have been issued, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. Furthermore, even if they are unchallenged, our patent and patent applications may not adequately protect our intellectual property, provide exclusivity for our product candidates and technologies, or prevent others from designing around our claims.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">If the breadth or strength of protection provided by our patents is challenged, or if they fail to provide meaningful exclusivity for our product candidates, it could prevent us from asserting exclusivity over the covered product and allow generic competition. We cannot offer any assurances about which, if any, of our patent applications will issue, the breadth of any such issued patent, or whether any issued patents will be found invalid and unenforceable or will be threatened by third parties. Any successful opposition or other challenge to our patents or patent applications could significantly diminish the commercial prospects of any products that we develop. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">In addition, patents have a limited lifespan. In the United States and in many other countries, the natural expiration of a patent is generally 20 years after it is filed, and once any patents covering a product expire, generic competitors may enter the market. Our granted U.S. patents covering PN-943 and PTG-200 expire in 2035, and our granted U.S. patent covering rusfertide expires in 2034. Although the life of a patent can be increased based on certain delays caused by the U.S. Patent and Trademark Office (the &#8220;PTO&#8221;), this increase can be reduced or eliminated based on certain delays caused by the patent applicant during patent prosecution. If we encounter delays in our clinical trials or in gaining regulatory approval, the period of time during which we could market any of our product candidates under patent protection, if approved, would be reduced. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We may not be able to protect our intellectual property rights throughout the world. Filing, prosecuting and defending patents on all of our product candidates throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States may be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights, including trade secrets, to the same extent as federal and state laws of the United States and many countries limit the enforceability of patents against third parties, including government agencies or government contractors. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but enforcement is not as strong as in the United States. These products may compete with our products in jurisdictions where we do not have any issued patents and our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing. Also, if our trade secrets are disclosed in a foreign jurisdiction, competitors worldwide could have access to our proprietary information and we may be without satisfactory recourse. Such disclosure could have a material adverse effect on our business. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Obtaining and maintaining patents depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. Periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents or applications will be due to be paid to the USPTO and various government patent agencies outside of the United States over the lifetime of our patents and applications. Non-compliance could result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market with similar or identical products or platforms, which could have a material adverse effect on our business prospects and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We also rely on trade secret protection and confidentiality agreements to protect proprietary scientific, business and technical information and know-how that is not or may not be patentable or that we elect not to patent. For example, we primarily rely on trade secrets and confidentiality agreements to protect our peptide therapeutics technology platform. Any disclosure to or misappropriation by third parties of our confidential proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, thus eroding our competitive position in our market. If we are unable to protect the confidentiality of our trade secrets and proprietary know-how or if competitors independently develop viable competing products, our business and competitive position may be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Although we require all of our employees to assign their inventions to us, and endeavor to execute confidentiality agreements with all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how and other confidential information related to such technology, we cannot be certain that we have executed such agreements with all third parties who may have helped to develop our intellectual property or who had access to our proprietary information, nor can be we certain that our agreements will not be breached. If any of the parties to these confidentiality agreements breaches or violates the terms of such agreements, we may not have adequate remedies for any such breach or violation, and we could lose our trade secrets as a result.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Even if we are able to adequately protect our trade secrets and proprietary information, our trade secrets could otherwise become known or could be independently discovered by our competitors. Competitors could purchase our products and attempt to replicate some or all of the competitive advantages we derive from our development efforts, willfully infringe our intellectual property rights, design around our protected technology or develop their own competitive technologies that fall outside of our intellectual property rights. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, in the absence of patent protection, we would have no right to prevent them, or those to whom they communicate, from using that technology or information to compete with us. If our trade secrets are not adequately protected so as to protect our market against competitors&#8217; products, others may be able to exploit our proprietary peptide product candidate discovery technologies to identify and develop competing product candidates, and thus our competitive position could be adversely affected, as could our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be involved in lawsuits and other legal proceedings to protect or enforce our intellectual property, which could be expensive, time consuming and unsuccessful.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Competitors may infringe our issued patents or any patents issued as a result of our pending or future patent applications. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours is not valid or is unenforceable or may refuse to stop the other party in such infringement proceeding from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly, and could put any of our patent applications at risk of not yielding an issued patent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The filing of a patent application or the issuance of a patent is not conclusive as to its ownership, inventorship, scope, patentability, validity or enforceability. Issued patents and patent applications may be challenged in the courts and in the patent office in the United States and abroad. For example, our patent applications, or any patents that grant therefrom, may be challenged through third-party submissions, opposition or derivation proceedings, and our patents may be challenged through reexamination, inter partes review or post-grant review proceedings before the USPTO, or in declaratory judgment actions or counterclaims. An adverse determination in any such submission, proceeding or litigation could prevent the issuance of, reduce the scope of, invalidate or render unenforceable our patent rights, result in the loss of exclusivity, or limit our ability to stop others from using or commercializing our platform technology and products. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Interference or derivation proceedings provoked by third parties or brought by us, the PTO or any foreign patent authority may be necessary to determine the priority or ownership of inventions with respect to our patent or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms, if any license is offered at all. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Any issued patents covering our product candidates, including any patent that may issue as a result of our pending or future patent applications, could be found invalid or unenforceable if challenged in court in the United States or abroad.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">As more groups become engaged in scientific research and product development in fields related to our product candidates, such as IL-23R, &#945;4&#946;7integrin or hepcidin mimetics, the risk of our patents, or patents that we have in-licensed, being challenged through patent interferences, derivation proceedings, oppositions, re-examinations, litigation or other means will likely increase. An adverse outcome in a patent dispute could have a material adverse effect on our business by:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">causing us to lose patent rights in the relevant jurisdiction(s);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">subjecting Janssen or us to litigation, or otherwise preventing the commercialization of product candidates in the relevant jurisdiction(s);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">requiring Janssen or us to obtain licenses to the disputed patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">forcing Janssen or us to cease using the disputed technology; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">requiring Janssen or us to develop or obtain alternative technologies.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">An adverse outcome in a patent dispute could severely harm our collaboration with Janssen or cause Janssen to terminate the Janssen License and Collaboration Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">Intellectual property disputes could cause us to spend substantial resources and distract our personnel from their normal responsibilities. Litigation or other legal proceedings relating to intellectual property claims, with or without merit, are unpredictable and generally expensive and time-consuming and, even if resolved in our favor, are likely to divert significant resources from our core business, including distracting our technical and management personnel from </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the market price of our common stock. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating or from successfully challenging our intellectual property rights. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Third party claims of intellectual property infringement may prevent or delay our drug discovery and development efforts.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Our commercial success depends in part on our ability to develop, manufacture, market and sell our drug candidates and use our proprietary technologies without infringing or otherwise violating the patents and proprietary rights of third parties. Numerous third-party U.S. and foreign issued patents and pending patent applications exist in the fields in which we are developing product candidates, and there may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates and technologies. Third parties may initiate legal proceedings against us alleging that we are infringing or otherwise violating their patent or other intellectual property rights. Given the vast number of patents in our field of technology, marketing of our product candidates or practice of our technologies could infringe existing patents or patents granted in the future. Because patent applications can take many years to issue and may be confidential for 18 months or more after filing, and because pending patent claims can be revised before issuance, there may be applications now pending of which we are unaware that may later result in issued patents that may be infringed by the practice of our peptide therapeutics technology platform or the manufacture, use or sale of our product candidates. In addition, third parties may obtain patents in the future and claim that our product candidates or technologies infringe upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our product candidates, any molecules formed during the manufacturing process or any final product or formulation itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire. As our industry expands and more patents are issued, the risk increases that our product candidates or technologies may give rise to claims of infringement of the patent rights of others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to commercialize our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. Even if we are successful in defending against any infringement claims, litigation is expensive and time-consuming and is likely to divert management&#8217;s attention and substantial resources from our core business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, limit our uses, pay royalties or redesign our infringing product candidates, which may be impossible or require substantial time and monetary expenditure. We may choose to seek, or may be required to seek, a license from the third-party patent holder and would most likely be required to pay license fees or royalties or both, each of which could be substantial. These licenses may not be available on commercially reasonable terms, however, or at all. Even if we were able to obtain a license, the rights we obtain may be nonexclusive, which would provide our competitors access to the same intellectual property rights upon which we are forced to rely. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates, and we have done so from time to time. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In such an event, we would be unable to further practice our technologies or develop and commercialize any of our product candidates at issue, which could harm our business significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not identify relevant third party patents or may incorrectly interpret the relevance, scope or expiration of a third party patent which might adversely affect our ability to develop and market our products.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third party patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our products. We may incorrectly determine that our products are not covered by a third party patent or may incorrectly predict whether a third party&#8217;s pending application will issue with claims of relevant scope. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We may not be successful in obtaining or maintaining necessary rights to protect our product candidates through acquisitions and in-licenses. We may find that our programs require the use of proprietary rights held by third parties or the growth of our business may depend in part on our ability to acquire, in-license or use these proprietary rights. We may be unable to acquire or in-license compositions, methods of use, processes or other third party intellectual property rights from third parties we identify as necessary for our product candidates. Even if we are able to obtain a license to intellectual property of interest, we may not be able to secure exclusive rights, in which case others could use the same rights and compete with us. If we are unable to successfully obtain rights to required third party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of that program and our business and financial condition could suffer. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of former or other employers.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Many of our employees and consultants, including our senior management and our scientific founders, have been employed or retained at universities or by other biotechnology or pharmaceutical companies, including potential competitors. Some of our employees and consultants, including each member of our senior management and each of our scientific founders, executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment or retention. We may be subject to claims that we or these employees, consultants or independent contractors have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee&#8217;s or consultant&#8217;s former or other employer. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to claims challenging the inventorship or ownership of our issued patents, any patents issued as a result of our pending or future patent applications and other intellectual property.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We may be subject to claims that former employees, collaborators or other third parties have an ownership interest in our issued patents, any patents issued as a result of our pending or future applications or other intellectual property. We have had in the past, and we may also have in the future, ownership disputes arising, for example, from conflicting obligations of consultants or others who are involved in developing our product candidates and technologies. Litigation may be necessary to defend against these and other claims. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Some of our intellectual property was generated through government funded programs and thus may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights and limit our ability to contract with non-U.S. manufacturers.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">Some of our intellectual property rights were generated through the use of U.S. government funding and are therefore subject to certain federal regulations. As a result, the U.S. government may have certain rights to intellectual property embodied in our current or future product candidates pursuant to the Bayh-Dole Act of 1980, or Bayh-Dole Act, and implementing regulations.&#160; These U.S. government rights in certain inventions developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">governmental purpose. In addition, the U.S. government has the right to require us or our licensors to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party in certain circumstances (also referred to as &#8220;march-in rights&#8221;). The U.S. government also has the right to take title to these inventions if we, or the applicable licensor, fail to disclose the invention to the government and fail to file an application to register the intellectual property within specified time limits. In addition, the U.S. government requires that any products embodying the subject invention or produced through the use of the subject invention be manufactured substantially in the United States, subject to a potential waiver. This preference for U.S. manufacturers may limit our ability to contract with non-U.S. product manufacturers for products covered by such intellectual property. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Because we expect to rely on third parties in the development and manufacture of our product candidates, we must, at times, share trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on our business and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We may not obtain registered trademarks for commercial trade names for our product candidates. Any trademarks or trade names that we do obtain may be challenged, infringed, circumvented, declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively, and our business may be materially adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intellectual property rights do not necessarily address all potential threats to our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business. The following examples are illustrative:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">others may be able to make compounds or formulations that are similar to our product candidates, but that are not covered by the claims of any patents that we own, license or control;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">we or any strategic partners might not have been the first to make the inventions covered by the issued patents or pending patent applications that we own;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">we might not have been the first to file patent applications covering certain of our inventions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">others may independently develop the same, similar, or alternative technologies without infringing, misappropriating or violating our intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">it is possible that our pending patent applications will not lead to issued patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">issued patents may not provide us with any competitive advantages, or may be narrowed or held invalid or unenforceable, including as a result of legal challenges;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">our competitors might conduct research and development activities in the United States and other countries that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights, and may then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such trade secrets or know-how; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the patents of others may have an adverse effect on our business.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Should any of these events occur, they could have a material adverse impact on our business and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Ownership of our Common Stock </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background-color:#ffffff;font-style:italic;font-weight:bold;">Our stock price has been and will likely continue to be volatile and may decline regardless of our operating performance.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">Our stock price has fluctuated in the past and is likely to be volatile in the future.  </span><span style="background-color:#ffffff;">From January 1, 2018 through December 31, 2020, the reported sale price of our common stock has fluctuated between $4.47 and $25.65 per share. </span>The stock market in general and the market for biotechnology companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, investors may experience losses on their investment in our common stock, including due to the factors discussed in these &#8220;Risk Factors&#8221; and elsewhere in this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Volatility in our share price could subject us to securities class action litigation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Securities class action litigations have often been brought against companies following a decline in the market price of their securities. If we face such litigation, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are obligated to develop and maintain proper and effective internal controls over financial reporting and any failure to maintain the adequacy of these internal controls may adversely affect investor confidence in our company and, as a result, the value of our common stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We are required, pursuant to Section 404 of the Sarbanes-Oxley Act (Section 404), to furnish a report by management on the effectiveness of our internal control over financial reporting. This assessment needs to include disclosure of any material weaknesses identified by our management in our internal control over financial reporting. In addition, if our public float on June 30, 2021 is greater than or equal to $700.0 million, our independent registered public accounting firm will be required to attest to the effectiveness of our internal control over financial reporting beginning with our Annual Report required to be filed with the SEC for the fiscal year ending December 31, 2021. At that time, if we have a material weakness, we would receive an adverse opinion regarding our internal control over financial reporting from our independent registered accounting firm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We currently do not have an internal audit group, and we may need to hire additional accounting and financial staff with appropriate public company experience and technical accounting knowledge and continue the costly and challenging process of compiling the system and processing documentation necessary to perform the evaluation needed to comply with Section 404. We may not complete our continued evaluation, testing and any required remediation in a timely fashion. During our evaluation of our internal control, if we identify one or more material weaknesses in our internal control over financial reporting or fail to remediate any material weaknesses, we will be unable to assert that our internal control over financial reporting is effective. Any material weakness or other failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition or results of operations. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Our amended and restated certificate of incorporation (&#8220;Certificate of Incorporation&#8221;) provides that the Court of Chancery of the State of Delaware will be the exclusive forum for certain actions and proceedings. Furthermore, Section 22 of the Securities Act of 1933 (the &#8220;Securities Act&#8221;), as amended, creates concurrent jurisdiction for federal and state courts over all Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. The choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes, which may discourage such lawsuits. Alternatively, if a court were to find the choice of forum provision contained in our Certificate of Incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background-color:#ffffff;font-style:italic;font-weight:bold;">Some provisions of our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders and may prevent attempts by our stockholders to replace or remove our current management.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background-color:#ffffff;font-style:italic;font-weight:bold;"> </span><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">There are provisions in our Certificate of Incorporation and Bylaws, such as the existence of a classified board and the authorization of &#8220;blank-check&#8221; preferred stock, that may make it difficult for a third party to acquire, or attempt to acquire, control of our company, even if a change in control was considered favorable by our stockholders.  These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, who are responsible for appointing the members of our management.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibit a person who owns 15% or more of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. Any provision in our Certificate of Incorporation, our Bylaws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock, and could also affect the price that some investors are willing to pay for our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">General Risk Factors</b></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our ability to use net operating loss carryforwards to offset future taxable income, and our ability to use tax credit carryforwards, may be subject to certain limitations.</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:6pt;text-indent:27.8pt;margin:0pt;">Our ability to use our federal and state net operating losses (&#8220;NOLs&#8221;) to offset potential future taxable income and related income taxes that would otherwise be due is dependent upon our generation of future taxable income, and we cannot predict with certainty when, or whether, we will generate sufficient taxable income to use our NOLs. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any, until such unused losses expire.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;text-indent:27.8pt;margin:0pt;">Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an &#8220;ownership change&#8221;, generally defined as a greater than fifty percentage point change (by value) in its equity ownership by certain stockholders over a three-year period, the corporation&#8217;s ability to use its pre-change net operating loss carryforwards, or NOLs, and other pre-change tax attributes (such as research and development tax credits) to offset its post-change taxable income or tax liability may be limited. We have experienced ownership changes in the past and in the current year, resulting in annual limitations in our ability to use our NOLs and credits. In addition, we may experience subsequent ownership changes as a result of future equity offerings or other changes in the ownership of our stock, some of which are beyond our control. As a result, the amount of the NOLs and tax credit carryforwards presented in our financial statements could be limited and may expire unused. Any such material limitation or expiration of our NOLs may harm our future operating results by effectively increasing our future tax obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:75.8pt;text-indent:-75.8pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may have additional tax liabilities.</span></p><a id="_cp_text_1_17"></a><a id="_AEIOULastRenderedPageBreakAEIOU48"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We are regularly subject to audits by tax authorities in the jurisdictions in which we conduct business. Although we believe our tax positions are reasonable, the final outcome of tax audits and related litigation could be materially different than that reflected in our historical income tax provisions and accruals, and we could be subject to assessments of additional taxes and/or substantial fines or penalties. The resolution of any audits or litigation could have an adverse effect on our financial position and results of operations. We and our subsidiary are engaged in intercompany transactions, the terms and conditions of which may be scrutinized by tax authorities, which could result in additional tax and/or penalties becoming due.</p><a id="_c8dae0ec_1ac5_4744_b46a_d49f56402143"></a><a id="Item1BUnresolvedStaffComments_95714"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> </span><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item&#160;1B.</b></span>Unresolved Staff Comments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_cc2f7fb6_8a5a_4107_a23e_95a078e5d8df"></a><a id="Item2Properties_349128"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item&#160;2.</b></span>Properties </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We lease approximately 42,877 square feet of office and laboratory space in Newark, California under a lease agreement that expires in May&#160;2024. We believe that our existing facilities are adequate to meet our business needs for at least the next 12&#160;months and that additional space will be available on commercially reasonable terms, if required.</p><a id="_c7d35bbe_61ae_4091_acae_b4ea1d52079f"></a><a id="Item3LegalProceedings_994436"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item&#160;3.</b></span>Legal Proceedings </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may become subject to litigation and claims arising in the ordinary course of business. We are not currently a party to any material legal proceedings and we are not aware of any pending or threatened legal proceeding against us that we believe could have a material adverse effect on our business, operating results or financial condition. We are a party in the arbitration proceeding described in Note 11 to the Consolidated Financial Statements elsewhere in this Annual Report on Form 10-K.</p><a id="_30a70608_5bb1_4e1f_8bd9_ed8c54846d1c"></a><a id="Item4MineSafetyDisclosures_51645"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item&#160;4.</b></span>Mine Safety Disclosures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_d1d59942_4f4d_4121_b784_49928bd3b5cc"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="PARTII_909557"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;II</p><a id="Item5MarketforRegistrants_334448"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Item&#160;5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;margin:0pt;">Market Information</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Our common stock began trading on The Nasdaq Global Market on August&#160;11, 2016 and trades under the symbol &#8220;PTGX.&#8221; Prior to such time, there was no public market for our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stockholders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:22.5pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">As of the close of business on February&#160;26, 2021, there were 2 stockholders of record of our common stock. The number of stockholders of record is based upon the actual number of stockholders registered at such date and does not include holders of shares in &#8220;street names&#8221; or persons, partnerships, associates, or corporations, or other entities identified in security listings maintained by depositories.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Dividends</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We have never declared or paid any cash dividends. We currently expect to retain all future earnings, if any, for use in the operation and expansion of our business, and therefore do not anticipate paying any cash dividends in the foreseeable future.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:282pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Performance Graph </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The following is not deemed &#8220;filed&#8221; with the Securities and Exchange Commission and is not to be incorporated by reference into any filing we make under the Securities Act of 1933, as amended, whether made before or after the date hereof and irrespective of any general incorporation by reference language in such filing. The graph below shows the cumulative total stockholder return assuming the investment on the date specified in each of our common stock, the Nasdaq Composite Index, the Nasdaq Biotechnology Index, and the Nasdaq Pharmaceutical Index. The graph tracks the performance of a $100 investment in our common stock and in each index (with the reinvestment of all dividends) from August&#160;11, 2016 to December&#160;31, 2020. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><img src="ptgx-20201231x10k012.jpg" alt="Graphic" style="display:inline-block;height:281.8pt;left:0%;padding-bottom:0.2pt;position:relative;top:0pt;width:485.3pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="ptgx-20201231x10k013.jpg" alt="Graphic" style="display:inline-block;height:82.45pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:485.3pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Sale of Unregistered Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:22.5pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">None.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Repurchases of Shares or of Company Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_c6b91284_5580_48dd_abc5_a63087581f53"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Item6SelectedFinancialData_924114"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;width:72pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item 6. </b></span><b style="font-weight:bold;">Selected Financial Data</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.5pt;margin:0pt 0pt 12pt 0pt;">This item is no longer required as we have elected to early adopt<b style="font-weight:bold;"> </b>the changes to Item 301 of Regulation S-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_3616495e_5e94_47f6_a6a7_aad1414c8557"></a><a id="Item7ManagementsDiscussionandAnalysis_85"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item&#160;7.</b></span><b style="font-weight:bold;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</b><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with the consolidated financial statements and related notes included elsewhere in this Annual Report. This discussion contains forward-looking statements based upon current expectations that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those discussed in &#8220;Item&#160;1A. Risk Factors&#8221; and in other parts of this Annual Report. </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">Our most advanced clinical asset, rusfertide (generic name for PTG-300) is an injectable hepcidin mimetic in development for the potential treatment of erythrocytosis, iron overload and other blood disorders. Hepcidin is a key hormone in regulating iron equilibrium and is critical to the proper development of red blood cells. Rusfertide mimics the effect of the natural hormone hepcidin, but with greater potency, solubility and stability. We initiated Phase&#160;2 proof of concept (&#8220;POC&#8221;) studies in the blood disorders polycythemia vera (&#8220;PV&#8221;) in the third quarter of 2019 and hereditary hemochromatosis (&#8220;HH&#8221;) in January&#160;2020. In December 2020, we presented four posters and one oral presentation relating to rusfertide at the American Society for Hematology&#8217;s virtual annual meeting, including updated interim Phase&#160;2 results for rusfertide in PV. We believe these interim results provide evidence regarding the potential of rusfertide to eliminate the need for phlebotomy by controlling hematocrit levels below 45% on an individual patient basis. Rusfertide has a unique mechanism of action in the potential treatment of PV, which may enable it to decrease and maintain hematocrit levels within the range of recommended clinical guidelines without causing the iron deficiency that may occur with frequent phlebotomy. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">We selected PV as our first indication for potential pivotal study in rusfertide and expect to complete patient enrollment in the ongoing Phase 2 clinical trial by mid-2021. We are consulting with regulatory authorities in the first half of 2021 to discuss the registrational clinical development plan. In June&#160;2020, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) granted orphan drug designation for rusfertide for the treatment of PV. In October&#160;2020, the European Medicines Agency granted orphan drug designation for rusfertide for the treatment of PV. In December&#160;2020, the FDA granted Fast Track designation for rusfertide for the treatment of PV. In addition, we expect to disclose preliminary data from our Phase 2 POC study in HH, our second indication, in the second half of 2021. We discontinued development of rusfertide for anemia associated with beta-thalassemia and myelodysplastic syndromes during the first half of 2020. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Our clinical assets PTG-943 and PTG-200 are orally delivered investigational drugs currently in development for inflammatory bowel disease (&#8220;IBD&#8221;), a gastrointestinal (&#8220;GI&#8221;) disease consisting primarily of ulcerative colitis (&#8220;UC&#8221;) and Crohn&#8217;s disease (&#8220;CD&#8221;), that are designed to block biological pathways currently targeted by marketed injectable antibody drugs. Our orally stable peptide approach may offer targeted delivery to the GI tissue compartment. We believe that, compared to antibody drugs, these product candidates have the potential to provide improved safety due to minimal exposure in the blood, increased convenience and compliance due to oral delivery, and the opportunity for the earlier introduction of targeted oral therapy. As a result, if successfully developed and approved, we believe they may transform the existing treatment paradigm for IBD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">PN-943 is an investigational, orally delivered, gut-restricted alpha-4-beta-7 (&#8220;&#945;4&#946;7&#8221;) specific integrin antagonist. We developed PN-943 as a potentially more potent orally delivered, gut-restricted &#945;4&#946;7 backup compound to PTG-100, our first-generation orally delivered gut-restricted &#945;4&#946;7 inhibitor that was being developed for treatment of IBD. In 2019, we completed a Phase&#160;1 single ascending dose (&#8220;SAD&#8221;) and multiple ascending dose (&#8220;MAD&#8221;) clinical study of PN-943 in healthy volunteers to evaluate safety, pharmacokinetics and pharmacodynamics. The pharmacodynamic results indicated that the administration of PN-943 was well tolerated and showed results of target engagement that were </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">suggestive of higher potency for PN-943 as compared to PTG-100. We submitted a U.S. Investigational New Drug application (&#8220;IND&#8221;) with the FDA for PN-943 in December&#160;2019, which took effect in January&#160;2020, and we initiated a Phase&#160;2 POC study in UC in the second quarter of 2020 which is expected to be completed in 2022, subject to delays related to the COVID-19 pandemic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">PTG-200 (also referenced as JNJ-67864238) is an investigational, orally delivered, gut-restricted Interleukin-23 receptor (&#8220;IL-23R&#8221;) antagonist for the treatment of IBD. In May&#160;2017, we entered into a worldwide license and collaboration agreement with Janssen Biotech, Inc. (&#8220;Janssen&#8221;), a Johnson &amp; Johnson company, to co-develop and co-detail PTG-200 and certain related compounds for all indications, including IBD. The agreement with Janssen was amended in May&#160;2019 to expand the collaboration by supporting efforts towards second-generation IL-&#160;23R antagonists, triggering a $25.0&#160;million milestone payment to us. In January&#160;2020, as part of the expanded research collaboration, we announced the identification and nomination of an orally delivered IL-23R antagonist peptide as a second-generation development candidate, triggering a $5.0&#160;million milestone payment to us. Janssen initiated a global Phase&#160;2 POC clinical study for PTG-200 in moderate-to-severe CD in the fourth quarter of 2019. Due to the uncertain effect on the timing of clinical trials caused by the COVID-19 pandemic, we have suspended guidance on a timeline for completion of the PTG-200 Phase&#160;2 study. In October&#160;2020, we announced the selection of two second-generation IL-R antagonists for advancement into clinical development, PN-235 (also referenced as JNJ-77242113) and PN-232 (also referenced as JNJ-75105186). A Phase 1 study was initiated for PN-235 in December 2020 and is expected to be completed in 2021. PN-232 is in the late preclinical stage and we expect to initiate and complete a Phase 1 study for PN-232 in 2021. The advancement of three different oral co-development candidates provides us with several strategic options for development in multiple indications. We are also continuing our joint research efforts to identify additional IL-23R antagonists.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Our clinical assets are all derived from our proprietary discovery platform. Our platform enables us to engineer novel, structurally constrained peptides that are designed to retain key advantages of both orally delivered small molecules and injectable antibody drugs in an effort to overcome many of their limitations as therapeutic agents. Importantly, constrained peptides can be designed to potentially alleviate the fundamental instability inherent in traditional peptides to allow different delivery forms, such as oral, subcutaneous, intravenous, and rectal. We continue to use our peptide technology platform to discover product candidates against targets in disease areas with significant unmet medical needs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">COVID-19 Business Impact </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We are subject to risks and uncertainties as a result of the&#160;COVID-19&#160;pandemic. We are continuing to closely monitor the impact of the COVID-19 pandemic on our business and have taken and continue to take proactive efforts to protect the health and safety of our patients, study investigators, clinical research staff and employees, and to maintain business continuity. The extent of the impact of the&#160;COVID-19&#160;pandemic on our activities is highly uncertain and difficult to predict, as the pandemic and the response to the pandemic continue to evolve. Capital markets and economies worldwide have been significantly impacted by the&#160;COVID-19&#160;pandemic, and the pandemic has contributed to a global economic recession. Such economic disruption could have a material adverse effect on our business. Policymakers around the globe have responded with fiscal policy actions to support the healthcare industry and economy as a whole. The magnitude and overall effectiveness of these actions remains uncertain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">The severity of the impact of the&#160;COVID-19&#160;pandemic on our activities will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic, including the severity of any additional periods of increases or spikes in the number of cases in the areas we, our suppliers and our manufacturers operate and areas where our clinical trial sites are located. Accordingly, the extent and severity of the impact on our existing and planned clinical trials, manufacturing, collaboration activities and operations is uncertain and cannot be fully predicted. We have experienced delays in our existing and planned clinical trials due to the worldwide impacts of the pandemic. Our future results of operations and liquidity could be adversely impacted by further delays in existing and planned clinical trials and collaboration activities, continued difficulty in recruiting patients for these clinical trials, delays in manufacturing and collaboration activities, supply chain disruptions, the ongoing impact on operating activities and employees, and the ongoing impact of any initiatives or programs that we may undertake to address financial and operational challenges. As </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">of the date of issuance of this Annual Report on Form 10-K, the extent to which the&#160;COVID-19&#160;pandemic may materially impact our future financial condition, liquidity or results of operations is uncertain. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We have incurred net losses in each year since inception and we do not anticipate achieving sustained profitability in the foreseeable future. Our net losses were $66.2 million, $77.2 million and $38.9 million for the years ended December 31, 2020, 2019 and 2018, respectively. As of December 31, 2020, we had an accumulated deficit of $283.8 million. Substantially all of our net losses have resulted from costs incurred in connection with our research and development programs and from general and administrative costs associated with our operations. We expect to continue to incur significant research, development and other expenses related to our ongoing operations, product development, including clinical development activities under our worldwide license and collaboration agreement with Janssen, and pre-commercialization activities. As a result, we expect to continue to incur losses in the future as we continue our development of, and seek regulatory approval for, our product candidates. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Janssen License and Collaboration Agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">On May 26, 2017, we and Janssen, one of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson, entered into an exclusive license and collaboration agreement for the clinical development, manufacture and potential commercialization of PTG-200 worldwide for the treatment of CD and UC (the &#8220;Janssen License and Collaboration Agreement&#8221;), which was subsequently amended effective May 7, 2019 (the &#8220;First Amendment&#8221;). The First Amendment expanded the scope of the Janssen License and Collaboration Agreement by supporting efforts towards identifying and development second-generation compounds. Janssen is a related party to us as Johnson &amp; Johnson Innovation - JJDC, Inc., a significant stockholder of ours, and Janssen are both subsidiaries of Johnson &amp; Johnson. During the third quarter of 2017, we received a non-refundable, upfront cash payment of $50.0 million from Janssen. During the second quarter of 2019, we received a non-refundable cash payment of $25.0 million upon execution of the First Amendment. During the first quarter of 2020, we received a cash payment of $5.0 million upon the successful nomination of a second-generation development candidate. See Note 3 to the Consolidated Financial Statements included elsewhere in this Annual Report on Form 10-K for additional information. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Critical Accounting Polices and Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with United States generally accepted accounting principles. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported revenue generated and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management&#8217;s judgments and estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Due to the COVID-19 pandemic, there has been uncertainty and disruption in the global economy and financial markets. We have taken into consideration any known COVD-19 impacts in our accounting estimates to date and are not aware of any additional specific events or circumstances that would require any additional updates to our estimates or judgments or a revision of the carrying value of our assets or liabilities as of the date of issuance of this Annual Report on Form 10-K. These estimates may change as new events occur and additional information is obtained. Actual results could differ materially from these estimates under different assumptions or conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt;">We adopted Accounting Standards Codification Topic 842, <i style="font-style:italic;">Leases,</i> (&#8220;ASC 842&#8221;) effective January 1, 2019. We determine if an arrangement is a lease at inception. Pursuant to ASC 842, operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets, operating lease liabilities, and noncurrent operating lease liabilities on the consolidated balance sheets. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. If our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. Lease terms include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.5pt;margin:0pt;">We record tenant improvement allowances as a reduction to the ROU asset with the impact of the decrease recognized prospectively over the remaining lease term. The leasehold improvements will be amortized over the shorter of their useful life or the remaining term of the lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:31.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We follow Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). Under ASC 606, we recognize revenue when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of ASC 606, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. We apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer. At contract inception, we assess the goods or services promised within each contract, determine those that are performance obligations, and assess whether each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligations when (or as) the performance obligations are satisfied. We constrain our estimate of the transaction price up to the amount (the &#8220;variable consideration constraint&#8221;) that a significant reversal of recognized revenue is not probable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Licenses of intellectual property:</i><span style="white-space:pre-wrap;">  If a license to our intellectual property is determined to be distinct from the other performance obligations identified in an arrangement, we recognize revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring proportional performance for purposes of recognizing revenue from non-refundable, upfront fees. We evaluate the measure of proportional performance each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><i style="font-style:italic;">Milestone payments:</i><span style="white-space:pre-wrap;">  At the inception of each arrangement or amendment that includes development, regulatory or commercial milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. Whichever method is used, it should be consistently applied throughout the life of the contract; however, it is not necessary for us to use the same approach for all contracts. We expect to use the most likely amount method for development and regulatory milestone payments. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our control or the control of the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. If there is more than one performance obligation, the transaction price is then allocated to </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">each performance obligation on a relative stand-alone selling price basis. We recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability or achievement of each such milestone and any related constraint, and if necessary, adjust our estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Royalties:</i><span style="white-space:pre-wrap;">  For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until we perform our obligations under these arrangements. Amounts payable to us are recorded as accounts receivable when our right to consideration is unconditional. Amounts payable to us and not yet billed to the collaboration partner are recorded as contract assets. We do not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Contractual cost sharing payments made to a customer or collaboration partner are accounted for as a reduction to the transaction price if such payments are not related to distinct goods or services received from the customer or collaboration partner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Contracts may be amended to account for changes in contract specifications and requirements. Contract modifications exist when the amendment either creates new, or changes existing, enforceable rights and obligations. When contract modifications create new performance obligations and the increase in consideration approximates the standalone selling price for goods and services related to such new performance obligations as adjusted for specific facts and circumstances of the contract, the modification is considered to be a separate contract and revenue is recognized prospectively. If a contract modification is not accounted for as a separate contract, we account for the promised goods or services not yet transferred at the date of the contract modification (the remaining promised goods or services) prospectively, as if it were a termination of the existing contract and the creation of a new contract, if the remaining goods or services are distinct from the goods or services transferred on or before the date of the contract modification. We account for a contract modification as if it were a part of the existing contract if the remaining goods or services are not distinct and, therefore, form part of a single performance obligation that is partially satisfied at the date of the contract modification. In such case the effect that the contract modification has on the transaction price, and on the entity&#8217;s measure of progress toward complete satisfaction of the performance obligation, is recognized as an adjustment to revenue (either as an increase in or a reduction of revenue) at the date of the contract modification (the adjustment to revenue is made on a cumulative catch-up basis).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The period between when we transfer control of promised goods or services and when we receive payment is expected to be one year or less, which is consistent with our historical experience. Upfront payment contract liabilities resulting from our license and collaboration agreements do not represent a financing component as the payment is not financing the transfer of goods and services, and the technology underlying the licenses granted reflects research and development expenses already incurred by us. As such, we do not adjust our revenues for the effects of a significant financing component.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred, unless there is an alternate future use in other research and development projects or otherwise. Research and development costs include salaries and benefits, stock-based compensation expense, laboratory supplies and facility-related overhead, outside contracted services including clinical trial costs, manufacturing and process development costs for both clinical and pre-clinical materials, research costs, development milestone payments under license and collaboration agreements, and other consulting services.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We accrue for estimated costs of research and development activities conducted by third-party service providers, which include the conduct of pre-clinical studies and clinical trials, and contract manufacturing activities. We record the estimated costs of research and development activities based upon the estimated services provided but not yet invoiced and includes these costs in accrued expenses and other payables in the consolidated balance sheets and within research and development expense in the consolidated statements of operations. We accrue for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers. As actual costs become known, we adjust our accrued liabilities. We have not experienced any material differences between accrued liabilities and actual costs incurred. However, the status and timing of actual services performed, number of patients enrolled, the rate of patient enrollment and number and location of sites activated may vary from our estimates, resulting in adjustments to expense in future periods. Changes in these estimates that result in material changes to our accruals could materially affect our results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.5pt;margin:0pt 0pt 12pt 0pt;">We have received orphan drug designation from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) for our clinical asset rusfertide (generic name for PTG-300) for the treatment of PV and beta-thalassemia and may qualify for a related 25% U.S. Federal income tax credit on qualifying clinical study expenditures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We recognize compensation costs related to stock options accounted for under Accounting Standards Codification Topic 718 &#8211; &#8220;<i style="font-style:italic;">Stock Compensation&#8221;</i> based on the estimated fair value of the awards on the date of grant. We estimate the fair value, and the resulting stock-based compensation expense, using the Black-Scholes option-pricing model. The estimated fair value of the stock-based awards is generally recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the respective awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Black-Scholes option-pricing model requires the use of subjective assumptions which determine the fair value of stock-based awards. Expected volatility generally requires significant judgement to determine. Prior to January 1, 2020, our expected volatility was estimated based on the average volatility for comparable publicly traded biopharmaceutical companies over a period equal to the expected term of the stock option grants. Beginning January 1, 2020, our expected volatility was estimated based upon a mix of 75% of the average volatility for comparable publicly traded biopharmaceutical companies over a period equal to the expected term of the stock option grants and 25% of the volatility of our own stock price since our initial public offering in August 2016. These comparable companies are chosen based on their similar size, stage in the life cycle, or area of specialty. We will continue to apply this process until a longer period of historical information regarding the volatility of our own stock price becomes available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We use the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. We assess the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not that all or some portion of a deferred tax asset will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">At December 31, 2020, our total gross deferred tax assets were $72.9 million and our gross deferred tax liabilities were $1.0 million. Due to our lack of earnings history and uncertainties surrounding our ability to generate future taxable income, our net deferred tax assets have been offset by a valuation allowance of $71.9 million. The deferred tax assets were primarily comprised of federal and state tax net operating loss and tax credit carryforwards. At December&#160;31, 2020, we had $222.8 million of federal net operating loss carryforwards and $214.3 million of state net operating loss carryforwards. $78.7 million of the federal net operating loss carryforwards will begin to expire in 2033, if not utilized, and the remaining $144.1 million have no expiration date. The state net operating loss carryforwards will begin to expire in 2035, if not utilized. As of December 31, 2020, we also had accumulated Australian tax losses of AUD 3.7 million ($2.8 million) available for carry forward against future earnings, which under relevant tax laws do not expire but may not be available under certain circumstances.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Utilization of the net operating loss carryforwards may be subject to a substantial annual limitation due to ownership changes that may have occurred or that could occur in the future, as required by Section 382 of the Internal Revenue Code (the &#8220;Code&#8221;), and similar state provisions. These ownership change limitations may limit the amount of net operating loss carryforwards and other tax attributes that can be utilized annually to offset future taxable income and tax, respectively. In general, an &#8220;ownership change&#8221; as defined by Section 382 of the Code results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points (by value) of the outstanding stock of a company by certain stockholders. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Information regarding recent accounting pronouncements applicable to us is included in Note 2 to the Consolidated Financial Statements included elsewhere in this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Components of Our Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">License and Collaboration Revenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Our license and collaboration revenue is derived from payments we receive under the Janssen License and Collaboration Agreement. See Note 3 to the Consolidated Financial Statements included elsewhere in this Annual Report on Form 10-K for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses represent costs incurred to conduct research, such as the discovery and development of our product candidates. We recognize all research and development costs as they are incurred, unless there is an alternative future use in other research and development projects or otherwise. Non-refundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when payment has been made. In instances where we enter into agreements with third parties to provide research and development services to us, costs are expensed as services are performed. Amounts due under such arrangements may be either fixed fee or fee for service and may include upfront payments,&#160;monthly payments, and payments upon the completion of milestones or the receipt of deliverables.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses consist primarily of the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">expenses incurred under agreements with clinical study sites that conduct research and development activities on our behalf;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">employee-related expenses, which include salaries, benefits and stock-based compensation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">laboratory vendor expenses related to the preparation and conduct of pre-clinical, non-clinical, and clinical studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">costs related to production of clinical supplies and non-clinical materials, including fees paid to contract manufacturers; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">license fees and milestone payments under license and collaboration agreements; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">facilities and other allocated expenses, which include expenses for rent and maintenance of facilities, information technology, depreciation and amortization expense and other supplies.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">We recognize the funds from grants under government programs as a reduction of research and development expenses when the related research costs are incurred. In addition, we recognize the funds related to our Australian </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">research and development refundable cash tax incentive that are not subject to refund provisions as a reduction of research and development expenses. The research and development tax incentives are recognized when there is reasonable assurance that the incentives will be received, the relevant expenditure has been incurred and the amount of the consideration can be reliably measured. We evaluate our eligibility under the tax incentive program as of each balance sheet date and make accruals and related adjustments based on the most current and relevant data available. We may alternatively be eligible for a taxable credit in the form of a non-cash tax incentive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We allocate direct costs and indirect costs incurred to product candidates when they enter clinical development. For product candidates in clinical development, direct costs consist primarily of clinical, pre-clinical, and drug discovery costs, costs of supplying drug substance and drug product for use in clinical and pre-clinical studies, including clinical manufacturing costs, contract research organization fees, and other contracted services pertaining to specific clinical and pre-clinical studies. Indirect costs allocated to our product candidates on a program specific basis include research and development employee salaries, benefits, and stock-based compensation, and indirect overhead and other administrative support costs. Program-specific costs are unallocated when the clinical expenses are incurred for our early stage research and drug discovery projects, our internal resources, employees and infrastructure are not tied to any one research or drug discovery project and are typically deployed across multiple projects. As such, we do not provide financial information regarding the costs incurred for early stage pre-clinical and drug discovery programs on a program-specific basis prior to the clinical development stage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our research and development expenses incurred during the periods indicated:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:38.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:59.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:37.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Dollars in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Clinical and development expense &#8212; rusfertide (PTG-300)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 32,395</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 30,325</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14,304</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Clinical and development expense &#8212; PN-943</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 23,354</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 20,924</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 523</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Clinical and development expense &#8212; PTG-200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 925</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,414</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 16,120</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Clinical and development expense &#8212; PN-235</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 317</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Clinical and development expense &#8212; PTG-100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 540</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 288</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 20,443</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Milestone payment obligation to former collaboration partner</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 500</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pre-clinical and drug discovery research expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 18,453</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,162</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,837</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Grants and tax incentives expense reimbursement, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,478)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (110)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,230)</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 74,506</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 65,003</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 59,497</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We expect our research and development expenses will increase as we progress our product candidates into later stage clinical trials, expand the number of ongoing clinical trials, advance development activities under the Janssen License and Collaboration Agreement, advance our discovery research projects into the pre-clinical stage and continue our early-stage research. The process of conducting research, identifying potential product candidates and conducting pre-clinical and clinical trials necessary to obtain regulatory approval is costly and time intensive. We may never succeed in achieving marketing approval for our product candidates regardless of our costs and efforts. The probability of success of our product candidates may be affected by numerous factors, including pre-clinical data, clinical data, competition, manufacturing capability, our ability to receive, and the timing of, regulatory approvals, market conditions, and our ability to successfully commercialize our products if they are approved for marketing. As a result, we are unable to determine the duration and completion costs of our research and development projects or when and to what extent we will generate revenue from the commercialization and sale of any of our product candidates. Our research and development programs are subject to change from time to time as we evaluate our priorities and available resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">General and Administrative Expenses </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">General and administrative expenses consist of personnel costs, allocated facilities costs and other expenses for outside professional services, including legal, human resources, audit and accounting services, and pre-commercial selling and marketing costs. Personnel costs consist of salaries, benefits and stock-based compensation. Allocated expenses consist of expenses for rent and maintenance of facilities, information technology, depreciation and amortization expense and other supplies. We expect to continue to incur expenses to support our continued operations as </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">a public company, including expenses related to existing and future compliance with rules&#160;and regulations of the SEC and those of the national securities exchange on which our securities are traded, insurance expenses, investor relations, professional services and general overhead and administrative costs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Interest Income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Interest income consists of interest earned on our cash, cash equivalents, and marketable securities, which is comprised of contractual interest, premium amortization and discount accretion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Interest Expense</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Interest expense consists of interest recognized on our long-term debt, which is comprised of contractual interest, amortization of origination fees and other issuance costs, and accretion of final payment fees. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Loss on Early Repayment of Debt</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Loss on early repayment of debt consists of prepayment and final payment fees paid upon the early repayment of our long-term debt.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other Expense, Net</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt 0pt 12pt 0pt;">Other expense, net consists primarily of amounts related to foreign exchange gains and losses and related items.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Results of Operations </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Comparison of the&#160;Year ended December&#160;31, 2020 and 2019</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:53.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Dollar</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="12" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:53.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:34.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Dollars in&#160;thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:53.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">License and collaboration revenue - related party</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 28,628</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 231</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 28,397</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td></tr><tr><td style="vertical-align:bottom;width:53.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Research and development <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 74,506</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 65,003</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 9,503</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 15</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">General and administrative <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 18,638</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 15,749</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,889</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 18</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total operating expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 93,144</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 80,752</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 12,392</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 15</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (64,516)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (80,521)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 16,005</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (20)</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest income</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 900</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,813</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,913)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (68)</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (598)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (169)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (429)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 254</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss on early repayment of debt</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (585)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (585)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 100</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other expense, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (46)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (45)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss before income tax (expense) benefit</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (64,845)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (77,878)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 13,033</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (17)</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax (expense) benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,305)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 691</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,996)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (289)</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (66,150)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (77,187)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 11,037</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (14)</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;padding-left:9pt;text-indent:-9pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1) </sup>Includes $4.1 million and $4.4 million of non-cash stock-based compensation expense for the year ended December 31, 2020 and 2019, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;padding-left:9pt;text-indent:-9pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2) </sup>Includes $3.8 million and $4.0 million of non-cash stock-based compensation expense for the year ended December 31, 2020 and 2019, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;padding-left:9pt;text-indent:-9pt;margin:0pt;">*Percentage not meaningful</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">License and Collaboration Revenue</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">License and collaboration revenue increased $28.4 million from $0.2 million for the year ended December 31, 2019 to $28.6 million for the year ended December 31, 2020. The increase in license and collaboration revenue was primarily due <span style="background-color:#ffffff;">to an update in the amounts forecast for future services remaining to be performed under the </span>Janssen License and Collaboration Agreement, correspondingly increasing our overall cumulative percentage of completion of our performance obligation during year ended December 31, 2020, coupled with continued performance and delivery of services under the ongoing Janssen License and Collaboration Agreement. The increase in license and collaboration revenue for the year ended December 31, 2020 also included the impact of a<span style="background-color:#ffffff;"> one-time cumulative adjustment related to the application of revenue recognition principles following the May 2019 amendment of the Janssen License and Collaboration Agreement that reduced 2019 revenue by $9.4 million. </span>The contract modification resulted in an increase in the transaction price and additional deliverables under the initial performance obligation, leading to an overall corresponding decrease in the cumulative percentage of completion of our performance obligation for the Janssen License and Collaboration Agreement during the second quarter of 2019. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We determined that the transaction price of the Janssen License and Collaboration Agreement was $98.6 million as of December 31, 2020, a decrease of $14.3 million from the transaction price of $112.9 million at December 31, 2019. In order to determine the transaction price, we evaluated all payments expected to be received during the duration of the contract, net of development costs reimbursement expected to be payable to Janssen. We determined that the transaction price includes the $50.0 million upfront payment, the $25.0 million payment received upon the effectiveness of the First Amendment, the $5.0 million payment triggered by the successful nomination of a second-generation compound, $17.9 million of reimbursement from Janssen for services performed for PTG-200 Phase 2 and for second-generation compound research costs and other services, and estimated variable consideration consisting of a $7.5 million milestone payment subject to the completion of a Phase 1 study for a second-generation compound, offset by $6.8 million of net cost reimbursement to Janssen for services performed. The decrease in transaction price from December 31, 2019 to December 31, 2020 was due primarily to a decrease in the forecast of remaining services to be provided under the initial performance obligation. We re-evaluate the transaction price each reporting period and as uncertain events are resolved or other changes in circumstances occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Expenses </span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:53.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Dollar</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="12" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:53.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:34.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Dollars in&#160;thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Clinical and development expense &#8212; rusfertide (PTG-300)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;">32,395</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;">30,325</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;">2,070</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;">7</p></td></tr><tr><td style="vertical-align:bottom;width:53.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Clinical and development expense &#8212; PN-943</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;">23,354</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;">20,924</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;">2,430</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;">12</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Clinical and development expense &#8212; PTG-200</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;">925</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;">9,414</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(8,489)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(90)</p></td></tr><tr><td style="vertical-align:bottom;width:53.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Clinical and development expense &#8212; PN-235</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;">317</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;">317</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;">100</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Clinical and development expense &#8212; PTG-100</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;">540</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;">288</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;">252</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;">88</p></td></tr><tr><td style="vertical-align:bottom;width:53.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Preclinical and drug discovery research expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;">18,453</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;">4,162</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;">14,291</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;">344</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grants and tax incentive expense reimbursement, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(1,478)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(110)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(1,368)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;">*</p></td></tr><tr><td style="vertical-align:bottom;width:53.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;">74,506</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;">65,003</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;">9,503</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;">15</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;min-height:1.43em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;padding-left:9pt;text-indent:-9pt;margin:0pt;">*Percentage not meaningful</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;padding-left:9pt;text-indent:-9pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="white-space:pre-wrap;">  Research and development expenses increased $9.5 million, or 15%, from $65.0 million for the year ended December 31, 2019 to $74.5 million for the year ended December 31, 2020. The increase included a $14.3 million increase in pre-clinical and discovery research expenses, including pre-clinical costs related to our second-generation research collaboration efforts with Janssen, a $2.4 million increase in PN-943 clinical trial and development expenses following the initiation of the Phase 2 trial in UC in 2020, a $2.1 million increase in rusfertide clinical trial and development expenses, including the ongoing Phase 2 trials in PV and HH, and $0.3 million of Phase 1 clinical trial and development expenses for PN-235. These increases were partially offset by a decrease of $8.5 million for PTG-200 clinical trial and development expenses under the Janssen License and Collaboration Agreement due to timing of </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">deliverables and related cost sharing arrangements, and the impact of a $1.3 million reversal of previously recorded reductions to research and development expenses in connection with the tax incentive from Australia in 2019. Research and development expenses for the year ended December 31, 2020 included increased personnel costs due to an increase in research and development headcount from 54 full-time equivalent employees at December 31, 2019 to 59 full-time equivalent employees at December 31, 2020.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">General and Administrative Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses increased $2.9 million, or 18%, from $15.7 million for the year ended December 31, 2019 to $18.6 million for the year ended December 31, 2020 primarily due to increases of $1.4 million in compensation-related expenses to support the growth of our operations, $1.3 million in legal expenses and $0.8 million in insurance expense, partially offset by a $0.6 decrease in other expenses, including accounting fees, market research, recruiting fees and travel expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Interest Income</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Interest income decreased $1.9 million, or 68%, from $2.8 million for the year ended December 31, 2019 to $0.9 million for the year ended December 31, 2020. This decrease was primarily due to the declining interest rate environment and a change in the mix of marketable securities compared to the prior year period, despite higher interest-earning asset balances. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Interest Expense</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Interest expense increased $0.4 million, or 254%, from $0.2 million for the year ended December 31, 2019 to $0.6 million for the year ended December 31, 2020. Interest expense reflects contractual interest, amortization of origination fees and other issuance costs, and accretion of final payment fees on our term loan that funded in October 2019 and was repaid in full in June 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Income Tax Expense</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt 0pt 12pt 0pt;">Income tax expense increased by $2.0 million, or 289%, from an income tax benefit of $0.7 million for the year ended December 31, 2019 to income tax expense of $1.3 million for the year ended December 31, 2020. Our effective income tax rate was (2.0)% for the year ended December 31, 2020 as compared to 0.9% for the year ended December 31, 2019. Our effective income tax rate differs from our federal statutory rate of 21% primarily because our losses cannot be benefited due to our full valuation allowance position. During the second quarter of 2020, our Australia subsidiary sold beneficial rights to discovery intellectual property to our U.S. entity, and the U.S. entity reimbursed the Australia subsidiary for certain direct development costs. Upon completion of the sale, we analyzed tax planning strategies and future income and concluded that a valuation allowance is necessary for our Australia subsidiary.<span style="white-space:pre-wrap;"> Income tax expense for year ended December 31, 2020 reflects this sale of intellectual property rights, cost reimbursements and related adjustments to the deferred tax asset, establishing a valuation allowance and certain uncertain tax position liabilities. Income tax benefit for the year ended December 31, 2019 included a discrete tax benefit of approximately $1.1 million for the 2017 Australia refundable R&amp;D tax offset.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Comparison of the Years ended December&#160;31, 2019 and 2018 </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:53.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Dollar</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="12" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:53.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:34.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Dollars in&#160;thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:53.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">License and collaboration revenue - related party</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">231</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">30,925</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(30,694)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(99)</p></td></tr><tr><td style="vertical-align:bottom;width:53.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Research and development <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">65,003</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">59,497</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">5,506</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">9</p></td></tr><tr><td style="vertical-align:bottom;width:53.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">General and administrative <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">15,749</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">13,697</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">2,052</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">15</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total operating expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">80,752</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">73,194</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">7,558</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">10</p></td></tr><tr><td style="vertical-align:bottom;width:53.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(80,521)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(42,269)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(38,252)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">90</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest income</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">2,813</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">2,566</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">247</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">10</p></td></tr><tr><td style="vertical-align:bottom;width:53.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(169)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(169)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">100</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other expense, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(1)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(20)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">19</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(95)</p></td></tr><tr><td style="vertical-align:bottom;width:53.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss before income tax benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(77,878)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(39,723)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(38,155)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">96</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax benefit</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">691</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">799</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(108)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(14)</p></td></tr><tr><td style="vertical-align:bottom;width:53.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(77,187)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(38,924)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(38,263)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">98</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;padding-left:9pt;text-indent:-9pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1) </sup>Includes $4.4 million and $3.4 million of non-cash stock-based compensation expense for the year ended December 31, 2019 and 2018, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;padding-left:9pt;text-indent:-9pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2) </sup>Includes $4.0 million and $3.5 million of non-cash stock-based compensation expense for the year ended December 31, 2019 and 2018, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">License and Collaboration Revenue </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">License and collaboration revenue decreased $30.7 million, or 99%, from $30.9 million for the year ended December 31, 2018 to $0.2 million for the year ended December 31, 2019. The decrease in license and collaboration revenue was primarily due to a contract modification for the First Amendment to the Janssen License and Collaboration Agreement and the related cumulative catchup adjustment during the second quarter of 2019. The contract modification resulted in an increase in the transaction price and additional deliverables under the performance obligation, leading to an overall corresponding decrease in the cumulative percentage of completion of our performance obligation for the Janssen License and Collaboration Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We determined that the transaction price of the Janssen License and Collaboration Agreement was $112.9 million as of December 31, 2019, an increase of $52.2 million from the transaction price of $60.7 million at December 31, 2018. In order to determine the transaction price, we evaluated all payments to be received during the duration of the contract, net of Phase 2 development costs reimbursement expected to be payable to Janssen. We determined that the transaction price includes the $50.0 million upfront payment, the $25.0 million payment received upon the effectiveness of the First Amendment, the $5.0 million payment triggered by the successful nomination of a second-generation compound, $18.3 million of reimbursement from Janssen for services performed for PTG-200 Phase 2 and for second-generation compound research costs and other services, and $14.6 million of estimated variable consideration, which includes a $7.5 million milestone payment subject to the completion of a Phase 1 study for a second-generation compound. The increase in transaction price from December 31, 2018 to December 31, 2019 was due to an increase in fixed and variable consideration related to the contract modification for First Amendment to the Janssen License and Collaboration Agreement effective May 7, 2019. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Expenses</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:52.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Dollar</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="12" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:52.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:34.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Dollars in&#160;thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Clinical and development expense &#8212; rusfertide (PTG-300)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;">30,325</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;">14,304</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;">16,021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;">112</p></td></tr><tr><td style="vertical-align:bottom;width:52.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Clinical and development expense &#8212; PN-943</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;">20,924</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;">523</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;">20,401</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;">*</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Clinical and development expense &#8212; PTG-200</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;">9,414</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;">16,120</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(6,706)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(42)</p></td></tr><tr><td style="vertical-align:top;width:52.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Clinical and development expense &#8212; PTG-100</p></td><td style="vertical-align:top;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;">288</p></td><td style="vertical-align:top;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;">20,443</p></td><td style="vertical-align:top;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(20,155)</p></td><td style="vertical-align:top;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(99)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Milestone payment obligation to former collaboration partner</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;">500</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(500)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(100)</p></td></tr><tr><td style="vertical-align:top;width:52.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Preclinical and drug discovery research expense</p></td><td style="vertical-align:top;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;">4,162</p></td><td style="vertical-align:top;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;">9,837</p></td><td style="vertical-align:top;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(5,675)</p></td><td style="vertical-align:top;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(58)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grants and tax incentive expense reimbursement, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(110)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(2,230)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;">2,120</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(95)</p></td></tr><tr><td style="vertical-align:bottom;width:52.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;">65,003</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;">59,497</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;">5,506</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;">9</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;min-height:1.43em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;padding-left:9pt;text-indent:-9pt;margin:0pt 0pt 12pt 0pt;">*Percentage not meaningful </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses increased $5.5 million, or 9%, from $59.5 million for the year ended December 31, 2018 to $65.0 million for the year ended December 31, 2019. The increase included $20.4 million of PN-943 clinical trial and development expenses, an increase of $16.0 million in rusfertide clinical trial and development expenses and a $1.3 million reversal of previously recorded reductions to research and development expenses in connection with the tax incentive from Australia, partially offset by a decrease of $20.1 million in PTG-100 clinical trial and development expenses due to the halting of further development during 2018 and related credit adjustments, a decrease of $6.7 million for PTG-200 clinical trial and development expenses under the Janssen License and Collaboration Agreement due to timing of deliverables and a decrease of $5.7 million in pre-clinical and discovery research expenses. Research and development expenses for the year ended December 31, 2019 included increased personnel costs due to an increase in research and development headcount from 49 employees at December 31, 2018 to 54 employees at December 31, 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">General and Administrative Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses increased $2.0 million, or 15%, from $13.7 million for the year ended December 31, 2018 to $15.7 million for the year ended December 31, 2019 primarily due to increases of $1.0 million in personnel costs to support the growth of our operations, $0.7 million in professional fees and $0.3 million in insurance expense. The increase in personnel costs for the year ended December 31, 2019 reflected an increase in general and administrative headcount from 15 employees at December 31, 2018 to 19 employees at December 31, 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Interest Income</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Interest income increased $0.2 million, or 10%, from $2.6 million for the year ended December 31, 2018 to $2.8 million for the year ended December 31, 2019 primarily due to higher interest income related to an increase in marketable securities balances. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Income Tax Benefit</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Income tax benefit decreased $0.1 million, or 14%, from $0.8 million for the year ended December 31, 2018, representing an effective income tax rate of 2.0%, to $0.7 million for the year ended December 31, 2019, representing an effective income tax rate of 0.9%. Our effective income tax rate differs from our federal statutory rate of 21%, primarily because our U.S. loss cannot be benefited due to the full valuation allowance position and reduced by foreign taxes. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity and Capital Resources </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity and Capital Expenditures </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27.35pt;margin:0pt;">As of December 31, 2020, we had $307.8 million of cash, cash equivalents and marketable securities and an accumulated deficit of $283.8 million. Our operations have been financed primarily by net proceeds from the sale of shares of our capital stock and payments under the Janssen License and Collaboration Agreement. During the third quarter of 2017 we received a non-refundable, upfront payment of $50.0 million from Janssen. During the second quarter of 2019, we received a nonrefundable $25.0 million payment from Janssen upon execution of the First Amendment. During the first quarter of 2020, we received a nonrefundable $5.0 million payment from Janssen. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27.35pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:25.3pt;margin:0pt 0pt 13.19pt 0pt;">In September 2017, we filed a registration statement on Form S-3 with the Securities and Exchange Commission (File No. 333-220314) that was declared effective as of October 5, 2017 and permits the offering, issuance, and sale by us of up to a maximum aggregate offering price of $200.0 million of our common stock, preferred stock and certain debt securities (the &#8220;2017 Form S-3&#8221;). Up to a maximum of $50.0 million of the maximum aggregate offering price of $200.0 million could be issued and sold pursuant to an at-the-market (&#8220;ATM&#8221;) financing facility under a sales agreement (the &#8220;2017 Sales Agreement&#8221;). The 2017 Sales Agreement was terminated in 2019. During the year ended December 31, 2019, prior to the termination of the 2017 Sales Agreement, we sold 2,846,641 shares of our common stock for net proceeds of $34.5 million, after deducting issuance costs. We sold 151,273 shares of our common stock pursuant to the 2017 Sales Agreement during the year ended December 31, 2018 for net proceeds of $1.5 million, after deducting issuance costs. The 2017 Form S-3 expired in October 2020. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:25.3pt;margin:0pt 0pt 13.19pt 0pt;">In August 2018, we entered into a Securities Purchase Agreement with certain accredited investors (each, an &#8220;Investor&#8221; and, collectively, the &#8220;Investors&#8221;), pursuant to which we sold an aggregate of 2,750,000 shares of our common stock at a price of $8.00 per share, for aggregate net proceeds of $21.7 million, after deducting offering expenses payable by us. In a concurrent private placement, we issued the Investors warrants to purchase an aggregate of 2,750,000 shares of our common stock (each, a &#8220;Warrant&#8221; and, collectively, the &#8220;Warrants&#8221;). Each Warrant is exercisable from August 8, 2018 through August 8, 2023. Warrants to purchase 1,375,000 shares of our common stock have an exercise price of $10.00 per share and Warrants to purchase 1,375,000 shares of our common stock have an exercise price of $15.00 per share. The exercise price and number of shares of common stock issuable upon the exercise of the Warrants (the &#8220;Warrant Shares&#8221;) are subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described in the Warrants. Under certain circumstances, the Warrants may be exercisable on a &#8220;cashless&#8221; basis. In connection with the issuance and sale of the common stock and Warrants, we granted the Investors certain registration rights with respect to the Warrants and the Warrant Shares. The common stock and Warrants are classified as equity in accordance with Accounting Standards Codification Topic 480<i style="font-style:italic;">, Distinguishing Liabilities from Equity </i>(&#8220;ASC 480&#8221;)<i style="font-style:italic;">,</i> and the net proceeds from the transaction were recorded as a credit to additional paid-in capital. As of December 31, 2020, none of the Warrants have been exercised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:25.3pt;margin:0pt;">In December 2018, we entered into an exchange agreement (the &#8220;Exchange Agreement&#8221;) with an Investor and its affiliates (the &#8220;Exchanging Stockholders&#8221;), pursuant to which we exchanged an aggregate of 1,000,000 shares of our common stock, par value $0.00001 per share, owned by the Exchanging Stockholders for pre-funded warrants (the &#8220;Exchange Warrants&#8221;) to purchase an aggregate of 1,000,000 shares of common stock (subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described in the Exchange Warrants), with an exercise price of $0.00001 per share. The Exchange Warrants will expire ten years from the date of issuance. The Exchange Warrants are exercisable at any time prior to expiration except that the Exchange Warrants cannot be exercised by the Exchanging Stockholders if, after giving effect thereto, the Exchanging Stockholders would beneficially own more than 9.99% of our&#160;common stock, subject to certain exceptions. In accordance with Accounting Standards Codification Topic 505,<i style="font-style:italic;"> Equity</i>, we recorded the retirement of the common stock exchanged as a reduction of common stock shares outstanding and a corresponding debit to additional paid-in-capital at the fair value of the Exchange Warrants on the issuance date. The Exchange Warrants are classified as equity in accordance with ASC 480<i style="font-style:italic;">,</i> and fair value of the Exchange Warrants was recorded as a credit to additional paid-in capital and is not subject to remeasurement. We determined that the fair value of the Exchange Warrants is substantially similar to the fair value of the retired shares on the issuance date due to the negligible exercise price for the Exchange Warrants. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 13.19pt 0pt;">During the year ended December 31, 2019, Exchange Warrants to purchase 600,000 shares were net exercised, resulting in the issuance of 599,997 shares of common stock. As of December 31, 2020, 400,000 of the Exchange Warrants remain unexercised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">In October 2019, we filed a registration statement on Form S-3 (File no. 333-234414) that was declared effective as of November 22, 2019 and permits the offering, issuance, and sale by us of up to a maximum aggregate offering price of $250.0 million of our common stock, preferred stock, debt securities and warrants (the &#8220;2019 Form S-3&#8221;). Up to a maximum of $75.0 million of the maximum aggregate offering price of $250.0 million may be issued and sold pursuant to an ATM financing facility under a sales agreement we entered into on November 27, 2019 (the &#8220;2019 Sales Agreement&#8221;). In May 2020, we completed an underwritten public offering of 7,000,000 shares of common stock at a public offering price of $14.00 per share and issued an additional 1,050,000 shares of our common stock at a price of $14.00 per share following the underwriters&#8217; exercise of their option to purchase additional shares. Net proceeds, after deducting underwriting commissions and offering costs paid us, were $105.3 million. We sold 2,483,719 shares of our common stock pursuant to the 2019 Sales Agreement during the year ended December 31, 2020 for net proceeds of $41.9 million, after deducting issuance costs. As of December 31, 2020, a total of $94.2 million of common stock remained available for sale under the 2019 Form S-3, $31.9 million of which remained available for sale under the ATM financing facility. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27.8pt;margin:0pt;">In October 2019, we entered into a credit and security agreement pursuant to which the lenders party thereto agreed to make term loans available to us for working capital and general business purposes, in a principal amount of up to $50.0 million, including a $10.0 million term loan which was funded at closing (October 30, 2019), with the ability to access the remaining $40.0 million in two additional tranches of $20.0 million, subject to specified availability periods, the achievement of certain clinical development milestones, minimum cash requirements and other customary conditions. In June 2020, we prepaid the outstanding $10.0 million balance on the term loan as well as $0.6 million for related prepayment and exit fees. We did not exercise our option to borrow the $20.0 million second tranche of Term Loans, which expired on December 31, 2020, and therefore have one remaining $20.0 million tranche available under the Term Loan Credit Agreement and no related outstanding balance as of December 31, 2020. Additional information about this credit facility and our long-term debt is presented in Note 9 to the consolidated financial statements included elsewhere in this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27.8pt;margin:0pt;"><span style="background-color:#ffff00;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27.8pt;margin:0pt;">In December 2020, we filed an automatic registration statement on Form S-3ASR and an accompanying prospectus (Registration Statement No. 333-251254), pursuant to which we completed an underwritten public offering of 4,761,904 shares of common stock at a public offering price of $21.00 per share and issued an additional 714,285 shares of our common stock at a price of $21.00 per share following the underwriters&#8217; exercise of their option to purchase additional shares. Net proceeds, after deducting underwriting commissions and offering costs paid by us, were $107.6 million. This Form S-3ASR expires in December 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27.8pt;margin:0pt;"><span style="background-color:#ffff00;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Our primary uses of cash are to fund operating expenses, primarily research and development expenditures and pre-commercialization costs. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">We believe, based on our current operating plan and expected expenditures, that our existing cash, cash equivalents and marketable securities and access to our term loan facility will be sufficient to meet our anticipated operating and capital expenditure requirements for at least the next 12&#160;months from the date of this filing. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. If our planned pre-clinical and clinical trials are successful, or our other product candidates enter clinical trials or advance beyond the discovery stage, we will need to raise additional funding, which may come from raising additional capital, seeking access to additional debt, and additional collaborative or other arrangements with corporate sources in order to further advance our product candidates towards potential regulatory approval, but such funding may not be available at terms acceptable to us, if at all. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">product candidates and to fund operations for the foreseeable future. We anticipate that we will need to raise substantial additional funding, the requirements of which will depend on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the progress, timing, scope, results and costs of our pre-clinical studies and clinical trials for our product candidates, including the ability to enroll patients in a timely manner for our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the costs of and ability to obtain clinical and commercial supplies and any other product candidates we may identify and develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">our ability to successfully commercialize the product candidates we may identify and develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the selling and marketing costs associated with our current product candidates and any other product candidates we may identify and develop, including the cost and timing of expanding our sales and marketing capabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the achievement of development, regulatory and sales milestones resulting in payments to us from Janssen under the Janssen License and Collaboration Agreement or other such arrangements we may enter into, and the timing of receipt of such payments, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the timing, receipt and amount of royalties under the Janssen License and Collaboration Agreement on worldwide net sales of PTG-200, including any second-generation compounds, upon regulatory approval or clearance, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the amount and timing of sales and other revenues from our current product candidates and any other product candidates we may identify and develop, including the sales price and the availability of adequate third-party reimbursement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the cash requirements of any future acquisitions or discovery of product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the time and cost necessary to respond to technological and market developments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the extent to which we may acquire or in-license other product candidates and technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">costs necessary to attract, hire and retain qualified personnel; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the costs of maintaining, expanding and protecting our intellectual property portfolio; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the costs of ongoing general and administrative activities to support the growth of our business.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Adequate additional funding may not be available to us on acceptable terms, or at all. Any failure to raise capital as and when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies. Further, our operating plans may change, and we may need additional funds to meet operational needs and capital requirements for clinical trials, other research and development activities and pre-commercialization costs. If we do raise additional capital through public or private equity offerings or convertible debt securities, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#8217; rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated product development programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24pt;margin:0pt;">The following table summarizes our cash flows for the periods indicated:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:8.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:normal;width:34.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:63.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:normal;width:34.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In&#160;thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash used in operating activities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (72,484)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (41,527)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (49,947)</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash (used in) provided by investing activities</p></td><td style="vertical-align:bottom;white-space:normal;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (90,965)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (53,710)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,213</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash provided by financing activities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 247,626</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 46,036</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 24,115</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash Flows from Operating Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Cash used in operating activities for the year ended December 31, 2020 was $72.5 million, consisting or our net loss of $66.2 million and a net change of $19.0 million in net operating assets and liabilities, partially offset by non-cash charges of $12.7 million. Non-cash charges were primarily comprised of $7.9 million of stock-based compensation, $1.8 million of operating lease ROU asset amortization, a $1.4 million change in net deferred tax asset, $0.8 million of depreciation and amortization, a $0.6 million loss on early prepayment of long-term debt and $0.2 million of amortization of debt issuance costs and accretion of debt discount. The change in net operating assets and liabilities was primarily due to a decrease of $27.0 million in deferred revenue related to the Janssen License and Collaboration Agreement, a $1.9 million decrease in operating lease liability, a $1.1 million increase in prepaid expenses and other assets and a $1.0 million increase in Australia research and development refundable cash tax incentive receivable, partially offset by an increase of $5.8 million in accrued expenses and other liabilities, a decrease of $4.3 million in receivable from collaboration partner, an increase of $1.5 million in payable to collaboration partner, an increase of $0.3 million in accounts payable, and an increase of $0.1 million in other liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Cash used in operating activities for the year ended December 31, 2019 was $41.5 million, consisting of our net loss of $77.2 million, partially offset by a net change of $26.1 million in net operating assets and liabilities and non-cash charges of $9.5 million. The change in net operating assets and liabilities was primarily due to a net increase of $33.5 million in deferred revenue related to the Janssen License and Collaboration Agreement, a decrease of $1.4 million in research and development refundable cash tax incentive receivable and an increase of $1.1 million in accrued expenses and other payables, partially offset by an decrease of $3.0 million in accounts payable, an increase of $2.8 million in prepaid expenses and other assets, an increase of $2.2 million in receivable from collaboration partner and a decrease of $1.9 million in operating lease liability. Non-cash charges were primarily comprised of $8.4 million of stock-based compensation, $1.8 million of operating lease right-of-use asset amortization and $0.7 million of depreciation and amortization, partially offset by a $0.8 million increase in deferred tax assets and $0.6 million of net accretion of discount on marketable securities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Cash used in operating activities for the year ended December 31, 2018 was $49.9 million, consisting of our net loss of $38.9 million and a net change of $18.0 million in net operating assets and liabilities, partially offset by non-cash charges of $7.0 million. The change in net operating assets and liabilities was primarily due to a net decrease of $23.5 million in deferred revenue related to the Janssen License and Collaboration Agreement and an increase of $2.8 million in receivable from collaboration partner, partially offset by an increase of $4.4 million in accounts payable, an increase of $1.9 million in accrued expenses and other payables, an increase of $1.1 million in payable to collaboration partner and a decrease of $1.1 million in prepaid expenses and other assets. Non-cash charges were primarily comprised of $6.9 million of stock-based compensation, $0.5 million of depreciation and amortization and $0.2 million of net amortization of premium on marketable securities, partially offset by a $0.7 million increase in deferred tax assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash Flows from Investing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Cash used in investing activities for the year ended December 31, 2020 was $91.0 million, consisting of purchases of marketable securities of $280.0 million and purchases of property and equipment of $0.5 million, partially offset by proceeds from maturities of marketable securities of $189.5 million. Purchases of property and equipment were primarily related to purchases of laboratory equipment, furniture and computer equipment.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Cash used in investing activities for the year ended December 31, 2019 was $53.7 million, consisting of purchases of marketable securities of $166.9 million and purchases of property and equipment of $1.0 million, partially offset by proceeds from maturities of marketable securities of $114.2 million. Purchases of property and equipment were primarily related to purchases of scientific equipment and leasehold improvements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:22.5pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Cash provided by investing activities for the year ended December 31, 2018 was $2.2 million, consisting of proceeds from marketable securities of $73.8 million, partially offset by purchases of marketable securities of $71.1 million and purchases of property and equipment of $0.5 million. Purchases of property and equipment were primarily related to purchases of scientific equipment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash Flows from Financing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Cash provided by financing activities for the year ended December 31, 2020 was $247.6 million, consisting primarily of cash proceeds from our public offerings of common stock of $213.3 million, cash proceeds from ATM sales of $42.1 million, and proceeds from the issuance of common stock upon exercise of stock options and purchases of common stock under our employee stock purchase plan of $2.8 million, partially offset by early repayment of long-term debt of $10.5 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Cash provided by financing activities for the year ended December 31, 2019 was $46.0 million, consisting of $34.5 million of net proceeds from sales of common stock through our ATM financing facility, $9.8 million of net proceeds from long-term debt and $1.8 million from the issuance of common stock upon exercise of stock options and purchases of common stock under our employee stock purchase plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Cash provided by financing activities for the year ended December 31, 2018 was $24.1 million, consisting of $21.7 million of net proceeds from issuance of our common stock and warrants in a private placement, $1.5 million of net proceeds from sales through our ATM financing facility and $0.9 million from the issuance of common stock upon exercise of stock options and purchases of common stock under our employee stock purchase plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Contractual Obligations and Other Commitments </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.5pt;margin:0pt;">Our contractual obligations include minimum lease payments under our operating lease obligations. See Note 10 to the consolidated financial statements elsewhere in this Annual Report on Form 10-K for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.5pt;margin:0pt 0pt 12pt 0pt;">We enter into agreements in the normal course of business with contract research organizations for clinical trials and with vendors for pre-clinical studies and other services and products for operating purposes, which are cancelable at any time by us, generally upon 30 to 60 days prior written notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.5pt;margin:0pt 0pt 12pt 0pt;">Under the Janssen License and Collaboration Agreement, we share with Janssen certain development, regulatory and compound supply costs. The actual amounts that we pay Janssen or that Janssen pays us will depend on numerous factors, some of which are outside of our control and some of which are contingent upon the success of certain development and regulatory activities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">In June&#160;2012, we entered into a Research Collaboration and License Agreement with Zealand Pharma A/S to identify, optimize and develop novel disulfide-rich peptides to discover a hepcidin mimetic. We amended this agreement on February 28, 2014, at which point Protagonist assumed responsibility for the development program. See &#8220;Item 3. Legal Proceedings&#8221;, &#8220;Item 7. Management&#8217;s Discussion and Analysis &#8211; Contractual Obligations and Other Commitments&#8221; and Note 7 and Note 11 to the Consolidated Financial Statements included elsewhere in this Annual Report on Form 10-K for additional information. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"> <span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_34edb65c_9aed_4222_a749_a2b9986cabc8"></a><a id="Item7AQuantitativeandQualitative_863327"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item&#160;7A.</b></span>Quantitative and Qualitative Disclosures about Market Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate sensitivities related to our investments and borrowings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We had $307.8 million and $133.0 million in cash, cash equivalents and marketable securities at December 31, 2020 and December 31, 2019, respectively. Cash and cash equivalents consist of cash, money market funds, commercial paper and government bonds. Marketable securities consist of corporate bonds, commercial paper and government bonds. A portion of our investments may be subject to interest rate risk and could fall in value if market interest rates increase. Based on our interest rate sensitivity analysis, an immediate 1% increase in interest rates would increase our interest income by approximately $2.3 million, while an immediate 1% decrease in interest rates would decrease our interest income by approximately $0.4 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Approximately $1.0 million and $0.6 million of our cash balance was located in Australia at December 31, 2020 and December 31, 2019, respectively. Our expenses, except those related to our Australian operations, are generally denominated in U.S. dollars. For our operations in Australia, the majority of the expenses are denominated in Australian dollars. To date, we have not had a formal hedging program with respect to foreign currency, but we may do so in the future if our exposure to foreign currency becomes more significant. A 10% increase or decrease in current exchange rates would not have a material effect on our results of operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_f68993c7_27b3_4420_97e8_547ba3147e44"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Item8FinancialStatements_472680"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item&#160;8.</b></span>Financial Statements and Supplementary Data</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PROTAGONIST THERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:90.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:90.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Audited Consolidated Financial Statements</b></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.39%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:90.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ReportofIndependentRegisteredPublicAccou"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Reports of Independent Registered Public Accounting Firm</span></a>s</p></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.39%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">75</p></td></tr><tr><td style="vertical-align:top;width:90.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ConsolidatedBalanceSheets_106330"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Consolidated Balance Sheets</span></a></p></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">77</p></td></tr><tr><td style="vertical-align:top;width:90.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ConsolidatedStatementsofOperations_86382"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Consolidated Statements of Operations</span></a></p></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">78</p></td></tr><tr><td style="vertical-align:top;width:90.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ConsolidatedStatementsofComprehensiveLos"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Consolidated Statements of Comprehensive Loss</span></a></p></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">79</p></td></tr><tr><td style="vertical-align:top;width:90.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ConsolidatedStatementsofRedeemableConver"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Consolidated Statements of Stockholders&#8217; Equity</span></a></p></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">80</p></td></tr><tr><td style="vertical-align:top;width:90.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ConsolidatedStatementsofCashFlows_519948"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Consolidated Statements of Cash Flows</span></a></p></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">81</p></td></tr><tr><td style="vertical-align:top;width:90.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NotestoConsolidatedFinancialStatemen"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Notes&#160;to the Consolidated Financial Statements</span></a></p></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">82</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_59c0fc5e_b691_42cb_af69_5764a0e2daa4"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="ReportofIndependentRegisteredPublicAccou"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Report of Independent Registered Public Accounting Firm</b><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:21.0pt;margin:0pt 0pt 9pt 0pt;">To the Stockholders and the Board of Directors of Protagonist Therapeutics, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:21.0pt;margin:0pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Opinion on the Financial Statements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have audited the accompanying consolidated balance sheet of Protagonist Therapeutics, Inc. (the Company) as of December 31, 2020, the related consolidated statements of operations, comprehensive loss, stockholders&#39; equity and cash flows for the year ended December 31, 2020, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2020, and the results of its operations and its cash flows for the year then ended, in conformity with U.S. generally accepted accounting principles.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Basis for Opinion</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">These financial statements are the responsibility of the Company&#39;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#39;s internal control over financial reporting. Accordingly, we express no such opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Ernst &amp; Young LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have served as the Company&#8217;s auditor since 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Redwood City, California</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 10, 2021</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Report of Independent Registered Public Accounting Firm </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">To the Board of Directors and Stockholders of Protagonist Therapeutics, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Opinion on the Financial Statements </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have audited the consolidated balance sheet of Protagonist Therapeutics, Inc. and its subsidiaries (the &#8220;Company&#8221;) as of December 31, 2019, and the related consolidated statements of operations, comprehensive loss, stockholders&#8217; equity and cash flows for each of the two years in the period ended December 31, 2019, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of<b style="font-weight:bold;"> </b>the Company as of December 31, 2019, and the results of its operations and its<b style="font-weight:bold;"> </b>cash flows for each of the two years in the period ended December 31, 2019<b style="font-weight:bold;"> </b><span style="white-space:pre-wrap;">in conformity with accounting principles generally accepted in the United States of America.    </span></p><p style="color:#3016f2;font-family:'Georgia';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><i style="color:#000000;font-family:'Times New Roman','Times','serif';font-style:italic;">Change in Accounting Principle</i></p><p style="font-family:'Georgia';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p><p style="font-family:'Georgia';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">As discussed in Note 2 to the consolidated financial statements, the Company changed the manner in which it accounts for leases in 2019.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Basis for Opinion </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">These consolidated financial statements are the responsibility of the Company&#39;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated<b style="font-weight:bold;"> </b>financial statements. We believe that our audits provide a reasonable basis for our opinion. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ PricewaterhouseCoopers LLP </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">San Jose, California</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 10, 2020</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We served as the Company&#39;s auditor from 2015 to 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_06efac5c_f1f0_4ad6_94e3_ea1333613bd9"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;"><span style="font-weight:normal;">PR</span>OTAGONIST THERAPEUTICS,&#160;INC.</p><a id="ConsolidatedBalanceSheets_106330"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Balance Sheets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(In thousands, except share data)</b></p><a id="_d85ee536_8077_4a3a_b73e_8350bc0b7210"></a><a id="Tc_GRanCdwQzkCKfkCtPFwbeQ_1_2"></a><a id="Tc_bJ-1zrsgd02r9tf3bCCBTg_2_2"></a><a id="Tc_2gJta0ROyUaR9xPImLOxgg_2_5"></a><a id="Tc_kQri_vKyNk-Jn24ZYgz3Lw_3_0"></a><a id="Tc_YWRtqzrED06YTfbcnX9jKg_4_0"></a><a id="Tc_hwXo3ouof0q5m_jLNfGsmg_5_0"></a><a id="Tc_d84O-vAMuk2iiXblJ3ieRw_5_2"></a><a id="Tc_kVu9pMwdCUW7YXIMV5fe7w_5_5"></a><a id="Tc_u0Wmmwwv_kiYZ7Y0xmBHsQ_6_0"></a><a id="Tc_GJ4Tclhvp0KoRdch3UnweQ_7_0"></a><a id="Tc_krlY0Rij80O4wOuA10KL2A_8_0"></a><a id="Tc_fXGQKzStoESV6ulTd9jt7A_9_0"></a><a id="Tc_zatPFmtDNUKl0kdDSBSugQ_9_6"></a><a id="Tc_PRne959jC0-hlynDAXSnCA_10_0"></a><a id="Tc_mMXsTn_Zb0qsCh3BA_lbaQ_11_0"></a><a id="Tc_5IINQm88xEyb3Q56DTCsyg_12_0"></a><a id="Tc_IEDtSclla0a9ja6xlzjm8A_12_6"></a><a id="Tc_QxnEi6VPbEe_OuCXkmj_tw_13_0"></a><a id="Tc_uJJmAtnajU-AM3cNPRHttQ_14_0"></a><a id="Tc__9AspogtKk-p7AbiV23_8A_15_0"></a><a id="Tc_d5BSDZWJ00Go1pQaCYvAsQ_16_0"></a><a id="Tc_AAzE6KO00Eq3vaQ7kwQEHQ_16_3"></a><a id="Tc_CJX-MECLVU-anU_EVpE5vw_17_0"></a><a id="Tc_R9ZXa0VSP06zUKwLPWh5pQ_17_2"></a><a id="Tc_fcAKDFMEaEuB18Wh2y2qQQ_17_5"></a><a id="Tc_8gwMTQd0J0eTNYMGSOPTqw_18_0"></a><a id="Tc_96W1-sn8VkyfL-VYFx7Kaw_19_0"></a><a id="Tc_4ZDjNpPvPESh_nFSXa6SIg_20_0"></a><a id="Tc_XwXAdBSiwUWPBi-5lZC_qg_20_2"></a><a id="Tc_4SDTO_N5FE6XotpebAKHow_20_5"></a><a id="Tc_67lGvOIs10OCM1zwV6Y_YA_21_0"></a><a id="Tc_7lNkYygM0kOuIy-sHoSy7g_22_0"></a><a id="Tc_rDCjX1vxqkeAvOriO189sQ_23_0"></a><a id="Tc_GqwLiV5XJUGeCf2LLbPQkg_24_0"></a><a id="Tc__c-bqDE1akOBG-DO-sH9Gw_25_0"></a><a id="Tc_moEzFV8uTEiKo-BLoTpZag_26_0"></a><a id="Tc_j4bYv-f9DU-AqzZHIIE7lw_26_3"></a><a id="Tc_iL7pQcbHcU-WhnFrYp5eWw_27_0"></a><a id="Tc_Q1qA2OxjnE2ATuXF3Cc3-Q_27_3"></a><a id="Tc_97gHGp1Wi0OdKpYuAaNyAg_28_0"></a><a id="Tc_E-P4SA7F9U696mc9JrxaKQ_29_0"></a><a id="Tc_VB4RFpbJu0W3uR7_YzyFgg_29_6"></a><a id="Tc_v85jRP6Atkyul3ajHlt0pA_30_0"></a><a id="Tc_LkL5tEdFW0KZJFAfJ7ppcA_31_0"></a><a id="Tc_V03FLCOlNE2co1PWbgn3KQ_32_0"></a><a id="Tc__Z_qJGUh-kCCevlK5horJg_33_0"></a><a id="_3ed86e22_bd0b_47dc_ae0b_23eda004d093"></a><a id="_3ed86e22_bd0b_47dc_ae0b_23eda004d093_2"></a><a id="_3ed86e22_bd0b_47dc_ae0b_23eda004d093_3"></a><a id="Tc_CgY9BtQmNUCqsQPORbFzfw_34_0"></a><a id="Tc_eyglxmfX4keLafUBe3Yk_Q_35_0"></a><a id="Tc_Fx87i7L8GU6HJKuinTpp_w_36_0"></a><a id="Tc_KrqPq9adZEu3oKGbzzQABQ_37_0"></a><a id="Tc_8nlaay6s8ES0HSrKR-uTrw_38_0"></a><a id="Tc_dM_SGeh6qUaWkd3u4yREjQ_39_0"></a><a id="Tc_IVhWOBXHxEu4GNT1uBJ-NA_39_2"></a><a id="Tc_ti8pK4xqbUOwAKk_qqgU6w_39_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash and cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_1xfkqn6FkkOURlgOXUqBUA_5_3">117,358</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_KO59ZgQWQkuXwgMvCOXiMg_5_6">33,006</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" id="Tc_H--sYW5-JkqDltHndsD-bw_6_3">188,451</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" id="Tc_uIRhGbgA10OpUXOieGGE_Q_6_6">100,011</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Restricted cash - current</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashCurrent" scale="3" id="Tc_3MU_wgeZaECmGFGKQDv0OA_7_3">10</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashCurrent" scale="3" id="Tc_UbnSPsThvEezH8CmV3y5aA_7_6">10</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Receivable from collaboration partner and contract asset - related party</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DueFromRelatedPartiesCurrent" scale="3" id="Tc_lMdLGMtXc0aMuux5vED1aw_8_3">2,426</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DueFromRelatedPartiesCurrent" scale="3" id="Tc_AvFfifL860GHKazsMB5TZg_8_6">6,755</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development tax incentive receivable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesReceivable" scale="3" id="Tc_1fPJL5Xcr0qWlJZGJDg31w_9_3">1,084</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_Em60m9RWAUeao9Ku8koFWg_10_3">6,277</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_HYGmhFEPuEesGBb9i1egDQ_10_6">5,529</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total current assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_qYd2C-GwqEaVG6_XL43EXg_11_3">315,606</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_gdzKrQqrPEeXn4d88r50zQ_11_6">145,311</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable securities - noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="3" id="Tc_eVyKqS-BzEiDrWdQPNeYXg_12_3">2,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_KK8oZGh75UmgtRh7OzlFeQ_13_3">1,462</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_OQAM64EMfUa5toEtNM79-Q_13_6">1,681</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted cash - noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="Tc_oq9wXy8evU25iDRr6YzADg_14_3">450</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="Tc_PGfbo5fM5k-MnFqEVzkFqQ_14_6">450</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease right-of-use asset </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_Vhyt_4tZQUSNPxLrNXbs2w_15_3">4,950</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_QOCeqWAmWE6oW-oEkZAOgA_15_6">6,042</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="Tc_yS1nBg43Ukyp3jnyOf4fSQ_16_6">1,433</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total assets </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_lZoIs-401kGIZIcX5xlHzQ_17_3">324,468</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_xwwwgCcMHUGFmxEMrBNqxA_17_6">154,917</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Liabilities and Stockholders&#8217; Equity </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current liabilities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_FbTHJIOv0kuMXzN2m-NVcA_20_3">3,075</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_gO2X-vwG-0KVAK7CIMG78w_20_6">2,790</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Payable to collaboration partner - related party</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="3" id="Tc_UB2sn8r0NUakgB9o0yVWmA_21_3">2,732</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="3" id="Tc_HGe8BBjSEUKn5oc8PZpEow_21_6">1,262</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued expenses and other payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_5DcZOvDU2EG70Uz88c788g_22_3">18,498</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_ktWAtQxvbEKMzH8OIYSbUg_22_6">12,360</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Deferred revenue - related party - current</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_bPtGJk0cSUi0DkxzmhrSIg_23_3">14,477</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_8FjAUV6t8EeJLp_O_hCfRg_23_6">17,738</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating lease liability - current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_nNjT-MVCJECW0t2LoAvkqQ_24_3">1,459</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_x1AiJIwIa0mlt4IHdrqc4w_24_6">1,256</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total current liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_2sc5_-y0EEOZ1bBlzWwnmg_25_3">40,241</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_82REulkqR0qIUXYv4fRt1Q_25_6">35,406</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term debt, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="Tc_rPrDgrxa_EycX5Q9d6PH1Q_26_6">9,794</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred revenue - related party - noncurrent</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="Tc_LMTEoH_npEaYbXw9YhnCvw_27_6">23,792</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease liability - noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_22N0Xa5sTUqV3nRi-OWmVg_28_3">4,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_ofibZrOjDUmIE7LBUOLJdg_28_6">5,961</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_JdXez2GBskCfMGsN2fLNUA_29_3">121</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_h1GjSL5Ms0uJhbfpTDwR0A_30_3">44,862</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_l3I5JC5YUUuNzyhZ1f6tjg_30_6">74,953</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commitments and contingencies (Note 11)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stockholders&#8217; equity:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_hBhZcz4_mEWQGovfdwWndA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_GGZGaYAGdE-_T1w3jKkzJw">0.00001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_02w3suN3JUyyebZCyhpG0A"><ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_NFaFigz4mU-FsDD5dUjKEQ">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_s3V1sEUCBEigiZvwmuuOng"><ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_I45uvbdf_kuk9qOqAkJogw">no</ix:nonFraction></ix:nonFraction> shares issued and outstanding </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_kE3TOWjbKkC77ExmcLKTfQ;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"> &#8212;</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_KKfUiE90KUuaywhloS9gMQ;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_Z4A_qzvjFku7WhxziXMUvg"><ix:nonFraction unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_4zzb3zKGBk-924ZmDXEt6A">0.00001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_SdksiWDEhku_EAOe5svDkg"><ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_qcscwVTvGkKaGnfxeNRooQ">90,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_lgUTYBMrikOiNchXRbkv7w">43,745,465</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_Hs6FurJeiUya2vRV7boSvQ">27,217,649</ix:nonFraction> shares <span style="-sec-ix-hidden:Hidden_zGKgQSrOrEauSny-uH-IKw;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_E8kndXbr3EajcZS50zXaqQ;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">outstanding</span></span> as of December&#160;31,&#160;2020 and December&#160;31,&#160;2019, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_B2SDxtiWdkCPUjOMj_8kQA;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_xVeETI8KxU-fJOYA-X9IVg;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:right;"> &#8212;</span></span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Additional paid-in capital</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_z-3tsjzElkq0PBD-wBdIGQ_35_3">563,389</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_B_ZtN6_ovE-UWCr3CiCgOw_35_6">297,846</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accumulated other comprehensive gain (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="Tc_T_grB8RxY0ugXHCCTMwpBA_36_3">28</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_CGFd3OlCXUqy-PZGzzCZaQ_36_6">221</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accumulated deficit</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_K8unkvd3KkWyClXKuhcAsw_37_3">283,811</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_st_nUL9ISkqsL6BSbXt0NQ_37_6">217,661</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total stockholders&#8217; equity </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_e38rkBONlkiLsrmv2-EbZA_38_3">279,606</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_5kKfulh4ykeqCeu-RPM9Fw_38_6">79,964</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total liabilities and stockholders&#8217; equity </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_L2HeozcBjUKEpD25DtznHQ_39_3">324,468</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_X8fh8JIli0ykr1JcHv33Ug_39_6">154,917</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:23.75pt;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_d34de98b_479c_4e46_a424_de3f4c6e5fff"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTAGONIST THERAPEUTICS,&#160;INC.</p><a id="ConsolidatedStatementsofOperations_86382"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(In thousands, except share and per share data)</b></p><a id="_e317ad75_1d3b_478a_a7e6_64533fd734bd"></a><a id="Tc_gU6WqsON7UmkVmqiP8c01g_1_2"></a><a id="Tc_FaX-wVmbYUmgudgy0bOXVg_2_2"></a><a id="Tc_MzFXtUlULUi6Dx70cJMYHQ_2_5"></a><a id="Tc_s7ve9zEdw0qYdDdmPAFDjw_2_8"></a><a id="Tc_Bjn-jI2NYUeLP43vW_NJFw_3_0"></a><a id="Tc_--h_opGcKkWCkU0FLqy_Jg_3_2"></a><a id="Tc_TosTXo53mUWIYWR5dzDuHQ_3_5"></a><a id="Tc_-v7_QGGiwEqmsb_Zwh0EJA_3_8"></a><a id="Tc_raQn8P6HOECmRBVMUDo39Q_4_0"></a><a id="Tc_VP5LhXdAY0aLlKZGoweGsQ_5_0"></a><a id="Tc_3geBjPvUdk2zbhu-WAZnyA_6_0"></a><a id="Tc_qy5udR4pD02j7LUMfziZoA_7_0"></a><a id="Tc_Q0oubrsRfEm1AxL2EZuUTg_8_0"></a><a id="Tc_rfLtNRxV4Uy_fQ0lEtzvQA_9_0"></a><a id="Tc_6n3Cgf9lEEexODfFAoR-4A_10_0"></a><a id="Tc_kY3YFdo2AEOZZPTrxqM8Sw_10_9"></a><a id="Tc_q0bFc5hiAUG65ExmCqJfdQ_11_0"></a><a id="Tc_U5V1xUIL10uZTooj_N4lyg_11_6"></a><a id="Tc_DmucrEgDOEuoh4d7b5xLcQ_11_9"></a><a id="Tc_S-w_WoGzQUSxpZ2rGpx3bw_12_0"></a><a id="Tc_tOkNKIFMRUGNMSaMkSg1yw_13_0"></a><a id="Tc_HkqOFJ9I20i6FhP6JTqNlA_14_0"></a><a id="Tc_PHgGrmUTNkWo8hjMhq9WzA_15_0"></a><a id="Tc_1lVRPRVmUUSWaYuaG9hPuQ_15_2"></a><a id="Tc_EmMxW1C6r0uteveaYfeM_w_15_5"></a><a id="Tc_F1f0Pn5w1Uim4omSo-v_wg_15_8"></a><a id="Tc_wchGAYbO6kWkaxuLkCxqZQ_16_0"></a><a id="Tc_fdvVpvQA-U-QBc1cT8jHSQ_16_2"></a><a id="Tc_V1ERllDn-UaDE9ovkGDwxA_16_5"></a><a id="Tc_TZTnMTNGCkW7o-sE8ge0kg_16_8"></a><a id="Tc_J3n-Jk2ixE-q6fD7Ig9vog_17_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">License and collaboration revenue - related party</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="ptgx:RevenueFromContractWithCustomerIncludingCumulativeCatchUpAdjustmentToRevenueModificationOfContract" scale="3" id="Tc_XymsiGbaKkm6clhmM7KjDA_3_3">28,628</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="ptgx:RevenueFromContractWithCustomerIncludingCumulativeCatchUpAdjustmentToRevenueModificationOfContract" scale="3" id="Tc_SC_PuobfJkOmIWlci3h3IQ_3_6">231</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="ptgx:RevenueFromContractWithCustomerIncludingCumulativeCatchUpAdjustmentToRevenueModificationOfContract" scale="3" id="Tc_trCkfwt_6EKoM4JhEx6n3g_3_9">30,925</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_YBRph1c-3EeC5OQYWheN1Q_5_3">74,506</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_p72i2J_CF0KvfvTHE0VleQ_5_6">65,003</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_ruzBHw6AnkuGwwIEQqU_pQ_5_9">59,497</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_U2VZqeGbu02v3orZz_qwrw_6_3">18,638</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_ECW20krrY0C_4t-i_mAKaA_6_6">15,749</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_gv15ACH2lkKb3LlR2YmIvA_6_9">13,697</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total operating expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_8sVe8oufhU2aWrEp1Nb-FQ_7_3">93,144</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_f4WEOxR7K0qa1bZa9BsA7A_7_6">80,752</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_kKTB0bQv3Uq0oHRPx5jq3g_7_9">73,194</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_e9V11expqEu5m9aYJDglaw_8_3">64,516</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_yUibFZ9w50utIKrHjc4jJg_8_6">80,521</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_t-qyGFjb4kGWmU03SmZvuw_8_9">42,269</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest income</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_II94ju6SPUSgyy16fsQ0PA_9_3">900</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_W-aGcJ4BKEy8pgbrcLaKdA_9_6">2,813</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_UxfXoKSadUyi8uBRL5ZsuQ_9_9">2,566</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_FrVXeW9AtkaFOdHImIT2Gw_10_3">598</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_Zcj6yGVxnEe-1sUuq14hdA_10_6">169</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss on early repayment of debt</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" sign="-" scale="3" id="Tc_Q9LyQeEYvUagQ_8tMLRatA_11_3">585</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:60.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other expense, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" sign="-" scale="3" id="Tc_bi8YZ7bPLkeF1iAmVEb9CA_12_3">46</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" sign="-" scale="3" id="Tc_G7scI2GGpECzy0JCFlW-cQ_12_6">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" sign="-" scale="3" id="Tc_VUwGvKjeBUuzssn_LG8owg_12_9">20</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss before income tax (expense) benefit</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_n8HUkQeV6Ei23nsxN_WloA_13_3">64,845</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_AMm2H5UiDUaDOPDFi9v9lQ_13_6">77,878</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_Z6eteAj910GpmtSLHyqMMw_13_9">39,723</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income tax (expense) benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_ZcXecLNX9EiYEnQCFTeOtQ_14_3">1,305</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_x7mck_0e5kurf5k7QfvmGQ_14_6">691</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_akmwV6d7C0uU-KcGqJ8yJA_14_9">799</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_IqEcBcFDUUWhnPT1gVuoqg_15_3">66,150</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_Z5nBxVUHIkmsvcTXsbUJoQ_15_6">77,187</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_4DkyCzglLEu1eWXEitR-tw_15_9">38,924</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_nAs_tpU510eP3bKWr5GJpg_16_3">1.92</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_RzzJNDWqJk-lytcgmMP-XQ_16_6">2.98</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_puWMSM0ZhkK28g8ZP4gSoA_16_9">1.74</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average shares used to compute net loss per share, basic and diluted</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_QG8M43hiv0G17WEQjdFPYA_17_3">34,396,446</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_hV-RisUJ60ifqXH55sAaXA_17_6">25,894,024</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_X1OvC0Ilv0-dskuR9OGEUw_17_9">22,364,515</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:23.75pt;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_6c1fb438_67d5_43f0_b39c_58f9fa7a1aca"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTAGONIST THERAPEUTICS,&#160;INC.</p><a id="ConsolidatedStatementsofComprehensiveLos"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Comprehensive Loss</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p><a id="_ec865be3_0a53_4fe0_a33a_88eebfcb2ef7"></a><a id="Tc_7d0H6eGErUGCXIlk7HpanQ_1_2"></a><a id="Tc_qI_96Dqx8E6cdW9lt-8R6Q_2_2"></a><a id="Tc_SIkrhLejcESZLVO9Uc4myw_2_5"></a><a id="Tc_CCiRI3yB3kuSowI6_m0ERA_2_8"></a><a id="Tc_1Li6WHuJkk6P16vj-hydwQ_3_0"></a><a id="Tc_LOLNbt1g7Uq3CLFq45E_Sw_3_2"></a><a id="Tc_KLfrEIRnqEay_qw7ehWh0w_3_5"></a><a id="Tc_o8YZv89ctUyv2lMkGWp0Cw_3_8"></a><a id="Tc_jNgrprC67kSgv2qhWsmUhQ_4_0"></a><a id="Tc_6vi6C26RqE20Knb60kNUsA_5_0"></a><a id="Tc_NtLLS83bWk2Id8gcpNeDiQ_6_0"></a><a id="Tc_P5Op712BqU-7VQfbYvy-ZQ_7_0"></a><a id="Tc_XRKWL0BFyEGgzYNJQkI-JQ_7_2"></a><a id="Tc_jAFnuOORb0yBrmhzo2xU1w_7_5"></a><a id="Tc_CfchvUCsjkuXwxJi6jhUww_7_8"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:61.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_a2bhNxHp5EWDwueSBjPJew_3_3">66,150</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_ZjmyJojjFUaFmM5dPt1QHA_3_6">77,187</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_-eDNmPMNwkO2RI5AVRoDeA_3_9">38,924</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:61.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other comprehensive loss:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:61.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Gain (loss) on translation of foreign operations</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="Tc_SMY3FUuO60-dipXjWdhgGg_5_3">266</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc_v28kGMpjZkm3OdikhoOqwQ_5_6">44</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc_ehto5YePmEyQZw_ck70xrA_5_9">322</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:61.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Unrealized (loss) gain on marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" sign="-" scale="3" id="Tc_b369Jgc16kOAKTbpvt_16A_6_3">17</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="Tc_i3FIy-xlV0-oW09K7_kaiQ_6_6">56</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="Tc_OREAsYtQjEW9kXT6xnWnUw_6_9">95</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:61.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Comprehensive loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_Yfe23P90aEajTQoOVZV04w_7_3">65,901</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_Wyez8V5WTU6UAsCvVqcjIA_7_6">77,175</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_kTPDBy_v-0iva6u9qdvq0Q_7_9">39,151</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_7b77ceae_a186_49fa_a11a_6406d699a8c7"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;min-height:5.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTAGONIST THERAPEUTICS,&#160;INC.</p><a id="ConsolidatedStatementsofRedeemableConver"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Stockholders&#8217; Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(In thousands, except share and per share data)</b></p><a id="_5e9e7b91_48c6_42c7_9d27_5cc9fdca34d4"></a><a id="Tc_KFTWkt9ZtECo3UAtumyY0A_1_10"></a><a id="Tc_BZUx95XL-UW2FMWlrI8CTw_2_7"></a><a id="Tc_scRqa1ALm0GCRHidblbb1A_2_10"></a><a id="Tc_615TGLopCU2ITaV8kxXDwA_2_16"></a><a id="Tc_gcbavU_F0kKdOyfK7pATzg_3_2"></a><a id="Tc_2ASxSmV2EESRLfb2e0-cVw_3_7"></a><a id="Tc_E8BaAOaXOkGtxBew-Td8yQ_3_10"></a><a id="Tc_8x-RWGM3yk2ZIEU-15azsA_3_13"></a><a id="Tc_lBlgeHuPPEqKhNxlHRKdPw_3_16"></a><a id="Tc_VBbCW7LtZUmuKMR7PlaeEQ_4_2"></a><a id="Tc_dVylRatYB06yvCVVe4K8aw_4_7"></a><a id="Tc_ZBjRBIYQAEKHg5zsJfKEbg_4_10"></a><a id="Tc_BxSWprqXbUe72n1T7Oz6Ng_4_13"></a><a id="Tc_W_9wDStm9EyOMjG-0kjL8g_4_16"></a><a id="Tc_3lw2i9wUf0mrXyjhie10LA_5_2"></a><a id="Tc_hd5QkdJD3Uiw0nx8Cebjog_5_4"></a><a id="Tc_hX--h4If60iEFbVizGikhw_6_0"></a><a id="Tc_lio6ElY1eE2OXIhjX7XisA_6_4"></a><a id="Tc_HUCZPmUPgESAwpARZSYMyA_6_5"></a><a id="Tc_fx7WNSOqik-bEzQDvM1azQ_6_7"></a><a id="Tc_xGbZn5hvk0aVaoMEeFEwYA_6_10"></a><a id="Tc_F1tpi5zuPU-zatg-gfy_VQ_6_13"></a><a id="Tc_fW4OiNTWZEOZKjJMxUSLcg_6_16"></a><a id="Tc_GqxjmfjSlkWtBXc5FdNjmA_7_0"></a><a id="Tc_jIsBLEExxUaUPB1O8cxPCQ_7_5"></a><a id="Tc_2h3OHIcONUWYIeD6yBz1xg_7_11"></a><a id="Tc_j0zYCZ8q1EGtA3ObelGw7Q_7_14"></a><a id="Tc_NtLJQncF2k-uivgJAjBIyQ_8_0"></a><a id="Tc_lkG-bfxCz0CXn2tgMsdrmw_8_5"></a><a id="Tc_RQCBOLmMuke9yOvEeRdqeA_8_11"></a><a id="Tc_2zrkYAnLuEuEQ3gdNmPl7w_8_14"></a><a id="Tc_AOWPFyJ860qkRTkM2vkP6w_9_0"></a><a id="Tc_PQeZEq1sPEqkXcJagclntg_9_5"></a><a id="Tc_mbYbIah8Y06mFE6_v3w9YQ_9_11"></a><a id="Tc_A5byX_Y6qkusOblBLQbZ6A_9_14"></a><a id="Tc_cUNWUKvbLE244crGF-XwZg_10_0"></a><a id="Tc_4w_H6A6GHUGy57oAxl8xvQ_10_5"></a><a id="Tc_lcESb-_fa063zQuNM2t-gA_10_11"></a><a id="Tc_q23UFkXHnU-zNcTcwOqcAQ_10_14"></a><a id="Tc_ZkhwysaaPUiCLY6qrqwNeA_11_0"></a><a id="Tc_XSWlvavcY0evFByqivXTkg_11_2"></a><a id="Tc_SDHCmiDby0SCxD6r0oSgcQ_11_5"></a><a id="Tc_tgTCrdeyC0efhnS_93RLgQ_11_11"></a><a id="Tc_6BoJuKSEMECtj1QB6hjU3g_11_14"></a><a id="Tc_NiOPnA8ZJkmi1iY2WGeZ7A_12_0"></a><a id="Tc_Sf9qL4Z5O0C14Y3DSMJz-w_12_2"></a><a id="Tc_xmsERtOf6kehLQ_mYBhHRA_12_5"></a><a id="Tc_4o5V6xbJT0G4ihmnChGkMA_12_11"></a><a id="Tc_3ZUZPRbHZEucSpP_8ucMzw_12_14"></a><a id="Tc_6jh7zFXZwUW7zpPBzpbWnQ_13_0"></a><a id="Tc_1TAuMgIa20uYkxKuFzrGRQ_13_2"></a><a id="Tc_UK_0SoLz6UeYqOxqg9SHaw_13_5"></a><a id="Tc_rabicN0rL0yuwwEnuP0kOA_13_8"></a><a id="Tc_r_yWz9yyP02Pf-1uV303yw_13_14"></a><a id="Tc_EP7MiyW93kK8te_SYqku-A_14_0"></a><a id="Tc__f9Jf8Vg00moxTQi3SWlPQ_14_2"></a><a id="Tc_z8mHIdDfvk-HMk2Q733plw_14_5"></a><a id="Tc_YFBORloNv0KNOChRWkM8WA_14_8"></a><a id="Tc_aMSNuLxO5E2H4TtFkt79MQ_14_11"></a><a id="Tc_r73XAKhv_USiaMgpcr6Qlw_15_0"></a><a id="Tc_PT8pz4b7Kk29ktB3eYF0tA_15_5"></a><a id="Tc_aUCGrAd5Fk6ILs0xX_hjyw_16_0"></a><a id="Tc_N0VN8cH3kUyT19O-klS1Yg_16_5"></a><a id="Tc_Eg50lS3MZUysUz3fl-t3NQ_16_11"></a><a id="Tc_Xa55NCOUw0STjsBxnePqWg_16_14"></a><a id="Tc_U1fFVqTkD0K4o71pNCw-MA_17_0"></a><a id="Tc_tRg4t16dt0-qC25aIOdSiQ_17_5"></a><a id="Tc_GQK4oVtIhUmROxZcuPW7Mg_17_11"></a><a id="Tc_Fz7JMyf2UUuD-BWc2CRZIA_17_14"></a><a id="Tc_JDeRim4wnki25AbIjsydWg_18_0"></a><a id="Tc_PalI0fTiB06Oz-1TGgUOQQ_18_5"></a><a id="Tc_9EPT4V_cJ0ynd75miwKa8w_18_8"></a><a id="Tc_-6m-IYN3AkuDB9ltnEKSkQ_18_11"></a><a id="Tc_oPO1ygQhJUiKExlUVSwazQ_18_14"></a><a id="Tc_fVmhs0z880eiJSJwU-AnXg_18_17"></a><a id="Tc_S2K8XDs3oEyrwIrnyQvmiQ_19_0"></a><a id="Tc_vQ0A93tixESLJfDekuEMjQ_19_2"></a><a id="Tc_Gb-MdQXLhUGs3QgNchr9Sg_19_5"></a><a id="Tc_vIVg2Kf01Eyj9EFVPlXgKg_19_11"></a><a id="Tc_mMV4mnpRWkKuf3vg11tbZQ_19_14"></a><a id="Tc_mBIYFhMFO0aYDv0hbpk5TA_20_0"></a><a id="Tc_sLL5oIt2jEek_kwfJbiuVA_20_2"></a><a id="Tc_b2ibhkfks024LxIO4NBiuQ_20_5"></a><a id="Tc_GMszeDkPGku6-JRRsIztBw_20_8"></a><a id="Tc_XfP2zvw8HUmHy9ockK8jSA_20_14"></a><a id="Tc_EVzfTgMwt0e3g2P_itPy3w_21_0"></a><a id="Tc_5V7AJqq1nUiLf6GwG0VHoQ_21_2"></a><a id="Tc_AaRXqrWlKkeFMCTC9CmClQ_21_5"></a><a id="Tc_aPMNK18Trk2lHPotKtHQtA_21_8"></a><a id="Tc_rQzOlY4BHEeGUelQwDmxPw_21_11"></a><a id="Tc_wwQ4VXQ_80Kp5Us3VEUaIw_22_0"></a><a id="Tc_KZQlfSSoGUqIfIQjyoAXdw_22_5"></a><a id="Tc_Sxl4xtb0V0aoJyiFm3UL0Q_23_0"></a><a id="Tc_cv2ySwF3cU29du4nCwvMog_23_5"></a><a id="Tc_og405Ub0tEKgveZbZ2ZCJA_23_11"></a><a id="Tc_F6iCxu5RjUO_NeL50kmSWw_23_14"></a><a id="Tc_mcr4w7murECrnVKuyItPww_24_0"></a><a id="Tc_O-cuUVrmnEKHyb2EIe1PWA_24_5"></a><a id="Tc_hlYfGIDVTUyl3IAYeJdenw_24_11"></a><a id="Tc_dxOxFMD8PkGJbXEQL7hERA_24_14"></a><a id="Tc_ps6e7yzsWEK2xJj2dB-XuQ_25_0"></a><a id="Tc_qT8DiKx4zEWljcuemH-DRg_25_5"></a><a id="Tc_JsrHrhtPe0CipiWOHM6Cpw_25_11"></a><a id="Tc__9BF4BnkQUKodDvkS2Cweg_25_14"></a><a id="Tc_KEKtyO0HlEWsKAtf2OGo3Q_26_0"></a><a id="Tc_9aXfYo07t0uyO_6_TEOmGw_26_2"></a><a id="Tc_KMVJUp1YL0CPYBQIBWfBrQ_26_5"></a><a id="Tc_XONuV-yhoUmjB_xd-BAMHQ_26_11"></a><a id="Tc_dTet-uXKC06ZR2AniCKrYA_26_14"></a><a id="Tc_TIxdAxlJrEyjTw9mwsjj7Q_27_0"></a><a id="Tc_xScyjku_-UqWkAOcyYwFLw_27_2"></a><a id="Tc_apL06AB3fEuZUkxA-wJfiQ_27_5"></a><a id="Tc_WWPV60RTZE6x27aWgpDYqw_27_8"></a><a id="Tc_MhPQylOPt0ahMCfR4xKf7w_27_14"></a><a id="Tc_VZ0HQT8WOkeOHNG8WqF25Q_28_0"></a><a id="Tc_KmxrkICWYkuRQbavZszeaw_28_2"></a><a id="Tc_WDuXC-bk90CVssxEowE4ZA_28_5"></a><a id="Tc_KpnzQO0jM0-oVatymgPS9g_28_8"></a><a id="Tc_DQAeBpvMEU-MWpecAyKi1Q_28_11"></a><a id="Tc_2OvlFexY-06PryiEfVJ5mg_29_0"></a><a id="Tc_mBYyStCi8kyrK075L2TTmA_29_4"></a><a id="Tc_34Db6xDkokyt_aZs8zwBzg_29_5"></a><a id="Tc_YQSZjptvI0-oPZ8XmPCNHw_29_7"></a><a id="Tc_vFK3WZHcyUKbc1xF9bn6XQ_29_10"></a><a id="Tc_5rUw7URX7EG1W3pN1L7e3g_29_13"></a><a id="Tc_TiGWaq0IJEGdDyBVvW4jEg_29_16"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:15.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gain (Loss)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:40.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Balance at December&#160;31,&#160;2017</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ruvLYZdTr0WCWpXD9VpjZw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Tc_Z1oVUovacU670DuxJgOZdw_6_2">21,088,306</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2yPAw-zRyEu3cnkGbo1BJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_G-XNnv9Z2UCbmWDK3NyzjQ_6_8">222,188</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_xs61-k8jCUqUc6YQqT9vow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_Ja_2zvTNj0a4uCZcvo5aYg_6_11">6</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jUszAT7WFEGWt9BqEE93VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_EVPgL9_3mkC0sn3ksLzb4w_6_14">101,550</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2017_uBPncpspM02T8SbWW1EWfg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_gvtwKtyieUSj0n6nUoCxHg_6_17">120,632</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock and warrants upon private placement, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YxGs3yboJkG0guGsknqgmA" decimals="INF" format="ixt:numdotdecimal" name="ptgx:StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants" scale="0" id="Tc_dp4gvgT05ECcxREUV-4IRw_7_2">2,750,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iSQxa82RA0epFzR7vgagyQ" decimals="-3" format="ixt:numdotdecimal" name="ptgx:StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants" scale="3" id="Tc_zVhTWikfw0q9-kzIOFBK9g_7_8">21,673</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="ptgx:StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants" scale="3" id="Tc_YgkZolkgrUevSuYyJ9txjQ_7_17">21,673</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:40.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock pursuant to at-the-market offering, net of issuance costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_DzfKu3ClMU-xwF3bQXP75g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_kffaRRhBFkCPpQDOc903FQ_8_2">151,273</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_pKAkXlxvhUWymzMXd4z0KQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_24DzNA9mwkCUoVyy9HIwDw_8_8">1,508</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_g3Hzv49Z9UGzLyh7mHry3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_leKbQEdfG0qLEKMBX3QtKA_8_17">1,508</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock under equity incentive and employee stock purchase plans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YxGs3yboJkG0guGsknqgmA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="Tc_L3s1-nufZ0iyNp4LLItC4g_9_2">197,640</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iSQxa82RA0epFzR7vgagyQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_jmnrmeeDD0uVgRzwcsM_uQ_9_8">934</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_j8JimrCvikCUbJod_55pMg_9_17">934</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:40.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Retirement of common stock in exchange for common stock warrant</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YxGs3yboJkG0guGsknqgmA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="0" id="Tc_cxulgiHsfkmcxTZfzKxupQ_10_2">1,000,000</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iSQxa82RA0epFzR7vgagyQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="3" id="Tc_R5PuqkihMkuO0Ya2jLot9A_10_8">6,670</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="3" id="Tc_f7Dn-Tua00Krml_ODU6Udg_10_17">6,670</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:40.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock warrant in exchange for retirement of common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iSQxa82RA0epFzR7vgagyQ" decimals="-3" format="ixt:numdotdecimal" name="ptgx:StockWarrantIssuedDuringPeriodValueInExchangeForRetirementOfCommonStock" scale="3" id="Tc_u6AG3dizzEq3sXGDAY8odg_11_8">6,670</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="ptgx:StockWarrantIssuedDuringPeriodValueInExchangeForRetirementOfCommonStock" scale="3" id="Tc_Wtttwva0fEyUaJhu3y_NRg_11_17">6,670</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:40.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Stock-based compensation expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iSQxa82RA0epFzR7vgagyQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_0bXyNtTvEUqM-7gYF1Lv5Q_12_8">6,919</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_XATsGkLGcUa_nyYHKSg2HQ_12_17">6,919</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Other comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DrgcQsWLEUegsx9gQx7K3w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc_YMQ__0-fl0m7cB0-OjquWw_13_11">227</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc_v7rA5-VbmUWfYVXl9gstWQ_13_17">227</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:40.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_e0vNep3u2EaW55wxjoopSw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_1CQ1mbL8cUyA0PmjlI8wrw_14_14">38,924</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_YYW7s28UH0Cs-k7AMwaVUA_14_17">38,924</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:40.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Balance at December&#160;31,&#160;2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ZQ8gS7l_jUWwlHn2F0NYhw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Tc_SdIajRUKxkKu849bTgQqDQ_15_2">23,187,219</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8FClLya93E-DGTAwVTTPLg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_RXkrVmhXXUel90OHWbd9tA_15_8">253,222</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_XXYc_qkz7EiiqGkSkihtnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_Xmv73yhpu0SgaI3AzyHERQ_15_11">233</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Ju5ZnA-BP0-NMMz3dq161g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_HsSXPuTqZEy6zNZBLMG3yw_15_14">140,474</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2018_rK3dysi-wkKgewxxLVB-Eg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_lSMFWyqmS0WSy6f6OVc8zA_15_17">112,515</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:40.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock pursuant to at-the-market offering, net of issuance costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_s2huIh7nUE-p0G6YC_4NhQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_0DCq8mqPHUuOCteelX-wPg_16_2">2,846,641</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_yGP8DkufmUSzKSdAVZGGrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_cheyjiaa9kyIqQqL7dbVHg_16_8">34,492</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_yOGBS9pihEKHtHPrOQel3w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_QvCjRHOsWkyt77asqfydOA_16_17">34,492</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock under equity incentive and employee stock purchase plans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bsxNEJcruUKB7husbni8Lw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="Tc_gRjBpIS1QUy1CHJuouBPog_17_2">583,792</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_enQYGgNfqUCc5y0GKYBXkg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_Vt9TbXLr9EymEOF1PDZtLg_17_8">1,779</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_QX3sI256gEitJcBzslwdmw_17_17">1,779</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:40.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock upon exercise of Exchange Warrants</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bsxNEJcruUKB7husbni8Lw" decimals="INF" format="ixt:numdotdecimal" name="ptgx:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="Tc_nhWwkKizOkiMG3sG6GviHA_18_2">599,997</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:40.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_enQYGgNfqUCc5y0GKYBXkg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_xa1Qwdsf1kGOYHzC0ZDMvQ_19_8">8,353</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_kMymqk5nDEuVFee1_7HklA_19_17">8,353</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:40.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Other comprehensive gain</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a0-ROxHHoku-VkXZ66GSxQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="Tc_mRaMJQn_wUmj7RuI-bB7_w_20_11">12</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="Tc_VxezL6p570m6PspsN0njqg_20_17">12</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_hM1ehx9ooUyOxNDleNQQrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_szjrh57WpUeR3MQMjYPGdg_21_14">77,187</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_hL2F9ZPj4kSUaNKMgAGcDg_21_17">77,187</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:40.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Balance at December&#160;31,&#160;2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_CPGeoM_E_U2hv7Q6-PEH9g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Tc_24qM32JDLEyH4mxMfeds9g_22_2">27,217,649</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_PlWiT4oT-U-bNw8fFk2KMA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_tRk6bp-oPkG4koBZ1nQ__g_22_8">297,846</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_uLTlN99bs0KmTjmkSZDZtQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_4s9LEcSBiE-VcOayTfoeFg_22_11">221</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__O0aR-_h3kehqx2ICyExMA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_rQKGZUombkyXPnt1XFNHUQ_22_14">217,661</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_NS9Oxi6GM02ntVOKNir_Jg_22_17">79,964</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock pursuant to public offerings, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YoX0pmi6v0e7iaLUqL8YHg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_MgSj0mkMlUODtIRzOO32XQ_23_2">13,526,189</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NemxNYQEjkS5VxdYCUEGfA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_nngczcALqUi7pid4k3WW1Q_23_8">212,974</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_GxcsIB0ZIUmRIrpIV9MH-g_23_17">212,974</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:40.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock pursuant to at-the-market offering, net of issuance costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_8hhxYFRmo0SmVd81EZvSIw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_94Gi9KxU3EGkpOnxSdJjnw_24_2">2,483,719</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_1odXtzTk20OYdf78bv-6Bg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_YFXbW9_4QU-gWJOx0Zhj4A_24_8">41,871</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_fuC6tZWyUkSX0CU0In2zWQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_hc2NjrSrA02Ck32EjTJcLg_24_17">41,871</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock under equity incentive and employee stock purchase plans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YoX0pmi6v0e7iaLUqL8YHg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="Tc_8-Q0KAMz5k6rxSg-2NDDeA_25_2">517,908</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NemxNYQEjkS5VxdYCUEGfA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_N62pwiP68kuwmtL0t-AB1g_25_8">2,799</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_CmYWIesx2UO0d1zrQQFbdA_25_17">2,799</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:40.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Stock-based compensation expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NemxNYQEjkS5VxdYCUEGfA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_UidDxU-JLUmcypnY81p2_A_26_8">7,899</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_6MCYOV1iNE6jPsGqQUoJWA_26_17">7,899</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Other comprehensive gain</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_NzJb7MJr5kOz1KdJ49FjiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="Tc_zTrrIaI2d0ij6UCaOF0oeQ_27_11">249</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="Tc_oDNeJSGujkKbDM_Vi5NVEQ_27_17">249</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:40.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_8neM6oYNfUCXGVbkjiKc6Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_JsaniQlquUuaeJ2ZWg9KyA_28_14">66,150</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_l_wxD8-S2kGq3rPs1lEEEQ_28_17">66,150</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:40.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Balance at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_E5rQEhmdCkiUzPRvbbp87g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Tc_XA7djNyg4UGp_lB_20m3bQ_29_2">43,745,465</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kO1ACPpowkmGPJDGZK-oJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_oRfRN8JbfUmmHTWoS5v9eg_29_8">563,389</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Snnu9PZVQ0SEUhYgRyxRiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_x-FiCWu1uUSWWrVPRPdTVQ_29_11">28</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dCBVr6oE30ePiiOHcTfKVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_vNRwcwcozUa9RPG4O2GznQ_29_14">283,811</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_E_3O4Vg7zUm6ZDhuoA7b2Q_29_17">279,606</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:23.75pt;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_6e333348_5d6f_455a_8bd4_fefbc26fd250"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;min-height:5.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTAGONIST THERAPEUTICS,&#160;INC.</p><a id="ConsolidatedStatementsofCashFlows_519948"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_b64e3133_1647_4b12_bb4c_9262aa5c926a"></a><a id="Tc_CDdinAivU0KKwoqYimZFsA_1_2"></a><a id="Tc_EQhVuVEBkE2sHX3ql-sgDw_2_2"></a><a id="Tc_-4OdD0fPJUGMfPm7TFqUNg_2_5"></a><a id="Tc_HGwGYLBOlUSDQFpUOYmUpQ_2_8"></a><a id="Tc_UQ9Rq7Dc3EG7n5qc0NDmAw_3_0"></a><a id="Tc_e4Xv42SQJUOu8M45AtIvIQ_4_0"></a><a id="Tc_Mew4p6_XMESd3JeWXsBu6g_4_2"></a><a id="Tc_W7iLbF80lUyB8dZAPowW7w_4_5"></a><a id="Tc_KVlsTvRPAEygmKMcCoC0FQ_4_8"></a><a id="Tc_anZLhr9LNEaW1tnOJyzlNA_5_0"></a><a id="Tc_cVrGRpdHVE2HV9Og3e_Cjw_6_0"></a><a id="Tc_hGfEpbA3dU-qRBi7uRx6AQ_7_0"></a><a id="Tc_das8l2eVGU2V5SWRapiPlw_7_9"></a><a id="Tc_7g0PQfpzF0GumJV4mcU5VQ_8_0"></a><a id="Tc_dRILxxpRFU-UHJxnT-oblQ_9_0"></a><a id="Tc_XV4ViNd2T0GmG7874EbDxA_9_6"></a><a id="Tc_OExffAHHS0u4RQc8dyzvpg_9_9"></a><a id="Tc_Wf8RwXjTOkiEusFzJRbYgA_10_0"></a><a id="Tc_cW45eCOIpkKcMsAQl-pJ6g_11_0"></a><a id="Tc_S5j6gxum8UGkEoF_FSW8fw_11_9"></a><a id="Tc_8IcPej0v4kK92T9yk7PUCw_12_0"></a><a id="Tc_n13uX0hrikmW5ZNeCOOS8w_12_3"></a><a id="Tc_X3gmRP5gskq2xYykC2aC3w_12_9"></a><a id="Tc_bqScqOD6J0eATfALDuNBfA_13_0"></a><a id="Tc_AobhPQNKZky_3aV4g5ka6Q_14_0"></a><a id="Tc_JNuufZSaLkmTZ94vhWvI2w_15_0"></a><a id="Tc_SaYkhEySpUiNhajLgMDNmw_16_0"></a><a id="Tc_Y3OWjms-QkqFb0YJeqWUHw_17_0"></a><a id="Tc_ihDDT7R4fkCX0JsgsxteEQ_18_0"></a><a id="Tc_s6UK7KlkG0OzqSEGmRouZw_19_0"></a><a id="Tc_wkHqY2uCEkSmrrDL-2j7AA_20_0"></a><a id="Tc_RsKBjV2z50WwtbAyKe4QZg_21_0"></a><a id="Tc_pIHni4hyw0enH4bMdy8Arw_22_0"></a><a id="Tc_G_qsUZwyBkuStSQf-62Oqw_22_9"></a><a id="Tc_QGx8GXOPxESfeVfJxR6nkA_23_0"></a><a id="Tc_2uGqkAZgKUSvYCttHL0_Qw_23_6"></a><a id="Tc_KspaJM9W80yE3D5dvzbBMg_23_9"></a><a id="Tc_EOiZJRBa1EiowKHp2SrVsA_24_0"></a><a id="Tc_0TvOB0CzxUylq9wi3TQw6w_25_0"></a><a id="Tc_-yGXEXz0ukqKFQqdPAlbAQ_26_0"></a><a id="Tc_E_jdYFXF30KX88Z8mB90iQ_27_0"></a><a id="Tc_8GfGTlnLPEeST3LFjtHhvQ_28_0"></a><a id="Tc_NMjnSqlieUym0qZa132zrA_29_0"></a><a id="Tc__02eCy2qZUy2px9Mje3qcQ_30_0"></a><a id="Tc_vlMHC0PzmUCHla9h9WXuNw_31_0"></a><a id="Tc_OmVM7uEcHEicsj-YRpLr5Q_31_6"></a><a id="Tc_N2syrivmmUuAp31TkRoCmg_31_9"></a><a id="Tc_RuhgZpYFqE6ko1_60n3Odg_32_0"></a><a id="Tc_jhJTDQRCk0eSY7gWGjKoYg_32_3"></a><a id="Tc_HQADIqFT6E6oxeBCv3NAJQ_32_6"></a><a id="Tc_BBzHc2VLzkKCol1rv_nwEA_33_0"></a><a id="Tc_J6krx_NXqUOzgnVO9f1ApA_34_0"></a><a id="Tc_Nhs5DEOblEOYsr8jYprU5w_35_0"></a><a id="Tc_kLTPkWoplkuOgT53OAlQPA_35_3"></a><a id="Tc_y4D4Et8GvkO2ltQWqNH63A_35_9"></a><a id="Tc_6nUmkCIeyEmFaH8Hf4w30w_36_0"></a><a id="Tc_SuTrWW_ItkCxkV9fzZi-gA_36_6"></a><a id="Tc_b5bg7a8sfUGTA53xlqg-Qg_36_9"></a><a id="Tc_RINxBLYMM06ffLATuWrfTg_37_0"></a><a id="Tc_Rx-0cqVj9EyyRkCM4YPFBw_37_6"></a><a id="Tc_t1DxRdcbRUuAme0gpFdEAg_37_9"></a><a id="Tc_nv_THtZufEevMiWmygEbwA_38_0"></a><a id="Tc_mSER5VQVLUe0Wo9GSmBA3g_39_0"></a><a id="Tc_cxRE679e4kes5Yq8UNhtcQ_40_0"></a><a id="Tc_mXh9NDdm2Eq-uEay7LdQ1Q_41_0"></a><a id="Tc_H6NVcXukr0Or4oeWSgn36Q_42_0"></a><a id="Tc_fZ6fohhuRUCz71TBVRhaBg_42_2"></a><a id="Tc_KSWO0MQD5kuV_j4BECYtQg_42_5"></a><a id="Tc_YlwJr-fEEUeqE0ZiUEfK3A_42_8"></a><a id="Tc_gO6xdOM9MEKMdZ-nbUfEiQ_43_0"></a><a id="Tc_nfRX5spgSUuPdUulWTvasA_44_0"></a><a id="Tc_PPnoj_pKX0CmhRt_Y8l1Sw_44_2"></a><a id="Tc_qLtzkrqbeUemnK44u9Dhpw_44_5"></a><a id="Tc_PlW9wwvaDkGO89Bm5i8QoQ_44_8"></a><a id="Tc_En4h6oEOo02DINWYs93VPw_44_9"></a><a id="Tc_uZODuZDfW0CJvpAbbywOFg_45_0"></a><a id="Tc_nFCnjhdZBk6Uvnk_v16tQg_46_0"></a><a id="Tc_9T-ZJwM5xkOVdbyteE4_Dw_46_2"></a><a id="Tc_ytlCfCJS_0yF14rxIOc5uQ_46_5"></a><a id="Tc_lJBsGvkVxEOvULqI2xAQOA_46_8"></a><a id="Tc_TeWUN1pwbEqIVp2pWZ4TRw_46_9"></a><a id="Tc_GVqgr8BLBU6zCJlfqHzpwA_47_0"></a><a id="Tc_0xlcz2AMPUKMPBvy8que6g_47_2"></a><a id="Tc_upyaYWA4iUqVTZuhkG45KA_47_5"></a><a id="Tc_lN_YuTd9RkqcHXD1HSwhjA_47_6"></a><a id="Tc_8U_RLtxVq0m_PP7SHQYyHg_47_8"></a><a id="Tc_zFOEVjRvAkWaewgHIzoR7Q_47_9"></a><a id="Tc_BCJJ8DkqiUao2SKW9BQKVQ_48_0"></a><a id="Tc_GhAVrfP3_U23c-fdfXJozw_48_2"></a><a id="Tc_lsxQdkSlsEiqT355wB9Wog_48_5"></a><a id="Tc_uTGAIPVbIkSO49oBfx4lbQ_48_6"></a><a id="Tc_2rt2nSIw9UiYJdv-4zI7hw_48_8"></a><a id="Tc_v5u3evVCZEeEGls9EmIWLw_48_9"></a><a id="Tc_FWHb2ch32Eq4Uf1cc2xZxw_49_0"></a><a id="Tc_NgJXc52qQ0ir6csxLwSlLQ_49_2"></a><a id="Tc_8Aw1wDkHPkyhN3nTBbJMlA_49_5"></a><a id="Tc_5UVqD3cvdUCIXaRf_-GtwQ_49_8"></a><a id="Tc_RAytl04uGEOoNdxauxhNsQ_50_0"></a><a id="Tc_n5ETj1qY70WZlTaI2ZPyHA_50_2"></a><a id="Tc_FbAF7e92vUuVNQL7OMoIag_50_3"></a><a id="Tc_BuaSi7OYy06kFOMixesG9A_50_5"></a><a id="Tc_DVRbDcAaqUa8CL3GfPFP_A_50_6"></a><a id="Tc_8igRq3jP2EmGBx1ZUJ7EHQ_50_8"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash Flows from Operating Activities</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_1G9weokUzEic_N9n-O9m8Q_4_3">66,150</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_Uda91xRLMk-arbQ05F4q3w_4_6">77,187</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_b9uMh3IXAkCDNIKT1W4HKw_4_9">38,924</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_9vWw1WoyKkipx5zg3R9GbA_6_3">7,899</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_xKDKm3rB-UitR13cD9rvFg_6_6">8,353</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_LxEqScsl4UKLmUZ-Kl6nag_6_9">6,919</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Operating lease right-of-use asset amortization</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="ptgx:OperatingLeaseRightOfUseAssetAmortization" scale="3" id="Tc_sT90factYkmL3i7bBQ8RcQ_7_3">1,775</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="ptgx:OperatingLeaseRightOfUseAssetAmortization" scale="3" id="Tc_os-GwFBMvUGmDcyaSSlGHg_7_6">1,792</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Tc_EMFOl-egSES0NwqzSv8goA_8_3">789</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Tc_nbTqrk2EWkaxG_ZS26LqMA_8_6">703</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Tc_Cpi68ho1Dk2641wz_5RCFA_8_9">527</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Loss on early repayment of debt</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" sign="-" scale="3" id="Tc_LxMGLoho7EO-Y5ezqktfsg_9_3">585</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Net amortization of premium (accretion of discount) on marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" sign="-" scale="3" id="Tc_Vj5QXKZNA06YnYsBfH2Kkg_10_3">37</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="Tc_d7gZi2wbwE6TIiT0sQq97A_10_6">594</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" sign="-" scale="3" id="Tc_UtqEKlbe20KTt4Y748voCw_10_9">206</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Amortization of debt issuance costs and accretion of debt discount</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="ptgx:AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee" scale="3" id="Tc_M7KIbwfbWUGJkXVhJQ_8pw_11_3">159</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="ptgx:AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee" scale="3" id="Tc_Wm7SC2FxI0av0Zv4Ime8Rw_11_6">29</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Gain on disposal of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" sign="-" scale="3" id="Tc_hKUETJzGakC33psbtCVKZQ_12_6">8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Change in deferred tax asset</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxCreditsAndAdjustments" scale="3" id="Tc_rtvWeqIGe0u9rTx2nv7CTA_13_3">1,438</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxCreditsAndAdjustments" sign="-" scale="3" id="Tc_-2E8fNdgmUqeZ4xXy8mjNQ_13_6">775</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxCreditsAndAdjustments" sign="-" scale="3" id="Tc_daBRyVTgvUyKGK3HnYaFhw_13_9">658</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Research and development tax incentive receivable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" scale="3" id="Tc_AXKyaH9AFEupbSul-87XJA_15_3">990</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" sign="-" scale="3" id="Tc_hKbVxBKBuUqCZ1ip1Qu2Aw_15_6">1,411</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" scale="3" id="Tc_YH-YRa2P_E2gvaaVZjfOCA_15_9">236</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Receivable from collaboration partner - related party</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties" sign="-" scale="3" id="Tc_k9Oegn-KWUOxKQ-dr6W3IA_16_3">4,329</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties" scale="3" id="Tc_6LZmHQujsE-T_K9loVPaSg_16_6">2,168</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties" scale="3" id="Tc_XCEcymOdu06kb8DE0T8jWA_16_9">2,771</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Prepaid expenses and other assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_mTqMth619UWf_KEn8YFV0g_17_3">1,102</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_mWRS6iiryk60gMKu_YZCgQ_17_6">2,820</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="3" id="Tc_eFIpzSGNm0G_iOQv9dN-nQ_17_9">1,117</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" id="Tc_HVTDAzaE80SWZGzWxK34Iw_18_3">309</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" sign="-" scale="3" id="Tc_wCy0O318WkS8DO6NLlM72Q_18_6">3,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" id="Tc_48hsKY_NwESR40Iv3FZ8zw_18_9">4,430</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Payable to collaboration partner - related party</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" scale="3" id="Tc_gOALQF8y6E61eSsNbseXCQ_19_3">1,471</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" scale="3" id="Tc_D36NrAYrRE64HL2beeLzZg_19_6">201</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" scale="3" id="Tc_3Yder3QQNkaJjHc0uoa3fA_19_9">1,061</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Accrued expenses and other payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_wy2JFxI86Ei0rIrcffYDqA_20_3">5,840</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_FWKVV9chIkCv5yZPidRQYg_20_6">1,098</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_rqoeHU4XWUi5_Zf1cPWORA_20_9">1,911</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Deferred revenue - related party</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" sign="-" scale="3" id="Tc_q4vGZ6OpRUONob1SasKubw_21_3">27,053</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="Tc_lrfMduQjeUuiuOK1Dn3nCw_21_6">33,307</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" sign="-" scale="3" id="Tc_2khU4Fok3EiBYgQkyQk95A_21_9">23,529</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liability </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="ptgx:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="Tc_4oL-c473cEup0WfA8rcV8A_22_3">1,941</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="ptgx:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="Tc_IaASZHQVvEqgmdzlSIEJNA_22_6">1,885</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Other liability</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="Tc_L06naFRYM0ahjnbLbrXJzg_23_3">121</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 18pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_2JD09p69Zky1X-8qlZym0A_24_3">72,484</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_Bc_FtS-QEEKzOcbF68UUFQ_24_6">41,527</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_3Hu94hqYZ0CzwrXulaf-sw_24_9">49,947</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash Flows from Investing Activities</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Purchase of marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="Tc_6P97hKM8a0mu3KTU3DYYhA_26_3">280,027</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="Tc_LIZRXZvr0E6pXtUarYdASw_26_6">166,936</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="Tc_3U4mzl6ZYk-BO3HxSyY53g_26_9">71,060</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Proceeds from maturities of marketable securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" id="Tc_KGapb_6wAU6CrH6QYPqE4g_27_3">189,533</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" id="Tc_sLNxJAXxn0Ck6NxPV8IUZA_27_6">114,193</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" id="Tc_pbBre_sv4kCgvcZsnSpl8w_27_9">73,759</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Purchases of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_Je1Ikze3bESf5Fgk_HA5tw_28_3">471</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_qCYZ6Q1De0-Y3SjoJNc5IA_28_6">967</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_6XMTL3_SXk6v3lnyQIn5XA_28_9">486</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 18pt;">Net cash (used in) provided by investing activities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_mZkpO3qip0GEGzBHABBolg_29_3">90,965</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_RorHiDyfo0evv2bAyQOgiQ_29_6">53,710</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="Tc_SIpwf672RUep445SEUzjfw_29_9">2,213</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash Flows from Financing Activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Proceeds from public offering of common stock, net of issuance costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_S_nE7eVh7km8pI2MWGG1EA_31_3">213,303</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Proceeds from issuance of common stock and warrants in private placement, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="ptgx:ProceedsFromIssuanceOfCommonStockAndWarrantsInPrivatePlacementNetOfIssuanceCosts" scale="3" id="Tc_cAUQwK3XOUWu8OPWAKzMvw_32_9">21,673</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Proceeds from at-the-market offering, net of issuance costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="3" id="Tc_aGRzm5tUlkSN4NabaOSk3w_33_3">42,062</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="3" id="Tc_6oIjlrCfk06OFOz8bUsvIA_33_6">34,492</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="3" id="Tc_IaEBc_jPpEuEOFLo0ewCwQ_33_9">1,508</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Proceeds from issuance of common stock upon exercise of stock options and purchases under employee stock purchase plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="Tc_v7NrwFiSQ0e6dCExT4UVWQ_34_3">2,799</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="Tc_hDImT_dYVEugIJ_vaTDOag_34_6">1,779</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="Tc_DdDSSbJ0mEmq-qMgHkwqSw_34_9">934</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Proceeds from issuance of long-term debt, net of issuance costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="3" id="Tc_0JUxvJfK6EO0Cga21-Jytg_35_6">9,765</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Issuance costs related to long-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="Tc_lEuI4sck4EapRGhtuVW1ug_36_3">14</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Early repayment of long-term debt</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="Tc_FVoxta_VJEKYQ_cghGF7nQ_37_3">10,524</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 18pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_1GuIzKaVb0qWY_WK686jTQ_38_3">247,626</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_ss3UYfyW7UGsP9V_zqnFkQ_38_6">46,036</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_HsQ396S6dEiG_xqhGqFm7g_38_9">24,115</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Effect of exchange rate changes on cash, cash equivalents and restricted cash</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_FsJjn6-OhUKZlRBwlqTi8g_39_3">175</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" sign="-" scale="3" id="Tc_qtBwuBPEWUOme-t-fkkkHA_39_6">26</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" sign="-" scale="3" id="Tc_4HaPpFZmnUi0WgseEinQuQ_39_9">177</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Net increase (decrease) in cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_2R4unw7Eb0-arLE5gW6Fow_40_3">84,352</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_M8CHfPaVJUahpI5oJBfaaA_40_6">49,227</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_vmJBKisBJU--ZZuNrthtOQ_40_9">23,796</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Cash, cash equivalents and restricted cash, beginning of period</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_dUEFBH26nkyLEbrispRY-g_41_3">33,466</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2018_rK3dysi-wkKgewxxLVB-Eg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_rMMI1yajh0mBpnaDChXL9Q_41_6">82,693</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2017_uBPncpspM02T8SbWW1EWfg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_tHeRPqmL8EaR7cxobo22WA_41_9">106,489</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash, cash equivalents and restricted cash, end of period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_X1619x7TNke-qQjVJG1pgQ_42_3">117,818</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_H9WI63IXrUKAv-4o2hUQNw_42_6">33,466</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2018_rK3dysi-wkKgewxxLVB-Eg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_IHVsk8VudEGrlwZ19TtOyg_42_9">82,693</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Supplemental Disclosure of Cash Flow Information:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for interest </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_UZ89g2iPZ0SgF20imHyhKA_44_3">438</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_Aa-38epHaU2dCJ_GdO56PA_44_6">70</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Supplemental Disclosure of Non-Cash Financing and Investing Information:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Issuance costs related to public offering of common stock included in accrued liabilities and other payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_BalanceSheetLocationAxis_ptgx_AccruedLiabilitiesAndOtherPayablesMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_YMLB38vu2U6BmlQp_T1TCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" scale="3" id="Tc_Ivby-rEkQ0qtWK8tIdA8GQ_46_3">205</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_BalanceSheetLocationAxis_ptgx_AccruedLiabilitiesAndOtherPayablesMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_nqaO_sxQyESRu9HD_l6AJQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" scale="3" id="Tc_j3875-oRjkikECzlGrvKRw_46_6">80</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Issuance costs related to at-the-market offering of common stock included in prepaid expenses and other assets at the end of the previous year</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_N8l2Scu7LECQV05gQhBpcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" scale="3" id="Tc_bKM_dmkeqUqLl9gfC1rMQg_47_3">191</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Issuance costs related to public offering of common stock included in prepaid expenses and other assets at the end of the previous year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_s0YO-nVtg0inq7Ue9XzaAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" scale="3" id="Tc_RYuPP7P1aECPV_n0dHpkag_48_3">124</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Purchases of property and equipment in accounts payable and accrued liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc_fjWSGYBZPUeEirBVqC4ojA_49_3">85</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc__FVUqVgBYEGTJZvJlF6BuQ_49_6">100</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc_rZuBIkVAwECVMsoJJEKgKA_49_9">24</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Fair value of common stock retired in exchange for issuance of common stock warrant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="ptgx:FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant" scale="3" id="Tc_MdqAlMAAp0iZ8EPD-YQzaA_50_9">6,670</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:23.75pt;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:9.56%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="NotestoConsolidatedFinancialStatemen"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Tb_ZJkx-UusSUGmm_vs9CtM8Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PROTAGONIST THERAPEUTICS,&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Notes&#160;to Consolidated Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 1.&#160;&#160;&#160;&#160;Organization and Description of Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:25.3pt;margin:0pt 0pt 13.19pt 0pt;">Protagonist Therapeutics, Inc. (the &#8220;Company&#8221;) is headquartered in Newark, California. The Company is a clinical-stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based therapeutics to address significant unmet medical needs and transform existing treatment paradigms for patients. Protagonist Pty Limited (&#8220;Protagonist Australia&#8221;) is a wholly-owned subsidiary of the Company and is located in Brisbane, Queensland, Australia. Protagonist Australia was incorporated in Australia in September 2001. The Company manages its operations as a single operating segment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 13.19pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liquidity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:25.3pt;margin:0pt 0pt 13.19pt 0pt;">The Company has incurred net losses from operations since inception and has an accumulated deficit of $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="6" id="Narr_sokugfJ3H0W29299nJqriA">283.8</ix:nonFraction> million as of December 31, 2020. The Company&#8217;s ultimate success depends on the outcome of its research and development and collaboration activities. The Company expects to incur additional losses in the future and anticipates the need to raise additional capital to continue to execute its long-range business plan. Since the Company&#8217;s initial public offering in August 2016, it has financed its operations primarily through offerings of common stock and payments received under a license and collaboration agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;white-space:pre-wrap;">Risks and Uncertainties  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to risks and uncertainties as a result of the&#160;COVID-19&#160;pandemic. The Company is continuing to closely monitor the impact of the COVID-19 pandemic on its business and has taken and continues to take proactive efforts to protect the health and safety of its patients, clinical research staff and employees, and to maintain business continuity. The extent of the impact of the&#160;COVID-19&#160;pandemic on the Company&#39;s activities is highly uncertain and difficult to predict, as the response to the pandemic is ongoing and information continues to evolve. Capital markets and economies worldwide have been negatively impacted by the&#160;COVID-19&#160;pandemic, which has contributed to the current global economic recession. Such economic disruption could have a material adverse effect on the Company&#8217;s business. Policymakers around the globe have responded with fiscal policy actions to support the healthcare industry and economy as a whole. The magnitude and overall effectiveness of these actions remains uncertain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The severity of the impact of the&#160;COVID-19&#160;pandemic on the Company&#39;s activities will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic, including the severity of any additional periods of increases or spikes in the number of cases in the areas the Company and its suppliers operate and areas where the Company&#8217;s clinical trial sites are located. Accordingly, the extent and severity of the impact on the Company&#39;s existing and planned clinical trials, manufacturing, collaboration activities and operations, is uncertain and cannot be fully predicted. The Company has experienced delays in its existing and planned clinical trials due to the worldwide impacts of the pandemic. The Company&#39;s future results of operations and liquidity could be adversely impacted by further delays in existing and planned clinical trials, continued difficulty in recruiting patients for these clinical trials, delays in manufacturing and collaboration activities, supply chain disruptions, the ongoing impact on its operating activities and employees, and the ongoing impact of any initiatives or programs that the Company may undertake to address financial and operational challenges. As of the date of issuance of these consolidated financial statements, the extent to which the&#160;COVID-19&#160;pandemic may materially impact the Company&#39;s future financial condition, liquidity or results of operations remains uncertain.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="_b47fcb87_d548_4af0_95a3_4392e840312f"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:80.09%;border:0;margin:30pt 9.56% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:9.56%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_Z8DK6gSRxUCWNIaHUKBfpA" continuedAt="Tb_Z8DK6gSRxUCWNIaHUKBfpA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note<span style="font-weight:normal;"> </span>2.&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="us-gaap:ConsolidationPolicyTextBlock" id="Tb_spVNgUJXFkikbnJW24H08g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation and Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Protagonist Australia, and have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). All intercompany balances and transactions have been eliminated upon consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The financial statements of Protagonist Australia use the Australian dollar as the functional currency since the majority of expense transactions occur in such currency. Gains and losses from foreign currency transactions were not material for all periods presented. The re-measurement from Australian dollar to U.S. dollars is outlined below:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Equity accounts, except for the change in retained earnings during the&#160;year, have been translated using historical exchange rates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">All other Australian dollar denominated assets and liabilities as of December&#160;31, 2020 and 2019 have been translated using the&#160;year-end exchange rate.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">The consolidated statements of operations have been translated at the weighted average exchange rates in effect during each&#160;year.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Foreign currency translation gains and losses are reported as a component of stockholders&#8217; equity in accumulated other comprehensive loss on the consolidated balance sheets.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="us-gaap:UseOfEstimates" id="Tb__skX5tseB0esPiQW_Y_x_w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, accruals for research and development activities, stock-based compensation, income taxes, marketable securities and leases. Estimates related to revenue recognition include actual costs incurred versus total estimated costs of the Company&#8217;s deliverables to determine percentage of completion in addition to the application and estimates of potential revenue constraints in the determination of the transaction price under its license and collaboration agreements. Management bases these estimates on historical and anticipated results, trends and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to forecasted amounts and future events. Actual results may differ significantly from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Due to the COVID-19 pandemic, there has been uncertainty and disruption in the global economy and financial markets. The Company has taken into consideration any known COVID-19 impacts in its accounting estimates to date and is not aware of any additional specific events or circumstances that would require any additional updates to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of the date of issuance of this Annual Report on Form 10-K. These estimates may change as new events occur and additional information is obtained. Actual results could differ materially from these estimates under different assumptions or conditions.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_W8wv1mwxjUS-j7kKq9UcHg" continuedAt="Tb_W8wv1mwxjUS-j7kKq9UcHg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentrations of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and marketable securities. Substantially all of the Company&#8217;s cash is held by <ix:nonFraction unitRef="Unit_Standard_Institution_l_EWsumXIkS46w5G4NlRGw" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="0" format="ixt-sec:numwordsen" name="ptgx:CashNumberOfFinancialInstitutions" scale="0" id="Narr_yH3ANECyU06dcfNjbZqsBg">two</ix:nonFraction> financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. The primary focus of the Company&#8217;s investment strategy is to preserve capital and to meet liquidity requirements. The Company&#8217;s cash equivalents and marketable securities are managed by external managers within the guidelines of the Company&#8217;s investment policy. The Company&#8217;s investment policy addresses the level of credit exposure by limiting concentration in </p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:80.09%;border:0;margin:30pt 9.56% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:9.56%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_e2xWJPQC5Eu1DaJH87lLnA_1_2"></a><a id="Tc_gSTTW6_PmE-d1e-2CpIwQQ_2_2"></a><a id="Tc_t9Rx8ED3S0WG0jw4lBfvQg_2_5"></a><a id="Tc_p3RBrBK6LEaudjcmcc4Nnw_2_8"></a><a id="Tc_49s2NCI-dUqZuguptDlOVg_3_0"></a><a id="Tc_dRBHKWT1ikusSpg64WL0eQ_3_2"></a><a id="Tc_KtFuXRCluEevYMeWOwWE3g_3_5"></a><a id="Tc_kQZe_CKLTUSkYbMWnF9wMw_3_8"></a><a id="Tc_Sz0TnWfq0keGAsFVF8ECrg_4_0"></a><a id="Tc_LkjZq1jYxUqavYqelTjlHg_5_0"></a><a id="Tc_bm8yfPmrEUWa23xTMi9rhA_6_0"></a><a id="Tc_RzaT64AHWUKfhWFJJDBoUQ_6_2"></a><a id="Tc_9ZQxywT-G0qCxNvcAB-adw_6_5"></a><a id="Tc_jC6aC1qoQkCfxe5ULPApWQ_6_8"></a><ix:continuation id="Tb_Z8DK6gSRxUCWNIaHUKBfpA_cont1" continuedAt="Tb_Z8DK6gSRxUCWNIaHUKBfpA_cont2"><ix:continuation id="Tb_W8wv1mwxjUS-j7kKq9UcHg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">any one corporate issuer and establishing a minimum allowable credit rating. To manage its credit risk exposure, the Company maintains its portfolio of cash equivalents and marketable securities in fixed income securities denominated and payable in U.S. dollars. Permissible investments of fixed income securities include obligations of the U.S. government and its agencies, money market instruments including commercial paper and negotiable certificates of deposit, and highly rated corporate debt obligations and money market funds.</span><span style="white-space:pre-wrap;"> </span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" id="Tb_5VcabXYEQkWKK-fGVOY_kQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Cash equivalents that are readily convertible to cash are stated at cost, which approximates fair value. The Company considers all highly liquid investments purchased with an original maturity of three&#160;months or less to be cash equivalents. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="Tb_VEOS5fyKj0qOAjEt56s08A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Restricted Cash</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Restricted cash consists of cash balances primarily held as security in connection with a letter of credit related to the Company&#8217;s facility lease entered into in March 2017 and the Company&#8217;s corporate credit card.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_Ah-w7pZLvkyGqyiHbrZ2Pg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash as Reported in Consolidated Statements of Cash Flows</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Cash as reported in the consolidated statements of cash flows includes the aggregate amounts of cash and cash equivalents and the restricted cash as presented on the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Cash as reported in the consolidated statements of cash flows consists of (in thousands):</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="Tb_GpDv5o2i9kqE_hBRQLIgnw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:95.58%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_JPcwsc6OIUuSREiTEVoHQQ_3_3">117,358</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_FygAed5WQEOf2iWGfs9JxA_3_6">33,006</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2018_rK3dysi-wkKgewxxLVB-Eg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_R5dRuSekMEqxR-SNxULNKg_3_9">82,233</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash - current</p></td><td style="vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashCurrent" scale="3" id="Tc_I4YHYaM2f0ijQF0joDMYBA_4_3">10</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashCurrent" scale="3" id="Tc_pm0iuxn7dEmTc_dKqx0gWg_4_6">10</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2018_rK3dysi-wkKgewxxLVB-Eg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashCurrent" scale="3" id="Tc_YIheXkQ56UylgX1v9XO47Q_4_9">10</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash - noncurrent</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="Tc_hJooOYbQLUuFIlxrrAGrWQ_5_3">450</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="Tc_Pkmp6mln30eKlDkocf7BQw_5_6">450</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2018_rK3dysi-wkKgewxxLVB-Eg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="Tc_3mWw4DwwEUqTaWo9py4RfQ_5_9">450</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total cash, cash equivalent and restricted cash in consolidated statements of cash flows</p></td><td style="vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_qjat_6dZIUyv_gurc3-7uw_6_3">117,818</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_wBbfGiO_90--cvFaYCkwmA_6_6">33,466</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2018_rK3dysi-wkKgewxxLVB-Eg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc__e82SGTxE0KtwHE80_9bzQ_6_9">82,693</ix:nonFraction></p></td></tr></table></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="us-gaap:MarketableSecuritiesPolicy" id="Tb_Vax0YrH2IEGPNsKZu5Ocuw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:12pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Marketable Securities  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;All marketable securities have been classified as &#8220;available-for-sale&#8221; and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation as of each balance sheet date. Short-term marketable securities have maturities greater than three months but not longer than 365 days as of the balance sheet date. Long-term marketable securities have maturities of 365&#160;days or longer as of the balance sheet date. Unrealized gains and losses are excluded from earnings and are reported as a component of comprehensive loss. Realized gains and losses and declines in fair value judged to be other than temporary, if any, on available-for-sale securities are included in interest income. The cost of securities sold is based on the specific-identification method. Interest on marketable securities is included in interest income.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="Tb_eAzROlKqwUuYAcFcbpkiwg" continuedAt="Tb_eAzROlKqwUuYAcFcbpkiwg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Fair value accounting is applied to all financial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis (at least annually). The carrying amount of the Company&#8217;s financial instruments, including cash equivalents, receivable from collaboration partner, accounts payable, payable to collaboration partner and accrued expenses and other payables approximate fair value due to their short-term maturities. See Note&#160;4. to the Consolidated Financial Statements for additional information regarding the fair value of the Company&#8217;s other financial assets and liabilities.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:80.09%;border:0;margin:30pt 9.56% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:9.56%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Z8DK6gSRxUCWNIaHUKBfpA_cont2" continuedAt="Tb_Z8DK6gSRxUCWNIaHUKBfpA_cont3"><ix:continuation id="Tb_eAzROlKqwUuYAcFcbpkiwg_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Tb_XBC9SMgV1k-3zvLhM02aYg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, ranging from <span style="-sec-ix-hidden:Hidden_MwXrAUuc4UmOUGbm0YW9XQ;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">three</span></span> to <ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_R76-sonyg0uleRlU84c1jA" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_LOetEyhVek-omw-4bAXtsg">five&#160;years</ix:nonNumeric>. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful lives of the assets. Maintenance and repairs are charged to expense as incurred. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the consolidated balance sheet and any resulting gain or loss is reflected in operations in the period realized.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="us-gaap:LesseeLeasesPolicyTextBlock" id="Tb_69sQPvpEI0SOvp7YpoccQg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company adopted Accounting Standards Codification Topic 842, <i style="font-style:italic;">Leases,</i> (&#8220;ASC 842&#8221;) effective January 1, 2019. The Company determines if an arrangement is a lease at inception. Pursuant to ASC 842, operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets, operating lease liabilities, and noncurrent operating lease liabilities on the consolidated balance sheets. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. If the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. Lease terms include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:31.5pt;margin:0pt;">The Company records tenant improvement allowances as a reduction to the ROU asset with the impact of the decrease recognized prospectively over the remaining lease term. The leasehold improvements will be amortized over the shorter of their useful life or the remaining term of the lease. </p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="Tb_m_ssPk_7nE-GdRZZeu2JNA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Impairment of Long-Lived Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Company reviews long-lived assets, primarily comprised of property, equipment and operating lease right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount to the future net cash flows which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset. There have been <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:TangibleAssetImpairmentCharges" scale="0" id="Narr_YK_VPd96M0en2_Ac3sIYNA">no</ix:nonFraction> such impairments of long-lived assets for any of the periods presented.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="us-gaap:DebtPolicyTextBlock" id="Tb_z_BcwqSeCEefb-lU9RjU-w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Long Term Debt  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for interest on its long-term debt under the effective interest method, with interest expense comprised of contractual interest, amortization of origination fees and other issuance costs, and accretion of final payment fees. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="Tb_u0lCa4L3k0S3Eo1_PFVjDg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Comprehensive Loss</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity that result from transactions and economic events other than those from stockholders. The Company&#8217;s foreign currency translation and unrealized gains and losses on available-for-sale securities represent the only components of other comprehensive loss that are excluded from reported net loss and that are presented in the consolidated statements of comprehensive loss.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_dRl1RWIO7EC-32lnVnj1JQ" continuedAt="Tb_dRl1RWIO7EC-32lnVnj1JQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">The Company uses the asset and liability method to account for income taxes in accordance with the authoritative guidance for income taxes. Under this method, deferred tax assets and liabilities are determined based on future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:80.09%;border:0;margin:30pt 9.56% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:9.56%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Z8DK6gSRxUCWNIaHUKBfpA_cont3" continuedAt="Tb_Z8DK6gSRxUCWNIaHUKBfpA_cont4"><ix:continuation id="Tb_dRl1RWIO7EC-32lnVnj1JQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">and their respective tax bases, and tax loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates applied to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than a 50% likelihood of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest and penalties related to unrecognized tax benefits in income tax expense. To date, there have been <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" scale="0" id="Narr_GZ482zBBR0awiZDwu7WVvQ">no</ix:nonFraction> interest or penalties recorded in relation to unrecognized tax benefits.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="Tb_NMgO_NVWSky71jDC5C6gxQ" continuedAt="Tb_NMgO_NVWSky71jDC5C6gxQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">The Company follows Accounting Standards Codification Topic 606, <i style="font-style:italic;">Revenue from Contracts with Customers </i>(&#8220;ASC 606&#8221;). Under ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the Company satisfies a performance obligation. The Company applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract, determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligations when (or as) the performance obligations are satisfied. The Company constrains its estimate of the transaction price up to the amount (the &#8220;variable consideration constraint&#8221;) that a significant reversal of recognized revenue is not probable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><i style="font-style:italic;">Licenses of intellectual property:</i><span style="white-space:pre-wrap;">  If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in an arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring proportional performance for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of proportional performance each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><i style="font-style:italic;">Milestone payments:</i><span style="white-space:pre-wrap;">  At the inception of each arrangement or amendment that includes development, regulatory or commercial milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. Whichever method is used, it should be consistently applied throughout the life of the contract; however, it is not necessary for the Company to use the same approach for all contracts. The Company expects to use the most likely amount method for development and regulatory milestone payments. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. If there is more than one performance obligation, the transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any </span></p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:80.09%;border:0;margin:30pt 9.56% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:9.56%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Z8DK6gSRxUCWNIaHUKBfpA_cont4" continuedAt="Tb_Z8DK6gSRxUCWNIaHUKBfpA_cont5"><ix:continuation id="Tb_NMgO_NVWSky71jDC5C6gxQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Royalties:</i><span style="white-space:pre-wrap;">  For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional. Amounts payable to the Company and not yet billed to the collaboration partner are recorded as contract assets. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one&#160;year or less.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Contractual cost sharing payments made to a customer or collaboration partner are accounted for as a reduction to the transaction price if such payments are not related to distinct goods or services received from the customer or collaboration partner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"><span style="background-color:#ffffff;">Contracts may be amended to account for changes in contract specifications and requirements.&#160;Contract modifications exist when the amendment either creates new, or changes existing, enforceable rights and obligations. When&#160;contract modifications&#160;create new performance obligations and the increase in consideration approximates the standalone selling price for goods and services related to such new performance obligations as adjusted for specific facts and circumstances of the contract, the modification is considered to be a separate contract. If a contract modification is not accounted for as a separate contract, the Company accounts for the promised goods or services not yet transferred at the date of the contract modification (the remaining promised goods or services) prospectively, as if it were a termination of the existing contract and the creation of a new contract, if the remaining goods or services are distinct from the goods or services transferred on or before the date of the contract modification. The Company accounts for a contract modification as if it were a part of the existing contract if the remaining goods or services are not distinct and, therefore, form part of a single performance obligation that is partially satisfied at the date of the contract modification. In such case the effect that the contract modification has on the transaction price, and on the entity&#8217;s measure of progress toward complete satisfaction of the performance obligation, is recognized as an adjustment to revenue (either as an increase in or a reduction of revenue) at the date of the contract modification (the adjustment to revenue is made on a cumulative catch-up basis).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"><span style="background-color:#ffffff;">The period between when the Company transfers control of promised goods or services and when the Company receives payment is expected to be one year or less, which is consistent with the Company&#8217;s historical experience. Upfront payment contract liabilities resulting from the Company&#8217;s license and collaboration agreements do not represent a financing component as the payment is not financing the transfer of goods and services, and the technology underlying the licenses granted reflects research and development expenses already incurred by the Company. As such, the Company does not adjust its revenues for the effects of a significant financing component.</span><span style="background-color:#ffffff;"> </span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_aDoOOnK0BEqylXEJ_ThPwg" continuedAt="Tb_aDoOOnK0BEqylXEJ_ThPwg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred, unless there is an alternate future use in other research and development projects or otherwise. Research and development costs include salaries and benefits, stock-based compensation expense, laboratory supplies and facility-related overhead, outside contracted services including clinical trial costs, manufacturing and process development costs for both clinical and pre-clinical materials, research costs, development milestone payments under license and collaboration agreements, and other consulting services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">The Company accrues for estimated costs of research and development activities conducted by third-party service providers, which include the conduct of pre-clinical studies and clinical trials, and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated services provided </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:80.09%;border:0;margin:30pt 9.56% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:9.56%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Z8DK6gSRxUCWNIaHUKBfpA_cont5" continuedAt="Tb_Z8DK6gSRxUCWNIaHUKBfpA_cont6"><ix:continuation id="Tb_aDoOOnK0BEqylXEJ_ThPwg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">but not yet invoiced and includes these costs in accrued expenses and other payables in the consolidated balance sheets and within research and development expense in the consolidated statements of operations. The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers. As actual costs become known, the Company adjusts its accrued liabilities. The Company has not experienced any material differences between accrued liabilities and actual costs incurred. However, the status and timing of actual services performed, number of patients enrolled, the rate of patient enrollment and number and location of sites activated may vary from the Company&#8217;s estimates, resulting in adjustments to expense in future periods. Changes in these estimates that result in material changes to the Company&#8217;s accruals could materially affect the Company&#8217;s results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.5pt;margin:0pt 0pt 12pt 0pt;">The Company has received orphan drug designation from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) for its clinical asset rusfertide (generic name for PTG-300) for the treatment of polycythemia vera and beta-thalassemia and may qualify for a related 25% U.S. Federal income tax credit on qualifying clinical study expenditures.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="ptgx:ResearchAndDevelopmentIncentiveGrantPolicyTextBlock" id="Tb_pUCu9KbkdkepA0fASMUkvQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Tax Incentive</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Company is eligible under the AusIndustry research and development tax incentive program to obtain either a refundable cash tax incentive or a taxable credit in the form of a non-cash tax incentive from the Australian Taxation Office (&#8220;ATO&#8221;). The refundable cash tax incentive is available to the Company on the basis of specific criteria with which the Company must comply. Specifically, the Company must have annual turnover of less than AUD 20.0 million and cannot be controlled by income tax exempt entities.&#160;The refundable cash tax incentive is recognized as a reduction to research and development expense when the right to receive has been attained and funds are considered to be collectible. The tax incentive is denominated in Australian dollars and, therefore, the related receivable is remeasured into U.S. dollars as of each reporting date. The Company may alternatively be eligible for a taxable credit in the form of a non-cash tax incentive in years when the annual turnover exceeds the limit. The Company evaluates its eligibility under tax incentive programs as of each balance sheet date and makes accrual and related adjustments based on the most current and relevant data available. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="ptgx:SmallBusinessInnovationResearchSbirGrantsPolicyTextBlock" id="Tb_lTmbcf29wUSOT1VkcalYSQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Small Business Innovation Research (&#8220;SBIR&#8221;) Grants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Company has received SBIR grants from the National Institutes of Health (&#8220;NIH&#8221;) in support of its research activities. The Company recognizes a reduction to research and development expenses when expenses related to grants have been incurred and the grant funds become contractually due from NIH. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="Tb_dmBlvIxX3EKZGwtBAp2GgQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Company measures its stock-based awards made to its equity plan participants based on the estimated fair values of the awards as of the grant date. For stock option awards, the Company uses the Black-Scholes option-pricing model to estimate fair values. For restricted stock unit awards, the estimated fair value is generally the fair market value of the underlying stock on the grant date. Stock-based compensation expense is recognized over the requisite service period and is based on the value of the portion of stock-based payment awards that is ultimately expected to vest. The Company recognizes forfeitures of stock-based awards as they occur. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_2e9G6G3nVEShcGJxsbp6aA" continuedAt="Tb_2e9G6G3nVEShcGJxsbp6aA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net Loss per Share </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is calculated by dividing the Company&#8217;s net loss by the weighted average number of shares of common stock and Exchange Warrants outstanding during the period, without consideration of potentially dilutive securities. In accordance with Accounting Standards Codification Topic 260, <i style="font-style:italic;">Earnings Per Share</i>, the Exchange Warrants are included in the computation of basic net loss per share because the exercise price is negligible and they are fully vested and exercisable after the original issuance date. Diluted net loss per share is the same as basic net loss per share for all periods presented since the effect of potentially dilutive securities is anti-dilutive given the net loss of the Company in each period. See Note 12. Stockholders&#39; Equity for additional information regarding the Exchange Warrants.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:80.09%;border:0;margin:30pt 9.56% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:9.56%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Z8DK6gSRxUCWNIaHUKBfpA_cont6"><ix:continuation id="Tb_2e9G6G3nVEShcGJxsbp6aA_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_lXIULz79cUi0fPWAtvWSUA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Recently Adopted Accounting Pronouncements </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">In August 2018, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2018-13, <i style="font-style:italic;">Fair Value Measurement (Topic 820) &#8211; Disclosure Framework &#8211; Changes to the Disclosure Requirements for Fair Value Measurement</i>, which modifies the disclosure requirements on fair value measurements and is intended to improve the effectiveness of disclosures, including the consideration of costs and benefits. The Company adopted this guidance as of January 1, 2020. The adoption of this guidance did not have a material impact on the Company&#8217;s consolidated financial statements or disclosures. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">In November 2018, the FASB issued ASU No. 2018-18, <i style="font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606</i>, which is intended to clarify the circumstances under which certain transactions in collaborative arrangements should be accounted for under the revenue recognition standard. Certain transactions between collaboration arrangement participants should be accounted for as revenue under ASC Topic 606 when the collaborative arrangement participant is a customer in the context of a unit of account. This guidance is effective for fiscal years and interim periods within those years beginning after December 15, 2019. The Company adopted this guidance as of January 1, 2020. The adoption of this guidance did not have a material impact on the Company&#8217;s consolidated financial statements and disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Recently Issued Accounting Pronouncements Not Yet Adopted as of December 31, 2020</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2016, the FASB issued ASU No.&#160;2016-13,&#160;<i style="font-style:italic;">Financial Instruments&#160;- Credit Losses (Topic 326)</i>, which is intended to provide financial statement users with more useful information about expected credit losses on financial assets held by a reporting entity at each reporting date. The new standard replaces the existing incurred loss impairment methodology with a methodology that requires consideration of a broader range of reasonable and supportable forward-looking information to estimate all expected credit losses. This guidance was originally effective for fiscal&#160;years and interim periods within those&#160;years beginning after December&#160;15, 2019, with early adoption permitted for fiscal&#160;years and interim periods within those&#160;years beginning after December&#160;15, 2018. In November 2019, the FASB issued ASU No. 2019-10, <i style="font-style:italic;">Financial Instruments &#8211; Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates</i>, which amended the mandatory effective date of ASU No. 2016-13 for smaller reporting companies. Based on the Company&#8217;s status as a smaller reporting company as of November 15, 2019, ASU 2016-13 is effective for the Company for fiscal years and interim periods beginning after December 15, 2022. The Company is currently evaluating the impact of this new guidance on its consolidated financial statements and disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">In December 2019, the FASB issued ASU No. 2019-12, <i style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, </i>which removes certain exceptions and amends certain requirements in the existing income tax guidance to ease accounting requirements. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020 and must be applied on a retrospective basis. The Company does not expect the adoption of this guidance to have a material impact on its consolidated financial statements and disclosures.</p></ix:nonNumeric></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_ptgx_JanssenLicenseAndCollaborationAgreement26May2017Member_C_BnSjKn10WVjRwNMh3ISQ" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="Tb_Vcj16TERP0G28qs-ytsD8g" continuedAt="Tb_Vcj16TERP0G28qs-ytsD8g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 3.&#160;&#160;&#160;&#160;<b style="font-weight:bold;white-space:pre-wrap;">License and Collaboration Agreement   </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Agreement Terms</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">On May 26, 2017, the Company and Janssen Biotech, Inc., (&#8220;Janssen&#8221;), one of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson, entered into an exclusive license and collaboration agreement (the &#8220;Janssen License and Collaboration Agreement&#8221;) for the development, manufacture and potential commercialization of PTG-200 worldwide for the treatment of Crohn&#8217;s disease (&#8220;CD&#8221;) and ulcerative colitis (&#8220;UC&#8221;). Janssen is a related party to the Company as Johnson &amp; Johnson Innovation - JJDC, Inc., a significant stockholder of the Company, and Janssen are both subsidiaries of Johnson &amp; Johnson. PTG-200 is the Company&#8217;s orally delivered gut-restricted Interleukin 23 receptor (&#8220;IL-23R&#8221;) antagonist drug candidate currently in development. The Janssen License and Collaboration Agreement became effective on July 13, 2017. Upon the effectiveness of the agreement, the Company received a non-refundable, upfront cash payment of $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_7_13_2017_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_UpfrontCashPaymentMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_8ZzG4TogRUeK22l7bZWg6Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="Narr_tRcVKm68X0-1sv71KxgH7A">50.0</ix:nonFraction> million from Janssen.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:80.09%;border:0;margin:30pt 9.56% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:9.56%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Vcj16TERP0G28qs-ytsD8g_cont1" continuedAt="Tb_Vcj16TERP0G28qs-ytsD8g_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Under the Janssen License and Collaboration Agreement, the Company granted to Janssen an exclusive worldwide license to develop, manufacture and commercialize PTG-200 and related IL-23R compounds for all indications, including CD and UC. The Company was responsible, at its own expense, for the conduct of the Phase 1 clinical trial for PTG-200, and Janssen is responsible for the conduct of the Phase 2 clinical trial for PTG-200 in CD, including filing the U.S. Investigational New Drug application (&#8220;IND&#8221;). Development costs for the Phase 2 clinical trial are shared between the parties on an <ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_ptgx_SecondGenerationAnalogPhase2CdClinicalTrialPrimaryClinicalEndpointMember_JacSAA95dUyCrU6tGgPPmQ" decimals="2" format="ixt:numdotdecimal" name="ptgx:CollaborativeArrangementPercentageOfDevelopmentCostsIncurred" scale="-2" id="Narr_2e4fPZss20ifp48rFvK3pA">80</ix:nonFraction>/<ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember_d9hGXjKIFEOZdcykv_sYsw" decimals="2" format="ixt:numdotdecimal" name="ptgx:CollaborativeArrangementPercentageOfDevelopmentCostsIncurred" scale="-2" id="Narr_RDa_bdH4j0OFGLtJTHuaFg">20</ix:nonFraction> basis, with Janssen assuming the larger share. Janssen submitted an IND for PTG-200 in CD during the second quarter of 2019, which took effect in July 2019. The Company initiated a Phase 2 clinical study for PTG-200 in CD with Janssen in the fourth quarter of 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Company entered into an amendment (the &#8220;First Amendment&#8221;) to the Janssen License and Collaboration Agreement effective May 7, 2019. The First Amendment builds upon the Company&#8217;s ongoing development collaboration with Janssen for PTG-200 and, upon the effectiveness of the First Amendment, the Company became eligible to receive a $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_6_30_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_LicenseAndCollaborativeRevenueMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendmentMember_t7Zx6qmuv02vXASmqBWLvw" decimals="-5" format="ixt:numdotdecimal" name="ptgx:CollaborativeArrangementEligibleAmountReceived" scale="6" id="Narr_DRVrZAlQd0G1ZfoeVDT2YQ">25.0</ix:nonFraction> million payment from Janssen, which was received during the second quarter of 2019. The First Amendment expanded the scope of the Janssen License and Collaboration Agreement by supporting research efforts towards identifying and developing second-generation IL-23R antagonists (&#8220;second-generation compounds&#8221;).  Two second-generation IL-23R compounds have been nominated and are currently in development: PN-235, in a Phase 1 clinical study, and PN-232, in preclinical studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">As part of the services added in the First Amendment, Janssen will pay certain costs and milestones related to advancing pre-clinical candidates from the second-generation research program through Phase 1 studies, including funding of a certain number of full-time equivalent employees (&#8220;FTEs&#8221;) at the Company for an agreed upon period of time. The Company will pay <ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember_us-gaap_TypeOfArrangementAxis_ptgx_CollaborationAgreementTrancheThreeMember_tvpE-SkS6k2HRTzbxgh_wg" decimals="2" format="ixt:numdotdecimal" name="ptgx:CollaborativeArrangementPercentageOfResearchProgramCostsIncurred" scale="-2" id="Narr_z2S-wLAHmUG6WHtmrcV4oQ">100</ix:nonFraction>% of the costs for the preclinical studies and Phase 1 studies for the first second-generation compound, and <ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember_us-gaap_TypeOfArrangementAxis_ptgx_CollaborationAgreementTrancheFourMember_bqQIT5Ulw0CqIqPYWi81Yw" decimals="2" format="ixt:numdotdecimal" name="ptgx:CollaborativeArrangementPercentageOfResearchProgramCostsIncurred" scale="-2" id="Narr_B8VGcUBiMkad2wCriZ1Kiw">50</ix:nonFraction>% of the costs of the Phase 1 studies for the second and third second-generation compounds; thereafter Janssen will pay <ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember_us-gaap_TypeOfArrangementAxis_ptgx_CollaborationAgreementTrancheFiveMember_zUOiK1ho7EWtoDBGEsNNOw" decimals="2" format="ixt:numdotdecimal" name="ptgx:CollaborativeArrangementPercentageOfResearchProgramCostsIncurred" scale="-2" id="Narr_GZ7wY1MqukSq-4VMMajRKw">100</ix:nonFraction>% of any further Phase 1 development costs. Development costs for the Phase 2 clinical trials for second-generation compounds are shared between the parties on an <ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_ptgx_SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember_mwtEbZMbFUWPqDXv33EobA" decimals="2" format="ixt:numdotdecimal" name="ptgx:CollaborativeArrangementPercentageOfDevelopmentCostsIncurred" scale="-2" id="Narr_T7rU-3j94EuFzA9KG1Kkkw">80</ix:nonFraction>/<ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember_d9hGXjKIFEOZdcykv_sYsw" decimals="2" format="ixt:numdotdecimal" name="ptgx:CollaborativeArrangementPercentageOfDevelopmentCostsIncurred" scale="-2" id="Narr_aYnZyMa0T0GA4UCeyNDHNA">20</ix:nonFraction> basis, with Janssen assuming the larger share. The Company&#8217;s Phase 1 and Phase 2 development costs are also limited by overall spending caps. In December 2019, the Company became eligible to receive a $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_12_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_ptgx_SecondGenerationDevelopmentCompoundMember_P6e595XTnUiY7TVn8K6bmQ" decimals="-5" format="ixt:numdotdecimal" name="ptgx:CollaborativeArrangementPayableUponEffectivenessOfAmendment" scale="6" id="Narr_mlpJ7QNfpkSzHR6pzDF1PA">5.0</ix:nonFraction> million payment trigged by the successful nomination of a second-generation development compound, which was received during the first quarter of 2020. The Company will be eligible to receive a $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_MilestonePaymentsMember_us-gaap_TypeOfArrangementAxis_ptgx_CollaborationAgreementTrancheThreeMember_2JbTuvZF1E6as5O_Zhxubg" decimals="-5" format="ixt:numdotdecimal" name="ptgx:CollaborativeArrangementPayableUponEffectivenessOfAmendment" scale="6" id="Narr_GWTjw1x7xkOuj30tizgsIw">7.5</ix:nonFraction> million milestone payment at the completion of a Phase 1 study for the first second-generation compound. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Prior to the effectiveness of the First Amendment, the Company had been eligible to receive a $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_4_1_2019_To_6_30_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_MilestonePaymentsMember_srt_StatementScenarioAxis_srt_ProFormaMember_cUCCwM3epUW2i97GGepUZw" decimals="-5" format="ixt:numdotdecimal" name="ptgx:CollaborativeArrangementPayableUponEffectivenessOfAmendment" scale="6" id="Narr_BM__T0CNfUmz7PCQKnBOTg">25.0</ix:nonFraction> million milestone payment upon Janssen&#8217;s filing of the IND. This amount had been considered constrained until a time at which the Company would have become eligible to receive the $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_4_1_2019_To_6_30_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_LicenseAndCollaborativeRevenueMember_srt_StatementScenarioAxis_srt_ProFormaMember_D0E1ttaBzUyFCH2yOPFdiQ" decimals="-5" format="ixt:numdotdecimal" name="ptgx:CollaborativeArrangementPayableUponEffectivenessOfAmendment" scale="6" id="Narr_VWQCpdN2a0O7ogDvSTd8_A">25.0</ix:nonFraction> million payment from Janssen. Payments to the Company for research and development services are generally billed and collected as services are performed or assets are delivered, including research activities and Phase 1 and Phase 2 development activities. Janssen bills the Company for its <ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_ptgx_LicenseAndCollaborativeRevenueMember_8kLGBjtrT0WDvA027jn2RQ" decimals="2" format="ixt:numdotdecimal" name="ptgx:CollaborativeArrangementPercentageOfDevelopmentCostsIncurred" scale="-2" id="Narr_o75WNe28_UiXrYO-A9GnwA">20</ix:nonFraction>% share of the Phase 2 development costs as expenses are incurred by Janssen. Milestone payments are received after the related milestones are achieved. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the First Amendment, the Company will be eligible to receive clinical development, regulatory and sales milestones, if and as achieved, and/or payments relating to Janssen&#8217;s elections to maintain or expand its license rights. The next possible milestone or opt-in election events based on a Phase 2 clinical trial in CD are as follows: </p><table style="border-collapse:collapse;border:0;"><tr><td style="width:27pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:4.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-size:12pt;">&#8226;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"> Janssen can elect to advance PTG-200 into Phase 2b following receipt of the top line results of the CD Phase 2a clinical trial for PTG-200 by paying a $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_UpfrontCashPaymentMember_us-gaap_TypeOfArrangementAxis_ptgx_AmendedCollaborationAgreementTrancheOneMember_c9va82PLx0uSFetk0cbloQ" decimals="-5" format="ixt:numdotdecimal" name="ptgx:CollaborativeArrangementPayableUponEffectivenessOfAmendment" scale="6" id="Narr_wGjLbLEWi0uTQxBwzIE3Qg">50.0</ix:nonFraction> million maintenance fee (the &#8220;Amended First Opt-in Election&#8221;); or </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:4.5pt;text-indent:-4.5pt;margin:0pt 0pt 12pt 27pt;"><span style="font-size:12pt;">&#8226;</span> Janssen would make a $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_SecondGenerationPhase2bMilestonePaymentMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendmentMember_H5wv-w3AKUSR5s2BPJL4Kg" decimals="-5" format="ixt:numdotdecimal" name="ptgx:CollaborativeArrangementPayableUponEffectivenessOfAmendment" scale="6" id="Narr_63tHmwv3806S4-osOZNQBg">50.0</ix:nonFraction> million milestone payment following dosing of the third patient in the first Phase 2b clinical trial for CD for a second-generation product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">Janssen can also then elect to receive exclusive, world-wide commercial rights for both PTG-200 and second-generation products following the Phase 2b completion date for PTG-200 or a second-generation product by paying a $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_UpfrontCashPaymentMember_us-gaap_TypeOfArrangementAxis_ptgx_AmendedSecondOptInMember_cppdcoBeEkOHH_mebXmIVg" decimals="-5" format="ixt:numdotdecimal" name="ptgx:CollaborativeArrangementPayableUponEffectivenessOfAmendment" scale="6" id="Narr_A3uZIHITiUm3BMBT-caVxQ">50.0</ix:nonFraction> million payment (the &#8220;Amended Second Opt-in Election&#8221;). The Company will also be eligible for certain additional milestone payments including a potential payment of either $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_5_7_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_Ptg200Phase3CdClinicalTrialPrimaryClinicalEndpointMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendmentMember_Bn4vSCBoGEOTDsfBtOVnNQ" decimals="-5" format="ixt:numdotdecimal" name="ptgx:ContingentConsiderationReceivable" scale="6" id="Narr_TqIRf6JjWUKAmRXGUEPLzA">100.0</ix:nonFraction> million upon a Phase 3 CD clinical trial meeting a </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:80.09%;border:0;margin:30pt 9.56% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:9.56%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Vcj16TERP0G28qs-ytsD8g_cont2" continuedAt="Tb_Vcj16TERP0G28qs-ytsD8g_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">primary clinical endpoint with respect to PTG-200 or $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_5_7_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendmentMember_9gK_kOJw_ESqRE-bsagxFg" decimals="-5" format="ixt:numdotdecimal" name="ptgx:ContingentConsiderationReceivable" scale="6" id="Narr_sellXPH4bEigCFTh0_bKBQ">115.0</ix:nonFraction> million upon a Phase 3 CD clinical trial meeting a primary clinical endpoint with respect to a second-generation compound.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the First Amendment, the Company will be eligible to receive tiered royalties on net product sales at percentages ranging from mid-single digits to <ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_5_7_2019_To_5_7_2019_srt_ProductOrServiceAxis_ptgx_DevelopmentRegulatoryAndSalesMilestonePaymentsMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendmentMember_nG2wMUofPkqcS4glTe3R0w" decimals="2" format="ixt-sec:numwordsen" name="ptgx:PercentagesRoyaltiesOnNetProductSales" scale="-2" id="Narr_j9VUc6yfGUa3zigF8GYhvQ">ten</ix:nonFraction> percent. Under the terms of the First Amendment, the Company will be eligible to receive up to an aggregate $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_5_7_2019_srt_ProductOrServiceAxis_ptgx_DevelopmentRegulatoryAndSalesMilestonePaymentsMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendmentMember_PNZUEJ__x0m4Tx70AGON6A" decimals="-8" format="ixt:numdotdecimal" name="ptgx:ContingentConsiderationReceivable" scale="9" id="Narr_8HKhXlZsmEelwPLF1y09Qw">1.0</ix:nonFraction> billion in research, development, regulatory and sales milestones.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Janssen License and Collaboration Agreement remains in effect until the royalty obligations cease following patent and regulatory expiry, unless terminated earlier. Upon a termination of the Janssen License and Collaboration Agreement, all rights revert back to the Company, and in certain circumstances, if such termination occurs during ongoing clinical trials, Janssen would, if requested, provide certain financial and operational support to the Company for the completion of such trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The Company concluded that the amended Janssen License and Collaboration Agreement continued to contain a single performance obligation including the development license; second-generation compound research services; Phase 1 development services for PTG-200 and potential second-generation compounds; the Company&#8217;s services associated with Phase 2 development for PTG-200 until Phase 2a; the Company&#8217;s services associated with Phase 2 development for  second-generation products until the dosing of the third patient in Phase 2b in CD or UC, or Phase 2 in an additional indication; and all other such services that the Company may perform at the request of Janssen to support the development of PTG-200, second-generation research services, or the development of second-generation compounds. The Company concluded that the Amended First Opt-in Election and the Amended Second Opt-in Election options are not considered to be material rights.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Company determined that the license was not distinct from the added research and development services within the context of the agreement because the added research and development services significantly increase the utility of the intellectual property. The Company also determined that the remaining research and development services are not distinct from the partially delivered combined promise comprised under the agreement prior to the First Amendment of the development license and PTG-200 services, including compound supply and other services. Therefore, the First Amendment is treated as if it were part of the original Janssen License and Collaboration Agreement. The First Amendment was accounted for as if it were an extension of services under the initial Janssen License and Collaboration Agreement by applying a cumulative catch-up adjustment to revenue. As of the effective date of the First Amendment, the Company calculated the adjusted cumulative revenue under the amended Janssen License and Collaboration Agreement by updating the transaction price for the incremental consideration to be received, net of the incremental development cost reimbursement to be paid to Janssen, and an updated percentage complete, which resulted in a cumulative adjustment recorded during the year ended December 31, 2019 that reduced revenue by $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendmentMember_0gY4oTF5r0WEXzTC15E-FQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" sign="-" scale="6" id="Narr_IlY877AjlkuvoyHfXciWVg">9.4</ix:nonFraction> million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The contract duration is defined as the period in which parties to the contract have present enforceable rights and obligations. For revenue recognition purposes, the Company determined that the duration of the Janssen License and Collaboration Agreement, as amended, began on the effective date of July 13, 2017 and is estimated to end upon the later of end of Phase 2a for PTG-200 or upon dosing of the third patient in Phase 2b for a second-generation compound.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Company uses the most likely amount method to estimate variable consideration included in the transaction price. Variable consideration after the First Amendment consists of future milestone payments and cost sharing payments from Janssen for agreed upon services, offset by development cost reimbursements payable to Janssen. Cost sharing payments from Janssen relate to the agreed upon services for development activities that the Company performs within the duration of the contract and are included in the transaction price at the Company&#8217;s share of estimated budgeted costs for these activities, including primarily internal full-time equivalent effort and third party contract costs. Cost sharing payments to Janssen relate to agreed upon services for Phase 2 activities that Janssen performs within the duration of the contract and are not a distinct service that Janssen transfers to the Company. Therefore, the consideration payable to Janssen is accounted for as a reduction in the transaction price.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:80.09%;border:0;margin:30pt 9.56% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:9.56%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Vcj16TERP0G28qs-ytsD8g_cont3" continuedAt="Tb_Vcj16TERP0G28qs-ytsD8g_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the transaction price of the initial performance obligation under the Janssen License and Collaboration Agreement was $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_X-3f2T5tzkO0bujYt1VHYg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="Narr_gZV7gy5_qUCvb0KrIFTGDw">98.6</ix:nonFraction> million as of December 31, 2020, a decrease of $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_OTlJVqmnGkadZNc3gOI6uA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" sign="-" scale="6" id="Narr_SMTBDmTMYEm6v0kazZUeZA">14.3</ix:nonFraction> million from the transaction price of $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_Iek_4R-H0EOc28_Wvd-Hnw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="Narr_D76IcT-cyUaIQVLwjLrqOg">112.9</ix:nonFraction> million at December 31, 2019 and an increase of $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_H-NgQaNu50uhdMckH4xw9Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" scale="6" id="Narr_FoqKcTcOJ0CLjilwqB4X-Q">37.9</ix:nonFraction> million from the transaction price of $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2018_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_dyHYhh53okOYGwIKFCa5Ag" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="Narr_HM0179qdt0mml9QoeU02sg">60.7</ix:nonFraction> million at December 31, 2018. In order to determine the transaction price, the Company evaluated all payments to be received during the duration of the contract, net of Phase 2 development costs reimbursement expected to be payable to Janssen. The Company determined that the transaction price of the initial performance obligation as of December 31, 2020 includes the $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_7_13_2017_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_UpfrontCashPaymentMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_8ZzG4TogRUeK22l7bZWg6Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="Narr_8KKvXtmpp0qosV5ZN5RGUg">50.0</ix:nonFraction> million upfront payment, the $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_4_1_2019_To_6_30_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_LicenseAndCollaborativeRevenueMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendmentMember_XvMY8HCh9EOEQkePbHrEeg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="Narr_r3rsyg-0OEGKSgN0GkhHjw">25.0</ix:nonFraction> million payment received upon the effectiveness of the First Amendment, the $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendmentMember_GtedaLqT9E2-CCUloPfAtw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="Narr_nmu50FrhhkmtfeiLHEEyQg">5.0</ix:nonFraction> million payment triggered by the successful nomination of a second-generation compound, $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_LicenseAndCollaborativeRevenueMember_us-gaap_TypeOfArrangementAxis_ptgx_PhaseTwoClinicalTrialMember_BryyTsUuxEmwlP3YXd1gUg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="Narr_WmX0A9EAokWmoK6Rx_oztg">17.9</ix:nonFraction> million of reimbursement from Janssen for services performed for PTG-200 Phase 2 and for second-generation compound research and development costs and other services, and estimated variable consideration consisting of a $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_LicenseAndCollaborativeRevenueMember_us-gaap_TypeOfArrangementAxis_ptgx_EstimatedVariableConsiderationMember_arxMJ0T-00eGdw9zoeZApA" decimals="-5" format="ixt:numdotdecimal" name="ptgx:CollaborativeArrangementPayableUponEffectivenessOfAmendment" scale="6" id="Narr_vQD5Ehj7g0OJSo8xD3MXFg">7.5</ix:nonFraction> million milestone payment subject to the completion of a Phase 1 study for a second-generation compound, partially offset by $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_MilestonePaymentsMember_us-gaap_TypeOfArrangementAxis_ptgx_SecondGenerationDevelopmentCompoundMember_sAqgbJv3QkOF-0V4dOsnIw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="Narr_nxnqcvhGp0C0RVTubiDePA">6.8</ix:nonFraction> million of net cost reimbursement to Janssen for services performed. The Company evaluated whether the variable component of the transaction price should be constrained to ensure that a significant reversal of revenue recognized on a cumulative basis as of December 31, 2020 is not probable. The Company concluded that the variable consideration constraint does not further decrease the estimated transaction price as of December 31, 2020. The additional potential development, regulatory and sales milestone payments after the completion of Phase 2a activities in UC and CD that the Company would be eligible to receive are currently outside the contract term as defined for revenue recognition purposes and as such have been excluded from the transaction price. Janssen has also opted in for certain additional services to be performed by the Company that are outside the initial performance obligation; revenue is recognized as these services are performed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Company re-evaluates the transaction price, including variable consideration, at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur. The Company and Janssen make quarterly cost sharing payments to one another in amounts necessary to ensure that each party bears its contractual share of the overall shared costs incurred. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Company utilizes a cost-based input method to measure proportional performance and to calculate the corresponding amount of revenue to recognize. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to expected costs to fulfill the combined performance obligation. These costs consist primarily of internal FTE effort and third-party contract costs. Revenue will be recognized based on actual costs incurred as a percentage of total estimated costs as the Company completes its performance obligations. A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company&#8217;s performance obligations. The Company believes this is the best measure of progress because other measures do not reflect how the Company transfers its performance obligation to Janssen. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company&#8217;s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2020, the Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_LicenseAndCollaborativeRevenueMember_TvNWwGu2eEC6vYE7HcfZ-A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="Narr_2Zk2ASXHlUi2X9I-plTcig">28.6</ix:nonFraction> million of license and collaboration revenue. This amount included $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_LicenseAndCollaborativeRevenueMember_TvNWwGu2eEC6vYE7HcfZ-A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="Narr_-foJRKvKY0G4QuLBwUVbDQ">27.1</ix:nonFraction> million of the transaction price based on proportional performance and an update in forecasted amounts for future services remaining to be performed and recognized under the Janssen License and Collaboration Agreement. In addition, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_FinancialServiceOtherMember_NBguqYBUHku6qOzTYn42VQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="Narr_2Sb-cBvVaEKjYaxZfxshdQ">1.5</ix:nonFraction> million of revenue for the year ended December 31, 2020 related to additional services provided by the Company under the Janssen License and Collaboration Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2019, the Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_LicenseAndCollaborativeRevenueMember_3QxHrdZZck25Pg-JQIj-nw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="Narr_AWfbDfSoA0-k-HZUxW_Qeg">0.2</ix:nonFraction> million of license and collaboration revenue. This amount included a $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendmentMember_0gY4oTF5r0WEXzTC15E-FQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" sign="-" scale="6" id="Narr_ceBhLYwaqkGJ4PfPIe8Qtw">9.4</ix:nonFraction> million cumulative catchup adjustment as a reduction of revenue, offset by $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_LicenseAndCollaborativeRevenueMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendmentMember_y5i3Re06f0iiRKOUUagPDA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" scale="6" id="Narr_HBD6nu_dl0267Ey8nGSQQw">8.0</ix:nonFraction> million of license and collaboration revenue recognized following the contract modification for the First Amendment and $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_3_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_LicenseAndCollaborativeRevenueMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendmentMember_OXDfxfH58kqhheU3GQGUvA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="Narr_K2PodkCeQ0SirpXrY1pSDg">1.6</ix:nonFraction> million of collaboration revenue recognized during the first quarter of 2019 under the original Janssen License and Collaboration Agreement prior to the effectiveness of the First Amendment. <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_FinancialServiceOtherMember_mIs-a5_M8Ey3l6XrIQVjEw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="Narr_rXaFKHGTXkKeSXLEoBGcdg">No</ix:nonFraction> revenue for additional services was recognized for the year ended December 31, 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">For the year ended December 31, 2018, the Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_LicenseAndCollaborativeRevenueMember_KsXkSwmdJk6E8sIAWg2nyA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="Narr_P4zqNxHC7ke52Kd77hn84w">30.9</ix:nonFraction> million of license and collaboration revenue. This amount included $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_vfjwayMYI0exJuQhXetAgw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="Narr_-RSsxBOFtUGJG4DSlp0YQg">30.8</ix:nonFraction> million of the transaction price for the Janssen License and Collaboration </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:80.09%;border:0;margin:30pt 9.56% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:9.56%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e2b2a43b_212a_457d_9510_25c1d1c1a2ca"></a><a id="Tc_c75W5STKwUOhjetnYO2iSQ_1_2"></a><a id="Tc_j8_6OubvC0-HEceEDH0iTQ_1_11"></a><a id="Tc_qwrnsjMoykqpw9wEsh33QQ_2_2"></a><a id="Tc_kTVgWpOJ2EuXh-BbIlo33g_2_11"></a><a id="Tc_GIguGMfq60GCZ3za5O3oaA_3_0"></a><a id="Tc_X4UDQSc-pkuL2bq4Qa_FuA_3_2"></a><a id="Tc_WuDjJjNIMkmeQ6tqBhvB_g_3_5"></a><a id="Tc_KSZI74ErJEyg38s9yzRvbQ_3_8"></a><a id="Tc_xJcKlxC-YUiZFDMF0toOCg_3_11"></a><a id="Tc_ummN_HnvG0yu22TWvQBqUQ_4_0"></a><a id="Tc_rwlzv_xcREaOXl6zLm-_og_5_0"></a><a id="Tc_ljVxYWIjE0KqLE2HaCguqA_5_2"></a><a id="Tc_owDyeNkvc0OPNmstqmotWw_5_5"></a><a id="Tc_qZM1CsHIvkKfQnvt6nDcRQ_5_8"></a><a id="Tc_Kce14HOnFEK5_ynMYrhcsg_5_11"></a><a id="Tc_nMrhRt7H3E-l3fZmf__3Ug_6_0"></a><a id="Tc_5vwIU9PRNUu35w_QVVI63w_6_2"></a><a id="Tc_ZB1oLK9c30i1oBqKL0PfEw_6_5"></a><a id="Tc_6K6AM8BQLkWi4irsIrthuQ_6_8"></a><a id="Tc_c2r7_IXEgk6lvyvK7qGeJw_6_11"></a><a id="Tc_HYPGW3TRf0OPzk5Jvi1tRg_6_12"></a><a id="Tc_LL5fSUkNvESSNoUHFbRg-w_7_0"></a><a id="Tc_Dfwa9qBeCk6oZY0QSQD6mw_8_0"></a><a id="Tc_yFPuWCVTcUC-G0XoeN6JQg_8_2"></a><a id="Tc_Ex71jpKqZ0unxVPd5c_eRQ_8_5"></a><a id="Tc_svQyYU98nkiZRnwKoYBOXQ_8_8"></a><a id="Tc_qTwDGcTb0EmULhg5ShI0Zw_8_11"></a><a id="Tc_kg27wyirfEmt5AHEuDIEgQ_9_0"></a><a id="Tc_cS9ccK1EMkqsQT1kynIvmQ_9_2"></a><a id="Tc_Cp3LAbCSZ0SosRNubLtFXg_9_5"></a><a id="Tc_A6ahJihzSkWynuB_K852FA_9_8"></a><a id="Tc_pBysXW53nEC0njgR7RiMeQ_9_11"></a><a id="Tc_edNdzZjJLUC3YgYFLKBbmg_12_2"></a><a id="Tc_00fVZQe0xkiOuw6k5uTb2A_12_11"></a><a id="Tc_HyvcjC4rVEWS9L6bn7fz2w_13_2"></a><a id="Tc_tUAvx6TkQ0ui2JPQEDlVbg_13_11"></a><a id="Tc_jFPq05btzkiMgwciK0N2sQ_14_0"></a><a id="Tc_UCRKNC9GLkSlE4lqY8y_UQ_14_2"></a><a id="Tc_TP8YQRELBUKanUc2qtzhFg_14_5"></a><a id="Tc_Bt4MRK-0qEOdX3SaipMdug_14_8"></a><a id="Tc_izUHb_RhGkuq7Af8uhQYjA_14_11"></a><a id="Tc__b7DcGd8PkOrVJ8zplzTBA_15_0"></a><a id="Tc_8R_x8HZn-kCV9VHJRJfeug_16_0"></a><a id="Tc_0s2TYFyJUUSx3HAozHAxKg_16_2"></a><a id="Tc_FaoToEXnmUOJw7T0vkXEYw_16_5"></a><a id="Tc_YTtLCjn59UigGSpfWO24nQ_16_8"></a><a id="Tc_ycxA0XL_U0mrBWCU7YL3Ew_16_11"></a><a id="Tc_ue_HaPgjbEO1-vAa2o1CiQ_17_0"></a><a id="Tc_ktEhqSNb60a5s63ukbfNjw_17_2"></a><a id="Tc_VG4x8uOCSkei80ck-9RkDQ_17_5"></a><a id="Tc_YLZGu1teu0e12C5b731sWQ_17_8"></a><a id="Tc_lM-sL1KCk0CQ4NLB5JXH9Q_17_11"></a><a id="Tc_FnTNpeqbSUGIqm96kGzulg_18_0"></a><a id="Tc__Z7Se7SnY0KyLL0kNraDEw_19_0"></a><a id="Tc_j9hcS1XPl0m0cw1avqw_7A_19_2"></a><a id="Tc_md9HuapgDUWOQcR4ZsGSDA_19_5"></a><a id="Tc_Q5Mw53Ej4U--vCWTTjRPtw_19_8"></a><a id="Tc_zMoWgiZM_E6sxNiCM_su6w_19_11"></a><a id="Tc_abP0h0RHBE6kVaopRRjAOQ_20_0"></a><a id="Tc_nHbaVJiD_0m_OIBAtiHLmA_20_2"></a><a id="Tc_IwER2zSKtkqcYU8vyJ71Ng_20_5"></a><a id="Tc_Zab8f1ICnUSdk9jJ87JXiA_20_8"></a><a id="Tc_3QCET9LmmkSm_1_3_9DToQ_20_11"></a><ix:continuation id="Tb_Vcj16TERP0G28qs-ytsD8g_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Agreement recognized based on proportional performance, and $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_srt_ProductOrServiceAxis_us-gaap_FinancialServiceOtherMember_us-gaap_TypeOfArrangementAxis_ptgx_PhaseTwoClinicalTrialMember_lxJPPTHjz0OKFor2aG-yUQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="Narr_U8feGsKAy06KmV5DqwAJNA">0.1</ix:nonFraction> million, net, for other services related to Phase 2 activities performed by the Company on behalf of Janssen that were not included in the performance obligations identified under the Janssen License and Collaboration Agreement. </span></p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="Group_cM-oJUPu_ESkzeKc8-5FZQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The following table presents changes in the Company&#8217;s contract assets and liabilities during the periods presented (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance&#160;at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance&#160;at</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Beginning&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">End&#160;of</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deductions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract assets:</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Receivable from collaboration partner - related party</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_Iek_4R-H0EOc28_Wvd-Hnw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNet" scale="3" id="Tc_qTI5egQB2EmJ3951JFgq2Q_5_3">5,955</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_OTlJVqmnGkadZNc3gOI6uA" decimals="-3" format="ixt:numdotdecimal" name="ptgx:ContractWithCustomerAssetAdditions" scale="3" id="Tc_Kj21c40dCkOxw_QguJuIPw_5_6">6,221</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_OTlJVqmnGkadZNc3gOI6uA" decimals="-3" format="ixt:numdotdecimal" name="ptgx:ContractWithCustomerAssetDeduction" scale="3" id="Tc_FxFADoVGIEGR4Yl_JLG14w_5_9">9,750</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_X-3f2T5tzkO0bujYt1VHYg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNet" scale="3" id="Tc_fUbaXJCS-U-Xf492p9uX6A_5_12">2,426</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Contract asset - related party</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_Iek_4R-H0EOc28_Wvd-Hnw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="3" id="Tc_vApwUqJPS0KjTm0ojSnRxA_6_3">800</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_OTlJVqmnGkadZNc3gOI6uA" decimals="-3" format="ixt:numdotdecimal" name="ptgx:ContractWithCustomerAssetRelatedPartyAdditions" scale="3" id="Tc_o0boBfozcECL-X3BPj_eaA_6_6">342</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_OTlJVqmnGkadZNc3gOI6uA" decimals="-3" format="ixt:numdotdecimal" name="ptgx:ContractWithCustomerAssetRelatedPartyDeduction" sign="-" scale="3" id="Tc_pNyWTrhN2E-6Swn2__CTtA_6_9">1,142</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract liabilities:</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Deferred revenue - related party</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_Iek_4R-H0EOc28_Wvd-Hnw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_VgN-N-MXVE2TqrS2jxGgiw_8_3">41,530</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_OTlJVqmnGkadZNc3gOI6uA" decimals="-3" format="ixt:numdotdecimal" name="ptgx:ContractWithCustomerLiabilityAdditions" scale="3" id="Tc_9BEWfQn6602IDaMF8ZrMsw_8_6">3,963</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_OTlJVqmnGkadZNc3gOI6uA" decimals="-3" format="ixt:numdotdecimal" name="ptgx:ContractWithCustomerLiabilityDeduction" scale="3" id="Tc_CDVeYSryn0q1Ini9VAOetA_8_9">31,016</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_X-3f2T5tzkO0bujYt1VHYg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_0_a5DxiQ3U-8uviHrm1Xwg_8_12">14,477</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Payable to collaboration partner - related party</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_Iek_4R-H0EOc28_Wvd-Hnw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="3" id="Tc_x0bNNpShbEmOupwESlGsyg_9_3">1,262</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_OTlJVqmnGkadZNc3gOI6uA" decimals="-3" format="ixt:numdotdecimal" name="ptgx:DueToRelatedPartyAdditions" scale="3" id="Tc_8hoPHQkb0k6Q5zI9hjrf1Q_9_6">3,800</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_OTlJVqmnGkadZNc3gOI6uA" decimals="-3" format="ixt:numdotdecimal" name="ptgx:DueToRelatedPartyDeductions" scale="3" id="Tc_cCTHOmVjiE-f6ku85GIDhg_9_9">2,330</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_X-3f2T5tzkO0bujYt1VHYg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="3" id="Tc_iROiiKi0hEawtTRjJE-c9A_9_12">2,732</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance&#160;at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance&#160;at</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Beginning&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">End&#160;of</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deductions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract assets:</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Receivable from collaboration partner - related party</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2018_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_dyHYhh53okOYGwIKFCa5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNet" scale="3" id="Tc_gxt54gBOKE-pmMpIZlhDIg_16_3">2,042</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_H-NgQaNu50uhdMckH4xw9Q" decimals="-3" format="ixt:numdotdecimal" name="ptgx:ContractWithCustomerAssetAdditions" scale="3" id="Tc_185dN3lbaE69OCsrYup2MA_16_6">36,837</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_H-NgQaNu50uhdMckH4xw9Q" decimals="-3" format="ixt:numdotdecimal" name="ptgx:ContractWithCustomerAssetDeduction" scale="3" id="Tc__LPERQxb60KCR8Qd1ruDGg_16_9">32,924</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_Iek_4R-H0EOc28_Wvd-Hnw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNet" scale="3" id="Tc_vz7jhw1Y90mP7UYd-VeY0g_16_12">5,955</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Contract asset - related party</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2018_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_dyHYhh53okOYGwIKFCa5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="3" id="Tc_wWopQHCqXE2Adv1-UID_uQ_17_3">2,545</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_H-NgQaNu50uhdMckH4xw9Q" decimals="-3" format="ixt:numdotdecimal" name="ptgx:ContractWithCustomerAssetRelatedPartyAdditions" scale="3" id="Tc_U4gXhrZ9oE2pK4QSdzcqcA_17_6">800</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_H-NgQaNu50uhdMckH4xw9Q" decimals="-3" format="ixt:numdotdecimal" name="ptgx:ContractWithCustomerAssetRelatedPartyDeduction" sign="-" scale="3" id="Tc_auLA7SfCTk2qbB5fNBBMaA_17_9">2,545</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_Iek_4R-H0EOc28_Wvd-Hnw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="3" id="Tc_CxtmnTPt_U6-X9Gegw9yEw_17_12">800</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract liabilities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Deferred revenue - related party</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2018_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_dyHYhh53okOYGwIKFCa5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_Xsv_5pmK5E-bvk7sPWzdhQ_19_3">8,223</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_H-NgQaNu50uhdMckH4xw9Q" decimals="-3" format="ixt:numdotdecimal" name="ptgx:ContractWithCustomerLiabilityAdditions" scale="3" id="Tc_5PvniKA1IUGQCP18XM8n4w_19_6">42,456</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_H-NgQaNu50uhdMckH4xw9Q" decimals="-3" format="ixt:numdotdecimal" name="ptgx:ContractWithCustomerLiabilityDeduction" scale="3" id="Tc_Y6eytbdPe0OJTx97h4K1nw_19_9">9,149</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_Iek_4R-H0EOc28_Wvd-Hnw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_XxnLN4fFrkmj9k579kfMnQ_19_12">41,530</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Payable to collaboration partner - related party</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2018_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_dyHYhh53okOYGwIKFCa5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="3" id="Tc_H_ZQSoZiUkW7iPgVdNEnpA_20_3">1,061</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_H-NgQaNu50uhdMckH4xw9Q" decimals="-3" format="ixt:numdotdecimal" name="ptgx:DueToRelatedPartyAdditions" scale="3" id="Tc_dyxih49sJkKHNY5X3AM1SQ_20_6">1,468</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_H-NgQaNu50uhdMckH4xw9Q" decimals="-3" format="ixt:numdotdecimal" name="ptgx:DueToRelatedPartyDeductions" scale="3" id="Tc_MYXjh1KsYEivx0gCkELDQw_20_9">1,267</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_Iek_4R-H0EOc28_Wvd-Hnw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="3" id="Tc_vgk3nNNskU2If_uheQvs5g_20_12">1,262</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2020, the Company recognized revenue of $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="Narr_LcsuUM3CcEyUUIOjn0zz5Q">14.1</ix:nonFraction> million from amounts included in the deferred revenue contract liability balance at the beginning of the year. During the year ended December 31, 2019, the Company recognized revenue of $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="Narr_po7O2dVDEUm967YjQBUhsA">1.6</ix:nonFraction> million from amounts included in the deferred revenue contract liability balance at the beginning of the year, which represents the revenue recognized during the first quarter of 2019 prior to the effectiveness of the First Amendment. During the year ended December 31, 2018, the Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="Narr_9_MFxtdLAkSUJQlSM3_oLw">23.5</ix:nonFraction> million in revenue from the deferred revenue contract liability balance at the beginning of the year. <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2018_rK3dysi-wkKgewxxLVB-Eg" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:CapitalizedContractCostNet" scale="6" id="Narr_C-7dWTDR9ki2ipoDyFGHEg"><ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:CapitalizedContractCostNet" scale="6" id="Narr_Yrm8Zv8rFkCJP4JpU7iuYg"><ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:CapitalizedContractCostNet" scale="6" id="Narr_mkJW3P4sCUGScMf4ARX2-A">None</ix:nonFraction></ix:nonFraction></ix:nonFraction> of the costs to obtain or fulfill the contract were capitalized.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_Y2XYm8e7ZkimDUTFVsCirQ" continuedAt="Tb_Y2XYm8e7ZkimDUTFVsCirQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 4.&#160;&#160;&#160;&#160;Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Financial assets and liabilities are recorded at fair value. The accounting guidance for fair value provides a framework for measuring fair value, clarifies the definition of fair value and expands disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 22.5pt;"><i style="font-style:italic;">Level 1</i>&#8212;Inputs are unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 22.5pt;"><i style="font-style:italic;">Level 2&#8212;</i>Inputs (other than quoted market prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument&#8217;s anticipated life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 22.5pt;"><i style="font-style:italic;">Level 3</i>&#8212;Inputs reflect management&#8217;s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:80.09%;border:0;margin:30pt 9.56% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:9.56%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_8ad76551_aac3_4154_bb77_e4d14678a608"></a><a id="Tc_TCLJj7PB306Jn3J4CNO47A_1_2"></a><a id="Tc_k9WHhL4LY0qCHwSmsWqKow_2_2"></a><a id="Tc_zMqWuEERw0uEaqMd67-aiw_2_5"></a><a id="Tc_0Pw3cqUm4UWVCs4MfOBr8g_2_8"></a><a id="Tc_QxhxNVCDME67_n35oLZ0VA_2_11"></a><a id="Tc_25_rG_Fuf0m2H6naSNNdcw_3_0"></a><a id="Tc_ACcvH7ttdkitZo9h_i16bw_4_0"></a><a id="Tc_lu0AkS3ohUeuULIpU9nPEg_4_2"></a><a id="Tc_LUskm4CflkyXyFOZrFbfNA_4_5"></a><a id="Tc_tY_d8EUBekO63pQZlr52ZA_4_6"></a><a id="Tc_N-dxqnx37EyqX-pnoo0zBw_4_8"></a><a id="Tc_g1aNpj881UGvupfW3YzyfQ_4_9"></a><a id="Tc_Lm0KGMKIkk6foh7W5E9BJw_4_11"></a><a id="Tc_mc6N1we5DE-L8tCvmEXURQ_5_0"></a><a id="Tc_AQy6M1lSPkiOeSv-YuJITw_5_3"></a><a id="Tc_1CRUvFr1sk6bBQQDC6uPOw_5_9"></a><a id="Tc_j5-LczWLyE20Rww65MMmug_6_0"></a><a id="Tc_Jz44FDJfiEib6dkgR4vxxQ_6_3"></a><a id="Tc_jFBxrSJ1RUKb-SUtJ9H4uQ_6_9"></a><a id="Tc_KYPfEa60o0C6BVEUwaMelA_7_0"></a><a id="Tc_uG7zUzHfxUeqEHFkyynr-g_7_3"></a><a id="Tc_mF7t3JKb_EuABaKjgqdang_7_9"></a><a id="Tc_GOYEpjF9h0OsJkd5wQdGeg_8_0"></a><a id="Tc_S5VoqAQYfE2MhJufPy-Fkg_8_2"></a><a id="Tc_sDxyrF2k-0WBPkaODvHb9A_8_5"></a><a id="Tc_tRM3sxefwUOtjVtPe_tm_A_8_8"></a><a id="Tc_6RPwYlH6a0CFWOOTrtwVAg_8_9"></a><a id="Tc_2ZsRn8puOUiBETgQNquuwg_8_11"></a><a id="_37696941_d4c8_4b52_b79d_c4c9a2230ab3"></a><a id="Tc_GxuWgDBg3EKjsUDAojIIfg_1_2"></a><a id="Tc_OU8I2ew6NkKw2pdbCrL1qA_2_2"></a><a id="Tc_6Rl4GEJND0eW5PI7jMmzGg_2_5"></a><a id="Tc_SVQIoUdhc0iPj_GI8frdTQ_2_8"></a><a id="Tc_Lcc6kkI00EC-EG5M1to5ig_2_11"></a><a id="Tc_q2XUwaWVbUSeveDOhk7pVg_3_0"></a><a id="Tc_11choN5EaEK26CDWZMLXJA_4_0"></a><a id="Tc_ks92cpfnJE-er0M7PmpPWQ_4_2"></a><a id="Tc_3jd5HxV56kW4fcPbHRDCDA_4_5"></a><a id="Tc_XMNZmInhvUanqPhei35gaw_4_6"></a><a id="Tc_BcT0XZp4E0qnTcnzN1WEdw_4_8"></a><a id="Tc__LqzZlZ-eUac50B5d5Q_aQ_4_9"></a><a id="Tc_NkMFYZJvbEKj3OrBh3BS0g_4_11"></a><a id="Tc_D_F8gvAYLkqkfytq8HawgA_5_0"></a><a id="Tc_OAeEyVAof0q0kGaU6drfHA_5_3"></a><a id="Tc_mm8p4f9r10Owu4HctyGlgw_5_9"></a><a id="Tc_Sy1Iuy1j9EatZQ7WFp6M-w_6_0"></a><a id="Tc_LNffHFqfKk-j7LMgxpHVEw_6_3"></a><a id="Tc_3K-zrkiXsU6DthUg2OXOzQ_6_9"></a><a id="Tc_-Rho22hrOEmWAMPANmuFfg_7_0"></a><a id="Tc_K-obK9xHqkGC0RtWds7vFQ_7_3"></a><a id="Tc_j_JG9Cp2mk2lO1dHDx3D_Q_7_9"></a><a id="Tc_Mc7K_rcBf0-jv4mVIYdXPA_8_0"></a><a id="Tc_ttEq41mmJU-7xqUa2ncPvw_8_2"></a><a id="Tc_nwRP4S77vEWpo22ac9zo_Q_8_5"></a><a id="Tc_DpQzKnjkVUWqxeW7Yt1KpQ_8_8"></a><a id="Tc_YlOtGgXTrECBy4kNJIa9vQ_8_9"></a><a id="Tc_adDCNpgKTUO91QQnBskU8w_8_11"></a><ix:continuation id="Tb_Y2XYm8e7ZkimDUTFVsCirQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">In determining fair value, the Company utilizes quoted market prices, broker or dealer quotations, or valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="Tb_HYiCPNEWAUmAKXmGixxs1w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The following table presents the fair value of the Company&#8217;s financial assets determined using the inputs defined above (in thousands).</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:46.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_5KKCr5eHQEygdYItDdw9RQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_WOj7ZtyWbEKxKEE4Cx8sCQ_4_3">27,481</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_uzJVCv1ct0mqY9ZIAM4vDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_FcCNCiM-7U2nbklJxQUSkQ_4_12">27,481</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember_RcUZPhnZn0yecR06vLTPmQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_sPAO5PUnQ06GLHF4g29bWQ_5_6">65,863</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember_5sHQft-r50evFl5UcMy5tw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_HOPwh5qaG0ie_Qaay9DwxA_5_12">65,863</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_Py5g_H7ZS0mto91KY61Pqg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_JwrC8s9Kr0OrU_MxevVOmg_6_6">27,590</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_o8lJ8OmQqUuIzV1asN5-7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_yKQ1I9jNqEqGLyAQobRlrw_6_12">27,590</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury and agency securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_uVbhr5AkeEyXPse4j8Vtdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_GAHI9UzXDU-lc3tKSpghyg_7_6">183,210</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_GPbqzeyzuEyJ1N6rb_ntwQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_U5vrwcpBnkqUezP4kg7YlA_7_12">183,210</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total financial assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_pDkR-5RKjEyn9NkwkBrP6Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_T9lPUPb3l0OfprKK9VH3RQ_8_3">27,481</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_K9-l4NAY-kmFaLEyWQ4rSQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_3KihObZ3NUqcceogPC-T1w_8_6">276,663</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember__UoGf4iXl0-vwHR1RxDl_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_LhCWAHlJ10m6aybp3XFtdA_8_12">304,144</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:46.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_FOvlkFRNTEmtTcC9nd5x6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_VmpK8Scu1UmttdZB4Tr9_A_4_3">12,964</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_WRekQb2CvU25FJAvTO5BBg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_-Jc3hPm7-kCClrTaD063eg_4_12">12,964</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember_9p8nfsfW6EKn9p_BdoPZZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_mA9sLLLEWku7_ZLf4iuC9Q_5_6">44,282</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember_LaPN7nYw4E2V8LpCkDOHiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_CMhAQMb3VkWP45Jzdl_uKw_5_12">44,282</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_XbTJJV-aUUKkYoe9CCHwlg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_NE090oxkf0uemIFCtFZOZg_6_6">33,662</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_wEd8XK0sFEmZYH9nDuBq9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_0Y8Dke7MB0mAYdyEwBEPDg_6_12">33,662</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury and agency securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_wRs9ZU4Bekq5XgF2kvDBig" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_labCykxvNEean7Iao1MX4w_7_6">40,810</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_EE8cQuRZ_UmapNGf-h67ng" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_6iWpKmnVF0uI1gDNZnMf3Q_7_12">40,810</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total financial assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_aNicgv3ij0eMkeM8EWdR-w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_1D6UJom9B0e-GmD3T1dQWw_8_3">12,964</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_z50eFBlU2Ee-Syluh-tL9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_-Fr6h7ZxbEqig11w7acxGA_8_6">118,754</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wuEhdkxUmkStpEwG9Rhsew" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_RywgpEv9sE69_emzFDPm6g_8_12">131,718</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s commercial paper, corporate debt securities and U.S. Treasury and agency securities, including U.S. Treasury bills, are classified as Level 2 as they were valued based upon quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Fair Value of Other Financial Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The carrying value of long-term debt as of December 31, 2019 approximated fair value because the Term Loan bore interest at a rate that approximated prevailing market rates for instruments with similar characteristics and there was no significant change in the credit worthiness of the Company. The Company had <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:LongTermDebtFairValue" scale="3" id="Narr_2ihLj1dy_kG8mhIkctJpmg">no</ix:nonFraction> long-term debt balance as of December 31, 2020.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">94</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:80.09%;border:0;margin:30pt 9.56% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:9.56%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_15bac302_2f4b_4e96_9fb3_2d051dcf27bd"></a><a id="Tc_PShTwabpnUuWRZLiSDTLZw_1_2"></a><a id="Tc_KJcdMJ6GkUmc7rGAOzFYow_2_2"></a><a id="Tc_9h4K7BmG-0uyvduAxWxofw_2_5"></a><a id="Tc_lXlg-Ii_1EG1KsWUEFtz9A_3_2"></a><a id="Tc_SMLMW8Y9sESVauGm_Q1bIg_3_5"></a><a id="Tc__Afsc49dAESlviKpansh9A_3_8"></a><a id="Tc_qXWsrjU2b0WIbsUEiypOqg_3_11"></a><a id="Tc_lt6yAMTJcEqfmSWjcTcwMw_4_0"></a><a id="Tc_wUS21yU_jEqcrJYqt0-MKA_4_2"></a><a id="Tc_YDirZyYAAUKTBgrEStafqQ_4_5"></a><a id="Tc_iWdv3BMu-0G6CkkUjosk2g_4_6"></a><a id="Tc_W9Y55uIHIE6lD8ZVRuRezw_4_8"></a><a id="Tc_8Q3vKy6yL0SGAXqr7EdCGQ_4_9"></a><a id="Tc_fl4wDM6I00uCVniLrg-VRg_4_11"></a><a id="Tc_iHWOMFxQhUWKJuGhIr3y-g_5_0"></a><a id="Tc_ntzm1AwBW0mcLEAlTmGVIA_5_6"></a><a id="Tc_lpMdEddjPUmJ78M5Do5SzQ_6_0"></a><a id="Tc_HWbwbnybOkyWAhtVnU9aPg_7_0"></a><a id="Tc_1y9_WdIau0afcNAzRlLGjA_8_0"></a><a id="Tc_ljvyNVIy40aZeRlyTX0uCQ_8_2"></a><a id="Tc_qQFPkcK74Uqyx4aDgcWfhQ_8_5"></a><a id="Tc_QGmcacuNBUKT7R3kCFitkA_8_8"></a><a id="Tc_gll5UyH58EadQCXGoELQTQ_8_11"></a><a id="Tc_JFp8VxQ_7EeemgHCG1zMWA_9_0"></a><a id="Tc_jZU-TebElUi9DbgKprl2Nw_10_0"></a><a id="Tc_rjKlwJFuv0-v9MzuTKt8jw_10_11"></a><a id="Tc_EMPGpf9FZUSzig6iEhpZXA_11_0"></a><a id="Tc_y0Z3ohGxOE6f4klPDOZPZA_12_0"></a><a id="Tc_z1xvDlJBGUKuiPpNavq8_w_13_0"></a><a id="Tc_HQHsvNEr9UWjYa06I9OT5w_13_11"></a><a id="_20d3482a_24e0_4f08_9f4d_fb87afe66c55"></a><a id="Tc_vPlNpwnO80aFvigx2FhvPg_1_2"></a><a id="Tc_cXO4UVD-SkKXwwN6C7nXvg_2_2"></a><a id="Tc_6DOwJrNc5EytU75BA1FppA_2_5"></a><a id="Tc_5j_hEpKPHUKohJSs1mU7aQ_3_2"></a><a id="Tc_IZp4IVGllESaMon_7v24aQ_3_5"></a><a id="Tc_nYG-ZnxbxUC-1j9w27QWJw_3_8"></a><a id="Tc_TqvlIGiHNkun1MM-YUx2fQ_3_11"></a><a id="Tc_NQT7eSi0q0-DwPSYFePvJw_4_0"></a><a id="Tc_a94PrYsGsEitO-LHkCReLQ_4_2"></a><a id="Tc_Atvg9ExIMUeTWtrWGKW_rg_4_5"></a><a id="Tc_nDm1NMxl1ECDK3gi6glEVQ_4_6"></a><a id="Tc_dusnhkjnsU-8VeOIPDNyxw_4_8"></a><a id="Tc_aQZUwVaeaUCXemD3-Qdebg_4_9"></a><a id="Tc_yz7grAYbmEKETpnP9rElfg_4_11"></a><a id="Tc_YEaFKGTfjkyHT8iFyIw--Q_5_0"></a><a id="Tc_X2dtFUvh9kqJz_LJu4AxLw_6_0"></a><a id="Tc_nWMHHV238ESARAYmyDyAfA_7_0"></a><a id="Tc_v21z8NsNhE6mkHz0c1d2tQ_8_0"></a><a id="Tc_5Q_I01yszEqlI8w4xkQoLA_8_2"></a><a id="Tc_ApKQLZ9YHUmBucmSJMfQuQ_8_5"></a><a id="Tc_8qXFWt5N9ECZO6WnuxbZyw_8_8"></a><a id="Tc_MVHd8MlfIkeLVN-CErsAEQ_8_11"></a><a id="Tc_YHwAINt-1UW5XfcnFgUwDg_9_0"></a><a id="Tc_OSHPJwVHwUynB_dmYt5gYg_10_0"></a><a id="Tc_T-PY7cj3bUS2mrGjWv04Aw_10_11"></a><a id="Tc_HEhh2oWdfUihuDwhy09Seg_11_0"></a><a id="Tc_CvadVRNyjE2iMMiwHLJUvg_12_0"></a><a id="Tc_Xaalpl8keECNJXkL_0WO7Q_12_11"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="Tb_2CvTwQHtmUaIkTY81Bv75g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 5.&#160;&#160;&#160;&#160;Cash Equivalents and Marketable Securities </p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="us-gaap:MarketableSecuritiesTextBlock" id="Tb_b8M2gjilqEOHxDa5D--Yrw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Cash equivalents and marketable securities consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:46.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross&#160;Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_1lnDMEXB70mrHe1LD59Ocw" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost" scale="3" id="Tc_P2Np9ZeN6U6jXdsm7JHMEQ_4_3">27,481</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_1lnDMEXB70mrHe1LD59Ocw" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesFairValue" scale="3" id="Tc_P-IQT1KP5kqidq_kFdMS5g_4_12">27,481</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_poqDHHPT202Brw2nGTuPeA" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost" scale="3" id="Tc_HEGT5P5vxE2CZP_oAAwRdw_5_3">65,866</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_poqDHHPT202Brw2nGTuPeA" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss" scale="3" id="Tc_1e9ckBV86kOb_uv-I_6MAg_5_9">3</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_poqDHHPT202Brw2nGTuPeA" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesFairValue" scale="3" id="Tc_qOB-98J-AkmjnKGVMuNXCw_5_12">65,863</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_WIiZJQ_HGE6FfcxqDuIIGA" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost" scale="3" id="Tc_ruJTc9NHKUOe9iS9MQPflg_6_3">27,592</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_WIiZJQ_HGE6FfcxqDuIIGA" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain" scale="3" id="Tc_4QjytLwgT0engJJ0EaBSyw_6_6">2</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_WIiZJQ_HGE6FfcxqDuIIGA" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss" scale="3" id="Tc_ge7nkbfTyU6RJdwIGqTQYw_6_9">4</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_WIiZJQ_HGE6FfcxqDuIIGA" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesFairValue" scale="3" id="Tc_8vtOXTaZVkG46A9IJzm-IQ_6_12">27,590</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury and agency securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_eDAghYO6dkquiKdNvv7gGw" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost" scale="3" id="Tc_ulkEgEXdzEKIAHaDU3gf7Q_7_3">183,203</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_eDAghYO6dkquiKdNvv7gGw" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain" scale="3" id="Tc_aDzlmiAdKEi9azVpoKeFTQ_7_6">10</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_eDAghYO6dkquiKdNvv7gGw" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss" scale="3" id="Tc_85tf0W5SKU2E-9vsy8HqQA_7_9">3</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_eDAghYO6dkquiKdNvv7gGw" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesFairValue" scale="3" id="Tc_5yiZ1_ImIkKdAQhxLnGGCw_7_12">183,210</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total cash equivalents and marketable securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost" scale="3" id="Tc_sKYT1G3sA02WdulXXjBFRA_8_3">304,142</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain" scale="3" id="Tc_rZ8vifwg20S3JHJtkZoXeg_8_6">12</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss" scale="3" id="Tc_VvFw0EsP3ka-OiWGK2GpOA_8_9">10</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesFairValue" scale="3" id="Tc_tM0CeM2MXU6d_K2rwaG9wg_8_12">304,144</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Classified as:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="Tc_R6ujF1em9UCXHvoQrbqg7g_10_12">113,693</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Marketable securities - current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" id="Tc_Tp0YiPcagUOwDoRF-WVLoA_11_12">188,451</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Marketable securities - noncurrent</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="3" id="Tc_yrfPj8f9i0-IyhkOBiRpTQ_12_12">2,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total cash equivalents and marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesFairValue" scale="3" id="Tc_SmlBI9e1Y0-Lj0MBGIYgQw_13_12">304,144</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:45.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross&#160;Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_b5xheGic50m0BOMQi6R-nw" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost" scale="3" id="Tc_wgXJIacg6UmeAbjTnmTzAw_4_3">12,964</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_b5xheGic50m0BOMQi6R-nw" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesFairValue" scale="3" id="Tc_mpqc_PoUzkiF5oBF7VMIGA_4_12">12,964</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_E4MJhmAIOEC2XR0v8l-IgA" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost" scale="3" id="Tc_Ac4KqgJn80ijaNjcJZus-A_5_3">44,284</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_E4MJhmAIOEC2XR0v8l-IgA" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain" scale="3" id="Tc_o5AuaEgXrkCXbn8Y_ijy3w_5_6">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_E4MJhmAIOEC2XR0v8l-IgA" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss" scale="3" id="Tc_PGZ6SbROW0mVE62TdXr9kQ_5_9">4</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_E4MJhmAIOEC2XR0v8l-IgA" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesFairValue" scale="3" id="Tc_0OAiS8bQikOaJzOL4Q0nLg_5_12">44,282</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_NCJa5a9fSEq4urrjZGFZCg" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost" scale="3" id="Tc_AZE1FtFrRkqhvplBWOTh6w_6_3">33,653</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_NCJa5a9fSEq4urrjZGFZCg" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain" scale="3" id="Tc_-WUbx3HZ2kabjtsRI-_MAA_6_6">11</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_NCJa5a9fSEq4urrjZGFZCg" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss" scale="3" id="Tc_wphSMOmZ7k-4vsOvpLHEqQ_6_9">2</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_NCJa5a9fSEq4urrjZGFZCg" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesFairValue" scale="3" id="Tc_bJ1qtviiJUKwTe85vW097A_6_12">33,662</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury and agency securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_gb9tp0RYKkSz5MvwQ_K0Hg" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost" scale="3" id="Tc_OM951KPo7ECAMrl8UMkczQ_7_3">40,798</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_gb9tp0RYKkSz5MvwQ_K0Hg" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain" scale="3" id="Tc_RcuB09Wbh02GCtsk1hMKgA_7_6">14</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_gb9tp0RYKkSz5MvwQ_K0Hg" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss" scale="3" id="Tc_MaBBp5mq_0Wxo1b0Txch-g_7_9">2</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_gb9tp0RYKkSz5MvwQ_K0Hg" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesFairValue" scale="3" id="Tc_kzrRCIg0Ek217HmiUxe9vA_7_12">40,810</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total cash equivalents and marketable securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost" scale="3" id="Tc_KnKStL16nEmyXLs85F59kA_8_3">131,699</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain" scale="3" id="Tc_ZNDIppRZFECx-snRjuYVXQ_8_6">27</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss" scale="3" id="Tc_OV4g9lN010mxXSP1Pxum2Q_8_9">8</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesFairValue" scale="3" id="Tc_nCGl05Q4NUW_pRJMQEgN2Q_8_12">131,718</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Classified as:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="Tc_R5mRuNCBcUyFr3epIf9mPA_10_12">31,707</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Marketable securities - current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" id="Tc_VG0Sr1OuvEqIlv419bbXgQ_11_12">100,011</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total cash equivalents and marketable securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="ptgx:CashEquivalentsAndMarketableSecuritiesFairValue" scale="3" id="Tc_wi8CxeZec0myVrqLBr_mCA_12_12">131,718</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:12pt 0pt 12pt 0pt;">Marketable securities &#8211; current of $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="Narr_NBqWa-Hmd0y8xQ88ZR3rCQ">188.5</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="Narr_t8RJMrlok0OhPCQjVI3y5w">100.0</ix:nonFraction> million held at December 31, 2020 and December&#160;31, 2019, respectively, had contractual maturities of less than <ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" format="ixt-sec:durwordsen" name="ptgx:CurrentContractualMaturitiesMaximumPeriod" id="Narr_zLajmSovUEGERmKClx5tvA">one&#160;year</ix:nonNumeric>. Marketable securities &#8211; noncurrent of $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="Narr_hvuMRk6R2k-0FEG_KubamQ">2.0</ix:nonFraction> million held at December 31, 2020 had contractual maturities of at least <ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" format="ixt-sec:durwordsen" name="ptgx:NoncurrentContractualMaturitiesMinimumPeriod" id="Narr_WqS6iGBGpEy_BumbZ8MKDQ">one year</ix:nonNumeric> but less than <ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" format="ixt-sec:durwordsen" name="ptgx:NoncurrentContractualMaturitiesMaximumPeriod" id="Narr_dp1LHkSxy0OwhsV_sFwasg">two years</ix:nonNumeric>. The Company did not hold any marketable securities &#8211; noncurrent at December 31, 2019. The Company has not experienced any material credit losses on its investments. The Company does not intend to sell its securities that are in an unrealized loss position, and it is unlikely that the Company will be required to sell its securities before recovery of their amortized cost basis at maturity. There were <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" scale="3" id="Narr_9x5fRDfPekioiU3e6UJ0jg"><ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" scale="3" id="Narr_QWqEzOMW_0iefWuEvgW8Fg">no</ix:nonFraction></ix:nonFraction> realized gains or realized losses on marketable securities for the periods presented. Factors considered in determining whether a loss is temporary include the length of time and extent to which the fair value has been less than the amortized cost basis and whether the Company intends to sell the security or whether it is more likely than not that the Company would be required to sell the security before recovery of the amortized cost basis. </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">95</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:80.09%;border:0;margin:30pt 9.56% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:9.56%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_378d620e_f0a2_4594_af0e_7e9223c526f2"></a><a id="Tc_Y8awPr45tEG1XzANY33cgw_1_2"></a><a id="Tc_xvrLwJH0K0a65bAKndOy_g_2_2"></a><a id="Tc_V02leGf6YUexOrF9AssPMw_2_5"></a><a id="Tc_noiSzNjfWUOZzkVt1M43ww_3_0"></a><a id="Tc_5KbVqZ9aWEKbJ2RpZTtK6g_3_2"></a><a id="Tc_NZWzWkJh3ESY4PYfDgxieQ_3_5"></a><a id="Tc_YUFW_eZV0EqmVWl8H-sssA_4_0"></a><a id="Tc_Zjx0mILvaEuOA-tnNEA6Hw_5_0"></a><a id="Tc_aFsdGBbhN0aW2kbxzz7ULA_6_0"></a><a id="Tc_sufrkz5i20KioKPZiMJKsQ_7_0"></a><a id="Tc_8TmLzk3pSEeu_NuHoxidtA_7_2"></a><a id="Tc_sGmWsy5B3UyTPJxBVu6IGA_7_5"></a><a id="_75c0750c_f95c_4086_8150_610b711ec3f9"></a><a id="Tc__Y_jpFEsd0eZJToTmzw6Yg_1_2"></a><a id="Tc_BfxUFfbw8kaex-hX2-537g_2_2"></a><a id="Tc_FcbbLby1wkW6NF-cSnP8Zw_2_5"></a><a id="Tc_JjhMLnJy70upucH6zYMluA_3_0"></a><a id="Tc_o5wsGE0UHEu5frApbFIQRw_3_2"></a><a id="Tc_szvbcFEQqE6MTAGW1KHXMQ_3_5"></a><a id="Tc_umu6ZpEwPkKnrR34PqAbpw_4_0"></a><a id="Tc_SyaCqh7AnU2C3wSyCowjQg_5_0"></a><a id="Tc_hNgFrdNlF0yXyZ2mhKChvw_6_0"></a><a id="Tc_GU0hq4R-YUeG2vP4IJBr7w_7_0"></a><a id="Tc_21VF7ruj_Uem1655htwcTA_8_0"></a><a id="Tc_GhB64kk7-U-J6qyYvpPXgA_8_2"></a><a id="Tc_k2Izvr0_QEOAxxge9FlXdw_8_5"></a><a id="_0999980c_894f_4434_bb4e_91d184a93e15"></a><a id="Tc_Bv1ZaH9sOkuApOPwFdF-ig_1_2"></a><a id="Tc_ii8GS1WQcU6f1HcnTrohEg_2_2"></a><a id="Tc_09z6ec2svEOsOHX2xV_P1w_2_5"></a><a id="Tc_VCajKeOdlEKoYLkwgLi4Gg_3_0"></a><a id="Tc_YmN9YTRfqku0igFlz-QMKQ_3_2"></a><a id="Tc_iBi3EChmzUqbKZMbaToK1w_3_5"></a><a id="Tc_7h9vwzAj9kylbGcQ075lmw_4_0"></a><a id="Tc_I4tVmBJTtkm5lQOrSl-RmA_5_0"></a><a id="Tc_JTfkmZMTBE-nr6mmS5X5Gg_6_0"></a><a id="Tc_5x6OOxO3iU6ruRoCiDM0fA_6_3"></a><a id="Tc_jQQlztI6L0ieKjsgky2nAQ_7_0"></a><a id="Tc_OE5unKAMc0-y-yfeGlgRoA_8_0"></a><a id="Tc_kloMufA1i0yiJOx3hlekEQ_8_2"></a><a id="Tc_UJDfd3Osc0yaW5lL05RYxg_8_5"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="Tb_6wTbVUGP20a7ZZ405TIzww" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 6.&#160;&#160;&#160;&#160;Balance Sheet Components </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Prepaid Expenses and Other Current Assets</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" id="Tb_h_vFDP0r1ki9zMkwgfB-QA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Prepaid expenses and other current assets consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid clinical and research related expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="ptgx:PrepaidManufacturingOfClinicalMaterials" scale="3" id="Tc_YxGEuw0SXUaBpALuOGCdDQ_3_3">3,517</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="ptgx:PrepaidManufacturingOfClinicalMaterials" scale="3" id="Tc_JuAZTxbll0K_oWxuU0GW2Q_3_6">2,567</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidInsurance" scale="3" id="Tc_-3n2yVCD2EmTl0aNr2WDNA_4_3">1,440</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidInsurance" scale="3" id="Tc_mpD39iDbF0m7ZLMuRxoLQQ_4_6">1,161</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other prepaid expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="Tc_HwtFkaceqU-gKzsSDbdAMw_5_3">1,009</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="Tc_uMnbp-xJxU6aI39wXz7Tyg_5_6">1,057</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="Tc_PcrHwWc7502JdutLuVDH6w_6_3">311</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="Tc_oRW1KbTnN0aLuRNxKetAvw_6_6">744</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Prepaid expenses and other current assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_PJD0SGbMEkqtOEqQIn9Cuw_7_3">6,277</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_hq_RkemUQUS8EH37eJqi3Q_7_6">5,529</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and Equipment, Net</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb_7lOHUB5gFkuyXXtDpy7K0Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Property and equipment, net consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Laboratory equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ptgx_LaboratoryEquipmentMember_mEJwmnq980i_X0P_Pcmk2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_yzkKZR9FW0qwCsKTFIgKnQ_3_3">3,539</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ptgx_LaboratoryEquipmentMember_nelsuh6t-0G0_6xLI9TWow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_UDkHUeDUokGoy41UnXdZhQ_3_6">2,947</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Furniture and computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ptgx_FurnitureAndComputerEquipmentMember_exDGgu7H0EeD4_dWpv6kGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_DiTpPxSaiE2iAf3v0bxA-w_4_3">648</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ptgx_FurnitureAndComputerEquipmentMember_NDe2QtR56ES1v6jXmD0-nw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_O4IESfSfuEa9rtvI1BLH5w_4_6">512</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Leasehold improvements</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_th9MyYrG-kOe4hdG7OWBYQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc__iWl9g1_1U6NAJtIrMe62A_5_3">748</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_XC_R2C90rU2vG1oQ__VR5Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_X5ysFxhPlkqKPQnND1f5aQ_5_6">863</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Total property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_sVU8rBK0Gk268OvnVBMGsg_6_3">4,935</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_JFqwobCK0keszBMR116V5Q_6_6">4,322</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Less: accumulated depreciation and amortization</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_MHiDmakksEWEV8wJ9LXJKw_7_3">3,473</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_-4WmeJGC8k6UT9nAQgm3ow_7_6">2,641</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_su8MW10v50Ke70KHHQ7wbw_8_3">1,462</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_Nhj1vUD_QUyg05a2dCHSPg_8_6">1,681</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background-color:#ffff00;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Depreciation expense for the&#160;years ended December&#160;31, 2020, 2019, and 2018 was $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="0" id="Narr_KY_AAlofT0GXBndGCl6weA">789,000</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="0" id="Narr_CVizsxQO8kyWo7DrPuk44g">703,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="0" id="Narr_B2BY6OWQekSXQ7f5n4VvRA">527,000</ix:nonFraction>, respectively. As of December&#160;31, 2020, 2019 and 2018, $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_srt_StatementGeographicalAxis_country_AU_xtyNGWRadEizaBfhvBzeOA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="Narr_HvGpktliA06Q7cuPtZoIog">46,000</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_srt_StatementGeographicalAxis_country_AU_NLZm2dhYp0akSbHnuso5uQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="Narr_QFxC-l9GVEquh3-RgFFz7g">37,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2018_srt_StatementGeographicalAxis_country_AU_J8ZYPbFagkiWnbQOuxYMlQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="Narr_epeeJl6ZvkWZ2bzW2m4afQ">200</ix:nonFraction>, respectively, of property and equipment, net, was located in Australia. The remainder of the Company&#8217;s property and equipment is located in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Accrued Expenses and Other Payables</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="Tb_fwBrPJfy3UGQyEX93Aj3eg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Accrued expenses and other payables consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:28.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:12.88%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:12.86%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued clinical and research related expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="ptgx:AccruedClinicalAndResearchRelatedExpensesCurrent" scale="3" id="Tc_nDUY4jpEME-HLQ4Kj2Vftg_3_3">11,335</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="ptgx:AccruedClinicalAndResearchRelatedExpensesCurrent" scale="3" id="Tc_YnN_tpVhEUKqStwxVAdBrg_3_6">7,232</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued employee related expenses</p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="3" id="Tc_g_FU7EtAlES3LAAo4-Ac7w_4_3">6,413</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="3" id="Tc_NUVWAfwwLkKZHBsJeoXdQw_4_6">4,637</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued professional service fees</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_-4rfKlFy1kKda2Zcu4M4KQ_5_3">668</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_b2OTqg1f20KiV-f8yDQ2mA_5_6">301</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued interest payable</p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPayableCurrent" scale="3" id="Tc_u1hQEkxC5U--lk-cBZBSRQ_6_6">68</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_61dbSnn9VUWkpEncjPQ4mg_7_3">82</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_eC70AbfNwkuQnhmXMEOlXA_7_6">122</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total accrued expenses and other payables</p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:11.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_J9egrOsSPEGJapPfRLFffQ_8_3">18,498</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:11.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_jb5PxQ50_UeVPRUP1s97Yg_8_6">12,360</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member_ui-WhgpxI0OwEii6l0-3yQ" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="Tb_6PesyRKXGke1BDnJKCX4Zw" continuedAt="Tb_6PesyRKXGke1BDnJKCX4Zw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 7.&#160;&#160;&#160;&#160;Research Collaboration and License Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">The Company and Zealand Pharma A/S entered into a collaboration agreement in June 2012. In October 2013, Zealand Pharma abandoned the collaboration and the collaboration agreement was terminated in 2014. The agreement provides for certain post-termination payment obligations to Zealand with respect to compounds related to the collaboration that meet specified conditions set forth in the collaboration agreement and which the Company elects to further develop following Zealand&#8217;s abandonment of the collaboration. The Company has the right, but not the obligation, to further develop and commercialize such compounds. The agreement provides for payments to Zealand for the </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">96</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:80.09%;border:0;margin:30pt 9.56% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:9.56%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_6PesyRKXGke1BDnJKCX4Zw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">achievement of certain development, regulatory and sales milestone events that occur prior to a partnering arrangement related to such compounds between the Company and a third party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Company initially determined that rusfertide is a compound for which the post-termination payments described above are required under the collaboration agreement and has made <ix:nonFraction unitRef="Unit_Standard_item_hG9CfJX4lUefEcY3aN9DsQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member_ui-WhgpxI0OwEii6l0-3yQ" decimals="INF" format="ixt-sec:numwordsen" name="ptgx:NumberOfDevelopmentMilestonePayments" scale="0" id="Narr_k7zRe2vwr0yyzlz-49AJBA">three</ix:nonFraction> development milestone payments for an aggregate amount of $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member_ui-WhgpxI0OwEii6l0-3yQ" decimals="-5" format="ixt:numdotdecimal" name="ptgx:AggregateAmountOfDevelopmentMilestonePayment" scale="6" id="Narr_6s3e-15Ny0iETQa5L-bmiQ">1.0</ix:nonFraction> million under the agreement. However, the Company concluded in 2019 that rusfertide is not a compound with respect to which post-termination payments are required under the agreement, and initiated the arbitration proceeding described in Note 11 below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Milestone payments to collaboration partners are recorded as research and development expenses in the period that the expense is incurred. <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_TypeOfArrangementAxis_ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member_D025L8JB50ySUyUf-9SxEg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Narr_in79lzZ-aUuOLSJD_aAa7Q"><ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member_ui-WhgpxI0OwEii6l0-3yQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Narr_ULY_Hn3UEkyrqXOmlk1oTA">No</ix:nonFraction></ix:nonFraction> research and development expense was recorded under this agreement for the years ended December 31, 2020 or 2019. For the&#160;year ended December 31, 2018, the Company recorded research and development expense of $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_TypeOfArrangementAxis_ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member__cZnEeVU-k2FtUN8yE2uXw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Narr_QOQTpRNQ5UCq1hyITQSMbA">500,000</ix:nonFraction> under this agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;"> If the Company is required to continue to make payments with respect to rusfertide under the collaboration agreement, the next two milestones that would be due under the agreement include:  $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_srt_ProductOrServiceAxis_ptgx_PhaseTwoBClinicalTrailOfPtg300Member_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_ptgx_EntityRequiredToContinueToMakePaymentsMember_us-gaap_TypeOfArrangementAxis_ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member_lKJ-7ATDp0CLQ8bWUlojWQ" decimals="-5" format="ixt:numdotdecimal" name="ptgx:AdditionalPaymentObligationToFormerCollaborationPartner" scale="6" id="Narr_qqzCROSgZk2xsQsJx4PjFQ">1.0</ix:nonFraction> million to $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_srt_ProductOrServiceAxis_ptgx_PhaseTwoBClinicalTrailOfPtg300Member_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_ptgx_EntityRequiredToContinueToMakePaymentsMember_us-gaap_TypeOfArrangementAxis_ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member_GeOAJmLB2U-rVK1O1SLjzw" decimals="-5" format="ixt:numdotdecimal" name="ptgx:AdditionalPaymentObligationToFormerCollaborationPartner" scale="6" id="Narr_L4Or_AtXD0m0qDE-nx15RQ">3.0</ix:nonFraction> million for initiation of placebo-controlled Phase 2b clinical trial; and $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_srt_ProductOrServiceAxis_ptgx_PhaseThreeClinicalTrailOfPtg300Member_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_ptgx_EntityRequiredToContinueToMakePaymentsMember_us-gaap_TypeOfArrangementAxis_ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member_Mg3iwj6jfU-W-XYzhf-LYg" decimals="-5" format="ixt:numdotdecimal" name="ptgx:AdditionalPaymentObligationToFormerCollaborationPartner" scale="6" id="Narr_d-21cCsy1Em3NqY_5P7WSg">1.5</ix:nonFraction> million to $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_srt_ProductOrServiceAxis_ptgx_PhaseThreeClinicalTrailOfPtg300Member_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_ptgx_EntityRequiredToContinueToMakePaymentsMember_us-gaap_TypeOfArrangementAxis_ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member_NW5Hup9pVUGA-2WwTWjPHw" decimals="-5" format="ixt:numdotdecimal" name="ptgx:AdditionalPaymentObligationToFormerCollaborationPartner" scale="6" id="Narr_uQ2_V81iA02LOwpwcMYVeg">4.5</ix:nonFraction> million for initiation of a Phase 3 clinical trial. The milestone amounts vary depending on the number of patients in the applicable clinical trial, and the Company expects the milestones would be the lowest amount within the specified range. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">See Note 11. Commitments and Contingencies &#8211; Legal Proceedings for additional information on arbitration proceedings related to this research and collaboration agreement.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="ptgx:GovernmentProgramsDisclosureTextBlock" id="Tb_Q4MzuLkCMEmv5TLVw0Mnvg" continuedAt="Tb_Q4MzuLkCMEmv5TLVw0Mnvg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 8.&#160;&#160;&#160;&#160;Government Programs </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Tax Incentive</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">During the years ended December 31, 2020 and 2018, the Company recognized AUD <ix:nonFraction unitRef="Unit_Standard_AUD_SNsUSUMs1k6MNx0ouGjszw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_g6Lfapz3kUapxhOM2FxjaQ" decimals="-5" format="ixt:numdotdecimal" name="ptgx:ResearchAndDevelopmentExpensesReduction" scale="6" id="Narr_D4kxhorIrEqqW952WdWckA">1.4</ix:nonFraction> million ($<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_g6Lfapz3kUapxhOM2FxjaQ" decimals="-5" format="ixt:numdotdecimal" name="ptgx:ResearchAndDevelopmentExpensesReduction" scale="6" id="Narr_8XL0bKadkEm3i4KEEnJ8YA">1.0</ix:nonFraction> million) and AUD <ix:nonFraction unitRef="Unit_Standard_AUD_SNsUSUMs1k6MNx0ouGjszw" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember__jiivLyteUW8NPb8U-43uw" decimals="-5" format="ixt:numdotdecimal" name="ptgx:ResearchAndDevelopmentExpensesReduction" scale="6" id="Narr_Lyy9h-UU6USjFv1ePRlKsg">2.1</ix:nonFraction> million ($<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember__jiivLyteUW8NPb8U-43uw" decimals="-5" format="ixt:numdotdecimal" name="ptgx:ResearchAndDevelopmentExpensesReduction" scale="6" id="Narr_Eag_juuPQ06ErW4P55PTpw">1.6</ix:nonFraction> million), respectively, as a reduction of research and development expenses in connection with the research and development cash tax incentive from the ATO. During the year ended December 31, 2019, the Company recognized AUD <ix:nonFraction unitRef="Unit_Standard_AUD_SNsUSUMs1k6MNx0ouGjszw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_3n6ishFs0EuWYpP4sr_RiA" decimals="-5" format="ixt:numdotdecimal" name="ptgx:ResearchAndDevelopmentExpensesReduction" scale="6" id="Narr_qyvV-WazvE66vSel_zRUsw">1.9</ix:nonFraction> million ($<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_3n6ishFs0EuWYpP4sr_RiA" decimals="-5" format="ixt:numdotdecimal" name="ptgx:ResearchAndDevelopmentExpensesReduction" scale="6" id="Narr_6DraHostfkq5BT1K3e2nBA">1.3</ix:nonFraction> million) of research and development expenses in connection with the research and development tax incentive from the ATO because the Company determined that it had exceeded the annual turnover limit to claim such amounts following the receipt of certain payments under the Janssen License and Collaboration Agreement. As of December&#160;31, 2020, the research and development tax incentive receivable was AUD <ix:nonFraction unitRef="Unit_Standard_AUD_SNsUSUMs1k6MNx0ouGjszw" contextRef="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_ptgx_OverseasFindingsMember_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_Ni5ZAEOX-UqebOcqRpBGAA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesReceivable" scale="6" id="Narr_caqrQXKri025WU83ixtUQg">1.4</ix:nonFraction> million ($<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_ptgx_OverseasFindingsMember_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_Ni5ZAEOX-UqebOcqRpBGAA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesReceivable" scale="6" id="Narr_LyoAz_sb2k-l7BF133rmyA">1.1</ix:nonFraction> million). There was <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_us-gaap_IncomeTaxAuthorityAxis_ptgx_OverseasFindingsMember_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_-NKTzbOHOE-9ja3vgdH8Wg" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxesReceivable" scale="6" id="Narr_5JlCVNaYbUiNbdzuSiKcrg">no</ix:nonFraction> research and development tax incentive receivable as of December 31, 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Small Business Innovation Research (&#8220;SBIR&#8221;) Grants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">In May 2017, the Company was awarded a Phase 2 SBIR grant from the National Institute of Diabetes and Digestive and Kidney Diseases of the NIH in support of research aimed at developing biomarkers that define IL-23R target engagement by orally delivered peptide antagonists and the effects of that engagement of downstream signaling. The total grant award was $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_5_1_2017_To_5_31_2017_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_yYD_ZbiKRkiaHuGwQjinPA" decimals="-5" format="ixt:numdotdecimal" name="ptgx:ResearchAndDevelopmentGrants" scale="6" id="Narr_Hg_prqMGOku0awirNyY7kw">1.3</ix:nonFraction> million and was originally for the period from May 2017 to April 2019. During the year ended December 31, 2019, the Company requested and received an extension of this grant through April 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">In September 2018, the Company was awarded a Phase 2 SBIR Grant from the National Heart, Lungs and blood Institute of the NIH in support of research aimed at developing the Company&#8217;s novel hepcidin mimetic rusfertide for the potential treatment of chronic anemia and iron overload in rare blood disorders, including beta-thalassemia. The total grant award was $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_9_1_2018_To_9_30_2018_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_uaChjCsyD0SFXSDtolYQ1A" decimals="-5" format="ixt:numdotdecimal" name="ptgx:ResearchAndDevelopmentGrants" scale="6" id="Narr_CkKQYnffV0yovhUvV3uLUg">1.5</ix:nonFraction> million and was originally for the period from September 2018 to August 2020. During the year ended December 31, 2020, the Company requested an extension of this grant through July 2021, which was received in February 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">The Company recognizes a reduction to research and development expenses when expenses related to the grants have been incurred and the grant funds become contractually due from NIH. The Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_qd1j0yCx90GcZk8LgZ8W2g" decimals="-5" format="ixt:numdotdecimal" name="ptgx:ResearchAndDevelopmentExpensesReduction" scale="6" id="Narr_R4RdqM6sBEWoYgVznSB7gQ">0.5</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_tYZjiAg9zECpkNJndjRsBA" decimals="-5" format="ixt:numdotdecimal" name="ptgx:ResearchAndDevelopmentExpensesReduction" scale="6" id="Narr_rQMI0mcDeU26eMmuN6af1Q">1.4</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_IH_M_FrIX0SJO0xc0LNU4A" decimals="-5" format="ixt:numdotdecimal" name="ptgx:ResearchAndDevelopmentExpensesReduction" scale="6" id="Narr_ZUoCfOqPvkSx0CiHW8ojlg">0.7</ix:nonFraction> million, as a reduction of research and development expenses for the&#160;years ended December&#160;31, 2020, </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">97</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:80.09%;border:0;margin:30pt 9.56% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:9.56%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Q4MzuLkCMEmv5TLVw0Mnvg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">2019 and 2018, respectively. The Company recorded a receivable for $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_Ug74VWMPT0WLeBk_hPZxCg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GrantsReceivable" scale="6" id="Narr_9zNQQvHflUSJ4bMHYicNSw">0.3</ix:nonFraction> million as of December&#160;31, 2019 to reflect the eligible costs incurred under the grants that were contractually due to the Company. This receivable is included in prepaid expenses and other current assets on the consolidated balance sheets. There was <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_GicVha9PoUm3BEgizkKmRQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:GrantsReceivable" scale="6" id="Narr_yzlm9ow9NEuIqlsL90Hgzg">no</ix:nonFraction> such receivable as of December 31, 2020.</span></p></ix:continuation><a id="_38faf7c3_7d3a_480b_a8d8_ac5522746666"></a><a id="Tc_RQUlN6MtcE-X2rKqcGJ7zA_1_2"></a><a id="Tc_eOdaxW-qoUa6x1v1JwBQjg_1_4"></a><a id="Tc_76GSCi-geE6Hubk1O4o-7w_1_7"></a><a id="Tc_P5XyR5P3xkifSS2Eahj4Kg_2_2"></a><a id="Tc_4zHPqFPaDEy9-dWG4Lu54w_2_4"></a><a id="Tc_D2ZNzXRFdEWFY4e916Usew_2_7"></a><a id="Tc_yVEMrI4GSUOCyfr1DCHdrw_3_0"></a><a id="Tc_Cd3PqyBeO0yPxI01yCQQ6A_3_4"></a><a id="Tc_bp5H2kztQEuVD0cjiujeIw_3_5"></a><a id="Tc_U7YMrH1lYEmz45Laf-mQOw_3_7"></a><a id="Tc_QL6Cx4ihW0yPjVF-0i25Xw_4_0"></a><a id="Tc_SfrxIOKFPUq2a6Z2i4RFYg_4_5"></a><a id="Tc_MDsIHXNpz0ytUA8x6eYBqQ_5_0"></a><a id="Tc_tu7a0JslN0-foT2uBLGYng_5_5"></a><a id="Tc_YYDm1Irr3UaD3BWWibkbig_6_0"></a><a id="Tc_AsimXGS0g027QQuytcBihg_6_4"></a><a id="Tc_-EckBLLQvkSzNs2bPBffgA_6_5"></a><a id="Tc_XcSMxpT8BkChzq_yGujUjQ_6_7"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="us-gaap:DebtDisclosureTextBlock" id="Tb_QRf7SU7qiEyFHlVd2w-CsA" continuedAt="Tb_QRf7SU7qiEyFHlVd2w-CsA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Note 9.    Debt</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">On October 30, 2019, the Company entered into a Credit and Security Agreement, dated as of October 30, 2019 (the &#8220;Closing Date&#8221;) by and among the Company, MidCap Financial Trust, as a lender, Silicon Valley Bank, as a lender, the other lenders party thereto from time to time and MidCap Financial Trust, as administrative agent and collateral agent (&#8220;Agent&#8221;), (the &#8220;Term Loan Credit Agreement&#8221;), which provides for a $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_29P04bh0akmybtKqt9iLyg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="Narr_u1ZbRCSqhEWFOJK4RQumnA">50.0</ix:nonFraction> million term loan facility. The Term Loan Credit Agreement provides for (i) on the Closing Date, $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_29P04bh0akmybtKqt9iLyg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="Narr_EAEAbMURPESkOOq_Im9fJQ">10.0</ix:nonFraction> million aggregate principal amount of term loans, (ii) at the Company&#8217;s option, until December 31, 2020, an additional $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_29P04bh0akmybtKqt9iLyg" decimals="-5" format="ixt:numdotdecimal" name="ptgx:DebtInstrumentTrancheInstallmentAmount" scale="6" id="Narr_tbyTcC0AQU27jGMAwnQuPQ">20.0</ix:nonFraction> million term loan facility subject to the satisfaction of certain conditions, including clinical milestone achievement, and (iii) at the Company&#8217;s option, until September 30, 2021, an additional $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_29P04bh0akmybtKqt9iLyg" decimals="-5" format="ixt:numdotdecimal" name="ptgx:DebtInstrumentTrancheInstallmentAmount" scale="6" id="Narr_Zz-oELs6HkO8CZqo2D-9-A">20.0</ix:nonFraction> million term loan facility subject to the satisfaction of certain conditions, including clinical milestone achievement, (collectively, the &#8220;Term Loans&#8221;). The Company intends to use any proceeds of the Term Loans for general corporate purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Term Loans are subject to an origination fee of <ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_10_1_2019_To_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember__7GvdZr7Sk-sWaDylYb_nQ" decimals="4" format="ixt:numdotdecimal" name="ptgx:DebtInstrumentLoanOriginationFeePercentage" scale="-2" id="Narr_UI6Nx5yyFU6sWOEQa08T1Q">0.25</ix:nonFraction>% for each funded tranche under the Term Loan Credit Agreement and bear interest at an annual rate based on prime rate plus <ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_10_1_2019_To_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember_irqRQWto80mZoPOcLzfEEw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="Narr_P9n-jPbsiEaURvwoUDrSUA">2.91</ix:nonFraction>%, subject to a prime rate floor of <ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_10_1_2019_To_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember_irqRQWto80mZoPOcLzfEEw" decimals="4" format="ixt:numdotdecimal" name="ptgx:DebtInstrumentFloorRate" scale="-2" id="Narr_qqTXAixnq0qIOrgl087hJg">4.94</ix:nonFraction>%. The Company will make interest-only payments on the Term Loans for <ix:nonNumeric contextRef="Duration_10_31_2019_To_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_AItPGKFJaUGXTtctj0S3sw" format="ixt-sec:durwordsen" name="ptgx:DebtInstrumentPeriodOfInterestOnlyPayments" id="Narr_RGlJn7wJaEu2a3Nr5nufSw">24 months</ix:nonNumeric>, followed by <ix:nonNumeric contextRef="Duration_10_31_2019_To_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_AItPGKFJaUGXTtctj0S3sw" format="ixt-sec:durwordsen" name="ptgx:DebtInstrumentPeriodOfPrincipalAndInterestPayments" id="Narr_2EvA6P1De0aM6LwoIQRIzg">24 months</ix:nonNumeric> of principal and interest payments. At the Company&#8217;s option, the Company may prepay the outstanding principal balance of the Term Loans in whole or in part, subject to a prepayment premium of <ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_10_1_2019_To_10_31_2019_srt_StatementScenarioAxis_ptgx_DebtInstrumentRepaymentOnOrBeforeFirstAnniversaryMember_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_-UR7DvCLZkiYmYD5NsiohA" decimals="3" format="ixt:numdotdecimal" name="ptgx:DebtInstrumentPrepaymentPremiumPercentage" scale="-2" id="Narr_cDW5puxiYEKaJ_D7BomQ5g">3.0</ix:nonFraction>% of any amount prepaid if the prepayment occurs through and including the first anniversary of the closing date, <ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_10_1_2019_To_10_31_2019_srt_StatementScenarioAxis_ptgx_DebtInstrumentRepaymentBetweenFirstAndSecondAnniversaryMember_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_0-kZriq9PE--kjrBZbtCWQ" decimals="3" format="ixt:numdotdecimal" name="ptgx:DebtInstrumentPrepaymentPremiumPercentage" scale="-2" id="Narr_Ncir25NIuEaZbSHkj0fn8g">2.0</ix:nonFraction>% of the amount prepaid if the prepayment occurs after the first anniversary of the closing date through and including the second anniversary of the closing date, and <ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_10_1_2019_To_10_31_2019_srt_StatementScenarioAxis_ptgx_DebtInstrumentRepaymentAfterSecondAnniversaryMember_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_yTz9fr8XpUmkKw5s-q0s6g" decimals="3" format="ixt:numdotdecimal" name="ptgx:DebtInstrumentPrepaymentPremiumPercentage" scale="-2" id="Narr_Gdkfd4ysfkytNLsjT_i1aQ">1.0</ix:nonFraction>% of any amount prepaid after the second anniversary of the closing date and prior to October 1, 2023. An additional fee of <ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_10_1_2019_To_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember__7GvdZr7Sk-sWaDylYb_nQ" decimals="4" format="ixt:numdotdecimal" name="ptgx:DebtInstrumentAdditionalPrepaymentOrRepaymentPremiumPercentage" scale="-2" id="Narr_LhEfLUExtEihEON9mcjQGw">2.85</ix:nonFraction>% of the amount of Term Loans advanced by the Lenders will be due upon prepayment or repayment of the Term Loans. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Term Loan Credit Agreement requires the Company to maintain cash and cash equivalents of at least <ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_10_1_2019_To_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember__7GvdZr7Sk-sWaDylYb_nQ" decimals="2" format="ixt:numdotdecimal" name="ptgx:DebtInstrumentThresholdPercentageOnOutstandingDebtToBeMaintainedAsCashAndCashEquivalentsBalance" scale="-2" id="Narr_7yq3mBxM3kmbVsBfJvZ_nw">35</ix:nonFraction>% of the outstanding Term Loans at all times and is secured by a perfected security interest in all of the Company&#39;s assets except for intellectual property and certain other customary excluded property pursuant to the terms of the Term Loan Credit Agreement. The Term Loan Credit Agreement contains other covenants that limit the Company&#8217;s ability and the ability of its subsidiaries to perform certain actions, including obligations to not pay dividends and to maintain unrestricted cash balances above certain threshold, non-occurrence of material adverse change, non-occurrence of change of control and other customary affirmative and negative covenants. The violation of any provision of covenants will result in default for the Company. The Term Loan Credit Agreement includes a clause which allows lenders to accelerate repayment upon the occurrence of certain events of default. In June 2020, the Company prepaid its outstanding $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_6_1_2020_To_6_30_2020_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_jtE4FD5lLEuVCNA6A73V0A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="6" id="Narr_9pGp9t_puUmVvpnvIDq50Q">10.0</ix:nonFraction> million balance on the term loan as well as $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_6_30_2020_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_cqtN9FUFIUSxqCPfOydBcA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFeeAmount" scale="6" id="Narr_LOp2dtWnpkOKd4rvVVTRbA">0.6</ix:nonFraction> million for related prepayment and exit fees. Accordingly, the company accelerated amortization of $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_6_30_2020_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_cqtN9FUFIUSxqCPfOydBcA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet" scale="6" id="Narr_8Cr8aL3-VU6hSRLYRNK6fA">0.1</ix:nonFraction> million related to capitalized and unamortized debt issuance costs, which is included as part of the $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_6_1_2020_To_6_30_2020_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_jtE4FD5lLEuVCNA6A73V0A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="Narr_xJzAQl_pWkWA98oiDYIu5w">0.6</ix:nonFraction> million loss on early repayment of debt. The Company did not exercise its option to borrow the $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_cKfYUU8Sf0-u1ytV-rCvdg" decimals="-5" format="ixt:numdotdecimal" name="ptgx:DebtInstrumentTrancheInstallmentAmount" scale="6" id="Narr_v0V44sTTTkiVujarEyq5Uw">20.0</ix:nonFraction> million second tranche of Term Loans, which expired on December 31, 2020, and therefore has <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_cKfYUU8Sf0-u1ytV-rCvdg" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:LongTermDebt" scale="6" id="Narr_zzDaVywlHUurO8wFk7SYCA">no</ix:nonFraction> outstanding balance as of December 31, 2020 related to the Term Loan Credit Agreement. As of December 31, 2020, the Company was in compliance with the debt covenants, no event of default occurred and the probability of occurrence of event of default was considered remote.</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="Tb_NFM8oo39akaTOLIaqY1n3w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt 0pt 6pt 0pt;">The Company&#8217;s long-term debt balance was as follows for the periods presented (dollars in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Annual </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance at</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Interest Rate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Term loan (maturity date October 1, 2023) </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Tc_cMTOdoLnREaAMzUImHvxTg_3_2">7.85</ix:nonFraction>%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$<span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$<span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="Tc_ZFQQq2bHj0m4OQLDxn6YNA_3_8">10,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Debt issuance costs, net of amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="3" id="Tc_UpdnYtGYwUK689z-5ZoPaQ_4_8">222</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued final payment fees</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="ptgx:DebtInstrumentAccruedFinalPaymentFee" scale="3" id="Tc_PROUBe-5F0uOp9Mt3AEjyQ_5_8">16</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:55.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Long-term debt, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$<span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$<span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="Tc_0s4dsh_m5EO9oT7LiQzE4g_6_8">9,794</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">98</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:80.09%;border:0;margin:30pt 9.56% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:9.56%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_QRf7SU7qiEyFHlVd2w-CsA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The effective interest rate on long-term debt was <ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="Narr_XS9c_dXk2UqEqZa9xfHBgw">9.85</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="Narr_WvzSdY5t30m9q-zInXbYEw">9.81</ix:nonFraction>% for the years ended December 31, 2020 and 2019, respectively.</p></ix:continuation><a id="Tc_a2FiymXku0GwMRUmuxPLAA_1_2"></a><a id="Tc_F1y3I0yCD0WV5PjcvStk-g_2_2"></a><a id="Tc_bShuEebW80yaQRDXCBJVXg_2_5"></a><a id="Tc_eroPErs7y0aNSin9HOWyZg_3_0"></a><a id="Tc_KBnhIn-A40qg5vCXxU1OzA_4_0"></a><a id="Tc_TLaIEn_1_0ev2H7CgUdgRg_4_3"></a><a id="Tc_XAyuD9ruhkqiiQkJjBK43g_4_6"></a><a id="Tc_DYBwa3azBE6guJyjwR-GIQ_5_0"></a><a id="_bf24fde2_327b_49fa_a7f7_a71eb31aaecd"></a><a id="Tc_RiCvPDusMEOmhMAu-GOfSQ_1_0"></a><a id="Tc_Ooqlj8ewN0yr7uf6bqsesA_1_2"></a><a id="Tc_D3UlZM7-lE--LWkVE-qIcw_2_0"></a><a id="Tc_DTUFvSEu5ki_RjJin5kXQw_2_2"></a><a id="Tc_pogKS90470SGTMCd2jHYHw_3_0"></a><a id="Tc_cwvYhb7bkUWL5i7b0__mDw_4_0"></a><a id="Tc_g92KsnWiGUSEzUD4MtHWOg_5_0"></a><a id="Tc_8eXEDN2e0EaUQJgonBjVuw_6_0"></a><a id="Tc_PTkEIM3pKka0YiPzrV1ruQ_6_3"></a><a id="Tc_m-JCz6hnG02eTfCVwCGSDA_7_0"></a><a id="Tc_L4KhEO8j3UW56SdkDie1lA_7_3"></a><a id="Tc_iAGaSQ7h0E6KVyxoH7KpwA_8_0"></a><a id="Tc_SMHuXN3oBUCfhN2MEdQDUA_9_0"></a><a id="Tc_K86H-f3PqkWMlqUwhNlqcw_10_0"></a><a id="Tc_jx8dc5J57kmsBwFBubPJPQ_11_0"></a><a id="Tc_GgSxwHZpA0eX1ArvzFk0CQ_12_0"></a><a id="Tc_JuvNrV2tuUGaMus0aHaWCw_12_2"></a><a id="_fccda296_afea_43fc_8afe_15b6574a2042"></a><a id="Tc_G6bdQ-fkO0aMY0a3OCybXw_1_2"></a><a id="Tc_bZVnpYz9w0Ci-JmxOSki4g_2_2"></a><a id="Tc_QOdaniayEEafAvjqj6JbgA_2_5"></a><a id="Tc_qoCnmYkZQECHBaKAdtA_Wg_3_0"></a><a id="Tc_LubxmAwm3Em9k9f5MxAgKg_3_2"></a><a id="Tc_Uzuefb0UPU2X3xDJ6p-ZVA_3_5"></a><a id="_d995b4f1_29d4_4692_bb76_2113f7021cdb"></a><a id="Tc_revkJOaSbUK3TtCwKg1o7A_1_2"></a><a id="Tc_2cXOiwmJzEixeFEBLW-3Iw_2_2"></a><a id="Tc_nd_ewXe8CEiQryeMREpkFw_2_5"></a><a id="Tc_o_haQ7OWq0m9MyoV_Sqtkw_3_0"></a><a id="Tc_Xt8yeg_ZV0qEDTH3YtAU7g_4_2"></a><a id="Tc_NC8wpyBaPEqe1CCfsQGWpw_4_5"></a><a id="Tc_5Qx4moYitEyHetGMsWfd-A_6_2"></a><a id="Tc_jQOVMBuSkEe_HVaqebX_mA_6_5"></a><a id="Tc_2XdLqSeG5kCWT871dK54aA_8_2"></a><a id="Tc_SkEv2erNGkaqZkzEHdOw-A_8_5"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="us-gaap:LesseeOperatingLeasesTextBlock" id="Tb_qgohR3b7eUqHRjXlU0Uznw" continuedAt="Tb_qgohR3b7eUqHRjXlU0Uznw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 10.&#160;&#160;&#160;&#160;Leases </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:31.5pt;margin:0pt;">On January 1, 2019, the Company adopted ASC 842, which requires entities to recognize assets and liabilities for leases with lease terms of more than 12 months on the balance sheet. Leases with terms of 12 months or less are not recorded on the balance sheet, and the related lease expenses are recognized on a straight-line basis over the lease term. The Company has <ix:nonFraction unitRef="Unit_Standard_lease_62oZzE0uRUioB8CqY7th5A" contextRef="Duration_3_1_2017_To_3_31_2017_srt_StatementGeographicalAxis_stpr_CA__NT8mR3K4kK7AM6iJIYK3g" decimals="INF" format="ixt-sec:numwordsen" name="ptgx:NumberOfOperatingLeaseAgreement" scale="0" id="Narr_yBxRXsgYckCBzfVjYpBmlQ">one</ix:nonFraction> operating lease agreement entered into in March 2017 for laboratory and office space located in Newark, California. The Company provided the landlord with a $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_3_31_2017_zWxDm9xYR0y9NPetyRPWMQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SecurityDeposit" scale="0" id="Narr_uVTDVMs9cEaOfaSZJhMlZA">450,000</ix:nonFraction> letter of credit collateralized by restricted cash as security deposit for the lease, which expires in May 2024. During the years ended December 31, 2020 and 2019, the Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SubleaseIncome" scale="0" id="Narr__lU8KTpvkkKmHWMA9fiIOA">89,400</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SubleaseIncome" scale="0" id="Narr_2MoRVA77Hk2KHkOLHBYnVA">64,000</ix:nonFraction> of sublease income, respectively. The Company did <span style="-sec-ix-hidden:Hidden_lqQvOls2gkKPXAv7NbH0Aw;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">not</span></span> recognize any sublease income for the year ended December 31, 2018. Under the terms of the lease, the Company is responsible for certain taxes, insurance and maintenance expenses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:31.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">The weighted average lease term and discount rate are as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="ptgx:LeaseQuantitativeDisclosureTableTextBlock" id="Tb_eF46KSUyjku7Y7vOgkrQFA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Operating Lease Term and Discount Rate:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average remaining lease term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Narr_NbqQtSAf40qwWKp61uWbQw">3.4</ix:nonNumeric> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Narr_u2TyMH7pIU2jcKBatMmhBQ">4.4</ix:nonNumeric> years</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average discount rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_knAbqhWTzEOWhfdsOdBsZw_5_3">11.0</ix:nonFraction>%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_GRWjEc47v0eSzfma4eZNEA_5_6">11.0</ix:nonFraction>%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb_CBoVfluIKkCx0iXXPWxkcQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the Company&#8217;s minimum lease payments and lease liability as of December&#160;31, 2020 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Year Ending December 31:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_Ktx66arbSkuYtGlNFC6oSA_2_3">2,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_n3A733M2zUeB1bGq0tsc2A_3_3">2,059</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_OC0P0ia8C0WOTJozhHw9wA_4_3">2,121</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="Tc_Ga_71EMYdU2qeb6-mDH_pA_5_3">895</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:84.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total future minimum lease payments</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_Cufh9RQRSUOJwDE3bH3Ecw_8_3">7,075</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">    Less: imputed interest</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_Kzh9AGGhokiRLYIJryQ2Bw_9_3">1,116</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:84.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Present value of future minimum lease payments</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_4x2_CQVP-EyE3xwYmFUOWg_10_3">5,959</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">    Less: current portion of operating lease liability</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_m0q62FJ9YE6sE7G-_rJfAA_11_3">1,459</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:84.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease liability - noncurrent</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_-hI-k3ojDk-uzqQXWeME_w_12_3">4,500</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="us-gaap:LeaseCostTableTextBlock" id="Tb_Gkhj2eYpk0Cfq0PQgNdJaQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Supplemental lease cost information is as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease cost</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_fnE11xS3i0CfnZ3q_bBGtw_3_3">1,775</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_pDAiZy-Pd0m_5w-pHbpt4g_3_6">1,792</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="ptgx:LeaseBalanceSheetDisclosureTableTextBlock" id="Tb_o6SXgSeV8USll1qHoW8nHQ" continuedAt="Tb_o6SXgSeV8USll1qHoW8nHQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Supplemental balance sheet information is as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:10pt;"><td style="vertical-align:bottom;width:68.68%;margin:0pt;padding:0pt;"><div style="height:10pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:10pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:10pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"><div style="height:10pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:10pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:10pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><div style="height:10pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Operating Leases:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:68.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_zm9XCbYtdUWCFJoLceZSNQ;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Operating lease right-of-use asset</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_QhjB7AoMf0m2CRaMSdXO0Q_4_3">4,950</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_Wq2xxYcPUU2QJG-Gks5XKA_4_6">6,042</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:68.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_NUnmw_5Jc0GQOhDxxgb5HA;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Operating lease liability - current</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_kjUI_9_VqkmCwssghg0oNw_6_3">1,459</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_-EP5WNZVD0qGSSyR-oLfTA_6_6">1,256</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_ffN_Bd0u6EuABPUHJggLOw;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Operating lease liability - noncurrent</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_R-mgHIzREEi0J5M0QVMDqQ_7_3">4,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_GKVXP0WmrUW70oCmRn-KMg_7_6">5,961</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:68.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_yNAOiRCkP0mEzcqrTZongA;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;">  Total operating lease liabilities</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_KPq2XQwac0qg3TeobytW_Q_8_3">5,959</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_XYsxAMHUB06dL4u6H63QFg_8_6">7,217</ix:nonFraction></p></td></tr></table></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">99</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:80.09%;border:0;margin:30pt 9.56% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:9.56%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_dbe99be6_e2f1_4202_ae21_2afc093464b5"></a><a id="Tc_3FS1nRmN6EqydAJ_-gx0Lw_1_2"></a><a id="Tc_1kdtx39HA06u6gMbRmQoWg_2_3"></a><a id="Tc_Pe8_bht3pEuss7KBA-2_RA_2_6"></a><a id="Tc_syfgb-IM60iQHDD2y-uwtA_3_0"></a><a id="Tc_csHm0T17zEGMl9l_RyPrOw_4_0"></a><a id="Tc_QMXqBRBujUO-2cCp2K6ZiQ_4_2"></a><a id="Tc_dzoSNNCoxEK3rU0TlVUrVA_4_5"></a><ix:continuation id="Tb_qgohR3b7eUqHRjXlU0Uznw_cont1"><ix:continuation id="Tb_o6SXgSeV8USll1qHoW8nHQ_cont1"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="ptgx:LeaseCashFlowInformationDisclosureTableTextBlock" id="Tb_UdLJmfjjAU2cMSBepGLgAQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Supplemental cash flow information is as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Cash paid for amounts included in the measurement of lease liabilities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:67.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating cash flow used by operating leases</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_R3tF-H53g0C8PLwDZ6bN1A_4_3">1,941</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_Si_DmqeRyUO6rMYKrx6zdg_4_6">1,885</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Prior to the adoption of ASC 842, the Company&#8217;s rent expense was $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesRentExpenseNet" scale="6" id="Narr_gN95qvmXjU2spNc78pgbtw">1.9</ix:nonFraction> million for the&#160;year ended December&#160;31, 2018. Rent expense was recognized on a straight-line basis over the term of the lease and accordingly, the Company recorded the difference between cash rent payments and the recognition of rent expense as a deferred rent liability.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_0DGt4tAAXEu7z7jnS8J-kQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Note 11.    Commitments and Contingencies </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has also entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by California corporate law. The Company carries a directors&#8217; and officers&#8217; insurance policy. To date, the Company has not incurred material costs to defend lawsuits or settle claims related to the indemnification agreements. The Company believes that the fair value of these indemnification agreements is minimal and has not accrued any amounts for the obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Legal Proceedings </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Company is a party to the legal action described below. The Company recognizes accruals for such actions to the extent that it concludes that a loss is both probable and reasonably estimable. The Company accrues for the best estimate of a loss within a range; however, if no estimate in the range is better than any other, it accrues the minimum amount in the range. If the Company determines that a loss is reasonably possible and the loss or range of loss can be estimated, it discloses the possible loss. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">On January 23, 2020, the Company initiated arbitration proceedings with the International Court of Arbitration of the International Chamber of Commerce against Zealand Pharma A/S (&#8220;Zealand&#8221;) related to a collaboration agreement the Company and Zealand entered into in 2012 and terminated in 2014.&#160;The agreement provides for certain post-termination payment obligations to Zealand with respect to compounds related to the collaboration that the Company elects to further develop and meet specified conditions. In the Company&#8217;s arbitration claim, it is seeking a declaration that the Company has no past, present or future milestone or royalty payment obligations under the agreement with respect to rusfertide because it is not a compound relating to the collaboration for which post-termination payments to Zealand apply. The Company is also seeking repayment of $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_ZealandPharmaMember_EFYZYS2pyEi6iqunSu7VTw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LossContingencyDamagesSoughtValue" scale="6" id="Narr_ljDu7ceS2E67dKZNSERitg">1.0</ix:nonFraction> million in milestone payments it has made, as well as its costs, fees, and expenses of the proceeding.&#160;Zealand disputes the Company&#8217;s claims and has filed counterclaims for payment of a development milestone Zealand claims is due, as well as payment of their arbitration costs, fees and expenses<i style="font-style:italic;">. </i>The arbitration is pending. If Zealand prevails in the arbitration, the Company could be required to reimburse Zealand&#8217;s arbitration costs, fees and expenses, and make contractual payments to Zealand described in its prior periodic reports filed with the SEC. If we successfully develop and commercialize rusfertide without a partner, those payments could include up to an additional aggregate of $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_srt_CounterpartyNameAxis_ptgx_ZealandPharmaMember_srt_StatementScenarioAxis_ptgx_SuccessfullyDevelopAndCommercializeRusfertideComponentWithOutPartnerMember_zvHiCT5gZESB6MhV_EqkXg" decimals="-5" format="ixt:numdotdecimal" name="ptgx:PotentialDevelopmentAndRegulatoryMilestonePaymentsOnContractualObligation" scale="6" id="Narr_k6VMgUhM0USI3mmiKWcZjA">28.0</ix:nonFraction> million for achievement of certain development and regulatory milestones, and up to $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_srt_CounterpartyNameAxis_ptgx_ZealandPharmaMember_srt_StatementScenarioAxis_ptgx_SuccessfullyDevelopAndCommercializeRusfertideComponentWithOutPartnerMember_zvHiCT5gZESB6MhV_EqkXg" decimals="-5" format="ixt:numdotdecimal" name="ptgx:PotentialSalesMilestonePaymentsOnContractualObligation" scale="6" id="Narr_FAe4LjvOoEm5QdZWuxDlbQ">100.0</ix:nonFraction> million for achievement of sales milestones. In addition, Zealand could be eligible to receive a low single digit royalty on worldwide net sales of the product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Although the Company cannot predict with certainty the ultimate outcome of these arbitration proceedings, it has concluded that the probability of any related loss is remote and therefore <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_srt_CounterpartyNameAxis_ptgx_ZealandPharmaMember_Z1DSgl1avkK9ttj7siMlow" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="6" id="Narr_gdk-vTSYN0i7Dxxes0-Sbg">no</ix:nonFraction> related accruals were recognized as of December 31, 2020.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">100</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:80.09%;border:0;margin:30pt 9.56% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:9.56%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_STS4uB8ar0icDfqicZAYbw" continuedAt="Tb_STS4uB8ar0icDfqicZAYbw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Note 12.    Stockholders&#8217; Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:25.3pt;margin:0pt 0pt 13.19pt 0pt;">In September 2017, the Company filed a registration statement on Form S-3 with the Securities and Exchange Commission (File No. 333-220314) that was declared effective as of October 5, 2017 and permitted the offering, issuance, and sale by the Company of up to a maximum aggregate offering price of $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_9_1_2017_To_9_30_2017_us-gaap_SubsidiarySaleOfStockAxis_ptgx_CommonStockPreferredStockAndCertainDebtSecuritiesMember_zx3lVa2z8kOfh7KC7iZGpg" decimals="-5" format="ixt:numdotdecimal" name="ptgx:SaleOfStockValueOfSharesAuthorized" scale="6" id="Narr_bY74ofXZvEOn8nbH-gOgBQ">200.0</ix:nonFraction> million of its common stock, preferred stock and certain debt securities (the &#8220;2017 Form S-3&#8221;). Up to a maximum of $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_9_1_2017_To_9_30_2017_srt_CounterpartyNameAxis_ptgx_AtMarketOfferingMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_SalesAgreementFrom2017Member__YoSlLwDmEWFZ2JYQBWSFw" decimals="-5" format="ixt:numdotdecimal" name="ptgx:SaleOfStockValueOfSharesAuthorized" scale="6" id="Narr_JH_bVq7wikm6F9SVvccmoQ">50.0</ix:nonFraction> million of the maximum aggregate offering price of $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_9_1_2017_To_9_30_2017_us-gaap_SubsidiarySaleOfStockAxis_ptgx_CommonStockPreferredStockAndCertainDebtSecuritiesMember_zx3lVa2z8kOfh7KC7iZGpg" decimals="-5" format="ixt:numdotdecimal" name="ptgx:SaleOfStockValueOfSharesAuthorized" scale="6" id="Narr_A8f4N-E0AkumIVLIamyaCg">200.0</ix:nonFraction> million could be issued and sold pursuant to an at-the-market (&#8220;ATM&#8221;) financing facility under a sales agreement (the &#8220;2017 Sales Agreement&#8221;). The 2017 Sales Agreement was terminated in 2019. During the year ended December 31, 2019, prior to the termination of the 2017 Sales Agreement, the Company sold <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_SalesAgreementFrom2017Member_4-Top2Z7HEGnoubmcpaUQg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_45GOoJqtqUqF1mMQgBACwQ">2,846,641</ix:nonFraction> shares of its common stock for net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_SalesAgreementFrom2017Member_4-Top2Z7HEGnoubmcpaUQg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_rMH9lBabNEesGdBTl_GTCA">34.5</ix:nonFraction> million, after deducting issuance costs. The Company sold <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_SalesAgreementFrom2017Member_qkNym65oekWLKJu7qHfcDA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_K5X8zK0wlUKz1AVd4mLN1Q">151,273</ix:nonFraction> shares of its common stock pursuant to the 2017 Sales Agreement during the year ended December 31, 2018 for net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_SalesAgreementFrom2017Member_qkNym65oekWLKJu7qHfcDA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_95ewQRyquUe4xmJpPzjWFA">1.5</ix:nonFraction> million, after deducting issuance costs. The 2017 Form S-3 expired in October 2020. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:25.3pt;margin:0pt 0pt 13.19pt 0pt;">In August 2018, the Company entered into a Securities Purchase Agreement with certain accredited investors (each, an &#8220;Investor&#8221; and, collectively, the &#8220;Investors&#8221;), pursuant to which the Company sold an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="Duration_8_1_2018_To_8_31_2018_srt_CounterpartyNameAxis_ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_j6JfV1HdAU2VL5Av0thXjA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_TrBnDSYx40umZUlER-dEHg">2,750,000</ix:nonFraction> shares of its common stock at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q" contextRef="As_Of_8_6_2018_srt_CounterpartyNameAxis_ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VeE0MBURAUmr6KszgYXA8g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_06nclWeSmkOEauCcz54fsA">8.00</ix:nonFraction> per share, for aggregate net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_8_6_2018_srt_CounterpartyNameAxis_ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VeE0MBURAUmr6KszgYXA8g" decimals="-5" format="ixt:numdotdecimal" name="ptgx:AggregateGrossProceedsFromIssuanceStock" scale="6" id="Narr_E6yfS_fQnUaxHxHICYV2Og">21.7</ix:nonFraction> million, after deducting offering expenses payable by the Company. In a concurrent private placement, the Company issued the Investors warrants to purchase an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="As_Of_8_6_2018_srt_CounterpartyNameAxis_ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_z3QoxAuYuUKbQDm_MCaYpQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_xajRf4hSYk2zNIsyOk9K6A">2,750,000</ix:nonFraction> shares of its common stock (each, a &#8220;Warrant&#8221; and, collectively, the &#8220;Warrants&#8221;). Each Warrant is exercisable from August 8, 2018 through August 8, 2023. Warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="As_Of_8_6_2018_us-gaap_ClassOfWarrantOrRightAxis_ptgx_WarrantsPurchaseAmountPerSharePriceOneMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_186kOF-nN0ak3sZ7B7mYIg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Narr_QISDTgIMz0WfpojFasj9ug">1,375,000</ix:nonFraction> shares of the Company&#8217;s common stock have an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q" contextRef="As_Of_8_6_2018_us-gaap_ClassOfWarrantOrRightAxis_ptgx_WarrantsPurchaseAmountPerSharePriceOneMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_186kOF-nN0ak3sZ7B7mYIg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_IrqR4du0S0-yYp79CZ4KpQ">10.00</ix:nonFraction> per share and Warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="As_Of_8_6_2018_us-gaap_ClassOfWarrantOrRightAxis_ptgx_WarrantsPurchaseAmountPerSharePriceTwoMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_GKATHoBzkEKJSJRivO9SBQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Narr_-rXgz7UIUEmd55mHmkYP_g">1,375,000</ix:nonFraction> shares of the Company&#8217;s common stock have an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q" contextRef="As_Of_8_6_2018_us-gaap_ClassOfWarrantOrRightAxis_ptgx_WarrantsPurchaseAmountPerSharePriceTwoMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_GKATHoBzkEKJSJRivO9SBQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_WG1bgfYzQEmvVhW9UV4KLg">15.00</ix:nonFraction> per share. The exercise price and number of shares of common stock issuable upon the exercise of the Warrants (the &#8220;Warrant Shares&#8221;) are subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described in the Warrants. Under certain circumstances, the Warrants may be exercisable on a &#8220;cashless&#8221; basis. In connection with the issuance and sale of the common stock and Warrants, the Company granted the Investors certain registration rights with respect to the Warrants and the Warrant Shares. The common stock and warrants are classified as equity in accordance with Accounting Standards Codification Topic 480<i style="font-style:italic;">, Distinguishing Liabilities from Equity </i>(&#8220;ASC 480&#8221;)<i style="font-style:italic;">,</i> and the net proceeds from the transaction were recorded as a credit to additional paid-in capital. As of December 31, 2020, <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_KjsvtwPBSUeomIS3nTcYHQ" decimals="INF" format="ixt-sec:numwordsen" name="ptgx:NumberOfWarrantsExercised" scale="0" id="Narr_nFal3k-nkUWT1fKJKU8IKg">none</ix:nonFraction> of the Warrants have been exercised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:25.3pt;margin:0pt 0pt 13.19pt 0pt;">In December 2018, the Company entered into an exchange agreement (the &#8220;Exchange Agreement&#8221;) with an Investor and its affiliates (the &#8220;Exchanging Stockholders&#8221;), pursuant to which the Company exchanged an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="As_Of_12_21_2018_srt_CounterpartyNameAxis_ptgx_BiotechnologyValueFundL.pMember_us-gaap_TypeOfArrangementAxis_ptgx_ExchangeAgreementMember_BJDxU0LhGkitpW7AZKjqUg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_A8Gz8IrJ4U-QIyiHaMPc4Q">1,000,000</ix:nonFraction> shares of the Company&#8217;s common stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q" contextRef="As_Of_12_21_2018_srt_CounterpartyNameAxis_ptgx_BiotechnologyValueFundL.pMember_us-gaap_TypeOfArrangementAxis_ptgx_ExchangeAgreementMember_BJDxU0LhGkitpW7AZKjqUg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_egfds-91r0KW-q-pfdKp_A">0.00001</ix:nonFraction> per share, owned by the Exchanging Stockholders for pre-funded warrants (the &#8220;Exchange Warrants&#8221;) to purchase an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="Duration_12_1_2018_To_12_31_2018_srt_CounterpartyNameAxis_ptgx_BiotechnologyValueFundL.pMember_us-gaap_TypeOfArrangementAxis_ptgx_ExchangeAgreementMember_JivbDCfMDUKimc02lEUXQg" decimals="INF" format="ixt:numdotdecimal" name="ptgx:StockExchangedForPreFundedWarrants" scale="0" id="Narr_PrBCgcIng0GaPQKoWvK7Dw">1,000,000</ix:nonFraction> shares of common stock (subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described in the Exchange Warrants), with an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q" contextRef="As_Of_12_21_2018_srt_CounterpartyNameAxis_ptgx_BiotechnologyValueFundL.pMember_us-gaap_TypeOfArrangementAxis_ptgx_ExchangeAgreementMember_BJDxU0LhGkitpW7AZKjqUg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_WoCOrz1PfUCTEb2l7CG7_A">0.00001</ix:nonFraction> per share. The Exchange Warrants will expire <ix:nonNumeric contextRef="Duration_12_21_2018_To_12_21_2018_srt_CounterpartyNameAxis_ptgx_BiotechnologyValueFundL.pMember_us-gaap_TypeOfArrangementAxis_ptgx_ExchangeAgreementMember_vOU5zedUDk2RWTFaLEzOWw" format="ixt-sec:durwordsen" name="ptgx:ClassOfWarrantOrRightTermOfWarrants" id="Narr_H-4waa7ElkudlQzlO_eX8A">ten years</ix:nonNumeric> from the date of issuance. The Exchange Warrants are exercisable at any time prior to expiration except that the Exchange Warrants cannot be exercised by the Exchanging Stockholders if, after giving effect thereto, the Exchanging Stockholders would beneficially own more than <ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="As_Of_12_21_2018_srt_CounterpartyNameAxis_ptgx_BiotechnologyValueFundL.pMember_us-gaap_TypeOfArrangementAxis_ptgx_ExchangeAgreementMember_BJDxU0LhGkitpW7AZKjqUg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="Narr__34ymE7o902fpjp8sLBRlA">9.99</ix:nonFraction>% of the Company&#8217;s common stock, subject to certain exceptions. In accordance with Accounting Standards Codification Topic 505,<i style="font-style:italic;"> Equity</i>, the Company recorded the retirement of the common stock exchanged as a reduction of common stock shares outstanding and a corresponding debit to additional paid-in-capital at the fair value of the Exchange Warrants on the issuance date. The Exchange Warrants are classified as equity in accordance with ASC 480<i style="font-style:italic;">,</i> and the fair value of the Exchange Warrants was recorded as a credit to additional paid-in capital and is not subject to remeasurement. The Company determined that the fair value of the Exchange Warrants is substantially similar to the fair value of the retired shares on the issuance date due to the negligible exercise price for the Exchange Warrants. During the year ended December 31, 2019, Exchange Warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_ptgx_BiotechnologyValueFundL.pMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_ptgx_ExchangeAgreementMember_mgjJN8kSnkmKkWqgSyHErQ" decimals="INF" format="ixt:numdotdecimal" name="ptgx:NumberOfWarrantsExercised" scale="0" id="Narr_FjBWT4yeD0-mMKXuTWzuFw">600,000</ix:nonFraction> shares were net exercised, resulting in the issuance of <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_ptgx_BiotechnologyValueFundL.pMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_ptgx_ExchangeAgreementMember_cUqXG1yQX0uQTBHVoh090Q" decimals="INF" format="ixt:numdotdecimal" name="ptgx:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="Narr_pkB76s018UqoeoNygdwXEQ">599,997</ix:nonFraction> shares of common stock. As of December 31, 2020, <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="As_Of_12_31_2020_srt_CounterpartyNameAxis_ptgx_BiotechnologyValueFundL.pMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_ptgx_ExchangeAgreementMember_Ik7tchK9-Ue8oyRnGIgm_g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_oi6qRvxPsky7S6Ot_wS2YA">400,000</ix:nonFraction> of the Exchange Warrants remain unexercised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">In October 2019, the Company filed a registration statement on Form S-3 (File no. 333-234414) that was declared effective as of November 22, 2019 and permits the offering, issuance, and sale by the Company of up to a maximum aggregate offering price of $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_10_1_2019_To_10_31_2019_us-gaap_SubsidiarySaleOfStockAxis_ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember_2WMpGtC9OEOlBeqopXrQRw" decimals="-5" format="ixt:numdotdecimal" name="ptgx:SaleOfStockValueOfSharesAuthorized" scale="6" id="Narr_Ja4bJzdlik6DQHjeo_Oh5g">250.0</ix:nonFraction> million of its common stock, preferred stock, debt securities and warrants (the &#8220;2019 Form S-3&#8221;). Up to a maximum of $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_10_1_2019_To_10_31_2019_srt_CounterpartyNameAxis_ptgx_AtMarketOfferingMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember_yaqgEgG5X0iZ4CZKQUqb8g" decimals="-5" format="ixt:numdotdecimal" name="ptgx:SaleOfStockValueOfSharesAuthorized" scale="6" id="Narr_Yey2vG56a0CVWvnAj4ANTw">75.0</ix:nonFraction> million of the maximum aggregate offering price of $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_10_1_2019_To_10_31_2019_us-gaap_SubsidiarySaleOfStockAxis_ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember_2WMpGtC9OEOlBeqopXrQRw" decimals="-5" format="ixt:numdotdecimal" name="ptgx:SaleOfStockValueOfSharesAuthorized" scale="6" id="Narr_x4xw074L9USo41VuaXWFHw">250.0</ix:nonFraction> million may be issued and sold pursuant to an ATM financing facility under a sales agreement entered into by the Company on November 27, </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">101</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:80.09%;border:0;margin:30pt 9.56% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:9.56%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_STS4uB8ar0icDfqicZAYbw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">2019 (the &#8220;2019 Sales Agreement&#8221;). In May 2020, the Company completed an underwritten public offering of <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="Duration_5_1_2020_To_5_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GUwt944WL0uotoTy8UvAVQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_lxQ3B0GFvUCB32S9JfmgwQ">7,000,000</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q" contextRef="As_Of_5_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_kre8MFx27UW7IW8Z8ld4mw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_vhEXGE63L0SRqxLtgXNlBQ">14.00</ix:nonFraction> per share and issued an additional <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="Duration_5_1_2020_To_5_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_4Kh5pBSECkypUOYucapGkA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_wGgId3bY-Uy9t4HGT7Josw">1,050,000</ix:nonFraction> shares of its common stock at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q" contextRef="As_Of_5_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_hOb9HKro90mY6okLdtMCHA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_ViG5lCgYEEirWdQfHADy_A">14.00</ix:nonFraction> per share following the underwriters&#8217; exercise of their option to purchase additional shares. Net proceeds, after deducting underwriting commissions and offering costs paid by the Company, were $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_5_1_2020_To_5_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_SalesAgreementFrom2017Member_tZp0EkKbX0KKXBjYlmFbBg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_3kLaflciwE6XzDt-2cJFdA">105.3</ix:nonFraction> million. The Company sold <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember_jKn-PPj_GUaOCF64euSSCg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_POiyyI09bUqSNVL0G7dmQg">2,483,719</ix:nonFraction> shares of its common stock pursuant to the 2019 Sales Agreement during the year ended December 31, 2020 for net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember_jKn-PPj_GUaOCF64euSSCg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_jh9NsCbwBUW3SqpQuCyVXA">41.9</ix:nonFraction> million, after deducting issuance costs. As of December 31, 2020, a total of $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_SubsidiarySaleOfStockAxis_ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember_p8qynIyKyk-zMkGoWZcW3A" decimals="-5" format="ixt:numdotdecimal" name="ptgx:SaleOfStockValueOfSharesAuthorized" scale="6" id="Narr_E264CAYO4EqSGmimnQ11kw">94.2</ix:nonFraction> million of common stock remained available for sale under the 2019 Form S-3, $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_AtMarketOfferingMember_iy5bZi35C0SnS_cAS0HmXw" decimals="-5" format="ixt:numdotdecimal" name="ptgx:SaleOfStockValueOfSharesAuthorized" scale="6" id="Narr_9ApaVuK4R0y2534RpQxXBg">31.9</ix:nonFraction> million of which remained available for sale under the ATM financing facility. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">In December 2020, the Company filed an automatic registration statement on Form S-3ASR and an accompanying prospectus (Registration Statement No. 333-251254), pursuant to which the Company completed an underwritten public offering of <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="Duration_12_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0ejK20BXz0WlKLitqx2O8A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_jlxjNH9dZ0a0RLOYS4VgRg">4,761,904</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_E5rQEhmdCkiUzPRvbbp87g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_hPNuHOrflEeRNEXn75zWrA">21.00</ix:nonFraction> per share and issued an additional <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="Duration_12_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_agJoJQfoR0S_u2bStgWXxQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_n8uW-JMu-kmGowYWGcEGXA">714,285</ix:nonFraction> shares of its common stock at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_SBZjOH40VUWH7eyCsHOxeQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_beFUlc7sFU--VveqIuvKfg">21.00</ix:nonFraction> per share following the underwriters&#8217; exercise of their option to purchase additional shares. Net proceeds, after deducting underwriting commissions and offering costs paid by the Company, were $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_12_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_agJoJQfoR0S_u2bStgWXxQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_hKWdL_ml6Uug2ZmuY3kfNg">107.6</ix:nonFraction> million.</p></ix:continuation><a id="_AEIOULastRenderedPageBreakAEIOU73"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_t4-TByv8VE-QN7Pj0avJ1g" continuedAt="Tb_t4-TByv8VE-QN7Pj0avJ1g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 13.&#160;&#160;&#160;&#160;Equity Plans </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Equity Incentive Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">In May&#160;2007, the Company established the 2007 Stock Option and Incentive Plan (&#8220;2007 Plan&#8221;) which provided for the granting of stock options to employees and consultants of the Company. Options granted under the 2007 Plan were either incentive stock options (&#8220;ISOs&#8221;) or nonqualified stock options (&#8220;NSOs&#8221;). ISOs were granted only to Company employees (including officers and directors who are also employees). NSOs were granted to Company employees and consultants. Options under the 2007 Plan have a term of <ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_ptgx_StockOptionAndIncentivePlanAsAmendedAndRestated2007Member_jktel6yu6kK7pWrzaSuY2Q" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_pDuvaeXkjESn_4kEaD9wRQ">ten&#160;years</ix:nonNumeric> and generally vest over a <ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_ptgx_StockOptionAndIncentivePlanAsAmendedAndRestated2007Member_9U0z6hszwEGi_P9hNkxE5Q" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_EodajTHFtEWtbyaI9LQgjw">four-year</ix:nonNumeric> period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">In July&#160;2016, the Company&#8217;s board of directors and stockholders approved the 2016 Equity Incentive Plan (&#8220;2016 Plan&#8221;) to replace the 2007 Plan. Under the 2016 Plan, <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="As_Of_7_31_2016_us-gaap_PlanNameAxis_ptgx_EquityIncentivePlan2016Member_X9g55Fo86EaIMiverpOurg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_n7lXEVC2eEWVCnEnfVCMAA">1,200,000</ix:nonFraction> shares of the Company&#8217;s common stock were initially reserved for the issuance of stock options, restricted stock units and other awards to employees, directors and consultants. Pursuant to the &#8220;evergreen&#8221; provision contained in the 2016 Plan, the number of shares reserved for issuance under the 2016 Plan automatically increases on January 1 of each year, starting on January 1, 2017 and continuing through (and including) January 1, 2026, by <ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_ptgx_EquityIncentivePlan2016Member_Q2OzhxYJoE2GLzRZOait5w" decimals="2" format="ixt:numdotdecimal" name="ptgx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum" scale="-2" id="Narr_CNKO0zvu_UuK9b68av-yOA">4</ix:nonFraction>% of the total number of shares of the Company&#8217;s capital stock outstanding on December 31 of the preceding fiscal year, or a lesser number of shares determined by the Company&#8217;s board of directors. Upon adoption of the 2016 Plan, <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="As_Of_7_31_2016_us-gaap_PlanNameAxis_ptgx_StockOptionAndIncentivePlanAsAmendedAndRestated2007Member_Q8ASK54YZEa5T6ejJrDeJw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_GpT6x9-7HUuUpEIcNVzJcw">no</ix:nonFraction> additional stock awards were issued under the 2007 Plan. Options granted under the 2007 Plan that were outstanding on the date the 2016 Plan became effective remain subject to the terms of the 2007 Plan. The number of options available for grant under the 2007 Plan was ceased and the number was added to the common stock reserved for issuance under the 2016 Plan. As of December&#160;31, 2020, approximately <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="As_Of_12_31_2019_us-gaap_PlanNameAxis_ptgx_EquityIncentivePlan2016Member_F6df0QQhrU6i9GJCdhqPDg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_y1H1PbRiMUW4OcPuvCigUQ">538,374</ix:nonFraction> shares of common stock were available for issuance under the 2016 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The 2016 Plan is administered by the board of directors or a committee appointed by the board of directors, which determines the types of awards to be granted, including the number of shares subject to the awards, the exercise price and the vesting schedule. Options granted under the 2016 Plan expire no later than <ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_ptgx_EquityIncentivePlan2016Member_eF2snCub_Eahp8p8BWAONg" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_6YBaPISwqEyeSCMbsP2xpg">ten years</ix:nonNumeric> from the date of grant. The exercise price of each option may not be less than <ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_ptgx_EquityIncentivePlan2016Member_uoGvCjLpdkK2StizIEWf5w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="Narr_3-JwjC5l_UWEQmFZjiQDXg">100</ix:nonFraction>% of the fair market value of the common stock at the date of grant. Options may be granted to stockholders possessing more than 10% of the total combined voting power of all classes of stocks of the Company at an exercise price at least <ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_ptgx_EquityIncentivePlan2016Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_PrincipalOwnerMember_ExSFV52WIEW8KwIeap4Bxw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="Narr_cXazfp6mhkuyWqBFRaX_-w">110</ix:nonFraction>% of the fair value of the common stock at the date of grant and the options are not exercisable after the expiration of 10&#160;years from the date of grant. Employee stock options generally vest over a period of approximately <ix:nonNumeric contextRef="Duration_7_1_2016_To_7_31_2016_us-gaap_PlanNameAxis_ptgx_EquityIncentivePlan2016Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_Pl5aD902hUizaGvF0_Ag0w" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_BdMV7hQa20-8WfEMUyAOow">four years</ix:nonNumeric>. Non-employee director initial stock options generally vest monthly over a period of approximately <ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_ptgx_NonEmployeeDirectorInitialStockOptionsMember_us-gaap_PlanNameAxis_ptgx_EquityIncentivePlan2016Member_jCMUIflu30Chq-y0-NBBeQ" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_lZ6BIzqs60yVafvk-MBIFw">three years</ix:nonNumeric>, and non-employee director annual refresher stock options generally vest over a period of approximately <ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_ptgx_NonemployeeDirectorAnnualRefresherStockOptionsMember_us-gaap_PlanNameAxis_ptgx_EquityIncentivePlan2016Member_ZyLhj6L8U0eoAkYv_BvxHQ" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_whVvrnuZAUK37dlfidHN6A">one year</ix:nonNumeric>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:8pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Inducement Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27.8pt;margin:6pt 0pt 0pt 0pt;">In May 2018, the Company&#8217;s board of directors approved the 2018 Inducement Plan, a non-stockholder approved stock plan, under which it reserved and authorized <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="As_Of_5_31_2018_us-gaap_PlanNameAxis_ptgx_InducementStockPlanMember_3YM3Ufo1cE24pa1he7vSAQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_VrbVRYIEx0Gq8kvuyhiZcQ">750,000</ix:nonFraction> shares of the Company&#8217;s common stock in order to award </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">102</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:80.09%;border:0;margin:30pt 9.56% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:9.56%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_84d98ba5_7613_407e_925f_12b4d8513c90"></a><a id="Tc_MH7Ezx9GFUCnXQ9txUXUrw_2_4"></a><a id="Tc_ol_gClbbcEGu-APS2AcwSw_2_7"></a><a id="Tc_iKsxxJQr00S86zc8mYtMsw_3_4"></a><a id="Tc__OA-yTczDkeC0WP0ejOqMA_3_7"></a><a id="Tc_awK5MFKIJEa24gwteGJZiA_4_4"></a><a id="Tc_Bf6wEVjXsES3Ue3AG-Vv1A_4_7"></a><a id="Tc_UOUp97LjfEaaZXCuKPpYZw_4_9"></a><a id="Tc_ucaq95EOB0-_Wxh01J1NGg_5_2"></a><a id="Tc_u9JhLmTwNEC5teLicZ3G5g_5_4"></a><a id="Tc_0XRKTGnOeE66NjcYoBjeMw_5_7"></a><a id="Tc_bbZuJCJ-NUyHthb0LIWnDQ_5_9"></a><a id="Tc_lMZKnEiiEEOhbdRcM7_Mgw_6_2"></a><a id="Tc_oypg0lXFmkS5xlu8SG-Zag_6_4"></a><a id="Tc__ewkw3ZZtkGUTAGtUV1KHw_6_7"></a><a id="Tc_JFcojOYLtkqpdMTEKRbTFQ_6_9"></a><a id="Tc_GrTYLVVskUWA_OTF6zZoeg_7_9"></a><a id="Tc_shZxba9On0SHQkuw-JDhuA_8_0"></a><a id="Tc_ILak8oQKh0GKTcmXInMSnw_8_4"></a><a id="Tc_OjL4nMIj-U6dAZIm3JOSPQ_8_9"></a><a id="Tc_90Nz9rSRlUuwkQzJMiXlqg_9_0"></a><a id="Tc_8WNz0mTYTky1EXaYgRg5Gw_10_0"></a><a id="Tc_NyuBfrWo8kCMz4IbOltWUg_11_0"></a><a id="Tc_KMmG8K4dz067u3ebU7fi6A_12_0"></a><a id="Tc_2OXBAbWLAkWOvxApU7XOVw_12_4"></a><a id="Tc_w0v3BViwX0GyakbXTE6Isg_12_9"></a><a id="Tc_mLHujr6bNkGY5qfCK6f_dA_13_0"></a><a id="Tc_GY7czLicYUOCdKBjn9Xolg_13_4"></a><a id="Tc_KHSyQiRYMk-oQCwmvbNdww_13_9"></a><a id="Tc_lFK7tcpdKUmgj4J_fkrhQw_14_0"></a><a id="Tc_V7z0_zjHVkOVUc5lLPdc_w_14_4"></a><a id="Tc_JWaf6bPllkC07a7DC1_vjQ_14_9"></a><a id="Tc_nsfVuqsq5UmqWg9AcuyXHA_1_2"></a><a id="Tc_PCk98uq85UCyjOtVwt3nog_2_2"></a><a id="Tc_NRLTbvSyUEahZ7pWgnSUlg_2_4"></a><a id="Tc_LeyDvc0x1EGsZhvfa4eIBw_2_6"></a><a id="Tc_jYSlBkMzl06QRcv33-6LzQ_3_0"></a><a id="Tc_GaK3cZtW60OpWvv1hQS4VQ_3_2"></a><a id="Tc_tNGV1kVi5ki_mE7oU-CWtQ_3_4"></a><a id="Tc_NdwQvfkLKEK8I0O2s6QNcQ_3_6"></a><a id="Tc_NZAf6Loi6UuHwFUfPy6KnQ_4_0"></a><a id="Tc__dgdTytGbUCqLoY-O77mPg_4_2"></a><a id="Tc_qULI_EKZBEegR99t7b0O-Q_4_4"></a><a id="Tc_NNCpFKrDf0yZvTm6i_WWPw_4_6"></a><a id="Tc_9u3tO75D50SfZUvafw2mNA_5_0"></a><a id="Tc_ncsnAYqzYku6--E4qwWzXw_5_2"></a><a id="Tc_onL8xhJ2NESZE200lCSG4w_5_4"></a><a id="Tc_WjTczlxbG0u219MAQyrA7g_5_6"></a><a id="Tc_OTSiub9NrEOuTtuW1x4UJQ_6_0"></a><a id="Tc_BU3QNE0hPkib2y_xM1Qi0A_6_2"></a><a id="Tc_RK_UsIV6OUK0knzWLXu3LA_6_4"></a><a id="Tc_WHZeuvm9SEqcq37wX28sJQ_6_6"></a><ix:continuation id="Tb_t4-TByv8VE-QN7Pj0avJ1g_cont1" continuedAt="Tb_t4-TByv8VE-QN7Pj0avJ1g_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">options and restricted stock unit awards&#160;to persons that were not previously employees or directors of the Company, or following a bona fide period of non-employment, as an inducement material to such persons entering into employment with the Company, within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. The 2018 Inducement Plan is administered by the board of directors or the Compensation Committee of the board, which determines the types of awards to be granted, including the number of shares subject to the awards, the exercise price and the vesting schedule. Awards granted under the 2018 Inducement Plan expire no later than <ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_ptgx_InducementStockPlanMember_yAEykxLHsUSSNG0CUEUjkA" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_GDJw1bNNgEGArF3uhNhlGA">ten years</ix:nonNumeric> from the date of grant. As of December 31, 2020, approximately <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_ptgx_InducementStockPlanMember_KE5aREx68U2i_cgMV6Pj_A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_9fSVRM8dNka1q7LHWfayAQ">574,375</ix:nonFraction> shares were available for issuance under the 2018 Inducement Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Options</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Activity under the Company&#8217;s equity incentive plans is set forth below:</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="Tb_xC8fjqbm30a5DWyWahJJjw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.5396309%;padding-left:0pt;padding-right:0pt;width:101.07%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:37.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price&#160;Per</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Life&#160;(years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value (1)</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;millions)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balances at December&#160;31,&#160;2019</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_Z3KekqxpdU6WrlgnbNvuag_8_2">3,681,521</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_r0FibSlYmESJ8tUr9da-sw_8_5">11.64</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_BZQ-EtYMbUqQug8nwTAoLA_8_7"> 7.78</ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="Tc_n5i7f2SBJ0iiNlgkDRIRBg_8_10">2.4</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_WhjMusuZ9Ea8itFht3al6w_9_2">1,536,400</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_A9R5Fl89gEC2IK3omh4noQ_9_5">11.53</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_je5j5dm8P0SIgeLAk-Dr_A_10_2">294,238</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_xsKbYgvnsUyfLuEgIMvw9A_10_5">7.49</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" scale="0" id="Tc_EWoG88W0a0GGO4puqv4Row_11_2">275,563</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_XoIaefH3Rkmg2NuuqRUtww_11_5">11.54</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balances at December&#160;31,&#160;2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_ITsO4v6ookqnfI7uKtAl5A_12_2">4,648,120</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_RraBfbPhnkKAWAoWhORXEw_12_5">11.87</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="Tc_Hj2cxE7M_0WrB0FQ62o2rw_12_7"> 7.61</ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="Tc_GkoJnXYCvEyDdtPZLHbQ6A_12_10">40.0</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options exercisable &#8211; December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_VNVFAR5XbUCcLuCwBuZoXQ_13_2">2,619,943</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_AMNpvpky7EqCsILAaT0grg_13_5">12.10</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Tc_TjBTGFXui0WO87nb47nxoQ_13_7"> 6.65</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="Tc_6QZ7Fa8N3kuAM_Nn0gpxXQ_13_10">22.1</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options vested and expected to vest &#8211; December&#160;31,&#160;2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="Tc_mYiWKCXf_ECiE7o7HBa0dw_14_2">4,648,120</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_7BvGuSOfuky4O2VEw8SDUw_14_5">11.87</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_oeDCJ-ehf0afu0z1Ti6zMQ_14_7"> 7.61</ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="6" id="Tc_r8wSFYvwyEaFFv9q7yF0AQ_14_10">40.0</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;padding-left:9pt;text-indent:-9pt;margin:3pt 0pt 0pt 0pt;"><b style="font-weight:bold;">____________________</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-indent:-9pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1) </sup>The aggregate intrinsic values were calculated as the difference between the exercise price of the options and the closing price of the Company&#8217;s common stock on December 31, 2020. The calculation excludes options with an exercise price higher than the closing price of the Company&#8217;s common stock on December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The aggregate intrinsic value of options exercised was $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="Narr_ZxS4aIrCcE6sKd9aXmsygQ">3.0</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="Narr_16jd461Cy0WGXBi4CfOjMQ">2.6</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="Narr_5lhZGAtFB06XmjiASmr8uA">1.3</ix:nonFraction> million for the&#160;years ended December&#160;31, 2020, 2019 and 2018, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">During the&#160;years ended December&#160;31, 2020, 2019 and 2018, the estimated weighted-average grant-date fair value of common stock underlying options granted was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_btYxB5eJxkiS8SbeRk-59A">7.76</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_p6wymIaCfkizCzVlevNrpA">5.45</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_gyy4kxlpjUO-tAFFPVLEow">8.12</ix:nonFraction> per share, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Options Valuation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The fair value of stock option awards accounted for under ASC 718 was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions:</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_y_lWVCdXEkurpTEfNZLamw" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_-HpoRnoGM0ek-SFMzJnFcw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:57.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:40.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (in years)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zQrIRwTjBUOg--pd-u3-dg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_vbKrW9re00W-QvD8z3T81A">5.27</ix:nonNumeric> - <ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_gc3icTBxzk6z-01YFoMDcQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_PtsxDTv_0UqoM_ocn9Fshg">6.08</ix:nonNumeric> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_jA3zrw10lUyty-qrneby5g" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_QVewDEdg2ky23m8nQgKQNg">5.00</ix:nonNumeric> - <ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_K2QYwOvGJUmiUg9ZTS1GqA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_aWEUsHLO60Wl6NVREyvuDQ">6.08</ix:nonNumeric> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2018_To_12_31_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ZbXixFzUcUGHwVYHkj-L5Q" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_n4_dsuNxs0G-cyR7XTcuQA">5.49</ix:nonNumeric> - <ix:nonNumeric contextRef="Duration_1_1_2018_To_12_31_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_5o84alY-YEe58-Qyx7km0A" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_wgG3FN90kUS06ZeMWGZMIQ">6.08</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:57.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_y_lWVCdXEkurpTEfNZLamw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_LmHQko_ahEyyeOJUeaVWWA">72.1</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_y_lWVCdXEkurpTEfNZLamw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_qbZtj5ZfzEO5C78lRltVFg">87.5</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_JMFKex3X3ESe5V_o92xQHA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_bBsNItto2UKecWOLSoR0ew">61.0</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_JMFKex3X3ESe5V_o92xQHA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_qbwrew8a5UKmCg9lK3R9bQ">64.8</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_H_jddmjI8U639x1Gtx8lig" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_D8ebKhZwe0GE6oINUhxSNA">62.0</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_H_jddmjI8U639x1Gtx8lig" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_g88WOrn-e0Gl50aRj5yLVw">66.5</ix:nonFraction>%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_y_lWVCdXEkurpTEfNZLamw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_z7pTHD3Yzki55Ekua0IfUQ">0.23</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_y_lWVCdXEkurpTEfNZLamw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_kuwfXFKYUkSfWdPT4-k2Yw">1.44</ix:nonFraction>%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_JMFKex3X3ESe5V_o92xQHA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_6HOofL94T0CLDSrtmDCQnQ">1.42</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_JMFKex3X3ESe5V_o92xQHA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_tG-9FUUcY0qvCkbSTwqFYQ">2.58</ix:nonFraction>%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_H_jddmjI8U639x1Gtx8lig" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_YbAyH_h3REmKNQ8BOONXRQ">2.42</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_H_jddmjI8U639x1Gtx8lig" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_nc1mSGYNbUiWxTkmei11FA">3.03</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:bottom;width:57.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">In determining the fair value of the options granted, the Company uses the Black-Scholes option-pricing model and assumptions discussed below. Each of these inputs is subjective, and expected volatility generally requires significant judgment to determine.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">103</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:80.09%;border:0;margin:30pt 9.56% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:9.56%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_l95fKzOp10GITPiIZo-IVw_1_4"></a><a id="Tc_xqD3rXz090yEiQeRLgvL_g_2_4"></a><a id="Tc_PVvayPfYpUKGmcM-ySc01Q_3_2"></a><a id="Tc_LDwphBITjEOOOLgN5Om_1A_3_4"></a><a id="Tc_9NYbIbCdTE6snEwUHvEFVA_4_2"></a><a id="Tc_yQ0A6GZHik2XbTklL-cTYw_4_4"></a><a id="Tc_cHVc0oGWJUCBAjtymKLPaA_6_0"></a><a id="Tc_7sBL4eUBKUCDDd1aFnI01A_6_4"></a><a id="Tc_mFps1zgaZ0unaV4MjHyTmQ_7_0"></a><a id="Tc_gYx7fy_S_UO9pK29mc1bdg_8_0"></a><a id="Tc_i5k4C1OGxkm3Eg2onH408Q_9_0"></a><a id="Tc_S-H_7kmB40uS2shm4mkZnA_10_0"></a><a id="Tc_hE8O616gXUG3XMsJ0Pwq-w_10_4"></a><ix:continuation id="Tb_t4-TByv8VE-QN7Pj0avJ1g_cont2" continuedAt="Tb_t4-TByv8VE-QN7Pj0avJ1g_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Term</i>&#8212;The Company&#8217;s expected term represents the period that the Company&#8217;s options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term). The Company has limited historical exercise information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Volatility</i>&#8212; Prior to January 1, 2020, the Company&#8217;s expected volatility was estimated based on the average volatility for comparable publicly traded biopharmaceutical companies over a period equal to the expected term of the awards. Beginning January 1, 2020, the Company&#8217;s expected volatility is based upon a blend of <ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="2" format="ixt:numdotdecimal" name="ptgx:ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants" scale="-2" id="Narr_-NPx-TwYHUCl2stDE4pZ9Q">75</ix:nonFraction>% of the average volatility for comparable publicly traded biopharmaceutical companies and <ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="2" format="ixt:numdotdecimal" name="ptgx:ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo" scale="-2" id="Narr_76DFUF7QnU-VJP2J3Qgyow">25</ix:nonFraction>% of the volatility of the Company&#8217;s stock price since its initial public offering in August 2016. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Risk-Free Interest Rate</i>&#8212;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Dividend</i>&#8212;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Restricted Stock Units</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27.8pt;margin:4pt 0pt 0pt 0pt;">The Company began issuing restricted stock units under the 2016 Plan during the year ended December 31, 2018. A restricted stock unit is an agreement to issue shares of the Company&#8217;s common stock at the time of vesting. Restricted stock unit annual refresher awards vest in <ix:nonFraction unitRef="Unit_Standard_installment_pPbBqyhnckSax7ouQFoPyQ" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="INF" format="ixt-sec:numwordsen" name="ptgx:NumberOfEqualInstallmentsRequiredForVestingOfRestrictedStockUnits" scale="0" id="Narr_jt9yHbPFrUG0AYJjerTlhw">four</ix:nonFraction> equal installments on approximately the first, second, third and fourth anniversaries of the grant date. Restricted stock unit incentive awards granted during 2018 vested in <ix:nonFraction unitRef="Unit_Standard_installment_pPbBqyhnckSax7ouQFoPyQ" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_PlanNameAxis_ptgx_InducementStockPlanMember_1aFOsX_HY0KODJxVov4uuA" decimals="INF" format="ixt-sec:numwordsen" name="ptgx:NumberOfEqualInstallmentsRequiredForVestingOfRestrictedStockUnits" scale="0" id="Narr_Jx-nOK6bcUa47k31aB7yuw">three</ix:nonFraction> equal installments at six months intervals over a period of <ix:nonNumeric contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_PlanNameAxis_ptgx_InducementStockPlanMember_1aFOsX_HY0KODJxVov4uuA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_KAwwYUyZwkOIAts6JTFyUQ">18 months</ix:nonNumeric>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:28.1pt;margin:9pt 0pt 0pt 0pt;">Restricted stock unit activity under the Company&#8217;s equity incentive plans is set forth below:</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_eremZ34RS0u0oYjA1BqUtA" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="Tb_0wJot7m770GMD2F2LkTcXg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted </b></p></td></tr><tr><td style="vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Unvested at December&#160;31,&#160;2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="As_Of_12_31_2019_us-gaap_PlanNameAxis_ptgx_InducementStockPlanMember_uV2sRVuEEkSt7OepkbYJpA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_2QMRcYz2QkCv6buIqa5hkg_6_2">278,482</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q" contextRef="As_Of_12_31_2019_us-gaap_PlanNameAxis_ptgx_InducementStockPlanMember_uV2sRVuEEkSt7OepkbYJpA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_WgU04RXzpkC2ZW-dXFefMA_6_5">10.08</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_ptgx_InducementStockPlanMember_yAEykxLHsUSSNG0CUEUjkA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_xUp3gcLE8UamFiE63_RoXw_7_2">142,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_ptgx_InducementStockPlanMember_yAEykxLHsUSSNG0CUEUjkA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_7apuYa5ZMUG5cIyx72Dm2w_7_5">7.80</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_ptgx_InducementStockPlanMember_yAEykxLHsUSSNG0CUEUjkA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Tc_geEVAGDyYkman6-bV65E7Q_8_2">131,147</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_ptgx_InducementStockPlanMember_yAEykxLHsUSSNG0CUEUjkA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc__vdVelPjrEGA42YpfdQwFA_8_5">9.52</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_ptgx_InducementStockPlanMember_yAEykxLHsUSSNG0CUEUjkA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="Tc_VJISjr3Xkkm6-QNGZJeYjw_9_2">44,790</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_ptgx_InducementStockPlanMember_yAEykxLHsUSSNG0CUEUjkA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="Tc_1Whr0C43ZkOi11LcxkMMIw_9_5">8.67</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Unvested at December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_ptgx_InducementStockPlanMember_KE5aREx68U2i_cgMV6Pj_A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_FZe23UaPzkuD9p04uXEHPw_10_2">244,545</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q" contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_ptgx_InducementStockPlanMember_KE5aREx68U2i_cgMV6Pj_A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_08bI1niOWUy5z-HQeC5Gnw_10_5">9.31</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Stock-based compensation expense associated with restricted stock units is based on the fair value of the Company&#8217;s common stock on the grant date, which equals the closing market price of the Company&#8217;s common stock on the grant date. For restricted stock units, the Company recognizes compensation expense over the vesting period of the awards that are ultimately expected to vest. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Employee Stock Purchase Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">In July&#160;2016, the Company&#8217;s board of directors and stockholders approved the 2016 Employee Stock Purchase Plan (&#8220;2016 ESPP&#8221;). The 2016 ESPP is intended to qualify as an employee stock purchase plan under Section&#160;423 of the Internal Revenue Code of 1986, as amended, and is administered by the Company&#8217;s board of directors and the Compensation Committee of the board of directors. Under the 2016 ESPP, <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="As_Of_7_31_2016_us-gaap_PlanNameAxis_ptgx_EmployeeStockPurchasePlan2016Member_nIsT07dVFEyHghpDxZtPUg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_hEM8NEuNmECi2IIheA3fDA">150,000</ix:nonFraction> shares of the Company&#8217;s common stock were initially reserved for employee purchases of the Company&#8217;s common stock. Pursuant to the &#8220;evergreen&#8221; provision contained in the 2016 ESPP, the number of shares reserved for issuance automatically increases on January 1 of each year, starting on January 1, 2017 and continuing through (and including) January 1, 2026 by the lesser of (i)&#160;<ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_ptgx_EmployeeStockPurchasePlan2016Member_4XSs44uQyEamm2z9D2PFFQ" decimals="2" format="ixt:numdotdecimal" name="ptgx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum" scale="-2" id="Narr_o7jwgLSTZEic1HTgswZwQg">1</ix:nonFraction>% of the total number of shares of common stock outstanding on December&#160;31 of the preceding fiscal&#160;year (ii) <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_ptgx_EmployeeStockPurchasePlan2016Member_4XSs44uQyEamm2z9D2PFFQ" decimals="INF" format="ixt:numdotdecimal" name="ptgx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualNumberOfAdditionalSharesAuthorized" scale="0" id="Narr_z_JVwdXPpkufx2ji48rzAw">300,000</ix:nonFraction> shares, or (iii)&#160;such other number of shares determined by the board of directors. The 2016 ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to <ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_ptgx_EmployeeStockPurchasePlan2016Member_U56QTHCCKEa3NKcZoAUUQw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="Narr_ux4VRD4Mc02QDKJe4rWFkA">15</ix:nonFraction>% of their eligible </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">104</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:80.09%;border:0;margin:30pt 9.56% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:9.56%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_22wfRMf8u0O60QgbCeD4WA_1_2"></a><a id="Tc_2Gniawy8WkautprAz4XueA_2_2"></a><a id="Tc_QR7-7dRCr0WOk9aYglm-Dg_2_4"></a><a id="Tc_8Myu6wmyJ0Ke8sXxwHEwHg_2_6"></a><a id="Tc_oMUHGC1ZCkCfzAGtGkQUow_3_0"></a><a id="Tc_b2c2Py5Lw0q69rg8ECggEw_4_0"></a><a id="Tc_JFVMo-SysEm4tXoPCxxomQ_4_2"></a><a id="Tc_IOqD34rhnUaNLBX5bb806g_4_4"></a><a id="Tc_eE_PG56K806Z9T09_NvbXg_4_6"></a><a id="Tc_2TeCAbzrKUmlrnV3y2ZTwg_5_0"></a><a id="Tc_hv_C1fcsbUSTLwz9SvfNOw_5_2"></a><a id="Tc_RnBgbVD5-kuruu8VLrhKqQ_5_4"></a><a id="Tc_cRNC0nKufEmT9SOSkhtaqA_5_6"></a><a id="Tc_lyrSYP3jpECHaiTj1ROTtA_6_0"></a><a id="Tc_ocuAR-XbpkCE1ZeLFzq01Q_6_2"></a><a id="Tc_hDE_zyDDJUexMueyfefcqg_6_4"></a><a id="Tc_6RPKZ25PhkeEolR_uisIOw_6_6"></a><a id="_743d12d8_d213_4811_9d76_a049b11d8958"></a><a id="Tc_JdrpBaNk90Ghyh62h2JTCA_1_2"></a><a id="Tc_sW0IHoUmUEmS4mpPrMUtmg_2_2"></a><a id="Tc_mj_Nthz45E-LNQv261fJ1A_2_5"></a><a id="Tc_Jnl_YNj2_EWBsc_LjmIrrQ_2_8"></a><a id="Tc_uJj-Q20YE0CA_6QLsJZliQ_3_0"></a><a id="Tc_-ep8sE2IMUWtmguw7FDOig_3_2"></a><a id="Tc_Ca3_K702KE68l1jpSet3Lw_3_5"></a><a id="Tc_qE0TCgPukkGdt7ZNhyW2Sg_3_8"></a><a id="Tc_aYNfYxXXFUCFx06nvpxpcQ_4_0"></a><a id="Tc_Gvm2Pn4cHka2y-HW7XdOCQ_5_0"></a><a id="Tc_bIkXLG4Jq02tvqQwKyMdbQ_5_2"></a><a id="Tc__2RET9iZ7E2IrhOLUnGsZg_5_5"></a><a id="Tc_eoWSqQpB7kiUCQhOOvgtUQ_5_8"></a><ix:continuation id="Tb_t4-TByv8VE-QN7Pj0avJ1g_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">compensation. At the end of each offering period, eligible employees are able to purchase shares at <ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_ptgx_EmployeeStockPurchasePlan2016Member_4XSs44uQyEamm2z9D2PFFQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="Narr_rIxykZnVdkKHttV9yBsUag">85</ix:nonFraction>% of the lower of the fair market value of the Company&#8217;s common stock at the beginning of the offering period or at the end of each applicable purchase period. During the year ended December 31, 2020, <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_PlanNameAxis_ptgx_EmployeeStockPurchasePlan2016Member_GMhjmWwDW0OtNx4nu-iZpQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="Narr_BGb1jC4BSUS4m1Qtqj8Kgw">92,523</ix:nonFraction> shares were issued under the ESPP. As of December 31, 2020, <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="As_Of_12_31_2019_us-gaap_PlanNameAxis_ptgx_EmployeeStockPurchasePlan2016Member_C-KW8xTQ90aKeamFtuPrNQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr__4gjURJItUWeiTXP2uDc1A">757,647</ix:nonFraction> shares are available for issuance.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The fair value of the rights granted under the 2016 ESPP was calculated using the Black-Scholes option-pricing model with the following assumptions:</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_62ZwKcYzp0eJm6qW-U5FhA" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_4wfQ09l-AU6QMXCw6U0Owg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.4488411%;padding-left:0pt;padding-right:0pt;width:100.89%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:41.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr style="height:8.15pt;"><td style="vertical-align:bottom;width:57.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (in years)</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.35pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_62ZwKcYzp0eJm6qW-U5FhA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_ovNSAFRBuE6RbAV57e-jLQ_3_2">0.50</ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_pgiKOe1_8Ey6gxPzOimNvw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_NxKXaDb9aUemxvtX94O2_A_3_4"> 0.50</ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_-b9HV2D17EWHTYX42MHUeg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_SwVUhEuR9kepYA9Kuyxw1g_3_6"> 0.50</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:57.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_62ZwKcYzp0eJm6qW-U5FhA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_NrX036nimkizhQvYHCC_SQ">89.1</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_62ZwKcYzp0eJm6qW-U5FhA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr__d6jdEmIxkySsfqkI-62jw">120.4</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_pgiKOe1_8Ey6gxPzOimNvw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_LoOc6AcbrEOGZkYVdU41mQ">58.9</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_pgiKOe1_8Ey6gxPzOimNvw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_DZWHeMm5d0evTPWw3neNnQ">65.3</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_-b9HV2D17EWHTYX42MHUeg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_J6bL926TNkul7sj_weHIYg">49.0</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_-b9HV2D17EWHTYX42MHUeg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_VLBqOHlsdkW18vhk1Kqnnw">63.4</ix:nonFraction>%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate </p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_62ZwKcYzp0eJm6qW-U5FhA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_powMWO0-5kWu53hNzdGZIA">0.12</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_62ZwKcYzp0eJm6qW-U5FhA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_5QphBkV-3kuYaKn_zhRbBw">0.43</ix:nonFraction>%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_pgiKOe1_8Ey6gxPzOimNvw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_5Uhz3MBNK0W29isDHbHqjg">1.89</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_pgiKOe1_8Ey6gxPzOimNvw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_gbpw-9bHdUaoBtGJPjLaDA">2.32</ix:nonFraction>%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_-b9HV2D17EWHTYX42MHUeg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_eMKiUUykqkKj7kp9B3CIBg">1.89</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_-b9HV2D17EWHTYX42MHUeg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_7yXvSWrEI02FrgiNiZ2lNg">2.32</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:bottom;width:57.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend yield </p></td><td style="vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_d3AAhbsHBk2jpQdAYq3dZQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Total stock-based compensation expense was as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:38.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_xH_J2AHGC0KEIm_y_jQVKg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_7VOmFWMF1EyEHUA2TY63fw_3_3">4,121</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_S8RyftvJ9k2sDQkwn9INpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_x-2lqupB4UGLYg4hqGwmgg_3_6">4,350</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_5KLlildJr02InYyNq32knQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_gZkDV7RC60uCEr2oWofp_w_3_9">3,424</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_4LOUmK3YM0qXjTWQBtwesw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_tezJ8IxFvkG1TTGbaDGY4w_4_3">3,778</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_hCAO4XqfOUC_Xr8C0zgyIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_93RmFqsG1U-mN-1SmHCNIw_4_6">4,003</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_5l8l7REXdEuTVwF8ShcykQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_DJ2dWzg8tE-bBbkZ92j50Q_4_9">3,495</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total stock-based compensation expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_4JNgPxO590yk_2OJc7YKng_5_3">7,899</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_UPRy20fYsEClsMCh9Rlj0A_5_6">8,353</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_58sfIx-_aUaSt8LirxNTtw_5_9">6,919</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2020, total unrecognized stock-based compensation expense was $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="Narr_wajD7_kt6EO4ij1yQOxXzQ">16.0</ix:nonFraction> million, which the Company expects to recognize over a period of approximately <ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_po6WNcXlhkqvneMyHNaLpw"><span style="white-space:pre-wrap;">2.7</span></ix:nonNumeric><span style="white-space:pre-wrap;">&#160;years.</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="Tb_iGaGOE_4GUSI7eApWM8Zdg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 14.&#160;&#160;&#160;&#160;401(k)&#160;Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Company has a retirement and savings plan under Section&#160;of 401(k)&#160;of Internal Revenue Code (the &#8220;401(k)&#160;Plan&#8221;) covering all U.S. employees. The 401(k)&#160;Plan allows employees to make pre- and post-tax contributions up to the maximum allowable amount set by the Internal Revenue Service. For the years ended December 31, 2020, 2019 and 2018, the Company did not make matching contributions to the 401(k)&#160;Plan on behalf of participants.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_CDfMhl9Ly0qZiAaYDrXM3w" continuedAt="Tb_CDfMhl9Ly0qZiAaYDrXM3w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 15.&#160;&#160;&#160;&#160;Income Taxes </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Company recorded income tax expense of $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="Narr_47NRyzi2ykG71fZaQi2CEw">1.3</ix:nonFraction> million for the year ended December 31, 2020. During the second quarter of 2020, the Company&#8217;s Australia subsidiary sold beneficial rights to discovery intellectual property to its U.S. entity, and the U.S. entity reimbursed the Australia subsidiary for certain direct development costs. Upon completion of the sale, the Company analyzed tax planning strategies and future income and concluded that a full valuation allowance is necessary for its Australia subsidiary. Income tax expense for the year ended December 31, 2020 reflects this sale of intellectual property rights, cost reimbursements and related adjustments to the deferred tax asset, establishing a valuation allowance and certain uncertain unrecognized tax benefits. The Company continues to maintain a full valuation allowance against its U.S. net deferred tax assets due to the uncertainty surrounding the realization of such assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Company recorded an income tax benefit of $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="6" id="Narr_JefCnDJASkCA7azqVUTL1g">0.7</ix:nonFraction> million for the year ended December 31, 2019 primarily due to research and development tax credits and the recognition of deferred tax assets in Protagonist Australia. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Company recorded an income tax benefit of $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="6" id="Narr_GXi4eEKlnkCfCuMKauz7aw">0.8</ix:nonFraction> million for the year ended December 31, 2018 from the recognition of deferred tax assets in Protagonist Australia. </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">105</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:80.09%;border:0;margin:30pt 9.56% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:9.56%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_443143f3_34ae_47ed_847a_bc8ed4a956fa"></a><a id="Tc_VUSBFgunaU-ze_NYsO5v-g_1_2"></a><a id="Tc_3SzbXu3o7ky15TDHQA-3Wg_2_2"></a><a id="Tc_2y-jOcxL2Eaz0YRkxyztwg_2_5"></a><a id="Tc_7U7uzzqFCE6KazeP4xEnLA_2_8"></a><a id="Tc_ypL_NZkyEUy-DEEtF_6ZAA_3_0"></a><a id="Tc_B63nRv_K40GrtT0rWYw56g_3_2"></a><a id="Tc_mtkaak6taEGPOclQFT5hPw_3_5"></a><a id="Tc_HoowAjP2BU63tYXKe__y1Q_3_8"></a><a id="Tc_Rffd38nQtUSwTX_L20RU-A_4_0"></a><a id="Tc_nF9lTQ01r0ibAijkPmTZ4g_5_0"></a><a id="Tc_HgLkKa3ehkGS6M1tA5IU3w_5_2"></a><a id="Tc_vtr4ybkTxE2BGowFJSGR1g_5_5"></a><a id="Tc_E3VcsRPO_U6pOChcW_xaKw_5_8"></a><a id="Tc_gbQOL9bCY0--pyUxEJ4DUA_1_2"></a><a id="Tc_H_SLnplPrEir-NtnboCNRg_2_2"></a><a id="Tc_cseAaStfMUObvZQs3R99zw_2_5"></a><a id="Tc_kv9dWQJSYkKL4SslGjP16g_2_8"></a><a id="Tc_vgZsVDti10WSqnxoM444Nw_3_0"></a><a id="Tc_FCp55pImkEyUXS6FUHpXTA_4_0"></a><a id="Tc_iy__JrMCCUO-JDo2cEKEAQ_4_2"></a><a id="Tc_K6-Ng5zJCkaRNGALQ2QdkQ_4_3"></a><a id="Tc_NlChb4zAPEyooxA_8t_iUQ_4_5"></a><a id="Tc_ljx8Cy5xxkSDv4D_DSDQCQ_4_6"></a><a id="Tc_R02o7Q65QEiTPNRz6odPfg_4_8"></a><a id="Tc_L74q3G7jYkaz4icFIGceXA_4_9"></a><a id="Tc_5JbvIQQ1M0WyM8GfA3n2-w_5_0"></a><a id="Tc_BZzrE6WnDkSNKNHFpUYt3Q_5_3"></a><a id="Tc_mL4maTQeuEmVbqPFw_AlGA_5_6"></a><a id="Tc_Pm6iora4IE6f34I6JCeCJg_5_9"></a><a id="Tc_h-q6F3RtxEm7FHQX1HbQ6g_6_0"></a><a id="Tc_8LiQcN0cKk-70iOfvrlIzA_6_9"></a><a id="Tc_F-r2iQ_RBkWIzNUGXF-1vA_7_0"></a><a id="Tc_oK_Q0i8ikkWttyAgyZb9Nw_7_9"></a><a id="Tc_vORE5Jn5V0acR4WfCZIGOg_8_0"></a><a id="Tc_yfRR1w3djk67goOB1RgiEw_9_0"></a><a id="Tc_54xVOUVatEWkPidXzWirSA_9_3"></a><a id="Tc_ISttkGcTBkaJFiXPuPoTRw_9_6"></a><a id="Tc_lrk1F5Zzx0aHMBxB2FW1KA_9_9"></a><a id="Tc_RJMgCbti80WZuN65L_UHNA_10_0"></a><a id="Tc_HyJQbg_cM0iLQK9ZfYDgbA_10_3"></a><a id="Tc_ufNYNvye-kqHNCwZu2pZBQ_10_6"></a><a id="Tc_vAgYcrt7EUqNAATJIuVNbQ_10_9"></a><a id="Tc_P1wJ7CVtXkOb1-uw659GHw_11_0"></a><a id="Tc_MaZ-uZWXfUqN06iD699hSw_12_0"></a><a id="Tc_-JmspF27b02Lc59hUn6Mew_13_0"></a><a id="Tc_8bWRXRPbokS7Gb8LmaovyQ_13_2"></a><a id="Tc_VSVSLeCWBEG_-QeoToHZ9A_13_5"></a><a id="Tc_U_0nbO5sL0-qE6CxT7JW8g_13_8"></a><a id="Tc_wZAujQ7NsECY5NbnOZfN_Q_1_2"></a><a id="Tc_3QyqMKZoE0WM27Ww9Ary-w_2_2"></a><a id="Tc_Oi7OsOevykGc_iZuZEHRTw_2_4"></a><a id="Tc_7_veLoNDHUeRkFDF6Gqn8w_2_6"></a><a id="Tc_pLRUo6kjUUiQl8RXcLz92g_3_0"></a><a id="Tc_RScU7wOgA0a9rjjAjrjC_w_3_3"></a><a id="Tc_-CtXIndQb0edPaFb6xivZg_3_5"></a><a id="Tc_CEnfntUZY0i5pQB-8J8XUw_3_7"></a><a id="Tc_AYwtsHhKykqMuBvRzNfEVA_4_0"></a><a id="Tc_mnBseuqNq0eUe_YobHpfYw_5_0"></a><a id="Tc_jjwkGwtw702g4cLd0uhjMQ_6_0"></a><a id="Tc_URaEVDjQeEeymPhmBVeLtw_7_0"></a><a id="Tc_pWPhe8-JpEme7ztPk5wclw_8_0"></a><a id="Tc_5c1pHoaBYEGh-lityVzBlA_9_0"></a><a id="Tc_kJ_XFLctl062vSjWiOQodg_9_3"></a><a id="Tc_m-VNxq1VhE671CR1JqaYYA_9_5"></a><a id="Tc_89is5zEOQU6L-WmsqiE24g_9_7"></a><a id="_93883dbb_55f8_4850_9dd3_def714ea31d1"></a><a id="Tc_rk9K71DyJE-Sf0jRUnH1Cg_1_2"></a><a id="Tc_6bvlBrlfZESo8ULh6rXpPA_2_2"></a><a id="Tc_lIDh8CPSTUOxyJSLi5VEPw_2_5"></a><a id="Tc_r-bndZbxsUq96ION1V1pcw_3_0"></a><a id="Tc_X2XimYo_O06_1HceXukFmg_4_0"></a><a id="Tc_TsbrNFCncUmu6R7R5mJmfw_4_2"></a><a id="Tc_uZQkneyE70C__Um0FsAVuQ_4_5"></a><a id="Tc_Mzoa91IP8USHF-hlRWLsEw_5_0"></a><a id="Tc_9tDzWG4rgkWVuKTBk0GqYw_6_0"></a><a id="Tc_ohjC4ZBpwEC-e06XCShnAQ_7_0"></a><a id="Tc_V9bgrLpY1US0EBjBYEmINg_8_0"></a><a id="Tc_9gpiMcEVHkKLTcjoHov9Kw_9_0"></a><a id="Tc_DkOl-pfvGkCX1gHILDjoXA_10_0"></a><a id="Tc_nCc5Cid9cE-Qj69icBQXPQ_11_0"></a><a id="Tc_otORkciuvE2x6RBUPatD4w_12_0"></a><a id="Tc_l8YCgDcFmEqxpiY8qRUAeA_13_0"></a><a id="Tc_IrfNNW5fj0WZ9QxMzJC_EA_14_0"></a><a id="Tc_Np3_OmxGGEi7XiU4TySoZg_14_2"></a><a id="Tc_K1bOJWa4kk2_MwvAGHTnEg_14_3"></a><a id="Tc_7-KSjUr1DUqUE0nY_Xlkcw_14_5"></a><ix:continuation id="Tb_CDfMhl9Ly0qZiAaYDrXM3w_cont1" continuedAt="Tb_CDfMhl9Ly0qZiAaYDrXM3w_cont2"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="Tb_-CLo7DPv40Slme6MyLPwlA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The following table presents domestic and foreign components of net loss before income taxes (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:54.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Domestic</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" sign="-" scale="3" id="Tc_q3XVghNxFEaTenS_t-dEFA_3_3">71,073</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" sign="-" scale="3" id="Tc_d3nVNCHexEmjhXom_XGTng_3_6">72,271</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" sign="-" scale="3" id="Tc_Syev0k7SGk6gbRRKmq7g6w_3_9">37,511</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:43.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="Tc_OkHM-uIa70K9M-bNbWg7zw_4_3">6,228</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" sign="-" scale="3" id="Tc_U_CU8_07XUmdmUqulJSFNA_4_6">5,607</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" sign="-" scale="3" id="Tc__b21wqnxskO6pTL5CjFXVQ_4_9">2,212</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Total net loss before taxes</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_rI0vwCLYhkGchD8WpaNdZQ_5_3">64,845</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_gKP-CQJCNUmhWeZqJpTd2Q_5_6">77,878</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc__8FAFAtqZkeMsXvk543vWg_5_9">39,723</ix:nonFraction>)</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The federal, state and foreign components of the income tax expense (benefit) are summarized as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="Tb_yFY-iMB4G06iN0bVv3LEyA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:38.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current:</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Federal</span></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">State </p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Foreign</p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentForeignTaxExpenseBenefit" sign="-" scale="3" id="Tc_KL35RjJlXUmmxERSpgm2dg_6_3">88</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="Tc_4nV4mZUAi0W8KIYSGnwDow_6_6">84</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total current tax (benefit) expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_RbsYUccwj02iMwr64nNOYQ_7_3">88</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="Tc_SlEeJLeO7Ea-UhmGb7d1hg_7_6">84</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred:</p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Federal</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   State</span></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Foreign</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="Tc_YJZderFT70qYi98SMdJC7g_11_3">1,393</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_jpMRAIw7QEC1X3mAXIWMfQ_11_6">775</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_72zWICAtW0e5HjEHnkxATQ_11_9">799</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax expense (benefit)</p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="Tc_qzwdsAsOdkOLBi5DQ1To0g_12_3">1,393</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_FJsHqAFjfEK7XpjyTOlkgA_12_6">775</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_-QpA3rNnWkWyR15WecjlAw_12_9">799</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total income tax expense (benefit)</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_hB---8PHn0mcff3e872-xg_13_3">1,305</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_CfF5mrjGHEyT9hBlsRX-4w_13_6">691</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_c2w0D8jo6EuEEgKRTEvapQ_13_9">799</ix:nonFraction>)</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The effective tax rate of the provision for income taxes differs from the federal statutory rate as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_jBWG7vHRnUqB7rFjRoJjMw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal statutory income tax rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_3Sqa9RRX-kqU4t7rLgi1qw_3_2">21.0</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_pCCsQ8gU7kSxViBtpr_FDA_3_4">21.0</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_Sz-69TXb0kqZHE-4CHDKpg_3_6">21.0</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:60.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_vpXb2_yIrUWI46QQcfmAjw_4_2">1.9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_ivZhBAtdMkiLPOzq30Rjvg_4_4">1.2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_Ht5MnX_530aaCF1vBsbKCQ_4_6">7.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development credits</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="3" format="ixt:numdotdecimal" name="ptgx:EffectiveIncomeTaxRateReconciliationTaxCreditResearchAdjustmentPercent" scale="-2" id="Tc_eoH_mSgkYkSuFadGBbbTTQ_5_2">6.5</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="3" format="ixt:numdotdecimal" name="ptgx:EffectiveIncomeTaxRateReconciliationTaxCreditResearchAdjustmentPercent" scale="-2" id="Tc_EfhxICXnYkeAPclaD3dJzw_5_4">4.3</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="3" format="ixt:numdotdecimal" name="ptgx:EffectiveIncomeTaxRateReconciliationTaxCreditResearchAdjustmentPercent" sign="-" scale="-2" id="Tc_ix8x-Eka8EyqDpxTYaqIkQ_5_6">1.3</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign tax rate difference</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" sign="-" scale="-2" id="Tc_L73IzP8wBU20ICieElA1Qw_6_2">0.9</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="Tc_5MbPQOB7z0iREaxY1XLAoQ_6_4">0.7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="Tc_v-8mR2x0mEaK_fNVnyW3JA_6_6">0.4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_8M7rHnevP0uaKwWKRWkJXw_7_2">34.3</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_0G_CRRe3_Uu1w15lUaWPag_7_4">23.8</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_A55B2hlSXUSdS1peJm1uVA_7_6">22.2</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:60.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="Tc_SRj39eprEkWjG3fLxi_kQQ_8_2">3.8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" sign="-" scale="-2" id="Tc_HE5Ewrx3Q0qJl780F542hQ_8_4">2.5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" sign="-" scale="-2" id="Tc_KOQZpVulL0CB8y61IpK7mA_8_6">2.9</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Provision (benefit) for income taxes</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" sign="-" scale="-2" id="Tc_T86GK1SJYUK8p1ra2Go0Hg_9_2">2.0</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Tc_FEz0WQJ0bUSn_8qFj7Y0bQ_9_4">0.9</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Tc_Kqwl_hqe2EmpY7N48xu7NA_9_6">2.0</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_52vPCAU780SDhz-MGgj-hA" continuedAt="Tb_52vPCAU780SDhz-MGgj-hA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The components of the deferred tax assets are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_X7Of-0KuWk-e3Dp1iPA1Eg_4_3">50,272</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_BO5pLOTyKEuzceXzwxTMLg_4_6">39,907</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Depreciation and amortization</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" id="Tc_pN_XlT981Uy07_yqB74IPg_5_3">1,237</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" id="Tc_Oglam1V0tUOKCXF3QhHp0w_5_6">318</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accruals/other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="ptgx:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther" scale="3" id="Tc_IkfzGzpIdkyrQFQ09ci2Cw_6_3">5,332</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="ptgx:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther" scale="3" id="Tc_ciOUZsGQoUCjMPUQj6mAQg_6_6">5,454</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating lease liability</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="ptgx:DeferredTaxAssetsOperatingLeaseLiability" scale="3" id="Tc_NNijLz9r8UqYC1JP1T4BvQ_7_3">1,252</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="ptgx:DeferredTaxAssetsOperatingLeaseLiability" scale="3" id="Tc_xQXDGl-I6Um9cpY2cnv7RQ_7_6">1,516</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development and foreign credits&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="3" id="Tc_P1sRkEqT9kis3xfrmp9NSQ_8_3">14,856</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="3" id="Tc_r9uFWf02SUa10GlAgF40Ag_8_6">8,038</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total deferred tax assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_0gRtn0wZyE6nbZDkQF5dQg_9_3">72,949</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_s1dKpx3jrESQgcZYe6px1Q_9_6">55,233</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating right-of-use asset</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" id="Tc_QoRmHw-zLUGEVEZOmFGmgg_11_3">1,040</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" id="Tc_8WfSWde3QEyaa5K61vniFQ_11_6">1,269</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="Tc_saAJtVYz9EO_pJOpKEZVog_12_3">1,040</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="Tc_e15U8EuMwE6H8xTEq8RgxA_12_6">1,269</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valuation allowance</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_rXhAZQOmJkCpN-bgZ50zbw_13_3">71,909</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_Smh1ILbxx0K3x-jvDjY6cA_13_6">52,531</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:68.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc_nb08MUP7q0Coqykh_j9KlA_14_6">1,433</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">106</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:80.09%;border:0;margin:30pt 9.56% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:9.56%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_4a9fcaa9_8c8b_4783_936f_f961adb835d7"></a><a id="Tc_oPl9FDe0TkOJjqDi7BEADA_1_2"></a><a id="Tc_HyCOaohCwUKxNhS7UbmMbw_2_2"></a><a id="Tc_pSsQ4i-9X0CGJUvr-rLF8g_2_5"></a><a id="Tc_nQe3QKPByka7grF3spkvfg_2_8"></a><a id="Tc_ihs0p5qm4k-jamOIqCoqiA_3_0"></a><a id="Tc_F2Ar0qHFYkm18ZJlCYJxJg_3_2"></a><a id="Tc_uv7765BGdk-LtiQQaPC5Ug_3_5"></a><a id="Tc_WZKqEup9ekOcgotSTdXxrg_3_8"></a><a id="Tc_V_qjdhYhmE6US-8zW6wczA_4_0"></a><a id="Tc_qpWu5HpZTEOWgC3lrAfYmA_5_0"></a><a id="Tc_NPlxt8ORPESH9O4At4OjXg_6_0"></a><a id="Tc_2rFg55KFp06d7PGZMbqY0A_6_2"></a><a id="Tc_E5VC7RfMS0yhTwmIIzFq8g_6_5"></a><a id="Tc_MPPuQ3tAa0Wpg55XsK6GBw_6_8"></a><ix:continuation id="Tb_CDfMhl9Ly0qZiAaYDrXM3w_cont2" continuedAt="Tb_CDfMhl9Ly0qZiAaYDrXM3w_cont3"><ix:continuation id="Tb_52vPCAU780SDhz-MGgj-hA_cont1"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Realization of the deferred tax assets is dependent upon future taxable income, if any, the amount and timing of which are uncertain. The Company has established a valuation allowance to offset U.S. deferred tax assets as of December&#160;31, 2020, 2019 and 2018 due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets. The Company has also established a valuation allowance to offset Australian deferred tax assets as of December 31, 2020. The valuation allowance increased by approximately $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="Narr_zuD535QS6k6HxdP2gPmALg">19.4</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="Narr_Ln2bQzn9p0SH9qFxyoBoyA">18.5</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="Narr_47Tn64QD5UClezy4ubIw2w">8.2</ix:nonFraction> million during the&#160;years ended December&#160;31, 2020, 2019 and 2018, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Federal and state laws impose substantial restrictions on the utilization of net operating loss and tax credit carryforwards in the event of an ownership change for tax purposes, as defined in Section&#160;382 of the Internal Revenue Code. As a result of such ownership changes, the annual limitation may result in the expiration of net operating losses and credits before utilization. The Company performed a Section 382 analysis through December 31, 2020. The Company has experienced ownership changes in the past and in the current year. The ownership changes will not result in a limitation that will materially reduce the total amount of net operation loss carryforwards and credits that can be utilized. Subsequent ownership changes may affect the limitation in future years. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">At December&#160;31, 2020, the Company had $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_1DfwcEBf-ECRIZv8PZ8Rdw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_-piJR_KaSEaXRTbsENV7mw">222.8</ix:nonFraction> million of federal net operating loss carryforwards and $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_U65aTwB6ukC7yChGSORF8Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_FQupL5ibNEa4_WjzjrRp1w">214.3</ix:nonFraction> million of state net operating loss carryforwards. $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_1DfwcEBf-ECRIZv8PZ8Rdw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="Narr_INiK0ziH8UuOu35dW4g8Ug">78.7</ix:nonFraction> million of the federal net operating loss carryforwards will begin to expire in 2033, if not utilized, and the remaining $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_1DfwcEBf-ECRIZv8PZ8Rdw" decimals="-5" format="ixt:numdotdecimal" name="ptgx:OperatingLossCarryforwardsNoExpiration" scale="6" id="Narr_GA2nb_76wEugtu7IO2FCZg">144.1</ix:nonFraction> million have no expiration. The state net operating loss carryforwards will begin to expire in 2035, if not utilized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">At December&#160;31, 2020, the Company also had accumulated Australian tax losses of AUD <ix:nonFraction unitRef="Unit_Standard_AUD_SNsUSUMs1k6MNx0ouGjszw" contextRef="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_hYnmxupXL0yNnBeGNa_apA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_zywcS6RomUmYRjWEKV0-GQ">3.7</ix:nonFraction> million ($<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_hYnmxupXL0yNnBeGNa_apA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_MNd-oWvHjUq-8s6RNgCwzg">2.8</ix:nonFraction> million) available for carry forward against future earnings which, under relevant tax laws, do not expire but may be limited under certain circumstances. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2020, the Company had $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_gRii_fhTDk-huJXJ4UdCVQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="Narr_aa4Eay2LfEGqX2goatA2QQ">12.3</ix:nonFraction> million of federal and $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_8i0o-skGv0azxibqP5J0Sw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="Narr_Tj4ZYT9ZBUS16TVG-byk7A">4.8</ix:nonFraction> million of state research and development tax credit carryforwards available to reduce future income taxes. The federal research and development tax credits will begin to expire in 2035, if not utilized. The state research and development tax credits have no expiration date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2020, the Company had AUD <ix:nonFraction unitRef="Unit_Standard_AUD_SNsUSUMs1k6MNx0ouGjszw" contextRef="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_l4fVgIKvNUamq8cgrPWShQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="Narr_7YDbeLayKUei14zLiE03iQ">3.6</ix:nonFraction> million ($<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_l4fVgIKvNUamq8cgrPWShQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="Narr_DkPo9xH2u0yFoFVavnUlog">2.8</ix:nonFraction> million) of Australian research and development tax credit carryforwards available to reduce future income taxes. The Australian research and development tax credits have no expiration date. </p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="Tb_AIlZW7EkD0OGxodxYDLEQA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:43.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Balance at beginning of year</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_2kMYLF8Lfk26vcIrcaYkVQ_3_3">16,631</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2018_rK3dysi-wkKgewxxLVB-Eg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_cUKHYPw0XU2S1tsTDUtZLQ_3_6">9,466</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2017_uBPncpspM02T8SbWW1EWfg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_6hUU1T166UyRxD5X6hqJJA_3_9">5,414</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">(Decreases) increases based on tax positions related to prior years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="Tc_hTpmwYpb3EmEYVsUpyKopQ_4_3">3,799</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="Tc_kvs63WmAWEuAQIgJwahH8w_4_6">184</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="Tc_nw8q_C_RO0emTDpBj7slvw_4_9">108</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Increases based on tax positions related to current year</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="Tc_woWLc89ZdkSOIvrCG_FWlQ_5_3">7,053</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="Tc_M1wRgHe1OUSybNqqQWvrjA_5_6">6,981</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="Tc_pu0HquGtSE69fSWb1rwV2w_5_9">3,944</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Balance at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_WrOCbvSOak-Pr7N5n4uLdA_6_3">19,885</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_i-Bnl8GnYUupKIGdIyGVyw_6_6">16,631</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2018_rK3dysi-wkKgewxxLVB-Eg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_uJvnvHtZMkaNNAcpmZPeRg_6_9">9,466</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">At December 31, 2020, the Company had unrecognized tax benefits of $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="Narr_oa5ww8Kx0kmcMok95WpO4w">19.9</ix:nonFraction> million, which are subject to a valuation allowance and would not affect the effective tax rate if recognized. The Company does not anticipate that the total amounts of unrecognized tax benefits will significantly increase or decrease in the next 12 months. The Company&#8217;s policy is to include interest and penalties related to unrecognized tax benefits within the provision for income taxes, as necessary. Management determined that <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2018_rK3dysi-wkKgewxxLVB-Eg" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="Narr_UZ1NCEIdBEa8yKyhAJ-eFQ"><ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="Narr_fZOBz2fVBUG1-3RaHOTX-g"><ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="Narr__TlpEm8QiUm9SlllkIHuXQ">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> accrual for interest or penalties was required as of December 31, 2020, 2019 and 2018.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Company files income tax returns in the United States federal jurisdiction, the State of California and Australia. The Company is not currently under examination by income tax authorities in federal, state or other jurisdictions. The Company&#8217;s tax returns remain open for examination for all years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.5pt;margin:0pt;">The Company&#8217;s Australia subsidiary had an accumulated deficit at December 31, 2020 and, accordingly, <ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_g6Lfapz3kUapxhOM2FxjaQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations" scale="6" id="Narr_py-uj-3tdke80w3tYUHNyg">no</ix:nonFraction> provision has been provided thereon for any unremitted earnings.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">107</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:80.09%;border:0;margin:30pt 9.56% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:9.56%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_CDfMhl9Ly0qZiAaYDrXM3w_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt;">The Company has elected to recognize any potential global intangible low-taxed income (&#8220;GILTI&#8221;) obligation as an expense in the period it is incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">2020 Tax Law Updates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt 0pt 12pt 0pt;">On March 27, 2020, the Coronavirus Aid, Relief and Economic Security Act (&#8220;CARES Act&#8221;) was enacted and signed into law in response to the COVID-19 pandemic. GAAP requires recognition of the tax effects of new legislation during the reporting period that includes the enactment date. The CARES Act includes changes to the tax provisions that benefits business entities and makes certain technical corrections to the 2017 Tax Cuts and Jobs Act. The tax relief measures for businesses include a <ix:nonNumeric contextRef="Duration_3_27_2020_To_3_27_2020_d48ZoY7v8UOWrUfq_VZsYw" format="ixt-sec:durwordsen" name="ptgx:NetOperatingLossCarryback" id="Narr_S4shBuUGAkOI0v6gY99PLw">five-year</ix:nonNumeric> net operating loss carryback, suspension of the annual deduction limitation of <ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_3_27_2020_To_3_27_2020_d48ZoY7v8UOWrUfq_VZsYw" decimals="2" format="ixt:numdotdecimal" name="ptgx:DeductionOfTaxableIncomePercentage" scale="-2" id="Narr_fqRNpONUuUWAR8TFxHf6nQ">80</ix:nonFraction>% of taxable income from net operating losses generated in a tax year beginning after December 31, 2017, changes in the deductibility of interest, acceleration of alternative minimum tax credit refunds, payroll tax relief, technical corrections on net operating loss carryforwards for fiscal year taxpayers and allows accelerated deduction qualified improvement property. The CARES Act also provides other non-tax benefits to assist those impacted by the pandemic.&#160;The Company evaluated the impact of the CARES Act and determined that there is no material impact to the for the year ended December 31, 2020. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt 0pt 12pt 0pt;">On June 29, 2020, California Assembly Bill 85 was signed into law. The legislation suspends the California net operating loss deductions for 2020, 2021, and 2022 for certain taxpayers and imposes a limitation of certain California tax credits for 2020, 2021, and 2022. The legislation disallows the use of California net operating loss deductions if the taxpayer recognizes business income and its adjusted gross income is greater than $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_6_29_2020_To_6_29_2020_UccmW4dFl06gNFN5lNnw9A" decimals="0" format="ixt:numdotdecimal" name="ptgx:CaliforniaNetOperatingLossDeductionsLimitOfIncome" scale="0" id="Narr_EQH_p4yjEEOjF59CyzGmdA">1,000,000</ix:nonFraction>. The carryover periods for net operating loss deductions disallowed by this provision will be extended. Additionally, any business credit will only offset a maximum of $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_6_29_2020_To_6_29_2020_UccmW4dFl06gNFN5lNnw9A" decimals="0" format="ixt:numdotdecimal" name="ptgx:MaximumOffsetOfCaliforniaTax" scale="0" id="Narr_guAkYgY-TkGvwKI_PvUEUA">5,000,000</ix:nonFraction> of California tax. Given the Company&#8217;s loss position in the current year, the new legislation will not impact the current year provision. The Company will continue to monitor possible California net operating loss and credit limitations in future periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt 0pt 12pt 0pt;">On December 27, 2020, the Consolidated Appropriations Act, 2021 was signed into law, including further COVID-19 economic relief and the extension of certain expiring tax provisions. The relief package includes a tax provision clarifying that businesses with forgiven Paycheck Protection Program loans can deduct regular business expenses that are paid for with the loan proceeds. Additional pandemic relief tax measures include an expansion of the employee retention credit, enhanced charitable contribution deductions, and a temporary full deduction for business expenses for food and beverages provided by a restaurant. The provisions are not impactful for the Company as it has not participated in previous COVID-19 economic relief measures. </p></ix:continuation><a id="_4ca12e2b_1a5e_4c14_9fa1_708c03fed997"></a><a id="Tc_TvpO8JX4uEm_u9W6oAqtPg_1_2"></a><a id="Tc_eQ4mt0KWR02gUt77Ws6QhA_2_2"></a><a id="Tc_1I00W_GOV0WuR_eJ-wp7YQ_2_5"></a><a id="Tc_6XorwIFKTEG7h9yJ3ru0AA_2_8"></a><a id="Tc_JcwpohKcOk-B1j4i8T6lgg_3_0"></a><a id="Tc_Ztu63Dp6qEq5f6xMZUqjew_4_0"></a><a id="Tc_HkH8jcPPfUuYzMd7V0YWUA_4_2"></a><a id="Tc_me8rOSqvz0uk2Ajapsd77A_4_5"></a><a id="Tc_cx8GAfVZ8UKzwte6ty6PtA_4_8"></a><a id="Tc_BpsHz9HRvkCE2H3IEjmhdw_5_0"></a><a id="Tc_0Vzehc4sZUqZkbA3vhxLHA_6_0"></a><a id="Tc_xn72TY-FpU28QOOPt-8uaw_7_0"></a><a id="Tc_H0RDH0R4BEq8y-7bazs1ug_7_2"></a><a id="Tc_oRqxEfxdLkiJbRSZgAbszg_7_5"></a><a id="Tc_j8C2agtv9k-BiH9UPIjlIQ_7_8"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="us-gaap:EarningsPerShareTextBlock" id="Tb_houPp3FujkyhMBuB-V6zfg" continuedAt="Tb_houPp3FujkyhMBuB-V6zfg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 16.&#160;&#160;&#160;&#160;Net Loss per Share </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">As the Company had a net loss for the&#160;years ended December&#160;31, 2020, 2019 and 2018, all potential common shares were determined to be anti-dilutive. The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per share data):</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Tb_No_RmR1-vUGXQmJcU1sW_Q" escape="true"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_tBhMF7TjgUm_Wl0cdn8VPA_4_3">66,150</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_n27n_SsXVk2BCVXfK6aRPg_4_6">77,187</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_2V0NDJ7yeES3YnV6rE0yPg_4_9">38,924</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted-average shares used to compute net loss per common share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_W8l6C1nfdE-oJ-3YY5kocA_6_3">34,396,446</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_DZTjezo5WUC-AfECoQ3G7w_6_6">25,894,024</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_6YxNxAOAu0i3N4blJXmfag_6_9">22,364,515</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per shares, basic and diluted</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_9st-M-t0hEqtm1yRffRYaw_7_3">1.92</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_5SG3n3-AU02VlmOrwJe-Vg_7_6">2.98</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_wRkF2cLr5kSMIVgD0WTbCg_7_9">1.74</ix:nonFraction>)</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">108</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:80.09%;border:0;margin:30pt 9.56% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:9.56%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_9BGJHsFFKkOXxMhPR2IHIg_1_2"></a><a id="Tc_8HXjXQ3lkESxezcrnyBHGA_2_2"></a><a id="Tc_3ch5DtieAUeWEFjzeN5yjw_2_4"></a><a id="Tc_WW2w_u1FjUyMu_vMwqXqyA_2_6"></a><a id="Tc_G8ncQi3c_06SiACG_AUpSQ_3_0"></a><a id="Tc_tXtCHDSxrk-ie2jkcWFYOw_4_0"></a><a id="Tc_uJzDYBpbC06t4OuFIxhY4Q_5_0"></a><a id="Tc_c06OzcdgyUOaNGDxlXxbPw_6_0"></a><a id="Tc_T6mg9BE_gE2qHXenLDvEtw_7_0"></a><ix:continuation id="Tb_houPp3FujkyhMBuB-V6zfg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The following outstanding shares of potentially dilutive securities have been excluded from diluted net loss per share calculations for the&#160;years ended December&#160;31, 2020, 2019 and 2018 because their inclusion would be anti-dilutive:</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_itDi3U8chE6Kt9q94qx1tQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options to purchase common stock</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_EAbWdmtN8E-9JmN6JhqI_w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_ozLxvF4KI0WNeGPlL8eaZg_3_2">4,648,120</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_ooH8n7lz1E2xsje_V6E6Pg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_MuH_vSZ5VkeXlTF0PHOcdQ_3_4">3,681,521</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_WaiBERwpsUS_GxNwwF2grw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_NY85_1viaUKJw9Zy-UMfpw_3_6">3,178,441</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Common stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_NoteWarrantMember_Dh7N5o3ASEqLQ1SQSZ-iVA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_vBVk3CtOm0exqWb7W0jEfg_4_2">2,750,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_NoteWarrantMember_hBQwDx7S2ku26XmUy_6zMQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_miyu2JMRxkKgRPOoo649Mg_4_4">2,750,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_NoteWarrantMember_Ho8wL7fGKESaYVujfGx0mg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_AUauPKIvt0ClTQJHaltvVQ_4_6">2,750,000</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted stock units</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_j8Vx4K3ol0uyTIToUJMT7g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_E4KF5T23WUawg0Qdrvqp6Q_5_2">244,545</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_YwszWFT2W0SpYFDZtJaxqg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_X9WbJEuzLkKDEI7FHvOrQQ_5_4">278,482</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_Ncd5mq0QL0CQQWUc-ElGVw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_KaLxYVj4XU6ULIJqksaFng_5_6">418,450</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ESPP shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember_NJHZZccCf0a0YBEfSxOf_Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_bzr4yb19L0Kb90ZAU9BPVg_6_2">28,445</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember_bPuHxQjxo0m7NoN0XMxgBA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_Z149d0ah2keFqwmqi5_qCg_6_4">40,275</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember_kEHM0bCdFEWZb0Y5aC4cvw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_O4Q_1T1Mw06NaNvMDE7FRw_6_6">52,134</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_VSHDrh7qkEG1ln4AYSzd6w_7_2">7,671,110</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_vJpBE80jUUmLfdrYK0yuAw_7_4">6,750,278</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA" contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_LbgRZN_7VEmccUBQ2fxFBw_7_6">6,399,025</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="Tb_wdmphprohkGaMcY6oXeKfQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 17.&#160;&#160;&#160;&#160;Restructuring </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">On May 7, 2020, the Company approved a limited reduction in force plan affecting approximately <ix:nonFraction unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg" contextRef="Duration_3_7_2020_To_3_7_2020_OZuW7QpORUGdPGLaaZ6w3Q" decimals="2" format="ixt:numdotdecimal" name="ptgx:PercentageOfEmployeeBaseImpactedByRestructuringPlan" scale="-2" id="Narr_GOoaV7aAe0mB-EVeJE7UgQ">12</ix:nonFraction>% of the Company&#8217;s employee base and informed the affected employees. The reduction-in-force plan was completed by the end of the second quarter of 2020. Total cash expenditures for the reduction in force plan were $<ix:nonFraction unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg" contextRef="Duration_3_7_2020_To_3_7_2020_OZuW7QpORUGdPGLaaZ6w3Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestructuringCharges" scale="6" id="Narr_DyIjtJO_UUizHG-Hww9KSg">0.3</ix:nonFraction> million, substantially all of which were related to employee severance and benefits costs.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-indent:-9pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><a id="_1c64c1a5_ffae_4a2c_9f4e_43269b73a150"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">109</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:80.09%;border:0;margin:30pt 9.56% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Item9ChangesinandDisagreementswithAccoun"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item 9.</b></span><b style="font-weight:bold;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_b4b56b29_47c0_419f_b19e_eaa6e3c92726"></a><a id="ControlsandProcedures_351029"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item&#160;9A.</b></span>Controls and Procedures </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Evaluation of disclosure controls and procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">Management, under the supervision and with the participation of our Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer), has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Exchange Act) as of December&#160;31, 2020. Based on the evaluation of our disclosure controls and procedures, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures as of December&#160;31, 2020 were effective at the reasonable assurance level. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Management&#8217;s annual report on internal control over financial reporting</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27.8pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.5pt;margin:0pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Our management, including our Chief Executive Officer and Chief Financial Officer, conducted an evaluation of the effectiveness of our internal control over financial reporting based on the criteria set forth in <i style="font-style:italic;">Internal Control-Integrated Framework</i> (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on its evaluation under the criteria set forth in <i style="font-style:italic;">Internal Control-Integrated Framework</i>, our management concluded that our internal control over financial reporting was effective as of December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.5pt;margin:0pt;">This annual report does not include an attestation report of the Company&#8217;s registered public accounting firm regarding internal control over financial reporting. Management&#8217;s report was not subject to attestation by the Company&#8217;s registered public accounting firm pursuant to rules of the Securities and Exchange Commission that permit the Company to provide only management&#8217;s report in this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Changes in internal control over financial reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">There have been no changes in our internal control over financial reporting that occurred during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p><a id="_4a651c38_fcf9_46c6_9416_3e35f2726c51"></a><a id="OtherInformation_301461"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item&#160;9B.</b></span>Other Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_6e5aca53_cd60_4a8c_84e2_fd4002725845"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">110</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk508122748"></a><a id="PARTIII_634690"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;III</p><a id="Item10DirectorsExecutiveOfficers_302483"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item&#160;10.</b></span>Directors, Executive Officers, and Corporate Governance</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Except as set forth below, the information required by this item is incorporated by reference from our definitive Proxy Statement to be filed with the SEC in connection with our 2021 Annual Meeting of Stockholders within 120&#160;days after the end of the fiscal&#160;year ended December&#160;31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We have adopted a Code of Business Conduct and Ethics that applies to all directors, officers and employees, including our principal executive officer and principal financial officer. The Code of Business Conduct and Ethics is posted on our website at www.protagonist-inc.com.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">We intend to satisfy the disclosure requirement under Item&#160;5.05 of Form&#160;8-K regarding an amendment to, or waiver from, a provision of this Code of Business Conduct and Ethics by posting such information on our website, at the address and location specified above and, to the extent required by the listing standards of The Nasdaq Global Market, by filing a Current Report on Form&#160;8-K with the SEC, disclosing such information.</p><a id="_bcc6a3e9_cf68_45b6_8dae_1f8a6182eaaf"></a><a id="Item11ExecutiveCompensation_184435"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item&#160;11.</b></span>Executive Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The information required by this item is incorporated by reference from our definitive Proxy Statement to be filed with the SEC in connection with our 2021 Annual Meeting of Stockholders within 120&#160;days after the end of the fiscal&#160;year ended December&#160;31, 2020.</p><a id="_ef0ae018_2b37_4343_8a2c_49d6483ff2d8"></a><a id="Item12SecurityOwnership_537465"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Item&#160;12.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The information required by this item is incorporated by reference from our definitive Proxy Statement to be filed with the SEC in connection with our 2021 Annual Meeting of Stockholders within 120&#160;days after the end of the fiscal&#160;year ended December&#160;31, 2020.</p><a id="_dc2afc20_4239_43ab_ac0c_05c02d98cea1"></a><a id="Item13CertainRelationships_158382"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item&#160;13.</b></span>Certain Relationships and Related Transactions, and Director Independence</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The information required by this item is incorporated by reference from our definitive Proxy Statement to be filed with the SEC in connection with our 2021 Annual Meeting of Stockholders within 120&#160;days after the end of the fiscal&#160;year ended December&#160;20, 2020.</p><a id="_8d57aaa9_54ab_4aa1_824d_c9960cb728bf"></a><a id="Item14PrincipalAccountantFees_983878"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item&#160;14.</b></span>Principal Accounting Fees and Services</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The information required by this item is incorporated by reference from our definitive Proxy Statement to be filed with the SEC in connection with our 2021 Annual Meeting of Stockholders within 120&#160;days after the end of the fiscal&#160;year ended December&#160;31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_dffb248b_4011_4c9f_b4bd_b75068c9d850"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">111</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="PARTIV_305182"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;IV</p><a id="Item15ExhibitsandFinancial_120427"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item&#160;15.</b></span>Exhibits, Financial Statement Schedules</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(a)&#160;&#160;&#160;&#160;&#160;The following documents are filed as part of this report:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:22.3pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">FINANCIAL STATEMENTS</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 40.5pt;">The financial statements filed as part of this Annual Report on Form&#160;10-K are included in Part&#160;II, Item&#160;8 of this Annual Report on Form&#160;10-K.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:22.3pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">FINANCIAL STATEMENT SCHEDULES</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 40.5pt;">Financial statement schedules have been omitted in this Annual Report on Form&#160;10-K because they are not applicable, not required under the instructions, or the information requested is set forth in the financial statements or related notes thereto.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:22.3pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">EXHIBITS</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 40.5pt;">The exhibits listed in the accompanying Exhibit&#160;Index are filed as part of, or incorporated by reference into, this Annual Report on Form&#160;10-K.</p><a id="_ba03cfaf_2ef9_4b8e_9c50_c5a9ddb3a03a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">EXHIBIT&#160;INDEX </p><a id="_623a8947_b2e2_4ccc_a616_94c113f5695a"></a><a id="_350d0f01_b1c7_4cff_8899_6c8901734327"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.84%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:34.74%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th colspan="9" style="font-weight:normal;text-align:left;vertical-align:bottom;width:49.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporation&#160;By&#160;Reference</b></p></th></tr><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.84%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:34.74%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.52%;border-top:1px solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.7%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.73%;border-top:1px solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.7%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.45%;border-top:1px solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.7%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.41%;border-top:1px solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.7%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.73%;border-top:1px solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed</b></p></th></tr><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.84%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.35%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:34.74%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.35%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.52%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.7%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.73%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SEC&#160;File&#160;No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.7%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.45%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.7%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.41%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Date</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.7%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.73%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Herewith</b></p></th></tr><tr style="height:1pt;"><td style="vertical-align:top;width:10.84%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 2pt 0pt 15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.74%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1377121/000119312516683189/d237730dex31.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Amended and Restated Certificate of Incorporation</span></a></p></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.52%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.73%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">001-37852</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">8/16/2016</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.73%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt 2pt 0pt 15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">3.2</p></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.74%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1377121/000119312516665762/d144462dex32b.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Amended and Restated Bylaws</span></a></p></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.52%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.73%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">333-212476</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">3.2</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">8/1/2016</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.73%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt 2pt 0pt 15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">4.1</p></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.74%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1377121/000119312516665762/d144462dex41.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Specimen stock certificate evidencing the shares of common stock</span></a></p></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.52%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.73%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">333-212476</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">4.1</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">8/1/2016</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.73%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt 2pt 0pt 15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">4.2</p></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.74%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1377121/000119312516665762/d144462dex42.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Third Amended and Restated Investor Rights Agreement, by and among Protagonist Therapeutics,&#160;Inc. and the stockholders named therein, dated July&#160;31, 2016.</span></a></p></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.52%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.73%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">333-212476</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">4.2</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">8/1/2016</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.73%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt 2pt 0pt 15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">4.3</p></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.74%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1377121/000104746917005511/a2233108zex-4_5.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Indenture</span></a></p></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.52%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">S-3</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.73%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">333-220314</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">4.5</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">9/1/2017</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.73%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt 2pt 0pt 15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">4.4</p></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.74%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1377121/000110465918049963/a18-18323_3ex4d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Class A Common Stock Purchase Warrant</span></a></p></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.52%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.73%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">001-37852</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">4.1</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">8/7/2018</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.73%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt 2pt 0pt 15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">4.5</p></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.74%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1377121/000110465918049963/a18-18323_3ex4d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Class B Common Stock Purchase Warrant</span></a></p></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.52%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.73%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">001-37852</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">4.2</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">8/7/2018</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.73%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt 2pt 0pt 15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">4.6</p></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.74%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1377121/000110465918075322/a18-42204_1ex4d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Warrant</span></a></p></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.52%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.73%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">001-37852</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">4.1</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">12/31/2018</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.73%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt 2pt 0pt 15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">4.7</p></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.74%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="ptgx-20201231xex4d7.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Description of Protagonist Therapeutics, Inc.&#8217;s Securities Registered Pursuant to Section 12 of the Exchange Act</span></a></p></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.52%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.73%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.73%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">X</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">112</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.84%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:34.74%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th colspan="9" style="font-weight:normal;text-align:left;vertical-align:bottom;width:49.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporation&#160;By&#160;Reference</b></p></th></tr><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.84%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:34.74%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.52%;border-top:1px solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.7%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.73%;border-top:1px solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.7%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.45%;border-top:1px solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.7%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.41%;border-top:1px solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.7%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.73%;border-top:1px solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed</b></p></th></tr><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.84%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.35%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:34.74%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.35%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.52%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.7%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.73%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SEC&#160;File&#160;No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.7%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.45%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.7%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.41%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Date</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.7%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.73%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Herewith</b></p></th></tr><tr style="height:1pt;"><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt 2pt 0pt 15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.1+</p></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.74%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1377121/000119312516645574/d144462dex101.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Protagonist Therapeutics,&#160;Inc. 2007 Stock Option and Incentive Plan, as amended and restated, and form of option agreement, exercise notice, joinder, and adoption agreement thereunder.</span></a></p></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.52%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.73%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">333-212476</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">7/11/2016</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.73%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt 2pt 0pt 15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.2+</p></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.74%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1377121/000119312516665762/d144462dex102.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Protagonist Therapeutics,&#160;Inc. 2016 Equity Incentive Plan and forms of stock option grant notice, option agreement, notice of exercise, restricted stock unit grant notice and restricted stock unit agreement thereunder.</span></a></p></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.52%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.73%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">333-212476</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">8/1/2016</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.73%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt 2pt 0pt 15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.3+</p></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.74%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1377121/000119312516665762/d144462dex103.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Protagonist Therapeutics,&#160;Inc. 2016 Employee Stock Purchase Plan.</span></a></p></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.52%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.73%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">333-212476</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">10.3</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">8/1/2016</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.73%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt 2pt 0pt 15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.4+</p></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.74%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1377121/000119312516665762/d144462dex104.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form&#160;of Indemnity Agreement for Directors and Officers.</span></a></p></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.52%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.73%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">333-212476</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">10.4</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">8/1/2016</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.73%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt 2pt 0pt 15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.5+</p></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.74%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1377121/000110465920024253/tm209742d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Amended and Restated Protagonist Therapeutics, Inc. 2018 Inducement Plan, form of stock option grant notice, form of option agreement, form of restricted stock unit grant notice and form of restricted stock unit agreement.</span></a></p></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.52%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.73%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">001-37852</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">2/24/2020</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.73%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt 2pt 0pt 15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.6</p></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.74%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1377121/000119312517073383/d310331dex109.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Lease, dated March&#160;6, 2017, by and between the Registrant and BMR-Pacific Research Center&#160;LP.</span></a></p></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.52%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.73%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">001-37852</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.45%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">10.9</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">3/7/2017</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.73%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt 2pt 0pt 15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.7+</p></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.74%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1377121/000119312516665762/d144462dex109.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Severance Agreement, dated August&#160;1, 2016, by and between the Registrant and Dinesh Patel.</span></a></p></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.52%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.73%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">333-212476</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">10.9</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">8/1/2016</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.73%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:38.35pt;"><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt 2pt 0pt 15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.8+</p></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.74%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1377121/000119312516665762/d144462dex1010.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Severance Agreement, dated August&#160;1, 2016, by and between the Registrant and David Y. Liu, Ph.D.</span></a></p></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.52%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.73%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">333-212476</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">10.10</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">8/1/2016</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.73%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt 2pt 0pt 15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.9+</p></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.74%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1377121/000155837018006639/ptgx-20180630ex1029c1683.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;">Employment Offer Letter, dated May 21, 2018,  by and between the Registrant and Samuel Saks, M.D.</span></a></p></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.52%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.73%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">001-37852</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">8/7/2018</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.73%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt 2pt 0pt 15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.10&#8224;</p></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.74%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1377121/000119312516645574/d144462dex1017.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Research and Collaboration Agreement, dated June&#160;16, 2012, by and among the Registrant, Protagonist Pty.&#160;Ltd. and Zealand Pharma A/S.</span></a></p></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.52%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.73%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">333-212476</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">10.17</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">7/11/2016</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.73%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt 2pt 0pt 15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.11&#8224;</p></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.74%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1377121/000119312516645574/d144462dex1018.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Contract Extension Letter of Agreement, dated June&#160;1, 2013, by and among the Registrant, Protagonist Pty.&#160;Ltd. and Zealand Pharma A/S</span></a>.</p></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.52%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.73%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">333-212476</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">10.18</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">7/11/2016</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.73%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt 2pt 0pt 15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.12&#8224;</p></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.74%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1377121/000119312516645574/d144462dex1019.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Agreement on Addition of Additional Collaboration Program, dated September&#160;16, 2013, by and among the Registrant, Protagonist Pty.&#160;Ltd. and Zealand Pharma A/S.</span></a></p></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.52%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.73%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">333-212476</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">10.19</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">7/11/2016</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.73%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">113</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.84%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:34.74%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th colspan="9" style="font-weight:normal;text-align:left;vertical-align:bottom;width:49.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporation&#160;By&#160;Reference</b></p></th></tr><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.84%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:34.74%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.52%;border-top:1px solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.7%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.73%;border-top:1px solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.7%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.45%;border-top:1px solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.7%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.41%;border-top:1px solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.7%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.73%;border-top:1px solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed</b></p></th></tr><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.84%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.35%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:34.74%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.35%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.52%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.7%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.73%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SEC&#160;File&#160;No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.7%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.45%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.7%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.41%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Date</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.7%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.73%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Herewith</b></p></th></tr><tr style="height:1pt;"><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt 2pt 0pt 15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.13&#8224;</p></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.74%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1377121/000119312516645574/d144462dex1020.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Protagonist Assumption of Responsibility, dated January&#160;28, 2014, by and between the Registrant and Zealand Pharma A/S.</span></a></p></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.52%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.73%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">333-212476</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">10.20</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">7/11/2016</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.73%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt 2pt 0pt 15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.14&#8224;</p></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.74%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1377121/000119312516645574/d144462dex1021.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Agreement to Assign Patent Applications, dated February&#160;7, 2014, by and between the Registrant, Protagonist Pty.&#160;Ltd. and Zealand Pharma A/S.</span></a></p></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.52%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.73%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">333-212476</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">10.21</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">7/11/2016</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.73%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt 2pt 0pt 15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.15&#8224;</p></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.74%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1377121/000119312516645574/d144462dex1022.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Abandonment Agreement, dated February&#160;28, 2014, by and among the Registrant, Protagonist Pty.&#160;Ltd. and Zealand Pharma A/S.</span></a></p></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.52%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.73%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">333-212476</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">10.22</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">7/11/2016</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.73%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt 2pt 0pt 15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.16&#8224;</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.74%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1377121/000110465917048066/a17-18281_1ex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Exclusive License and Collaboration Agreement, dated May 26, 2017, by and between the Registrant and Janssen Biotech, Inc.</span></a></p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.52%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">8-K/A</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.73%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">001-37852</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.45%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">7/31/2017</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.73%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt 2pt 0pt 15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.17</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.74%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1377121/000110465918049963/a18-18323_3ex4d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Registration Rights Agreement, dated August 8, 2018, by and between the Registrant and certain parties identified on the signature pages thereto</span></a></p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.52%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.73%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">001-37852</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.45%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">4.3</p></td><td style="vertical-align:top;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">8/7/2018</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.73%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt 2pt 0pt 15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.18</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.74%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1377121/000104746918006015/a2236589zex-10_1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Securities Purchase Agreement, dated August 6, 2018, by and between the Registrant and certain purchasers identified on the signature pages thereto</span></a></p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.52%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">S-3</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.73%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">333-227216</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.45%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">9/7/2018</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.73%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt 2pt 0pt 15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.19</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.74%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1377121/000110465918075322/a18-42204_1ex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Exchange Agreement, dated December 21, 2018, by and between the Registrant and Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P. and Biotechnology Value Trading Fund OS, L.P.</span></a> </p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.52%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.73%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">001-37852</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.45%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">12/31/2018</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.73%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt 2pt 0pt 15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.20</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.74%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1377121/000155837019004481/ptgx-20190331ex1035be89e.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">First Amendment, dated January 31, 2019, to Lease, dated March 6, 2017, by and between Protagonist Therapeutics, Inc., as Tenant, and BMR-Pacific Research Center LP, as Landlord</span></a>.</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.52%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.73%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">001-37852</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.45%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">10.3</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">5/8/2019</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.73%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt 2pt 0pt 15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.21+</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.74%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1377121/000155837019004481/ptgx-20190331ex10415180f.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Severance Agreement, dated March 14, 2019, by and among Protagonist Therapeutics, Inc. and Suneel Gupta, Ph.D.</span></a>&#160;</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.52%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.73%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">001-37852</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.45%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">10.4</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">5/8/2019</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.73%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt 2pt 0pt 15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.22#</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.74%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1377121/000155837019007515/ptgx-20190630ex101076de1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">First Amendment to Exclusive License and Collaboration Agreement, by and between Protagonist Therapeutics, Inc. and Janssen Biotech, Inc., dated May 7, 2019.</span></a></p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.52%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.73%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">001-37852</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.45%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">8/7/2019</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.73%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt 2pt 0pt 15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.23+</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.74%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1377121/000110465919032445/a19-10820_1ex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Offer Letter, by and between Protagonist Therapeutics Inc. and Donald Kalkofen, dated May 20, 2019.</span></a></p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.52%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.73%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">001-37852</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.45%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">5/29/2019</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.73%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">114</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.84%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:34.74%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th colspan="9" style="font-weight:normal;text-align:left;vertical-align:bottom;width:49.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporation&#160;By&#160;Reference</b></p></th></tr><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.84%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:34.74%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.52%;border-top:1px solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.7%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.73%;border-top:1px solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.7%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.45%;border-top:1px solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.7%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.41%;border-top:1px solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.7%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.73%;border-top:1px solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed</b></p></th></tr><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.84%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.35%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:34.74%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.35%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.52%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.7%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.73%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SEC&#160;File&#160;No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.7%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.45%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.7%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.41%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Date</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.7%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.73%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Herewith</b></p></th></tr><tr style="height:1pt;"><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt 2pt 0pt 15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.24+</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.74%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1377121/000155837019010201/ptgx-20190930ex1011a63b3.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Severance Agreement, dated July 19, 2019, by and between Protagonist Therapeutics, Inc. and Samuel Saks, M.D.</span></a></p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.52%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.73%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">001-37852</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.45%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">11/6/2019</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.73%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt 2pt 0pt 15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.25</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background-color:#ffff00;font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.74%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1377121/000155837020002334/ptgx-20191231ex1025844a2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Credit and Security Agreement, dated October 30, 2019, by and between Protagonist Therapeutics, Inc., MidCap Financial, and Silicon Valley Bank.</span></a></p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background-color:#ffff00;font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.52%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.73%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">001-37852</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.45%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">10.25</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">3/10/2020</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.73%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt 2pt 0pt 15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.26</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.74%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1377121/000110465919068332/a19-20376_6ex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Open Market Sale Agreement</span><sup style="font-family:'Times New Roman','Times','serif';font-size:4.87pt;font-style:normal;font-weight:normal;line-height:100%;text-align:left;top:0pt;vertical-align:top;">SM</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">, dated November 27, 2019, by and between Protagonist Therapeutics, Inc. and Jefferies LLC.</span></a></p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.52%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.73%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">001-37852</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.45%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">11/27/2019</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.73%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt 2pt 0pt 15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">10.27+</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.74%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1377121/000155837020009681/ptgx-20200630xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Severance Agreement, dated August 4, 2020, by and between Protagonist Therapeutics, Inc. and Donald Kalkofen.</span></a></p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.52%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.73%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37852</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.45%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">8/6/2020</p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.73%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt 2pt 0pt 15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">21.1</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.74%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="ptgx-20201231xex21d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">List of Subsidiaries</span></a></p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.52%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.73%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.45%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.73%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">X</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt 2pt 0pt 15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">23.1</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.74%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="ptgx-20201231xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Consent of Ernst &amp; Young LLP, Independent Registered Public Accounting Firm</span></a></p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.52%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.73%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.45%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.73%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">X</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt 2pt 0pt 15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">23.2</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.74%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="ptgx-20201231xex23d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm</span></a></p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.52%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.73%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.45%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.73%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">X</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt 2pt 0pt 15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">24.1</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.74%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SIGNATURES_83339"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Power of Attorney (included in signature page&#160;of this Form&#160;10-K)</span></a></p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.52%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.73%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.45%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.73%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">X</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt 2pt 0pt 15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">31.1</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.74%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="ptgx-20201231xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certification of Chief Executive Officer required by Rule&#160;13a-14(a)&#160;or Rule&#160;15d-14(a)&#160;of the Securities Exchange Act of 1934, as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.52%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.73%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.45%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.73%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">X</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt 2pt 0pt 15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">31.2</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.74%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="ptgx-20201231xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certification of Chief Financial Officer required by Rule&#160;13a-14(a)&#160;or Rule&#160;15d-14(a)&#160;of the Securities Exchange Act of 1934, as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.52%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.73%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.45%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.73%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">X</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt 2pt 0pt 15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">32.1*</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.74%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="ptgx-20201231xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:left;">Certification of Chief Executive Officer and Chief Financial Officer, as required by Rule&#160;13a-14(b)&#160;or Rule&#160;15d-14(b)&#160;and Section&#160;1350 of Chapter&#160;63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.52%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.73%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.45%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.73%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">X</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt 2pt 0pt 15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">101.INS</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.74%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL Document</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.52%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.73%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.45%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.73%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">X</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt 2pt 0pt 15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">101.SCH</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.74%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Inline XBRL Taxonomy Extension Schema Document</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.52%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.73%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.45%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.73%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">X</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">115</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.84%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:34.74%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th colspan="9" style="font-weight:normal;text-align:left;vertical-align:bottom;width:49.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporation&#160;By&#160;Reference</b></p></th></tr><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.84%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:34.74%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.52%;border-top:1px solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.7%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.73%;border-top:1px solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.7%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.45%;border-top:1px solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.7%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.41%;border-top:1px solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.7%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.73%;border-top:1px solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed</b></p></th></tr><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.84%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.35%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:34.74%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.35%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.52%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.7%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.73%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SEC&#160;File&#160;No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.7%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.45%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.7%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.41%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Date</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.7%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.73%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Herewith</b></p></th></tr><tr style="height:1pt;"><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt 2pt 0pt 15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">101.CAL</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.74%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.52%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.73%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.45%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.73%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">X</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt 2pt 0pt 15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">101.DEF</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.74%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.52%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.73%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.45%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.73%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">X</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt 2pt 0pt 15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">101.LAB</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.74%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Inline XBRL Taxonomy Extension Labels Linkbase Document</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.52%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.73%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.45%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.73%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">X</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt 2pt 0pt 15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">101.PRE</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.74%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.52%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.73%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.45%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.73%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">X</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt 2pt 0pt 15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.74%;margin:0pt;padding:0pt 2pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Cover Page Interactive Data File &#8211; the cover page interactive data file does into appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.52%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.73%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.45%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.41%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.7%;margin:0pt;padding:0pt 0pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.73%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">X</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;">+&#160;&#160;&#160;&#160;&#160;Indicates management contract or compensatory plan, contract or agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;">&#8224;&#160;&#160;&#160;&#160;&#160;Confidential treatment has been granted for a portion of this exhibit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;">*&#160;&#160;&#160;&#160;&#160;This certification attached as Exhibit&#160;32.1 that accompanies this Annual Report on Form&#160;10-K is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Protagonist Therapeutics,&#160;Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of the Form&#160;10-K, irrespective of any general incorporation language contained in such filing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="white-space:pre-wrap;">#     Portions of this exhibit (indicated by hashtag) have been omitted as the registrant has determined that (i) the omitted information is not&#160;material and (ii) the omitted information would likely cause competitive harm to the registrant if publicly disclosed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_4c49f18b_5f48_4c71_8847_171fa68fcea0"></a><a id="_cp_text_1_124"></a><a id="Item16Form10KSummary_140453"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item&#160;16.</b></span>Form 10-K Summary</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:6pt 0pt 0pt 0pt;">None.</p><a id="_d233793a_c4c5_482a_b22c_9bb813c7cb0c"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">116</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="SIGNATURES_83339"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.84%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.38%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:44.98%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:49.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:50.15%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PROTAGONIST THERAPEUTICS,&#160;INC.</p></td></tr><tr><td style="vertical-align:bottom;width:49.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:46.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.84%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:&#160;March&#160;10, 2021</p></td><td style="vertical-align:bottom;width:3.38%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:44.98%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Dinesh V. Patel, Ph.D.</p></td></tr><tr><td style="vertical-align:top;width:49.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:44.98%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dinesh V. Patel, Ph.D.</p></td></tr><tr><td style="vertical-align:top;width:49.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:44.98%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President, Chief Executive Officer and Director</p></td></tr><tr><td style="vertical-align:top;width:49.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:44.98%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">POWER OF ATTORNEY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Dinesh V. Patel and Don Kalkofen, and each of them, his true and lawful attorneys-in-fact, with full power of substitution, for him in any and all capacities, to sign any and all amendments to this Annual Report on Form&#160;10-K, and to file the same, with exhibits thereto and other documents in connection therewith with the Securities and Exchange Commission, hereby ratifying and confirming all that said attorneys-in-fact or any of them or their substitute or substitutes may lawfully do or cause to be done by virtue thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-1.431076%;padding-left:0pt;padding-right:0pt;width:102.86%;"><tr><td style="vertical-align:bottom;width:32.03%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.79%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.72%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.03%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Signature</b></p></td><td style="vertical-align:bottom;width:2.78%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:48.79%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title</b></p></td><td style="vertical-align:bottom;width:2.66%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:13.72%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:32.03%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.79%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.72%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.03%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Dinesh V. Patel, Ph.D.</p></td><td style="vertical-align:bottom;width:2.78%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.79%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">President,&#160;Chief&#160;Executive&#160;Officer&#160;and&#160;Director</p></td><td style="vertical-align:bottom;width:2.66%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.72%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;10,&#160;2021</p></td></tr><tr><td style="vertical-align:top;width:32.03%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Dinesh V. Patel, Ph.D.</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.79%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(Principal Executive Officer)</i></p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.03%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Don Kalkofen</p></td><td style="vertical-align:bottom;width:2.78%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.79%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Chief Financial Officer</p></td><td style="vertical-align:bottom;width:2.66%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.72%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;10, 2021</p></td></tr><tr><td style="vertical-align:top;width:32.03%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Don Kalkofen</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.79%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(Principal Financial and Accounting Officer)</i></p></td><td style="vertical-align:top;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:32.03%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Harold E. Selick, Ph.D.</p></td><td style="vertical-align:bottom;width:2.78%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.79%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Chairman of the Board of Directors</p></td><td style="vertical-align:bottom;width:2.66%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.72%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;10, 2021</p></td></tr><tr><td style="vertical-align:top;width:32.03%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Harold E. Selick, Ph.D.</p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:32.03%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Bryan Giraudo</p></td><td style="vertical-align:bottom;width:2.78%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.79%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:2.66%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.72%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 10, 2021</p></td></tr><tr><td style="vertical-align:top;width:32.03%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Bryan Giraudo</p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.79%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.72%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:32.03%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.79%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.72%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:32.03%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Sarah Noonberg, M.D., Ph.D.</p></td><td style="vertical-align:bottom;width:2.78%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.79%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:2.66%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.72%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;10, 2021</p></td></tr><tr><td style="vertical-align:top;width:32.03%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Sarah Noonberg, M.D., Ph.D.</p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:32.03%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Sarah O&#8217;Dowd</p></td><td style="vertical-align:bottom;width:2.78%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.79%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:2.66%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.72%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;10, 2021</p></td></tr><tr><td style="vertical-align:top;width:32.03%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Sarah O&#8217;Dowd</p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.79%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.72%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.03%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.79%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.72%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.03%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ William D. Waddill</p></td><td style="vertical-align:bottom;width:2.78%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.79%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:2.66%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.72%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;10, 2021</p></td></tr><tr><td style="vertical-align:top;width:32.03%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">William D. Waddill</p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:32.03%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:32.03%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Lewis T. Williams, M.D., Ph.D.</p></td><td style="vertical-align:bottom;width:2.78%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.79%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:2.66%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.72%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;10, 2021</p></td></tr><tr><td style="vertical-align:top;width:32.03%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Lewis T. Williams, M.D., Ph.D.</p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">117</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.7
<SEQUENCE>2
<FILENAME>ptgx-20201231xex4d7.htm
<DESCRIPTION>EX-4.7
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.9.1.77--><!--Created on: 3/10/2021 09:28:20 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><b style="font-size:10pt;font-weight:bold;">Exhibit 4.7</b></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 108pt 0pt 108pt;"><b style="font-weight:bold;">DESCRIPTION OF THE REGISTRANT&#8217;S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:24.5pt;margin:8pt 0pt 0pt 0pt;"><font style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-top:8pt;text-align:justify;text-indent:24.5pt;margin:0pt;">The following is a description of the authorized capital stock of Protagonist Therapeutics, Inc., a Delaware Corporation (&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; or the &#8220;Company&#8221;). The following summaries and descriptions are not complete and are subject to and qualified by reference to the actual provisions of the Company&#8217;s Amended and Restated Certificate of Incorporation (the &#8220;Charter&#8221;) and Amended and Restated Bylaws (the &#8220;Bylaws&#8221;), both of which have been filed with the Securities and Exchange Commission and are incorporated by reference herein. We encourage you to read our Charter, our Bylaws, and the applicable provisions of the Delaware General Corporation Law for more information.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-top:8pt;margin:0pt;"><b style="font-weight:bold;">General</b></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-top:8pt;text-align:justify;text-indent:24.5pt;margin:0pt;">Pursuant to the Company&#8217;s Charter, the Company is authorized to issue up to 90,000,000 shares of common stock, par value $0.00001 per share (the &#8220;Common Stock&#8221;), and up to 10,000,000 shares of preferred stock, par value $0.00001 per share (the Preferred Stock&#8221;). As of December&#160;31, 2020, there were 43,745,465 shares of our Common Stock were issued and outstanding. No Preferred Stock is currently outstanding.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-top:8pt;margin:0pt;"><b style="font-weight:bold;">Common Stock</b></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-top:8pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Voting Rights</i></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-top:8pt;text-align:justify;text-indent:24.5pt;margin:0pt;">Holders of our Common Stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders, including the election of directors, and do not have cumulative voting rights.&#160;Accordingly, the holders of a majority of the outstanding shares of Common Stock entitled to vote in any election of directors can elect all of the directors standing for election, if they so choose, other than any directors that holders of any Preferred Stock we may issue may be entitled to elect. </p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-top:8pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Dividend Rights</i></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-top:8pt;text-align:justify;text-indent:24.5pt;margin:0pt;">Subject to preferences that may be applicable to any then outstanding Preferred Stock, holders of Common Stock are entitled to receive ratably those dividends, if any, as may be declared by the board of directors out of legally available funds. </p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-top:8pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Liquidation</i></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-top:8pt;text-align:justify;text-indent:24.5pt;margin:0pt;">In the event of our liquidation, dissolution or winding up, the holders of Common Stock will be entitled to share ratably in the assets legally available for distribution to stockholders after the payment of or provision for all of our debts and other liabilities, subject to the prior rights of any Preferred Stock then outstanding. </p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-top:8pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Rights and Preferences</i></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-top:8pt;text-align:justify;text-indent:24.5pt;margin:0pt;">Holders of Common Stock have no preemptive or conversion rights or other subscription rights and there are no redemption or sinking funds provisions applicable to the Common Stock.&#160;The rights, preferences and privileges of holders of Common Stock are subject to and may be adversely affected by the rights of the holders of shares of any series of Preferred Stock that we may designate and issue in the future.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:14pt;padding-left:10pt;padding-top:14pt;text-indent:-10pt;margin:0pt;"><b style="font-weight:bold;">Anti-Takeover Effects of Delaware Law and our Certificate of Incorporation and Bylaws</b></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Some provisions of Delaware law, our certificate of incorporation and our bylaws contain provisions that could make the following transactions more difficult: an acquisition of us by means of a tender offer; an acquisition of us by means of a proxy contest or otherwise; or the removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:14pt;text-align:justify;margin:0pt;">consider to be in their best interest or in our best interests, including transactions which provide for payment of a premium over the market price for our shares.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:14pt;text-align:justify;margin:0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;These provisions, summarized below, are intended to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of the increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:14pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Undesignated Preferred Stock</i>&#8212;The ability to authorize undesignated Preferred Stock makes it possible for our board of directors to issue Preferred Stock with voting or other rights or preferences that could impede the success of any attempt to change control of us. These and other provisions may have the effect of deterring hostile takeovers or delaying changes in control or management of our company.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:14pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Stockholder Meetings</i>&#8212;Our bylaws provide that a special meeting of stockholders may be called only by our chairman of the board, chief executive officer or president, or by a resolution adopted by a majority of our board of directors.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:14pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Requirements for Advance Notification of Stockholder Nominations and Proposals</i>&#8212;Our bylaws establish advance notice procedures with respect to stockholder proposals to be brought before a stockholder meeting and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:14pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Elimination of Stockholder Action by Written Consent</i>&#8212;Our certificate of incorporation and bylaws eliminate the right of stockholders to act by written consent without a meeting.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:14pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Staggered Board</i>&#8212;Our board of directors is divided into three classes. The directors in each class will serve for a three-year term, one class being elected each year by our stockholders. This system of electing and removing directors may tend to discourage a third-party from making a tender offer or otherwise attempting to obtain control of us, because it generally makes it more difficult for stockholders to replace a majority of the directors.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:14pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Removal of Directors</i>&#8212;Our certificate of incorporation provides that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than two thirds of the total voting power of all of our outstanding voting stock then entitled to vote in the election of directors.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:14pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Stockholders Not Entitled to Cumulative Voting</i>&#8212;Our certificate of incorporation does not permit stockholders to cumulate their votes in the election of directors. Accordingly, the holders of a majority of the outstanding shares of our Common Stock entitled to vote in any election of directors can elect all of the directors standing for election, if they choose, other than any directors that holders of our Preferred Stock may be entitled to elect.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:14pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Delaware Anti-Takeover Statute</i>&#8212;We are subject to Section&#160;203 of the Delaware General Corporation Law, which prohibits persons deemed to be &quot;interested stockholders&quot; from engaging in a &quot;business combination&quot; with a publicly held Delaware corporation for three years following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &quot;interested stockholder&quot; is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#39;s voting stock. Generally, a &quot;business combination&quot; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by the board of directors.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:14pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Choice of Forum</i>&#8212;Our certificate of incorporation provides that, unless we consent in writing to the selection of an alternative form, the Court of Chancery of the State of Delaware is the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: (1) any derivative action or proceeding brought on our behalf; (2) any action asserting a claim of breach of a fiduciary duty or other wrongdoing by any of our directors, officers, employees or agents to us or our stockholders; (3) any action asserting a claim against us arising pursuant to any provision of the General Corporation Law of the State of Delaware or our certificate of incorporation or bylaws; (4) any action to interpret, apply, enforce or determine the validity of our certificate of incorporation or bylaws; or (5) any action asserting a claim governed by the internal affairs doctrine. This provision does not apply to suits brought to enforce a duty or liability created by the Exchange Act or any other claim for which the U.S. federal courts have exclusive jurisdiction. Our certificate of incorporation also provides that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice of and to have consented to this choice of forum provision. It is possible that a court of law could rule that the choice of forum provision contained in our certificate of incorporation is inapplicable or unenforceable if it is challenged in a proceeding or otherwise.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:14pt;text-align:justify;margin:0pt;"> &#160; <i style="font-style:italic;"> &#160; &#160; Amendment of Charter Provisions</i>&#8212;The amendment of any of the above provisions, except for the provision making it possible for our board of directors to issue Preferred Stock, would require approval by holders of at least two thirds of the total voting power of all of our outstanding voting stock.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:14pt;text-align:justify;margin:0pt;"><font style="white-space:pre-wrap;">        </font>The provisions of Delaware law, our certificate of incorporation and our bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our Common Stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in the composition of our board and management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Symbol and Listing</b></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-top:8pt;text-indent:24.5pt;margin:0pt;">Our Common Stock is listed on The Nasdaq Global Market under the symbol &#8220;PTGX.&#8221;</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-top:14pt;margin:0pt;"><b style="font-weight:bold;">Transfer Agent and Registrar</b></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-top:8pt;text-align:justify;text-indent:24.5pt;margin:0pt;">The transfer agent and registrar for our Common Stock is American Stock Transfer &amp; Trust Company, LLC. The transfer agent and registrar&#8217;s address is 6201 15<sup style="font-size:7.5pt;vertical-align:top;">th</sup> Avenue, Brooklyn, New York 11219. Telephone number is (800) 937-5449.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>ptgx-20201231xex21d1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.9.1.77--><!--Created on: 3/10/2021 09:28:23 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-bottom:12pt;text-align:right;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit&#160;21.1</b></p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">SUBSIDIARIES OF PROTAGONIST THERAPEUTICS, INC.</b></p><div><table style="background-color:#ffffff;border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="background-color:#ffffff;vertical-align:bottom;white-space:nowrap;width:49%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Subsidiary</b></p></td><td style="background-color:#ffffff;vertical-align:bottom;width:2.12%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#160;&#160;&#160;&#160;</font></p></td><td style="background-color:#ffffff;vertical-align:bottom;width:48.87%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Jurisdiction of Formation/Organization</b></p></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Protagonist Pty Limited</font></p></td><td style="background-color:#ffffff;vertical-align:bottom;width:2.12%;margin:0pt;padding:0pt;"></td><td style="background-color:#ffffff;vertical-align:top;width:48.87%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Australia</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>ptgx-20201231xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.9.1.77--><!--Created on: 3/10/2021 09:28:26 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit&#160;23.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">CONSENT OF ERNST &amp; YOUNG LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">We consent to the incorporation by reference in the Registration Statements&#160;on Form&#160;S-8&#160;&#160;(No. 333-230213, No.&#160;333-213120, No.&#160;333-216532, No.&#160;333-223500, No.&#160;333-225294, and No. 333-237066) and in the Registration Statements on Form&#160;S-3 (No.&#160;333-220314, No.&#160;333-227216, No. 333-234414, and No. 333-251254) of Protagonist Therapeutics,&#160;Inc. and in the related Prospectuses, as applicable, of our report dated March 10, 2021, with respect to the consolidated financial statements of Protagonist Therapeutics, Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2020.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">/s/ Ernst &amp; Young LLP </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Redwood City, CA </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">March&#160;10, 2021</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>5
<FILENAME>ptgx-20201231xex23d2.htm
<DESCRIPTION>EX-23.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.9.1.77--><!--Created on: 3/10/2021 09:28:29 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit&#160;23.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">We hereby consent to the incorporation by reference in the Registration Statements on Form</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">S-8 (No. 333-237066, No. 333-230213, No. 333-213120, No. 333-216532, No. 333-223500 and No. 333-225294) and Form S-3 (No. 333-251254, No.&#160;333-227216 and No. 333-234414) of Protagonist Therapeutics of our report dated March 10, 2020 relating to the financial statements, which appears in this Form 10-K.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><a name="_2et92p0"></a><font style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">/s/ PricewaterhouseCoopers LLP </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">San Jose, CA </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">March&#160;10, 2021 </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>ptgx-20201231xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.9.1.77--><!--Created on: 3/10/2021 09:28:32 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit&#160;31.1 </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002 </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">I, Dinesh V. Patel, certify that: </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.&#160;&#160;&#160;&#160;I have reviewed this Annual Report on Form 10-K of Protagonist Therapeutics, Inc.; </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have: </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="font-family:'Times New Roman','Times','serif';">a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">b)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">;</font></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="font-family:'Times New Roman','Times','serif';">c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="font-family:'Times New Roman','Times','serif';">d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an Annual Report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions): </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="font-family:'Times New Roman','Times','serif';">a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="font-family:'Times New Roman','Times','serif';">b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#160;&#160;&#160;&#160;</font></p></td><td style="vertical-align:bottom;width:48.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">/s/ Dinesh V. Patel, Ph.D.</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Date: March&#160;10, 2021</font></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:48.95%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Dinesh V. Patel, Ph.D.</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">President, Chief Executive Officer</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>ptgx-20201231xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.9.1.77--><!--Created on: 3/10/2021 09:28:35 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit&#160;31.2 </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">CERTIFICATION OF CHIEF FINANCIAL OFFICER </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002 </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">I, Don Kalkofen, certify that: </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.&#160;&#160;&#160;&#160;I have reviewed this Annual Report on Form 10-K of Protagonist Therapeutics, Inc.; </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have: </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="font-family:'Times New Roman','Times','serif';">a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">b)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">;</font></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="font-family:'Times New Roman','Times','serif';">c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="font-family:'Times New Roman','Times','serif';">d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an Annual Report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions): </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="font-family:'Times New Roman','Times','serif';">a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="font-family:'Times New Roman','Times','serif';">b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#160;&#160;&#160;&#160;</font></p></td><td style="vertical-align:bottom;width:48.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">/s/ Don Kalkofen</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Date: March&#160;10, 2021</font></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:48.95%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Don Kalkofen</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p></td><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Chief Financial Officer</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>ptgx-20201231xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.9.1.77--><!--Created on: 3/10/2021 09:28:38 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit&#160;32.1 </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;) and Section&#160;1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), Dinesh V. Patel, Chief Executive Officer of Protagonist Therapeutics, Inc. (the &#8220;Company&#8221;), and Don Kalkofen, Chief Financial Officer of the Company, each hereby certify that, to the best of his knowledge: </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">1.&#160;The Company&#8217;s Annual Report on Form 10-K for the period ended December&#160;31, 2020 (the &#8220;Annual Report&#8221;), to which this Certification is attached as Exhibit 32.1, fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Exchange Act; and </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">2.&#160;The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:48.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#160;&#160;&#160;&#160;</font></p></td><td style="vertical-align:bottom;width:48.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 1pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">/s/ Dinesh V. Patel, Ph.D.</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Date: March&#160;10, 2021</font></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:48.98%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Dinesh V. Patel, Ph.D.</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">President, Chief Executive Officer</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 1pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 1pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#160;&#160;&#160;&#160;</font></p></td><td style="vertical-align:bottom;width:48.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 1pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">/s/ Don Kalkofen.</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Date: March&#160;10, 2021</font></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:48.98%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Don Kalkofen</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Chief Financial Officer</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Protagonist Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing. </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ptgx-20201231x10k006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ptgx-20201231x10k006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &S \L# 2(  A$! Q$!_\0
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M*\#HI^Q\P]MY'OGV^S_Y^X/^_@H^WV?_ #]P?]_!7@=%'L?,/;>1[Y]OL_\
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ME^/_  #W#[=9_P#/U!_W\%'VZS_Y^H/^_@KQ4Z9?AY$-E<[HUW./*;*CU/'
MIDME=0JS2VTT:J0&+(1C/3-']FP_G&^(:JWI?B_\CVW[=9_\_4'_ '\%'VZS
M_P"?J#_OX*\6ATK4;B$2PV%S)&>CI$Q!_$"F)87DD!G2UG:$'!D$9*@_6E_9
ML/YP_P!8*W_/G\7_ )'MGVZS_P"?J#_OX*/MUG_S]0?]_!7B\VDZC;Q&2:PN
MHXQU9X6 'XD4V73+^ QB6RN(S(<)NB8;CZ#CFC^SH/[8WQ!66]'\7_D>U?;K
M/_GZ@_[^"C[=9_\ /U!_W\%>)_8+S<5^RSY#^61Y9X;^[]?:G3Z9?VH4W%E<
MQ!CA2\3+D^G(H_LV'\XO]8:UK^R_%_Y'M7VZS_Y^H/\ OX*/MUG_ ,_4'_?P
M5XC<6EQ9R".Y@EA<C(61"I(]>:AJEED7JIDOB.HG9TOQ_P" >Z?;K/\ Y^H/
M^_@H^W6?_/U!_P!_!7A=%']EK^;\!?ZRS_Y]_C_P#W3[=9_\_4'_ '\%'VZS
M_P"?J#_OX*\+HH_LM?S?@'^LL_\ GW^/_ /=/MUG_P _4'_?P4?;K/\ Y^H/
M^_@KPNBC^RU_-^ ?ZRS_ .??X_\  /=/MUG_ ,_4'_?P4?;K/_GZ@_[^"O"Z
M*/[+7\WX!_K+/_GW^/\ P#W3[=9_\_4'_?P4?;K/_GZ@_P"_@KPNBC^RU_-^
M ?ZRS_Y]_C_P#WF*:*8$Q2I(!U*L#BGUQ/PW_P"0???]=5_E7;5YE>G[*HX7
MV/HL'B'B:$:K5KG+^/O^19D_WQ7D=>U^)=.&JZ4;4RF,,P.X+FN+_P"$ 3_H
M(M_WY_\ KTZ<DEJ74BV]#B*W=&OK6TT35H[@)(\HCV0LQ7?AN>1SQUK:_P"$
M 3_H(M_WY_\ KT?\( G_ $$6_P"_/_UZMSBR%"2((/$-G=V4TFHQ1EGN8_W*
M.RD(J@9!![>]&I7=OJ-I=VL>I6Z2&\$P<DJKQ[, 9]1BI_\ A $_Z"+?]^?_
M *]'_" )_P!!%O\ OS_]>IO'N5:?8;?:I8:@EQ;17,2L)(VWR,468*,'D<T^
MXU31HX+R)I/M*.8 R^<Y+8#;BISG R*3_A $_P"@BW_?G_Z]'_" )_T$6_[\
M_P#UZ+Q[CM/L2_VWI]A=7=\+H3R3.B1+ 0&6,=CD5/8ZGHEO]NMGNXS;75YY
MHYZ JK?^A BJ?_" )_T$6_[\_P#UZ/\ A $_Z"+?]^?_ *]'N]P]_L/OM<MK
MK5X)HKJVVM:M&ZRYV-_LDCI]:YGQ#);2ZS*]I,TL15?F9R_.T9&3R171_P#"
M )_T$6_[\_\ UZ/^$ 3_ *"+?]^?_KTU**ZB<9/H<117;_\ " )_T$6_[\__
M %Z/^$ 3_H(M_P!^?_KU7M(D^SD<117;_P#" )_T$6_[\_\ UZ/^$ 3_ *"+
M?]^?_KT>TB'LY&+9313^'&L$NX[:X6X$I,C;0ZXQC/L>:UM/U>RTB-Y9;Y[V
MYGN 'D0X;8O'S9SP:D_X0!/^@BW_ 'Y_^O1_P@"?]!%O^_/_ ->I<HOJ4HR7
M0GL=6T>QB>QDN$EMI=0,FX'E!\K*WT!&*JWEW:WBQ&#4X(3%?22DLY!VD\$>
MM/\ ^$ 3_H(M_P!^?_KT?\( G_01;_OS_P#7I7CW':78L2:UIEUM\JXBA#PW
M:X8XVERFW/UP352PU'3["&V-Q=I/<64+LK1MG<6Z*I([4_\ X0!/^@BW_?G_
M .O1_P ( G_01;_OS_\ 7HO'N%I]B#^TM/D\3:3JB7.Q&C N/,/S*R@KEL>H
MQ5?3;JT?2M1@FDMF>2Y#HD\K(".><CFK_P#P@"?]!%O^_/\ ]>C_ (0!/^@B
MW_?G_P"O3O'N+EEV./NU5;N0)Y>W/'EL67\">34%=O\ \( G_01;_OS_ /7H
M_P"$ 3_H(M_WY_\ KU7/$GV<CB**[?\ X0!/^@BW_?G_ .O1_P ( G_01;_O
MS_\ 7H]I$/9R./LW6.^MW<X59%))[#-=B-1LK;4+N5[Z"6.YO8'CV-G:%<,6
M/IP#^=)_P@"?]!%O^_/_ ->C_A $_P"@BW_?G_Z]2Y1?4:C)=!MGJ5F9[]9;
MV$6TEU)(,.R2*#T92.N?2J=]<PW<EM=6>K+:QQ6QC*EB) 0#G '7=5[_ (0!
M/^@BW_?G_P"O1_P@"?\ 01;_ +\__7I7CW':78KI?VKZC9ZFM_'';0P!6M23
MN&!@J%Z$$TLFNV+: UTI5=3\M[-4[B-CG/T R*G_ .$ 3_H(M_WY_P#KT?\
M" )_T$6_[\__ %Z+Q[A:?8BU6YL+B_CNHY+)@H3,GGOOXQGY>E)JVKV$MIJI
ML)5AN7N48L')\Y!T*YZ$'GBIO^$ 3_H(M_WY_P#KT?\ " )_T$6_[\__ %Z+
MQ[A:78R/$6KKJ%K8I&\?,?F3J@Q^]/4GWKGZ[?\ X0!/^@BW_?G_ .O1_P (
M G_01;_OS_\ 7JE.*$X29Q%%=O\ \( G_01;_OS_ /7H_P"$ 3_H(M_WY_\
MKT_:1%[.1Q%;'AJZ@L]5:6X=5C\EQ\QP"2.E;_\ P@"?]!%O^_/_ ->C_A $
M_P"@BW_?G_Z])SBP4))W*>G>(H6M[F&>&&&".SD2*'>WSL2.,YSV]:OKJ6FR
MQ2+'-;K ]BD44$LC H<Y*LPYZYYIG_" )_T$6_[\_P#UZ/\ A $_Z"+?]^?_
M *]3>/<JT^QAB33;35(I9H\['1U%K-O3@Y.=V2:M7TJ?;[B[36$:":X#B%&)
M+#.?F';%:7_" )_T$6_[\_\ UZ/^$ 3_ *"+?]^?_KT^:/<7++L1QW%G;^*;
MS4&O[5H)TD"[7R<E>,C%:$WB#2KB*XB>:,216H2&0?Q9'*_@:I_\( G_ $$6
M_P"_/_UZ/^$ 3_H(M_WY_P#KTKQ[E6EV$U?4;/4K*6TM;^&*7=%)O9MJN F,
M9]0:CT_5[/1XY9Y;Y[VYFG52\9PVQ?4G/!J7_A $_P"@BW_?G_Z]'_" )_T$
M6_[\_P#UZ+QVN*T[WL5+T6$^EWME:ZA;#-_Y\?F-M!0KVX]3C\*Y0C#$9!P>
MHKMO^$ 3_H(M_P!^?_KT?\( G_01;_OS_P#7JE.*ZB<)/H<117;_ /" )_T$
M6_[\_P#UZ/\ A $_Z"+?]^?_ *]/VD1>SD<117;_ /" )_T$6_[\_P#UZ/\
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M_P"O1_P@"?\ 01;_ +\__7I^TB+V<CB**[?_ (0!/^@BW_?G_P"O1_P@"?\
M01;_ +\__7H]I$/9R.(HKM_^$ 3_ *"+?]^?_KT?\( G_01;_OS_ /7H]I$/
M9R.(K9\,W<%EJCRW+JL?D.OS' )(Z<5O?\( G_01;_OS_P#7H_X0!/\ H(M_
MWY_^O2<XM H23N4M/\0020W45Q##%!'8O%##N;YR64D9SGMZU>CU?2X/(OQ(
MJR0V*11PQ/EE8]0,YZ>])_P@"?\ 01;_ +\__7H_X0!/^@BW_?G_ .O4W@5:
M?8KR:A9MXB>]M;J!8[JT(E6?)!8C!5B.G0<BK5Q>:7+;7T$=Q!-OF1E%Q<.
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MCID 9K3_ .$%3_H(-_WZ_P#KT?\ ""I_T$&_[]?_ %Z(U\-%WYN_3O\ (53
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M]UORH 2BG;'_ +C?E1L?^XWY4 -HIVQ_[C?E1L?^XWY4 -HIVQ_[C?E1L?\
MN-^5 #:*=L?^XWY4;'_N-^5 #:*=L?\ N-^5&Q_[C?E0 VBG;'_N-^5&Q_[C
M?E0 VBG;'_N-^5&Q_P"XWY4 -HIVQ_[C?E1L?^XWY4 -HIVQ_P"XWY4;'_N-
M^5 #:*=L?^XWY4;'_N-^5 #:*=L?^XWY4;'_ +C?E0 VBG;'_N-^5&Q_[C?E
M0 VBG;'_ +C?E1L?^XWY4 -HIVQ_[C?E1L?^XWY4 -HIVQ_[C?E1L?\ N-^5
M #:*=L?^XWY4;'_N-^5 #:*=L?\ N-^5&Q_[C?E0 VBG;'_N-^5&Q_[C?E0
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M95.UBAS@USL=U*GPY@EG0R,]HB9.?ND !FQSTY-4?!M\MOJMQI3S1WDK)O\
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MN[B%K82KI+ZI;E(3"57B-]YVD<#E0<C!J1-'8:A!&EAA(=0N5AS%PB<[<''
MSTHL%ST!7A!?:T8(Y;!'ZU7@@L[8R.C(!+(7Y8$!CUQZ5YH--O#IL^%;[6ME
M,EQ'#8NA=B1_K'+D.<\@J#WZ5HZMI;0-:(;>)+,V6V-38O/MD/7 5EVN?[QH
ML%ST _9E(1O*!Y 4X[]:&CMFD"LD1<#@$#.*\\DT>9H]9FN+::XNXH;/R9Y(
MCOW#&XKUP>.<'\:TH(HUU2Y^W65S+J;W :UF6(DJF/E^?@!?49_"BP7.KOK6
MVU.V>UFE/EY!=8Y,$X['VJ94MY8E0".2-> .& KS?3--N#&%F,T=PMK*EX+6
MQ97<Y&=[L^)#G)! Y!/3I74>$D"-=B.VB2+"!9HK=[=9#CG,;$\CN1UHL%SH
MF@A<@M$A*C RHX%17-C!=6DMLZE8Y1M?RSM)'ID59HI#&+$B1")441@;0N.
M/2D2"*/&R)%QTPH&*DHH **** "BBB@ HHHH 8/]:WTI],'^M;Z4^@!C_?3Z
MT^F/]]/K3Z "BBB@ HHHH **** "BBB@ HHHH **** "F2?='UI],D^Z/K0
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MM#^3?X4?\)MX;_Z"T/Y-_A1RR[!RR[&K_9MC_P ^5M_WZ7_"C^S;'_GRMO\
MOTO^%97_  FWAO\ Z"T/Y-_A1_PFWAO_ *"T/Y-_A1RR[!RR[&K_ &;8_P#/
ME;?]^E_PH_LVQ_Y\K;_OTO\ A65_PFWAO_H+0_DW^%'_  FWAO\ Z"T/Y-_A
M1RR[!RR[&K_9MC_SY6W_ 'Z7_"FQ:;8^6/\ 0K?_ +]+_A69_P )MX;_ .@M
M#^3?X4R/QKX<" '58?R;_"CEEV#EEV-C^S;'_GRMO^_2_P"%']FV/_/E;?\
M?I?\*RO^$V\-_P#06A_)O\*/^$V\-_\ 06A_)O\ "CEEV#EEV-7^S;'_ )\K
M;_OTO^%']FV/_/E;?]^E_P *RO\ A-O#?_06A_)O\*/^$V\-_P#06A_)O\*.
M678.678U?[-L?^?*V_[]+_A1_9MC_P ^5M_WZ7_"LK_A-O#?_06A_)O\*/\
MA-O#?_06A_)O\*.678.678U?[-L?^?*V_P"_2_X4?V;8_P#/E;?]^E_PK*_X
M3;PW_P!!:'\F_P */^$V\-_]!:'\F_PHY9=@Y9=C5_LVQ_Y\K;_OTO\ A1_9
MMC_SY6W_ 'Z7_"LK_A-O#?\ T%H?R;_"C_A-O#?_ $%H?R;_  HY9=@Y9=C5
M_LVQ_P"?*V_[]+_A1_9MC_SY6W_?I?\ "LK_ (3;PW_T%H?R;_"C_A-O#?\
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M +]+_A1_9MC_ ,^5M_WZ7_"K5%*XBM_9UB/^7*W_ ._2_P"%6>E%% !1110
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M';UK>\.:?/I>BQVEQM\Q9)6.TY&&D9A^A%#L!JT444AA3)/NCZT^F2?='UH
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M.5<9X..E(OCC[-8VP_T?SC"\S_:[H(2 [*%4XY;Y3Q]*V%\)1*WF?VA=-/\
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M:='$BK<3QR-(Z6[S9*G& J\C/Z5T=MX8TJT-L88'!MVD:/,C'!<8;OSTI/\
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MOK>*WC01;8(WB3*]FZYY]Z[#_A4MU_T%H?\ OT?\:/\ A4MU_P!!:'_OT?\
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M_B:6TM))8U.&91P#77"G!Q39U0IP<4V=]_PMQ_\ H"K_ .!/_P!C1_PMQ_\
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M?8/90['HW_"W'_Z J_\ @3_]C1_PMQ_^@*O_ ($__8UYI11[&'8/90['I?\
MPMQ_^@*O_@3_ /8TU?BTZKC^Q5_\"?\ [&O-J*/8P[![*'8]+_X6X_\ T!5_
M\"?_ +&C_A;C_P#0%7_P)_\ L:\THH]C#L'LH=CU&U^+,<EU&ESI1AA9L/(L
M^XJ/7&T9KT.WN(;NW2>"19(G&Y64Y!%?-==;X-\8S:!<"VN69[!SRO\ </J*
MSJ4%:\3.=%6O$]LHJ*VN8;NW2>"19(G&593P:EKD.8**** "BBB@ HHHH *8
MWWT^I_E3Z8WWT^I_E0 ^BBB@ HHHH **** "BBB@ HHHH **** "F#_7-_NC
M^M/I@_US?[H_K0 ^BBB@ HHHH **** "BBB@ HHHH **** "F?\ +8?[M/IG
M_+8?[M #Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &#_ %K?2GTP
M?ZUOI3Z &/\ ?3ZT^F/]]/K3Z "BBB@ HHHH **** "BBB@ HHHH **** "F
M2?='UI],D^Z/K0 ^LK7]6;2+!98D62>618HE8X&X]S[5JUFZWI0U>P$(D\N5
M'$D;XSAATIQM?4:M?4SWUF_TC4(+;5C;SI<1.Z26T90JR*692"QSD=#D=.E.
M3Q=:OIR7XL;[[/(?D8J@!]3DM@#ZXID^@WVIW27.HW$'F0021P+"#MW.I4LV
M?\]:JR>%+O\ LS2K=+F!FL@0R2 ['XZXK3W>I?N]2>W\4F_UK2H;-5-G>PR.
MQ=?G!4XQP<?SJ+5_%DFD>*8-/FCC^Q21@M)@Y1CTR?2F:/X2N=-O-,GDNH7%
MFDJL%!&[><\5:U7PL-6U>:YGD3R)+;R=N/F#=C1[E_(/<N4;'Q5J&H16EM$E
MLM[=7$J!RI*1HAZE<Y)/U%6]:U;6=$T=YYVL6E\]424(P4H3C)4G@C_>-5M.
M\'W6FV=BT5W$U]9RR.KL#L=7QD'OVJYJVB:KK&EM!<7=MYOG+(BA#L4 YQGJ
M:'RWTV'[M_(T=*N9KAI"^J6%ZJXXM8]NWZ_.W]*TZHV$5[&[_:8K)%(X^SA@
M2??-7JS>YF]SR+XK?\C':?\ 7J/_ $)JR=/>T3P7<F\@FFC^V)A8I1&<[6[E
M6_E6M\5O^1CM/^O4?^A-7";FV[=QV]<9XKMIJ\$=<%>".T75(KOPY<W2VD,2
MQ2P6L?F*LK)%MP?F(Z\=<59UZUTZ/2[A'@E2V4P^1/':1J$SC)#;P9,C=Q_+
M%<%N8*5W':>2,\4YI9&0(TC%1T!/ JO9ZZ%<FNATMI##-X<U*STB2:XG,J.0
M8@DCQ@<_*&.0#VS6KH=M>PP30:DZ.?LT06%AEXT\]/E?CZ\'-<(CO&VY&93Z
MJ<4OG2%BWF/N/4[CDT.%P<;GI$L=O!=V5NEG:^7<WUQ%)F!22H8X ..,>U4[
MBQA@MII+&UC>^CL(C"@B#DYE8,VT@[C@ 9P:X/S9"0?,?(.1\W0T":56#"1P
MP&,ACG%+V?F+D\ST/1]-G:6.2\L[:#SKDB6*"T24=.0[%L1CV'-<_P"*8EAL
M=)B1=J(DZJ/0"9ZYT3S+G$L@R<G#'FFL[/C<Q..F334&G<:@[W&T445H6%%%
M% !1110 4 $G &31C)P*].\#>!MHCU758N?O0PL.GN:B<U!79,I**NS6^'6E
M:IIVE/)?2LL$V#%;L.5]_;/I7:T=**X)2YG<X92YG<****D04444 %%%% !3
M&^^GU/\ *GTQOOI]3_*@!]%%% !1110 4444 %%%% !1110 4444 %,'^N;_
M '1_6GTP?ZYO]T?UH ?1110 4444 %%%% !1110 4444 %%%% !3/^6P_P!V
MGTS_ );#_=H R?$&OKH$=I(]NTRSS"-MK8V#&2W3G%*?$-K'?W,4I1+:"V6X
M-P6R"#[8HUK39=0O-+9$5XH+@O,&/\)4C\>M<W+X1U,2ZG'&R/ 4C^R%FZ[7
M#[#Z#C'XT]!'2GQ/HX@$QNRJF3RL-$X8/C."N,@_A20^*-(N7$5O=AI65BJM
M&Z@D DC)7@\'CK[5A2Z!JE]K2:G+;1P[KR.1H?,!*HJ;<DC@DTH\-Z@+:W01
M1[TU&6X;YQ]QHV4?J1Q19!J:\?BW21#"9[I4DDB25EC21U4, 0=VT<<]2!5J
M;Q#I5O>"TDNL2EE3B-BH9ON@L!M!/N:YBS\+ZE#IEW!)%'YDFGV]NOSC[Z !
MA3;_ $#7;J;8R,T:3V\B8N (]B%205[MP>:+(-3<L?%UA=64UU/OMUCN&@52
MCLSD'J!MR?P'%;$%]:W%B+V*96MBI?S.@P.N<],8-<:_AO5%(<129@O9I5$-
MP$:1'/4'L1[UNZ?IEU8^&)[6!%BNW61D5I"^';.,D]>?PHT NV&N:=J<S16D
MY>15W%6C9#M]1N R/I536?$]EI DCSYUTAC!B4-@;V"C+ $ ]3@\\5F>']'U
M2UUW[;>QRA#;"(F6X$A# YXQT%,U71-4:?5(;6VCGAOYX)_-:0 Q["N1@\G[
MHQ]:- -T>(M+^U&V-U^^&00$8C(&2-V,$^V<T]M=TQ5A8W:!9H3<(<'!C&,M
MTXZCK7-67AB\AU*..>*22WCNC<"4W7R#O]SKG]*2+PG?O9:K!,47*^38D-TC
M\PR<^F2=O_ 119!J;5QXJLEACDM,W!:XCA9&#1E=YP#AAG%65\1:4]S+ MV/
M,B#EOD8#Y?O8;&"1W )KF3X9U"8K*;:1)1-!N,]UYC%48$GT XX[TDFA:G#8
M1VTL"+;V'VJ47 <$S!@V!CJ#\W.?2BR Z)/%>B/!+,+X>7''YK,8W&5]1D?,
M/IFD'BS1#)L^VX;<%(,+C!.,9^7@'(P>AKD1H6JZWX=MMMHD/E6#0QYD'[TM
M_(?6MF^\/7T[ZP8XH_\ 28;=(OF Y3&[Z=*+(+LWCKNFC418&Z'VDMMV[6V[
ML9V[L;<^V<U5'BS1Y$D\BY,KJC,H$3@/MZ@';@GZ5AQ>&+U-3"212RVQNTN?
M,^U;47&#RG4L"/I3[7PWJ$6FZ7 T:![=[@R?.. ^<?6BR#4Z/2=6BU31HM2*
M^1&Z%F#D@(!UY(''O42>)M(>W><79V(P4@Q.&)/3"D9.?852BT:[N/ \FCS*
M(+AK=X0=P89YP>.U07D.O7EM'ML$MMCH'2*=1+(H'.&Z#^= &D?%.C"**3[6
M2)69$40N6++C(V[<Y&1VI;CQ+I4%E%="Y#K,A>((C$L .X ) ]S7/Z-X<U.U
MU6QN+B(>7#=3S,S2AVP\8 Y[G(I+7P_JVG1P2QVL<\GV>2W>(R@!<DD-D_6B
MR#4V=/\ %5K=63W=R8[=%CB<JK,[ R9P,;1D\<8SGVHM?%VGSQW$LI:*..<P
MQX1V:3'?:%W#Z8K M/"NJV]N',49EA:TD2,2#$AC#AESV^_Q4QT?7S)+,+<Q
M)/=/+)%!<*C@$<?-_.G9!J;4?BNQGUBULH27AN+9YQ<;6"C:<8.1QWR21C'O
M5_3]:T_5'=+.?S&09(*,IQZC<!D>XKDK3PMJB6MK;RHHS:7=K)()0=ADDWJW
MN#T]:U/#VC7=KJ N;RWE1HX/)5Y+KS<_0=A2T ZBBBBD,**** "BBB@ HHHH
M **** "BBB@!@_UK?2GTP?ZUOI3Z &/]]/K3Z8_WT^M/H **** "BBB@ HHH
MH **** "BBB@ HHHH *9)]T?6GTR3[H^M #Z*** "BBB@ HHHH **** "BBB
M@#'U3PUI&MW@FU&S$\B($5B[+@9)QP1ZU3_X0'PQ_P! M?\ O])_\570C_6M
M]!3ZKGDMF4I274YO_A ?#'_0+7_O])_\51_P@/AC_H%K_P!_I/\ XJNDHHYY
M=PYY=SF_^$!\,?\ 0+7_ +_2?_%4?\(#X8_Z!:_]_I/_ (JNDHHYY=PYY=SF
M_P#A ?#'_0+7_O\ 2?\ Q5'_  @/AC_H%K_W^D_^*KI**.>7<.>7<YO_ (0'
MPQ_T"U_[_2?_ !5'_" ^&/\ H%K_ -_I/_BJZ2BCGEW#GEW.;_X0'PQ_T"U_
M[_2?_%4?\(#X8_Z!:_\ ?Z3_ .*KI**.>7<.>7<YO_A ?#'_ $"U_P"_TG_Q
M5,C\!>&2@)TM<_\ 7:3_ .*KIZ9%_JQ1SR[ASR[G/?\ " ^&/^@6O_?Z3_XJ
MC_A ?#'_ $"U_P"_TG_Q5=)11SR[ASR[G/VW@GPY:7"3PZ8@DC.Y2TCL ?H3
MBN@HHI-M[B;;W"BBBD(**** "BBB@ HHHH *8WWT^I_E3Z8WWT^I_E0 ^BBB
M@ HHHH **** "BBB@ HHHH **** "F#_ %S?[H_K3Z8/]<W^Z/ZT /HHHH *
M*** "BBB@ HHHH **** "BBB@ IG_+8?[M/IG_+8?[M #Z*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_CU4:*5AW+W]H#_GG_X]1_: _P">?_CU4:*+!<O?V@/^>?\ X]1_: _YY_\
MCU4:*+!<O?V@/^>?_CU']H#_ )Y_^/51HHL%R]_: _YY_P#CU']H#_GG_P"/
M51HHL%R]_: _YY_^/4?V@/\ GG_X]5&BBP7+W]H#_GG_ ./4?V@/^>?_ (]5
M&BBP7+W]H#_GG_X]1_: _P">?_CU4:*+!<O?V@/^>?\ X]1_: _YY_\ CU4:
M*+!<O?V@/^>?_CU']H#_ )Y_^/51HHL%R]_: _YY_P#CU']H#_GG_P"/51HH
ML%R]_: _YY_^/4?V@/\ GG_X]5&BBP7+W]H#_GG_ ./4?V@/^>?_ (]5&BBP
M7+W]H#_GG_X]1_: _P">?_CU4:*+!<O?V@/^>?\ X]1_: _YY_\ CU4:*+!<
MO?V@/^>?_CU']H#_ )Y_^/51HHL%R]_: _YY_P#CU']H#_GG_P"/51HHL%R]
M_: _YY_^/4?V@/\ GG_X]5&BBP7+W]H#_GG_ ./4?V@/^>?_ (]5&BBP7-2W
ME$Y9]N,<=:GJGI_^K?ZU<I#*M\,Q+CUK/VM_=/Y5KO\ ?3ZT[ ]!3N(QMK?W
M3^5&UO[I_*G1^)M)EG2-9GVNYC28PL(G8=EDQM/X&M?Y?:BX6,;:W]T_E1M;
M^Z?RK1N+VVM9[>&5\/<,4C 4G)_I4=_J=IIOE+<%C)*2(XHHS([XY.%4$G%%
MPL4MK?W3^5&UO[I_*IDU_3'@642LH:80;6C9660_PLI&1^-2ZCJMII9@6X$I
M>=BL:10M(S$#)X4$]* *FUO[I_*C:W]T_E5S3]5L]3,RVYD#PD"2.6)HW7/J
MK &KOR^U%PL8VUO[I_*C:W]T_E6@;ZU&HBP+_P"DF,RA=I^[G&<]*E\Y/M!@
MVON";]VP[<9Q][IGCI1<+&5M;^Z?RHVM_=/Y5H3WUK;7-M;ROB6Y8K$-I.2
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MH4:"1Y(_F;AFX)ZUUN!Z"C ]!1<+'(P^&]-@N4FCMG!1RZ(9',:,>I5,[1^
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MN%CG;+3H-.A>*UB9$=VD89)RQZGFJESX<L+N\FNI([@2S +(8YY$#@# !"D
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MJ37+7LW[D'3$=K1T=<-YA4_Q ]03G ."!6HOB74-K7J+ -/@N8K5X2A\QBQ
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M=)N(9O+9D*F(RI(N2KK[$#^=3['#WMRK[B_K>/M?GE]YL?\ ">ZY_P ](/\
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M ,_']YT__">ZY_ST@_[]"C_A/=<_YZ0?]^A7,44?5:/\J#^T<7_S\?WG3_\
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MCM;)./3W]ZBUW;Y&EG_EH;1-_K[?I6.I"NI*A@#DJ>A]JGO;R2_NWN)0H9N
MJC 4#H!35-J5_P"NPI5XNFXI=$E][=RO1116IR!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5;TW3KG5+Q+:V0L[=3V4>IHT[3KG
M5+Q+:U0L['KV ]37K>@Z#;:%9B*(!IFYDE(Y8_X5R8K%1H1LMSU<LRR>,G=Z
M06[_ $19TFQ;3=,AM6F:5D&"S?YZ5=HHKYZ4G)W9]Y""A%1CL@HHHI%!1110
M 4444 %%%% !3/\ EL/]VGTS_EL/]V@#'\20K/:P++8RW, DW.T&?-B/9E Y
M-<W/9WLT)G>UO+BSAU"WDC-Q 3.45AO^7&XC'MZUW]%.XK'GT=C?)>Q6*V5T
M&359YO.\EO+"-NVMNZ=Q3;/1S=7.G6-QIEQ%Y<=S%=SM"0IWJP!W=#G/6O0Z
M;+%'-$\4J*\;J59&&0P/4$>E%PL<YX/$]Q9RZA=C,TF(@V<Y5!MR/8D$_C6/
M8:-/)XCM6N["1K<3W;,9(SMPRH%)^O.*[J&&*WA2&&-(XD4*B(,!0.@ '2GT
M7"QQ;03V_P +)8;J*1)4M2&1P0PYZ5D76FW&H1I-9:9<1VICLXW1H2OF,L@+
M-CN ,_-[UZ1-#%<1-%-&DD;##(ZY!'N*<JJBA5 50,  < 47"QPFK:9<B[U"
M!-/FEGN6B^Q3QQ'9"  ,;NB8-5;B VU[;6]U:2M?'61(+CRSM9"O&'Z'@=/:
MO1JI1:1IL-X;R+3[5+IB29EA4.<]?FQFBX6.(CT:]A\/Z4PM9(S%<N]P@M?,
M?!S@E.K4O]F3VUA PMKYY#',(UDLO,0AFR$* DQY)X)Z ^U>AT47"QQ!LYX]
M6CV:?,9'DA:2.2W+1@#&2LH^[CTKKK:PM;-Y&MX5C:0Y<C^(Y)Y_.K-%%QA1
M112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@!@_P!:WTI],'^M;Z4^@!C_ 'T^M5;S4XK*\L;9T=FO)#&A7&%(4MS^56G^
M^GUK'UFTN+C6=$FBB9XX+EGE8?PCRV&3^)% %[2M2BU;3X[R%'1'SA7QG@X[
M5%J>K2:=GR].NKI4C:61HMH5%'NQ )]ADUC^&VO+;1XM+ELK^UG&X>?Y2E5Y
MSG))_E1K/]J!8]+(O[FUD4FXNX8DWL/^>8QM SSDXZ4["+MUXFAMX8KE;*ZE
MLF17:Y50$0-TZD$_AFDG\2.ES?QV^E75REECS9(WC ^[NX#,">*H:Y#+=:9%
M86VDW@"HK6Q1\(I])%SCCT.:JR^&;^^;7)'FNH+F8QF-HYV2.;$8# JIP02"
M/QHT Z^VO8;K3X[V)LPO'Y@/MC-4=,\0V6I:?->DFVBB?8_GD+C(!4_0A@1]
M:I:@E[<^%(K2SLI+::8+"8P!^Y7H3^%8NK>'M2M([VUMS/J$%];(A)1!L>-E
MP"% &"I/_?-%@.BO?%>CVEB+M;Z">(RK%F&53AB?KVZU>&L::;X6(U"V-V<8
M@\U=YXSTSGIS7)ZKH]\UU>2063LA^RL @'S;"-V/<57N[+6;R_4"TN(8EU'S
MMJ0QK&%P0'W ;BW//-%@N=I%K&FSW9M(K^V>X!(,2RJ6! R>,YI(]:TN9)WC
MU&U=(#B5EF4B/G'S<\<UP=I%)<7VF:9%#LNK>&Y1[A2""2K -D'N2.M27&C:
MC>Z<D4>E20&WTU+5T8 >:X=3\N.HX)S[T6"YV@UW3Y41[6ZM[E6F6$F*=,*S
M' []?8<U%=^)M(M;:[E%_;RM:@F6..52RG.,$9X.:YV\T6^.NQRPV;>0);)F
M*X ^1OF/X"HX]+U!K:ZM8;"X2!;61(TN$0F-B<A8W W,/K[4607.K@U[2I_L
MJB_MEEN45XHC*NYL^@SS5^3[H^M<4ME?"6#R-/ND:46_FQS1H\+[2,EL\J0,
MD8]J[63[H^HH ?1112&%%%% !1110 4444 %%%% &7=:#I=]>R3W5E'+*P&6
M;.3@8_I4?_"*:%_T#8?U_P :Y_QEXAU+1]6ABLIQ&CPAF!16YR1W'M7._P#"
M<:__ ,_B_P#?E/\ "O1I87$3@I1EIZL\#$YC@*-:4*E.[6_NK_,]"_X130O^
M@;#^O^-'_"*:%_T#8?U_QKSW_A.-?_Y_%_[\I_A1_P )QK__ #^+_P!^4_PK
M3ZGBOY_Q9A_:^6_\^O\ R6/^9Z%_PBFA?] V']?\:/\ A%-"_P"@;#^O^->>
M_P#"<:__ ,_B_P#?E/\ "C_A.-?_ .?Q?^_*?X4?4\5_/^+#^U\M_P"?7_DL
M?\ST+_A%-"_Z!L/Z_P"-'_"*:%_T#8?U_P :\]_X3C7_ /G\7_ORG^%'_"<:
M_P#\_B_]^4_PH^IXK^?\6']KY;_SZ_\ )8_YGH7_  BFA?\ 0-A_7_&C_A%-
M"_Z!L/Z_XUY[_P )QK__ #^+_P!^4_PH_P"$XU__ )_%_P"_*?X4?4\5_/\
MBP_M?+?^?7_DL?\ ,]"_X130O^@;#^O^-'_"*:%_T#8?U_QKSW_A.-?_ .?Q
M?^_*?X4?\)QK_P#S^+_WY3_"CZGBOY_Q8?VOEO\ SZ_\EC_F>A?\(IH7_0-A
M_7_&F1^%=#* G38?U_QK@/\ A.-?_P"?Q?\ ORG^%(/&VO*,"\7'_7%/\*/J
M>*_G_%A_:^6_\^O_ "6/^9Z'_P (IH7_ $#8?U_QH_X130O^@;#^O^->>_\
M"<:__P _B_\ ?E/\*/\ A.-?_P"?Q?\ ORG^%'U/%?S_ (L/[7RW_GU_Y+'_
M #/0O^$4T+_H&P_K_C1_PBFA?] V']?\:\]_X3C7_P#G\7_ORG^%'_"<:_\
M\_B_]^4_PH^IXK^?\6']KY;_ ,^O_)8_YGH7_"*:%_T#8?U_QH_X130O^@;#
M^O\ C7GO_"<:_P#\_B_]^4_PH_X3C7_^?Q?^_*?X4?4\5_/^+#^U\M_Y]?\
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M?^2Q_P ST+_A%-"_Z!L/Z_XT?\(IH7_0-A_7_&O/1XXU\$$W:$>GDI_A7?\
MAWQ%!KEKU"7*#]Y'_4>U8UJ.)HQYG*Z\FSJPF+R_%3]G""3\TM1__"*:%_T#
M8?U_QH_X130O^@;#^O\ C6Q17)[:I_,_O/4^J8?_ )]K[D8__"*:%_T#8?U_
MQH_X130O^@;#^O\ C6Q11[:I_,_O#ZIA_P#GVON1C_\ "*:%_P! V']?\:/^
M$4T+_H&P_K_C6Q11[:I_,_O#ZIA_^?:^Y&/_ ,(IH7_0-A_7_&C_ (130O\
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M>#45[SY4?_/-?RH\J/\ YYK^5']J?W/Q_P" +_5I_P#/W\/^">#45[SY4?\
MSS7\J;%%'Y8^1?RH_M3^Y^/_   _U:?_ #]_#_@GA%%>\^5'_P \U_*CRH_^
M>:_E1_:G]S\?^ '^K3_Y^_A_P3P:BO>?*C_YYK^5'E1_\\U_*C^U/[GX_P#
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M5/:5)<UMM+?JPHHHKSCWPHHHH **** "BBB@ I@_US?[H_K3Z8/]<W^Z/ZT
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MK7_0,NO^_9KW\/*FZ$8R:/AL?"O'&U)TXOKT?56+&FZR[7LDM_<846SQH F
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M':KY0J !D[0,^IK5T;3/[)L#:^=YO[UY-VW;]YB<8R?6M"BE<84444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 P?ZUOI3Z8/]:WTI] #'^^G
MUI]%% !1110 4444 %%%% !1110 4444 %%%% !3)/NCZT44 /HHHH ****
M"BBB@ HHHH **** &#_6M]!3Z** "BBB@ HHHH **** "BBB@ HHHH *9%_J
MQ110 ^BBB@ HHHH **** "BBB@ HHHH **** "F-]]/J?Y444 /HHHH ****
M "BBB@ HHHH **** "BBB@ I@_US?[H_K110 ^BBB@ HHHH **** "BBB@ H
MHHH **** "F?\MA_NT44 /HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
-HH 8/]:WTI]%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ptgx-20201231x10k007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ptgx-20201231x10k007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %G \4# 2(  A$! Q$!_\0
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MI_W[/^-<C4BP2M"TRQL8E.&<#@'ZT>QI]@]M4[G5?\+'US^[:?\ ?L_XT?\
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MIGFQ_P!]?SH\V/\ OK^= #Z*9YL?]]?SH\V/^^OYT /HIGFQ_P!]?SH\V/\
MOK^= #Z*9YL?]]?SH\V/^^OYT /HIGFQ_P!]?SH\V/\ OK^= 'C?CC_D<=0^
MJ?\ H"USU=!XW(/C"_(Y&4_] 6N?KUJ7P(\BI\;"BBBK("BBB@ KL+5T\->%
M(-1BC1M2OW(CD<9\M!W'Z?G7'UUVI(VI^ ]+N8 7^PNT4RKR5!QR?R'YUE5Z
M)[&M/JUN4M/\8:I;WJ27=R]S;LP$L4OS KWQZ5H>&I+*;QZLNG)(EJVXHK@
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M\^#M*H ??(K1S:3]3-03:]#,TKP]-J5K)>27$%I9H=IFG; )]!ZUOOI;Z9X
MU13/#/')/&\<L+;E894?G5+5LGP%HAASY(=Q)C^]D]?UHL/-_P"%<ZMNSY7V
MF/9]<KG'Z5+;E9WZE)):6Z&-J.CS:=;6=R\D<D-TF]&3/'J#[TCZ3+%HL>J2
M2(L<DAC2/G<V.I^E;>G(=<\&W%@H+75A*LT0QR48X(_G^E0>+I4AN;7283^Z
ML8@AQW<\DU<9MOEZDR@DN;H96B?\AVP_Z^(__0A71^*/$>KV/B>]@MKZ2.*-
M@%0=!\H-<YHG_(>L/^OB/_T(5?\ &8_XJ[4./XU_]!%$DG42?8$VJ;-:&Y_X
M2WP]?K>1H=1LE$L<ZJ 77T./I^H]*Y_2M"N-4BEN/-AM[6'_ %D\[;5!]/<U
MM^&8VT[PWK.J3C9')%Y,1;^)N_\ ,?K5BWET^/X?6K7EI-<0?:6WB&3:0W."
M?;_ZU9\SBVH]R^522<C!U'P[+9V7VVWNK>]M VUI(&SL/^T.U2VWAAGLX+F]
MU&TL5G&Z%9F.6'K["M2TU#3UT754TS1KORY(2LKM,&5.N"?QIK:E:?8+*S\2
M:5+^[A @GC;#>7VXI\\]A<D-S)?1;_2=>M+7S(A+(RM!,AW(P/0BDN=+U'4/
M$UQ8DK/>F5M[CA<CJ?85L3:9%9:SH=U:WDMQ9W+ PB4_,@!''TJ]8G/BWQ,D
M?%RT,OE>O49Q^E'M'NNP^1;/N8Z>#);B<6]GJEC<S @2HCG*>IQW JA:>&[N
M]O[ZR@>-IK0,2.?GP<8''>I?""SGQ98^5N#"0[^/X<'.?PK=TB1HO$'B:1"0
MRPS$'W&:;G.-U<2C&23L9"^$)IHI!;:E8W%U&I9[>*3+ #M[FN=(()!ZBNB\
M#$CQ5;<]5;^58-Q_Q\R_[Y_G5P;YN5ZF<DN6Z(J***U,PHHHH ****!GONE_
M\@FS_P"N"?\ H(JV*I:9(@TJS!=?]0G?_9%6O-C_ +Z_G7CO<]B.P^BF>;'_
M 'U_.CS8_P"^OYTACZ*9YL?]]?SH\V/^^OYT /HIGFQ_WU_.CS8_[Z_G0 ^B
MF>;'_?7\Z/-C_OK^= #Z*9YL?]]?SH\V/^^OYT /HIGFQ_WU_.E#JW1@?H:
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M'$,40VJGT%:*>,+D['N;&SN;A  L\L8+<>OK53_A%M<_Z!L_Y"C_ (1;7/\
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M0_\ !A/_ /%T<H<QT6*,5SO]CVW_ #VU#_P83_\ Q=']CVW_ #VU#_P83_\
MQ='*',=%BC%<[_8]M_SVU#_P83__ !=']CVW_/;4/_!A/_\ %T<H<QT6*,5S
MO]CVW_/;4/\ P83_ /Q=']CVW_/;4/\ P83_ /Q='*',=%BC%<[_ &/;?\]M
M0_\ !A/_ /%T?V/;?\]M0_\ !A/_ /%T<H<QT6*,5SO]CVW_ #VU#_P83_\
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M\YO_ $.*FA,LT4459 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<F19&SR<'Y<<]LUU/Q!E5M%TO4('W,EU')$X[YYS0!W%%(I)12?2EH ****
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MT 3T444 %%-EDCAB:65U2-!N9F. !ZDUF:MX@L-'TI-2N&=[9V 5HEW9STH
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MO@O3M6ETYYGD1;)5157&'4$<-Q[5=UCP_;ZS=6$\TTD9LI1*@3&&/H<UKT4
M8K^&K1M>EU5))(WGB,4\2XV2CID^]9@\"0+;O91ZK?IISL2;,.-F"<D9QG'X
MUUM% '%^+[-;B'1?#5DFU9IU+*/X(D&23_GM79(@1%1> HP*SK'7;/4=4O=/
M@\SS[(@2[EP.?0]^E:= &;JW^LTW_K\7_P!!:M*LW5O]9IO_ %^+_P"@M4FJ
MZO8Z+9FZOYUBB!P,\ECZ =S0!>HKE-/^(GA[4;M;99Y87;A6F3:I.>F<UU=
M!1110!D:WX?@UQK-III(S:S"5=F/F(['-:]%% '-7/@RVFU6YOH+^\M?M0Q<
M1PN )!WSQD?A3$\#V4?ARXT1;JX^S32^9NXW+SG XKIV8*I8] ,UG:+K=IK]
MD;NR\SR@Y3]XN#D4 /GTF"XT/^RI2S0&$0D]\ 8S]>*AT'13H=G]E%_<740
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MENHVWPL>I0C^M=1I&GMI>F0VCW$ERZ#YYI#RY]: .#UN]OK'XG&;3]/-_/\
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M:F9+5V9W+QK:JJ*/X/+ ^Z0.I_G77444 %%%% !1110 4444 %%%% !1110
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ML_W2!P![UQ5]XPUBSMA?KK4,TXFQ)906ZM"B^ADQG]:ZV#0=:O6OY-;U5?\
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M;=31L\TLC;H23@, .X'-<^/ ^O+H-SH2:AIZV+,75Q$WFR'.0K'H!GG(R>*
M-*XU[4(-9\/7#S!=/U&,)+%M&!(1P<XSU([U2TKQ;?R^*KQ;N8?V2WG"W!50
M!Y?7D#//UK7U7PU<ZCX1M--6:*._M?+:.4$[59>^<9Z9[5E7W@2\E\+Z=I]K
M=0QWML6,DI)"MNSNYQGO0!%I_B#7)/!]QJ\UY;H\]P5@><*JQ1YQD8'S'K^5
M)HGB;4#XQMM+?5#J=G<1%A,]L(L$ G*X R..M;&N>$6O_#VGZ?8SQPR6!1HO
M,&48J,<_6JUOX8UM_%.GZY?7=B[0(8WA@1D5%Y VYSGJ3SB@"/PI_P CYXH_
MWT_F:[>N=T70+G3?$NL:E++$T5ZRF-5)W+C/7BNBH S=6_UFF_\ 7XO_ *"U
M<KXCCBO_ (D:-97JA[58#(J-]UFR>H[]!75:M_K--_Z_%_\ 06JCXG\,)X@C
M@FAN&M+^V.Z"=1T]C[4 5/B#8VD_A&YEEC026X#0O@ J<C@?7I6%+KVN0V_A
M2WLKD))>Q;9!(@8,> "<C/OP15J7P?XEUJ2&#Q#KL4MC&=QCMUP7Y'!^51^)
MSBHO&=GCQ-X8M+.3[,58K$ZKG801@X[T :%MJFK:/XOM]&U.^%_!=Q%XI3"L
M;(0"<8'&.*P&\;WM]'>ZA'KMO8>4Y^SZ>T(;S5']YB,\^U=38>'=2F\1C6M<
MN;626&,QP16JL$4'J3NY]:SU\'ZSIRW=EI%]8QZ?<R;P\T;>=!D\A"./S_2@
M"'6?%NH2>&-#U/3)%@FO)Q'(I0,">01R.F1VJ:^U'7M \1Z1%=:DE[;:@Y1X
MC J",Y'W2.?XNYJ_KGA6XU#3=)M+:Y5C93+(\EPQW/CJ> >2:G\1>'[G6-5T
M6[@EA1+"8O(')RP)7I@>QH Z";_4R?[I_E7&_##_ )%=_P#KX?\ I79NI:-E
M'4@BO/=,\*>--%MC;:?K6GPPER^TINY/N4- '0^+=4NM/AMDM[ZVL4EDQ)<S
M88HO^RIZFL7PSXBU"]UO4]*NKMKV". R13RP")^@_A ''-3WWA;7[Y=+OIM0
MLYM5LF;=YJ'RG!/'  _E4^E>&-6M?$UUJ]]>6L[7=OLD6-638V  %'.5& ,D
MYH YWPG!KC^%[^?3=2CLT@N)75!"KF1@ 3N)Z#IC SUJ[=^/;H^%=-N(C%;W
ME[(87F<96+!P7Q^(J?3_  GXFTG2[JQLM1T_R[MV:3S%<F//&4/J1U!'85=N
M_ D9\/6%E970CO+!_-AG=<AGZG(]"<>M %/0_%4O_"3Q:2^L1:M;W*$I.L(C
M9' S@@<8P#4G@C_D8_%/_7ZW_H35J:1HVKKJYU'5[RV&U-D=M9!EB]V.[O3O
M#V@7.D:KK-W/+$Z7UP98PA.5&2><CKS0!C?$QY(H-'>*/S)%O 53.-QQTJY8
M>(?$MQ?P17'A9H(7<*\OG9V#UZ59\8^'K[7[>R&GW$$,UM-YNZ;..GL#5&'2
M_'ZS1F77K!HPPW*(ADCO_P LZ (/$WB+5O"^M.TDWVBQNX&%M&44>7*,8R0
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M?\:/^%4W'_05B_[\G_&BP<LNQZO]HA_YZQ_]]"C[1#_SUC_[Z%>4?\*IN/\
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M?\*IN/\ H*Q?]^3_ (T?\*IN/^@K%_WY/^-%@Y9=CU?[1#_SVC_[Z%'GP_\
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M%>7_ /"H+G_H,0_]^#_C1_PJ"Y_Z#$/_ 'X/^-'M8=P]G+L>H>?#_P ]8_\
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M\'_&C_A4%S_T&(?^_!_QH]K#N'LY=CU#SX?^>L?_ 'T*//A_Y[1_]]"O+_\
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M_P *JN/^@K%_WY/^-'_"JKC_ *"L7_?D_P"- 'K7VB'_ )[1_P#?0H^T0_\
M/:/_ +Z%>2_\*JN/^@K%_P!^3_C1_P *JN/^@K%_WY/^- 'K7VB'_GM'_P!]
M"CSX?^>T?_?0KR7_ (55<?\ 05B_[\G_ !H_X55<?]!6+_OR?\: /6OM$/\
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MY61[6/<]4^T0_P#/:/\ [Z%'VB'_ )[1_P#?0KRO_A4ES_T%X?\ OR?\:/\
MA4ES_P!!:'_OR?\ &CD8>VCW/5/M$/\ SVC_ .^A1]HA_P">T?\ WT*\K_X5
M)<_]!:'_ +\G_&C_ (5)<_\ 06A_[\G_ !HY&'MH]SU3[1#_ ,]H_P#OH4>?
M#_SVC_[Z%>5_\*DN?^@M#_WY/^-'_"I+G_H+P_\ ?D_XT<C#VT>YZI]HA_Y[
M1_\ ?0H\^'_GK'_WT*\K_P"%27/_ $%H?^_)_P :/^%27/\ T%H?^_)_QHY&
M'MH]SU3[1#_SVC_[Z%'VB'_GM'_WT*\K_P"%27/_ $%H?^_)_P :/^%27/\
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MT/\ WY/^-'_"I+G_ *"T/_?D_P"-'(P]M'N>J?:(?^>T?_?0H^T0_P#/:/\
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MBBBMCD"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@!LD4<J%)$5U/4,,BK=D/WK?2JU6;+_6M_NU$_A9I1^-%^
MBBBN8]$*K7__ !ZM]15FJU__ ,>K?44UN-;F31116A84444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% %+5M172M+GO7C,@B7(0'!8]AFL6'6M;L[RR
M76;6R%M>OY<;6S-NB8C(#9Z]^GI5WQ7<>1H$RF-'\YEA^?[J[CC<?IUK"O-+
MET&32K^749M02*58A#<8(&[C*8[CWS02WJ:MYJVL76J7%EH=O9L+0#SY;MF
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M7Z***YCT0JM?_P#'JWU%6:K7_P#QZM]136XUN9-%%%:%A1110 4444 %%%%
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M,,92,X&,]*L_\+?O/^@3!_W]/^%4Z$[B52-CUFBO)O\ A;]Y_P! F#_OZ?\
M"C_A;]Y_T"8/^_I_PI>PF/VL3UFBO)O^%OWG_0)@_P"_I_PH_P"%OWG_ $"8
M/^_I_P */83#VL3UFBO)O^%OWG_0)@_[^G_"C_A;]Y_T"8/^_I_PH]A,/:Q/
M6:*\F_X6_>?] F#_ +^G_"C_ (6_>?\ 0)@_[^G_  H]A,/:Q/6:*\F_X6_>
M?] F#_OZ?\*/^%OWG_0)@_[^G_"CV$P]K$]9HKR;_A;]Y_T"8/\ OZ?\*/\
MA;]Y_P! F#_OZ?\ "CV$P]K$]9HKR;_A;]Y_T"8/^_I_PH_X6_>?] F#_OZ?
M\*/83#VL3UFBO)O^%OWG_0)@_P"_I_PH_P"%OWG_ $"8/^_I_P */83#VL3U
MFBO)O^%OWG_0)@_[^G_"C_A;]Y_T"8/^_I_PH]A,/:Q/6:*\F_X6_>?] F#_
M +^G_"C_ (6_>?\ 0)@_[^G_  H]A,/:Q/6:*\F_X6_>?] F#_OZ?\*/^%OW
MG_0)@_[^G_"CV$P]K$]9HKR;_A;]Y_T"8/\ OZ?\*/\ A;]Y_P! F#_OZ?\
M"CV$P]K$]&/4TE>8_P#"T[O/_(+A_P"_I_PH_P"%IW?_ $#(?^_I_P *[DCF
MN>G45YC_ ,+3N_\ H&0_]_3_ (4?\+3N_P#H&0_]_3_A18+GIU%>8_\ "T[O
M_H&0_P#?T_X4?\+3N_\ H&0_]_3_ (46"YZ=17F/_"T[O_H&0_\ ?T_X4?\
M"T[O_H&0_P#?T_X46"YZ!K7_ " M0_Z]I/\ T$UE:)K^CVWAS3TFU2R1X[6,
M.AG7<"%&1C.<^U<D_P 4+B1&1])MV1AAE:0D$>_%4AXWLU((\+Z6".01&O\
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M(Y_92/5**\K_ .%M7?\ T"H/^_I_PH_X6U=_] J#_OZ?\*.9![*1ZI17E?\
MPMJ[_P"@5!_W]/\ A1_PMJ[_ .@5!_W]/^%',@]E(]4HKRO_ (6U=_\ 0*@_
M[^G_  H_X6U=_P#0*@_[^G_"CF0>RD>J45Y7_P +:N_^@5!_W]/^%'_"VKO_
M *!4'_?T_P"%',@]E(]4HKRO_A;5W_T"H/\ OZ?\*/\ A;5W_P! J#_OZ?\
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M^G"SM+>*X@1CM\R-FVYY(&".YH%S+FN>TT5Y5_PL?Q)_T#+7_OQ)_P#%4?\
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MU_\ \>K?44UN-;F31116A84444#"BBB@ HHHH$%%%% !1110,**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@0J_>'UJR;B '!FC!';<*K+]\?6O/K
M[X43WE_<7(U:-1+(S[3 3C)SZUS5U%M78TVMD>E?:;?_ )[Q_P#?0KD/B7+#
M)X-F"RHQ$J$ ,#WKG?\ A3]Q_P!!F+_OP?\ XJC_ (4_<?\ 09B_[\'_ .*K
M*,:<6GS";DU:QU/PW.?!=K[.X_6NMK+\/:+'H&C0Z?&Y?8,LQ[L>I]A6I6,W
M>39I%65@HHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** ,P]324IZFDKTUL<84444Q!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !5F+_5BJU68O]6*N&YAB/A'
MT445L<84444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "K-E_K6_W:K59LO]:W^[43^%FE'XT7Z***YCT0JM?_\
M'JWU%6:K7_\ QZM]136XUN9-%%%:%A1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 J_>'UJ]5%?O#ZU>KCQ6Z+
MB%%%%<I84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 9AZFDI3U-)7IK8XPHHHIB"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "K,7^K%5JLQ?ZL5<-S
M#$?"/HHHK8XPHHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M '!_WT*/[/N?[@_[Z%;5%%PL8O\ 9]S_ '!_WT*/[/N?[@_[Z%;5%%PL8O\
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MOO&&EV%QY$@NG<*&E$4#/Y(//SD?=HL!T%%8]_XETW3DMGFE9A=(7A\I"Q<
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
;%%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ptgx-20201231x10k008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ptgx-20201231x10k008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %P \4# 2(  A$! Q$!_\0
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MHH **** "BBB@ HHHH **** &2R+#$\C_=4$GZ5RX^(?A_KYT_\ WX:NBO\
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M8_\ ?IO_ (JC_A9.M_\ /&Q_[]-_\57'T5T>QI]CF]M4[G8?\+)UO_GC8_\
M?IO_ (JC_A9.M_\ /&Q_[]-_\57'T4>QI]@]M4[G8?\ "R=;_P">-C_WZ;_X
MJC_A9.M_\\;'_OTW_P 57'T4>QI]@]M4[G8?\+)UO_GC8_\ ?IO_ (JC_A9.
MM_\ /&Q_[]-_\57'T4>QI]@]M4[G8?\ "R=;_P">-C_WZ;_XJC_A9.M_\\;'
M_OTW_P 57'T4>QI]@]M4[G8?\+)UO_GC8_\ ?IO_ (JC_A9.M_\ /&Q_[]-_
M\57'T4>QI]@]M4[G8?\ "R=;_P">-C_WZ;_XJC_A9.M_\\;'_OTW_P 57'T4
M>QI]@]M4[G8?\+)UO_GC8_\ ?IO_ (JC_A9.M_\ /&Q_[]-_\57'UL:?H]K<
MZ3+J-YJ!M8DE$6%A,A)(]C2E3IQU:&JM1Z)FQ_PLG6_^>-C_ -^F_P#BJ/\
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M\51_PLG6_P#GC8_]^F_^*KCZ*?L:?87MJG<[#_A9.M_\\;'_ +]-_P#%4?\
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M!]*]XOK"S6PN"+2 $1MSY:^GTKP<?='TKMPFS.'%[H6BBBNPXPHHHH ****
M"BBB@ HHHH **** .NGT^&]\+Z/YNI6MGM#X\_/S<]L"DEL8K/P7=I#?VUYO
MN4^: G ]CD5D:AJ$%SHNFVD9?S;<-YF5P.3V/>EM]2@B\-7-B2WVB2=9$^7C
M ]ZY^65OF='-&_R-;_A&[6U:"VN;'5;B655+W%NO[N,GI@8^;'?FH1X?L;"U
MU&;4WN&-G<+&%AP#("..O2I9-:L=0>&ZN-6U*S=459;:'<5<C^Z0P S]*H7&
MKVL^D7]L@F5Y[E9(U=B^% [L3UI+G>X/D6Q:N-.T"UBL[MQ?O#>+E( ZAH^<
M$EL<U7DTG3K/6KJUN9KB2*(!H8HES)-GH,X(%5;[4(+C3]*AC+;[5"LF5P,[
ML\>M;*>(+%M1U%UN)[0W,:+'=)%EDP.1CK@^U/WUW#W&1R:-90VUIJ8LM0M4
M^TK&\%PPRWH5) _E4^K:?87OB+4KB7SXK:T7?<$,"SGL%XXJI<ZQIXT;[)'=
MWEW<+<I,99U(#XZXR3C\:EN-:TJ34+TF6X>TU&,";]UAH6'3'/S5/O;C]VUB
MG_95CJEBUQI*W$4D4BI)#.X?AC@," *DN+'P_:WDFFS27BSQ@JUWN&P/CILQ
MG':FKJ5AH]@\&F3RW4\LBN\KQ>6JJIR% R33Y[K0+F_DU262X=GRS61AX+D?
MW\],U5Y>=B?=\KC'T_1K/0K6\NC=RSW*/M6)@%!'<Y[>U:^G6UM9^)HXY6N9
MRUCO5FER5RG(Z=/2N;U*_@N]*TZWB!$D"N'&W &3D8/>M,:]9?\ "0VUX?-^
MSK:B!R$^8';@D#O0U)K[QIQ3^XYVY,1N9# KI$6.U7;) ]S452W2PI=2+;RM
M+#N^5V3:2/IVJ*MUL8/<****8@HHHH **** "BBB@ HHHH *]<\"75O%X4ME
MDGB1@S\,X!^\:\CKUOP+:6TWA2V>6WB=BS\L@)^\:YL5\!U83XSI?M]I_P _
M4'_?P?XT?;[3_GZ@_P"_@_QI/[/LO^?2W_[]+_A1_9]E_P ^EO\ ]^E_PKSS
MT!Z7=O*P6.>)V/97!-35D7EK;P:EI;1011DSL,H@!_U;>E:] !1110 4444
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ML[0?^01'_P!=)/\ T-J -*BBB@ HHHH @O$:2SG1!EF0@#U.*\9'@_Q#@?\
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MU50%$1  ' &*;I?_ "";/_K@G_H(I]__ ,>%Q_US;^5,TO\ Y!-G_P!<$_\
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M"D__ 'Z6C_A5]M_T%)_^_2UW]%/V]3N'L*?8X#_A5]M_T%)_^_2T?\*OMO\
MH*3_ /?I:[^BCV]3N'L*?8X#_A5]M_T%)_\ OTM'_"K[;_H*3_\ ?I:[^BCV
M]3N'L*?8X#_A5]M_T%)_^_2T?\*OMO\ H*3_ /?I:[^BCV]3N'L*?8X#_A5]
MM_T%)_\ OTM'_"K[;_H*3_\ ?I:[^BCV]3N'L*?8X#_A5]M_T%)_^_2T?\*O
MMO\ H*3_ /?I:[^BCV]3N'L*?8X#_A5]M_T%)_\ OTM'_"K[;_H*3_\ ?I:[
M^BCV]3N'L*?8X#_A5]M_T%)_^_2T?\*OMO\ H*3_ /?I:[^BCV]3N'L*?8X
M_"^V((_M6?G_ *9+7<VT'V:UBA#%A&@7)[X&*FHJ)U)3^)EPIQA\*"BBBH+"
MBBB@ HHHH X[QG_Q]6O^X?YT4>,_^/JU_P!P_P Z*8'8T444@"BBB@ HHHH
M0]#6=H/_ ""(_P#KI)_Z&U:)Z&L[0?\ D$1_]=)/_0VH TJ*** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#-U'_D(Z7_U\
M-_Z+:M*LW4?^0CI?_7PW_HMJTJ "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@"O?_ /'A<?\ 7-OY4S2_^039_P#7!/\ T$4^_P#^/"X_ZYM_*F:7_P @
MFS_ZX)_Z"* +=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 <=XS_P"/JU_W#_.BCQG_ ,?5K_N'^=%,#L:***0!
M1110 4444 (>AK.T'_D$1_\ 723_ -#:M$]#6=H/_((C_P"NDG_H;4 :5%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!F
MZC_R$=+_ .OAO_1;5I5FZC_R$=+_ .OAO_1;5I4 %%%% !1110 4444 %%%%
M !1110 4444 %%%% %>__P"/"X_ZYM_*F:7_ ,@FS_ZX)_Z"*??_ /'A<?\
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M"?OF1G]47 _G4E%%(04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!FZC_R$=+_Z^&_]%M6E6;J/_(1TO_KX;_T6U:5 !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 <=XS_P"/JU_W#_.BCQG_ ,?5K_N'^=%,#L:***0!1110
M!0U:QDU&T$$<XB&]68-'O#@'.TC(X/'>N<.A:G'#;M*C7$JQSQXMYO(*,[[E
M;.[D<<_7H:Z^21(HVDD8*B@EF/  '>LF7Q9H,%I;74FJ6RP76?)<MQ)C@XIA
M8MKIT4UI M_%#<W$<85I'0'+8Y//J:B\/J%T>)5  #R  =AO:M$,'3<IR",@
MUDZ)=V\6EHDD\2L)),AG (^=J0&Q15?[=:?\_4'_ '\%'VZT_P"?J'_OX/\
M&G9BNBG/;L-1AC%U<A) Y($GIZ5IJ-J@9)P,9)YK,GN[8ZI:L+B':%?)WCCI
M5S[=:?\ /U!_W\%%F%T6**K_ &ZT_P"?J#_OX*/MUI_S]0?]_!19A=%BBJ_V
MZT_Y^H/^_@H^W6G_ #]0?]_!19A=%BBJ_P!NM/\ GZ@_[^"C[=:?\_4'_?P4
M68718HJO]NM/^?J#_OX*/MUI_P _4'_?P468718HJO\ ;K3_ )^H/^_@J.:Y
MM98RHODC/]Y)5!_6BS"Z+>:6L;3;F,JTD^I%B'90KR+C';M6B+ZTQ_Q]0?\
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M_P"WM)_Z"5I_W^6C^WM)_P"@E:?]_EHY)=@YH]S0JMJ/_(/N/]PU!_;VD_\
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M45G_ -O:3_T$K3_O\M']O:3_ -!*T_[_ "T<DNP<T>YH4F:H?V]I/_02M/\
MO\M9]]K4&X/:ZU: %@-GRM@=SG-')+L-2B^IT%%9,&M:=''B;6+.5_[P=5_3
M-3?V]I/_ $$K3_O\M')+L+FCW-"BL_\ M[2?^@E:?]_EH_M[2?\ H)6G_?Y:
M.278.:/<T**S_P"WM)_Z"5I_W^6C^WM)_P"@E:?]_EHY)=@YH]S0HK/_ +>T
MG_H)6G_?Y:/[>TG_ *"5I_W^6CDEV#FCW-"BL_\ M[2?^@E:?]_EH_M[2?\
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M '#_ "H]K/\ F8*G"^Q@VW@S0)K:*62QR[J&8^8W)_.I/^$'\/?\^'_D5_\
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M (0?P]_SX?\ D5_\:Z*BCVM3^9A[.'8YW_A!_#W_ #X?^17_ ,:/^$'\/?\
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M8:G_ 'VW^-;]%'M9]V'LX]CFO^$;TC^US!]B3R_(#[<GKN(]:F_X0KP[_P!
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M .NDG_H;4 :594=K#=:E>><A?:4"_,>./K6K5"S_ .0C??5/Y4 ._LBQR#Y
MR.AW'_&JU_8V]M LL,>QQ(@!#'^\/>M;-4=5_P"/(?\ 75/_ $(4 7J*** "
MB@]*S8+F_N8S)%%;A-S ;G;/!QZ46"Q)!_R%+K_=3^M7JS$AU%+F6;9:YD &
M-[<8_"I%N;N.]AAGCAQ+G!C<G&!GN*;0[%^BBBD(**** *&D_P#'K)_UV?\
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MV)\L8Y"')_6K>E?\>?3^-OYFKM/9CV*D=^'G2)[>>)GSM,B@ X_&KE4KH?\
M$PL_J_\ *KM#$PIDLHAA>5ONHI8X]J?5:_\ ^0?<_P#7-OY4@*XU9& (MK@@
M\]%_^*JM8WOV>.17M9\M*[C&WH22/XJNV]C:&VC)M8"=H_Y9CTJ3[!9_\^D'
M_?L?X55T5=#;6_CNI7B"2(Z ,0X'0_0GTJW6;;11PZU<+%&B+Y*'"J .K5I4
MF)F;J/\ R$=+_P"OAO\ T6U:59NH_P#(1TO_ *^&_P#1;5I4A!1110 4444
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MIJ5K*Q=CL$@#<GT/-'0B>'JP5W'0Z*BDS1FD8"FLJ*V6ZN[LRR3?+)@!964
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MRFS/;396&UM1N6![$(1_Z#6!#X*\/ZM9%KS386F#L/.0>6_7KE<5UQJAH_\
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M5!)!"A+ &51E3@_G1)I$$R%))KEU/8SL:=J7W(/^NR_SJ]3O9(=[(STTF&)
MD<UTJCH!.P%+I2"."506($K#+')_.KYJCIW^KF_Z[-1>Z"]R]24M)2$49?\
MD-6__7)JOU0E_P"0W;_]<FJ_38V0W/\ QZ3?[C?RJ/3?^0;;_P"X*DN?^/2;
M_<;^51Z;_P @VW_W!1T#H6J***0C&N+%FOYY7L/M"OC:1*%Q@?6HF@B25(CH
MYWODJ//';\:WJI7'_(3M?]U_Z52D4F9LNGM($6+2_*8.IWF8' !^M;PHI:3=
MQ-W"BBBD(**** "BBB@ HHHH CFF2",N^[:/[JEC^0K/TFX0B2(K*KM+(XW1
M,."Q(Y(K4HIW&%%%%(1FZC_R$=+_ .OAO_1;5I5FZC_R$=+_ .OAO_1;5I4
M%%%% !1110 4444 %%%% %74I9(-,NI8I(XY$B9E>3[JD X)]JY;P[>BYU"V
M)U;Q#<.Z%C%=V6R$_+_>$0'T^;TZUU.I)%)IETD\GEQ-$P=\ [1CD\\5RWAR
MYD;4((9-6UQHMA\B+4+2.-+A0.H8*&.!@\D']:!'9T444#"BBB@"O?\ _'A<
M?]<V_E3-+_Y!-G_UP3_T$4^__P"/"X_ZYM_*F:7_ ,@FS_ZX)_Z"* +=%%%
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M **** "BBB@ HHHH **** (6MH'8LT,9)ZDH.:D1510JJ%4= !BG44 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!QWC/\ X^K7_</\Z*/&?_'U
M:_[A_G13 [&BBBD 4444 9^L&W&G2"Y, C) _P!(8K&3GC<1VKB+IR^DV<1>
M)-D=SM:Z<^2P#\>4<Y+?W,_PUZ/BDQ0!GI;O=V5M(+J]M_W2Y4E=W0?>R#SZ
MTWP^,:/$,DX>09/4_.U:1^Z:SM!_Y!$?_723_P!#:@#2HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** ..\9_P#'U:_[A_G11XS_ ./JU_W#
M_.BF!V-%%%( HHHH **** $/0UG:#_R"(_\ KI)_Z&U:)Z&L[0?^01'_ -=)
M/_0VH TJ*** "BBB@ HHHH **** "BBB@ HHHH **** *&D_\>LG_79_YU?J
MAI/_ !ZR?]=G_G5^F]QRW"BBBD(*KWW_ !XS_P"X?Y58JO??\>,_^X?Y4+<:
MW"Q_X\8/^N:_RJQ5>Q_X\8/^N:_RJQ0)A1110 51U/\ X]X_^NJ_SJ]5.[L6
MNF&;J9%!!"J%QD?44UN-;ENEJ.&-HHPKRM(?[S 9_2I*0@HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@#-U'_D(Z7_U\-_Z+:M*LW4?^0CI
M?_7PW_HMJTJ "BBB@ HHHH **** "BBB@"KJ3SQZ9=/;9\]8F,>$W'=@XX[\
M]JY7PZ[/J5L99?%9E*DNM_$5@!V\Y.T#Z<^E=5J+SQZ;<O:C-PL3&,8SEL''
M'UKE=)AU6W\16\<M]K5S$1O;[1&HA,9CZE@HPP?C;U]J!':4444#"BBB@"O?
M_P#'A<?]<V_E3-+_ .039_\ 7!/_ $$4^_\ ^/"X_P"N;?RIFE_\@FS_ .N"
M?^@B@"W1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*JP:G'K6N6,NFQW9@M_,,\TD,D*8*X"8<#<<[3TXQ0(Z6BBB@84444 5[_\
MX\+C_KFW\J9I?_()L_\ K@G_ *"*??\ _'A<?]<V_E3-+_Y!-G_UP3_T$4 6
MZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH X[QG_P ?5K_N'^=%'C/_ (^K7_</\Z*8'8T444@"BBB@ HHHH 0]
M#6=H/_((C_ZZ2?\ H;5HGH:SM!_Y!$?_ %TD_P#0VH TJ*** "BBB@ HHHH
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M3_T$4 6Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH X[QG_ ,?5K_N'^=%'C/\ X^K7_</\Z*8'8T444@"BBB@"
MGJ6#9NI8@D@ "<PECZ;AR/PKD+C5;[_A'0BR7P$7G&6XB5G(*.0L>\=1ZMW
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MU_X%2?\ Q5 %"ZTZ[FN?.CA9'DC10PFVF%@>X!YZ^];XZ<UC1:0#?3B1[OR
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M.K-K"8;6*)L%D0*<>H%3;1Z4 4/[;TS_ )_8OSH_MO3/^?V+\ZO[1Z4;1Z4
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M&ST&,5U Z4ABT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7MG%?V<UK."8I5*, <'!]ZGHH R&\-::\&GPF-]M@P,/SG/X^M%UX=M+J_\
MMGG7D+L09$@N7C24CIN4'!K7HH QW\-V;:E]M6:]B)8.\,5TZQ.WJR@X-/;P
M]8-*LH$JR*[OO60@G?\ >&?3VK5HH R]+T*UTJ66:.6ZGFD 4R7,[2L%'103
MT%:E%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
' 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>ptgx-20201231x10k009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ptgx-20201231x10k009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '0 \L# 2(  A$! Q$!_\0
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M;_GTLO\ OE__ (JC_A9NK?\ /I9?]\O_ /%5Q5%'L:?8/;U.YVO_  LW5O\
MGTLO^^7_ /BJ/^%FZM_SZ67_ 'R__P 57%5NPZ'IXT>TU"^U5[;[27"HMJ9,
M;3CKN%)TJ:W0U5JO9FQ_PLW5O^?2R_[Y?_XJC_A9NK?\^EE_WR__ ,57,7]M
M80M&+"^>[W9W;K<Q[?3N<U!<65U:;?M-M-#OY7S(RN[Z9H5*F^@.K474Z[_A
M9NK?\^EE_P!\O_\ %4?\+-U;_GTLO^^7_P#BJY3^S;_&?L5SC<$SY3?>/0=.
MOM4T.DSF*5[B&ZA"Q&2,_9F8/CW[#WH]E2[ JM5]3I?^%FZM_P ^EE_WR_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBHKFY@L[=Y[J>."%/O22N%
M5?J3Q0!+15.RU;3=29UL=0M+ID&6$$RN5'O@\5<H **** "J6E?\>"_[[_\
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MCGEW#DCV,7_A$= _Z!<'Z_XT?\(CH'_0+@_7_&MJBCGEW#DCV,7_ (1'0/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5@:FTUIJ;7\XFDL5$:A8KIDV-N()* @-U7KZ5OU5ETVRFN1<RVT;S#&'*Y/'
M2A;@3R1I*FUU#+UP:YE[9R-/-L&#1^>X52<-AA\I^HR*ZFJ-JEU:P>5Y*-AF
M.0^,Y)/I[T 0:($N-*CF*M\[NPW9!QO./TJ[/!;&"03?+%M.YBY7 ^N>*/-N
M?^?=?^_G_P!:CS;G_GW7_OY_]:@#F[6V@GT9([2W\]?.D67R9%RB;F('+#J,
M?A6MX?B5O#]AOB9&$*C#'VZ\&K37=PMPD/V8;F4L#OXXQ[>]2>;<_P#/NO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P"%H3_] N/_ +_'_"CZO4[!]9I]STFBO-O^%H3_ /0+C_[_ !_PH_X6A/\
M] N/_O\ '_"CZO4[!]9I]STFBN2\+>,I/$6I2VCV20!(3+N$A;."!CI[UUM9
M2@XNS-834U=!1114E!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !117+7OC[2+"^GM)H[HR0N48K&",CTYJHQE+9$R
MG&.[.IHKC_\ A9.B?\\KS_OVO_Q5'_"R=$_YY7G_ '[7_P"*JO8U.Q'MJ?<[
M"BN/_P"%DZ)_SRO/^_:__%4?\+)T3_GE>?\ ?M?_ (JCV-3L'MJ?<["BN/\
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M=_FJ!][.,8)]#2=.<5=HI582=DS8HHHJ"PHHHH **** "BBB@ HHHH ****
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M6ZZN5 [!%50/T KGC4DTCHE3BFS%/AR&"18+[5[2UNV _<,&;;GH&8#"GZU
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M?]/'_@+)_P#$U9M[B*ZA$L))0DCE2IR#@\'F@"6BBB@ HHHH **** "BBB@
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MO_(\G_Q5'_""^&_^@=_Y'D_^*H^M0[,/JD^Z/&:*]F_X07PW_P! [_R/)_\
M%4?\(+X;_P"@=_Y'D_\ BJ/K4.S#ZI/NCQF@'!R*]F_X07PW_P! [_R/)_\
M%4?\(+X;_P"@=_Y'D_\ BJ/K4.S#ZI/NCRM=>U-+V:\6Z(N)X_*D<(OS+@#&
M,8["JAO+AK);,R9MUD,@3 ^\1@G/7M7K_P#P@OAO_H'?^1Y/_BJ/^$%\-_\
M0._\CR?_ !53]9I]A_5JG<\P@\3ZQ;P+%'>$JHPI>-791[,02/SJG%J=Y#)<
MR).V^Y1HYF8!BZGKU^E>M_\ ""^&_P#H'?\ D>3_ .*H_P"$%\-_] [_ ,CR
M?_%4?6*78/JU7N>06EW/8W*W%L^R500&P#U!!Z^Q-0'DYKV;_A!?#?\ T#O_
M "/)_P#%4?\ ""^&_P#H'?\ D>3_ .*I_6H=F+ZK4[H\9HKV;_A!?#?_ $#O
M_(\G_P 51_P@OAO_ *!W_D>3_P"*I_6H=F'U2?='C-%>S?\ ""^&_P#H'?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %VE_P#0S0!<HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2M/:+';RNLLX94)'[T^E6H23#&2<DJ,_E4-U/$;28"5/N-_%[5+!_P >\?\
MNC^5'0.A)5/3?^/5_P#KM+_Z&:N53TW_ (]7_P"NTO\ Z&:0BY1110 4444
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M@ HHHH *.@HHH K)?122^6JR;O=",59JO'_Q^S_[J_UJQ38V%%%%(05%=?\
M'I-_N-_*I:BNO^/2;_<;^5" =#_J8_\ ='\J?3(?]3'_ +H_E3Z "BBB@ HH
MJJ]ZJ3>48)RQSC"<''?]: +5%%% %/4?]1%_U\1?^AK5RJ>H_P"HB_Z^(O\
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MI3_='\J?5;[!:_\ /!:6Q&+1!V!('YF@"Q1112$5GEG:X>.(1X0 DMGG.?\
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M:QV\9Z0LA3SB6&>$PW\LU"/%5K-?(\-CJ4N(V "6K<\KZXHV-50J?RLZ>BL
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MF\,BX_X_=6U.Y]5$_EJ?P3%&F^&M&@1F&G0NXD<;I1YA^\>[9K=JO9_ZI_\
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MD%NQ)03@9-49-9TR'_6:A:K]95_QJM+XGT148?VG;$XZ*^?Y47*5*;V3+?\
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MW61+:))G5Y50!V1=H)QR0.P]JDIO<2V"BBBD,JZC_P >O_;1/_0A5JJNH_\
M'K_VT3_T(5:H **** "BBB@ HHHH ***@DNX8I-CL0WIM- $]%(I#*".AI:
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M/[%O^G_/N/\ &N@NO^/27_<-2I]Q?I1SP_E_$=IVW.>'BN)0 -)U( =A!_\
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M]:E_X2V/_H%:G_WX_P#KUM0_\?-Q]5_E4]#E#^7\1N,^YSW_  EL?_0*U/\
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MZ]/UJO8>&M(%])++9R7$JJIWWK&1L\\_,371)&D:A4154= HP*3N2_91[O\
M#_,P1?\ B.^/^C:5#91GI)>2Y;_OE<_SJ"[T75;IH%O-<F^9S\EL@B4?*>X^
M;]:Z>J]Q_P ?%K_UT/\ Z":$AJLU\*2_KSN8L/A&PA(86MO)+G/FR[G<G_>)
M)K4ECN8[5U#0!0A& A'&/K5ZH[C_ (]I?]P_RIHSE4E-WD[BP_ZF/_=%/ID/
M^IC_ -T?RI](@*@MNL__ %U/]*GJFDKP23*;>5LN6!4 @CCWIH:+E5G_ .0C
M%_US?^:TT7V7*"VGW#!(VC_&A&>:]1_)D15C8$N,<DC_  HL%BW1112$07?^
MH'^^O\Q4]07?^H'^^O\ ,5/3Z %5['_CT7ZM_,U8JO8_\>B_5OYFCH/H6***
M*0@JO)_Q_P '_7-_YK5BJ\G_ !_P?]<W_FM-#18HHHI"*>H_ZB+_ *^(O_0U
MJY5/4?\ 41?]?$7_ *&M7* "BBB@ HHHH *Q?$R73:>C6T=W*B/F:*TD*2NN
M"!@@@]<$C(XK:K$\20J]O:W$GF>3;S[Y!'<>0Q&TCARRXY([BDP17\+-J<R/
M-?07=O']GAB6*Z/S&100[@9. <K]<9KHZ\\T5KC4/$UM<&*XFFA"I]I$ZNL4
M8#;E;#'))*\X.<$UZ'5RUU)CIH9M[8S203*HCOEE(S;7I BQZ A"?S!Z4NDZ
M<UII@MKE8F^=F$:Y9(P3D*N1T'0<#Z"M&BI**FG +9*   &8 #ZFK=5=/_X\
MU_WF_P#0C5J@ HHHH **** "BBB@ HHHH **** "BBB@"*:WBN !*NX#MDBG
M10I"NV,8'7KFGT4 %%%% !1110!5N+IXKA8U0$''7.3DXXJU110 4444 %%%
M% $$/_'S<?5?Y5/4$/\ Q\W'U7^53TV-A1112$%%%% %>Q_X\8?]T58JO8_\
M>,/^Z*L4WN#"BBBD 4444 %%%% !5/3?^/5_^NTO_H9JY5/3?^/5_P#KM+_Z
M&: +E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5P6M:=83:[>2:IX<U;569AY,UL&VJFT?+]]>ASTSUKO:\[\4Z)9S:A<WE
MW!;75V)P4AFU 0;X2F !D\8;GIS1U [S3TC33K9(8'@B6)0D,@^:,8X4\GD=
M.M6*IZ3$T&C6,3/$[) BEX0-C$*.5QV]*N4Y;L4=@KF=2\7_ -GZM);+ITLU
MI;O&EW=B15$1<_+A3RWOZ5TU<QJ'A*2^U2XF743%974D4ES;^4"7,?3#YX!X
MSP:<;7U*5NIJ:VUXMDWV5(F.5QO8CYMPQ69]H\7_ //E8_\ ?=;FH_\ 'K_V
MT3_T(5:IQGR]$R)1OU.7>3Q;+&T;V=B%<%20_8TZ3_A*9(&A,%B%9=O4_P"-
M=-39)%B7<YP/I5>U_NH2A;JSSX>&=6N6><QC]ZQ<A;R10#[ -@4T^$=34G%A
M'("<Y:^E_P#BJ[NPE1[=54G<O4$$=ZM4N=7^%&[JU=E-KYGG0\*:CWT>T;_>
MNY#_ .S4O_"*7W?P_II^LSG_ -FKT2BCVB_E1/M*W_/R7WGG#^&[J%U+>'=+
MR00/O,/YTUM%N0Z'_A'M)4YX C//?^E>DU7G_P!?;?[Y_P#035*I'^5!SU7O
M4E]YQZKK:J(X]'TV,$C'EQ;3UX[5HB?Q<.EE8#_@==/11[5?RHR<6]Y,YG[1
MXO\ ^?*Q_P"^_P#Z]'VCQ?\ \^5C_P!]_P#UZZ:BE[5?RH7LW_,SDHV\91H$
M6VL<#I\]*MSXPDW;+>R.T[6R_>NLJM9];G_KL?Y"G[5?RH?(^[.=1_&"R,YM
M+$LP ^_Z?_KJ7[1XO_Y\K'_OO_Z]=-12]JOY4+V;_F9S/VCQ?_SY6/\ WW_]
M>FF3Q8\B,]G9?(<C#]\8]?>NHHH]JOY4"@UU9S3W?BB--S6EH!P/O>O'K2O+
MXI=&4V=I@C!^?_Z];E[_ ,>I_P!Y?_0A5BCVB_E17+YG,+/XN50HL[' &!\]
M+]H\7_\ /E8_]]__ %ZZ:BCVJ_E1/LW_ #,YG[1XO_Y\K'_OO_Z]'VCQ?_SY
M6/\ WW_]>NFHH]JOY4'LW_,SE%G\5_:)"+.R\S W#?QCG%2_:/%__/E8_P#?
M?_UZWH_^/V?_ '5_K5BG[5?RH'3_ +S.9^T>+_\ GRL?^^__ *]'VCQ?_P ^
M5C_WW_\ 7KIJ*7M5_*@]F_YF<K-/XL,?[RSL@N1T?OGBI/M'B_\ Y\K'_ONM
MZ\XM\X/#*3@>](;ZW )+$ =]II^T_NH?LW;=F%]H\7_\^5C_ -]U%;S^*Q"!
M%9V13)P2_OS71B^@(R&;'^Z:++/V1,@C))Y'N:/:?W4'LW;=F#]H\7_\^5C_
M -]__7H^T>+_ /GRL?\ OO\ ^O7344O:K^5"]F_YF<S]H\7_ //E8_\ ??\
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MD:7J6E[ITT:".,)8*0N%# 2/D#YV[X_NCDUV=5+<40HHHJ1E73_^/-?]YO\
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MCW^I7(N--EL)K62QFG$<D@;>S9Z!<< <'G/X5M51U#2TU!H2]Q<1>2P=1$P
MW#H>0:%N'0H3ZK=-XBM;:#8++S&AE8C)>386X] ,#ZD^U&AZA<SR>1J,TBWI
M0O\ 9Y(/+  ;&5/\0Z?G5B7PWH\M]%>MIUL+J-S)YJQ*&9L=20,D]_K4UII4
M-K<_:3-//.(_*5YY-Q5,Y('U(&3U.!3$+J<T:1)$QP[.F!C_ &A5ZJNH_P#'
MK_VT3_T(5:I#"HYI/)@>0*6VJ3@=ZDHH KVEP;B(LP7(;&5.0?I5B@  <44
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M5RI!]B#D4 )93+<6B2(9".1^\QNR#@YQQ5BHHEA@B6*+8J*,  T_>G]]?SH
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MO(TXW7VC='YF[=_K.-V,9VYQG'?&: +U%1?:8/\ GO'_ -]BC[3!_P ]X_\
MOL4 0:C_ *B+_KXB_P#0UJY5#4)X7AB594)-Q%P&!_C6K] !1110 4444 %%
M%% !1110 4444 5CIUFS%C;1$DY)VTG]FV7_ #ZQ?]\U:HH J_V;9?\ /K%_
MWS49TFS,ZR>1& JD%=O7.*O5RGCEI)=(N+<P3M:BWDED>-206 ^0'VSS^ H
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M9[6.X@\Q+AA(/-N'(^YURP7&?08 '2FD)NQT']FV7_/K%_WS1_9ME_SZQ?\
M?-6J*0RK_9ME_P ^L7_?-']FV7_/K%_WS5JJ>JB Z7<"ZG\B$H0\GF>7@?[W
M;TI-V0(;)I-F\D3""-0C9("_>X(Q^OZ5)_9ME_SZQ?\ ?-<1]I@N- \-0M=6
M/]GBVVS-<CS(?-6-=JN-P!/WL GJ/45V>C3-<:+92M;+;%H5/DJN G'0#L*M
MJPD[V)/[-LO^?6+_ +YH_LVR_P"?6+_OFK5%2,J_V;9?\^L7_?-']FV7_/K%
M_P!\U:JKJ4MI!IMQ+?LJVBH3*6Z;>^?\* &)I-FLLCF",AL87;TQ3_[-LO\
MGUB_[YKC8#IKVMJY-BFBS7[/-;!T,4*^6=BN!\HRP!(Z9(KI?#8VZ,H3/V<2
MR"W_ .N.\[,>VW&/;%,5R[_9ME_SZQ?]\T?V;9?\^L7_ 'S5JBD,J_V;9?\
M/K%_WS1_9ME_SZQ?]\U:KF_&$NE_88[:^%JUS<!DM1<L J,1R^3TV]<]>PZT
M :T&DV<,"1M!&Y48+%>M2?V;9?\ /K%_WS7*:E+(VHZ4\@N)[:UFA6WE1=RS
M,1\TF1P>, ?\"]:[6FT*Y5_LVR_Y]8O^^:/[-LO^?6+_ +YJU12&5?[-LO\
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M]%(9!]BM?^?:'_O@4?8K7_GVA_[X%3T4 5)]-M9HB@AB7)!R$'8@U)]BM?\
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M5@RV\08'((0<5-110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>/8A8L>22Q/)))Y)]S4]% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_'/<QP?9X6,!553()++N^9C@9.1TZ4CZ%(]T^+L"R>Y6Z:#ROFW@@\/N^[D
LXQ^-;-%.XK%-['=K$5_YF/+@>'9MZ[F4YS_P']:N444AA1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>ptgx-20201231x10k010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ptgx-20201231x10k010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &F ]0# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#WQF"*68\
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MY)Q1Q1R(/:,];_X2S0_^?Y/^^6_PH_X2S0_^?Y/^^3_A7DG%'%'(@]HSUO\
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MB@"&Z_X])O\ KFW\J\4.?/.,9W\9]<U[7=?\>DW_ %S;^5>)/_K7'^T?YUI
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M84444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $-W_QZ3?\
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MU'Z"LNFB6%%%%,04444 %0W7_'L_TJ:H;K_CV?Z4#1*.@I:0=!]*6@04444
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MC_GB?SK?HHNPY4<Y)X-T<O'F YSQS4G_  AVD?\ /$_G6W)]Z/ZU)1S,?*C
M_P"$.TC_ )XG\Z/^$.TC_GB?SK?HHNQ<J,#_ (0[2/\ GB?SH_X0[2/^>)_.
MM^BB[#E1@?\ "':1_P \3^='_"':1_SQ/YUOT478<J,#_A#M(_YXG\Z/^$.T
MC_GB?SK?K!\2>(7T6W(@M'GG9<@_P)VR3^-%V'*A/^$.TC_GB?SH_P"$.TC_
M )XG\ZCU76;ZQTS3-I@CGN]HDGD4[(R0#TS[^M7/#FIW&J:>\MP$+)(8Q)&,
M+(!_$/K3;8617_X0[2/^>)_.C_A#M(_YXG\ZWZ*7,PY48'_"':1_SQ/YT?\
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M2C=9:>73=GYW &/KCFJQTJ-- TRXP_\ :%]>;E?<?E!)Z#MQBG8+GHQ( ).
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MLCC&6('4U@>$)X=3NKG5)+E9;UU"F-!A8$[*/TJSI8-UXMUB\F_Y=E2"//\
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M=<6 CC@"*]QYBLK@$8VX//.*]*TKC2K,?],E_E6/'X*T5)%8Q3/&AW+"\S%
M>W%="NQ0$4J,#  -#86.5\,Z==VWB+7YKB!HXIY 8W./F&.U<[-X;N-,NKZ)
MM".H^=(6MYPX"C/9J]./UI:+A8X35]!NDTO0[>ULE#0W(DF2$_*GKUJMJ6E:
MH?$E_)<Z4VHI,!]E<N D?'<&O1111<+'FZ:#JDGP[?31:L+N.?>8R0-P#9XJ
M75M)O]8@TS5#I4A-KF*6RD<!G7 Y!SBO0Q]>*6BX6.$T;P\UVNH.^D)IL<T1
MBA+-NDP1SG''ZU0>V\0Q^%)?#BZ2S/&I7SPXVLH/;OGBO2:7(SC-%PL9OA^"
M6VT"RAF0I(D0#*>QK3HHI#%%% HH **** "BBB@!&^Z:K<=^U66^Z:JGD$9Z
MT >>F_DLO%%SX@9S]D-P;1\]    ?SS5C1+C4$M=/TRP:.&XO%>[FF=<[5)[
M#UY%=(_AO3I-(ETQU<V\KF1CGYMQ.2<_C3KKP]8W4=NO[V)K=-D<D388+Z9J
MKH1%X>U*YOOML%TR22VDWE>:@P'XS4OB'5)-*TT36\8>XD<11!N@8\<TZ+0;
M*"W@@@\R..&3S,*_+MZMZU:O["VU.T:VNDW1MZ'!![$4@L<W<:GJ^FW<EE=7
MD,TDEJ\RRK& 8F49Y&.E3^#-,^QZ.+V;8]Q=9D9]H#8]">]78_#-A'#<H6FD
M>X3RY)7?+[?0&M2&WBAM4MD'[I4" >U-L+'(_P!NZN-:\FYE6S1I]D:R0$QN
MF< A\=3]:LOK]VNE:S?*Z[(IO)M/E[YQ^-7XO"VFQ7$<N9V2)_,CB=\HC9SP
M/K3#X0TMF.?.V&43>7YGRA@<]* ,1CJ5]XDGNK>XBBDL;)%DE=0?F.2<"I8M
M<?46T5[F"/\ U;W,P* _=SR/3.,UKW'A33II9YB9Q).<R;),;P!POTJ'1]*N
MO[7FO;RTCMH4A%O;P!MV$'<_6BZ QX?%&L2I;Z@$=[>1_FMQ;-A8_P"]OQR?
MQK4T^\UW4H(]3CGMH[>20JELX RF<9W>M7K;PQIUK.)(_-**25A9_D7/' I+
M;POIUK<I,GG$1L7CB:3*(3U(%&@:F)#=ZPVH:YJ%O*+K[.3!! 0 &('0?0_G
M5_PWJUY?7LL%W=[G2/<T$L!CD4YZ@8&15S_A%]-"72#SMMS)YK#?C:V<Y'XU
M8T[1+33;B2XC:66XD7:TLK;FQZ4M ,?7_$-UI.L26ZL'1[7=!&!DF3)K+'BJ
M_GTJ64R(3:VC-=':#NE.<+_*NNN]&L[W4K:_G0F>W!$9SQS51/"VF1Z?-9*K
MB*:;SI/FY8YS^5--!8PB+X:KI-I#.MO#;VQNIHHT 48'<?C56QNM5T[2?[3@
MEB5+V^.(BF6D!..3VZ5UUUH%E=7QO&,JS&$PG8V 4(QBG-HEFUM8VY#^59MN
MB7/?W]:+A8J>,+FYM?#\K6DQAG=EB4@<Y8XP/3K69%<ZTE^=+MKN,Q6=JKSS
M,@)SUX]\9KHM5TJVUFU%O=;]H<."AP01T-+9Z5;V4]S-$6:2XQYC.<YQ23"Q
MR,7B;6;B-+V%&:(R[!;BV.&3."V_&/UJ:]\2Z@EZDMK<I+ ]TL*Q+ =A&[!^
M<CK]#6Y#X9TZ&Y\U/.";BXAW_(&/?%10^$M,@N(ID,X,4WG1IO\ E5LYZ?6F
MF@L8UQ?ZA#JNMZD+O,5C&(HXL#&YC3X]3\0G48K-KFW#268N)&\L?NNOMR:V
MI/#&GR/=,3*!=2"250_!(.15AM$M'NKFY._S9X1 QST09Z?G1<+'-1^*-2DT
MO3(P +N\+EIEA+80$_,% ZG'I2?\)#K>(+-0/M4EWY<<LD)021X))VD>PKHI
MO#EA+8VMJ!)&+50L,D;8=<>]+;^'[&VNK>X3S#);[BA=LY+=2?>C0+'/W&LZ
MK!%KL$MW&S6:+LF6,#!;^'I]*T-'U6#2K>STK4+F6:^*JS'RV(^89P3C'?K5
MZ7PWI\UO>PR"0B\D\R4[N<XP,?E5Y+*)+(6N2RA-F\_>QC&<^M*Z"QR*^(=9
M329=8E>,VWFF."()RY)P,GT%.77=5@%P+SS);<VS2>8;<Q^6_P#=Y S72KHM
MBNCKI1C+6JK@ GGZY]:J#PO8?99H'DN)!*H5F>3)VCM]*=T%CGK:]N])T.SM
M+6Z$,D=J)YPL)D8$C//! '-.N=1U35?[!3[3]G-PK7$RHO4+W/\ A6_?>%M.
MOYWED\Y#)&(G$;X#*!@9%2_\([8?:;.X'F"2T3RX\-U7T/K1=!8YM?$VL7*&
M]MU9HA-L6W6V)#H#@DMCKU[U-?:YJUQI^J:G:RPPV-JSQ)$RY:0C@G/8YK<C
M\,Z?#=&=#,%W[Q"'_=AO7%0W7A'2[J2=G\Y5F?S'C5\+NSG.*+H+"Z2T6A>$
M(99_E6.'S'SW)_R*Y70+N%O%5EJ!NEEN=0\SSHU;/E_W0?PKNK_2[;4;6*VG
MW>3&RMM4X#8Z ^U)<:197$]M-Y0CDMGWQF,8Y]Z5PL<EY3ZEXCU:Z_L5-2B6
M3R4+LH"[>#C/TKL=.MX[6QCCCM$M1C)A3&%/X5EKX4LXVE:*\O8O-8NP27 )
M/7M6W%&(84C!)"C&6.2:&,?1112 **** "BBB@ HHHH 9)]]/]ZGU')]^/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1+@,T$<  09/)?//Y5WXI#%HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ3CO0 M%5+6_MKYI!;R!_*;:Q .,_7O5N@ HJ)YXXY(XW<!Y#A >YQG^E24
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M1$JADYR01T&,9Q18+G8P:A9W#,L-U%(5&6VMTJI::TNH00SVB*R-,8WWN 0
M.H]:Y;33!+XHTZ-&TXH8Y%9;-<#&T\,<\TFFB".UTQ( BNNI,'"\$'8V,T60
M7.X>_LX[@6[7,:S'HA;FB>^M;;)GN(H\?WFQUKSN11Y5\EY?6<-T9WW+)#F?
MK\I4]>F,8KHK*P@O/%,_VV-;ETLXA^]7J2!DX]:+(+FU<ZS:6MU90%U8W;%4
M8,,#C-67O[2*X$$ES$LQ'"%N:X2SBM%_L*2X6/:EY)&&?L,<#\Z9J$EK;:A?
M3)-:70-QN>VN5VS!L#A&&#CTHL!Z.*R-8U>YT^[L[6TLUN9KG=@-)M "X[X/
MK6A!<Q3$HK 2*H9X\_,N?6L/7KF&T\2Z+-<RI%$!*"[G 'W:0RQ:ZW=+?PVF
MIZ?]E>?(B=)-ZL?3H.:U/M]H+G[*;F/S_P"YNYKGM4U"VUF_L+33)DN)(YA-
M(\9W",#U(KEHU)LG2ZO[2&]\[#*8";@/N['KU_2G85STNXO[2T=5N;B.,MT#
M-@FEEO[2 *9;F) W3+#G-<ENTR'6-0&O&(NT:>2UP."F#G;GOFC2;;3K_7QL
MMMUNEBODI,"<#>W.#19!<ZQM0LX[A;=KF-9CT0MS2W-]:V8!N+B.+=TW-C->
M;.O[F^2]OK.&[\Y@RR0YGSGY2IZ_3%:6I7,(U00SK8B>.U0&:_R0X.?NKG&>
M*+!<[A[VUCMQ<//&(3T<MQ2I>VTEO]H2>-H<9+AN*\\M_(D\+:=YMY' RW4O
ME-*F8C\QX8'H/2FRSO-HQ6.*VA@BO5^T2P F!P<\XSTSC(Z46"YZ+;WMM=QF
M2WG21%X)4]*S[K7K>*YM8('CG::<0OM?[F?_ -=<G;1N\NHFPO8)W^R89+*+
M:G7CIQNQFG++HC7/AU-/$0N5F0/Y8^8=,[O?.>M%@N=Q=W$T A\N-'WN%;<^
MW ]1ZTDNI6,+K')=Q*Y. "PSFLCQ41MTO_K]C_G6/#IUG-I6OW4D$;S"X?#L
M,E<!<8]/PH [L'(R**I:.S-HMBS$DFWC))[_ "BKM(84444 -;[II<TC?=-'
M:@!=PHSG.*XK2K]]+DU26>1V25I9HPQZ%6(VC\J33=1ET+1[@3.9;A[KRP9"
M<!CUS["G85SMLXHS7$WFM:A>6C0Q/$)8IDW2HK!7!SQS]*O:OKM]II<EK0"%
M QC8DM*<9.,?=_6BP7.HS1FN4%WJ=QKLS:<L05[9';SB<#V _K4L6N:AJ1\K
M3H(EDB3?.922 <D8'Y'FBP7.FS0#FN0FU5KJ6.[\L@"SEWPEN"RE@1^8H'B*
MYCG2)1;1(JH%27<#(#U(;H*+!<Z_-&:YF[UK5%N+T6L%N8K1$=B['+9SP/RZ
MU8TW5+^748H+R*$1W,/G1>63E1Z'UHL%S>S1FN?UK5KNQF989+6)%4L/.))<
M^@ Z?6H!K>I7LEG'810*9[=I6:4DA<'&/>E89T^:0-DUSD.MW]]';PVL,*7;
M!C(7)*J%8J<>N2#5GPW)<RV]XUT LPNG#!3D#GM[46 V\T9KEDUO5?+-Y)#;
MBS%P8=H)WD>O_P!:K3:W.NE75WY:;H;EH0.V Y7-%A7-_.32;AFN1AU#5+4:
MQ<LT4NR9%C0Y&"6 _+FF:S=ZBD<T0,"70ME=I%ST+'@<T[!<[$,#2YKFIM5F
ML;FX$D"27"1QKE"0'=L #V&323ZSJ=A%/'=PP-<>3YL1C)"GY@"#_P!]"E8+
MG349K#T[4-1.HQVM_' /-A\U#$3\OJ#_ (T^[OM0DU"6UTV.$F!0SF8GYB1G
M Q['K189L;AQ[TN:XNRU2>UTVRE\CS9_LKO]XD@[E'XCG/X5=LO$<S6MU-.U
MO.L2!@825.3_  E3_.G85SI\T9KGEU34[639J$,(,L3R1F(GY2JD[3Z].M10
M:MJTT-K&(K;[3=J9$'.V-!USZGD>E*P7.E#9I<UQD.LW>GK>_:1&MW+>>6.2
M47"+SZXYZ5:7Q%>/8.8HHGN4GCB#\A'#$#//3K3L%SJ<TM<G<:_J%K>FVF-K
M$Z!>) P$I/7:>WXUU,3^9$CX + ' .:0Q]%%% !1110 4444 %%%% !1110
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M8[C49I)G9663:HV8Z8 &.]0W/A@W$EP?MLJ+=+B;"*23C&02,CIT%=%11<#
M;P],EP)[;498)#"L+;5!!4>Q'7WI3X<\C8UC=RVTFSRY&&&\P9)YSGGD\^];
MU% &&?#D C1(Y'55@:'KDG=G+?7)-13^&FE3R?MDGV9E"R1,JMG'H2/E_"NA
MHH R/["C"WBK*X%RBIC^Z%Z5-'I:QW=K<>8V;>'R0/4>M:-% &)?: ;N_DNH
M[IX3*FR0!%;(QV)!Q^%26.AI92V[B9V,,)B&>X)SDUKT4 87_"/-"B-:7DD-
MPCN1* #D,Q8@@C'>KFDZ7_9=O)%Y\DYDD,C/)C))K1HH R#H:'339>:VTS>;
MN[]<XJK<>&6F:9$OYH[:67SC$ /O9R><9QGM70T4 8DF@;WN_P#27$5RR.8\
M#AE8'(/X4^^T-+Z::1I70RP"'C'&"3G]:V** ,630%N!,US.\DDL:(SC (9<
M888[Y&:C'AUY4F-W>RSS.@C5R -B[@<  >PK>HH H#35&H07>]LQ1&(+Z^]5
M[[1Y9[IKFUO9;6210DNP [A^(X/O6O10!@P>&TAM[>(7,V886B5P<-R0<_I2
M0^&8R\TE[.UQ))'Y6[8J87_@(&36_11<##BT"3<6NKZ:Y98VBB+@#8",9X')
MQZU)+H>;:T6"YDAN+5=J3* 21W!!&"*V** .>C\,[(),WLS7+3^>LY W*V /
M3&.!Q5A-%E>%5N;V6>03),78 #Y2"  !@=*V:* ,74-">^FD(O'2"48EB**X
M/N,@X_"M6W@2VMXX(\[(U"C)["I:* "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH AE_UL/^]4U0R_ZV'_>J:@ HHHH **** $YK 70;V.^FNX]4
M<22-G+1HQ4>@)' KH** *&J6CW>E2P YDP&7W93D?J*<\)OM+\F0-&TD>ULC
MD&KM% &?<:8+C1O[.,C*IB$>\8SP,9J>2V:4.CMN@>,HT>/7OGZ59HH Q8-#
M>.:$SWLL\%NVZ&)@ %/N0,FI]+MI!<7MW,A1YY<J#U"@!1_+-:=% !1110 4
M444 %0W7_'L_TJ:H;K_CV?Z4 2KTI:1>E+0 4444 %%%% !1110 V2-98VC=
M0RL,$'N*QK3P^;>XA:6\EF@MCF"%@,(<8SD#)X)ZUMT4 %%%% !1110 4444
M %%%% #6[?6G4UNWUIU !2-]P_2EI&^X?I0!3HHHH *44E** ,+7M.NKZ9-M
MC:WMOMP8Y3M96]0U9S>&+L:=8E_)NKFU9OW$S;D*MCY<GTP.:Z^CO3N(YVPT
M.1K.^CNK.TM1<+L2*%1\H]SWYJ/3_#US)HE[;ZE(OVN[&QG7G  PO]*Z;%'3
MVHN%D<G8Z'>)<P"33-/MTAR7F0!F?C QZ?6K1T:[;PC)IV$^T,[L!NXP7)Z_
M0UL_;K;;"PE#"9ML;("03^'2K5%QV,9;.X@\17%VZ1FRG@".Q;!7 ]/3BLOP
MC9 W]Y="7SK>W8V]H_;9G+8_2NK=$EC:-U#(X((/0@T0016\*Q01+'&HP%48
M _"BX&=K%C<SR6EW9;#<VKEE1^%<'J/;I67<:1J>HV^H7%RD,=U<0>1%"C9"
MKUY/KQ74]ZA-W"MZMF7_ 'Y3S G/W11<0^W4QP1(WWE0*?P%8MMHDK:=JUG<
MD*MY,[*5YPI ']*VGFBB>-)'56D.$!/+'KQ4AH Y'3_#][%=6JRZ;IT20,"]
MPJ@M)CH0.QINH>']2O+YV^R6HE\P,E]&Y1U7/< \FNQ'2EHY@.9&G:SIDMW'
MIR03PW3;R\C8,;$ 'Z],U-IV@2:=?Z>5*R06UH868]68GTK<$\1N# )%\T*&
M*9YQTS^E2CH*+CL<OI?ANXMM3N6N64VJ*\=H <E5?[W\A5*'PQ>P;+1=-TYT
M5^+R106*YSROKVKMAUI:+B.:FT_5K*\OCIJ0R0WOS$R-@Q-C'XUIZ#936&B6
MUK<X\V-<-@Y&<FM*HHKB*622.-U9XSAP#RN?6BX'*'PK<27FHJY7[*Z,+7GE
M6;EN/J:=!X=U#^SK,S^6;W[8+BY(/'7M774M%PL<E<Z'J4C:E"L49BGNDGC?
M?SQU!'X5L3V$\GB.SO5"^3%"Z,<\Y/2M6BBXP%+0**0!1110 4444 -;[IHS
M@4-]TTO:@#G](UZ6]EU%+I$B%M(VPC^) <9_,&C1?$37ED\]^BP,9_*11[GC
M-9<^C:BT"B&$JT\TL4WM&SL<_K5F?3+Q+>Y>*W+%+T3)&."Z@]J=A&Y<ZQ96
M;RI--AH@NY0,GG./Y&D36["2R>[$V(HSARP((/IBN>N;2]U">\NY=-F56\HQ
MJKE9!C=D@COSTH@T_56M#))')(D5PDL<<^!(X7&0Q[].,T6 WH-=L+@(4F(+
MR>6%*X.[!.,?A3-2UE+976W*O-'(B.I[;L_X5FW:W][Y=\NF&/R)U?R\8DD
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M10!<:WC>99F0&100K=Q4@XJM#?PW$L\<1+& X<XXSZ5);7,=W%YL1RN2/Q%
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M921MP/EW9R><U5O"MCJ4TOFF<12@ )<,DL8!X7:3R/PYKNDM8(UC5(D"Q\H
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MH 2F^8F[;O7=Z9YI37):Q81V,J74*3&5I0\EZ7)$0STQZ>W2@#K<X!).!02
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M]\8Y]/PS181KB12NX.NWUS2[UV@[ACUS7$JGVF[N;+3;>9;0)%*87RN\98,
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M1110 4444 %%%% !1110 4444 0R_P"MA_WJFJ&7_6P_[U34 %%%% !1110
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MC;"#ZD $G]<?A0!LBBBB@ HHHH *ANO^/9_I4U0W7_'L_P!* )5Z4M(O2EH
M**** "BBB@ HHHH AN[A;2SFN'^[$A<_@*P8-0U*&2QN+R2)[>\?9Y:+@Q$@
MD<]^F/QK>N[=;NSFMV)"RH4)'N*P+>PU.XELK:\AB2"R;>9%?/FD @8&..N:
M .EHHHH **** "BBB@ HHHH :W;ZTZFMV^M.H *1ON'Z4M(WW#]* *=%%% !
M2BDI1TH YV[AN&\=6#K<%8Q QV;0>.<C\:H1ZGJ<6AS:U+>-)R8H[=4&T?,
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M96MY(=3N89881!O7JZCU_*K^G:9<V4KO-J=Q= C 67H/>@9I4ZFTZD 4444
M***!10 4444 %%%% #6^Z:<.E-;[IH9MJD^@S0 ZBL"/7KV:W:YATB:2!68;
MED3)"D@X&<]JTHM5LY+&&\:X2."4 JTC!<Y^M %VBJ\M[;0HKRW$2(PR"S@
MC\:#>6P@\\SQ>3_STWC;^?2@"Q16=<:M;Q"V,;"99Y?*5HV! ."?Z5=EFC@C
M,DLB1H.K.< ?B: )**K"_M&B$JW,)B)P'#C!/UIT=Y;RPF:.>)XAU=7!4?C0
M!/16=;ZO!=:B]I RRA8Q)YB,"O)(QQ]*N^=&&9=Z[E&6&>1]: )**JOJ%JFT
M&YAWL,HID +?2F#4K=(%DN)X8=PSAI5_GF@"[15>2\MH85FEN(DB/(=G 4_C
M2-?VJQ+*US"(V^ZQD&#]#0!9HJ$74#1>:)HS'_?##'YTZ2:.&,R2NJ(.2S'
M'XT 245EIK4,LMPD!241!#O61=K;CV.:MK?6S3>0+F$S#K&'&X?A0!9HJN;V
MW6<0-/$LQ'$9<;C^%'VVV\TQ?:(O, )*;QD =>* +%%9T>L6T^HI:02)+N0O
MOC<,!CMQ5F.^M93(([B)S']\*X.WZ^E %BBJAU.Q5"YO+<(#@L95P#Z=:LI(
MDJ!T964]"IR#0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH AE_UL/^]4U0R_ZV'_>J:@ HHHH **** "BBH+N[ALK=I[B0
M)&HY)H F95=2K %3P01UH  & , 51TG4X]6L1=1(Z(690'&#P<=*)=3C2XN(
M@"?L\>^1NPZX'Z&@"_165IVJ75\4=]/:*%UW!S(IX/3(!S3]0U4V<T-O#;O<
M7,V2L:$#@=22> * -*FI&D8PBA03G@8YK,BUI'ABD>)X]TODNK=8W]#6J.E
M!1110 4444 %0W7_ ![/]*FJ&Z_X]G^E $J]*6D7I2T %%%% !1110 4444
M%%-D=8HV=V"JHR2>PK&M-?\ M$\"R6DL,-P2()7(PYQGIU' /6@#;HHHH **
M** "BBB@ HHHH :W;ZTZFMV^M.H *1ON'Z4M(WW#]* *=%%% !2BDI10 M%%
M% !1110 4M)2T %.IM+VH 6BBB@!110** %'2EI!TI: "E[4E+0 HZTM(.M+
M0 4444 %+24M !1110 HHH%% !1110 4444 -;[IIK_ZMOI3F^Z:,=* .)73
M;_\ X1\SP7EUM$TC26H.-Z;VR%]"12WT40N;*19#;Z?]FVQ%H#(%/'!&>#C-
M=J% '2DV+C&!CTQ3%8Y&TTZ.6;1XY!)<0CSG!ECVX^[CC)P.M5W'V2U:/[.H
MB%Z^UY$9EB'KM'6NWVBDV#!! Q1<+'"6,<GVE2 S+_:"L"(B@P5;D#G KH/$
MTOEP6V85<&3F1U++'[D#DUN;5]!05!&" ?K1<+'!6UK]I>2.6,R0OJ$)XB**
MPPN2!GI5W4+3R;R]6.%A:+-"\L:#[RX.<#ZXKL-H]!1M'H*+A8Y?16LY?%%[
M-80.D!MXP6V%59LMTS^%/O;I+#6-2:=)<3VZ^5M0MO(&,#'>NE"A>@ H*@G)
M )H&<?HMF'E:66 [TT]0I9>AQ_.DTZPCN+ZP^TP%PEI)C<#@'<:['8!T H"@
M=A1<#A]QM[&SB>%4433!9I8V=8P'; VCVQ2:;9^=-IZ31%T6^E;!C*C&UL''
M85W)12,;1BC:,YP,T7%8Y.>!U\0C250_9IW%T3V '!7^5:7B!0/L<DR-):1S
M;IU49X[$CN :OPZ;'%?S7A=Y)I %!<\(H["KA7/7!^M(9Q %O+_;$EA ZPO)
M;X^0KN.\9(%1(C6VH1I HG<7&3!-"5D7/\0<9!%=WL &,#'THV#.<#/KBG<5
MCB+B.,6MY:O!*=8:X=HGVG)RQ*,&Z8 Q5A[%_L&J3+"QD-WF3 ^9D##(%=>4
M&<XY]:-O/047"QP\H@NM7F.C0.C&R9=^PJI.>!SWIEI"C(GE7,CS1VSAHUM2
MF/E/#'//X9KNP@'11^ I-@&< <]:+A8XJXLH;?3=+==UL5C(W-"9$R>S '.?
M>M[PRTK:2!+ L6'8+MR X]0#T^E;!0$8P,>E*%QTI7"PHHHHH&%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $,O\ K8?]ZIJAE_UL
M/^]4U !1110 4444 %,D1)%PZAAZ$4^D(S0!E: I6RG!4@_:92 1C^(U3@17
M&N1R1F5C+RBG!9<#']:Z$#'857%G&MZUTN0[J%89X;'3^M '-Z?]C_M&S.E1
MRQ(J'[2&4@  < Y[_2K>L2PF:TO$N);<[2$N%B+K@]F'7FN@" '@ 9ZX[T;%
M(Q@8]*=Q'(+!(GAV[EE:0O<7(DB,@PQZ '';H:[!<[!GKCFJ\]G'<O$TF2(F
MW*O8GWJS2&%%%% !1110 5#=?\>S_2IJANO^/9_I0!*O2EI%Z4M !1110 44
M44 %%%% %74H'NM,N;>/[\D3*/J17.1W U%-)LX8Y!-;R!Y@R$! %(Z_4BNM
MIH0#L.>M #J*** "BBB@ HHHH **** &MV^M.IK=OK3J "D;[A^E+2-]P_2@
M"G1110 4HI*44 +1110 4444 %+24M !2]J2E[4 +1110 HZ44"B@!1TI:04
MM !VI:2EH 4=:6D%+0 4444 '>EI,4M !1110 HHI*6@ HHHH **** &M]TT
MN<#-(WW339/]6W^Z: *9US2U<H=0M@0<',@X-7U8, 000>A%<%'>7=MH9!TJ
MU>WDFE3[1))]W+M\S#;T_&KLTM[:-9Z1;R7#"*W#M);XW,1@=STYIV%<[&BN
M,EO]8>&V,WGH K>8+8J9"0>"03C'T-217MWJ5U86\.J,D<D+%W";69E)'3/!
MXYHL%SJVFC218V<!W^Z">M25R$>H7@NH8'G$ABDFC,FW[^U6P?KQ3DN+J/1K
M::?4YS+=/@*B L<$\(,\?6BP7.K9T3&YE7)P,G&3Z4ZN",MW?ND,MY=(L%_&
MJ%\!\':><$CC-:<UQ?2QZA>IJ!A%G(R+#CA@O][ZT6 ZJBN7MY=0U#4+UEO9
M(DBAC:.)1QN()JQI.I3:G>P@2'9! !.N.LO0BD!T%%%% PHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M (P>F,4-]TT=* *RZ=:I8M9B(&W?=N0\@[B2?YU6FT*QGMX8F5_W(VHZR,&
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M;]P! QT&#R*E@UZ?>%O+!K?S(S)"=^[<!V/'!Y%0Q>'YY(Y8[EK1$:/8OV:
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M]*NZ-=/=6/[PYEC=HW^H/^&*H0Z(]G?"ZDF4P0/),@"_,2PZ$U<T*W:&Q9Y
M5>>1I2#VSP/T I#-2BBB@ HHHH :W;ZTZFMV^M.H **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH 0\BDR:** #)HR:**0!DT9-%% !DT9-%%, R:,FBB@ R
M:,FBBD 9-&3113 ,FC)HHH ,FC)HHH ,FC)HHI &31DT44 &31DT44 &31DT
M44 &31DT44P#)HR:** #)HR:** #)HR:** #)HR:**0!DT9-%%, R:,FBB@
MR:,FBB@ R:,FBB@ R:,FBB@ R:,FBB@!CH69#G[IS3\FBB@ R:,FBB@ R:,F
MBB@ R:,FBB@!"3WI>1Z444 &31DT44 '(I #VQ110 N3[49-%% !DT9-%% !
MDTR53)&5SUHHH >,@ 49-%% !DT9-%% !DT9-%%  2<9I!GGI110 N31DT44
M &31DT44 (2<=J,D8HHH 7)HR:** #)HR:** #DFG444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
24444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>ptgx-20201231x10k011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ptgx-20201231x10k011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'J \4# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W*BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#H,9P*KG*YC!\)36\.@W-W-(JR&>5[AF/(.3U_#%8%LR+X,U:\B&W^T;PHA
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MXI 020",CKSTH *S];U5=$T>?4'B,JQ;<H#@G+!>OXUHUS?CW_D2]0_[9_\
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MDD4JP^H-:OAO06U_4UMV<Q0+S++Z9Z >Y-)TJ:5Q.E!*YVG_  M.V_Z!<O\
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M"S^SRQ,7M[B,21LW7T(/N#35.F^@*G!G?_\ "T[7_H%R_P#?T?X4?\+3M?\
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M1110 5#>2&&SFD$B1E4)#N,A?<U-6?KG_(#OO^N+?RH SXD\23Q)+'?Z:R.
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M;7(](T8:9I:747V-<N;,2X.3QDCBN!FE>>9Y9#EY&+,?4GK4J7]Y&@1+N=5
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M( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\@*^_P"N+_RIK< T;_D"67_7!/Y5>JEHW_($LO\ K@G\JO4@$HI:* $HI:*
M$HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:*
M$HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:*
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MR+__ )]7H_LB_P#^?5Z+A8I5J&6/_A'!%O7S/.SM[XJ#^R+_ /Y]7H_LB_\
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M_P _0_[]K_A1_P )1J__ #]#_OVO^%8]%')'L'M)=S8_X2C5_P#GZ'_?M?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,@CC0[F.<@<BLBXF:XN99FZR.6/XFM'_ (1O6/\ GS;_ +[7_&C_ (1O5_\
MGR;_ +[7_&G%Q6MQ24GT&:'*J:CY;G FC>+/H6&!^M)YJ1Z)+:NV)Q=!MG?
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M_P"?)O\ OM?\:/\ A&]7_P"?)O\ OM?\:.>/<.278RJ*U?\ A&]7_P"?)O\
MOM?\:/\ A&]7_P"?)O\ OM?\:.>/<.278RJ*U?\ A&]7_P"?)O\ OM?\:/\
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M/V[^J_\ H- %FBEQ1B@!**7%&* $HI<48H 2BEQ1B@!**7%% !1110 4444
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M^-6J* *O]I6/_/[;?]_5_P :/[2L?^?VV_[^K_C5JB@"K_:5C_S^VW_?U?\
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M(/2;_OP_^%6J* *O]H0>DW_?A_\ "C^T(/2;_OP_^%6J* *O]H0>DW_?A_\
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M_M"#TF_[\/\ X4?VA!Z3?]^'_P *M44 5?[0@])O^_#_ .%']H0>DW_?A_\
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M %%%% !574?^0=<?[AJU574?^0=<?[AH M4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH *KWR-+8S(@RS(0!ZU8HH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&L13[[F4<F96^ZP]NU<_XHBT"&]U:>&[OU\1LZF!"S*=_P#"$4 !E^N:]/\
M+7<6"C<>IQS33#&SARBEAT)'-%PL>=>)/$T)>'P[)=P65S/"O]HWKC&P8Y4>
MK']*[O1H[.+1[./3G#V:Q*(6!R"H'!JRUM"[;FBC8GN5!J15"*%4  = *06%
MHHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3)=7T'21"\RQ-/&=]TDKM]YCC:1N/8G - 'I)Z53MM6TZ[NI+6VU"UGN(O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MTUS--OFE92"N6(Q@8 P /ZUHPZ/;V^LSZG$\J2W$:QRQ@C8^WHQ&,[NV<]*
M(=?TRSU/2Y1=P^<L*-(BLQV[MIP2.A_&LOPW'8GP!HTVHK"8+>VCFW3 $(5'
M#<]Q7330K/!)"Y.V12I(ZX(Q6%>^#[.]\-VFA&\OH;6UV;'AD59&V],G;^/
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M5TO7+35YKZ*UW[K*<P2[EQ\P]/45HYKQ;5+R[L/#WBZ>RNIK:;^VP!)#(48
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MIWB[[5-J_AZRM]1GL4NKB5)7A?:641$X],\<>AYI6 ZR@M@9->?_ &R70_\
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M_P"2?:1_UR;_ -"-97B+P=K^IZS>7-K)H<L-Q$8TDN[8B:W!&"%91SQT)_\
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MMK.WM/-^SPI%YTAEDVC&YSU8^] $]%%%(84444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
:%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>ptgx-20201231x10k012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ptgx-20201231x10k012.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (T \L# 2(  A$! Q$!_\0
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MTSP=IZ7%\SO-,VRW@C&7E<] * .BHKB+?Q/XLCL/[3U+PO!'9>69"EM=&2X
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M 2,?2@#MZ*X";X@WWA_6[;3_ !?I,&GQ7@"VUU:7!GC+DXVL2JX_7K5;Q_\
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M75PJO"_VY@I4D@9_=\'@T >IT5RVLZUXDL=0TVVLM(T^X6[^5VDO&0HX&6
M0Y&!UKEO$'Q+\1:!XMLO#\GA[3Y)[W_4N+YL8]_W?% 'J5%16K3O:Q-=1I'<
M%09$C;<JMW .!D?A7/\ CKQ?#X*\-R:K)#Y[A@J1;L;B?>@#I:*YR]\32?\
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M8&<A0A]?6J>@_$3Q/K6CV6LKX:LAIMS*(V:.]9I$!;;DKLQU]Z /3:*X._\
MB'+=>)V\.^%M/CU2_A&ZY>68Q0Q#W8!CG) Z46GQ"FLO$T?A_P 4Z='IM[<X
M^RR03&6&7U&XA2#T[4 =Y17G7B#QWXFT:#5[^+PY9R:9I\[1"66\9'E  .X+
ML([^M1Z#X_\ $VL:7INL-X;LTTN]D">9'>L\D8+;<E=@'7WH ])HKCO''CZU
M\%S:7'-#YS7LXB/S8V*<_-[\XKI;VXN1I4MQIL<-Q<>7NA220HCGW8 X'X4
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M?UZ'/2@#Q>TO/$6E?"BPF:07?AB=S'?6T:;)%0@9&\<X(S7L=O'HD?P>O?\
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MB>Z?S)BHQN; &?R H \9^*7_ "63PE_NG^9KU#Q]_P B'K7_ %[-6?JWPO\
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M9KV1H?Q0G&/PH DU.-9/ L:.N5=H@0>X,BUYCH\ESX ^*&L^'((RUOJW[VV
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M/]WG@?2@#:\7?\BEJG_7!JX#]GW_ ))_+_U^2?TKT+5?#EGK&BII5U->?9E
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M?VNQN_[0#[UN!<-O0?W0>H4]QTY/K72@8&*** "BBB@ HHHH **** "BBB@
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M/%JQO<V<Q(1A$Y9B#@_(!N['M6)XKM=3N_%'AV[@T&2]MK$R22GS(QM9U &
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MS2-'U)[RXAC@E>ZLY((X5"C<Q9P > <8-7'L9-:U"ST"UU#5]-&E6:HUQ':
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)[5JT 1P3Q7,*S0N'C;E6'>I*S/#_P#R!+?ZO_Z&:TZ "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** ,SP__P @2W^K_P#H9K3K,\/_ /($M_J__H9K3H **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH S/#__ "!+?ZO_ .AFM.LSP_\ \@2W^K_^AFM.@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI
MLDB1+ND=47U8X%)'-%,,Q2*X]5.:5U>P#Z***8!1110 4444 %%%% !1110
M4444 %%%% !1110 45QWBGQI/H^K6^DZ98+>WSX9T>81X4^F1SG]*H:W\3QI
M6B6^H6_A^_O7:+S9X4^7[.O/+'!]#^5 'H%%<AJ/CL0^&-/UC2]'N]5>^&8K
M6W^_[]CTP?RJ#_A/KE-,T][GP]<6VJ7\C1P:=-*%?C)RS%>!@>E ';45D^'-
M?@\1:4+R%#&ZL8YHBV3'(/O+GO@]ZUJ ,SP__P @2W^K_P#H9K3K,\/_ /($
MM_J__H9K3H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHJ"ZNH[6+>_)/"J.K'T%)M)78-V.9\5O,+F)<
MD0[>/3/>J_AAYAJ85"WED'>.U=$FG_;6\^_0-G[D1Z(/\:N6]G;V@(@B6,'K
MBO.6$G.O[:]E^)A[-N?,3T445Z1N%%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH.>*WZ6'C4G33K;A!2:]X155%"J  .@%+1176:!1110 4444 %%%% !1110
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M+NQC;T '3M4>B^#8=)\-7&A3:A=7UK*6(,X563<<G&T#N<UTU-9U4J&8 MP
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M,X/K3Z** "BBB@ HHHH S/#_ /R!+?ZO_P"AFM.LSP__ ,@2W^K_ /H9K3H
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHIL@<Q.$.'*G:?0T
M D0N4#J7')7/(IU>/>'U%A\0+NW\07%W9:NT@:&X,S-#<*<\ 9*#/''!]*Z?
MQ$EY;_$?PS*NI7!MK@3H;48$8*JIW<<DG/?TH Z?P_\ \@2W^K_^AFKUS*(8
M'?N!Q]:\SL87\2WM[;7$]Q%;Z9;N8%AF:/\ ?;F.\[2,]1P>..E,@U*X\87>
MB:+=32K;B.22Z\J0HTNQB@^88(SP>*SJM\MH[O8J.]V>FVD)AMP&^^WS-]34
M]<OX+N9C!J&G2R-*EC<M%$[DEMF3M!)ZX ZGFNHITX*$5%=!2;;NPHHHJQ!1
M110 4444 %%%% !1110 $9&#TJG:GR9Y+8] =R?0_P"%7*IW_P"Z5;L=8N6_
MW>]<^(7+:JOL_EU_S^1I!WO%]2Y16$?%5D)MFR3;G[_:MN.198U=#E6&0:NG
M6IU+\CN8J2>PZBF-+&GWG4?4XJ)KZU7K/&?8,#5N26['=%BFLZHNYV"CU)Q5
M1M4MAT\QO]V-C_2N<\27LL\D:J)$AQ_$",FL*^*A2@Y+4B=115SKDD2091U8
M?[)S3JX;P_-=K?A+<Y##Y@V=HKJS;7DG^LN]@](U']14X?%.M#F40A4YE>Q<
M=U12S, !W-9L5Y!+.;F64;1Q&@Y(]\"HWL(Y[H0[Y'"\R,7./IZ5IQVL$0&R
M%!COM%3>=>?]V+^]_P# _/T-O>BO-E274#+$ZV\$TC%2 <;?YUPDT4JSLLB,
M),G((YS7H\\HM[>68@D1H6('? S7$O\ $/2BX9]-DWGH6VYK6IE=;&*\'>QY
M^+KT:32JSLV;VD65TVFQB:YDC7L@ Z?7K6@FF6ZG+!Y#_MN6_G46BZM'K6G+
M>11-&A8KM;&>*T:T6&5+W)+5::G32<)P4HZID:011_<B1?\ =4"I***M)+8U
M"BBBF 54OT/E+,OWHFW#^1JW374.C*>A&*SK4_:0<2H2Y9)BJP= PZ$9%+52
MP8^2T3?>C8K^':K=%&I[2"EW"4>6304445H2%%%% !1167J7B#3=(G2&]G,;
MNNX (3Q^ JH0E-VBKLBI4A3CS3=EYFI16+9^*]'O[N.UM[DO-(<*OEL,_I5^
M[U2RL5)GN$4CJN<G\NM5*C4B^5Q=R(8BC./-&2:]2W1T&37)3^,WN7,.C:?+
M>2G[K$80_4]OQI!HFO:QAM5U$VL)Y\BVP#]"?_KU?L''6;M^92FY?"OT-/6_
M$.F6-G/%)=H9FC8+&F7.<'L,U\YWCSO.6FSN/2OI/3_#NEZ8N(+1"YZO)\['
M\3DT7?AS1[UXGGTZW9HFW+A .?PZUT8?%4Z":2;N73]VHIM)Z?/Y'&_"C4G;
M1Y;*YGB!5\Q1DX<YZ]>O:O1JPM5\+6&H(&AC6UN4_P!7+"-A'Y5D6VM:OH,G
MV75H6N8%^[.H^8C\.OTZUG4BJ\G.&_8CVB3M)6_([2BJMCJ%KJ, EMIE<$<C
M/*_4=15JN5IK1FAGZEH]OJ04R95UZ,O6DTW1K?326CRSG^)JT:*Q]C3Y_:6U
M)Y(WO;4****U*"BBJ6KSR6NCWD\+;9(X693C."!3C'F:2ZDSDH1<GT+M%>+3
M?$75X)UB:_R3U(C7C]*]-\+ZJ=1T&WN+JYC>=]VXY /4XXKLKX&I0CS2:?H<
M>'QT:S2Y)1NKIM63_$W**0$,,@@CVI:XCN"BBLS4]?TW2)4BO9S&[KN4!"<C
M\*J$)3=HJ[(J5(4X\TW9>9IT5BVGBS1[Z[CMK>Z+2R'"KY;#)_*MJG.G.#M-
M6%2K4ZJO3DFO+4****@T"BBB@ HHHH **R]5\0:=I"$W,X,G:)/F8_@*PQ=Z
M_P")?EM4_LRQ)P9'&9&'M6L*,I+F>B[DRDHZ,X7XK7SQ^)?)B(P8%W,#]>*P
MO VNMHWB.VED1I(22K8_A!&,_AUKU\^ -"EMREU ]Q*PPTTDC%C[]:?H?@71
M-#PT5OYTPR#)+SD'VZ5Z*QM)4O9ZO2Q,*=.,&N17;O\ \'U1N6NH6=ZH:VN8
MI0?[C@FK-<_>^#M+N6,D"R6<QYWV[E/T'%46L/%6D@FSOH]0B'W8IP ?S&*\
M]4X2^&7WZ#<[;K]3KJ*Y*/QG);.4U73)K?;UD497\!U-;5IXATJ\3='>1KQG
M;*=A_(XI2HSCNBHRC)7B[FG17+ZKX^T32=2M[*2<2M*<,\1#+'[DBHK[Q3+J
M-Q_9_A]//D;AKG'R)]/6FJ%1]!R]V/,]C5UGQ!;Z4!$BFXO7XCMX^6/U]!]:
MIV.@SW]TFIZZPEG',5L#F.$?3N?<U8T+PW#I.ZXF<W-_)S)._)^@]!6X3@9-
M$I1AI#[R8MO4IW0\V>&V7[H^9@.P'3]15RJ=D#(\MR?XSA?8#_Z]7*X,/[UZ
MK^U^73_/YFU32T>P4445TF84444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%9FL>(=)T!(FU2_@M1*VU/-<+N/
MXTMSXAT:S6!KK5;.$7'^I,DZKYGTR>: -*D<%D90Q4D8##J*JWNJ:?IMJ+J^
MO;>VMSC$LT@53^)I+G5=/L[%;ZYOK>&T8!EGDD"H0>0<GB@#B[GPAKVJ:Z/[
M3N[)]/BDC=9T0^?)LR!GL"<\X ]JU-=\/ZUJ/BG1M1M+FPCM-.W?)*CF1RX
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M]6TG65T^6%II93B)T!(>O4/#W@C5=.TF..6^C+GYO+8'">V1S6GJE^)M425
M"(3\IQ6_!J1FA606[D$=5YK@I<2T\5.5%:./7OY^1Z&(H2=./-%-'/GP]J\?
M*&Q;W#S _P#H6*0Z=X@B^Y&3_P!<IA_[,372_P!H1C[T4X_[9FE&H6_=RO\
MO#%="S.#WFOF<#P</Y/NT_(Y<OXD@^]#?8_ZZPL/T&:X7Q[J]ZMS;BYBE67R
MB%,BXXS7LHO;5NEQ'_WT*S]<TW3-:TV:&\6.1=IPW&5^AKIH9E3A+GT^5C.6
M!I3M&I%M7VN_U9X3X5U]M*UZUN)U>:-9-Q5>OX5[;:^--$N9/*:\2&7NLAQC
M\37/^!/!^F::\]Q)BYN0Q"%Q]U>W'KTKM9=+L)AB2R@;_MF*JICL-C$JE/WE
MT:-JN'C2J/V:Y;[Z;DD%[:W0S;W,,H_Z9N&_E4]85QX/T68';:F%C_%%(RG^
M=9K^#KJV'_$NU>X0>DC;C62A3EM*WJB')QW3^1U]9<_B'2[?5XM+ENT6[D&5
M3/\ ,]C7):Q'XETK2+F5=1O"ZK\KL8V7K[+Q^->-W,UY-J#2SR2-=,V2Y/.:
MZJ.!YTY-Z>1="5*K)QYM4KVV?XGTIJ.MV.FC$LN^4_=BC&YS^ YKG;C5=9UN
M3[/8H;5#U*X+X]ST'TZU5\&Z!=76AV]QJ+J/-&X[,EW'^TQSC\,5W$%O#;1B
M.&-44>E8R5.B[;O\#)RG-VAHN_?T_P W]Q@Z3X1M;)_/NO\ 2)SSER2%/XUT
M0 4    =A2T5A.I*;O)E0IQAL%%%%06%%%% $<UO#.NV6)''^T,US'B#PI8/
MI=Y- # XB=CMYSQ[YKJZ9+$D\+Q2+NC=2K*>X-:TZLJ;33T,JE*,U>VO1GR[
M<V<T-QL8%BQ^4^M>V_"_2VL?#/G22;GG<G;@?)@D8%;I\(: 2"=,B)'3YF_Q
MK3L[*VT^V6WM8A%"I)"@GC/UKMQ6,IU:?+!,FG/%248UN6R6MNK^[0L55OG(
M@\M?O2'8/QJU5-?W^HD_P0C _P!X]?Z5XN);Y>1;RT_S_ ZJ:UN^A:C01Q*@
MZ 8IU%%;I)*R(;N%%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH \J^)-AJ$&O6^N64<6IPVY1;G32,R$'
MIM'J<'M65XPETJ]^$.EW.EPNMN+N 1B49=/W@R,UZ'XB\&0Z]>17D6H7EA<J
M5WO;.!YBCIG(/([?6JVI?#?1]3T*TT8W-_;V-L0RQV\JKN8'(+94Y.: .>\1
MLT_C;PI9RJ'M382.8V&5+>4XZ5QF@7MW?:CX:L;HM+9KJ%V C\J=K2 #Z <5
M[#>^#+*_L+&WFO+\3V0*PWBR*)P"""-VW'0D=*2X\#Z1-I=G8QB>V-FQ>&X@
M8+*KD$%LD$9.3GCO0!C?"J>:71=2BD),4.H3)%GH%#=!["N5^+,\\?B%$0$1
MFW7+#ZGBO6-&T>TT+38[&S#>6O)=SEG8]68]R:JZMX7TO6YC+>PEW*;,@]O\
MFM\/B/83Y[7]")TU-QNDTG?7^MSQ#P+?ZA9^)(&L;<W3X;]UG&>#WKUF;Q#X
MD3IX??\  [OY4WPIX0TFRLK>]@CD6XW,=^[GAB/3TKL:>(Q,:\[N&B\_\F:5
M(Q<FXZ7[?KYG"OXIU]?]9H%]_P!LXB?Z4T>*;\_ZW3-4C^N%_FM=Y2%%/50?
MPK+]SUA^+_S,'1_OO\/\CS^\\2H]C<++!.N8F&9+A>./3%>3W.L.9QY'$:GG
M_:KZ3EM;>:-XY(8V1P58%1R#7F>O_"A;K6(IM*=(+21OWR$_<'JM>A@L32HI
MQ2Y;^I,<!AZE53K^]965[=?1(O>!=8T>YT!5G5A-&Y\QB#M7)XYZ5V=LFE78
MS;-#*/\ 8?/]:R[3P+H=G:)##;E'4 &56PS'U/:H;GP:V=UKJ,H8=!<#>!^6
M*Y:L<-5J.>S?D$:#I)0I6Y5LG_GK^1T8L;8?\L5IPM+<?\LE_*N3&F^*=/&8
M;A+K'\(?RU_(Y/ZTY?$>NV('V_2)9?5HHR%'X\U'U6+^!IE<TE\4/NU_X/X&
M[J6BV]_"% $;KT8"JVF>'$L;@3R2^8Z_=P, 5Q'BKQ\ZR0FPNI+8JA\R($9)
MSQ6)H/Q$U%M5@_M*_E^SB0%@2,%?2K62J=JSM?\ KY'.ZS<I25*346M?^!OI
MU/;J*X]O&-Q>\:982R@])$0RC\ABF^7XDU ?O('13W:4(O\ WP1G]:7U=KXV
MD=/M)/X8OYZ?GK^!U-SJ%I9_\?%Q'&?1F )KG_$NLQ2^'+\103M'Y1W2E"%
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MHRMOL (8 @Y!I:HH6L9O+<DP,?D;^Z?2KU.E5YU9JS6Z"4;>@4445J2%%%%
M!1110 4$X!)Z"BJU](4@V+]^0[5K.K-4X.3Z%1CS.PVS'FR2W)_C.%^@JW3(
MHUAB6->BC I]*A!P@D]^OKU"<KRN@HHHK4D**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#,\/_\ ($M_J_\ Z&:TZS/#_P#R!+?ZO_Z&:TZ "BBB@ HHHH ****
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MKZXB9!\L<&X\[1]X_B0#6O0!$UO"\Z3-$AE3.UR.1FI" >HI:* # /:BBB@
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M9K3K,\/_ /($M_J__H9K3H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#C/B/!HEUX?ECU:46\JQ2/:SLVS8X'9NF3QP>M4/!6N"\\+747B
M6ZLY["SF6&&_N-J1W*;58,<_*<$[>./E]:[J]L;34;9[>\MXYX7&"DBY%(-/
MLA:+:?9(/LZC"Q&,%1^% '->$K>QBU/5FT>7S-)D=60(V^(.0,^6W0C.<X.
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MUO\ Z!UI_P"!1_\ B: -6BLK[3K?_0.M/_ H_P#Q-'VG6_\ H'6G_@4?_B:
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MVK'VG6_^@=:?^!1_^)H U:*ROM.M_P#0.M/_  */_P 31]IUO_H'6G_@4?\
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M 35P_BF?Q#JB3P>'YA9WNGR"39)_R\+@' ]N<?6F>+M%\4:W?&;1]:^PVMO
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M\6ZGXCG61?#2*MWITGF36\W6X3^$+['!ZXJSX5\3:/XQT>YB,:6]W)E+VTD
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>ptgx-20201231x10k013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ptgx-20201231x10k013.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "E \L# 2(  A$! Q$!_\0
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M860,HZX)[^U26?CS0K_Q!_8L$LYN"SHDAA(B=E )"OT/4=* .FHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBH9KJWMR!--'&3R S 9I-I:L":
MBJO]I6/_ #]P?]]BLO4/$L-M-Y<"B7N6!XK*>(I05Y,ESBE=LWJ*S;+6[.ZM
MQ(\J1-T*NP!JQ_:5C_S]P?\ ?8JHUJ<E=,%)/J6J*X;XAVWB&6&UE\-:K<6U
MX [B%2#'*$&[!&,Y/3K69X9\1-XPO-)NXM7O;>9-T5[8QNH02(">01GGCO6A
M1Z917FWQ&\4ZMH.JZ//I\C+I\5TJ7Y7I\W !]N0:;XZ\4-IGB'2XKO5;S3-'
MN8-\5W:KPTV1M5R00%QD_A0!Z717D_BJ_P!>M/ATNJ)XAD^UK=,$GL9%\N6-
MF^7U[>]22:OK/@WQ;H-O<:K<ZIIFL_NV%V09('&.00!P<GC% 'JE%>>_%+Q)
MJV@Z5!=:.S 6TJ2W>WKY?H?8X-'BWQ==-'X?TS1;@1W&M.%-R.L2<98>_)_*
M@#T*BO,]2U+4_ 'BG0X[K6+O5-,U63[*ZW; NDO9E( P,D<8-=1XY\3GPGX7
MN-2CC$MP"$A0]"[$ 9]N: .DHK@;#0_%7]A0:C'XDGFU&X599(9\&!%8ABJ#
M@C .,DFM.W\?:&VHIIC3S&??Y)F\H^4T@!RH?H6X/'M0!U=%<4_Q5\+QSW$,
MD]U&UO/]GFWV[ (_/4]AP:N)\0M DT_4KU)+AHM-Q]I @;<H.<''<<'F@#J:
M*Y70OB%H'B&]CM+.2X266/S8OM$#1B1/52>H^E26/CW0=0U/[!#/*KDL$EDB
M*Q2%>3M<\-CVH Z:BN1'CO2M2T_5/LAOX6MK9Y3,UHX 4$KO7^\ 0>GI7/:7
M\2;>T_X1S3&GNM5EU#<SW2VS;BN6P=OL0/PYH ]/HKG;3QMHE]KC:1!.[7 8
MHK^6?+=AU57Z%A@\>QKHJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]#VM$Q!V?Q=#\OYUZ3H1U)K OJD\4TKNS(8X]@"9.WC)YQB@#3HHHH ****
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M/E@[E;MDY''6O0/AM_R3K1/^O?\ ]F- '54444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MAM%E;9&96QN/H*\]^&.E3ZRVJ>(=::"[DN;LF$F+!380 0<]..E9\ZZAK'Q
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M.KR:A++=$O:BU:'>/+VC.#C&<C)[UUU% '!6_P )=#M[I9Q>ZD[+;FW4-,N
MISS]WJ-QQ4T?PPTF"QL;>VO]2@DLI&DAN8Y5\P%A@C.W&.3VKMZ* ./U3X<:
M3JBVP>ZOX3!"T.Z*4 R*Q);=D'DDDU67X7:47L#-J6J3BRA:")9)5P4/8X4=
M.,?2NYHH Y&Q^'.BV?AZZT5FN;BUN7+R><X+9SGL!4NJ> =(U&/3TB:XL/L
M(@-JP!4'&1\P/H*ZFB@#/CT:TCT=M+VLUNR%&W'E@>N:X'5M"C\%0PC2].U3
M6;V[ADM;>9SO%H,?*.%X4ECR:].HH X^V,W@/P!:"+3+C49H-HD@M@2Y+O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
$B@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>17
<FILENAME>ptgx-20201231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7713.40453 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/10/2021 9:29:12 PM-->
<!--Modified on: 3/10/2021 9:29:12 PM-->
<schema targetNamespace="http://www.protagonist-inc.com/20201231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ptgx="http://www.protagonist-inc.com/20201231" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfOperations" id="StatementConsolidatedStatementsOfOperations">
        <link:definition>00200 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" id="StatementConsolidatedStatementsOfComprehensiveLoss">
        <link:definition>00300 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>00500 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails">
        <link:definition>40202 - Disclosure - Summary of Significant Accounting Policies - Cash and Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails" id="DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails">
        <link:definition>40501 - Disclosure - Cash Equivalents and Marketable Securities - Cash Equivalents and Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesClassificationOfCashEquivalentsAndMarketableSecuritiesDetails" id="DisclosureCashEquivalentsAndMarketableSecuritiesClassificationOfCashEquivalentsAndMarketableSecuritiesDetails">
        <link:definition>40502 - Disclosure - Cash Equivalents and Marketable Securities - Classification of Cash Equivalents and Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails" id="DisclosureBalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails">
        <link:definition>40601 - Disclosure - Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails" id="DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails">
        <link:definition>40602 - Disclosure - Balance Sheet Components - Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsAccruedExpensesAndOtherPayablesDetails" id="DisclosureBalanceSheetComponentsAccruedExpensesAndOtherPayablesDetails">
        <link:definition>40603 - Disclosure - Balance Sheet Components - Accrued Expenses and Other Payables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureDebtLongTermDebtDetails" id="DisclosureDebtLongTermDebtDetails">
        <link:definition>40902 - Disclosure - Debt - Long-term debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureLeasesMinimumLeasePaymentsDetails" id="DisclosureLeasesMinimumLeasePaymentsDetails">
        <link:definition>41003 - Disclosure - Leases - Minimum lease payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureLeasesMinimumLeasePaymentsDetailsCalc2" id="DisclosureLeasesMinimumLeasePaymentsDetailsCalc2">
        <link:definition>41004 - Disclosure - Leases - Minimum lease payments (Details) (Calc 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureIncomeTaxesProvisionAndComponentsOfNetLossDetails" id="DisclosureIncomeTaxesProvisionAndComponentsOfNetLossDetails">
        <link:definition>41501 - Disclosure - Income Taxes - Provision and Components of Net Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureIncomeTaxesComponentsOfFederalStateAndForeignIncomeTaxExpenseBenefitDetails" id="DisclosureIncomeTaxesComponentsOfFederalStateAndForeignIncomeTaxExpenseBenefitDetails">
        <link:definition>41502 - Disclosure - Income Taxes - Components of Federal, State and Foreign Income Tax Expense (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureIncomeTaxesProvisionDifferenceFromFederalStatutoryRateDetails" id="DisclosureIncomeTaxesProvisionDifferenceFromFederalStatutoryRateDetails">
        <link:definition>41503 - Disclosure - Income Taxes - Provision Difference from Federal Statutory Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndValuationAllowanceDetails" id="DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndValuationAllowanceDetails">
        <link:definition>41504 - Disclosure - Income Taxes - Components of Deferred Tax Assets and Valuation Allowance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfStockholdersEquity" id="StatementConsolidatedStatementsOfStockholdersEquity">
        <link:definition>00400 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreement" id="DisclosureLicenseAndCollaborationAgreement">
        <link:definition>10301 - Disclosure - License and Collaboration Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreement" id="DisclosureResearchCollaborationAndLicenseAgreement">
        <link:definition>10701 - Disclosure - Research Collaboration and License Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureLeasesTables" id="DisclosureLeasesTables">
        <link:definition>31003 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureEquityPlansTables" id="DisclosureEquityPlansTables">
        <link:definition>31303 - Disclosure - Equity Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureOrganizationAndDescriptionOfBusinessLiquidityDetails" id="DisclosureOrganizationAndDescriptionOfBusinessLiquidityDetails">
        <link:definition>40101 - Disclosure - Organization and Description of Business - Liquidity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails">
        <link:definition>40201 - Disclosure - Summary of Significant Accounting Policies - Concentrations of Credit Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAndImpairmentOfLongLivedAssetsDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAndImpairmentOfLongLivedAssetsDetails">
        <link:definition>40203 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment and Impairment of Long-Lived Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesIncomeTaxesDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesIncomeTaxesDetails">
        <link:definition>40204 - Disclosure - Summary of Significant Accounting Policies - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails" id="DisclosureLicenseAndCollaborationAgreementDetails">
        <link:definition>40301 - Disclosure - License and Collaboration Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails" id="DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails">
        <link:definition>40302 - Disclosure - License and Collaboration Agreement - Contract Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsDetails" id="DisclosureFairValueMeasurementsDetails">
        <link:definition>40401 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreementDetails" id="DisclosureResearchCollaborationAndLicenseAgreementDetails">
        <link:definition>40701 - Disclosure - Research Collaboration and License Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureGovernmentProgramsDetails" id="DisclosureGovernmentProgramsDetails">
        <link:definition>40801 - Disclosure - Government Programs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureDebtDetails" id="DisclosureDebtDetails">
        <link:definition>40901 - Disclosure - Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureLeasesAgreementDetails" id="DisclosureLeasesAgreementDetails">
        <link:definition>41001 - Disclosure - Leases - Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingenciesDetails" id="DisclosureCommitmentsAndContingenciesDetails">
        <link:definition>41101 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails" id="DisclosureStockholdersEquityDetails">
        <link:definition>41201 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails" id="DisclosureEquityPlansNarrativeDetails">
        <link:definition>41301 - Disclosure - Equity Plans - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureEquityPlansActivityDetails" id="DisclosureEquityPlansActivityDetails">
        <link:definition>41302 - Disclosure - Equity Plans - Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockOptionsValuationAssumptionsDetails" id="DisclosureEquityPlansEmployeeStockOptionsValuationAssumptionsDetails">
        <link:definition>41303 - Disclosure - Equity Plans - Employee Stock Options Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureEquityPlansRestrictedStockUnitsDetails" id="DisclosureEquityPlansRestrictedStockUnitsDetails">
        <link:definition>41304 - Disclosure - Equity Plans - Restricted Stock Units - (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockPurchasePlanDetails" id="DisclosureEquityPlansEmployeeStockPurchasePlanDetails">
        <link:definition>41305 - Disclosure - Equity Plans - Employee Stock Purchase Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureEquityPlansStockBasedCompensationExpenseDetails" id="DisclosureEquityPlansStockBasedCompensationExpenseDetails">
        <link:definition>41306 - Disclosure - Equity Plans - Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails" id="DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails">
        <link:definition>41505 - Disclosure - Income Taxes - Net Operating Loss Carryforwards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureIncomeTaxesResearchAndDevelopmentTaxCreditCarryforwardsDetails" id="DisclosureIncomeTaxesResearchAndDevelopmentTaxCreditCarryforwardsDetails">
        <link:definition>41506 - Disclosure - Income Taxes - Research and Development Tax Credit Carryforwards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureIncomeTaxes2020TaxLawUpdatesDetails" id="DisclosureIncomeTaxes2020TaxLawUpdatesDetails">
        <link:definition>41508 - Disclosure - Income Taxes - 2020 Tax Law Updates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" id="DisclosureNetLossPerShareAntidilutiveSecuritiesDetails">
        <link:definition>41602 - Disclosure - Net Loss per Share - Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureRestructuringDetails" id="DisclosureRestructuringDetails">
        <link:definition>41701 - Disclosure - Restructuring (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureOrganizationAndDescriptionOfBusiness" id="DisclosureOrganizationAndDescriptionOfBusiness">
        <link:definition>10101 - Disclosure - Organization and Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>10401 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecurities" id="DisclosureCashEquivalentsAndMarketableSecurities">
        <link:definition>10501 - Disclosure - Cash Equivalents and Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponents" id="DisclosureBalanceSheetComponents">
        <link:definition>10601 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureGovernmentPrograms" id="DisclosureGovernmentPrograms">
        <link:definition>10801 - Disclosure - Government Programs</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureDebt" id="DisclosureDebt">
        <link:definition>10901 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureLeases" id="DisclosureLeases">
        <link:definition>11001 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>11101 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>11201 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureEquityPlans" id="DisclosureEquityPlans">
        <link:definition>11301 - Disclosure - Equity Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/Disclosure401KPlan" id="Disclosure401KPlan">
        <link:definition>11401 - Disclosure - 401(k) Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>11501 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>11601 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureRestructuring" id="DisclosureRestructuring">
        <link:definition>11701 - Disclosure - Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>30203 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementTables" id="DisclosureLicenseAndCollaborationAgreementTables">
        <link:definition>30303 - Disclosure - License and Collaboration Agreement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>30403 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesTables" id="DisclosureCashEquivalentsAndMarketableSecuritiesTables">
        <link:definition>30503 - Disclosure - Cash Equivalents and Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsTables" id="DisclosureBalanceSheetComponentsTables">
        <link:definition>30603 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureDebtTables" id="DisclosureDebtTables">
        <link:definition>30903 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>31503 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>31603 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureLeasesWeightedAverageLeaseTermAndDiscountRateDetails" id="DisclosureLeasesWeightedAverageLeaseTermAndDiscountRateDetails">
        <link:definition>41002 - Disclosure - Leases - Weighted average lease term and discount rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureLeasesLeaseCostInformationDetails" id="DisclosureLeasesLeaseCostInformationDetails">
        <link:definition>41004 - Disclosure - Leases - Lease cost information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails" id="DisclosureLeasesSupplementalBalanceSheetInformationDetails">
        <link:definition>41005 - Disclosure - Leases - Supplemental balance sheet information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureLeasesCashFlowInformationDetails" id="DisclosureLeasesCashFlowInformationDetails">
        <link:definition>41006 - Disclosure - Leases - Cash flow information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails" id="DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails">
        <link:definition>41507 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protagonist-inc.com/role/DisclosureNetLossPerShareComputationDetails" id="DisclosureNetLossPerShareComputationDetails">
        <link:definition>41601 - Disclosure - Net Loss per Share - Computation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="ptgx-20201231_pre.xml" xlink:title="Presentation Links, all" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ptgx-20201231_cal.xml" xlink:title="Calculation Links, all" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ptgx-20201231_def.xml" xlink:title="Definition Links, all" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ptgx-20201231_lab.xml" xlink:title="Label Links, all" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <import namespace="http://fasb.org/us-roles/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" />
  <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
  <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
  <import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
  <import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <element name="AccruedClinicalAndResearchRelatedExpensesCurrent" id="ptgx_AccruedClinicalAndResearchRelatedExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <element id="ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems" name="CashEquivalentsAndAvailableForSaleSecuritiesLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element name="FurnitureAndComputerEquipmentMember" id="ptgx_FurnitureAndComputerEquipmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <element name="GovernmentProgramsDisclosureTextBlock" id="ptgx_GovernmentProgramsDisclosureTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="ptgx_GovernmentProgramsLineItems" name="GovernmentProgramsLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element name="GovernmentProgramsTable" id="ptgx_GovernmentProgramsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <element name="LaboratoryEquipmentMember" id="ptgx_LaboratoryEquipmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <element name="OverseasFindingsMember" id="ptgx_OverseasFindingsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <element name="PrepaidManufacturingOfClinicalMaterials" id="ptgx_PrepaidManufacturingOfClinicalMaterials" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <element name="PTG300Member" id="ptgx_PTG300Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <element name="ResearchAndDevelopmentExpensesReduction" id="ptgx_ResearchAndDevelopmentExpensesReduction" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <element name="ResearchAndDevelopmentGrants" id="ptgx_ResearchAndDevelopmentGrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <element name="ResearchAndDevelopmentIncentiveGrantPolicyTextBlock" id="ptgx_ResearchAndDevelopmentIncentiveGrantPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element name="ScheduleCashEquivalentsAndAvailableForSaleSecuritiesTable" id="ptgx_ScheduleCashEquivalentsAndAvailableForSaleSecuritiesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <element name="SmallBusinessInnovationResearchGrantMember" id="ptgx_SmallBusinessInnovationResearchGrantMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <element name="CashNumberOfFinancialInstitutions" id="ptgx_CashNumberOfFinancialInstitutions" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <element name="ResearchCollaborationAndLicenseAgreementDisclosureAbstract" id="ptgx_ResearchCollaborationAndLicenseAgreementDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <element name="ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member" id="ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <element name="CollaborativeArrangementDisclosureAbstract" id="ptgx_CollaborativeArrangementDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <element name="JanssenLicenseAndCollaborationAgreement26May2017Member" id="ptgx_JanssenLicenseAndCollaborationAgreement26May2017Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <element name="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther" id="ptgx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <element id="ptgx_AtMarketOfferingMember" name="AtMarketOfferingMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element name="SaleOfStockValueOfSharesAuthorized" id="ptgx_SaleOfStockValueOfSharesAuthorized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <element name="IncomeTaxTable" id="ptgx_IncomeTaxTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <element name="IncomeTaxLineItems" id="ptgx_IncomeTaxLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <element id="ptgx_PhaseTwoClinicalTrialMember" name="PhaseTwoClinicalTrialMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_JanssenBiotechIncMember" name="JanssenBiotechIncMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element name="CollaborativeArrangementPercentageOfDevelopmentCostsIncurred" id="ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurred" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="ptgx_ContractWithCustomerAssetNetRollForward" name="ContractWithCustomerAssetNetRollForward" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element name="ContractWithCustomerAssetAdditions" id="ptgx_ContractWithCustomerAssetAdditions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <element name="ContractWithCustomerAssetDeduction" id="ptgx_ContractWithCustomerAssetDeduction" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <element id="ptgx_ContractWithCustomerLiabilityNetRollForward" name="ContractWithCustomerLiabilityNetRollForward" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element name="ContractWithCustomerLiabilityAdditions" id="ptgx_ContractWithCustomerLiabilityAdditions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <element id="ptgx_ContractWithCustomerLiabilityDeduction" name="ContractWithCustomerLiabilityDeduction" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="ptgx_ContingentConsiderationReceivable" name="ContingentConsiderationReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="ptgx_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAdjustmentPercent" name="EffectiveIncomeTaxRateReconciliationTaxCreditResearchAdjustmentPercent" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_EquityIncentivePlan2016Member" name="EquityIncentivePlan2016Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_StockOptionAndIncentivePlanAsAmendedAndRestated2007Member" name="StockOptionAndIncentivePlanAsAmendedAndRestated2007Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_EmployeeStockPurchasePlan2016Member" name="EmployeeStockPurchasePlan2016Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember" name="EmployeeConsultantsAndDirectorsStockOptionsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualNumberOfAdditionalSharesAuthorized" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualNumberOfAdditionalSharesAuthorized" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_AdditionalPaymentObligationToFormerCollaborationPartner" name="AdditionalPaymentObligationToFormerCollaborationPartner" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="ptgx_GovernmentProgramsAbstract" name="GovernmentProgramsAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_NumberOfEqualInstallmentsRequiredForVestingOfRestrictedStockUnits" name="NumberOfEqualInstallmentsRequiredForVestingOfRestrictedStockUnits" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_NonEmployeeDirectorInitialStockOptionsMember" name="NonEmployeeDirectorInitialStockOptionsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_NonemployeeDirectorAnnualRefresherStockOptionsMember" name="NonemployeeDirectorAnnualRefresherStockOptionsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_RevenueSourceAxis" name="RevenueSourceAxis" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_RevenueSourceDomain" name="RevenueSourceDomain" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_LicenseAndCollaborativeRevenueMember" name="LicenseAndCollaborativeRevenueMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_PayableToCollaborationPartnerRelatedPartyAbstract" name="PayableToCollaborationPartnerRelatedPartyAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_InducementStockPlanMember" name="InducementStockPlanMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember" name="SecuritiesPurchaseAgreementWithAccreditedInvestorsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_AggregateGrossProceedsFromIssuanceStock" name="AggregateGrossProceedsFromIssuanceStock" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="ptgx_NumberOfWarrantsExercised" name="NumberOfWarrantsExercised" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <element id="ptgx_ProceedsFromIssuanceOfCommonStockAndWarrantsInPrivatePlacementNetOfIssuanceCosts" name="ProceedsFromIssuanceOfCommonStockAndWarrantsInPrivatePlacementNetOfIssuanceCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="ptgx_WarrantsPurchaseAmountPerSharePriceOneMember" name="WarrantsPurchaseAmountPerSharePriceOneMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_WarrantsPurchaseAmountPerSharePriceTwoMember" name="WarrantsPurchaseAmountPerSharePriceTwoMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_UpfrontCashPaymentMember" name="UpfrontCashPaymentMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_SmallBusinessInnovationResearchSbirGrantsPolicyTextBlock" name="SmallBusinessInnovationResearchSbirGrantsPolicyTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_BiotechnologyValueFundL.pMember" name="BiotechnologyValueFundL.pMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants" name="StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="ptgx_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants" name="StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_StockWarrantIssuedDuringPeriodValueInExchangeForRetirementOfCommonStock" name="StockWarrantIssuedDuringPeriodValueInExchangeForRetirementOfCommonStock" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="ptgx_AtMarketingOfferingMember" name="AtMarketingOfferingMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_ExchangeAgreementMember" name="ExchangeAgreementMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_StockExchangedForPreFundedWarrants" name="StockExchangedForPreFundedWarrants" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_ClassOfWarrantOrRightTermOfWarrants" name="ClassOfWarrantOrRightTermOfWarrants" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant" name="FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="ptgx_ContractWithCustomerAssetRelatedPartyAdditions" name="ContractWithCustomerAssetRelatedPartyAdditions" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="ptgx_ContractWithCustomerAssetRelatedPartyDeduction" name="ContractWithCustomerAssetRelatedPartyDeduction" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="ptgx_DevelopmentRegulatoryAndSalesMilestonePaymentsMember" name="DevelopmentRegulatoryAndSalesMilestonePaymentsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_OperatingLossCarryforwardsNoExpiration" name="OperatingLossCarryforwardsNoExpiration" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="ptgx_OperatingLeaseRightOfUseAssetAmortization" name="OperatingLeaseRightOfUseAssetAmortization" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="ptgx_IncreaseDecreaseInOperatingLeaseLiability" name="IncreaseDecreaseInOperatingLeaseLiability" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="ptgx_NumberOfOperatingLeaseAgreement" name="NumberOfOperatingLeaseAgreement" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_LicenseAndCollaborativeAgreementAmendmentMember" name="LicenseAndCollaborativeAgreementAmendmentMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_LeaseQuantitativeDisclosureTableTextBlock" name="LeaseQuantitativeDisclosureTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_LeaseBalanceSheetDisclosureTableTextBlock" name="LeaseBalanceSheetDisclosureTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_LeaseCashFlowInformationDisclosureTableTextBlock" name="LeaseCashFlowInformationDisclosureTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_MilestonePaymentsMember" name="MilestonePaymentsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_AmendedCollaborationAgreementTrancheOneMember" name="AmendedCollaborationAgreementTrancheOneMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_AmendedSecondOptInMember" name="AmendedSecondOptInMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_Ptg200Phase3CdClinicalTrialPrimaryClinicalEndpointMember" name="Ptg200Phase3CdClinicalTrialPrimaryClinicalEndpointMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember" name="SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_StockIssuedDuringPeriodValueWarrantsExercised" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="ptgx_StockIssuedDuringPeriodSharesWarrantsExercised" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_PhaseOneClinicalTrialMember" name="PhaseOneClinicalTrialMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_CollaborationAgreementTrancheThreeMember" name="CollaborationAgreementTrancheThreeMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_CollaborationAgreementTrancheFourMember" name="CollaborationAgreementTrancheFourMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_CollaborationAgreementTrancheFiveMember" name="CollaborationAgreementTrancheFiveMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_CollaborativeArrangementPercentageOfResearchProgramCostsIncurred" name="CollaborativeArrangementPercentageOfResearchProgramCostsIncurred" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_CollaborativeArrangementPayableUponEffectivenessOfAmendment" name="CollaborativeArrangementPayableUponEffectivenessOfAmendment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="ptgx_RevenueFromContractWithCustomerIncludingCumulativeCatchUpAdjustmentToRevenueModificationOfContract" name="RevenueFromContractWithCustomerIncludingCumulativeCatchUpAdjustmentToRevenueModificationOfContract" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="ptgx_DebtInstrumentLoanOriginationFeePercentage" name="DebtInstrumentLoanOriginationFeePercentage" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_TermLoanCreditAgreementMember" name="TermLoanCreditAgreementMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_DebtInstrumentTrancheInstallmentAmount" name="DebtInstrumentTrancheInstallmentAmount" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="ptgx_DebtInstrumentThresholdPercentageOnOutstandingDebtToBeMaintainedAsCashAndCashEquivalentsBalance" name="DebtInstrumentThresholdPercentageOnOutstandingDebtToBeMaintainedAsCashAndCashEquivalentsBalance" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_DebtInstrumentFloorRate" name="DebtInstrumentFloorRate" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_DebtInstrumentPeriodOfInterestOnlyPayments" name="DebtInstrumentPeriodOfInterestOnlyPayments" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_DebtInstrumentPeriodOfPrincipalAndInterestPayments" name="DebtInstrumentPeriodOfPrincipalAndInterestPayments" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_DebtInstrumentRepaymentOnOrBeforeFirstAnniversaryMember" name="DebtInstrumentRepaymentOnOrBeforeFirstAnniversaryMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_DebtInstrumentRepaymentBetweenFirstAndSecondAnniversaryMember" name="DebtInstrumentRepaymentBetweenFirstAndSecondAnniversaryMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_DebtInstrumentRepaymentAfterSecondAnniversaryMember" name="DebtInstrumentRepaymentAfterSecondAnniversaryMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_DebtInstrumentPrepaymentPremiumPercentage" name="DebtInstrumentPrepaymentPremiumPercentage" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_DebtInstrumentAdditionalPrepaymentOrRepaymentPremiumPercentage" name="DebtInstrumentAdditionalPrepaymentOrRepaymentPremiumPercentage" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_SecondGenerationPhase2bMilestonePaymentMember" name="SecondGenerationPhase2bMilestonePaymentMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_EstimatedVariableConsiderationMember" name="EstimatedVariableConsiderationMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_DueToRelatedPartyAdditions" name="DueToRelatedPartyAdditions" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="ptgx_DueToRelatedPartyDeductions" name="DueToRelatedPartyDeductions" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="ptgx_AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee" name="AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="ptgx_SecondGenerationDevelopmentCompoundMember" name="SecondGenerationDevelopmentCompoundMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_DebtInstrumentAccruedFinalPaymentFee" name="DebtInstrumentAccruedFinalPaymentFee" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="ptgx_UsTreasuryAndAgencySecuritiesMember" name="UsTreasuryAndAgencySecuritiesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_SecondGenerationAnalogPhase2CdClinicalTrialPrimaryClinicalEndpointMember" name="SecondGenerationAnalogPhase2CdClinicalTrialPrimaryClinicalEndpointMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost" name="CashEquivalentsAndMarketableSecuritiesAmortizedCost" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain" name="CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss" name="CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="ptgx_CashEquivalentsAndMarketableSecuritiesFairValue" name="CashEquivalentsAndMarketableSecuritiesFairValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="ptgx_CommonStockPreferredStockAndCertainDebtSecuritiesMember" name="CommonStockPreferredStockAndCertainDebtSecuritiesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember" name="CommonStockPreferredStockDebtSecuritiesAndWarrantsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_DeferredTaxAssetsOperatingLeaseLiability" name="DeferredTaxAssetsOperatingLeaseLiability" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="ptgx_SalesAgreementFrom2017Member" name="SalesAgreementFrom2017Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_CashEquivalentsAndMarketableSecuritiesAbstract" name="CashEquivalentsAndMarketableSecuritiesAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants" name="ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo" name="ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_PercentageOfEmployeeBaseImpactedByRestructuringPlan" name="PercentageOfEmployeeBaseImpactedByRestructuringPlan" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_AccruedLiabilitiesAndOtherPayablesMember" name="AccruedLiabilitiesAndOtherPayablesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_NetOperatingLossCarryback" name="NetOperatingLossCarryback" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_DeductionOfTaxableIncomePercentage" name="DeductionOfTaxableIncomePercentage" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_CaliforniaNetOperatingLossDeductionsLimitOfIncome" name="CaliforniaNetOperatingLossDeductionsLimitOfIncome" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="ptgx_MaximumOffsetOfCaliforniaTax" name="MaximumOffsetOfCaliforniaTax" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="ptgx_PercentagesRoyaltiesOnNetProductSales" name="PercentagesRoyaltiesOnNetProductSales" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_CollaborativeArrangementEligibleAmountReceived" name="CollaborativeArrangementEligibleAmountReceived" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="ptgx_ZealandPharmaMember" name="ZealandPharmaMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_PotentialDevelopmentAndRegulatoryMilestonePaymentsOnContractualObligation" name="PotentialDevelopmentAndRegulatoryMilestonePaymentsOnContractualObligation" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="ptgx_PotentialSalesMilestonePaymentsOnContractualObligation" name="PotentialSalesMilestonePaymentsOnContractualObligation" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="ptgx_PhaseTwoBClinicalTrailOfPtg300Member" name="PhaseTwoBClinicalTrailOfPtg300Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_PhaseThreeClinicalTrailOfPtg300Member" name="PhaseThreeClinicalTrailOfPtg300Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_EntityRequiredToContinueToMakePaymentsMember" name="EntityRequiredToContinueToMakePaymentsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_AggregateAmountOfDevelopmentMilestonePayment" name="AggregateAmountOfDevelopmentMilestonePayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="ptgx_NumberOfDevelopmentMilestonePayments" name="NumberOfDevelopmentMilestonePayments" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_SuccessfullyDevelopAndCommercializeRusfertideComponentWithOutPartnerMember" name="SuccessfullyDevelopAndCommercializeRusfertideComponentWithOutPartnerMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="ptgx_NoncurrentContractualMaturitiesMaximumPeriod" name="NoncurrentContractualMaturitiesMaximumPeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_NoncurrentContractualMaturitiesMinimumPeriod" name="NoncurrentContractualMaturitiesMinimumPeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="ptgx_CurrentContractualMaturitiesMaximumPeriod" name="CurrentContractualMaturitiesMaximumPeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>18
<FILENAME>ptgx-20201231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7713.40453 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/10/2021 9:29:12 PM-->
<!--Modified on: 3/10/2021 9:29:12 PM-->
<linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#StatementConsolidatedStatementsOfComprehensiveLoss" roleURI="http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureCashEquivalentsAndMarketableSecuritiesClassificationOfCashEquivalentsAndMarketableSecuritiesDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesClassificationOfCashEquivalentsAndMarketableSecuritiesDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureBalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureBalanceSheetComponentsAccruedExpensesAndOtherPayablesDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsAccruedExpensesAndOtherPayablesDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureDebtLongTermDebtDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureDebtLongTermDebtDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureLeasesMinimumLeasePaymentsDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureLeasesMinimumLeasePaymentsDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureLeasesMinimumLeasePaymentsDetailsCalc2" roleURI="http://www.protagonist-inc.com/role/DisclosureLeasesMinimumLeasePaymentsDetailsCalc2" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureIncomeTaxesProvisionAndComponentsOfNetLossDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureIncomeTaxesProvisionAndComponentsOfNetLossDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureIncomeTaxesComponentsOfFederalStateAndForeignIncomeTaxExpenseBenefitDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureIncomeTaxesComponentsOfFederalStateAndForeignIncomeTaxExpenseBenefitDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureIncomeTaxesProvisionDifferenceFromFederalStatutoryRateDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureIncomeTaxesProvisionDifferenceFromFederalStatutoryRateDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndValuationAllowanceDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndValuationAllowanceDetails" />
  <calculationLink xlink:role="http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Balance Sheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="Assets" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637510085485000858" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_AssetsCurrent_637510085485000858" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637510085485000858" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637510085485000858" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637510085485000858" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent_637510085485000858" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637510085485000858" xlink:to="us-gaap_RestrictedCashCurrent_637510085485000858" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent_637510085485000858" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637510085485000858" xlink:to="us-gaap_MarketableSecuritiesCurrent_637510085485000858" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_637510085485000858" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637510085485000858" xlink:to="us-gaap_DueFromRelatedPartiesCurrent_637510085485000858" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="us-gaap_IncomeTaxesReceivable_637510085485000858" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637510085485000858" xlink:to="us-gaap_IncomeTaxesReceivable_637510085485000858" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637510085485000858" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637510085485000858" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637510085485000858" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637510085485010862" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637510085485010862" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_637510085485010862" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_MarketableSecuritiesNoncurrent_637510085485010862" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637510085485010862" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637510085485010862" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_637510085485010862" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_RestrictedCashNoncurrent_637510085485010862" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_637510085485010862" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_637510085485010862" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637510085485010862" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_637510085485010862" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637510085485010862" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637510085485010862" xlink:to="us-gaap_LiabilitiesCurrent_637510085485010862" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637510085485020846" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637510085485010862" xlink:to="us-gaap_AccountsPayableCurrent_637510085485020846" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent_637510085485020846" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637510085485010862" xlink:to="us-gaap_DueToRelatedPartiesCurrent_637510085485020846" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities_637510085485020846" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637510085485010862" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities_637510085485020846" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_637510085485020846" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637510085485010862" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_637510085485020846" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637510085485020846" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637510085485010862" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637510085485020846" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_637510085485020846" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637510085485010862" xlink:to="us-gaap_LongTermDebt_637510085485020846" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_637510085485020846" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637510085485010862" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_637510085485020846" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637510085485020846" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637510085485010862" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637510085485020846" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_637510085485030844" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637510085485010862" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_637510085485030844" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637510085485030844" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_637510085485030844" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_637510085485030844" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637510085485030844" xlink:to="us-gaap_PreferredStockValue_637510085485030844" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637510085485030844" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637510085485030844" xlink:to="us-gaap_CommonStockValue_637510085485030844" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_637510085485030844" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637510085485030844" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_637510085485030844" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637510085485030844" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637510085485030844" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637510085485030844" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637510085485030844" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637510085485030844" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637510085485030844" order="5" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statements of Operations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637510085485040844" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637510085485040844" order="1" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637510085485040844" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637510085485040844" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_637510085485040844" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637510085485040844" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_637510085485040844" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_637510085485040844" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637510085485040844" xlink:to="us-gaap_InvestmentIncomeInterest_637510085485040844" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_637510085485040844" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637510085485040844" xlink:to="us-gaap_InterestExpense_637510085485040844" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_637510085485040844" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637510085485040844" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_637510085485040844" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637510085485040844" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637510085485040844" xlink:to="us-gaap_OperatingIncomeLoss_637510085485040844" order="5" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_RevenueFromContractWithCustomerIncludingCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:label="ptgx_RevenueFromContractWithCustomerIncludingCumulativeCatchUpAdjustmentToRevenueModificationOfContract_637510085485050853" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637510085485040844" xlink:to="ptgx_RevenueFromContractWithCustomerIncludingCumulativeCatchUpAdjustmentToRevenueModificationOfContract_637510085485050853" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_637510085485050853" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637510085485040844" xlink:to="us-gaap_OperatingExpenses_637510085485050853" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637510085485050853" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637510085485050853" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637510085485050853" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637510085485050853" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637510085485050853" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637510085485050853" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended" xlink:title="00300 - Statement - Consolidated Statements of Comprehensive Loss">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="ComprehensiveIncomeNetOfTax" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637510085485050853" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss_637510085485050853" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_637510085485050853" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_637510085485050853" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_637510085485050853" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_637510085485050853" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00500 - Statement - Consolidated Statements of Cash Flows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637510085485060854" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637510085485060854" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637510085485060854" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637510085485060854" xlink:to="us-gaap_ProfitLoss_637510085485060854" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_637510085485060854" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637510085485060854" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_637510085485060854" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_637510085485060854" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637510085485060854" xlink:to="us-gaap_DepreciationDepletionAndAmortization_637510085485060854" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee" xlink:label="ptgx_AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee_637510085485060854" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637510085485060854" xlink:to="ptgx_AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee_637510085485060854" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_637510085485060854" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637510085485060854" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_637510085485060854" order="5" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxCreditsAndAdjustments" xlink:label="us-gaap_IncomeTaxCreditsAndAdjustments_637510085485060854" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637510085485060854" xlink:to="us-gaap_IncomeTaxCreditsAndAdjustments_637510085485060854" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_637510085485060854" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637510085485060854" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_637510085485060854" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637510085485060854" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637510085485060854" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637510085485060854" order="8" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_637510085485060854" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637510085485060854" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_637510085485060854" order="9" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637510085485073254" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637510085485060854" xlink:to="us-gaap_ShareBasedCompensation_637510085485073254" order="10" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="ptgx_IncreaseDecreaseInOperatingLeaseLiability_637510085485073254" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637510085485060854" xlink:to="ptgx_IncreaseDecreaseInOperatingLeaseLiability_637510085485073254" order="11" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_OperatingLeaseRightOfUseAssetAmortization" xlink:label="ptgx_OperatingLeaseRightOfUseAssetAmortization_637510085485073254" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637510085485060854" xlink:to="ptgx_OperatingLeaseRightOfUseAssetAmortization_637510085485073254" order="12" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_637510085485073254" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637510085485060854" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_637510085485073254" order="13" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_637510085485073254" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637510085485060854" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_637510085485073254" order="14" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637510085485073254" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637510085485060854" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637510085485073254" order="15" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_637510085485080852" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637510085485060854" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_637510085485080852" order="16" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637510085485080852" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637510085485060854" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637510085485080852" order="17" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_637510085485080852" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637510085485060854" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_637510085485080852" order="18" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637510085485080852" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637510085485080852" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_637510085485080852" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637510085485080852" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_637510085485080852" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637510085485080852" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637510085485080852" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637510085485080852" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_637510085485080852" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637510085485080852" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_637510085485080852" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637510085485090846" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637510085485090846" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ProceedsFromIssuanceOfCommonStockAndWarrantsInPrivatePlacementNetOfIssuanceCosts" xlink:label="ptgx_ProceedsFromIssuanceOfCommonStockAndWarrantsInPrivatePlacementNetOfIssuanceCosts_637510085485090846" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637510085485090846" xlink:to="ptgx_ProceedsFromIssuanceOfCommonStockAndWarrantsInPrivatePlacementNetOfIssuanceCosts_637510085485090846" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt_637510085485090846" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637510085485090846" xlink:to="us-gaap_RepaymentsOfLongTermDebt_637510085485090846" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637510085485090846" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637510085485090846" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637510085485090846" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_637510085485090846" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637510085485090846" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_637510085485090846" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_637510085485090846" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637510085485090846" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_637510085485090846" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_637510085485090846" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637510085485090846" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_637510085485090846" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_637510085485100847" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637510085485090846" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_637510085485100847" order="7" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637510085485100847" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637510085485100847" order="4" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Summary of Significant Accounting Policies - Cash and Cash Equivalents and Restricted Cash (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637510085485100847" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637510085485100847" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent_637510085485100847" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashCurrent_637510085485100847" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_637510085485100847" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashNoncurrent_637510085485100847" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Cash Equivalents and Marketable Securities - Cash Equivalents and Marketable Securities (Details)">
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain_637510085485150846" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost" xlink:to="ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain_637510085485150846" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss_637510085485150846" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost" xlink:to="ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss_637510085485150846" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CashEquivalentsAndMarketableSecuritiesFairValue" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesFairValue_637510085485150846" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost" xlink:to="ptgx_CashEquivalentsAndMarketableSecuritiesFairValue_637510085485150846" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesClassificationOfCashEquivalentsAndMarketableSecuritiesDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Cash Equivalents and Marketable Securities - Classification of Cash Equivalents and Marketable Securities (Details)">
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CashEquivalentsAndMarketableSecuritiesFairValue" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesFairValue" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_637510085485150846" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ptgx_CashEquivalentsAndMarketableSecuritiesFairValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_637510085485150846" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent_637510085485150846" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ptgx_CashEquivalentsAndMarketableSecuritiesFairValue" xlink:to="us-gaap_MarketableSecuritiesCurrent_637510085485150846" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_637510085485150846" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ptgx_CashEquivalentsAndMarketableSecuritiesFairValue" xlink:to="us-gaap_MarketableSecuritiesNoncurrent_637510085485150846" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_PrepaidManufacturingOfClinicalMaterials" xlink:label="ptgx_PrepaidManufacturingOfClinicalMaterials_637510085485160867" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="ptgx_PrepaidManufacturingOfClinicalMaterials_637510085485160867" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance_637510085485160867" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance_637510085485160867" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_637510085485160867" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_637510085485160867" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent_637510085485160867" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_637510085485160867" order="4" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Balance Sheet Components - Property and Equipment, Net (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_637510085485160867" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_637510085485160867" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637510085485160867" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637510085485160867" order="2" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsAccruedExpensesAndOtherPayablesDetails" xlink:type="extended" xlink:title="40603 - Disclosure - Balance Sheet Components - Accrued Expenses and Other Payables (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_AccruedClinicalAndResearchRelatedExpensesCurrent" xlink:label="ptgx_AccruedClinicalAndResearchRelatedExpensesCurrent_637510085485160867" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="ptgx_AccruedClinicalAndResearchRelatedExpensesCurrent_637510085485160867" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_637510085485160867" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_637510085485160867" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_637510085485170869" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_637510085485170869" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent_637510085485170869" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_InterestPayableCurrent_637510085485170869" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_637510085485170869" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_637510085485170869" order="5" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureDebtLongTermDebtDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Debt - Long-term debt (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DebtInstrumentAccruedFinalPaymentFee" xlink:label="ptgx_DebtInstrumentAccruedFinalPaymentFee_637510085485170869" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="ptgx_DebtInstrumentAccruedFinalPaymentFee_637510085485170869" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet_637510085485170869" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_DeferredFinanceCostsNet_637510085485170869" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_637510085485170869" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_DebtInstrumentCarryingAmount_637510085485170869" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureLeasesMinimumLeasePaymentsDetails" xlink:type="extended" xlink:title="41003 - Disclosure - Leases - Minimum lease payments (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637510085485170869" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637510085485170869" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637510085485170869" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637510085485170869" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637510085485180861" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637510085485180861" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637510085485180861" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637510085485180861" order="4" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureLeasesMinimumLeasePaymentsDetailsCalc2" xlink:type="extended" xlink:title="41004 - Disclosure - Leases - Minimum lease payments (Details) (Calc 2)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_637510085485180861" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_637510085485180861" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_637510085485180861" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability_637510085485180861" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637510085485180861" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability_637510085485180861" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637510085485180861" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637510085485180861" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability_637510085485180861" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637510085485180861" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureIncomeTaxesProvisionAndComponentsOfNetLossDetails" xlink:type="extended" xlink:title="41501 - Disclosure - Income Taxes - Provision and Components of Net Loss (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_637510085485180861" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_637510085485180861" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_637510085485180861" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_637510085485180861" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureIncomeTaxesComponentsOfFederalStateAndForeignIncomeTaxExpenseBenefitDetails" xlink:type="extended" xlink:title="41502 - Disclosure - Income Taxes - Components of Federal, State and Foreign Income Tax Expense (Benefit) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_637510085485190855" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_637510085485190855" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_637510085485190855" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit_637510085485190855" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_637510085485190855" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_637510085485190855" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_637510085485190855" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_637510085485190855" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit_637510085485190855" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_637510085485190855" order="1" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureIncomeTaxesProvisionDifferenceFromFederalStatutoryRateDetails" xlink:type="extended" xlink:title="41503 - Disclosure - Income Taxes - Provision Difference from Federal Statutory Rate (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="EffectiveIncomeTaxRateContinuingOperations" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637510085485190855" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637510085485190855" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637510085485190855" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637510085485190855" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAdjustmentPercent" xlink:label="ptgx_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAdjustmentPercent_637510085485200868" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="ptgx_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAdjustmentPercent_637510085485200868" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_637510085485200868" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_637510085485200868" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637510085485200868" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637510085485200868" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_637510085485200868" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_637510085485200868" order="6" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndValuationAllowanceDetails" xlink:type="extended" xlink:title="41504 - Disclosure - Income Taxes - Components of Deferred Tax Assets and Valuation Allowance (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_637510085485200868" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross_637510085485200868" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637510085485200868" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637510085485200868" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637510085485200868" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_637510085485200868" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637510085485200868" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_637510085485200868" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther" xlink:label="ptgx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther_637510085485200868" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637510085485200868" xlink:to="ptgx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther_637510085485200868" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="ptgx_DeferredTaxAssetsOperatingLeaseLiability_637510085485200868" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637510085485200868" xlink:to="ptgx_DeferredTaxAssetsOperatingLeaseLiability_637510085485200868" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_637510085485210864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637510085485200868" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_637510085485210864" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_637510085485210864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_637510085485210864" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_637510085485210864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_637510085485210864" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_637510085485210864" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_637510085485210864" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_637510085485210864" order="3" use="optional" weight="-1" priority="3" />
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>19
<FILENAME>ptgx-20201231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7713.40453 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/10/2021 9:29:12 PM-->
<!--Modified on: 3/10/2021 9:29:12 PM-->
<linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#StatementConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfStockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureLicenseAndCollaborationAgreement" roleURI="http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreement" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureResearchCollaborationAndLicenseAgreement" roleURI="http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreement" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureEquityPlansTables" roleURI="http://www.protagonist-inc.com/role/DisclosureEquityPlansTables" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAndImpairmentOfLongLivedAssetsDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAndImpairmentOfLongLivedAssetsDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureLicenseAndCollaborationAgreementDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureFairValueMeasurementsDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureResearchCollaborationAndLicenseAgreementDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreementDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureGovernmentProgramsDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureGovernmentProgramsDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureDebtDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureDebtDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureLeasesAgreementDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureLeasesAgreementDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingenciesDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureStockholdersEquityDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureEquityPlansNarrativeDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureEquityPlansEmployeeStockOptionsValuationAssumptionsDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockOptionsValuationAssumptionsDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureEquityPlansRestrictedStockUnitsDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureEquityPlansRestrictedStockUnitsDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureEquityPlansEmployeeStockPurchasePlanDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockPurchasePlanDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureEquityPlansStockBasedCompensationExpenseDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureEquityPlansStockBasedCompensationExpenseDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureIncomeTaxesResearchAndDevelopmentTaxCreditCarryforwardsDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureIncomeTaxesResearchAndDevelopmentTaxCreditCarryforwardsDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureIncomeTaxes2020TaxLawUpdatesDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureIncomeTaxes2020TaxLawUpdatesDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" />
  <definitionLink xlink:role="http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statements of Stockholders' Equity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637510085485220861" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_637510085485220861" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637510085485230863" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637510085485230863" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_AtMarketingOfferingMember" xlink:label="ptgx_AtMarketingOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="ptgx_AtMarketingOfferingMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants" xlink:label="ptgx_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="ptgx_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants" xlink:label="ptgx_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ptgx_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants" xlink:to="ptgx_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_StockWarrantIssuedDuringPeriodValueInExchangeForRetirementOfCommonStock" xlink:label="ptgx_StockWarrantIssuedDuringPeriodValueInExchangeForRetirementOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="ptgx_StockWarrantIssuedDuringPeriodValueInExchangeForRetirementOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="ptgx_StockIssuedDuringPeriodValueWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="ptgx_StockIssuedDuringPeriodValueWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="ptgx_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ptgx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="ptgx_StockIssuedDuringPeriodSharesWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00500 - Statement - Consolidated Statements of Cash Flows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_AtMarketingOfferingMember" xlink:label="ptgx_AtMarketingOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="ptgx_AtMarketingOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_637510085485270868" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_637510085485270868" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_AccruedLiabilitiesAndOtherPayablesMember" xlink:label="ptgx_AccruedLiabilitiesAndOtherPayablesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="ptgx_AccruedLiabilitiesAndOtherPayablesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_OperatingLeaseRightOfUseAssetAmortization" xlink:label="ptgx_OperatingLeaseRightOfUseAssetAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ptgx_OperatingLeaseRightOfUseAssetAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee" xlink:label="ptgx_AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ptgx_AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxCreditsAndAdjustments" xlink:label="us-gaap_IncomeTaxCreditsAndAdjustments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncomeTaxCreditsAndAdjustments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="ptgx_IncreaseDecreaseInOperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="ptgx_IncreaseDecreaseInOperatingLeaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ProceedsFromIssuanceOfCommonStockAndWarrantsInPrivatePlacementNetOfIssuanceCosts" xlink:label="ptgx_ProceedsFromIssuanceOfCommonStockAndWarrantsInPrivatePlacementNetOfIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ptgx_ProceedsFromIssuanceOfCommonStockAndWarrantsInPrivatePlacementNetOfIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant" xlink:label="ptgx_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="ptgx_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreement" xlink:type="extended" xlink:title="10301 - Disclosure - License and Collaboration Agreement">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637510085485370861" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637510085485370861" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_JanssenLicenseAndCollaborationAgreement26May2017Member" xlink:label="ptgx_JanssenLicenseAndCollaborationAgreement26May2017Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ptgx_JanssenLicenseAndCollaborationAgreement26May2017Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreement" xlink:type="extended" xlink:title="10701 - Disclosure - Research Collaboration and License Agreement">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member" xlink:label="ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protagonist-inc.com/role/DisclosureEquityPlansTables" xlink:type="extended" xlink:title="31303 - Disclosure - Equity Plans (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637510085485390880" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637510085485390880" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAndImpairmentOfLongLivedAssetsDetails" xlink:type="extended" xlink:title="40203 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment and Impairment of Long-Lived Assets (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637510085485400870" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_637510085485400870" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="us-gaap_TangibleAssetImpairmentCharges" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_TangibleAssetImpairmentCharges" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails" xlink:type="extended" xlink:title="40301 - Disclosure - License and Collaboration Agreement (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637510085485410933" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637510085485410933" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_JanssenBiotechIncMember" xlink:label="ptgx_JanssenBiotechIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ptgx_JanssenBiotechIncMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_637510085485410933" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_637510085485410933" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProFormaMember" xlink:label="srt_ProFormaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ProFormaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_PhaseOneClinicalTrialMember" xlink:label="ptgx_PhaseOneClinicalTrialMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ProductMember" xlink:to="ptgx_PhaseOneClinicalTrialMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CollaborationAgreementTrancheThreeMember" xlink:label="ptgx_CollaborationAgreementTrancheThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ptgx_PhaseOneClinicalTrialMember" xlink:to="ptgx_CollaborationAgreementTrancheThreeMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CollaborationAgreementTrancheFourMember" xlink:label="ptgx_CollaborationAgreementTrancheFourMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ptgx_PhaseOneClinicalTrialMember" xlink:to="ptgx_CollaborationAgreementTrancheFourMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CollaborationAgreementTrancheFiveMember" xlink:label="ptgx_CollaborationAgreementTrancheFiveMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ptgx_PhaseOneClinicalTrialMember" xlink:to="ptgx_CollaborationAgreementTrancheFiveMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_SecondGenerationDevelopmentCompoundMember" xlink:label="ptgx_SecondGenerationDevelopmentCompoundMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ProductMember" xlink:to="ptgx_SecondGenerationDevelopmentCompoundMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_PhaseTwoClinicalTrialMember" xlink:label="ptgx_PhaseTwoClinicalTrialMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ProductMember" xlink:to="ptgx_PhaseTwoClinicalTrialMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_LicenseAndCollaborativeAgreementAmendmentMember" xlink:label="ptgx_LicenseAndCollaborativeAgreementAmendmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ptgx_LicenseAndCollaborativeAgreementAmendmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_AmendedCollaborationAgreementTrancheOneMember" xlink:label="ptgx_AmendedCollaborationAgreementTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ptgx_AmendedCollaborationAgreementTrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_AmendedSecondOptInMember" xlink:label="ptgx_AmendedSecondOptInMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ptgx_AmendedSecondOptInMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_EstimatedVariableConsiderationMember" xlink:label="ptgx_EstimatedVariableConsiderationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ptgx_EstimatedVariableConsiderationMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637510085485440866" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_637510085485440866" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_LicenseAndCollaborativeRevenueMember" xlink:label="ptgx_LicenseAndCollaborativeRevenueMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ptgx_LicenseAndCollaborativeRevenueMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_UpfrontCashPaymentMember" xlink:label="ptgx_UpfrontCashPaymentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ptgx_UpfrontCashPaymentMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DevelopmentRegulatoryAndSalesMilestonePaymentsMember" xlink:label="ptgx_DevelopmentRegulatoryAndSalesMilestonePaymentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ptgx_DevelopmentRegulatoryAndSalesMilestonePaymentsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialServiceOtherMember" xlink:label="us-gaap_FinancialServiceOtherMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_FinancialServiceOtherMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_MilestonePaymentsMember" xlink:label="ptgx_MilestonePaymentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ptgx_MilestonePaymentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_Ptg200Phase3CdClinicalTrialPrimaryClinicalEndpointMember" xlink:label="ptgx_Ptg200Phase3CdClinicalTrialPrimaryClinicalEndpointMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ptgx_MilestonePaymentsMember" xlink:to="ptgx_Ptg200Phase3CdClinicalTrialPrimaryClinicalEndpointMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember" xlink:label="ptgx_SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ptgx_MilestonePaymentsMember" xlink:to="ptgx_SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_SecondGenerationAnalogPhase2CdClinicalTrialPrimaryClinicalEndpointMember" xlink:label="ptgx_SecondGenerationAnalogPhase2CdClinicalTrialPrimaryClinicalEndpointMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ptgx_MilestonePaymentsMember" xlink:to="ptgx_SecondGenerationAnalogPhase2CdClinicalTrialPrimaryClinicalEndpointMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_SecondGenerationPhase2bMilestonePaymentMember" xlink:label="ptgx_SecondGenerationPhase2bMilestonePaymentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ptgx_MilestonePaymentsMember" xlink:to="ptgx_SecondGenerationPhase2bMilestonePaymentMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurred" xlink:label="ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurred" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurred" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CollaborativeArrangementEligibleAmountReceived" xlink:label="ptgx_CollaborativeArrangementEligibleAmountReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ptgx_CollaborativeArrangementEligibleAmountReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CollaborativeArrangementPercentageOfResearchProgramCostsIncurred" xlink:label="ptgx_CollaborativeArrangementPercentageOfResearchProgramCostsIncurred" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ptgx_CollaborativeArrangementPercentageOfResearchProgramCostsIncurred" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CollaborativeArrangementPayableUponEffectivenessOfAmendment" xlink:label="ptgx_CollaborativeArrangementPayableUponEffectivenessOfAmendment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ptgx_CollaborativeArrangementPayableUponEffectivenessOfAmendment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ContingentConsiderationReceivable" xlink:label="ptgx_ContingentConsiderationReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ptgx_ContingentConsiderationReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_PercentagesRoyaltiesOnNetProductSales" xlink:label="ptgx_PercentagesRoyaltiesOnNetProductSales" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ptgx_PercentagesRoyaltiesOnNetProductSales" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:label="us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CapitalizedContractCostNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails" xlink:type="extended" xlink:title="40302 - Disclosure - License and Collaboration Agreement - Contract Assets and Liabilities (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_JanssenBiotechIncMember" xlink:label="ptgx_JanssenBiotechIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ptgx_JanssenBiotechIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract" xlink:label="us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ContractWithCustomerAssetNetRollForward" xlink:label="ptgx_ContractWithCustomerAssetNetRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract" xlink:to="ptgx_ContractWithCustomerAssetNetRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ptgx_ContractWithCustomerAssetNetRollForward" xlink:to="us-gaap_ContractWithCustomerAssetNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ContractWithCustomerAssetAdditions" xlink:label="ptgx_ContractWithCustomerAssetAdditions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ptgx_ContractWithCustomerAssetNetRollForward" xlink:to="ptgx_ContractWithCustomerAssetAdditions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ContractWithCustomerAssetDeduction" xlink:label="ptgx_ContractWithCustomerAssetDeduction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ptgx_ContractWithCustomerAssetNetRollForward" xlink:to="ptgx_ContractWithCustomerAssetDeduction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrentAbstract" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ptgx_ContractWithCustomerAssetNetRollForward" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ContractWithCustomerAssetNetCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ContractWithCustomerAssetRelatedPartyAdditions" xlink:label="ptgx_ContractWithCustomerAssetRelatedPartyAdditions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ContractWithCustomerAssetNetCurrentAbstract" xlink:to="ptgx_ContractWithCustomerAssetRelatedPartyAdditions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ContractWithCustomerAssetRelatedPartyDeduction" xlink:label="ptgx_ContractWithCustomerAssetRelatedPartyDeduction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ContractWithCustomerAssetNetCurrentAbstract" xlink:to="ptgx_ContractWithCustomerAssetRelatedPartyDeduction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ContractWithCustomerLiabilityNetRollForward" xlink:label="ptgx_ContractWithCustomerLiabilityNetRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract" xlink:to="ptgx_ContractWithCustomerLiabilityNetRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ptgx_ContractWithCustomerLiabilityNetRollForward" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ContractWithCustomerLiabilityAdditions" xlink:label="ptgx_ContractWithCustomerLiabilityAdditions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ptgx_ContractWithCustomerLiabilityNetRollForward" xlink:to="ptgx_ContractWithCustomerLiabilityAdditions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ContractWithCustomerLiabilityDeduction" xlink:label="ptgx_ContractWithCustomerLiabilityDeduction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ptgx_ContractWithCustomerLiabilityNetRollForward" xlink:to="ptgx_ContractWithCustomerLiabilityDeduction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_PayableToCollaborationPartnerRelatedPartyAbstract" xlink:label="ptgx_PayableToCollaborationPartnerRelatedPartyAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ptgx_ContractWithCustomerLiabilityNetRollForward" xlink:to="ptgx_PayableToCollaborationPartnerRelatedPartyAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ptgx_PayableToCollaborationPartnerRelatedPartyAbstract" xlink:to="us-gaap_DueToRelatedPartiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DueToRelatedPartyAdditions" xlink:label="ptgx_DueToRelatedPartyAdditions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ptgx_PayableToCollaborationPartnerRelatedPartyAbstract" xlink:to="ptgx_DueToRelatedPartyAdditions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DueToRelatedPartyDeductions" xlink:label="ptgx_DueToRelatedPartyDeductions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ptgx_PayableToCollaborationPartnerRelatedPartyAbstract" xlink:to="ptgx_DueToRelatedPartyDeductions" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Fair Value Measurements (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_637510085485550874" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_637510085485550874" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637510085485550874" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637510085485550874" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_637510085485560889" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_637510085485560889" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_UsTreasuryAndAgencySecuritiesMember" xlink:label="ptgx_UsTreasuryAndAgencySecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="ptgx_UsTreasuryAndAgencySecuritiesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="us-gaap_LongTermDebtFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LongTermDebtFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Cash Equivalents and Marketable Securities - Cash Equivalents and Marketable Securities (Details)">
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ScheduleCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:label="ptgx_ScheduleCashEquivalentsAndAvailableForSaleSecuritiesTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ptgx_ScheduleCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637510085485570875" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637510085485570875" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ptgx_ScheduleCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_UsTreasuryAndAgencySecuritiesMember" xlink:label="ptgx_UsTreasuryAndAgencySecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="ptgx_UsTreasuryAndAgencySecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:label="ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:to="ptgx_ScheduleCashEquivalentsAndAvailableForSaleSecuritiesTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:to="ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:to="ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:to="ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CashEquivalentsAndMarketableSecuritiesFairValue" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:to="ptgx_CashEquivalentsAndMarketableSecuritiesFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Balance Sheet Components - Property and Equipment, Net (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637510085485590878" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637510085485590878" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_LaboratoryEquipmentMember" xlink:label="ptgx_LaboratoryEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ptgx_LaboratoryEquipmentMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_FurnitureAndComputerEquipmentMember" xlink:label="ptgx_FurnitureAndComputerEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ptgx_FurnitureAndComputerEquipmentMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637510085485600884" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_637510085485600884" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_AU" xlink:label="country_AU" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_AU" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract" xlink:to="us-gaap_Depreciation" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreementDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Research Collaboration and License Agreement (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member" xlink:label="ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_PTG300Member" xlink:label="ptgx_PTG300Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ptgx_PTG300Member" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_PhaseTwoBClinicalTrailOfPtg300Member" xlink:label="ptgx_PhaseTwoBClinicalTrailOfPtg300Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ptgx_PTG300Member" xlink:to="ptgx_PhaseTwoBClinicalTrailOfPtg300Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_PhaseThreeClinicalTrailOfPtg300Member" xlink:label="ptgx_PhaseThreeClinicalTrailOfPtg300Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ptgx_PTG300Member" xlink:to="ptgx_PhaseThreeClinicalTrailOfPtg300Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_EntityRequiredToContinueToMakePaymentsMember" xlink:label="ptgx_EntityRequiredToContinueToMakePaymentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ptgx_EntityRequiredToContinueToMakePaymentsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_NumberOfDevelopmentMilestonePayments" xlink:label="ptgx_NumberOfDevelopmentMilestonePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ptgx_NumberOfDevelopmentMilestonePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_AggregateAmountOfDevelopmentMilestonePayment" xlink:label="ptgx_AggregateAmountOfDevelopmentMilestonePayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ptgx_AggregateAmountOfDevelopmentMilestonePayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_AdditionalPaymentObligationToFormerCollaborationPartner" xlink:label="ptgx_AdditionalPaymentObligationToFormerCollaborationPartner" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ptgx_AdditionalPaymentObligationToFormerCollaborationPartner" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protagonist-inc.com/role/DisclosureGovernmentProgramsDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Government Programs (Details)">
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_GovernmentProgramsTable" xlink:label="ptgx_GovernmentProgramsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ptgx_GovernmentProgramsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_637510085485650876" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_637510085485650876" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_OverseasFindingsMember" xlink:label="ptgx_OverseasFindingsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="ptgx_OverseasFindingsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ptgx_GovernmentProgramsTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_637510085485650876" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_637510085485650876" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AustralianTaxationOfficeMember" xlink:label="us-gaap_AustralianTaxationOfficeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_AustralianTaxationOfficeMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_RevenueSourceAxis" xlink:label="ptgx_RevenueSourceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ptgx_GovernmentProgramsTable" xlink:to="ptgx_RevenueSourceAxis" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_RevenueSourceDomain" xlink:label="ptgx_RevenueSourceDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ptgx_RevenueSourceAxis" xlink:to="ptgx_RevenueSourceDomain" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_RevenueSourceDomain" xlink:label="ptgx_RevenueSourceDomain_637510085485660891" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ptgx_RevenueSourceAxis" xlink:to="ptgx_RevenueSourceDomain_637510085485660891" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_SmallBusinessInnovationResearchGrantMember" xlink:label="ptgx_SmallBusinessInnovationResearchGrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ptgx_RevenueSourceDomain" xlink:to="ptgx_SmallBusinessInnovationResearchGrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_GovernmentProgramsLineItems" xlink:label="ptgx_GovernmentProgramsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ptgx_GovernmentProgramsLineItems" xlink:to="ptgx_GovernmentProgramsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ResearchAndDevelopmentExpensesReduction" xlink:label="ptgx_ResearchAndDevelopmentExpensesReduction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ptgx_GovernmentProgramsLineItems" xlink:to="ptgx_ResearchAndDevelopmentExpensesReduction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="us-gaap_IncomeTaxesReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ptgx_GovernmentProgramsLineItems" xlink:to="us-gaap_IncomeTaxesReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ResearchAndDevelopmentGrants" xlink:label="ptgx_ResearchAndDevelopmentGrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ptgx_GovernmentProgramsLineItems" xlink:to="ptgx_ResearchAndDevelopmentGrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ptgx_GovernmentProgramsLineItems" xlink:to="us-gaap_GrantsReceivable" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protagonist-inc.com/role/DisclosureDebtDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Debt (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DebtInstrumentRepaymentOnOrBeforeFirstAnniversaryMember" xlink:label="ptgx_DebtInstrumentRepaymentOnOrBeforeFirstAnniversaryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ptgx_DebtInstrumentRepaymentOnOrBeforeFirstAnniversaryMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DebtInstrumentRepaymentBetweenFirstAndSecondAnniversaryMember" xlink:label="ptgx_DebtInstrumentRepaymentBetweenFirstAndSecondAnniversaryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ptgx_DebtInstrumentRepaymentBetweenFirstAndSecondAnniversaryMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DebtInstrumentRepaymentAfterSecondAnniversaryMember" xlink:label="ptgx_DebtInstrumentRepaymentAfterSecondAnniversaryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ptgx_DebtInstrumentRepaymentAfterSecondAnniversaryMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VariableRateAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_637510085485840899" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain_637510085485840899" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_PrimeRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637510085485850872" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_637510085485850872" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_TermLoanCreditAgreementMember" xlink:label="ptgx_TermLoanCreditAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ptgx_TermLoanCreditAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DebtInstrumentTrancheInstallmentAmount" xlink:label="ptgx_DebtInstrumentTrancheInstallmentAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ptgx_DebtInstrumentTrancheInstallmentAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DebtInstrumentThresholdPercentageOnOutstandingDebtToBeMaintainedAsCashAndCashEquivalentsBalance" xlink:label="ptgx_DebtInstrumentThresholdPercentageOnOutstandingDebtToBeMaintainedAsCashAndCashEquivalentsBalance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ptgx_DebtInstrumentThresholdPercentageOnOutstandingDebtToBeMaintainedAsCashAndCashEquivalentsBalance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DebtInstrumentLoanOriginationFeePercentage" xlink:label="ptgx_DebtInstrumentLoanOriginationFeePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ptgx_DebtInstrumentLoanOriginationFeePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DebtInstrumentFloorRate" xlink:label="ptgx_DebtInstrumentFloorRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ptgx_DebtInstrumentFloorRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DebtInstrumentPeriodOfInterestOnlyPayments" xlink:label="ptgx_DebtInstrumentPeriodOfInterestOnlyPayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ptgx_DebtInstrumentPeriodOfInterestOnlyPayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DebtInstrumentPeriodOfPrincipalAndInterestPayments" xlink:label="ptgx_DebtInstrumentPeriodOfPrincipalAndInterestPayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ptgx_DebtInstrumentPeriodOfPrincipalAndInterestPayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DebtInstrumentPrepaymentPremiumPercentage" xlink:label="ptgx_DebtInstrumentPrepaymentPremiumPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ptgx_DebtInstrumentPrepaymentPremiumPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DebtInstrumentAdditionalPrepaymentOrRepaymentPremiumPercentage" xlink:label="ptgx_DebtInstrumentAdditionalPrepaymentOrRepaymentPremiumPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ptgx_DebtInstrumentAdditionalPrepaymentOrRepaymentPremiumPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFeeAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protagonist-inc.com/role/DisclosureLeasesAgreementDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Leases - Agreement (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CA" xlink:label="stpr_CA" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_NumberOfOperatingLeaseAgreement" xlink:label="ptgx_NumberOfOperatingLeaseAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ptgx_NumberOfOperatingLeaseAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_SecurityDeposit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_SubleaseIncome" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Commitments and Contingencies (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ZealandPharmaMember" xlink:label="ptgx_ZealandPharmaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ptgx_ZealandPharmaMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_SuccessfullyDevelopAndCommercializeRusfertideComponentWithOutPartnerMember" xlink:label="ptgx_SuccessfullyDevelopAndCommercializeRusfertideComponentWithOutPartnerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ptgx_SuccessfullyDevelopAndCommercializeRusfertideComponentWithOutPartnerMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="us-gaap_LossContingencyDamagesSoughtValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingencyDamagesSoughtValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_PotentialDevelopmentAndRegulatoryMilestonePaymentsOnContractualObligation" xlink:label="ptgx_PotentialDevelopmentAndRegulatoryMilestonePaymentsOnContractualObligation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="ptgx_PotentialDevelopmentAndRegulatoryMilestonePaymentsOnContractualObligation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_PotentialSalesMilestonePaymentsOnContractualObligation" xlink:label="ptgx_PotentialSalesMilestonePaymentsOnContractualObligation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="ptgx_PotentialSalesMilestonePaymentsOnContractualObligation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Stockholders' Equity (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_637510085485900886" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_637510085485900886" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_WarrantsPurchaseAmountPerSharePriceOneMember" xlink:label="ptgx_WarrantsPurchaseAmountPerSharePriceOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="ptgx_WarrantsPurchaseAmountPerSharePriceOneMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_WarrantsPurchaseAmountPerSharePriceTwoMember" xlink:label="ptgx_WarrantsPurchaseAmountPerSharePriceTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="ptgx_WarrantsPurchaseAmountPerSharePriceTwoMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ExchangeAgreementMember" xlink:label="ptgx_ExchangeAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ptgx_ExchangeAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_AtMarketOfferingMember" xlink:label="ptgx_AtMarketOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ptgx_AtMarketOfferingMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_BiotechnologyValueFundL.pMember" xlink:label="ptgx_BiotechnologyValueFundL.pMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ptgx_BiotechnologyValueFundL.pMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember" xlink:label="ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CommonStockPreferredStockAndCertainDebtSecuritiesMember" xlink:label="ptgx_CommonStockPreferredStockAndCertainDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="ptgx_CommonStockPreferredStockAndCertainDebtSecuritiesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember" xlink:label="ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_SalesAgreementFrom2017Member" xlink:label="ptgx_SalesAgreementFrom2017Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="ptgx_SalesAgreementFrom2017Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ClassOfStockDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_SaleOfStockValueOfSharesAuthorized" xlink:label="ptgx_SaleOfStockValueOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="ptgx_SaleOfStockValueOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_AggregateGrossProceedsFromIssuanceStock" xlink:label="ptgx_AggregateGrossProceedsFromIssuanceStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="ptgx_AggregateGrossProceedsFromIssuanceStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_NumberOfWarrantsExercised" xlink:label="ptgx_NumberOfWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="ptgx_NumberOfWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="ptgx_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="ptgx_StockIssuedDuringPeriodSharesWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_StockExchangedForPreFundedWarrants" xlink:label="ptgx_StockExchangedForPreFundedWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="ptgx_StockExchangedForPreFundedWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ClassOfWarrantOrRightTermOfWarrants" xlink:label="ptgx_ClassOfWarrantOrRightTermOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="ptgx_ClassOfWarrantOrRightTermOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Equity Plans - Narrative (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember" xlink:label="ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_NonEmployeeDirectorInitialStockOptionsMember" xlink:label="ptgx_NonEmployeeDirectorInitialStockOptionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember" xlink:to="ptgx_NonEmployeeDirectorInitialStockOptionsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_NonemployeeDirectorAnnualRefresherStockOptionsMember" xlink:label="ptgx_NonemployeeDirectorAnnualRefresherStockOptionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember" xlink:to="ptgx_NonemployeeDirectorAnnualRefresherStockOptionsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637510085485970891" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_637510085485970891" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_StockOptionAndIncentivePlanAsAmendedAndRestated2007Member" xlink:label="ptgx_StockOptionAndIncentivePlanAsAmendedAndRestated2007Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="ptgx_StockOptionAndIncentivePlanAsAmendedAndRestated2007Member" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_EquityIncentivePlan2016Member" xlink:label="ptgx_EquityIncentivePlan2016Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="ptgx_EquityIncentivePlan2016Member" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_InducementStockPlanMember" xlink:label="ptgx_InducementStockPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PlanNameDomain" xlink:to="ptgx_InducementStockPlanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_637510085485980899" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_637510085485980899" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_637510085485990884" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_637510085485990884" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrincipalOwnerMember" xlink:label="us-gaap_PrincipalOwnerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_PrincipalOwnerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum" xlink:label="ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants" xlink:label="ptgx_ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ptgx_ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo" xlink:label="ptgx_ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ptgx_ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockOptionsValuationAssumptionsDetails" xlink:type="extended" xlink:title="41303 - Disclosure - Equity Plans - Employee Stock Options Valuation Assumptions (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protagonist-inc.com/role/DisclosureEquityPlansRestrictedStockUnitsDetails" xlink:type="extended" xlink:title="41304 - Disclosure - Equity Plans - Restricted Stock Units - (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_InducementStockPlanMember" xlink:label="ptgx_InducementStockPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="ptgx_InducementStockPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_NumberOfEqualInstallmentsRequiredForVestingOfRestrictedStockUnits" xlink:label="ptgx_NumberOfEqualInstallmentsRequiredForVestingOfRestrictedStockUnits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ptgx_NumberOfEqualInstallmentsRequiredForVestingOfRestrictedStockUnits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockPurchasePlanDetails" xlink:type="extended" xlink:title="41305 - Disclosure - Equity Plans - Employee Stock Purchase Plan (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_EmployeeStockPurchasePlan2016Member" xlink:label="ptgx_EmployeeStockPurchasePlan2016Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="ptgx_EmployeeStockPurchasePlan2016Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum" xlink:label="ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualNumberOfAdditionalSharesAuthorized" xlink:label="ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualNumberOfAdditionalSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualNumberOfAdditionalSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protagonist-inc.com/role/DisclosureEquityPlansStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="41306 - Disclosure - Equity Plans - Stock-based Compensation Expense (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637510085486090892" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_637510085486090892" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protagonist-inc.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails" xlink:type="extended" xlink:title="41505 - Disclosure - Income Taxes - Net Operating Loss Carryforwards (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AustralianTaxationOfficeMember" xlink:label="us-gaap_AustralianTaxationOfficeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_AustralianTaxationOfficeMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_OperatingLossCarryforwardsNoExpiration" xlink:label="ptgx_OperatingLossCarryforwardsNoExpiration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="ptgx_OperatingLossCarryforwardsNoExpiration" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protagonist-inc.com/role/DisclosureIncomeTaxesResearchAndDevelopmentTaxCreditCarryforwardsDetails" xlink:type="extended" xlink:title="41506 - Disclosure - Income Taxes - Research and Development Tax Credit Carryforwards (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="us-gaap_TaxCreditCarryforwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AustralianTaxationOfficeMember" xlink:label="us-gaap_AustralianTaxationOfficeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_AustralianTaxationOfficeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_637510085486120908" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_637510085486120908" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="us-gaap_TaxCreditCarryforwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_TaxCreditCarryforwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protagonist-inc.com/role/DisclosureIncomeTaxes2020TaxLawUpdatesDetails" xlink:type="extended" xlink:title="41508 - Disclosure - Income Taxes - 2020 Tax Law Updates (Details)">
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_IncomeTaxTable" xlink:label="ptgx_IncomeTaxTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ptgx_IncomeTaxTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AustralianTaxationOfficeMember" xlink:label="us-gaap_AustralianTaxationOfficeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_AustralianTaxationOfficeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_IncomeTaxLineItems" xlink:label="ptgx_IncomeTaxLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ptgx_IncomeTaxLineItems" xlink:to="ptgx_IncomeTaxTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ptgx_IncomeTaxLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_NetOperatingLossCarryback" xlink:label="ptgx_NetOperatingLossCarryback" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="ptgx_NetOperatingLossCarryback" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DeductionOfTaxableIncomePercentage" xlink:label="ptgx_DeductionOfTaxableIncomePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="ptgx_DeductionOfTaxableIncomePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CaliforniaNetOperatingLossDeductionsLimitOfIncome" xlink:label="ptgx_CaliforniaNetOperatingLossDeductionsLimitOfIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="ptgx_CaliforniaNetOperatingLossDeductionsLimitOfIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_MaximumOffsetOfCaliforniaTax" xlink:label="ptgx_MaximumOffsetOfCaliforniaTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="ptgx_MaximumOffsetOfCaliforniaTax" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protagonist-inc.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" xlink:type="extended" xlink:title="41602 - Disclosure - Net Loss per Share - Antidilutive Securities (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_637510085486150907" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_637510085486150907" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoteWarrantMember" xlink:label="us-gaap_NoteWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_NoteWarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>20
<FILENAME>ptgx-20201231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7713.40453 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/10/2021 9:29:12 PM-->
<!--Modified on: 3/10/2021 9:29:12 PM-->
<linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Document And Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US">Document Information [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US">Document Information [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Entity Ex Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Consolidated Balance Sheets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xml:lang="en-US">Available-for-sale Securities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xml:lang="en-US">Marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xml:lang="en-US">Marketable securities - current</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US">Restricted Cash, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US">Restricted cash - current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US">Restricted cash - current</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedPartiesCurrent" xlink:to="us-gaap_DueFromRelatedPartiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_lbl" xml:lang="en-US">Due from Affiliate, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_lbl" xml:lang="en-US">Receivable from collaboration partner and contract asset - related party</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="us-gaap_IncomeTaxesReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesReceivable" xlink:to="us-gaap_IncomeTaxesReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesReceivable_lbl" xml:lang="en-US">Income Taxes Receivable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesReceivable_lbl" xml:lang="en-US">Research and development tax incentive receivable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesNoncurrent" xlink:to="us-gaap_MarketableSecuritiesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xml:lang="en-US">Marketable Securities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xml:lang="en-US">Marketable securities - noncurrent</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US">Restricted Cash, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US">Restricted cash - noncurrent</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use asset</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xml:lang="en-US">Deferred Tax Assets, Net, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xml:lang="en-US">Deferred tax asset</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US">Due to Affiliate, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US">Balance at End of Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US">Balance at Beginning of Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US">Payable to collaboration partner - related party</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Other Accounts Payable and Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses and other payables</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Contract with Customer, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Balance at End of Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Balance at Beginning of Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Deferred revenue - related party - current</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Less: current portion of operating lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liability - current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liability - current</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Long-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Long-term debt, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Long-term debt, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US">Deferred revenue - related party - noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US">Upfront payments and fees</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liability - noncurrent</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (Note 11)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' equity:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.00001 par value, 10,000,000 shares authorized; no shares issued and outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.00001 par value, 90,000,000 shares authorized; 43,745,465 and 27,217,649 shares issued and outstanding as of December 31, 2020 and December 31, 2019, respectively</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive gain (loss)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Balance, Ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Balance, Beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US">Temporary Equity, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Par value (per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Balance, Ending (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Balance, Beginning (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Consolidated Statements of Operations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CondensedStatementOfComprehensiveIncomeTable" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedStatementOfComprehensiveIncomeTable" xlink:to="srt_CondensedStatementOfComprehensiveIncomeTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTable_lbl" xml:lang="en-US">Condensed Statement of Comprehensive Income [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:label="srt_CondensedStatementOfIncomeCaptionsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="srt_CondensedStatementOfIncomeCaptionsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedStatementOfIncomeCaptionsLineItems_lbl" xml:lang="en-US">Condensed Statement of Income Captions [Line Items]</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_RevenueFromContractWithCustomerIncludingCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:label="ptgx_RevenueFromContractWithCustomerIncludingCumulativeCatchUpAdjustmentToRevenueModificationOfContract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_RevenueFromContractWithCustomerIncludingCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:to="ptgx_RevenueFromContractWithCustomerIncludingCumulativeCatchUpAdjustmentToRevenueModificationOfContract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_RevenueFromContractWithCustomerIncludingCumulativeCatchUpAdjustmentToRevenueModificationOfContract_lbl" xml:lang="en-US">Amount of revenue, net, from satisfaction of performance obligation by transferring promised good or service to customer, including amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from contract modification. Amount includes tax collected from customer, if applicable. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_RevenueFromContractWithCustomerIncludingCumulativeCatchUpAdjustmentToRevenueModificationOfContract_lbl" xml:lang="en-US">Revenue From Contract With Customer Including Cumulative Catch Up Adjustment To Revenue Modification Of Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_RevenueFromContractWithCustomerIncludingCumulativeCatchUpAdjustmentToRevenueModificationOfContract_lbl" xml:lang="en-US">License and collaboration revenue - related party</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Investment Income, Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Loss on early repayment of debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Loss on early repayment of debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other expense, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before income tax (expense) benefit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax (expense) benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total income tax expense (benefit)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Net loss per shares, basic and diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Net loss per share, basic and diluted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted-average shares used to compute net loss per common share, basic and diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted-average shares used to compute net loss per share, basic and diluted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US">Consolidated Statements of Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract_lbl" xml:lang="en-US">Other Comprehensive Income (Loss) Net of Tax, Period Change [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract_lbl" xml:lang="en-US">Other comprehensive loss:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US">Gain (loss) on translation of foreign operations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US">Unrealized (loss) gain on marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Consolidated Statements of Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Common stock sold (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock, net of issuance costs (in shares)</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants" xlink:label="ptgx_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants" xlink:to="ptgx_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants_lbl" xml:lang="en-US">Value of common stock and warrants for common stock issued in private placement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants_lbl" xml:lang="en-US">Stock and Warrants Issued During Period, Value, Common Stock and Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants_lbl" xml:lang="en-US">Issuance of common stock and warrants upon private placement, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants" xlink:label="ptgx_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants" xlink:to="ptgx_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants_lbl" xml:lang="en-US">Number of common stock and warrants for common stock issued in private placement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants_lbl" xml:lang="en-US">Stock and Warrants Issued During Period, Shares, Common Stock and Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants_lbl" xml:lang="en-US">Issuance of common stock and warrants upon private placement, net of issuance costs (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Issuance of common stock upon under equity incentive and employee stock purchase plans</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Issuance of common stock upon under equity incentive and employee stock purchase plans (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_lbl" xml:lang="en-US">Stock Repurchased and Retired During Period, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_lbl" xml:lang="en-US">Retirement of common stock in exchange for common stock warrant</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl" xml:lang="en-US">Retirement of common stock in exchange for common stock warrant (in shares)</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_StockWarrantIssuedDuringPeriodValueInExchangeForRetirementOfCommonStock" xlink:label="ptgx_StockWarrantIssuedDuringPeriodValueInExchangeForRetirementOfCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_StockWarrantIssuedDuringPeriodValueInExchangeForRetirementOfCommonStock" xlink:to="ptgx_StockWarrantIssuedDuringPeriodValueInExchangeForRetirementOfCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_StockWarrantIssuedDuringPeriodValueInExchangeForRetirementOfCommonStock_lbl" xml:lang="en-US">The value of common stock warrant issued in exchange for retirement of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_StockWarrantIssuedDuringPeriodValueInExchangeForRetirementOfCommonStock_lbl" xml:lang="en-US">Stock Warrant Issued During Period, Value, in Exchange for Retirement of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_StockWarrantIssuedDuringPeriodValueInExchangeForRetirementOfCommonStock_lbl" xml:lang="en-US">Issuance of common stock warrant in exchange for retirement of common stock</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="ptgx_StockIssuedDuringPeriodValueWarrantsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="ptgx_StockIssuedDuringPeriodValueWarrantsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US">Value of stock issued as a result of the exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US">Issuance of common stock upon exercise of Exchange Warrants</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="ptgx_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="ptgx_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US">Number of warrants exercised during the current period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US">Issuance of common stock upon exercise of Exchange Warrants (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US">Other comprehensive gain (loss)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Consolidated Statements of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_OperatingLeaseRightOfUseAssetAmortization" xlink:label="ptgx_OperatingLeaseRightOfUseAssetAmortization" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_OperatingLeaseRightOfUseAssetAmortization" xlink:to="ptgx_OperatingLeaseRightOfUseAssetAmortization_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_OperatingLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US">Amount of amortization expense attributable to right-of-use asset from operating lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_OperatingLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US">Operating Lease Right of Use Asset Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_OperatingLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US">Operating lease right-of-use asset amortization</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xml:lang="en-US">Net amortization of premium (accretion of discount) on marketable securities</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee" xlink:label="ptgx_AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee" xlink:to="ptgx_AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee_lbl" xml:lang="en-US">Amount of amortization expense attributable to debt issuance costs and accretion of final payment fee under debt instrument.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee_lbl" xml:lang="en-US">Amortization Of Debt Issuance Costs And Debt Instrument, Accretion Of Final Payment Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee_lbl" xml:lang="en-US">Amortization of debt issuance costs and accretion of debt discount</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Gain on disposal of property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxCreditsAndAdjustments" xlink:label="us-gaap_IncomeTaxCreditsAndAdjustments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxCreditsAndAdjustments" xlink:to="us-gaap_IncomeTaxCreditsAndAdjustments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxCreditsAndAdjustments_lbl" xml:lang="en-US">Income Tax Credits and Adjustments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxCreditsAndAdjustments_lbl" xml:lang="en-US">Change in deferred tax asset</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xml:lang="en-US">Increase (Decrease) in Income Taxes Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xml:lang="en-US">Research and development tax incentive receivable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable, Related Parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_lbl" xml:lang="en-US">Receivable from collaboration partner - related party</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Related Parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_lbl" xml:lang="en-US">Payable to collaboration partner - related party</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable and Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses and other payables</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Deferred revenue - related party</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="ptgx_IncreaseDecreaseInOperatingLeaseLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="ptgx_IncreaseDecreaseInOperatingLeaseLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Amount of increase (decrease) in operating lease liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Increase Decrease in Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptgx_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xml:lang="en-US">Other liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xml:lang="en-US">Payments to Acquire Available-for-sale Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xml:lang="en-US">Purchase of marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xml:lang="en-US">Proceeds from Sale and Maturity of Available-for-sale Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xml:lang="en-US">Proceeds from maturities of marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash (used in) provided by investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from public offering of common stock, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ProceedsFromIssuanceOfCommonStockAndWarrantsInPrivatePlacementNetOfIssuanceCosts" xlink:label="ptgx_ProceedsFromIssuanceOfCommonStockAndWarrantsInPrivatePlacementNetOfIssuanceCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_ProceedsFromIssuanceOfCommonStockAndWarrantsInPrivatePlacementNetOfIssuanceCosts" xlink:to="ptgx_ProceedsFromIssuanceOfCommonStockAndWarrantsInPrivatePlacementNetOfIssuanceCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_ProceedsFromIssuanceOfCommonStockAndWarrantsInPrivatePlacementNetOfIssuanceCosts_lbl" xml:lang="en-US">The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_ProceedsFromIssuanceOfCommonStockAndWarrantsInPrivatePlacementNetOfIssuanceCosts_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock and Warrants in Private Placement, Net of Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_ProceedsFromIssuanceOfCommonStockAndWarrantsInPrivatePlacementNetOfIssuanceCosts_lbl" xml:lang="en-US">Proceeds from issuance of common stock and warrants in private placement, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xml:lang="en-US">Proceeds from at-the-market offering, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xml:lang="en-US">Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xml:lang="en-US">Proceeds from issuance of common stock upon exercise of stock options and purchases under employee stock purchase plan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xml:lang="en-US">Proceeds from issuance of long-term debt, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US">Payments of Debt Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US">Issuance costs related to long-term debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US">Repayments of Long-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US">Early repayment of long-term debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Effect of exchange rate changes on cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Total cash, cash equivalent and restricted cash in consolidated statements of cash flows</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL DISCLOSURE OF NON-CASH FINANCING AND INVESTING INFORMATION:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL DISCLOSURE OF NON-CASH FINANCING AND INVESTING INFORMATION:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" xml:lang="en-US">Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" xml:lang="en-US">Issuance costs related to common stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Purchases of property and equipment in accounts payable and accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant" xlink:label="ptgx_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant" xlink:to="ptgx_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant_lbl" xml:lang="en-US">Fair value of retired common stock in exchange for issuance of common stock warrant in noncash transactions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant_lbl" xml:lang="en-US">Fair Value of Common Stock Retired in Exchange for Issuance of Common Stock Warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant_lbl" xml:lang="en-US">Fair value of common stock retired in exchange for issuance of common stock warrant</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization and Description of Business</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization and Description of Business</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CollaborativeArrangementDisclosureAbstract" xlink:label="ptgx_CollaborativeArrangementDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_CollaborativeArrangementDisclosureAbstract" xlink:to="ptgx_CollaborativeArrangementDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_CollaborativeArrangementDisclosureAbstract_lbl" xml:lang="en-US">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_CollaborativeArrangementDisclosureAbstract_lbl" xml:lang="en-US">License and Collaboration Agreement.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Arrangements And Nonarrangement Transactions [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_JanssenLicenseAndCollaborationAgreement26May2017Member" xlink:label="ptgx_JanssenLicenseAndCollaborationAgreement26May2017Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_JanssenLicenseAndCollaborationAgreement26May2017Member" xlink:to="ptgx_JanssenLicenseAndCollaborationAgreement26May2017Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_JanssenLicenseAndCollaborationAgreement26May2017Member_lbl" xml:lang="en-US">The license and collaboration agreement with Janssen Biotech, Inc. (Janssen) dated May 26, 2017.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_JanssenLicenseAndCollaborationAgreement26May2017Member_lbl" xml:lang="en-US">Janssen License And Collaboration Agreement26 May2017 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_JanssenLicenseAndCollaborationAgreement26May2017Member_lbl" xml:lang="en-US">License and Collaboration Agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Research Collaboration and License Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">License and Collaboration Agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US">License and Collaboration Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US">Research Collaboration and License Agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="ptgx_CashEquivalentsAndMarketableSecuritiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesAbstract_lbl" xml:lang="en-US">NA</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesAbstract_lbl" xml:lang="en-US">Cash Equivalents and Marketable Securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl" xml:lang="en-US">Cash Equivalents and Marketable Securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xml:lang="en-US">Balance Sheet Components</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xml:lang="en-US">Balance Sheet Components</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ResearchCollaborationAndLicenseAgreementDisclosureAbstract" xlink:label="ptgx_ResearchCollaborationAndLicenseAgreementDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_ResearchCollaborationAndLicenseAgreementDisclosureAbstract" xlink:to="ptgx_ResearchCollaborationAndLicenseAgreementDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_ResearchCollaborationAndLicenseAgreementDisclosureAbstract_lbl" xml:lang="en-US">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_ResearchCollaborationAndLicenseAgreementDisclosureAbstract_lbl" xml:lang="en-US">Research Collaboration and License Agreement</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member" xlink:label="ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member" xlink:to="ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member_lbl" xml:lang="en-US">This member stands for research collaboration and license agreement abandoned October2013.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member_lbl" xml:lang="en-US">Research Collaboration And License Agreement Abandoned October2013 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member_lbl" xml:lang="en-US">Research Collaboration and License Agreement</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_GovernmentProgramsAbstract" xlink:label="ptgx_GovernmentProgramsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_GovernmentProgramsAbstract" xlink:to="ptgx_GovernmentProgramsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_GovernmentProgramsAbstract_lbl" xml:lang="en-US">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_GovernmentProgramsAbstract_lbl" xml:lang="en-US">Government Programs</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_GovernmentProgramsDisclosureTextBlock" xlink:label="ptgx_GovernmentProgramsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_GovernmentProgramsDisclosureTextBlock" xlink:to="ptgx_GovernmentProgramsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_GovernmentProgramsDisclosureTextBlock_lbl" xml:lang="en-US">The entire disclosure pertaining to the government programs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_GovernmentProgramsDisclosureTextBlock_lbl" xml:lang="en-US">Government Programs Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_GovernmentProgramsDisclosureTextBlock_lbl" xml:lang="en-US">Government Programs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Equity Plans</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Equity Plans</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">401(k) Plan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US">Pension and Other Postretirement Benefits Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US">401(k) Plan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Net Loss per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Net Loss per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" xml:lang="en-US">Restructuring</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xml:lang="en-US">Restructuring</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation and Consolidation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentrations of Credit Risk</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Restricted Cash</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash as Reported in Consolidated Statements of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xml:lang="en-US">Marketable Securities, Available-for-sale Securities, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xml:lang="en-US">Marketable Securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US">Debt, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US">Long Term Debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Costs</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ResearchAndDevelopmentIncentiveGrantPolicyTextBlock" xlink:label="ptgx_ResearchAndDevelopmentIncentiveGrantPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_ResearchAndDevelopmentIncentiveGrantPolicyTextBlock" xlink:to="ptgx_ResearchAndDevelopmentIncentiveGrantPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_ResearchAndDevelopmentIncentiveGrantPolicyTextBlock_lbl" xml:lang="en-US">Disclosure of accounting policy for research and development incentive grants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_ResearchAndDevelopmentIncentiveGrantPolicyTextBlock_lbl" xml:lang="en-US">Research And Development Incentive Grant [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_ResearchAndDevelopmentIncentiveGrantPolicyTextBlock_lbl" xml:lang="en-US">Research and Development Tax Incentive</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_SmallBusinessInnovationResearchSbirGrantsPolicyTextBlock" xlink:label="ptgx_SmallBusinessInnovationResearchSbirGrantsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_SmallBusinessInnovationResearchSbirGrantsPolicyTextBlock" xlink:to="ptgx_SmallBusinessInnovationResearchSbirGrantsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_SmallBusinessInnovationResearchSbirGrantsPolicyTextBlock_lbl" xml:lang="en-US">Disclosure of accounting policy for small business innovation research (SBIR) grants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_SmallBusinessInnovationResearchSbirGrantsPolicyTextBlock_lbl" xml:lang="en-US">Small Business Innovation Research (SBIR) Grants [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_SmallBusinessInnovationResearchSbirGrantsPolicyTextBlock_lbl" xml:lang="en-US">Small Business Innovation Research ("SBIR") Grants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Stock-based Compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Pronouncements Adopted and Recently Issued Accounting Pronouncements Not Yet Adopted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US">Schedule of cash as reported in the consolidated statements of cash flows</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xml:lang="en-US">Contract with Customer, Asset and Liability [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xml:lang="en-US">Schedule of changes in contract assets and liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US">Schedule of fair value of financial assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTextBlock" xlink:to="us-gaap_MarketableSecuritiesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xml:lang="en-US">Marketable Securities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xml:lang="en-US">Schedule of cash equivalents and marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Other Current Assets [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US">Summary of Prepaid Expenses and Other Current Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Summary of Property and Equipment Net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accrued Expenses and Other Payables</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xml:lang="en-US">Schedule of maturities of long-term debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US">Lessee, Lease, Description [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US">Lessee, Lease, Description [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US">Leases</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_LeaseQuantitativeDisclosureTableTextBlock" xlink:label="ptgx_LeaseQuantitativeDisclosureTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_LeaseQuantitativeDisclosureTableTextBlock" xlink:to="ptgx_LeaseQuantitativeDisclosureTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_LeaseQuantitativeDisclosureTableTextBlock_lbl" xml:lang="en-US">The tabular disclosure of lease quantitative information.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_LeaseQuantitativeDisclosureTableTextBlock_lbl" xml:lang="en-US">Lease Quantitative Disclosure [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_LeaseQuantitativeDisclosureTableTextBlock_lbl" xml:lang="en-US">Schedule of weighted average lease term and discounts rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of minimum lease payments and lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of least cost information</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_LeaseBalanceSheetDisclosureTableTextBlock" xlink:label="ptgx_LeaseBalanceSheetDisclosureTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_LeaseBalanceSheetDisclosureTableTextBlock" xlink:to="ptgx_LeaseBalanceSheetDisclosureTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_LeaseBalanceSheetDisclosureTableTextBlock_lbl" xml:lang="en-US">The tabular disclosure of lease balance sheet.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_LeaseBalanceSheetDisclosureTableTextBlock_lbl" xml:lang="en-US">Lease Balance Sheet Disclosure [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_LeaseBalanceSheetDisclosureTableTextBlock_lbl" xml:lang="en-US">Schedule of balance sheet information</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_LeaseCashFlowInformationDisclosureTableTextBlock" xlink:label="ptgx_LeaseCashFlowInformationDisclosureTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_LeaseCashFlowInformationDisclosureTableTextBlock" xlink:to="ptgx_LeaseCashFlowInformationDisclosureTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_LeaseCashFlowInformationDisclosureTableTextBlock_lbl" xml:lang="en-US">The tabular disclosure of lease cash flow information.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_LeaseCashFlowInformationDisclosureTableTextBlock_lbl" xml:lang="en-US">Lease Cash Flow Information Disclosure [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_LeaseCashFlowInformationDisclosureTableTextBlock_lbl" xml:lang="en-US">Schedule of cash flow information</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Compensation, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of activity under equity incentive plans</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Black-Scholes option-pricing model assumptions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US">Schedule of domestic and foreign components of net loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of federal, state and foreign of the income tax expense (benefit)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of provision differences from federal statutory rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of components of deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US">Schedule of reconciliation of beginning and ending unrecognized tax benefits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of computation of the basic and diluted net loss per share attributable to common stockholders</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of potentially dilutive securities excluded from diluted net loss per share calculations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsNoteDisclosureAbstract" xlink:label="us-gaap_RetainedEarningsNoteDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsNoteDisclosureAbstract" xlink:to="us-gaap_RetainedEarningsNoteDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsNoteDisclosureAbstract_lbl" xml:lang="en-US">Retained Earnings Note Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsNoteDisclosureAbstract_lbl" xml:lang="en-US">Net losses from operations since inception</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CashNumberOfFinancialInstitutions" xlink:label="ptgx_CashNumberOfFinancialInstitutions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_CashNumberOfFinancialInstitutions" xlink:to="ptgx_CashNumberOfFinancialInstitutions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_CashNumberOfFinancialInstitutions_lbl" xml:lang="en-US">The number of financial institutions that hold the entity's cash.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_CashNumberOfFinancialInstitutions_lbl" xml:lang="en-US">Cash, Number of Financial Institutions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_CashNumberOfFinancialInstitutions_lbl" xml:lang="en-US">Number of financial institutions at which cash is held</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xml:lang="en-US">Aggregate amounts of cash and cash equivalents and the restricted cash</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Useful lives</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="us-gaap_TangibleAssetImpairmentCharges" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TangibleAssetImpairmentCharges" xlink:to="us-gaap_TangibleAssetImpairmentCharges_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TangibleAssetImpairmentCharges_lbl" xml:lang="en-US">Tangible Asset Impairment Charges</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TangibleAssetImpairmentCharges_lbl" xml:lang="en-US">Impairments of long-lived assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xml:lang="en-US">Income Tax Examination, Penalties and Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xml:lang="en-US">Interest or penalties recorded in relation to unrecognized tax benefits</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurred" xlink:label="ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurred" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurred" xlink:to="ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurred_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurred_lbl" xml:lang="en-US">Represents the percentage of development cost incurred.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurred_lbl" xml:lang="en-US">Collaborative Arrangement Percentage of Development Costs Incurred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurred_lbl" xml:lang="en-US">Development cost</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CollaborativeArrangementEligibleAmountReceived" xlink:label="ptgx_CollaborativeArrangementEligibleAmountReceived" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_CollaborativeArrangementEligibleAmountReceived" xlink:to="ptgx_CollaborativeArrangementEligibleAmountReceived_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_CollaborativeArrangementEligibleAmountReceived_lbl" xml:lang="en-US">Represents the amount received from a collaborative arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_CollaborativeArrangementEligibleAmountReceived_lbl" xml:lang="en-US">Collaborative Arrangement, Eligible Amount Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_CollaborativeArrangementEligibleAmountReceived_lbl" xml:lang="en-US">Eligible amount received</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CollaborativeArrangementPercentageOfResearchProgramCostsIncurred" xlink:label="ptgx_CollaborativeArrangementPercentageOfResearchProgramCostsIncurred" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_CollaborativeArrangementPercentageOfResearchProgramCostsIncurred" xlink:to="ptgx_CollaborativeArrangementPercentageOfResearchProgramCostsIncurred_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_CollaborativeArrangementPercentageOfResearchProgramCostsIncurred_lbl" xml:lang="en-US">Represents the percentage of research program cost incurred.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_CollaborativeArrangementPercentageOfResearchProgramCostsIncurred_lbl" xml:lang="en-US">Collaborative Arrangement Percentage Of Research Program Costs Incurred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_CollaborativeArrangementPercentageOfResearchProgramCostsIncurred_lbl" xml:lang="en-US">Research program cost</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CollaborativeArrangementPayableUponEffectivenessOfAmendment" xlink:label="ptgx_CollaborativeArrangementPayableUponEffectivenessOfAmendment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_CollaborativeArrangementPayableUponEffectivenessOfAmendment" xlink:to="ptgx_CollaborativeArrangementPayableUponEffectivenessOfAmendment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_CollaborativeArrangementPayableUponEffectivenessOfAmendment_lbl" xml:lang="en-US">Payment payable upon the effectiveness of the First Amendment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_CollaborativeArrangementPayableUponEffectivenessOfAmendment_lbl" xml:lang="en-US">Collaborative Arrangement, Payable Upon Effectiveness Of Amendment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_CollaborativeArrangementPayableUponEffectivenessOfAmendment_lbl" xml:lang="en-US">Amount payable upon the effectiveness of the First Amendment</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ContingentConsiderationReceivable" xlink:label="ptgx_ContingentConsiderationReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_ContingentConsiderationReceivable" xlink:to="ptgx_ContingentConsiderationReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_ContingentConsiderationReceivable_lbl" xml:lang="en-US">Contingent Consideration Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_ContingentConsiderationReceivable_lbl" xml:lang="en-US">Contingent Consideration Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_ContingentConsiderationReceivable_lbl" xml:lang="en-US">Eligible payment receivable</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_PercentagesRoyaltiesOnNetProductSales" xlink:label="ptgx_PercentagesRoyaltiesOnNetProductSales" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_PercentagesRoyaltiesOnNetProductSales" xlink:to="ptgx_PercentagesRoyaltiesOnNetProductSales_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_PercentagesRoyaltiesOnNetProductSales_lbl" xml:lang="en-US">The percentages on net product sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_PercentagesRoyaltiesOnNetProductSales_lbl" xml:lang="en-US">Percentages Royalties on Net Product Sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_PercentagesRoyaltiesOnNetProductSales_lbl" xml:lang="en-US">Percentages on net product sales</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:to="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_lbl" xml:lang="en-US">Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_lbl" xml:lang="en-US">Increase (decrease) in transaction price</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligation" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xml:lang="en-US">Revenue, Remaining Performance Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xml:lang="en-US">Transaction price</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US">Revenue Recognition, Milestone Method, Revenue Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US">Revenue</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xml:lang="en-US">Revenue recognized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:to="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract_lbl" xml:lang="en-US">Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Modification of Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract_lbl" xml:lang="en-US">Revenue following contract modification</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:label="us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:to="us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_lbl" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_lbl" xml:lang="en-US">Revenue recognized from performance obligations in previous periods</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostNet" xlink:to="us-gaap_CapitalizedContractCostNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedContractCostNet_lbl" xml:lang="en-US">Capitalized Contract Cost, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CapitalizedContractCostNet_lbl" xml:lang="en-US">Costs to obtain or fulfill the contract that were capitalized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US">Repurchase Agreement Counterparty Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_JanssenBiotechIncMember" xlink:label="ptgx_JanssenBiotechIncMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_JanssenBiotechIncMember" xlink:to="ptgx_JanssenBiotechIncMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_JanssenBiotechIncMember_lbl" xml:lang="en-US">Represents the information pertaining to the related party Janssen Biotech Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_JanssenBiotechIncMember_lbl" xml:lang="en-US">Janssen Biotech Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_JanssenBiotechIncMember_lbl" xml:lang="en-US">Janssen Biotech, Inc.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Product [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">License and Collaboration Agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract" xlink:label="us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract" xlink:to="us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract_lbl" xml:lang="en-US">Change in Contract with Customer, Asset and Liability [Abstract]</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ContractWithCustomerAssetNetRollForward" xlink:label="ptgx_ContractWithCustomerAssetNetRollForward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_ContractWithCustomerAssetNetRollForward" xlink:to="ptgx_ContractWithCustomerAssetNetRollForward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_ContractWithCustomerAssetNetRollForward_lbl" xml:lang="en-US">A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_ContractWithCustomerAssetNetRollForward_lbl" xml:lang="en-US">Contract with Customer, Asset, Net [Roll forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_ContractWithCustomerAssetNetRollForward_lbl" xml:lang="en-US">Receivable from collaboration partner - related party</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetNet" xlink:to="us-gaap_ContractWithCustomerAssetNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerAssetNet_lbl" xml:lang="en-US">Contract with Customer, Asset, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ContractWithCustomerAssetNet_lbl" xml:lang="en-US">Balance at End of Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ContractWithCustomerAssetNet_lbl" xml:lang="en-US">Balance at Beginning of Period</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ContractWithCustomerAssetAdditions" xlink:label="ptgx_ContractWithCustomerAssetAdditions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_ContractWithCustomerAssetAdditions" xlink:to="ptgx_ContractWithCustomerAssetAdditions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_ContractWithCustomerAssetAdditions_lbl" xml:lang="en-US">Addition in the amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_ContractWithCustomerAssetAdditions_lbl" xml:lang="en-US">Contract with Customer, Asset, Additions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_ContractWithCustomerAssetAdditions_lbl" xml:lang="en-US">Additions</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ContractWithCustomerAssetDeduction" xlink:label="ptgx_ContractWithCustomerAssetDeduction" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_ContractWithCustomerAssetDeduction" xlink:to="ptgx_ContractWithCustomerAssetDeduction_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_ContractWithCustomerAssetDeduction_lbl" xml:lang="en-US">Deduction in the amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_ContractWithCustomerAssetDeduction_lbl" xml:lang="en-US">Contract with Customer, Asset, Deduction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptgx_ContractWithCustomerAssetDeduction_lbl" xml:lang="en-US">Deductions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrentAbstract" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetNetCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrentAbstract_lbl" xml:lang="en-US">Contract with Customer, Asset, Net, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrentAbstract_lbl" xml:lang="en-US">Contract asset - related party</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" xml:lang="en-US">Contract with Customer, Asset, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" xml:lang="en-US">Contract asset - related party, Balance at End of Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" xml:lang="en-US">Contract asset - related party, Balance at Beginning of Period</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ContractWithCustomerAssetRelatedPartyAdditions" xlink:label="ptgx_ContractWithCustomerAssetRelatedPartyAdditions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_ContractWithCustomerAssetRelatedPartyAdditions" xlink:to="ptgx_ContractWithCustomerAssetRelatedPartyAdditions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_ContractWithCustomerAssetRelatedPartyAdditions_lbl" xml:lang="en-US">Addition in the amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to a related party when right is conditioned on something other than passage of time.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_ContractWithCustomerAssetRelatedPartyAdditions_lbl" xml:lang="en-US">Contract With Customer Asset Related Party Additions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_ContractWithCustomerAssetRelatedPartyAdditions_lbl" xml:lang="en-US">Contract asset - related party, Additions</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ContractWithCustomerAssetRelatedPartyDeduction" xlink:label="ptgx_ContractWithCustomerAssetRelatedPartyDeduction" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_ContractWithCustomerAssetRelatedPartyDeduction" xlink:to="ptgx_ContractWithCustomerAssetRelatedPartyDeduction_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_ContractWithCustomerAssetRelatedPartyDeduction_lbl" xml:lang="en-US">Deduction in the amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to related party when right is conditioned on something other than passage of time.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_ContractWithCustomerAssetRelatedPartyDeduction_lbl" xml:lang="en-US">Contract With Customer Asset Related Party Deduction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_ContractWithCustomerAssetRelatedPartyDeduction_lbl" xml:lang="en-US">Contract asset - related party, Deductions</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ContractWithCustomerLiabilityNetRollForward" xlink:label="ptgx_ContractWithCustomerLiabilityNetRollForward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_ContractWithCustomerLiabilityNetRollForward" xlink:to="ptgx_ContractWithCustomerLiabilityNetRollForward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_ContractWithCustomerLiabilityNetRollForward_lbl" xml:lang="en-US">A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_ContractWithCustomerLiabilityNetRollForward_lbl" xml:lang="en-US">Contract with Customer, Liability, Net [Roll forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_ContractWithCustomerLiabilityNetRollForward_lbl" xml:lang="en-US">Deferred revenue - related party</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ContractWithCustomerLiabilityAdditions" xlink:label="ptgx_ContractWithCustomerLiabilityAdditions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_ContractWithCustomerLiabilityAdditions" xlink:to="ptgx_ContractWithCustomerLiabilityAdditions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_ContractWithCustomerLiabilityAdditions_lbl" xml:lang="en-US">Addition in the amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_ContractWithCustomerLiabilityAdditions_lbl" xml:lang="en-US">Contract with Customer, Liability, Additions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_ContractWithCustomerLiabilityAdditions_lbl" xml:lang="en-US">Additions</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ContractWithCustomerLiabilityDeduction" xlink:label="ptgx_ContractWithCustomerLiabilityDeduction" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_ContractWithCustomerLiabilityDeduction" xlink:to="ptgx_ContractWithCustomerLiabilityDeduction_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_ContractWithCustomerLiabilityDeduction_lbl" xml:lang="en-US">Deduction in the amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_ContractWithCustomerLiabilityDeduction_lbl" xml:lang="en-US">Contract with Customer, Liability, Deduction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptgx_ContractWithCustomerLiabilityDeduction_lbl" xml:lang="en-US">Deductions</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_PayableToCollaborationPartnerRelatedPartyAbstract" xlink:label="ptgx_PayableToCollaborationPartnerRelatedPartyAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_PayableToCollaborationPartnerRelatedPartyAbstract" xlink:to="ptgx_PayableToCollaborationPartnerRelatedPartyAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_PayableToCollaborationPartnerRelatedPartyAbstract_lbl" xml:lang="en-US">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_PayableToCollaborationPartnerRelatedPartyAbstract_lbl" xml:lang="en-US">Payable to Collaboration Partner - Related Party [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_PayableToCollaborationPartnerRelatedPartyAbstract_lbl" xml:lang="en-US">Payable to collaboration partner - related party</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DueToRelatedPartyAdditions" xlink:label="ptgx_DueToRelatedPartyAdditions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_DueToRelatedPartyAdditions" xlink:to="ptgx_DueToRelatedPartyAdditions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_DueToRelatedPartyAdditions_lbl" xml:lang="en-US">Additional amount of payable due to a related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_DueToRelatedPartyAdditions_lbl" xml:lang="en-US">Due To Related Party Additions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_DueToRelatedPartyAdditions_lbl" xml:lang="en-US">Additions</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DueToRelatedPartyDeductions" xlink:label="ptgx_DueToRelatedPartyDeductions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_DueToRelatedPartyDeductions" xlink:to="ptgx_DueToRelatedPartyDeductions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_DueToRelatedPartyDeductions_lbl" xml:lang="en-US">Deduction from obligation to transfer good or service to related party for payable amounts.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_DueToRelatedPartyDeductions_lbl" xml:lang="en-US">Due To Related Party Deductions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptgx_DueToRelatedPartyDeductions_lbl" xml:lang="en-US">Deductions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US">Assets, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US">Total financial assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="us-gaap_LongTermDebtFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtFairValue" xlink:to="us-gaap_LongTermDebtFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtFairValue_lbl" xml:lang="en-US">Long-term Debt, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtFairValue_lbl" xml:lang="en-US">Fair Value of Long-term Debt</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ScheduleCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:label="ptgx_ScheduleCashEquivalentsAndAvailableForSaleSecuritiesTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_ScheduleCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:to="ptgx_ScheduleCashEquivalentsAndAvailableForSaleSecuritiesTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_ScheduleCashEquivalentsAndAvailableForSaleSecuritiesTable_lbl" xml:lang="en-US">Schedule cash equivalents and available for sale securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_ScheduleCashEquivalentsAndAvailableForSaleSecuritiesTable_lbl" xml:lang="en-US">Schedule Cash Equivalents and Available for Sale Securities [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_ScheduleCashEquivalentsAndAvailableForSaleSecuritiesTable_lbl" xml:lang="en-US">Schedule Cash Equivalents and Available-for-Sale Securities [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xml:lang="en-US">Cash and Cash Equivalents [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US">Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US">Cash and Cash Equivalents [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US">Money Market Funds [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US">Money Market Funds</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommercialPaperMember_lbl" xml:lang="en-US">Commercial Paper [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommercialPaperMember_lbl" xml:lang="en-US">Commercial Paper</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:label="ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:to="ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems_lbl" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems_lbl" xml:lang="en-US">Cash Equivalents and Available for Sale Securities [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems_lbl" xml:lang="en-US">Cash Equivalents and Marketable Securities</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost" xlink:to="ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost_lbl" xml:lang="en-US">This item represents the cost of debt and equity securities, including cash equivalents which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost_lbl" xml:lang="en-US">Cash Equivalents And Marketable Securities Amortized Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost_lbl" xml:lang="en-US">Total cash equivalents and marketable securities, Amortized Cost</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain" xlink:to="ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain_lbl" xml:lang="en-US">Amount of unrealized gain before deducting unrealized loss on investments in debt and equity securities classified as cash equivalents and marketable securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain_lbl" xml:lang="en-US">Cash Equivalents And Marketable Securities Gross Unrealized Gain</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain_lbl" xml:lang="en-US">Total cash equivalents and marketable securities, Gross Unrealized Gains</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss" xlink:to="ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss_lbl" xml:lang="en-US">Amount of unrealized loss before deducting unrealized gain on investments in cash equivalents and marketable securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss_lbl" xml:lang="en-US">Cash Equivalents And Marketable Securities Gross Unrealized Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss_lbl" xml:lang="en-US">Total cash equivalents and marketable securities, Gross Unrealized Losses</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CashEquivalentsAndMarketableSecuritiesFairValue" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_CashEquivalentsAndMarketableSecuritiesFairValue" xlink:to="ptgx_CashEquivalentsAndMarketableSecuritiesFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesFairValue_lbl" xml:lang="en-US">The aggregate fair value of amount of investment in debt and equity securities and cash equivalents categorized neither as held-to-maturity nor trading.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesFairValue_lbl" xml:lang="en-US">Cash Equivalents And Marketable Securities Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesFairValue_lbl" xml:lang="en-US">Total cash equivalents and marketable securities, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesFairValue_lbl" xml:lang="en-US">Total cash equivalents and marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsAndCashAbstract" xlink:label="us-gaap_InvestmentsAndCashAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAndCashAbstract" xlink:to="us-gaap_InvestmentsAndCashAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsAndCashAbstract_lbl" xml:lang="en-US">Investments and Cash [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentsAndCashAbstract_lbl" xml:lang="en-US">Classified as:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_lbl" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Fair Value, Rolling Maturity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_lbl" xml:lang="en-US">Contractual maturities</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CurrentContractualMaturitiesMaximumPeriod" xlink:label="ptgx_CurrentContractualMaturitiesMaximumPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_CurrentContractualMaturitiesMaximumPeriod" xlink:to="ptgx_CurrentContractualMaturitiesMaximumPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_CurrentContractualMaturitiesMaximumPeriod_lbl" xml:lang="en-US">Represents the maximum period of current contractual maturities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_CurrentContractualMaturitiesMaximumPeriod_lbl" xml:lang="en-US">Current Contractual Maturities, Maximum Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_CurrentContractualMaturitiesMaximumPeriod_lbl" xml:lang="en-US">Maximum period of current contractual maturities</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_NoncurrentContractualMaturitiesMinimumPeriod" xlink:label="ptgx_NoncurrentContractualMaturitiesMinimumPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_NoncurrentContractualMaturitiesMinimumPeriod" xlink:to="ptgx_NoncurrentContractualMaturitiesMinimumPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_NoncurrentContractualMaturitiesMinimumPeriod_lbl" xml:lang="en-US">Represents the minimum period of noncurrent contractual maturities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_NoncurrentContractualMaturitiesMinimumPeriod_lbl" xml:lang="en-US">Noncurrent Contractual Maturities, Minimum Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_NoncurrentContractualMaturitiesMinimumPeriod_lbl" xml:lang="en-US">Minimum period of noncurrent contractual maturities</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_NoncurrentContractualMaturitiesMaximumPeriod" xlink:label="ptgx_NoncurrentContractualMaturitiesMaximumPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_NoncurrentContractualMaturitiesMaximumPeriod" xlink:to="ptgx_NoncurrentContractualMaturitiesMaximumPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_NoncurrentContractualMaturitiesMaximumPeriod_lbl" xml:lang="en-US">Represents the maximum period of contractual maturities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_NoncurrentContractualMaturitiesMaximumPeriod_lbl" xml:lang="en-US">Noncurrent Contractual Maturities, Maximum Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_NoncurrentContractualMaturitiesMaximumPeriod_lbl" xml:lang="en-US">Maximum period of Noncurrent contractual maturities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:to="us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_lbl" xml:lang="en-US">Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_lbl" xml:lang="en-US">Realized Gain (loss)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xml:lang="en-US">Prepaid Expense and Other Assets, Current [Abstract]</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_PrepaidManufacturingOfClinicalMaterials" xlink:label="ptgx_PrepaidManufacturingOfClinicalMaterials" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_PrepaidManufacturingOfClinicalMaterials" xlink:to="ptgx_PrepaidManufacturingOfClinicalMaterials_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_PrepaidManufacturingOfClinicalMaterials_lbl" xml:lang="en-US">Amount of asset related to consideration paid in advance for Prepaid manufacturing of clinical materials that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_PrepaidManufacturingOfClinicalMaterials_lbl" xml:lang="en-US">Prepaid Manufacturing of Clinical Materials</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_PrepaidManufacturingOfClinicalMaterials_lbl" xml:lang="en-US">Prepaid clinical and research related expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid Insurance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Other Prepaid Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Other prepaid expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Other Receivables, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Other receivable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Segment Geographical [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_AU" xlink:label="country_AU" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_AU" xlink:to="country_AU_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_AU_lbl" xml:lang="en-US">A [U]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_AU_lbl" xml:lang="en-US">Australia</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Property Plant And Equipment Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_LaboratoryEquipmentMember" xlink:label="ptgx_LaboratoryEquipmentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_LaboratoryEquipmentMember" xlink:to="ptgx_LaboratoryEquipmentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_LaboratoryEquipmentMember_lbl" xml:lang="en-US">This member stands for laboratory equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_LaboratoryEquipmentMember_lbl" xml:lang="en-US">Laboratory Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_LaboratoryEquipmentMember_lbl" xml:lang="en-US">Laboratory equipment</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_FurnitureAndComputerEquipmentMember" xlink:label="ptgx_FurnitureAndComputerEquipmentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_FurnitureAndComputerEquipmentMember" xlink:to="ptgx_FurnitureAndComputerEquipmentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_FurnitureAndComputerEquipmentMember_lbl" xml:lang="en-US">This member stands for furniture and computer equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_FurnitureAndComputerEquipmentMember_lbl" xml:lang="en-US">Furniture And Computer Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_FurnitureAndComputerEquipmentMember_lbl" xml:lang="en-US">Furniture and computer equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold improvements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Total property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_lbl" xml:lang="en-US">Property Plant and Equipment Income Statement Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_lbl" xml:lang="en-US">Property and equipment income statement disclosure</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" xml:lang="en-US">Accrued Expenses and Other Payables</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_AccruedClinicalAndResearchRelatedExpensesCurrent" xlink:label="ptgx_AccruedClinicalAndResearchRelatedExpensesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_AccruedClinicalAndResearchRelatedExpensesCurrent" xlink:to="ptgx_AccruedClinicalAndResearchRelatedExpensesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_AccruedClinicalAndResearchRelatedExpensesCurrent_lbl" xml:lang="en-US">Current portion of accrued clinical and research related expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_AccruedClinicalAndResearchRelatedExpensesCurrent_lbl" xml:lang="en-US">Accrued Clinical and Research Related Expenses Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_AccruedClinicalAndResearchRelatedExpensesCurrent_lbl" xml:lang="en-US">Accrued clinical and research related expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xml:lang="en-US">Accrued Employee Benefits, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xml:lang="en-US">Accrued employee related expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued Professional Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued professional service fees</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Interest Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Accrued interest payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Total accrued expenses and other payables</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Products and Services [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Products And Services [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Products and Services [Domain]</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_PTG300Member" xlink:label="ptgx_PTG300Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_PTG300Member" xlink:to="ptgx_PTG300Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_PTG300Member_lbl" xml:lang="en-US">This member stands for PTG 300 product candidate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_PTG300Member_lbl" xml:lang="en-US">P T G300 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_PTG300Member_lbl" xml:lang="en-US">PTG-300</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_PhaseTwoBClinicalTrailOfPtg300Member" xlink:label="ptgx_PhaseTwoBClinicalTrailOfPtg300Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_PhaseTwoBClinicalTrailOfPtg300Member" xlink:to="ptgx_PhaseTwoBClinicalTrailOfPtg300Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_PhaseTwoBClinicalTrailOfPtg300Member_lbl" xml:lang="en-US">Represents the information pertaining to Phase two B clinical trail of PTG-300.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_PhaseTwoBClinicalTrailOfPtg300Member_lbl" xml:lang="en-US">Phase Two B Clinical Trail Of Ptg300 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_PhaseTwoBClinicalTrailOfPtg300Member_lbl" xml:lang="en-US">Phase 2b</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_PhaseThreeClinicalTrailOfPtg300Member" xlink:label="ptgx_PhaseThreeClinicalTrailOfPtg300Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_PhaseThreeClinicalTrailOfPtg300Member" xlink:to="ptgx_PhaseThreeClinicalTrailOfPtg300Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_PhaseThreeClinicalTrailOfPtg300Member_lbl" xml:lang="en-US">Represents the information pertaining to Phase three clinical trail of PTG-300.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_PhaseThreeClinicalTrailOfPtg300Member_lbl" xml:lang="en-US">Phase Three Clinical Trail Of Ptg300 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_PhaseThreeClinicalTrailOfPtg300Member_lbl" xml:lang="en-US">Phase 3</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_NumberOfDevelopmentMilestonePayments" xlink:label="ptgx_NumberOfDevelopmentMilestonePayments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_NumberOfDevelopmentMilestonePayments" xlink:to="ptgx_NumberOfDevelopmentMilestonePayments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_NumberOfDevelopmentMilestonePayments_lbl" xml:lang="en-US">The number of development milestone payments in collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_NumberOfDevelopmentMilestonePayments_lbl" xml:lang="en-US">Number of Development Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_NumberOfDevelopmentMilestonePayments_lbl" xml:lang="en-US">Number of development milestone payments</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_AggregateAmountOfDevelopmentMilestonePayment" xlink:label="ptgx_AggregateAmountOfDevelopmentMilestonePayment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_AggregateAmountOfDevelopmentMilestonePayment" xlink:to="ptgx_AggregateAmountOfDevelopmentMilestonePayment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_AggregateAmountOfDevelopmentMilestonePayment_lbl" xml:lang="en-US">The aggregate amount of development milestone payment made by the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_AggregateAmountOfDevelopmentMilestonePayment_lbl" xml:lang="en-US">Aggregate Amount Of Development Milestone Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_AggregateAmountOfDevelopmentMilestonePayment_lbl" xml:lang="en-US">Aggregate development milestone payment</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_AdditionalPaymentObligationToFormerCollaborationPartner" xlink:label="ptgx_AdditionalPaymentObligationToFormerCollaborationPartner" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_AdditionalPaymentObligationToFormerCollaborationPartner" xlink:to="ptgx_AdditionalPaymentObligationToFormerCollaborationPartner_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_AdditionalPaymentObligationToFormerCollaborationPartner_lbl" xml:lang="en-US">Additional payment obligation from the company to the former collaboration partner.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_AdditionalPaymentObligationToFormerCollaborationPartner_lbl" xml:lang="en-US">Additional Payment Obligation To Former Collaboration Partner</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_AdditionalPaymentObligationToFormerCollaborationPartner_lbl" xml:lang="en-US">Additional payment obligation to the former collaboration partner</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_GovernmentProgramsTable" xlink:label="ptgx_GovernmentProgramsTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_GovernmentProgramsTable" xlink:to="ptgx_GovernmentProgramsTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_GovernmentProgramsTable_lbl" xml:lang="en-US">Disclosure of government programs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_GovernmentProgramsTable_lbl" xml:lang="en-US">Government Programs [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_GovernmentProgramsTable_lbl" xml:lang="en-US">Government Programs [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US">Income Tax Authority [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US">Income Tax Authority [Domain]</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_OverseasFindingsMember" xlink:label="ptgx_OverseasFindingsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_OverseasFindingsMember" xlink:to="ptgx_OverseasFindingsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_OverseasFindingsMember_lbl" xml:lang="en-US">This member stands for overseas findings.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_OverseasFindingsMember_lbl" xml:lang="en-US">Overseas Findings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_OverseasFindingsMember_lbl" xml:lang="en-US">Overseas Findings</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xml:lang="en-US">Income Tax Authority, Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xml:lang="en-US">Income Tax Authority Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xml:lang="en-US">Income Tax Authority, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AustralianTaxationOfficeMember" xlink:label="us-gaap_AustralianTaxationOfficeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AustralianTaxationOfficeMember" xlink:to="us-gaap_AustralianTaxationOfficeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AustralianTaxationOfficeMember_lbl" xml:lang="en-US">Australian Taxation Office [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AustralianTaxationOfficeMember_lbl" xml:lang="en-US">Australian</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_GovernmentProgramsLineItems" xlink:label="ptgx_GovernmentProgramsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_GovernmentProgramsLineItems" xlink:to="ptgx_GovernmentProgramsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_GovernmentProgramsLineItems_lbl" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_GovernmentProgramsLineItems_lbl" xml:lang="en-US">Government Programs [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_GovernmentProgramsLineItems_lbl" xml:lang="en-US">Government Programs</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ResearchAndDevelopmentExpensesReduction" xlink:label="ptgx_ResearchAndDevelopmentExpensesReduction" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_ResearchAndDevelopmentExpensesReduction" xlink:to="ptgx_ResearchAndDevelopmentExpensesReduction_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_ResearchAndDevelopmentExpensesReduction_lbl" xml:lang="en-US">The amount of reduction of research and development expense in connection with the research and development tax incentive.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_ResearchAndDevelopmentExpensesReduction_lbl" xml:lang="en-US">Research And Development Expenses Reduction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_ResearchAndDevelopmentExpensesReduction_lbl" xml:lang="en-US">Reduction of research and development expenses related to tax</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ResearchAndDevelopmentGrants" xlink:label="ptgx_ResearchAndDevelopmentGrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_ResearchAndDevelopmentGrants" xlink:to="ptgx_ResearchAndDevelopmentGrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_ResearchAndDevelopmentGrants_lbl" xml:lang="en-US">The amount of research and development grants awarded during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_ResearchAndDevelopmentGrants_lbl" xml:lang="en-US">Research And Development Grants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_ResearchAndDevelopmentGrants_lbl" xml:lang="en-US">Research and development grants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivable" xlink:to="us-gaap_GrantsReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrantsReceivable_lbl" xml:lang="en-US">Grants Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GrantsReceivable_lbl" xml:lang="en-US">Grants receivable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Debt Instrument [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US">Loan facility for general corporate</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DebtInstrumentTrancheInstallmentAmount" xlink:label="ptgx_DebtInstrumentTrancheInstallmentAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_DebtInstrumentTrancheInstallmentAmount" xlink:to="ptgx_DebtInstrumentTrancheInstallmentAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_DebtInstrumentTrancheInstallmentAmount_lbl" xml:lang="en-US">Represents the tranche installment amount under the debt instrument.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_DebtInstrumentTrancheInstallmentAmount_lbl" xml:lang="en-US">Debt Instrument, Tranche Installment Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_DebtInstrumentTrancheInstallmentAmount_lbl" xml:lang="en-US">Tranche Installment Amount</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DebtInstrumentThresholdPercentageOnOutstandingDebtToBeMaintainedAsCashAndCashEquivalentsBalance" xlink:label="ptgx_DebtInstrumentThresholdPercentageOnOutstandingDebtToBeMaintainedAsCashAndCashEquivalentsBalance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_DebtInstrumentThresholdPercentageOnOutstandingDebtToBeMaintainedAsCashAndCashEquivalentsBalance" xlink:to="ptgx_DebtInstrumentThresholdPercentageOnOutstandingDebtToBeMaintainedAsCashAndCashEquivalentsBalance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_DebtInstrumentThresholdPercentageOnOutstandingDebtToBeMaintainedAsCashAndCashEquivalentsBalance_lbl" xml:lang="en-US">Represents the percentage on outstanding debt to be maintained as balance under cash and cash equivalents by the company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_DebtInstrumentThresholdPercentageOnOutstandingDebtToBeMaintainedAsCashAndCashEquivalentsBalance_lbl" xml:lang="en-US">Debt Instrument, Threshold Percentage On Outstanding Debt To Be Maintained As Cash And Cash Equivalents Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_DebtInstrumentThresholdPercentageOnOutstandingDebtToBeMaintainedAsCashAndCashEquivalentsBalance_lbl" xml:lang="en-US">Cash and cash equivalents ( In percentage)</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DebtInstrumentLoanOriginationFeePercentage" xlink:label="ptgx_DebtInstrumentLoanOriginationFeePercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_DebtInstrumentLoanOriginationFeePercentage" xlink:to="ptgx_DebtInstrumentLoanOriginationFeePercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_DebtInstrumentLoanOriginationFeePercentage_lbl" xml:lang="en-US">Represents the percentage of loan origination fee under the debt instrument.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_DebtInstrumentLoanOriginationFeePercentage_lbl" xml:lang="en-US">Debt Instrument, Loan Origination Fee Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_DebtInstrumentLoanOriginationFeePercentage_lbl" xml:lang="en-US">Loan Origination Fee (In Percentage)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US">prime rate (In Percentage)</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DebtInstrumentFloorRate" xlink:label="ptgx_DebtInstrumentFloorRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_DebtInstrumentFloorRate" xlink:to="ptgx_DebtInstrumentFloorRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_DebtInstrumentFloorRate_lbl" xml:lang="en-US">Represents the floor rate of the debt instrument</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_DebtInstrumentFloorRate_lbl" xml:lang="en-US">Debt Instrument, Floor Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_DebtInstrumentFloorRate_lbl" xml:lang="en-US">Floor rate (In Percentage)</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DebtInstrumentPeriodOfInterestOnlyPayments" xlink:label="ptgx_DebtInstrumentPeriodOfInterestOnlyPayments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_DebtInstrumentPeriodOfInterestOnlyPayments" xlink:to="ptgx_DebtInstrumentPeriodOfInterestOnlyPayments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_DebtInstrumentPeriodOfInterestOnlyPayments_lbl" xml:lang="en-US">Represents the period for which the company is required to pay interest-only payments on the debt instrument.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_DebtInstrumentPeriodOfInterestOnlyPayments_lbl" xml:lang="en-US">Debt Instrument, Period Of Interest Only Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_DebtInstrumentPeriodOfInterestOnlyPayments_lbl" xml:lang="en-US">Period Of Interest Only Payments</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DebtInstrumentPeriodOfPrincipalAndInterestPayments" xlink:label="ptgx_DebtInstrumentPeriodOfPrincipalAndInterestPayments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_DebtInstrumentPeriodOfPrincipalAndInterestPayments" xlink:to="ptgx_DebtInstrumentPeriodOfPrincipalAndInterestPayments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_DebtInstrumentPeriodOfPrincipalAndInterestPayments_lbl" xml:lang="en-US">Represents the period for which the company will pay principal and interest payments on the debt instrument.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_DebtInstrumentPeriodOfPrincipalAndInterestPayments_lbl" xml:lang="en-US">Debt Instrument, Period Of Principal And Interest Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_DebtInstrumentPeriodOfPrincipalAndInterestPayments_lbl" xml:lang="en-US">Consecutive monthly payments</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DebtInstrumentPrepaymentPremiumPercentage" xlink:label="ptgx_DebtInstrumentPrepaymentPremiumPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_DebtInstrumentPrepaymentPremiumPercentage" xlink:to="ptgx_DebtInstrumentPrepaymentPremiumPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_DebtInstrumentPrepaymentPremiumPercentage_lbl" xml:lang="en-US">The percentage of prepayment premium under the debt instrument.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_DebtInstrumentPrepaymentPremiumPercentage_lbl" xml:lang="en-US">Debt Instrument, Prepayment Premium Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_DebtInstrumentPrepaymentPremiumPercentage_lbl" xml:lang="en-US">Prepayment premium (In Percentage)</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DebtInstrumentAdditionalPrepaymentOrRepaymentPremiumPercentage" xlink:label="ptgx_DebtInstrumentAdditionalPrepaymentOrRepaymentPremiumPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_DebtInstrumentAdditionalPrepaymentOrRepaymentPremiumPercentage" xlink:to="ptgx_DebtInstrumentAdditionalPrepaymentOrRepaymentPremiumPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_DebtInstrumentAdditionalPrepaymentOrRepaymentPremiumPercentage_lbl" xml:lang="en-US">The additional percentage of prepayment premium on the amount advanced by the lenders will be due upon prepayments or repayment of the debt instrument.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_DebtInstrumentAdditionalPrepaymentOrRepaymentPremiumPercentage_lbl" xml:lang="en-US">Debt Instrument, Additional Prepayment Or Repayment Premium Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_DebtInstrumentAdditionalPrepaymentOrRepaymentPremiumPercentage_lbl" xml:lang="en-US">Additional Prepayment (In Percentage)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US">Repayments of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US">Outstanding balance paid</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFeeAmount" xlink:to="us-gaap_DebtInstrumentFeeAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xml:lang="en-US">Debt Instrument, Fee Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xml:lang="en-US">Prepayment and exit fees</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_lbl" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium), Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_lbl" xml:lang="en-US">Accelerated capitalized and unamortized debt issuance costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Long-term Debt, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Term loan (matures October 1, 2023)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xml:lang="en-US">Debt Issuance Costs, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xml:lang="en-US">Debt issuance costs, net of amortization</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DebtInstrumentAccruedFinalPaymentFee" xlink:label="ptgx_DebtInstrumentAccruedFinalPaymentFee" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_DebtInstrumentAccruedFinalPaymentFee" xlink:to="ptgx_DebtInstrumentAccruedFinalPaymentFee_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_DebtInstrumentAccruedFinalPaymentFee_lbl" xml:lang="en-US">The amount of accrued final payment fee under the debt instrument arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_DebtInstrumentAccruedFinalPaymentFee_lbl" xml:lang="en-US">Debt Instrument, Accrued Final Payment Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_DebtInstrumentAccruedFinalPaymentFee_lbl" xml:lang="en-US">Accrued final payment fee</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Annual interest rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US">Effective interest rate on long-term debt</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_NumberOfOperatingLeaseAgreement" xlink:label="ptgx_NumberOfOperatingLeaseAgreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_NumberOfOperatingLeaseAgreement" xlink:to="ptgx_NumberOfOperatingLeaseAgreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_NumberOfOperatingLeaseAgreement_lbl" xml:lang="en-US">Represents the number of operating lease agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_NumberOfOperatingLeaseAgreement_lbl" xml:lang="en-US">Number of Operating Lease Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_NumberOfOperatingLeaseAgreement_lbl" xml:lang="en-US">Number of operating lease agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security Deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security deposit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubleaseIncome_lbl" xml:lang="en-US">Sublease Income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted-average remaining lease term</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted-average discount rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US">Operating Lease Liabilities, Payments Due [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US">Minimum lease payments:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2021</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2022</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2023</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2024</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total future minimum lease payments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: imputed interest</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Present value of future minimum lease payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease cost</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorDisclosureAbstract" xlink:label="us-gaap_LessorDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_LessorDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LessorDisclosureAbstract_lbl" xml:lang="en-US">Leases, Operating [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LessorDisclosureAbstract_lbl" xml:lang="en-US">Operating Leases:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US">Financial position</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US">Financial position</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US">Financial position</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US">Operating Lease, Liability, Statement of Financial Position [Extensible List]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US">Financial position</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating Lease, Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating cash flow used by operating leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseNet" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xml:lang="en-US">Operating Leases, Rent Expense, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xml:lang="en-US">Rent expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US">Loss Contingencies [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US">Loss Contingencies [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="us-gaap_LossContingencyDamagesSoughtValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyDamagesSoughtValue" xlink:to="us-gaap_LossContingencyDamagesSoughtValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyDamagesSoughtValue_lbl" xml:lang="en-US">Loss Contingency, Damages Sought, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingencyDamagesSoughtValue_lbl" xml:lang="en-US">Amount of damages sought</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_PotentialDevelopmentAndRegulatoryMilestonePaymentsOnContractualObligation" xlink:label="ptgx_PotentialDevelopmentAndRegulatoryMilestonePaymentsOnContractualObligation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_PotentialDevelopmentAndRegulatoryMilestonePaymentsOnContractualObligation" xlink:to="ptgx_PotentialDevelopmentAndRegulatoryMilestonePaymentsOnContractualObligation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_PotentialDevelopmentAndRegulatoryMilestonePaymentsOnContractualObligation_lbl" xml:lang="en-US">Amount of potential development and regulatory milestone payments on contractual obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_PotentialDevelopmentAndRegulatoryMilestonePaymentsOnContractualObligation_lbl" xml:lang="en-US">Potential Development and Regulatory Milestone Payments on Contractual Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_PotentialDevelopmentAndRegulatoryMilestonePaymentsOnContractualObligation_lbl" xml:lang="en-US">Potential development and regulatory milestone payments on contractual obligation</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_PotentialSalesMilestonePaymentsOnContractualObligation" xlink:label="ptgx_PotentialSalesMilestonePaymentsOnContractualObligation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_PotentialSalesMilestonePaymentsOnContractualObligation" xlink:to="ptgx_PotentialSalesMilestonePaymentsOnContractualObligation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_PotentialSalesMilestonePaymentsOnContractualObligation_lbl" xml:lang="en-US">Amount if potential sales milestone payments on contractual obligation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_PotentialSalesMilestonePaymentsOnContractualObligation_lbl" xml:lang="en-US">Potential Sales Milestone Payments On Contractual Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_PotentialSalesMilestonePaymentsOnContractualObligation_lbl" xml:lang="en-US">Potential sales milestone payments on contractual obligation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xml:lang="en-US">Loss Contingency Accrual</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xml:lang="en-US">Loss contingency accrual</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_ClassOfStockDisclosuresAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract_lbl" xml:lang="en-US">Class of Stock Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract_lbl" xml:lang="en-US">Stock transactions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_SaleOfStockValueOfSharesAuthorized" xlink:label="ptgx_SaleOfStockValueOfSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_SaleOfStockValueOfSharesAuthorized" xlink:to="ptgx_SaleOfStockValueOfSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_SaleOfStockValueOfSharesAuthorized_lbl" xml:lang="en-US">The maximum amount of shares permits the offering, issuance, and sale by the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_SaleOfStockValueOfSharesAuthorized_lbl" xml:lang="en-US">Sale Of Stock, Value Of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_SaleOfStockValueOfSharesAuthorized_lbl" xml:lang="en-US">Maximum aggregate offering price</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_AggregateGrossProceedsFromIssuanceStock" xlink:label="ptgx_AggregateGrossProceedsFromIssuanceStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_AggregateGrossProceedsFromIssuanceStock" xlink:to="ptgx_AggregateGrossProceedsFromIssuanceStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_AggregateGrossProceedsFromIssuanceStock_lbl" xml:lang="en-US">The gross cash inflow from the additional capital contribution to the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_AggregateGrossProceedsFromIssuanceStock_lbl" xml:lang="en-US">Aggregate Gross Proceeds from Issuance Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_AggregateGrossProceedsFromIssuanceStock_lbl" xml:lang="en-US">Aggregate gross proceeds</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants to purchase common stock, number of shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Number of shares to be converted for each warrant</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_NumberOfWarrantsExercised" xlink:label="ptgx_NumberOfWarrantsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_NumberOfWarrantsExercised" xlink:to="ptgx_NumberOfWarrantsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_NumberOfWarrantsExercised_lbl" xml:lang="en-US">The number of warrants exercised for the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_NumberOfWarrantsExercised_lbl" xml:lang="en-US">Number of Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_NumberOfWarrantsExercised_lbl" xml:lang="en-US">Number of warrants exercised</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_StockExchangedForPreFundedWarrants" xlink:label="ptgx_StockExchangedForPreFundedWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_StockExchangedForPreFundedWarrants" xlink:to="ptgx_StockExchangedForPreFundedWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_StockExchangedForPreFundedWarrants_lbl" xml:lang="en-US">The number of shares exchanged for pre-funded warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_StockExchangedForPreFundedWarrants_lbl" xml:lang="en-US">Stock Exchanged for Pre-funded Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_StockExchangedForPreFundedWarrants_lbl" xml:lang="en-US">Common stock exchanged for pre-funded warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise Price (per share)</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ClassOfWarrantOrRightTermOfWarrants" xlink:label="ptgx_ClassOfWarrantOrRightTermOfWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_ClassOfWarrantOrRightTermOfWarrants" xlink:to="ptgx_ClassOfWarrantOrRightTermOfWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_ClassOfWarrantOrRightTermOfWarrants_lbl" xml:lang="en-US">The duration of warrants from date of issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_ClassOfWarrantOrRightTermOfWarrants_lbl" xml:lang="en-US">Class of Warrant or Right, Term of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_ClassOfWarrantOrRightTermOfWarrants_lbl" xml:lang="en-US">Duration of warrants from date of issuance (in years)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Equity method investment, ownership percentage</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Exchange warrants unexercised</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Equity Plans</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Expiration period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Number of shares authorized</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum" xlink:label="ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum" xlink:to="ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum_lbl" xml:lang="en-US">Maximum annual number of additional shares authorized for issuance under an established share-based compensation plan as a proportion of outstanding capital stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Annual Additional Shares Authorized, Percentage of Outstanding Stock Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum_lbl" xml:lang="en-US">Maximum annual additional authorized shares as a percentage of outstanding shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Number of shares available for issuance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US">Exercise price as a percentage of the fair market value of common stock on grant date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US">Purchase price of stock (as a percent)</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants" xlink:label="ptgx_ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants" xlink:to="ptgx_ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants_lbl" xml:lang="en-US">Represents the percentage of average volatility for comparable publicly traded biopharmaceutical companies over a period equal to the expected term of the stock option grants, used in the calculation of expected volatility.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants_lbl" xml:lang="en-US">Expected Volatility Calculation, Percentage Of Average Volatility Expected Term Of Stock Option Grants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants_lbl" xml:lang="en-US">Average volatility</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo" xlink:label="ptgx_ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo" xlink:to="ptgx_ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo_lbl" xml:lang="en-US">Represents the percentage of volatility of stock price since its initial public offering used in the calculation of expected volatility.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo_lbl" xml:lang="en-US">Expected Volatility Calculation, Percentage Of Volatility Of Stock Price Since IPO</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo_lbl" xml:lang="en-US">Percentage of volatility of stock options since IPO</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US">Options Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options Outstanding, Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options Outstanding, Beginning balance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Options Outstanding, Options granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Options Outstanding, Options exercised</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xml:lang="en-US">Options Outstanding, Options forfeited</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Options Outstanding, Options exercisable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Options Outstanding, Options vested and expected to vest</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">Weighted-Average Exercise Price Per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price Per Share, Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price Per Share, Beginning balance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price Per Share, Options granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price Per Share, Options exercised</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price Per Share, Options forfeited</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price Per Share, Options exercisable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price Per Share, Options vested and expected to vest</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US">Weighted-Average Remaining Contractual Life (years)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted-Average Remaining Contractual Life (years)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted-Average Remaining Contractual Life (years), Options exercisable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted-Average Remaining Contractual Life (years), Options vested and expected to vest</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:label="ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xml:lang="en-US">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xml:lang="en-US">Aggregate Intrinsic Value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Options Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Options exercisable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Options vested and expected to vest</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value of options exercised</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Options, weighted-average grant-date fair value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Equity Award [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Employee Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Options to purchase common stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Expected volatility, Minimum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Expected volatility, Maximum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Risk-free interest rate, Minimum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Risk-free interest rate, Maximum</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_NumberOfEqualInstallmentsRequiredForVestingOfRestrictedStockUnits" xlink:label="ptgx_NumberOfEqualInstallmentsRequiredForVestingOfRestrictedStockUnits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_NumberOfEqualInstallmentsRequiredForVestingOfRestrictedStockUnits" xlink:to="ptgx_NumberOfEqualInstallmentsRequiredForVestingOfRestrictedStockUnits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_NumberOfEqualInstallmentsRequiredForVestingOfRestrictedStockUnits_lbl" xml:lang="en-US">The number of equal installments established for the restricted stock units vesting schedule.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_NumberOfEqualInstallmentsRequiredForVestingOfRestrictedStockUnits_lbl" xml:lang="en-US">Number of Equal Installments Required For Vesting of Restricted Stock Units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_NumberOfEqualInstallmentsRequiredForVestingOfRestrictedStockUnits_lbl" xml:lang="en-US">Restricted stock units vesting, number of equal installments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US">Number of Shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of shares, Unvested, Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of shares, Unvested, Beginning balance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of shares, Granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Number of shares, Vested</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Number of Shares, Forfeited</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US">Weighted-Average Grant Date Fair Value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-Average Grant Date Fair Value, Unvested, Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-Average Grant Date Fair Value, Unvested, Beginning balance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-Average Grant Date Fair Value, Granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-Average Grant Date Fair Value, Vested</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-Average Grant Date Fair Value, Forfeited</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_EmployeeStockPurchasePlan2016Member" xlink:label="ptgx_EmployeeStockPurchasePlan2016Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_EmployeeStockPurchasePlan2016Member" xlink:to="ptgx_EmployeeStockPurchasePlan2016Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_EmployeeStockPurchasePlan2016Member_lbl" xml:lang="en-US">Represents the 2016 Employee Stock Purchase Plan approved by the board of directors and stockholders in July 2016.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_EmployeeStockPurchasePlan2016Member_lbl" xml:lang="en-US">Employee Stock Purchase Plan2016 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_EmployeeStockPurchasePlan2016Member_lbl" xml:lang="en-US">2016 ESPP</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockMember_lbl" xml:lang="en-US">Employee Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockMember_lbl" xml:lang="en-US">ESPP rights</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xml:lang="en-US">Maximum payroll deduction for share purchases (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US">Shares issued in period</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualNumberOfAdditionalSharesAuthorized" xlink:label="ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualNumberOfAdditionalSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualNumberOfAdditionalSharesAuthorized" xlink:to="ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualNumberOfAdditionalSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US">Number of annual additional shares authorized for issuance under an established share-based compensation plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Annual Number of Additional Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US">Maximum annual additional authorized shares (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research And Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General And Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Total unrecognized stock-based compensation costs related to stock options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Period of unrecognized stock-based compensation costs to be recognized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_lbl" xml:lang="en-US">Domestic and foreign components of net loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US">Domestic</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US">Foreign</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US">Components of the income tax expense (benefit)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US">Current:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xml:lang="en-US">Foreign</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Current Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total current tax (benefit) expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US">Deferred:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Foreign</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total deferred tax expense (benefit)</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_IncomeTaxTable" xlink:label="ptgx_IncomeTaxTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_IncomeTaxTable" xlink:to="ptgx_IncomeTaxTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_IncomeTaxTable_lbl" xml:lang="en-US">The disclosure on income taxes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_IncomeTaxTable_lbl" xml:lang="en-US">Income Tax [Table]</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_IncomeTaxLineItems" xlink:label="ptgx_IncomeTaxLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_IncomeTaxLineItems" xlink:to="ptgx_IncomeTaxLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_IncomeTaxLineItems_lbl" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_IncomeTaxLineItems_lbl" xml:lang="en-US">Income tax [Line items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US">Effective tax rate of provision for income taxes difference from federal statutory rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal statutory income tax rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State taxes, net of federal benefit (as a percent)</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAdjustmentPercent" xlink:label="ptgx_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAdjustmentPercent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAdjustmentPercent" xlink:to="ptgx_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAdjustmentPercent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAdjustmentPercent_lbl" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to and adjustment to the research tax credit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAdjustmentPercent_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Adjustment, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAdjustmentPercent_lbl" xml:lang="en-US">Research and development credits (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">Foreign tax rate difference (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Provision (benefit) for income taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US">Operating Loss Carryforwards [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US">Net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Components of deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xml:lang="en-US">Deferred tax assets:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Operating loss carryforwards available to offset future taxable income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther" xlink:label="ptgx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther" xlink:to="ptgx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther_lbl" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from other reserves and accruals not separately disclosed.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals and Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther_lbl" xml:lang="en-US">Accruals/other</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="ptgx_DeferredTaxAssetsOperatingLeaseLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_DeferredTaxAssetsOperatingLeaseLiability" xlink:to="ptgx_DeferredTaxAssetsOperatingLeaseLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_DeferredTaxAssetsOperatingLeaseLiability_lbl" xml:lang="en-US">Represents deferred tax assets, operating lease liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_DeferredTaxAssetsOperatingLeaseLiability_lbl" xml:lang="en-US">Deferred Tax Assets, Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_DeferredTaxAssetsOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xml:lang="en-US">Research and development and foreign credits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US">Deferred tax liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xml:lang="en-US">Operating right-of-use asset</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Deferred Tax Liabilities, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Total deferred tax liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceAbstract" xlink:label="us-gaap_ValuationAllowanceAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceAbstract" xlink:to="us-gaap_ValuationAllowanceAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceAbstract_lbl" xml:lang="en-US">Valuation Allowance [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceAbstract_lbl" xml:lang="en-US">Valuation allowance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Increase in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_OperatingLossCarryforwardsNoExpiration" xlink:label="ptgx_OperatingLossCarryforwardsNoExpiration" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_OperatingLossCarryforwardsNoExpiration" xlink:to="ptgx_OperatingLossCarryforwardsNoExpiration_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_OperatingLossCarryforwardsNoExpiration_lbl" xml:lang="en-US">Amount of operating loss carryforward that do not expire, before tax effects, available to reduce future taxable income under enacted tax laws.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_OperatingLossCarryforwardsNoExpiration_lbl" xml:lang="en-US">Operating Loss Carryforwards, No Expiration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_OperatingLossCarryforwardsNoExpiration_lbl" xml:lang="en-US">Net operating loss carryforwards with no expiration</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="us-gaap_TaxCreditCarryforwardTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_TaxCreditCarryforwardTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardTable_lbl" xml:lang="en-US">Tax Credit Carryforward [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State And Local Jurisdiction [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xml:lang="en-US">Tax Credit Carryforward [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xml:lang="en-US">Tax Credit Carryforward Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US">Research [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US">Research and Development Tax Incentive</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="us-gaap_TaxCreditCarryforwardLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_TaxCreditCarryforwardLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardLineItems_lbl" xml:lang="en-US">Tax Credit Carryforward [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardLineItems_lbl" xml:lang="en-US">Tax credit carryforwards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US">Tax Credit Carryforward, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US">Tax credit carryforwards available to reduce future income taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xml:lang="en-US">Reconciliation of beginning and ending amount of unrecognized tax benefits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Balance at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Balance at beginning of year</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US">(Decreases) increases based on tax positions related to prior years</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US">(Decreases) increases based on tax positions related to prior years</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US">Increase based on tax positions related to current year</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xml:lang="en-US">Accrual for interest or penalties</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:to="us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_lbl" xml:lang="en-US">Foreign Income Tax Expense (Benefit), Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_lbl" xml:lang="en-US">Foreign income tax benefit</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_NetOperatingLossCarryback" xlink:label="ptgx_NetOperatingLossCarryback" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_NetOperatingLossCarryback" xlink:to="ptgx_NetOperatingLossCarryback_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_NetOperatingLossCarryback_lbl" xml:lang="en-US">The period of net operating loss carryback.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_NetOperatingLossCarryback_lbl" xml:lang="en-US">Net Operating Loss Carryback</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DeductionOfTaxableIncomePercentage" xlink:label="ptgx_DeductionOfTaxableIncomePercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_DeductionOfTaxableIncomePercentage" xlink:to="ptgx_DeductionOfTaxableIncomePercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_DeductionOfTaxableIncomePercentage_lbl" xml:lang="en-US">The percentage of taxable income deduction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_DeductionOfTaxableIncomePercentage_lbl" xml:lang="en-US">Deduction of Taxable Income, Percentage</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CaliforniaNetOperatingLossDeductionsLimitOfIncome" xlink:label="ptgx_CaliforniaNetOperatingLossDeductionsLimitOfIncome" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_CaliforniaNetOperatingLossDeductionsLimitOfIncome" xlink:to="ptgx_CaliforniaNetOperatingLossDeductionsLimitOfIncome_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_CaliforniaNetOperatingLossDeductionsLimitOfIncome_lbl" xml:lang="en-US">The amount of income limit for California Net Operating Loss Deductions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_CaliforniaNetOperatingLossDeductionsLimitOfIncome_lbl" xml:lang="en-US">California Net Operating Loss Deductions, Limit of Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_CaliforniaNetOperatingLossDeductionsLimitOfIncome_lbl" xml:lang="en-US">Amount of income limit for California Net Operating Loss deductions</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_MaximumOffsetOfCaliforniaTax" xlink:label="ptgx_MaximumOffsetOfCaliforniaTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_MaximumOffsetOfCaliforniaTax" xlink:to="ptgx_MaximumOffsetOfCaliforniaTax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_MaximumOffsetOfCaliforniaTax_lbl" xml:lang="en-US">The amount of California tax offset for business credit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_MaximumOffsetOfCaliforniaTax_lbl" xml:lang="en-US">Maximum Offset of California tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_MaximumOffsetOfCaliforniaTax_lbl" xml:lang="en-US">Amount of California tax offset for business credit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xml:lang="en-US">Numerator:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Denominator:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units R S U [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted stock units</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Potentially dilutive securities have been excluded from diluted net loss per share calculations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Anti-dilutive securities (in shares)</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_PercentageOfEmployeeBaseImpactedByRestructuringPlan" xlink:label="ptgx_PercentageOfEmployeeBaseImpactedByRestructuringPlan" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_PercentageOfEmployeeBaseImpactedByRestructuringPlan" xlink:to="ptgx_PercentageOfEmployeeBaseImpactedByRestructuringPlan_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_PercentageOfEmployeeBaseImpactedByRestructuringPlan_lbl" xml:lang="en-US">Represents the percentage of employee base impacted by the restructuring plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_PercentageOfEmployeeBaseImpactedByRestructuringPlan_lbl" xml:lang="en-US">Percentage of Employee Base Impacted by Restructuring Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_PercentageOfEmployeeBaseImpactedByRestructuringPlan_lbl" xml:lang="en-US">Percentage of employee base impacted by the restructuring plan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCharges" xlink:to="us-gaap_RestructuringCharges_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCharges_lbl" xml:lang="en-US">Restructuring Charges</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringCharges_lbl" xml:lang="en-US">Total cash expenditures for the reduction in force plan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid In Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-In Capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated Other Comprehensive Gain (Loss)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale Of Stock Name Of Transaction [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_AtMarketingOfferingMember" xlink:label="ptgx_AtMarketingOfferingMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_AtMarketingOfferingMember" xlink:to="ptgx_AtMarketingOfferingMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_AtMarketingOfferingMember_lbl" xml:lang="en-US">The sale of stock by a private company to public at market offer price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_AtMarketingOfferingMember_lbl" xml:lang="en-US">At Marketing Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_AtMarketingOfferingMember_lbl" xml:lang="en-US">At-the-market offering</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">I P O [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">Public Offering</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xml:lang="en-US">Balance Sheet Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xml:lang="en-US">Balance Sheet Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xml:lang="en-US">Balance Sheet Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_AccruedLiabilitiesAndOtherPayablesMember" xlink:label="ptgx_AccruedLiabilitiesAndOtherPayablesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_AccruedLiabilitiesAndOtherPayablesMember" xlink:to="ptgx_AccruedLiabilitiesAndOtherPayablesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_AccruedLiabilitiesAndOtherPayablesMember_lbl" xml:lang="en-US">It represents the information pertaining to the accrued liabilities and other payables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_AccruedLiabilitiesAndOtherPayablesMember_lbl" xml:lang="en-US">Accrued Liabilities And Other Payables [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_AccruedLiabilitiesAndOtherPayablesMember_lbl" xml:lang="en-US">Accrued liabilities and other payables</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xml:lang="en-US">Prepaid Expenses And Other Current Assets [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xml:lang="en-US">Prepaid expenses and other assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario Unspecified [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario, Unspecified [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProFormaMember" xlink:label="srt_ProFormaMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProFormaMember" xlink:to="srt_ProFormaMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProFormaMember_lbl" xml:lang="en-US">Pro Forma [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ProFormaMember_lbl" xml:lang="en-US">Pro Forma</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_PhaseOneClinicalTrialMember" xlink:label="ptgx_PhaseOneClinicalTrialMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_PhaseOneClinicalTrialMember" xlink:to="ptgx_PhaseOneClinicalTrialMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_PhaseOneClinicalTrialMember_lbl" xml:lang="en-US">Represents the first, second-generation compound.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_PhaseOneClinicalTrialMember_lbl" xml:lang="en-US">Phase One Clinical Trial [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_PhaseOneClinicalTrialMember_lbl" xml:lang="en-US">Phase 1 clinical term</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CollaborationAgreementTrancheThreeMember" xlink:label="ptgx_CollaborationAgreementTrancheThreeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_CollaborationAgreementTrancheThreeMember" xlink:to="ptgx_CollaborationAgreementTrancheThreeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_CollaborationAgreementTrancheThreeMember_lbl" xml:lang="en-US">Represents the first, second-generation compound.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_CollaborationAgreementTrancheThreeMember_lbl" xml:lang="en-US">Collaboration Agreement Tranche Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_CollaborationAgreementTrancheThreeMember_lbl" xml:lang="en-US">First, second-generation compound</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CollaborationAgreementTrancheFourMember" xlink:label="ptgx_CollaborationAgreementTrancheFourMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_CollaborationAgreementTrancheFourMember" xlink:to="ptgx_CollaborationAgreementTrancheFourMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_CollaborationAgreementTrancheFourMember_lbl" xml:lang="en-US">Represents the second and third second-generation compounds.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_CollaborationAgreementTrancheFourMember_lbl" xml:lang="en-US">Collaboration Agreement Tranche Four [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_CollaborationAgreementTrancheFourMember_lbl" xml:lang="en-US">Second and third, second-generation compounds</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CollaborationAgreementTrancheFiveMember" xlink:label="ptgx_CollaborationAgreementTrancheFiveMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_CollaborationAgreementTrancheFiveMember" xlink:to="ptgx_CollaborationAgreementTrancheFiveMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_CollaborationAgreementTrancheFiveMember_lbl" xml:lang="en-US">Represents the period after third second-generation compounds.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_CollaborationAgreementTrancheFiveMember_lbl" xml:lang="en-US">Collaboration Agreement Tranche Five [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_CollaborationAgreementTrancheFiveMember_lbl" xml:lang="en-US">Thereafter</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_SecondGenerationDevelopmentCompoundMember" xlink:label="ptgx_SecondGenerationDevelopmentCompoundMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_SecondGenerationDevelopmentCompoundMember" xlink:to="ptgx_SecondGenerationDevelopmentCompoundMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_SecondGenerationDevelopmentCompoundMember_lbl" xml:lang="en-US">Represents the second-generation development compound.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_SecondGenerationDevelopmentCompoundMember_lbl" xml:lang="en-US">Second Generation Development Compound [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_SecondGenerationDevelopmentCompoundMember_lbl" xml:lang="en-US">Second-Generation Phase 2b Milestone</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_PhaseTwoClinicalTrialMember" xlink:label="ptgx_PhaseTwoClinicalTrialMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_PhaseTwoClinicalTrialMember" xlink:to="ptgx_PhaseTwoClinicalTrialMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_PhaseTwoClinicalTrialMember_lbl" xml:lang="en-US">This member stands for phase 2 clinical trial, related to a specific collaborative arrangement in which the entity provides product it manufactures to collaborative arrangement partners. A collaborative arrangement is a contractual arrangement with a specific party or parties that both: (i) actively participate in a joint operating activity and (ii) is (are) exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_PhaseTwoClinicalTrialMember_lbl" xml:lang="en-US">Phase Two Clinical Trial [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_PhaseTwoClinicalTrialMember_lbl" xml:lang="en-US">Phase 2 clinical trial</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_LicenseAndCollaborativeAgreementAmendmentMember" xlink:label="ptgx_LicenseAndCollaborativeAgreementAmendmentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_LicenseAndCollaborativeAgreementAmendmentMember" xlink:to="ptgx_LicenseAndCollaborativeAgreementAmendmentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_LicenseAndCollaborativeAgreementAmendmentMember_lbl" xml:lang="en-US">Represents information pertaining to license and collaborative amended agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_LicenseAndCollaborativeAgreementAmendmentMember_lbl" xml:lang="en-US">License And Collaborative Agreement Amendment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_LicenseAndCollaborativeAgreementAmendmentMember_lbl" xml:lang="en-US">First Amendment</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_AmendedCollaborationAgreementTrancheOneMember" xlink:label="ptgx_AmendedCollaborationAgreementTrancheOneMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_AmendedCollaborationAgreementTrancheOneMember" xlink:to="ptgx_AmendedCollaborationAgreementTrancheOneMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_AmendedCollaborationAgreementTrancheOneMember_lbl" xml:lang="en-US">Represents the Amended first opt-in license rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_AmendedCollaborationAgreementTrancheOneMember_lbl" xml:lang="en-US">Amended Collaboration Agreement Tranche One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_AmendedCollaborationAgreementTrancheOneMember_lbl" xml:lang="en-US">Amended First Opt-in</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_AmendedSecondOptInMember" xlink:label="ptgx_AmendedSecondOptInMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_AmendedSecondOptInMember" xlink:to="ptgx_AmendedSecondOptInMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_AmendedSecondOptInMember_lbl" xml:lang="en-US">Represents the Amended Second Opt-in license rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_AmendedSecondOptInMember_lbl" xml:lang="en-US">Amended Second Opt In [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_AmendedSecondOptInMember_lbl" xml:lang="en-US">Amended Second Opt-in</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_EstimatedVariableConsiderationMember" xlink:label="ptgx_EstimatedVariableConsiderationMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_EstimatedVariableConsiderationMember" xlink:to="ptgx_EstimatedVariableConsiderationMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_EstimatedVariableConsiderationMember_lbl" xml:lang="en-US">Represents the estimated variable consideration.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_EstimatedVariableConsiderationMember_lbl" xml:lang="en-US">Estimated Variable Consideration [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_EstimatedVariableConsiderationMember_lbl" xml:lang="en-US">Estimated variable consideration</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_LicenseAndCollaborativeRevenueMember" xlink:label="ptgx_LicenseAndCollaborativeRevenueMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_LicenseAndCollaborativeRevenueMember" xlink:to="ptgx_LicenseAndCollaborativeRevenueMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_LicenseAndCollaborativeRevenueMember_lbl" xml:lang="en-US">Represents information pertaining to license and collaborative revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_LicenseAndCollaborativeRevenueMember_lbl" xml:lang="en-US">License And Collaborative Revenue [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_LicenseAndCollaborativeRevenueMember_lbl" xml:lang="en-US">License and Collaborative Revenue</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_UpfrontCashPaymentMember" xlink:label="ptgx_UpfrontCashPaymentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_UpfrontCashPaymentMember" xlink:to="ptgx_UpfrontCashPaymentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_UpfrontCashPaymentMember_lbl" xml:lang="en-US">Represents the upfront cash payment received as part of the license and collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_UpfrontCashPaymentMember_lbl" xml:lang="en-US">Upfront Cash Payment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_UpfrontCashPaymentMember_lbl" xml:lang="en-US">Upfront cash payment</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DevelopmentRegulatoryAndSalesMilestonePaymentsMember" xlink:label="ptgx_DevelopmentRegulatoryAndSalesMilestonePaymentsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_DevelopmentRegulatoryAndSalesMilestonePaymentsMember" xlink:to="ptgx_DevelopmentRegulatoryAndSalesMilestonePaymentsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_DevelopmentRegulatoryAndSalesMilestonePaymentsMember_lbl" xml:lang="en-US">Represents payments from development, regulatory and sales milestones related to a collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_DevelopmentRegulatoryAndSalesMilestonePaymentsMember_lbl" xml:lang="en-US">Development Regulatory And Sales Milestone Payments [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_DevelopmentRegulatoryAndSalesMilestonePaymentsMember_lbl" xml:lang="en-US">Development, regulatory and sales milestone payments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialServiceOtherMember" xlink:label="us-gaap_FinancialServiceOtherMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialServiceOtherMember" xlink:to="us-gaap_FinancialServiceOtherMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialServiceOtherMember_lbl" xml:lang="en-US">Financial Service Other [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinancialServiceOtherMember_lbl" xml:lang="en-US">Additional services</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_MilestonePaymentsMember" xlink:label="ptgx_MilestonePaymentsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_MilestonePaymentsMember" xlink:to="ptgx_MilestonePaymentsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_MilestonePaymentsMember_lbl" xml:lang="en-US">At the inception of each arrangement that includes development, regulatory or commercial milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_MilestonePaymentsMember_lbl" xml:lang="en-US">Milestone Payments [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_MilestonePaymentsMember_lbl" xml:lang="en-US">Milestone payment</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_Ptg200Phase3CdClinicalTrialPrimaryClinicalEndpointMember" xlink:label="ptgx_Ptg200Phase3CdClinicalTrialPrimaryClinicalEndpointMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_Ptg200Phase3CdClinicalTrialPrimaryClinicalEndpointMember" xlink:to="ptgx_Ptg200Phase3CdClinicalTrialPrimaryClinicalEndpointMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_Ptg200Phase3CdClinicalTrialPrimaryClinicalEndpointMember_lbl" xml:lang="en-US">Represents the phase 3 CD clinical trial reaching a primary clinical endpoint with respect to the PTG-200.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_Ptg200Phase3CdClinicalTrialPrimaryClinicalEndpointMember_lbl" xml:lang="en-US">Ptg200 Phase3 Cd Clinical Trial Primary Clinical Endpoint [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_Ptg200Phase3CdClinicalTrialPrimaryClinicalEndpointMember_lbl" xml:lang="en-US">PTG-200, Phase 3 CD Clinical Trial Primary Clinical Endpoint</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember" xlink:label="ptgx_SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember" xlink:to="ptgx_SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember_lbl" xml:lang="en-US">Represents the phase 3 CD clinical trial reaching a primary clinical endpoint with respect to the second-generation analog.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember_lbl" xml:lang="en-US">Second Generation Analog Phase3 Cd Clinical Trial Primary Clinical Endpoint [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember_lbl" xml:lang="en-US">Second-Generation Analog, Phase 3 CD Clinical Trial Primary Clinical Endpoint [Member]</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_SecondGenerationAnalogPhase2CdClinicalTrialPrimaryClinicalEndpointMember" xlink:label="ptgx_SecondGenerationAnalogPhase2CdClinicalTrialPrimaryClinicalEndpointMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_SecondGenerationAnalogPhase2CdClinicalTrialPrimaryClinicalEndpointMember" xlink:to="ptgx_SecondGenerationAnalogPhase2CdClinicalTrialPrimaryClinicalEndpointMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_SecondGenerationAnalogPhase2CdClinicalTrialPrimaryClinicalEndpointMember_lbl" xml:lang="en-US">Represents the phase 2 CD clinical trial reaching a primary clinical endpoint with respect to the second-generation analog.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_SecondGenerationAnalogPhase2CdClinicalTrialPrimaryClinicalEndpointMember_lbl" xml:lang="en-US">Second Generation Analog Phase2 Cd Clinical Trial Primary Clinical Endpoint [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_SecondGenerationAnalogPhase2CdClinicalTrialPrimaryClinicalEndpointMember_lbl" xml:lang="en-US">Second Generation Analog Phase 2 Cd Clinical Trial Primary Clinical</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_SecondGenerationPhase2bMilestonePaymentMember" xlink:label="ptgx_SecondGenerationPhase2bMilestonePaymentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_SecondGenerationPhase2bMilestonePaymentMember" xlink:to="ptgx_SecondGenerationPhase2bMilestonePaymentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_SecondGenerationPhase2bMilestonePaymentMember_lbl" xml:lang="en-US">Represents the information pertaining to second generation phase 2b milestone payment for clinical trail for CD for a second generation product</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_SecondGenerationPhase2bMilestonePaymentMember_lbl" xml:lang="en-US">Second Generation Phase2b Milestone Payment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_SecondGenerationPhase2bMilestonePaymentMember_lbl" xml:lang="en-US">Second-Generation Phase 2b Milestone Payment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US">Fair Value Measurement Frequency [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Fair Value Measurements Recurring [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Recurring</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value, Hierarchy [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Measurements Fair Value Hierarchy [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value Inputs Level1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Level 1</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value Inputs Level2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Level 2</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xml:lang="en-US">Investment Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xml:lang="en-US">Investment Type Categorization [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xml:lang="en-US">Investments [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xml:lang="en-US">Corporate Debt Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xml:lang="en-US">Corporate debt securities</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_UsTreasuryAndAgencySecuritiesMember" xlink:label="ptgx_UsTreasuryAndAgencySecuritiesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_UsTreasuryAndAgencySecuritiesMember" xlink:to="ptgx_UsTreasuryAndAgencySecuritiesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_UsTreasuryAndAgencySecuritiesMember_lbl" xml:lang="en-US">This category includes information about debt securities issued by the United States Department of the Treasury and Agency.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_UsTreasuryAndAgencySecuritiesMember_lbl" xml:lang="en-US">Us Treasury And Agency Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_UsTreasuryAndAgencySecuritiesMember_lbl" xml:lang="en-US">U.S. Treasury and agency securities</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_EntityRequiredToContinueToMakePaymentsMember" xlink:label="ptgx_EntityRequiredToContinueToMakePaymentsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_EntityRequiredToContinueToMakePaymentsMember" xlink:to="ptgx_EntityRequiredToContinueToMakePaymentsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_EntityRequiredToContinueToMakePaymentsMember_lbl" xml:lang="en-US">Represents information if the company is required to continue to make payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_EntityRequiredToContinueToMakePaymentsMember_lbl" xml:lang="en-US">Entity Required To Continue To Make Payments [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_EntityRequiredToContinueToMakePaymentsMember_lbl" xml:lang="en-US">Entity Required to Continue to Make Payments</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_RevenueSourceAxis" xlink:label="ptgx_RevenueSourceAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_RevenueSourceAxis" xlink:to="ptgx_RevenueSourceAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_RevenueSourceAxis_lbl" xml:lang="en-US">Information by source of revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_RevenueSourceAxis_lbl" xml:lang="en-US">Revenue Source [Axis]</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_RevenueSourceDomain" xlink:label="ptgx_RevenueSourceDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_RevenueSourceDomain" xlink:to="ptgx_RevenueSourceDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_RevenueSourceDomain_lbl" xml:lang="en-US">Major payer source of revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_RevenueSourceDomain_lbl" xml:lang="en-US">Revenue Source [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_RevenueSourceDomain_lbl" xml:lang="en-US">Revenue Source [Domain]</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_SmallBusinessInnovationResearchGrantMember" xlink:label="ptgx_SmallBusinessInnovationResearchGrantMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_SmallBusinessInnovationResearchGrantMember" xlink:to="ptgx_SmallBusinessInnovationResearchGrantMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_SmallBusinessInnovationResearchGrantMember_lbl" xml:lang="en-US">This member stands for small business innovation research grant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_SmallBusinessInnovationResearchGrantMember_lbl" xml:lang="en-US">Small Business Innovation Research Grant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_SmallBusinessInnovationResearchGrantMember_lbl" xml:lang="en-US">SBIR Grant</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DebtInstrumentRepaymentOnOrBeforeFirstAnniversaryMember" xlink:label="ptgx_DebtInstrumentRepaymentOnOrBeforeFirstAnniversaryMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_DebtInstrumentRepaymentOnOrBeforeFirstAnniversaryMember" xlink:to="ptgx_DebtInstrumentRepaymentOnOrBeforeFirstAnniversaryMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_DebtInstrumentRepaymentOnOrBeforeFirstAnniversaryMember_lbl" xml:lang="en-US">Represents the debt instrument repayment occurring through and including the first anniversary of the closing date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_DebtInstrumentRepaymentOnOrBeforeFirstAnniversaryMember_lbl" xml:lang="en-US">Debt Instrument Repayment On Or Before First Anniversary [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_DebtInstrumentRepaymentOnOrBeforeFirstAnniversaryMember_lbl" xml:lang="en-US">Debt Instrument Repayment On Or Before First Anniversary</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DebtInstrumentRepaymentBetweenFirstAndSecondAnniversaryMember" xlink:label="ptgx_DebtInstrumentRepaymentBetweenFirstAndSecondAnniversaryMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_DebtInstrumentRepaymentBetweenFirstAndSecondAnniversaryMember" xlink:to="ptgx_DebtInstrumentRepaymentBetweenFirstAndSecondAnniversaryMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_DebtInstrumentRepaymentBetweenFirstAndSecondAnniversaryMember_lbl" xml:lang="en-US">Represents the debt instrument repayment occurring after first anniversary and through and including the second anniversary of the closing date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_DebtInstrumentRepaymentBetweenFirstAndSecondAnniversaryMember_lbl" xml:lang="en-US">Debt Instrument Repayment Between First And Second Anniversary [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_DebtInstrumentRepaymentBetweenFirstAndSecondAnniversaryMember_lbl" xml:lang="en-US">Debt Instrument Repayment Between First And Second Anniversary</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DebtInstrumentRepaymentAfterSecondAnniversaryMember" xlink:label="ptgx_DebtInstrumentRepaymentAfterSecondAnniversaryMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_DebtInstrumentRepaymentAfterSecondAnniversaryMember" xlink:to="ptgx_DebtInstrumentRepaymentAfterSecondAnniversaryMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_DebtInstrumentRepaymentAfterSecondAnniversaryMember_lbl" xml:lang="en-US">Represents the debt instrument repayment occurring after second anniversary of the closing date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_DebtInstrumentRepaymentAfterSecondAnniversaryMember_lbl" xml:lang="en-US">Debt Instrument Repayment After Second Anniversary [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_DebtInstrumentRepaymentAfterSecondAnniversaryMember_lbl" xml:lang="en-US">Debt Instrument Repayment After Second Anniversary</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateAxis_lbl" xml:lang="en-US">Variable Rate [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateDomain_lbl" xml:lang="en-US">Variable Rate [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VariableRateDomain_lbl" xml:lang="en-US">Variable Rate [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrimeRateMember" xlink:to="us-gaap_PrimeRateMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrimeRateMember_lbl" xml:lang="en-US">Prime Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrimeRateMember_lbl" xml:lang="en-US">Prime Rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_TermLoanCreditAgreementMember" xlink:label="ptgx_TermLoanCreditAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_TermLoanCreditAgreementMember" xlink:to="ptgx_TermLoanCreditAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_TermLoanCreditAgreementMember_lbl" xml:lang="en-US">Represents information pertaining to term loan credit agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_TermLoanCreditAgreementMember_lbl" xml:lang="en-US">Term Loan Credit Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_TermLoanCreditAgreementMember_lbl" xml:lang="en-US">Term Loan Credit Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CA" xlink:label="stpr_CA" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_CA" xlink:to="stpr_CA_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="stpr_CA_lbl" xml:lang="en-US">C [A]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="stpr_CA_lbl" xml:lang="en-US">Newark, California</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ZealandPharmaMember" xlink:label="ptgx_ZealandPharmaMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_ZealandPharmaMember" xlink:to="ptgx_ZealandPharmaMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_ZealandPharmaMember_lbl" xml:lang="en-US">Represents information pertaining to Zealand Pharma.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_ZealandPharmaMember_lbl" xml:lang="en-US">Zealand Pharma [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_ZealandPharmaMember_lbl" xml:lang="en-US">Zealand Pharma</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_SuccessfullyDevelopAndCommercializeRusfertideComponentWithOutPartnerMember" xlink:label="ptgx_SuccessfullyDevelopAndCommercializeRusfertideComponentWithOutPartnerMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_SuccessfullyDevelopAndCommercializeRusfertideComponentWithOutPartnerMember" xlink:to="ptgx_SuccessfullyDevelopAndCommercializeRusfertideComponentWithOutPartnerMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_SuccessfullyDevelopAndCommercializeRusfertideComponentWithOutPartnerMember_lbl" xml:lang="en-US">Represents information pertaining to successfully develop and commercialize Rusfertide Component with out partner.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_SuccessfullyDevelopAndCommercializeRusfertideComponentWithOutPartnerMember_lbl" xml:lang="en-US">Successfully Develop And Commercialize Rusfertide Component With Out Partner [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_SuccessfullyDevelopAndCommercializeRusfertideComponentWithOutPartnerMember_lbl" xml:lang="en-US">Successfully develop and commercialize Rusfertide Component with out partner</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class Of Warrant Or Right [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_WarrantsPurchaseAmountPerSharePriceOneMember" xlink:label="ptgx_WarrantsPurchaseAmountPerSharePriceOneMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_WarrantsPurchaseAmountPerSharePriceOneMember" xlink:to="ptgx_WarrantsPurchaseAmountPerSharePriceOneMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_WarrantsPurchaseAmountPerSharePriceOneMember_lbl" xml:lang="en-US">Represents the first group of warrants which may be purchased at a different price than another group of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_WarrantsPurchaseAmountPerSharePriceOneMember_lbl" xml:lang="en-US">Warrants Purchase Amount Per Share Price One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_WarrantsPurchaseAmountPerSharePriceOneMember_lbl" xml:lang="en-US">Group one</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_WarrantsPurchaseAmountPerSharePriceTwoMember" xlink:label="ptgx_WarrantsPurchaseAmountPerSharePriceTwoMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_WarrantsPurchaseAmountPerSharePriceTwoMember" xlink:to="ptgx_WarrantsPurchaseAmountPerSharePriceTwoMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_WarrantsPurchaseAmountPerSharePriceTwoMember_lbl" xml:lang="en-US">Represents the second group of warrants which may be purchased at a different price than another group of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_WarrantsPurchaseAmountPerSharePriceTwoMember_lbl" xml:lang="en-US">Warrants Purchase Amount Per Share Price Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_WarrantsPurchaseAmountPerSharePriceTwoMember_lbl" xml:lang="en-US">Group two</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ExchangeAgreementMember" xlink:label="ptgx_ExchangeAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_ExchangeAgreementMember" xlink:to="ptgx_ExchangeAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_ExchangeAgreementMember_lbl" xml:lang="en-US">This member stands for exchange agreement for common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_ExchangeAgreementMember_lbl" xml:lang="en-US">Exchange Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_ExchangeAgreementMember_lbl" xml:lang="en-US">Exchange Agreement</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_AtMarketOfferingMember" xlink:label="ptgx_AtMarketOfferingMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_AtMarketOfferingMember" xlink:to="ptgx_AtMarketOfferingMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_AtMarketOfferingMember_lbl" xml:lang="en-US">The sale of newly issued shares into the secondary trading market through a designated broker-dealer at prevailing market prices.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_AtMarketOfferingMember_lbl" xml:lang="en-US">At Market Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_AtMarketOfferingMember_lbl" xml:lang="en-US">At-the-market offering (ATM)</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_BiotechnologyValueFundL.pMember" xlink:label="ptgx_BiotechnologyValueFundL.pMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_BiotechnologyValueFundL.pMember" xlink:to="ptgx_BiotechnologyValueFundL.pMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_BiotechnologyValueFundL.pMember_lbl" xml:lang="en-US">Represents Exchange Agreement with Biotechnology Value Fund, L.P</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_BiotechnologyValueFundL.pMember_lbl" xml:lang="en-US">Biotechnology Value Fund L.p [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_BiotechnologyValueFundL.pMember_lbl" xml:lang="en-US">Exchanging Stockholders</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember" xlink:label="ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember" xlink:to="ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_lbl" xml:lang="en-US">This member represents transactions associated with the Securities Purchase Agreement with certain accredited investors (each, an "Investor" and, collectively, the "Investors").</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_lbl" xml:lang="en-US">Securities Purchase Agreement With Accredited Investors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_lbl" xml:lang="en-US">Investors</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CommonStockPreferredStockAndCertainDebtSecuritiesMember" xlink:label="ptgx_CommonStockPreferredStockAndCertainDebtSecuritiesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_CommonStockPreferredStockAndCertainDebtSecuritiesMember" xlink:to="ptgx_CommonStockPreferredStockAndCertainDebtSecuritiesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_CommonStockPreferredStockAndCertainDebtSecuritiesMember_lbl" xml:lang="en-US">Represents common stock, preferred stock and certain debt securities (the "Sales Agreement").</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_CommonStockPreferredStockAndCertainDebtSecuritiesMember_lbl" xml:lang="en-US">Common Stock Preferred Stock And Certain Debt Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_CommonStockPreferredStockAndCertainDebtSecuritiesMember_lbl" xml:lang="en-US">2017 Form S-3</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember" xlink:label="ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember" xlink:to="ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember_lbl" xml:lang="en-US">Represents common stock, preferred stock, debt securities and warrants (the "2019 Form S-3").</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember_lbl" xml:lang="en-US">Common Stock Preferred Stock Debt Securities And Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember_lbl" xml:lang="en-US">2019 Form S-3</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US">Over Allotment Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US">Underwriter overallotment option</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_SalesAgreementFrom2017Member" xlink:label="ptgx_SalesAgreementFrom2017Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_SalesAgreementFrom2017Member" xlink:to="ptgx_SalesAgreementFrom2017Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_SalesAgreementFrom2017Member_lbl" xml:lang="en-US">Represents the 2017 Sales Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_SalesAgreementFrom2017Member_lbl" xml:lang="en-US">Sales Agreement From2017 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_SalesAgreementFrom2017Member_lbl" xml:lang="en-US">2017 Sales Agreement</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember" xlink:label="ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember" xlink:to="ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember_lbl" xml:lang="en-US">An arrangement whereby an employee, consultant, or member of the Board of Directors is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember_lbl" xml:lang="en-US">Employee Consultants And Directors Stock Options [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember_lbl" xml:lang="en-US">Stock options - employees, consultants, directors</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_NonEmployeeDirectorInitialStockOptionsMember" xlink:label="ptgx_NonEmployeeDirectorInitialStockOptionsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_NonEmployeeDirectorInitialStockOptionsMember" xlink:to="ptgx_NonEmployeeDirectorInitialStockOptionsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_NonEmployeeDirectorInitialStockOptionsMember_lbl" xml:lang="en-US">Represent the information pertaining to Non employee Director Initial Stock Options member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_NonEmployeeDirectorInitialStockOptionsMember_lbl" xml:lang="en-US">Non Employee Director Initial Stock Options [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_NonEmployeeDirectorInitialStockOptionsMember_lbl" xml:lang="en-US">Non Employee Director Initial Stock Options</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_NonemployeeDirectorAnnualRefresherStockOptionsMember" xlink:label="ptgx_NonemployeeDirectorAnnualRefresherStockOptionsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_NonemployeeDirectorAnnualRefresherStockOptionsMember" xlink:to="ptgx_NonemployeeDirectorAnnualRefresherStockOptionsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_NonemployeeDirectorAnnualRefresherStockOptionsMember_lbl" xml:lang="en-US">Represents the information pertaining to Non employee Director Annual Refresher Stock Options member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_NonemployeeDirectorAnnualRefresherStockOptionsMember_lbl" xml:lang="en-US">Nonemployee Director Annual Refresher Stock Options [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_NonemployeeDirectorAnnualRefresherStockOptionsMember_lbl" xml:lang="en-US">Nonemployee Director Annual Refresher Stock Options</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_StockOptionAndIncentivePlanAsAmendedAndRestated2007Member" xlink:label="ptgx_StockOptionAndIncentivePlanAsAmendedAndRestated2007Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_StockOptionAndIncentivePlanAsAmendedAndRestated2007Member" xlink:to="ptgx_StockOptionAndIncentivePlanAsAmendedAndRestated2007Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_StockOptionAndIncentivePlanAsAmendedAndRestated2007Member_lbl" xml:lang="en-US">Represents the 2007 Stock Option and Incentive Plan, as amended and restated, established in May 2007.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_StockOptionAndIncentivePlanAsAmendedAndRestated2007Member_lbl" xml:lang="en-US">Stock Option And Incentive Plan As Amended And Restated2007 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_StockOptionAndIncentivePlanAsAmendedAndRestated2007Member_lbl" xml:lang="en-US">2007 Stock Option and Incentive Plan</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_EquityIncentivePlan2016Member" xlink:label="ptgx_EquityIncentivePlan2016Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_EquityIncentivePlan2016Member" xlink:to="ptgx_EquityIncentivePlan2016Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_EquityIncentivePlan2016Member_lbl" xml:lang="en-US">Represents the 2016 Equity Incentive Plan approved by the entity's board of directors and stockholders in July 2016.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_EquityIncentivePlan2016Member_lbl" xml:lang="en-US">Equity Incentive Plan2016 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_EquityIncentivePlan2016Member_lbl" xml:lang="en-US">2016 Equity Incentive Plan</label>
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_InducementStockPlanMember" xlink:label="ptgx_InducementStockPlanMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgx_InducementStockPlanMember" xlink:to="ptgx_InducementStockPlanMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ptgx_InducementStockPlanMember_lbl" xml:lang="en-US">Represents the 2018 Inducement plan, a non-stockholder approved stock plan in order to award options and restricted stock unit awards to persons that were not previously employees or directors of the Company, or following a bona fide period of non-employment, as an inducement material to such persons entering into employment with the Company, within the meaning of Rule 5635(c)(4) of the NASDAQ Listing Rules.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgx_InducementStockPlanMember_lbl" xml:lang="en-US">Inducement Stock Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ptgx_InducementStockPlanMember_lbl" xml:lang="en-US">Restricted stock unit incentive awards granted in 2018</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US">Vesting [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US">Vesting [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US">Vesting [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US">Share Based Compensation Award Tranche Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US">Tranche two</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrincipalOwnerMember" xlink:label="us-gaap_PrincipalOwnerMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrincipalOwnerMember" xlink:to="us-gaap_PrincipalOwnerMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrincipalOwnerMember_lbl" xml:lang="en-US">Principal Owner [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrincipalOwnerMember_lbl" xml:lang="en-US">Stockholders possessing more than 10% of the total combined voting power</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Domestic Country [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Federal</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoteWarrantMember" xlink:label="us-gaap_NoteWarrantMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoteWarrantMember" xlink:to="us-gaap_NoteWarrantMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoteWarrantMember_lbl" xml:lang="en-US">Note Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoteWarrantMember_lbl" xml:lang="en-US">Common stock warrants</label>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>21
<FILENAME>ptgx-20201231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7713.40453 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/10/2021 9:29:12 PM-->
<!--Modified on: 3/10/2021 9:29:12 PM-->
<linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheetsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#StatementConsolidatedStatementsOfComprehensiveLoss" roleURI="http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#StatementConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfStockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureOrganizationAndDescriptionOfBusiness" roleURI="http://www.protagonist-inc.com/role/DisclosureOrganizationAndDescriptionOfBusiness" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPolicies" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureLicenseAndCollaborationAgreement" roleURI="http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreement" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureFairValueMeasurements" roleURI="http://www.protagonist-inc.com/role/DisclosureFairValueMeasurements" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureCashEquivalentsAndMarketableSecurities" roleURI="http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecurities" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureBalanceSheetComponents" roleURI="http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponents" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureResearchCollaborationAndLicenseAgreement" roleURI="http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreement" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureGovernmentPrograms" roleURI="http://www.protagonist-inc.com/role/DisclosureGovernmentPrograms" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureDebt" roleURI="http://www.protagonist-inc.com/role/DisclosureDebt" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureLeases" roleURI="http://www.protagonist-inc.com/role/DisclosureLeases" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingencies" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureStockholdersEquity" roleURI="http://www.protagonist-inc.com/role/DisclosureStockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureEquityPlans" roleURI="http://www.protagonist-inc.com/role/DisclosureEquityPlans" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#Disclosure401KPlan" roleURI="http://www.protagonist-inc.com/role/Disclosure401KPlan" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureIncomeTaxes" roleURI="http://www.protagonist-inc.com/role/DisclosureIncomeTaxes" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureNetLossPerShare" roleURI="http://www.protagonist-inc.com/role/DisclosureNetLossPerShare" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureRestructuring" roleURI="http://www.protagonist-inc.com/role/DisclosureRestructuring" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureLicenseAndCollaborationAgreementTables" roleURI="http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementTables" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureFairValueMeasurementsTables" roleURI="http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsTables" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureCashEquivalentsAndMarketableSecuritiesTables" roleURI="http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesTables" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureBalanceSheetComponentsTables" roleURI="http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsTables" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureDebtTables" roleURI="http://www.protagonist-inc.com/role/DisclosureDebtTables" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureLeasesTables" roleURI="http://www.protagonist-inc.com/role/DisclosureLeasesTables" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureEquityPlansTables" roleURI="http://www.protagonist-inc.com/role/DisclosureEquityPlansTables" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.protagonist-inc.com/role/DisclosureIncomeTaxesTables" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureNetLossPerShareTables" roleURI="http://www.protagonist-inc.com/role/DisclosureNetLossPerShareTables" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureOrganizationAndDescriptionOfBusinessLiquidityDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureOrganizationAndDescriptionOfBusinessLiquidityDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAndImpairmentOfLongLivedAssetsDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAndImpairmentOfLongLivedAssetsDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesIncomeTaxesDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesIncomeTaxesDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureLicenseAndCollaborationAgreementDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureFairValueMeasurementsDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureCashEquivalentsAndMarketableSecuritiesClassificationOfCashEquivalentsAndMarketableSecuritiesDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesClassificationOfCashEquivalentsAndMarketableSecuritiesDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureBalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureBalanceSheetComponentsAccruedExpensesAndOtherPayablesDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsAccruedExpensesAndOtherPayablesDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureResearchCollaborationAndLicenseAgreementDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreementDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureGovernmentProgramsDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureGovernmentProgramsDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureDebtDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureDebtDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureDebtLongTermDebtDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureDebtLongTermDebtDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureLeasesAgreementDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureLeasesAgreementDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureLeasesWeightedAverageLeaseTermAndDiscountRateDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureLeasesWeightedAverageLeaseTermAndDiscountRateDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureLeasesMinimumLeasePaymentsDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureLeasesMinimumLeasePaymentsDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureLeasesLeaseCostInformationDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureLeasesLeaseCostInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureLeasesSupplementalBalanceSheetInformationDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureLeasesCashFlowInformationDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureLeasesCashFlowInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingenciesDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureStockholdersEquityDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureEquityPlansNarrativeDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureEquityPlansActivityDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureEquityPlansActivityDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureEquityPlansEmployeeStockOptionsValuationAssumptionsDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockOptionsValuationAssumptionsDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureEquityPlansRestrictedStockUnitsDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureEquityPlansRestrictedStockUnitsDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureEquityPlansEmployeeStockPurchasePlanDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockPurchasePlanDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureEquityPlansStockBasedCompensationExpenseDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureEquityPlansStockBasedCompensationExpenseDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureIncomeTaxesProvisionAndComponentsOfNetLossDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureIncomeTaxesProvisionAndComponentsOfNetLossDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureIncomeTaxesComponentsOfFederalStateAndForeignIncomeTaxExpenseBenefitDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureIncomeTaxesComponentsOfFederalStateAndForeignIncomeTaxExpenseBenefitDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureIncomeTaxesProvisionDifferenceFromFederalStatutoryRateDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureIncomeTaxesProvisionDifferenceFromFederalStatutoryRateDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndValuationAllowanceDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndValuationAllowanceDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureIncomeTaxesResearchAndDevelopmentTaxCreditCarryforwardsDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureIncomeTaxesResearchAndDevelopmentTaxCreditCarryforwardsDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureIncomeTaxes2020TaxLawUpdatesDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureIncomeTaxes2020TaxLawUpdatesDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureNetLossPerShareComputationDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureNetLossPerShareComputationDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" />
  <roleRef xlink:type="simple" xlink:href="ptgx-20201231.xsd#DisclosureRestructuringDetails" roleURI="http://www.protagonist-inc.com/role/DisclosureRestructuringDetails" />
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637510085486190895" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_637510085486190895" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_637510085486205760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport_637510085486205760" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_637510085486205760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_637510085486205760" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637510085486205760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_637510085486205760" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637510085486205760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_637510085486205760" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637510085486205760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_637510085486205760" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637510085486205760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637510085486205760" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637510085486205760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637510085486205760" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637510085486210910" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_637510085486210910" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637510085486210910" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_637510085486210910" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637510085486210910" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_637510085486210910" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637510085486210910" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_637510085486210910" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637510085486210910" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_637510085486210910" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637510085486210910" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_637510085486210910" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637510085486210910" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_637510085486210910" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637510085486210910" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_637510085486210910" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637510085486210910" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_637510085486210910" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_637510085486210910" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_637510085486210910" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_637510085486210910" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_637510085486210910" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_637510085486210910" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_637510085486210910" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_637510085486220894" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_637510085486220894" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_637510085486220894" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_637510085486220894" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_637510085486220894" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod_637510085486220894" order="23" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_637510085486220894" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_637510085486220894" order="24" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_637510085486220894" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag_637510085486220894" order="25" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637510085486220894" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637510085486220894" order="26" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_637510085486220894" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_637510085486220894" order="27" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_637510085486220894" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat_637510085486220894" order="28" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_637510085486220894" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_637510085486220894" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_637510085486230895" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_637510085486230895" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_637510085486230895" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_637510085486230895" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_637510085486230895" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_637510085486230895" order="32" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637510085486230895" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_637510085486230895" order="33" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637510085486230895" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_637510085486230895" order="34" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Balance Sheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_637510085486230895" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_637510085486230895" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_637510085486230895" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637510085486230895" xlink:to="us-gaap_AssetsCurrentAbstract_637510085486230895" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637510085486240907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637510085486230895" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637510085486240907" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent_637510085486240907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637510085486230895" xlink:to="us-gaap_MarketableSecuritiesCurrent_637510085486240907" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent_637510085486240907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637510085486230895" xlink:to="us-gaap_RestrictedCashCurrent_637510085486240907" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_637510085486240907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637510085486230895" xlink:to="us-gaap_DueFromRelatedPartiesCurrent_637510085486240907" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="us-gaap_IncomeTaxesReceivable_637510085486240907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637510085486230895" xlink:to="us-gaap_IncomeTaxesReceivable_637510085486240907" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637510085486240907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637510085486230895" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637510085486240907" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637510085486240907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637510085486230895" xlink:to="us-gaap_AssetsCurrent_637510085486240907" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_637510085486240907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637510085486230895" xlink:to="us-gaap_MarketableSecuritiesNoncurrent_637510085486240907" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637510085486240907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637510085486230895" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637510085486240907" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_637510085486240907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637510085486230895" xlink:to="us-gaap_RestrictedCashNoncurrent_637510085486240907" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637510085486240907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637510085486230895" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637510085486240907" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_637510085486240907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637510085486230895" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_637510085486240907" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_637510085486240907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637510085486230895" xlink:to="us-gaap_Assets_637510085486240907" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637510085486240907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637510085486240907" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_637510085486250896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637510085486240907" xlink:to="us-gaap_LiabilitiesCurrentAbstract_637510085486250896" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637510085486250896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637510085486250896" xlink:to="us-gaap_AccountsPayableCurrent_637510085486250896" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent_637510085486250896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637510085486250896" xlink:to="us-gaap_DueToRelatedPartiesCurrent_637510085486250896" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities_637510085486250896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637510085486250896" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities_637510085486250896" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_637510085486250896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637510085486250896" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_637510085486250896" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637510085486250896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637510085486250896" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637510085486250896" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637510085486250896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637510085486250896" xlink:to="us-gaap_LiabilitiesCurrent_637510085486250896" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_637510085486250896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637510085486240907" xlink:to="us-gaap_LongTermDebt_637510085486250896" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_637510085486250896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637510085486240907" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_637510085486250896" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637510085486250896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637510085486240907" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637510085486250896" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_637510085486260892" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637510085486240907" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_637510085486260892" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637510085486260892" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637510085486240907" xlink:to="us-gaap_Liabilities_637510085486260892" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_637510085486260892" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637510085486240907" xlink:to="us-gaap_CommitmentsAndContingencies_637510085486260892" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_637510085486260892" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637510085486240907" xlink:to="us-gaap_StockholdersEquityAbstract_637510085486260892" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_637510085486260892" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637510085486260892" xlink:to="us-gaap_PreferredStockValue_637510085486260892" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637510085486260892" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637510085486260892" xlink:to="us-gaap_CommonStockValue_637510085486260892" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_637510085486260892" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637510085486260892" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_637510085486260892" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637510085486260892" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637510085486260892" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637510085486260892" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637510085486270896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637510085486260892" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637510085486270896" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637510085486270896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637510085486260892" xlink:to="us-gaap_StockholdersEquity_637510085486270896" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637510085486270896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637510085486240907" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_637510085486270896" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - Consolidated Balance Sheets (Parenthetical)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_637510085486270896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_637510085486270896" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_637510085486270896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_637510085486270896" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_637510085486270896" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued_637510085486270896" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_637510085486280909" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_637510085486280909" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637510085486280909" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637510085486280909" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637510085486280909" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_637510085486280909" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637510085486280909" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_637510085486280909" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637510085486280909" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_637510085486280909" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statements of Operations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_RevenueFromContractWithCustomerIncludingCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:label="ptgx_RevenueFromContractWithCustomerIncludingCumulativeCatchUpAdjustmentToRevenueModificationOfContract_637510085486280909" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="ptgx_RevenueFromContractWithCustomerIncludingCumulativeCatchUpAdjustmentToRevenueModificationOfContract_637510085486280909" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_637510085486280909" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_637510085486280909" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637510085486280909" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637510085486280909" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637510085486280909" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637510085486280909" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637510085486280909" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637510085486280909" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_637510085486280909" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637510085486280909" xlink:to="us-gaap_OperatingExpenses_637510085486280909" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637510085486280909" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss_637510085486280909" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_637510085486280909" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_InvestmentIncomeInterest_637510085486280909" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_637510085486280909" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_InterestExpense_637510085486280909" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_637510085486280909" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_637510085486280909" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_637510085486290907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_637510085486290907" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637510085486290907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637510085486290907" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637510085486290907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637510085486290907" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637510085486290907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_637510085486290907" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_637510085486290907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_637510085486290907" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_637510085486290907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_637510085486290907" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended" xlink:title="00300 - Statement - Consolidated Statements of Comprehensive Loss">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637510085486290907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss_637510085486290907" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract_637510085486290907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract_637510085486290907" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_637510085486290907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract_637510085486290907" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_637510085486290907" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_637510085486290907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract_637510085486290907" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_637510085486290907" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_637510085486290907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_637510085486290907" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statements of Stockholders' Equity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637510085486350898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_637510085486350898" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637510085486350898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637510085486350898" xlink:to="us-gaap_StatementEquityComponentsAxis_637510085486350898" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637510085486350898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637510085486350898" xlink:to="us-gaap_CommonStockMember_637510085486350898" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_637510085486350898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637510085486350898" xlink:to="us-gaap_AdditionalPaidInCapitalMember_637510085486350898" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_637510085486350898" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637510085486350898" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_637510085486350898" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_637510085486360916" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637510085486350898" xlink:to="us-gaap_RetainedEarningsMember_637510085486360916" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637510085486360916" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637510085486350898" xlink:to="us-gaap_EquityComponentDomain_637510085486360916" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637510085486360916" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637510085486350898" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637510085486360916" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_AtMarketingOfferingMember" xlink:label="ptgx_AtMarketingOfferingMember_637510085486360916" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637510085486360916" xlink:to="ptgx_AtMarketingOfferingMember_637510085486360916" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637510085486360916" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637510085486360916" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637510085486360916" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637510085486360916" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637510085486350898" xlink:to="us-gaap_StatementLineItems_637510085486360916" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637510085486360916" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637510085486360916" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637510085486360916" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637510085486360916" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637510085486360916" xlink:to="us-gaap_StockholdersEquity_637510085486360916" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637510085486360916" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637510085486360916" xlink:to="us-gaap_CommonStockSharesOutstanding_637510085486360916" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_637510085486360916" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637510085486360916" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_637510085486360916" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637510085486360916" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_637510085486360916" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637510085486360916" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants" xlink:label="ptgx_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants_637510085486360916" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637510085486360916" xlink:to="ptgx_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants_637510085486360916" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants" xlink:label="ptgx_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants_637510085486360916" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants_637510085486360916" xlink:to="ptgx_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants_637510085486360916" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_637510085486370903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637510085486360916" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_637510085486370903" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_637510085486370903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_637510085486370903" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_637510085486370903" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_637510085486370903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637510085486360916" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_637510085486370903" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_637510085486370903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_637510085486370903" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_637510085486370903" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_StockWarrantIssuedDuringPeriodValueInExchangeForRetirementOfCommonStock" xlink:label="ptgx_StockWarrantIssuedDuringPeriodValueInExchangeForRetirementOfCommonStock_637510085486370903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637510085486360916" xlink:to="ptgx_StockWarrantIssuedDuringPeriodValueInExchangeForRetirementOfCommonStock_637510085486370903" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="ptgx_StockIssuedDuringPeriodValueWarrantsExercised_637510085486370903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637510085486360916" xlink:to="ptgx_StockIssuedDuringPeriodValueWarrantsExercised_637510085486370903" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="ptgx_StockIssuedDuringPeriodSharesWarrantsExercised_637510085486370903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_StockIssuedDuringPeriodValueWarrantsExercised_637510085486370903" xlink:to="ptgx_StockIssuedDuringPeriodSharesWarrantsExercised_637510085486370903" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637510085486370903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637510085486360916" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637510085486370903" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_637510085486370903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637510085486360916" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_637510085486370903" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637510085486380903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637510085486360916" xlink:to="us-gaap_NetIncomeLoss_637510085486380903" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637510085486380903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637510085486360916" xlink:to="us-gaap_StockholdersEquity_637510085486380903" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637510085486380903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637510085486360916" xlink:to="us-gaap_CommonStockSharesOutstanding_637510085486380903" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00500 - Statement - Consolidated Statements of Cash Flows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637510085486380903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable_637510085486380903" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637510085486380903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637510085486380903" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637510085486380903" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637510085486380903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637510085486380903" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637510085486380903" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_637510085486380903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637510085486380903" xlink:to="us-gaap_IPOMember_637510085486380903" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_AtMarketingOfferingMember" xlink:label="ptgx_AtMarketingOfferingMember_637510085486380903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637510085486380903" xlink:to="ptgx_AtMarketingOfferingMember_637510085486380903" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_637510085486380903" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637510085486380903" xlink:to="us-gaap_BalanceSheetLocationAxis_637510085486380903" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_637510085486390918" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis_637510085486380903" xlink:to="us-gaap_BalanceSheetLocationDomain_637510085486390918" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_AccruedLiabilitiesAndOtherPayablesMember" xlink:label="ptgx_AccruedLiabilitiesAndOtherPayablesMember_637510085486390918" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain_637510085486390918" xlink:to="ptgx_AccruedLiabilitiesAndOtherPayablesMember_637510085486390918" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_637510085486390918" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain_637510085486390918" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_637510085486390918" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637510085486390918" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637510085486380903" xlink:to="us-gaap_StatementLineItems_637510085486390918" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637510085486390918" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637510085486390918" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637510085486390918" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637510085486390918" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637510085486390918" xlink:to="us-gaap_ProfitLoss_637510085486390918" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637510085486390918" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637510085486390918" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637510085486390918" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637510085486390918" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637510085486390918" xlink:to="us-gaap_ShareBasedCompensation_637510085486390918" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_OperatingLeaseRightOfUseAssetAmortization" xlink:label="ptgx_OperatingLeaseRightOfUseAssetAmortization_637510085486390918" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637510085486390918" xlink:to="ptgx_OperatingLeaseRightOfUseAssetAmortization_637510085486390918" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_637510085486390918" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637510085486390918" xlink:to="us-gaap_DepreciationDepletionAndAmortization_637510085486390918" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_637510085486390918" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637510085486390918" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_637510085486390918" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_637510085486390918" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637510085486390918" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_637510085486390918" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee" xlink:label="ptgx_AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee_637510085486400901" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637510085486390918" xlink:to="ptgx_AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee_637510085486400901" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637510085486400901" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637510085486390918" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637510085486400901" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxCreditsAndAdjustments" xlink:label="us-gaap_IncomeTaxCreditsAndAdjustments_637510085486400901" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637510085486390918" xlink:to="us-gaap_IncomeTaxCreditsAndAdjustments_637510085486400901" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637510085486400901" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637510085486390918" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637510085486400901" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_637510085486400901" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637510085486400901" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_637510085486400901" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_637510085486400901" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637510085486400901" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_637510085486400901" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637510085486400901" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637510085486400901" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637510085486400901" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_637510085486400901" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637510085486400901" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_637510085486400901" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_637510085486400901" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637510085486400901" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_637510085486400901" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_637510085486400901" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637510085486400901" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_637510085486400901" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637510085486410904" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637510085486400901" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637510085486410904" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="ptgx_IncreaseDecreaseInOperatingLeaseLiability_637510085486410904" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637510085486400901" xlink:to="ptgx_IncreaseDecreaseInOperatingLeaseLiability_637510085486410904" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_637510085486410904" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637510085486400901" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_637510085486410904" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637510085486410904" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637510085486390918" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637510085486410904" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637510085486410904" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637510085486390918" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637510085486410904" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_637510085486410904" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637510085486410904" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_637510085486410904" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_637510085486410904" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637510085486410904" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_637510085486410904" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637510085486410904" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637510085486410904" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637510085486410904" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637510085486420906" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637510085486410904" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637510085486420906" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637510085486420906" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637510085486390918" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637510085486420906" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637510085486420906" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637510085486420906" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637510085486420906" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ProceedsFromIssuanceOfCommonStockAndWarrantsInPrivatePlacementNetOfIssuanceCosts" xlink:label="ptgx_ProceedsFromIssuanceOfCommonStockAndWarrantsInPrivatePlacementNetOfIssuanceCosts_637510085486420906" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637510085486420906" xlink:to="ptgx_ProceedsFromIssuanceOfCommonStockAndWarrantsInPrivatePlacementNetOfIssuanceCosts_637510085486420906" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_637510085486420906" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637510085486420906" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_637510085486420906" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_637510085486420906" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637510085486420906" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_637510085486420906" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_637510085486420906" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637510085486420906" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_637510085486420906" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_637510085486430905" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637510085486420906" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_637510085486430905" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt_637510085486430905" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637510085486420906" xlink:to="us-gaap_RepaymentsOfLongTermDebt_637510085486430905" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637510085486430905" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637510085486420906" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637510085486430905" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637510085486430905" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637510085486390918" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637510085486430905" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637510085486430905" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637510085486390918" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637510085486430905" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637510085486430905" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637510085486390918" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637510085486430905" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637510085486440905" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637510085486390918" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637510085486440905" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_637510085486440905" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637510085486390918" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_637510085486440905" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_637510085486440905" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637510085486440905" xlink:to="us-gaap_InterestPaidNet_637510085486440905" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_637510085486440905" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637510085486390918" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_637510085486440905" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_637510085486440905" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_637510085486440905" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_637510085486440905" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_637510085486440905" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_637510085486440905" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_637510085486440905" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant" xlink:label="ptgx_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant_637510085486450902" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_637510085486440905" xlink:to="ptgx_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant_637510085486450902" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureOrganizationAndDescriptionOfBusiness" xlink:type="extended" xlink:title="10101 - Disclosure - Organization and Description of Business">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_637510085486450902" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_637510085486450902" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - Summary of Significant Accounting Policies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_637510085486460921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_637510085486460921" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreement" xlink:type="extended" xlink:title="10301 - Disclosure - License and Collaboration Agreement">
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CollaborativeArrangementDisclosureAbstract" xlink:label="ptgx_CollaborativeArrangementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637510085486460921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_CollaborativeArrangementDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637510085486460921" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637510085486460921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637510085486460921" xlink:to="us-gaap_TypeOfArrangementAxis_637510085486460921" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637510085486460921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637510085486460921" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637510085486460921" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_JanssenLicenseAndCollaborationAgreement26May2017Member" xlink:label="ptgx_JanssenLicenseAndCollaborationAgreement26May2017Member_637510085486460921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637510085486460921" xlink:to="ptgx_JanssenLicenseAndCollaborationAgreement26May2017Member_637510085486460921" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637510085486460921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637510085486460921" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637510085486460921" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_637510085486460921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637510085486460921" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_637510085486460921" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureFairValueMeasurements" xlink:type="extended" xlink:title="10401 - Disclosure - Fair Value Measurements">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_637510085486460921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_637510085486460921" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecurities" xlink:type="extended" xlink:title="10501 - Disclosure - Cash Equivalents and Marketable Securities">
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_637510085486470921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_637510085486470921" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponents" xlink:type="extended" xlink:title="10601 - Disclosure - Balance Sheet Components">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_637510085486470921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_637510085486470921" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreement" xlink:type="extended" xlink:title="10701 - Disclosure - Research Collaboration and License Agreement">
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ResearchCollaborationAndLicenseAgreementDisclosureAbstract" xlink:label="ptgx_ResearchCollaborationAndLicenseAgreementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637510085486470921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_ResearchCollaborationAndLicenseAgreementDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637510085486470921" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637510085486470921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637510085486470921" xlink:to="us-gaap_TypeOfArrangementAxis_637510085486470921" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637510085486470921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637510085486470921" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637510085486470921" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member" xlink:label="ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member_637510085486470921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637510085486470921" xlink:to="ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member_637510085486470921" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637510085486470921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637510085486470921" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637510085486470921" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_637510085486470921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637510085486470921" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_637510085486470921" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureGovernmentPrograms" xlink:type="extended" xlink:title="10801 - Disclosure - Government Programs">
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_GovernmentProgramsAbstract" xlink:label="ptgx_GovernmentProgramsAbstract" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_GovernmentProgramsDisclosureTextBlock" xlink:label="ptgx_GovernmentProgramsDisclosureTextBlock_637510085486480924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_GovernmentProgramsAbstract" xlink:to="ptgx_GovernmentProgramsDisclosureTextBlock_637510085486480924" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureDebt" xlink:type="extended" xlink:title="10901 - Disclosure - Debt">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock_637510085486480924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock_637510085486480924" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureLeases" xlink:type="extended" xlink:title="11001 - Disclosure - Leases">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_637510085486480924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_637510085486480924" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="11101 - Disclosure - Commitments and Contingencies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637510085486480924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637510085486480924" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureStockholdersEquity" xlink:type="extended" xlink:title="11201 - Disclosure - Stockholders' Equity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637510085486490923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637510085486490923" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureEquityPlans" xlink:type="extended" xlink:title="11301 - Disclosure - Equity Plans">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_637510085486490923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_637510085486490923" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/Disclosure401KPlan" xlink:type="extended" xlink:title="11401 - Disclosure - 401(k) Plan">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_637510085486490923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_637510085486490923" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="11501 - Disclosure - Income Taxes">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_637510085486500921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_637510085486500921" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureNetLossPerShare" xlink:type="extended" xlink:title="11601 - Disclosure - Net Loss per Share">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_637510085486500921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_637510085486500921" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureRestructuring" xlink:type="extended" xlink:title="11701 - Disclosure - Restructuring">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_637510085486500921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_637510085486500921" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - Summary of Significant Accounting Policies (Policies)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock_637510085486500921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock_637510085486500921" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_637510085486510922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_637510085486510922" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_637510085486510922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk_637510085486510922" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_637510085486510922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_637510085486510922" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_637510085486510922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_637510085486510922" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637510085486510922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637510085486510922" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy_637510085486510922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy_637510085486510922" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_637510085486510922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_637510085486510922" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_637510085486510922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_637510085486510922" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_637510085486510922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_637510085486510922" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_637510085486510922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_637510085486510922" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock_637510085486510922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock_637510085486510922" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_637510085486510922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_637510085486510922" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_637510085486510922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_637510085486510922" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_637510085486510922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_637510085486510922" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_637510085486520907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_637510085486520907" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ResearchAndDevelopmentIncentiveGrantPolicyTextBlock" xlink:label="ptgx_ResearchAndDevelopmentIncentiveGrantPolicyTextBlock_637510085486520907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ptgx_ResearchAndDevelopmentIncentiveGrantPolicyTextBlock_637510085486520907" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_SmallBusinessInnovationResearchSbirGrantsPolicyTextBlock" xlink:label="ptgx_SmallBusinessInnovationResearchSbirGrantsPolicyTextBlock_637510085486520907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ptgx_SmallBusinessInnovationResearchSbirGrantsPolicyTextBlock_637510085486520907" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_637510085486520907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_637510085486520907" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_637510085486520907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_637510085486520907" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637510085486520907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637510085486520907" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30203 - Disclosure - Summary of Significant Accounting Policies (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_637510085486520907" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_637510085486520907" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementTables" xlink:type="extended" xlink:title="30303 - Disclosure - License and Collaboration Agreement (Tables)">
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CollaborativeArrangementDisclosureAbstract" xlink:label="ptgx_CollaborativeArrangementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_637510085486530921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_CollaborativeArrangementDisclosureAbstract" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_637510085486530921" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsTables" xlink:type="extended" xlink:title="30403 - Disclosure - Fair Value Measurements (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_637510085486530921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_637510085486530921" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesTables" xlink:type="extended" xlink:title="30503 - Disclosure - Cash Equivalents and Marketable Securities (Tables)">
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock_637510085486530921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTextBlock_637510085486530921" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsTables" xlink:type="extended" xlink:title="30603 - Disclosure - Balance Sheet Components (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_637510085486540922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_637510085486540922" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_637510085486540922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_637510085486540922" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_637510085486540922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_637510085486540922" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureDebtTables" xlink:type="extended" xlink:title="30903 - Disclosure - Debt (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_637510085486540922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_637510085486540922" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureLeasesTables" xlink:type="extended" xlink:title="31003 - Disclosure - Leases (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_LeaseQuantitativeDisclosureTableTextBlock" xlink:label="ptgx_LeaseQuantitativeDisclosureTableTextBlock_637510085486540922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="ptgx_LeaseQuantitativeDisclosureTableTextBlock_637510085486540922" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_637510085486540922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_637510085486540922" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock_637510085486540922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock_637510085486540922" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_LeaseBalanceSheetDisclosureTableTextBlock" xlink:label="ptgx_LeaseBalanceSheetDisclosureTableTextBlock_637510085486540922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="ptgx_LeaseBalanceSheetDisclosureTableTextBlock_637510085486540922" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_LeaseCashFlowInformationDisclosureTableTextBlock" xlink:label="ptgx_LeaseCashFlowInformationDisclosureTableTextBlock_637510085486540922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="ptgx_LeaseCashFlowInformationDisclosureTableTextBlock_637510085486540922" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureEquityPlansTables" xlink:type="extended" xlink:title="31303 - Disclosure - Equity Plans (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637510085486550923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable_637510085486550923" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637510085486550923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637510085486550923" xlink:to="us-gaap_AwardTypeAxis_637510085486550923" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637510085486550923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637510085486550923" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637510085486550923" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637510085486550923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637510085486550923" xlink:to="us-gaap_EmployeeStockOptionMember_637510085486550923" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_637510085486550923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637510085486550923" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_637510085486550923" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember_637510085486550923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637510085486550923" xlink:to="us-gaap_EmployeeStockMember_637510085486550923" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637510085486550923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637510085486550923" xlink:to="us-gaap_StatementLineItems_637510085486550923" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_637510085486550923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637510085486550923" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_637510085486550923" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637510085486550923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637510085486550923" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637510085486550923" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_637510085486550923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637510085486550923" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_637510085486550923" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="31503 - Disclosure - Income Taxes (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_637510085486560919" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_637510085486560919" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_637510085486560919" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_637510085486560919" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_637510085486560919" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_637510085486560919" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_637510085486560919" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_637510085486560919" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_637510085486560919" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_637510085486560919" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureNetLossPerShareTables" xlink:type="extended" xlink:title="31603 - Disclosure - Net Loss per Share (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_637510085486560919" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_637510085486560919" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_637510085486560919" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_637510085486560919" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureOrganizationAndDescriptionOfBusinessLiquidityDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Organization and Description of Business - Liquidity (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsNoteDisclosureAbstract" xlink:label="us-gaap_RetainedEarningsNoteDisclosureAbstract_637510085486560919" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RetainedEarningsNoteDisclosureAbstract_637510085486560919" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637510085486570923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetainedEarningsNoteDisclosureAbstract_637510085486560919" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637510085486570923" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary of Significant Accounting Policies - Concentrations of Credit Risk (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CashNumberOfFinancialInstitutions" xlink:label="ptgx_CashNumberOfFinancialInstitutions_637510085486570923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ptgx_CashNumberOfFinancialInstitutions_637510085486570923" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Summary of Significant Accounting Policies - Cash and Cash Equivalents and Restricted Cash (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_637510085486570923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_637510085486570923" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637510085486570923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_637510085486570923" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637510085486570923" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent_637510085486570923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_637510085486570923" xlink:to="us-gaap_RestrictedCashCurrent_637510085486570923" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_637510085486570923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_637510085486570923" xlink:to="us-gaap_RestrictedCashNoncurrent_637510085486570923" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637510085486570923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_637510085486570923" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637510085486570923" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAndImpairmentOfLongLivedAssetsDetails" xlink:type="extended" xlink:title="40203 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment and Impairment of Long-Lived Assets (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637510085486570923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637510085486570923" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637510085486570923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637510085486570923" xlink:to="srt_RangeAxis_637510085486570923" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637510085486570923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637510085486570923" xlink:to="srt_RangeMember_637510085486570923" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637510085486570923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637510085486570923" xlink:to="srt_MinimumMember_637510085486570923" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637510085486580924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637510085486570923" xlink:to="srt_MaximumMember_637510085486580924" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_637510085486580924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637510085486570923" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_637510085486580924" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_637510085486580924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637510085486580924" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_637510085486580924" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="us-gaap_TangibleAssetImpairmentCharges_637510085486580924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637510085486580924" xlink:to="us-gaap_TangibleAssetImpairmentCharges_637510085486580924" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesIncomeTaxesDetails" xlink:type="extended" xlink:title="40204 - Disclosure - Summary of Significant Accounting Policies - Income Taxes (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_637503627981677369" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_637510085486580924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637503627981677369" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_637510085486580924" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails" xlink:type="extended" xlink:title="40301 - Disclosure - License and Collaboration Agreement (Details)">
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CollaborativeArrangementDisclosureAbstract" xlink:label="ptgx_CollaborativeArrangementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637510085486580924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_CollaborativeArrangementDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637510085486580924" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637510085486580924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637510085486580924" xlink:to="srt_CounterpartyNameAxis_637510085486580924" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637510085486580924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637510085486580924" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637510085486580924" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_JanssenBiotechIncMember" xlink:label="ptgx_JanssenBiotechIncMember_637510085486580924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637510085486580924" xlink:to="ptgx_JanssenBiotechIncMember_637510085486580924" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_637510085486580924" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637510085486580924" xlink:to="srt_StatementScenarioAxis_637510085486580924" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_637510085486590921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_637510085486580924" xlink:to="srt_ScenarioUnspecifiedDomain_637510085486590921" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProFormaMember" xlink:label="srt_ProFormaMember_637510085486590921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637510085486590921" xlink:to="srt_ProFormaMember_637510085486590921" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637510085486590921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637510085486580924" xlink:to="us-gaap_TypeOfArrangementAxis_637510085486590921" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637510085486590921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637510085486590921" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637510085486590921" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_637510085486590921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637510085486590921" xlink:to="us-gaap_ProductMember_637510085486590921" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_PhaseOneClinicalTrialMember" xlink:label="ptgx_PhaseOneClinicalTrialMember_637510085486590921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductMember_637510085486590921" xlink:to="ptgx_PhaseOneClinicalTrialMember_637510085486590921" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CollaborationAgreementTrancheThreeMember" xlink:label="ptgx_CollaborationAgreementTrancheThreeMember_637510085486590921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_PhaseOneClinicalTrialMember_637510085486590921" xlink:to="ptgx_CollaborationAgreementTrancheThreeMember_637510085486590921" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CollaborationAgreementTrancheFourMember" xlink:label="ptgx_CollaborationAgreementTrancheFourMember_637510085486590921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_PhaseOneClinicalTrialMember_637510085486590921" xlink:to="ptgx_CollaborationAgreementTrancheFourMember_637510085486590921" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CollaborationAgreementTrancheFiveMember" xlink:label="ptgx_CollaborationAgreementTrancheFiveMember_637510085486590921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_PhaseOneClinicalTrialMember_637510085486590921" xlink:to="ptgx_CollaborationAgreementTrancheFiveMember_637510085486590921" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_SecondGenerationDevelopmentCompoundMember" xlink:label="ptgx_SecondGenerationDevelopmentCompoundMember_637510085486590921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductMember_637510085486590921" xlink:to="ptgx_SecondGenerationDevelopmentCompoundMember_637510085486590921" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_PhaseTwoClinicalTrialMember" xlink:label="ptgx_PhaseTwoClinicalTrialMember_637510085486590921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductMember_637510085486590921" xlink:to="ptgx_PhaseTwoClinicalTrialMember_637510085486590921" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_LicenseAndCollaborativeAgreementAmendmentMember" xlink:label="ptgx_LicenseAndCollaborativeAgreementAmendmentMember_637510085486590921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637510085486590921" xlink:to="ptgx_LicenseAndCollaborativeAgreementAmendmentMember_637510085486590921" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_AmendedCollaborationAgreementTrancheOneMember" xlink:label="ptgx_AmendedCollaborationAgreementTrancheOneMember_637510085486590921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637510085486590921" xlink:to="ptgx_AmendedCollaborationAgreementTrancheOneMember_637510085486590921" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_AmendedSecondOptInMember" xlink:label="ptgx_AmendedSecondOptInMember_637510085486600910" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637510085486590921" xlink:to="ptgx_AmendedSecondOptInMember_637510085486600910" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_EstimatedVariableConsiderationMember" xlink:label="ptgx_EstimatedVariableConsiderationMember_637510085486600910" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637510085486590921" xlink:to="ptgx_EstimatedVariableConsiderationMember_637510085486600910" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_637510085486600910" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637510085486580924" xlink:to="srt_ProductOrServiceAxis_637510085486600910" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637510085486600910" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_637510085486600910" xlink:to="srt_ProductsAndServicesDomain_637510085486600910" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_LicenseAndCollaborativeRevenueMember" xlink:label="ptgx_LicenseAndCollaborativeRevenueMember_637510085486600910" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637510085486600910" xlink:to="ptgx_LicenseAndCollaborativeRevenueMember_637510085486600910" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_UpfrontCashPaymentMember" xlink:label="ptgx_UpfrontCashPaymentMember_637510085486600910" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637510085486600910" xlink:to="ptgx_UpfrontCashPaymentMember_637510085486600910" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DevelopmentRegulatoryAndSalesMilestonePaymentsMember" xlink:label="ptgx_DevelopmentRegulatoryAndSalesMilestonePaymentsMember_637510085486600910" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637510085486600910" xlink:to="ptgx_DevelopmentRegulatoryAndSalesMilestonePaymentsMember_637510085486600910" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialServiceOtherMember" xlink:label="us-gaap_FinancialServiceOtherMember_637510085486600910" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637510085486600910" xlink:to="us-gaap_FinancialServiceOtherMember_637510085486600910" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_MilestonePaymentsMember" xlink:label="ptgx_MilestonePaymentsMember_637510085486600910" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637510085486600910" xlink:to="ptgx_MilestonePaymentsMember_637510085486600910" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_Ptg200Phase3CdClinicalTrialPrimaryClinicalEndpointMember" xlink:label="ptgx_Ptg200Phase3CdClinicalTrialPrimaryClinicalEndpointMember_637510085486610911" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_MilestonePaymentsMember_637510085486600910" xlink:to="ptgx_Ptg200Phase3CdClinicalTrialPrimaryClinicalEndpointMember_637510085486610911" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember" xlink:label="ptgx_SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember_637510085486610911" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_MilestonePaymentsMember_637510085486600910" xlink:to="ptgx_SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember_637510085486610911" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_SecondGenerationAnalogPhase2CdClinicalTrialPrimaryClinicalEndpointMember" xlink:label="ptgx_SecondGenerationAnalogPhase2CdClinicalTrialPrimaryClinicalEndpointMember_637510085486610911" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_MilestonePaymentsMember_637510085486600910" xlink:to="ptgx_SecondGenerationAnalogPhase2CdClinicalTrialPrimaryClinicalEndpointMember_637510085486610911" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_SecondGenerationPhase2bMilestonePaymentMember" xlink:label="ptgx_SecondGenerationPhase2bMilestonePaymentMember_637510085486610911" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_MilestonePaymentsMember_637510085486600910" xlink:to="ptgx_SecondGenerationPhase2bMilestonePaymentMember_637510085486610911" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637510085486610911" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637510085486580924" xlink:to="srt_RangeAxis_637510085486610911" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637510085486610911" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637510085486610911" xlink:to="srt_RangeMember_637510085486610911" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637510085486610911" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637510085486610911" xlink:to="srt_MaximumMember_637510085486610911" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637510085486610911" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637510085486580924" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637510085486610911" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_637510085486620912" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637510085486610911" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_637510085486620912" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurred" xlink:label="ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurred_637510085486620912" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637510085486610911" xlink:to="ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurred_637510085486620912" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CollaborativeArrangementEligibleAmountReceived" xlink:label="ptgx_CollaborativeArrangementEligibleAmountReceived_637510085486620912" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637510085486610911" xlink:to="ptgx_CollaborativeArrangementEligibleAmountReceived_637510085486620912" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CollaborativeArrangementPercentageOfResearchProgramCostsIncurred" xlink:label="ptgx_CollaborativeArrangementPercentageOfResearchProgramCostsIncurred_637510085486620912" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637510085486610911" xlink:to="ptgx_CollaborativeArrangementPercentageOfResearchProgramCostsIncurred_637510085486620912" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CollaborativeArrangementPayableUponEffectivenessOfAmendment" xlink:label="ptgx_CollaborativeArrangementPayableUponEffectivenessOfAmendment_637510085486620912" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637510085486610911" xlink:to="ptgx_CollaborativeArrangementPayableUponEffectivenessOfAmendment_637510085486620912" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ContingentConsiderationReceivable" xlink:label="ptgx_ContingentConsiderationReceivable_637510085486620912" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637510085486610911" xlink:to="ptgx_ContingentConsiderationReceivable_637510085486620912" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_PercentagesRoyaltiesOnNetProductSales" xlink:label="ptgx_PercentagesRoyaltiesOnNetProductSales_637510085486620912" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637510085486610911" xlink:to="ptgx_PercentagesRoyaltiesOnNetProductSales_637510085486620912" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_637510085486630912" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637510085486610911" xlink:to="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_637510085486630912" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_637510085486640916" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637510085486610911" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_637510085486640916" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_637510085486640916" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637510085486610911" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_637510085486640916" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_637510085486640916" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637510085486610911" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_637510085486640916" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract_637510085486640916" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637510085486610911" xlink:to="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract_637510085486640916" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:label="us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_637510085486640916" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637510085486610911" xlink:to="us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_637510085486640916" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet_637510085486640916" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637510085486610911" xlink:to="us-gaap_CapitalizedContractCostNet_637510085486640916" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails" xlink:type="extended" xlink:title="40302 - Disclosure - License and Collaboration Agreement - Contract Assets and Liabilities (Details)">
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CollaborativeArrangementDisclosureAbstract" xlink:label="ptgx_CollaborativeArrangementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637510085486650927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_CollaborativeArrangementDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637510085486650927" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637510085486650927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637510085486650927" xlink:to="srt_CounterpartyNameAxis_637510085486650927" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637510085486650927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637510085486650927" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637510085486650927" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_JanssenBiotechIncMember" xlink:label="ptgx_JanssenBiotechIncMember_637510085486650927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637510085486650927" xlink:to="ptgx_JanssenBiotechIncMember_637510085486650927" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637510085486650927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637510085486650927" xlink:to="us-gaap_TypeOfArrangementAxis_637510085486650927" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637510085486650927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637510085486650927" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637510085486650927" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_637510085486650927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637510085486650927" xlink:to="us-gaap_ProductMember_637510085486650927" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637510085486650927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637510085486650927" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637510085486650927" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract" xlink:label="us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract_637510085486660918" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637510085486650927" xlink:to="us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract_637510085486660918" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ContractWithCustomerAssetNetRollForward" xlink:label="ptgx_ContractWithCustomerAssetNetRollForward_637510085486660918" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract_637510085486660918" xlink:to="ptgx_ContractWithCustomerAssetNetRollForward_637510085486660918" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet_637510085486660918" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_ContractWithCustomerAssetNetRollForward_637510085486660918" xlink:to="us-gaap_ContractWithCustomerAssetNet_637510085486660918" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ContractWithCustomerAssetAdditions" xlink:label="ptgx_ContractWithCustomerAssetAdditions_637510085486660918" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_ContractWithCustomerAssetNetRollForward_637510085486660918" xlink:to="ptgx_ContractWithCustomerAssetAdditions_637510085486660918" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ContractWithCustomerAssetDeduction" xlink:label="ptgx_ContractWithCustomerAssetDeduction_637510085486660918" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_ContractWithCustomerAssetNetRollForward_637510085486660918" xlink:to="ptgx_ContractWithCustomerAssetDeduction_637510085486660918" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet_6375100854866609181" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_ContractWithCustomerAssetNetRollForward_637510085486660918" xlink:to="us-gaap_ContractWithCustomerAssetNet_6375100854866609181" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrentAbstract" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrentAbstract_637510085486660918" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_ContractWithCustomerAssetNetRollForward_637510085486660918" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrentAbstract_637510085486660918" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_637510085486660918" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerAssetNetCurrentAbstract_637510085486660918" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent_637510085486660918" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ContractWithCustomerAssetRelatedPartyAdditions" xlink:label="ptgx_ContractWithCustomerAssetRelatedPartyAdditions_637510085486660918" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerAssetNetCurrentAbstract_637510085486660918" xlink:to="ptgx_ContractWithCustomerAssetRelatedPartyAdditions_637510085486660918" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ContractWithCustomerAssetRelatedPartyDeduction" xlink:label="ptgx_ContractWithCustomerAssetRelatedPartyDeduction_637510085486660918" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerAssetNetCurrentAbstract_637510085486660918" xlink:to="ptgx_ContractWithCustomerAssetRelatedPartyDeduction_637510085486660918" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_6375100854866609181" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerAssetNetCurrentAbstract_637510085486660918" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent_6375100854866609181" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ContractWithCustomerLiabilityNetRollForward" xlink:label="ptgx_ContractWithCustomerLiabilityNetRollForward_637510085486670921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract_637510085486660918" xlink:to="ptgx_ContractWithCustomerLiabilityNetRollForward_637510085486670921" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_637510085486670921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_ContractWithCustomerLiabilityNetRollForward_637510085486670921" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_637510085486670921" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ContractWithCustomerLiabilityAdditions" xlink:label="ptgx_ContractWithCustomerLiabilityAdditions_637510085486670921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_ContractWithCustomerLiabilityNetRollForward_637510085486670921" xlink:to="ptgx_ContractWithCustomerLiabilityAdditions_637510085486670921" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ContractWithCustomerLiabilityDeduction" xlink:label="ptgx_ContractWithCustomerLiabilityDeduction_637510085486670921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_ContractWithCustomerLiabilityNetRollForward_637510085486670921" xlink:to="ptgx_ContractWithCustomerLiabilityDeduction_637510085486670921" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_6375100854866709211" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_ContractWithCustomerLiabilityNetRollForward_637510085486670921" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_6375100854866709211" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_PayableToCollaborationPartnerRelatedPartyAbstract" xlink:label="ptgx_PayableToCollaborationPartnerRelatedPartyAbstract_637510085486670921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_ContractWithCustomerLiabilityNetRollForward_637510085486670921" xlink:to="ptgx_PayableToCollaborationPartnerRelatedPartyAbstract_637510085486670921" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent_637510085486670921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_PayableToCollaborationPartnerRelatedPartyAbstract_637510085486670921" xlink:to="us-gaap_DueToRelatedPartiesCurrent_637510085486670921" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DueToRelatedPartyAdditions" xlink:label="ptgx_DueToRelatedPartyAdditions_637510085486670921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_PayableToCollaborationPartnerRelatedPartyAbstract_637510085486670921" xlink:to="ptgx_DueToRelatedPartyAdditions_637510085486670921" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DueToRelatedPartyDeductions" xlink:label="ptgx_DueToRelatedPartyDeductions_637510085486670921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_PayableToCollaborationPartnerRelatedPartyAbstract_637510085486670921" xlink:to="ptgx_DueToRelatedPartyDeductions_637510085486670921" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent_637510085486680916" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_PayableToCollaborationPartnerRelatedPartyAbstract_637510085486670921" xlink:to="us-gaap_DueToRelatedPartiesCurrent_637510085486680916" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Fair Value Measurements (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637510085486680916" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637510085486680916" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_637510085486680916" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637510085486680916" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_637510085486680916" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_637510085486680916" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_637510085486680916" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_637510085486680916" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_637510085486680916" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_637510085486680916" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_637510085486680916" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_637510085486680916" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637510085486680916" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_637510085486680916" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637510085486680916" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_637510085486680916" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637510085486680916" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_637510085486680916" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637510085486680916" xlink:to="us-gaap_FairValueInputsLevel1Member_637510085486680916" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member_637510085486680916" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637510085486680916" xlink:to="us-gaap_FairValueInputsLevel2Member_637510085486680916" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis_637510085486680916" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637510085486680916" xlink:to="us-gaap_InvestmentTypeAxis_637510085486680916" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_637510085486690930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis_637510085486680916" xlink:to="us-gaap_InvestmentTypeCategorizationMember_637510085486690930" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember_637510085486690930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember_637510085486690930" xlink:to="us-gaap_MoneyMarketFundsMember_637510085486690930" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember_637510085486690930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember_637510085486690930" xlink:to="us-gaap_CommercialPaperMember_637510085486690930" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember_637510085486690930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember_637510085486690930" xlink:to="us-gaap_CorporateDebtSecuritiesMember_637510085486690930" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_UsTreasuryAndAgencySecuritiesMember" xlink:label="ptgx_UsTreasuryAndAgencySecuritiesMember_637510085486690930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember_637510085486690930" xlink:to="ptgx_UsTreasuryAndAgencySecuritiesMember_637510085486690930" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637510085486690930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637510085486680916" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637510085486690930" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure_637510085486690930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637510085486690930" xlink:to="us-gaap_AssetsFairValueDisclosure_637510085486690930" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="us-gaap_LongTermDebtFairValue_637510085486690930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637510085486690930" xlink:to="us-gaap_LongTermDebtFairValue_637510085486690930" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Cash Equivalents and Marketable Securities - Cash Equivalents and Marketable Securities (Details)">
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesAbstract" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ScheduleCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:label="ptgx_ScheduleCashEquivalentsAndAvailableForSaleSecuritiesTable_637510085486690930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="ptgx_ScheduleCashEquivalentsAndAvailableForSaleSecuritiesTable_637510085486690930" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis_637510085486700930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_ScheduleCashEquivalentsAndAvailableForSaleSecuritiesTable_637510085486690930" xlink:to="us-gaap_CashAndCashEquivalentsAxis_637510085486700930" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637510085486700930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis_637510085486700930" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637510085486700930" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember_637510085486700930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637510085486700930" xlink:to="us-gaap_MoneyMarketFundsMember_637510085486700930" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember_637510085486700930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637510085486700930" xlink:to="us-gaap_CommercialPaperMember_637510085486700930" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis_637510085486700930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_ScheduleCashEquivalentsAndAvailableForSaleSecuritiesTable_637510085486690930" xlink:to="us-gaap_InvestmentTypeAxis_637510085486700930" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_637510085486700930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis_637510085486700930" xlink:to="us-gaap_InvestmentTypeCategorizationMember_637510085486700930" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember_637510085486700930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember_637510085486700930" xlink:to="us-gaap_CorporateDebtSecuritiesMember_637510085486700930" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_UsTreasuryAndAgencySecuritiesMember" xlink:label="ptgx_UsTreasuryAndAgencySecuritiesMember_637510085486700930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember_637510085486700930" xlink:to="ptgx_UsTreasuryAndAgencySecuritiesMember_637510085486700930" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:label="ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems_637510085486700930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_ScheduleCashEquivalentsAndAvailableForSaleSecuritiesTable_637510085486690930" xlink:to="ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems_637510085486700930" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost_637510085486700930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems_637510085486700930" xlink:to="ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost_637510085486700930" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain_637510085486700930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems_637510085486700930" xlink:to="ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain_637510085486700930" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss_637510085486700930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems_637510085486700930" xlink:to="ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss_637510085486700930" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CashEquivalentsAndMarketableSecuritiesFairValue" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesFairValue_637510085486700930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems_637510085486700930" xlink:to="ptgx_CashEquivalentsAndMarketableSecuritiesFairValue_637510085486700930" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesClassificationOfCashEquivalentsAndMarketableSecuritiesDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Cash Equivalents and Marketable Securities - Classification of Cash Equivalents and Marketable Securities (Details)">
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsAndCashAbstract" xlink:label="us-gaap_InvestmentsAndCashAbstract_637510085486710922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_InvestmentsAndCashAbstract_637510085486710922" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_637510085486710922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAndCashAbstract_637510085486710922" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_637510085486710922" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent_637510085486710922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAndCashAbstract_637510085486710922" xlink:to="us-gaap_MarketableSecuritiesCurrent_637510085486710922" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_637510085486710922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAndCashAbstract_637510085486710922" xlink:to="us-gaap_MarketableSecuritiesNoncurrent_637510085486710922" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CashEquivalentsAndMarketableSecuritiesFairValue" xlink:label="ptgx_CashEquivalentsAndMarketableSecuritiesFairValue_637510085486710922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAndCashAbstract_637510085486710922" xlink:to="ptgx_CashEquivalentsAndMarketableSecuritiesFairValue_637510085486710922" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_637510085486710922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_637510085486710922" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CurrentContractualMaturitiesMaximumPeriod" xlink:label="ptgx_CurrentContractualMaturitiesMaximumPeriod_637510085486710922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_637510085486710922" xlink:to="ptgx_CurrentContractualMaturitiesMaximumPeriod_637510085486710922" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_NoncurrentContractualMaturitiesMinimumPeriod" xlink:label="ptgx_NoncurrentContractualMaturitiesMinimumPeriod_637510085486710922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_637510085486710922" xlink:to="ptgx_NoncurrentContractualMaturitiesMinimumPeriod_637510085486710922" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_NoncurrentContractualMaturitiesMaximumPeriod" xlink:label="ptgx_NoncurrentContractualMaturitiesMaximumPeriod_637510085486710922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_637510085486710922" xlink:to="ptgx_NoncurrentContractualMaturitiesMaximumPeriod_637510085486710922" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_637510085486710922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract_637510085486710922" xlink:to="us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_637510085486710922" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_637510085486720926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_637510085486720926" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_PrepaidManufacturingOfClinicalMaterials" xlink:label="ptgx_PrepaidManufacturingOfClinicalMaterials_637510085486720926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_637510085486720926" xlink:to="ptgx_PrepaidManufacturingOfClinicalMaterials_637510085486720926" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance_637510085486720926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_637510085486720926" xlink:to="us-gaap_PrepaidInsurance_637510085486720926" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_637510085486720926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_637510085486720926" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_637510085486720926" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent_637510085486720926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_637510085486720926" xlink:to="us-gaap_OtherReceivablesNetCurrent_637510085486720926" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637510085486720926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_637510085486720926" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637510085486720926" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Balance Sheet Components - Property and Equipment, Net (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637510085486720926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637510085486720926" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_637510085486720926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637510085486720926" xlink:to="srt_StatementGeographicalAxis_637510085486720926" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637510085486720926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_637510085486720926" xlink:to="srt_SegmentGeographicalDomain_637510085486720926" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_AU" xlink:label="country_AU_637510085486720926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637510085486720926" xlink:to="country_AU_637510085486720926" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637510085486720926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637510085486720926" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637510085486720926" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637510085486730933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637510085486720926" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637510085486730933" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_LaboratoryEquipmentMember" xlink:label="ptgx_LaboratoryEquipmentMember_637510085486730933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637510085486730933" xlink:to="ptgx_LaboratoryEquipmentMember_637510085486730933" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_FurnitureAndComputerEquipmentMember" xlink:label="ptgx_FurnitureAndComputerEquipmentMember_637510085486730933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637510085486730933" xlink:to="ptgx_FurnitureAndComputerEquipmentMember_637510085486730933" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_637510085486730933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637510085486730933" xlink:to="us-gaap_LeaseholdImprovementsMember_637510085486730933" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_637510085486730933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637510085486720926" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_637510085486730933" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_637510085486730933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637510085486730933" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_637510085486730933" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637510085486730933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637510085486730933" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637510085486730933" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637510085486730933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637510085486730933" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637510085486730933" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_637510085486730933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637510085486730933" xlink:to="us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_637510085486730933" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637510085486730933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_637510085486730933" xlink:to="us-gaap_Depreciation_637510085486730933" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsAccruedExpensesAndOtherPayablesDetails" xlink:type="extended" xlink:title="40603 - Disclosure - Balance Sheet Components - Accrued Expenses and Other Payables (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637510085486740931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637510085486740931" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_AccruedClinicalAndResearchRelatedExpensesCurrent" xlink:label="ptgx_AccruedClinicalAndResearchRelatedExpensesCurrent_637510085486740931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637510085486740931" xlink:to="ptgx_AccruedClinicalAndResearchRelatedExpensesCurrent_637510085486740931" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_637510085486740931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637510085486740931" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_637510085486740931" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_637510085486740931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637510085486740931" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_637510085486740931" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent_637510085486740931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637510085486740931" xlink:to="us-gaap_InterestPayableCurrent_637510085486740931" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_637510085486740931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637510085486740931" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_637510085486740931" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637510085486740931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637510085486740931" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637510085486740931" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreementDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Research Collaboration and License Agreement (Details)">
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ResearchCollaborationAndLicenseAgreementDisclosureAbstract" xlink:label="ptgx_ResearchCollaborationAndLicenseAgreementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637510085486740931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_ResearchCollaborationAndLicenseAgreementDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637510085486740931" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637510085486740931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637510085486740931" xlink:to="us-gaap_TypeOfArrangementAxis_637510085486740931" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637510085486740931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637510085486740931" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637510085486740931" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member" xlink:label="ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member_637510085486740931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637510085486740931" xlink:to="ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member_637510085486740931" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_637510085486740931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637510085486740931" xlink:to="srt_ProductOrServiceAxis_637510085486740931" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637510085486740931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_637510085486740931" xlink:to="srt_ProductsAndServicesDomain_637510085486740931" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_PTG300Member" xlink:label="ptgx_PTG300Member_637510085486750929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637510085486740931" xlink:to="ptgx_PTG300Member_637510085486750929" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_PhaseTwoBClinicalTrailOfPtg300Member" xlink:label="ptgx_PhaseTwoBClinicalTrailOfPtg300Member_637510085486750929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_PTG300Member_637510085486750929" xlink:to="ptgx_PhaseTwoBClinicalTrailOfPtg300Member_637510085486750929" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_PhaseThreeClinicalTrailOfPtg300Member" xlink:label="ptgx_PhaseThreeClinicalTrailOfPtg300Member_637510085486750929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_PTG300Member_637510085486750929" xlink:to="ptgx_PhaseThreeClinicalTrailOfPtg300Member_637510085486750929" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637510085486750929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637510085486740931" xlink:to="srt_RangeAxis_637510085486750929" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637510085486750929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637510085486750929" xlink:to="srt_RangeMember_637510085486750929" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637510085486750929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637510085486750929" xlink:to="srt_MinimumMember_637510085486750929" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637510085486750929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637510085486750929" xlink:to="srt_MaximumMember_637510085486750929" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_637510085486750929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637510085486740931" xlink:to="srt_StatementScenarioAxis_637510085486750929" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_637510085486750929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_637510085486750929" xlink:to="srt_ScenarioUnspecifiedDomain_637510085486750929" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_EntityRequiredToContinueToMakePaymentsMember" xlink:label="ptgx_EntityRequiredToContinueToMakePaymentsMember_637510085486750929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637510085486750929" xlink:to="ptgx_EntityRequiredToContinueToMakePaymentsMember_637510085486750929" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637510085486750929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637510085486740931" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637510085486750929" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_NumberOfDevelopmentMilestonePayments" xlink:label="ptgx_NumberOfDevelopmentMilestonePayments_637510085486750929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637510085486750929" xlink:to="ptgx_NumberOfDevelopmentMilestonePayments_637510085486750929" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_AggregateAmountOfDevelopmentMilestonePayment" xlink:label="ptgx_AggregateAmountOfDevelopmentMilestonePayment_637510085486760922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637510085486750929" xlink:to="ptgx_AggregateAmountOfDevelopmentMilestonePayment_637510085486760922" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_AdditionalPaymentObligationToFormerCollaborationPartner" xlink:label="ptgx_AdditionalPaymentObligationToFormerCollaborationPartner_637510085486760922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637510085486750929" xlink:to="ptgx_AdditionalPaymentObligationToFormerCollaborationPartner_637510085486760922" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637510085486760922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637510085486750929" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637510085486760922" order="4" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureGovernmentProgramsDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Government Programs (Details)">
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_GovernmentProgramsAbstract" xlink:label="ptgx_GovernmentProgramsAbstract" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_GovernmentProgramsTable" xlink:label="ptgx_GovernmentProgramsTable_637510085486760922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_GovernmentProgramsAbstract" xlink:to="ptgx_GovernmentProgramsTable_637510085486760922" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_637510085486760922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_GovernmentProgramsTable_637510085486760922" xlink:to="us-gaap_IncomeTaxAuthorityAxis_637510085486760922" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_637510085486760922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_637510085486760922" xlink:to="us-gaap_IncomeTaxAuthorityDomain_637510085486760922" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_OverseasFindingsMember" xlink:label="ptgx_OverseasFindingsMember_637510085486760922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_637510085486760922" xlink:to="ptgx_OverseasFindingsMember_637510085486760922" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_637510085486760922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_GovernmentProgramsTable_637510085486760922" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_637510085486760922" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_637510085486760922" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis_637510085486760922" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_637510085486760922" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AustralianTaxationOfficeMember" xlink:label="us-gaap_AustralianTaxationOfficeMember_637510085486770930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain_637510085486760922" xlink:to="us-gaap_AustralianTaxationOfficeMember_637510085486770930" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_RevenueSourceAxis" xlink:label="ptgx_RevenueSourceAxis_637510085486770930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_GovernmentProgramsTable_637510085486760922" xlink:to="ptgx_RevenueSourceAxis_637510085486770930" order="3" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_RevenueSourceDomain" xlink:label="ptgx_RevenueSourceDomain_637510085486770930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_RevenueSourceAxis_637510085486770930" xlink:to="ptgx_RevenueSourceDomain_637510085486770930" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_SmallBusinessInnovationResearchGrantMember" xlink:label="ptgx_SmallBusinessInnovationResearchGrantMember_637510085486770930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_RevenueSourceDomain_637510085486770930" xlink:to="ptgx_SmallBusinessInnovationResearchGrantMember_637510085486770930" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_GovernmentProgramsLineItems" xlink:label="ptgx_GovernmentProgramsLineItems_637510085486770930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_GovernmentProgramsTable_637510085486760922" xlink:to="ptgx_GovernmentProgramsLineItems_637510085486770930" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ResearchAndDevelopmentExpensesReduction" xlink:label="ptgx_ResearchAndDevelopmentExpensesReduction_637510085486770930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_GovernmentProgramsLineItems_637510085486770930" xlink:to="ptgx_ResearchAndDevelopmentExpensesReduction_637510085486770930" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="us-gaap_IncomeTaxesReceivable_637510085486770930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_GovernmentProgramsLineItems_637510085486770930" xlink:to="us-gaap_IncomeTaxesReceivable_637510085486770930" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ResearchAndDevelopmentGrants" xlink:label="ptgx_ResearchAndDevelopmentGrants_637510085486770930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_GovernmentProgramsLineItems_637510085486770930" xlink:to="ptgx_ResearchAndDevelopmentGrants_637510085486770930" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable_637510085486770930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_GovernmentProgramsLineItems_637510085486770930" xlink:to="us-gaap_GrantsReceivable_637510085486770930" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureDebtDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Debt (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_637510085486780935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable_637510085486780935" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_637510085486780935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637510085486780935" xlink:to="srt_StatementScenarioAxis_637510085486780935" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_637510085486780935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_637510085486780935" xlink:to="srt_ScenarioUnspecifiedDomain_637510085486780935" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DebtInstrumentRepaymentOnOrBeforeFirstAnniversaryMember" xlink:label="ptgx_DebtInstrumentRepaymentOnOrBeforeFirstAnniversaryMember_637510085486780935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637510085486780935" xlink:to="ptgx_DebtInstrumentRepaymentOnOrBeforeFirstAnniversaryMember_637510085486780935" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DebtInstrumentRepaymentBetweenFirstAndSecondAnniversaryMember" xlink:label="ptgx_DebtInstrumentRepaymentBetweenFirstAndSecondAnniversaryMember_637510085486780935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637510085486780935" xlink:to="ptgx_DebtInstrumentRepaymentBetweenFirstAndSecondAnniversaryMember_637510085486780935" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DebtInstrumentRepaymentAfterSecondAnniversaryMember" xlink:label="ptgx_DebtInstrumentRepaymentAfterSecondAnniversaryMember_637510085486780935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637510085486780935" xlink:to="ptgx_DebtInstrumentRepaymentAfterSecondAnniversaryMember_637510085486780935" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis_637510085486780935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637510085486780935" xlink:to="us-gaap_VariableRateAxis_637510085486780935" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_637510085486780935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis_637510085486780935" xlink:to="us-gaap_VariableRateDomain_637510085486780935" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember_637510085486780935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain_637510085486780935" xlink:to="us-gaap_PrimeRateMember_637510085486780935" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637510085486780935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637510085486780935" xlink:to="us-gaap_DebtInstrumentAxis_637510085486780935" order="3" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637510085486780935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637510085486780935" xlink:to="us-gaap_DebtInstrumentNameDomain_637510085486780935" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_TermLoanCreditAgreementMember" xlink:label="ptgx_TermLoanCreditAgreementMember_637510085486780935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637510085486780935" xlink:to="ptgx_TermLoanCreditAgreementMember_637510085486780935" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_637510085486799934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637510085486780935" xlink:to="us-gaap_DebtInstrumentLineItems_637510085486799934" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_637510085486800921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637510085486799934" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_637510085486800921" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_637510085486800921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637510085486799934" xlink:to="us-gaap_LongTermDebt_637510085486800921" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DebtInstrumentTrancheInstallmentAmount" xlink:label="ptgx_DebtInstrumentTrancheInstallmentAmount_637510085486800921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637510085486799934" xlink:to="ptgx_DebtInstrumentTrancheInstallmentAmount_637510085486800921" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DebtInstrumentThresholdPercentageOnOutstandingDebtToBeMaintainedAsCashAndCashEquivalentsBalance" xlink:label="ptgx_DebtInstrumentThresholdPercentageOnOutstandingDebtToBeMaintainedAsCashAndCashEquivalentsBalance_637510085486800921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637510085486799934" xlink:to="ptgx_DebtInstrumentThresholdPercentageOnOutstandingDebtToBeMaintainedAsCashAndCashEquivalentsBalance_637510085486800921" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DebtInstrumentLoanOriginationFeePercentage" xlink:label="ptgx_DebtInstrumentLoanOriginationFeePercentage_637510085486800921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637510085486799934" xlink:to="ptgx_DebtInstrumentLoanOriginationFeePercentage_637510085486800921" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_637510085486800921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637510085486799934" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_637510085486800921" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DebtInstrumentFloorRate" xlink:label="ptgx_DebtInstrumentFloorRate_637510085486800921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637510085486799934" xlink:to="ptgx_DebtInstrumentFloorRate_637510085486800921" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DebtInstrumentPeriodOfInterestOnlyPayments" xlink:label="ptgx_DebtInstrumentPeriodOfInterestOnlyPayments_637510085486800921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637510085486799934" xlink:to="ptgx_DebtInstrumentPeriodOfInterestOnlyPayments_637510085486800921" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DebtInstrumentPeriodOfPrincipalAndInterestPayments" xlink:label="ptgx_DebtInstrumentPeriodOfPrincipalAndInterestPayments_637510085486800921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637510085486799934" xlink:to="ptgx_DebtInstrumentPeriodOfPrincipalAndInterestPayments_637510085486800921" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DebtInstrumentPrepaymentPremiumPercentage" xlink:label="ptgx_DebtInstrumentPrepaymentPremiumPercentage_637510085486810927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637510085486799934" xlink:to="ptgx_DebtInstrumentPrepaymentPremiumPercentage_637510085486810927" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DebtInstrumentAdditionalPrepaymentOrRepaymentPremiumPercentage" xlink:label="ptgx_DebtInstrumentAdditionalPrepaymentOrRepaymentPremiumPercentage_637510085486810927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637510085486799934" xlink:to="ptgx_DebtInstrumentAdditionalPrepaymentOrRepaymentPremiumPercentage_637510085486810927" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt_637510085486810927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637510085486799934" xlink:to="us-gaap_RepaymentsOfDebt_637510085486810927" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_637510085486810927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637510085486799934" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_637510085486810927" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount_637510085486810927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637510085486799934" xlink:to="us-gaap_DebtInstrumentFeeAmount_637510085486810927" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_637510085486810927" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637510085486799934" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_637510085486810927" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureDebtLongTermDebtDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Debt - Long-term debt (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_637510085486820936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentCarryingAmount_637510085486820936" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet_637510085486820936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DeferredFinanceCostsNet_637510085486820936" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DebtInstrumentAccruedFinalPaymentFee" xlink:label="ptgx_DebtInstrumentAccruedFinalPaymentFee_637510085486820936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="ptgx_DebtInstrumentAccruedFinalPaymentFee_637510085486820936" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_637510085486820936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebt_637510085486820936" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_637510085486820936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_637510085486820936" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_637510085486820936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_637510085486820936" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureLeasesAgreementDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Leases - Agreement (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_637510085486820936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable_637510085486820936" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_637510085486820936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_637510085486820936" xlink:to="srt_StatementGeographicalAxis_637510085486820936" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637510085486820936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_637510085486820936" xlink:to="srt_SegmentGeographicalDomain_637510085486820936" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CA" xlink:label="stpr_CA_637510085486820936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637510085486820936" xlink:to="stpr_CA_637510085486820936" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_637510085486820936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_637510085486820936" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_637510085486820936" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_NumberOfOperatingLeaseAgreement" xlink:label="ptgx_NumberOfOperatingLeaseAgreement_637510085486830937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637510085486820936" xlink:to="ptgx_NumberOfOperatingLeaseAgreement_637510085486830937" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit_637510085486830937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637510085486820936" xlink:to="us-gaap_SecurityDeposit_637510085486830937" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome_637510085486830937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637510085486820936" xlink:to="us-gaap_SubleaseIncome_637510085486830937" order="3" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureLeasesWeightedAverageLeaseTermAndDiscountRateDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Leases - Weighted average lease term and discount rate (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_637510085486830937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_637510085486830937" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_637510085486830937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_637510085486830937" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureLeasesMinimumLeasePaymentsDetails" xlink:type="extended" xlink:title="41003 - Disclosure - Leases - Minimum lease payments (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637510085486890936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637510085486890936" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637510085486890936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637510085486890936" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637510085486890936" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637510085486890936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637510085486890936" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637510085486890936" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637510085486890936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637510085486890936" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637510085486890936" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637510085486890936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637510085486890936" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637510085486890936" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_637510085486890936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637510085486890936" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_637510085486890936" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_637510085486890936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637510085486890936" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_637510085486890936" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_637510085486890936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637510085486890936" xlink:to="us-gaap_OperatingLeaseLiability_637510085486890936" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637510085486890936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637510085486890936" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637510085486890936" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637510085486890936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637510085486890936" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637510085486890936" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureLeasesLeaseCostInformationDetails" xlink:type="extended" xlink:title="41004 - Disclosure - Leases - Lease cost information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_637510085486900942" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseCost_637510085486900942" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails" xlink:type="extended" xlink:title="41005 - Disclosure - Leases - Supplemental balance sheet information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorDisclosureAbstract" xlink:label="us-gaap_LessorDisclosureAbstract_637510085486900942" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LessorDisclosureAbstract_637510085486900942" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637510085486900942" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract_637510085486900942" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637510085486900942" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_637510085486900942" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract_637510085486900942" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_637510085486900942" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637510085486900942" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract_637510085486900942" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637510085486900942" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_637510085486900942" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract_637510085486900942" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_637510085486900942" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637510085486900942" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract_637510085486900942" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637510085486900942" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_637510085486900942" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract_637510085486900942" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_637510085486900942" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_637510085486900942" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract_637510085486900942" xlink:to="us-gaap_OperatingLeaseLiability_637510085486900942" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_637510085486900942" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract_637510085486900942" xlink:to="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_637510085486900942" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureLeasesCashFlowInformationDetails" xlink:type="extended" xlink:title="41006 - Disclosure - Leases - Cash flow information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_637510085486910938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasePayments_637510085486910938" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_637510085486910938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_637510085486910938" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Commitments and Contingencies (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable_637510085486910938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LossContingenciesTable_637510085486910938" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637510085486910938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_637510085486910938" xlink:to="srt_CounterpartyNameAxis_637510085486910938" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637510085486910938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637510085486910938" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637510085486910938" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ZealandPharmaMember" xlink:label="ptgx_ZealandPharmaMember_637510085486910938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637510085486910938" xlink:to="ptgx_ZealandPharmaMember_637510085486910938" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_637510085486910938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_637510085486910938" xlink:to="srt_StatementScenarioAxis_637510085486910938" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_637510085486910938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_637510085486910938" xlink:to="srt_ScenarioUnspecifiedDomain_637510085486910938" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_SuccessfullyDevelopAndCommercializeRusfertideComponentWithOutPartnerMember" xlink:label="ptgx_SuccessfullyDevelopAndCommercializeRusfertideComponentWithOutPartnerMember_637510085486920938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637510085486910938" xlink:to="ptgx_SuccessfullyDevelopAndCommercializeRusfertideComponentWithOutPartnerMember_637510085486920938" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems_637510085486920938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_637510085486910938" xlink:to="us-gaap_LossContingenciesLineItems_637510085486920938" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="us-gaap_LossContingencyDamagesSoughtValue_637510085486920938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_637510085486920938" xlink:to="us-gaap_LossContingencyDamagesSoughtValue_637510085486920938" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_PotentialDevelopmentAndRegulatoryMilestonePaymentsOnContractualObligation" xlink:label="ptgx_PotentialDevelopmentAndRegulatoryMilestonePaymentsOnContractualObligation_637510085486920938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_637510085486920938" xlink:to="ptgx_PotentialDevelopmentAndRegulatoryMilestonePaymentsOnContractualObligation_637510085486920938" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_PotentialSalesMilestonePaymentsOnContractualObligation" xlink:label="ptgx_PotentialSalesMilestonePaymentsOnContractualObligation_637510085486920938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_637510085486920938" xlink:to="ptgx_PotentialSalesMilestonePaymentsOnContractualObligation_637510085486920938" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_637510085486920938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_637510085486920938" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue_637510085486920938" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Stockholders' Equity (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637510085486920938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637510085486920938" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_637510085486920938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637510085486920938" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_637510085486920938" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_637510085486920938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_637510085486920938" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_637510085486920938" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_WarrantsPurchaseAmountPerSharePriceOneMember" xlink:label="ptgx_WarrantsPurchaseAmountPerSharePriceOneMember_637510085486920938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637510085486920938" xlink:to="ptgx_WarrantsPurchaseAmountPerSharePriceOneMember_637510085486920938" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_WarrantsPurchaseAmountPerSharePriceTwoMember" xlink:label="ptgx_WarrantsPurchaseAmountPerSharePriceTwoMember_637510085486920938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637510085486920938" xlink:to="ptgx_WarrantsPurchaseAmountPerSharePriceTwoMember_637510085486920938" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637510085486930935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637510085486920938" xlink:to="us-gaap_TypeOfArrangementAxis_637510085486930935" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637510085486930935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637510085486930935" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637510085486930935" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ExchangeAgreementMember" xlink:label="ptgx_ExchangeAgreementMember_637510085486930935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637510085486930935" xlink:to="ptgx_ExchangeAgreementMember_637510085486930935" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637510085486930935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637510085486920938" xlink:to="srt_CounterpartyNameAxis_637510085486930935" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637510085486930935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637510085486930935" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637510085486930935" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_AtMarketOfferingMember" xlink:label="ptgx_AtMarketOfferingMember_637510085486930935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637510085486930935" xlink:to="ptgx_AtMarketOfferingMember_637510085486930935" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_BiotechnologyValueFundL.pMember" xlink:label="ptgx_BiotechnologyValueFundL.pMember_637510085486930935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637510085486930935" xlink:to="ptgx_BiotechnologyValueFundL.pMember_637510085486930935" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember" xlink:label="ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_637510085486930935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637510085486930935" xlink:to="ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_637510085486930935" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637510085486930935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637510085486920938" xlink:to="us-gaap_StatementEquityComponentsAxis_637510085486930935" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637510085486930935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637510085486930935" xlink:to="us-gaap_EquityComponentDomain_637510085486930935" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637510085486930935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637510085486930935" xlink:to="us-gaap_CommonStockMember_637510085486930935" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637510085486930935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637510085486920938" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637510085486930935" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637510085486930935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637510085486930935" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637510085486930935" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CommonStockPreferredStockAndCertainDebtSecuritiesMember" xlink:label="ptgx_CommonStockPreferredStockAndCertainDebtSecuritiesMember_637510085486940926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637510085486930935" xlink:to="ptgx_CommonStockPreferredStockAndCertainDebtSecuritiesMember_637510085486940926" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember" xlink:label="ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember_637510085486940926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637510085486930935" xlink:to="ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember_637510085486940926" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_637510085486940926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637510085486930935" xlink:to="us-gaap_OverAllotmentOptionMember_637510085486940926" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_637510085486940926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637510085486930935" xlink:to="us-gaap_PrivatePlacementMember_637510085486940926" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_SalesAgreementFrom2017Member" xlink:label="ptgx_SalesAgreementFrom2017Member_637510085486940926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637510085486930935" xlink:to="ptgx_SalesAgreementFrom2017Member_637510085486940926" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_637510085486940926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637510085486920938" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_637510085486940926" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract_637510085486940926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637510085486940926" xlink:to="us-gaap_ClassOfStockDisclosuresAbstract_637510085486940926" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_637510085486940926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract_637510085486940926" xlink:to="us-gaap_SharesIssuedPricePerShare_637510085486940926" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637510085486940926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract_637510085486940926" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637510085486940926" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_SaleOfStockValueOfSharesAuthorized" xlink:label="ptgx_SaleOfStockValueOfSharesAuthorized_637510085486950940" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract_637510085486940926" xlink:to="ptgx_SaleOfStockValueOfSharesAuthorized_637510085486950940" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_AggregateGrossProceedsFromIssuanceStock" xlink:label="ptgx_AggregateGrossProceedsFromIssuanceStock_637510085486950940" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract_637510085486940926" xlink:to="ptgx_AggregateGrossProceedsFromIssuanceStock_637510085486950940" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637510085486950940" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract_637510085486940926" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637510085486950940" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_637510085486950940" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract_637510085486940926" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_637510085486950940" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_NumberOfWarrantsExercised" xlink:label="ptgx_NumberOfWarrantsExercised_637510085486950940" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract_637510085486940926" xlink:to="ptgx_NumberOfWarrantsExercised_637510085486950940" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="ptgx_StockIssuedDuringPeriodSharesWarrantsExercised_637510085486950940" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract_637510085486940926" xlink:to="ptgx_StockIssuedDuringPeriodSharesWarrantsExercised_637510085486950940" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637510085486950940" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract_637510085486940926" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637510085486950940" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_StockExchangedForPreFundedWarrants" xlink:label="ptgx_StockExchangedForPreFundedWarrants_637510085486950940" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract_637510085486940926" xlink:to="ptgx_StockExchangedForPreFundedWarrants_637510085486950940" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637510085486960932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract_637510085486940926" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637510085486960932" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637510085486960932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract_637510085486940926" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637510085486960932" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ClassOfWarrantOrRightTermOfWarrants" xlink:label="ptgx_ClassOfWarrantOrRightTermOfWarrants_637510085486960932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract_637510085486940926" xlink:to="ptgx_ClassOfWarrantOrRightTermOfWarrants_637510085486960932" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_637510085486960932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract_637510085486940926" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_637510085486960932" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_637510085486960932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract_637510085486940926" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_637510085486960932" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Equity Plans - Narrative (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637510085486970930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637510085486970930" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637510085486970930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637510085486970930" xlink:to="us-gaap_AwardTypeAxis_637510085486970930" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637510085486970930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637510085486970930" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637510085486970930" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember" xlink:label="ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember_637510085486970930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637510085486970930" xlink:to="ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember_637510085486970930" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_NonEmployeeDirectorInitialStockOptionsMember" xlink:label="ptgx_NonEmployeeDirectorInitialStockOptionsMember_637510085486970930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember_637510085486970930" xlink:to="ptgx_NonEmployeeDirectorInitialStockOptionsMember_637510085486970930" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_NonemployeeDirectorAnnualRefresherStockOptionsMember" xlink:label="ptgx_NonemployeeDirectorAnnualRefresherStockOptionsMember_637510085486970930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember_637510085486970930" xlink:to="ptgx_NonemployeeDirectorAnnualRefresherStockOptionsMember_637510085486970930" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637510085486970930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637510085486970930" xlink:to="us-gaap_PlanNameAxis_637510085486970930" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637510085486970930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637510085486970930" xlink:to="us-gaap_PlanNameDomain_637510085486970930" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_StockOptionAndIncentivePlanAsAmendedAndRestated2007Member" xlink:label="ptgx_StockOptionAndIncentivePlanAsAmendedAndRestated2007Member_637510085486970930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637510085486970930" xlink:to="ptgx_StockOptionAndIncentivePlanAsAmendedAndRestated2007Member_637510085486970930" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_EquityIncentivePlan2016Member" xlink:label="ptgx_EquityIncentivePlan2016Member_637510085486970930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637510085486970930" xlink:to="ptgx_EquityIncentivePlan2016Member_637510085486970930" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_InducementStockPlanMember" xlink:label="ptgx_InducementStockPlanMember_637510085486970930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637510085486970930" xlink:to="ptgx_InducementStockPlanMember_637510085486970930" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_637510085486980946" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637510085486970930" xlink:to="us-gaap_VestingAxis_637510085486980946" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_637510085486980946" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_637510085486980946" xlink:to="us-gaap_VestingDomain_637510085486980946" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_637510085486980946" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_637510085486980946" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_637510085486980946" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637510085486980946" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637510085486970930" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637510085486980946" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_637510085486980946" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637510085486980946" xlink:to="us-gaap_RelatedPartyDomain_637510085486980946" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrincipalOwnerMember" xlink:label="us-gaap_PrincipalOwnerMember_637510085486980946" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_637510085486980946" xlink:to="us-gaap_PrincipalOwnerMember_637510085486980946" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637510085486980946" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637510085486970930" xlink:to="srt_RangeAxis_637510085486980946" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637510085486980946" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637510085486980946" xlink:to="srt_RangeMember_637510085486980946" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637510085486980946" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637510085486980946" xlink:to="srt_MinimumMember_637510085486980946" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637510085486980946" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637510085486980946" xlink:to="srt_MaximumMember_637510085486980946" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637510085486980946" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637510085486970930" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637510085486980946" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637510085486980946" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637510085486980946" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637510085486980946" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637510085486990934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637510085486980946" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637510085486990934" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_637510085486990934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637510085486980946" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_637510085486990934" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum" xlink:label="ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum_637510085486990934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637510085486980946" xlink:to="ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum_637510085486990934" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_637510085486990934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637510085486980946" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_637510085486990934" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_637510085486990934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637510085486980946" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_637510085486990934" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants" xlink:label="ptgx_ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants_637510085486990934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637510085486980946" xlink:to="ptgx_ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants_637510085486990934" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo" xlink:label="ptgx_ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo_637510085486990934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637510085486980946" xlink:to="ptgx_ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo_637510085486990934" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureEquityPlansActivityDetails" xlink:type="extended" xlink:title="41302 - Disclosure - Equity Plans - Activity (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637510085487000933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637510085487000933" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637510085487000933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637510085487000933" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637510085487000933" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637510085487000933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637510085487000933" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637510085487000933" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637510085487000933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637510085487000933" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637510085487000933" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_637510085487000933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637510085487000933" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_637510085487000933" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6375100854870009331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637510085487000933" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6375100854870009331" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637510085487000933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637510085487000933" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637510085487000933" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_637510085487000933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637510085487000933" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_637510085487000933" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637510085487000933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637510085487000933" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637510085487000933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637510085487000933" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637510085487000933" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637510085487000933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637510085487000933" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637510085487000933" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637510085487000933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637510085487000933" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637510085487000933" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_637510085487010941" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637510085487000933" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_637510085487010941" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637510085487010941" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637510085487000933" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637510085487010941" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637510085487010941" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637510085487000933" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637510085487010941" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_637510085487010941" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637510085487000933" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_637510085487010941" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637510085487010941" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637510085487010941" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637510085487010941" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637510085487010941" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637510085487010941" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_637510085487010941" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637510085487010941" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_637510085487010941" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_637510085487010941" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637510085487010941" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_637510085487010941" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:label="ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_637510085487010941" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_637510085487010941" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637510085487010941" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_637510085487010941" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637510085487010941" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_637510085487020932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_637510085487010941" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_637510085487020932" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_637510085487020932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_637510085487010941" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_637510085487020932" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_637510085487020932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_637510085487020932" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637510085487020932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637510085487020932" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockOptionsValuationAssumptionsDetails" xlink:type="extended" xlink:title="41303 - Disclosure - Equity Plans - Employee Stock Options Valuation Assumptions (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637510085487020932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637510085487020932" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637510085487020932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637510085487020932" xlink:to="us-gaap_AwardTypeAxis_637510085487020932" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637510085487020932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637510085487020932" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637510085487020932" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637510085487020932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637510085487020932" xlink:to="us-gaap_EmployeeStockOptionMember_637510085487020932" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637510085487030943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637510085487020932" xlink:to="srt_RangeAxis_637510085487030943" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637510085487030943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637510085487030943" xlink:to="srt_RangeMember_637510085487030943" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637510085487030943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637510085487030943" xlink:to="srt_MinimumMember_637510085487030943" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637510085487030943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637510085487030943" xlink:to="srt_MaximumMember_637510085487030943" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637510085487030943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637510085487020932" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637510085487030943" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637510085487030943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637510085487030943" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637510085487030943" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_637510085487030943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637510085487030943" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_637510085487030943" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_637510085487030943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637510085487030943" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_637510085487030943" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_637510085487030943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637510085487030943" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_637510085487030943" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_637510085487030943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637510085487030943" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_637510085487030943" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureEquityPlansRestrictedStockUnitsDetails" xlink:type="extended" xlink:title="41304 - Disclosure - Equity Plans - Restricted Stock Units - (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636590679422769450" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637510085487040944" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636590679422769450" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637510085487040944" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637510085487040944" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637510085487040944" xlink:to="us-gaap_PlanNameAxis_637510085487040944" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637510085487040944" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637510085487040944" xlink:to="us-gaap_PlanNameDomain_637510085487040944" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_InducementStockPlanMember" xlink:label="ptgx_InducementStockPlanMember_637510085487040944" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637510085487040944" xlink:to="ptgx_InducementStockPlanMember_637510085487040944" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637510085487040944" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637510085487040944" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637510085487040944" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_NumberOfEqualInstallmentsRequiredForVestingOfRestrictedStockUnits" xlink:label="ptgx_NumberOfEqualInstallmentsRequiredForVestingOfRestrictedStockUnits_637510085487040944" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637510085487040944" xlink:to="ptgx_NumberOfEqualInstallmentsRequiredForVestingOfRestrictedStockUnits_637510085487040944" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637510085487040944" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637510085487040944" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637510085487040944" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637510085487040944" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637510085487040944" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637510085487040944" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637510085487040944" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637510085487040944" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637510085487040944" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_637510085487040944" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637510085487040944" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_637510085487040944" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_637510085487040944" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637510085487040944" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_637510085487040944" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_637510085487040944" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637510085487040944" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_637510085487040944" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6375100854870409441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637510085487040944" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6375100854870409441" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637510085487040944" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637510085487040944" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637510085487040944" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_637510085487040944" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637510085487040944" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_637510085487040944" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637510085487050932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637510085487040944" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637510085487050932" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_637510085487050932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637510085487040944" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_637510085487050932" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_637510085487050932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637510085487040944" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_637510085487050932" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_637510085487050932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637510085487040944" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_637510085487050932" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockPurchasePlanDetails" xlink:type="extended" xlink:title="41305 - Disclosure - Equity Plans - Employee Stock Purchase Plan (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637510085487050932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637510085487050932" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637510085487050932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637510085487050932" xlink:to="us-gaap_PlanNameAxis_637510085487050932" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637510085487050932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637510085487050932" xlink:to="us-gaap_PlanNameDomain_637510085487050932" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_EmployeeStockPurchasePlan2016Member" xlink:label="ptgx_EmployeeStockPurchasePlan2016Member_637510085487050932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637510085487050932" xlink:to="ptgx_EmployeeStockPurchasePlan2016Member_637510085487050932" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637510085487050932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637510085487050932" xlink:to="us-gaap_AwardTypeAxis_637510085487050932" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637510085487060943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637510085487050932" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637510085487060943" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember_637510085487060943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637510085487060943" xlink:to="us-gaap_EmployeeStockMember_637510085487060943" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637510085487060943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637510085487050932" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637510085487060943" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_637510085487060943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637510085487060943" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_637510085487060943" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_637510085487060943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637510085487060943" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_637510085487060943" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_637510085487060943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637510085487060943" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_637510085487060943" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_637510085487060943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637510085487060943" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_637510085487060943" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_637510085487060943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637510085487060943" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_637510085487060943" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum" xlink:label="ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum_637510085487060943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637510085487060943" xlink:to="ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum_637510085487060943" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualNumberOfAdditionalSharesAuthorized" xlink:label="ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualNumberOfAdditionalSharesAuthorized_637510085487060943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637510085487060943" xlink:to="ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualNumberOfAdditionalSharesAuthorized_637510085487060943" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637510085487060943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637510085487060943" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637510085487060943" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_637510085487060943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637510085487060943" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_637510085487060943" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_637510085487070939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637510085487060943" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_637510085487070939" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_637510085487070939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637510085487060943" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_637510085487070939" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_637510085487070939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637510085487060943" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_637510085487070939" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureEquityPlansStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="41306 - Disclosure - Equity Plans - Stock-based Compensation Expense (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637510085487070939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637510085487070939" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637510085487070939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637510085487070939" xlink:to="us-gaap_IncomeStatementLocationAxis_637510085487070939" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637510085487070939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637510085487070939" xlink:to="us-gaap_IncomeStatementLocationDomain_637510085487070939" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_637510085487070939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637510085487070939" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_637510085487070939" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_637510085487070939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637510085487070939" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_637510085487070939" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637510085487070939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637510085487070939" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637510085487070939" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637510085487080945" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637510085487070939" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637510085487080945" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_637510085487080945" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637510085487070939" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_637510085487080945" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637510085487080945" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637510085487070939" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637510085487080945" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureIncomeTaxesProvisionAndComponentsOfNetLossDetails" xlink:type="extended" xlink:title="41501 - Disclosure - Income Taxes - Provision and Components of Net Loss (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_636507492912358877" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637510085487080945" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_636507492912358877" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637510085487080945" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_637510085487080945" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_636507492912358877" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_637510085487080945" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_637510085487080945" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_637510085487080945" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_637510085487080945" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_637510085487080945" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_637510085487080945" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_637510085487080945" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637510085487080945" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_637510085487080945" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637510085487080945" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureIncomeTaxesComponentsOfFederalStateAndForeignIncomeTaxExpenseBenefitDetails" xlink:type="extended" xlink:title="41502 - Disclosure - Income Taxes - Components of Federal, State and Foreign Income Tax Expense (Benefit) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_637510085487080945" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_637510085487080945" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_637510085487080945" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_637510085487080945" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_637510085487080945" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_637510085487090950" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_637510085487080945" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_637510085487090950" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_637510085487090950" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_637510085487090950" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_637510085487090950" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_637510085487090950" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_637510085487090950" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_637510085487090950" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_637510085487090950" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_637510085487090950" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637510085487090950" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637510085487090950" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="8" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureIncomeTaxesProvisionDifferenceFromFederalStatutoryRateDetails" xlink:type="extended" xlink:title="41503 - Disclosure - Income Taxes - Provision Difference from Federal Statutory Rate (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637510085487090950" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637510085487090950" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637510085487090950" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637510085487090950" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637510085487090950" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637510085487090950" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637510085487090950" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637510085487090950" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAdjustmentPercent" xlink:label="ptgx_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAdjustmentPercent_637510085487090950" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637510085487090950" xlink:to="ptgx_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAdjustmentPercent_637510085487090950" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_637510085487090950" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637510085487090950" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_637510085487090950" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637510085487090950" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637510085487090950" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637510085487090950" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_637510085487090950" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637510085487090950" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_637510085487090950" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637510085487090950" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637510085487090950" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637510085487090950" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndValuationAllowanceDetails" xlink:type="extended" xlink:title="41504 - Disclosure - Income Taxes - Components of Deferred Tax Assets and Valuation Allowance (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637510085487100945" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637510085487100945" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_637510085487100945" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637510085487100945" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_637510085487100945" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637510085487100945" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_637510085487100945" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637510085487100945" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_637510085487100945" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_637510085487100945" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_637510085487100945" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther" xlink:label="ptgx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther_637510085487100945" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_637510085487100945" xlink:to="ptgx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther_637510085487100945" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="ptgx_DeferredTaxAssetsOperatingLeaseLiability_637510085487100945" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_637510085487100945" xlink:to="ptgx_DeferredTaxAssetsOperatingLeaseLiability_637510085487100945" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_637510085487110948" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_637510085487100945" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_637510085487110948" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_637510085487110948" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_637510085487100945" xlink:to="us-gaap_DeferredTaxAssetsGross_637510085487110948" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_637510085487110948" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637510085487100945" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_637510085487110948" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_637510085487110948" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_637510085487110948" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_637510085487110948" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_637510085487110948" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_637510085487110948" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_637510085487110948" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_637510085487110948" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637510085487100945" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_637510085487110948" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_637510085487110948" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637510085487100945" xlink:to="us-gaap_DeferredTaxAssetsNet_637510085487110948" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceAbstract" xlink:label="us-gaap_ValuationAllowanceAbstract_637510085487110948" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ValuationAllowanceAbstract_637510085487110948" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_637510085487110948" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceAbstract_637510085487110948" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_637510085487110948" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails" xlink:type="extended" xlink:title="41505 - Disclosure - Income Taxes - Net Operating Loss Carryforwards (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable_637510085487110948" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable_637510085487110948" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_637510085487120945" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_637510085487110948" xlink:to="us-gaap_IncomeTaxAuthorityAxis_637510085487120945" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_637510085487120945" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_637510085487120945" xlink:to="us-gaap_IncomeTaxAuthorityDomain_637510085487120945" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember_637510085487120945" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_637510085487120945" xlink:to="us-gaap_StateAndLocalJurisdictionMember_637510085487120945" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_637510085487120945" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_637510085487120945" xlink:to="us-gaap_DomesticCountryMember_637510085487120945" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_637510085487120945" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_637510085487110948" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_637510085487120945" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_637510085487120945" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis_637510085487120945" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_637510085487120945" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AustralianTaxationOfficeMember" xlink:label="us-gaap_AustralianTaxationOfficeMember_637510085487120945" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain_637510085487120945" xlink:to="us-gaap_AustralianTaxationOfficeMember_637510085487120945" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_637510085487120945" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_637510085487110948" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_637510085487120945" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_637510085487120945" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637510085487120945" xlink:to="us-gaap_OperatingLossCarryforwards_637510085487120945" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637510085487120945" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637510085487120945" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637510085487120945" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_OperatingLossCarryforwardsNoExpiration" xlink:label="ptgx_OperatingLossCarryforwardsNoExpiration_637510085487120945" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637510085487120945" xlink:to="ptgx_OperatingLossCarryforwardsNoExpiration_637510085487120945" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureIncomeTaxesResearchAndDevelopmentTaxCreditCarryforwardsDetails" xlink:type="extended" xlink:title="41506 - Disclosure - Income Taxes - Research and Development Tax Credit Carryforwards (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="us-gaap_TaxCreditCarryforwardTable_637510085487120945" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_TaxCreditCarryforwardTable_637510085487120945" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_637510085487130948" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardTable_637510085487120945" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_637510085487130948" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_637510085487130948" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis_637510085487130948" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_637510085487130948" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AustralianTaxationOfficeMember" xlink:label="us-gaap_AustralianTaxationOfficeMember_637510085487130948" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain_637510085487130948" xlink:to="us-gaap_AustralianTaxationOfficeMember_637510085487130948" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_637510085487130948" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardTable_637510085487120945" xlink:to="us-gaap_IncomeTaxAuthorityAxis_637510085487130948" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_637510085487130948" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_637510085487130948" xlink:to="us-gaap_IncomeTaxAuthorityDomain_637510085487130948" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember_637510085487130948" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_637510085487130948" xlink:to="us-gaap_StateAndLocalJurisdictionMember_637510085487130948" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_637510085487130948" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_637510085487130948" xlink:to="us-gaap_DomesticCountryMember_637510085487130948" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_637510085487130948" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardTable_637510085487120945" xlink:to="us-gaap_TaxCreditCarryforwardAxis_637510085487130948" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_637510085487130948" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis_637510085487130948" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_637510085487130948" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember_637510085487130948" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain_637510085487130948" xlink:to="us-gaap_ResearchMember_637510085487130948" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="us-gaap_TaxCreditCarryforwardLineItems_637510085487130948" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardTable_637510085487120945" xlink:to="us-gaap_TaxCreditCarryforwardLineItems_637510085487130948" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount_637510085487130948" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems_637510085487130948" xlink:to="us-gaap_TaxCreditCarryforwardAmount_637510085487130948" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails" xlink:type="extended" xlink:title="41507 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_637510085487140945" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_637510085487140945" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_637510085487140945" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_637510085487140945" xlink:to="us-gaap_UnrecognizedTaxBenefits_637510085487140945" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_637510085487140945" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_637510085487140945" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_637510085487140945" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_637510085487140945" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_637510085487140945" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_637510085487140945" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_637510085487140945" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_637510085487140945" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_637510085487140945" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_6375100854871409451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_637510085487140945" xlink:to="us-gaap_UnrecognizedTaxBenefits_6375100854871409451" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_637510085487140945" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_637510085487140945" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureIncomeTaxes2020TaxLawUpdatesDetails" xlink:type="extended" xlink:title="41508 - Disclosure - Income Taxes - 2020 Tax Law Updates (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_636607825133049664" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_IncomeTaxTable" xlink:label="ptgx_IncomeTaxTable_637510085487140945" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_636607825133049664" xlink:to="ptgx_IncomeTaxTable_637510085487140945" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_637510085487140945" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_IncomeTaxTable_637510085487140945" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_637510085487140945" order="1" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_637510085487140945" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis_637510085487140945" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_637510085487140945" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AustralianTaxationOfficeMember" xlink:label="us-gaap_AustralianTaxationOfficeMember_637510085487150951" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain_637510085487140945" xlink:to="us-gaap_AustralianTaxationOfficeMember_637510085487150951" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_IncomeTaxLineItems" xlink:label="ptgx_IncomeTaxLineItems_637510085487150951" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_IncomeTaxTable_637510085487140945" xlink:to="ptgx_IncomeTaxLineItems_637510085487150951" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637510085487150951" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ptgx_IncomeTaxLineItems_637510085487150951" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637510085487150951" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_637510085487150951" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637510085487150951" xlink:to="us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_637510085487150951" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_NetOperatingLossCarryback" xlink:label="ptgx_NetOperatingLossCarryback_637510085487150951" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637510085487150951" xlink:to="ptgx_NetOperatingLossCarryback_637510085487150951" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_DeductionOfTaxableIncomePercentage" xlink:label="ptgx_DeductionOfTaxableIncomePercentage_637510085487150951" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637510085487150951" xlink:to="ptgx_DeductionOfTaxableIncomePercentage_637510085487150951" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_CaliforniaNetOperatingLossDeductionsLimitOfIncome" xlink:label="ptgx_CaliforniaNetOperatingLossDeductionsLimitOfIncome_637510085487150951" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637510085487150951" xlink:to="ptgx_CaliforniaNetOperatingLossDeductionsLimitOfIncome_637510085487150951" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_MaximumOffsetOfCaliforniaTax" xlink:label="ptgx_MaximumOffsetOfCaliforniaTax_637510085487150951" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637510085487150951" xlink:to="ptgx_MaximumOffsetOfCaliforniaTax_637510085487150951" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureNetLossPerShareComputationDetails" xlink:type="extended" xlink:title="41601 - Disclosure - Net Loss per Share - Computation (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_636878483028362637" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract_637510085487150951" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_636878483028362637" xlink:to="us-gaap_NetIncomeLossAbstract_637510085487150951" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637510085487160950" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_637510085487150951" xlink:to="us-gaap_NetIncomeLoss_637510085487160950" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_637510085487160950" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_636878483028362637" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_637510085487160950" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_637510085487160950" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_637510085487160950" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_637510085487160950" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_637510085487160950" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_637510085487160950" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_637510085487160950" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" xlink:type="extended" xlink:title="41602 - Disclosure - Net Loss per Share - Antidilutive Securities (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637510085487160950" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637510085487160950" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637510085487160950" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637510085487160950" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637510085487160950" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_637510085487160950" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637510085487160950" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_637510085487160950" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637510085487160950" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637510085487160950" xlink:to="us-gaap_EmployeeStockOptionMember_637510085487160950" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoteWarrantMember" xlink:label="us-gaap_NoteWarrantMember_637510085487160950" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637510085487160950" xlink:to="us-gaap_NoteWarrantMember_637510085487160950" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_637510085487160950" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637510085487160950" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_637510085487160950" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember_637510085487160950" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637510085487160950" xlink:to="us-gaap_EmployeeStockMember_637510085487160950" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637510085487160950" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637510085487160950" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637510085487160950" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637510085487160950" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637510085487160950" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637510085487160950" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protagonist-inc.com/role/DisclosureRestructuringDetails" xlink:type="extended" xlink:title="41701 - Disclosure - Restructuring (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract" />
    <loc xlink:type="locator" xlink:href="ptgx-20201231.xsd#ptgx_PercentageOfEmployeeBaseImpactedByRestructuringPlan" xlink:label="ptgx_PercentageOfEmployeeBaseImpactedByRestructuringPlan_637510085487170942" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="ptgx_PercentageOfEmployeeBaseImpactedByRestructuringPlan_637510085487170942" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges_637510085487170942" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringCharges_637510085487170942" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>ptgx-20201231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:ptgx="http://www.protagonist-inc.com/20201231"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ptgx-20201231.xsd" xlink:type="simple"/>
    <context id="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_8i0o-skGv0azxibqP5J0Sw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_gRii_fhTDk-huJXJ4UdCVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_l4fVgIKvNUamq8cgrPWShQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_1odXtzTk20OYdf78bv-6Bg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:AtMarketingOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_fuC6tZWyUkSX0CU0In2zWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:AtMarketingOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_yGP8DkufmUSzKSdAVZGGrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:AtMarketingOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_yOGBS9pihEKHtHPrOQel3w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:AtMarketingOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_pKAkXlxvhUWymzMXd4z0KQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:AtMarketingOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_g3Hzv49Z9UGzLyh7mHry3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:AtMarketingOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0ejK20BXz0WlKLitqx2O8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2020_To_5_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_4Kh5pBSECkypUOYucapGkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2020_To_5_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GUwt944WL0uotoTy8UvAVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_8hhxYFRmo0SmVd81EZvSIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:AtMarketingOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YoX0pmi6v0e7iaLUqL8YHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_s2huIh7nUE-p0G6YC_4NhQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:AtMarketingOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2018_To_8_31_2018_srt_CounterpartyNameAxis_ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_j6JfV1HdAU2VL5Av0thXjA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:SecuritiesPurchaseAgreementWithAccreditedInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_DzfKu3ClMU-xwF3bQXP75g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:AtMarketingOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dCBVr6oE30ePiiOHcTfKVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kO1ACPpowkmGPJDGZK-oJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Snnu9PZVQ0SEUhYgRyxRiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__O0aR-_h3kehqx2ICyExMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_PlWiT4oT-U-bNw8fFk2KMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_uLTlN99bs0KmTjmkSZDZtQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Ju5ZnA-BP0-NMMz3dq161g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8FClLya93E-DGTAwVTTPLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_XXYc_qkz7EiiqGkSkihtnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jUszAT7WFEGWt9BqEE93VQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2yPAw-zRyEu3cnkGbo1BJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_xs61-k8jCUqUc6YQqT9vow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_SBZjOH40VUWH7eyCsHOxeQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_hOb9HKro90mY6okLdtMCHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_kre8MFx27UW7IW8Z8ld4mw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_PlanNameAxis_ptgx_EmployeeStockPurchasePlan2016Member_GMhjmWwDW0OtNx4nu-iZpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:EmployeeStockPurchasePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_ptgx_EquityIncentivePlan2016Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_PrincipalOwnerMember_ExSFV52WIEW8KwIeap4Bxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:EquityIncentivePlan2016Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:PrincipalOwnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_ptgx_EquityIncentivePlan2016Member_uoGvCjLpdkK2StizIEWf5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ptgx:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_PlanNameAxis_ptgx_EquityIncentivePlan2016Member_F6df0QQhrU6i9GJCdhqPDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_PlanNameAxis_ptgx_EmployeeStockPurchasePlan2016Member_C-KW8xTQ90aKeamFtuPrNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:EmployeeStockPurchasePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_7_31_2016_us-gaap_PlanNameAxis_ptgx_StockOptionAndIncentivePlanAsAmendedAndRestated2007Member_Q8ASK54YZEa5T6ejJrDeJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:StockOptionAndIncentivePlanAsAmendedAndRestated2007Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-07-31</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2018_us-gaap_PlanNameAxis_ptgx_InducementStockPlanMember_3YM3Ufo1cE24pa1he7vSAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:InducementStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="As_Of_7_31_2016_us-gaap_PlanNameAxis_ptgx_EquityIncentivePlan2016Member_X9g55Fo86EaIMiverpOurg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-07-31</instant>
        </period>
    </context>
    <context id="As_Of_7_31_2016_us-gaap_PlanNameAxis_ptgx_EmployeeStockPurchasePlan2016Member_nIsT07dVFEyHghpDxZtPUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:EmployeeStockPurchasePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-07-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PlanNameAxis_ptgx_EmployeeStockPurchasePlan2016Member_U56QTHCCKEa3NKcZoAUUQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:EmployeeStockPurchasePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_JMFKex3X3ESe5V_o92xQHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_H_jddmjI8U639x1Gtx8lig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zQrIRwTjBUOg--pd-u3-dg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_gc3icTBxzk6z-01YFoMDcQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_jA3zrw10lUyty-qrneby5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_K2QYwOvGJUmiUg9ZTS1GqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_pgiKOe1_8Ey6gxPzOimNvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ZbXixFzUcUGHwVYHkj-L5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_5o84alY-YEe58-Qyx7km0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_-b9HV2D17EWHTYX42MHUeg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_ptgx_StockOptionAndIncentivePlanAsAmendedAndRestated2007Member_jktel6yu6kK7pWrzaSuY2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ptgx:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:StockOptionAndIncentivePlanAsAmendedAndRestated2007Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_ptgx_EquityIncentivePlan2016Member_eF2snCub_Eahp8p8BWAONg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ptgx:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PlanNameAxis_ptgx_InducementStockPlanMember_KE5aREx68U2i_cgMV6Pj_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:InducementStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_PlanNameAxis_ptgx_InducementStockPlanMember_uV2sRVuEEkSt7OepkbYJpA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:InducementStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_ptgx_InducementStockPlanMember_yAEykxLHsUSSNG0CUEUjkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:InducementStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_ptgx_NonemployeeDirectorAnnualRefresherStockOptionsMember_us-gaap_PlanNameAxis_ptgx_EquityIncentivePlan2016Member_ZyLhj6L8U0eoAkYv_BvxHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ptgx:NonemployeeDirectorAnnualRefresherStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_ptgx_StockOptionAndIncentivePlanAsAmendedAndRestated2007Member_9U0z6hszwEGi_P9hNkxE5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ptgx:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:StockOptionAndIncentivePlanAsAmendedAndRestated2007Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_ptgx_NonEmployeeDirectorInitialStockOptionsMember_us-gaap_PlanNameAxis_ptgx_EquityIncentivePlan2016Member_jCMUIflu30Chq-y0-NBBeQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ptgx:NonEmployeeDirectorInitialStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2016_To_7_31_2016_us-gaap_PlanNameAxis_ptgx_EquityIncentivePlan2016Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_Pl5aD902hUizaGvF0_Ag0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:EquityIncentivePlan2016Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-01</startDate>
            <endDate>2016-07-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2017_zWxDm9xYR0y9NPetyRPWMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
        </entity>
        <period>
            <instant>2017-03-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_y_lWVCdXEkurpTEfNZLamw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_62ZwKcYzp0eJm6qW-U5FhA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_eremZ34RS0u0oYjA1BqUtA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_LicenseAndCollaborativeRevenueMember_us-gaap_TypeOfArrangementAxis_ptgx_PhaseTwoClinicalTrialMember_BryyTsUuxEmwlP3YXd1gUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:LicenseAndCollaborativeRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:PhaseTwoClinicalTrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_FinancialServiceOtherMember_NBguqYBUHku6qOzTYn42VQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:FinancialServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_FinancialServiceOtherMember_mIs-a5_M8Ey3l6XrIQVjEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:FinancialServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_srt_ProductOrServiceAxis_us-gaap_FinancialServiceOtherMember_us-gaap_TypeOfArrangementAxis_ptgx_PhaseTwoClinicalTrialMember_lxJPPTHjz0OKFor2aG-yUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:FinancialServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:PhaseTwoClinicalTrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_vfjwayMYI0exJuQhXetAgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_TypeOfArrangementAxis_ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member_D025L8JB50ySUyUf-9SxEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_TypeOfArrangementAxis_ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member__cZnEeVU-k2FtUN8yE2uXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_aheLDwWGAUeZQPwvqQVzZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_R76-sonyg0uleRlU84c1jA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2020_srt_StatementGeographicalAxis_country_AU_xtyNGWRadEizaBfhvBzeOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_srt_StatementGeographicalAxis_country_AU_NLZm2dhYp0akSbHnuso5uQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_srt_StatementGeographicalAxis_country_AU_J8ZYPbFagkiWnbQOuxYMlQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_th9MyYrG-kOe4hdG7OWBYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ptgx_LaboratoryEquipmentMember_mEJwmnq980i_X0P_Pcmk2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ptgx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ptgx_FurnitureAndComputerEquipmentMember_exDGgu7H0EeD4_dWpv6kGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ptgx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_XC_R2C90rU2vG1oQ__VR5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ptgx_LaboratoryEquipmentMember_nelsuh6t-0G0_6xLI9TWow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ptgx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ptgx_FurnitureAndComputerEquipmentMember_NDe2QtR56ES1v6jXmD0-nw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ptgx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_12_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_agJoJQfoR0S_u2bStgWXxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2020_To_5_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_SalesAgreementFrom2017Member_tZp0EkKbX0KKXBjYlmFbBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:SalesAgreementFrom2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_SalesAgreementFrom2017Member_4-Top2Z7HEGnoubmcpaUQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:SalesAgreementFrom2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember_jKn-PPj_GUaOCF64euSSCg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:CommonStockPreferredStockDebtSecuritiesAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_SalesAgreementFrom2017Member_qkNym65oekWLKJu7qHfcDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:SalesAgreementFrom2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_NzJb7MJr5kOz1KdJ49FjiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a0-ROxHHoku-VkXZ66GSxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DrgcQsWLEUegsx9gQx7K3w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_U65aTwB6ukC7yChGSORF8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_hYnmxupXL0yNnBeGNa_apA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_8neM6oYNfUCXGVbkjiKc6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_hM1ehx9ooUyOxNDleNQQrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_e0vNep3u2EaW55wxjoopSw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_ZealandPharmaMember_EFYZYS2pyEi6iqunSu7VTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:ZealandPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2020_srt_CounterpartyNameAxis_ptgx_ZealandPharmaMember_Z1DSgl1avkK9ttj7siMlow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:ZealandPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_ptgx_OverseasFindingsMember_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_Ni5ZAEOX-UqebOcqRpBGAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">ptgx:OverseasFindingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_IncomeTaxAuthorityAxis_ptgx_OverseasFindingsMember_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_-NKTzbOHOE-9ja3vgdH8Wg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">ptgx:OverseasFindingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_GicVha9PoUm3BEgizkKmRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ptgx:RevenueSourceAxis">ptgx:SmallBusinessInnovationResearchGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_Ug74VWMPT0WLeBk_hPZxCg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ptgx:RevenueSourceAxis">ptgx:SmallBusinessInnovationResearchGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_6_1_2020_To_6_30_2020_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_jtE4FD5lLEuVCNA6A73V0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptgx:TermLoanCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_s0YO-nVtg0inq7Ue9XzaAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_N8l2Scu7LECQV05gQhBpcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:AtMarketingOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_BalanceSheetLocationAxis_ptgx_AccruedLiabilitiesAndOtherPayablesMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_YMLB38vu2U6BmlQp_T1TCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ptgx:AccruedLiabilitiesAndOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_BalanceSheetLocationAxis_ptgx_AccruedLiabilitiesAndOtherPayablesMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_nqaO_sxQyESRu9HD_l6AJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ptgx:AccruedLiabilitiesAndOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2020_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_cqtN9FUFIUSxqCPfOydBcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptgx:TermLoanCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_3_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_LicenseAndCollaborativeRevenueMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendmentMember_OXDfxfH58kqhheU3GQGUvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:LicenseAndCollaborativeRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_MilestonePaymentsMember_us-gaap_TypeOfArrangementAxis_ptgx_SecondGenerationDevelopmentCompoundMember_sAqgbJv3QkOF-0V4dOsnIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:MilestonePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:SecondGenerationDevelopmentCompoundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_LicenseAndCollaborativeRevenueMember_TvNWwGu2eEC6vYE7HcfZ-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:LicenseAndCollaborativeRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendmentMember_GtedaLqT9E2-CCUloPfAtw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2019_To_6_30_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_LicenseAndCollaborativeRevenueMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendmentMember_XvMY8HCh9EOEQkePbHrEeg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:LicenseAndCollaborativeRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_LicenseAndCollaborativeRevenueMember_3QxHrdZZck25Pg-JQIj-nw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:LicenseAndCollaborativeRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_LicenseAndCollaborativeRevenueMember_KsXkSwmdJk6E8sIAWg2nyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:LicenseAndCollaborativeRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_7_13_2017_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_UpfrontCashPaymentMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_8ZzG4TogRUeK22l7bZWg6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:UpfrontCashPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-07-13</instant>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_LicenseAndCollaborativeRevenueMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendmentMember_y5i3Re06f0iiRKOUUagPDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:LicenseAndCollaborativeRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendmentMember_0gY4oTF5r0WEXzTC15E-FQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_X-3f2T5tzkO0bujYt1VHYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_Iek_4R-H0EOc28_Wvd-Hnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_dyHYhh53okOYGwIKFCa5Ag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_E5rQEhmdCkiUzPRvbbp87g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_CPGeoM_E_U2hv7Q6-PEH9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ZQ8gS7l_jUWwlHn2F0NYhw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ruvLYZdTr0WCWpXD9VpjZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_ptgx_JanssenLicenseAndCollaborationAgreement26May2017Member_C_BnSjKn10WVjRwNMh3ISQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:JanssenLicenseAndCollaborationAgreement26May2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2020_srt_CounterpartyNameAxis_ptgx_BiotechnologyValueFundL.pMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_ptgx_ExchangeAgreementMember_Ik7tchK9-Ue8oyRnGIgm_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:BiotechnologyValueFundL.pMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:ExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_8_6_2018_srt_CounterpartyNameAxis_ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_z3QoxAuYuUKbQDm_MCaYpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:SecuritiesPurchaseAgreementWithAccreditedInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-06</instant>
        </period>
    </context>
    <context id="As_Of_12_21_2018_srt_CounterpartyNameAxis_ptgx_BiotechnologyValueFundL.pMember_us-gaap_TypeOfArrangementAxis_ptgx_ExchangeAgreementMember_BJDxU0LhGkitpW7AZKjqUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:BiotechnologyValueFundL.pMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:ExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-21</instant>
        </period>
    </context>
    <context id="As_Of_8_6_2018_us-gaap_ClassOfWarrantOrRightAxis_ptgx_WarrantsPurchaseAmountPerSharePriceTwoMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_GKATHoBzkEKJSJRivO9SBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ptgx:WarrantsPurchaseAmountPerSharePriceTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-06</instant>
        </period>
    </context>
    <context id="As_Of_8_6_2018_us-gaap_ClassOfWarrantOrRightAxis_ptgx_WarrantsPurchaseAmountPerSharePriceOneMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_186kOF-nN0ak3sZ7B7mYIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ptgx:WarrantsPurchaseAmountPerSharePriceOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-06</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2017_uBPncpspM02T8SbWW1EWfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_rK3dysi-wkKgewxxLVB-Eg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_Py5g_H7ZS0mto91KY61Pqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember_RcUZPhnZn0yecR06vLTPmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_uVbhr5AkeEyXPse4j8Vtdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">ptgx:UsTreasuryAndAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_5KKCr5eHQEygdYItDdw9RQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_uzJVCv1ct0mqY9ZIAM4vDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_o8lJ8OmQqUuIzV1asN5-7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember_5sHQft-r50evFl5UcMy5tw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_GPbqzeyzuEyJ1N6rb_ntwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">ptgx:UsTreasuryAndAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_K9-l4NAY-kmFaLEyWQ4rSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_pDkR-5RKjEyn9NkwkBrP6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember__UoGf4iXl0-vwHR1RxDl_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_XbTJJV-aUUKkYoe9CCHwlg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember_9p8nfsfW6EKn9p_BdoPZZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_wRs9ZU4Bekq5XgF2kvDBig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">ptgx:UsTreasuryAndAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_FOvlkFRNTEmtTcC9nd5x6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_WRekQb2CvU25FJAvTO5BBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_wEd8XK0sFEmZYH9nDuBq9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember_LaPN7nYw4E2V8LpCkDOHiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_EE8cQuRZ_UmapNGf-h67ng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">ptgx:UsTreasuryAndAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_z50eFBlU2Ee-Syluh-tL9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_aNicgv3ij0eMkeM8EWdR-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wuEhdkxUmkStpEwG9Rhsew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_j8Vx4K3ol0uyTIToUJMT7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_NoteWarrantMember_Dh7N5o3ASEqLQ1SQSZ-iVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:NoteWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_EAbWdmtN8E-9JmN6JhqI_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember_NJHZZccCf0a0YBEfSxOf_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_YwszWFT2W0SpYFDZtJaxqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_NoteWarrantMember_hBQwDx7S2ku26XmUy_6zMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:NoteWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_ooH8n7lz1E2xsje_V6E6Pg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember_bPuHxQjxo0m7NoN0XMxgBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_Ncd5mq0QL0CQQWUc-ElGVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_NoteWarrantMember_Ho8wL7fGKESaYVujfGx0mg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:NoteWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_WaiBERwpsUS_GxNwwF2grw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember_kEHM0bCdFEWZb0Y5aC4cvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_xH_J2AHGC0KEIm_y_jQVKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_4LOUmK3YM0qXjTWQBtwesw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_S8RyftvJ9k2sDQkwn9INpg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_hCAO4XqfOUC_Xr8C0zgyIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_5KLlildJr02InYyNq32knQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_5l8l7REXdEuTVwF8ShcykQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NemxNYQEjkS5VxdYCUEGfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_enQYGgNfqUCc5y0GKYBXkg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_ptgx_BiotechnologyValueFundL.pMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_ptgx_ExchangeAgreementMember_cUqXG1yQX0uQTBHVoh090Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:BiotechnologyValueFundL.pMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:ExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bsxNEJcruUKB7husbni8Lw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2018_To_12_31_2018_srt_CounterpartyNameAxis_ptgx_BiotechnologyValueFundL.pMember_us-gaap_TypeOfArrangementAxis_ptgx_ExchangeAgreementMember_JivbDCfMDUKimc02lEUXQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:BiotechnologyValueFundL.pMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:ExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iSQxa82RA0epFzR7vgagyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YxGs3yboJkG0guGsknqgmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_ptgx_EquityIncentivePlan2016Member_Q2OzhxYJoE2GLzRZOait5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_ptgx_EmployeeStockPurchasePlan2016Member_4XSs44uQyEamm2z9D2PFFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:EmployeeStockPurchasePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_SubsidiarySaleOfStockAxis_ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember_p8qynIyKyk-zMkGoWZcW3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:CommonStockPreferredStockDebtSecuritiesAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_AtMarketOfferingMember_iy5bZi35C0SnS_cAS0HmXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2019_To_10_31_2019_srt_CounterpartyNameAxis_ptgx_AtMarketOfferingMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember_yaqgEgG5X0iZ4CZKQUqb8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:AtMarketOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:CommonStockPreferredStockDebtSecuritiesAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2019_To_10_31_2019_us-gaap_SubsidiarySaleOfStockAxis_ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember_2WMpGtC9OEOlBeqopXrQRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:CommonStockPreferredStockDebtSecuritiesAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2017_To_9_30_2017_srt_CounterpartyNameAxis_ptgx_AtMarketOfferingMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_SalesAgreementFrom2017Member__YoSlLwDmEWFZ2JYQBWSFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:AtMarketOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:SalesAgreementFrom2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2017_To_9_30_2017_us-gaap_SubsidiarySaleOfStockAxis_ptgx_CommonStockPreferredStockAndCertainDebtSecuritiesMember_zx3lVa2z8kOfh7KC7iZGpg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptgx:CommonStockPreferredStockAndCertainDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2018_To_9_30_2018_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_uaChjCsyD0SFXSDtolYQ1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ptgx:RevenueSourceAxis">ptgx:SmallBusinessInnovationResearchGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2017_To_5_31_2017_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_yYD_ZbiKRkiaHuGwQjinPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ptgx:RevenueSourceAxis">ptgx:SmallBusinessInnovationResearchGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_g6Lfapz3kUapxhOM2FxjaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_qd1j0yCx90GcZk8LgZ8W2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ptgx:RevenueSourceAxis">ptgx:SmallBusinessInnovationResearchGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_3n6ishFs0EuWYpP4sr_RiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_tYZjiAg9zECpkNJndjRsBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ptgx:RevenueSourceAxis">ptgx:SmallBusinessInnovationResearchGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember__jiivLyteUW8NPb8U-43uw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_IH_M_FrIX0SJO0xc0LNU4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ptgx:RevenueSourceAxis">ptgx:SmallBusinessInnovationResearchGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2020_srt_CounterpartyNameAxis_ptgx_ZealandPharmaMember_srt_StatementScenarioAxis_ptgx_SuccessfullyDevelopAndCommercializeRusfertideComponentWithOutPartnerMember_zvHiCT5gZESB6MhV_EqkXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:ZealandPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ptgx:SuccessfullyDevelopAndCommercializeRusfertideComponentWithOutPartnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_5_7_2019_To_5_7_2019_srt_ProductOrServiceAxis_ptgx_DevelopmentRegulatoryAndSalesMilestonePaymentsMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendmentMember_nG2wMUofPkqcS4glTe3R0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:DevelopmentRegulatoryAndSalesMilestonePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-07</startDate>
            <endDate>2019-05-07</endDate>
        </period>
    </context>
    <context id="Duration_3_7_2020_To_3_7_2020_OZuW7QpORUGdPGLaaZ6w3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
        </entity>
        <period>
            <startDate>2020-03-07</startDate>
            <endDate>2020-03-07</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_1DfwcEBf-ECRIZv8PZ8Rdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_KjsvtwPBSUeomIS3nTcYHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_srt_CounterpartyNameAxis_ptgx_BiotechnologyValueFundL.pMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_ptgx_ExchangeAgreementMember_mgjJN8kSnkmKkWqgSyHErQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:BiotechnologyValueFundL.pMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:ExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_3_1_2017_To_3_31_2017_srt_StatementGeographicalAxis_stpr_CA__NT8mR3K4kK7AM6iJIYK3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_PlanNameAxis_ptgx_InducementStockPlanMember_1aFOsX_HY0KODJxVov4uuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptgx:InducementStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_3_27_2020_To_3_27_2020_d48ZoY7v8UOWrUfq_VZsYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
        </entity>
        <period>
            <startDate>2020-03-27</startDate>
            <endDate>2020-03-27</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_cKfYUU8Sf0-u1ytV-rCvdg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptgx:TermLoanCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_29P04bh0akmybtKqt9iLyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptgx:TermLoanCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="Duration_10_1_2019_To_10_31_2019_srt_StatementScenarioAxis_ptgx_DebtInstrumentRepaymentOnOrBeforeFirstAnniversaryMember_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_-UR7DvCLZkiYmYD5NsiohA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ptgx:DebtInstrumentRepaymentOnOrBeforeFirstAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptgx:TermLoanCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2019_To_10_31_2019_srt_StatementScenarioAxis_ptgx_DebtInstrumentRepaymentBetweenFirstAndSecondAnniversaryMember_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_0-kZriq9PE--kjrBZbtCWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ptgx:DebtInstrumentRepaymentBetweenFirstAndSecondAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptgx:TermLoanCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2019_To_10_31_2019_srt_StatementScenarioAxis_ptgx_DebtInstrumentRepaymentAfterSecondAnniversaryMember_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_yTz9fr8XpUmkKw5s-q0s6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ptgx:DebtInstrumentRepaymentAfterSecondAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptgx:TermLoanCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="Duration_10_31_2019_To_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_AItPGKFJaUGXTtctj0S3sw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptgx:TermLoanCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-31</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2019_To_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember_irqRQWto80mZoPOcLzfEEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptgx:TermLoanCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2019_To_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember__7GvdZr7Sk-sWaDylYb_nQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ptgx:TermLoanCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_OTlJVqmnGkadZNc3gOI6uA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_H-NgQaNu50uhdMckH4xw9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_5_7_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendmentMember_9gK_kOJw_ESqRE-bsagxFg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-07</instant>
        </period>
    </context>
    <context id="As_Of_5_7_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_Ptg200Phase3CdClinicalTrialPrimaryClinicalEndpointMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendmentMember_Bn4vSCBoGEOTDsfBtOVnNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:Ptg200Phase3CdClinicalTrialPrimaryClinicalEndpointMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-07</instant>
        </period>
    </context>
    <context id="As_Of_5_7_2019_srt_ProductOrServiceAxis_ptgx_DevelopmentRegulatoryAndSalesMilestonePaymentsMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendmentMember_PNZUEJ__x0m4Tx70AGON6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:DevelopmentRegulatoryAndSalesMilestonePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-07</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember_us-gaap_TypeOfArrangementAxis_ptgx_CollaborationAgreementTrancheThreeMember_tvpE-SkS6k2HRTzbxgh_wg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:CollaborationAgreementTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember_us-gaap_TypeOfArrangementAxis_ptgx_CollaborationAgreementTrancheFourMember_bqQIT5Ulw0CqIqPYWi81Yw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:CollaborationAgreementTrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember_us-gaap_TypeOfArrangementAxis_ptgx_CollaborationAgreementTrancheFiveMember_zUOiK1ho7EWtoDBGEsNNOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:CollaborationAgreementTrancheFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember_d9hGXjKIFEOZdcykv_sYsw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_ptgx_SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember_mwtEbZMbFUWPqDXv33EobA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_ptgx_SecondGenerationAnalogPhase2CdClinicalTrialPrimaryClinicalEndpointMember_JacSAA95dUyCrU6tGgPPmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:SecondGenerationAnalogPhase2CdClinicalTrialPrimaryClinicalEndpointMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_ptgx_LicenseAndCollaborativeRevenueMember_8kLGBjtrT0WDvA027jn2RQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:LicenseAndCollaborativeRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_UpfrontCashPaymentMember_us-gaap_TypeOfArrangementAxis_ptgx_AmendedSecondOptInMember_cppdcoBeEkOHH_mebXmIVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:UpfrontCashPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:AmendedSecondOptInMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_UpfrontCashPaymentMember_us-gaap_TypeOfArrangementAxis_ptgx_AmendedCollaborationAgreementTrancheOneMember_c9va82PLx0uSFetk0cbloQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:UpfrontCashPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:AmendedCollaborationAgreementTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_SecondGenerationPhase2bMilestonePaymentMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendmentMember_H5wv-w3AKUSR5s2BPJL4Kg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:SecondGenerationPhase2bMilestonePaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_MilestonePaymentsMember_us-gaap_TypeOfArrangementAxis_ptgx_CollaborationAgreementTrancheThreeMember_2JbTuvZF1E6as5O_Zhxubg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:MilestonePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:CollaborationAgreementTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_LicenseAndCollaborativeRevenueMember_us-gaap_TypeOfArrangementAxis_ptgx_EstimatedVariableConsiderationMember_arxMJ0T-00eGdw9zoeZApA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:LicenseAndCollaborativeRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:EstimatedVariableConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_ptgx_SecondGenerationDevelopmentCompoundMember_P6e595XTnUiY7TVn8K6bmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:SecondGenerationDevelopmentCompoundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2019_To_6_30_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_MilestonePaymentsMember_srt_StatementScenarioAxis_srt_ProFormaMember_cUCCwM3epUW2i97GGepUZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:MilestonePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ProFormaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2019_To_6_30_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_LicenseAndCollaborativeRevenueMember_srt_StatementScenarioAxis_srt_ProFormaMember_D0E1ttaBzUyFCH2yOPFdiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:LicenseAndCollaborativeRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ProFormaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_LicenseAndCollaborativeRevenueMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendmentMember_t7Zx6qmuv02vXASmqBWLvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:JanssenBiotechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:LicenseAndCollaborativeRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:LicenseAndCollaborativeAgreementAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="Duration_12_21_2018_To_12_21_2018_srt_CounterpartyNameAxis_ptgx_BiotechnologyValueFundL.pMember_us-gaap_TypeOfArrangementAxis_ptgx_ExchangeAgreementMember_vOU5zedUDk2RWTFaLEzOWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:BiotechnologyValueFundL.pMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:ExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-21</startDate>
            <endDate>2018-12-21</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_1lnDMEXB70mrHe1LD59Ocw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_WIiZJQ_HGE6FfcxqDuIIGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_poqDHHPT202Brw2nGTuPeA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_eDAghYO6dkquiKdNvv7gGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">ptgx:UsTreasuryAndAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_b5xheGic50m0BOMQi6R-nw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_NCJa5a9fSEq4urrjZGFZCg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_E4MJhmAIOEC2XR0v8l-IgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_gb9tp0RYKkSz5MvwQ_K0Hg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">ptgx:UsTreasuryAndAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_6_29_2020_To_6_29_2020_UccmW4dFl06gNFN5lNnw9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-06-29</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_8_6_2018_srt_CounterpartyNameAxis_ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VeE0MBURAUmr6KszgYXA8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ptgx:SecuritiesPurchaseAgreementWithAccreditedInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-06</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member_ui-WhgpxI0OwEii6l0-3yQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2020_srt_ProductOrServiceAxis_ptgx_PhaseTwoBClinicalTrailOfPtg300Member_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_ptgx_EntityRequiredToContinueToMakePaymentsMember_us-gaap_TypeOfArrangementAxis_ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member_lKJ-7ATDp0CLQ8bWUlojWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:PhaseTwoBClinicalTrailOfPtg300Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ptgx:EntityRequiredToContinueToMakePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_srt_ProductOrServiceAxis_ptgx_PhaseTwoBClinicalTrailOfPtg300Member_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_ptgx_EntityRequiredToContinueToMakePaymentsMember_us-gaap_TypeOfArrangementAxis_ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member_GeOAJmLB2U-rVK1O1SLjzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:PhaseTwoBClinicalTrailOfPtg300Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ptgx:EntityRequiredToContinueToMakePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_srt_ProductOrServiceAxis_ptgx_PhaseThreeClinicalTrailOfPtg300Member_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_ptgx_EntityRequiredToContinueToMakePaymentsMember_us-gaap_TypeOfArrangementAxis_ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member_Mg3iwj6jfU-W-XYzhf-LYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:PhaseThreeClinicalTrailOfPtg300Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ptgx:EntityRequiredToContinueToMakePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_srt_ProductOrServiceAxis_ptgx_PhaseThreeClinicalTrailOfPtg300Member_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_ptgx_EntityRequiredToContinueToMakePaymentsMember_us-gaap_TypeOfArrangementAxis_ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member_NW5Hup9pVUGA-2WwTWjPHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ptgx:PhaseThreeClinicalTrailOfPtg300Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ptgx:EntityRequiredToContinueToMakePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ptgx:ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_PsWEw3NZiEeVLOnWFnbiGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_2_26_2021_n-kaUE9lQUKHL57qjKx1HQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
        </entity>
        <period>
            <instant>2021-02-26</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_Institution_l_EWsumXIkS46w5G4NlRGw">
        <measure>ptgx:Institution</measure>
    </unit>
    <unit id="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_item_hG9CfJX4lUefEcY3aN9DsQ">
        <measure>ptgx:item</measure>
    </unit>
    <unit id="Unit_Standard_installment_pPbBqyhnckSax7ouQFoPyQ">
        <measure>ptgx:installment</measure>
    </unit>
    <unit id="Unit_Standard_lease_62oZzE0uRUioB8CqY7th5A">
        <measure>ptgx:lease</measure>
    </unit>
    <unit id="Unit_Standard_AUD_SNsUSUMs1k6MNx0ouGjszw">
        <measure>iso4217:AUD</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      id="Hidden_0OM1DusEFUmqbPoDuT7X_Q"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      id="Hidden_wm3XtSRd8kOC2xAeypDG3w"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="INF"
      id="Hidden_vRN-MNGrlkCdyrjuSkYNyw"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="INF"
      id="Hidden_EjGcvmCxpEiSI52QmVUDEA"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      id="Hidden_AQ9zi8pi-EaxuyzCo-xXWQ">us-gaap:OperatingLeaseRightOfUseAsset</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      id="Hidden_wWgcpLSf2kWkjdeeAc953A">us-gaap:OperatingLeaseLiabilityCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      id="Hidden_hlbRDx7p30CKaUxxFEW_Yg">us-gaap:OperatingLeaseLiabilityNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      id="Hidden_ovgfxS-wnkODM924xAwfoA">us-gaap:OperatingLeaseLiabilityCurrent us-gaap:OperatingLeaseLiabilityNoncurrent</us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tc_6wgYli4F9EO94vNoCiMkFQ_2_1">0001377121</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tc_abAF5-1xEUSzl_47R_5xCw_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tc_ZEaUUkUOo0y2Vg_yhrL01A_4_1">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tc_W4bVqBaK9Ui9OupcVEc1ig_5_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tc__7Z0SxMeukO7PZqqN1lIVw_6_1">false</dei:AmendmentFlag>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      id="Hidden_kE3TOWjbKkC77ExmcLKTfQ"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      id="Hidden_KKfUiE90KUuaywhloS9gMQ"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="INF"
      id="Hidden_zGKgQSrOrEauSny-uH-IKw"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">27217649</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="INF"
      id="Hidden_E8kndXbr3EajcZS50zXaqQ"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">43745465</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      id="Hidden_B2SDxtiWdkCPUjOMj_8kQA"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      id="Hidden_xVeETI8KxU-fJOYA-X9IVg"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_aheLDwWGAUeZQPwvqQVzZA"
      id="Hidden_MwXrAUuc4UmOUGbm0YW9XQ">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:SubleaseIncome
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Hidden_lqQvOls2gkKPXAv7NbH0Aw"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">0</us-gaap:SubleaseIncome>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      id="Hidden_zm9XCbYtdUWCFJoLceZSNQ">us-gaap:OperatingLeaseRightOfUseAsset</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      id="Hidden_NUnmw_5Jc0GQOhDxxgb5HA">us-gaap:OperatingLeaseLiabilityCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      id="Hidden_ffN_Bd0u6EuABPUHJggLOw">us-gaap:OperatingLeaseLiabilityNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      id="Hidden_yNAOiRCkP0mEzcqrTZongA">us-gaap:OperatingLeaseLiabilityCurrent us-gaap:OperatingLeaseLiabilityNoncurrent</us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Narr_NpJxfLDNaUGJVNrUYebpPA">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tc_E62Of-astEW0P8g_yfF7rQ_1_0">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Narr_tyPXJd1zqEWXE_0e8Nz-ow">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tc_60V8cW3R2Um-mMVRMz740w_1_0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Narr_W0g2mvwkeke4b-v95KXLAA">001-37852</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Narr_Zo41dg7Jjk-GiL2qambHyQ">PROTAGONIST THERAPEUTICS,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tc_zZy58tZmtUSxMtSVyvUsoA_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tc_599Dvm2hZEmeqM6ZHNMpIQ_1_1">98-0505495</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Narr_VWNqYqpfxke_MBO9PY-AFA">7707 Gateway Boulevard, Suite 140</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Narr_-rf3Y893F0auiQSKM9aaEQ">Newark</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Narr_FcrIsBCbUkGeWZMI9OLVXw">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Narr_N1GyRUTaq0i5TNC_TGwe5w">94560</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Narr_q4o-kNPDQUub7lyXHAiVWw">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Narr_Z3sQhc3B6E-YHsrM42JHBQ">474-0170</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tc_n-dDfRx-70KZpk7Hwkmiyw_2_0">Common Stock, $0.00001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tc_nfH7JUevT0q2snJf7Pk2mQ_2_1">PTGX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Narr__L6S9JCx-U-pErz-kzUV_Q">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Narr_DYoTeRRRdEqU3htVv7hy7w">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Narr_zR_v7fskJUa9-FNBU_UUWg">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Narr_O9h9qN17BkO3F61BkMG8aQ">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Narr_ko1UGJiniUqWx7aL9zN4vw">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tc_t4ihd17nnEiP1XtrBBrjUQ_3_0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tc_7pv7lOHq6UisnzQ6KeXHEw_3_3">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tc_o1KmtdoQdEikoHx9ewbPiA_4_3">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Narr_lW6ffmkFL0yTcaxQiGAz1A">true</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Narr_15tPIRbhPEeRa4KtskVXpw">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Narr_0JU_GDIIhEuuK63Am2qBGw">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_30_2020_PsWEw3NZiEeVLOnWFnbiGw"
      decimals="-5"
      id="Narr_laadgjm7-ECvMv9lZVFzDA"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">640700000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_2_26_2021_n-kaUE9lQUKHL57qjKx1HQ"
      decimals="INF"
      id="Narr_wvMAE897REui6YvLB0QIjw"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">43808308</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_1xfkqn6FkkOURlgOXUqBUA_5_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">117358000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_KO59ZgQWQkuXwgMvCOXiMg_5_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">33006000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_H--sYW5-JkqDltHndsD-bw_6_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">188451000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_uIRhGbgA10OpUXOieGGE_Q_6_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">100011000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_3MU_wgeZaECmGFGKQDv0OA_7_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">10000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_UbnSPsThvEezH8CmV3y5aA_7_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">10000</us-gaap:RestrictedCashCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_lMdLGMtXc0aMuux5vED1aw_8_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">2426000</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_AvFfifL860GHKazsMB5TZg_8_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">6755000</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:IncomeTaxesReceivable
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_1fPJL5Xcr0qWlJZGJDg31w_9_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1084000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_Em60m9RWAUeao9Ku8koFWg_10_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">6277000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_HYGmhFEPuEesGBb9i1egDQ_10_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">5529000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_qYd2C-GwqEaVG6_XL43EXg_11_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">315606000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_gdzKrQqrPEeXn4d88r50zQ_11_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">145311000</us-gaap:AssetsCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_eVyKqS-BzEiDrWdQPNeYXg_12_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">2000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_KK8oZGh75UmgtRh7OzlFeQ_13_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1462000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_OQAM64EMfUa5toEtNM79-Q_13_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1681000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_oq9wXy8evU25iDRr6YzADg_14_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">450000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_PGfbo5fM5k-MnFqEVzkFqQ_14_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">450000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_Vhyt_4tZQUSNPxLrNXbs2w_15_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">4950000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_QOCeqWAmWE6oW-oEkZAOgA_15_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">6042000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_yS1nBg43Ukyp3jnyOf4fSQ_16_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1433000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_lZoIs-401kGIZIcX5xlHzQ_17_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">324468000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_xwwwgCcMHUGFmxEMrBNqxA_17_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">154917000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_FbTHJIOv0kuMXzN2m-NVcA_20_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">3075000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_gO2X-vwG-0KVAK7CIMG78w_20_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">2790000</us-gaap:AccountsPayableCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_UB2sn8r0NUakgB9o0yVWmA_21_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">2732000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_HGe8BBjSEUKn5oc8PZpEow_21_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1262000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_5DcZOvDU2EG70Uz88c788g_22_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">18498000</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_ktWAtQxvbEKMzH8OIYSbUg_22_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">12360000</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_bPtGJk0cSUi0DkxzmhrSIg_23_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">14477000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_8FjAUV6t8EeJLp_O_hCfRg_23_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">17738000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_nNjT-MVCJECW0t2LoAvkqQ_24_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1459000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_x1AiJIwIa0mlt4IHdrqc4w_24_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1256000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_2sc5_-y0EEOZ1bBlzWwnmg_25_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">40241000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_82REulkqR0qIUXYv4fRt1Q_25_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">35406000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebt
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_rPrDgrxa_EycX5Q9d6PH1Q_26_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">9794000</us-gaap:LongTermDebt>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_LMTEoH_npEaYbXw9YhnCvw_27_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">23792000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_22N0Xa5sTUqV3nRi-OWmVg_28_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">4500000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_ofibZrOjDUmIE7LBUOLJdg_28_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">5961000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_JdXez2GBskCfMGsN2fLNUA_29_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">121000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_h1GjSL5Ms0uJhbfpTDwR0A_30_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">44862000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_l3I5JC5YUUuNzyhZ1f6tjg_30_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">74953000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="INF"
      id="Narr_hBhZcz4_mEWQGovfdwWndA"
      unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="INF"
      id="Narr_GGZGaYAGdE-_T1w3jKkzJw"
      unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="INF"
      id="Narr_02w3suN3JUyyebZCyhpG0A"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="INF"
      id="Narr_NFaFigz4mU-FsDD5dUjKEQ"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="INF"
      id="Narr_s3V1sEUCBEigiZvwmuuOng"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="INF"
      id="Narr_I45uvbdf_kuk9qOqAkJogw"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="INF"
      id="Narr_Z4A_qzvjFku7WhxziXMUvg"
      unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="INF"
      id="Narr_4zzb3zKGBk-924ZmDXEt6A"
      unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="INF"
      id="Narr_SdksiWDEhku_EAOe5svDkg"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">90000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="INF"
      id="Narr_qcscwVTvGkKaGnfxeNRooQ"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">90000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="INF"
      id="Narr_lgUTYBMrikOiNchXRbkv7w"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">43745465</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="INF"
      id="Narr_Hs6FurJeiUya2vRV7boSvQ"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">27217649</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_z-3tsjzElkq0PBD-wBdIGQ_35_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">563389000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_B_ZtN6_ovE-UWCr3CiCgOw_35_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">297846000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_T_grB8RxY0ugXHCCTMwpBA_36_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">28000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_CGFd3OlCXUqy-PZGzzCZaQ_36_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-221000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_K8unkvd3KkWyClXKuhcAsw_37_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-283811000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_st_nUL9ISkqsL6BSbXt0NQ_37_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-217661000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_e38rkBONlkiLsrmv2-EbZA_38_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">279606000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_5kKfulh4ykeqCeu-RPM9Fw_38_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">79964000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_L2HeozcBjUKEpD25DtznHQ_39_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">324468000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_X8fh8JIli0ykr1JcHv33Ug_39_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">154917000</us-gaap:LiabilitiesAndStockholdersEquity>
    <ptgx:RevenueFromContractWithCustomerIncludingCumulativeCatchUpAdjustmentToRevenueModificationOfContract
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_XymsiGbaKkm6clhmM7KjDA_3_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">28628000</ptgx:RevenueFromContractWithCustomerIncludingCumulativeCatchUpAdjustmentToRevenueModificationOfContract>
    <ptgx:RevenueFromContractWithCustomerIncludingCumulativeCatchUpAdjustmentToRevenueModificationOfContract
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_SC_PuobfJkOmIWlci3h3IQ_3_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">231000</ptgx:RevenueFromContractWithCustomerIncludingCumulativeCatchUpAdjustmentToRevenueModificationOfContract>
    <ptgx:RevenueFromContractWithCustomerIncludingCumulativeCatchUpAdjustmentToRevenueModificationOfContract
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_trCkfwt_6EKoM4JhEx6n3g_3_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">30925000</ptgx:RevenueFromContractWithCustomerIncludingCumulativeCatchUpAdjustmentToRevenueModificationOfContract>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_YBRph1c-3EeC5OQYWheN1Q_5_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">74506000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_p72i2J_CF0KvfvTHE0VleQ_5_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">65003000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_ruzBHw6AnkuGwwIEQqU_pQ_5_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">59497000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_U2VZqeGbu02v3orZz_qwrw_6_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">18638000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_ECW20krrY0C_4t-i_mAKaA_6_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">15749000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_gv15ACH2lkKb3LlR2YmIvA_6_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">13697000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_8sVe8oufhU2aWrEp1Nb-FQ_7_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">93144000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_f4WEOxR7K0qa1bZa9BsA7A_7_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">80752000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_kKTB0bQv3Uq0oHRPx5jq3g_7_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">73194000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_e9V11expqEu5m9aYJDglaw_8_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-64516000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_yUibFZ9w50utIKrHjc4jJg_8_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-80521000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_t-qyGFjb4kGWmU03SmZvuw_8_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-42269000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_II94ju6SPUSgyy16fsQ0PA_9_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">900000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_W-aGcJ4BKEy8pgbrcLaKdA_9_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">2813000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_UxfXoKSadUyi8uBRL5ZsuQ_9_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">2566000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_FrVXeW9AtkaFOdHImIT2Gw_10_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">598000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_Zcj6yGVxnEe-1sUuq14hdA_10_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">169000</us-gaap:InterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_Q9LyQeEYvUagQ_8tMLRatA_11_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-585000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_bi8YZ7bPLkeF1iAmVEb9CA_12_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-46000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_G7scI2GGpECzy0JCFlW-cQ_12_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-1000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_VUwGvKjeBUuzssn_LG8owg_12_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-20000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_n8HUkQeV6Ei23nsxN_WloA_13_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-64845000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_AMm2H5UiDUaDOPDFi9v9lQ_13_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-77878000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_Z6eteAj910GpmtSLHyqMMw_13_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-39723000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_ZcXecLNX9EiYEnQCFTeOtQ_14_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1305000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_x7mck_0e5kurf5k7QfvmGQ_14_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-691000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_akmwV6d7C0uU-KcGqJ8yJA_14_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-799000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_IqEcBcFDUUWhnPT1gVuoqg_15_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-66150000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_Z5nBxVUHIkmsvcTXsbUJoQ_15_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-77187000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_4DkyCzglLEu1eWXEitR-tw_15_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-38924000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="2"
      id="Tc_nAs_tpU510eP3bKWr5GJpg_16_3"
      unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q">-1.92</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="2"
      id="Tc_RzzJNDWqJk-lytcgmMP-XQ_16_6"
      unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q">-2.98</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="2"
      id="Tc_puWMSM0ZhkK28g8ZP4gSoA_16_9"
      unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q">-1.74</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="0"
      id="Tc_QG8M43hiv0G17WEQjdFPYA_17_3"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">34396446</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="0"
      id="Tc_hV-RisUJ60ifqXH55sAaXA_17_6"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">25894024</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="0"
      id="Tc_X1OvC0Ilv0-dskuR9OGEUw_17_9"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">22364515</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_a2bhNxHp5EWDwueSBjPJew_3_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-66150000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_ZjmyJojjFUaFmM5dPt1QHA_3_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-77187000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_-eDNmPMNwkO2RI5AVRoDeA_3_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-38924000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_SMY3FUuO60-dipXjWdhgGg_5_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">266000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_v28kGMpjZkm3OdikhoOqwQ_5_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-44000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_ehto5YePmEyQZw_ck70xrA_5_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-322000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_b369Jgc16kOAKTbpvt_16A_6_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-17000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_i3FIy-xlV0-oW09K7_kaiQ_6_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">56000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_OREAsYtQjEW9kXT6xnWnUw_6_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">95000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_Yfe23P90aEajTQoOVZV04w_7_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-65901000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_Wyez8V5WTU6UAsCvVqcjIA_7_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-77175000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_kTPDBy_v-0iva6u9qdvq0Q_7_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-39151000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ruvLYZdTr0WCWpXD9VpjZw"
      decimals="INF"
      id="Tc_Z1oVUovacU670DuxJgOZdw_6_2"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">21088306</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2yPAw-zRyEu3cnkGbo1BJA"
      decimals="-3"
      id="Tc_G-XNnv9Z2UCbmWDK3NyzjQ_6_8"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">222188000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_xs61-k8jCUqUc6YQqT9vow"
      decimals="-3"
      id="Tc_Ja_2zvTNj0a4uCZcvo5aYg_6_11"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jUszAT7WFEGWt9BqEE93VQ"
      decimals="-3"
      id="Tc_EVPgL9_3mkC0sn3ksLzb4w_6_14"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-101550000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2017_uBPncpspM02T8SbWW1EWfg"
      decimals="-3"
      id="Tc_gvtwKtyieUSj0n6nUoCxHg_6_17"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">120632000</us-gaap:StockholdersEquity>
    <ptgx:StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YxGs3yboJkG0guGsknqgmA"
      decimals="INF"
      id="Tc_dp4gvgT05ECcxREUV-4IRw_7_2"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">2750000</ptgx:StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants>
    <ptgx:StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iSQxa82RA0epFzR7vgagyQ"
      decimals="-3"
      id="Tc_zVhTWikfw0q9-kzIOFBK9g_7_8"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">21673000</ptgx:StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants>
    <ptgx:StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_YgkZolkgrUevSuYyJ9txjQ_7_17"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">21673000</ptgx:StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_DzfKu3ClMU-xwF3bQXP75g"
      decimals="INF"
      id="Tc_kffaRRhBFkCPpQDOc903FQ_8_2"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">151273</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_pKAkXlxvhUWymzMXd4z0KQ"
      decimals="-3"
      id="Tc_24DzNA9mwkCUoVyy9HIwDw_8_8"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1508000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_g3Hzv49Z9UGzLyh7mHry3A"
      decimals="-3"
      id="Tc_leKbQEdfG0qLEKMBX3QtKA_8_17"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1508000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YxGs3yboJkG0guGsknqgmA"
      decimals="INF"
      id="Tc_L3s1-nufZ0iyNp4LLItC4g_9_2"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">197640</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iSQxa82RA0epFzR7vgagyQ"
      decimals="-3"
      id="Tc_jmnrmeeDD0uVgRzwcsM_uQ_9_8"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">934000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_j8JimrCvikCUbJod_55pMg_9_17"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">934000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YxGs3yboJkG0guGsknqgmA"
      decimals="INF"
      id="Tc_cxulgiHsfkmcxTZfzKxupQ_10_2"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">1000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iSQxa82RA0epFzR7vgagyQ"
      decimals="-3"
      id="Tc_R5PuqkihMkuO0Ya2jLot9A_10_8"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">6670000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_f7Dn-Tua00Krml_ODU6Udg_10_17"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">6670000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <ptgx:StockWarrantIssuedDuringPeriodValueInExchangeForRetirementOfCommonStock
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iSQxa82RA0epFzR7vgagyQ"
      decimals="-3"
      id="Tc_u6AG3dizzEq3sXGDAY8odg_11_8"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">6670000</ptgx:StockWarrantIssuedDuringPeriodValueInExchangeForRetirementOfCommonStock>
    <ptgx:StockWarrantIssuedDuringPeriodValueInExchangeForRetirementOfCommonStock
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_Wtttwva0fEyUaJhu3y_NRg_11_17"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">6670000</ptgx:StockWarrantIssuedDuringPeriodValueInExchangeForRetirementOfCommonStock>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iSQxa82RA0epFzR7vgagyQ"
      decimals="-3"
      id="Tc_0bXyNtTvEUqM-7gYF1Lv5Q_12_8"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">6919000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_XATsGkLGcUa_nyYHKSg2HQ_12_17"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">6919000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DrgcQsWLEUegsx9gQx7K3w"
      decimals="-3"
      id="Tc_YMQ__0-fl0m7cB0-OjquWw_13_11"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-227000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_v7rA5-VbmUWfYVXl9gstWQ_13_17"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-227000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_e0vNep3u2EaW55wxjoopSw"
      decimals="-3"
      id="Tc_1CQ1mbL8cUyA0PmjlI8wrw_14_14"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-38924000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_YYW7s28UH0Cs-k7AMwaVUA_14_17"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-38924000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ZQ8gS7l_jUWwlHn2F0NYhw"
      decimals="INF"
      id="Tc_SdIajRUKxkKu849bTgQqDQ_15_2"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">23187219</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8FClLya93E-DGTAwVTTPLg"
      decimals="-3"
      id="Tc_RXkrVmhXXUel90OHWbd9tA_15_8"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">253222000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_XXYc_qkz7EiiqGkSkihtnA"
      decimals="-3"
      id="Tc_Xmv73yhpu0SgaI3AzyHERQ_15_11"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-233000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Ju5ZnA-BP0-NMMz3dq161g"
      decimals="-3"
      id="Tc_HsSXPuTqZEy6zNZBLMG3yw_15_14"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-140474000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_rK3dysi-wkKgewxxLVB-Eg"
      decimals="-3"
      id="Tc_lSMFWyqmS0WSy6f6OVc8zA_15_17"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">112515000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_s2huIh7nUE-p0G6YC_4NhQ"
      decimals="INF"
      id="Tc_0DCq8mqPHUuOCteelX-wPg_16_2"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">2846641</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_yGP8DkufmUSzKSdAVZGGrg"
      decimals="-3"
      id="Tc_cheyjiaa9kyIqQqL7dbVHg_16_8"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">34492000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_yOGBS9pihEKHtHPrOQel3w"
      decimals="-3"
      id="Tc_QvCjRHOsWkyt77asqfydOA_16_17"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">34492000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bsxNEJcruUKB7husbni8Lw"
      decimals="INF"
      id="Tc_gRjBpIS1QUy1CHJuouBPog_17_2"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">583792</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_enQYGgNfqUCc5y0GKYBXkg"
      decimals="-3"
      id="Tc_Vt9TbXLr9EymEOF1PDZtLg_17_8"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1779000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_QX3sI256gEitJcBzslwdmw_17_17"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1779000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <ptgx:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bsxNEJcruUKB7husbni8Lw"
      decimals="INF"
      id="Tc_nhWwkKizOkiMG3sG6GviHA_18_2"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">599997</ptgx:StockIssuedDuringPeriodSharesWarrantsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_enQYGgNfqUCc5y0GKYBXkg"
      decimals="-3"
      id="Tc_xa1Qwdsf1kGOYHzC0ZDMvQ_19_8"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">8353000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_kMymqk5nDEuVFee1_7HklA_19_17"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">8353000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a0-ROxHHoku-VkXZ66GSxQ"
      decimals="-3"
      id="Tc_mRaMJQn_wUmj7RuI-bB7_w_20_11"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">12000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_VxezL6p570m6PspsN0njqg_20_17"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">12000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_hM1ehx9ooUyOxNDleNQQrg"
      decimals="-3"
      id="Tc_szjrh57WpUeR3MQMjYPGdg_21_14"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-77187000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_hL2F9ZPj4kSUaNKMgAGcDg_21_17"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-77187000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_CPGeoM_E_U2hv7Q6-PEH9g"
      decimals="INF"
      id="Tc_24qM32JDLEyH4mxMfeds9g_22_2"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">27217649</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_PlWiT4oT-U-bNw8fFk2KMA"
      decimals="-3"
      id="Tc_tRk6bp-oPkG4koBZ1nQ__g_22_8"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">297846000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_uLTlN99bs0KmTjmkSZDZtQ"
      decimals="-3"
      id="Tc_4s9LEcSBiE-VcOayTfoeFg_22_11"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-221000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__O0aR-_h3kehqx2ICyExMA"
      decimals="-3"
      id="Tc_rQKGZUombkyXPnt1XFNHUQ_22_14"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-217661000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_NS9Oxi6GM02ntVOKNir_Jg_22_17"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">79964000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YoX0pmi6v0e7iaLUqL8YHg"
      decimals="INF"
      id="Tc_MgSj0mkMlUODtIRzOO32XQ_23_2"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">13526189</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NemxNYQEjkS5VxdYCUEGfA"
      decimals="-3"
      id="Tc_nngczcALqUi7pid4k3WW1Q_23_8"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">212974000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_GxcsIB0ZIUmRIrpIV9MH-g_23_17"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">212974000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_8hhxYFRmo0SmVd81EZvSIw"
      decimals="INF"
      id="Tc_94Gi9KxU3EGkpOnxSdJjnw_24_2"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">2483719</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_1odXtzTk20OYdf78bv-6Bg"
      decimals="-3"
      id="Tc_YFXbW9_4QU-gWJOx0Zhj4A_24_8"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">41871000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_fuC6tZWyUkSX0CU0In2zWQ"
      decimals="-3"
      id="Tc_hc2NjrSrA02Ck32EjTJcLg_24_17"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">41871000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YoX0pmi6v0e7iaLUqL8YHg"
      decimals="INF"
      id="Tc_8-Q0KAMz5k6rxSg-2NDDeA_25_2"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">517908</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NemxNYQEjkS5VxdYCUEGfA"
      decimals="-3"
      id="Tc_N62pwiP68kuwmtL0t-AB1g_25_8"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">2799000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_CmYWIesx2UO0d1zrQQFbdA_25_17"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">2799000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NemxNYQEjkS5VxdYCUEGfA"
      decimals="-3"
      id="Tc_UidDxU-JLUmcypnY81p2_A_26_8"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">7899000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_6MCYOV1iNE6jPsGqQUoJWA_26_17"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">7899000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_NzJb7MJr5kOz1KdJ49FjiQ"
      decimals="-3"
      id="Tc_zTrrIaI2d0ij6UCaOF0oeQ_27_11"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">249000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_oDNeJSGujkKbDM_Vi5NVEQ_27_17"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">249000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_8neM6oYNfUCXGVbkjiKc6Q"
      decimals="-3"
      id="Tc_JsaniQlquUuaeJ2ZWg9KyA_28_14"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-66150000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_l_wxD8-S2kGq3rPs1lEEEQ_28_17"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-66150000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_E5rQEhmdCkiUzPRvbbp87g"
      decimals="INF"
      id="Tc_XA7djNyg4UGp_lB_20m3bQ_29_2"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">43745465</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kO1ACPpowkmGPJDGZK-oJg"
      decimals="-3"
      id="Tc_oRfRN8JbfUmmHTWoS5v9eg_29_8"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">563389000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Snnu9PZVQ0SEUhYgRyxRiw"
      decimals="-3"
      id="Tc_x-FiCWu1uUSWWrVPRPdTVQ_29_11"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">28000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dCBVr6oE30ePiiOHcTfKVg"
      decimals="-3"
      id="Tc_vNRwcwcozUa9RPG4O2GznQ_29_14"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-283811000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_E_3O4Vg7zUm6ZDhuoA7b2Q_29_17"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">279606000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_1G9weokUzEic_N9n-O9m8Q_4_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-66150000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_Uda91xRLMk-arbQ05F4q3w_4_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-77187000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_b9uMh3IXAkCDNIKT1W4HKw_4_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-38924000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_9vWw1WoyKkipx5zg3R9GbA_6_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">7899000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_xKDKm3rB-UitR13cD9rvFg_6_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">8353000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_LxEqScsl4UKLmUZ-Kl6nag_6_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">6919000</us-gaap:ShareBasedCompensation>
    <ptgx:OperatingLeaseRightOfUseAssetAmortization
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_sT90factYkmL3i7bBQ8RcQ_7_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1775000</ptgx:OperatingLeaseRightOfUseAssetAmortization>
    <ptgx:OperatingLeaseRightOfUseAssetAmortization
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_os-GwFBMvUGmDcyaSSlGHg_7_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1792000</ptgx:OperatingLeaseRightOfUseAssetAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_EMFOl-egSES0NwqzSv8goA_8_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">789000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_nbTqrk2EWkaxG_ZS26LqMA_8_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">703000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_Cpi68ho1Dk2641wz_5RCFA_8_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">527000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_LxMGLoho7EO-Y5ezqktfsg_9_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-585000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_Vj5QXKZNA06YnYsBfH2Kkg_10_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-37000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_d7gZi2wbwE6TIiT0sQq97A_10_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">594000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_UtqEKlbe20KTt4Y748voCw_10_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-206000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <ptgx:AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_M7KIbwfbWUGJkXVhJQ_8pw_11_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">159000</ptgx:AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee>
    <ptgx:AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_Wm7SC2FxI0av0Zv4Ime8Rw_11_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">29000</ptgx:AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_hKUETJzGakC33psbtCVKZQ_12_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-8000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:IncomeTaxCreditsAndAdjustments
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_rtvWeqIGe0u9rTx2nv7CTA_13_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1438000</us-gaap:IncomeTaxCreditsAndAdjustments>
    <us-gaap:IncomeTaxCreditsAndAdjustments
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_-2E8fNdgmUqeZ4xXy8mjNQ_13_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-775000</us-gaap:IncomeTaxCreditsAndAdjustments>
    <us-gaap:IncomeTaxCreditsAndAdjustments
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_daBRyVTgvUyKGK3HnYaFhw_13_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-658000</us-gaap:IncomeTaxCreditsAndAdjustments>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_AXKyaH9AFEupbSul-87XJA_15_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">990000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_hKbVxBKBuUqCZ1ip1Qu2Aw_15_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-1411000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_YH-YRa2P_E2gvaaVZjfOCA_15_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">236000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_k9Oegn-KWUOxKQ-dr6W3IA_16_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-4329000</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_6LZmHQujsE-T_K9loVPaSg_16_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">2168000</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_XCEcymOdu06kb8DE0T8jWA_16_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">2771000</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_mTqMth619UWf_KEn8YFV0g_17_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1102000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_mWRS6iiryk60gMKu_YZCgQ_17_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">2820000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_eFIpzSGNm0G_iOQv9dN-nQ_17_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-1117000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_HVTDAzaE80SWZGzWxK34Iw_18_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">309000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_wCy0O318WkS8DO6NLlM72Q_18_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-3000000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_48hsKY_NwESR40Iv3FZ8zw_18_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">4430000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_gOALQF8y6E61eSsNbseXCQ_19_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1471000</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_D36NrAYrRE64HL2beeLzZg_19_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">201000</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_3Yder3QQNkaJjHc0uoa3fA_19_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1061000</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_wy2JFxI86Ei0rIrcffYDqA_20_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">5840000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_FWKVV9chIkCv5yZPidRQYg_20_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1098000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_rqoeHU4XWUi5_Zf1cPWORA_20_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1911000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_q4vGZ6OpRUONob1SasKubw_21_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-27053000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_lrfMduQjeUuiuOK1Dn3nCw_21_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">33307000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_2khU4Fok3EiBYgQkyQk95A_21_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-23529000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <ptgx:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_4oL-c473cEup0WfA8rcV8A_22_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1941000</ptgx:IncreaseDecreaseInOperatingLeaseLiability>
    <ptgx:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_IaASZHQVvEqgmdzlSIEJNA_22_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1885000</ptgx:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_L06naFRYM0ahjnbLbrXJzg_23_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">121000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_2JD09p69Zky1X-8qlZym0A_24_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-72484000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_Bc_FtS-QEEKzOcbF68UUFQ_24_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-41527000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_3Hu94hqYZ0CzwrXulaf-sw_24_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-49947000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_6P97hKM8a0mu3KTU3DYYhA_26_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">280027000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_LIZRXZvr0E6pXtUarYdASw_26_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">166936000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_3U4mzl6ZYk-BO3HxSyY53g_26_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">71060000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_KGapb_6wAU6CrH6QYPqE4g_27_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">189533000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_sLNxJAXxn0Ck6NxPV8IUZA_27_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">114193000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_pbBre_sv4kCgvcZsnSpl8w_27_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">73759000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_Je1Ikze3bESf5Fgk_HA5tw_28_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">471000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_qCYZ6Q1De0-Y3SjoJNc5IA_28_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">967000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_6XMTL3_SXk6v3lnyQIn5XA_28_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">486000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_mZkpO3qip0GEGzBHABBolg_29_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-90965000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_RorHiDyfo0evv2bAyQOgiQ_29_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-53710000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_SIpwf672RUep445SEUzjfw_29_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">2213000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_S_nE7eVh7km8pI2MWGG1EA_31_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">213303000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ptgx:ProceedsFromIssuanceOfCommonStockAndWarrantsInPrivatePlacementNetOfIssuanceCosts
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_cAUQwK3XOUWu8OPWAKzMvw_32_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">21673000</ptgx:ProceedsFromIssuanceOfCommonStockAndWarrantsInPrivatePlacementNetOfIssuanceCosts>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_aGRzm5tUlkSN4NabaOSk3w_33_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">42062000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_6oIjlrCfk06OFOz8bUsvIA_33_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">34492000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_IaEBc_jPpEuEOFLo0ewCwQ_33_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1508000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_v7NrwFiSQ0e6dCExT4UVWQ_34_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">2799000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_hDImT_dYVEugIJ_vaTDOag_34_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1779000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_DdDSSbJ0mEmq-qMgHkwqSw_34_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">934000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_0JUxvJfK6EO0Cga21-Jytg_35_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">9765000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_lEuI4sck4EapRGhtuVW1ug_36_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">14000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_FVoxta_VJEKYQ_cghGF7nQ_37_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">10524000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_1GuIzKaVb0qWY_WK686jTQ_38_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">247626000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_ss3UYfyW7UGsP9V_zqnFkQ_38_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">46036000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_HsQ396S6dEiG_xqhGqFm7g_38_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">24115000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_FsJjn6-OhUKZlRBwlqTi8g_39_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">175000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_qtBwuBPEWUOme-t-fkkkHA_39_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-26000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_4HaPpFZmnUi0WgseEinQuQ_39_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-177000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_2R4unw7Eb0-arLE5gW6Fow_40_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">84352000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_M8CHfPaVJUahpI5oJBfaaA_40_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-49227000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_vmJBKisBJU--ZZuNrthtOQ_40_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-23796000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_dUEFBH26nkyLEbrispRY-g_41_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">33466000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2018_rK3dysi-wkKgewxxLVB-Eg"
      decimals="-3"
      id="Tc_rMMI1yajh0mBpnaDChXL9Q_41_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">82693000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2017_uBPncpspM02T8SbWW1EWfg"
      decimals="-3"
      id="Tc_tHeRPqmL8EaR7cxobo22WA_41_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">106489000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_X1619x7TNke-qQjVJG1pgQ_42_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">117818000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_H9WI63IXrUKAv-4o2hUQNw_42_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">33466000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2018_rK3dysi-wkKgewxxLVB-Eg"
      decimals="-3"
      id="Tc_IHVsk8VudEGrlwZ19TtOyg_42_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">82693000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_UZ89g2iPZ0SgF20imHyhKA_44_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">438000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_Aa-38epHaU2dCJ_GdO56PA_44_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">70000</us-gaap:InterestPaidNet>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_BalanceSheetLocationAxis_ptgx_AccruedLiabilitiesAndOtherPayablesMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_YMLB38vu2U6BmlQp_T1TCw"
      decimals="-3"
      id="Tc_Ivby-rEkQ0qtWK8tIdA8GQ_46_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">205000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_BalanceSheetLocationAxis_ptgx_AccruedLiabilitiesAndOtherPayablesMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_nqaO_sxQyESRu9HD_l6AJQ"
      decimals="-3"
      id="Tc_j3875-oRjkikECzlGrvKRw_46_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">80000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_AtMarketingOfferingMember_N8l2Scu7LECQV05gQhBpcg"
      decimals="-3"
      id="Tc_bKM_dmkeqUqLl9gfC1rMQg_47_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">191000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_s0YO-nVtg0inq7Ue9XzaAQ"
      decimals="-3"
      id="Tc_RYuPP7P1aECPV_n0dHpkag_48_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">124000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_fjWSGYBZPUeEirBVqC4ojA_49_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">85000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc__FVUqVgBYEGTJZvJlF6BuQ_49_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">100000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_rZuBIkVAwECVMsoJJEKgKA_49_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">24000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <ptgx:FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_MdqAlMAAp0iZ8EPD-YQzaA_50_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">6670000</ptgx:FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_ZJkx-UusSUGmm_vs9CtM8Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;PROTAGONIST THERAPEUTICS,&#160;INC.&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"&gt;Notes&#160;to Consolidated Financial Statements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 1.&#160;&#160;&#160;&#160;Organization and Description of Business&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:25.3pt;margin:0pt 0pt 13.19pt 0pt;"&gt;Protagonist Therapeutics, Inc. (the &#x201c;Company&#x201d;) is headquartered in Newark, California. The Company is a clinical-stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based therapeutics to address significant unmet medical needs and transform existing treatment paradigms for patients. Protagonist Pty Limited (&#x201c;Protagonist Australia&#x201d;) is a wholly-owned subsidiary of the Company and is located in Brisbane, Queensland, Australia. Protagonist Australia was incorporated in Australia in September 2001. The Company manages its operations as a single operating segment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 13.19pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Liquidity&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:25.3pt;margin:0pt 0pt 13.19pt 0pt;"&gt;The Company has incurred net losses from operations since inception and has an accumulated deficit of $283.8 million as of December 31, 2020. The Company&#x2019;s ultimate success depends on the outcome of its research and development and collaboration activities. The Company expects to incur additional losses in the future and anticipates the need to raise additional capital to continue to execute its long-range business plan. Since the Company&#x2019;s initial public offering in August 2016, it has financed its operations primarily through offerings of common stock and payments received under a license and collaboration agreement. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:bold;white-space:pre-wrap;"&gt;Risks and Uncertainties  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is subject to risks and uncertainties as a result of the&#160;COVID-19&#160;pandemic. The Company is continuing to closely monitor the impact of the COVID-19 pandemic on its business and has taken and continues to take proactive efforts to protect the health and safety of its patients, clinical research staff and employees, and to maintain business continuity. The extent of the impact of the&#160;COVID-19&#160;pandemic on the Company's activities is highly uncertain and difficult to predict, as the response to the pandemic is ongoing and information continues to evolve. Capital markets and economies worldwide have been negatively impacted by the&#160;COVID-19&#160;pandemic, which has contributed to the current global economic recession. Such economic disruption could have a material adverse effect on the Company&#x2019;s business. Policymakers around the globe have responded with fiscal policy actions to support the healthcare industry and economy as a whole. The magnitude and overall effectiveness of these actions remains uncertain.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The severity of the impact of the&#160;COVID-19&#160;pandemic on the Company's activities will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic, including the severity of any additional periods of increases or spikes in the number of cases in the areas the Company and its suppliers operate and areas where the Company&#x2019;s clinical trial sites are located. Accordingly, the extent and severity of the impact on the Company's existing and planned clinical trials, manufacturing, collaboration activities and operations, is uncertain and cannot be fully predicted. The Company has experienced delays in its existing and planned clinical trials due to the worldwide impacts of the pandemic. The Company's future results of operations and liquidity could be adversely impacted by further delays in existing and planned clinical trials, continued difficulty in recruiting patients for these clinical trials, delays in manufacturing and collaboration activities, supply chain disruptions, the ongoing impact on its operating activities and employees, and the ongoing impact of any initiatives or programs that the Company may undertake to address financial and operational challenges. As of the date of issuance of these consolidated financial statements, the extent to which the&#160;COVID-19&#160;pandemic may materially impact the Company's future financial condition, liquidity or results of operations remains uncertain.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-5"
      id="Narr_sokugfJ3H0W29299nJqriA"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-283800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_Z8DK6gSRxUCWNIaHUKBfpA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Note&lt;span style="font-weight:normal;"&gt; &lt;/span&gt;2.&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Basis of Presentation and Consolidation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Protagonist Australia, and have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). All intercompany balances and transactions have been eliminated upon consolidation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The financial statements of Protagonist Australia use the Australian dollar as the functional currency since the majority of expense transactions occur in such currency. Gains and losses from foreign currency transactions were not material for all periods presented. The re-measurement from Australian dollar to U.S. dollars is outlined below:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;a.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;Equity accounts, except for the change in retained earnings during the&#160;year, have been translated using historical exchange rates.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;b.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;All other Australian dollar denominated assets and liabilities as of December&#160;31, 2020 and 2019 have been translated using the&#160;year-end exchange rate.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;c.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;The consolidated statements of operations have been translated at the weighted average exchange rates in effect during each&#160;year.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Foreign currency translation gains and losses are reported as a component of stockholders&#x2019; equity in accumulated other comprehensive loss on the consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, accruals for research and development activities, stock-based compensation, income taxes, marketable securities and leases. Estimates related to revenue recognition include actual costs incurred versus total estimated costs of the Company&#x2019;s deliverables to determine percentage of completion in addition to the application and estimates of potential revenue constraints in the determination of the transaction price under its license and collaboration agreements. Management bases these estimates on historical and anticipated results, trends and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to forecasted amounts and future events. Actual results may differ significantly from those estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Due to the COVID-19 pandemic, there has been uncertainty and disruption in the global economy and financial markets. The Company has taken into consideration any known COVID-19 impacts in its accounting estimates to date and is not aware of any additional specific events or circumstances that would require any additional updates to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of the date of issuance of this Annual Report on Form 10-K. These estimates may change as new events occur and additional information is obtained. Actual results could differ materially from these estimates under different assumptions or conditions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Concentrations of Credit Risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and marketable securities. Substantially all of the Company&#x2019;s cash is held by two financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. The primary focus of the Company&#x2019;s investment strategy is to preserve capital and to meet liquidity requirements. The Company&#x2019;s cash equivalents and marketable securities are managed by external managers within the guidelines of the Company&#x2019;s investment policy. The Company&#x2019;s investment policy addresses the level of credit exposure by limiting concentration in &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;any one corporate issuer and establishing a minimum allowable credit rating. To manage its credit risk exposure, the Company maintains its portfolio of cash equivalents and marketable securities in fixed income securities denominated and payable in U.S. dollars. Permissible investments of fixed income securities include obligations of the U.S. government and its agencies, money market instruments including commercial paper and negotiable certificates of deposit, and highly rated corporate debt obligations and money market funds.&lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Cash Equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash equivalents that are readily convertible to cash are stated at cost, which approximates fair value. The Company considers all highly liquid investments purchased with an original maturity of three&#160;months or less to be cash equivalents. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Restricted Cash&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Restricted cash consists of cash balances primarily held as security in connection with a letter of credit related to the Company&#x2019;s facility lease entered into in March 2017 and the Company&#x2019;s corporate credit card.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Cash as Reported in Consolidated Statements of Cash Flows&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash as reported in the consolidated statements of cash flows includes the aggregate amounts of cash and cash equivalents and the restricted cash as presented on the consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash as reported in the consolidated statements of cash flows consists of (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:95.58%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:64.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; 117,358&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 33,006&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 82,233&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted cash - current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 10&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:64.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted cash - noncurrent&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; 450&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 450&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 450&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total cash, cash equivalent and restricted cash in consolidated statements of cash flows&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;117,818&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 33,466&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 82,693&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:12pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Marketable Securities  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;All marketable securities have been classified as &#x201c;available-for-sale&#x201d; and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation as of each balance sheet date. Short-term marketable securities have maturities greater than three months but not longer than 365 days as of the balance sheet date. Long-term marketable securities have maturities of 365&#160;days or longer as of the balance sheet date. Unrealized gains and losses are excluded from earnings and are reported as a component of comprehensive loss. Realized gains and losses and declines in fair value judged to be other than temporary, if any, on available-for-sale securities are included in interest income. The cost of securities sold is based on the specific-identification method. Interest on marketable securities is included in interest income.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Fair Value of Financial Instruments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Fair value accounting is applied to all financial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis (at least annually). The carrying amount of the Company&#x2019;s financial instruments, including cash equivalents, receivable from collaboration partner, accounts payable, payable to collaboration partner and accrued expenses and other payables approximate fair value due to their short-term maturities. See Note&#160;4. to the Consolidated Financial Statements for additional information regarding the fair value of the Company&#x2019;s other financial assets and liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Property and Equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, ranging from &lt;span style="-sec-ix-hidden:Hidden_MwXrAUuc4UmOUGbm0YW9XQ;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;three&lt;/span&gt;&lt;/span&gt; to five&#160;years. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful lives of the assets. Maintenance and repairs are charged to expense as incurred. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the consolidated balance sheet and any resulting gain or loss is reflected in operations in the period realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The Company adopted Accounting Standards Codification Topic 842, &lt;i style="font-style:italic;"&gt;Leases,&lt;/i&gt; (&#x201c;ASC 842&#x201d;) effective January 1, 2019. The Company determines if an arrangement is a lease at inception. Pursuant to ASC 842, operating leases are included in operating lease right-of-use (&#x201c;ROU&#x201d;) assets, operating lease liabilities, and noncurrent operating lease liabilities on the consolidated balance sheets. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. If the Company&#x2019;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. Lease terms include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:31.5pt;margin:0pt;"&gt;The Company records tenant improvement allowances as a reduction to the ROU asset with the impact of the decrease recognized prospectively over the remaining lease term. The leasehold improvements will be amortized over the shorter of their useful life or the remaining term of the lease. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Impairment of Long-Lived Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company reviews long-lived assets, primarily comprised of property, equipment and operating lease right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount to the future net cash flows which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset. There have been no such impairments of long-lived assets for any of the periods presented.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Long Term Debt  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for interest on its long-term debt under the effective interest method, with interest expense comprised of contractual interest, amortization of origination fees and other issuance costs, and accretion of final payment fees. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive Loss&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive loss includes net loss as well as other changes in stockholders&#x2019; equity that result from transactions and economic events other than those from stockholders. The Company&#x2019;s foreign currency translation and unrealized gains and losses on available-for-sale securities represent the only components of other comprehensive loss that are excluded from reported net loss and that are presented in the consolidated statements of comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Income Taxes &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"&gt;The Company uses the asset and liability method to account for income taxes in accordance with the authoritative guidance for income taxes. Under this method, deferred tax assets and liabilities are determined based on future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;and their respective tax bases, and tax loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates applied to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than a 50% likelihood of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest and penalties related to unrecognized tax benefits in income tax expense. To date, there have been no interest or penalties recorded in relation to unrecognized tax benefits.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Revenue Recognition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"&gt;The Company follows Accounting Standards Codification Topic 606, &lt;i style="font-style:italic;"&gt;Revenue from Contracts with Customers &lt;/i&gt;(&#x201c;ASC 606&#x201d;). Under ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the Company satisfies a performance obligation. The Company applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract, determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligations when (or as) the performance obligations are satisfied. The Company constrains its estimate of the transaction price up to the amount (the &#x201c;variable consideration constraint&#x201d;) that a significant reversal of recognized revenue is not probable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Licenses of intellectual property:&lt;/i&gt;&lt;span style="white-space:pre-wrap;"&gt;  If a license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in an arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring proportional performance for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of proportional performance each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Milestone payments:&lt;/i&gt;&lt;span style="white-space:pre-wrap;"&gt;  At the inception of each arrangement or amendment that includes development, regulatory or commercial milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. Whichever method is used, it should be consistently applied throughout the life of the contract; however, it is not necessary for the Company to use the same approach for all contracts. The Company expects to use the most likely amount method for development and regulatory milestone payments. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. If there is more than one performance obligation, the transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Royalties:&lt;/i&gt;&lt;span style="white-space:pre-wrap;"&gt;  For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional. Amounts payable to the Company and not yet billed to the collaboration partner are recorded as contract assets. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one&#160;year or less.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Contractual cost sharing payments made to a customer or collaboration partner are accounted for as a reduction to the transaction price if such payments are not related to distinct goods or services received from the customer or collaboration partner.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background-color:#ffffff;"&gt;Contracts may be amended to account for changes in contract specifications and requirements.&#160;Contract modifications exist when the amendment either creates new, or changes existing, enforceable rights and obligations. When&#160;contract modifications&#160;create new performance obligations and the increase in consideration approximates the standalone selling price for goods and services related to such new performance obligations as adjusted for specific facts and circumstances of the contract, the modification is considered to be a separate contract. If a contract modification is not accounted for as a separate contract, the Company accounts for the promised goods or services not yet transferred at the date of the contract modification (the remaining promised goods or services) prospectively, as if it were a termination of the existing contract and the creation of a new contract, if the remaining goods or services are distinct from the goods or services transferred on or before the date of the contract modification. The Company accounts for a contract modification as if it were a part of the existing contract if the remaining goods or services are not distinct and, therefore, form part of a single performance obligation that is partially satisfied at the date of the contract modification. In such case the effect that the contract modification has on the transaction price, and on the entity&#x2019;s measure of progress toward complete satisfaction of the performance obligation, is recognized as an adjustment to revenue (either as an increase in or a reduction of revenue) at the date of the contract modification (the adjustment to revenue is made on a cumulative catch-up basis).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background-color:#ffffff;"&gt;The period between when the Company transfers control of promised goods or services and when the Company receives payment is expected to be one year or less, which is consistent with the Company&#x2019;s historical experience. Upfront payment contract liabilities resulting from the Company&#x2019;s license and collaboration agreements do not represent a financing component as the payment is not financing the transfer of goods and services, and the technology underlying the licenses granted reflects research and development expenses already incurred by the Company. As such, the Company does not adjust its revenues for the effects of a significant financing component.&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Research and Development Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Research and development costs are expensed as incurred, unless there is an alternate future use in other research and development projects or otherwise. Research and development costs include salaries and benefits, stock-based compensation expense, laboratory supplies and facility-related overhead, outside contracted services including clinical trial costs, manufacturing and process development costs for both clinical and pre-clinical materials, research costs, development milestone payments under license and collaboration agreements, and other consulting services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"&gt;The Company accrues for estimated costs of research and development activities conducted by third-party service providers, which include the conduct of pre-clinical studies and clinical trials, and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated services provided &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;but not yet invoiced and includes these costs in accrued expenses and other payables in the consolidated balance sheets and within research and development expense in the consolidated statements of operations. The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers. As actual costs become known, the Company adjusts its accrued liabilities. The Company has not experienced any material differences between accrued liabilities and actual costs incurred. However, the status and timing of actual services performed, number of patients enrolled, the rate of patient enrollment and number and location of sites activated may vary from the Company&#x2019;s estimates, resulting in adjustments to expense in future periods. Changes in these estimates that result in material changes to the Company&#x2019;s accruals could materially affect the Company&#x2019;s results of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.5pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has received orphan drug designation from the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) for its clinical asset rusfertide (generic name for PTG-300) for the treatment of polycythemia vera and beta-thalassemia and may qualify for a related 25% U.S. Federal income tax credit on qualifying clinical study expenditures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Research and Development Tax Incentive&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is eligible under the AusIndustry research and development tax incentive program to obtain either a refundable cash tax incentive or a taxable credit in the form of a non-cash tax incentive from the Australian Taxation Office (&#x201c;ATO&#x201d;). The refundable cash tax incentive is available to the Company on the basis of specific criteria with which the Company must comply. Specifically, the Company must have annual turnover of less than AUD 20.0 million and cannot be controlled by income tax exempt entities.&#160;The refundable cash tax incentive is recognized as a reduction to research and development expense when the right to receive has been attained and funds are considered to be collectible. The tax incentive is denominated in Australian dollars and, therefore, the related receivable is remeasured into U.S. dollars as of each reporting date. The Company may alternatively be eligible for a taxable credit in the form of a non-cash tax incentive in years when the annual turnover exceeds the limit. The Company evaluates its eligibility under tax incentive programs as of each balance sheet date and makes accrual and related adjustments based on the most current and relevant data available. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Small Business Innovation Research (&#x201c;SBIR&#x201d;) Grants&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has received SBIR grants from the National Institutes of Health (&#x201c;NIH&#x201d;) in support of its research activities. The Company recognizes a reduction to research and development expenses when expenses related to grants have been incurred and the grant funds become contractually due from NIH. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock-based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company measures its stock-based awards made to its equity plan participants based on the estimated fair values of the awards as of the grant date. For stock option awards, the Company uses the Black-Scholes option-pricing model to estimate fair values. For restricted stock unit awards, the estimated fair value is generally the fair market value of the underlying stock on the grant date. Stock-based compensation expense is recognized over the requisite service period and is based on the value of the portion of stock-based payment awards that is ultimately expected to vest. The Company recognizes forfeitures of stock-based awards as they occur. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Net Loss per Share &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic net loss per share is calculated by dividing the Company&#x2019;s net loss by the weighted average number of shares of common stock and Exchange Warrants outstanding during the period, without consideration of potentially dilutive securities. In accordance with Accounting Standards Codification Topic 260, &lt;i style="font-style:italic;"&gt;Earnings Per Share&lt;/i&gt;, the Exchange Warrants are included in the computation of basic net loss per share because the exercise price is negligible and they are fully vested and exercisable after the original issuance date. Diluted net loss per share is the same as basic net loss per share for all periods presented since the effect of potentially dilutive securities is anti-dilutive given the net loss of the Company in each period. See Note 12. Stockholders' Equity for additional information regarding the Exchange Warrants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:bold;"&gt;Recently Adopted Accounting Pronouncements &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;In August 2018, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2018-13, &lt;i style="font-style:italic;"&gt;Fair Value Measurement (Topic 820) &#x2013; Disclosure Framework &#x2013; Changes to the Disclosure Requirements for Fair Value Measurement&lt;/i&gt;, which modifies the disclosure requirements on fair value measurements and is intended to improve the effectiveness of disclosures, including the consideration of costs and benefits. The Company adopted this guidance as of January 1, 2020. The adoption of this guidance did not have a material impact on the Company&#x2019;s consolidated financial statements or disclosures. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;In November 2018, the FASB issued ASU No. 2018-18, &lt;i style="font-style:italic;"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606&lt;/i&gt;, which is intended to clarify the circumstances under which certain transactions in collaborative arrangements should be accounted for under the revenue recognition standard. Certain transactions between collaboration arrangement participants should be accounted for as revenue under ASC Topic 606 when the collaborative arrangement participant is a customer in the context of a unit of account. This guidance is effective for fiscal years and interim periods within those years beginning after December 15, 2019. The Company adopted this guidance as of January 1, 2020. The adoption of this guidance did not have a material impact on the Company&#x2019;s consolidated financial statements and disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:bold;"&gt;Recently Issued Accounting Pronouncements Not Yet Adopted as of December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;In June&#160;2016, the FASB issued ASU No.&#160;2016-13,&#160;&lt;i style="font-style:italic;"&gt;Financial Instruments&#160;- Credit Losses (Topic 326)&lt;/i&gt;, which is intended to provide financial statement users with more useful information about expected credit losses on financial assets held by a reporting entity at each reporting date. The new standard replaces the existing incurred loss impairment methodology with a methodology that requires consideration of a broader range of reasonable and supportable forward-looking information to estimate all expected credit losses. This guidance was originally effective for fiscal&#160;years and interim periods within those&#160;years beginning after December&#160;15, 2019, with early adoption permitted for fiscal&#160;years and interim periods within those&#160;years beginning after December&#160;15, 2018. In November 2019, the FASB issued ASU No. 2019-10, &lt;i style="font-style:italic;"&gt;Financial Instruments &#x2013; Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates&lt;/i&gt;, which amended the mandatory effective date of ASU No. 2016-13 for smaller reporting companies. Based on the Company&#x2019;s status as a smaller reporting company as of November 15, 2019, ASU 2016-13 is effective for the Company for fiscal years and interim periods beginning after December 15, 2022. The Company is currently evaluating the impact of this new guidance on its consolidated financial statements and disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;i style="font-style:italic;"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, &lt;/i&gt;which removes certain exceptions and amends certain requirements in the existing income tax guidance to ease accounting requirements. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020 and must be applied on a retrospective basis. The Company does not expect the adoption of this guidance to have a material impact on its consolidated financial statements and disclosures.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_spVNgUJXFkikbnJW24H08g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Basis of Presentation and Consolidation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Protagonist Australia, and have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). All intercompany balances and transactions have been eliminated upon consolidation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The financial statements of Protagonist Australia use the Australian dollar as the functional currency since the majority of expense transactions occur in such currency. Gains and losses from foreign currency transactions were not material for all periods presented. The re-measurement from Australian dollar to U.S. dollars is outlined below:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;a.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;Equity accounts, except for the change in retained earnings during the&#160;year, have been translated using historical exchange rates.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;b.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;All other Australian dollar denominated assets and liabilities as of December&#160;31, 2020 and 2019 have been translated using the&#160;year-end exchange rate.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;c.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;The consolidated statements of operations have been translated at the weighted average exchange rates in effect during each&#160;year.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Foreign currency translation gains and losses are reported as a component of stockholders&#x2019; equity in accumulated other comprehensive loss on the consolidated balance sheets.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb__skX5tseB0esPiQW_Y_x_w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, accruals for research and development activities, stock-based compensation, income taxes, marketable securities and leases. Estimates related to revenue recognition include actual costs incurred versus total estimated costs of the Company&#x2019;s deliverables to determine percentage of completion in addition to the application and estimates of potential revenue constraints in the determination of the transaction price under its license and collaboration agreements. Management bases these estimates on historical and anticipated results, trends and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to forecasted amounts and future events. Actual results may differ significantly from those estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Due to the COVID-19 pandemic, there has been uncertainty and disruption in the global economy and financial markets. The Company has taken into consideration any known COVID-19 impacts in its accounting estimates to date and is not aware of any additional specific events or circumstances that would require any additional updates to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of the date of issuance of this Annual Report on Form 10-K. These estimates may change as new events occur and additional information is obtained. Actual results could differ materially from these estimates under different assumptions or conditions.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_W8wv1mwxjUS-j7kKq9UcHg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Concentrations of Credit Risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and marketable securities. Substantially all of the Company&#x2019;s cash is held by two financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. The primary focus of the Company&#x2019;s investment strategy is to preserve capital and to meet liquidity requirements. The Company&#x2019;s cash equivalents and marketable securities are managed by external managers within the guidelines of the Company&#x2019;s investment policy. The Company&#x2019;s investment policy addresses the level of credit exposure by limiting concentration in &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;any one corporate issuer and establishing a minimum allowable credit rating. To manage its credit risk exposure, the Company maintains its portfolio of cash equivalents and marketable securities in fixed income securities denominated and payable in U.S. dollars. Permissible investments of fixed income securities include obligations of the U.S. government and its agencies, money market instruments including commercial paper and negotiable certificates of deposit, and highly rated corporate debt obligations and money market funds.&lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <ptgx:CashNumberOfFinancialInstitutions
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="0"
      id="Narr_yH3ANECyU06dcfNjbZqsBg"
      unitRef="Unit_Standard_Institution_l_EWsumXIkS46w5G4NlRGw">2</ptgx:CashNumberOfFinancialInstitutions>
    <us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_5VcabXYEQkWKK-fGVOY_kQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Cash Equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash equivalents that are readily convertible to cash are stated at cost, which approximates fair value. The Company considers all highly liquid investments purchased with an original maturity of three&#160;months or less to be cash equivalents. &lt;/p&gt;</us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_VEOS5fyKj0qOAjEt56s08A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Restricted Cash&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Restricted cash consists of cash balances primarily held as security in connection with a letter of credit related to the Company&#x2019;s facility lease entered into in March 2017 and the Company&#x2019;s corporate credit card.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_Ah-w7pZLvkyGqyiHbrZ2Pg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Cash as Reported in Consolidated Statements of Cash Flows&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash as reported in the consolidated statements of cash flows includes the aggregate amounts of cash and cash equivalents and the restricted cash as presented on the consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash as reported in the consolidated statements of cash flows consists of (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:95.58%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:64.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; 117,358&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 33,006&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 82,233&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted cash - current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 10&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:64.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted cash - noncurrent&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; 450&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 450&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 450&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total cash, cash equivalent and restricted cash in consolidated statements of cash flows&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;117,818&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 33,466&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 82,693&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_GpDv5o2i9kqE_hBRQLIgnw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:95.58%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:64.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; 117,358&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 33,006&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 82,233&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted cash - current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 10&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:64.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted cash - noncurrent&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; 450&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 450&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 450&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total cash, cash equivalent and restricted cash in consolidated statements of cash flows&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;117,818&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 33,466&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 82,693&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_JPcwsc6OIUuSREiTEVoHQQ_3_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">117358000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_FygAed5WQEOf2iWGfs9JxA_3_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">33006000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2018_rK3dysi-wkKgewxxLVB-Eg"
      decimals="-3"
      id="Tc_R5dRuSekMEqxR-SNxULNKg_3_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">82233000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_I4YHYaM2f0ijQF0joDMYBA_4_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">10000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_pm0iuxn7dEmTc_dKqx0gWg_4_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">10000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="As_Of_12_31_2018_rK3dysi-wkKgewxxLVB-Eg"
      decimals="-3"
      id="Tc_YIheXkQ56UylgX1v9XO47Q_4_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">10000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_hJooOYbQLUuFIlxrrAGrWQ_5_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">450000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_Pkmp6mln30eKlDkocf7BQw_5_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">450000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_12_31_2018_rK3dysi-wkKgewxxLVB-Eg"
      decimals="-3"
      id="Tc_3mWw4DwwEUqTaWo9py4RfQ_5_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">450000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_qjat_6dZIUyv_gurc3-7uw_6_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">117818000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_wBbfGiO_90--cvFaYCkwmA_6_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">33466000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2018_rK3dysi-wkKgewxxLVB-Eg"
      decimals="-3"
      id="Tc__e82SGTxE0KtwHE80_9bzQ_6_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">82693000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_Vax0YrH2IEGPNsKZu5Ocuw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:12pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Marketable Securities  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;All marketable securities have been classified as &#x201c;available-for-sale&#x201d; and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation as of each balance sheet date. Short-term marketable securities have maturities greater than three months but not longer than 365 days as of the balance sheet date. Long-term marketable securities have maturities of 365&#160;days or longer as of the balance sheet date. Unrealized gains and losses are excluded from earnings and are reported as a component of comprehensive loss. Realized gains and losses and declines in fair value judged to be other than temporary, if any, on available-for-sale securities are included in interest income. The cost of securities sold is based on the specific-identification method. Interest on marketable securities is included in interest income.&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_eAzROlKqwUuYAcFcbpkiwg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Fair Value of Financial Instruments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Fair value accounting is applied to all financial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis (at least annually). The carrying amount of the Company&#x2019;s financial instruments, including cash equivalents, receivable from collaboration partner, accounts payable, payable to collaboration partner and accrued expenses and other payables approximate fair value due to their short-term maturities. See Note&#160;4. to the Consolidated Financial Statements for additional information regarding the fair value of the Company&#x2019;s other financial assets and liabilities.&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_XBC9SMgV1k-3zvLhM02aYg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Property and Equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, ranging from &lt;span style="-sec-ix-hidden:Hidden_MwXrAUuc4UmOUGbm0YW9XQ;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;three&lt;/span&gt;&lt;/span&gt; to five&#160;years. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful lives of the assets. Maintenance and repairs are charged to expense as incurred. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the consolidated balance sheet and any resulting gain or loss is reflected in operations in the period realized.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_R76-sonyg0uleRlU84c1jA"
      id="Narr_LOetEyhVek-omw-4bAXtsg">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_69sQPvpEI0SOvp7YpoccQg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The Company adopted Accounting Standards Codification Topic 842, &lt;i style="font-style:italic;"&gt;Leases,&lt;/i&gt; (&#x201c;ASC 842&#x201d;) effective January 1, 2019. The Company determines if an arrangement is a lease at inception. Pursuant to ASC 842, operating leases are included in operating lease right-of-use (&#x201c;ROU&#x201d;) assets, operating lease liabilities, and noncurrent operating lease liabilities on the consolidated balance sheets. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. If the Company&#x2019;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. Lease terms include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:31.5pt;margin:0pt;"&gt;The Company records tenant improvement allowances as a reduction to the ROU asset with the impact of the decrease recognized prospectively over the remaining lease term. The leasehold improvements will be amortized over the shorter of their useful life or the remaining term of the lease. &lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_m_ssPk_7nE-GdRZZeu2JNA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Impairment of Long-Lived Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company reviews long-lived assets, primarily comprised of property, equipment and operating lease right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount to the future net cash flows which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset. There have been no such impairments of long-lived assets for any of the periods presented.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="0"
      id="Narr_YK_VPd96M0en2_Ac3sIYNA"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">0</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:DebtPolicyTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_z_BcwqSeCEefb-lU9RjU-w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Long Term Debt  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for interest on its long-term debt under the effective interest method, with interest expense comprised of contractual interest, amortization of origination fees and other issuance costs, and accretion of final payment fees. &lt;/p&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_u0lCa4L3k0S3Eo1_PFVjDg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive Loss&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive loss includes net loss as well as other changes in stockholders&#x2019; equity that result from transactions and economic events other than those from stockholders. The Company&#x2019;s foreign currency translation and unrealized gains and losses on available-for-sale securities represent the only components of other comprehensive loss that are excluded from reported net loss and that are presented in the consolidated statements of comprehensive loss.&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_dRl1RWIO7EC-32lnVnj1JQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Income Taxes &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"&gt;The Company uses the asset and liability method to account for income taxes in accordance with the authoritative guidance for income taxes. Under this method, deferred tax assets and liabilities are determined based on future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;and their respective tax bases, and tax loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates applied to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than a 50% likelihood of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest and penalties related to unrecognized tax benefits in income tax expense. To date, there have been no interest or penalties recorded in relation to unrecognized tax benefits.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="0"
      id="Narr_GZ482zBBR0awiZDwu7WVvQ"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_NMgO_NVWSky71jDC5C6gxQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Revenue Recognition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"&gt;The Company follows Accounting Standards Codification Topic 606, &lt;i style="font-style:italic;"&gt;Revenue from Contracts with Customers &lt;/i&gt;(&#x201c;ASC 606&#x201d;). Under ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the Company satisfies a performance obligation. The Company applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract, determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligations when (or as) the performance obligations are satisfied. The Company constrains its estimate of the transaction price up to the amount (the &#x201c;variable consideration constraint&#x201d;) that a significant reversal of recognized revenue is not probable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Licenses of intellectual property:&lt;/i&gt;&lt;span style="white-space:pre-wrap;"&gt;  If a license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in an arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring proportional performance for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of proportional performance each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Milestone payments:&lt;/i&gt;&lt;span style="white-space:pre-wrap;"&gt;  At the inception of each arrangement or amendment that includes development, regulatory or commercial milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. Whichever method is used, it should be consistently applied throughout the life of the contract; however, it is not necessary for the Company to use the same approach for all contracts. The Company expects to use the most likely amount method for development and regulatory milestone payments. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. If there is more than one performance obligation, the transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Royalties:&lt;/i&gt;&lt;span style="white-space:pre-wrap;"&gt;  For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional. Amounts payable to the Company and not yet billed to the collaboration partner are recorded as contract assets. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one&#160;year or less.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Contractual cost sharing payments made to a customer or collaboration partner are accounted for as a reduction to the transaction price if such payments are not related to distinct goods or services received from the customer or collaboration partner.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background-color:#ffffff;"&gt;Contracts may be amended to account for changes in contract specifications and requirements.&#160;Contract modifications exist when the amendment either creates new, or changes existing, enforceable rights and obligations. When&#160;contract modifications&#160;create new performance obligations and the increase in consideration approximates the standalone selling price for goods and services related to such new performance obligations as adjusted for specific facts and circumstances of the contract, the modification is considered to be a separate contract. If a contract modification is not accounted for as a separate contract, the Company accounts for the promised goods or services not yet transferred at the date of the contract modification (the remaining promised goods or services) prospectively, as if it were a termination of the existing contract and the creation of a new contract, if the remaining goods or services are distinct from the goods or services transferred on or before the date of the contract modification. The Company accounts for a contract modification as if it were a part of the existing contract if the remaining goods or services are not distinct and, therefore, form part of a single performance obligation that is partially satisfied at the date of the contract modification. In such case the effect that the contract modification has on the transaction price, and on the entity&#x2019;s measure of progress toward complete satisfaction of the performance obligation, is recognized as an adjustment to revenue (either as an increase in or a reduction of revenue) at the date of the contract modification (the adjustment to revenue is made on a cumulative catch-up basis).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background-color:#ffffff;"&gt;The period between when the Company transfers control of promised goods or services and when the Company receives payment is expected to be one year or less, which is consistent with the Company&#x2019;s historical experience. Upfront payment contract liabilities resulting from the Company&#x2019;s license and collaboration agreements do not represent a financing component as the payment is not financing the transfer of goods and services, and the technology underlying the licenses granted reflects research and development expenses already incurred by the Company. As such, the Company does not adjust its revenues for the effects of a significant financing component.&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_aDoOOnK0BEqylXEJ_ThPwg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Research and Development Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Research and development costs are expensed as incurred, unless there is an alternate future use in other research and development projects or otherwise. Research and development costs include salaries and benefits, stock-based compensation expense, laboratory supplies and facility-related overhead, outside contracted services including clinical trial costs, manufacturing and process development costs for both clinical and pre-clinical materials, research costs, development milestone payments under license and collaboration agreements, and other consulting services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"&gt;The Company accrues for estimated costs of research and development activities conducted by third-party service providers, which include the conduct of pre-clinical studies and clinical trials, and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated services provided &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;but not yet invoiced and includes these costs in accrued expenses and other payables in the consolidated balance sheets and within research and development expense in the consolidated statements of operations. The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers. As actual costs become known, the Company adjusts its accrued liabilities. The Company has not experienced any material differences between accrued liabilities and actual costs incurred. However, the status and timing of actual services performed, number of patients enrolled, the rate of patient enrollment and number and location of sites activated may vary from the Company&#x2019;s estimates, resulting in adjustments to expense in future periods. Changes in these estimates that result in material changes to the Company&#x2019;s accruals could materially affect the Company&#x2019;s results of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.5pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has received orphan drug designation from the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) for its clinical asset rusfertide (generic name for PTG-300) for the treatment of polycythemia vera and beta-thalassemia and may qualify for a related 25% U.S. Federal income tax credit on qualifying clinical study expenditures.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <ptgx:ResearchAndDevelopmentIncentiveGrantPolicyTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_pUCu9KbkdkepA0fASMUkvQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Research and Development Tax Incentive&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is eligible under the AusIndustry research and development tax incentive program to obtain either a refundable cash tax incentive or a taxable credit in the form of a non-cash tax incentive from the Australian Taxation Office (&#x201c;ATO&#x201d;). The refundable cash tax incentive is available to the Company on the basis of specific criteria with which the Company must comply. Specifically, the Company must have annual turnover of less than AUD 20.0 million and cannot be controlled by income tax exempt entities.&#160;The refundable cash tax incentive is recognized as a reduction to research and development expense when the right to receive has been attained and funds are considered to be collectible. The tax incentive is denominated in Australian dollars and, therefore, the related receivable is remeasured into U.S. dollars as of each reporting date. The Company may alternatively be eligible for a taxable credit in the form of a non-cash tax incentive in years when the annual turnover exceeds the limit. The Company evaluates its eligibility under tax incentive programs as of each balance sheet date and makes accrual and related adjustments based on the most current and relevant data available. &lt;/p&gt;</ptgx:ResearchAndDevelopmentIncentiveGrantPolicyTextBlock>
    <ptgx:SmallBusinessInnovationResearchSbirGrantsPolicyTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_lTmbcf29wUSOT1VkcalYSQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Small Business Innovation Research (&#x201c;SBIR&#x201d;) Grants&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has received SBIR grants from the National Institutes of Health (&#x201c;NIH&#x201d;) in support of its research activities. The Company recognizes a reduction to research and development expenses when expenses related to grants have been incurred and the grant funds become contractually due from NIH. &lt;/p&gt;</ptgx:SmallBusinessInnovationResearchSbirGrantsPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_dmBlvIxX3EKZGwtBAp2GgQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock-based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company measures its stock-based awards made to its equity plan participants based on the estimated fair values of the awards as of the grant date. For stock option awards, the Company uses the Black-Scholes option-pricing model to estimate fair values. For restricted stock unit awards, the estimated fair value is generally the fair market value of the underlying stock on the grant date. Stock-based compensation expense is recognized over the requisite service period and is based on the value of the portion of stock-based payment awards that is ultimately expected to vest. The Company recognizes forfeitures of stock-based awards as they occur. &lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_2e9G6G3nVEShcGJxsbp6aA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Net Loss per Share &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic net loss per share is calculated by dividing the Company&#x2019;s net loss by the weighted average number of shares of common stock and Exchange Warrants outstanding during the period, without consideration of potentially dilutive securities. In accordance with Accounting Standards Codification Topic 260, &lt;i style="font-style:italic;"&gt;Earnings Per Share&lt;/i&gt;, the Exchange Warrants are included in the computation of basic net loss per share because the exercise price is negligible and they are fully vested and exercisable after the original issuance date. Diluted net loss per share is the same as basic net loss per share for all periods presented since the effect of potentially dilutive securities is anti-dilutive given the net loss of the Company in each period. See Note 12. Stockholders' Equity for additional information regarding the Exchange Warrants.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_lXIULz79cUi0fPWAtvWSUA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:bold;"&gt;Recently Adopted Accounting Pronouncements &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;In August 2018, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2018-13, &lt;i style="font-style:italic;"&gt;Fair Value Measurement (Topic 820) &#x2013; Disclosure Framework &#x2013; Changes to the Disclosure Requirements for Fair Value Measurement&lt;/i&gt;, which modifies the disclosure requirements on fair value measurements and is intended to improve the effectiveness of disclosures, including the consideration of costs and benefits. The Company adopted this guidance as of January 1, 2020. The adoption of this guidance did not have a material impact on the Company&#x2019;s consolidated financial statements or disclosures. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;In November 2018, the FASB issued ASU No. 2018-18, &lt;i style="font-style:italic;"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606&lt;/i&gt;, which is intended to clarify the circumstances under which certain transactions in collaborative arrangements should be accounted for under the revenue recognition standard. Certain transactions between collaboration arrangement participants should be accounted for as revenue under ASC Topic 606 when the collaborative arrangement participant is a customer in the context of a unit of account. This guidance is effective for fiscal years and interim periods within those years beginning after December 15, 2019. The Company adopted this guidance as of January 1, 2020. The adoption of this guidance did not have a material impact on the Company&#x2019;s consolidated financial statements and disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:bold;"&gt;Recently Issued Accounting Pronouncements Not Yet Adopted as of December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;In June&#160;2016, the FASB issued ASU No.&#160;2016-13,&#160;&lt;i style="font-style:italic;"&gt;Financial Instruments&#160;- Credit Losses (Topic 326)&lt;/i&gt;, which is intended to provide financial statement users with more useful information about expected credit losses on financial assets held by a reporting entity at each reporting date. The new standard replaces the existing incurred loss impairment methodology with a methodology that requires consideration of a broader range of reasonable and supportable forward-looking information to estimate all expected credit losses. This guidance was originally effective for fiscal&#160;years and interim periods within those&#160;years beginning after December&#160;15, 2019, with early adoption permitted for fiscal&#160;years and interim periods within those&#160;years beginning after December&#160;15, 2018. In November 2019, the FASB issued ASU No. 2019-10, &lt;i style="font-style:italic;"&gt;Financial Instruments &#x2013; Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates&lt;/i&gt;, which amended the mandatory effective date of ASU No. 2016-13 for smaller reporting companies. Based on the Company&#x2019;s status as a smaller reporting company as of November 15, 2019, ASU 2016-13 is effective for the Company for fiscal years and interim periods beginning after December 15, 2022. The Company is currently evaluating the impact of this new guidance on its consolidated financial statements and disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;i style="font-style:italic;"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, &lt;/i&gt;which removes certain exceptions and amends certain requirements in the existing income tax guidance to ease accounting requirements. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020 and must be applied on a retrospective basis. The Company does not expect the adoption of this guidance to have a material impact on its consolidated financial statements and disclosures.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_ptgx_JanssenLicenseAndCollaborationAgreement26May2017Member_C_BnSjKn10WVjRwNMh3ISQ"
      id="Tb_Vcj16TERP0G28qs-ytsD8g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Note 3.&#160;&#160;&#160;&#160;&lt;b style="font-weight:bold;white-space:pre-wrap;"&gt;License and Collaboration Agreement   &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Agreement Terms&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;On May 26, 2017, the Company and Janssen Biotech, Inc., (&#x201c;Janssen&#x201d;), one of the Janssen Pharmaceutical Companies of Johnson &amp;amp; Johnson, entered into an exclusive license and collaboration agreement (the &#x201c;Janssen License and Collaboration Agreement&#x201d;) for the development, manufacture and potential commercialization of PTG-200 worldwide for the treatment of Crohn&#x2019;s disease (&#x201c;CD&#x201d;) and ulcerative colitis (&#x201c;UC&#x201d;). Janssen is a related party to the Company as Johnson &amp;amp; Johnson Innovation - JJDC, Inc., a significant stockholder of the Company, and Janssen are both subsidiaries of Johnson &amp;amp; Johnson. PTG-200 is the Company&#x2019;s orally delivered gut-restricted Interleukin 23 receptor (&#x201c;IL-23R&#x201d;) antagonist drug candidate currently in development. The Janssen License and Collaboration Agreement became effective on July 13, 2017. Upon the effectiveness of the agreement, the Company received a non-refundable, upfront cash payment of $50.0 million from Janssen.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the Janssen License and Collaboration Agreement, the Company granted to Janssen an exclusive worldwide license to develop, manufacture and commercialize PTG-200 and related IL-23R compounds for all indications, including CD and UC. The Company was responsible, at its own expense, for the conduct of the Phase 1 clinical trial for PTG-200, and Janssen is responsible for the conduct of the Phase 2 clinical trial for PTG-200 in CD, including filing the U.S. Investigational New Drug application (&#x201c;IND&#x201d;). Development costs for the Phase 2 clinical trial are shared between the parties on an 80/20 basis, with Janssen assuming the larger share. Janssen submitted an IND for PTG-200 in CD during the second quarter of 2019, which took effect in July 2019. The Company initiated a Phase 2 clinical study for PTG-200 in CD with Janssen in the fourth quarter of 2019.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company entered into an amendment (the &#x201c;First Amendment&#x201d;) to the Janssen License and Collaboration Agreement effective May 7, 2019. The First Amendment builds upon the Company&#x2019;s ongoing development collaboration with Janssen for PTG-200 and, upon the effectiveness of the First Amendment, the Company became eligible to receive a $25.0 million payment from Janssen, which was received during the second quarter of 2019. The First Amendment expanded the scope of the Janssen License and Collaboration Agreement by supporting research efforts towards identifying and developing second-generation IL-23R antagonists (&#x201c;second-generation compounds&#x201d;).  Two second-generation IL-23R compounds have been nominated and are currently in development: PN-235, in a Phase 1 clinical study, and PN-232, in preclinical studies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;As part of the services added in the First Amendment, Janssen will pay certain costs and milestones related to advancing pre-clinical candidates from the second-generation research program through Phase 1 studies, including funding of a certain number of full-time equivalent employees (&#x201c;FTEs&#x201d;) at the Company for an agreed upon period of time. The Company will pay 100% of the costs for the preclinical studies and Phase 1 studies for the first second-generation compound, and 50% of the costs of the Phase 1 studies for the second and third second-generation compounds; thereafter Janssen will pay 100% of any further Phase 1 development costs. Development costs for the Phase 2 clinical trials for second-generation compounds are shared between the parties on an 80/20 basis, with Janssen assuming the larger share. The Company&#x2019;s Phase 1 and Phase 2 development costs are also limited by overall spending caps. In December 2019, the Company became eligible to receive a $5.0 million payment trigged by the successful nomination of a second-generation development compound, which was received during the first quarter of 2020. The Company will be eligible to receive a $7.5 million milestone payment at the completion of a Phase 1 study for the first second-generation compound. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Prior to the effectiveness of the First Amendment, the Company had been eligible to receive a $25.0 million milestone payment upon Janssen&#x2019;s filing of the IND. This amount had been considered constrained until a time at which the Company would have become eligible to receive the $25.0 million payment from Janssen. Payments to the Company for research and development services are generally billed and collected as services are performed or assets are delivered, including research activities and Phase 1 and Phase 2 development activities. Janssen bills the Company for its 20% share of the Phase 2 development costs as expenses are incurred by Janssen. Milestone payments are received after the related milestones are achieved. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Pursuant to the First Amendment, the Company will be eligible to receive clinical development, regulatory and sales milestones, if and as achieved, and/or payments relating to Janssen&#x2019;s elections to maintain or expand its license rights. The next possible milestone or opt-in election events based on a Phase 2 clinical trial in CD are as follows: &lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:27pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:4.5pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;span style="font-size:12pt;"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt; Janssen can elect to advance PTG-200 into Phase 2b following receipt of the top line results of the CD Phase 2a clinical trial for PTG-200 by paying a $50.0 million maintenance fee (the &#x201c;Amended First Opt-in Election&#x201d;); or &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:4.5pt;text-indent:-4.5pt;margin:0pt 0pt 12pt 27pt;"&gt;&lt;span style="font-size:12pt;"&gt;&#x2022;&lt;/span&gt; Janssen would make a $50.0 million milestone payment following dosing of the third patient in the first Phase 2b clinical trial for CD for a second-generation product.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"&gt;Janssen can also then elect to receive exclusive, world-wide commercial rights for both PTG-200 and second-generation products following the Phase 2b completion date for PTG-200 or a second-generation product by paying a $50.0 million payment (the &#x201c;Amended Second Opt-in Election&#x201d;). The Company will also be eligible for certain additional milestone payments including a potential payment of either $100.0 million upon a Phase 3 CD clinical trial meeting a &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;primary clinical endpoint with respect to PTG-200 or $115.0 million upon a Phase 3 CD clinical trial meeting a primary clinical endpoint with respect to a second-generation compound.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Pursuant to the First Amendment, the Company will be eligible to receive tiered royalties on net product sales at percentages ranging from mid-single digits to ten percent. Under the terms of the First Amendment, the Company will be eligible to receive up to an aggregate $1.0 billion in research, development, regulatory and sales milestones.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The Janssen License and Collaboration Agreement remains in effect until the royalty obligations cease following patent and regulatory expiry, unless terminated earlier. Upon a termination of the Janssen License and Collaboration Agreement, all rights revert back to the Company, and in certain circumstances, if such termination occurs during ongoing clinical trials, Janssen would, if requested, provide certain financial and operational support to the Company for the completion of such trials.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Revenue Recognition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;The Company concluded that the amended Janssen License and Collaboration Agreement continued to contain a single performance obligation including the development license; second-generation compound research services; Phase 1 development services for PTG-200 and potential second-generation compounds; the Company&#x2019;s services associated with Phase 2 development for PTG-200 until Phase 2a; the Company&#x2019;s services associated with Phase 2 development for  second-generation products until the dosing of the third patient in Phase 2b in CD or UC, or Phase 2 in an additional indication; and all other such services that the Company may perform at the request of Janssen to support the development of PTG-200, second-generation research services, or the development of second-generation compounds. The Company concluded that the Amended First Opt-in Election and the Amended Second Opt-in Election options are not considered to be material rights.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company determined that the license was not distinct from the added research and development services within the context of the agreement because the added research and development services significantly increase the utility of the intellectual property. The Company also determined that the remaining research and development services are not distinct from the partially delivered combined promise comprised under the agreement prior to the First Amendment of the development license and PTG-200 services, including compound supply and other services. Therefore, the First Amendment is treated as if it were part of the original Janssen License and Collaboration Agreement. The First Amendment was accounted for as if it were an extension of services under the initial Janssen License and Collaboration Agreement by applying a cumulative catch-up adjustment to revenue. As of the effective date of the First Amendment, the Company calculated the adjusted cumulative revenue under the amended Janssen License and Collaboration Agreement by updating the transaction price for the incremental consideration to be received, net of the incremental development cost reimbursement to be paid to Janssen, and an updated percentage complete, which resulted in a cumulative adjustment recorded during the year ended December 31, 2019 that reduced revenue by $9.4 million. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The contract duration is defined as the period in which parties to the contract have present enforceable rights and obligations. For revenue recognition purposes, the Company determined that the duration of the Janssen License and Collaboration Agreement, as amended, began on the effective date of July 13, 2017 and is estimated to end upon the later of end of Phase 2a for PTG-200 or upon dosing of the third patient in Phase 2b for a second-generation compound.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company uses the most likely amount method to estimate variable consideration included in the transaction price. Variable consideration after the First Amendment consists of future milestone payments and cost sharing payments from Janssen for agreed upon services, offset by development cost reimbursements payable to Janssen. Cost sharing payments from Janssen relate to the agreed upon services for development activities that the Company performs within the duration of the contract and are included in the transaction price at the Company&#x2019;s share of estimated budgeted costs for these activities, including primarily internal full-time equivalent effort and third party contract costs. Cost sharing payments to Janssen relate to agreed upon services for Phase 2 activities that Janssen performs within the duration of the contract and are not a distinct service that Janssen transfers to the Company. Therefore, the consideration payable to Janssen is accounted for as a reduction in the transaction price.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company concluded that the transaction price of the initial performance obligation under the Janssen License and Collaboration Agreement was $98.6 million as of December 31, 2020, a decrease of $14.3 million from the transaction price of $112.9 million at December 31, 2019 and an increase of $37.9 million from the transaction price of $60.7 million at December 31, 2018. In order to determine the transaction price, the Company evaluated all payments to be received during the duration of the contract, net of Phase 2 development costs reimbursement expected to be payable to Janssen. The Company determined that the transaction price of the initial performance obligation as of December 31, 2020 includes the $50.0 million upfront payment, the $25.0 million payment received upon the effectiveness of the First Amendment, the $5.0 million payment triggered by the successful nomination of a second-generation compound, $17.9 million of reimbursement from Janssen for services performed for PTG-200 Phase 2 and for second-generation compound research and development costs and other services, and estimated variable consideration consisting of a $7.5 million milestone payment subject to the completion of a Phase 1 study for a second-generation compound, partially offset by $6.8 million of net cost reimbursement to Janssen for services performed. The Company evaluated whether the variable component of the transaction price should be constrained to ensure that a significant reversal of revenue recognized on a cumulative basis as of December 31, 2020 is not probable. The Company concluded that the variable consideration constraint does not further decrease the estimated transaction price as of December 31, 2020. The additional potential development, regulatory and sales milestone payments after the completion of Phase 2a activities in UC and CD that the Company would be eligible to receive are currently outside the contract term as defined for revenue recognition purposes and as such have been excluded from the transaction price. Janssen has also opted in for certain additional services to be performed by the Company that are outside the initial performance obligation; revenue is recognized as these services are performed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company re-evaluates the transaction price, including variable consideration, at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur. The Company and Janssen make quarterly cost sharing payments to one another in amounts necessary to ensure that each party bears its contractual share of the overall shared costs incurred. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company utilizes a cost-based input method to measure proportional performance and to calculate the corresponding amount of revenue to recognize. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to expected costs to fulfill the combined performance obligation. These costs consist primarily of internal FTE effort and third-party contract costs. Revenue will be recognized based on actual costs incurred as a percentage of total estimated costs as the Company completes its performance obligations. A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company&#x2019;s performance obligations. The Company believes this is the best measure of progress because other measures do not reflect how the Company transfers its performance obligation to Janssen. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company&#x2019;s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;For the year ended December 31, 2020, the Company recognized $28.6 million of license and collaboration revenue. This amount included $27.1 million of the transaction price based on proportional performance and an update in forecasted amounts for future services remaining to be performed and recognized under the Janssen License and Collaboration Agreement. In addition, the Company recorded $1.5 million of revenue for the year ended December 31, 2020 related to additional services provided by the Company under the Janssen License and Collaboration Agreement. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;For the year ended December 31, 2019, the Company recognized $0.2 million of license and collaboration revenue. This amount included a $9.4 million cumulative catchup adjustment as a reduction of revenue, offset by $8.0 million of license and collaboration revenue recognized following the contract modification for the First Amendment and $1.6 million of collaboration revenue recognized during the first quarter of 2019 under the original Janssen License and Collaboration Agreement prior to the effectiveness of the First Amendment. No revenue for additional services was recognized for the year ended December 31, 2019.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"&gt;For the year ended December 31, 2018, the Company recognized $30.9 million of license and collaboration revenue. This amount included $30.8 million of the transaction price for the Janssen License and Collaboration &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Agreement recognized based on proportional performance, and $0.1 million, net, for other services related to Phase 2 activities performed by the Company on behalf of Janssen that were not included in the performance obligations identified under the Janssen License and Collaboration Agreement. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table presents changes in the Company&#x2019;s contract assets and liabilities during the periods presented (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance&#160;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance&#160;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Beginning&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;End&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Period&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Additions&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deductions&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Period&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Contract assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Receivable from collaboration partner - related party&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,955&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,221&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,750)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,426&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Contract asset - related party&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 800&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 342&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,142)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Contract liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Deferred revenue - related party&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 41,530&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,963&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (31,016)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,477&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Payable to collaboration partner - related party&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,262&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,800&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,330)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,732&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance&#160;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance&#160;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Beginning&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;End&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Period&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Additions&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deductions&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Period&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Contract assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Receivable from collaboration partner - related party&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,042&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36,837&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (32,924)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,955&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Contract asset - related party&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,545&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 800&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,545)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 800&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Contract liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Deferred revenue - related party&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,223&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42,456&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,149)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 41,530&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Payable to collaboration partner - related party&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,061&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,468&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,267)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,262&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended December 31, 2020, the Company recognized revenue of $14.1 million from amounts included in the deferred revenue contract liability balance at the beginning of the year. During the year ended December 31, 2019, the Company recognized revenue of $1.6 million from amounts included in the deferred revenue contract liability balance at the beginning of the year, which represents the revenue recognized during the first quarter of 2019 prior to the effectiveness of the First Amendment. During the year ended December 31, 2018, the Company recognized $23.5 million in revenue from the deferred revenue contract liability balance at the beginning of the year. None of the costs to obtain or fulfill the contract were capitalized.&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="As_Of_7_13_2017_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_UpfrontCashPaymentMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_8ZzG4TogRUeK22l7bZWg6Q"
      decimals="-5"
      id="Narr_tRcVKm68X0-1sv71KxgH7A"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">50000000.0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <ptgx:CollaborativeArrangementPercentageOfDevelopmentCostsIncurred
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_ptgx_SecondGenerationAnalogPhase2CdClinicalTrialPrimaryClinicalEndpointMember_JacSAA95dUyCrU6tGgPPmQ"
      decimals="2"
      id="Narr_2e4fPZss20ifp48rFvK3pA"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.80</ptgx:CollaborativeArrangementPercentageOfDevelopmentCostsIncurred>
    <ptgx:CollaborativeArrangementPercentageOfDevelopmentCostsIncurred
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember_d9hGXjKIFEOZdcykv_sYsw"
      decimals="2"
      id="Narr_RDa_bdH4j0OFGLtJTHuaFg"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.20</ptgx:CollaborativeArrangementPercentageOfDevelopmentCostsIncurred>
    <ptgx:CollaborativeArrangementEligibleAmountReceived
      contextRef="As_Of_6_30_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_LicenseAndCollaborativeRevenueMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendmentMember_t7Zx6qmuv02vXASmqBWLvw"
      decimals="-5"
      id="Narr_DRVrZAlQd0G1ZfoeVDT2YQ"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">25000000.0</ptgx:CollaborativeArrangementEligibleAmountReceived>
    <ptgx:CollaborativeArrangementPercentageOfResearchProgramCostsIncurred
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember_us-gaap_TypeOfArrangementAxis_ptgx_CollaborationAgreementTrancheThreeMember_tvpE-SkS6k2HRTzbxgh_wg"
      decimals="2"
      id="Narr_z2S-wLAHmUG6WHtmrcV4oQ"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">1</ptgx:CollaborativeArrangementPercentageOfResearchProgramCostsIncurred>
    <ptgx:CollaborativeArrangementPercentageOfResearchProgramCostsIncurred
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember_us-gaap_TypeOfArrangementAxis_ptgx_CollaborationAgreementTrancheFourMember_bqQIT5Ulw0CqIqPYWi81Yw"
      decimals="2"
      id="Narr_B8VGcUBiMkad2wCriZ1Kiw"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.50</ptgx:CollaborativeArrangementPercentageOfResearchProgramCostsIncurred>
    <ptgx:CollaborativeArrangementPercentageOfResearchProgramCostsIncurred
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember_us-gaap_TypeOfArrangementAxis_ptgx_CollaborationAgreementTrancheFiveMember_zUOiK1ho7EWtoDBGEsNNOw"
      decimals="2"
      id="Narr_GZ7wY1MqukSq-4VMMajRKw"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">1</ptgx:CollaborativeArrangementPercentageOfResearchProgramCostsIncurred>
    <ptgx:CollaborativeArrangementPercentageOfDevelopmentCostsIncurred
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_ptgx_SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember_mwtEbZMbFUWPqDXv33EobA"
      decimals="2"
      id="Narr_T7rU-3j94EuFzA9KG1Kkkw"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.80</ptgx:CollaborativeArrangementPercentageOfDevelopmentCostsIncurred>
    <ptgx:CollaborativeArrangementPercentageOfDevelopmentCostsIncurred
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember_d9hGXjKIFEOZdcykv_sYsw"
      decimals="2"
      id="Narr_aYnZyMa0T0GA4UCeyNDHNA"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.20</ptgx:CollaborativeArrangementPercentageOfDevelopmentCostsIncurred>
    <ptgx:CollaborativeArrangementPayableUponEffectivenessOfAmendment
      contextRef="Duration_12_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_ptgx_SecondGenerationDevelopmentCompoundMember_P6e595XTnUiY7TVn8K6bmQ"
      decimals="-5"
      id="Narr_mlpJ7QNfpkSzHR6pzDF1PA"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">5000000.0</ptgx:CollaborativeArrangementPayableUponEffectivenessOfAmendment>
    <ptgx:CollaborativeArrangementPayableUponEffectivenessOfAmendment
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_MilestonePaymentsMember_us-gaap_TypeOfArrangementAxis_ptgx_CollaborationAgreementTrancheThreeMember_2JbTuvZF1E6as5O_Zhxubg"
      decimals="-5"
      id="Narr_GWTjw1x7xkOuj30tizgsIw"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">7500000</ptgx:CollaborativeArrangementPayableUponEffectivenessOfAmendment>
    <ptgx:CollaborativeArrangementPayableUponEffectivenessOfAmendment
      contextRef="Duration_4_1_2019_To_6_30_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_MilestonePaymentsMember_srt_StatementScenarioAxis_srt_ProFormaMember_cUCCwM3epUW2i97GGepUZw"
      decimals="-5"
      id="Narr_BM__T0CNfUmz7PCQKnBOTg"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">25000000.0</ptgx:CollaborativeArrangementPayableUponEffectivenessOfAmendment>
    <ptgx:CollaborativeArrangementPayableUponEffectivenessOfAmendment
      contextRef="Duration_4_1_2019_To_6_30_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_LicenseAndCollaborativeRevenueMember_srt_StatementScenarioAxis_srt_ProFormaMember_D0E1ttaBzUyFCH2yOPFdiQ"
      decimals="-5"
      id="Narr_VWQCpdN2a0O7ogDvSTd8_A"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">25000000.0</ptgx:CollaborativeArrangementPayableUponEffectivenessOfAmendment>
    <ptgx:CollaborativeArrangementPercentageOfDevelopmentCostsIncurred
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_ptgx_LicenseAndCollaborativeRevenueMember_8kLGBjtrT0WDvA027jn2RQ"
      decimals="2"
      id="Narr_o75WNe28_UiXrYO-A9GnwA"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.20</ptgx:CollaborativeArrangementPercentageOfDevelopmentCostsIncurred>
    <ptgx:CollaborativeArrangementPayableUponEffectivenessOfAmendment
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_UpfrontCashPaymentMember_us-gaap_TypeOfArrangementAxis_ptgx_AmendedCollaborationAgreementTrancheOneMember_c9va82PLx0uSFetk0cbloQ"
      decimals="-5"
      id="Narr_wGjLbLEWi0uTQxBwzIE3Qg"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">50000000.0</ptgx:CollaborativeArrangementPayableUponEffectivenessOfAmendment>
    <ptgx:CollaborativeArrangementPayableUponEffectivenessOfAmendment
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_SecondGenerationPhase2bMilestonePaymentMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendmentMember_H5wv-w3AKUSR5s2BPJL4Kg"
      decimals="-5"
      id="Narr_63tHmwv3806S4-osOZNQBg"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">50000000.0</ptgx:CollaborativeArrangementPayableUponEffectivenessOfAmendment>
    <ptgx:CollaborativeArrangementPayableUponEffectivenessOfAmendment
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_UpfrontCashPaymentMember_us-gaap_TypeOfArrangementAxis_ptgx_AmendedSecondOptInMember_cppdcoBeEkOHH_mebXmIVg"
      decimals="-5"
      id="Narr_A3uZIHITiUm3BMBT-caVxQ"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">50000000.0</ptgx:CollaborativeArrangementPayableUponEffectivenessOfAmendment>
    <ptgx:ContingentConsiderationReceivable
      contextRef="As_Of_5_7_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_Ptg200Phase3CdClinicalTrialPrimaryClinicalEndpointMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendmentMember_Bn4vSCBoGEOTDsfBtOVnNQ"
      decimals="-5"
      id="Narr_TqIRf6JjWUKAmRXGUEPLzA"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">100000000.0</ptgx:ContingentConsiderationReceivable>
    <ptgx:ContingentConsiderationReceivable
      contextRef="As_Of_5_7_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendmentMember_9gK_kOJw_ESqRE-bsagxFg"
      decimals="-5"
      id="Narr_sellXPH4bEigCFTh0_bKBQ"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">115000000.0</ptgx:ContingentConsiderationReceivable>
    <ptgx:PercentagesRoyaltiesOnNetProductSales
      contextRef="Duration_5_7_2019_To_5_7_2019_srt_ProductOrServiceAxis_ptgx_DevelopmentRegulatoryAndSalesMilestonePaymentsMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendmentMember_nG2wMUofPkqcS4glTe3R0w"
      decimals="2"
      id="Narr_j9VUc6yfGUa3zigF8GYhvQ"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.10</ptgx:PercentagesRoyaltiesOnNetProductSales>
    <ptgx:ContingentConsiderationReceivable
      contextRef="As_Of_5_7_2019_srt_ProductOrServiceAxis_ptgx_DevelopmentRegulatoryAndSalesMilestonePaymentsMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendmentMember_PNZUEJ__x0m4Tx70AGON6A"
      decimals="-8"
      id="Narr_8HKhXlZsmEelwPLF1y09Qw"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1000000000.0</ptgx:ContingentConsiderationReceivable>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendmentMember_0gY4oTF5r0WEXzTC15E-FQ"
      decimals="-5"
      id="Narr_IlY877AjlkuvoyHfXciWVg"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-9400000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="As_Of_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_X-3f2T5tzkO0bujYt1VHYg"
      decimals="-5"
      id="Narr_gZV7gy5_qUCvb0KrIFTGDw"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">98600000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_OTlJVqmnGkadZNc3gOI6uA"
      decimals="-5"
      id="Narr_SMTBDmTMYEm6v0kazZUeZA"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-14300000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_Iek_4R-H0EOc28_Wvd-Hnw"
      decimals="-5"
      id="Narr_D76IcT-cyUaIQVLwjLrqOg"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">112900000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_H-NgQaNu50uhdMckH4xw9Q"
      decimals="-5"
      id="Narr_FoqKcTcOJ0CLjilwqB4X-Q"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">37900000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="As_Of_12_31_2018_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_dyHYhh53okOYGwIKFCa5Ag"
      decimals="-5"
      id="Narr_HM0179qdt0mml9QoeU02sg"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">60700000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="As_Of_7_13_2017_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_UpfrontCashPaymentMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_8ZzG4TogRUeK22l7bZWg6Q"
      decimals="-5"
      id="Narr_8KKvXtmpp0qosV5ZN5RGUg"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">50000000.0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="Duration_4_1_2019_To_6_30_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_LicenseAndCollaborativeRevenueMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendmentMember_XvMY8HCh9EOEQkePbHrEeg"
      decimals="-5"
      id="Narr_r3rsyg-0OEGKSgN0GkhHjw"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">25000000.0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendmentMember_GtedaLqT9E2-CCUloPfAtw"
      decimals="-5"
      id="Narr_nmu50FrhhkmtfeiLHEEyQg"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">5000000.0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_LicenseAndCollaborativeRevenueMember_us-gaap_TypeOfArrangementAxis_ptgx_PhaseTwoClinicalTrialMember_BryyTsUuxEmwlP3YXd1gUg"
      decimals="-5"
      id="Narr_WmX0A9EAokWmoK6Rx_oztg"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">17900000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <ptgx:CollaborativeArrangementPayableUponEffectivenessOfAmendment
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_LicenseAndCollaborativeRevenueMember_us-gaap_TypeOfArrangementAxis_ptgx_EstimatedVariableConsiderationMember_arxMJ0T-00eGdw9zoeZApA"
      decimals="-5"
      id="Narr_vQD5Ehj7g0OJSo8xD3MXFg"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">7500000</ptgx:CollaborativeArrangementPayableUponEffectivenessOfAmendment>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_MilestonePaymentsMember_us-gaap_TypeOfArrangementAxis_ptgx_SecondGenerationDevelopmentCompoundMember_sAqgbJv3QkOF-0V4dOsnIw"
      decimals="-5"
      id="Narr_nxnqcvhGp0C0RVTubiDePA"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">6800000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_LicenseAndCollaborativeRevenueMember_TvNWwGu2eEC6vYE7HcfZ-A"
      decimals="-5"
      id="Narr_2Zk2ASXHlUi2X9I-plTcig"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">28600000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_LicenseAndCollaborativeRevenueMember_TvNWwGu2eEC6vYE7HcfZ-A"
      decimals="-5"
      id="Narr_-foJRKvKY0G4QuLBwUVbDQ"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">27100000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_FinancialServiceOtherMember_NBguqYBUHku6qOzTYn42VQ"
      decimals="-5"
      id="Narr_2Sb-cBvVaEKjYaxZfxshdQ"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1500000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_LicenseAndCollaborativeRevenueMember_3QxHrdZZck25Pg-JQIj-nw"
      decimals="-5"
      id="Narr_AWfbDfSoA0-k-HZUxW_Qeg"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">200000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendmentMember_0gY4oTF5r0WEXzTC15E-FQ"
      decimals="-5"
      id="Narr_ceBhLYwaqkGJ4PfPIe8Qtw"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-9400000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_LicenseAndCollaborativeRevenueMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendmentMember_y5i3Re06f0iiRKOUUagPDA"
      decimals="-5"
      id="Narr_HBD6nu_dl0267Ey8nGSQQw"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">8000000.0</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="Duration_1_1_2019_To_3_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_LicenseAndCollaborativeRevenueMember_us-gaap_TypeOfArrangementAxis_ptgx_LicenseAndCollaborativeAgreementAmendmentMember_OXDfxfH58kqhheU3GQGUvA"
      decimals="-5"
      id="Narr_K2PodkCeQ0SirpXrY1pSDg"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1600000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_us-gaap_FinancialServiceOtherMember_mIs-a5_M8Ey3l6XrIQVjEw"
      decimals="-5"
      id="Narr_rXaFKHGTXkKeSXLEoBGcdg"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="Duration_1_1_2018_To_12_31_2018_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_srt_ProductOrServiceAxis_ptgx_LicenseAndCollaborativeRevenueMember_KsXkSwmdJk6E8sIAWg2nyA"
      decimals="-5"
      id="Narr_P4zqNxHC7ke52Kd77hn84w"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">30900000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2018_To_12_31_2018_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_vfjwayMYI0exJuQhXetAgw"
      decimals="-5"
      id="Narr_-RSsxBOFtUGJG4DSlp0YQg"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">30800000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2018_To_12_31_2018_srt_ProductOrServiceAxis_us-gaap_FinancialServiceOtherMember_us-gaap_TypeOfArrangementAxis_ptgx_PhaseTwoClinicalTrialMember_lxJPPTHjz0OKFor2aG-yUQ"
      decimals="-5"
      id="Narr_U8feGsKAy06KmV5DqwAJNA"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">100000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Group_cM-oJUPu_ESkzeKc8-5FZQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table presents changes in the Company&#x2019;s contract assets and liabilities during the periods presented (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance&#160;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance&#160;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Beginning&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;End&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Period&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Additions&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deductions&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Period&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Contract assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Receivable from collaboration partner - related party&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,955&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,221&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,750)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,426&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Contract asset - related party&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 800&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 342&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,142)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Contract liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Deferred revenue - related party&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 41,530&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,963&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (31,016)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,477&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Payable to collaboration partner - related party&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,262&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,800&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,330)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,732&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance&#160;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance&#160;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Beginning&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;End&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Period&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Additions&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deductions&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Period&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Contract assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Receivable from collaboration partner - related party&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,042&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36,837&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (32,924)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,955&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Contract asset - related party&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,545&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 800&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,545)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 800&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Contract liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Deferred revenue - related party&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,223&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42,456&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,149)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 41,530&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Payable to collaboration partner - related party&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,061&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,468&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,267)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,262&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_Iek_4R-H0EOc28_Wvd-Hnw"
      decimals="-3"
      id="Tc_qTI5egQB2EmJ3951JFgq2Q_5_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">5955000</us-gaap:ContractWithCustomerAssetNet>
    <ptgx:ContractWithCustomerAssetAdditions
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_OTlJVqmnGkadZNc3gOI6uA"
      decimals="-3"
      id="Tc_Kj21c40dCkOxw_QguJuIPw_5_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">6221000</ptgx:ContractWithCustomerAssetAdditions>
    <ptgx:ContractWithCustomerAssetDeduction
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_OTlJVqmnGkadZNc3gOI6uA"
      decimals="-3"
      id="Tc_FxFADoVGIEGR4Yl_JLG14w_5_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">9750000</ptgx:ContractWithCustomerAssetDeduction>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="As_Of_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_X-3f2T5tzkO0bujYt1VHYg"
      decimals="-3"
      id="Tc_fUbaXJCS-U-Xf492p9uX6A_5_12"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">2426000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_Iek_4R-H0EOc28_Wvd-Hnw"
      decimals="-3"
      id="Tc_vApwUqJPS0KjTm0ojSnRxA_6_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">800000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <ptgx:ContractWithCustomerAssetRelatedPartyAdditions
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_OTlJVqmnGkadZNc3gOI6uA"
      decimals="-3"
      id="Tc_o0boBfozcECL-X3BPj_eaA_6_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">342000</ptgx:ContractWithCustomerAssetRelatedPartyAdditions>
    <ptgx:ContractWithCustomerAssetRelatedPartyDeduction
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_OTlJVqmnGkadZNc3gOI6uA"
      decimals="-3"
      id="Tc_pNyWTrhN2E-6Swn2__CTtA_6_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-1142000</ptgx:ContractWithCustomerAssetRelatedPartyDeduction>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_Iek_4R-H0EOc28_Wvd-Hnw"
      decimals="-3"
      id="Tc_VgN-N-MXVE2TqrS2jxGgiw_8_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">41530000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <ptgx:ContractWithCustomerLiabilityAdditions
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_OTlJVqmnGkadZNc3gOI6uA"
      decimals="-3"
      id="Tc_9BEWfQn6602IDaMF8ZrMsw_8_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">3963000</ptgx:ContractWithCustomerLiabilityAdditions>
    <ptgx:ContractWithCustomerLiabilityDeduction
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_OTlJVqmnGkadZNc3gOI6uA"
      decimals="-3"
      id="Tc_CDVeYSryn0q1Ini9VAOetA_8_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">31016000</ptgx:ContractWithCustomerLiabilityDeduction>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_X-3f2T5tzkO0bujYt1VHYg"
      decimals="-3"
      id="Tc_0_a5DxiQ3U-8uviHrm1Xwg_8_12"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">14477000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_Iek_4R-H0EOc28_Wvd-Hnw"
      decimals="-3"
      id="Tc_x0bNNpShbEmOupwESlGsyg_9_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1262000</us-gaap:DueToRelatedPartiesCurrent>
    <ptgx:DueToRelatedPartyAdditions
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_OTlJVqmnGkadZNc3gOI6uA"
      decimals="-3"
      id="Tc_8hoPHQkb0k6Q5zI9hjrf1Q_9_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">3800000</ptgx:DueToRelatedPartyAdditions>
    <ptgx:DueToRelatedPartyDeductions
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_OTlJVqmnGkadZNc3gOI6uA"
      decimals="-3"
      id="Tc_cCTHOmVjiE-f6ku85GIDhg_9_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">2330000</ptgx:DueToRelatedPartyDeductions>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="As_Of_12_31_2020_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_X-3f2T5tzkO0bujYt1VHYg"
      decimals="-3"
      id="Tc_iROiiKi0hEawtTRjJE-c9A_9_12"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">2732000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="As_Of_12_31_2018_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_dyHYhh53okOYGwIKFCa5Ag"
      decimals="-3"
      id="Tc_gxt54gBOKE-pmMpIZlhDIg_16_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">2042000</us-gaap:ContractWithCustomerAssetNet>
    <ptgx:ContractWithCustomerAssetAdditions
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_H-NgQaNu50uhdMckH4xw9Q"
      decimals="-3"
      id="Tc_185dN3lbaE69OCsrYup2MA_16_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">36837000</ptgx:ContractWithCustomerAssetAdditions>
    <ptgx:ContractWithCustomerAssetDeduction
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_H-NgQaNu50uhdMckH4xw9Q"
      decimals="-3"
      id="Tc__LPERQxb60KCR8Qd1ruDGg_16_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">32924000</ptgx:ContractWithCustomerAssetDeduction>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_Iek_4R-H0EOc28_Wvd-Hnw"
      decimals="-3"
      id="Tc_vz7jhw1Y90mP7UYd-VeY0g_16_12"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">5955000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="As_Of_12_31_2018_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_dyHYhh53okOYGwIKFCa5Ag"
      decimals="-3"
      id="Tc_wWopQHCqXE2Adv1-UID_uQ_17_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">2545000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <ptgx:ContractWithCustomerAssetRelatedPartyAdditions
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_H-NgQaNu50uhdMckH4xw9Q"
      decimals="-3"
      id="Tc_U4gXhrZ9oE2pK4QSdzcqcA_17_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">800000</ptgx:ContractWithCustomerAssetRelatedPartyAdditions>
    <ptgx:ContractWithCustomerAssetRelatedPartyDeduction
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_H-NgQaNu50uhdMckH4xw9Q"
      decimals="-3"
      id="Tc_auLA7SfCTk2qbB5fNBBMaA_17_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-2545000</ptgx:ContractWithCustomerAssetRelatedPartyDeduction>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_Iek_4R-H0EOc28_Wvd-Hnw"
      decimals="-3"
      id="Tc_CxtmnTPt_U6-X9Gegw9yEw_17_12"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">800000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2018_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_dyHYhh53okOYGwIKFCa5Ag"
      decimals="-3"
      id="Tc_Xsv_5pmK5E-bvk7sPWzdhQ_19_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">8223000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <ptgx:ContractWithCustomerLiabilityAdditions
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_H-NgQaNu50uhdMckH4xw9Q"
      decimals="-3"
      id="Tc_5PvniKA1IUGQCP18XM8n4w_19_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">42456000</ptgx:ContractWithCustomerLiabilityAdditions>
    <ptgx:ContractWithCustomerLiabilityDeduction
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_H-NgQaNu50uhdMckH4xw9Q"
      decimals="-3"
      id="Tc_Y6eytbdPe0OJTx97h4K1nw_19_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">9149000</ptgx:ContractWithCustomerLiabilityDeduction>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_Iek_4R-H0EOc28_Wvd-Hnw"
      decimals="-3"
      id="Tc_XxnLN4fFrkmj9k579kfMnQ_19_12"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">41530000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="As_Of_12_31_2018_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_dyHYhh53okOYGwIKFCa5Ag"
      decimals="-3"
      id="Tc_H_ZQSoZiUkW7iPgVdNEnpA_20_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1061000</us-gaap:DueToRelatedPartiesCurrent>
    <ptgx:DueToRelatedPartyAdditions
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_H-NgQaNu50uhdMckH4xw9Q"
      decimals="-3"
      id="Tc_dyxih49sJkKHNY5X3AM1SQ_20_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1468000</ptgx:DueToRelatedPartyAdditions>
    <ptgx:DueToRelatedPartyDeductions
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_H-NgQaNu50uhdMckH4xw9Q"
      decimals="-3"
      id="Tc_MYXjh1KsYEivx0gCkELDQw_20_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1267000</ptgx:DueToRelatedPartyDeductions>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_Iek_4R-H0EOc28_Wvd-Hnw"
      decimals="-3"
      id="Tc_vgk3nNNskU2If_uheQvs5g_20_12"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1262000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-5"
      id="Narr_LcsuUM3CcEyUUIOjn0zz5Q"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">14100000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-5"
      id="Narr_po7O2dVDEUm967YjQBUhsA"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1600000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-5"
      id="Narr_9_MFxtdLAkSUJQlSM3_oLw"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">23500000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:CapitalizedContractCostNet
      contextRef="As_Of_12_31_2018_rK3dysi-wkKgewxxLVB-Eg"
      decimals="-5"
      id="Narr_C-7dWTDR9ki2ipoDyFGHEg"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">0</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-5"
      id="Narr_Yrm8Zv8rFkCJP4JpU7iuYg"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">0</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-5"
      id="Narr_mkJW3P4sCUGScMf4ARX2-A"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">0</us-gaap:CapitalizedContractCostNet>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_Y2XYm8e7ZkimDUTFVsCirQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Note 4.&#160;&#160;&#160;&#160;Fair Value Measurements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Financial assets and liabilities are recorded at fair value. The accounting guidance for fair value provides a framework for measuring fair value, clarifies the definition of fair value and expands disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 22.5pt;"&gt;&lt;i style="font-style:italic;"&gt;Level 1&lt;/i&gt;&#x2014;Inputs are unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 22.5pt;"&gt;&lt;i style="font-style:italic;"&gt;Level 2&#x2014;&lt;/i&gt;Inputs (other than quoted market prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument&#x2019;s anticipated life.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 22.5pt;"&gt;&lt;i style="font-style:italic;"&gt;Level 3&lt;/i&gt;&#x2014;Inputs reflect management&#x2019;s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;In determining fair value, the Company utilizes quoted market prices, broker or dealer quotations, or valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table presents the fair value of the Company&#x2019;s financial assets determined using the inputs defined above (in thousands).&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:46.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,481&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,481&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 65,863&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 65,863&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,590&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,590&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;U.S. Treasury and agency securities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 183,210&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 183,210&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,481&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 276,663&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 304,144&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:52.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:46.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:52.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 12,964&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 12,964&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:52.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 44,282&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 44,282&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 33,662&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 33,662&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:52.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;U.S. Treasury and agency securities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 40,810&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 40,810&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 12,964&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 118,754&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 131,718&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s commercial paper, corporate debt securities and U.S. Treasury and agency securities, including U.S. Treasury bills, are classified as Level 2 as they were valued based upon quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Fair Value of Other Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The carrying value of long-term debt as of December 31, 2019 approximated fair value because the Term Loan bore interest at a rate that approximated prevailing market rates for instruments with similar characteristics and there was no significant change in the credit worthiness of the Company. The Company had no long-term debt balance as of December 31, 2020.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_HYiCPNEWAUmAKXmGixxs1w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table presents the fair value of the Company&#x2019;s financial assets determined using the inputs defined above (in thousands).&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:46.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,481&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,481&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 65,863&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 65,863&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,590&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,590&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;U.S. Treasury and agency securities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 183,210&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 183,210&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,481&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 276,663&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 304,144&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:52.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:46.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:52.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 12,964&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 12,964&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:52.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 44,282&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 44,282&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 33,662&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 33,662&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:52.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;U.S. Treasury and agency securities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 40,810&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 40,810&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 12,964&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 118,754&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 131,718&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_5KKCr5eHQEygdYItDdw9RQ"
      decimals="-3"
      id="Tc_WOj7ZtyWbEKxKEE4Cx8sCQ_4_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">27481000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_uzJVCv1ct0mqY9ZIAM4vDg"
      decimals="-3"
      id="Tc_FcCNCiM-7U2nbklJxQUSkQ_4_12"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">27481000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember_RcUZPhnZn0yecR06vLTPmQ"
      decimals="-3"
      id="Tc_sPAO5PUnQ06GLHF4g29bWQ_5_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">65863000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember_5sHQft-r50evFl5UcMy5tw"
      decimals="-3"
      id="Tc_HOPwh5qaG0ie_Qaay9DwxA_5_12"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">65863000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_Py5g_H7ZS0mto91KY61Pqg"
      decimals="-3"
      id="Tc_JwrC8s9Kr0OrU_MxevVOmg_6_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">27590000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_o8lJ8OmQqUuIzV1asN5-7g"
      decimals="-3"
      id="Tc_yKQ1I9jNqEqGLyAQobRlrw_6_12"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">27590000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_uVbhr5AkeEyXPse4j8Vtdw"
      decimals="-3"
      id="Tc_GAHI9UzXDU-lc3tKSpghyg_7_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">183210000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_GPbqzeyzuEyJ1N6rb_ntwQ"
      decimals="-3"
      id="Tc_U5vrwcpBnkqUezP4kg7YlA_7_12"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">183210000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_pDkR-5RKjEyn9NkwkBrP6Q"
      decimals="-3"
      id="Tc_T9lPUPb3l0OfprKK9VH3RQ_8_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">27481000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_K9-l4NAY-kmFaLEyWQ4rSQ"
      decimals="-3"
      id="Tc_3KihObZ3NUqcceogPC-T1w_8_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">276663000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember__UoGf4iXl0-vwHR1RxDl_w"
      decimals="-3"
      id="Tc_LhCWAHlJ10m6aybp3XFtdA_8_12"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">304144000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_FOvlkFRNTEmtTcC9nd5x6w"
      decimals="-3"
      id="Tc_VmpK8Scu1UmttdZB4Tr9_A_4_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">12964000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember_WRekQb2CvU25FJAvTO5BBg"
      decimals="-3"
      id="Tc_-Jc3hPm7-kCClrTaD063eg_4_12"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">12964000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember_9p8nfsfW6EKn9p_BdoPZZQ"
      decimals="-3"
      id="Tc_mA9sLLLEWku7_ZLf4iuC9Q_5_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">44282000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember_LaPN7nYw4E2V8LpCkDOHiQ"
      decimals="-3"
      id="Tc_CMhAQMb3VkWP45Jzdl_uKw_5_12"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">44282000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_XbTJJV-aUUKkYoe9CCHwlg"
      decimals="-3"
      id="Tc_NE090oxkf0uemIFCtFZOZg_6_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">33662000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_wEd8XK0sFEmZYH9nDuBq9Q"
      decimals="-3"
      id="Tc_0Y8Dke7MB0mAYdyEwBEPDg_6_12"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">33662000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_wRs9ZU4Bekq5XgF2kvDBig"
      decimals="-3"
      id="Tc_labCykxvNEean7Iao1MX4w_7_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">40810000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_EE8cQuRZ_UmapNGf-h67ng"
      decimals="-3"
      id="Tc_6iWpKmnVF0uI1gDNZnMf3Q_7_12"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">40810000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_aNicgv3ij0eMkeM8EWdR-w"
      decimals="-3"
      id="Tc_1D6UJom9B0e-GmD3T1dQWw_8_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">12964000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_z50eFBlU2Ee-Syluh-tL9w"
      decimals="-3"
      id="Tc_-Fr6h7ZxbEqig11w7acxGA_8_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">118754000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wuEhdkxUmkStpEwG9Rhsew"
      decimals="-3"
      id="Tc_RywgpEv9sE69_emzFDPm6g_8_12"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">131718000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LongTermDebtFairValue
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Narr_2ihLj1dy_kG8mhIkctJpmg"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">0</us-gaap:LongTermDebtFairValue>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_2CvTwQHtmUaIkTY81Bv75g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Note 5.&#160;&#160;&#160;&#160;Cash Equivalents and Marketable Securities &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash equivalents and marketable securities consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:46.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&#160;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,481&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,481&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 65,866&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 65,863&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,592&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,590&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;U.S. Treasury and agency securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 183,203&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 183,210&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total cash equivalents and marketable securities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 304,142&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (10)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 304,144&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Classified as:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 113,693&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Marketable securities - current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 188,451&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Marketable securities - noncurrent&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total cash equivalents and marketable securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 304,144&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:45.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&#160;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 12,964&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 12,964&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 44,284&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 44,282&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 33,653&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 11&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 33,662&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;U.S. Treasury and agency securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 40,798&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 40,810&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total cash equivalents and marketable securities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 131,699&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 27&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 131,718&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Classified as:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 31,707&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Marketable securities - current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 100,011&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total cash equivalents and marketable securities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 131,718&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:12pt 0pt 12pt 0pt;"&gt;Marketable securities &#x2013; current of $188.5 million and $100.0 million held at December 31, 2020 and December&#160;31, 2019, respectively, had contractual maturities of less than one&#160;year. Marketable securities &#x2013; noncurrent of $2.0 million held at December 31, 2020 had contractual maturities of at least one year but less than two years. The Company did not hold any marketable securities &#x2013; noncurrent at December 31, 2019. The Company has not experienced any material credit losses on its investments. The Company does not intend to sell its securities that are in an unrealized loss position, and it is unlikely that the Company will be required to sell its securities before recovery of their amortized cost basis at maturity. There were no realized gains or realized losses on marketable securities for the periods presented. Factors considered in determining whether a loss is temporary include the length of time and extent to which the fair value has been less than the amortized cost basis and whether the Company intends to sell the security or whether it is more likely than not that the Company would be required to sell the security before recovery of the amortized cost basis. &lt;/p&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_b8M2gjilqEOHxDa5D--Yrw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash equivalents and marketable securities consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:46.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&#160;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,481&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,481&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 65,866&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 65,863&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,592&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,590&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;U.S. Treasury and agency securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 183,203&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 183,210&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total cash equivalents and marketable securities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 304,142&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (10)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 304,144&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Classified as:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 113,693&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Marketable securities - current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 188,451&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Marketable securities - noncurrent&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total cash equivalents and marketable securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 304,144&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:45.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&#160;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 12,964&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 12,964&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 44,284&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 44,282&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 33,653&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 11&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 33,662&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;U.S. Treasury and agency securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 40,798&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 40,810&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total cash equivalents and marketable securities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 131,699&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 27&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 131,718&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Classified as:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 31,707&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Marketable securities - current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 100,011&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total cash equivalents and marketable securities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 131,718&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost
      contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_1lnDMEXB70mrHe1LD59Ocw"
      decimals="-3"
      id="Tc_P2Np9ZeN6U6jXdsm7JHMEQ_4_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">27481000</ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost>
    <ptgx:CashEquivalentsAndMarketableSecuritiesFairValue
      contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_1lnDMEXB70mrHe1LD59Ocw"
      decimals="-3"
      id="Tc_P-IQT1KP5kqidq_kFdMS5g_4_12"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">27481000</ptgx:CashEquivalentsAndMarketableSecuritiesFairValue>
    <ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost
      contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_poqDHHPT202Brw2nGTuPeA"
      decimals="-3"
      id="Tc_HEGT5P5vxE2CZP_oAAwRdw_5_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">65866000</ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost>
    <ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss
      contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_poqDHHPT202Brw2nGTuPeA"
      decimals="-3"
      id="Tc_1e9ckBV86kOb_uv-I_6MAg_5_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">3000</ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss>
    <ptgx:CashEquivalentsAndMarketableSecuritiesFairValue
      contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_poqDHHPT202Brw2nGTuPeA"
      decimals="-3"
      id="Tc_qOB-98J-AkmjnKGVMuNXCw_5_12"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">65863000</ptgx:CashEquivalentsAndMarketableSecuritiesFairValue>
    <ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost
      contextRef="As_Of_12_31_2020_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_WIiZJQ_HGE6FfcxqDuIIGA"
      decimals="-3"
      id="Tc_ruJTc9NHKUOe9iS9MQPflg_6_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">27592000</ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost>
    <ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain
      contextRef="As_Of_12_31_2020_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_WIiZJQ_HGE6FfcxqDuIIGA"
      decimals="-3"
      id="Tc_4QjytLwgT0engJJ0EaBSyw_6_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">2000</ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain>
    <ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss
      contextRef="As_Of_12_31_2020_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_WIiZJQ_HGE6FfcxqDuIIGA"
      decimals="-3"
      id="Tc_ge7nkbfTyU6RJdwIGqTQYw_6_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">4000</ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss>
    <ptgx:CashEquivalentsAndMarketableSecuritiesFairValue
      contextRef="As_Of_12_31_2020_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_WIiZJQ_HGE6FfcxqDuIIGA"
      decimals="-3"
      id="Tc_8vtOXTaZVkG46A9IJzm-IQ_6_12"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">27590000</ptgx:CashEquivalentsAndMarketableSecuritiesFairValue>
    <ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost
      contextRef="As_Of_12_31_2020_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_eDAghYO6dkquiKdNvv7gGw"
      decimals="-3"
      id="Tc_ulkEgEXdzEKIAHaDU3gf7Q_7_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">183203000</ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost>
    <ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain
      contextRef="As_Of_12_31_2020_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_eDAghYO6dkquiKdNvv7gGw"
      decimals="-3"
      id="Tc_aDzlmiAdKEi9azVpoKeFTQ_7_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">10000</ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain>
    <ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss
      contextRef="As_Of_12_31_2020_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_eDAghYO6dkquiKdNvv7gGw"
      decimals="-3"
      id="Tc_85tf0W5SKU2E-9vsy8HqQA_7_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">3000</ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss>
    <ptgx:CashEquivalentsAndMarketableSecuritiesFairValue
      contextRef="As_Of_12_31_2020_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_eDAghYO6dkquiKdNvv7gGw"
      decimals="-3"
      id="Tc_5yiZ1_ImIkKdAQhxLnGGCw_7_12"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">183210000</ptgx:CashEquivalentsAndMarketableSecuritiesFairValue>
    <ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_sKYT1G3sA02WdulXXjBFRA_8_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">304142000</ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost>
    <ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_rZ8vifwg20S3JHJtkZoXeg_8_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">12000</ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain>
    <ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_VvFw0EsP3ka-OiWGK2GpOA_8_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">10000</ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss>
    <ptgx:CashEquivalentsAndMarketableSecuritiesFairValue
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_tM0CeM2MXU6d_K2rwaG9wg_8_12"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">304144000</ptgx:CashEquivalentsAndMarketableSecuritiesFairValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_R6ujF1em9UCXHvoQrbqg7g_10_12"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">113693000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_Tp0YiPcagUOwDoRF-WVLoA_11_12"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">188451000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_yrfPj8f9i0-IyhkOBiRpTQ_12_12"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">2000000</us-gaap:MarketableSecuritiesNoncurrent>
    <ptgx:CashEquivalentsAndMarketableSecuritiesFairValue
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_SmlBI9e1Y0-Lj0MBGIYgQw_13_12"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">304144000</ptgx:CashEquivalentsAndMarketableSecuritiesFairValue>
    <ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost
      contextRef="As_Of_12_31_2019_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_b5xheGic50m0BOMQi6R-nw"
      decimals="-3"
      id="Tc_wgXJIacg6UmeAbjTnmTzAw_4_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">12964000</ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost>
    <ptgx:CashEquivalentsAndMarketableSecuritiesFairValue
      contextRef="As_Of_12_31_2019_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_b5xheGic50m0BOMQi6R-nw"
      decimals="-3"
      id="Tc_mpqc_PoUzkiF5oBF7VMIGA_4_12"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">12964000</ptgx:CashEquivalentsAndMarketableSecuritiesFairValue>
    <ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost
      contextRef="As_Of_12_31_2019_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_E4MJhmAIOEC2XR0v8l-IgA"
      decimals="-3"
      id="Tc_Ac4KqgJn80ijaNjcJZus-A_5_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">44284000</ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost>
    <ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain
      contextRef="As_Of_12_31_2019_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_E4MJhmAIOEC2XR0v8l-IgA"
      decimals="-3"
      id="Tc_o5AuaEgXrkCXbn8Y_ijy3w_5_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">2000</ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain>
    <ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss
      contextRef="As_Of_12_31_2019_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_E4MJhmAIOEC2XR0v8l-IgA"
      decimals="-3"
      id="Tc_PGZ6SbROW0mVE62TdXr9kQ_5_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">4000</ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss>
    <ptgx:CashEquivalentsAndMarketableSecuritiesFairValue
      contextRef="As_Of_12_31_2019_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_E4MJhmAIOEC2XR0v8l-IgA"
      decimals="-3"
      id="Tc_0OAiS8bQikOaJzOL4Q0nLg_5_12"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">44282000</ptgx:CashEquivalentsAndMarketableSecuritiesFairValue>
    <ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost
      contextRef="As_Of_12_31_2019_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_NCJa5a9fSEq4urrjZGFZCg"
      decimals="-3"
      id="Tc_AZE1FtFrRkqhvplBWOTh6w_6_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">33653000</ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost>
    <ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain
      contextRef="As_Of_12_31_2019_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_NCJa5a9fSEq4urrjZGFZCg"
      decimals="-3"
      id="Tc_-WUbx3HZ2kabjtsRI-_MAA_6_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">11000</ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain>
    <ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss
      contextRef="As_Of_12_31_2019_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_NCJa5a9fSEq4urrjZGFZCg"
      decimals="-3"
      id="Tc_wphSMOmZ7k-4vsOvpLHEqQ_6_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">2000</ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss>
    <ptgx:CashEquivalentsAndMarketableSecuritiesFairValue
      contextRef="As_Of_12_31_2019_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember_NCJa5a9fSEq4urrjZGFZCg"
      decimals="-3"
      id="Tc_bJ1qtviiJUKwTe85vW097A_6_12"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">33662000</ptgx:CashEquivalentsAndMarketableSecuritiesFairValue>
    <ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost
      contextRef="As_Of_12_31_2019_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_gb9tp0RYKkSz5MvwQ_K0Hg"
      decimals="-3"
      id="Tc_OM951KPo7ECAMrl8UMkczQ_7_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">40798000</ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost>
    <ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain
      contextRef="As_Of_12_31_2019_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_gb9tp0RYKkSz5MvwQ_K0Hg"
      decimals="-3"
      id="Tc_RcuB09Wbh02GCtsk1hMKgA_7_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">14000</ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain>
    <ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss
      contextRef="As_Of_12_31_2019_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_gb9tp0RYKkSz5MvwQ_K0Hg"
      decimals="-3"
      id="Tc_MaBBp5mq_0Wxo1b0Txch-g_7_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">2000</ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss>
    <ptgx:CashEquivalentsAndMarketableSecuritiesFairValue
      contextRef="As_Of_12_31_2019_us-gaap_InvestmentTypeAxis_ptgx_UsTreasuryAndAgencySecuritiesMember_gb9tp0RYKkSz5MvwQ_K0Hg"
      decimals="-3"
      id="Tc_kzrRCIg0Ek217HmiUxe9vA_7_12"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">40810000</ptgx:CashEquivalentsAndMarketableSecuritiesFairValue>
    <ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_KnKStL16nEmyXLs85F59kA_8_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">131699000</ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost>
    <ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_ZNDIppRZFECx-snRjuYVXQ_8_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">27000</ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain>
    <ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_OV4g9lN010mxXSP1Pxum2Q_8_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">8000</ptgx:CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss>
    <ptgx:CashEquivalentsAndMarketableSecuritiesFairValue
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_nCGl05Q4NUW_pRJMQEgN2Q_8_12"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">131718000</ptgx:CashEquivalentsAndMarketableSecuritiesFairValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_R5mRuNCBcUyFr3epIf9mPA_10_12"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">31707000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_VG0Sr1OuvEqIlv419bbXgQ_11_12"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">100011000</us-gaap:MarketableSecuritiesCurrent>
    <ptgx:CashEquivalentsAndMarketableSecuritiesFairValue
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_wi8CxeZec0myVrqLBr_mCA_12_12"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">131718000</ptgx:CashEquivalentsAndMarketableSecuritiesFairValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-5"
      id="Narr_NBqWa-Hmd0y8xQ88ZR3rCQ"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">188500000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-5"
      id="Narr_t8RJMrlok0OhPCQjVI3y5w"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">100000000.0</us-gaap:MarketableSecuritiesCurrent>
    <ptgx:CurrentContractualMaturitiesMaximumPeriod
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Narr_zLajmSovUEGERmKClx5tvA">P1Y</ptgx:CurrentContractualMaturitiesMaximumPeriod>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-5"
      id="Narr_hvuMRk6R2k-0FEG_KubamQ"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">2000000.0</us-gaap:MarketableSecuritiesNoncurrent>
    <ptgx:NoncurrentContractualMaturitiesMinimumPeriod
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Narr_WqS6iGBGpEy_BumbZ8MKDQ">P1Y</ptgx:NoncurrentContractualMaturitiesMinimumPeriod>
    <ptgx:NoncurrentContractualMaturitiesMaximumPeriod
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Narr_dp1LHkSxy0OwhsV_sFwasg">P2Y</ptgx:NoncurrentContractualMaturitiesMaximumPeriod>
    <us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Narr_9x5fRDfPekioiU3e6UJ0jg"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">0</us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments>
    <us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Narr_QWqEzOMW_0iefWuEvgW8Fg"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">0</us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_6wTbVUGP20a7ZZ405TIzww">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Note 6.&#160;&#160;&#160;&#160;Balance Sheet Components &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Prepaid Expenses and Other Current Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Prepaid expenses and other current assets consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:74.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid clinical and research related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,517&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,567&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid insurance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,440&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,161&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:74.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other prepaid expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,009&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,057&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other receivable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="text-decoration:underline;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 311&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 744&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:74.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Prepaid expenses and other current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,277&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,529&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Property and Equipment, Net&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,539&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,947&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Furniture and computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 648&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 512&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 748&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 863&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Total property and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,935&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,322&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Less: accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,473)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,641)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,462&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,681&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="background-color:#ffff00;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Depreciation expense for the&#160;years ended December&#160;31, 2020, 2019, and 2018 was $789,000, $703,000 and $527,000, respectively. As of December&#160;31, 2020, 2019 and 2018, $46,000, $37,000 and $200, respectively, of property and equipment, net, was located in Australia. The remainder of the Company&#x2019;s property and equipment is located in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Accrued Expenses and Other Payables&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Accrued expenses and other payables consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:normal;width:28.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:12.88%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.43%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:12.86%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued clinical and research related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,335&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,232&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued employee related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,413&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,637&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:69.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued professional service fees&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 668&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 301&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:69.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued interest payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 68&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 82&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 122&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total accrued expenses and other payables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,498&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,360&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_h_vFDP0r1ki9zMkwgfB-QA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Prepaid expenses and other current assets consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:74.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid clinical and research related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,517&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,567&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid insurance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,440&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,161&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:74.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other prepaid expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,009&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,057&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other receivable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="text-decoration:underline;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 311&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 744&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:74.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Prepaid expenses and other current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,277&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,529&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <ptgx:PrepaidManufacturingOfClinicalMaterials
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_YxGEuw0SXUaBpALuOGCdDQ_3_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">3517000</ptgx:PrepaidManufacturingOfClinicalMaterials>
    <ptgx:PrepaidManufacturingOfClinicalMaterials
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_JuAZTxbll0K_oWxuU0GW2Q_3_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">2567000</ptgx:PrepaidManufacturingOfClinicalMaterials>
    <us-gaap:PrepaidInsurance
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_-3n2yVCD2EmTl0aNr2WDNA_4_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1440000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_mpD39iDbF0m7ZLMuRxoLQQ_4_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1161000</us-gaap:PrepaidInsurance>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_HwtFkaceqU-gKzsSDbdAMw_5_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1009000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_uMnbp-xJxU6aI39wXz7Tyg_5_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1057000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_PcrHwWc7502JdutLuVDH6w_6_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">311000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_oRW1KbTnN0aLuRNxKetAvw_6_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">744000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_PJD0SGbMEkqtOEqQIn9Cuw_7_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">6277000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_hq_RkemUQUS8EH37eJqi3Q_7_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">5529000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_7lOHUB5gFkuyXXtDpy7K0Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,539&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,947&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Furniture and computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 648&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 512&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 748&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 863&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Total property and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,935&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,322&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Less: accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,473)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,641)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,462&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,681&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ptgx_LaboratoryEquipmentMember_mEJwmnq980i_X0P_Pcmk2g"
      decimals="-3"
      id="Tc_yzkKZR9FW0qwCsKTFIgKnQ_3_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">3539000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ptgx_LaboratoryEquipmentMember_nelsuh6t-0G0_6xLI9TWow"
      decimals="-3"
      id="Tc_UDkHUeDUokGoy41UnXdZhQ_3_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">2947000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ptgx_FurnitureAndComputerEquipmentMember_exDGgu7H0EeD4_dWpv6kGQ"
      decimals="-3"
      id="Tc_DiTpPxSaiE2iAf3v0bxA-w_4_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">648000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ptgx_FurnitureAndComputerEquipmentMember_NDe2QtR56ES1v6jXmD0-nw"
      decimals="-3"
      id="Tc_O4IESfSfuEa9rtvI1BLH5w_4_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">512000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_th9MyYrG-kOe4hdG7OWBYQ"
      decimals="-3"
      id="Tc__iWl9g1_1U6NAJtIrMe62A_5_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">748000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_XC_R2C90rU2vG1oQ__VR5Q"
      decimals="-3"
      id="Tc_X5ysFxhPlkqKPQnND1f5aQ_5_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">863000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_sVU8rBK0Gk268OvnVBMGsg_6_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">4935000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_JFqwobCK0keszBMR116V5Q_6_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">4322000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_MHiDmakksEWEV8wJ9LXJKw_7_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">3473000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_-4WmeJGC8k6UT9nAQgm3ow_7_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">2641000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_su8MW10v50Ke70KHHQ7wbw_8_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1462000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_Nhj1vUD_QUyg05a2dCHSPg_8_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1681000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="0"
      id="Narr_KY_AAlofT0GXBndGCl6weA"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">789000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="0"
      id="Narr_CVizsxQO8kyWo7DrPuk44g"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">703000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="0"
      id="Narr_B2BY6OWQekSXQ7f5n4VvRA"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">527000</us-gaap:Depreciation>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2020_srt_StatementGeographicalAxis_country_AU_xtyNGWRadEizaBfhvBzeOA"
      decimals="0"
      id="Narr_HvGpktliA06Q7cuPtZoIog"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">46000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2019_srt_StatementGeographicalAxis_country_AU_NLZm2dhYp0akSbHnuso5uQ"
      decimals="0"
      id="Narr_QFxC-l9GVEquh3-RgFFz7g"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">37000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2018_srt_StatementGeographicalAxis_country_AU_J8ZYPbFagkiWnbQOuxYMlQ"
      decimals="0"
      id="Narr_epeeJl6ZvkWZ2bzW2m4afQ"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">200</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_fwBrPJfy3UGQyEX93Aj3eg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Accrued expenses and other payables consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:normal;width:28.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:12.88%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.43%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:12.86%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued clinical and research related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,335&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,232&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued employee related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,413&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,637&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:69.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued professional service fees&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 668&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 301&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:69.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued interest payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 68&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 82&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 122&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total accrued expenses and other payables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,498&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,360&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <ptgx:AccruedClinicalAndResearchRelatedExpensesCurrent
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_nDUY4jpEME-HLQ4Kj2Vftg_3_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">11335000</ptgx:AccruedClinicalAndResearchRelatedExpensesCurrent>
    <ptgx:AccruedClinicalAndResearchRelatedExpensesCurrent
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_YnN_tpVhEUKqStwxVAdBrg_3_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">7232000</ptgx:AccruedClinicalAndResearchRelatedExpensesCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_g_FU7EtAlES3LAAo4-Ac7w_4_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">6413000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_NUVWAfwwLkKZHBsJeoXdQw_4_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">4637000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_-4rfKlFy1kKda2Zcu4M4KQ_5_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">668000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_b2OTqg1f20KiV-f8yDQ2mA_5_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">301000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_u1hQEkxC5U--lk-cBZBSRQ_6_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">68000</us-gaap:InterestPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_61dbSnn9VUWkpEncjPQ4mg_7_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">82000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_eC70AbfNwkuQnhmXMEOlXA_7_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">122000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_J9egrOsSPEGJapPfRLFffQ_8_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">18498000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_jb5PxQ50_UeVPRUP1s97Yg_8_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">12360000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member_ui-WhgpxI0OwEii6l0-3yQ"
      id="Tb_6PesyRKXGke1BDnJKCX4Zw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Note 7.&#160;&#160;&#160;&#160;Research Collaboration and License Agreement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"&gt;The Company and Zealand Pharma A/S entered into a collaboration agreement in June 2012. In October 2013, Zealand Pharma abandoned the collaboration and the collaboration agreement was terminated in 2014. The agreement provides for certain post-termination payment obligations to Zealand with respect to compounds related to the collaboration that meet specified conditions set forth in the collaboration agreement and which the Company elects to further develop following Zealand&#x2019;s abandonment of the collaboration. The Company has the right, but not the obligation, to further develop and commercialize such compounds. The agreement provides for payments to Zealand for the &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;achievement of certain development, regulatory and sales milestone events that occur prior to a partnering arrangement related to such compounds between the Company and a third party.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company initially determined that rusfertide is a compound for which the post-termination payments described above are required under the collaboration agreement and has made three development milestone payments for an aggregate amount of $1.0 million under the agreement. However, the Company concluded in 2019 that rusfertide is not a compound with respect to which post-termination payments are required under the agreement, and initiated the arbitration proceeding described in Note 11 below.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Milestone payments to collaboration partners are recorded as research and development expenses in the period that the expense is incurred. No research and development expense was recorded under this agreement for the years ended December 31, 2020 or 2019. For the&#160;year ended December 31, 2018, the Company recorded research and development expense of $500,000 under this agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; If the Company is required to continue to make payments with respect to rusfertide under the collaboration agreement, the next two milestones that would be due under the agreement include:  $1.0 million to $3.0 million for initiation of placebo-controlled Phase 2b clinical trial; and $1.5 million to $4.5 million for initiation of a Phase 3 clinical trial. The milestone amounts vary depending on the number of patients in the applicable clinical trial, and the Company expects the milestones would be the lowest amount within the specified range. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;See Note 11. Commitments and Contingencies &#x2013; Legal Proceedings for additional information on arbitration proceedings related to this research and collaboration agreement.&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <ptgx:NumberOfDevelopmentMilestonePayments
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member_ui-WhgpxI0OwEii6l0-3yQ"
      decimals="INF"
      id="Narr_k7zRe2vwr0yyzlz-49AJBA"
      unitRef="Unit_Standard_item_hG9CfJX4lUefEcY3aN9DsQ">3</ptgx:NumberOfDevelopmentMilestonePayments>
    <ptgx:AggregateAmountOfDevelopmentMilestonePayment
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member_ui-WhgpxI0OwEii6l0-3yQ"
      decimals="-5"
      id="Narr_6s3e-15Ny0iETQa5L-bmiQ"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1000000.0</ptgx:AggregateAmountOfDevelopmentMilestonePayment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_TypeOfArrangementAxis_ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member_D025L8JB50ySUyUf-9SxEg"
      decimals="0"
      id="Narr_in79lzZ-aUuOLSJD_aAa7Q"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member_ui-WhgpxI0OwEii6l0-3yQ"
      decimals="0"
      id="Narr_ULY_Hn3UEkyrqXOmlk1oTA"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_TypeOfArrangementAxis_ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member__cZnEeVU-k2FtUN8yE2uXw"
      decimals="0"
      id="Narr_QOQTpRNQ5UCq1hyITQSMbA"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">500000</us-gaap:ResearchAndDevelopmentExpense>
    <ptgx:AdditionalPaymentObligationToFormerCollaborationPartner
      contextRef="As_Of_12_31_2020_srt_ProductOrServiceAxis_ptgx_PhaseTwoBClinicalTrailOfPtg300Member_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_ptgx_EntityRequiredToContinueToMakePaymentsMember_us-gaap_TypeOfArrangementAxis_ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member_lKJ-7ATDp0CLQ8bWUlojWQ"
      decimals="-5"
      id="Narr_qqzCROSgZk2xsQsJx4PjFQ"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1000000.0</ptgx:AdditionalPaymentObligationToFormerCollaborationPartner>
    <ptgx:AdditionalPaymentObligationToFormerCollaborationPartner
      contextRef="As_Of_12_31_2020_srt_ProductOrServiceAxis_ptgx_PhaseTwoBClinicalTrailOfPtg300Member_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_ptgx_EntityRequiredToContinueToMakePaymentsMember_us-gaap_TypeOfArrangementAxis_ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member_GeOAJmLB2U-rVK1O1SLjzw"
      decimals="-5"
      id="Narr_L4Or_AtXD0m0qDE-nx15RQ"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">3000000.0</ptgx:AdditionalPaymentObligationToFormerCollaborationPartner>
    <ptgx:AdditionalPaymentObligationToFormerCollaborationPartner
      contextRef="As_Of_12_31_2020_srt_ProductOrServiceAxis_ptgx_PhaseThreeClinicalTrailOfPtg300Member_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_ptgx_EntityRequiredToContinueToMakePaymentsMember_us-gaap_TypeOfArrangementAxis_ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member_Mg3iwj6jfU-W-XYzhf-LYg"
      decimals="-5"
      id="Narr_d-21cCsy1Em3NqY_5P7WSg"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1500000</ptgx:AdditionalPaymentObligationToFormerCollaborationPartner>
    <ptgx:AdditionalPaymentObligationToFormerCollaborationPartner
      contextRef="As_Of_12_31_2020_srt_ProductOrServiceAxis_ptgx_PhaseThreeClinicalTrailOfPtg300Member_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_ptgx_EntityRequiredToContinueToMakePaymentsMember_us-gaap_TypeOfArrangementAxis_ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member_NW5Hup9pVUGA-2WwTWjPHw"
      decimals="-5"
      id="Narr_uQ2_V81iA02LOwpwcMYVeg"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">4500000</ptgx:AdditionalPaymentObligationToFormerCollaborationPartner>
    <ptgx:GovernmentProgramsDisclosureTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_Q4MzuLkCMEmv5TLVw0Mnvg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Note 8.&#160;&#160;&#160;&#160;Government Programs &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Research and Development Tax Incentive&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;During the years ended December 31, 2020 and 2018, the Company recognized AUD 1.4 million ($1.0 million) and AUD 2.1 million ($1.6 million), respectively, as a reduction of research and development expenses in connection with the research and development cash tax incentive from the ATO. During the year ended December 31, 2019, the Company recognized AUD 1.9 million ($1.3 million) of research and development expenses in connection with the research and development tax incentive from the ATO because the Company determined that it had exceeded the annual turnover limit to claim such amounts following the receipt of certain payments under the Janssen License and Collaboration Agreement. As of December&#160;31, 2020, the research and development tax incentive receivable was AUD 1.4 million ($1.1 million). There was no research and development tax incentive receivable as of December 31, 2019.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Small Business Innovation Research (&#x201c;SBIR&#x201d;) Grants&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;In May 2017, the Company was awarded a Phase 2 SBIR grant from the National Institute of Diabetes and Digestive and Kidney Diseases of the NIH in support of research aimed at developing biomarkers that define IL-23R target engagement by orally delivered peptide antagonists and the effects of that engagement of downstream signaling. The total grant award was $1.3 million and was originally for the period from May 2017 to April 2019. During the year ended December 31, 2019, the Company requested and received an extension of this grant through April 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;In September 2018, the Company was awarded a Phase 2 SBIR Grant from the National Heart, Lungs and blood Institute of the NIH in support of research aimed at developing the Company&#x2019;s novel hepcidin mimetic rusfertide for the potential treatment of chronic anemia and iron overload in rare blood disorders, including beta-thalassemia. The total grant award was $1.5 million and was originally for the period from September 2018 to August 2020. During the year ended December 31, 2020, the Company requested an extension of this grant through July 2021, which was received in February 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"&gt;The Company recognizes a reduction to research and development expenses when expenses related to the grants have been incurred and the grant funds become contractually due from NIH. The Company recorded $0.5 million, $1.4 million and $0.7 million, as a reduction of research and development expenses for the&#160;years ended December&#160;31, 2020, &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;2019 and 2018, respectively. The Company recorded a receivable for $0.3 million as of December&#160;31, 2019 to reflect the eligible costs incurred under the grants that were contractually due to the Company. This receivable is included in prepaid expenses and other current assets on the consolidated balance sheets. There was no such receivable as of December 31, 2020.&lt;/span&gt;&lt;/p&gt;</ptgx:GovernmentProgramsDisclosureTextBlock>
    <ptgx:ResearchAndDevelopmentExpensesReduction
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_g6Lfapz3kUapxhOM2FxjaQ"
      decimals="-5"
      id="Narr_D4kxhorIrEqqW952WdWckA"
      unitRef="Unit_Standard_AUD_SNsUSUMs1k6MNx0ouGjszw">1400000</ptgx:ResearchAndDevelopmentExpensesReduction>
    <ptgx:ResearchAndDevelopmentExpensesReduction
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_g6Lfapz3kUapxhOM2FxjaQ"
      decimals="-5"
      id="Narr_8XL0bKadkEm3i4KEEnJ8YA"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1000000.0</ptgx:ResearchAndDevelopmentExpensesReduction>
    <ptgx:ResearchAndDevelopmentExpensesReduction
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember__jiivLyteUW8NPb8U-43uw"
      decimals="-5"
      id="Narr_Lyy9h-UU6USjFv1ePRlKsg"
      unitRef="Unit_Standard_AUD_SNsUSUMs1k6MNx0ouGjszw">2100000</ptgx:ResearchAndDevelopmentExpensesReduction>
    <ptgx:ResearchAndDevelopmentExpensesReduction
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember__jiivLyteUW8NPb8U-43uw"
      decimals="-5"
      id="Narr_Eag_juuPQ06ErW4P55PTpw"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1600000</ptgx:ResearchAndDevelopmentExpensesReduction>
    <ptgx:ResearchAndDevelopmentExpensesReduction
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_3n6ishFs0EuWYpP4sr_RiA"
      decimals="-5"
      id="Narr_qyvV-WazvE66vSel_zRUsw"
      unitRef="Unit_Standard_AUD_SNsUSUMs1k6MNx0ouGjszw">1900000</ptgx:ResearchAndDevelopmentExpensesReduction>
    <ptgx:ResearchAndDevelopmentExpensesReduction
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_3n6ishFs0EuWYpP4sr_RiA"
      decimals="-5"
      id="Narr_6DraHostfkq5BT1K3e2nBA"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1300000</ptgx:ResearchAndDevelopmentExpensesReduction>
    <us-gaap:IncomeTaxesReceivable
      contextRef="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_ptgx_OverseasFindingsMember_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_Ni5ZAEOX-UqebOcqRpBGAA"
      decimals="-5"
      id="Narr_caqrQXKri025WU83ixtUQg"
      unitRef="Unit_Standard_AUD_SNsUSUMs1k6MNx0ouGjszw">1400000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable
      contextRef="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_ptgx_OverseasFindingsMember_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_Ni5ZAEOX-UqebOcqRpBGAA"
      decimals="-5"
      id="Narr_LyoAz_sb2k-l7BF133rmyA"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1100000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable
      contextRef="As_Of_12_31_2019_us-gaap_IncomeTaxAuthorityAxis_ptgx_OverseasFindingsMember_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_-NKTzbOHOE-9ja3vgdH8Wg"
      decimals="-5"
      id="Narr_5JlCVNaYbUiNbdzuSiKcrg"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">0</us-gaap:IncomeTaxesReceivable>
    <ptgx:ResearchAndDevelopmentGrants
      contextRef="Duration_5_1_2017_To_5_31_2017_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_yYD_ZbiKRkiaHuGwQjinPA"
      decimals="-5"
      id="Narr_Hg_prqMGOku0awirNyY7kw"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1300000</ptgx:ResearchAndDevelopmentGrants>
    <ptgx:ResearchAndDevelopmentGrants
      contextRef="Duration_9_1_2018_To_9_30_2018_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_uaChjCsyD0SFXSDtolYQ1A"
      decimals="-5"
      id="Narr_CkKQYnffV0yovhUvV3uLUg"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1500000</ptgx:ResearchAndDevelopmentGrants>
    <ptgx:ResearchAndDevelopmentExpensesReduction
      contextRef="Duration_1_1_2020_To_12_31_2020_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_qd1j0yCx90GcZk8LgZ8W2g"
      decimals="-5"
      id="Narr_R4RdqM6sBEWoYgVznSB7gQ"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">500000</ptgx:ResearchAndDevelopmentExpensesReduction>
    <ptgx:ResearchAndDevelopmentExpensesReduction
      contextRef="Duration_1_1_2019_To_12_31_2019_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_tYZjiAg9zECpkNJndjRsBA"
      decimals="-5"
      id="Narr_rQMI0mcDeU26eMmuN6af1Q"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1400000</ptgx:ResearchAndDevelopmentExpensesReduction>
    <ptgx:ResearchAndDevelopmentExpensesReduction
      contextRef="Duration_1_1_2018_To_12_31_2018_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_IH_M_FrIX0SJO0xc0LNU4A"
      decimals="-5"
      id="Narr_ZUoCfOqPvkSx0CiHW8ojlg"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">700000</ptgx:ResearchAndDevelopmentExpensesReduction>
    <us-gaap:GrantsReceivable
      contextRef="As_Of_12_31_2019_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_Ug74VWMPT0WLeBk_hPZxCg"
      decimals="-5"
      id="Narr_9zNQQvHflUSJ4bMHYicNSw"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">300000</us-gaap:GrantsReceivable>
    <us-gaap:GrantsReceivable
      contextRef="As_Of_12_31_2020_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_GicVha9PoUm3BEgizkKmRQ"
      decimals="-5"
      id="Narr_yzlm9ow9NEuIqlsL90Hgzg"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">0</us-gaap:GrantsReceivable>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_QRf7SU7qiEyFHlVd2w-CsA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;white-space:pre-wrap;"&gt;Note 9.    Debt&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;On October 30, 2019, the Company entered into a Credit and Security Agreement, dated as of October 30, 2019 (the &#x201c;Closing Date&#x201d;) by and among the Company, MidCap Financial Trust, as a lender, Silicon Valley Bank, as a lender, the other lenders party thereto from time to time and MidCap Financial Trust, as administrative agent and collateral agent (&#x201c;Agent&#x201d;), (the &#x201c;Term Loan Credit Agreement&#x201d;), which provides for a $50.0 million term loan facility. The Term Loan Credit Agreement provides for (i) on the Closing Date, $10.0 million aggregate principal amount of term loans, (ii) at the Company&#x2019;s option, until December 31, 2020, an additional $20.0 million term loan facility subject to the satisfaction of certain conditions, including clinical milestone achievement, and (iii) at the Company&#x2019;s option, until September 30, 2021, an additional $20.0 million term loan facility subject to the satisfaction of certain conditions, including clinical milestone achievement, (collectively, the &#x201c;Term Loans&#x201d;). The Company intends to use any proceeds of the Term Loans for general corporate purposes.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The Term Loans are subject to an origination fee of 0.25% for each funded tranche under the Term Loan Credit Agreement and bear interest at an annual rate based on prime rate plus 2.91%, subject to a prime rate floor of 4.94%. The Company will make interest-only payments on the Term Loans for 24 months, followed by 24 months of principal and interest payments. At the Company&#x2019;s option, the Company may prepay the outstanding principal balance of the Term Loans in whole or in part, subject to a prepayment premium of 3.0% of any amount prepaid if the prepayment occurs through and including the first anniversary of the closing date, 2.0% of the amount prepaid if the prepayment occurs after the first anniversary of the closing date through and including the second anniversary of the closing date, and 1.0% of any amount prepaid after the second anniversary of the closing date and prior to October 1, 2023. An additional fee of 2.85% of the amount of Term Loans advanced by the Lenders will be due upon prepayment or repayment of the Term Loans. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The Term Loan Credit Agreement requires the Company to maintain cash and cash equivalents of at least 35% of the outstanding Term Loans at all times and is secured by a perfected security interest in all of the Company's assets except for intellectual property and certain other customary excluded property pursuant to the terms of the Term Loan Credit Agreement. The Term Loan Credit Agreement contains other covenants that limit the Company&#x2019;s ability and the ability of its subsidiaries to perform certain actions, including obligations to not pay dividends and to maintain unrestricted cash balances above certain threshold, non-occurrence of material adverse change, non-occurrence of change of control and other customary affirmative and negative covenants. The violation of any provision of covenants will result in default for the Company. The Term Loan Credit Agreement includes a clause which allows lenders to accelerate repayment upon the occurrence of certain events of default. In June 2020, the Company prepaid its outstanding $10.0 million balance on the term loan as well as $0.6 million for related prepayment and exit fees. Accordingly, the company accelerated amortization of $0.1 million related to capitalized and unamortized debt issuance costs, which is included as part of the $0.6 million loss on early repayment of debt. The Company did not exercise its option to borrow the $20.0 million second tranche of Term Loans, which expired on December 31, 2020, and therefore has no outstanding balance as of December 31, 2020 related to the Term Loan Credit Agreement. As of December 31, 2020, the Company was in compliance with the debt covenants, no event of default occurred and the probability of occurrence of event of default was considered remote.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt 0pt 6pt 0pt;"&gt;The Company&#x2019;s long-term debt balance was as follows for the periods presented (dollars in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:55.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Annual &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Interest Rate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:55.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Term loan (maturity date October 1, 2023) &lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;7.85%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Debt issuance costs, net of amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (222)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:55.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued final payment fees&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:55.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Long-term debt, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,794&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The effective interest rate on long-term debt was 9.85% and 9.81% for the years ended December 31, 2020 and 2019, respectively.&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_29P04bh0akmybtKqt9iLyg"
      decimals="-5"
      id="Narr_u1ZbRCSqhEWFOJK4RQumnA"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">50000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LongTermDebt
      contextRef="As_Of_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_29P04bh0akmybtKqt9iLyg"
      decimals="-5"
      id="Narr_EAEAbMURPESkOOq_Im9fJQ"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">10000000.0</us-gaap:LongTermDebt>
    <ptgx:DebtInstrumentTrancheInstallmentAmount
      contextRef="As_Of_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_29P04bh0akmybtKqt9iLyg"
      decimals="-5"
      id="Narr_tbyTcC0AQU27jGMAwnQuPQ"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">20000000.0</ptgx:DebtInstrumentTrancheInstallmentAmount>
    <ptgx:DebtInstrumentTrancheInstallmentAmount
      contextRef="As_Of_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_29P04bh0akmybtKqt9iLyg"
      decimals="-5"
      id="Narr_Zz-oELs6HkO8CZqo2D-9-A"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">20000000.0</ptgx:DebtInstrumentTrancheInstallmentAmount>
    <ptgx:DebtInstrumentLoanOriginationFeePercentage
      contextRef="Duration_10_1_2019_To_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember__7GvdZr7Sk-sWaDylYb_nQ"
      decimals="4"
      id="Narr_UI6Nx5yyFU6sWOEQa08T1Q"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.0025</ptgx:DebtInstrumentLoanOriginationFeePercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="Duration_10_1_2019_To_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember_irqRQWto80mZoPOcLzfEEw"
      decimals="4"
      id="Narr_P9n-jPbsiEaURvwoUDrSUA"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.0291</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <ptgx:DebtInstrumentFloorRate
      contextRef="Duration_10_1_2019_To_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember_irqRQWto80mZoPOcLzfEEw"
      decimals="4"
      id="Narr_qqTXAixnq0qIOrgl087hJg"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.0494</ptgx:DebtInstrumentFloorRate>
    <ptgx:DebtInstrumentPeriodOfInterestOnlyPayments
      contextRef="Duration_10_31_2019_To_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_AItPGKFJaUGXTtctj0S3sw"
      id="Narr_RGlJn7wJaEu2a3Nr5nufSw">P24M</ptgx:DebtInstrumentPeriodOfInterestOnlyPayments>
    <ptgx:DebtInstrumentPeriodOfPrincipalAndInterestPayments
      contextRef="Duration_10_31_2019_To_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_AItPGKFJaUGXTtctj0S3sw"
      id="Narr_2EvA6P1De0aM6LwoIQRIzg">P24M</ptgx:DebtInstrumentPeriodOfPrincipalAndInterestPayments>
    <ptgx:DebtInstrumentPrepaymentPremiumPercentage
      contextRef="Duration_10_1_2019_To_10_31_2019_srt_StatementScenarioAxis_ptgx_DebtInstrumentRepaymentOnOrBeforeFirstAnniversaryMember_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_-UR7DvCLZkiYmYD5NsiohA"
      decimals="3"
      id="Narr_cDW5puxiYEKaJ_D7BomQ5g"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.030</ptgx:DebtInstrumentPrepaymentPremiumPercentage>
    <ptgx:DebtInstrumentPrepaymentPremiumPercentage
      contextRef="Duration_10_1_2019_To_10_31_2019_srt_StatementScenarioAxis_ptgx_DebtInstrumentRepaymentBetweenFirstAndSecondAnniversaryMember_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_0-kZriq9PE--kjrBZbtCWQ"
      decimals="3"
      id="Narr_Ncir25NIuEaZbSHkj0fn8g"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.020</ptgx:DebtInstrumentPrepaymentPremiumPercentage>
    <ptgx:DebtInstrumentPrepaymentPremiumPercentage
      contextRef="Duration_10_1_2019_To_10_31_2019_srt_StatementScenarioAxis_ptgx_DebtInstrumentRepaymentAfterSecondAnniversaryMember_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_yTz9fr8XpUmkKw5s-q0s6g"
      decimals="3"
      id="Narr_Gdkfd4ysfkytNLsjT_i1aQ"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.010</ptgx:DebtInstrumentPrepaymentPremiumPercentage>
    <ptgx:DebtInstrumentAdditionalPrepaymentOrRepaymentPremiumPercentage
      contextRef="Duration_10_1_2019_To_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember__7GvdZr7Sk-sWaDylYb_nQ"
      decimals="4"
      id="Narr_LhEfLUExtEihEON9mcjQGw"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.0285</ptgx:DebtInstrumentAdditionalPrepaymentOrRepaymentPremiumPercentage>
    <ptgx:DebtInstrumentThresholdPercentageOnOutstandingDebtToBeMaintainedAsCashAndCashEquivalentsBalance
      contextRef="Duration_10_1_2019_To_10_31_2019_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember__7GvdZr7Sk-sWaDylYb_nQ"
      decimals="2"
      id="Narr_7yq3mBxM3kmbVsBfJvZ_nw"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.35</ptgx:DebtInstrumentThresholdPercentageOnOutstandingDebtToBeMaintainedAsCashAndCashEquivalentsBalance>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_6_1_2020_To_6_30_2020_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_jtE4FD5lLEuVCNA6A73V0A"
      decimals="-5"
      id="Narr_9pGp9t_puUmVvpnvIDq50Q"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">10000000.0</us-gaap:RepaymentsOfDebt>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="As_Of_6_30_2020_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_cqtN9FUFIUSxqCPfOydBcA"
      decimals="-5"
      id="Narr_LOp2dtWnpkOKd4rvVVTRbA"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">600000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet
      contextRef="As_Of_6_30_2020_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_cqtN9FUFIUSxqCPfOydBcA"
      decimals="-5"
      id="Narr_8Cr8aL3-VU6hSRLYRNK6fA"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">100000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_6_1_2020_To_6_30_2020_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_jtE4FD5lLEuVCNA6A73V0A"
      decimals="-5"
      id="Narr_xJzAQl_pWkWA98oiDYIu5w"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">600000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <ptgx:DebtInstrumentTrancheInstallmentAmount
      contextRef="As_Of_12_31_2020_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_cKfYUU8Sf0-u1ytV-rCvdg"
      decimals="-5"
      id="Narr_v0V44sTTTkiVujarEyq5Uw"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">20000000.0</ptgx:DebtInstrumentTrancheInstallmentAmount>
    <us-gaap:LongTermDebt
      contextRef="As_Of_12_31_2020_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_cKfYUU8Sf0-u1ytV-rCvdg"
      decimals="-5"
      id="Narr_zzDaVywlHUurO8wFk7SYCA"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">0</us-gaap:LongTermDebt>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_NFM8oo39akaTOLIaqY1n3w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt 0pt 6pt 0pt;"&gt;The Company&#x2019;s long-term debt balance was as follows for the periods presented (dollars in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:55.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Annual &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Interest Rate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:55.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Term loan (maturity date October 1, 2023) &lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;7.85%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Debt issuance costs, net of amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (222)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:55.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued final payment fees&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:55.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Long-term debt, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,794&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="4"
      id="Tc_cMTOdoLnREaAMzUImHvxTg_3_2"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.0785</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_ZFQQq2bHj0m4OQLDxn6YNA_3_8"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">10000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_UpdnYtGYwUK689z-5ZoPaQ_4_8"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">222000</us-gaap:DeferredFinanceCostsNet>
    <ptgx:DebtInstrumentAccruedFinalPaymentFee
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_PROUBe-5F0uOp9Mt3AEjyQ_5_8"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">16000</ptgx:DebtInstrumentAccruedFinalPaymentFee>
    <us-gaap:LongTermDebt
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_0s4dsh_m5EO9oT7LiQzE4g_6_8"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">9794000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="4"
      id="Narr_XS9c_dXk2UqEqZa9xfHBgw"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.0985</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="4"
      id="Narr_WvzSdY5t30m9q-zInXbYEw"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.0981</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_qgohR3b7eUqHRjXlU0Uznw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Note 10.&#160;&#160;&#160;&#160;Leases &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:31.5pt;margin:0pt;"&gt;On January 1, 2019, the Company adopted ASC 842, which requires entities to recognize assets and liabilities for leases with lease terms of more than 12 months on the balance sheet. Leases with terms of 12 months or less are not recorded on the balance sheet, and the related lease expenses are recognized on a straight-line basis over the lease term. The Company has one operating lease agreement entered into in March 2017 for laboratory and office space located in Newark, California. The Company provided the landlord with a $450,000 letter of credit collateralized by restricted cash as security deposit for the lease, which expires in May 2024. During the years ended December 31, 2020 and 2019, the Company recognized $89,400 and $64,000 of sublease income, respectively. The Company did &lt;span style="-sec-ix-hidden:Hidden_lqQvOls2gkKPXAv7NbH0Aw;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;not&lt;/span&gt;&lt;/span&gt; recognize any sublease income for the year ended December 31, 2018. Under the terms of the lease, the Company is responsible for certain taxes, insurance and maintenance expenses. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:31.5pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"&gt;The weighted average lease term and discount rate are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating Lease Term and Discount Rate:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-average remaining lease term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3.4 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;4.4 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-average discount rate&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;11.0%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;11.0%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes the Company&#x2019;s minimum lease payments and lease liability as of December&#160;31, 2020 (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ending December 31:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,059&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,121&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 895&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:84.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total future minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,075&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,116)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:84.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Present value of future minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,959&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Less: current portion of operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,459)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:84.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating lease liability - noncurrent&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Supplemental lease cost information is as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,775&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,792&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Supplemental balance sheet information is as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:10pt;"&gt;&lt;td style="vertical-align:bottom;width:68.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:10pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:10pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:10pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:10pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:10pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:10pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:10pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating Leases:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:68.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_zm9XCbYtdUWCFJoLceZSNQ;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;Operating lease right-of-use asset&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,950&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,042&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:68.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_NUnmw_5Jc0GQOhDxxgb5HA;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;Operating lease liability - current&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,459&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,256&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_ffN_Bd0u6EuABPUHJggLOw;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;Operating lease liability - noncurrent&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,961&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:68.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_yNAOiRCkP0mEzcqrTZongA;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;"&gt;  Total operating lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,959&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,217&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Supplemental cash flow information is as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:67.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating cash flow used by operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,941&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,885&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Prior to the adoption of ASC 842, the Company&#x2019;s rent expense was $1.9 million for the&#160;year ended December&#160;31, 2018. Rent expense was recognized on a straight-line basis over the term of the lease and accordingly, the Company recorded the difference between cash rent payments and the recognition of rent expense as a deferred rent liability.&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <ptgx:NumberOfOperatingLeaseAgreement
      contextRef="Duration_3_1_2017_To_3_31_2017_srt_StatementGeographicalAxis_stpr_CA__NT8mR3K4kK7AM6iJIYK3g"
      decimals="INF"
      id="Narr_yBxRXsgYckCBzfVjYpBmlQ"
      unitRef="Unit_Standard_lease_62oZzE0uRUioB8CqY7th5A">1</ptgx:NumberOfOperatingLeaseAgreement>
    <us-gaap:SecurityDeposit
      contextRef="As_Of_3_31_2017_zWxDm9xYR0y9NPetyRPWMQ"
      decimals="0"
      id="Narr_uVTDVMs9cEaOfaSZJhMlZA"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">450000</us-gaap:SecurityDeposit>
    <us-gaap:SubleaseIncome
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="0"
      id="Narr__lU8KTpvkkKmHWMA9fiIOA"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">89400</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="0"
      id="Narr_2MoRVA77Hk2KHkOLHBYnVA"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">64000</us-gaap:SubleaseIncome>
    <ptgx:LeaseQuantitativeDisclosureTableTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_eF46KSUyjku7Y7vOgkrQFA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating Lease Term and Discount Rate:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-average remaining lease term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3.4 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;4.4 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-average discount rate&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;11.0%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;11.0%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ptgx:LeaseQuantitativeDisclosureTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      id="Narr_NbqQtSAf40qwWKp61uWbQw">P3Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      id="Narr_u2TyMH7pIU2jcKBatMmhBQ">P4Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="3"
      id="Tc_knAbqhWTzEOWhfdsOdBsZw_5_3"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.110</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="3"
      id="Tc_GRWjEc47v0eSzfma4eZNEA_5_6"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.110</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_CBoVfluIKkCx0iXXPWxkcQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes the Company&#x2019;s minimum lease payments and lease liability as of December&#160;31, 2020 (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ending December 31:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,059&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,121&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 895&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:84.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total future minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,075&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,116)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:84.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Present value of future minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,959&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Less: current portion of operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,459)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:84.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating lease liability - noncurrent&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_Ktx66arbSkuYtGlNFC6oSA_2_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">2000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_n3A733M2zUeB1bGq0tsc2A_3_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">2059000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_OC0P0ia8C0WOTJozhHw9wA_4_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">2121000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_Ga_71EMYdU2qeb6-mDH_pA_5_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">895000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_Cufh9RQRSUOJwDE3bH3Ecw_8_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">7075000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_Kzh9AGGhokiRLYIJryQ2Bw_9_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1116000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_4x2_CQVP-EyE3xwYmFUOWg_10_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">5959000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_m0q62FJ9YE6sE7G-_rJfAA_11_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1459000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_-hI-k3ojDk-uzqQXWeME_w_12_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">4500000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_Gkhj2eYpk0Cfq0PQgNdJaQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Supplemental lease cost information is as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,775&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,792&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_fnE11xS3i0CfnZ3q_bBGtw_3_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1775000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_pDAiZy-Pd0m_5w-pHbpt4g_3_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1792000</us-gaap:OperatingLeaseCost>
    <ptgx:LeaseBalanceSheetDisclosureTableTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_o6SXgSeV8USll1qHoW8nHQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Supplemental balance sheet information is as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:10pt;"&gt;&lt;td style="vertical-align:bottom;width:68.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:10pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:10pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:10pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:10pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:10pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:10pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:10pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating Leases:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:68.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_zm9XCbYtdUWCFJoLceZSNQ;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;Operating lease right-of-use asset&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,950&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,042&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:68.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_NUnmw_5Jc0GQOhDxxgb5HA;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;Operating lease liability - current&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,459&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,256&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_ffN_Bd0u6EuABPUHJggLOw;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;Operating lease liability - noncurrent&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,961&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:68.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_yNAOiRCkP0mEzcqrTZongA;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;"&gt;  Total operating lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,959&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,217&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ptgx:LeaseBalanceSheetDisclosureTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_QhjB7AoMf0m2CRaMSdXO0Q_4_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">4950000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_Wq2xxYcPUU2QJG-Gks5XKA_4_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">6042000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_kjUI_9_VqkmCwssghg0oNw_6_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1459000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_-EP5WNZVD0qGSSyR-oLfTA_6_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1256000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_R-mgHIzREEi0J5M0QVMDqQ_7_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">4500000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_GKVXP0WmrUW70oCmRn-KMg_7_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">5961000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_KPq2XQwac0qg3TeobytW_Q_8_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">5959000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_XYsxAMHUB06dL4u6H63QFg_8_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">7217000</us-gaap:OperatingLeaseLiability>
    <ptgx:LeaseCashFlowInformationDisclosureTableTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_UdLJmfjjAU2cMSBepGLgAQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Supplemental cash flow information is as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:67.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating cash flow used by operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,941&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,885&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ptgx:LeaseCashFlowInformationDisclosureTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_R3tF-H53g0C8PLwDZ6bN1A_4_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1941000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_Si_DmqeRyUO6rMYKrx6zdg_4_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1885000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasesRentExpenseNet
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-5"
      id="Narr_gN95qvmXjU2spNc78pgbtw"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1900000</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_0DGt4tAAXEu7z7jnS8J-kQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;white-space:pre-wrap;"&gt;Note 11.    Commitments and Contingencies &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has also entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by California corporate law. The Company carries a directors&#x2019; and officers&#x2019; insurance policy. To date, the Company has not incurred material costs to defend lawsuits or settle claims related to the indemnification agreements. The Company believes that the fair value of these indemnification agreements is minimal and has not accrued any amounts for the obligations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Legal Proceedings &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is a party to the legal action described below. The Company recognizes accruals for such actions to the extent that it concludes that a loss is both probable and reasonably estimable. The Company accrues for the best estimate of a loss within a range; however, if no estimate in the range is better than any other, it accrues the minimum amount in the range. If the Company determines that a loss is reasonably possible and the loss or range of loss can be estimated, it discloses the possible loss. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"&gt;On January 23, 2020, the Company initiated arbitration proceedings with the International Court of Arbitration of the International Chamber of Commerce against Zealand Pharma A/S (&#x201c;Zealand&#x201d;) related to a collaboration agreement the Company and Zealand entered into in 2012 and terminated in 2014.&#160;The agreement provides for certain post-termination payment obligations to Zealand with respect to compounds related to the collaboration that the Company elects to further develop and meet specified conditions. In the Company&#x2019;s arbitration claim, it is seeking a declaration that the Company has no past, present or future milestone or royalty payment obligations under the agreement with respect to rusfertide because it is not a compound relating to the collaboration for which post-termination payments to Zealand apply. The Company is also seeking repayment of $1.0 million in milestone payments it has made, as well as its costs, fees, and expenses of the proceeding.&#160;Zealand disputes the Company&#x2019;s claims and has filed counterclaims for payment of a development milestone Zealand claims is due, as well as payment of their arbitration costs, fees and expenses&lt;i style="font-style:italic;"&gt;. &lt;/i&gt;The arbitration is pending. If Zealand prevails in the arbitration, the Company could be required to reimburse Zealand&#x2019;s arbitration costs, fees and expenses, and make contractual payments to Zealand described in its prior periodic reports filed with the SEC. If we successfully develop and commercialize rusfertide without a partner, those payments could include up to an additional aggregate of $28.0 million for achievement of certain development and regulatory milestones, and up to $100.0 million for achievement of sales milestones. In addition, Zealand could be eligible to receive a low single digit royalty on worldwide net sales of the product.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Although the Company cannot predict with certainty the ultimate outcome of these arbitration proceedings, it has concluded that the probability of any related loss is remote and therefore no related accruals were recognized as of December 31, 2020.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_ZealandPharmaMember_EFYZYS2pyEi6iqunSu7VTw"
      decimals="-5"
      id="Narr_ljDu7ceS2E67dKZNSERitg"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1000000.0</us-gaap:LossContingencyDamagesSoughtValue>
    <ptgx:PotentialDevelopmentAndRegulatoryMilestonePaymentsOnContractualObligation
      contextRef="As_Of_12_31_2020_srt_CounterpartyNameAxis_ptgx_ZealandPharmaMember_srt_StatementScenarioAxis_ptgx_SuccessfullyDevelopAndCommercializeRusfertideComponentWithOutPartnerMember_zvHiCT5gZESB6MhV_EqkXg"
      decimals="-5"
      id="Narr_k6VMgUhM0USI3mmiKWcZjA"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">28000000.0</ptgx:PotentialDevelopmentAndRegulatoryMilestonePaymentsOnContractualObligation>
    <ptgx:PotentialSalesMilestonePaymentsOnContractualObligation
      contextRef="As_Of_12_31_2020_srt_CounterpartyNameAxis_ptgx_ZealandPharmaMember_srt_StatementScenarioAxis_ptgx_SuccessfullyDevelopAndCommercializeRusfertideComponentWithOutPartnerMember_zvHiCT5gZESB6MhV_EqkXg"
      decimals="-5"
      id="Narr_FAe4LjvOoEm5QdZWuxDlbQ"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">100000000.0</ptgx:PotentialSalesMilestonePaymentsOnContractualObligation>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="As_Of_12_31_2020_srt_CounterpartyNameAxis_ptgx_ZealandPharmaMember_Z1DSgl1avkK9ttj7siMlow"
      decimals="-5"
      id="Narr_gdk-vTSYN0i7Dxxes0-Sbg"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_STS4uB8ar0icDfqicZAYbw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;white-space:pre-wrap;"&gt;Note 12.    Stockholders&#x2019; Equity&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:25.3pt;margin:0pt 0pt 13.19pt 0pt;"&gt;In September 2017, the Company filed a registration statement on Form S-3 with the Securities and Exchange Commission (File No. 333-220314) that was declared effective as of October 5, 2017 and permitted the offering, issuance, and sale by the Company of up to a maximum aggregate offering price of $200.0 million of its common stock, preferred stock and certain debt securities (the &#x201c;2017 Form S-3&#x201d;). Up to a maximum of $50.0 million of the maximum aggregate offering price of $200.0 million could be issued and sold pursuant to an at-the-market (&#x201c;ATM&#x201d;) financing facility under a sales agreement (the &#x201c;2017 Sales Agreement&#x201d;). The 2017 Sales Agreement was terminated in 2019. During the year ended December 31, 2019, prior to the termination of the 2017 Sales Agreement, the Company sold 2,846,641 shares of its common stock for net proceeds of $34.5 million, after deducting issuance costs. The Company sold 151,273 shares of its common stock pursuant to the 2017 Sales Agreement during the year ended December 31, 2018 for net proceeds of $1.5 million, after deducting issuance costs. The 2017 Form S-3 expired in October 2020. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:25.3pt;margin:0pt 0pt 13.19pt 0pt;"&gt;In August 2018, the Company entered into a Securities Purchase Agreement with certain accredited investors (each, an &#x201c;Investor&#x201d; and, collectively, the &#x201c;Investors&#x201d;), pursuant to which the Company sold an aggregate of 2,750,000 shares of its common stock at a price of $8.00 per share, for aggregate net proceeds of $21.7 million, after deducting offering expenses payable by the Company. In a concurrent private placement, the Company issued the Investors warrants to purchase an aggregate of 2,750,000 shares of its common stock (each, a &#x201c;Warrant&#x201d; and, collectively, the &#x201c;Warrants&#x201d;). Each Warrant is exercisable from August 8, 2018 through August 8, 2023. Warrants to purchase 1,375,000 shares of the Company&#x2019;s common stock have an exercise price of $10.00 per share and Warrants to purchase 1,375,000 shares of the Company&#x2019;s common stock have an exercise price of $15.00 per share. The exercise price and number of shares of common stock issuable upon the exercise of the Warrants (the &#x201c;Warrant Shares&#x201d;) are subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described in the Warrants. Under certain circumstances, the Warrants may be exercisable on a &#x201c;cashless&#x201d; basis. In connection with the issuance and sale of the common stock and Warrants, the Company granted the Investors certain registration rights with respect to the Warrants and the Warrant Shares. The common stock and warrants are classified as equity in accordance with Accounting Standards Codification Topic 480&lt;i style="font-style:italic;"&gt;, Distinguishing Liabilities from Equity &lt;/i&gt;(&#x201c;ASC 480&#x201d;)&lt;i style="font-style:italic;"&gt;,&lt;/i&gt; and the net proceeds from the transaction were recorded as a credit to additional paid-in capital. As of December 31, 2020, none of the Warrants have been exercised.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:25.3pt;margin:0pt 0pt 13.19pt 0pt;"&gt;In December 2018, the Company entered into an exchange agreement (the &#x201c;Exchange Agreement&#x201d;) with an Investor and its affiliates (the &#x201c;Exchanging Stockholders&#x201d;), pursuant to which the Company exchanged an aggregate of 1,000,000 shares of the Company&#x2019;s common stock, par value $0.00001 per share, owned by the Exchanging Stockholders for pre-funded warrants (the &#x201c;Exchange Warrants&#x201d;) to purchase an aggregate of 1,000,000 shares of common stock (subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described in the Exchange Warrants), with an exercise price of $0.00001 per share. The Exchange Warrants will expire ten years from the date of issuance. The Exchange Warrants are exercisable at any time prior to expiration except that the Exchange Warrants cannot be exercised by the Exchanging Stockholders if, after giving effect thereto, the Exchanging Stockholders would beneficially own more than 9.99% of the Company&#x2019;s common stock, subject to certain exceptions. In accordance with Accounting Standards Codification Topic 505,&lt;i style="font-style:italic;"&gt; Equity&lt;/i&gt;, the Company recorded the retirement of the common stock exchanged as a reduction of common stock shares outstanding and a corresponding debit to additional paid-in-capital at the fair value of the Exchange Warrants on the issuance date. The Exchange Warrants are classified as equity in accordance with ASC 480&lt;i style="font-style:italic;"&gt;,&lt;/i&gt; and the fair value of the Exchange Warrants was recorded as a credit to additional paid-in capital and is not subject to remeasurement. The Company determined that the fair value of the Exchange Warrants is substantially similar to the fair value of the retired shares on the issuance date due to the negligible exercise price for the Exchange Warrants. During the year ended December 31, 2019, Exchange Warrants to purchase 600,000 shares were net exercised, resulting in the issuance of 599,997 shares of common stock. As of December 31, 2020, 400,000 of the Exchange Warrants remain unexercised.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"&gt;In October 2019, the Company filed a registration statement on Form S-3 (File no. 333-234414) that was declared effective as of November 22, 2019 and permits the offering, issuance, and sale by the Company of up to a maximum aggregate offering price of $250.0 million of its common stock, preferred stock, debt securities and warrants (the &#x201c;2019 Form S-3&#x201d;). Up to a maximum of $75.0 million of the maximum aggregate offering price of $250.0 million may be issued and sold pursuant to an ATM financing facility under a sales agreement entered into by the Company on November 27, &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;2019 (the &#x201c;2019 Sales Agreement&#x201d;). In May 2020, the Company completed an underwritten public offering of 7,000,000 shares of common stock at a public offering price of $14.00 per share and issued an additional 1,050,000 shares of its common stock at a price of $14.00 per share following the underwriters&#x2019; exercise of their option to purchase additional shares. Net proceeds, after deducting underwriting commissions and offering costs paid by the Company, were $105.3 million. The Company sold 2,483,719 shares of its common stock pursuant to the 2019 Sales Agreement during the year ended December 31, 2020 for net proceeds of $41.9 million, after deducting issuance costs. As of December 31, 2020, a total of $94.2 million of common stock remained available for sale under the 2019 Form S-3, $31.9 million of which remained available for sale under the ATM financing facility. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;In December 2020, the Company filed an automatic registration statement on Form S-3ASR and an accompanying prospectus (Registration Statement No. 333-251254), pursuant to which the Company completed an underwritten public offering of 4,761,904 shares of common stock at a public offering price of $21.00 per share and issued an additional 714,285 shares of its common stock at a price of $21.00 per share following the underwriters&#x2019; exercise of their option to purchase additional shares. Net proceeds, after deducting underwriting commissions and offering costs paid by the Company, were $107.6 million.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <ptgx:SaleOfStockValueOfSharesAuthorized
      contextRef="Duration_9_1_2017_To_9_30_2017_us-gaap_SubsidiarySaleOfStockAxis_ptgx_CommonStockPreferredStockAndCertainDebtSecuritiesMember_zx3lVa2z8kOfh7KC7iZGpg"
      decimals="-5"
      id="Narr_bY74ofXZvEOn8nbH-gOgBQ"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">200000000.0</ptgx:SaleOfStockValueOfSharesAuthorized>
    <ptgx:SaleOfStockValueOfSharesAuthorized
      contextRef="Duration_9_1_2017_To_9_30_2017_srt_CounterpartyNameAxis_ptgx_AtMarketOfferingMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_SalesAgreementFrom2017Member__YoSlLwDmEWFZ2JYQBWSFw"
      decimals="-5"
      id="Narr_JH_bVq7wikm6F9SVvccmoQ"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">50000000.0</ptgx:SaleOfStockValueOfSharesAuthorized>
    <ptgx:SaleOfStockValueOfSharesAuthorized
      contextRef="Duration_9_1_2017_To_9_30_2017_us-gaap_SubsidiarySaleOfStockAxis_ptgx_CommonStockPreferredStockAndCertainDebtSecuritiesMember_zx3lVa2z8kOfh7KC7iZGpg"
      decimals="-5"
      id="Narr_A8f4N-E0AkumIVLIamyaCg"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">200000000.0</ptgx:SaleOfStockValueOfSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_SalesAgreementFrom2017Member_4-Top2Z7HEGnoubmcpaUQg"
      decimals="INF"
      id="Narr_45GOoJqtqUqF1mMQgBACwQ"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">2846641</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_SalesAgreementFrom2017Member_4-Top2Z7HEGnoubmcpaUQg"
      decimals="-5"
      id="Narr_rMH9lBabNEesGdBTl_GTCA"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">34500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_SalesAgreementFrom2017Member_qkNym65oekWLKJu7qHfcDA"
      decimals="INF"
      id="Narr_K5X8zK0wlUKz1AVd4mLN1Q"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">151273</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_SalesAgreementFrom2017Member_qkNym65oekWLKJu7qHfcDA"
      decimals="-5"
      id="Narr_95ewQRyquUe4xmJpPzjWFA"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_8_1_2018_To_8_31_2018_srt_CounterpartyNameAxis_ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_j6JfV1HdAU2VL5Av0thXjA"
      decimals="INF"
      id="Narr_TrBnDSYx40umZUlER-dEHg"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">2750000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_8_6_2018_srt_CounterpartyNameAxis_ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VeE0MBURAUmr6KszgYXA8g"
      decimals="INF"
      id="Narr_06nclWeSmkOEauCcz54fsA"
      unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q">8.00</us-gaap:SharesIssuedPricePerShare>
    <ptgx:AggregateGrossProceedsFromIssuanceStock
      contextRef="As_Of_8_6_2018_srt_CounterpartyNameAxis_ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VeE0MBURAUmr6KszgYXA8g"
      decimals="-5"
      id="Narr_E6yfS_fQnUaxHxHICYV2Og"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">21700000</ptgx:AggregateGrossProceedsFromIssuanceStock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_8_6_2018_srt_CounterpartyNameAxis_ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_z3QoxAuYuUKbQDm_MCaYpQ"
      decimals="INF"
      id="Narr_xajRf4hSYk2zNIsyOk9K6A"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">2750000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_8_6_2018_us-gaap_ClassOfWarrantOrRightAxis_ptgx_WarrantsPurchaseAmountPerSharePriceOneMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_186kOF-nN0ak3sZ7B7mYIg"
      decimals="INF"
      id="Narr_QISDTgIMz0WfpojFasj9ug"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">1375000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_8_6_2018_us-gaap_ClassOfWarrantOrRightAxis_ptgx_WarrantsPurchaseAmountPerSharePriceOneMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_186kOF-nN0ak3sZ7B7mYIg"
      decimals="INF"
      id="Narr_IrqR4du0S0-yYp79CZ4KpQ"
      unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q">10.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_8_6_2018_us-gaap_ClassOfWarrantOrRightAxis_ptgx_WarrantsPurchaseAmountPerSharePriceTwoMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_GKATHoBzkEKJSJRivO9SBQ"
      decimals="INF"
      id="Narr_-rXgz7UIUEmd55mHmkYP_g"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">1375000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_8_6_2018_us-gaap_ClassOfWarrantOrRightAxis_ptgx_WarrantsPurchaseAmountPerSharePriceTwoMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_GKATHoBzkEKJSJRivO9SBQ"
      decimals="INF"
      id="Narr_WG1bgfYzQEmvVhW9UV4KLg"
      unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q">15.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ptgx:NumberOfWarrantsExercised
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_KjsvtwPBSUeomIS3nTcYHQ"
      decimals="INF"
      id="Narr_nFal3k-nkUWT1fKJKU8IKg"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">0</ptgx:NumberOfWarrantsExercised>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_21_2018_srt_CounterpartyNameAxis_ptgx_BiotechnologyValueFundL.pMember_us-gaap_TypeOfArrangementAxis_ptgx_ExchangeAgreementMember_BJDxU0LhGkitpW7AZKjqUg"
      decimals="INF"
      id="Narr_A8Gz8IrJ4U-QIyiHaMPc4Q"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">1000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_21_2018_srt_CounterpartyNameAxis_ptgx_BiotechnologyValueFundL.pMember_us-gaap_TypeOfArrangementAxis_ptgx_ExchangeAgreementMember_BJDxU0LhGkitpW7AZKjqUg"
      decimals="INF"
      id="Narr_egfds-91r0KW-q-pfdKp_A"
      unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q">0.00001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ptgx:StockExchangedForPreFundedWarrants
      contextRef="Duration_12_1_2018_To_12_31_2018_srt_CounterpartyNameAxis_ptgx_BiotechnologyValueFundL.pMember_us-gaap_TypeOfArrangementAxis_ptgx_ExchangeAgreementMember_JivbDCfMDUKimc02lEUXQg"
      decimals="INF"
      id="Narr_PrBCgcIng0GaPQKoWvK7Dw"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">1000000</ptgx:StockExchangedForPreFundedWarrants>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_21_2018_srt_CounterpartyNameAxis_ptgx_BiotechnologyValueFundL.pMember_us-gaap_TypeOfArrangementAxis_ptgx_ExchangeAgreementMember_BJDxU0LhGkitpW7AZKjqUg"
      decimals="INF"
      id="Narr_WoCOrz1PfUCTEb2l7CG7_A"
      unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <ptgx:ClassOfWarrantOrRightTermOfWarrants
      contextRef="Duration_12_21_2018_To_12_21_2018_srt_CounterpartyNameAxis_ptgx_BiotechnologyValueFundL.pMember_us-gaap_TypeOfArrangementAxis_ptgx_ExchangeAgreementMember_vOU5zedUDk2RWTFaLEzOWw"
      id="Narr_H-4waa7ElkudlQzlO_eX8A">P10Y</ptgx:ClassOfWarrantOrRightTermOfWarrants>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="As_Of_12_21_2018_srt_CounterpartyNameAxis_ptgx_BiotechnologyValueFundL.pMember_us-gaap_TypeOfArrangementAxis_ptgx_ExchangeAgreementMember_BJDxU0LhGkitpW7AZKjqUg"
      decimals="4"
      id="Narr__34ymE7o902fpjp8sLBRlA"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.0999</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <ptgx:NumberOfWarrantsExercised
      contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_ptgx_BiotechnologyValueFundL.pMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_ptgx_ExchangeAgreementMember_mgjJN8kSnkmKkWqgSyHErQ"
      decimals="INF"
      id="Narr_FjBWT4yeD0-mMKXuTWzuFw"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">600000</ptgx:NumberOfWarrantsExercised>
    <ptgx:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_ptgx_BiotechnologyValueFundL.pMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_ptgx_ExchangeAgreementMember_cUqXG1yQX0uQTBHVoh090Q"
      decimals="INF"
      id="Narr_pkB76s018UqoeoNygdwXEQ"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">599997</ptgx:StockIssuedDuringPeriodSharesWarrantsExercised>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2020_srt_CounterpartyNameAxis_ptgx_BiotechnologyValueFundL.pMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_ptgx_ExchangeAgreementMember_Ik7tchK9-Ue8oyRnGIgm_g"
      decimals="INF"
      id="Narr_oi6qRvxPsky7S6Ot_wS2YA"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">400000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <ptgx:SaleOfStockValueOfSharesAuthorized
      contextRef="Duration_10_1_2019_To_10_31_2019_us-gaap_SubsidiarySaleOfStockAxis_ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember_2WMpGtC9OEOlBeqopXrQRw"
      decimals="-5"
      id="Narr_Ja4bJzdlik6DQHjeo_Oh5g"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">250000000.0</ptgx:SaleOfStockValueOfSharesAuthorized>
    <ptgx:SaleOfStockValueOfSharesAuthorized
      contextRef="Duration_10_1_2019_To_10_31_2019_srt_CounterpartyNameAxis_ptgx_AtMarketOfferingMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember_yaqgEgG5X0iZ4CZKQUqb8g"
      decimals="-5"
      id="Narr_Yey2vG56a0CVWvnAj4ANTw"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">75000000.0</ptgx:SaleOfStockValueOfSharesAuthorized>
    <ptgx:SaleOfStockValueOfSharesAuthorized
      contextRef="Duration_10_1_2019_To_10_31_2019_us-gaap_SubsidiarySaleOfStockAxis_ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember_2WMpGtC9OEOlBeqopXrQRw"
      decimals="-5"
      id="Narr_x4xw074L9USo41VuaXWFHw"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">250000000.0</ptgx:SaleOfStockValueOfSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_5_1_2020_To_5_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GUwt944WL0uotoTy8UvAVQ"
      decimals="INF"
      id="Narr_lxQ3B0GFvUCB32S9JfmgwQ"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">7000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_5_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_kre8MFx27UW7IW8Z8ld4mw"
      decimals="2"
      id="Narr_vhEXGE63L0SRqxLtgXNlBQ"
      unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q">14.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_5_1_2020_To_5_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_4Kh5pBSECkypUOYucapGkA"
      decimals="INF"
      id="Narr_wGgId3bY-Uy9t4HGT7Josw"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">1050000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_5_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_hOb9HKro90mY6okLdtMCHA"
      decimals="2"
      id="Narr_ViG5lCgYEEirWdQfHADy_A"
      unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q">14.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_5_1_2020_To_5_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_SalesAgreementFrom2017Member_tZp0EkKbX0KKXBjYlmFbBg"
      decimals="-5"
      id="Narr_3kLaflciwE6XzDt-2cJFdA"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">105300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember_jKn-PPj_GUaOCF64euSSCg"
      decimals="INF"
      id="Narr_POiyyI09bUqSNVL0G7dmQg"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">2483719</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember_jKn-PPj_GUaOCF64euSSCg"
      decimals="-5"
      id="Narr_jh9NsCbwBUW3SqpQuCyVXA"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">41900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ptgx:SaleOfStockValueOfSharesAuthorized
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_SubsidiarySaleOfStockAxis_ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember_p8qynIyKyk-zMkGoWZcW3A"
      decimals="-5"
      id="Narr_E264CAYO4EqSGmimnQ11kw"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">94200000</ptgx:SaleOfStockValueOfSharesAuthorized>
    <ptgx:SaleOfStockValueOfSharesAuthorized
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_AtMarketOfferingMember_iy5bZi35C0SnS_cAS0HmXw"
      decimals="-5"
      id="Narr_9ApaVuK4R0y2534RpQxXBg"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">31900000</ptgx:SaleOfStockValueOfSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_12_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0ejK20BXz0WlKLitqx2O8A"
      decimals="INF"
      id="Narr_jlxjNH9dZ0a0RLOYS4VgRg"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">4761904</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_E5rQEhmdCkiUzPRvbbp87g"
      decimals="2"
      id="Narr_hPNuHOrflEeRNEXn75zWrA"
      unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q">21.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_12_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_agJoJQfoR0S_u2bStgWXxQ"
      decimals="INF"
      id="Narr_n8uW-JMu-kmGowYWGcEGXA"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">714285</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_SBZjOH40VUWH7eyCsHOxeQ"
      decimals="2"
      id="Narr_beFUlc7sFU--VveqIuvKfg"
      unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q">21.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_12_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_agJoJQfoR0S_u2bStgWXxQ"
      decimals="-5"
      id="Narr_hKWdL_ml6Uug2ZmuY3kfNg"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">107600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_t4-TByv8VE-QN7Pj0avJ1g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Note 13.&#160;&#160;&#160;&#160;Equity Plans &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Equity Incentive Plan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;In May&#160;2007, the Company established the 2007 Stock Option and Incentive Plan (&#x201c;2007 Plan&#x201d;) which provided for the granting of stock options to employees and consultants of the Company. Options granted under the 2007 Plan were either incentive stock options (&#x201c;ISOs&#x201d;) or nonqualified stock options (&#x201c;NSOs&#x201d;). ISOs were granted only to Company employees (including officers and directors who are also employees). NSOs were granted to Company employees and consultants. Options under the 2007 Plan have a term of ten&#160;years and generally vest over a four-year period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;In July&#160;2016, the Company&#x2019;s board of directors and stockholders approved the 2016 Equity Incentive Plan (&#x201c;2016 Plan&#x201d;) to replace the 2007 Plan. Under the 2016 Plan, 1,200,000 shares of the Company&#x2019;s common stock were initially reserved for the issuance of stock options, restricted stock units and other awards to employees, directors and consultants. Pursuant to the &#x201c;evergreen&#x201d; provision contained in the 2016 Plan, the number of shares reserved for issuance under the 2016 Plan automatically increases on January 1 of each year, starting on January 1, 2017 and continuing through (and including) January 1, 2026, by 4% of the total number of shares of the Company&#x2019;s capital stock outstanding on December 31 of the preceding fiscal year, or a lesser number of shares determined by the Company&#x2019;s board of directors. Upon adoption of the 2016 Plan, no additional stock awards were issued under the 2007 Plan. Options granted under the 2007 Plan that were outstanding on the date the 2016 Plan became effective remain subject to the terms of the 2007 Plan. The number of options available for grant under the 2007 Plan was ceased and the number was added to the common stock reserved for issuance under the 2016 Plan. As of December&#160;31, 2020, approximately 538,374 shares of common stock were available for issuance under the 2016 Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The 2016 Plan is administered by the board of directors or a committee appointed by the board of directors, which determines the types of awards to be granted, including the number of shares subject to the awards, the exercise price and the vesting schedule. Options granted under the 2016 Plan expire no later than ten years from the date of grant. The exercise price of each option may not be less than 100% of the fair market value of the common stock at the date of grant. Options may be granted to stockholders possessing more than 10% of the total combined voting power of all classes of stocks of the Company at an exercise price at least 110% of the fair value of the common stock at the date of grant and the options are not exercisable after the expiration of 10&#160;years from the date of grant. Employee stock options generally vest over a period of approximately four years. Non-employee director initial stock options generally vest monthly over a period of approximately three years, and non-employee director annual refresher stock options generally vest over a period of approximately one year.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:8pt 0pt 0pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Inducement Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27.8pt;margin:6pt 0pt 0pt 0pt;"&gt;In May 2018, the Company&#x2019;s board of directors approved the 2018 Inducement Plan, a non-stockholder approved stock plan, under which it reserved and authorized 750,000 shares of the Company&#x2019;s common stock in order to award &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;options and restricted stock unit awards&#160;to persons that were not previously employees or directors of the Company, or following a bona fide period of non-employment, as an inducement material to such persons entering into employment with the Company, within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. The 2018 Inducement Plan is administered by the board of directors or the Compensation Committee of the board, which determines the types of awards to be granted, including the number of shares subject to the awards, the exercise price and the vesting schedule. Awards granted under the 2018 Inducement Plan expire no later than ten years from the date of grant. As of December 31, 2020, approximately 574,375 shares were available for issuance under the 2018 Inducement Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock Options&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Activity under the Company&#x2019;s equity incentive plans is set forth below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.5396309%;padding-left:0pt;padding-right:0pt;width:101.07%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:37.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&#160;Per&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Life&#160;(years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value (1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;millions)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balances at December&#160;31,&#160;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,681,521&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.64&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.78&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.4&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,536,400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.53&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (294,238)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.49&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Options forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (275,563)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.54&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balances at December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,648,120&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.87&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.61&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40.0&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Options exercisable &#x2013; December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,619,943&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12.10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.65&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22.1&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Options vested and expected to vest &#x2013; December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,648,120&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.87&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.61&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40.0&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;padding-left:9pt;text-indent:-9pt;margin:3pt 0pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;____________________&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-indent:-9pt;margin:0pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1) &lt;/sup&gt;The aggregate intrinsic values were calculated as the difference between the exercise price of the options and the closing price of the Company&#x2019;s common stock on December 31, 2020. The calculation excludes options with an exercise price higher than the closing price of the Company&#x2019;s common stock on December 31, 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The aggregate intrinsic value of options exercised was $3.0 million, $2.6 million and $1.3 million for the&#160;years ended December&#160;31, 2020, 2019 and 2018, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;During the&#160;years ended December&#160;31, 2020, 2019 and 2018, the estimated weighted-average grant-date fair value of common stock underlying options granted was $7.76, $5.45 and $8.12 per share, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock Options Valuation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The fair value of stock option awards accounted for under ASC 718 was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:57.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:40.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:57.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:57.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;5.27 - 6.08 &lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;5.00 - 6.08 &lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;5.49 - 6.08&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;72.1% - 87.5%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;61.0% - 64.8%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;62.0% - 66.5%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:57.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0.23% - 1.44%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;1.42% - 2.58%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2.42% - 3.03%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"&gt;In determining the fair value of the options granted, the Company uses the Black-Scholes option-pricing model and assumptions discussed below. Each of these inputs is subjective, and expected volatility generally requires significant judgment to determine.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected Term&lt;/i&gt;&#x2014;The Company&#x2019;s expected term represents the period that the Company&#x2019;s options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term). The Company has limited historical exercise information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected Volatility&lt;/i&gt;&#x2014; Prior to January 1, 2020, the Company&#x2019;s expected volatility was estimated based on the average volatility for comparable publicly traded biopharmaceutical companies over a period equal to the expected term of the awards. Beginning January 1, 2020, the Company&#x2019;s expected volatility is based upon a blend of 75% of the average volatility for comparable publicly traded biopharmaceutical companies and 25% of the volatility of the Company&#x2019;s stock price since its initial public offering in August 2016. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Risk-Free Interest Rate&lt;/i&gt;&#x2014;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of option.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected Dividend&lt;/i&gt;&#x2014;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:bold;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27.8pt;margin:4pt 0pt 0pt 0pt;"&gt;The Company began issuing restricted stock units under the 2016 Plan during the year ended December 31, 2018. A restricted stock unit is an agreement to issue shares of the Company&#x2019;s common stock at the time of vesting. Restricted stock unit annual refresher awards vest in four equal installments on approximately the first, second, third and fourth anniversaries of the grant date. Restricted stock unit incentive awards granted during 2018 vested in three equal installments at six months intervals over a period of 18 months.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:28.1pt;margin:9pt 0pt 0pt 0pt;"&gt;Restricted stock unit activity under the Company&#x2019;s equity incentive plans is set forth below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unvested at December&#160;31,&#160;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 278,482&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10.08&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 142,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.80&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (131,147)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.52&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (44,790)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8.67&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unvested at December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 244,545&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.31&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Stock-based compensation expense associated with restricted stock units is based on the fair value of the Company&#x2019;s common stock on the grant date, which equals the closing market price of the Company&#x2019;s common stock on the grant date. For restricted stock units, the Company recognizes compensation expense over the vesting period of the awards that are ultimately expected to vest. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Employee Stock Purchase Plan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"&gt;In July&#160;2016, the Company&#x2019;s board of directors and stockholders approved the 2016 Employee Stock Purchase Plan (&#x201c;2016 ESPP&#x201d;). The 2016 ESPP is intended to qualify as an employee stock purchase plan under Section&#160;423 of the Internal Revenue Code of 1986, as amended, and is administered by the Company&#x2019;s board of directors and the Compensation Committee of the board of directors. Under the 2016 ESPP, 150,000 shares of the Company&#x2019;s common stock were initially reserved for employee purchases of the Company&#x2019;s common stock. Pursuant to the &#x201c;evergreen&#x201d; provision contained in the 2016 ESPP, the number of shares reserved for issuance automatically increases on January 1 of each year, starting on January 1, 2017 and continuing through (and including) January 1, 2026 by the lesser of (i)&#160;1% of the total number of shares of common stock outstanding on December&#160;31 of the preceding fiscal&#160;year (ii) 300,000 shares, or (iii)&#160;such other number of shares determined by the board of directors. The 2016 ESPP allows eligible employees to purchase shares of the Company&#x2019;s common stock at a discount through payroll deductions of up to 15% of their eligible &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;compensation. At the end of each offering period, eligible employees are able to purchase shares at 85% of the lower of the fair market value of the Company&#x2019;s common stock at the beginning of the offering period or at the end of each applicable purchase period. During the year ended December 31, 2020, 92,523 shares were issued under the ESPP. As of December 31, 2020, 757,647 shares are available for issuance.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The fair value of the rights granted under the 2016 ESPP was calculated using the Black-Scholes option-pricing model with the following assumptions:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.4488411%;padding-left:0pt;padding-right:0pt;width:100.89%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:41.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8.15pt;"&gt;&lt;td style="vertical-align:bottom;width:57.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:57.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.35pt 0pt 0pt;"&gt;0.50&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.50&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.50&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;89.1% - 120.4%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;58.9% - 65.3%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;49.0% - 63.4%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:57.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate &lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;0.12% - 0.43%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;1.89% - 2.32%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;1.89% - 2.32%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Dividend yield &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Total stock-based compensation expense was as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:38.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:59.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,121&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,350&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,424&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,778&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,003&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,495&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:59.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,899&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,353&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,919&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2020, total unrecognized stock-based compensation expense was $16.0 million, which the Company expects to recognize over a period of approximately &lt;span style="white-space:pre-wrap;"&gt;2.7&lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt;&#160;years.&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_ptgx_StockOptionAndIncentivePlanAsAmendedAndRestated2007Member_jktel6yu6kK7pWrzaSuY2Q"
      id="Narr_pDuvaeXkjESn_4kEaD9wRQ">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_ptgx_StockOptionAndIncentivePlanAsAmendedAndRestated2007Member_9U0z6hszwEGi_P9hNkxE5Q"
      id="Narr_EodajTHFtEWtbyaI9LQgjw">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_7_31_2016_us-gaap_PlanNameAxis_ptgx_EquityIncentivePlan2016Member_X9g55Fo86EaIMiverpOurg"
      decimals="INF"
      id="Narr_n7lXEVC2eEWVCnEnfVCMAA"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">1200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <ptgx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_ptgx_EquityIncentivePlan2016Member_Q2OzhxYJoE2GLzRZOait5w"
      decimals="2"
      id="Narr_CNKO0zvu_UuK9b68av-yOA"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.04</ptgx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_7_31_2016_us-gaap_PlanNameAxis_ptgx_StockOptionAndIncentivePlanAsAmendedAndRestated2007Member_Q8ASK54YZEa5T6ejJrDeJw"
      decimals="INF"
      id="Narr_GpT6x9-7HUuUpEIcNVzJcw"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2019_us-gaap_PlanNameAxis_ptgx_EquityIncentivePlan2016Member_F6df0QQhrU6i9GJCdhqPDg"
      decimals="INF"
      id="Narr_y1H1PbRiMUW4OcPuvCigUQ"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">538374</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_ptgx_EquityIncentivePlan2016Member_eF2snCub_Eahp8p8BWAONg"
      id="Narr_6YBaPISwqEyeSCMbsP2xpg">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember_us-gaap_PlanNameAxis_ptgx_EquityIncentivePlan2016Member_uoGvCjLpdkK2StizIEWf5w"
      decimals="INF"
      id="Narr_3-JwjC5l_UWEQmFZjiQDXg"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_ptgx_EquityIncentivePlan2016Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_PrincipalOwnerMember_ExSFV52WIEW8KwIeap4Bxw"
      decimals="INF"
      id="Narr_cXazfp6mhkuyWqBFRaX_-w"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">1.10</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_7_1_2016_To_7_31_2016_us-gaap_PlanNameAxis_ptgx_EquityIncentivePlan2016Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_Pl5aD902hUizaGvF0_Ag0w"
      id="Narr_BdMV7hQa20-8WfEMUyAOow">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_ptgx_NonEmployeeDirectorInitialStockOptionsMember_us-gaap_PlanNameAxis_ptgx_EquityIncentivePlan2016Member_jCMUIflu30Chq-y0-NBBeQ"
      id="Narr_lZ6BIzqs60yVafvk-MBIFw">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_ptgx_NonemployeeDirectorAnnualRefresherStockOptionsMember_us-gaap_PlanNameAxis_ptgx_EquityIncentivePlan2016Member_ZyLhj6L8U0eoAkYv_BvxHQ"
      id="Narr_whVvrnuZAUK37dlfidHN6A">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_5_31_2018_us-gaap_PlanNameAxis_ptgx_InducementStockPlanMember_3YM3Ufo1cE24pa1he7vSAQ"
      decimals="INF"
      id="Narr_VrbVRYIEx0Gq8kvuyhiZcQ"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_ptgx_InducementStockPlanMember_yAEykxLHsUSSNG0CUEUjkA"
      id="Narr_GDJw1bNNgEGArF3uhNhlGA">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_ptgx_InducementStockPlanMember_KE5aREx68U2i_cgMV6Pj_A"
      decimals="INF"
      id="Narr_9fSVRM8dNka1q7LHWfayAQ"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">574375</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_xC8fjqbm30a5DWyWahJJjw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.5396309%;padding-left:0pt;padding-right:0pt;width:101.07%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:37.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&#160;Per&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Life&#160;(years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value (1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;millions)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balances at December&#160;31,&#160;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,681,521&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.64&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.78&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.4&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,536,400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.53&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (294,238)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.49&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Options forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (275,563)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.54&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balances at December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,648,120&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.87&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.61&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40.0&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Options exercisable &#x2013; December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,619,943&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12.10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.65&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22.1&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Options vested and expected to vest &#x2013; December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,648,120&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.87&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.61&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40.0&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;padding-left:9pt;text-indent:-9pt;margin:3pt 0pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;____________________&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-indent:-9pt;margin:0pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1) &lt;/sup&gt;The aggregate intrinsic values were calculated as the difference between the exercise price of the options and the closing price of the Company&#x2019;s common stock on December 31, 2020. The calculation excludes options with an exercise price higher than the closing price of the Company&#x2019;s common stock on December 31, 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="INF"
      id="Tc_Z3KekqxpdU6WrlgnbNvuag_8_2"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">3681521</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="2"
      id="Tc_r0FibSlYmESJ8tUr9da-sw_8_5"
      unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q">11.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      id="Tc_BZQ-EtYMbUqQug8nwTAoLA_8_7">P7Y9M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-5"
      id="Tc_n5i7f2SBJ0iiNlgkDRIRBg_8_10"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">2400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="INF"
      id="Tc_WhjMusuZ9Ea8itFht3al6w_9_2"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">1536400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="2"
      id="Tc_A9R5Fl89gEC2IK3omh4noQ_9_5"
      unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q">11.53</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="INF"
      id="Tc_je5j5dm8P0SIgeLAk-Dr_A_10_2"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">294238</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="2"
      id="Tc_xsKbYgvnsUyfLuEgIMvw9A_10_5"
      unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q">7.49</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="INF"
      id="Tc_EWoG88W0a0GGO4puqv4Row_11_2"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">275563</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="2"
      id="Tc_XoIaefH3Rkmg2NuuqRUtww_11_5"
      unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q">11.54</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="INF"
      id="Tc_ITsO4v6ookqnfI7uKtAl5A_12_2"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">4648120</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="2"
      id="Tc_RraBfbPhnkKAWAoWhORXEw_12_5"
      unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q">11.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tc_Hj2cxE7M_0WrB0FQ62o2rw_12_7">P7Y7M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-5"
      id="Tc_GkoJnXYCvEyDdtPZLHbQ6A_12_10"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">40000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="INF"
      id="Tc_VNVFAR5XbUCcLuCwBuZoXQ_13_2"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">2619943</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="2"
      id="Tc_AMNpvpky7EqCsILAaT0grg_13_5"
      unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q">12.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tc_TjBTGFXui0WO87nb47nxoQ_13_7">P6Y7M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-5"
      id="Tc_6QZ7Fa8N3kuAM_Nn0gpxXQ_13_10"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">22100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="INF"
      id="Tc_mYiWKCXf_ECiE7o7HBa0dw_14_2"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">4648120</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="2"
      id="Tc_7BvGuSOfuky4O2VEw8SDUw_14_5"
      unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q">11.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tc_oeDCJ-ehf0afu0z1Ti6zMQ_14_7">P7Y7M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-5"
      id="Tc_r8wSFYvwyEaFFv9q7yF0AQ_14_10"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">40000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-5"
      id="Narr_ZxS4aIrCcE6sKd9aXmsygQ"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">3000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-5"
      id="Narr_16jd461Cy0WGXBi4CfOjMQ"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">2600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-5"
      id="Narr_5lhZGAtFB06XmjiASmr8uA"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="2"
      id="Narr_btYxB5eJxkiS8SbeRk-59A"
      unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q">7.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="2"
      id="Narr_p6wymIaCfkizCzVlevNrpA"
      unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q">5.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="2"
      id="Narr_gyy4kxlpjUO-tAFFPVLEow"
      unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q">8.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_y_lWVCdXEkurpTEfNZLamw"
      id="Tb_-HpoRnoGM0ek-SFMzJnFcw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:57.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:40.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:57.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:57.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;5.27 - 6.08 &lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;5.00 - 6.08 &lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;5.49 - 6.08&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;72.1% - 87.5%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;61.0% - 64.8%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;62.0% - 66.5%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:57.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0.23% - 1.44%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;1.42% - 2.58%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2.42% - 3.03%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zQrIRwTjBUOg--pd-u3-dg"
      id="Narr_vbKrW9re00W-QvD8z3T81A">P5Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_gc3icTBxzk6z-01YFoMDcQ"
      id="Narr_PtsxDTv_0UqoM_ocn9Fshg">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_jA3zrw10lUyty-qrneby5g"
      id="Narr_QVewDEdg2ky23m8nQgKQNg">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_K2QYwOvGJUmiUg9ZTS1GqA"
      id="Narr_aWEUsHLO60Wl6NVREyvuDQ">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2018_To_12_31_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ZbXixFzUcUGHwVYHkj-L5Q"
      id="Narr_n4_dsuNxs0G-cyR7XTcuQA">P5Y5M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2018_To_12_31_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_5o84alY-YEe58-Qyx7km0A"
      id="Narr_wgG3FN90kUS06ZeMWGZMIQ">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_y_lWVCdXEkurpTEfNZLamw"
      decimals="3"
      id="Narr_LmHQko_ahEyyeOJUeaVWWA"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.721</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_y_lWVCdXEkurpTEfNZLamw"
      decimals="3"
      id="Narr_qbZtj5ZfzEO5C78lRltVFg"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.875</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_JMFKex3X3ESe5V_o92xQHA"
      decimals="3"
      id="Narr_bBsNItto2UKecWOLSoR0ew"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.610</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_JMFKex3X3ESe5V_o92xQHA"
      decimals="3"
      id="Narr_qbwrew8a5UKmCg9lK3R9bQ"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.648</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_H_jddmjI8U639x1Gtx8lig"
      decimals="3"
      id="Narr_D8ebKhZwe0GE6oINUhxSNA"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.620</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_H_jddmjI8U639x1Gtx8lig"
      decimals="3"
      id="Narr_g88WOrn-e0Gl50aRj5yLVw"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.665</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_y_lWVCdXEkurpTEfNZLamw"
      decimals="4"
      id="Narr_z7pTHD3Yzki55Ekua0IfUQ"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.0023</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_y_lWVCdXEkurpTEfNZLamw"
      decimals="4"
      id="Narr_kuwfXFKYUkSfWdPT4-k2Yw"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.0144</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_JMFKex3X3ESe5V_o92xQHA"
      decimals="4"
      id="Narr_6HOofL94T0CLDSrtmDCQnQ"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.0142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_JMFKex3X3ESe5V_o92xQHA"
      decimals="4"
      id="Narr_tG-9FUUcY0qvCkbSTwqFYQ"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.0258</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_H_jddmjI8U639x1Gtx8lig"
      decimals="4"
      id="Narr_YbAyH_h3REmKNQ8BOONXRQ"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.0242</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_H_jddmjI8U639x1Gtx8lig"
      decimals="4"
      id="Narr_nc1mSGYNbUiWxTkmei11FA"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.0303</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <ptgx:ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="2"
      id="Narr_-NPx-TwYHUCl2stDE4pZ9Q"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.75</ptgx:ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants>
    <ptgx:ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="2"
      id="Narr_76DFUF7QnU-VJP2J3Qgyow"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.25</ptgx:ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo>
    <ptgx:NumberOfEqualInstallmentsRequiredForVestingOfRestrictedStockUnits
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="INF"
      id="Narr_jt9yHbPFrUG0AYJjerTlhw"
      unitRef="Unit_Standard_installment_pPbBqyhnckSax7ouQFoPyQ">4</ptgx:NumberOfEqualInstallmentsRequiredForVestingOfRestrictedStockUnits>
    <ptgx:NumberOfEqualInstallmentsRequiredForVestingOfRestrictedStockUnits
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_PlanNameAxis_ptgx_InducementStockPlanMember_1aFOsX_HY0KODJxVov4uuA"
      decimals="INF"
      id="Narr_Jx-nOK6bcUa47k31aB7yuw"
      unitRef="Unit_Standard_installment_pPbBqyhnckSax7ouQFoPyQ">3</ptgx:NumberOfEqualInstallmentsRequiredForVestingOfRestrictedStockUnits>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_PlanNameAxis_ptgx_InducementStockPlanMember_1aFOsX_HY0KODJxVov4uuA"
      id="Narr_KAwwYUyZwkOIAts6JTFyUQ">P18M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_eremZ34RS0u0oYjA1BqUtA"
      id="Tb_0wJot7m770GMD2F2LkTcXg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unvested at December&#160;31,&#160;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 278,482&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10.08&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 142,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.80&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (131,147)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.52&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (44,790)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8.67&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unvested at December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 244,545&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.31&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2019_us-gaap_PlanNameAxis_ptgx_InducementStockPlanMember_uV2sRVuEEkSt7OepkbYJpA"
      decimals="INF"
      id="Tc_2QMRcYz2QkCv6buIqa5hkg_6_2"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">278482</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2019_us-gaap_PlanNameAxis_ptgx_InducementStockPlanMember_uV2sRVuEEkSt7OepkbYJpA"
      decimals="2"
      id="Tc_WgU04RXzpkC2ZW-dXFefMA_6_5"
      unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q">10.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_ptgx_InducementStockPlanMember_yAEykxLHsUSSNG0CUEUjkA"
      decimals="INF"
      id="Tc_xUp3gcLE8UamFiE63_RoXw_7_2"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">142000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_ptgx_InducementStockPlanMember_yAEykxLHsUSSNG0CUEUjkA"
      decimals="2"
      id="Tc_7apuYa5ZMUG5cIyx72Dm2w_7_5"
      unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q">7.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_ptgx_InducementStockPlanMember_yAEykxLHsUSSNG0CUEUjkA"
      decimals="INF"
      id="Tc_geEVAGDyYkman6-bV65E7Q_8_2"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">131147</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_ptgx_InducementStockPlanMember_yAEykxLHsUSSNG0CUEUjkA"
      decimals="2"
      id="Tc__vdVelPjrEGA42YpfdQwFA_8_5"
      unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q">9.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_ptgx_InducementStockPlanMember_yAEykxLHsUSSNG0CUEUjkA"
      decimals="INF"
      id="Tc_VJISjr3Xkkm6-QNGZJeYjw_9_2"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">44790</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_ptgx_InducementStockPlanMember_yAEykxLHsUSSNG0CUEUjkA"
      decimals="2"
      id="Tc_1Whr0C43ZkOi11LcxkMMIw_9_5"
      unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q">8.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_ptgx_InducementStockPlanMember_KE5aREx68U2i_cgMV6Pj_A"
      decimals="INF"
      id="Tc_FZe23UaPzkuD9p04uXEHPw_10_2"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">244545</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_ptgx_InducementStockPlanMember_KE5aREx68U2i_cgMV6Pj_A"
      decimals="2"
      id="Tc_08bI1niOWUy5z-HQeC5Gnw_10_5"
      unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q">9.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_7_31_2016_us-gaap_PlanNameAxis_ptgx_EmployeeStockPurchasePlan2016Member_nIsT07dVFEyHghpDxZtPUg"
      decimals="INF"
      id="Narr_hEM8NEuNmECi2IIheA3fDA"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <ptgx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_ptgx_EmployeeStockPurchasePlan2016Member_4XSs44uQyEamm2z9D2PFFQ"
      decimals="2"
      id="Narr_o7jwgLSTZEic1HTgswZwQg"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.01</ptgx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum>
    <ptgx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualNumberOfAdditionalSharesAuthorized
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_ptgx_EmployeeStockPurchasePlan2016Member_4XSs44uQyEamm2z9D2PFFQ"
      decimals="INF"
      id="Narr_z_JVwdXPpkufx2ji48rzAw"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">300000</ptgx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_ptgx_EmployeeStockPurchasePlan2016Member_U56QTHCCKEa3NKcZoAUUQw"
      decimals="2"
      id="Narr_ux4VRD4Mc02QDKJe4rWFkA"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_ptgx_EmployeeStockPurchasePlan2016Member_4XSs44uQyEamm2z9D2PFFQ"
      decimals="2"
      id="Narr_rIxykZnVdkKHttV9yBsUag"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_PlanNameAxis_ptgx_EmployeeStockPurchasePlan2016Member_GMhjmWwDW0OtNx4nu-iZpQ"
      decimals="INF"
      id="Narr_BGb1jC4BSUS4m1Qtqj8Kgw"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">92523</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2019_us-gaap_PlanNameAxis_ptgx_EmployeeStockPurchasePlan2016Member_C-KW8xTQ90aKeamFtuPrNQ"
      decimals="INF"
      id="Narr__4gjURJItUWeiTXP2uDc1A"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">757647</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_62ZwKcYzp0eJm6qW-U5FhA"
      id="Tb_4wfQ09l-AU6QMXCw6U0Owg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.4488411%;padding-left:0pt;padding-right:0pt;width:100.89%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:41.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8.15pt;"&gt;&lt;td style="vertical-align:bottom;width:57.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:57.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.35pt 0pt 0pt;"&gt;0.50&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.50&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.50&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;89.1% - 120.4%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;58.9% - 65.3%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;49.0% - 63.4%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:57.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate &lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;0.12% - 0.43%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;1.89% - 2.32%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;1.89% - 2.32%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Dividend yield &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_62ZwKcYzp0eJm6qW-U5FhA"
      id="Tc_ovNSAFRBuE6RbAV57e-jLQ_3_2">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_pgiKOe1_8Ey6gxPzOimNvw"
      id="Tc_NxKXaDb9aUemxvtX94O2_A_3_4">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_-b9HV2D17EWHTYX42MHUeg"
      id="Tc_SwVUhEuR9kepYA9Kuyxw1g_3_6">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_62ZwKcYzp0eJm6qW-U5FhA"
      decimals="3"
      id="Narr_NrX036nimkizhQvYHCC_SQ"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.891</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_62ZwKcYzp0eJm6qW-U5FhA"
      decimals="3"
      id="Narr__d6jdEmIxkySsfqkI-62jw"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">1.204</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_pgiKOe1_8Ey6gxPzOimNvw"
      decimals="3"
      id="Narr_LoOc6AcbrEOGZkYVdU41mQ"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.589</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_pgiKOe1_8Ey6gxPzOimNvw"
      decimals="3"
      id="Narr_DZWHeMm5d0evTPWw3neNnQ"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.653</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_-b9HV2D17EWHTYX42MHUeg"
      decimals="3"
      id="Narr_J6bL926TNkul7sj_weHIYg"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.490</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_-b9HV2D17EWHTYX42MHUeg"
      decimals="3"
      id="Narr_VLBqOHlsdkW18vhk1Kqnnw"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.634</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_62ZwKcYzp0eJm6qW-U5FhA"
      decimals="4"
      id="Narr_powMWO0-5kWu53hNzdGZIA"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.0012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_62ZwKcYzp0eJm6qW-U5FhA"
      decimals="4"
      id="Narr_5QphBkV-3kuYaKn_zhRbBw"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.0043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_pgiKOe1_8Ey6gxPzOimNvw"
      decimals="4"
      id="Narr_5Uhz3MBNK0W29isDHbHqjg"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.0189</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_pgiKOe1_8Ey6gxPzOimNvw"
      decimals="4"
      id="Narr_gbpw-9bHdUaoBtGJPjLaDA"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.0232</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_-b9HV2D17EWHTYX42MHUeg"
      decimals="4"
      id="Narr_eMKiUUykqkKj7kp9B3CIBg"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.0189</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_-b9HV2D17EWHTYX42MHUeg"
      decimals="4"
      id="Narr_7yXvSWrEI02FrgiNiZ2lNg"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.0232</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_d3AAhbsHBk2jpQdAYq3dZQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Total stock-based compensation expense was as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:38.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:59.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,121&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,350&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,424&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,778&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,003&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,495&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:59.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,899&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,353&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,919&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_xH_J2AHGC0KEIm_y_jQVKg"
      decimals="-3"
      id="Tc_7VOmFWMF1EyEHUA2TY63fw_3_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">4121000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_S8RyftvJ9k2sDQkwn9INpg"
      decimals="-3"
      id="Tc_x-2lqupB4UGLYg4hqGwmgg_3_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">4350000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_5KLlildJr02InYyNq32knQ"
      decimals="-3"
      id="Tc_gZkDV7RC60uCEr2oWofp_w_3_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">3424000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_4LOUmK3YM0qXjTWQBtwesw"
      decimals="-3"
      id="Tc_tezJ8IxFvkG1TTGbaDGY4w_4_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">3778000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_hCAO4XqfOUC_Xr8C0zgyIQ"
      decimals="-3"
      id="Tc_93RmFqsG1U-mN-1SmHCNIw_4_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">4003000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_5l8l7REXdEuTVwF8ShcykQ"
      decimals="-3"
      id="Tc_DJ2dWzg8tE-bBbkZ92j50Q_4_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">3495000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_4JNgPxO590yk_2OJc7YKng_5_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">7899000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_UPRy20fYsEClsMCh9Rlj0A_5_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">8353000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_58sfIx-_aUaSt8LirxNTtw_5_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">6919000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-5"
      id="Narr_wajD7_kt6EO4ij1yQOxXzQ"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">16000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Narr_po6WNcXlhkqvneMyHNaLpw">P2Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_iGaGOE_4GUSI7eApWM8Zdg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Note 14.&#160;&#160;&#160;&#160;401(k)&#160;Plan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has a retirement and savings plan under Section&#160;of 401(k)&#160;of Internal Revenue Code (the &#x201c;401(k)&#160;Plan&#x201d;) covering all U.S. employees. The 401(k)&#160;Plan allows employees to make pre- and post-tax contributions up to the maximum allowable amount set by the Internal Revenue Service. For the years ended December 31, 2020, 2019 and 2018, the Company did not make matching contributions to the 401(k)&#160;Plan on behalf of participants.&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_CDfMhl9Ly0qZiAaYDrXM3w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Note 15.&#160;&#160;&#160;&#160;Income Taxes &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recorded income tax expense of $1.3 million for the year ended December 31, 2020. During the second quarter of 2020, the Company&#x2019;s Australia subsidiary sold beneficial rights to discovery intellectual property to its U.S. entity, and the U.S. entity reimbursed the Australia subsidiary for certain direct development costs. Upon completion of the sale, the Company analyzed tax planning strategies and future income and concluded that a full valuation allowance is necessary for its Australia subsidiary. Income tax expense for the year ended December 31, 2020 reflects this sale of intellectual property rights, cost reimbursements and related adjustments to the deferred tax asset, establishing a valuation allowance and certain uncertain unrecognized tax benefits. The Company continues to maintain a full valuation allowance against its U.S. net deferred tax assets due to the uncertainty surrounding the realization of such assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recorded an income tax benefit of $0.7 million for the year ended December 31, 2019 primarily due to research and development tax credits and the recognition of deferred tax assets in Protagonist Australia. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recorded an income tax benefit of $0.8 million for the year ended December 31, 2018 from the recognition of deferred tax assets in Protagonist Australia. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table presents domestic and foreign components of net loss before income taxes (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:43.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:54.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:43.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Domestic&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (71,073)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (72,271)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (37,511)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,228&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,607)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,212)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:43.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Total net loss before taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (64,845)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (77,878)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (39,723)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The federal, state and foreign components of the income tax expense (benefit) are summarized as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:38.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Current:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;State &lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (88)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total current tax (benefit) expense&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (88)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="text-decoration:underline;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="text-decoration:underline;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="text-decoration:underline;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="text-decoration:underline;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,393&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (775)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (799)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total deferred tax expense (benefit)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,393&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (775)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (799)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total income tax expense (benefit)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,305&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (691)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (799)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The effective tax rate of the provision for income taxes differs from the federal statutory rate as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:60.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Federal statutory income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:60.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development credits&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.5&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.3&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Foreign tax rate difference&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:60.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (34.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (23.8)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (22.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:60.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Provision (benefit) for income taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.9&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.0&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The components of the deferred tax assets are as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 50,272&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39,907&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,237&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 318&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Accruals/other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,332&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,454&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Operating lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,252&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,516&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Research and development and foreign credits&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,856&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,038&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 72,949&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 55,233&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Operating right-of-use asset&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,040)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="text-decoration:underline;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,269)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,040)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,269)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (71,909)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (52,531)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,433&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Realization of the deferred tax assets is dependent upon future taxable income, if any, the amount and timing of which are uncertain. The Company has established a valuation allowance to offset U.S. deferred tax assets as of December&#160;31, 2020, 2019 and 2018 due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets. The Company has also established a valuation allowance to offset Australian deferred tax assets as of December 31, 2020. The valuation allowance increased by approximately $19.4 million, $18.5 million and $8.2 million during the&#160;years ended December&#160;31, 2020, 2019 and 2018, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;Federal and state laws impose substantial restrictions on the utilization of net operating loss and tax credit carryforwards in the event of an ownership change for tax purposes, as defined in Section&#160;382 of the Internal Revenue Code. As a result of such ownership changes, the annual limitation may result in the expiration of net operating losses and credits before utilization. The Company performed a Section 382 analysis through December 31, 2020. The Company has experienced ownership changes in the past and in the current year. The ownership changes will not result in a limitation that will materially reduce the total amount of net operation loss carryforwards and credits that can be utilized. Subsequent ownership changes may affect the limitation in future years. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;At December&#160;31, 2020, the Company had $222.8 million of federal net operating loss carryforwards and $214.3 million of state net operating loss carryforwards. $78.7 million of the federal net operating loss carryforwards will begin to expire in 2033, if not utilized, and the remaining $144.1 million have no expiration. The state net operating loss carryforwards will begin to expire in 2035, if not utilized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;At December&#160;31, 2020, the Company also had accumulated Australian tax losses of AUD 3.7 million ($2.8 million) available for carry forward against future earnings which, under relevant tax laws, do not expire but may be limited under certain circumstances. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2020, the Company had $12.3 million of federal and $4.8 million of state research and development tax credit carryforwards available to reduce future income taxes. The federal research and development tax credits will begin to expire in 2035, if not utilized. The state research and development tax credits have no expiration date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2020, the Company had AUD 3.6 million ($2.8 million) of Australian research and development tax credit carryforwards available to reduce future income taxes. The Australian research and development tax credits have no expiration date. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:55.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:43.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:55.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Balance at beginning of year&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,631&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,466&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,414&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;(Decreases) increases based on tax positions related to prior years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,799)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 184&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 108&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:55.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Increases based on tax positions related to current year&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,053&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,981&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,944&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Balance at end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,885&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,631&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,466&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;At December 31, 2020, the Company had unrecognized tax benefits of $19.9 million, which are subject to a valuation allowance and would not affect the effective tax rate if recognized. The Company does not anticipate that the total amounts of unrecognized tax benefits will significantly increase or decrease in the next 12 months. The Company&#x2019;s policy is to include interest and penalties related to unrecognized tax benefits within the provision for income taxes, as necessary. Management determined that no accrual for interest or penalties was required as of December 31, 2020, 2019 and 2018.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company files income tax returns in the United States federal jurisdiction, the State of California and Australia. The Company is not currently under examination by income tax authorities in federal, state or other jurisdictions. The Company&#x2019;s tax returns remain open for examination for all years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.5pt;margin:0pt;"&gt;The Company&#x2019;s Australia subsidiary had an accumulated deficit at December 31, 2020 and, accordingly, no provision has been provided thereon for any unremitted earnings.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.5pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt;"&gt;The Company has elected to recognize any potential global intangible low-taxed income (&#x201c;GILTI&#x201d;) obligation as an expense in the period it is incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;2020 Tax Law Updates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt 0pt 12pt 0pt;"&gt;On March 27, 2020, the Coronavirus Aid, Relief and Economic Security Act (&#x201c;CARES Act&#x201d;) was enacted and signed into law in response to the COVID-19 pandemic. GAAP requires recognition of the tax effects of new legislation during the reporting period that includes the enactment date. The CARES Act includes changes to the tax provisions that benefits business entities and makes certain technical corrections to the 2017 Tax Cuts and Jobs Act. The tax relief measures for businesses include a five-year net operating loss carryback, suspension of the annual deduction limitation of 80% of taxable income from net operating losses generated in a tax year beginning after December 31, 2017, changes in the deductibility of interest, acceleration of alternative minimum tax credit refunds, payroll tax relief, technical corrections on net operating loss carryforwards for fiscal year taxpayers and allows accelerated deduction qualified improvement property. The CARES Act also provides other non-tax benefits to assist those impacted by the pandemic.&#160;The Company evaluated the impact of the CARES Act and determined that there is no material impact to the for the year ended December 31, 2020. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt 0pt 12pt 0pt;"&gt;On June 29, 2020, California Assembly Bill 85 was signed into law. The legislation suspends the California net operating loss deductions for 2020, 2021, and 2022 for certain taxpayers and imposes a limitation of certain California tax credits for 2020, 2021, and 2022. The legislation disallows the use of California net operating loss deductions if the taxpayer recognizes business income and its adjusted gross income is greater than $1,000,000. The carryover periods for net operating loss deductions disallowed by this provision will be extended. Additionally, any business credit will only offset a maximum of $5,000,000 of California tax. Given the Company&#x2019;s loss position in the current year, the new legislation will not impact the current year provision. The Company will continue to monitor possible California net operating loss and credit limitations in future periods.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt 0pt 12pt 0pt;"&gt;On December 27, 2020, the Consolidated Appropriations Act, 2021 was signed into law, including further COVID-19 economic relief and the extension of certain expiring tax provisions. The relief package includes a tax provision clarifying that businesses with forgiven Paycheck Protection Program loans can deduct regular business expenses that are paid for with the loan proceeds. Additional pandemic relief tax measures include an expansion of the employee retention credit, enhanced charitable contribution deductions, and a temporary full deduction for business expenses for food and beverages provided by a restaurant. The provisions are not impactful for the Company as it has not participated in previous COVID-19 economic relief measures. &lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-5"
      id="Narr_47NRyzi2ykG71fZaQi2CEw"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-5"
      id="Narr_JefCnDJASkCA7azqVUTL1g"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-700000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-5"
      id="Narr_GXi4eEKlnkCfCuMKauz7aw"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_-CLo7DPv40Slme6MyLPwlA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table presents domestic and foreign components of net loss before income taxes (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:43.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:54.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:43.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Domestic&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (71,073)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (72,271)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (37,511)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,228&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,607)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,212)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:43.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Total net loss before taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (64,845)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (77,878)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (39,723)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_q3XVghNxFEaTenS_t-dEFA_3_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-71073000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_d3nVNCHexEmjhXom_XGTng_3_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-72271000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_Syev0k7SGk6gbRRKmq7g6w_3_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-37511000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_OkHM-uIa70K9M-bNbWg7zw_4_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">6228000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_U_CU8_07XUmdmUqulJSFNA_4_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-5607000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc__b21wqnxskO6pTL5CjFXVQ_4_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-2212000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_rI0vwCLYhkGchD8WpaNdZQ_5_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-64845000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_gKP-CQJCNUmhWeZqJpTd2Q_5_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-77878000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc__8FAFAtqZkeMsXvk543vWg_5_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-39723000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_yFY-iMB4G06iN0bVv3LEyA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:38.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Current:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;State &lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (88)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total current tax (benefit) expense&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (88)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="text-decoration:underline;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="text-decoration:underline;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="text-decoration:underline;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="text-decoration:underline;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,393&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (775)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (799)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total deferred tax expense (benefit)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,393&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (775)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (799)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total income tax expense (benefit)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,305&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (691)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (799)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_KL35RjJlXUmmxERSpgm2dg_6_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-88000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_4nV4mZUAi0W8KIYSGnwDow_6_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">84000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_RbsYUccwj02iMwr64nNOYQ_7_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-88000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_SlEeJLeO7Ea-UhmGb7d1hg_7_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">84000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_YJZderFT70qYi98SMdJC7g_11_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1393000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_jpMRAIw7QEC1X3mAXIWMfQ_11_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-775000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_72zWICAtW0e5HjEHnkxATQ_11_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-799000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_qzwdsAsOdkOLBi5DQ1To0g_12_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1393000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_FJsHqAFjfEK7XpjyTOlkgA_12_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-775000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_-QpA3rNnWkWyR15WecjlAw_12_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-799000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_hB---8PHn0mcff3e872-xg_13_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1305000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_CfF5mrjGHEyT9hBlsRX-4w_13_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-691000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_c2w0D8jo6EuEEgKRTEvapQ_13_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-799000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_jBWG7vHRnUqB7rFjRoJjMw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:60.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Federal statutory income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:60.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development credits&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.5&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.3&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Foreign tax rate difference&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:60.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (34.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (23.8)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (22.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:60.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Provision (benefit) for income taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.9&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.0&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="3"
      id="Tc_3Sqa9RRX-kqU4t7rLgi1qw_3_2"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="3"
      id="Tc_pCCsQ8gU7kSxViBtpr_FDA_3_4"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="3"
      id="Tc_Sz-69TXb0kqZHE-4CHDKpg_3_6"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="3"
      id="Tc_vpXb2_yIrUWI46QQcfmAjw_4_2"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.019</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="3"
      id="Tc_ivZhBAtdMkiLPOzq30Rjvg_4_4"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="3"
      id="Tc_Ht5MnX_530aaCF1vBsbKCQ_4_6"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.070</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <ptgx:EffectiveIncomeTaxRateReconciliationTaxCreditResearchAdjustmentPercent
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="3"
      id="Tc_eoH_mSgkYkSuFadGBbbTTQ_5_2"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.065</ptgx:EffectiveIncomeTaxRateReconciliationTaxCreditResearchAdjustmentPercent>
    <ptgx:EffectiveIncomeTaxRateReconciliationTaxCreditResearchAdjustmentPercent
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="3"
      id="Tc_EfhxICXnYkeAPclaD3dJzw_5_4"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.043</ptgx:EffectiveIncomeTaxRateReconciliationTaxCreditResearchAdjustmentPercent>
    <ptgx:EffectiveIncomeTaxRateReconciliationTaxCreditResearchAdjustmentPercent
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="3"
      id="Tc_ix8x-Eka8EyqDpxTYaqIkQ_5_6"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">-0.013</ptgx:EffectiveIncomeTaxRateReconciliationTaxCreditResearchAdjustmentPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="3"
      id="Tc_L73IzP8wBU20ICieElA1Qw_6_2"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">-0.009</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="3"
      id="Tc_5MbPQOB7z0iREaxY1XLAoQ_6_4"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="3"
      id="Tc_v-8mR2x0mEaK_fNVnyW3JA_6_6"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="3"
      id="Tc_8M7rHnevP0uaKwWKRWkJXw_7_2"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">-0.343</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="3"
      id="Tc_0G_CRRe3_Uu1w15lUaWPag_7_4"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">-0.238</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="3"
      id="Tc_A55B2hlSXUSdS1peJm1uVA_7_6"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">-0.222</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="3"
      id="Tc_SRj39eprEkWjG3fLxi_kQQ_8_2"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.038</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="3"
      id="Tc_HE5Ewrx3Q0qJl780F542hQ_8_4"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">-0.025</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="3"
      id="Tc_KOQZpVulL0CB8y61IpK7mA_8_6"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">-0.029</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="3"
      id="Tc_T86GK1SJYUK8p1ra2Go0Hg_9_2"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">-0.020</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="3"
      id="Tc_FEz0WQJ0bUSn_8qFj7Y0bQ_9_4"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.009</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="3"
      id="Tc_Kqwl_hqe2EmpY7N48xu7NA_9_6"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.020</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_52vPCAU780SDhz-MGgj-hA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The components of the deferred tax assets are as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 50,272&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39,907&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,237&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 318&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Accruals/other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,332&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,454&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Operating lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,252&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,516&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Research and development and foreign credits&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,856&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,038&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 72,949&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 55,233&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Operating right-of-use asset&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,040)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="text-decoration:underline;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,269)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,040)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,269)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (71,909)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (52,531)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,433&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_X7Of-0KuWk-e3Dp1iPA1Eg_4_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">50272000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_BO5pLOTyKEuzceXzwxTMLg_4_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">39907000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_pN_XlT981Uy07_yqB74IPg_5_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1237000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_Oglam1V0tUOKCXF3QhHp0w_5_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">318000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <ptgx:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_IkfzGzpIdkyrQFQ09ci2Cw_6_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">5332000</ptgx:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther>
    <ptgx:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_ciOUZsGQoUCjMPUQj6mAQg_6_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">5454000</ptgx:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther>
    <ptgx:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_NNijLz9r8UqYC1JP1T4BvQ_7_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1252000</ptgx:DeferredTaxAssetsOperatingLeaseLiability>
    <ptgx:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_xQXDGl-I6Um9cpY2cnv7RQ_7_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1516000</ptgx:DeferredTaxAssetsOperatingLeaseLiability>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_P1sRkEqT9kis3xfrmp9NSQ_8_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">14856000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_r9uFWf02SUa10GlAgF40Ag_8_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">8038000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_0gRtn0wZyE6nbZDkQF5dQg_9_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">72949000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_s1dKpx3jrESQgcZYe6px1Q_9_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">55233000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_QoRmHw-zLUGEVEZOmFGmgg_11_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1040000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_8WfSWde3QEyaa5K61vniFQ_11_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1269000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_saAJtVYz9EO_pJOpKEZVog_12_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1040000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_e15U8EuMwE6H8xTEq8RgxA_12_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1269000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_rXhAZQOmJkCpN-bgZ50zbw_13_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">71909000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_Smh1ILbxx0K3x-jvDjY6cA_13_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">52531000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_nb08MUP7q0Coqykh_j9KlA_14_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1433000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-5"
      id="Narr_zuD535QS6k6HxdP2gPmALg"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">19400000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-5"
      id="Narr_Ln2bQzn9p0SH9qFxyoBoyA"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">18500000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-5"
      id="Narr_47Tn64QD5UClezy4ubIw2w"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">8200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_1DfwcEBf-ECRIZv8PZ8Rdw"
      decimals="-5"
      id="Narr_-piJR_KaSEaXRTbsENV7mw"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">222800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_U65aTwB6ukC7yChGSORF8Q"
      decimals="-5"
      id="Narr_FQupL5ibNEa4_WjzjrRp1w"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">214300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_1DfwcEBf-ECRIZv8PZ8Rdw"
      decimals="-5"
      id="Narr_INiK0ziH8UuOu35dW4g8Ug"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">78700000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <ptgx:OperatingLossCarryforwardsNoExpiration
      contextRef="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_1DfwcEBf-ECRIZv8PZ8Rdw"
      decimals="-5"
      id="Narr_GA2nb_76wEugtu7IO2FCZg"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">144100000</ptgx:OperatingLossCarryforwardsNoExpiration>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_hYnmxupXL0yNnBeGNa_apA"
      decimals="-5"
      id="Narr_zywcS6RomUmYRjWEKV0-GQ"
      unitRef="Unit_Standard_AUD_SNsUSUMs1k6MNx0ouGjszw">3700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_hYnmxupXL0yNnBeGNa_apA"
      decimals="-5"
      id="Narr_MNd-oWvHjUq-8s6RNgCwzg"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">2800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_gRii_fhTDk-huJXJ4UdCVQ"
      decimals="-5"
      id="Narr_aa4Eay2LfEGqX2goatA2QQ"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">12300000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_8i0o-skGv0azxibqP5J0Sw"
      decimals="-5"
      id="Narr_Tj4ZYT9ZBUS16TVG-byk7A"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">4800000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_l4fVgIKvNUamq8cgrPWShQ"
      decimals="-5"
      id="Narr_7YDbeLayKUei14zLiE03iQ"
      unitRef="Unit_Standard_AUD_SNsUSUMs1k6MNx0ouGjszw">3600000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_l4fVgIKvNUamq8cgrPWShQ"
      decimals="-5"
      id="Narr_DkPo9xH2u0yFoFVavnUlog"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">2800000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_AIlZW7EkD0OGxodxYDLEQA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:55.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:43.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:55.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Balance at beginning of year&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,631&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,466&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,414&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;(Decreases) increases based on tax positions related to prior years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,799)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 184&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 108&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:55.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"&gt;Increases based on tax positions related to current year&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,053&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,981&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,944&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Balance at end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,885&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,631&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,466&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_2kMYLF8Lfk26vcIrcaYkVQ_3_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">16631000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2018_rK3dysi-wkKgewxxLVB-Eg"
      decimals="-3"
      id="Tc_cUKHYPw0XU2S1tsTDUtZLQ_3_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">9466000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2017_uBPncpspM02T8SbWW1EWfg"
      decimals="-3"
      id="Tc_6hUU1T166UyRxD5X6hqJJA_3_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">5414000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_hTpmwYpb3EmEYVsUpyKopQ_4_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">3799000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_kvs63WmAWEuAQIgJwahH8w_4_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">184000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_nw8q_C_RO0emTDpBj7slvw_4_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">108000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_woWLc89ZdkSOIvrCG_FWlQ_5_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">7053000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_M1wRgHe1OUSybNqqQWvrjA_5_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">6981000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_pu0HquGtSE69fSWb1rwV2w_5_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">3944000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-3"
      id="Tc_WrOCbvSOak-Pr7N5n4uLdA_6_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">19885000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-3"
      id="Tc_i-Bnl8GnYUupKIGdIyGVyw_6_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">16631000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2018_rK3dysi-wkKgewxxLVB-Eg"
      decimals="-3"
      id="Tc_uJvnvHtZMkaNNAcpmZPeRg_6_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">9466000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-5"
      id="Narr_oa5ww8Kx0kmcMok95WpO4w"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">19900000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="As_Of_12_31_2018_rK3dysi-wkKgewxxLVB-Eg"
      decimals="-5"
      id="Narr_UZ1NCEIdBEa8yKyhAJ-eFQ"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q"
      decimals="-5"
      id="Narr_fZOBz2fVBUG1-3RaHOTX-g"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA"
      decimals="-5"
      id="Narr__TlpEm8QiUm9SlllkIHuXQ"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_g6Lfapz3kUapxhOM2FxjaQ"
      decimals="-5"
      id="Narr_py-uj-3tdke80w3tYUHNyg"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">0</us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations>
    <ptgx:NetOperatingLossCarryback
      contextRef="Duration_3_27_2020_To_3_27_2020_d48ZoY7v8UOWrUfq_VZsYw"
      id="Narr_S4shBuUGAkOI0v6gY99PLw">P5Y</ptgx:NetOperatingLossCarryback>
    <ptgx:DeductionOfTaxableIncomePercentage
      contextRef="Duration_3_27_2020_To_3_27_2020_d48ZoY7v8UOWrUfq_VZsYw"
      decimals="2"
      id="Narr_fqRNpONUuUWAR8TFxHf6nQ"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.80</ptgx:DeductionOfTaxableIncomePercentage>
    <ptgx:CaliforniaNetOperatingLossDeductionsLimitOfIncome
      contextRef="Duration_6_29_2020_To_6_29_2020_UccmW4dFl06gNFN5lNnw9A"
      decimals="0"
      id="Narr_EQH_p4yjEEOjF59CyzGmdA"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">1000000</ptgx:CaliforniaNetOperatingLossDeductionsLimitOfIncome>
    <ptgx:MaximumOffsetOfCaliforniaTax
      contextRef="Duration_6_29_2020_To_6_29_2020_UccmW4dFl06gNFN5lNnw9A"
      decimals="0"
      id="Narr_guAkYgY-TkGvwKI_PvUEUA"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">5000000</ptgx:MaximumOffsetOfCaliforniaTax>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_houPp3FujkyhMBuB-V6zfg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Note 16.&#160;&#160;&#160;&#160;Net Loss per Share &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;As the Company had a net loss for the&#160;years ended December&#160;31, 2020, 2019 and 2018, all potential common shares were determined to be anti-dilutive. The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per share data):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:57.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Net loss &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (66,150)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (77,187)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (38,924)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:57.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Weighted-average shares used to compute net loss per common share, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 34,396,446&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25,894,024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,364,515&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:57.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net loss per shares, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.92)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.98)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.74)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;The following outstanding shares of potentially dilutive securities have been excluded from diluted net loss per share calculations for the&#160;years ended December&#160;31, 2020, 2019 and 2018 because their inclusion would be anti-dilutive:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,648,120&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,681,521&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,178,441&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Common stock warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,750,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,750,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,750,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 244,545&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 278,482&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 418,450&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;ESPP shares&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,445&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40,275&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52,134&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,671,110&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,750,278&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,399,025&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_No_RmR1-vUGXQmJcU1sW_Q">&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:57.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Net loss &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (66,150)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (77,187)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (38,924)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:57.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Weighted-average shares used to compute net loss per common share, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 34,396,446&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25,894,024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,364,515&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:57.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net loss per shares, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.92)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.98)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.74)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="-3"
      id="Tc_tBhMF7TjgUm_Wl0cdn8VPA_4_3"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-66150000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="-3"
      id="Tc_n27n_SsXVk2BCVXfK6aRPg_4_6"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-77187000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="-3"
      id="Tc_2V0NDJ7yeES3YnV6rE0yPg_4_9"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">-38924000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="0"
      id="Tc_W8l6C1nfdE-oJ-3YY5kocA_6_3"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">34396446</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="0"
      id="Tc_DZTjezo5WUC-AfECoQ3G7w_6_6"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">25894024</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="0"
      id="Tc_6YxNxAOAu0i3N4blJXmfag_6_9"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">22364515</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="2"
      id="Tc_9st-M-t0hEqtm1yRffRYaw_7_3"
      unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q">-1.92</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="2"
      id="Tc_5SG3n3-AU02VlmOrwJe-Vg_7_6"
      unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q">-2.98</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="2"
      id="Tc_wRkF2cLr5kSMIVgD0WTbCg_7_9"
      unitRef="Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q">-1.74</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_itDi3U8chE6Kt9q94qx1tQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,648,120&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,681,521&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,178,441&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Common stock warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,750,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,750,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,750,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 244,545&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 278,482&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 418,450&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;ESPP shares&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,445&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40,275&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52,134&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,671,110&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,750,278&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,399,025&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_EAbWdmtN8E-9JmN6JhqI_w"
      decimals="INF"
      id="Tc_ozLxvF4KI0WNeGPlL8eaZg_3_2"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">4648120</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_ooH8n7lz1E2xsje_V6E6Pg"
      decimals="INF"
      id="Tc_MuH_vSZ5VkeXlTF0PHOcdQ_3_4"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">3681521</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_WaiBERwpsUS_GxNwwF2grw"
      decimals="INF"
      id="Tc_NY85_1viaUKJw9Zy-UMfpw_3_6"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">3178441</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_NoteWarrantMember_Dh7N5o3ASEqLQ1SQSZ-iVA"
      decimals="INF"
      id="Tc_vBVk3CtOm0exqWb7W0jEfg_4_2"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">2750000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_NoteWarrantMember_hBQwDx7S2ku26XmUy_6zMQ"
      decimals="INF"
      id="Tc_miyu2JMRxkKgRPOoo649Mg_4_4"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">2750000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_NoteWarrantMember_Ho8wL7fGKESaYVujfGx0mg"
      decimals="INF"
      id="Tc_AUauPKIvt0ClTQJHaltvVQ_4_6"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">2750000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_j8Vx4K3ol0uyTIToUJMT7g"
      decimals="INF"
      id="Tc_E4KF5T23WUawg0Qdrvqp6Q_5_2"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">244545</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_YwszWFT2W0SpYFDZtJaxqg"
      decimals="INF"
      id="Tc_X9WbJEuzLkKDEI7FHvOrQQ_5_4"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">278482</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_Ncd5mq0QL0CQQWUc-ElGVw"
      decimals="INF"
      id="Tc_KaLxYVj4XU6ULIJqksaFng_5_6"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">418450</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember_NJHZZccCf0a0YBEfSxOf_Q"
      decimals="INF"
      id="Tc_bzr4yb19L0Kb90ZAU9BPVg_6_2"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">28445</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember_bPuHxQjxo0m7NoN0XMxgBA"
      decimals="INF"
      id="Tc_Z149d0ah2keFqwmqi5_qCg_6_4"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">40275</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember_kEHM0bCdFEWZb0Y5aC4cvw"
      decimals="INF"
      id="Tc_O4Q_1T1Mw06NaNvMDE7FRw_6_6"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">52134</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      decimals="INF"
      id="Tc_VSHDrh7qkEG1ln4AYSzd6w_7_2"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">7671110</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2019_To_12_31_2019_E4_sP1QmdUSye-i68sy_VQ"
      decimals="INF"
      id="Tc_vJpBE80jUUmLfdrYK0yuAw_7_4"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">6750278</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2018_To_12_31_2018_QUQ_MzoB8UOuSpuTN9lWsw"
      decimals="INF"
      id="Tc_LbgRZN_7VEmccUBQ2fxFBw_7_6"
      unitRef="Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA">6399025</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA"
      id="Tb_wdmphprohkGaMcY6oXeKfQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Note 17.&#160;&#160;&#160;&#160;Restructuring &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"&gt;On May 7, 2020, the Company approved a limited reduction in force plan affecting approximately 12% of the Company&#x2019;s employee base and informed the affected employees. The reduction-in-force plan was completed by the end of the second quarter of 2020. Total cash expenditures for the reduction in force plan were $0.3 million, substantially all of which were related to employee severance and benefits costs.&lt;/p&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <ptgx:PercentageOfEmployeeBaseImpactedByRestructuringPlan
      contextRef="Duration_3_7_2020_To_3_7_2020_OZuW7QpORUGdPGLaaZ6w3Q"
      decimals="2"
      id="Narr_GOoaV7aAe0mB-EVeJE7UgQ"
      unitRef="Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg">0.12</ptgx:PercentageOfEmployeeBaseImpactedByRestructuringPlan>
    <us-gaap:RestructuringCharges
      contextRef="Duration_3_7_2020_To_3_7_2020_OZuW7QpORUGdPGLaaZ6w3Q"
      decimals="-5"
      id="Narr_DyIjtJO_UUizHG-Hww9KSg"
      unitRef="Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg">300000</us-gaap:RestructuringCharges>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681426417544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 26, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document And Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PROTAGONIST THERAPEUTICS,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0505495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7707 Gateway Boulevard, Suite 140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Newark<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">474-0170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.00001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PTGX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 640.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,808,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001377121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681355150872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 117,358<span></span>
</td>
<td class="nump">$ 33,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">188,451<span></span>
</td>
<td class="nump">100,011<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash - current</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Receivable from collaboration partner and contract asset - related party</a></td>
<td class="nump">2,426<span></span>
</td>
<td class="nump">6,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Research and development tax incentive receivable</a></td>
<td class="nump">1,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">6,277<span></span>
</td>
<td class="nump">5,529<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">315,606<span></span>
</td>
<td class="nump">145,311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities - noncurrent</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,462<span></span>
</td>
<td class="nump">1,681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash - noncurrent</a></td>
<td class="nump">450<span></span>
</td>
<td class="nump">450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">4,950<span></span>
</td>
<td class="nump">6,042<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,433<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">324,468<span></span>
</td>
<td class="nump">154,917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,075<span></span>
</td>
<td class="nump">2,790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Payable to collaboration partner - related party</a></td>
<td class="nump">2,732<span></span>
</td>
<td class="nump">1,262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities', window );">Accrued expenses and other payables</a></td>
<td class="nump">18,498<span></span>
</td>
<td class="nump">12,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue - related party - current</a></td>
<td class="nump">14,477<span></span>
</td>
<td class="nump">17,738<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability - current</a></td>
<td class="nump">1,459<span></span>
</td>
<td class="nump">1,256<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">40,241<span></span>
</td>
<td class="nump">35,406<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue - related party - noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,792<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability - noncurrent</a></td>
<td class="nump">4,500<span></span>
</td>
<td class="nump">5,961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">44,862<span></span>
</td>
<td class="nump">74,953<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.00001 par value, 10,000,000 shares authorized; no shares issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.00001 par value, 90,000,000 shares authorized; 43,745,465 and 27,217,649 shares issued and outstanding as of December 31, 2020 and December 31, 2019, respectively</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">563,389<span></span>
</td>
<td class="nump">297,846<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive gain (loss)</a></td>
<td class="nump">28<span></span>
</td>
<td class="num">(221)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(283,811)<span></span>
</td>
<td class="num">(217,661)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">279,606<span></span>
</td>
<td class="nump">79,964<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 324,468<span></span>
</td>
<td class="nump">$ 154,917<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681354824456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Consolidated Balance Sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">90,000,000<span></span>
</td>
<td class="nump">90,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">43,745,465<span></span>
</td>
<td class="nump">27,217,649<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">43,745,465<span></span>
</td>
<td class="nump">27,217,649<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681354073576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_RevenueFromContractWithCustomerIncludingCumulativeCatchUpAdjustmentToRevenueModificationOfContract', window );">License and collaboration revenue - related party</a></td>
<td class="nump">$ 28,628<span></span>
</td>
<td class="nump">$ 231<span></span>
</td>
<td class="nump">$ 30,925<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">74,506<span></span>
</td>
<td class="nump">65,003<span></span>
</td>
<td class="nump">59,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">18,638<span></span>
</td>
<td class="nump">15,749<span></span>
</td>
<td class="nump">13,697<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">93,144<span></span>
</td>
<td class="nump">80,752<span></span>
</td>
<td class="nump">73,194<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(64,516)<span></span>
</td>
<td class="num">(80,521)<span></span>
</td>
<td class="num">(42,269)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">900<span></span>
</td>
<td class="nump">2,813<span></span>
</td>
<td class="nump">2,566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(598)<span></span>
</td>
<td class="num">(169)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early repayment of debt</a></td>
<td class="num">(585)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(46)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax (expense) benefit</a></td>
<td class="num">(64,845)<span></span>
</td>
<td class="num">(77,878)<span></span>
</td>
<td class="num">(39,723)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (expense) benefit</a></td>
<td class="num">(1,305)<span></span>
</td>
<td class="nump">691<span></span>
</td>
<td class="nump">799<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (66,150)<span></span>
</td>
<td class="num">$ (77,187)<span></span>
</td>
<td class="num">$ (38,924)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td>
<td class="num">$ (1.92)<span></span>
</td>
<td class="num">$ (2.98)<span></span>
</td>
<td class="num">$ (1.74)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares used to compute net loss per share, basic and diluted</a></td>
<td class="nump">34,396,446<span></span>
</td>
<td class="nump">25,894,024<span></span>
</td>
<td class="nump">22,364,515<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_RevenueFromContractWithCustomerIncludingCumulativeCatchUpAdjustmentToRevenueModificationOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, net, from satisfaction of performance obligation by transferring promised good or service to customer, including amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from contract modification. Amount includes tax collected from customer, if applicable. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_RevenueFromContractWithCustomerIncludingCumulativeCatchUpAdjustmentToRevenueModificationOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681350087128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Consolidated Statements of Comprehensive Loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (66,150)<span></span>
</td>
<td class="num">$ (77,187)<span></span>
</td>
<td class="num">$ (38,924)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Gain (loss) on translation of foreign operations</a></td>
<td class="nump">266<span></span>
</td>
<td class="num">(44)<span></span>
</td>
<td class="num">(322)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) gain on marketable securities</a></td>
<td class="num">(17)<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (65,901)<span></span>
</td>
<td class="num">$ (77,175)<span></span>
</td>
<td class="num">$ (39,151)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681348531336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Common Stock </div>
<div>At-the-market offering</div>
</th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>At-the-market offering</div>
</th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Gain (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>At-the-market offering</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, Beginning at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 222,188<span></span>
</td>
<td class="num">$ (6)<span></span>
</td>
<td class="num">$ (101,550)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,632<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,088,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="nump">151,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants', window );">Issuance of common stock and warrants upon private placement, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants', window );">Issuance of common stock and warrants upon private placement, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock upon under equity incentive and employee stock purchase plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">934<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon under equity incentive and employee stock purchase plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Retirement of common stock in exchange for common stock warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,670)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,670)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock in exchange for common stock warrant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_StockWarrantIssuedDuringPeriodValueInExchangeForRetirementOfCommonStock', window );">Issuance of common stock warrant in exchange for retirement of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,919<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive gain (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(227)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(227)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(38,924)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(38,924)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, Ending at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">253,222<span></span>
</td>
<td class="num">(233)<span></span>
</td>
<td class="num">(140,474)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,515<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Ending (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,187,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="nump">2,846,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock upon under equity incentive and employee stock purchase plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,779<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon under equity incentive and employee stock purchase plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">583,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Issuance of common stock upon exercise of Exchange Warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">599,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive gain (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(77,187)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(77,187)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, Ending at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297,846<span></span>
</td>
<td class="num">(221)<span></span>
</td>
<td class="num">(217,661)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79,964<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Ending (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,217,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,217,649<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,871<span></span>
</td>
<td class="nump">212,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,871<span></span>
</td>
<td class="nump">$ 212,974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="nump">2,483,719<span></span>
</td>
<td class="nump">13,526,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock upon under equity incentive and employee stock purchase plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,799<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon under equity incentive and employee stock purchase plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">517,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,899<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive gain (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">249<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66,150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66,150)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, Ending at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 563,389<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="num">$ (283,811)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 279,606<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Ending (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,745,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,745,465<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common stock and warrants for common stock issued in private placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of common stock and warrants for common stock issued in private placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_StockWarrantIssuedDuringPeriodValueInExchangeForRetirementOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of common stock warrant issued in exchange for retirement of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_StockWarrantIssuedDuringPeriodValueInExchangeForRetirementOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681348535640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (66,150)<span></span>
</td>
<td class="num">$ (77,187)<span></span>
</td>
<td class="num">$ (38,924)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">7,899<span></span>
</td>
<td class="nump">8,353<span></span>
</td>
<td class="nump">6,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_OperatingLeaseRightOfUseAssetAmortization', window );">Operating lease right-of-use asset amortization</a></td>
<td class="nump">1,775<span></span>
</td>
<td class="nump">1,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">789<span></span>
</td>
<td class="nump">703<span></span>
</td>
<td class="nump">527<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early repayment of debt</a></td>
<td class="nump">585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net amortization of premium (accretion of discount) on marketable securities</a></td>
<td class="nump">37<span></span>
</td>
<td class="num">(594)<span></span>
</td>
<td class="nump">206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee', window );">Amortization of debt issuance costs and accretion of debt discount</a></td>
<td class="nump">159<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on disposal of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxCreditsAndAdjustments', window );">Change in deferred tax asset</a></td>
<td class="nump">1,438<span></span>
</td>
<td class="num">(775)<span></span>
</td>
<td class="num">(658)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable', window );">Research and development tax incentive receivable</a></td>
<td class="num">(990)<span></span>
</td>
<td class="nump">1,411<span></span>
</td>
<td class="num">(236)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties', window );">Receivable from collaboration partner - related party</a></td>
<td class="nump">4,329<span></span>
</td>
<td class="num">(2,168)<span></span>
</td>
<td class="num">(2,771)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(1,102)<span></span>
</td>
<td class="num">(2,820)<span></span>
</td>
<td class="nump">1,117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="nump">309<span></span>
</td>
<td class="num">(3,000)<span></span>
</td>
<td class="nump">4,430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties', window );">Payable to collaboration partner - related party</a></td>
<td class="nump">1,471<span></span>
</td>
<td class="nump">201<span></span>
</td>
<td class="nump">1,061<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accrued expenses and other payables</a></td>
<td class="nump">5,840<span></span>
</td>
<td class="nump">1,098<span></span>
</td>
<td class="nump">1,911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue - related party</a></td>
<td class="num">(27,053)<span></span>
</td>
<td class="nump">33,307<span></span>
</td>
<td class="num">(23,529)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="num">(1,941)<span></span>
</td>
<td class="num">(1,885)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liability</a></td>
<td class="nump">121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(72,484)<span></span>
</td>
<td class="num">(41,527)<span></span>
</td>
<td class="num">(49,947)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchase of marketable securities</a></td>
<td class="num">(280,027)<span></span>
</td>
<td class="num">(166,936)<span></span>
</td>
<td class="num">(71,060)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="nump">189,533<span></span>
</td>
<td class="nump">114,193<span></span>
</td>
<td class="nump">73,759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(471)<span></span>
</td>
<td class="num">(967)<span></span>
</td>
<td class="num">(486)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(90,965)<span></span>
</td>
<td class="num">(53,710)<span></span>
</td>
<td class="nump">2,213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from public offering of common stock, net of issuance costs</a></td>
<td class="nump">213,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ProceedsFromIssuanceOfCommonStockAndWarrantsInPrivatePlacementNetOfIssuanceCosts', window );">Proceeds from issuance of common stock and warrants in private placement, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from at-the-market offering, net of issuance costs</a></td>
<td class="nump">42,062<span></span>
</td>
<td class="nump">34,492<span></span>
</td>
<td class="nump">1,508<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from issuance of common stock upon exercise of stock options and purchases under employee stock purchase plan</a></td>
<td class="nump">2,799<span></span>
</td>
<td class="nump">1,779<span></span>
</td>
<td class="nump">934<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Issuance costs related to long-term debt</a></td>
<td class="num">(14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Early repayment of long-term debt</a></td>
<td class="num">(10,524)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">247,626<span></span>
</td>
<td class="nump">46,036<span></span>
</td>
<td class="nump">24,115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash, cash equivalents and restricted cash</a></td>
<td class="nump">175<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="num">(177)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">84,352<span></span>
</td>
<td class="num">(49,227)<span></span>
</td>
<td class="num">(23,796)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">33,466<span></span>
</td>
<td class="nump">82,693<span></span>
</td>
<td class="nump">106,489<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">117,818<span></span>
</td>
<td class="nump">33,466<span></span>
</td>
<td class="nump">82,693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF NON-CASH FINANCING AND INVESTING INFORMATION:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">438<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF NON-CASH FINANCING AND INVESTING INFORMATION:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment in accounts payable and accrued liabilities</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant', window );">Fair value of common stock retired in exchange for issuance of common stock warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,670<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Public Offering | Accrued liabilities and other payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF NON-CASH FINANCING AND INVESTING INFORMATION:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Issuance costs related to common stock</a></td>
<td class="nump">205<span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Public Offering | Prepaid expenses and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF NON-CASH FINANCING AND INVESTING INFORMATION:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Issuance costs related to common stock</a></td>
<td class="nump">124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ptgx_AtMarketingOfferingMember', window );">At-the-market offering | Prepaid expenses and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF NON-CASH FINANCING AND INVESTING INFORMATION:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Issuance costs related to common stock</a></td>
<td class="nump">$ 191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs and accretion of final payment fee under debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of retired common stock in exchange for issuance of common stock warrant in noncash transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_OperatingLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_OperatingLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_ProceedsFromIssuanceOfCommonStockAndWarrantsInPrivatePlacementNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_ProceedsFromIssuanceOfCommonStockAndWarrantsInPrivatePlacementNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxCreditsAndAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A credit or adjustment for government or taxing authority authorized decrease in taxes owed as a result of meeting certain tax policy conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxCreditsAndAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=ptgx_AccruedLiabilitiesAndOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=ptgx_AccruedLiabilitiesAndOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ptgx_AtMarketingOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ptgx_AtMarketingOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681349209112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Description of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Description of Business</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PROTAGONIST THERAPEUTICS,&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Notes&#160;to Consolidated Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 1.&#160;&#160;&#160;&#160;Organization and Description of Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:25.3pt;margin:0pt 0pt 13.19pt 0pt;">Protagonist Therapeutics, Inc. (the &#8220;Company&#8221;) is headquartered in Newark, California. The Company is a clinical-stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based therapeutics to address significant unmet medical needs and transform existing treatment paradigms for patients. Protagonist Pty Limited (&#8220;Protagonist Australia&#8221;) is a wholly-owned subsidiary of the Company and is located in Brisbane, Queensland, Australia. Protagonist Australia was incorporated in Australia in September 2001. The Company manages its operations as a single operating segment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 13.19pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liquidity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:25.3pt;margin:0pt 0pt 13.19pt 0pt;">The Company has incurred net losses from operations since inception and has an accumulated deficit of $283.8 million as of December 31, 2020. The Company&#8217;s ultimate success depends on the outcome of its research and development and collaboration activities. The Company expects to incur additional losses in the future and anticipates the need to raise additional capital to continue to execute its long-range business plan. Since the Company&#8217;s initial public offering in August 2016, it has financed its operations primarily through offerings of common stock and payments received under a license and collaboration agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;white-space:pre-wrap;">Risks and Uncertainties  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to risks and uncertainties as a result of the&#160;COVID-19&#160;pandemic. The Company is continuing to closely monitor the impact of the COVID-19 pandemic on its business and has taken and continues to take proactive efforts to protect the health and safety of its patients, clinical research staff and employees, and to maintain business continuity. The extent of the impact of the&#160;COVID-19&#160;pandemic on the Company's activities is highly uncertain and difficult to predict, as the response to the pandemic is ongoing and information continues to evolve. Capital markets and economies worldwide have been negatively impacted by the&#160;COVID-19&#160;pandemic, which has contributed to the current global economic recession. Such economic disruption could have a material adverse effect on the Company&#8217;s business. Policymakers around the globe have responded with fiscal policy actions to support the healthcare industry and economy as a whole. The magnitude and overall effectiveness of these actions remains uncertain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The severity of the impact of the&#160;COVID-19&#160;pandemic on the Company's activities will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic, including the severity of any additional periods of increases or spikes in the number of cases in the areas the Company and its suppliers operate and areas where the Company&#8217;s clinical trial sites are located. Accordingly, the extent and severity of the impact on the Company's existing and planned clinical trials, manufacturing, collaboration activities and operations, is uncertain and cannot be fully predicted. The Company has experienced delays in its existing and planned clinical trials due to the worldwide impacts of the pandemic. The Company's future results of operations and liquidity could be adversely impacted by further delays in existing and planned clinical trials, continued difficulty in recruiting patients for these clinical trials, delays in manufacturing and collaboration activities, supply chain disruptions, the ongoing impact on its operating activities and employees, and the ongoing impact of any initiatives or programs that the Company may undertake to address financial and operational challenges. As of the date of issuance of these consolidated financial statements, the extent to which the&#160;COVID-19&#160;pandemic may materially impact the Company's future financial condition, liquidity or results of operations remains uncertain.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681346574408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note<span style="font-weight:normal;"> </span>2.&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation and Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Protagonist Australia, and have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). All intercompany balances and transactions have been eliminated upon consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The financial statements of Protagonist Australia use the Australian dollar as the functional currency since the majority of expense transactions occur in such currency. Gains and losses from foreign currency transactions were not material for all periods presented. The re-measurement from Australian dollar to U.S. dollars is outlined below:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Equity accounts, except for the change in retained earnings during the&#160;year, have been translated using historical exchange rates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">All other Australian dollar denominated assets and liabilities as of December&#160;31, 2020 and 2019 have been translated using the&#160;year-end exchange rate.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">The consolidated statements of operations have been translated at the weighted average exchange rates in effect during each&#160;year.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Foreign currency translation gains and losses are reported as a component of stockholders&#8217; equity in accumulated other comprehensive loss on the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, accruals for research and development activities, stock-based compensation, income taxes, marketable securities and leases. Estimates related to revenue recognition include actual costs incurred versus total estimated costs of the Company&#8217;s deliverables to determine percentage of completion in addition to the application and estimates of potential revenue constraints in the determination of the transaction price under its license and collaboration agreements. Management bases these estimates on historical and anticipated results, trends and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to forecasted amounts and future events. Actual results may differ significantly from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Due to the COVID-19 pandemic, there has been uncertainty and disruption in the global economy and financial markets. The Company has taken into consideration any known COVID-19 impacts in its accounting estimates to date and is not aware of any additional specific events or circumstances that would require any additional updates to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of the date of issuance of this Annual Report on Form 10-K. These estimates may change as new events occur and additional information is obtained. Actual results could differ materially from these estimates under different assumptions or conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentrations of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and marketable securities. Substantially all of the Company&#8217;s cash is held by two financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. The primary focus of the Company&#8217;s investment strategy is to preserve capital and to meet liquidity requirements. The Company&#8217;s cash equivalents and marketable securities are managed by external managers within the guidelines of the Company&#8217;s investment policy. The Company&#8217;s investment policy addresses the level of credit exposure by limiting concentration in </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">any one corporate issuer and establishing a minimum allowable credit rating. To manage its credit risk exposure, the Company maintains its portfolio of cash equivalents and marketable securities in fixed income securities denominated and payable in U.S. dollars. Permissible investments of fixed income securities include obligations of the U.S. government and its agencies, money market instruments including commercial paper and negotiable certificates of deposit, and highly rated corporate debt obligations and money market funds.</span><span style="white-space:pre-wrap;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Cash equivalents that are readily convertible to cash are stated at cost, which approximates fair value. The Company considers all highly liquid investments purchased with an original maturity of three&#160;months or less to be cash equivalents. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Restricted Cash</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Restricted cash consists of cash balances primarily held as security in connection with a letter of credit related to the Company&#8217;s facility lease entered into in March 2017 and the Company&#8217;s corporate credit card.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash as Reported in Consolidated Statements of Cash Flows</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Cash as reported in the consolidated statements of cash flows includes the aggregate amounts of cash and cash equivalents and the restricted cash as presented on the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Cash as reported in the consolidated statements of cash flows consists of (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:95.58%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> 117,358</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 33,006</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 82,233</p></td></tr><tr><td style="vertical-align:bottom;width:64.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash - current</p></td><td style="vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 10</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash - noncurrent</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> 450</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 450</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 450</p></td></tr><tr><td style="vertical-align:bottom;width:64.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total cash, cash equivalent and restricted cash in consolidated statements of cash flows</p></td><td style="vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">117,818</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 33,466</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 82,693</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:12pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Marketable Securities  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;All marketable securities have been classified as &#8220;available-for-sale&#8221; and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation as of each balance sheet date. Short-term marketable securities have maturities greater than three months but not longer than 365 days as of the balance sheet date. Long-term marketable securities have maturities of 365&#160;days or longer as of the balance sheet date. Unrealized gains and losses are excluded from earnings and are reported as a component of comprehensive loss. Realized gains and losses and declines in fair value judged to be other than temporary, if any, on available-for-sale securities are included in interest income. The cost of securities sold is based on the specific-identification method. Interest on marketable securities is included in interest income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Fair value accounting is applied to all financial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis (at least annually). The carrying amount of the Company&#8217;s financial instruments, including cash equivalents, receivable from collaboration partner, accounts payable, payable to collaboration partner and accrued expenses and other payables approximate fair value due to their short-term maturities. See Note&#160;4. to the Consolidated Financial Statements for additional information regarding the fair value of the Company&#8217;s other financial assets and liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, ranging from <span style="-sec-ix-hidden:Hidden_MwXrAUuc4UmOUGbm0YW9XQ;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">three</span></span> to five&#160;years. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful lives of the assets. Maintenance and repairs are charged to expense as incurred. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the consolidated balance sheet and any resulting gain or loss is reflected in operations in the period realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company adopted Accounting Standards Codification Topic 842, <i style="font-style:italic;">Leases,</i> (&#8220;ASC 842&#8221;) effective January 1, 2019. The Company determines if an arrangement is a lease at inception. Pursuant to ASC 842, operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets, operating lease liabilities, and noncurrent operating lease liabilities on the consolidated balance sheets. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. If the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. Lease terms include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:31.5pt;margin:0pt;">The Company records tenant improvement allowances as a reduction to the ROU asset with the impact of the decrease recognized prospectively over the remaining lease term. The leasehold improvements will be amortized over the shorter of their useful life or the remaining term of the lease. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Impairment of Long-Lived Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Company reviews long-lived assets, primarily comprised of property, equipment and operating lease right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount to the future net cash flows which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset. There have been no such impairments of long-lived assets for any of the periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Long Term Debt  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for interest on its long-term debt under the effective interest method, with interest expense comprised of contractual interest, amortization of origination fees and other issuance costs, and accretion of final payment fees. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Comprehensive Loss</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity that result from transactions and economic events other than those from stockholders. The Company&#8217;s foreign currency translation and unrealized gains and losses on available-for-sale securities represent the only components of other comprehensive loss that are excluded from reported net loss and that are presented in the consolidated statements of comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">The Company uses the asset and liability method to account for income taxes in accordance with the authoritative guidance for income taxes. Under this method, deferred tax assets and liabilities are determined based on future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">and their respective tax bases, and tax loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates applied to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than a 50% likelihood of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest and penalties related to unrecognized tax benefits in income tax expense. To date, there have been no interest or penalties recorded in relation to unrecognized tax benefits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">The Company follows Accounting Standards Codification Topic 606, <i style="font-style:italic;">Revenue from Contracts with Customers </i>(&#8220;ASC 606&#8221;). Under ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the Company satisfies a performance obligation. The Company applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract, determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligations when (or as) the performance obligations are satisfied. The Company constrains its estimate of the transaction price up to the amount (the &#8220;variable consideration constraint&#8221;) that a significant reversal of recognized revenue is not probable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><i style="font-style:italic;">Licenses of intellectual property:</i><span style="white-space:pre-wrap;">  If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in an arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring proportional performance for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of proportional performance each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><i style="font-style:italic;">Milestone payments:</i><span style="white-space:pre-wrap;">  At the inception of each arrangement or amendment that includes development, regulatory or commercial milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. Whichever method is used, it should be consistently applied throughout the life of the contract; however, it is not necessary for the Company to use the same approach for all contracts. The Company expects to use the most likely amount method for development and regulatory milestone payments. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. If there is more than one performance obligation, the transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Royalties:</i><span style="white-space:pre-wrap;">  For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional. Amounts payable to the Company and not yet billed to the collaboration partner are recorded as contract assets. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one&#160;year or less.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Contractual cost sharing payments made to a customer or collaboration partner are accounted for as a reduction to the transaction price if such payments are not related to distinct goods or services received from the customer or collaboration partner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"><span style="background-color:#ffffff;">Contracts may be amended to account for changes in contract specifications and requirements.&#160;Contract modifications exist when the amendment either creates new, or changes existing, enforceable rights and obligations. When&#160;contract modifications&#160;create new performance obligations and the increase in consideration approximates the standalone selling price for goods and services related to such new performance obligations as adjusted for specific facts and circumstances of the contract, the modification is considered to be a separate contract. If a contract modification is not accounted for as a separate contract, the Company accounts for the promised goods or services not yet transferred at the date of the contract modification (the remaining promised goods or services) prospectively, as if it were a termination of the existing contract and the creation of a new contract, if the remaining goods or services are distinct from the goods or services transferred on or before the date of the contract modification. The Company accounts for a contract modification as if it were a part of the existing contract if the remaining goods or services are not distinct and, therefore, form part of a single performance obligation that is partially satisfied at the date of the contract modification. In such case the effect that the contract modification has on the transaction price, and on the entity&#8217;s measure of progress toward complete satisfaction of the performance obligation, is recognized as an adjustment to revenue (either as an increase in or a reduction of revenue) at the date of the contract modification (the adjustment to revenue is made on a cumulative catch-up basis).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"><span style="background-color:#ffffff;">The period between when the Company transfers control of promised goods or services and when the Company receives payment is expected to be one year or less, which is consistent with the Company&#8217;s historical experience. Upfront payment contract liabilities resulting from the Company&#8217;s license and collaboration agreements do not represent a financing component as the payment is not financing the transfer of goods and services, and the technology underlying the licenses granted reflects research and development expenses already incurred by the Company. As such, the Company does not adjust its revenues for the effects of a significant financing component.</span><span style="background-color:#ffffff;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred, unless there is an alternate future use in other research and development projects or otherwise. Research and development costs include salaries and benefits, stock-based compensation expense, laboratory supplies and facility-related overhead, outside contracted services including clinical trial costs, manufacturing and process development costs for both clinical and pre-clinical materials, research costs, development milestone payments under license and collaboration agreements, and other consulting services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">The Company accrues for estimated costs of research and development activities conducted by third-party service providers, which include the conduct of pre-clinical studies and clinical trials, and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated services provided </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">but not yet invoiced and includes these costs in accrued expenses and other payables in the consolidated balance sheets and within research and development expense in the consolidated statements of operations. The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers. As actual costs become known, the Company adjusts its accrued liabilities. The Company has not experienced any material differences between accrued liabilities and actual costs incurred. However, the status and timing of actual services performed, number of patients enrolled, the rate of patient enrollment and number and location of sites activated may vary from the Company&#8217;s estimates, resulting in adjustments to expense in future periods. Changes in these estimates that result in material changes to the Company&#8217;s accruals could materially affect the Company&#8217;s results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.5pt;margin:0pt 0pt 12pt 0pt;">The Company has received orphan drug designation from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) for its clinical asset rusfertide (generic name for PTG-300) for the treatment of polycythemia vera and beta-thalassemia and may qualify for a related 25% U.S. Federal income tax credit on qualifying clinical study expenditures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Tax Incentive</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Company is eligible under the AusIndustry research and development tax incentive program to obtain either a refundable cash tax incentive or a taxable credit in the form of a non-cash tax incentive from the Australian Taxation Office (&#8220;ATO&#8221;). The refundable cash tax incentive is available to the Company on the basis of specific criteria with which the Company must comply. Specifically, the Company must have annual turnover of less than AUD 20.0 million and cannot be controlled by income tax exempt entities.&#160;The refundable cash tax incentive is recognized as a reduction to research and development expense when the right to receive has been attained and funds are considered to be collectible. The tax incentive is denominated in Australian dollars and, therefore, the related receivable is remeasured into U.S. dollars as of each reporting date. The Company may alternatively be eligible for a taxable credit in the form of a non-cash tax incentive in years when the annual turnover exceeds the limit. The Company evaluates its eligibility under tax incentive programs as of each balance sheet date and makes accrual and related adjustments based on the most current and relevant data available. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Small Business Innovation Research (&#8220;SBIR&#8221;) Grants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Company has received SBIR grants from the National Institutes of Health (&#8220;NIH&#8221;) in support of its research activities. The Company recognizes a reduction to research and development expenses when expenses related to grants have been incurred and the grant funds become contractually due from NIH. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Company measures its stock-based awards made to its equity plan participants based on the estimated fair values of the awards as of the grant date. For stock option awards, the Company uses the Black-Scholes option-pricing model to estimate fair values. For restricted stock unit awards, the estimated fair value is generally the fair market value of the underlying stock on the grant date. Stock-based compensation expense is recognized over the requisite service period and is based on the value of the portion of stock-based payment awards that is ultimately expected to vest. The Company recognizes forfeitures of stock-based awards as they occur. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net Loss per Share </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is calculated by dividing the Company&#8217;s net loss by the weighted average number of shares of common stock and Exchange Warrants outstanding during the period, without consideration of potentially dilutive securities. In accordance with Accounting Standards Codification Topic 260, <i style="font-style:italic;">Earnings Per Share</i>, the Exchange Warrants are included in the computation of basic net loss per share because the exercise price is negligible and they are fully vested and exercisable after the original issuance date. Diluted net loss per share is the same as basic net loss per share for all periods presented since the effect of potentially dilutive securities is anti-dilutive given the net loss of the Company in each period. See Note 12. Stockholders' Equity for additional information regarding the Exchange Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Recently Adopted Accounting Pronouncements </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">In August 2018, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2018-13, <i style="font-style:italic;">Fair Value Measurement (Topic 820) &#8211; Disclosure Framework &#8211; Changes to the Disclosure Requirements for Fair Value Measurement</i>, which modifies the disclosure requirements on fair value measurements and is intended to improve the effectiveness of disclosures, including the consideration of costs and benefits. The Company adopted this guidance as of January 1, 2020. The adoption of this guidance did not have a material impact on the Company&#8217;s consolidated financial statements or disclosures. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">In November 2018, the FASB issued ASU No. 2018-18, <i style="font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606</i>, which is intended to clarify the circumstances under which certain transactions in collaborative arrangements should be accounted for under the revenue recognition standard. Certain transactions between collaboration arrangement participants should be accounted for as revenue under ASC Topic 606 when the collaborative arrangement participant is a customer in the context of a unit of account. This guidance is effective for fiscal years and interim periods within those years beginning after December 15, 2019. The Company adopted this guidance as of January 1, 2020. The adoption of this guidance did not have a material impact on the Company&#8217;s consolidated financial statements and disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Recently Issued Accounting Pronouncements Not Yet Adopted as of December 31, 2020</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2016, the FASB issued ASU No.&#160;2016-13,&#160;<i style="font-style:italic;">Financial Instruments&#160;- Credit Losses (Topic 326)</i>, which is intended to provide financial statement users with more useful information about expected credit losses on financial assets held by a reporting entity at each reporting date. The new standard replaces the existing incurred loss impairment methodology with a methodology that requires consideration of a broader range of reasonable and supportable forward-looking information to estimate all expected credit losses. This guidance was originally effective for fiscal&#160;years and interim periods within those&#160;years beginning after December&#160;15, 2019, with early adoption permitted for fiscal&#160;years and interim periods within those&#160;years beginning after December&#160;15, 2018. In November 2019, the FASB issued ASU No. 2019-10, <i style="font-style:italic;">Financial Instruments &#8211; Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates</i>, which amended the mandatory effective date of ASU No. 2016-13 for smaller reporting companies. Based on the Company&#8217;s status as a smaller reporting company as of November 15, 2019, ASU 2016-13 is effective for the Company for fiscal years and interim periods beginning after December 15, 2022. The Company is currently evaluating the impact of this new guidance on its consolidated financial statements and disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">In December 2019, the FASB issued ASU No. 2019-12, <i style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, </i>which removes certain exceptions and amends certain requirements in the existing income tax guidance to ease accounting requirements. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020 and must be applied on a retrospective basis. The Company does not expect the adoption of this guidance to have a material impact on its consolidated financial statements and disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681347769448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ptgx_JanssenLicenseAndCollaborationAgreement26May2017Member', window );">License and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License and Collaboration Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License and Collaboration Agreement</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 3.&#160;&#160;&#160;&#160;<b style="font-weight:bold;white-space:pre-wrap;">License and Collaboration Agreement   </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Agreement Terms</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">On May 26, 2017, the Company and Janssen Biotech, Inc., (&#8220;Janssen&#8221;), one of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson, entered into an exclusive license and collaboration agreement (the &#8220;Janssen License and Collaboration Agreement&#8221;) for the development, manufacture and potential commercialization of PTG-200 worldwide for the treatment of Crohn&#8217;s disease (&#8220;CD&#8221;) and ulcerative colitis (&#8220;UC&#8221;). Janssen is a related party to the Company as Johnson &amp; Johnson Innovation - JJDC, Inc., a significant stockholder of the Company, and Janssen are both subsidiaries of Johnson &amp; Johnson. PTG-200 is the Company&#8217;s orally delivered gut-restricted Interleukin 23 receptor (&#8220;IL-23R&#8221;) antagonist drug candidate currently in development. The Janssen License and Collaboration Agreement became effective on July 13, 2017. Upon the effectiveness of the agreement, the Company received a non-refundable, upfront cash payment of $50.0 million from Janssen.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Under the Janssen License and Collaboration Agreement, the Company granted to Janssen an exclusive worldwide license to develop, manufacture and commercialize PTG-200 and related IL-23R compounds for all indications, including CD and UC. The Company was responsible, at its own expense, for the conduct of the Phase 1 clinical trial for PTG-200, and Janssen is responsible for the conduct of the Phase 2 clinical trial for PTG-200 in CD, including filing the U.S. Investigational New Drug application (&#8220;IND&#8221;). Development costs for the Phase 2 clinical trial are shared between the parties on an 80/20 basis, with Janssen assuming the larger share. Janssen submitted an IND for PTG-200 in CD during the second quarter of 2019, which took effect in July 2019. The Company initiated a Phase 2 clinical study for PTG-200 in CD with Janssen in the fourth quarter of 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Company entered into an amendment (the &#8220;First Amendment&#8221;) to the Janssen License and Collaboration Agreement effective May 7, 2019. The First Amendment builds upon the Company&#8217;s ongoing development collaboration with Janssen for PTG-200 and, upon the effectiveness of the First Amendment, the Company became eligible to receive a $25.0 million payment from Janssen, which was received during the second quarter of 2019. The First Amendment expanded the scope of the Janssen License and Collaboration Agreement by supporting research efforts towards identifying and developing second-generation IL-23R antagonists (&#8220;second-generation compounds&#8221;).  Two second-generation IL-23R compounds have been nominated and are currently in development: PN-235, in a Phase 1 clinical study, and PN-232, in preclinical studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">As part of the services added in the First Amendment, Janssen will pay certain costs and milestones related to advancing pre-clinical candidates from the second-generation research program through Phase 1 studies, including funding of a certain number of full-time equivalent employees (&#8220;FTEs&#8221;) at the Company for an agreed upon period of time. The Company will pay 100% of the costs for the preclinical studies and Phase 1 studies for the first second-generation compound, and 50% of the costs of the Phase 1 studies for the second and third second-generation compounds; thereafter Janssen will pay 100% of any further Phase 1 development costs. Development costs for the Phase 2 clinical trials for second-generation compounds are shared between the parties on an 80/20 basis, with Janssen assuming the larger share. The Company&#8217;s Phase 1 and Phase 2 development costs are also limited by overall spending caps. In December 2019, the Company became eligible to receive a $5.0 million payment trigged by the successful nomination of a second-generation development compound, which was received during the first quarter of 2020. The Company will be eligible to receive a $7.5 million milestone payment at the completion of a Phase 1 study for the first second-generation compound. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Prior to the effectiveness of the First Amendment, the Company had been eligible to receive a $25.0 million milestone payment upon Janssen&#8217;s filing of the IND. This amount had been considered constrained until a time at which the Company would have become eligible to receive the $25.0 million payment from Janssen. Payments to the Company for research and development services are generally billed and collected as services are performed or assets are delivered, including research activities and Phase 1 and Phase 2 development activities. Janssen bills the Company for its 20% share of the Phase 2 development costs as expenses are incurred by Janssen. Milestone payments are received after the related milestones are achieved. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the First Amendment, the Company will be eligible to receive clinical development, regulatory and sales milestones, if and as achieved, and/or payments relating to Janssen&#8217;s elections to maintain or expand its license rights. The next possible milestone or opt-in election events based on a Phase 2 clinical trial in CD are as follows: </p><table style="border-collapse:collapse;border:0;"><tr><td style="width:27pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:4.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-size:12pt;">&#8226;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"> Janssen can elect to advance PTG-200 into Phase 2b following receipt of the top line results of the CD Phase 2a clinical trial for PTG-200 by paying a $50.0 million maintenance fee (the &#8220;Amended First Opt-in Election&#8221;); or </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:4.5pt;text-indent:-4.5pt;margin:0pt 0pt 12pt 27pt;"><span style="font-size:12pt;">&#8226;</span> Janssen would make a $50.0 million milestone payment following dosing of the third patient in the first Phase 2b clinical trial for CD for a second-generation product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">Janssen can also then elect to receive exclusive, world-wide commercial rights for both PTG-200 and second-generation products following the Phase 2b completion date for PTG-200 or a second-generation product by paying a $50.0 million payment (the &#8220;Amended Second Opt-in Election&#8221;). The Company will also be eligible for certain additional milestone payments including a potential payment of either $100.0 million upon a Phase 3 CD clinical trial meeting a </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">primary clinical endpoint with respect to PTG-200 or $115.0 million upon a Phase 3 CD clinical trial meeting a primary clinical endpoint with respect to a second-generation compound.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the First Amendment, the Company will be eligible to receive tiered royalties on net product sales at percentages ranging from mid-single digits to ten percent. Under the terms of the First Amendment, the Company will be eligible to receive up to an aggregate $1.0 billion in research, development, regulatory and sales milestones.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Janssen License and Collaboration Agreement remains in effect until the royalty obligations cease following patent and regulatory expiry, unless terminated earlier. Upon a termination of the Janssen License and Collaboration Agreement, all rights revert back to the Company, and in certain circumstances, if such termination occurs during ongoing clinical trials, Janssen would, if requested, provide certain financial and operational support to the Company for the completion of such trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The Company concluded that the amended Janssen License and Collaboration Agreement continued to contain a single performance obligation including the development license; second-generation compound research services; Phase 1 development services for PTG-200 and potential second-generation compounds; the Company&#8217;s services associated with Phase 2 development for PTG-200 until Phase 2a; the Company&#8217;s services associated with Phase 2 development for  second-generation products until the dosing of the third patient in Phase 2b in CD or UC, or Phase 2 in an additional indication; and all other such services that the Company may perform at the request of Janssen to support the development of PTG-200, second-generation research services, or the development of second-generation compounds. The Company concluded that the Amended First Opt-in Election and the Amended Second Opt-in Election options are not considered to be material rights.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Company determined that the license was not distinct from the added research and development services within the context of the agreement because the added research and development services significantly increase the utility of the intellectual property. The Company also determined that the remaining research and development services are not distinct from the partially delivered combined promise comprised under the agreement prior to the First Amendment of the development license and PTG-200 services, including compound supply and other services. Therefore, the First Amendment is treated as if it were part of the original Janssen License and Collaboration Agreement. The First Amendment was accounted for as if it were an extension of services under the initial Janssen License and Collaboration Agreement by applying a cumulative catch-up adjustment to revenue. As of the effective date of the First Amendment, the Company calculated the adjusted cumulative revenue under the amended Janssen License and Collaboration Agreement by updating the transaction price for the incremental consideration to be received, net of the incremental development cost reimbursement to be paid to Janssen, and an updated percentage complete, which resulted in a cumulative adjustment recorded during the year ended December 31, 2019 that reduced revenue by $9.4 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The contract duration is defined as the period in which parties to the contract have present enforceable rights and obligations. For revenue recognition purposes, the Company determined that the duration of the Janssen License and Collaboration Agreement, as amended, began on the effective date of July 13, 2017 and is estimated to end upon the later of end of Phase 2a for PTG-200 or upon dosing of the third patient in Phase 2b for a second-generation compound.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Company uses the most likely amount method to estimate variable consideration included in the transaction price. Variable consideration after the First Amendment consists of future milestone payments and cost sharing payments from Janssen for agreed upon services, offset by development cost reimbursements payable to Janssen. Cost sharing payments from Janssen relate to the agreed upon services for development activities that the Company performs within the duration of the contract and are included in the transaction price at the Company&#8217;s share of estimated budgeted costs for these activities, including primarily internal full-time equivalent effort and third party contract costs. Cost sharing payments to Janssen relate to agreed upon services for Phase 2 activities that Janssen performs within the duration of the contract and are not a distinct service that Janssen transfers to the Company. Therefore, the consideration payable to Janssen is accounted for as a reduction in the transaction price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the transaction price of the initial performance obligation under the Janssen License and Collaboration Agreement was $98.6 million as of December 31, 2020, a decrease of $14.3 million from the transaction price of $112.9 million at December 31, 2019 and an increase of $37.9 million from the transaction price of $60.7 million at December 31, 2018. In order to determine the transaction price, the Company evaluated all payments to be received during the duration of the contract, net of Phase 2 development costs reimbursement expected to be payable to Janssen. The Company determined that the transaction price of the initial performance obligation as of December 31, 2020 includes the $50.0 million upfront payment, the $25.0 million payment received upon the effectiveness of the First Amendment, the $5.0 million payment triggered by the successful nomination of a second-generation compound, $17.9 million of reimbursement from Janssen for services performed for PTG-200 Phase 2 and for second-generation compound research and development costs and other services, and estimated variable consideration consisting of a $7.5 million milestone payment subject to the completion of a Phase 1 study for a second-generation compound, partially offset by $6.8 million of net cost reimbursement to Janssen for services performed. The Company evaluated whether the variable component of the transaction price should be constrained to ensure that a significant reversal of revenue recognized on a cumulative basis as of December 31, 2020 is not probable. The Company concluded that the variable consideration constraint does not further decrease the estimated transaction price as of December 31, 2020. The additional potential development, regulatory and sales milestone payments after the completion of Phase 2a activities in UC and CD that the Company would be eligible to receive are currently outside the contract term as defined for revenue recognition purposes and as such have been excluded from the transaction price. Janssen has also opted in for certain additional services to be performed by the Company that are outside the initial performance obligation; revenue is recognized as these services are performed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Company re-evaluates the transaction price, including variable consideration, at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur. The Company and Janssen make quarterly cost sharing payments to one another in amounts necessary to ensure that each party bears its contractual share of the overall shared costs incurred. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Company utilizes a cost-based input method to measure proportional performance and to calculate the corresponding amount of revenue to recognize. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to expected costs to fulfill the combined performance obligation. These costs consist primarily of internal FTE effort and third-party contract costs. Revenue will be recognized based on actual costs incurred as a percentage of total estimated costs as the Company completes its performance obligations. A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company&#8217;s performance obligations. The Company believes this is the best measure of progress because other measures do not reflect how the Company transfers its performance obligation to Janssen. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company&#8217;s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2020, the Company recognized $28.6 million of license and collaboration revenue. This amount included $27.1 million of the transaction price based on proportional performance and an update in forecasted amounts for future services remaining to be performed and recognized under the Janssen License and Collaboration Agreement. In addition, the Company recorded $1.5 million of revenue for the year ended December 31, 2020 related to additional services provided by the Company under the Janssen License and Collaboration Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2019, the Company recognized $0.2 million of license and collaboration revenue. This amount included a $9.4 million cumulative catchup adjustment as a reduction of revenue, offset by $8.0 million of license and collaboration revenue recognized following the contract modification for the First Amendment and $1.6 million of collaboration revenue recognized during the first quarter of 2019 under the original Janssen License and Collaboration Agreement prior to the effectiveness of the First Amendment. No revenue for additional services was recognized for the year ended December 31, 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">For the year ended December 31, 2018, the Company recognized $30.9 million of license and collaboration revenue. This amount included $30.8 million of the transaction price for the Janssen License and Collaboration </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Agreement recognized based on proportional performance, and $0.1 million, net, for other services related to Phase 2 activities performed by the Company on behalf of Janssen that were not included in the performance obligations identified under the Janssen License and Collaboration Agreement. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The following table presents changes in the Company&#8217;s contract assets and liabilities during the periods presented (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance&#160;at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance&#160;at</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Beginning&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">End&#160;of</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deductions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract assets:</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Receivable from collaboration partner - related party</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,955</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,221</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,750)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,426</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Contract asset - related party</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 800</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 342</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,142)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract liabilities:</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Deferred revenue - related party</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41,530</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,963</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (31,016)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,477</p></td></tr><tr><td style="vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Payable to collaboration partner - related party</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,262</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,800</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,330)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,732</p></td></tr><tr><td style="vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance&#160;at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance&#160;at</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Beginning&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">End&#160;of</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deductions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract assets:</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Receivable from collaboration partner - related party</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,042</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,837</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (32,924)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,955</p></td></tr><tr><td style="vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Contract asset - related party</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,545</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 800</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,545)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 800</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract liabilities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Deferred revenue - related party</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,223</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,456</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,149)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41,530</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Payable to collaboration partner - related party</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,061</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,468</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,267)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,262</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2020, the Company recognized revenue of $14.1 million from amounts included in the deferred revenue contract liability balance at the beginning of the year. During the year ended December 31, 2019, the Company recognized revenue of $1.6 million from amounts included in the deferred revenue contract liability balance at the beginning of the year, which represents the revenue recognized during the first quarter of 2019 prior to the effectiveness of the First Amendment. During the year ended December 31, 2018, the Company recognized $23.5 million in revenue from the deferred revenue contract liability balance at the beginning of the year. None of the costs to obtain or fulfill the contract were capitalized.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ptgx_JanssenLicenseAndCollaborationAgreement26May2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ptgx_JanssenLicenseAndCollaborationAgreement26May2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681348391624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 4.&#160;&#160;&#160;&#160;Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Financial assets and liabilities are recorded at fair value. The accounting guidance for fair value provides a framework for measuring fair value, clarifies the definition of fair value and expands disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 22.5pt;"><i style="font-style:italic;">Level 1</i>&#8212;Inputs are unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 22.5pt;"><i style="font-style:italic;">Level 2&#8212;</i>Inputs (other than quoted market prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument&#8217;s anticipated life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 22.5pt;"><i style="font-style:italic;">Level 3</i>&#8212;Inputs reflect management&#8217;s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">In determining fair value, the Company utilizes quoted market prices, broker or dealer quotations, or valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The following table presents the fair value of the Company&#8217;s financial assets determined using the inputs defined above (in thousands).</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:46.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,481</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,481</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 65,863</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 65,863</p></td></tr><tr><td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,590</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,590</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury and agency securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 183,210</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 183,210</p></td></tr><tr><td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total financial assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,481</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 276,663</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 304,144</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:46.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12,964</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12,964</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 44,282</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 44,282</p></td></tr><tr><td style="vertical-align:bottom;width:52.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 33,662</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 33,662</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury and agency securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 40,810</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 40,810</p></td></tr><tr><td style="vertical-align:bottom;width:52.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total financial assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12,964</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 118,754</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 131,718</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s commercial paper, corporate debt securities and U.S. Treasury and agency securities, including U.S. Treasury bills, are classified as Level 2 as they were valued based upon quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Fair Value of Other Financial Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The carrying value of long-term debt as of December 31, 2019 approximated fair value because the Term Loan bore interest at a rate that approximated prevailing market rates for instruments with similar characteristics and there was no significant change in the credit worthiness of the Company. The Company had no long-term debt balance as of December 31, 2020.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681354704488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndMarketableSecuritiesAbstract', window );"><strong>Cash Equivalents and Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Cash Equivalents and Marketable Securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 5.&#160;&#160;&#160;&#160;Cash Equivalents and Marketable Securities </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Cash equivalents and marketable securities consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:46.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross&#160;Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,481</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,481</p></td></tr><tr><td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 65,866</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 65,863</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,592</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,590</p></td></tr><tr><td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury and agency securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 183,203</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 183,210</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total cash equivalents and marketable securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 304,142</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 304,144</p></td></tr><tr><td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Classified as:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 113,693</p></td></tr><tr><td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Marketable securities - current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 188,451</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Marketable securities - noncurrent</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,000</p></td></tr><tr><td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total cash equivalents and marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 304,144</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:45.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross&#160;Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12,964</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12,964</p></td></tr><tr><td style="vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 44,284</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 44,282</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 33,653</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 11</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 33,662</p></td></tr><tr><td style="vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury and agency securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 40,798</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 40,810</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total cash equivalents and marketable securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 131,699</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 27</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 131,718</p></td></tr><tr><td style="vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Classified as:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 31,707</p></td></tr><tr><td style="vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Marketable securities - current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 100,011</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total cash equivalents and marketable securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 131,718</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:12pt 0pt 12pt 0pt;">Marketable securities &#8211; current of $188.5 million and $100.0 million held at December 31, 2020 and December&#160;31, 2019, respectively, had contractual maturities of less than one&#160;year. Marketable securities &#8211; noncurrent of $2.0 million held at December 31, 2020 had contractual maturities of at least one year but less than two years. The Company did not hold any marketable securities &#8211; noncurrent at December 31, 2019. The Company has not experienced any material credit losses on its investments. The Company does not intend to sell its securities that are in an unrealized loss position, and it is unlikely that the Company will be required to sell its securities before recovery of their amortized cost basis at maturity. There were no realized gains or realized losses on marketable securities for the periods presented. Factors considered in determining whether a loss is temporary include the length of time and extent to which the fair value has been less than the amortized cost basis and whether the Company intends to sell the security or whether it is more likely than not that the Company would be required to sell the security before recovery of the amortized cost basis. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_CashEquivalentsAndMarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>NA</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_CashEquivalentsAndMarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681354375336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Components</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 6.&#160;&#160;&#160;&#160;Balance Sheet Components </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Prepaid Expenses and Other Current Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Prepaid expenses and other current assets consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid clinical and research related expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,517</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,567</p></td></tr><tr><td style="vertical-align:bottom;width:74.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,161</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other prepaid expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,009</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,057</p></td></tr><tr><td style="vertical-align:bottom;width:74.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 311</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 744</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Prepaid expenses and other current assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,277</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,529</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and Equipment, Net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Property and equipment, net consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Laboratory equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,539</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,947</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Furniture and computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 648</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 512</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Leasehold improvements</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 748</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 863</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Total property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,935</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,322</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Less: accumulated depreciation and amortization</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,473)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,641)</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,462</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,681</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background-color:#ffff00;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Depreciation expense for the&#160;years ended December&#160;31, 2020, 2019, and 2018 was $789,000, $703,000 and $527,000, respectively. As of December&#160;31, 2020, 2019 and 2018, $46,000, $37,000 and $200, respectively, of property and equipment, net, was located in Australia. The remainder of the Company&#8217;s property and equipment is located in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Accrued Expenses and Other Payables</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Accrued expenses and other payables consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:28.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:12.88%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:12.86%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued clinical and research related expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,335</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,232</p></td></tr><tr><td style="vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued employee related expenses</p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,413</p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,637</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued professional service fees</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 668</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 301</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued interest payable</p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 68</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 82</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 122</p></td></tr><tr><td style="vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total accrued expenses and other payables</p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:11.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,498</p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:11.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,360</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681347727288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research Collaboration and License Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member', window );">Research Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Research Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Research Collaboration and License Agreement</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 7.&#160;&#160;&#160;&#160;Research Collaboration and License Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">The Company and Zealand Pharma A/S entered into a collaboration agreement in June 2012. In October 2013, Zealand Pharma abandoned the collaboration and the collaboration agreement was terminated in 2014. The agreement provides for certain post-termination payment obligations to Zealand with respect to compounds related to the collaboration that meet specified conditions set forth in the collaboration agreement and which the Company elects to further develop following Zealand&#8217;s abandonment of the collaboration. The Company has the right, but not the obligation, to further develop and commercialize such compounds. The agreement provides for payments to Zealand for the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">achievement of certain development, regulatory and sales milestone events that occur prior to a partnering arrangement related to such compounds between the Company and a third party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Company initially determined that rusfertide is a compound for which the post-termination payments described above are required under the collaboration agreement and has made three development milestone payments for an aggregate amount of $1.0 million under the agreement. However, the Company concluded in 2019 that rusfertide is not a compound with respect to which post-termination payments are required under the agreement, and initiated the arbitration proceeding described in Note 11 below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Milestone payments to collaboration partners are recorded as research and development expenses in the period that the expense is incurred. No research and development expense was recorded under this agreement for the years ended December 31, 2020 or 2019. For the&#160;year ended December 31, 2018, the Company recorded research and development expense of $500,000 under this agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;"> If the Company is required to continue to make payments with respect to rusfertide under the collaboration agreement, the next two milestones that would be due under the agreement include:  $1.0 million to $3.0 million for initiation of placebo-controlled Phase 2b clinical trial; and $1.5 million to $4.5 million for initiation of a Phase 3 clinical trial. The milestone amounts vary depending on the number of patients in the applicable clinical trial, and the Company expects the milestones would be the lowest amount within the specified range. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">See Note 11. Commitments and Contingencies &#8211; Legal Proceedings for additional information on arbitration proceedings related to this research and collaboration agreement.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681348333448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Government Programs<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_GovernmentProgramsAbstract', window );"><strong>Government Programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_GovernmentProgramsDisclosureTextBlock', window );">Government Programs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 8.&#160;&#160;&#160;&#160;Government Programs </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Tax Incentive</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">During the years ended December 31, 2020 and 2018, the Company recognized AUD 1.4 million ($1.0 million) and AUD 2.1 million ($1.6 million), respectively, as a reduction of research and development expenses in connection with the research and development cash tax incentive from the ATO. During the year ended December 31, 2019, the Company recognized AUD 1.9 million ($1.3 million) of research and development expenses in connection with the research and development tax incentive from the ATO because the Company determined that it had exceeded the annual turnover limit to claim such amounts following the receipt of certain payments under the Janssen License and Collaboration Agreement. As of December&#160;31, 2020, the research and development tax incentive receivable was AUD 1.4 million ($1.1 million). There was no research and development tax incentive receivable as of December 31, 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Small Business Innovation Research (&#8220;SBIR&#8221;) Grants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">In May 2017, the Company was awarded a Phase 2 SBIR grant from the National Institute of Diabetes and Digestive and Kidney Diseases of the NIH in support of research aimed at developing biomarkers that define IL-23R target engagement by orally delivered peptide antagonists and the effects of that engagement of downstream signaling. The total grant award was $1.3 million and was originally for the period from May 2017 to April 2019. During the year ended December 31, 2019, the Company requested and received an extension of this grant through April 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">In September 2018, the Company was awarded a Phase 2 SBIR Grant from the National Heart, Lungs and blood Institute of the NIH in support of research aimed at developing the Company&#8217;s novel hepcidin mimetic rusfertide for the potential treatment of chronic anemia and iron overload in rare blood disorders, including beta-thalassemia. The total grant award was $1.5 million and was originally for the period from September 2018 to August 2020. During the year ended December 31, 2020, the Company requested an extension of this grant through July 2021, which was received in February 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">The Company recognizes a reduction to research and development expenses when expenses related to the grants have been incurred and the grant funds become contractually due from NIH. The Company recorded $0.5 million, $1.4 million and $0.7 million, as a reduction of research and development expenses for the&#160;years ended December&#160;31, 2020, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">2019 and 2018, respectively. The Company recorded a receivable for $0.3 million as of December&#160;31, 2019 to reflect the eligible costs incurred under the grants that were contractually due to the Company. This receivable is included in prepaid expenses and other current assets on the consolidated balance sheets. There was no such receivable as of December 31, 2020.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_GovernmentProgramsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_GovernmentProgramsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_GovernmentProgramsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure pertaining to the government programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_GovernmentProgramsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681354552296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Note 9.    Debt</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">On October 30, 2019, the Company entered into a Credit and Security Agreement, dated as of October 30, 2019 (the &#8220;Closing Date&#8221;) by and among the Company, MidCap Financial Trust, as a lender, Silicon Valley Bank, as a lender, the other lenders party thereto from time to time and MidCap Financial Trust, as administrative agent and collateral agent (&#8220;Agent&#8221;), (the &#8220;Term Loan Credit Agreement&#8221;), which provides for a $50.0 million term loan facility. The Term Loan Credit Agreement provides for (i) on the Closing Date, $10.0 million aggregate principal amount of term loans, (ii) at the Company&#8217;s option, until December 31, 2020, an additional $20.0 million term loan facility subject to the satisfaction of certain conditions, including clinical milestone achievement, and (iii) at the Company&#8217;s option, until September 30, 2021, an additional $20.0 million term loan facility subject to the satisfaction of certain conditions, including clinical milestone achievement, (collectively, the &#8220;Term Loans&#8221;). The Company intends to use any proceeds of the Term Loans for general corporate purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Term Loans are subject to an origination fee of 0.25% for each funded tranche under the Term Loan Credit Agreement and bear interest at an annual rate based on prime rate plus 2.91%, subject to a prime rate floor of 4.94%. The Company will make interest-only payments on the Term Loans for 24 months, followed by 24 months of principal and interest payments. At the Company&#8217;s option, the Company may prepay the outstanding principal balance of the Term Loans in whole or in part, subject to a prepayment premium of 3.0% of any amount prepaid if the prepayment occurs through and including the first anniversary of the closing date, 2.0% of the amount prepaid if the prepayment occurs after the first anniversary of the closing date through and including the second anniversary of the closing date, and 1.0% of any amount prepaid after the second anniversary of the closing date and prior to October 1, 2023. An additional fee of 2.85% of the amount of Term Loans advanced by the Lenders will be due upon prepayment or repayment of the Term Loans. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Term Loan Credit Agreement requires the Company to maintain cash and cash equivalents of at least 35% of the outstanding Term Loans at all times and is secured by a perfected security interest in all of the Company's assets except for intellectual property and certain other customary excluded property pursuant to the terms of the Term Loan Credit Agreement. The Term Loan Credit Agreement contains other covenants that limit the Company&#8217;s ability and the ability of its subsidiaries to perform certain actions, including obligations to not pay dividends and to maintain unrestricted cash balances above certain threshold, non-occurrence of material adverse change, non-occurrence of change of control and other customary affirmative and negative covenants. The violation of any provision of covenants will result in default for the Company. The Term Loan Credit Agreement includes a clause which allows lenders to accelerate repayment upon the occurrence of certain events of default. In June 2020, the Company prepaid its outstanding $10.0 million balance on the term loan as well as $0.6 million for related prepayment and exit fees. Accordingly, the company accelerated amortization of $0.1 million related to capitalized and unamortized debt issuance costs, which is included as part of the $0.6 million loss on early repayment of debt. The Company did not exercise its option to borrow the $20.0 million second tranche of Term Loans, which expired on December 31, 2020, and therefore has no outstanding balance as of December 31, 2020 related to the Term Loan Credit Agreement. As of December 31, 2020, the Company was in compliance with the debt covenants, no event of default occurred and the probability of occurrence of event of default was considered remote.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt 0pt 6pt 0pt;">The Company&#8217;s long-term debt balance was as follows for the periods presented (dollars in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Annual </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance at</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Interest Rate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Term loan (maturity date October 1, 2023) </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">7.85%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$<span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$<span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,000</p></td></tr><tr><td style="vertical-align:bottom;width:55.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Debt issuance costs, net of amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (222)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued final payment fees</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16</p></td></tr><tr><td style="vertical-align:middle;width:55.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Long-term debt, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$<span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$<span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,794</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The effective interest rate on long-term debt was 9.85% and 9.81% for the years ended December 31, 2020 and 2019, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681346564184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 10.&#160;&#160;&#160;&#160;Leases </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:31.5pt;margin:0pt;">On January 1, 2019, the Company adopted ASC 842, which requires entities to recognize assets and liabilities for leases with lease terms of more than 12 months on the balance sheet. Leases with terms of 12 months or less are not recorded on the balance sheet, and the related lease expenses are recognized on a straight-line basis over the lease term. The Company has one operating lease agreement entered into in March 2017 for laboratory and office space located in Newark, California. The Company provided the landlord with a $450,000 letter of credit collateralized by restricted cash as security deposit for the lease, which expires in May 2024. During the years ended December 31, 2020 and 2019, the Company recognized $89,400 and $64,000 of sublease income, respectively. The Company did <span style="-sec-ix-hidden:Hidden_lqQvOls2gkKPXAv7NbH0Aw;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">not</span></span> recognize any sublease income for the year ended December 31, 2018. Under the terms of the lease, the Company is responsible for certain taxes, insurance and maintenance expenses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:31.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">The weighted average lease term and discount rate are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Operating Lease Term and Discount Rate:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average remaining lease term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3.4 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4.4 years</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average discount rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">11.0%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">11.0%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the Company&#8217;s minimum lease payments and lease liability as of December&#160;31, 2020 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Year Ending December 31:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,000</p></td></tr><tr><td style="vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,059</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,121</p></td></tr><tr><td style="vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 895</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:84.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total future minimum lease payments</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,075</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">    Less: imputed interest</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,116)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:84.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Present value of future minimum lease payments</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,959</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">    Less: current portion of operating lease liability</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,459)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:84.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease liability - noncurrent</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,500</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Supplemental lease cost information is as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease cost</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,775</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,792</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Supplemental balance sheet information is as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:10pt;"><td style="vertical-align:bottom;width:68.68%;margin:0pt;padding:0pt;"><div style="height:10pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:10pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:10pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"><div style="height:10pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:10pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:10pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><div style="height:10pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Operating Leases:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:68.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_zm9XCbYtdUWCFJoLceZSNQ;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Operating lease right-of-use asset</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,950</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,042</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:68.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_NUnmw_5Jc0GQOhDxxgb5HA;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Operating lease liability - current</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,459</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,256</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_ffN_Bd0u6EuABPUHJggLOw;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Operating lease liability - noncurrent</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,961</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:68.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_yNAOiRCkP0mEzcqrTZongA;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;">  Total operating lease liabilities</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,959</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,217</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Supplemental cash flow information is as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Cash paid for amounts included in the measurement of lease liabilities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:67.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating cash flow used by operating leases</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,941</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,885</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Prior to the adoption of ASC 842, the Company&#8217;s rent expense was $1.9 million for the&#160;year ended December&#160;31, 2018. Rent expense was recognized on a straight-line basis over the term of the lease and accordingly, the Company recorded the difference between cash rent payments and the recognition of rent expense as a deferred rent liability.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681346568600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Note 11.    Commitments and Contingencies </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has also entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by California corporate law. The Company carries a directors&#8217; and officers&#8217; insurance policy. To date, the Company has not incurred material costs to defend lawsuits or settle claims related to the indemnification agreements. The Company believes that the fair value of these indemnification agreements is minimal and has not accrued any amounts for the obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Legal Proceedings </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Company is a party to the legal action described below. The Company recognizes accruals for such actions to the extent that it concludes that a loss is both probable and reasonably estimable. The Company accrues for the best estimate of a loss within a range; however, if no estimate in the range is better than any other, it accrues the minimum amount in the range. If the Company determines that a loss is reasonably possible and the loss or range of loss can be estimated, it discloses the possible loss. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">On January 23, 2020, the Company initiated arbitration proceedings with the International Court of Arbitration of the International Chamber of Commerce against Zealand Pharma A/S (&#8220;Zealand&#8221;) related to a collaboration agreement the Company and Zealand entered into in 2012 and terminated in 2014.&#160;The agreement provides for certain post-termination payment obligations to Zealand with respect to compounds related to the collaboration that the Company elects to further develop and meet specified conditions. In the Company&#8217;s arbitration claim, it is seeking a declaration that the Company has no past, present or future milestone or royalty payment obligations under the agreement with respect to rusfertide because it is not a compound relating to the collaboration for which post-termination payments to Zealand apply. The Company is also seeking repayment of $1.0 million in milestone payments it has made, as well as its costs, fees, and expenses of the proceeding.&#160;Zealand disputes the Company&#8217;s claims and has filed counterclaims for payment of a development milestone Zealand claims is due, as well as payment of their arbitration costs, fees and expenses<i style="font-style:italic;">. </i>The arbitration is pending. If Zealand prevails in the arbitration, the Company could be required to reimburse Zealand&#8217;s arbitration costs, fees and expenses, and make contractual payments to Zealand described in its prior periodic reports filed with the SEC. If we successfully develop and commercialize rusfertide without a partner, those payments could include up to an additional aggregate of $28.0 million for achievement of certain development and regulatory milestones, and up to $100.0 million for achievement of sales milestones. In addition, Zealand could be eligible to receive a low single digit royalty on worldwide net sales of the product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Although the Company cannot predict with certainty the ultimate outcome of these arbitration proceedings, it has concluded that the probability of any related loss is remote and therefore no related accruals were recognized as of December 31, 2020.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681347834888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Note 12.    Stockholders&#8217; Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:25.3pt;margin:0pt 0pt 13.19pt 0pt;">In September 2017, the Company filed a registration statement on Form S-3 with the Securities and Exchange Commission (File No. 333-220314) that was declared effective as of October 5, 2017 and permitted the offering, issuance, and sale by the Company of up to a maximum aggregate offering price of $200.0 million of its common stock, preferred stock and certain debt securities (the &#8220;2017 Form S-3&#8221;). Up to a maximum of $50.0 million of the maximum aggregate offering price of $200.0 million could be issued and sold pursuant to an at-the-market (&#8220;ATM&#8221;) financing facility under a sales agreement (the &#8220;2017 Sales Agreement&#8221;). The 2017 Sales Agreement was terminated in 2019. During the year ended December 31, 2019, prior to the termination of the 2017 Sales Agreement, the Company sold 2,846,641 shares of its common stock for net proceeds of $34.5 million, after deducting issuance costs. The Company sold 151,273 shares of its common stock pursuant to the 2017 Sales Agreement during the year ended December 31, 2018 for net proceeds of $1.5 million, after deducting issuance costs. The 2017 Form S-3 expired in October 2020. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:25.3pt;margin:0pt 0pt 13.19pt 0pt;">In August 2018, the Company entered into a Securities Purchase Agreement with certain accredited investors (each, an &#8220;Investor&#8221; and, collectively, the &#8220;Investors&#8221;), pursuant to which the Company sold an aggregate of 2,750,000 shares of its common stock at a price of $8.00 per share, for aggregate net proceeds of $21.7 million, after deducting offering expenses payable by the Company. In a concurrent private placement, the Company issued the Investors warrants to purchase an aggregate of 2,750,000 shares of its common stock (each, a &#8220;Warrant&#8221; and, collectively, the &#8220;Warrants&#8221;). Each Warrant is exercisable from August 8, 2018 through August 8, 2023. Warrants to purchase 1,375,000 shares of the Company&#8217;s common stock have an exercise price of $10.00 per share and Warrants to purchase 1,375,000 shares of the Company&#8217;s common stock have an exercise price of $15.00 per share. The exercise price and number of shares of common stock issuable upon the exercise of the Warrants (the &#8220;Warrant Shares&#8221;) are subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described in the Warrants. Under certain circumstances, the Warrants may be exercisable on a &#8220;cashless&#8221; basis. In connection with the issuance and sale of the common stock and Warrants, the Company granted the Investors certain registration rights with respect to the Warrants and the Warrant Shares. The common stock and warrants are classified as equity in accordance with Accounting Standards Codification Topic 480<i style="font-style:italic;">, Distinguishing Liabilities from Equity </i>(&#8220;ASC 480&#8221;)<i style="font-style:italic;">,</i> and the net proceeds from the transaction were recorded as a credit to additional paid-in capital. As of December 31, 2020, none of the Warrants have been exercised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:25.3pt;margin:0pt 0pt 13.19pt 0pt;">In December 2018, the Company entered into an exchange agreement (the &#8220;Exchange Agreement&#8221;) with an Investor and its affiliates (the &#8220;Exchanging Stockholders&#8221;), pursuant to which the Company exchanged an aggregate of 1,000,000 shares of the Company&#8217;s common stock, par value $0.00001 per share, owned by the Exchanging Stockholders for pre-funded warrants (the &#8220;Exchange Warrants&#8221;) to purchase an aggregate of 1,000,000 shares of common stock (subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described in the Exchange Warrants), with an exercise price of $0.00001 per share. The Exchange Warrants will expire ten years from the date of issuance. The Exchange Warrants are exercisable at any time prior to expiration except that the Exchange Warrants cannot be exercised by the Exchanging Stockholders if, after giving effect thereto, the Exchanging Stockholders would beneficially own more than 9.99% of the Company&#8217;s common stock, subject to certain exceptions. In accordance with Accounting Standards Codification Topic 505,<i style="font-style:italic;"> Equity</i>, the Company recorded the retirement of the common stock exchanged as a reduction of common stock shares outstanding and a corresponding debit to additional paid-in-capital at the fair value of the Exchange Warrants on the issuance date. The Exchange Warrants are classified as equity in accordance with ASC 480<i style="font-style:italic;">,</i> and the fair value of the Exchange Warrants was recorded as a credit to additional paid-in capital and is not subject to remeasurement. The Company determined that the fair value of the Exchange Warrants is substantially similar to the fair value of the retired shares on the issuance date due to the negligible exercise price for the Exchange Warrants. During the year ended December 31, 2019, Exchange Warrants to purchase 600,000 shares were net exercised, resulting in the issuance of 599,997 shares of common stock. As of December 31, 2020, 400,000 of the Exchange Warrants remain unexercised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">In October 2019, the Company filed a registration statement on Form S-3 (File no. 333-234414) that was declared effective as of November 22, 2019 and permits the offering, issuance, and sale by the Company of up to a maximum aggregate offering price of $250.0 million of its common stock, preferred stock, debt securities and warrants (the &#8220;2019 Form S-3&#8221;). Up to a maximum of $75.0 million of the maximum aggregate offering price of $250.0 million may be issued and sold pursuant to an ATM financing facility under a sales agreement entered into by the Company on November 27, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">2019 (the &#8220;2019 Sales Agreement&#8221;). In May 2020, the Company completed an underwritten public offering of 7,000,000 shares of common stock at a public offering price of $14.00 per share and issued an additional 1,050,000 shares of its common stock at a price of $14.00 per share following the underwriters&#8217; exercise of their option to purchase additional shares. Net proceeds, after deducting underwriting commissions and offering costs paid by the Company, were $105.3 million. The Company sold 2,483,719 shares of its common stock pursuant to the 2019 Sales Agreement during the year ended December 31, 2020 for net proceeds of $41.9 million, after deducting issuance costs. As of December 31, 2020, a total of $94.2 million of common stock remained available for sale under the 2019 Form S-3, $31.9 million of which remained available for sale under the ATM financing facility. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">In December 2020, the Company filed an automatic registration statement on Form S-3ASR and an accompanying prospectus (Registration Statement No. 333-251254), pursuant to which the Company completed an underwritten public offering of 4,761,904 shares of common stock at a public offering price of $21.00 per share and issued an additional 714,285 shares of its common stock at a price of $21.00 per share following the underwriters&#8217; exercise of their option to purchase additional shares. Net proceeds, after deducting underwriting commissions and offering costs paid by the Company, were $107.6 million.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681347944504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Equity Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity Plans</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 13.&#160;&#160;&#160;&#160;Equity Plans </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Equity Incentive Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">In May&#160;2007, the Company established the 2007 Stock Option and Incentive Plan (&#8220;2007 Plan&#8221;) which provided for the granting of stock options to employees and consultants of the Company. Options granted under the 2007 Plan were either incentive stock options (&#8220;ISOs&#8221;) or nonqualified stock options (&#8220;NSOs&#8221;). ISOs were granted only to Company employees (including officers and directors who are also employees). NSOs were granted to Company employees and consultants. Options under the 2007 Plan have a term of ten&#160;years and generally vest over a four-year period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">In July&#160;2016, the Company&#8217;s board of directors and stockholders approved the 2016 Equity Incentive Plan (&#8220;2016 Plan&#8221;) to replace the 2007 Plan. Under the 2016 Plan, 1,200,000 shares of the Company&#8217;s common stock were initially reserved for the issuance of stock options, restricted stock units and other awards to employees, directors and consultants. Pursuant to the &#8220;evergreen&#8221; provision contained in the 2016 Plan, the number of shares reserved for issuance under the 2016 Plan automatically increases on January 1 of each year, starting on January 1, 2017 and continuing through (and including) January 1, 2026, by 4% of the total number of shares of the Company&#8217;s capital stock outstanding on December 31 of the preceding fiscal year, or a lesser number of shares determined by the Company&#8217;s board of directors. Upon adoption of the 2016 Plan, no additional stock awards were issued under the 2007 Plan. Options granted under the 2007 Plan that were outstanding on the date the 2016 Plan became effective remain subject to the terms of the 2007 Plan. The number of options available for grant under the 2007 Plan was ceased and the number was added to the common stock reserved for issuance under the 2016 Plan. As of December&#160;31, 2020, approximately 538,374 shares of common stock were available for issuance under the 2016 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The 2016 Plan is administered by the board of directors or a committee appointed by the board of directors, which determines the types of awards to be granted, including the number of shares subject to the awards, the exercise price and the vesting schedule. Options granted under the 2016 Plan expire no later than ten years from the date of grant. The exercise price of each option may not be less than 100% of the fair market value of the common stock at the date of grant. Options may be granted to stockholders possessing more than 10% of the total combined voting power of all classes of stocks of the Company at an exercise price at least 110% of the fair value of the common stock at the date of grant and the options are not exercisable after the expiration of 10&#160;years from the date of grant. Employee stock options generally vest over a period of approximately four years. Non-employee director initial stock options generally vest monthly over a period of approximately three years, and non-employee director annual refresher stock options generally vest over a period of approximately one year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:8pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Inducement Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27.8pt;margin:6pt 0pt 0pt 0pt;">In May 2018, the Company&#8217;s board of directors approved the 2018 Inducement Plan, a non-stockholder approved stock plan, under which it reserved and authorized 750,000 shares of the Company&#8217;s common stock in order to award </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">options and restricted stock unit awards&#160;to persons that were not previously employees or directors of the Company, or following a bona fide period of non-employment, as an inducement material to such persons entering into employment with the Company, within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. The 2018 Inducement Plan is administered by the board of directors or the Compensation Committee of the board, which determines the types of awards to be granted, including the number of shares subject to the awards, the exercise price and the vesting schedule. Awards granted under the 2018 Inducement Plan expire no later than ten years from the date of grant. As of December 31, 2020, approximately 574,375 shares were available for issuance under the 2018 Inducement Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Options</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Activity under the Company&#8217;s equity incentive plans is set forth below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.5396309%;padding-left:0pt;padding-right:0pt;width:101.07%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:37.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price&#160;Per</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Life&#160;(years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value (1)</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;millions)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balances at December&#160;31,&#160;2019</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,681,521</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.64</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.78</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.4</p></td></tr><tr><td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,536,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.53</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (294,238)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.49</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (275,563)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.54</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balances at December&#160;31,&#160;2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,648,120</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.87</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.61</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40.0</p></td></tr><tr><td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options exercisable &#8211; December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,619,943</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22.1</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options vested and expected to vest &#8211; December&#160;31,&#160;2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,648,120</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.87</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.61</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40.0</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;padding-left:9pt;text-indent:-9pt;margin:3pt 0pt 0pt 0pt;"><b style="font-weight:bold;">____________________</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-indent:-9pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1) </sup>The aggregate intrinsic values were calculated as the difference between the exercise price of the options and the closing price of the Company&#8217;s common stock on December 31, 2020. The calculation excludes options with an exercise price higher than the closing price of the Company&#8217;s common stock on December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The aggregate intrinsic value of options exercised was $3.0 million, $2.6 million and $1.3 million for the&#160;years ended December&#160;31, 2020, 2019 and 2018, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">During the&#160;years ended December&#160;31, 2020, 2019 and 2018, the estimated weighted-average grant-date fair value of common stock underlying options granted was $7.76, $5.45 and $8.12 per share, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Options Valuation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The fair value of stock option awards accounted for under ASC 718 was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:57.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:40.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (in years)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5.27 - 6.08 </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5.00 - 6.08 </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5.49 - 6.08</p></td></tr><tr><td style="vertical-align:bottom;width:57.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">72.1% - 87.5%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">61.0% - 64.8%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">62.0% - 66.5%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.23% - 1.44%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1.42% - 2.58%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2.42% - 3.03%</p></td></tr><tr><td style="vertical-align:bottom;width:57.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">In determining the fair value of the options granted, the Company uses the Black-Scholes option-pricing model and assumptions discussed below. Each of these inputs is subjective, and expected volatility generally requires significant judgment to determine.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Term</i>&#8212;The Company&#8217;s expected term represents the period that the Company&#8217;s options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term). The Company has limited historical exercise information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Volatility</i>&#8212; Prior to January 1, 2020, the Company&#8217;s expected volatility was estimated based on the average volatility for comparable publicly traded biopharmaceutical companies over a period equal to the expected term of the awards. Beginning January 1, 2020, the Company&#8217;s expected volatility is based upon a blend of 75% of the average volatility for comparable publicly traded biopharmaceutical companies and 25% of the volatility of the Company&#8217;s stock price since its initial public offering in August 2016. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Risk-Free Interest Rate</i>&#8212;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Dividend</i>&#8212;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Restricted Stock Units</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27.8pt;margin:4pt 0pt 0pt 0pt;">The Company began issuing restricted stock units under the 2016 Plan during the year ended December 31, 2018. A restricted stock unit is an agreement to issue shares of the Company&#8217;s common stock at the time of vesting. Restricted stock unit annual refresher awards vest in four equal installments on approximately the first, second, third and fourth anniversaries of the grant date. Restricted stock unit incentive awards granted during 2018 vested in three equal installments at six months intervals over a period of 18 months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:28.1pt;margin:9pt 0pt 0pt 0pt;">Restricted stock unit activity under the Company&#8217;s equity incentive plans is set forth below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted </b></p></td></tr><tr><td style="vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Unvested at December&#160;31,&#160;2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 278,482</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10.08</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 142,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.80</p></td></tr><tr><td style="vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (131,147)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.52</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (44,790)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.67</p></td></tr><tr><td style="vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Unvested at December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 244,545</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.31</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Stock-based compensation expense associated with restricted stock units is based on the fair value of the Company&#8217;s common stock on the grant date, which equals the closing market price of the Company&#8217;s common stock on the grant date. For restricted stock units, the Company recognizes compensation expense over the vesting period of the awards that are ultimately expected to vest. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Employee Stock Purchase Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">In July&#160;2016, the Company&#8217;s board of directors and stockholders approved the 2016 Employee Stock Purchase Plan (&#8220;2016 ESPP&#8221;). The 2016 ESPP is intended to qualify as an employee stock purchase plan under Section&#160;423 of the Internal Revenue Code of 1986, as amended, and is administered by the Company&#8217;s board of directors and the Compensation Committee of the board of directors. Under the 2016 ESPP, 150,000 shares of the Company&#8217;s common stock were initially reserved for employee purchases of the Company&#8217;s common stock. Pursuant to the &#8220;evergreen&#8221; provision contained in the 2016 ESPP, the number of shares reserved for issuance automatically increases on January 1 of each year, starting on January 1, 2017 and continuing through (and including) January 1, 2026 by the lesser of (i)&#160;1% of the total number of shares of common stock outstanding on December&#160;31 of the preceding fiscal&#160;year (ii) 300,000 shares, or (iii)&#160;such other number of shares determined by the board of directors. The 2016 ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to 15% of their eligible </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">compensation. At the end of each offering period, eligible employees are able to purchase shares at 85% of the lower of the fair market value of the Company&#8217;s common stock at the beginning of the offering period or at the end of each applicable purchase period. During the year ended December 31, 2020, 92,523 shares were issued under the ESPP. As of December 31, 2020, 757,647 shares are available for issuance.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The fair value of the rights granted under the 2016 ESPP was calculated using the Black-Scholes option-pricing model with the following assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.4488411%;padding-left:0pt;padding-right:0pt;width:100.89%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:41.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr style="height:8.15pt;"><td style="vertical-align:bottom;width:57.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (in years)</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.35pt 0pt 0pt;">0.50</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.50</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.50</p></td></tr><tr><td style="vertical-align:bottom;width:57.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">89.1% - 120.4%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">58.9% - 65.3%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">49.0% - 63.4%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate </p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">0.12% - 0.43%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1.89% - 2.32%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1.89% - 2.32%</p></td></tr><tr><td style="vertical-align:bottom;width:57.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend yield </p></td><td style="vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Total stock-based compensation expense was as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:38.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,121</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,350</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,424</p></td></tr><tr><td style="vertical-align:bottom;width:59.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,778</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,003</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,495</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total stock-based compensation expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,899</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,353</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,919</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2020, total unrecognized stock-based compensation expense was $16.0 million, which the Company expects to recognize over a period of approximately <span style="white-space:pre-wrap;">2.7</span><span style="white-space:pre-wrap;">&#160;years.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681354382856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>401(k) Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">401(k) Plan</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 14.&#160;&#160;&#160;&#160;401(k)&#160;Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Company has a retirement and savings plan under Section&#160;of 401(k)&#160;of Internal Revenue Code (the &#8220;401(k)&#160;Plan&#8221;) covering all U.S. employees. The 401(k)&#160;Plan allows employees to make pre- and post-tax contributions up to the maximum allowable amount set by the Internal Revenue Service. For the years ended December 31, 2020, 2019 and 2018, the Company did not make matching contributions to the 401(k)&#160;Plan on behalf of participants.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681354311784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 15.&#160;&#160;&#160;&#160;Income Taxes </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Company recorded income tax expense of $1.3 million for the year ended December 31, 2020. During the second quarter of 2020, the Company&#8217;s Australia subsidiary sold beneficial rights to discovery intellectual property to its U.S. entity, and the U.S. entity reimbursed the Australia subsidiary for certain direct development costs. Upon completion of the sale, the Company analyzed tax planning strategies and future income and concluded that a full valuation allowance is necessary for its Australia subsidiary. Income tax expense for the year ended December 31, 2020 reflects this sale of intellectual property rights, cost reimbursements and related adjustments to the deferred tax asset, establishing a valuation allowance and certain uncertain unrecognized tax benefits. The Company continues to maintain a full valuation allowance against its U.S. net deferred tax assets due to the uncertainty surrounding the realization of such assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Company recorded an income tax benefit of $0.7 million for the year ended December 31, 2019 primarily due to research and development tax credits and the recognition of deferred tax assets in Protagonist Australia. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Company recorded an income tax benefit of $0.8 million for the year ended December 31, 2018 from the recognition of deferred tax assets in Protagonist Australia. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The following table presents domestic and foreign components of net loss before income taxes (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:54.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Domestic</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (71,073)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (72,271)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (37,511)</p></td></tr><tr><td style="vertical-align:bottom;width:43.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,228</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,607)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,212)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Total net loss before taxes</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (64,845)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (77,878)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (39,723)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The federal, state and foreign components of the income tax expense (benefit) are summarized as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:38.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current:</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Federal</span></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">State </p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Foreign</p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (88)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total current tax (benefit) expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (88)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred:</p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Federal</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   State</span></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Foreign</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,393</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (775)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (799)</p></td></tr><tr><td style="vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax expense (benefit)</p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,393</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (775)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (799)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total income tax expense (benefit)</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,305</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (691)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (799)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The effective tax rate of the provision for income taxes differs from the federal statutory rate as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal statutory income tax rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:60.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development credits</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.5</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.3</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.3)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign tax rate difference</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (34.3)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (23.8)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22.2)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:60.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Provision (benefit) for income taxes</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.0)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.9</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The components of the deferred tax assets are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,272</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,907</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Depreciation and amortization</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,237</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 318</p></td></tr><tr><td style="vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accruals/other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,332</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,454</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating lease liability</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,252</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,516</p></td></tr><tr><td style="vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development and foreign credits&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,856</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,038</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total deferred tax assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 72,949</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55,233</p></td></tr><tr><td style="vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating right-of-use asset</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,040)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,269)</p></td></tr><tr><td style="vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,040)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,269)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valuation allowance</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (71,909)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (52,531)</p></td></tr><tr><td style="vertical-align:middle;width:68.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,433</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Realization of the deferred tax assets is dependent upon future taxable income, if any, the amount and timing of which are uncertain. The Company has established a valuation allowance to offset U.S. deferred tax assets as of December&#160;31, 2020, 2019 and 2018 due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets. The Company has also established a valuation allowance to offset Australian deferred tax assets as of December 31, 2020. The valuation allowance increased by approximately $19.4 million, $18.5 million and $8.2 million during the&#160;years ended December&#160;31, 2020, 2019 and 2018, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Federal and state laws impose substantial restrictions on the utilization of net operating loss and tax credit carryforwards in the event of an ownership change for tax purposes, as defined in Section&#160;382 of the Internal Revenue Code. As a result of such ownership changes, the annual limitation may result in the expiration of net operating losses and credits before utilization. The Company performed a Section 382 analysis through December 31, 2020. The Company has experienced ownership changes in the past and in the current year. The ownership changes will not result in a limitation that will materially reduce the total amount of net operation loss carryforwards and credits that can be utilized. Subsequent ownership changes may affect the limitation in future years. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">At December&#160;31, 2020, the Company had $222.8 million of federal net operating loss carryforwards and $214.3 million of state net operating loss carryforwards. $78.7 million of the federal net operating loss carryforwards will begin to expire in 2033, if not utilized, and the remaining $144.1 million have no expiration. The state net operating loss carryforwards will begin to expire in 2035, if not utilized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">At December&#160;31, 2020, the Company also had accumulated Australian tax losses of AUD 3.7 million ($2.8 million) available for carry forward against future earnings which, under relevant tax laws, do not expire but may be limited under certain circumstances. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2020, the Company had $12.3 million of federal and $4.8 million of state research and development tax credit carryforwards available to reduce future income taxes. The federal research and development tax credits will begin to expire in 2035, if not utilized. The state research and development tax credits have no expiration date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2020, the Company had AUD 3.6 million ($2.8 million) of Australian research and development tax credit carryforwards available to reduce future income taxes. The Australian research and development tax credits have no expiration date. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:43.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Balance at beginning of year</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,631</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,466</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,414</p></td></tr><tr><td style="vertical-align:bottom;width:55.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">(Decreases) increases based on tax positions related to prior years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,799)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 184</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 108</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Increases based on tax positions related to current year</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,053</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,981</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,944</p></td></tr><tr><td style="vertical-align:bottom;width:55.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Balance at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,885</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,631</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,466</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">At December 31, 2020, the Company had unrecognized tax benefits of $19.9 million, which are subject to a valuation allowance and would not affect the effective tax rate if recognized. The Company does not anticipate that the total amounts of unrecognized tax benefits will significantly increase or decrease in the next 12 months. The Company&#8217;s policy is to include interest and penalties related to unrecognized tax benefits within the provision for income taxes, as necessary. Management determined that no accrual for interest or penalties was required as of December 31, 2020, 2019 and 2018.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Company files income tax returns in the United States federal jurisdiction, the State of California and Australia. The Company is not currently under examination by income tax authorities in federal, state or other jurisdictions. The Company&#8217;s tax returns remain open for examination for all years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.5pt;margin:0pt;">The Company&#8217;s Australia subsidiary had an accumulated deficit at December 31, 2020 and, accordingly, no provision has been provided thereon for any unremitted earnings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt;">The Company has elected to recognize any potential global intangible low-taxed income (&#8220;GILTI&#8221;) obligation as an expense in the period it is incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">2020 Tax Law Updates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt 0pt 12pt 0pt;">On March 27, 2020, the Coronavirus Aid, Relief and Economic Security Act (&#8220;CARES Act&#8221;) was enacted and signed into law in response to the COVID-19 pandemic. GAAP requires recognition of the tax effects of new legislation during the reporting period that includes the enactment date. The CARES Act includes changes to the tax provisions that benefits business entities and makes certain technical corrections to the 2017 Tax Cuts and Jobs Act. The tax relief measures for businesses include a five-year net operating loss carryback, suspension of the annual deduction limitation of 80% of taxable income from net operating losses generated in a tax year beginning after December 31, 2017, changes in the deductibility of interest, acceleration of alternative minimum tax credit refunds, payroll tax relief, technical corrections on net operating loss carryforwards for fiscal year taxpayers and allows accelerated deduction qualified improvement property. The CARES Act also provides other non-tax benefits to assist those impacted by the pandemic.&#160;The Company evaluated the impact of the CARES Act and determined that there is no material impact to the for the year ended December 31, 2020. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt 0pt 12pt 0pt;">On June 29, 2020, California Assembly Bill 85 was signed into law. The legislation suspends the California net operating loss deductions for 2020, 2021, and 2022 for certain taxpayers and imposes a limitation of certain California tax credits for 2020, 2021, and 2022. The legislation disallows the use of California net operating loss deductions if the taxpayer recognizes business income and its adjusted gross income is greater than $1,000,000. The carryover periods for net operating loss deductions disallowed by this provision will be extended. Additionally, any business credit will only offset a maximum of $5,000,000 of California tax. Given the Company&#8217;s loss position in the current year, the new legislation will not impact the current year provision. The Company will continue to monitor possible California net operating loss and credit limitations in future periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt 0pt 12pt 0pt;">On December 27, 2020, the Consolidated Appropriations Act, 2021 was signed into law, including further COVID-19 economic relief and the extension of certain expiring tax provisions. The relief package includes a tax provision clarifying that businesses with forgiven Paycheck Protection Program loans can deduct regular business expenses that are paid for with the loan proceeds. Additional pandemic relief tax measures include an expansion of the employee retention credit, enhanced charitable contribution deductions, and a temporary full deduction for business expenses for food and beverages provided by a restaurant. The provisions are not impactful for the Company as it has not participated in previous COVID-19 economic relief measures. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681354378344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 16.&#160;&#160;&#160;&#160;Net Loss per Share </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">As the Company had a net loss for the&#160;years ended December&#160;31, 2020, 2019 and 2018, all potential common shares were determined to be anti-dilutive. The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per share data):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (66,150)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (77,187)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (38,924)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted-average shares used to compute net loss per common share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,396,446</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,894,024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,364,515</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per shares, basic and diluted</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.92)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.98)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.74)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The following outstanding shares of potentially dilutive securities have been excluded from diluted net loss per share calculations for the&#160;years ended December&#160;31, 2020, 2019 and 2018 because their inclusion would be anti-dilutive:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options to purchase common stock</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,648,120</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,681,521</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,178,441</p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Common stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,750,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,750,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,750,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted stock units</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 244,545</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 278,482</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 418,450</p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ESPP shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,445</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,275</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,134</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,671,110</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,750,278</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,399,025</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681347778392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 17.&#160;&#160;&#160;&#160;Restructuring </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">On May 7, 2020, the Company approved a limited reduction in force plan affecting approximately 12% of the Company&#8217;s employee base and informed the affected employees. The reduction-in-force plan was completed by the end of the second quarter of 2020. Total cash expenditures for the reduction in force plan were $0.3 million, substantially all of which were related to employee severance and benefits costs.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI http://asc.fasb.org/topic&amp;trid=2175745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681354871704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Presentation and Consolidation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation and Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Protagonist Australia, and have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). All intercompany balances and transactions have been eliminated upon consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The financial statements of Protagonist Australia use the Australian dollar as the functional currency since the majority of expense transactions occur in such currency. Gains and losses from foreign currency transactions were not material for all periods presented. The re-measurement from Australian dollar to U.S. dollars is outlined below:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Equity accounts, except for the change in retained earnings during the&#160;year, have been translated using historical exchange rates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">All other Australian dollar denominated assets and liabilities as of December&#160;31, 2020 and 2019 have been translated using the&#160;year-end exchange rate.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">The consolidated statements of operations have been translated at the weighted average exchange rates in effect during each&#160;year.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Foreign currency translation gains and losses are reported as a component of stockholders&#8217; equity in accumulated other comprehensive loss on the consolidated balance sheets.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, accruals for research and development activities, stock-based compensation, income taxes, marketable securities and leases. Estimates related to revenue recognition include actual costs incurred versus total estimated costs of the Company&#8217;s deliverables to determine percentage of completion in addition to the application and estimates of potential revenue constraints in the determination of the transaction price under its license and collaboration agreements. Management bases these estimates on historical and anticipated results, trends and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to forecasted amounts and future events. Actual results may differ significantly from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Due to the COVID-19 pandemic, there has been uncertainty and disruption in the global economy and financial markets. The Company has taken into consideration any known COVID-19 impacts in its accounting estimates to date and is not aware of any additional specific events or circumstances that would require any additional updates to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of the date of issuance of this Annual Report on Form 10-K. These estimates may change as new events occur and additional information is obtained. Actual results could differ materially from these estimates under different assumptions or conditions.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentrations of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and marketable securities. Substantially all of the Company&#8217;s cash is held by two financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. The primary focus of the Company&#8217;s investment strategy is to preserve capital and to meet liquidity requirements. The Company&#8217;s cash equivalents and marketable securities are managed by external managers within the guidelines of the Company&#8217;s investment policy. The Company&#8217;s investment policy addresses the level of credit exposure by limiting concentration in </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">any one corporate issuer and establishing a minimum allowable credit rating. To manage its credit risk exposure, the Company maintains its portfolio of cash equivalents and marketable securities in fixed income securities denominated and payable in U.S. dollars. Permissible investments of fixed income securities include obligations of the U.S. government and its agencies, money market instruments including commercial paper and negotiable certificates of deposit, and highly rated corporate debt obligations and money market funds.</span><span style="white-space:pre-wrap;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy', window );">Cash Equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Cash equivalents that are readily convertible to cash are stated at cost, which approximates fair value. The Company considers all highly liquid investments purchased with an original maturity of three&#160;months or less to be cash equivalents. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Restricted Cash</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Restricted cash consists of cash balances primarily held as security in connection with a letter of credit related to the Company&#8217;s facility lease entered into in March 2017 and the Company&#8217;s corporate credit card.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash as Reported in Consolidated Statements of Cash Flows</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash as Reported in Consolidated Statements of Cash Flows</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Cash as reported in the consolidated statements of cash flows includes the aggregate amounts of cash and cash equivalents and the restricted cash as presented on the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Cash as reported in the consolidated statements of cash flows consists of (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:95.58%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> 117,358</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 33,006</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 82,233</p></td></tr><tr><td style="vertical-align:bottom;width:64.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash - current</p></td><td style="vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 10</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash - noncurrent</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> 450</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 450</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 450</p></td></tr><tr><td style="vertical-align:bottom;width:64.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total cash, cash equivalent and restricted cash in consolidated statements of cash flows</p></td><td style="vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">117,818</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 33,466</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 82,693</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:12pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Marketable Securities  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;All marketable securities have been classified as &#8220;available-for-sale&#8221; and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation as of each balance sheet date. Short-term marketable securities have maturities greater than three months but not longer than 365 days as of the balance sheet date. Long-term marketable securities have maturities of 365&#160;days or longer as of the balance sheet date. Unrealized gains and losses are excluded from earnings and are reported as a component of comprehensive loss. Realized gains and losses and declines in fair value judged to be other than temporary, if any, on available-for-sale securities are included in interest income. The cost of securities sold is based on the specific-identification method. Interest on marketable securities is included in interest income.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Fair value accounting is applied to all financial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis (at least annually). The carrying amount of the Company&#8217;s financial instruments, including cash equivalents, receivable from collaboration partner, accounts payable, payable to collaboration partner and accrued expenses and other payables approximate fair value due to their short-term maturities. See Note&#160;4. to the Consolidated Financial Statements for additional information regarding the fair value of the Company&#8217;s other financial assets and liabilities.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, ranging from <span style="-sec-ix-hidden:Hidden_MwXrAUuc4UmOUGbm0YW9XQ;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">three</span></span> to five&#160;years. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful lives of the assets. Maintenance and repairs are charged to expense as incurred. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the consolidated balance sheet and any resulting gain or loss is reflected in operations in the period realized.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company adopted Accounting Standards Codification Topic 842, <i style="font-style:italic;">Leases,</i> (&#8220;ASC 842&#8221;) effective January 1, 2019. The Company determines if an arrangement is a lease at inception. Pursuant to ASC 842, operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets, operating lease liabilities, and noncurrent operating lease liabilities on the consolidated balance sheets. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. If the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. Lease terms include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:31.5pt;margin:0pt;">The Company records tenant improvement allowances as a reduction to the ROU asset with the impact of the decrease recognized prospectively over the remaining lease term. The leasehold improvements will be amortized over the shorter of their useful life or the remaining term of the lease. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Impairment of Long-Lived Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Company reviews long-lived assets, primarily comprised of property, equipment and operating lease right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount to the future net cash flows which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset. There have been no such impairments of long-lived assets for any of the periods presented.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Long Term Debt</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Long Term Debt  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for interest on its long-term debt under the effective interest method, with interest expense comprised of contractual interest, amortization of origination fees and other issuance costs, and accretion of final payment fees. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Comprehensive Loss</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity that result from transactions and economic events other than those from stockholders. The Company&#8217;s foreign currency translation and unrealized gains and losses on available-for-sale securities represent the only components of other comprehensive loss that are excluded from reported net loss and that are presented in the consolidated statements of comprehensive loss.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">The Company uses the asset and liability method to account for income taxes in accordance with the authoritative guidance for income taxes. Under this method, deferred tax assets and liabilities are determined based on future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">and their respective tax bases, and tax loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates applied to taxable income in the&#160;years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than a 50% likelihood of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest and penalties related to unrecognized tax benefits in income tax expense. To date, there have been no interest or penalties recorded in relation to unrecognized tax benefits.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">The Company follows Accounting Standards Codification Topic 606, <i style="font-style:italic;">Revenue from Contracts with Customers </i>(&#8220;ASC 606&#8221;). Under ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the Company satisfies a performance obligation. The Company applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract, determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligations when (or as) the performance obligations are satisfied. The Company constrains its estimate of the transaction price up to the amount (the &#8220;variable consideration constraint&#8221;) that a significant reversal of recognized revenue is not probable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><i style="font-style:italic;">Licenses of intellectual property:</i><span style="white-space:pre-wrap;">  If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in an arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring proportional performance for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of proportional performance each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;"><i style="font-style:italic;">Milestone payments:</i><span style="white-space:pre-wrap;">  At the inception of each arrangement or amendment that includes development, regulatory or commercial milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. Whichever method is used, it should be consistently applied throughout the life of the contract; however, it is not necessary for the Company to use the same approach for all contracts. The Company expects to use the most likely amount method for development and regulatory milestone payments. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. If there is more than one performance obligation, the transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Royalties:</i><span style="white-space:pre-wrap;">  For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional. Amounts payable to the Company and not yet billed to the collaboration partner are recorded as contract assets. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one&#160;year or less.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Contractual cost sharing payments made to a customer or collaboration partner are accounted for as a reduction to the transaction price if such payments are not related to distinct goods or services received from the customer or collaboration partner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"><span style="background-color:#ffffff;">Contracts may be amended to account for changes in contract specifications and requirements.&#160;Contract modifications exist when the amendment either creates new, or changes existing, enforceable rights and obligations. When&#160;contract modifications&#160;create new performance obligations and the increase in consideration approximates the standalone selling price for goods and services related to such new performance obligations as adjusted for specific facts and circumstances of the contract, the modification is considered to be a separate contract. If a contract modification is not accounted for as a separate contract, the Company accounts for the promised goods or services not yet transferred at the date of the contract modification (the remaining promised goods or services) prospectively, as if it were a termination of the existing contract and the creation of a new contract, if the remaining goods or services are distinct from the goods or services transferred on or before the date of the contract modification. The Company accounts for a contract modification as if it were a part of the existing contract if the remaining goods or services are not distinct and, therefore, form part of a single performance obligation that is partially satisfied at the date of the contract modification. In such case the effect that the contract modification has on the transaction price, and on the entity&#8217;s measure of progress toward complete satisfaction of the performance obligation, is recognized as an adjustment to revenue (either as an increase in or a reduction of revenue) at the date of the contract modification (the adjustment to revenue is made on a cumulative catch-up basis).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;"><span style="background-color:#ffffff;">The period between when the Company transfers control of promised goods or services and when the Company receives payment is expected to be one year or less, which is consistent with the Company&#8217;s historical experience. Upfront payment contract liabilities resulting from the Company&#8217;s license and collaboration agreements do not represent a financing component as the payment is not financing the transfer of goods and services, and the technology underlying the licenses granted reflects research and development expenses already incurred by the Company. As such, the Company does not adjust its revenues for the effects of a significant financing component.</span><span style="background-color:#ffffff;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred, unless there is an alternate future use in other research and development projects or otherwise. Research and development costs include salaries and benefits, stock-based compensation expense, laboratory supplies and facility-related overhead, outside contracted services including clinical trial costs, manufacturing and process development costs for both clinical and pre-clinical materials, research costs, development milestone payments under license and collaboration agreements, and other consulting services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt;">The Company accrues for estimated costs of research and development activities conducted by third-party service providers, which include the conduct of pre-clinical studies and clinical trials, and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated services provided </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">but not yet invoiced and includes these costs in accrued expenses and other payables in the consolidated balance sheets and within research and development expense in the consolidated statements of operations. The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers. As actual costs become known, the Company adjusts its accrued liabilities. The Company has not experienced any material differences between accrued liabilities and actual costs incurred. However, the status and timing of actual services performed, number of patients enrolled, the rate of patient enrollment and number and location of sites activated may vary from the Company&#8217;s estimates, resulting in adjustments to expense in future periods. Changes in these estimates that result in material changes to the Company&#8217;s accruals could materially affect the Company&#8217;s results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.5pt;margin:0pt 0pt 12pt 0pt;">The Company has received orphan drug designation from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) for its clinical asset rusfertide (generic name for PTG-300) for the treatment of polycythemia vera and beta-thalassemia and may qualify for a related 25% U.S. Federal income tax credit on qualifying clinical study expenditures.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ResearchAndDevelopmentIncentiveGrantPolicyTextBlock', window );">Research and Development Tax Incentive</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Tax Incentive</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Company is eligible under the AusIndustry research and development tax incentive program to obtain either a refundable cash tax incentive or a taxable credit in the form of a non-cash tax incentive from the Australian Taxation Office (&#8220;ATO&#8221;). The refundable cash tax incentive is available to the Company on the basis of specific criteria with which the Company must comply. Specifically, the Company must have annual turnover of less than AUD 20.0 million and cannot be controlled by income tax exempt entities.&#160;The refundable cash tax incentive is recognized as a reduction to research and development expense when the right to receive has been attained and funds are considered to be collectible. The tax incentive is denominated in Australian dollars and, therefore, the related receivable is remeasured into U.S. dollars as of each reporting date. The Company may alternatively be eligible for a taxable credit in the form of a non-cash tax incentive in years when the annual turnover exceeds the limit. The Company evaluates its eligibility under tax incentive programs as of each balance sheet date and makes accrual and related adjustments based on the most current and relevant data available. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_SmallBusinessInnovationResearchSbirGrantsPolicyTextBlock', window );">Small Business Innovation Research ("SBIR") Grants</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Small Business Innovation Research (&#8220;SBIR&#8221;) Grants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Company has received SBIR grants from the National Institutes of Health (&#8220;NIH&#8221;) in support of its research activities. The Company recognizes a reduction to research and development expenses when expenses related to grants have been incurred and the grant funds become contractually due from NIH. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The Company measures its stock-based awards made to its equity plan participants based on the estimated fair values of the awards as of the grant date. For stock option awards, the Company uses the Black-Scholes option-pricing model to estimate fair values. For restricted stock unit awards, the estimated fair value is generally the fair market value of the underlying stock on the grant date. Stock-based compensation expense is recognized over the requisite service period and is based on the value of the portion of stock-based payment awards that is ultimately expected to vest. The Company recognizes forfeitures of stock-based awards as they occur. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net Loss per Share </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is calculated by dividing the Company&#8217;s net loss by the weighted average number of shares of common stock and Exchange Warrants outstanding during the period, without consideration of potentially dilutive securities. In accordance with Accounting Standards Codification Topic 260, <i style="font-style:italic;">Earnings Per Share</i>, the Exchange Warrants are included in the computation of basic net loss per share because the exercise price is negligible and they are fully vested and exercisable after the original issuance date. Diluted net loss per share is the same as basic net loss per share for all periods presented since the effect of potentially dilutive securities is anti-dilutive given the net loss of the Company in each period. See Note 12. Stockholders' Equity for additional information regarding the Exchange Warrants.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements Adopted and Recently Issued Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Recently Adopted Accounting Pronouncements </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">In August 2018, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2018-13, <i style="font-style:italic;">Fair Value Measurement (Topic 820) &#8211; Disclosure Framework &#8211; Changes to the Disclosure Requirements for Fair Value Measurement</i>, which modifies the disclosure requirements on fair value measurements and is intended to improve the effectiveness of disclosures, including the consideration of costs and benefits. The Company adopted this guidance as of January 1, 2020. The adoption of this guidance did not have a material impact on the Company&#8217;s consolidated financial statements or disclosures. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">In November 2018, the FASB issued ASU No. 2018-18, <i style="font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606</i>, which is intended to clarify the circumstances under which certain transactions in collaborative arrangements should be accounted for under the revenue recognition standard. Certain transactions between collaboration arrangement participants should be accounted for as revenue under ASC Topic 606 when the collaborative arrangement participant is a customer in the context of a unit of account. This guidance is effective for fiscal years and interim periods within those years beginning after December 15, 2019. The Company adopted this guidance as of January 1, 2020. The adoption of this guidance did not have a material impact on the Company&#8217;s consolidated financial statements and disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Recently Issued Accounting Pronouncements Not Yet Adopted as of December 31, 2020</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2016, the FASB issued ASU No.&#160;2016-13,&#160;<i style="font-style:italic;">Financial Instruments&#160;- Credit Losses (Topic 326)</i>, which is intended to provide financial statement users with more useful information about expected credit losses on financial assets held by a reporting entity at each reporting date. The new standard replaces the existing incurred loss impairment methodology with a methodology that requires consideration of a broader range of reasonable and supportable forward-looking information to estimate all expected credit losses. This guidance was originally effective for fiscal&#160;years and interim periods within those&#160;years beginning after December&#160;15, 2019, with early adoption permitted for fiscal&#160;years and interim periods within those&#160;years beginning after December&#160;15, 2018. In November 2019, the FASB issued ASU No. 2019-10, <i style="font-style:italic;">Financial Instruments &#8211; Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates</i>, which amended the mandatory effective date of ASU No. 2016-13 for smaller reporting companies. Based on the Company&#8217;s status as a smaller reporting company as of November 15, 2019, ASU 2016-13 is effective for the Company for fiscal years and interim periods beginning after December 15, 2022. The Company is currently evaluating the impact of this new guidance on its consolidated financial statements and disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">In December 2019, the FASB issued ASU No. 2019-12, <i style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, </i>which removes certain exceptions and amends certain requirements in the existing income tax guidance to ease accounting requirements. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020 and must be applied on a retrospective basis. The Company does not expect the adoption of this guidance to have a material impact on its consolidated financial statements and disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_ResearchAndDevelopmentIncentiveGrantPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for research and development incentive grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_ResearchAndDevelopmentIncentiveGrantPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_SmallBusinessInnovationResearchSbirGrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for small business innovation research (SBIR) grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_SmallBusinessInnovationResearchSbirGrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681347759032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of cash as reported in the consolidated statements of cash flows</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:95.58%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> 117,358</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 33,006</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 82,233</p></td></tr><tr><td style="vertical-align:bottom;width:64.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash - current</p></td><td style="vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 10</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:64.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash - noncurrent</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> 450</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 450</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 450</p></td></tr><tr><td style="vertical-align:bottom;width:64.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total cash, cash equivalent and restricted cash in consolidated statements of cash flows</p></td><td style="vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">117,818</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 33,466</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 82,693</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681347876504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreement (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CollaborativeArrangementDisclosureAbstract', window );"><strong>License and Collaboration Agreement.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of changes in contract assets and liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The following table presents changes in the Company&#8217;s contract assets and liabilities during the periods presented (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance&#160;at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance&#160;at</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Beginning&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">End&#160;of</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deductions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract assets:</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Receivable from collaboration partner - related party</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,955</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,221</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,750)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,426</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Contract asset - related party</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 800</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 342</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,142)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract liabilities:</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Deferred revenue - related party</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41,530</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,963</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (31,016)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,477</p></td></tr><tr><td style="vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Payable to collaboration partner - related party</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,262</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,800</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,330)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,732</p></td></tr><tr><td style="vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance&#160;at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance&#160;at</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Beginning&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">End&#160;of</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deductions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract assets:</p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Receivable from collaboration partner - related party</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,042</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,837</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (32,924)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,955</p></td></tr><tr><td style="vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Contract asset - related party</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,545</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 800</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,545)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 800</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract liabilities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Deferred revenue - related party</span></p></td><td style="vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,223</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,456</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,149)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41,530</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Payable to collaboration partner - related party</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,061</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,468</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,267)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,262</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_CollaborativeArrangementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_CollaborativeArrangementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681346315480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of fair value of financial assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The following table presents the fair value of the Company&#8217;s financial assets determined using the inputs defined above (in thousands).</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:46.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,481</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,481</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 65,863</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 65,863</p></td></tr><tr><td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,590</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,590</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury and agency securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 183,210</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 183,210</p></td></tr><tr><td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total financial assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,481</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 276,663</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 304,144</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:46.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12,964</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12,964</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 44,282</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 44,282</p></td></tr><tr><td style="vertical-align:bottom;width:52.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 33,662</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 33,662</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury and agency securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 40,810</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 40,810</p></td></tr><tr><td style="vertical-align:bottom;width:52.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total financial assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12,964</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 118,754</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 131,718</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681354494376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndMarketableSecuritiesAbstract', window );"><strong>Cash Equivalents and Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Schedule of cash equivalents and marketable securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Cash equivalents and marketable securities consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:46.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross&#160;Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,481</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,481</p></td></tr><tr><td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 65,866</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 65,863</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,592</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,590</p></td></tr><tr><td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury and agency securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 183,203</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 183,210</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total cash equivalents and marketable securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 304,142</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 304,144</p></td></tr><tr><td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Classified as:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 113,693</p></td></tr><tr><td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Marketable securities - current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 188,451</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Marketable securities - noncurrent</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,000</p></td></tr><tr><td style="vertical-align:bottom;width:51.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total cash equivalents and marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 304,144</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:45.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross&#160;Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12,964</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12,964</p></td></tr><tr><td style="vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 44,284</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 44,282</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 33,653</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 11</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 33,662</p></td></tr><tr><td style="vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Treasury and agency securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 40,798</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 40,810</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total cash equivalents and marketable securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 131,699</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 27</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 131,718</p></td></tr><tr><td style="vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Classified as:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 31,707</p></td></tr><tr><td style="vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Marketable securities - current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 100,011</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total cash equivalents and marketable securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 131,718</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_CashEquivalentsAndMarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>NA</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_CashEquivalentsAndMarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681354105656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Components</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Summary of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Prepaid expenses and other current assets consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid clinical and research related expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,517</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,567</p></td></tr><tr><td style="vertical-align:bottom;width:74.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,161</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other prepaid expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,009</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,057</p></td></tr><tr><td style="vertical-align:bottom;width:74.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 311</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 744</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Prepaid expenses and other current assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,277</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,529</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment Net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Property and equipment, net consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Laboratory equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,539</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,947</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Furniture and computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 648</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 512</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Leasehold improvements</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 748</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 863</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Total property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,935</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,322</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Less: accumulated depreciation and amortization</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,473)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,641)</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,462</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,681</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Payables</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Accrued expenses and other payables consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:28.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:12.88%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:12.86%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued clinical and research related expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,335</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,232</p></td></tr><tr><td style="vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued employee related expenses</p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,413</p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,637</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued professional service fees</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 668</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 301</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued interest payable</p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 68</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 82</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 122</p></td></tr><tr><td style="vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total accrued expenses and other payables</p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:11.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,498</p></td><td style="vertical-align:bottom;white-space:normal;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:11.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,360</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681354206248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of maturities of long-term debt</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt 0pt 6pt 0pt;">The Company&#8217;s long-term debt balance was as follows for the periods presented (dollars in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Annual </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance at</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Interest Rate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Term loan (maturity date October 1, 2023) </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">7.85%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$<span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$<span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,000</p></td></tr><tr><td style="vertical-align:bottom;width:55.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Debt issuance costs, net of amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (222)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued final payment fees</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16</p></td></tr><tr><td style="vertical-align:middle;width:55.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Long-term debt, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$<span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$<span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,794</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681460813448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_LeaseQuantitativeDisclosureTableTextBlock', window );">Schedule of weighted average lease term and discounts rate</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Operating Lease Term and Discount Rate:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average remaining lease term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3.4 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4.4 years</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average discount rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">11.0%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">11.0%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of minimum lease payments and lease liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the Company&#8217;s minimum lease payments and lease liability as of December&#160;31, 2020 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Year Ending December 31:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,000</p></td></tr><tr><td style="vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,059</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,121</p></td></tr><tr><td style="vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 895</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:84.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total future minimum lease payments</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,075</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">    Less: imputed interest</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,116)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:84.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Present value of future minimum lease payments</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,959</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">    Less: current portion of operating lease liability</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,459)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:84.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease liability - noncurrent</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,500</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of least cost information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Supplemental lease cost information is as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease cost</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,775</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,792</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_LeaseBalanceSheetDisclosureTableTextBlock', window );">Schedule of balance sheet information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Supplemental balance sheet information is as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:10pt;"><td style="vertical-align:bottom;width:68.68%;margin:0pt;padding:0pt;"><div style="height:10pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:10pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:10pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"><div style="height:10pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:10pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:10pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><div style="height:10pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Operating Leases:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:68.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_zm9XCbYtdUWCFJoLceZSNQ;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Operating lease right-of-use asset</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,950</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,042</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:68.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_NUnmw_5Jc0GQOhDxxgb5HA;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Operating lease liability - current</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,459</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,256</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_ffN_Bd0u6EuABPUHJggLOw;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Operating lease liability - noncurrent</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,961</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:68.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_yNAOiRCkP0mEzcqrTZongA;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;">  Total operating lease liabilities</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,959</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,217</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_LeaseCashFlowInformationDisclosureTableTextBlock', window );">Schedule of cash flow information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Supplemental cash flow information is as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Cash paid for amounts included in the measurement of lease liabilities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:67.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating cash flow used by operating leases</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,941</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,885</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_LeaseBalanceSheetDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of lease balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_LeaseBalanceSheetDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_LeaseCashFlowInformationDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of lease cash flow information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_LeaseCashFlowInformationDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_LeaseQuantitativeDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of lease quantitative information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_LeaseQuantitativeDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681347749288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of activity under equity incentive plans</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.5396309%;padding-left:0pt;padding-right:0pt;width:101.07%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:37.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price&#160;Per</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Life&#160;(years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value (1)</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;millions)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balances at December&#160;31,&#160;2019</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,681,521</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.64</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.78</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.4</p></td></tr><tr><td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,536,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.53</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (294,238)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.49</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (275,563)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.54</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balances at December&#160;31,&#160;2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,648,120</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.87</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.61</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40.0</p></td></tr><tr><td style="vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options exercisable &#8211; December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,619,943</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22.1</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options vested and expected to vest &#8211; December&#160;31,&#160;2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,648,120</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.87</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.61</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40.0</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;padding-left:9pt;text-indent:-9pt;margin:3pt 0pt 0pt 0pt;"><b style="font-weight:bold;">____________________</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9pt;text-indent:-9pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1) </sup>The aggregate intrinsic values were calculated as the difference between the exercise price of the options and the closing price of the Company&#8217;s common stock on December 31, 2020. The calculation excludes options with an exercise price higher than the closing price of the Company&#8217;s common stock on December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of stock-based compensation expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">Total stock-based compensation expense was as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:38.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,121</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,350</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,424</p></td></tr><tr><td style="vertical-align:bottom;width:59.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,778</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,003</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,495</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total stock-based compensation expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,899</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,353</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,919</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Black-Scholes option-pricing model assumptions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:57.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:40.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (in years)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5.27 - 6.08 </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5.00 - 6.08 </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5.49 - 6.08</p></td></tr><tr><td style="vertical-align:bottom;width:57.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">72.1% - 87.5%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">61.0% - 64.8%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">62.0% - 66.5%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.23% - 1.44%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1.42% - 2.58%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2.42% - 3.03%</p></td></tr><tr><td style="vertical-align:bottom;width:57.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of activity under equity incentive plans</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted </b></p></td></tr><tr><td style="vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Unvested at December&#160;31,&#160;2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 278,482</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10.08</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 142,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.80</p></td></tr><tr><td style="vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (131,147)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.52</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (44,790)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.67</p></td></tr><tr><td style="vertical-align:bottom;width:69.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Unvested at December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 244,545</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.31</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP rights</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Black-Scholes option-pricing model assumptions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.4488411%;padding-left:0pt;padding-right:0pt;width:100.89%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:41.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr style="height:8.15pt;"><td style="vertical-align:bottom;width:57.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (in years)</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.35pt 0pt 0pt;">0.50</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.50</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.50</p></td></tr><tr><td style="vertical-align:bottom;width:57.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">89.1% - 120.4%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">58.9% - 65.3%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">49.0% - 63.4%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate </p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">0.12% - 0.43%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1.89% - 2.32%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1.89% - 2.32%</p></td></tr><tr><td style="vertical-align:bottom;width:57.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend yield </p></td><td style="vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681348554424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of domestic and foreign components of net loss</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The following table presents domestic and foreign components of net loss before income taxes (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:54.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Domestic</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (71,073)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (72,271)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (37,511)</p></td></tr><tr><td style="vertical-align:bottom;width:43.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,228</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,607)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,212)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Total net loss before taxes</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (64,845)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (77,878)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (39,723)</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of federal, state and foreign of the income tax expense (benefit)</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:38.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current:</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Federal</span></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">State </p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Foreign</p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (88)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total current tax (benefit) expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (88)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred:</p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Federal</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   State</span></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Foreign</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,393</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (775)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (799)</p></td></tr><tr><td style="vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax expense (benefit)</p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,393</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (775)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (799)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total income tax expense (benefit)</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,305</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (691)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (799)</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of provision differences from federal statutory rate</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal statutory income tax rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:60.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development credits</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.5</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.3</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.3)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign tax rate difference</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (34.3)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (23.8)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22.2)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:60.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Provision (benefit) for income taxes</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.0)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.9</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of components of deferred tax assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">The components of the deferred tax assets are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,272</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,907</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Depreciation and amortization</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,237</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 318</p></td></tr><tr><td style="vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accruals/other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,332</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,454</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating lease liability</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,252</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,516</p></td></tr><tr><td style="vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development and foreign credits&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,856</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,038</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total deferred tax assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 72,949</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55,233</p></td></tr><tr><td style="vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating right-of-use asset</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,040)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,269)</p></td></tr><tr><td style="vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,040)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,269)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valuation allowance</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (71,909)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (52,531)</p></td></tr><tr><td style="vertical-align:middle;width:68.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,433</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of reconciliation of beginning and ending unrecognized tax benefits</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 12pt 0pt;">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:43.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Balance at beginning of year</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,631</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,466</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,414</p></td></tr><tr><td style="vertical-align:bottom;width:55.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">(Decreases) increases based on tax positions related to prior years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,799)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 184</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 108</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Increases based on tax positions related to current year</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,053</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,981</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,944</p></td></tr><tr><td style="vertical-align:bottom;width:55.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Balance at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,885</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,631</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,466</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=121610041&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681346280648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of computation of the basic and diluted net loss per share attributable to common stockholders</a></td>
<td class="text"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:40.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (66,150)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (77,187)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (38,924)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted-average shares used to compute net loss per common share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,396,446</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,894,024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,364,515</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per shares, basic and diluted</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.92)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.98)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.74)</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of potentially dilutive securities excluded from diluted net loss per share calculations</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options to purchase common stock</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,648,120</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,681,521</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,178,441</p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Common stock warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,750,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,750,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,750,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted stock units</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 244,545</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 278,482</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 418,450</p></td></tr><tr><td style="vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ESPP shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,445</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,275</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,134</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,671,110</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,750,278</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,399,025</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681348691032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Description of Business - Liquidity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsNoteDisclosureAbstract', window );"><strong>Net losses from operations since inception</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (283,811)<span></span>
</td>
<td class="num">$ (217,661)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681346534696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Concentrations of Credit Risk (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>Institution</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashNumberOfFinancialInstitutions', window );">Number of financial institutions at which cash is held</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_CashNumberOfFinancialInstitutions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of financial institutions that hold the entity's cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_CashNumberOfFinancialInstitutions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681348583144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Cash and Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Aggregate amounts of cash and cash equivalents and the restricted cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 117,358<span></span>
</td>
<td class="nump">$ 33,006<span></span>
</td>
<td class="nump">$ 82,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash - current</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash - noncurrent</a></td>
<td class="nump">450<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalent and restricted cash in consolidated statements of cash flows</a></td>
<td class="nump">$ 117,818<span></span>
</td>
<td class="nump">$ 33,466<span></span>
</td>
<td class="nump">$ 82,693<span></span>
</td>
<td class="nump">$ 106,489<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681347764792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Property and Equipment and Impairment of Long-Lived Assets (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Impairments of long-lived assets</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TangibleAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TangibleAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681354517016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense', window );">Interest or penalties recorded in relation to unrecognized tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681342913384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreement (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 07, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jul. 13, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Upfront payments and fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,100<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">$ 23,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Costs to obtain or fulfill the contract that were capitalized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ptgx_LicenseAndCollaborativeRevenueMember', window );">License and Collaborative Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurred', window );">Development cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ptgx_SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember', window );">Second-Generation Analog, Phase 3 CD Clinical Trial Primary Clinical Endpoint [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurred', window );">Development cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ptgx_SecondGenerationAnalogPhase2CdClinicalTrialPrimaryClinicalEndpointMember', window );">Second Generation Analog Phase 2 Cd Clinical Trial Primary Clinical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurred', window );">Development cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ptgx_PhaseTwoClinicalTrialMember', window );">Phase 2 clinical trial | Additional services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ptgx_LicenseAndCollaborativeAgreementAmendmentMember', window );">First Amendment | Development, regulatory and sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ContingentConsiderationReceivable', window );">Eligible payment receivable</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ptgx_LicenseAndCollaborativeAgreementAmendmentMember', window );">First Amendment | Development, regulatory and sales milestone payments | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_PercentagesRoyaltiesOnNetProductSales', window );">Percentages on net product sales</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember', window );">Janssen Biotech, Inc. | License and Collaborative Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,600<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">30,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember', window );">Janssen Biotech, Inc. | Additional services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember', window );">Janssen Biotech, Inc. | Second-Generation Analog, Phase 3 CD Clinical Trial Primary Clinical Endpoint [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurred', window );">Development cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember', window );">Janssen Biotech, Inc. | License and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice', window );">Increase (decrease) in transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (14,300)<span></span>
</td>
<td class="nump">37,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,600<span></span>
</td>
<td class="nump">112,900<span></span>
</td>
<td class="nump">60,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember', window );">Janssen Biotech, Inc. | License and Collaboration Agreement | Upfront cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Upfront payments and fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember', window );">Janssen Biotech, Inc. | First, second-generation compound | Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CollaborativeArrangementPayableUponEffectivenessOfAmendment', window );">Amount payable upon the effectiveness of the First Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember', window );">Janssen Biotech, Inc. | First, second-generation compound | Second-Generation Analog, Phase 3 CD Clinical Trial Primary Clinical Endpoint [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CollaborativeArrangementPercentageOfResearchProgramCostsIncurred', window );">Research program cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember', window );">Janssen Biotech, Inc. | Second and third, second-generation compounds | Second-Generation Analog, Phase 3 CD Clinical Trial Primary Clinical Endpoint [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CollaborativeArrangementPercentageOfResearchProgramCostsIncurred', window );">Research program cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember', window );">Janssen Biotech, Inc. | Thereafter | Second-Generation Analog, Phase 3 CD Clinical Trial Primary Clinical Endpoint [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CollaborativeArrangementPercentageOfResearchProgramCostsIncurred', window );">Research program cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember', window );">Janssen Biotech, Inc. | Second-Generation Phase 2b Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CollaborativeArrangementPayableUponEffectivenessOfAmendment', window );">Amount payable upon the effectiveness of the First Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember', window );">Janssen Biotech, Inc. | Second-Generation Phase 2b Milestone | Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember', window );">Janssen Biotech, Inc. | Phase 2 clinical trial | License and Collaborative Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember', window );">Janssen Biotech, Inc. | First Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice', window );">Increase (decrease) in transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember', window );">Janssen Biotech, Inc. | First Amendment | License and Collaborative Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CollaborativeArrangementEligibleAmountReceived', window );">Eligible amount received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract', window );">Revenue following contract modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Revenue recognized from performance obligations in previous periods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember', window );">Janssen Biotech, Inc. | First Amendment | PTG-200, Phase 3 CD Clinical Trial Primary Clinical Endpoint</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ContingentConsiderationReceivable', window );">Eligible payment receivable</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember', window );">Janssen Biotech, Inc. | First Amendment | Second-Generation Analog, Phase 3 CD Clinical Trial Primary Clinical Endpoint [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ContingentConsiderationReceivable', window );">Eligible payment receivable</a></td>
<td class="nump">$ 115,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember', window );">Janssen Biotech, Inc. | First Amendment | Second-Generation Phase 2b Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CollaborativeArrangementPayableUponEffectivenessOfAmendment', window );">Amount payable upon the effectiveness of the First Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember', window );">Janssen Biotech, Inc. | Amended First Opt-in | Upfront cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CollaborativeArrangementPayableUponEffectivenessOfAmendment', window );">Amount payable upon the effectiveness of the First Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember', window );">Janssen Biotech, Inc. | Amended Second Opt-in | Upfront cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CollaborativeArrangementPayableUponEffectivenessOfAmendment', window );">Amount payable upon the effectiveness of the First Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember', window );">Janssen Biotech, Inc. | Estimated variable consideration | License and Collaborative Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CollaborativeArrangementPayableUponEffectivenessOfAmendment', window );">Amount payable upon the effectiveness of the First Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember', window );">Janssen Biotech, Inc. | Pro Forma | License and Collaborative Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CollaborativeArrangementPayableUponEffectivenessOfAmendment', window );">Amount payable upon the effectiveness of the First Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember', window );">Janssen Biotech, Inc. | Pro Forma | Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CollaborativeArrangementPayableUponEffectivenessOfAmendment', window );">Amount payable upon the effectiveness of the First Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_CollaborativeArrangementEligibleAmountReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount received from a collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_CollaborativeArrangementEligibleAmountReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_CollaborativeArrangementPayableUponEffectivenessOfAmendment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment payable upon the effectiveness of the First Amendment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_CollaborativeArrangementPayableUponEffectivenessOfAmendment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of development cost incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_CollaborativeArrangementPercentageOfResearchProgramCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of research program cost incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_CollaborativeArrangementPercentageOfResearchProgramCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_ContingentConsiderationReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Consideration Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_ContingentConsiderationReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_PercentagesRoyaltiesOnNetProductSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentages on net product sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_PercentagesRoyaltiesOnNetProductSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=68051541&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from contract modification which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12A<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL108322424-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ptgx_LicenseAndCollaborativeRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ptgx_LicenseAndCollaborativeRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ptgx_SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ptgx_SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ptgx_SecondGenerationAnalogPhase2CdClinicalTrialPrimaryClinicalEndpointMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ptgx_SecondGenerationAnalogPhase2CdClinicalTrialPrimaryClinicalEndpointMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ptgx_PhaseTwoClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ptgx_PhaseTwoClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_FinancialServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_FinancialServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ptgx_LicenseAndCollaborativeAgreementAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ptgx_LicenseAndCollaborativeAgreementAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ptgx_DevelopmentRegulatoryAndSalesMilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ptgx_DevelopmentRegulatoryAndSalesMilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ptgx_UpfrontCashPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ptgx_UpfrontCashPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ptgx_CollaborationAgreementTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ptgx_CollaborationAgreementTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ptgx_MilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ptgx_MilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ptgx_CollaborationAgreementTrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ptgx_CollaborationAgreementTrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ptgx_CollaborationAgreementTrancheFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ptgx_CollaborationAgreementTrancheFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ptgx_SecondGenerationDevelopmentCompoundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ptgx_SecondGenerationDevelopmentCompoundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ptgx_Ptg200Phase3CdClinicalTrialPrimaryClinicalEndpointMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ptgx_Ptg200Phase3CdClinicalTrialPrimaryClinicalEndpointMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ptgx_SecondGenerationPhase2bMilestonePaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ptgx_SecondGenerationPhase2bMilestonePaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ptgx_AmendedCollaborationAgreementTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ptgx_AmendedCollaborationAgreementTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ptgx_AmendedSecondOptInMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ptgx_AmendedSecondOptInMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ptgx_EstimatedVariableConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ptgx_EstimatedVariableConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ProFormaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ProFormaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681355211784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreement - Contract Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ContractWithCustomerLiabilityNetRollForward', window );"><strong>Deferred revenue - related party</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Balance at Beginning of Period</a></td>
<td class="nump">$ 17,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Balance at End of Period</a></td>
<td class="nump">14,477<span></span>
</td>
<td class="nump">$ 17,738<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_PayableToCollaborationPartnerRelatedPartyAbstract', window );"><strong>Payable to collaboration partner - related party</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Balance at Beginning of Period</a></td>
<td class="nump">1,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Balance at End of Period</a></td>
<td class="nump">2,732<span></span>
</td>
<td class="nump">1,262<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember', window );">Janssen Biotech, Inc. | License and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ContractWithCustomerAssetNetRollForward', window );"><strong>Receivable from collaboration partner - related party</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Balance at Beginning of Period</a></td>
<td class="nump">5,955<span></span>
</td>
<td class="nump">2,042<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ContractWithCustomerAssetAdditions', window );">Additions</a></td>
<td class="nump">6,221<span></span>
</td>
<td class="nump">36,837<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ContractWithCustomerAssetDeduction', window );">Deductions</a></td>
<td class="num">(9,750)<span></span>
</td>
<td class="num">(32,924)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Balance at End of Period</a></td>
<td class="nump">2,426<span></span>
</td>
<td class="nump">5,955<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrentAbstract', window );"><strong>Contract asset - related party</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract asset - related party, Balance at Beginning of Period</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">2,545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ContractWithCustomerAssetRelatedPartyAdditions', window );">Contract asset - related party, Additions</a></td>
<td class="nump">342<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ContractWithCustomerAssetRelatedPartyDeduction', window );">Contract asset - related party, Deductions</a></td>
<td class="num">(1,142)<span></span>
</td>
<td class="num">(2,545)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract asset - related party, Balance at End of Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ContractWithCustomerLiabilityNetRollForward', window );"><strong>Deferred revenue - related party</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Balance at Beginning of Period</a></td>
<td class="nump">41,530<span></span>
</td>
<td class="nump">8,223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ContractWithCustomerLiabilityAdditions', window );">Additions</a></td>
<td class="nump">3,963<span></span>
</td>
<td class="nump">42,456<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ContractWithCustomerLiabilityDeduction', window );">Deductions</a></td>
<td class="num">(31,016)<span></span>
</td>
<td class="num">(9,149)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Balance at End of Period</a></td>
<td class="nump">14,477<span></span>
</td>
<td class="nump">41,530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_PayableToCollaborationPartnerRelatedPartyAbstract', window );"><strong>Payable to collaboration partner - related party</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Balance at Beginning of Period</a></td>
<td class="nump">1,262<span></span>
</td>
<td class="nump">1,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_DueToRelatedPartyAdditions', window );">Additions</a></td>
<td class="nump">3,800<span></span>
</td>
<td class="nump">1,468<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_DueToRelatedPartyDeductions', window );">Deductions</a></td>
<td class="num">(2,330)<span></span>
</td>
<td class="num">(1,267)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Balance at End of Period</a></td>
<td class="nump">$ 2,732<span></span>
</td>
<td class="nump">$ 1,262<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_ContractWithCustomerAssetAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Addition in the amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_ContractWithCustomerAssetAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_ContractWithCustomerAssetDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deduction in the amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_ContractWithCustomerAssetDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_ContractWithCustomerAssetNetRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_ContractWithCustomerAssetNetRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_ContractWithCustomerAssetRelatedPartyAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Addition in the amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to a related party when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_ContractWithCustomerAssetRelatedPartyAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_ContractWithCustomerAssetRelatedPartyDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deduction in the amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to related party when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_ContractWithCustomerAssetRelatedPartyDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_ContractWithCustomerLiabilityAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Addition in the amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_ContractWithCustomerLiabilityAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_ContractWithCustomerLiabilityDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deduction in the amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_ContractWithCustomerLiabilityDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_ContractWithCustomerLiabilityNetRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_ContractWithCustomerLiabilityNetRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_DueToRelatedPartyAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional amount of payable due to a related party</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_DueToRelatedPartyAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_DueToRelatedPartyDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deduction from obligation to transfer good or service to related party for payable amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_DueToRelatedPartyDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_PayableToCollaborationPartnerRelatedPartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_PayableToCollaborationPartnerRelatedPartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681349403560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Fair Value of Long-term Debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">304,144<span></span>
</td>
<td class="nump">$ 131,718<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">27,481<span></span>
</td>
<td class="nump">12,964<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">65,863<span></span>
</td>
<td class="nump">44,282<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">27,590<span></span>
</td>
<td class="nump">33,662<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | U.S. Treasury and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">183,210<span></span>
</td>
<td class="nump">40,810<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">27,481<span></span>
</td>
<td class="nump">12,964<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1 | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">27,481<span></span>
</td>
<td class="nump">12,964<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">276,663<span></span>
</td>
<td class="nump">118,754<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2 | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">65,863<span></span>
</td>
<td class="nump">44,282<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">27,590<span></span>
</td>
<td class="nump">33,662<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2 | U.S. Treasury and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">$ 183,210<span></span>
</td>
<td class="nump">$ 40,810<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=ptgx_UsTreasuryAndAgencySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=ptgx_UsTreasuryAndAgencySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681425832184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities - Cash Equivalents and Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems', window );"><strong>Cash Equivalents and Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost', window );">Total cash equivalents and marketable securities, Amortized Cost</a></td>
<td class="nump">$ 304,142<span></span>
</td>
<td class="nump">$ 131,699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain', window );">Total cash equivalents and marketable securities, Gross Unrealized Gains</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss', window );">Total cash equivalents and marketable securities, Gross Unrealized Losses</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndMarketableSecuritiesFairValue', window );">Total cash equivalents and marketable securities, Fair Value</a></td>
<td class="nump">304,144<span></span>
</td>
<td class="nump">131,718<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems', window );"><strong>Cash Equivalents and Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost', window );">Total cash equivalents and marketable securities, Amortized Cost</a></td>
<td class="nump">27,592<span></span>
</td>
<td class="nump">33,653<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain', window );">Total cash equivalents and marketable securities, Gross Unrealized Gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss', window );">Total cash equivalents and marketable securities, Gross Unrealized Losses</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndMarketableSecuritiesFairValue', window );">Total cash equivalents and marketable securities, Fair Value</a></td>
<td class="nump">27,590<span></span>
</td>
<td class="nump">33,662<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=ptgx_UsTreasuryAndAgencySecuritiesMember', window );">U.S. Treasury and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems', window );"><strong>Cash Equivalents and Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost', window );">Total cash equivalents and marketable securities, Amortized Cost</a></td>
<td class="nump">183,203<span></span>
</td>
<td class="nump">40,798<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain', window );">Total cash equivalents and marketable securities, Gross Unrealized Gains</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss', window );">Total cash equivalents and marketable securities, Gross Unrealized Losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndMarketableSecuritiesFairValue', window );">Total cash equivalents and marketable securities, Fair Value</a></td>
<td class="nump">183,210<span></span>
</td>
<td class="nump">40,810<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems', window );"><strong>Cash Equivalents and Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost', window );">Total cash equivalents and marketable securities, Amortized Cost</a></td>
<td class="nump">27,481<span></span>
</td>
<td class="nump">12,964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndMarketableSecuritiesFairValue', window );">Total cash equivalents and marketable securities, Fair Value</a></td>
<td class="nump">27,481<span></span>
</td>
<td class="nump">12,964<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems', window );"><strong>Cash Equivalents and Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost', window );">Total cash equivalents and marketable securities, Amortized Cost</a></td>
<td class="nump">65,866<span></span>
</td>
<td class="nump">44,284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain', window );">Total cash equivalents and marketable securities, Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss', window );">Total cash equivalents and marketable securities, Gross Unrealized Losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndMarketableSecuritiesFairValue', window );">Total cash equivalents and marketable securities, Fair Value</a></td>
<td class="nump">$ 65,863<span></span>
</td>
<td class="nump">$ 44,282<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt and equity securities, including cash equivalents which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_CashEquivalentsAndMarketableSecuritiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value of amount of investment in debt and equity securities and cash equivalents categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_CashEquivalentsAndMarketableSecuritiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain before deducting unrealized loss on investments in debt and equity securities classified as cash equivalents and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss before deducting unrealized gain on investments in cash equivalents and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=ptgx_UsTreasuryAndAgencySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=ptgx_UsTreasuryAndAgencySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681354835256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities - Classification of Cash Equivalents and Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAndCashAbstract', window );"><strong>Classified as:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 113,693<span></span>
</td>
<td class="nump">$ 31,707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities - current</a></td>
<td class="nump">188,451<span></span>
</td>
<td class="nump">100,011<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities - noncurrent</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CashEquivalentsAndMarketableSecuritiesFairValue', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">$ 304,144<span></span>
</td>
<td class="nump">131,718<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract', window );"><strong>Contractual maturities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CurrentContractualMaturitiesMaximumPeriod', window );">Maximum period of current contractual maturities</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_NoncurrentContractualMaturitiesMinimumPeriod', window );">Minimum period of noncurrent contractual maturities</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_NoncurrentContractualMaturitiesMaximumPeriod', window );">Maximum period of Noncurrent contractual maturities</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments', window );">Realized Gain (loss)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_CashEquivalentsAndMarketableSecuritiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value of amount of investment in debt and equity securities and cash equivalents categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_CashEquivalentsAndMarketableSecuritiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_CurrentContractualMaturitiesMaximumPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum period of current contractual maturities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_CurrentContractualMaturitiesMaximumPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_NoncurrentContractualMaturitiesMaximumPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum period of contractual maturities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_NoncurrentContractualMaturitiesMaximumPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_NoncurrentContractualMaturitiesMinimumPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the minimum period of noncurrent contractual maturities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_NoncurrentContractualMaturitiesMinimumPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in marketable security, excluding other-than-temporary impairment (OTTI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681347740024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_PrepaidManufacturingOfClinicalMaterials', window );">Prepaid clinical and research related expenses</a></td>
<td class="nump">$ 3,517<span></span>
</td>
<td class="nump">$ 2,567<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">1,440<span></span>
</td>
<td class="nump">1,161<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid expenses</a></td>
<td class="nump">1,009<span></span>
</td>
<td class="nump">1,057<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivable</a></td>
<td class="nump">311<span></span>
</td>
<td class="nump">744<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 6,277<span></span>
</td>
<td class="nump">$ 5,529<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_PrepaidManufacturingOfClinicalMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for Prepaid manufacturing of clinical materials that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_PrepaidManufacturingOfClinicalMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681349394344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components - Property and Equipment, Net (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 4,935,000<span></span>
</td>
<td class="nump">$ 4,322,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(3,473,000)<span></span>
</td>
<td class="num">(2,641,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,462,000<span></span>
</td>
<td class="nump">1,681,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract', window );"><strong>Property and equipment income statement disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">789,000<span></span>
</td>
<td class="nump">703,000<span></span>
</td>
<td class="nump">$ 527,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ptgx_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">3,539,000<span></span>
</td>
<td class="nump">2,947,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ptgx_FurnitureAndComputerEquipmentMember', window );">Furniture and computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">648,000<span></span>
</td>
<td class="nump">512,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">748,000<span></span>
</td>
<td class="nump">863,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_AU', window );">Australia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 46,000<span></span>
</td>
<td class="nump">$ 37,000<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ptgx_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ptgx_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ptgx_FurnitureAndComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ptgx_FurnitureAndComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_AU">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_AU</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681347844360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Accrued Expenses and Other Payables (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Expenses and Other Payables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_AccruedClinicalAndResearchRelatedExpensesCurrent', window );">Accrued clinical and research related expenses</a></td>
<td class="nump">$ 11,335<span></span>
</td>
<td class="nump">$ 7,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued employee related expenses</a></td>
<td class="nump">6,413<span></span>
</td>
<td class="nump">4,637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional service fees</a></td>
<td class="nump">668<span></span>
</td>
<td class="nump">301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses and other payables</a></td>
<td class="nump">$ 18,498<span></span>
</td>
<td class="nump">$ 12,360<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_AccruedClinicalAndResearchRelatedExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current portion of accrued clinical and research related expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_AccruedClinicalAndResearchRelatedExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681437604584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research Collaboration and License Agreement (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Research Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="nump">$ 74,506,000<span></span>
</td>
<td class="nump">$ 65,003,000<span></span>
</td>
<td class="nump">$ 59,497,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member', window );">Research Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Research Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_NumberOfDevelopmentMilestonePayments', window );">Number of development milestone payments | item</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_AggregateAmountOfDevelopmentMilestonePayment', window );">Aggregate development milestone payment</a></td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member', window );">Research Collaboration and License Agreement | Phase 2b | Minimum | Entity Required to Continue to Make Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Research Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_AdditionalPaymentObligationToFormerCollaborationPartner', window );">Additional payment obligation to the former collaboration partner</a></td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member', window );">Research Collaboration and License Agreement | Phase 2b | Maximum | Entity Required to Continue to Make Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Research Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_AdditionalPaymentObligationToFormerCollaborationPartner', window );">Additional payment obligation to the former collaboration partner</a></td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member', window );">Research Collaboration and License Agreement | Phase 3 | Minimum | Entity Required to Continue to Make Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Research Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_AdditionalPaymentObligationToFormerCollaborationPartner', window );">Additional payment obligation to the former collaboration partner</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member', window );">Research Collaboration and License Agreement | Phase 3 | Maximum | Entity Required to Continue to Make Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Research Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_AdditionalPaymentObligationToFormerCollaborationPartner', window );">Additional payment obligation to the former collaboration partner</a></td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_AdditionalPaymentObligationToFormerCollaborationPartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional payment obligation from the company to the former collaboration partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_AdditionalPaymentObligationToFormerCollaborationPartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_AggregateAmountOfDevelopmentMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of development milestone payment made by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_AggregateAmountOfDevelopmentMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_NumberOfDevelopmentMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of development milestone payments in collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_NumberOfDevelopmentMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ptgx_PhaseTwoBClinicalTrailOfPtg300Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ptgx_PhaseTwoBClinicalTrailOfPtg300Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ptgx_EntityRequiredToContinueToMakePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ptgx_EntityRequiredToContinueToMakePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ptgx_PhaseThreeClinicalTrailOfPtg300Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ptgx_PhaseThreeClinicalTrailOfPtg300Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681432753784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Government Programs (Details)<br> $ in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="6">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>AUD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>AUD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>AUD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>AUD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_GovernmentProgramsLineItems', window );"><strong>Government Programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Research and development tax incentive receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_RevenueSourceAxis=ptgx_SmallBusinessInnovationResearchGrantMember', window );">SBIR Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_GovernmentProgramsLineItems', window );"><strong>Government Programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ResearchAndDevelopmentExpensesReduction', window );">Reduction of research and development expenses related to tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ResearchAndDevelopmentGrants', window );">Research and development grants</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Grants receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_AustralianTaxationOfficeMember', window );">Australian</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_GovernmentProgramsLineItems', window );"><strong>Government Programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ResearchAndDevelopmentExpensesReduction', window );">Reduction of research and development expenses related to tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="nump">$ 1.9<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="nump">$ 2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=ptgx_OverseasFindingsMember', window );">Overseas Findings | Australian</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_GovernmentProgramsLineItems', window );"><strong>Government Programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Research and development tax incentive receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_GovernmentProgramsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_GovernmentProgramsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_ResearchAndDevelopmentExpensesReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of reduction of research and development expense in connection with the research and development tax incentive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_ResearchAndDevelopmentExpensesReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_ResearchAndDevelopmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of research and development grants awarded during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_ResearchAndDevelopmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_RevenueSourceAxis=ptgx_SmallBusinessInnovationResearchGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_RevenueSourceAxis=ptgx_SmallBusinessInnovationResearchGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_AustralianTaxationOfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_AustralianTaxationOfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=ptgx_OverseasFindingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=ptgx_OverseasFindingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681426611560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Oct. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early repayment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (585)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ptgx_TermLoanCreditAgreementMember', window );">Term Loan Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Loan facility for general corporate</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_DebtInstrumentTrancheInstallmentAmount', window );">Tranche Installment Amount</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_DebtInstrumentThresholdPercentageOnOutstandingDebtToBeMaintainedAsCashAndCashEquivalentsBalance', window );">Cash and cash equivalents ( In percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_DebtInstrumentLoanOriginationFeePercentage', window );">Loan Origination Fee (In Percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_DebtInstrumentPeriodOfInterestOnlyPayments', window );">Period Of Interest Only Payments</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_DebtInstrumentPeriodOfPrincipalAndInterestPayments', window );">Consecutive monthly payments</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_DebtInstrumentAdditionalPrepaymentOrRepaymentPremiumPercentage', window );">Additional Prepayment (In Percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Outstanding balance paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early repayment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Prepayment and exit fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet', window );">Accelerated capitalized and unamortized debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember', window );">Prime Rate | Term Loan Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">prime rate (In Percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.91%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_DebtInstrumentFloorRate', window );">Floor rate (In Percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.94%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=ptgx_DebtInstrumentRepaymentOnOrBeforeFirstAnniversaryMember', window );">Debt Instrument Repayment On Or Before First Anniversary | Term Loan Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_DebtInstrumentPrepaymentPremiumPercentage', window );">Prepayment premium (In Percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=ptgx_DebtInstrumentRepaymentBetweenFirstAndSecondAnniversaryMember', window );">Debt Instrument Repayment Between First And Second Anniversary | Term Loan Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_DebtInstrumentPrepaymentPremiumPercentage', window );">Prepayment premium (In Percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=ptgx_DebtInstrumentRepaymentAfterSecondAnniversaryMember', window );">Debt Instrument Repayment After Second Anniversary | Term Loan Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_DebtInstrumentPrepaymentPremiumPercentage', window );">Prepayment premium (In Percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_DebtInstrumentAdditionalPrepaymentOrRepaymentPremiumPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The additional percentage of prepayment premium on the amount advanced by the lenders will be due upon prepayments or repayment of the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_DebtInstrumentAdditionalPrepaymentOrRepaymentPremiumPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_DebtInstrumentFloorRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the floor rate of the debt instrument</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_DebtInstrumentFloorRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_DebtInstrumentLoanOriginationFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of loan origination fee under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_DebtInstrumentLoanOriginationFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_DebtInstrumentPeriodOfInterestOnlyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the period for which the company is required to pay interest-only payments on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_DebtInstrumentPeriodOfInterestOnlyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_DebtInstrumentPeriodOfPrincipalAndInterestPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the period for which the company will pay principal and interest payments on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_DebtInstrumentPeriodOfPrincipalAndInterestPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_DebtInstrumentPrepaymentPremiumPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of prepayment premium under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_DebtInstrumentPrepaymentPremiumPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_DebtInstrumentThresholdPercentageOnOutstandingDebtToBeMaintainedAsCashAndCashEquivalentsBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage on outstanding debt to be maintained as balance under cash and cash equivalents by the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_DebtInstrumentThresholdPercentageOnOutstandingDebtToBeMaintainedAsCashAndCashEquivalentsBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_DebtInstrumentTrancheInstallmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the tranche installment amount under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_DebtInstrumentTrancheInstallmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount (premium).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28567-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ptgx_TermLoanCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ptgx_TermLoanCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ptgx_DebtInstrumentRepaymentOnOrBeforeFirstAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ptgx_DebtInstrumentRepaymentOnOrBeforeFirstAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ptgx_DebtInstrumentRepaymentBetweenFirstAndSecondAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ptgx_DebtInstrumentRepaymentBetweenFirstAndSecondAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ptgx_DebtInstrumentRepaymentAfterSecondAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ptgx_DebtInstrumentRepaymentAfterSecondAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681347827880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Long-term debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Term loan (matures October 1, 2023)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs, net of amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(222)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_DebtInstrumentAccruedFinalPaymentFee', window );">Accrued final payment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,794<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Annual interest rate</a></td>
<td class="nump">7.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate on long-term debt</a></td>
<td class="nump">9.85%<span></span>
</td>
<td class="nump">9.81%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_DebtInstrumentAccruedFinalPaymentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of accrued final payment fee under the debt instrument arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_DebtInstrumentAccruedFinalPaymentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681348669880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Agreement (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($) </div>
<div>lease</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="nump">$ 450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89,400<span></span>
</td>
<td class="nump">$ 64,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_CA', window );">Newark, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_NumberOfOperatingLeaseAgreement', window );">Number of operating lease agreement | lease</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_NumberOfOperatingLeaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of operating lease agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_NumberOfOperatingLeaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681347877064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Weighted average lease term and discount rate (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
<td class="text">4 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681349709048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Minimum lease payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Minimum lease payments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">2,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">2,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">7,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(1,116)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of future minimum lease payments</a></td>
<td class="nump">5,959<span></span>
</td>
<td class="nump">$ 7,217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion of operating lease liability</a></td>
<td class="num">(1,459)<span></span>
</td>
<td class="num">(1,256)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability - noncurrent</a></td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="nump">$ 5,961<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681346242488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Lease cost information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 1,775<span></span>
</td>
<td class="nump">$ 1,792<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681353996168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Supplemental balance sheet information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorDisclosureAbstract', window );"><strong>Operating Leases:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">$ 4,950<span></span>
</td>
<td class="nump">$ 6,042<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Financial position</a></td>
<td class="text">us-gaap:OperatingLeaseRightOfUseAsset<span></span>
</td>
<td class="text">us-gaap:OperatingLeaseRightOfUseAsset<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability - current</a></td>
<td class="nump">$ 1,459<span></span>
</td>
<td class="nump">$ 1,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Financial position</a></td>
<td class="text">us-gaap:OperatingLeaseLiabilityCurrent<span></span>
</td>
<td class="text">us-gaap:OperatingLeaseLiabilityCurrent<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability - noncurrent</a></td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="nump">$ 5,961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Financial position</a></td>
<td class="text">us-gaap:OperatingLeaseLiabilityNoncurrent<span></span>
</td>
<td class="text">us-gaap:OperatingLeaseLiabilityNoncurrent<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 5,959<span></span>
</td>
<td class="nump">$ 7,217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList', window );">Financial position</a></td>
<td class="text">us-gaap:OperatingLeaseLiabilityCurrent us-gaap:OperatingLeaseLiabilityNoncurrent<span></span>
</td>
<td class="text">us-gaap:OperatingLeaseLiabilityCurrent us-gaap:OperatingLeaseLiabilityNoncurrent<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681354499224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Cash flow information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flow used by operating leases</a></td>
<td class="nump">$ 1,941<span></span>
</td>
<td class="nump">$ 1,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681347719176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - Zealand Pharma<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Amount of damages sought</a></td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_ZealandPharmaMember', window );">Successfully develop and commercialize Rusfertide Component with out partner</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_PotentialDevelopmentAndRegulatoryMilestonePaymentsOnContractualObligation', window );">Potential development and regulatory milestone payments on contractual obligation</a></td>
<td class="nump">28.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_PotentialSalesMilestonePaymentsOnContractualObligation', window );">Potential sales milestone payments on contractual obligation</a></td>
<td class="nump">$ 100.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_PotentialDevelopmentAndRegulatoryMilestonePaymentsOnContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of potential development and regulatory milestone payments on contractual obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_PotentialDevelopmentAndRegulatoryMilestonePaymentsOnContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_PotentialSalesMilestonePaymentsOnContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount if potential sales milestone payments on contractual obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_PotentialSalesMilestonePaymentsOnContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ptgx_ZealandPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ptgx_ZealandPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ptgx_SuccessfullyDevelopAndCommercializeRusfertideComponentWithOutPartnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ptgx_SuccessfullyDevelopAndCommercializeRusfertideComponentWithOutPartnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681344028120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 21, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Oct. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Aug. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Aug. 06, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockDisclosuresAbstract', window );"><strong>Stock transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from public offering of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 213,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ptgx_CommonStockPreferredStockAndCertainDebtSecuritiesMember', window );">2017 Form S-3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockDisclosuresAbstract', window );"><strong>Stock transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_SaleOfStockValueOfSharesAuthorized', window );">Maximum aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember', window );">2019 Form S-3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockDisclosuresAbstract', window );"><strong>Stock transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_SaleOfStockValueOfSharesAuthorized', window );">Maximum aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockDisclosuresAbstract', window );"><strong>Stock transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.00<span></span>
</td>
<td class="nump">$ 14.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,761,904<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,526,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Issuance of common stock upon exercise of Exchange Warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">599,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | 2019 Form S-3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockDisclosuresAbstract', window );"><strong>Stock transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,483,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from public offering of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Underwriter overallotment option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockDisclosuresAbstract', window );"><strong>Stock transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.00<span></span>
</td>
<td class="nump">$ 14.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">714,285<span></span>
</td>
<td class="nump">1,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from public offering of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockDisclosuresAbstract', window );"><strong>Stock transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_NumberOfWarrantsExercised', window );">Number of warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | 2017 Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockDisclosuresAbstract', window );"><strong>Stock transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,846,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from public offering of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_AtMarketOfferingMember', window );">At-the-market offering (ATM)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockDisclosuresAbstract', window );"><strong>Stock transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_SaleOfStockValueOfSharesAuthorized', window );">Maximum aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_AtMarketOfferingMember', window );">At-the-market offering (ATM) | 2019 Form S-3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockDisclosuresAbstract', window );"><strong>Stock transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_SaleOfStockValueOfSharesAuthorized', window );">Maximum aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_AtMarketOfferingMember', window );">At-the-market offering (ATM) | 2017 Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockDisclosuresAbstract', window );"><strong>Stock transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_SaleOfStockValueOfSharesAuthorized', window );">Maximum aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember', window );">Investors | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockDisclosuresAbstract', window );"><strong>Stock transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_AggregateGrossProceedsFromIssuanceStock', window );">Aggregate gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember', window );">Investors | Common Stock | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockDisclosuresAbstract', window );"><strong>Stock transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock, number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,750,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ptgx_ExchangeAgreementMember', window );">Exchange Agreement | Exchanging Stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockDisclosuresAbstract', window );"><strong>Stock transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock, number of shares</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_StockExchangedForPreFundedWarrants', window );">Common stock exchanged for pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value (per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ClassOfWarrantOrRightTermOfWarrants', window );">Duration of warrants from date of issuance (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ptgx_ExchangeAgreementMember', window );">Exchange Agreement | Exchanging Stockholders | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockDisclosuresAbstract', window );"><strong>Stock transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_NumberOfWarrantsExercised', window );">Number of warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Issuance of common stock upon exercise of Exchange Warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">599,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Exchange warrants unexercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ptgx_WarrantsPurchaseAmountPerSharePriceOneMember', window );">Group one | Common Stock | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockDisclosuresAbstract', window );"><strong>Stock transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares to be converted for each warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,375,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ptgx_WarrantsPurchaseAmountPerSharePriceTwoMember', window );">Group two | Common Stock | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockDisclosuresAbstract', window );"><strong>Stock transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares to be converted for each warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,375,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_AggregateGrossProceedsFromIssuanceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_AggregateGrossProceedsFromIssuanceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_ClassOfWarrantOrRightTermOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The duration of warrants from date of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_ClassOfWarrantOrRightTermOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_NumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants exercised for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_NumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_SaleOfStockValueOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of shares permits the offering, issuance, and sale by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_SaleOfStockValueOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_StockExchangedForPreFundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares exchanged for pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_StockExchangedForPreFundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ptgx_CommonStockPreferredStockAndCertainDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ptgx_CommonStockPreferredStockAndCertainDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ptgx_SalesAgreementFrom2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ptgx_SalesAgreementFrom2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ptgx_AtMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ptgx_AtMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ptgx_ExchangeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ptgx_ExchangeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ptgx_BiotechnologyValueFundL.pMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ptgx_BiotechnologyValueFundL.pMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ptgx_WarrantsPurchaseAmountPerSharePriceOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ptgx_WarrantsPurchaseAmountPerSharePriceOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ptgx_WarrantsPurchaseAmountPerSharePriceTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ptgx_WarrantsPurchaseAmountPerSharePriceTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681354184248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Plans - Narrative (Details) - shares<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>May 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants', window );">Average volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo', window );">Percentage of volatility of stock options since IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptgx_StockOptionAndIncentivePlanAsAmendedAndRestated2007Member', window );">2007 Stock Option and Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for issuance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptgx_EquityIncentivePlan2016Member', window );">2016 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum', window );">Maximum annual additional authorized shares as a percentage of outstanding shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">538,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptgx_EquityIncentivePlan2016Member', window );">2016 Equity Incentive Plan | Stockholders possessing more than 10% of the total combined voting power | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Exercise price as a percentage of the fair market value of common stock on grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptgx_EquityIncentivePlan2016Member', window );">2016 Equity Incentive Plan | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptgx_InducementStockPlanMember', window );">Restricted stock unit incentive awards granted in 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">574,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember', window );">Stock options - employees, consultants, directors | 2007 Stock Option and Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember', window );">Stock options - employees, consultants, directors | 2007 Stock Option and Incentive Plan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember', window );">Stock options - employees, consultants, directors | 2016 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember', window );">Stock options - employees, consultants, directors | 2016 Equity Incentive Plan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Exercise price as a percentage of the fair market value of common stock on grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ptgx_NonEmployeeDirectorInitialStockOptionsMember', window );">Non Employee Director Initial Stock Options | 2016 Equity Incentive Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ptgx_NonemployeeDirectorAnnualRefresherStockOptionsMember', window );">Nonemployee Director Annual Refresher Stock Options | 2016 Equity Incentive Plan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of average volatility for comparable publicly traded biopharmaceutical companies over a period equal to the expected term of the stock option grants, used in the calculation of expected volatility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of volatility of stock price since its initial public offering used in the calculation of expected volatility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum annual number of additional shares authorized for issuance under an established share-based compensation plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptgx_StockOptionAndIncentivePlanAsAmendedAndRestated2007Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptgx_StockOptionAndIncentivePlanAsAmendedAndRestated2007Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptgx_EquityIncentivePlan2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptgx_EquityIncentivePlan2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_PrincipalOwnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_PrincipalOwnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptgx_InducementStockPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptgx_InducementStockPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ptgx_NonEmployeeDirectorInitialStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ptgx_NonEmployeeDirectorInitialStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ptgx_NonemployeeDirectorAnnualRefresherStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ptgx_NonemployeeDirectorAnnualRefresherStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681432751656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Plans - Activity (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Beginning balance</a></td>
<td class="nump">3,681,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options Outstanding, Options granted</a></td>
<td class="nump">1,536,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options Outstanding, Options exercised</a></td>
<td class="num">(294,238)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Options Outstanding, Options forfeited</a></td>
<td class="num">(275,563)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Ending balance</a></td>
<td class="nump">4,648,120<span></span>
</td>
<td class="nump">3,681,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Outstanding, Options exercisable</a></td>
<td class="nump">2,619,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options Outstanding, Options vested and expected to vest</a></td>
<td class="nump">4,648,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Beginning balance</a></td>
<td class="nump">$ 11.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Options granted</a></td>
<td class="nump">11.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Options exercised</a></td>
<td class="nump">7.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Options forfeited</a></td>
<td class="nump">11.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Ending balance</a></td>
<td class="nump">11.87<span></span>
</td>
<td class="nump">$ 11.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Options exercisable</a></td>
<td class="nump">12.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Options vested and expected to vest</a></td>
<td class="nump">$ 11.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted-Average Remaining Contractual Life (years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Life (years)</a></td>
<td class="text">7 years 7 months 9 days<span></span>
</td>
<td class="text">7 years 9 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Life (years), Options exercisable</a></td>
<td class="text">6 years 7 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Life (years), Options vested and expected to vest</a></td>
<td class="text">7 years 7 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Options Outstanding</a></td>
<td class="nump">$ 40.0<span></span>
</td>
<td class="nump">$ 2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Options exercisable</a></td>
<td class="nump">22.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Options vested and expected to vest</a></td>
<td class="nump">40.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of options exercised</a></td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Options, weighted-average grant-date fair value</a></td>
<td class="nump">$ 7.76<span></span>
</td>
<td class="nump">$ 5.45<span></span>
</td>
<td class="nump">$ 8.12<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681354805544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Plans - Employee Stock Options Valuation Assumptions (Details) - Options to purchase common stock<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, Minimum</a></td>
<td class="nump">72.10%<span></span>
</td>
<td class="nump">61.00%<span></span>
</td>
<td class="nump">62.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, Maximum</a></td>
<td class="nump">87.50%<span></span>
</td>
<td class="nump">64.80%<span></span>
</td>
<td class="nump">66.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, Minimum</a></td>
<td class="nump">0.23%<span></span>
</td>
<td class="nump">1.42%<span></span>
</td>
<td class="nump">2.42%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, Maximum</a></td>
<td class="nump">1.44%<span></span>
</td>
<td class="nump">2.58%<span></span>
</td>
<td class="nump">3.03%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 3 months 7 days<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years 5 months 26 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681354315144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Plans - Restricted Stock Units - (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>installment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>installment</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_NumberOfEqualInstallmentsRequiredForVestingOfRestrictedStockUnits', window );">Restricted stock units vesting, number of equal installments | installment</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptgx_InducementStockPlanMember', window );">Restricted stock unit incentive awards granted in 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_NumberOfEqualInstallmentsRequiredForVestingOfRestrictedStockUnits', window );">Restricted stock units vesting, number of equal installments | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, Unvested, Beginning balance | shares</a></td>
<td class="nump">278,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, Granted | shares</a></td>
<td class="nump">142,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of shares, Vested | shares</a></td>
<td class="num">(131,147)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Shares, Forfeited | shares</a></td>
<td class="num">(44,790)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, Unvested, Ending balance | shares</a></td>
<td class="nump">244,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, Unvested, Beginning balance | $ / shares</a></td>
<td class="nump">$ 10.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, Granted | $ / shares</a></td>
<td class="nump">7.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, Vested | $ / shares</a></td>
<td class="nump">9.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, Forfeited | $ / shares</a></td>
<td class="nump">8.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, Unvested, Ending balance | $ / shares</a></td>
<td class="nump">$ 9.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_NumberOfEqualInstallmentsRequiredForVestingOfRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equal installments established for the restricted stock units vesting schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_NumberOfEqualInstallmentsRequiredForVestingOfRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptgx_InducementStockPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptgx_InducementStockPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681354446696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Plans - Employee Stock Purchase Plan (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jul. 31, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, Minimum</a></td>
<td class="nump">89.10%<span></span>
</td>
<td class="nump">58.90%<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, Maximum</a></td>
<td class="nump">120.40%<span></span>
</td>
<td class="nump">65.30%<span></span>
</td>
<td class="nump">63.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, Minimum</a></td>
<td class="nump">0.12%<span></span>
</td>
<td class="nump">1.89%<span></span>
</td>
<td class="nump">1.89%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, Maximum</a></td>
<td class="nump">0.43%<span></span>
</td>
<td class="nump">2.32%<span></span>
</td>
<td class="nump">2.32%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptgx_EmployeeStockPurchasePlan2016Member', window );">2016 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum payroll deduction for share purchases (as a percent)</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of stock (as a percent)</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares issued in period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">757,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum', window );">Maximum annual additional authorized shares as a percentage of outstanding shares</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualNumberOfAdditionalSharesAuthorized', window );">Maximum annual additional authorized shares (in shares)</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum annual number of additional shares authorized for issuance under an established share-based compensation plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of annual additional shares authorized for issuance under an established share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptgx_EmployeeStockPurchasePlan2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptgx_EmployeeStockPurchasePlan2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681436378584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Plans - Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 7,899<span></span>
</td>
<td class="nump">$ 8,353<span></span>
</td>
<td class="nump">$ 6,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized stock-based compensation costs related to stock options</a></td>
<td class="nump">$ 16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period of unrecognized stock-based compensation costs to be recognized</a></td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 4,121<span></span>
</td>
<td class="nump">4,350<span></span>
</td>
<td class="nump">3,424<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 3,778<span></span>
</td>
<td class="nump">$ 4,003<span></span>
</td>
<td class="nump">$ 3,495<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681347726088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Provision and Components of Net Loss (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="num">$ (1,305)<span></span>
</td>
<td class="nump">$ 691<span></span>
</td>
<td class="nump">$ 799<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract', window );"><strong>Domestic and foreign components of net loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">(71,073)<span></span>
</td>
<td class="num">(72,271)<span></span>
</td>
<td class="num">(37,511)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">6,228<span></span>
</td>
<td class="num">(5,607)<span></span>
</td>
<td class="num">(2,212)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax (expense) benefit</a></td>
<td class="num">$ (64,845)<span></span>
</td>
<td class="num">$ (77,878)<span></span>
</td>
<td class="num">$ (39,723)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681354814968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Federal, State and Foreign Income Tax Expense (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="num">$ (88)<span></span>
</td>
<td class="nump">$ 84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax (benefit) expense</a></td>
<td class="num">(88)<span></span>
</td>
<td class="nump">84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">1,393<span></span>
</td>
<td class="num">(775)<span></span>
</td>
<td class="num">$ (799)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred tax expense (benefit)</a></td>
<td class="nump">1,393<span></span>
</td>
<td class="num">(775)<span></span>
</td>
<td class="num">(799)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense (benefit)</a></td>
<td class="nump">$ 1,305<span></span>
</td>
<td class="num">$ (691)<span></span>
</td>
<td class="num">$ (799)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681346460200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Provision Difference from Federal Statutory Rate (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective tax rate of provision for income taxes difference from federal statutory rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income tax rate (as a percent)</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit (as a percent)</a></td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAdjustmentPercent', window );">Research and development credits (as a percent)</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
<td class="num">(1.30%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign tax rate difference (as a percent)</a></td>
<td class="num">(0.90%)<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance (as a percent)</a></td>
<td class="num">(34.30%)<span></span>
</td>
<td class="num">(23.80%)<span></span>
</td>
<td class="num">(22.20%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other (as a percent)</a></td>
<td class="nump">3.80%<span></span>
</td>
<td class="num">(2.50%)<span></span>
</td>
<td class="num">(2.90%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Provision (benefit) for income taxes</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAdjustmentPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to and adjustment to the research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAdjustmentPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681426054984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Deferred Tax Assets and Valuation Allowance (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 50,272<span></span>
</td>
<td class="nump">$ 39,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Depreciation and amortization</a></td>
<td class="nump">1,237<span></span>
</td>
<td class="nump">318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther', window );">Accruals/other</a></td>
<td class="nump">5,332<span></span>
</td>
<td class="nump">5,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_DeferredTaxAssetsOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">1,252<span></span>
</td>
<td class="nump">1,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Research and development and foreign credits</a></td>
<td class="nump">14,856<span></span>
</td>
<td class="nump">8,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">72,949<span></span>
</td>
<td class="nump">55,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Operating right-of-use asset</a></td>
<td class="num">(1,040)<span></span>
</td>
<td class="num">(1,269)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(1,040)<span></span>
</td>
<td class="num">(1,269)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(71,909)<span></span>
</td>
<td class="num">(52,531)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceAbstract', window );"><strong>Valuation allowance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">$ 19,400<span></span>
</td>
<td class="nump">$ 18,500<span></span>
</td>
<td class="nump">$ 8,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_DeferredTaxAssetsOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents deferred tax assets, operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_DeferredTaxAssetsOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from other reserves and accruals not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681437112376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Net Operating Loss Carryforwards (Details)<br> $ in Thousands, $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>AUD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Net operating loss carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Operating loss carryforwards available to offset future taxable income</a></td>
<td class="nump">$ 50,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,907<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_AustralianTaxationOfficeMember', window );">Australian</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Net operating loss carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">2,800<span></span>
</td>
<td class="nump">$ 3.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Net operating loss carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">214,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Net operating loss carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">222,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Operating loss carryforwards available to offset future taxable income</a></td>
<td class="nump">78,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_OperatingLossCarryforwardsNoExpiration', window );">Net operating loss carryforwards with no expiration</a></td>
<td class="nump">$ 144,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_OperatingLossCarryforwardsNoExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward that do not expire, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_OperatingLossCarryforwardsNoExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_AustralianTaxationOfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_AustralianTaxationOfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681349854040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Research and Development Tax Credit Carryforwards (Details) - Dec. 31, 2020 - Research and Development Tax Incentive<br> $ in Millions, $ in Millions</strong></div></th>
<th class="th"><div>USD ($)</div></th>
<th class="th"><div>AUD ($)</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax credit carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards available to reduce future income taxes</a></td>
<td class="nump">$ 4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax credit carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards available to reduce future income taxes</a></td>
<td class="nump">12.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_AustralianTaxationOfficeMember', window );">Australian</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax credit carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards available to reduce future income taxes</a></td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="nump">$ 3.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_AustralianTaxationOfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_AustralianTaxationOfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681354645464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of beginning and ending amount of unrecognized tax benefits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at beginning of year</a></td>
<td class="nump">$ 16,631<span></span>
</td>
<td class="nump">$ 9,466<span></span>
</td>
<td class="nump">$ 5,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">(Decreases) increases based on tax positions related to prior years</a></td>
<td class="num">(3,799)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">(Decreases) increases based on tax positions related to prior years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184<span></span>
</td>
<td class="nump">108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increase based on tax positions related to current year</a></td>
<td class="nump">7,053<span></span>
</td>
<td class="nump">6,981<span></span>
</td>
<td class="nump">3,944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at end of year</a></td>
<td class="nump">19,885<span></span>
</td>
<td class="nump">16,631<span></span>
</td>
<td class="nump">9,466<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrual for interest or penalties</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681346421304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - 2020 Tax Law Updates (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 29, 2020</div></th>
<th class="th"><div>Mar. 27, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective tax rate of provision for income taxes difference from federal statutory rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_NetOperatingLossCarryback', window );">Net Operating Loss Carryback</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_DeductionOfTaxableIncomePercentage', window );">Deduction of Taxable Income, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_CaliforniaNetOperatingLossDeductionsLimitOfIncome', window );">Amount of income limit for California Net Operating Loss deductions</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_MaximumOffsetOfCaliforniaTax', window );">Amount of California tax offset for business credit</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_AustralianTaxationOfficeMember', window );">Australian</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective tax rate of provision for income taxes difference from federal statutory rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations', window );">Foreign income tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_CaliforniaNetOperatingLossDeductionsLimitOfIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income limit for California Net Operating Loss Deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_CaliforniaNetOperatingLossDeductionsLimitOfIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_DeductionOfTaxableIncomePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of taxable income deduction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_DeductionOfTaxableIncomePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_MaximumOffsetOfCaliforniaTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of California tax offset for business credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_MaximumOffsetOfCaliforniaTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_NetOperatingLossCarryback">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period of net operating loss carryback.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_NetOperatingLossCarryback</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred foreign income tax expense (benefit) attributable to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_AustralianTaxationOfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_AustralianTaxationOfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681355003112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Computation (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (66,150)<span></span>
</td>
<td class="num">$ (77,187)<span></span>
</td>
<td class="num">$ (38,924)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares used to compute net loss per common share, basic and diluted</a></td>
<td class="nump">34,396,446<span></span>
</td>
<td class="nump">25,894,024<span></span>
</td>
<td class="nump">22,364,515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per shares, basic and diluted</a></td>
<td class="num">$ (1.92)<span></span>
</td>
<td class="num">$ (2.98)<span></span>
</td>
<td class="num">$ (1.74)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681348918760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Antidilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Potentially dilutive securities have been excluded from diluted net loss per share calculations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">7,671,110<span></span>
</td>
<td class="nump">6,750,278<span></span>
</td>
<td class="nump">6,399,025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Potentially dilutive securities have been excluded from diluted net loss per share calculations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">4,648,120<span></span>
</td>
<td class="nump">3,681,521<span></span>
</td>
<td class="nump">3,178,441<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_NoteWarrantMember', window );">Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Potentially dilutive securities have been excluded from diluted net loss per share calculations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">2,750,000<span></span>
</td>
<td class="nump">2,750,000<span></span>
</td>
<td class="nump">2,750,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Potentially dilutive securities have been excluded from diluted net loss per share calculations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">244,545<span></span>
</td>
<td class="nump">278,482<span></span>
</td>
<td class="nump">418,450<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">ESPP rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Potentially dilutive securities have been excluded from diluted net loss per share calculations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">28,445<span></span>
</td>
<td class="nump">40,275<span></span>
</td>
<td class="nump">52,134<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_NoteWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_NoteWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140681346307496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Restructuring (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 07, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptgx_PercentageOfEmployeeBaseImpactedByRestructuringPlan', window );">Percentage of employee base impacted by the restructuring plan</a></td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Total cash expenditures for the reduction in force plan</a></td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgx_PercentageOfEmployeeBaseImpactedByRestructuringPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of employee base impacted by the restructuring plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgx_PercentageOfEmployeeBaseImpactedByRestructuringPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>100
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( -N#:E('04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " #;@VI2;3YJU>X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M2L0P$(9?17)O)VEP#Z';B^))07!!\1:2V=U@DX9DI-VW-ZV[740?P&-F_GSS
M#4QKHC)#PN<T1$SD,-],O@]9F;AE1Z*H +(YHM>Y+HE0FOLA>4WEF0X0M?G0
M!X2&\PUX)&TU:9B!55R)K&NM42:AIB&=\=:L^/B9^@5F#6"/'@-E$+4 ULT3
MXVGJ6[@"9AAA\OF[@'8E+M4_L4L'V#DY9;>FQG&L1[GDR@X"WIX>7Y9U*Q<R
MZ6"P_,I.T2GBEETFO\J[^]T#ZQK>B(K+2O"=V"C)E;Q]GUU_^%V%_6#=WOUC
MXXM@U\*ON^B^ %!+ P04    " #;@VI2F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M -N#:E*1R5K)\ 4  /$8   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
ME9EK<]HX%(8_[_X*#=O9:6="\(5;NH09ATO*MB4LT':[WX0MP!-;8F4Y)/]^
MCR_8)"..O?D0;./SZK&._!Y)#(Y"/D9[QA1Y#@,>W3;V2AT^MEJ1NV<AC:[%
M@7'X9BMD2!6<RETK.DA&O30H#%J6871;(?5Y8SA(KRWD<"!B%?B<+22)XC"D
M\N6.!>)XVS ;IPM+?[=7R876<'"@.[9BZMMA(>&L5:AX?LAXY M.)-O>-ASS
MX]CN)0'I'=]]=HS.CDGR*!LA'I.3F7?;,!(B%C!7)1(4/I[8B 5!H@0<_^:B
MC:+-)/#\^*0^31\>'F9#(S82P0_?4_O;1K]!/+:E<:"6XOB)Y0_42?1<$43I
M?W+,[NUT&\2-(R7"/!@(0I]GG_0Y[XBS +M](<#* ZPW >:E #L/L.L&M/.
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M/@(P"5 S[K%G\IGI7SA<*IF'VKV>^78+\359Z>4V[L$.=):7==@%KZP0N&@
MK;,]XL3^TKWVB+C)AD.V75Q<+?;SG707NU7>GOT8\)4F[AF1@&TA%%YV2)K,
M]M>S$R4.Z8[S1B@EPO1PSZC'9'(#?+\50IU.D@:*7SF&_P%02P,$%     @
MVX-J4A&F))6+!@  .AL  !@   !X;"]W;W)K<VAE971S+W-H965T,BYX;6RM
M66UOVS80_BN$46 M8,<BJ1<K2P*T#H8-6->@:;?/M$3'0B31)2DGV:_?478L
M6Z1H!]V'Q'HY'I\[WMUSI*Z>A'Q4*\XU>J[*6EV/5EJO+Z=3E:UXQ=2%6/,:
MWBR%K)B&6_DP56O)6=X.JLHI"8)X6K&B'MU<M<_NY,V5:'19U/Q.(M54%9,O
MGW@IGJY'>/3ZX&OQL-+FP?3F:LT>^#W7W]=W$NZF>RUY4?%:%:)&DB^O1Q_Q
MY9S&9D K\7?!G]3!-3*F+(1X-#=_Y->CP"#B)<^T4<'@9\/GO"R-)L#Q8Z=T
MM)_3##R\?M7^6VL\&+-@BL]%^4^1Z]7U:#9".5^RIM1?Q=/O?&=09/1EHE3M
M?_2TDPU&*&N4%M5N,""HBGK[RYYWCC@8@,.! 60W@)P[@.X&T-;0+;+6K%NF
MV<V5%$](&FG09BY:W[2CP9JB-LMXKR6\+6"<OIF+6HFRR)GF.?K$2E9G'-T;
M=0I-T/?[6_3^W0?T#A4U^K82C6)UKJZF&F8VXZ?9;I9/VUG(P"RW/+M %(\1
M"4C@&#X_>SA.CX=/P=Z]T61O-&GUT2&C&REYK1%3"NR\]&BD>XVTU1@.:61J
MA< W*#,7_$=3;%@)4SA]M565M*I,FFUN,$YH-+N:;@Y]8HM1"LFYESH"&NZ!
MAEZ@GYE\Y)HM2HX4SQI9Z(([06[5Q(<@9[,PPCV0#K$@"#!VHXSV*",ORJ]<
M:5ED)B9;ATX@%=HE<R&-'!!Z*+TB1PCC/<+X!,*,PQH;/RZEJ!#D8<D60K*V
M.*V9U#67VX@0M990K;;1!J9(7K;99H1>7 ;%%EH2DKAGDBT4)U'D-BK9&Y6<
M<CMG,MM&<LXW4.37E4D4S9ZA F1P"347#'BUW84^<?AZ%KJ!S?; 9EY@=Y*O
M69$C_@STI;AJ 0J] A=G1[GL C2S/462I.=.6RB*2.I&G>Y1IU[4WX1FY1D
M4VMNBJ,XZ*^X+8;#B ZE&@XZ!@C>7A(@3FM1>[)NI_0H2B'S!\ <T!$^L=+0
MH4!>M"MLZF@;@&-4<S<*['!*3'J><TG%LR''=2R"R1NKU F7$0M&&/5+U0FA
M8Z@=/6$_/WT!IT)IJA]0R:'I0=)T-Q.QG#1PTT:F$S"UL:0V8ELJ#D(R +DC
M*NQGJEN^Y.#*O"T^0Q#GV$% (:4#DW?\@_T$M$W=X93%-J-0$H9QG\,=<C@*
M4YP, .SH!\=GM3!EP19%V::LKX_!'05@/P=\S#+10.,"]/0R5.*Q7>-ID$1]
MVVTIDJ1#H=Q1 3[!!5M<2(L!TCV#8;%=[DE"K;)A2V$2#P5VQPK83PO@8=EP
M)YGM?.X..4?]GX6I%7$.,4+C ;>3CB6(GR7VZ2BA+Z@;WG>SOT<C-EO@,+18
MV"66)'0V +YC%>)GE7[Y>\V:4ZA=[!*E?= .*1(-].GD8(_B9Y?C[N$@SYU(
M':P1D+#?K3O$:!0.[2E(1R_$3R]_BOIAHKFLH&M<#++UG-A,D2;I0&](.J8@
M9S+%<&AZB7E.;!(A-$D',IUT+$+\+.(+.W^K0&S>@"Z@S[P.J2B-!_H:TG$+
M\>]MOK2UZ%3$V1L03(:F[MB'^-EG&_2GIK:))0QG5M?G$$N@?1GH#4A'0,1/
M0'-1584V;:G:;_!@C7F=F;[Y_5]"<X3Q!R=RKV9S9'>IUBSCUZ.UA+V8W/#1
M#7)&[,\K.K:^8R^2>AN/>RVRQY4H<R[5+VV'KE^\)R@=PU _P\ F;Y?'RLPQ
M1N^"B\ <)I@L1AM6-GR,<#"&1^8/J163ACT;O1*R^)?GOT)2O3XME#(<VU)K
MHY6&"U@CYVF,%]4;UN1_4'3LN8[>J)_>3$1" ^1Q6^IU6TC'21B-PSAJ'4:2
M,<'). Y3OS>A/T9BB6YYQJL%5(S7 [Y6KO<4IV,HRFK-VV/;TMF5^:U\RTK\
MO*+CE>A(F_I)^V.>%Z89A2)F#BPF10U;PW4!1<UIL$W'44SIK-]A..1(FLS"
M =ZF!Z>6?MZ&5K2IFBU5[HY31 4^69ES^@U'#PP,>%\*I9SEC-I\3JQ33%MF
M0H:(@G:<3_V<?X@\Y\LB*YP\2FUFGY 9G>%^9^04Q$D\Q*:T:P+H.5M)Y2B;
M3L VI<.FR3X,<L@E:1H/]%*TXW[JYWZ+@-MD/AM];)]9N[;%#CGGMGAZ\&'#
M?%7ZS.1#42MHIY8P,+A(P MR^Z%F>Z/%NOW6L1!:BZJ]7'$&L(T O%\*8.?=
MC?E\LO]<=O,?4$L#!!0    ( -N#:E(J2@!RGP(  #8)   8    >&PO=V]R
M:W-H965T<R]S:&5E=#,N>&ULG99=;YLP%(;_BH5VL4EM^8:D(DAKJFF[F!2U
MVG;MPDFP:C"S3=+MU\\VE(6&)*2Y"+8Y[^OGF -VLF/\610 $KV4M!(+JY"R
MOK5MD1508G'#:JC4G37C)9:JRS>VJ#G@W(A*:GN.$]DE)I65)F9LQ=.$-9*2
M"E8<B:8L,?]S!Y3M%I9KO0X\D$TA]8"=)C7>P"/('_6*JY[=N^2DA$H05B$.
MZX7UV;U=NHX6F(B?!'9BKXUT*D^,/>O.MWQA.9H(*&126V!UV<(2*-5.BN-W
M9VKU<VKA?OO5_8M)7B7SA 4L&?U%<EDLK)F%<ECCALH'MOL*74*A]LL8%>8?
M[=K8,+90U@C)RDZL"$I2M5?\TBW$GL -C@B\3N!-%?B=P#>)MF0FK7LL<9IP
MMD-<1RLWW3!K8]0J&U+IQ_@HN;I+E$ZF2U8)1DF.)>3H#E-<98 >M9U 'U>8
M0R4+D"3#]!.Z1A^0C42A1D5B2S6[]K"S;J:[=B;OR$SWD-T@W[U"GN,Y(_+E
M9+D['\IME7.?N-<G[AD___+$3[C[O;MOW(,C[BM5C,"YLE9/,'N^0C7F:(MI
M V,+UWK-C)=^[[:I"]=.F-C;_?4Y%S4 #7K0X#+0]O$BW,B"<?(7\C'@UC/:
M1W':WQOF"8$#[+#'#M^%381HQI'# Y*WK*<B!I!1#QF]"U)]387$54ZJS1AI
M=);T5,2 -.Y)XY.D2U:6ZILZI5;C2;5Z+FI .>LI9Q=03BK4V<%*S<<+=4+@
M@'G>,\\O9SY>I?,#C,"/@S"(WB[P8: 7>VX<!?-Q7M?YOR$XEQ.?*=G.<@+W
M2.01<'MO4],GBN^8;T@E$(6UDCHWL7I?>;M)MQW):K///3&I=DW3+-3!!K@.
M4/?7C,G7CMXZ^Z-2^@]02P,$%     @ VX-J4IIX+HR.!   >!   !@   !X
M;"]W;W)K<VAE971S+W-H965T-"YX;6RE6-MNVS@0_17"Z$,+-+%(W0/'0!/O
MI<!V&R3M]IFVQK902=22M)W\_0XE6;8E2LGNOEBW,Y<S0\YP/#L(^5-M 31Y
MSK-"W4ZV6I<WTZE:;2'GZEJ44."7M9 YU_@H-U-52N!))91G4^8XP33G:3&9
MSZIW#W(^$SN=I04\2*)V><[ERQUDXG [H9/CB\=TL]7FQ70^*_D&GD!_+Q\D
M/DU;+4F:0Z%241 )Z]O))WJSH)$1J!!_I7!09_?$4%D*\=,\?$YN)X[Q"#)8
M::."XV4/]Y!E1A/Z\7>C=-+:-(+G]T?MOU;DD<R2*[@7V8\TT=O;230A":SY
M+M./XO [-(1\HV\E,E7]DD.-#1&\VBDM\D88/<C3HK[RYR809P(T&!!@C0#K
M"G@# FXCX+Y5P&L$O"HR-94J#@NN^7PFQ8%(@T9MYJ8*9B6-]-/"Y/U)2_R:
MHIR>WXM"B2Q-N(:$/&F\8%*U(F)-OI8@N4F.(E?D^]."O'_W@;PC:4&^;<5.
M\2)1LZE&'XRFZ:JQ=U?;8P/V*"-?1*&WBOQ2))!<*IBB\RT#=F1PQT8U+F!U
M35SZD3"'.1:'[M\L3F.+^.+MXM$(&[?-AUOI<_]//D;L>*T=K[+C#=CY(UWA
MY@6"622XAC*^%+5RW,Q[*': .9>056Z47.H76ZIK$V%EPA28_9Q% <,P[,_C
M;T&Y]!*SZ&-<)V9^B[K@Z+<<_=%8-@$K-@2>2\-6W8Q$+FBU!J.1>P0%7*ZV
M5>@2#%8F2I,C6X!J3<$9K=#SG: 3H#XJ\!W'[82HC_)C+P[M(0I;,N$HF=^@
MP!AE%1>>8'U)E38QVX.-3MAS@4:!V\VW!>6'7MRA8T&YP1"=J*43C=+Y)C22
M$;V\V\A$/0=BEWI>ATP?%3FASSID^JC0I;%G)Q.W9.+Q+2J4(FLI\B.AWLZO
MB<0]XU>!Y]/N*K/ (L=GW9UH@7F,!;&="W5.?<899?.YT"!!:>P?*Y%;EU>C
MX2(ECM.A80&QB'8WBPWE!\$ B;-F2=]&HEE85A:T'T$_[FX2&XH.1IF='&2O
MKQDLXEBALA<LX"5_,;7)M(\$EM8:U6B\]#<:*+WTU,>H.^K)5[T%>8S31U*
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M6^ )2 / [VLA]/'!&&C_;)C_ U!+ P04    " #;@VI2:IC[5/("  ":"
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M'H@T ?!^*83>3TR"YG-D\A=02P,$%     @ VX-J4OV&EMFQ!@  'B,  !@
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MX1ZIIL,UUF$WUW==<-CH@I=%%QRW=,$WI<5&:2!$5'][I)K^UBB'W2S_1V!
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M=\#^/71$1OLGBNW"^5925=LPCQ@_ZQ6O/TVJ';A"".W\ 5J-]/1WU,P#A/#
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M ).1VK"V!&VL$_B=WM-]I!97GDE-G5[V\SXK(K/'?U/UIA>VZE/OCS>TJ^\
M(QQBKJ $+HVV[[$G.(G1).H]78 @J*$-BU^'R,&'0S9TY7/SCB\9'T+"P=L9
ML"=4'T<(._(RK2-*A\&@G^1P^H=<+B;$IX#"5_OS23RGS3()*S J/GD(Q<;.
M+89:G2DV=5,UZ[U \6KO9P@U@#5-)8E?+I>YXW?98X-DA=M ^WB17!&C<H5P
MM2#-H=>)@)>EDF.%$+]Z3R3*[KRYN1?Y\NV=2.J;A-0KOL+^X=A.Y(:[+SW7
M3C35;V=&O*JTH"%)&NBPYF]#GU6ONLHZ?)1GVK3$.L"/WEEG%E^C+ G!"0RK
MUOAJWO$7"?C=S#(50&2R7,_I2@T>]5+1W,,?)"PV=)@SO#H%<"2H@$G 4M*<
M2\B*M:CC][AH<Q"9P1[V40HG7!MM&V1,)O:&DUX2*^)4\KR9AR_\S5]N_55&
MZ4KI?!/Y!XDW'Z*-LZ37"09$-=QO>>2=6R^E$^])>,#;'_@Z<L]<966Q;3F'
MG]S[%<&Q6\YO!\N6O$Q)1XMM33CE.CH6/=OAT>@&HW,8'E$@;+K.S:KX?]MH
M<NMD.$N0)MUI&6Y8[/EVY&U#OTH1(^VZ<"8HQ8-:M:=:FH:WP,0'29KX:\;N
M 1U2\0TYQX4FW4=L+R*N-:T+Z>=1-A&OKPLHQ'-FU"&5>)A!WPDW"7)2[QYA
M8UL]>#O(TG"/ K\WX2!L2#*?_B0&+>3I[H''<+;1VTJ2-;P":JII:F)6;3R<
M>'W)(OO9UU8T .QZ#1WQKJVU]*+SP"AZ@MI@X^N>;]%!H^CTA'TUX9?*-[>V
MBK'T9_TUE$QTO/3YQ2M/SG*'%/1!BAP4V=]RK><8=DC>01.1AJT'>6+D]:-
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M%?B<_&H##8=2*.+GJ5. @H#PM.*FVDIWY>. #(E:PEAA(;L6WNT)DR[6SWF
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MW2HZ@'NFD+68$?PXX*4'08R1RB1[&WSV:;)4RR'*^&AP=3QMQK-Y4Y-#8A+
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M$Z\=\D1[G3U8;;\G'>1O5]O];39)VQK/QBB8Z&H_1CF5GG:7:Y,B;8,XT_N
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ML3MG*]P>OG> J[(NKIG4*KU^YF?D#(%W,D(<T(:Z5_XR)_ ";^TE@+14N!L
MQH@RE55&7CA._]SFWCZT\]Z'=&==/L SRURD>=T^N'OMUM]K+@NF1&4[%T%Q
MV#$0MT'2#D,=<=-XW^VM+5\Y'VUXZG 6+A3;B)8^:?9#JRJD_*'8[D@_'-F#
M\+OL4&/9:_7SN(_G_JN%"T55VKJU;U:;#R//Z^\!6_+ZJPJ*RMQEA:096,/N
MZ:##=/VEHIY8M?!?!Z;*6E7X84X< 7<$V)\I=)'KB5/0?"Z:_ M02P,$%
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MR$%'_X,;7T;Z) V0>$S.(9*E@HKQG-P]8F%JT(2)G/QIMJ#(;:T4\I!KK6'
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M%FD=A+$A3FV$&N]CP(PA4DDN4U*K?PCG"^CWNCT;I3886Q'@>;8KLT+!1N=
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MG.!3TS4WJ&80;!5O+:D-N /%QP*73G*\ .^7%F*V S;07V.O_@502P,$%
M  @ VX-J4M :9635!0  ?P\  !D   !X;"]W;W)K<VAE971S+W-H965T,34N
M>&ULM5=M<],X$/XKFAQS S,A+VZ! FUG6GI .. Z+=Q]ENV-K4&6C"0WS?WZ
M>U9VG(2F[=&;^Y)8]N[JV=UG=Z7#A77??$D4Q'6EC3\:E"'4K\9CGY5423^R
M-1E\F5M7R8"E*\:^=B3SJ%3I<3*9/!]74IG!\6%\=^Z.#VT3M#)T[H1OJDJZ
MY2EINS@:3 >K%Q>J* ._&!\?UK*@2PI?ZW.'U;BWDJN*C%?6"$?SH\')]-7I
M/LM'@3\5+?S&LV!/4FN_\6*6'PTF#(@T98$M2/Q=T1O2F@T!QO?.YJ#?DA4W
MGU?6WT;?X4LJ/;VQ^B^5A_)H<# 0.<UEH\.%7;RGSI]G;"^SVL=?L6AED\E
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M&PO[@SZE'0$S$! 'M7D$$U\;D7&TM8(E/D.-P5U02VL:Z>#,.L,QM4Z17\Q
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M-3G..LG -WL&"6> UF_ \I>-OC=?/[9:(D=*^)EDK7DB<\JJ&N6JH3=Y'5D
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M#<>+^<@OB>V#597[IK12%CGL_LP$AZ%T ;^OE;+M PGH/C)>_P=02P,$%
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M1E!@*5I%MZ;[@H.>$\^7&^7"+W1];#J+(&\=F7H <P6UU/U7;(=W. "<)B\
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MT!,R;4</\,X %R1Q'8H4IK-I&\@T*(L%7PIGZ,2)]XXD^:0TR#/T,)N &^,
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M>^5FCO(GVR<T8^:G=T\ RF [@GP89XFDSJ&3&LN*E .&/@TZ8++B0CD-"2<
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MA+,JG<-Z'^V(H-@=1]V=O@UN>M36HO$#2M4-;8ON;7=K=('>9'6WR$ULN#B
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MT=GY* #=3L#V8%7CI\Y:69IA?EO13P.U<Z#WA5)V?W "W6]H_A-02P,$%
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M;RL):4$'3H?I/:-AFCZYK5%*7SQQ7V&C^,\;1S+Y7S<.&L:#MYP6X3@=#1X
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M&A#=32B=8%7CIX*ULCAC^.T6ASK0[@#:*Z7L07 !AC%Q]3=02P,$%     @
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M<Y#& +^OA="=8 *X@7_Q'U!+ P04    " #;@VI2-[M_(,X"  #+!@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6RM56UOVC 0_BM6]B*0&'F!%MH"
M$K2;5FG5JK;;/IOD E8=.[,OH^S7[^R$C%8%[<,DA'WG>YY[\?DRV6CS:-<
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MI48:?GZ[IJ\-&&= Y[G6N!.<@_;[-?L#4$L#!!0    ( -N#:E*(R0CQ:@0
M '\/   9    >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;,U766_C-A#^*P/W
M0 (XT6'+1^(8R+%%"^RB09)VT4=:HFQB)5(EJ7C=7[]#ZK#DVVU1]$72:#C?
MW$-RLA3RBUI0JN%KFG!UUUEHG=TXC@H7-"7J6F24(R<6,B4:23EW5"8IB:Q0
MFCB^ZPZ<E##>F4[LOV<YG8A<)XS39PDJ3U,B5P\T$<N[CM>I?KRP^4*;'\YT
MDI$Y?:7ZM^Q9(N74*!%+*5=,<) TONO<>S</([/>+OB=T:5J?(/Q9";$%T/\
M$MUU7&,036BH#0+!USM]I$EB@-",/TO,3JW2"#:_*_2?K._HRXPH^BB2SRS2
MB[O.J ,1C4F>Z!>Q_)F6_@0&+Q2)LD]8%FN#<0?"7&F1EL)H0<IX\29?RS@T
M!$;N'@&_%/"MW84B:^43T60ZD6()TJQ&-/-A7;72:!SC)BFO6B*7H9R>?J3H
MDH*+-S)+J+J<.!I!#<L)2X"' L#? ^#Y\$EPO5#P@4<T:@,X:$UMDE^9]. ?
M1'RBX37TO"[XKN\>P.O5+O8L7N^@BP> ^C50WP+U]P"]8D=$>4)!Q+"TZ:81
MD'<JL7HA,5I 4YD"X1%$3(4BYUJ!))KN"NMA73]^-_+=WBW\6V\,*DUG5-K
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M]WJ(9S997/<*0HO,7K%F0N.%S7XN\(9,I5F _%@(71%&07WGGGX#4$L#!!0
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M" 81V5S#-(06&WOU<2VT%J5]77,&!=@L@.]+(71'& 7]9=CIWU!+ P04
M" #;@VI2QFKOL^D%   "%0  &0   'AL+W=O<FMS:&5E=',O<VAE970S-"YX
M;6R]6-MRVS80_16,>AEIAI%(\"K']HPO]30/:3RQFTX?(1*2,"4!%8 L.U_?
M!7B51;/R),Z#1  $SF)W#W:7.-T)^8]:4ZK18Y%S=39::[TYF<U4NJ8%45.Q
MH1S>+(4LB(:N7,W41E*2V45%/L.N&\T*POCH_-2.W<KS4['5.>/T5B*U+0HB
MGRYI+G9G(V]4#WQFJ[4V [/STPU9T3NJ_]S<2NC-&I2,%90K)CB2='DVNO!.
M+A,SWT[XPNA.==K(:+(0XA_3^9"=C5RS(9K35!L$ H\'>D7SW #!-OZM,$>-
M2+.PVZ[1;ZSNH,N"*'HE\K]8IM=GHV2$,KHDVUQ_%KO?::5/:/!2D2O[CW;E
MW#@>H72KM"BJQ;"#@O'R21XK.W06).X+"W"U -M]EX+L+J^))N>G4NR0-+,!
MS32LJG8U;(YQXY0[+>$M@W7Z_ -/14'1/7FD"HWOR2*G:G(ZTP!M)LS2"N:R
MA,$OP'@8?11<KQ7ZC6<TVP>8P9Z:C>%Z8Y=X$/&:IE/D>P["+G8'\/Q&4=_B
M^4<H.@ 7-'"!A0M>@+N#TY%M<XK$$F4 K#1+$>$9@G,"3. (I&T$IUPK,X7#
M\<J%4GV6'19TOZ: F</A87R%M'$0@N.G+/(K)*,%-1,0*^V@2X<SCO1:;!6L
M5Y,3].M/"7;]]V_V_)L263($@7]IL:#2^KA^;WP-?][<_"7HNE:O?O\S&L>>
MX\;^9&\(.SCV)J;IQT[H0?.FLD4]*W(P3IK>.'0B-YZ@,2ST\ 3="TWR TN5
M)NK(B0(G"<)]T;&3Q$DI>N[$V)\,<"MLN!4>S:TES:@DN8.4)IKN^1G>ZG77
MH8@^0JQ6%(T7E-,ET[T'>5CV6S/@6";L,:+M #,ZG01=;:4$IG\_YMZ4]N[X
MV+0\_/ZHD3OKI#[L[OQCQY^3N*%ODDP.!I/@19R2WFEI*DN4AB -9;Y5QC5=
M4L#/WLX3WVK-'^,;S_'G_J$UXS@\-.<XGL_KX)-5]NL_Q]]-S%"PZ/ 9X-UP
M+_3-O?VX!Y #D2YJ(EUT=*3;2/' ;*V7L248@_(4PN]2BJ(.@C8&;K603TB"
M+_N"VZ X4^">J U)Z=G(IE#Y0$=O%O%>F>MN#G3L^,JHB[ W==$OSQXEJVVJ
M<FP&:W,&JAR+O.D<?AC%L.(SJ$UDNK:9)*,/4)5O"A,64B ?TVV^BZ8M 8)I
MR[6Q-^UDW_H8-)ML?8?&[A1XYTYC^ 7H:DWXRF0K]$#R+2E+<E/6$#O7#PSL
M&/O3Q#SP%-+R)TAO8+-I @/3T P;P-N&)RUS(24^*VSPU)V >6 +QE;65 -\
MC1N^QD?S=;_,VCN_1"FJ>VN]87A3Z^W#F@3? XT(U"=$587AV]5Q_T/<Z\.=
M'2_[#T/6#1!5F\+6%EXID?()?+DC,NM67J$+!1[N#$"M-7=CD _'.&45F8#0
MI!!2LZ_E0!LKL1\W/1_.VD6:RBW)U4Q8AM6O0L?W<:<7A 'ZU.Z0PL<?RAE9
ML)SIIYZ0C$/<,QIZT<NG;J]N?W8"/2@WPZA-OH[K)WW9HJ)$/0^JX7G0EDEA
M".K[^ZZJE6#T%?ZJGZU%I/GB?2>6[[:*EKLXS#U0K0=N3TX":T7]R:^SN5?#
M?>D)+6T:]( T\W;Q.,1.Z$->,TP<LFA?Q><Y@=\$Q8'(DC21)3DZL@"G!4_!
M!J4J,+*@*\:YL;DA#.69:6ZYF;CB[&NU[2H<]@:>8>D7/3)-Z.F5"X=LRVVB
M>7$'B*D?$9Z^4^J])+EE"M$=A4&])P/3<7GD1+[7&9@[0129\.0$7H#&($J:
M&*$F)A>537MCE"%19LB-4,R85X&Y<\B68#0!=0^#[&5DM8P;^XXMVII0 )6W
MYR;HPRMPZWI_3XO8<<,VET?.//&0#_$BZ!H!_-RG_MQ)DO#0'I4=^L[ K',O
M55"YLK=O$.8-?\HKJF:TN>"[*.^UVNGE[>!'(L$S"J+P$I9"40&?L;*\<2L[
M6FSL+==":"T*VUQ3 H60F0#OET+HNF,$-->>Y_\!4$L#!!0    ( -N#:E*%
M$<N+=@,  %$)   9    >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;,56;6_;
M-A#^*X0V# W 61+UZLPVT*0M-F#-C+A;L8^T=+:$4*)&4G7Z[W>D+-D&4B/8
M,.R+Q*/N'C[WIN/B(-63K@ ,>6Y$JY=>94QWZ_NZJ*#A>B8[:/'+3JJ&&Q35
MWM>= EXZHT;X+ A2O^%UZZT6;F^M5@O9&U&WL%9$]TW#U=<[$/*P]$)OW'BL
M]Y6Q&_YJT?$];,#\WJT52OZ$4M8-M+J6+5&P6WIOP]N[Q.H[A3]J..BS-;&>
M;*5\LL(OY=(++"$04!B+P/'U!>Y!" N$-/XZ8GK3D=;P?#VB?W"^HR];KN%>
MBL]U::JEEWNDA!WOA7F4AY_AZ(\C6$BAW9,<CKJ!1XI>&]D<C9%!4[?#FS\?
MX_ : W8T8([W<)!C^8X;OEHH>2#*:B.:73A7G362JUN;E(U1^+5&.[-ZP+S_
M*K4F'2BRJ;@"\N83WPK0-PO?X %6S2^.8'<#&/L&6,C(1]F:2I/W;0GE)8"/
MS"9Z;*1WQZXBOH-B1J*0$A:PX I>-+D;.;SHU>Y> 8TGT-B!QM\ W6"GE+T
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MJ+K/,-1SZ_AR)8S_DF[P#0.2M\8J.8 Q \GK?F6O@PY'@.CF#" > /%[ <D
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M)G<1F&XY.H%I$P9R3>S&.QP;]YZ@\0[.7A'Q2? $_0N5OP%02P,$%     @
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M14[,,Q]Z/D, W$76E_+"L1<-0&LG+O:LT.YHLHN'L7D]KY>3*'"[X QB'DS
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MZ*;UVK3G%%@YM$^=3*B#RX@L5I@V7-^@#5D(]+7ESM7J&ZB;DG9)(H79:)?
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M,263+Z[=3-_R?4"Z"UVSU.1Z,$Q;]TJB\0EN?Z4U[0+?B..[6_T'4$L#!!0
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M\KQ>DNNK&W*%'N1[)7>:B4*GU& >EHWF?<RYCQF?B1G%Y%$*4VGR4110_$M
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MFJCJ#Q=UP\BB>M%^+XV1676YY@S.YK8#/%]*:9X;=H#V\]'D7U!+ P04
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M,[F_-@HXW@$<Z#F^:]OM</P*CG\^'/)!^)2*=D#^ :!K%+G("=L!!16@X'Q
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M=D%P3+B>H-[/&)/;!VV@.KT=_P]02P,$%     @ VX-J4KV;53,U P  APP
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MTM<(^[C3-ST0Y@/]?L.Y>FT8!\W=<?X?4$L#!!0    ( -N#:E*F@*XG @0
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MJLV0*GI$ZO1)D[[T0\JR)F6B39DFL7@6M9Y%QK/HB&=WGXCW?M2.#K! &%7
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M#)0%X/>UE.9]8C?HF[K%?U!+ P04    " #;@VI2AS]S1]\"  !:"   &0
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M+#.<PB"T W[?<*[V&_V#;JXO_@!02P,$%     @ VX-J4I47B2]I P  =PT
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MW]((^HM/$%BX.Y'B"#Z=?_A="W5[!NPX^3B93"^G3Q>W^YESE[J WJO \P.
M1V''0!<'J37/&XK-,T9P=1C!6^ACT->[T/W.[NRDYXXM#C/!^].;01O0R(AA
ML$8T@G>(DI4D9E6&&*$;&PY,(!%42*!TV6@JWT2J9YOVK6<JRN$PPH5LN2V#
M_5RYZ7N)K6<$$DH[@0&T@3@LD5)8\GOMM)/;X(L4</9R4VJ%N40;/YC#?D$[
M:)*5D"F6'8T/MZ$XI#@S<B3)"S,J47HFJ91@VD@)R@5'K8;M"F=HV 13^FB^
M;K^R'>PF&YS9U)P8[TPMR)D6QCH&?XAFL8>PP;MP04G60GVM]>OPUC=5AA\D
MSDC3^DW6"1A#]\?145G2S1=*<LZP??F#">,0;=>!0DCRK-E,J20Z@"4$:RP5
M28:1/Q*52]RH;3DUV;CFX 0U_]M]SC''$M&A:%W[Q[S+[U;L[J?_H;G]6=E7
M_*K(V=7Q:W3W\;&+7)R"R!,X[MG-\6MT'='1B?3<_3UH$G9:A"X*3"L6P9^F
MJ:,]*5C5A"K"G5>0-,7\1:>@X15:Z79_!U_/3W&&:JJ673*"O?T#IZ1F-]VL
M![,1;E9O?S>OYR]:POX_1?P74$L#!!0    ( -N#:E*7BKL<P    !,"   +
M    7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*
M19V_K]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>
M-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS
M#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C
M(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ VX-J4K/EM//W
M!0  KC(   \   !X;"]W;W)K8F]O:RYX;6S%FUM3VS@4@/^*)B]+'[))?&T[
MT!F60)<9*$RAW<>.8BN)!EORRC(4?GTEF;#':3BS+R<\);[$^7)LG>_HDL,'
M;>X66M^QGW6EVJ/1VMKFXV32%FM1\_9/W0CECBRUJ;EUFV8U:1LC>-FNA;!U
M-8FFTVQ2<ZE&GPXWU[HV$[BAK2BLU,KM]#N^2_'0_G?<;[)[V<J%K*1]/!J%
M]Y48L5HJ6<LG41Z-IB/6KO7#W]K()ZTLKVX*HZOJ:#3K#WP7QLKBM]TW'O*6
M+]JPQ_+%5^Y CD;9U%UP*4UKPQGA^MPQW@MW<K_567TF*RO,G%OQV>BND6KE
M+^-^Q03\C!"'S6L?Q(_F_X11+Y>R$'-==+50MH^C$94'5.U:-NV(*5Z+H]'F
M%,95R4Z5=4%BYZJ_E#O7_U+WU>=E_ZNMPP4Q-!^E.V#.RP!.!WGBMG4E2_?M
M)?N+5UP5@H7@M@ P0@"C-P-D!]<<0,8(9+Q'R!L/X3_0,KUD5XTP #)!(),W
M@SS1=0,@4P0R?3/(&ZL+ )DAD-G;19*W:P"9(Y Y+>2567$EG\*!D(+FHBV,
M;,*V7@+(]PCD>UK(FZZNN7D,MU>NE'0?XRYC'A>%[ES&!) ?$,@/M) 7[C35
MBA#$$Z<IOM"F#^OQR@@!$_D4R^136LPS+@W[SJM.L$O!V\[T3R7$0T5#;1K7
M,MCIOYV\YU5H+3Z<E]S<">?W:A!%3#<S8M\,%!,2HU;;8<1,,R-6S5?1"FZ*
M]=:3Z(/IGU.(B;EF1BR;S_I>&!7*'U=(K@RO!Q'$##,C5LQ<+"QDP40R(S;)
MA6NH8A 9S!@S8F6XI[V6MGYIG<YSUE7/0A5R"(D98T:M#%<&W*UU50K3_A$2
MBGV$;)@H9L2FZ&G8M4LA@_(9TT)$K(5D.CNX>Q>8(!*F@HA8!>>JT+5@M_SG
MX+&*T&X&<=[_XJY[H=N6N7K=)7]N8"J-L(P?T6=\:[K"=L:U10B%Y?>(.+^C
MA=N/"&)BN3XBSO4X9@PQ,0U$U!K *LQA-#$_1,1^>*7"9 >WOH(;-&7,$!&Q
M(=!*<QA-3!81L2Q>JS2?PPE'-C!_Q,3^\.72Y@Z_@U"806)B@_1UTTXL3"(Q
ML42@_W?"H6-4Q!Z!UMT)A_DD)O;)[_K=B8BY)"9V"3J@,D@K,>:2F-@EN/(2
MB(FY)"9V"8Z90DS,)?%;#E#]R" FYI*8V"4X9@X'H#&7),0NP>L<6(XEF%T2
M:KN@F+ ))9AM$F+;O%J.S5VA(RN(B7DGH9X<0<NQP4U'9T>HIT=0S,%-QRR4
M$%OHU:IQS*Z-@+,X"6:AA-A"**8>8&(62H@MA&"ZW#F8N,,LE!!;"!WT'90>
M"6:AA-A".P9]-\EH4,:EF(/2O?1G=E%ARDF)E1.HQJX$5JNQ%:9FY:N8F')2
M8N4\][O&_<Q7N-,[&3'?I,2^>6'\1\C5VD_1<O=8\I5@E3\",3'?I,2^><&\
M],MENKJG8PU_W)ZV2]'Y>&+?O&"&-ZS0K65RYRJ6%/--NI>)%(=YTS5-%9Y,
M7K'%<WH?1!/S34KLFQ?,4&TL*_T @\D@)N:;E'H$#9L(8@<0$_--2MWKV3$5
MM#,?99AP,F+A# :%QNP+-U[?]^*9%&)B!LJ(#;2%>>R7U8%X0DS,0-D^A]C&
M[+1N*OTH1%@==,>N("8FH8Q80EN880Y'%OUZ(0<*,3$)9<02PJ-Y#3$Q"67$
M$MK"#'3CA4NEY?;2M0Q=%D8LH<$(:^CH>(;G0OU$0TQ,0AFQA+8P0:]'+]D9
M+) R3$(9L81>C>9<+I>#1949)J&,6$)H-.<PFCEFH9S80EN8?KS=+TWEWNNN
MVP$Q,0OE>UP:T.?-ON/;C[??0TS,0CFQA;8PORDC"KU2?M&[WPDQ,0OE^YSR
M&;-H&DW]!KO@#^Q;4T),S$+Y_B=_^H;467\RQ,0LE!-;:"?FL:N,2UEU@\6J
M.6:AG-A"@_4B.\OA'%V6'.PS"2>WGPY+L91*E%_<I5NWO^!5<6V8?PFKK:(D
M]2NNEEU5G;A]5^I"\W+S=XO-7T4^_0)02P,$%     @ VX-J4GKM3FU6 @
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M()\_*" HY@_*$)3G#[J'H/OY@QX@Z&'^H+1$&9<$21.L";1.R'4B\#HAV(E
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MCGH[@=Z.>CN!WH%Z!X'>@7H'@=Z!>@>!WH%Z!X'>@7H'@=Z!>@>!WC'YV81
M[T"]@T#O0+V#0.] O8- [XQZ9P*],^J="?3.J'<FT#NCWIE [XQZ9P*],^J=
M"?3.J'<FT#M/?A;\2;V'\>M0AFO/]QJ?_Y-4C^=[R_7QE^7WR0D[%YSKVXKA
MZ2]02P,$%     @ VX-J4E6HN6<2 @  <RP  !,   !;0V]N=&5N=%]4>7!E
M<UTN>&ULS=K?3MLP% ;P5ZERBQK7_S=$N0%N-R[V EYRVD9-8LLVK+S]G!20
M-K$*5*1]-XU:V^<[\9%^5[WZ\10H+0Y#/Z9UM<LY7#*6FAT-+M4^T%A6-CX.
M+I>O<<N":_9N2TRL5H8U?LPTYF6>:E375[>T<0]]7MP=RL^I\^.ZBM2G:G%S
MW#AEK2L70M\U+I=U]CBV?Z4LGQ/J<G+>DW9=2!=E0\7>3)A6_AWP?.[[(\78
MM;2X=S%_<T/9Q0X]2_FIIU2?+O%&CWZSZ1IJ??,PE"-U"I%<FW9$>>CK8]&+
MT\FYW# =/_G9^7.94X%EYWWT(96)1?IXW,M(IM/+4 I1S-WI5WQ-+*7/?C^:
MIMU2^\[L<KV_?-S/\TAL?IQ_QW_.^+7^!_L0('U(D#X42!\:I \#TH<%Z>,+
M2!]?0?K@*Y1&4$3E**1R%%,Y"JH<156.PBI'<96CP,I19!4HL@H4606*K )%
M5H$BJT"15:#(*E!D%2BR"A19)8JL$D56B2*K1)%5HL@J4625*+)*%%DEBJP2
M15:%(JM"D56AR*I09%4HLBH4616*K I%5H4BJT*15:/(JE%DU2BR:A19-8JL
M&D56C2*K1I%5H\BJ460U*+(:%%D-BJP&15:#(JM!D=6@R&I09#4HLAH462V*
MK!9%5HLBJT61U:+(:E%DM2BRVO\IZT_O]Y\</S_KP77C2SZ;_VM\_1M02P$"
M% ,4    " #;@VI2!T%-8H$   "Q    $               @ $     9&]C
M4')O<',O87!P+GAM;%!+ 0(4 Q0    ( -N#:E)M/FK5[@   "L"   1
M          "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( -N#
M:E*97)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M92]T:&5M
M93$N>&UL4$L! A0#%     @ VX-J4I')6LGP!0  \1@  !@
M ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( -N#
M:E(1IB25BP8  #H;   8              " @3,.  !X;"]W;W)K<VAE971S
M+W-H965T,BYX;6Q02P$"% ,4    " #;@VI2*DH <I\"   V"0  &
M        @('T%   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%
M  @ VX-J4IIX+HR.!   >!   !@              ("!R1<  'AL+W=O<FMS
M:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( -N#:E)JF/M4\@(  )H(   8
M              " @8T<  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"
M% ,4    " #;@VI2_8:6V;$&   >(P  &               @(&U'P  >&PO
M=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ VX-J4K?\<^C "0
MW"L  !@              ("!G"8  'AL+W=O<FMS:&5E=',O<VAE970W+GAM
M;%!+ 0(4 Q0    ( -N#:E(OP5RH#0@  -\3   8              " @9(P
M  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " #;@VI2'<YU
MCT4?  !88@  &               @('5.   >&PO=V]R:W-H965T<R]S:&5E
M=#DN>&UL4$L! A0#%     @ VX-J4E88%QPI%0  O5   !D
M ("!4%@  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " #;
M@VI2N"]VE"4&  "8$0  &0              @(&P;0  >&PO=V]R:W-H965T
M<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( -N#:E*G0W(F6@4  #H2   9
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M970Q-BYX;6Q02P$"% ,4    " #;@VI2PULM(O4%  #'$0  &0
M    @(%HD@  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    (
M -N#:E)KQN2 U 8  !D1   9              " @928  !X;"]W;W)K<VAE
M971S+W-H965T,3@N>&UL4$L! A0#%     @ VX-J4L@08Q6)"   <!P  !D
M             ("!GY\  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"
M% ,4    " #;@VI2ODWB9-P-  #U+P  &0              @(%?J   >&PO
M=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( -N#:E(*8+[7N0(
M /@%   9              " @7*V  !X;"]W;W)K<VAE971S+W-H965T,C$N
M>&UL4$L! A0#%     @ VX-J4E!D*W0-$   !C,  !D              ("!
M8KD  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " #;@VI2
MP'IKO>X#  !0"@  &0              @(&FR0  >&PO=V]R:W-H965T<R]S
M:&5E=#(S+GAM;%!+ 0(4 Q0    ( -N#:E+ .VNPIP(  -T%   9
M      " @<O-  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%
M  @ VX-J4OAT"K+2(   ?VX  !D              ("!J=   'AL+W=O<FMS
M:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " #;@VI2M!;.1I,"  "2!@
M&0              @(&R\0  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+
M 0(4 Q0    ( -N#:E(0>*F1BP,  "D-   9              " @7ST  !X
M;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ VX-J4EY6K(,Y
M P  ,@H  !D              ("!/O@  'AL+W=O<FMS:&5E=',O<VAE970R
M."YX;6Q02P$"% ,4    " #;@VI2N*<PP)X#  !,#0  &0
M@(&N^P  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( -N#
M:E)P5P7X]P,  /P+   9              " @8/_  !X;"]W;W)K<VAE971S
M+W-H965T,S N>&UL4$L! A0#%     @ VX-J4C>[?R#. @  RP8  !D
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M=#,U+GAM;%!+ 0(4 Q0    ( -N#:E)AD7P%(P(  )<$   9
M  " @>\: 0!X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @
MVX-J4N4?8+#] 0  ) 0  !D              ("!21T! 'AL+W=O<FMS:&5E
M=',O<VAE970S-RYX;6Q02P$"% ,4    " #;@VI2)(N8 M@"  "G"   &0
M            @(%]'P$ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4
M Q0    ( -N#:E(!.Y#F>@(  /H&   9              " @8PB 0!X;"]W
M;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ VX-J4F%'"H@L @
MK00  !D              ("!/24! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX
M;6Q02P$"% ,4    " #;@VI2W5X4:_<(  #J/@  &0              @(&@
M)P$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( -N#:E*4
M)::(?P0  #@4   9              " @<XP 0!X;"]W;W)K<VAE971S+W-H
M965T-#(N>&UL4$L! A0#%     @ VX-J4E./U'XD!   %A<  !D
M     ("!A#4! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -N#:E)JR>[+MP(  ,\'   9              "
M@45( 0!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ VX-J
M4JBHDP>3 P   Q   !D              ("!,TL! 'AL+W=O<FMS:&5E=',O
M<VAE970T.2YX;6Q02P$"% ,4    " #;@VI24#72?+D#   D#P  &0
M        @(']3@$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0
M   ( -N#:E+3<.YTS@0  ",5   9              " @>U2 0!X;"]W;W)K
M<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ VX-J4CTX@1N8 @  *@<
M !D              ("!\E<! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q0
M2P$"% ,4    " #;@VI2Z3RCIJ4"  #@!P  &0              @('!6@$
M>&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( -N#:E*0]#?(
M$ (  (,%   9              " @9U= 0!X;"]W;W)K<VAE971S+W-H965T
M-30N>&UL4$L! A0#%     @ VX-J4K$SN=C3 @  N@@  !D
M ("!Y%\! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    " #;
M@VI2-5"S22@"  #^!   &0              @('N8@$ >&PO=V]R:W-H965T
M<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( -N#:E)R!:$[X@(   0+   9
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M970V,2YX;6Q02P$"% ,4    " #;@VI2 AN^IM$$  #)%0  &0
M    @(%[>P$ >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    (
M -N#:E*]FU4S-0,  (<,   9              " @8.  0!X;"]W;W)K<VAE
M971S+W-H965T-C,N>&UL4$L! A0#%     @ VX-J4J?SB#;# P  1PX  !D
M             ("![X,! 'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q02P$"
M% ,4    " #;@VI2IH"N)P($  "Y#P  &0              @('IAP$ >&PO
M=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( -N#:E)-S8$I8 ,
M % +   9              " @2*, 0!X;"]W;W)K<VAE971S+W-H965T-C8N
M>&UL4$L! A0#%     @ VX-J4GC_Y@#I @  <P@  !D              ("!
MN8\! 'AL+W=O<FMS:&5E=',O<VAE970V-RYX;6Q02P$"% ,4    " #;@VI2
M%:EEO>8"  #Q"   &0              @('9D@$ >&PO=V]R:W-H965T<R]S
M:&5E=#8X+GAM;%!+ 0(4 Q0    ( -N#:E)?ONWM9 ,  +@,   9
M      " @?:5 0!X;"]W;W)K<VAE971S+W-H965T-CDN>&UL4$L! A0#%
M  @ VX-J4O\^H_W; P  & T  !D              ("!D9D! 'AL+W=O<FMS
M:&5E=',O<VAE970W,"YX;6Q02P$"% ,4    " #;@VI27>D'UNT"  !C"@
M&0              @(&CG0$ >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+
M 0(4 Q0    ( -N#:E)KA5/ABP(  -$'   9              " @<>@ 0!X
M;"]W;W)K<VAE971S+W-H965T-S(N>&UL4$L! A0#%     @ VX-J4KQNEV4^
M P  X D  !D              ("!B:,! 'AL+W=O<FMS:&5E=',O<VAE970W
M,RYX;6Q02P$"% ,4    " #;@VI2AS]S1]\"  !:"   &0
M@('^I@$ >&PO=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+ 0(4 Q0    ( -N#
M:E)PT$"PW@(  .,'   9              " @12J 0!X;"]W;W)K<VAE971S
M+W-H965T-S4N>&UL4$L! A0#%     @ VX-J4I47B2]I P  =PT  !D
M         ("!*:T! 'AL+W=O<FMS:&5E=',O<VAE970W-BYX;6Q02P$"% ,4
M    " #;@VI2_) X)!<"  "0!   &0              @(')L $ >&PO=V]R
M:W-H965T<R]S:&5E=#<W+GAM;%!+ 0(4 Q0    ( -N#:E+7E^^)50(  & ,
M   -              "  1>S 0!X;"]S='EL97,N>&UL4$L! A0#%     @
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H0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !5 %4 2A<  '7! 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>257</ContextCount>
  <ElementCount>459</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>92</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00400 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00500 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureOrganizationAndDescriptionOfBusiness</Role>
      <ShortName>Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10301 - Disclosure - License and Collaboration Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreement</Role>
      <ShortName>License and Collaboration Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Cash Equivalents and Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecurities</Role>
      <ShortName>Cash Equivalents and Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Research Collaboration and License Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreement</Role>
      <ShortName>Research Collaboration and License Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Government Programs</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureGovernmentPrograms</Role>
      <ShortName>Government Programs</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureDebt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11201 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11301 - Disclosure - Equity Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureEquityPlans</Role>
      <ShortName>Equity Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>11401 - Disclosure - 401(k) Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/Disclosure401KPlan</Role>
      <ShortName>401(k) Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>11501 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>11601 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>11701 - Disclosure - Restructuring</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureRestructuring</Role>
      <ShortName>Restructuring</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>30203 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>30303 - Disclosure - License and Collaboration Agreement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementTables</Role>
      <ShortName>License and Collaboration Agreement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreement</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protagonist-inc.com/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Cash Equivalents and Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesTables</Role>
      <ShortName>Cash Equivalents and Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecurities</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponents</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>30903 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureDebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protagonist-inc.com/role/DisclosureDebt</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>31003 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protagonist-inc.com/role/DisclosureLeases</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>31303 - Disclosure - Equity Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureEquityPlansTables</Role>
      <ShortName>Equity Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protagonist-inc.com/role/DisclosureEquityPlans</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>31503 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protagonist-inc.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>31603 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protagonist-inc.com/role/DisclosureNetLossPerShare</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40101 - Disclosure - Organization and Description of Business - Liquidity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureOrganizationAndDescriptionOfBusinessLiquidityDetails</Role>
      <ShortName>Organization and Description of Business - Liquidity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Summary of Significant Accounting Policies - Concentrations of Credit Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Concentrations of Credit Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40202 - Disclosure - Summary of Significant Accounting Policies - Cash and Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Cash and Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40203 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment and Impairment of Long-Lived Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAndImpairmentOfLongLivedAssetsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Property and Equipment and Impairment of Long-Lived Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40204 - Disclosure - Summary of Significant Accounting Policies - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesIncomeTaxesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40301 - Disclosure - License and Collaboration Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails</Role>
      <ShortName>License and Collaboration Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40302 - Disclosure - License and Collaboration Agreement - Contract Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails</Role>
      <ShortName>License and Collaboration Agreement - Contract Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Cash Equivalents and Marketable Securities - Cash Equivalents and Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails</Role>
      <ShortName>Cash Equivalents and Marketable Securities - Cash Equivalents and Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40502 - Disclosure - Cash Equivalents and Marketable Securities - Classification of Cash Equivalents and Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesClassificationOfCashEquivalentsAndMarketableSecuritiesDetails</Role>
      <ShortName>Cash Equivalents and Marketable Securities - Classification of Cash Equivalents and Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40602 - Disclosure - Balance Sheet Components - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails</Role>
      <ShortName>Balance Sheet Components - Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>40603 - Disclosure - Balance Sheet Components - Accrued Expenses and Other Payables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsAccruedExpensesAndOtherPayablesDetails</Role>
      <ShortName>Balance Sheet Components - Accrued Expenses and Other Payables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Research Collaboration and License Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreementDetails</Role>
      <ShortName>Research Collaboration and License Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreement</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Government Programs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureGovernmentProgramsDetails</Role>
      <ShortName>Government Programs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protagonist-inc.com/role/DisclosureGovernmentPrograms</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureDebtDetails</Role>
      <ShortName>Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protagonist-inc.com/role/DisclosureDebtTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>40902 - Disclosure - Debt - Long-term debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureDebtLongTermDebtDetails</Role>
      <ShortName>Debt - Long-term debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Leases - Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureLeasesAgreementDetails</Role>
      <ShortName>Leases - Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>41002 - Disclosure - Leases - Weighted average lease term and discount rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureLeasesWeightedAverageLeaseTermAndDiscountRateDetails</Role>
      <ShortName>Leases - Weighted average lease term and discount rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>41003 - Disclosure - Leases - Minimum lease payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureLeasesMinimumLeasePaymentsDetails</Role>
      <ShortName>Leases - Minimum lease payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>41004 - Disclosure - Leases - Lease cost information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureLeasesLeaseCostInformationDetails</Role>
      <ShortName>Leases - Lease cost information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>41005 - Disclosure - Leases - Supplemental balance sheet information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails</Role>
      <ShortName>Leases - Supplemental balance sheet information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>41006 - Disclosure - Leases - Cash flow information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureLeasesCashFlowInformationDetails</Role>
      <ShortName>Leases - Cash flow information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>41201 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protagonist-inc.com/role/DisclosureStockholdersEquity</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>41301 - Disclosure - Equity Plans - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails</Role>
      <ShortName>Equity Plans - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>41302 - Disclosure - Equity Plans - Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureEquityPlansActivityDetails</Role>
      <ShortName>Equity Plans - Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>41303 - Disclosure - Equity Plans - Employee Stock Options Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockOptionsValuationAssumptionsDetails</Role>
      <ShortName>Equity Plans - Employee Stock Options Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>41304 - Disclosure - Equity Plans - Restricted Stock Units - (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureEquityPlansRestrictedStockUnitsDetails</Role>
      <ShortName>Equity Plans - Restricted Stock Units - (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>41305 - Disclosure - Equity Plans - Employee Stock Purchase Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockPurchasePlanDetails</Role>
      <ShortName>Equity Plans - Employee Stock Purchase Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>41306 - Disclosure - Equity Plans - Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureEquityPlansStockBasedCompensationExpenseDetails</Role>
      <ShortName>Equity Plans - Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>41501 - Disclosure - Income Taxes - Provision and Components of Net Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureIncomeTaxesProvisionAndComponentsOfNetLossDetails</Role>
      <ShortName>Income Taxes - Provision and Components of Net Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>41502 - Disclosure - Income Taxes - Components of Federal, State and Foreign Income Tax Expense (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureIncomeTaxesComponentsOfFederalStateAndForeignIncomeTaxExpenseBenefitDetails</Role>
      <ShortName>Income Taxes - Components of Federal, State and Foreign Income Tax Expense (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>41503 - Disclosure - Income Taxes - Provision Difference from Federal Statutory Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureIncomeTaxesProvisionDifferenceFromFederalStatutoryRateDetails</Role>
      <ShortName>Income Taxes - Provision Difference from Federal Statutory Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>41504 - Disclosure - Income Taxes - Components of Deferred Tax Assets and Valuation Allowance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndValuationAllowanceDetails</Role>
      <ShortName>Income Taxes - Components of Deferred Tax Assets and Valuation Allowance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>41505 - Disclosure - Income Taxes - Net Operating Loss Carryforwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails</Role>
      <ShortName>Income Taxes - Net Operating Loss Carryforwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>41506 - Disclosure - Income Taxes - Research and Development Tax Credit Carryforwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureIncomeTaxesResearchAndDevelopmentTaxCreditCarryforwardsDetails</Role>
      <ShortName>Income Taxes - Research and Development Tax Credit Carryforwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>41507 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>41508 - Disclosure - Income Taxes - 2020 Tax Law Updates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureIncomeTaxes2020TaxLawUpdatesDetails</Role>
      <ShortName>Income Taxes - 2020 Tax Law Updates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>41601 - Disclosure - Net Loss per Share - Computation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureNetLossPerShareComputationDetails</Role>
      <ShortName>Net Loss per Share - Computation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>41602 - Disclosure - Net Loss per Share - Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails</Role>
      <ShortName>Net Loss per Share - Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="ptgx-20201231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>41701 - Disclosure - Restructuring (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagonist-inc.com/role/DisclosureRestructuringDetails</Role>
      <ShortName>Restructuring (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protagonist-inc.com/role/DisclosureRestructuring</ParentRole>
      <Position>77</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="ptgx-20201231x10k.htm">ptgx-20201231x10k.htm</File>
    <File>ptgx-20201231.xsd</File>
    <File>ptgx-20201231_cal.xml</File>
    <File>ptgx-20201231_def.xml</File>
    <File>ptgx-20201231_lab.xml</File>
    <File>ptgx-20201231_pre.xml</File>
    <File>ptgx-20201231xex21d1.htm</File>
    <File>ptgx-20201231xex23d1.htm</File>
    <File>ptgx-20201231xex23d2.htm</File>
    <File>ptgx-20201231xex31d1.htm</File>
    <File>ptgx-20201231xex31d2.htm</File>
    <File>ptgx-20201231xex32d1.htm</File>
    <File>ptgx-20201231xex4d7.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ptgx-20201231x10k006.jpg</File>
    <File>ptgx-20201231x10k007.jpg</File>
    <File>ptgx-20201231x10k008.jpg</File>
    <File>ptgx-20201231x10k009.jpg</File>
    <File>ptgx-20201231x10k010.jpg</File>
    <File>ptgx-20201231x10k011.jpg</File>
    <File>ptgx-20201231x10k012.jpg</File>
    <File>ptgx-20201231x10k013.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/stpr/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>106
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ptgx-20201231x10k.htm": {
   "axisCustom": 1,
   "axisStandard": 26,
   "contextCount": 257,
   "dts": {
    "calculationLink": {
     "local": [
      "ptgx-20201231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ptgx-20201231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "ptgx-20201231x10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ptgx-20201231_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ptgx-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "ptgx-20201231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 645,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 20,
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 25
   },
   "keyCustom": 76,
   "keyStandard": 383,
   "memberCustom": 52,
   "memberStandard": 35,
   "nsprefix": "ptgx",
   "nsuri": "http://www.protagonist-inc.com/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_ptgx_JanssenLicenseAndCollaborationAgreement26May2017Member_C_BnSjKn10WVjRwNMh3ISQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - License and Collaboration Agreement",
     "role": "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreement",
     "shortName": "License and Collaboration Agreement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_ptgx_JanssenLicenseAndCollaborationAgreement26May2017Member_C_BnSjKn10WVjRwNMh3ISQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - Fair Value Measurements",
     "role": "http://www.protagonist-inc.com/role/DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - Cash Equivalents and Marketable Securities",
     "role": "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecurities",
     "shortName": "Cash Equivalents and Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - Balance Sheet Components",
     "role": "http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponents",
     "shortName": "Balance Sheet Components",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member_ui-WhgpxI0OwEii6l0-3yQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - Research Collaboration and License Agreement",
     "role": "http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreement",
     "shortName": "Research Collaboration and License Agreement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member_ui-WhgpxI0OwEii6l0-3yQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgx:GovernmentProgramsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - Government Programs",
     "role": "http://www.protagonist-inc.com/role/DisclosureGovernmentPrograms",
     "shortName": "Government Programs",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgx:GovernmentProgramsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - Debt",
     "role": "http://www.protagonist-inc.com/role/DisclosureDebt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - Leases",
     "role": "http://www.protagonist-inc.com/role/DisclosureLeases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11101 - Disclosure - Commitments and Contingencies",
     "role": "http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11201 - Disclosure - Stockholders' Equity",
     "role": "http://www.protagonist-inc.com/role/DisclosureStockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - Consolidated Balance Sheets",
     "role": "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DueFromRelatedPartiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11301 - Disclosure - Equity Plans",
     "role": "http://www.protagonist-inc.com/role/DisclosureEquityPlans",
     "shortName": "Equity Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11401 - Disclosure - 401(k) Plan",
     "role": "http://www.protagonist-inc.com/role/Disclosure401KPlan",
     "shortName": "401(k) Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11501 - Disclosure - Income Taxes",
     "role": "http://www.protagonist-inc.com/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11601 - Disclosure - Net Loss per Share",
     "role": "http://www.protagonist-inc.com/role/DisclosureNetLossPerShare",
     "shortName": "Net Loss per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11701 - Disclosure - Restructuring",
     "role": "http://www.protagonist-inc.com/role/DisclosureRestructuring",
     "shortName": "Restructuring",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20202 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30203 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - License and Collaboration Agreement (Tables)",
     "role": "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementTables",
     "shortName": "License and Collaboration Agreement (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30503 - Disclosure - Cash Equivalents and Marketable Securities (Tables)",
     "role": "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesTables",
     "shortName": "Cash Equivalents and Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_eIoe1E1VJU26vA2ChPFm7Q",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30603 - Disclosure - Balance Sheet Components (Tables)",
     "role": "http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsTables",
     "shortName": "Balance Sheet Components (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30903 - Disclosure - Debt (Tables)",
     "role": "http://www.protagonist-inc.com/role/DisclosureDebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgx:LeaseQuantitativeDisclosureTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31003 - Disclosure - Leases (Tables)",
     "role": "http://www.protagonist-inc.com/role/DisclosureLeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgx:LeaseQuantitativeDisclosureTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31303 - Disclosure - Equity Plans (Tables)",
     "role": "http://www.protagonist-inc.com/role/DisclosureEquityPlansTables",
     "shortName": "Equity Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31503 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31603 - Disclosure - Net Loss per Share (Tables)",
     "role": "http://www.protagonist-inc.com/role/DisclosureNetLossPerShareTables",
     "shortName": "Net Loss per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - Organization and Description of Business - Liquidity (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureOrganizationAndDescriptionOfBusinessLiquidityDetails",
     "shortName": "Organization and Description of Business - Liquidity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ptgx:CashNumberOfFinancialInstitutions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_Institution_l_EWsumXIkS46w5G4NlRGw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - Summary of Significant Accounting Policies - Concentrations of Credit Risk (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails",
     "shortName": "Summary of Significant Accounting Policies - Concentrations of Credit Risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ptgx:CashNumberOfFinancialInstitutions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_Institution_l_EWsumXIkS46w5G4NlRGw",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40202 - Disclosure - Summary of Significant Accounting Policies - Cash and Cash Equivalents and Restricted Cash (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails",
     "shortName": "Summary of Significant Accounting Policies - Cash and Cash Equivalents and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2018_rK3dysi-wkKgewxxLVB-Eg",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:TangibleAssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40203 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment and Impairment of Long-Lived Assets (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAndImpairmentOfLongLivedAssetsDetails",
     "shortName": "Summary of Significant Accounting Policies - Property and Equipment and Impairment of Long-Lived Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:TangibleAssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ptgx:RevenueFromContractWithCustomerIncludingCumulativeCatchUpAdjustmentToRevenueModificationOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - Consolidated Statements of Operations",
     "role": "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ptgx:RevenueFromContractWithCustomerIncludingCumulativeCatchUpAdjustmentToRevenueModificationOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40204 - Disclosure - Summary of Significant Accounting Policies - Income Taxes (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesIncomeTaxesDetails",
     "shortName": "Summary of Significant Accounting Policies - Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityNoncurrent",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - License and Collaboration Agreement (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails",
     "shortName": "License and Collaboration Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40302 - Disclosure - License and Collaboration Agreement - Contract Assets and Liabilities (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails",
     "shortName": "License and Collaboration Agreement - Contract Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2018_srt_CounterpartyNameAxis_ptgx_JanssenBiotechIncMember_us-gaap_TypeOfArrangementAxis_us-gaap_ProductMember_dyHYhh53okOYGwIKFCa5Ag",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - Fair Value Measurements (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - Cash Equivalents and Marketable Securities - Cash Equivalents and Marketable Securities (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails",
     "shortName": "Cash Equivalents and Marketable Securities - Cash Equivalents and Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ptgx:CashEquivalentsAndMarketableSecuritiesAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40502 - Disclosure - Cash Equivalents and Marketable Securities - Classification of Cash Equivalents and Marketable Securities (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesClassificationOfCashEquivalentsAndMarketableSecuritiesDetails",
     "shortName": "Cash Equivalents and Marketable Securities - Classification of Cash Equivalents and Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ptgx:PrepaidManufacturingOfClinicalMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails",
     "shortName": "Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ptgx:PrepaidManufacturingOfClinicalMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40602 - Disclosure - Balance Sheet Components - Property and Equipment, Net (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails",
     "shortName": "Balance Sheet Components - Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ptgx:AccruedClinicalAndResearchRelatedExpensesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40603 - Disclosure - Balance Sheet Components - Accrued Expenses and Other Payables (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsAccruedExpensesAndOtherPayablesDetails",
     "shortName": "Balance Sheet Components - Accrued Expenses and Other Payables (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ptgx:AccruedClinicalAndResearchRelatedExpensesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - Research Collaboration and License Agreement (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreementDetails",
     "shortName": "Research Collaboration and License Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member_ui-WhgpxI0OwEii6l0-3yQ",
      "decimals": "INF",
      "lang": null,
      "name": "ptgx:NumberOfDevelopmentMilestonePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_hG9CfJX4lUefEcY3aN9DsQ",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - Consolidated Statements of Comprehensive Loss",
     "role": "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfComprehensiveLoss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxesReceivable",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - Government Programs (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureGovernmentProgramsDetails",
     "shortName": "Government Programs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ptgx:GovernmentProgramsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_ptgx_RevenueSourceAxis_ptgx_SmallBusinessInnovationResearchGrantMember_qd1j0yCx90GcZk8LgZ8W2g",
      "decimals": "-5",
      "lang": null,
      "name": "ptgx:ResearchAndDevelopmentExpensesReduction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - Debt (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureDebtDetails",
     "shortName": "Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_DebtInstrumentAxis_ptgx_TermLoanCreditAgreementMember_cKfYUU8Sf0-u1ytV-rCvdg",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40902 - Disclosure - Debt - Long-term debt (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureDebtLongTermDebtDetails",
     "shortName": "Debt - Long-term debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "As_Of_3_31_2017_zWxDm9xYR0y9NPetyRPWMQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SecurityDeposit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41001 - Disclosure - Leases - Agreement (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureLeasesAgreementDetails",
     "shortName": "Leases - Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "As_Of_3_31_2017_zWxDm9xYR0y9NPetyRPWMQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SecurityDeposit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ptgx:LeaseQuantitativeDisclosureTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41002 - Disclosure - Leases - Weighted average lease term and discount rate (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureLeasesWeightedAverageLeaseTermAndDiscountRateDetails",
     "shortName": "Leases - Weighted average lease term and discount rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ptgx:LeaseQuantitativeDisclosureTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41003 - Disclosure - Leases - Minimum lease payments (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureLeasesMinimumLeasePaymentsDetails",
     "shortName": "Leases - Minimum lease payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41004 - Disclosure - Leases - Lease cost information (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureLeasesLeaseCostInformationDetails",
     "shortName": "Leases - Lease cost information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41005 - Disclosure - Leases - Supplemental balance sheet information (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails",
     "shortName": "Leases - Supplemental balance sheet information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ptgx:LeaseCashFlowInformationDisclosureTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41006 - Disclosure - Leases - Cash flow information (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureLeasesCashFlowInformationDetails",
     "shortName": "Leases - Cash flow information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ptgx:LeaseCashFlowInformationDisclosureTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_ZealandPharmaMember_EFYZYS2pyEi6iqunSu7VTw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:LossContingencyDamagesSoughtValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41101 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_ptgx_ZealandPharmaMember_EFYZYS2pyEi6iqunSu7VTw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:LossContingencyDamagesSoughtValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2yPAw-zRyEu3cnkGbo1BJA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - Consolidated Statements of Stockholders' Equity",
     "role": "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2yPAw-zRyEu3cnkGbo1BJA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41201 - Disclosure - Stockholders' Equity (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails",
     "shortName": "Stockholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_9_1_2017_To_9_30_2017_us-gaap_SubsidiarySaleOfStockAxis_ptgx_CommonStockPreferredStockAndCertainDebtSecuritiesMember_zx3lVa2z8kOfh7KC7iZGpg",
      "decimals": "-5",
      "lang": null,
      "name": "ptgx:SaleOfStockValueOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "ptgx:ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41301 - Disclosure - Equity Plans - Narrative (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails",
     "shortName": "Equity Plans - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "ptgx:ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41302 - Disclosure - Equity Plans - Activity (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureEquityPlansActivityDetails",
     "shortName": "Equity Plans - Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_y_lWVCdXEkurpTEfNZLamw",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41303 - Disclosure - Equity Plans - Employee Stock Options Valuation Assumptions (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockOptionsValuationAssumptionsDetails",
     "shortName": "Equity Plans - Employee Stock Options Valuation Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_y_lWVCdXEkurpTEfNZLamw",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ptgx:NumberOfEqualInstallmentsRequiredForVestingOfRestrictedStockUnits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_installment_pPbBqyhnckSax7ouQFoPyQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41304 - Disclosure - Equity Plans - Restricted Stock Units - (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureEquityPlansRestrictedStockUnitsDetails",
     "shortName": "Equity Plans - Restricted Stock Units - (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ptgx:NumberOfEqualInstallmentsRequiredForVestingOfRestrictedStockUnits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_installment_pPbBqyhnckSax7ouQFoPyQ",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_62ZwKcYzp0eJm6qW-U5FhA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41305 - Disclosure - Equity Plans - Employee Stock Purchase Plan (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockPurchasePlanDetails",
     "shortName": "Equity Plans - Employee Stock Purchase Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_62ZwKcYzp0eJm6qW-U5FhA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41306 - Disclosure - Equity Plans - Stock-based Compensation Expense (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockBasedCompensationExpenseDetails",
     "shortName": "Equity Plans - Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41501 - Disclosure - Income Taxes - Provision and Components of Net Loss (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesProvisionAndComponentsOfNetLossDetails",
     "shortName": "Income Taxes - Provision and Components of Net Loss (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentForeignTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41502 - Disclosure - Income Taxes - Components of Federal, State and Foreign Income Tax Expense (Benefit) (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesComponentsOfFederalStateAndForeignIncomeTaxExpenseBenefitDetails",
     "shortName": "Income Taxes - Components of Federal, State and Foreign Income Tax Expense (Benefit) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentForeignTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41503 - Disclosure - Income Taxes - Provision Difference from Federal Statutory Rate (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesProvisionDifferenceFromFederalStatutoryRateDetails",
     "shortName": "Income Taxes - Provision Difference from Federal Statutory Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00500 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41504 - Disclosure - Income Taxes - Components of Deferred Tax Assets and Valuation Allowance (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndValuationAllowanceDetails",
     "shortName": "Income Taxes - Components of Deferred Tax Assets and Valuation Allowance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_UcV8z9_nP0mpIRu7PDiwKA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41505 - Disclosure - Income Taxes - Net Operating Loss Carryforwards (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails",
     "shortName": "Income Taxes - Net Operating Loss Carryforwards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember_hYnmxupXL0yNnBeGNa_apA",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_8i0o-skGv0azxibqP5J0Sw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41506 - Disclosure - Income Taxes - Research and Development Tax Credit Carryforwards (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesResearchAndDevelopmentTaxCreditCarryforwardsDetails",
     "shortName": "Income Taxes - Research and Development Tax Credit Carryforwards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_8i0o-skGv0azxibqP5J0Sw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2019_GDqbfBZgRkOQOlXvD28u8Q",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41507 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "As_Of_12_31_2017_uBPncpspM02T8SbWW1EWfg",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_3_27_2020_To_3_27_2020_d48ZoY7v8UOWrUfq_VZsYw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgx:NetOperatingLossCarryback",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41508 - Disclosure - Income Taxes - 2020 Tax Law Updates (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureIncomeTaxes2020TaxLawUpdatesDetails",
     "shortName": "Income Taxes - 2020 Tax Law Updates (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_3_27_2020_To_3_27_2020_d48ZoY7v8UOWrUfq_VZsYw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ptgx:NetOperatingLossCarryback",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_3ukIWV7PlUKxUNKWlkTcpg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41601 - Disclosure - Net Loss per Share - Computation (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureNetLossPerShareComputationDetails",
     "shortName": "Net Loss per Share - Computation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41602 - Disclosure - Net Loss per Share - Antidilutive Securities (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails",
     "shortName": "Net Loss per Share - Antidilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares__DRgx7ohK06w1AdcSMXfiA",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_3_7_2020_To_3_7_2020_OZuW7QpORUGdPGLaaZ6w3Q",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "ptgx:PercentageOfEmployeeBaseImpactedByRestructuringPlan",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41701 - Disclosure - Restructuring (Details)",
     "role": "http://www.protagonist-inc.com/role/DisclosureRestructuringDetails",
     "shortName": "Restructuring (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_3_7_2020_To_3_7_2020_OZuW7QpORUGdPGLaaZ6w3Q",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "ptgx:PercentageOfEmployeeBaseImpactedByRestructuringPlan",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_bYBpL0d3nEGqP2qAHLEPYg",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - Organization and Description of Business",
     "role": "http://www.protagonist-inc.com/role/DisclosureOrganizationAndDescriptionOfBusiness",
     "shortName": "Organization and Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptgx-20201231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_4j35p0Rv9kaqRLyW3l3HYA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 92,
   "tag": {
    "country_AU": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "A [U]",
        "terseLabel": "Australia"
       }
      }
     },
     "localname": "AU",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document And Entity Information"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r515",
      "r516",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r515",
      "r516",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ptgx_AccruedClinicalAndResearchRelatedExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsAccruedExpensesAndOtherPayablesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current portion of accrued clinical and research related expenses.",
        "label": "Accrued Clinical and Research Related Expenses Current",
        "terseLabel": "Accrued clinical and research related expenses"
       }
      }
     },
     "localname": "AccruedClinicalAndResearchRelatedExpensesCurrent",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsAccruedExpensesAndOtherPayablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_AccruedLiabilitiesAndOtherPayablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents the information pertaining to the accrued liabilities and other payables.",
        "label": "Accrued Liabilities And Other Payables [Member]",
        "terseLabel": "Accrued liabilities and other payables"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherPayablesMember",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_AdditionalPaymentObligationToFormerCollaborationPartner": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional payment obligation from the company to the former collaboration partner.",
        "label": "Additional Payment Obligation To Former Collaboration Partner",
        "terseLabel": "Additional payment obligation to the former collaboration partner"
       }
      }
     },
     "localname": "AdditionalPaymentObligationToFormerCollaborationPartner",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_AggregateAmountOfDevelopmentMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of development milestone payment made by the entity.",
        "label": "Aggregate Amount Of Development Milestone Payment",
        "terseLabel": "Aggregate development milestone payment"
       }
      }
     },
     "localname": "AggregateAmountOfDevelopmentMilestonePayment",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_AggregateGrossProceedsFromIssuanceStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross cash inflow from the additional capital contribution to the entity.",
        "label": "Aggregate Gross Proceeds from Issuance Stock",
        "terseLabel": "Aggregate gross proceeds"
       }
      }
     },
     "localname": "AggregateGrossProceedsFromIssuanceStock",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_AmendedCollaborationAgreementTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Amended first opt-in license rights.",
        "label": "Amended Collaboration Agreement Tranche One [Member]",
        "terseLabel": "Amended First Opt-in"
       }
      }
     },
     "localname": "AmendedCollaborationAgreementTrancheOneMember",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_AmendedSecondOptInMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Amended Second Opt-in license rights.",
        "label": "Amended Second Opt In [Member]",
        "terseLabel": "Amended Second Opt-in"
       }
      }
     },
     "localname": "AmendedSecondOptInMember",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee": {
     "auth_ref": [],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs and accretion of final payment fee under debt instrument.",
        "label": "Amortization Of Debt Issuance Costs And Debt Instrument, Accretion Of Final Payment Fee",
        "terseLabel": "Amortization of debt issuance costs and accretion of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_AtMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sale of newly issued shares into the secondary trading market through a designated broker-dealer at prevailing market prices.",
        "label": "At Market Offering [Member]",
        "terseLabel": "At-the-market offering (ATM)"
       }
      }
     },
     "localname": "AtMarketOfferingMember",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_AtMarketingOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sale of stock by a private company to public at market offer price.",
        "label": "At Marketing Offering [Member]",
        "terseLabel": "At-the-market offering"
       }
      }
     },
     "localname": "AtMarketingOfferingMember",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_BiotechnologyValueFundL.pMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Exchange Agreement with Biotechnology Value Fund, L.P",
        "label": "Biotechnology Value Fund L.p [Member]",
        "terseLabel": "Exchanging Stockholders"
       }
      }
     },
     "localname": "BiotechnologyValueFundL.pMember",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_CaliforniaNetOperatingLossDeductionsLimitOfIncome": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income limit for California Net Operating Loss Deductions.",
        "label": "California Net Operating Loss Deductions, Limit of Income",
        "terseLabel": "Amount of income limit for California Net Operating Loss deductions"
       }
      }
     },
     "localname": "CaliforniaNetOperatingLossDeductionsLimitOfIncome",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxes2020TaxLawUpdatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_CashEquivalentsAndAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Cash Equivalents and Available for Sale Securities [Line Items]",
        "terseLabel": "Cash Equivalents and Marketable Securities"
       }
      }
     },
     "localname": "CashEquivalentsAndAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ptgx_CashEquivalentsAndMarketableSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NA",
        "label": "Cash Equivalents and Marketable Securities"
       }
      }
     },
     "localname": "CashEquivalentsAndMarketableSecuritiesAbstract",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "xbrltype": "stringItemType"
    },
    "ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the cost of debt and equity securities, including cash equivalents which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.",
        "label": "Cash Equivalents And Marketable Securities Amortized Cost",
        "totalLabel": "Total cash equivalents and marketable securities, Amortized Cost"
       }
      }
     },
     "localname": "CashEquivalentsAndMarketableSecuritiesAmortizedCost",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_CashEquivalentsAndMarketableSecuritiesFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost",
       "weight": 1.0
      },
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesClassificationOfCashEquivalentsAndMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate fair value of amount of investment in debt and equity securities and cash equivalents categorized neither as held-to-maturity nor trading.",
        "label": "Cash Equivalents And Marketable Securities Fair Value",
        "terseLabel": "Total cash equivalents and marketable securities, Fair Value",
        "totalLabel": "Total cash equivalents and marketable securities"
       }
      }
     },
     "localname": "CashEquivalentsAndMarketableSecuritiesFairValue",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails",
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesClassificationOfCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain": {
     "auth_ref": [],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain before deducting unrealized loss on investments in debt and equity securities classified as cash equivalents and marketable securities.",
        "label": "Cash Equivalents And Marketable Securities Gross Unrealized Gain",
        "terseLabel": "Total cash equivalents and marketable securities, Gross Unrealized Gains"
       }
      }
     },
     "localname": "CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "ptgx_CashEquivalentsAndMarketableSecuritiesAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized loss before deducting unrealized gain on investments in cash equivalents and marketable securities.",
        "label": "Cash Equivalents And Marketable Securities Gross Unrealized Loss",
        "negatedLabel": "Total cash equivalents and marketable securities, Gross Unrealized Losses"
       }
      }
     },
     "localname": "CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_CashNumberOfFinancialInstitutions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of financial institutions that hold the entity's cash.",
        "label": "Cash, Number of Financial Institutions",
        "terseLabel": "Number of financial institutions at which cash is held"
       }
      }
     },
     "localname": "CashNumberOfFinancialInstitutions",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ptgx_ClassOfWarrantOrRightTermOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The duration of warrants from date of issuance.",
        "label": "Class of Warrant or Right, Term of Warrants",
        "terseLabel": "Duration of warrants from date of issuance (in years)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTermOfWarrants",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ptgx_CollaborationAgreementTrancheFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the period after third second-generation compounds.",
        "label": "Collaboration Agreement Tranche Five [Member]",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "CollaborationAgreementTrancheFiveMember",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_CollaborationAgreementTrancheFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the second and third second-generation compounds.",
        "label": "Collaboration Agreement Tranche Four [Member]",
        "terseLabel": "Second and third, second-generation compounds"
       }
      }
     },
     "localname": "CollaborationAgreementTrancheFourMember",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_CollaborationAgreementTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the first, second-generation compound.",
        "label": "Collaboration Agreement Tranche Three [Member]",
        "terseLabel": "First, second-generation compound"
       }
      }
     },
     "localname": "CollaborationAgreementTrancheThreeMember",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_CollaborativeArrangementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "License and Collaboration Agreement."
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureAbstract",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "xbrltype": "stringItemType"
    },
    "ptgx_CollaborativeArrangementEligibleAmountReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount received from a collaborative arrangement.",
        "label": "Collaborative Arrangement, Eligible Amount Received",
        "terseLabel": "Eligible amount received"
       }
      }
     },
     "localname": "CollaborativeArrangementEligibleAmountReceived",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_CollaborativeArrangementPayableUponEffectivenessOfAmendment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment payable upon the effectiveness of the First Amendment",
        "label": "Collaborative Arrangement, Payable Upon Effectiveness Of Amendment",
        "terseLabel": "Amount payable upon the effectiveness of the First Amendment"
       }
      }
     },
     "localname": "CollaborativeArrangementPayableUponEffectivenessOfAmendment",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurred": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of development cost incurred.",
        "label": "Collaborative Arrangement Percentage of Development Costs Incurred",
        "terseLabel": "Development cost"
       }
      }
     },
     "localname": "CollaborativeArrangementPercentageOfDevelopmentCostsIncurred",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ptgx_CollaborativeArrangementPercentageOfResearchProgramCostsIncurred": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of research program cost incurred.",
        "label": "Collaborative Arrangement Percentage Of Research Program Costs Incurred",
        "terseLabel": "Research program cost"
       }
      }
     },
     "localname": "CollaborativeArrangementPercentageOfResearchProgramCostsIncurred",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ptgx_CommonStockPreferredStockAndCertainDebtSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents common stock, preferred stock and certain debt securities (the \"Sales Agreement\").",
        "label": "Common Stock Preferred Stock And Certain Debt Securities [Member]",
        "terseLabel": "2017 Form S-3"
       }
      }
     },
     "localname": "CommonStockPreferredStockAndCertainDebtSecuritiesMember",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_CommonStockPreferredStockDebtSecuritiesAndWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents common stock, preferred stock, debt securities and warrants (the \"2019 Form S-3\").",
        "label": "Common Stock Preferred Stock Debt Securities And Warrants [Member]",
        "terseLabel": "2019 Form S-3"
       }
      }
     },
     "localname": "CommonStockPreferredStockDebtSecuritiesAndWarrantsMember",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_ContingentConsiderationReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Consideration Receivable",
        "label": "Contingent Consideration Receivable",
        "terseLabel": "Eligible payment receivable"
       }
      }
     },
     "localname": "ContingentConsiderationReceivable",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_ContractWithCustomerAssetAdditions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Addition in the amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, Additions",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAdditions",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_ContractWithCustomerAssetDeduction": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deduction in the amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, Deduction",
        "negatedLabel": "Deductions"
       }
      }
     },
     "localname": "ContractWithCustomerAssetDeduction",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_ContractWithCustomerAssetNetRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Contract with Customer, Asset, Net [Roll forward]",
        "terseLabel": "Receivable from collaboration partner - related party"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetRollForward",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ptgx_ContractWithCustomerAssetRelatedPartyAdditions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Addition in the amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to a related party when right is conditioned on something other than passage of time.",
        "label": "Contract With Customer Asset Related Party Additions",
        "terseLabel": "Contract asset - related party, Additions"
       }
      }
     },
     "localname": "ContractWithCustomerAssetRelatedPartyAdditions",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_ContractWithCustomerAssetRelatedPartyDeduction": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deduction in the amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to related party when right is conditioned on something other than passage of time.",
        "label": "Contract With Customer Asset Related Party Deduction",
        "terseLabel": "Contract asset - related party, Deductions"
       }
      }
     },
     "localname": "ContractWithCustomerAssetRelatedPartyDeduction",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_ContractWithCustomerLiabilityAdditions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Addition in the amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability, Additions",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityAdditions",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_ContractWithCustomerLiabilityDeduction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deduction in the amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability, Deduction",
        "negatedLabel": "Deductions"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityDeduction",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_ContractWithCustomerLiabilityNetRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Contract with Customer, Liability, Net [Roll forward]",
        "terseLabel": "Deferred revenue - related party"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNetRollForward",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ptgx_CurrentContractualMaturitiesMaximumPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum period of current contractual maturities.",
        "label": "Current Contractual Maturities, Maximum Period",
        "terseLabel": "Maximum period of current contractual maturities"
       }
      }
     },
     "localname": "CurrentContractualMaturitiesMaximumPeriod",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesClassificationOfCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ptgx_DebtInstrumentAccruedFinalPaymentFee": {
     "auth_ref": [],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureDebtLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of accrued final payment fee under the debt instrument arrangement.",
        "label": "Debt Instrument, Accrued Final Payment Fee",
        "terseLabel": "Accrued final payment fee"
       }
      }
     },
     "localname": "DebtInstrumentAccruedFinalPaymentFee",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureDebtLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_DebtInstrumentAdditionalPrepaymentOrRepaymentPremiumPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The additional percentage of prepayment premium on the amount advanced by the lenders will be due upon prepayments or repayment of the debt instrument.",
        "label": "Debt Instrument, Additional Prepayment Or Repayment Premium Percentage",
        "terseLabel": "Additional Prepayment (In Percentage)"
       }
      }
     },
     "localname": "DebtInstrumentAdditionalPrepaymentOrRepaymentPremiumPercentage",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ptgx_DebtInstrumentFloorRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the floor rate of the debt instrument",
        "label": "Debt Instrument, Floor Rate",
        "terseLabel": "Floor rate (In Percentage)"
       }
      }
     },
     "localname": "DebtInstrumentFloorRate",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ptgx_DebtInstrumentLoanOriginationFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of loan origination fee under the debt instrument.",
        "label": "Debt Instrument, Loan Origination Fee Percentage",
        "terseLabel": "Loan Origination Fee (In Percentage)"
       }
      }
     },
     "localname": "DebtInstrumentLoanOriginationFeePercentage",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ptgx_DebtInstrumentPeriodOfInterestOnlyPayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the period for which the company is required to pay interest-only payments on the debt instrument.",
        "label": "Debt Instrument, Period Of Interest Only Payments",
        "terseLabel": "Period Of Interest Only Payments"
       }
      }
     },
     "localname": "DebtInstrumentPeriodOfInterestOnlyPayments",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureDebtDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ptgx_DebtInstrumentPeriodOfPrincipalAndInterestPayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the period for which the company will pay principal and interest payments on the debt instrument.",
        "label": "Debt Instrument, Period Of Principal And Interest Payments",
        "terseLabel": "Consecutive monthly payments"
       }
      }
     },
     "localname": "DebtInstrumentPeriodOfPrincipalAndInterestPayments",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureDebtDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ptgx_DebtInstrumentPrepaymentPremiumPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of prepayment premium under the debt instrument.",
        "label": "Debt Instrument, Prepayment Premium Percentage",
        "terseLabel": "Prepayment premium (In Percentage)"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPremiumPercentage",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ptgx_DebtInstrumentRepaymentAfterSecondAnniversaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the debt instrument repayment occurring after second anniversary of the closing date.",
        "label": "Debt Instrument Repayment After Second Anniversary [Member]",
        "terseLabel": "Debt Instrument Repayment After Second Anniversary"
       }
      }
     },
     "localname": "DebtInstrumentRepaymentAfterSecondAnniversaryMember",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_DebtInstrumentRepaymentBetweenFirstAndSecondAnniversaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the debt instrument repayment occurring after first anniversary and through and including the second anniversary of the closing date.",
        "label": "Debt Instrument Repayment Between First And Second Anniversary [Member]",
        "terseLabel": "Debt Instrument Repayment Between First And Second Anniversary"
       }
      }
     },
     "localname": "DebtInstrumentRepaymentBetweenFirstAndSecondAnniversaryMember",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_DebtInstrumentRepaymentOnOrBeforeFirstAnniversaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the debt instrument repayment occurring through and including the first anniversary of the closing date.",
        "label": "Debt Instrument Repayment On Or Before First Anniversary [Member]",
        "terseLabel": "Debt Instrument Repayment On Or Before First Anniversary"
       }
      }
     },
     "localname": "DebtInstrumentRepaymentOnOrBeforeFirstAnniversaryMember",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_DebtInstrumentThresholdPercentageOnOutstandingDebtToBeMaintainedAsCashAndCashEquivalentsBalance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage on outstanding debt to be maintained as balance under cash and cash equivalents by the company.",
        "label": "Debt Instrument, Threshold Percentage On Outstanding Debt To Be Maintained As Cash And Cash Equivalents Balance",
        "terseLabel": "Cash and cash equivalents ( In percentage)"
       }
      }
     },
     "localname": "DebtInstrumentThresholdPercentageOnOutstandingDebtToBeMaintainedAsCashAndCashEquivalentsBalance",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ptgx_DebtInstrumentTrancheInstallmentAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the tranche installment amount under the debt instrument.",
        "label": "Debt Instrument, Tranche Installment Amount",
        "terseLabel": "Tranche Installment Amount"
       }
      }
     },
     "localname": "DebtInstrumentTrancheInstallmentAmount",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_DeductionOfTaxableIncomePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of taxable income deduction.",
        "label": "Deduction of Taxable Income, Percentage"
       }
      }
     },
     "localname": "DeductionOfTaxableIncomePercentage",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxes2020TaxLawUpdatesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ptgx_DeferredTaxAssetsOperatingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndValuationAllowanceDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents deferred tax assets, operating lease liability.",
        "label": "Deferred Tax Assets, Operating Lease Liability",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeaseLiability",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndValuationAllowanceDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from other reserves and accruals not separately disclosed.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals and Other",
        "terseLabel": "Accruals/other"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_DevelopmentRegulatoryAndSalesMilestonePaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents payments from development, regulatory and sales milestones related to a collaboration agreement.",
        "label": "Development Regulatory And Sales Milestone Payments [Member]",
        "terseLabel": "Development, regulatory and sales milestone payments"
       }
      }
     },
     "localname": "DevelopmentRegulatoryAndSalesMilestonePaymentsMember",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_DueToRelatedPartyAdditions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional amount of payable due to a related party",
        "label": "Due To Related Party Additions",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "DueToRelatedPartyAdditions",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_DueToRelatedPartyDeductions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deduction from obligation to transfer good or service to related party for payable amounts.",
        "label": "Due To Related Party Deductions",
        "negatedLabel": "Deductions"
       }
      }
     },
     "localname": "DueToRelatedPartyDeductions",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_EffectiveIncomeTaxRateReconciliationTaxCreditResearchAdjustmentPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesProvisionDifferenceFromFederalStatutoryRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to and adjustment to the research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Adjustment, Percent",
        "terseLabel": "Research and development credits (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditResearchAdjustmentPercent",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesProvisionDifferenceFromFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ptgx_EmployeeConsultantsAndDirectorsStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An arrangement whereby an employee, consultant, or member of the Board of Directors is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement.",
        "label": "Employee Consultants And Directors Stock Options [Member]",
        "terseLabel": "Stock options - employees, consultants, directors"
       }
      }
     },
     "localname": "EmployeeConsultantsAndDirectorsStockOptionsMember",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_EmployeeStockPurchasePlan2016Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the 2016 Employee Stock Purchase Plan approved by the board of directors and stockholders in July 2016.",
        "label": "Employee Stock Purchase Plan2016 [Member]",
        "terseLabel": "2016 ESPP"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlan2016Member",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_EntityRequiredToContinueToMakePaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information if the company is required to continue to make payments.",
        "label": "Entity Required To Continue To Make Payments [Member]",
        "terseLabel": "Entity Required to Continue to Make Payments"
       }
      }
     },
     "localname": "EntityRequiredToContinueToMakePaymentsMember",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_EquityIncentivePlan2016Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the 2016 Equity Incentive Plan approved by the entity's board of directors and stockholders in July 2016.",
        "label": "Equity Incentive Plan2016 [Member]",
        "terseLabel": "2016 Equity Incentive Plan"
       }
      }
     },
     "localname": "EquityIncentivePlan2016Member",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_EstimatedVariableConsiderationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the estimated variable consideration.",
        "label": "Estimated Variable Consideration [Member]",
        "terseLabel": "Estimated variable consideration"
       }
      }
     },
     "localname": "EstimatedVariableConsiderationMember",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_ExchangeAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for exchange agreement for common stock.",
        "label": "Exchange Agreement [Member]",
        "terseLabel": "Exchange Agreement"
       }
      }
     },
     "localname": "ExchangeAgreementMember",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of average volatility for comparable publicly traded biopharmaceutical companies over a period equal to the expected term of the stock option grants, used in the calculation of expected volatility.",
        "label": "Expected Volatility Calculation, Percentage Of Average Volatility Expected Term Of Stock Option Grants",
        "terseLabel": "Average volatility"
       }
      }
     },
     "localname": "ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ptgx_ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of volatility of stock price since its initial public offering used in the calculation of expected volatility.",
        "label": "Expected Volatility Calculation, Percentage Of Volatility Of Stock Price Since IPO",
        "terseLabel": "Percentage of volatility of stock options since IPO"
       }
      }
     },
     "localname": "ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ptgx_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of retired common stock in exchange for issuance of common stock warrant in noncash transactions.",
        "label": "Fair Value of Common Stock Retired in Exchange for Issuance of Common Stock Warrant",
        "terseLabel": "Fair value of common stock retired in exchange for issuance of common stock warrant"
       }
      }
     },
     "localname": "FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_FurnitureAndComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for furniture and computer equipment.",
        "label": "Furniture And Computer Equipment [Member]",
        "terseLabel": "Furniture and computer equipment"
       }
      }
     },
     "localname": "FurnitureAndComputerEquipmentMember",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_GovernmentProgramsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Government Programs"
       }
      }
     },
     "localname": "GovernmentProgramsAbstract",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "xbrltype": "stringItemType"
    },
    "ptgx_GovernmentProgramsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure pertaining to the government programs.",
        "label": "Government Programs Disclosure [Text Block]",
        "terseLabel": "Government Programs"
       }
      }
     },
     "localname": "GovernmentProgramsDisclosureTextBlock",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureGovernmentPrograms"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ptgx_GovernmentProgramsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Government Programs [Line Items]",
        "terseLabel": "Government Programs"
       }
      }
     },
     "localname": "GovernmentProgramsLineItems",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureGovernmentProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ptgx_GovernmentProgramsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of government programs.",
        "label": "Government Programs [Table]",
        "terseLabel": "Government Programs [Table]"
       }
      }
     },
     "localname": "GovernmentProgramsTable",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureGovernmentProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ptgx_IncomeTaxLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income tax [Line items]"
       }
      }
     },
     "localname": "IncomeTaxLineItems",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxes2020TaxLawUpdatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ptgx_IncomeTaxTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure on income taxes.",
        "label": "Income Tax [Table]"
       }
      }
     },
     "localname": "IncomeTaxTable",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxes2020TaxLawUpdatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ptgx_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating lease liability.",
        "label": "Increase Decrease in Operating Lease Liability",
        "negatedLabel": "Operating lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_InducementStockPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the 2018 Inducement plan, a non-stockholder approved stock plan in order to award options and restricted stock unit awards to persons that were not previously employees or directors of the Company, or following a bona fide period of non-employment, as an inducement material to such persons entering into employment with the Company, within the meaning of Rule 5635(c)(4) of the NASDAQ Listing Rules.",
        "label": "Inducement Stock Plan [Member]",
        "terseLabel": "Restricted stock unit incentive awards granted in 2018"
       }
      }
     },
     "localname": "InducementStockPlanMember",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_JanssenBiotechIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to the related party Janssen Biotech Inc.",
        "label": "Janssen Biotech Inc [Member]",
        "terseLabel": "Janssen Biotech, Inc."
       }
      }
     },
     "localname": "JanssenBiotechIncMember",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails",
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_JanssenLicenseAndCollaborationAgreement26May2017Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The license and collaboration agreement with Janssen Biotech, Inc. (Janssen) dated May 26, 2017.",
        "label": "Janssen License And Collaboration Agreement26 May2017 [Member]",
        "terseLabel": "License and Collaboration Agreement"
       }
      }
     },
     "localname": "JanssenLicenseAndCollaborationAgreement26May2017Member",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreement"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for laboratory equipment.",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_LeaseBalanceSheetDisclosureTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of lease balance sheet.",
        "label": "Lease Balance Sheet Disclosure [Table Text Block]",
        "terseLabel": "Schedule of balance sheet information"
       }
      }
     },
     "localname": "LeaseBalanceSheetDisclosureTableTextBlock",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ptgx_LeaseCashFlowInformationDisclosureTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of lease cash flow information.",
        "label": "Lease Cash Flow Information Disclosure [Table Text Block]",
        "terseLabel": "Schedule of cash flow information"
       }
      }
     },
     "localname": "LeaseCashFlowInformationDisclosureTableTextBlock",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ptgx_LeaseQuantitativeDisclosureTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of lease quantitative information.",
        "label": "Lease Quantitative Disclosure [Table Text Block]",
        "terseLabel": "Schedule of weighted average lease term and discounts rate"
       }
      }
     },
     "localname": "LeaseQuantitativeDisclosureTableTextBlock",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ptgx_LicenseAndCollaborativeAgreementAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to license and collaborative amended agreement.",
        "label": "License And Collaborative Agreement Amendment [Member]",
        "terseLabel": "First Amendment"
       }
      }
     },
     "localname": "LicenseAndCollaborativeAgreementAmendmentMember",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_LicenseAndCollaborativeRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to license and collaborative revenue.",
        "label": "License And Collaborative Revenue [Member]",
        "terseLabel": "License and Collaborative Revenue"
       }
      }
     },
     "localname": "LicenseAndCollaborativeRevenueMember",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_MaximumOffsetOfCaliforniaTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of California tax offset for business credit.",
        "label": "Maximum Offset of California tax",
        "terseLabel": "Amount of California tax offset for business credit"
       }
      }
     },
     "localname": "MaximumOffsetOfCaliforniaTax",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxes2020TaxLawUpdatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_MilestonePaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At the inception of each arrangement that includes development, regulatory or commercial milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price.",
        "label": "Milestone Payments [Member]",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "localname": "MilestonePaymentsMember",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_NetOperatingLossCarryback": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period of net operating loss carryback.",
        "label": "Net Operating Loss Carryback"
       }
      }
     },
     "localname": "NetOperatingLossCarryback",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxes2020TaxLawUpdatesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ptgx_NonEmployeeDirectorInitialStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the information pertaining to Non employee Director Initial Stock Options member.",
        "label": "Non Employee Director Initial Stock Options [Member]",
        "terseLabel": "Non Employee Director Initial Stock Options"
       }
      }
     },
     "localname": "NonEmployeeDirectorInitialStockOptionsMember",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_NoncurrentContractualMaturitiesMaximumPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum period of contractual maturities.",
        "label": "Noncurrent Contractual Maturities, Maximum Period",
        "terseLabel": "Maximum period of Noncurrent contractual maturities"
       }
      }
     },
     "localname": "NoncurrentContractualMaturitiesMaximumPeriod",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesClassificationOfCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ptgx_NoncurrentContractualMaturitiesMinimumPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the minimum period of noncurrent contractual maturities.",
        "label": "Noncurrent Contractual Maturities, Minimum Period",
        "terseLabel": "Minimum period of noncurrent contractual maturities"
       }
      }
     },
     "localname": "NoncurrentContractualMaturitiesMinimumPeriod",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesClassificationOfCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ptgx_NonemployeeDirectorAnnualRefresherStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Non employee Director Annual Refresher Stock Options member.",
        "label": "Nonemployee Director Annual Refresher Stock Options [Member]",
        "terseLabel": "Nonemployee Director Annual Refresher Stock Options"
       }
      }
     },
     "localname": "NonemployeeDirectorAnnualRefresherStockOptionsMember",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_NumberOfDevelopmentMilestonePayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of development milestone payments in collaboration agreement.",
        "label": "Number of Development Milestone Payments",
        "terseLabel": "Number of development milestone payments"
       }
      }
     },
     "localname": "NumberOfDevelopmentMilestonePayments",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreementDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ptgx_NumberOfEqualInstallmentsRequiredForVestingOfRestrictedStockUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equal installments established for the restricted stock units vesting schedule.",
        "label": "Number of Equal Installments Required For Vesting of Restricted Stock Units",
        "terseLabel": "Restricted stock units vesting, number of equal installments"
       }
      }
     },
     "localname": "NumberOfEqualInstallmentsRequiredForVestingOfRestrictedStockUnits",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ptgx_NumberOfOperatingLeaseAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of operating lease agreement.",
        "label": "Number of Operating Lease Agreement",
        "terseLabel": "Number of operating lease agreement"
       }
      }
     },
     "localname": "NumberOfOperatingLeaseAgreement",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesAgreementDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ptgx_NumberOfWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants exercised for the period.",
        "label": "Number of Warrants Exercised",
        "terseLabel": "Number of warrants exercised"
       }
      }
     },
     "localname": "NumberOfWarrantsExercised",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ptgx_OperatingLeaseRightOfUseAssetAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from operating lease.",
        "label": "Operating Lease Right of Use Asset Amortization",
        "terseLabel": "Operating lease right-of-use asset amortization"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortization",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_OperatingLossCarryforwardsNoExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward that do not expire, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards, No Expiration",
        "terseLabel": "Net operating loss carryforwards with no expiration"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsNoExpiration",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_OverseasFindingsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for overseas findings.",
        "label": "Overseas Findings [Member]",
        "terseLabel": "Overseas Findings"
       }
      }
     },
     "localname": "OverseasFindingsMember",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureGovernmentProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_PTG300Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for PTG 300 product candidate.",
        "label": "P T G300 [Member]",
        "terseLabel": "PTG-300"
       }
      }
     },
     "localname": "PTG300Member",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_PayableToCollaborationPartnerRelatedPartyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Payable to Collaboration Partner - Related Party [Abstract]",
        "terseLabel": "Payable to collaboration partner - related party"
       }
      }
     },
     "localname": "PayableToCollaborationPartnerRelatedPartyAbstract",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ptgx_PercentageOfEmployeeBaseImpactedByRestructuringPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of employee base impacted by the restructuring plan.",
        "label": "Percentage of Employee Base Impacted by Restructuring Plan",
        "terseLabel": "Percentage of employee base impacted by the restructuring plan"
       }
      }
     },
     "localname": "PercentageOfEmployeeBaseImpactedByRestructuringPlan",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureRestructuringDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ptgx_PercentagesRoyaltiesOnNetProductSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentages on net product sales.",
        "label": "Percentages Royalties on Net Product Sales",
        "terseLabel": "Percentages on net product sales"
       }
      }
     },
     "localname": "PercentagesRoyaltiesOnNetProductSales",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ptgx_PhaseOneClinicalTrialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the first, second-generation compound.",
        "label": "Phase One Clinical Trial [Member]",
        "terseLabel": "Phase 1 clinical term"
       }
      }
     },
     "localname": "PhaseOneClinicalTrialMember",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_PhaseThreeClinicalTrailOfPtg300Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Phase three clinical trail of PTG-300.",
        "label": "Phase Three Clinical Trail Of Ptg300 [Member]",
        "terseLabel": "Phase 3"
       }
      }
     },
     "localname": "PhaseThreeClinicalTrailOfPtg300Member",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_PhaseTwoBClinicalTrailOfPtg300Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Phase two B clinical trail of PTG-300.",
        "label": "Phase Two B Clinical Trail Of Ptg300 [Member]",
        "terseLabel": "Phase 2b"
       }
      }
     },
     "localname": "PhaseTwoBClinicalTrailOfPtg300Member",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_PhaseTwoClinicalTrialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for phase 2 clinical trial, related to a specific collaborative arrangement in which the entity provides product it manufactures to collaborative arrangement partners. A collaborative arrangement is a contractual arrangement with a specific party or parties that both: (i) actively participate in a joint operating activity and (ii) is (are) exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Phase Two Clinical Trial [Member]",
        "terseLabel": "Phase 2 clinical trial"
       }
      }
     },
     "localname": "PhaseTwoClinicalTrialMember",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_PotentialDevelopmentAndRegulatoryMilestonePaymentsOnContractualObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of potential development and regulatory milestone payments on contractual obligation",
        "label": "Potential Development and Regulatory Milestone Payments on Contractual Obligation",
        "terseLabel": "Potential development and regulatory milestone payments on contractual obligation"
       }
      }
     },
     "localname": "PotentialDevelopmentAndRegulatoryMilestonePaymentsOnContractualObligation",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_PotentialSalesMilestonePaymentsOnContractualObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount if potential sales milestone payments on contractual obligation.",
        "label": "Potential Sales Milestone Payments On Contractual Obligation",
        "terseLabel": "Potential sales milestone payments on contractual obligation"
       }
      }
     },
     "localname": "PotentialSalesMilestonePaymentsOnContractualObligation",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_PrepaidManufacturingOfClinicalMaterials": {
     "auth_ref": [],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for Prepaid manufacturing of clinical materials that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Manufacturing of Clinical Materials",
        "terseLabel": "Prepaid clinical and research related expenses"
       }
      }
     },
     "localname": "PrepaidManufacturingOfClinicalMaterials",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_ProceedsFromIssuanceOfCommonStockAndWarrantsInPrivatePlacementNetOfIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds from Issuance of Common Stock and Warrants in Private Placement, Net of Issuance Costs",
        "terseLabel": "Proceeds from issuance of common stock and warrants in private placement, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockAndWarrantsInPrivatePlacementNetOfIssuanceCosts",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_Ptg200Phase3CdClinicalTrialPrimaryClinicalEndpointMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the phase 3 CD clinical trial reaching a primary clinical endpoint with respect to the PTG-200.",
        "label": "Ptg200 Phase3 Cd Clinical Trial Primary Clinical Endpoint [Member]",
        "terseLabel": "PTG-200, Phase 3 CD Clinical Trial Primary Clinical Endpoint"
       }
      }
     },
     "localname": "Ptg200Phase3CdClinicalTrialPrimaryClinicalEndpointMember",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_ResearchAndDevelopmentExpensesReduction": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of reduction of research and development expense in connection with the research and development tax incentive.",
        "label": "Research And Development Expenses Reduction",
        "terseLabel": "Reduction of research and development expenses related to tax"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensesReduction",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureGovernmentProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_ResearchAndDevelopmentGrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of research and development grants awarded during the period.",
        "label": "Research And Development Grants",
        "terseLabel": "Research and development grants"
       }
      }
     },
     "localname": "ResearchAndDevelopmentGrants",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureGovernmentProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_ResearchAndDevelopmentIncentiveGrantPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for research and development incentive grants.",
        "label": "Research And Development Incentive Grant [Policy Text Block]",
        "terseLabel": "Research and Development Tax Incentive"
       }
      }
     },
     "localname": "ResearchAndDevelopmentIncentiveGrantPolicyTextBlock",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ptgx_ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for research collaboration and license agreement abandoned October2013.",
        "label": "Research Collaboration And License Agreement Abandoned October2013 [Member]",
        "terseLabel": "Research Collaboration and License Agreement"
       }
      }
     },
     "localname": "ResearchCollaborationAndLicenseAgreementAbandonedOctober2013Member",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreement",
      "http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_ResearchCollaborationAndLicenseAgreementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Research Collaboration and License Agreement"
       }
      }
     },
     "localname": "ResearchCollaborationAndLicenseAgreementDisclosureAbstract",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "xbrltype": "stringItemType"
    },
    "ptgx_RevenueFromContractWithCustomerIncludingCumulativeCatchUpAdjustmentToRevenueModificationOfContract": {
     "auth_ref": [],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue, net, from satisfaction of performance obligation by transferring promised good or service to customer, including amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from contract modification. Amount includes tax collected from customer, if applicable. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue From Contract With Customer Including Cumulative Catch Up Adjustment To Revenue Modification Of Contract",
        "terseLabel": "License and collaboration revenue - related party"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingCumulativeCatchUpAdjustmentToRevenueModificationOfContract",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_RevenueSourceAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by source of revenue.",
        "label": "Revenue Source [Axis]"
       }
      }
     },
     "localname": "RevenueSourceAxis",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureGovernmentProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ptgx_RevenueSourceDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Major payer source of revenue.",
        "label": "Revenue Source [Domain]",
        "terseLabel": "Revenue Source [Domain]"
       }
      }
     },
     "localname": "RevenueSourceDomain",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureGovernmentProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_SaleOfStockValueOfSharesAuthorized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum amount of shares permits the offering, issuance, and sale by the entity.",
        "label": "Sale Of Stock, Value Of Shares Authorized",
        "terseLabel": "Maximum aggregate offering price"
       }
      }
     },
     "localname": "SaleOfStockValueOfSharesAuthorized",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_SalesAgreementFrom2017Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the 2017 Sales Agreement.",
        "label": "Sales Agreement From2017 [Member]",
        "terseLabel": "2017 Sales Agreement"
       }
      }
     },
     "localname": "SalesAgreementFrom2017Member",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_ScheduleCashEquivalentsAndAvailableForSaleSecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule cash equivalents and available for sale securities.",
        "label": "Schedule Cash Equivalents and Available for Sale Securities [Table]",
        "terseLabel": "Schedule Cash Equivalents and Available-for-Sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleCashEquivalentsAndAvailableForSaleSecuritiesTable",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ptgx_SecondGenerationAnalogPhase2CdClinicalTrialPrimaryClinicalEndpointMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the phase 2 CD clinical trial reaching a primary clinical endpoint with respect to the second-generation analog.",
        "label": "Second Generation Analog Phase2 Cd Clinical Trial Primary Clinical Endpoint [Member]",
        "terseLabel": "Second Generation Analog Phase 2 Cd Clinical Trial Primary Clinical"
       }
      }
     },
     "localname": "SecondGenerationAnalogPhase2CdClinicalTrialPrimaryClinicalEndpointMember",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the phase 3 CD clinical trial reaching a primary clinical endpoint with respect to the second-generation analog.",
        "label": "Second Generation Analog Phase3 Cd Clinical Trial Primary Clinical Endpoint [Member]",
        "terseLabel": "Second-Generation Analog, Phase 3 CD Clinical Trial Primary Clinical Endpoint [Member]"
       }
      }
     },
     "localname": "SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_SecondGenerationDevelopmentCompoundMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the second-generation development compound.",
        "label": "Second Generation Development Compound [Member]",
        "terseLabel": "Second-Generation Phase 2b Milestone"
       }
      }
     },
     "localname": "SecondGenerationDevelopmentCompoundMember",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_SecondGenerationPhase2bMilestonePaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to second generation phase 2b milestone payment for clinical trail for CD for a second generation product",
        "label": "Second Generation Phase2b Milestone Payment [Member]",
        "terseLabel": "Second-Generation Phase 2b Milestone Payment"
       }
      }
     },
     "localname": "SecondGenerationPhase2bMilestonePaymentMember",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_SecuritiesPurchaseAgreementWithAccreditedInvestorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member represents transactions associated with the Securities Purchase Agreement with certain accredited investors (each, an \"Investor\" and, collectively, the \"Investors\").",
        "label": "Securities Purchase Agreement With Accredited Investors [Member]",
        "terseLabel": "Investors"
       }
      }
     },
     "localname": "SecuritiesPurchaseAgreementWithAccreditedInvestorsMember",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum annual number of additional shares authorized for issuance under an established share-based compensation plan as a proportion of outstanding capital stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Annual Additional Shares Authorized, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Maximum annual additional authorized shares as a percentage of outstanding shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualAdditionalSharesAuthorizedPercentageOfOutstandingStockMaximum",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockPurchasePlanDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of annual additional shares authorized for issuance under an established share-based compensation plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Annual Number of Additional Shares Authorized",
        "terseLabel": "Maximum annual additional authorized shares (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ptgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ptgx_SmallBusinessInnovationResearchGrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for small business innovation research grant.",
        "label": "Small Business Innovation Research Grant [Member]",
        "terseLabel": "SBIR Grant"
       }
      }
     },
     "localname": "SmallBusinessInnovationResearchGrantMember",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureGovernmentProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_SmallBusinessInnovationResearchSbirGrantsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for small business innovation research (SBIR) grants.",
        "label": "Small Business Innovation Research (SBIR) Grants [Policy Text Block]",
        "terseLabel": "Small Business Innovation Research (\"SBIR\") Grants"
       }
      }
     },
     "localname": "SmallBusinessInnovationResearchSbirGrantsPolicyTextBlock",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ptgx_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common stock and warrants for common stock issued in private placement.",
        "label": "Stock and Warrants Issued During Period, Shares, Common Stock and Warrants",
        "terseLabel": "Issuance of common stock and warrants upon private placement, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "ptgx_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of common stock and warrants for common stock issued in private placement.",
        "label": "Stock and Warrants Issued During Period, Value, Common Stock and Warrants",
        "terseLabel": "Issuance of common stock and warrants upon private placement, net of issuance costs"
       }
      }
     },
     "localname": "StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_StockExchangedForPreFundedWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares exchanged for pre-funded warrants.",
        "label": "Stock Exchanged for Pre-funded Warrants",
        "terseLabel": "Common stock exchanged for pre-funded warrants"
       }
      }
     },
     "localname": "StockExchangedForPreFundedWarrants",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ptgx_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants exercised during the current period.",
        "label": "Stock Issued During Period, Shares, Warrants Exercised",
        "terseLabel": "Issuance of common stock upon exercise of Exchange Warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails",
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "ptgx_StockIssuedDuringPeriodValueWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of warrants.",
        "label": "Stock Issued During Period, Value, Warrants Exercised",
        "terseLabel": "Issuance of common stock upon exercise of Exchange Warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_StockOptionAndIncentivePlanAsAmendedAndRestated2007Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the 2007 Stock Option and Incentive Plan, as amended and restated, established in May 2007.",
        "label": "Stock Option And Incentive Plan As Amended And Restated2007 [Member]",
        "terseLabel": "2007 Stock Option and Incentive Plan"
       }
      }
     },
     "localname": "StockOptionAndIncentivePlanAsAmendedAndRestated2007Member",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_StockWarrantIssuedDuringPeriodValueInExchangeForRetirementOfCommonStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of common stock warrant issued in exchange for retirement of common stock.",
        "label": "Stock Warrant Issued During Period, Value, in Exchange for Retirement of Common Stock",
        "terseLabel": "Issuance of common stock warrant in exchange for retirement of common stock"
       }
      }
     },
     "localname": "StockWarrantIssuedDuringPeriodValueInExchangeForRetirementOfCommonStock",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ptgx_SuccessfullyDevelopAndCommercializeRusfertideComponentWithOutPartnerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to successfully develop and commercialize Rusfertide Component with out partner.",
        "label": "Successfully Develop And Commercialize Rusfertide Component With Out Partner [Member]",
        "terseLabel": "Successfully develop and commercialize Rusfertide Component with out partner"
       }
      }
     },
     "localname": "SuccessfullyDevelopAndCommercializeRusfertideComponentWithOutPartnerMember",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_TermLoanCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to term loan credit agreement.",
        "label": "Term Loan Credit Agreement [Member]",
        "terseLabel": "Term Loan Credit Agreement"
       }
      }
     },
     "localname": "TermLoanCreditAgreementMember",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_UpfrontCashPaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the upfront cash payment received as part of the license and collaboration agreement.",
        "label": "Upfront Cash Payment [Member]",
        "terseLabel": "Upfront cash payment"
       }
      }
     },
     "localname": "UpfrontCashPaymentMember",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_UsTreasuryAndAgencySecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and Agency.",
        "label": "Us Treasury And Agency Securities [Member]",
        "terseLabel": "U.S. Treasury and agency securities"
       }
      }
     },
     "localname": "UsTreasuryAndAgencySecuritiesMember",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails",
      "http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_WarrantsPurchaseAmountPerSharePriceOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the first group of warrants which may be purchased at a different price than another group of warrants.",
        "label": "Warrants Purchase Amount Per Share Price One [Member]",
        "terseLabel": "Group one"
       }
      }
     },
     "localname": "WarrantsPurchaseAmountPerSharePriceOneMember",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_WarrantsPurchaseAmountPerSharePriceTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the second group of warrants which may be purchased at a different price than another group of warrants.",
        "label": "Warrants Purchase Amount Per Share Price Two [Member]",
        "terseLabel": "Group two"
       }
      }
     },
     "localname": "WarrantsPurchaseAmountPerSharePriceTwoMember",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ptgx_ZealandPharmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Zealand Pharma.",
        "label": "Zealand Pharma [Member]",
        "terseLabel": "Zealand Pharma"
       }
      }
     },
     "localname": "ZealandPharmaMember",
     "nsuri": "http://www.protagonist-inc.com/20201231",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r59",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails",
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails",
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r262",
      "r264",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r472",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockOptionsValuationAssumptionsDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails",
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails",
      "http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreementDetails",
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAndImpairmentOfLongLivedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r262",
      "r264",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r472",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockOptionsValuationAssumptionsDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails",
      "http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreementDetails",
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAndImpairmentOfLongLivedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProFormaMember": {
     "auth_ref": [
      "r193",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pro Forma [Member]",
        "terseLabel": "Pro Forma"
       }
      }
     },
     "localname": "ProFormaMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r164",
      "r236",
      "r239",
      "r427",
      "r471",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Products and Services [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails",
      "http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r164",
      "r236",
      "r239",
      "r427",
      "r471",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Products And Services [Domain]",
        "terseLabel": "Products and Services [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails",
      "http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r242",
      "r262",
      "r264",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r472",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockOptionsValuationAssumptionsDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails",
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails",
      "http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreementDetails",
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAndImpairmentOfLongLivedAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r242",
      "r262",
      "r264",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r472",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockOptionsValuationAssumptionsDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails",
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails",
      "http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreementDetails",
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAndImpairmentOfLongLivedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repurchase Agreement Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails",
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails",
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario Unspecified [Domain]",
        "terseLabel": "Scenario, Unspecified [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.protagonist-inc.com/role/DisclosureDebtDetails",
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails",
      "http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r165",
      "r166",
      "r236",
      "r240",
      "r474",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails",
      "http://www.protagonist-inc.com/role/DisclosureLeasesAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r165",
      "r166",
      "r236",
      "r240",
      "r474",
      "r498",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails",
      "http://www.protagonist-inc.com/role/DisclosureLeasesAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r193",
      "r263",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.protagonist-inc.com/role/DisclosureDebtDetails",
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails",
      "http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "C [A]",
        "terseLabel": "Newark, California"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Net amortization of premium (accretion of discount) on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r12",
      "r13",
      "r47"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsAccruedExpensesAndOtherPayablesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Accrued employee related expenses"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsAccruedExpensesAndOtherPayablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses and Other Payables"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsAccruedExpensesAndOtherPayablesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsAccruedExpensesAndOtherPayablesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "totalLabel": "Total accrued expenses and other payables"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsAccruedExpensesAndOtherPayablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r12",
      "r13",
      "r47"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsAccruedExpensesAndOtherPayablesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional service fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsAccruedExpensesAndOtherPayablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r41",
      "r180"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r31",
      "r63",
      "r64",
      "r65",
      "r461",
      "r480",
      "r481"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive gain (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r62",
      "r65",
      "r66",
      "r119",
      "r120",
      "r121",
      "r365",
      "r476",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Accumulated Other Comprehensive Gain (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r299",
      "r300",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r266",
      "r268",
      "r305",
      "r306"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r268",
      "r295",
      "r304"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share-based Compensation Expense",
        "verboseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Potentially dilutive securities have been excluded from diluted net loss per share calculations"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreement",
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails",
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails",
      "http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreement",
      "http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreementDetails",
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r109",
      "r153",
      "r156",
      "r162",
      "r172",
      "r359",
      "r366",
      "r383",
      "r442",
      "r459"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r8",
      "r10",
      "r58",
      "r109",
      "r172",
      "r359",
      "r366",
      "r383"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r373"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Total financial assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AustralianTaxationOfficeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of Australia.",
        "label": "Australian Taxation Office [Member]",
        "terseLabel": "Australian"
       }
      }
     },
     "localname": "AustralianTaxationOfficeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureGovernmentProgramsDetails",
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxes2020TaxLawUpdatesDetails",
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails",
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesResearchAndDevelopmentTaxCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Available-for-sale Securities, Debt Maturities, Fair Value, Rolling Maturity [Abstract]",
        "terseLabel": "Contractual maturities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesClassificationOfCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r270",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockOptionsValuationAssumptionsDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockPurchasePlanDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r371",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Components"
       }
      }
     },
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r101",
      "r102",
      "r103"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchases of property and equipment in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostNet": {
     "auth_ref": [
      "r176"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost, Net",
        "verboseLabel": "Costs to obtain or fulfill the contract that were capitalized"
       }
      }
     },
     "localname": "CapitalizedContractCostNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r37",
      "r98"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails",
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r15",
      "r99",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash as Reported in Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r15",
      "r99",
      "r106",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r99",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.",
        "label": "Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "terseLabel": "Cash Equivalents and Marketable Securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r92",
      "r98",
      "r104"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period",
        "totalLabel": "Total cash, cash equivalent and restricted cash in consolidated statements of cash flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails",
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Aggregate amounts of cash and cash equivalents and the restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r92",
      "r384"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesClassificationOfCashEquivalentsAndMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "ptgx_CashEquivalentsAndMarketableSecuritiesFairValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesClassificationOfCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Contract with Customer, Asset and Liability [Abstract]"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerAssetAndLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock Disclosures [Abstract]",
        "terseLabel": "Stock transactions"
       }
      }
     },
     "localname": "ClassOfStockDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r218",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class Of Warrant Or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "verboseLabel": "Exercise Price (per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Number of shares to be converted for each warrant"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants to purchase common stock, number of shares"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "verboseLabel": "Exchange warrants unexercised"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r353",
      "r354",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "License and Collaboration Agreement",
        "verboseLabel": "Research Collaboration and License Agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreement",
      "http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]",
        "terseLabel": "Research Collaboration and License Agreement",
        "verboseLabel": "License and Collaboration Agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreement",
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails",
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails",
      "http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreement",
      "http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails",
      "http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r53",
      "r192",
      "r448",
      "r465"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies.",
        "terseLabel": "Commitments and contingencies (Note 11)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r119",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails",
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value",
        "verboseLabel": "Par value (per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails",
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r27",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance, Ending (in shares)",
        "periodStartLabel": "Balance, Beginning (in shares)",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.00001 par value, 90,000,000 shares authorized; 43,745,465 and 27,217,649 shares issued and outstanding as of December 31, 2020 and December 31, 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "401(k) Plan"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r105",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Components of deferred tax assets"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndValuationAllowanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndValuationAllowanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r69",
      "r71",
      "r72",
      "r77",
      "r451",
      "r468"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r141",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r106",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation and Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Asset and Liability [Table Text Block]",
        "terseLabel": "Schedule of changes in contract assets and liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r220",
      "r222",
      "r237"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, Net",
        "periodEndLabel": "Balance at End of Period",
        "periodStartLabel": "Balance at Beginning of Period"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "auth_ref": [
      "r220",
      "r222",
      "r237"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.",
        "label": "Contract with Customer, Asset, Net, Current",
        "periodEndLabel": "Contract asset - related party, Balance at End of Period",
        "periodStartLabel": "Contract asset - related party, Balance at Beginning of Period"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Asset, Net, Current [Abstract]",
        "terseLabel": "Contract asset - related party"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice": {
     "auth_ref": [
      "r223"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.",
        "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price",
        "terseLabel": "Increase (decrease) in transaction price"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract": {
     "auth_ref": [
      "r223"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from contract modification which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Modification of Contract",
        "terseLabel": "Revenue following contract modification"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r220",
      "r221",
      "r237"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability",
        "periodEndLabel": "Balance at End of Period",
        "periodStartLabel": "Balance at Beginning of Period",
        "verboseLabel": "Deferred revenue - related party - current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails",
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r220",
      "r221",
      "r237"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue - related party - noncurrent",
        "verboseLabel": "Upfront payments and fees"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails",
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r238"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "verboseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
     "auth_ref": [
      "r225"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "terseLabel": "Revenue recognized from performance obligations in previous periods"
       }
      }
     },
     "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r243",
      "r258",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails",
      "http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r116",
      "r335"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesComponentsOfFederalStateAndForeignIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesComponentsOfFederalStateAndForeignIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r110",
      "r335",
      "r343",
      "r345"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesComponentsOfFederalStateAndForeignIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current tax (benefit) expense"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesComponentsOfFederalStateAndForeignIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesComponentsOfFederalStateAndForeignIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r20",
      "r21",
      "r22",
      "r443",
      "r445",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "prime rate (In Percentage)"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r22",
      "r206",
      "r445",
      "r458"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureDebtLongTermDebtDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Term loan (matures October 1, 2023)"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureDebtLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "auth_ref": [
      "r50"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.",
        "label": "Debt Instrument, Fee Amount",
        "terseLabel": "Prepayment and exit fees"
       }
      }
     },
     "localname": "DebtInstrumentFeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r49",
      "r208",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate on long-term debt"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureDebtLongTermDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Annual interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureDebtLongTermDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r51",
      "r113",
      "r213",
      "r214",
      "r215",
      "r216",
      "r392",
      "r393",
      "r396",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": {
     "auth_ref": [
      "r392",
      "r393",
      "r394",
      "r395",
      "r396"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount (premium).",
        "label": "Debt Instrument, Unamortized Discount (Premium), Net",
        "terseLabel": "Accelerated capitalized and unamortized debt issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": {
     "auth_ref": [
      "r101",
      "r102",
      "r103"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.",
        "label": "Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction",
        "terseLabel": "Issuance costs related to common stock"
       }
      }
     },
     "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtPolicyTextBlock": {
     "auth_ref": [
      "r106",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.",
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "Long Term Debt"
       }
      }
     },
     "localname": "DebtPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r42",
      "r394"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureDebtLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "negatedLabel": "Debt issuance costs, net of amortization"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureDebtLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r110",
      "r336",
      "r343"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesComponentsOfFederalStateAndForeignIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesComponentsOfFederalStateAndForeignIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r312",
      "r313"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Tax Assets, Net, Noncurrent",
        "terseLabel": "Deferred tax asset"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r96",
      "r110",
      "r336",
      "r343",
      "r344",
      "r345"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesComponentsOfFederalStateAndForeignIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred tax expense (benefit)"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesComponentsOfFederalStateAndForeignIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesComponentsOfFederalStateAndForeignIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r23",
      "r24",
      "r325",
      "r444",
      "r457"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndValuationAllowanceDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r326"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndValuationAllowanceDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndValuationAllowanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r328"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndValuationAllowanceDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r333",
      "r334"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndValuationAllowanceDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "verboseLabel": "Operating loss carryforwards available to offset future taxable income"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndValuationAllowanceDetails",
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndValuationAllowanceDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r331",
      "r333",
      "r334"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndValuationAllowanceDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "verboseLabel": "Research and development and foreign credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r327"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndValuationAllowanceDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r333",
      "r334"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndValuationAllowanceDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedLabel": "Operating right-of-use asset"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r96",
      "r178"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r96",
      "r151"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]",
        "terseLabel": "Equity Plans"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Plans"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Country [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails",
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesResearchAndDevelopmentTaxCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueFromRelatedPartiesCurrent": {
     "auth_ref": [
      "r4",
      "r16",
      "r28",
      "r111",
      "r414"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).",
        "label": "Due from Affiliate, Current",
        "terseLabel": "Receivable from collaboration partner and contract asset - related party"
       }
      }
     },
     "localname": "DueFromRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r43",
      "r117",
      "r414"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Affiliate, Current",
        "periodEndLabel": "Balance at End of Period",
        "periodStartLabel": "Balance at Beginning of Period",
        "terseLabel": "Payable to collaboration partner - related party"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails",
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "positiveLabel": "Net loss per shares, basic and diluted",
        "terseLabel": "Net loss per share, basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureNetLossPerShareComputationDetails",
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r106",
      "r134",
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r134",
      "r135",
      "r136",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureNetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r384"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r315"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesProvisionDifferenceFromFederalStatutoryRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Provision (benefit) for income taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesProvisionDifferenceFromFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "terseLabel": "Effective tax rate of provision for income taxes difference from federal statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxes2020TaxLawUpdatesDetails",
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesProvisionDifferenceFromFederalStatutoryRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r315",
      "r347"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesProvisionDifferenceFromFederalStatutoryRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal statutory income tax rate (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesProvisionDifferenceFromFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r315",
      "r347"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesProvisionDifferenceFromFederalStatutoryRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesProvisionDifferenceFromFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r315",
      "r347"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesProvisionDifferenceFromFederalStatutoryRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Foreign tax rate difference (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesProvisionDifferenceFromFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r315",
      "r347"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesProvisionDifferenceFromFederalStatutoryRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesProvisionDifferenceFromFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r315",
      "r347"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesProvisionDifferenceFromFederalStatutoryRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes, net of federal benefit (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesProvisionDifferenceFromFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r296"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized",
        "terseLabel": "Total unrecognized stock-based compensation costs related to stock options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Period of unrecognized stock-based compensation costs to be recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "ESPP rights"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockPurchasePlanDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansTables",
      "http://www.protagonist-inc.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Options to purchase common stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockOptionsValuationAssumptionsDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansTables",
      "http://www.protagonist-inc.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r123",
      "r128",
      "r130",
      "r138",
      "r173",
      "r212",
      "r217",
      "r299",
      "r300",
      "r301",
      "r339",
      "r340",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r476",
      "r477",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails",
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity method investment, ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r373",
      "r374",
      "r375",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r373",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of fair value of financial assets"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r243",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r258",
      "r374",
      "r417",
      "r418",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value, Hierarchy [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r373",
      "r374",
      "r376",
      "r377",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r243",
      "r245",
      "r250",
      "r258",
      "r374",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value Inputs Level1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r243",
      "r245",
      "r250",
      "r258",
      "r374",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value Inputs Level2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Fair Value Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r243",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r258",
      "r417",
      "r418",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r378",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value Measurements Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r106",
      "r381",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialServiceOtherMember": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial assistance, including, but not limited to, management and maintenance of depositor account, credit card, merchant discount, trust, investment and insurance, classified as other.",
        "label": "Financial Service Other [Member]",
        "terseLabel": "Additional services"
       }
      }
     },
     "localname": "FinancialServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations": {
     "auth_ref": [
      "r115"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current and deferred foreign income tax expense (benefit) attributable to income (loss) from continuing operations.",
        "label": "Foreign Income Tax Expense (Benefit), Continuing Operations",
        "terseLabel": "Foreign income tax benefit"
       }
      }
     },
     "localname": "ForeignIncomeTaxExpenseBenefitContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxes2020TaxLawUpdatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Gain on disposal of property and equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r96",
      "r209",
      "r210"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Loss on early repayment of debt",
        "terseLabel": "Loss on early repayment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureDebtDetails",
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General And Administrative Expense [Member]",
        "terseLabel": "General and Administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrantsReceivable": {
     "auth_ref": [
      "r56"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.",
        "label": "Grants Receivable",
        "terseLabel": "Grants receivable"
       }
      }
     },
     "localname": "GrantsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureGovernmentProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "I P O [Member]",
        "terseLabel": "Public Offering"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r106",
      "r177",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r114",
      "r346"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesProvisionAndComponentsOfNetLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesProvisionAndComponentsOfNetLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r75",
      "r153",
      "r155",
      "r158",
      "r161",
      "r163",
      "r440",
      "r449",
      "r453",
      "r469"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesProvisionAndComponentsOfNetLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income tax (expense) benefit"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesProvisionAndComponentsOfNetLossDetails",
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r114",
      "r346"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesProvisionAndComponentsOfNetLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesProvisionAndComponentsOfNetLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]",
        "terseLabel": "Domestic and foreign components of net loss"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesProvisionAndComponentsOfNetLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Operations"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureGovernmentProgramsDetails",
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails",
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesResearchAndDevelopmentTaxCreditCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureGovernmentProgramsDetails",
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails",
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesResearchAndDevelopmentTaxCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureGovernmentProgramsDetails",
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxes2020TaxLawUpdatesDetails",
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails",
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesResearchAndDevelopmentTaxCreditCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority Name [Domain]",
        "terseLabel": "Income Tax Authority, Name [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureGovernmentProgramsDetails",
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxes2020TaxLawUpdatesDetails",
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails",
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesResearchAndDevelopmentTaxCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxCreditsAndAdjustments": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A credit or adjustment for government or taxing authority authorized decrease in taxes owed as a result of meeting certain tax policy conditions.",
        "label": "Income Tax Credits and Adjustments",
        "terseLabel": "Change in deferred tax asset"
       }
      }
     },
     "localname": "IncomeTaxCreditsAndAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r316",
      "r323",
      "r330",
      "r341",
      "r348",
      "r350",
      "r351",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r317"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.",
        "label": "Income Tax Examination, Penalties and Interest Expense",
        "terseLabel": "Interest or penalties recorded in relation to unrecognized tax benefits"
       }
      }
     },
     "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r110",
      "r129",
      "r130",
      "r152",
      "r314",
      "r342",
      "r349",
      "r470"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesComponentsOfFederalStateAndForeignIncomeTaxExpenseBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income tax benefit",
        "negatedLabel": "Income tax benefit",
        "negatedTerseLabel": "Income tax (expense) benefit",
        "totalLabel": "Total income tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesComponentsOfFederalStateAndForeignIncomeTaxExpenseBenefitDetails",
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesProvisionAndComponentsOfNetLossDetails",
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of the income tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r73",
      "r106",
      "r310",
      "r311",
      "r323",
      "r324",
      "r329",
      "r337",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesReceivable": {
     "auth_ref": [
      "r55",
      "r447",
      "r466"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.",
        "label": "Income Taxes Receivable, Current",
        "terseLabel": "Research and development tax incentive receivable"
       }
      }
     },
     "localname": "IncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureGovernmentProgramsDetails",
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.",
        "label": "Increase (Decrease) in Accounts Payable, Related Parties",
        "terseLabel": "Payable to collaboration partner - related party"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence.",
        "label": "Increase (Decrease) in Accounts Receivable, Related Parties",
        "negatedLabel": "Receivable from collaboration partner - related party"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue - related party"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.",
        "label": "Increase (Decrease) in Income Taxes Receivable",
        "negatedLabel": "Research and development tax incentive receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInIncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accrued expenses and other payables"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r74",
      "r150",
      "r391",
      "r394",
      "r452"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r90",
      "r93",
      "r100"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r13",
      "r14",
      "r47"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsAccruedExpensesAndOtherPayablesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Accrued interest payable"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsAccruedExpensesAndOtherPayablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r80",
      "r149"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails",
      "http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investment Type Categorization [Member]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails",
      "http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsAndCashAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments and Cash [Abstract]",
        "terseLabel": "Classified as:"
       }
      }
     },
     "localname": "InvestmentsAndCashAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesClassificationOfCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of least cost information"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of minimum lease payments and lease liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r410"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureLeasesMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.protagonist-inc.com/role/DisclosureLeasesMinimumLeasePaymentsDetailsCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r410"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureLeasesMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r410"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureLeasesMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r410"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureLeasesMinimumLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r410"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureLeasesMinimumLeasePaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r410"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureLeasesMinimumLeasePaymentsDetailsCalc2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases, Operating [Abstract]",
        "terseLabel": "Operating Leases:"
       }
      }
     },
     "localname": "LessorDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r45",
      "r109",
      "r157",
      "r172",
      "r360",
      "r366",
      "r367",
      "r383"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r34",
      "r109",
      "r172",
      "r383",
      "r446",
      "r463"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r48",
      "r109",
      "r172",
      "r360",
      "r366",
      "r367",
      "r383"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r44"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Loan facility for general corporate"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r22",
      "r207",
      "r445",
      "r460"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureDebtLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Long-term debt, net",
        "totalLabel": "Long-term debt, net"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureDebtDetails",
      "http://www.protagonist-inc.com/role/DisclosureDebtLongTermDebtDetails",
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-term Debt, Fair Value",
        "terseLabel": "Fair Value of Long-term Debt"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r192",
      "r193",
      "r194",
      "r196",
      "r197",
      "r198",
      "r200",
      "r202",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r192"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Loss contingency accrual"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "auth_ref": [
      "r192",
      "r195",
      "r199"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.",
        "label": "Loss Contingency, Damages Sought, Value",
        "terseLabel": "Amount of damages sought"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r5",
      "r46"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesClassificationOfCashEquivalentsAndMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "ptgx_CashEquivalentsAndMarketableSecuritiesFairValue",
       "weight": 1.0
      },
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Available-for-sale Securities, Current",
        "terseLabel": "Marketable securities",
        "verboseLabel": "Marketable securities - current"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesClassificationOfCashEquivalentsAndMarketableSecuritiesDetails",
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesClassificationOfCashEquivalentsAndMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "ptgx_CashEquivalentsAndMarketableSecuritiesFairValue",
       "weight": 1.0
      },
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Marketable securities - noncurrent"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesClassificationOfCashEquivalentsAndMarketableSecuritiesDetails",
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Available-for-sale Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in marketable security, excluding other-than-temporary impairment (OTTI).",
        "label": "Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss",
        "terseLabel": "Realized Gain (loss)"
       }
      }
     },
     "localname": "MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesClassificationOfCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Schedule of cash equivalents and marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails",
      "http://www.protagonist-inc.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r92",
      "r94",
      "r97"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r67",
      "r70",
      "r76",
      "r97",
      "r109",
      "r122",
      "r124",
      "r125",
      "r126",
      "r127",
      "r129",
      "r130",
      "r131",
      "r153",
      "r155",
      "r158",
      "r161",
      "r163",
      "r172",
      "r383",
      "r450",
      "r467"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureNetLossPerShareComputationDetails",
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfComprehensiveLoss",
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfOperations",
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureNetLossPerShareComputationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Pronouncements Adopted and Recently Issued Accounting Pronouncements Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "SUPPLEMENTAL DISCLOSURE OF NON-CASH FINANCING AND INVESTING INFORMATION:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoteWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A note that entitles the holder to buy stock of the company at a specified price, which is much higher than the stock price at the time of issue.",
        "label": "Note Warrant [Member]",
        "terseLabel": "Common stock warrants"
       }
      }
     },
     "localname": "NoteWarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r153",
      "r155",
      "r158",
      "r161",
      "r163"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r404",
      "r411"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesLeaseCostInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Liabilities, Payments Due [Abstract]",
        "terseLabel": "Minimum lease payments:"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r399"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureLeasesMinimumLeasePaymentsDetailsCalc2": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Present value of future minimum lease payments",
        "verboseLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesMinimumLeasePaymentsDetails",
      "http://www.protagonist-inc.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r399"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureLeasesMinimumLeasePaymentsDetailsCalc2": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedLabel": "Less: current portion of operating lease liability",
        "terseLabel": "Operating lease liability - current",
        "verboseLabel": "Operating lease liability - current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesMinimumLeasePaymentsDetails",
      "http://www.protagonist-inc.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails",
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]",
        "terseLabel": "Financial position"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r399"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureLeasesMinimumLeasePaymentsDetailsCalc2": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability - noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesMinimumLeasePaymentsDetails",
      "http://www.protagonist-inc.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails",
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]",
        "terseLabel": "Financial position"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease liability.",
        "label": "Operating Lease, Liability, Statement of Financial Position [Extensible List]",
        "terseLabel": "Financial position"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r401",
      "r406"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flow used by operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r398"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "positiveLabel": "Operating lease right-of-use asset",
        "terseLabel": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails",
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]",
        "terseLabel": "Financial position"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r408",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesWeightedAverageLeaseTermAndDiscountRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r407",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesWeightedAverageLeaseTermAndDiscountRateDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesRentExpenseNet": {
     "auth_ref": [
      "r397"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.",
        "label": "Operating Leases, Rent Expense, Net",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "OperatingLeasesRentExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r331"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Description of Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r2",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization and Description of Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureOrganizationAndDescriptionOfBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.",
        "label": "Other Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accrued expenses and other payables"
       }
      }
     },
     "localname": "OtherAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r47"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsAccruedExpensesAndOtherPayablesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsAccruedExpensesAndOtherPayablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r357",
      "r358",
      "r364"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Gain (loss) on translation of foreign operations"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss) Net of Tax, Period Change [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r68",
      "r71",
      "r357",
      "r358",
      "r364"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive gain (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r61",
      "r63"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent.",
        "terseLabel": "Unrealized (loss) gain on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r6",
      "r9",
      "r175"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Other prepaid expenses"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other receivable"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over Allotment Option [Member]",
        "terseLabel": "Underwriter overallotment option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedLabel": "Issuance costs related to long-term debt"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r82",
      "r84",
      "r169"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Available-for-sale Securities",
        "negatedLabel": "Purchase of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r242",
      "r244",
      "r250",
      "r251",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Pension and Other Postretirement Benefits Disclosure [Text Block]",
        "terseLabel": "401(k) Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/Disclosure401KPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r270",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockPurchasePlanDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockPurchasePlanDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.00001 par value, 10,000,000 shares authorized; no shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r8",
      "r35",
      "r36"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails",
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current [Abstract]"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.",
        "label": "Prepaid Expenses And Other Current Assets [Member]",
        "terseLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r7",
      "r9",
      "r174",
      "r175"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
        "label": "Prime Rate [Member]",
        "terseLabel": "Prime Rate"
       }
      }
     },
     "localname": "PrimeRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrincipalOwnerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Owner of record or known beneficial owner of more than 10 percent of the voting interests of the entity.",
        "label": "Principal Owner [Member]",
        "terseLabel": "Stockholders possessing more than 10% of the total combined voting power"
       }
      }
     },
     "localname": "PrincipalOwnerMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "terseLabel": "Proceeds from at-the-market offering, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from public offering of common stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails",
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Proceeds from issuance of long-term debt, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r86",
      "r298"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options",
        "terseLabel": "Proceeds from issuance of common stock upon exercise of stock options and purchases under employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r82",
      "r83",
      "r169"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Available-for-sale Securities",
        "terseLabel": "Proceeds from maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "License and Collaboration Agreement"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails",
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r67",
      "r70",
      "r91",
      "r109",
      "r122",
      "r129",
      "r130",
      "r153",
      "r155",
      "r158",
      "r161",
      "r163",
      "r172",
      "r357",
      "r362",
      "r363",
      "r368",
      "r369",
      "r383",
      "r453"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r41",
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r40",
      "r179"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Plant and Equipment Income Statement Disclosures [Abstract]",
        "terseLabel": "Property and equipment income statement disclosure"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails",
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAndImpairmentOfLongLivedAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r17",
      "r18",
      "r181",
      "r464"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails",
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r39",
      "r106",
      "r181",
      "r501",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r17",
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Summary of Property and Equipment Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r17",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property Plant And Equipment Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAndImpairmentOfLongLivedAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of beginning and ending amount of unrecognized tax benefits"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r252",
      "r413",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r252",
      "r413",
      "r415",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r88"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "terseLabel": "Outstanding balance paid"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedLabel": "Early repayment of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r308",
      "r512"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreementDetails",
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r106",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research [Member]",
        "terseLabel": "Research and Development Tax Incentive"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesResearchAndDevelopmentTaxCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureCashEquivalentsAndMarketableSecuritiesCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r3",
      "r15",
      "r104"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash - current",
        "verboseLabel": "Restricted cash - current"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails",
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r11",
      "r19",
      "r104",
      "r499"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash - noncurrent"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndRestrictedCashDetails",
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units R S U [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansTables",
      "http://www.protagonist-inc.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureRestructuring"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r96",
      "r185",
      "r186",
      "r187"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Total cash expenditures for the reduction in force plan"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureRestructuringDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r30",
      "r217",
      "r302",
      "r462",
      "r479",
      "r481"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureOrganizationAndDescriptionOfBusinessLiquidityDetails",
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r123",
      "r128",
      "r130",
      "r173",
      "r299",
      "r300",
      "r301",
      "r339",
      "r340",
      "r476",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsNoteDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings Note Disclosure [Abstract]",
        "terseLabel": "Net losses from operations since inception"
       }
      }
     },
     "localname": "RetainedEarningsNoteDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureOrganizationAndDescriptionOfBusinessLiquidityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r147",
      "r148",
      "r154",
      "r159",
      "r160",
      "r164",
      "r165",
      "r167",
      "r235",
      "r236",
      "r427"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue Recognition, Milestone Method, Revenue Recognized",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r107",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r226"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation",
        "terseLabel": "Transaction price"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails",
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses and Other Payables"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of potentially dilutive securities excluded from diluted net loss per share calculations"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "verboseLabel": "Schedule of cash as reported in the consolidated statements of cash flows"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]",
        "terseLabel": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreement",
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails",
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails",
      "http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreement",
      "http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of federal, state and foreign of the income tax expense (benefit)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of components of deferred tax assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of computation of the basic and diluted net loss per share attributable to common stockholders"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of provision differences from federal statutory rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r268",
      "r294",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r268",
      "r294",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]",
        "terseLabel": "Schedule of stock-based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of domestic and foreign components of net loss"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of maturities of long-term debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amounts of other current assets.",
        "label": "Schedule of Other Current Assets [Table Text Block]",
        "terseLabel": "Summary of Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r41",
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails",
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAndImpairmentOfLongLivedAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r281",
      "r286",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.",
        "label": "Schedule of Share-based Compensation, Activity [Table Text Block]",
        "terseLabel": "Schedule of activity under equity incentive plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r270",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockOptionsValuationAssumptionsDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockPurchasePlanDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Black-Scholes option-pricing model assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r322",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of beginning and ending unrecognized tax benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r57"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security Deposit",
        "terseLabel": "Security deposit"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Compensation",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Number of Shares, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-Average Grant Date Fair Value, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of shares, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-Average Grant Date Fair Value, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Number of shares, Unvested, Ending balance",
        "periodStartLabel": "Number of shares, Unvested, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted-Average Grant Date Fair Value, Unvested, Ending balance",
        "periodStartLabel": "Weighted-Average Grant Date Fair Value, Unvested, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Number of shares, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-Average Grant Date Fair Value, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, Maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockOptionsValuationAssumptionsDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, Minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockOptionsValuationAssumptionsDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, Maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockOptionsValuationAssumptionsDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, Minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockOptionsValuationAssumptionsDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Equity Plans"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockOptionsValuationAssumptionsDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockPurchasePlanDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Maximum payroll deduction for share purchases (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "verboseLabel": "Number of shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockPurchasePlanDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "verboseLabel": "Number of shares available for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockPurchasePlanDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted-Average Remaining Contractual Life (years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options Outstanding, Options exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, Options exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r288"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options Outstanding, Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Options, weighted-average grant-date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r297"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Options Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r277",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options Outstanding, Ending balance",
        "periodStartLabel": "Options Outstanding, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Options Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted-Average Exercise Price Per Share, Ending balance",
        "periodStartLabel": "Weighted-Average Exercise Price Per Share, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price Per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r289"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Options vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Options Outstanding, Options vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, Options vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "verboseLabel": "Shares issued in period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r267",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockOptionsValuationAssumptionsDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockPurchasePlanDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, Options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, Options forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share Based Compensation Award Tranche Two [Member]",
        "terseLabel": "Tranche two"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r292",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockOptionsValuationAssumptionsDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r297"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Life (years), Options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Life (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Life (years), Options vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Exercise price as a percentage of the fair market value of common stock on grant date",
        "verboseLabel": "Purchase price of stock (as a percent)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansEmployeeStockPurchasePlanDetails",
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Price (in dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State And Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesNetOperatingLossCarryforwardsDetails",
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesResearchAndDevelopmentTaxCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r54",
      "r119",
      "r120",
      "r121",
      "r123",
      "r128",
      "r130",
      "r138",
      "r173",
      "r212",
      "r217",
      "r299",
      "r300",
      "r301",
      "r339",
      "r340",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r476",
      "r477",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails",
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansTables",
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Balance Sheets"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Comprehensive Loss"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Stockholders' Equity"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r138",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansTables",
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r26",
      "r27",
      "r212",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Common stock sold (in shares)",
        "verboseLabel": "Issuance of common stock, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails",
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": {
     "auth_ref": [
      "r26",
      "r27",
      "r212",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited",
        "negatedLabel": "Options Outstanding, Options forfeited"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r26",
      "r27",
      "r212",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures",
        "terseLabel": "Issuance of common stock upon under equity incentive and employee stock purchase plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r26",
      "r27",
      "r212",
      "r217",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options Outstanding, Options exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r26",
      "r27",
      "r212",
      "r217"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r26",
      "r27",
      "r217",
      "r269",
      "r287"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures",
        "terseLabel": "Issuance of common stock upon under equity incentive and employee stock purchase plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r26",
      "r27",
      "r212",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "negatedLabel": "Retirement of common stock in exchange for common stock warrant (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": {
     "auth_ref": [
      "r26",
      "r27",
      "r212",
      "r217"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).",
        "label": "Stock Repurchased and Retired During Period, Value",
        "negatedLabel": "Retirement of common stock in exchange for common stock warrant"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r27",
      "r32",
      "r33",
      "r109",
      "r168",
      "r172",
      "r383"
     ],
     "calculation": {
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance, Ending",
        "periodStartLabel": "Balance, Beginning",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets",
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r108",
      "r217",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r405",
      "r411"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLeasesAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails",
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Components"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureBalanceSheetComponents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "SUPPLEMENTAL DISCLOSURE OF NON-CASH FINANCING AND INVESTING INFORMATION:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TangibleAssetImpairmentCharges": {
     "auth_ref": [
      "r0",
      "r182"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.",
        "label": "Tangible Asset Impairment Charges",
        "terseLabel": "Impairments of long-lived assets"
       }
      }
     },
     "localname": "TangibleAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAndImpairmentOfLongLivedAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r331"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforwards available to reduce future income taxes"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesResearchAndDevelopmentTaxCreditCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesResearchAndDevelopmentTaxCreditCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Tax Credit Carryforward [Line Items]",
        "terseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "TaxCreditCarryforwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesResearchAndDevelopmentTaxCreditCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesResearchAndDevelopmentTaxCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxCreditCarryforwardTable": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.",
        "label": "Tax Credit Carryforward [Table]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesResearchAndDevelopmentTaxCreditCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreement",
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementContractAssetsAndLiabilitiesDetails",
      "http://www.protagonist-inc.com/role/DisclosureLicenseAndCollaborationAgreementDetails",
      "http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreement",
      "http://www.protagonist-inc.com/role/DisclosureResearchCollaborationAndLicenseAgreementDetails",
      "http://www.protagonist-inc.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r309",
      "r319"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance at end of year",
        "periodStartLabel": "Balance at beginning of year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r320"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedLabel": "(Decreases) increases based on tax positions related to prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r317"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Accrual for interest or penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r321"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Increase based on tax positions related to current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r320"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "(Decreases) increases based on tax positions related to prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r139",
      "r140",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance [Abstract]",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndValuationAllowanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r328"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureEquityPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted-average shares used to compute net loss per common share, basic and diluted",
        "verboseLabel": "Weighted-average shares used to compute net loss per share, basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureNetLossPerShareComputationDetails",
      "http://www.protagonist-inc.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protagonist-inc.com/role/DisclosureNetLossPerShareComputationDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68051541&loc=SL49131252-203054"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "http://asc.fasb.org/topic&trid=2175745"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130533-203044"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL108322424-203045"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121610041&loc=d3e36027-109320"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28567-108399"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41499-112717"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918631-209977"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62652-112803"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.5(c))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r513": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r514": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r515": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r516": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r517": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r518": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r519": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r521": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8,17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>107
<FILENAME>0001558370-21-002715-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-21-002715-xbrl.zip
M4$L#!!0    ( -N#:E)![T>NL!H  +@K 0 1    <'1G>"TR,#(P,3(S,2YX
M<V3M7=USVSB2?[^J^Q]X?KE,U?I#=C(S3DUV2[;CE/?LR&<[LUOWL@61D(0+
M!6A!TK;FK[]N\%LD 9*25T@='V9BD=V-;OR:^&@T@-_^\KKTG6<J R;XIX/1
MT<F!0[DK/,;GGPZBX) $+F,'?_GSO__;;_]Q>/CWBX=;QQ-NM*0\=%Q)24@]
MYX6%"^=)K%:$.W=42N;[SH5DWIPZSOG1ST>__#(Z.WI_\O[#F7-XF$BZ( %P
M"NXHD:='H^S-92)5\(_.V?'HY/CTY'3DG'\\/?\X.G7N[S+".]!RQHR4@;N@
M2^*$1,YI^)4L:; B+OUTL C#U<?CXY>7EZ.5%"&9"\Z"\)!Q]\@52Y1U,CH]
M&QTX) PEFT8AO19R>45G)/)#J!O^SXCX2@&H,I]BC90("J^ACGE0*O'E[$C(
M.11R,CK^^]WMH](Q(?SX.I6^%V;T^#.E_G <OTQ)N> \6I9$9^1>*(_#]8H>
M ]$A4%')W)3/C:0$G-?E0@+J'LW%\W'Z5E7"X<GH$*LA8101#V437_RRALUG
M_'N]EF#4V3&^GH)'9&81Y@;U9:A7P#4:E4MH40WE*GBMZ)2 ,CH_/S]6;U/2
M@+GURL"+&F.1A&FL93P("7<S:U?A_+6#/\9,\&W."5EE?#,23%41R8L:O> -
M5D10RZ/>U##15W=1;SR^J6'P**NGAQ<UY$&XD@V5"V\0Z%\W&&389$;VJE@.
MM &.\QOA'.HTA%9._<8GJQ7C,Y'\A >(^$<I?/H$(AS\X]O#C1$7I#M^!-&J
M!;@4/! ^\[ %NR ^HORXH#0,#ASF?3IH09?IDVKDT1GC3&D.K<7)B7/H9&+@
M[Z(D)Q'EQ+)^.]X4L"D[@D9XPO^L_EY)&H!(54>W\"#A3DATG"[QW<COP9AK
MULR7/$UQ>3NXLH?!9#994:GLT>'6P* '\%0/8"[3$3,GESI V1?*2[&$ZEA0
M'K!G>BN"MHA6^?3 GG4!MB3<0>D#P+T!)L'BVA<OK8'-Z/6 ?N@$* AUE-0!
MR 8@KUC@^B*()'V,EDLBUY/9(YMS&"*[A(=C5PT>8=IQ#U7L,AI@E8ZYA_]\
M_F?$GHF/E0U/'F@  W(70,!W5S0DS$_ ?^,R= [S'IKV4W"27 7TGE@+])""
M'DZNB)-J@NZ%/D2X%_]1T$<]S#6*W[]+E/II<#BCPU7QO2/R.]3?U*>/%&8[
MH%WL#&:J!G][BR+T[O;A9+3I;K6.DY?@Y$5T(QY\;>>^YI,@4,T!ZAIW2F_M
M>UL5:?+%2M/7S1=+NF4=ZN"=N_;.XEP3!Z&"8^7>2[HBS/O\NH(1*457F(0+
M*B]5&"@<!P%,)AM\;WN!>L_ZN=K*E2:Y3EXHO$K*==*"E=>HHIVD;"<N?'":
M'3B-@.EIN 9P\3M=X5CX*PT[^HE6ALDU*HV.UC7BHI1+9(7]R8'B!F?8VAE@
M1"LC6OG@[\D:6^MNC4=+62;G..O@'$F1=>U&6NS@)!V<Y(I.PUO!YT\4%T2F
M38U"$YD>VO/J=X_,\ _*.@Q!F./A@P&Q]HC=4@)^?P=:+*.E^@&.K\(;#=B9
M&;0HCDZJ'V@L$OY(I#H^/G!6B=P!SUWB>0FVG78&->8R(?N^-[+..RS!.1T@
M-D-\P^$A?2*O%,=1SPR7\#&8E75LDQD,;C"XW/ )=Q>@![XF(A$7X:@RXD%8
M7$P<Y\J[8)CQX4 ,RQH^\WX^4(3MFGI4$E_%J '1:R$IF_.,.!GF7% .!C1U
MSKL4;?*;2H>^X3=E3TE4^%,<@U>NE*A1X$O'<LZ[1)>?!L?:LG&Y8K,9Q<00
M>BW%LN (42CD^@&PZ-#0M!=F<I[*.**QT<G+=&90:.I(3E:L@^4.?K)] W1%
MH:(E]>!%''"!IN)WXD?*QK'OBQ><BG5K>;K)-'E-98RB;7+2LE7+DH20L-W)
MRG<R!0;W,;M/DD&8_HOA'QZR<'W#9T(NE26)4[2AU*_CPGP1H4Z3%@M_JDB0
MDN84Q VH]5V)?PR%^WTA?&A4 XRPA>N62_(UC'I,WW=9FR]*_T\GEC^ ;)Y!
M,A?'3VI"X/MD*N)4I/%<4E6WE;FCB5X'Z>CDK#IY2"0F<X6"3"<3.N!HQ/$!
M;";27911X5Z*5Q.>K?GTN/Y2Q365O $JPIQ"/@#<-=3SI*+4]0&=Y)T.J#--
M0.Y=S#^,9\Q8Q+W+O4]X R!5 CTJ9U548A&.DC%@TQZ;B9P3SOY(V[$K&KB2
MK>)DB(LH8)P&P2V#RO6@>ANF)KUDZ)<S1M4&LEB*:A8+Y>"()BU)]9%)8<.T
M8_<9B *F<SQ,4K GLTN8 ++P@07?MTLZ-(HUY1E6'*9;GF&I?)5LHS1P4(7!
MC7;N1G5)#O#WS7)%F,0?DQDN7-ZR9^II<VW>NCB3VU5ZHDYN5Y^ H7[ENJ$H
MM8JKU!N2==[*)PLAMJV<K4:.R8LJ@;=.7E2*T@U^L;OI?-,R?TLV/>K])O<#
MOCO$%WI]Z/+=, N=WS(R9;XNKW@7(DU^45GY:^,7:@RCBB[&X@NE#Y[3P7.N
MH>_%=0QZ!]-]^*W+^M'2ZK%^7VT#4)I:0J%.4=Z WAN$]QH [<JNQWC+8-\
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M+AEPP*95"F!=[I^A_AN2_H8*;YGJ5Y_:IZ_TYE2^H=JW2=KKD*UG *AKFMZ
M6X_D/'-6G@&EENEX SA=5H<U*[\&. Q)=@,,1AA@POA?6%>;&&3/]0#4S#?A
MT;OO/RD AOKOL@*F6>DRH& XK7: H>N"E6%-R@!'S0RPNNPT@-)M24F[EF0
MQ+2(-&"QJ_-!M@I*MPI.GVYY.=V[]*]A76E7J-<?#]:)5X?XV9;GM0SGBNWL
MY(6&D_G:<>DQKDF];W6NQ@#N5HM.]8CJ2/4POJ_"V'@TP@#=;E>BZK'LQ*L'
MM^: ^BZ7&PYX;[<\58^OEE:/9Y>;Q0;T.JV+U&-5>*-'YKR*3'PPPH!"C\A*
M/1A5 BTFQNLY!FSZAEOJ\:DGTF-4TZ+59/P.2'5<<OP;9?-%2+WQ,Y5D'C_$
MFPXQ;Q!(<<JEN3.GEPP=SG@R2?6TM?1DDK0@A\0E)3>TJ<L4<73B):4Y<K@A
MIX\SJ/]?BB LW#2B15['8(*Y^?X]]8?C@EB'Y7('/#OC^1BM5KZ:DQ&_.)AL
M"V\'?A/:E7UZ&=K%0IQI,D@-U"!U0'\;]'$"=^V+E[9H:^A-Z%;VVF7HJEGD
M#*0.8&X_VOW&)77%G+,_U 5CR9V!+?;3&1CU\'XX^<6PJZXH7NVN2PL8@.X_
M=,89>A3J/ELS@Q[85JN9<;92*OC_%:#X/SPUX('.G%?U) 2B3P<!6T*/=9 \
M6T@Z^W2P"N>OA[B"-3H]&_T#S#UZ7?HI2<A"'_CN"Y7@H%+!GQSB9U2H1<EG
M7J?2/Q)R?GQZ<G(6>\MF/2;JI2*(="M27LZ4C-'Y^?FQH@(AZI![1H/CU,0#
MYWAGQ@-B-<9?YCCVM'W#$VPT'7RNQO2KS!-[6EYV91L-]\FTQO!;,J5^3YM]
MY'T;<W\[)JL5#D?4;_C%N8@_J?@!6"MDZ'"RI,&*N#I5&0]"'+ >.(&[H$MR
M*UPE2,."OPY3OD-\=#@Z/3P;';T&7JIC%Q5R^[JID/)MIX(7RF-TDF,N^"&/
MEE0RMYTF1<ZO,2.J<HZJC'[>2I5^:O34H5BU']0O+VR-1<J I7[H4%Y W:.Y
M>(:6@1WC1WAX,@+\ZHL-FICPC\.<NY\#GL>?*Z=SW/#;SG!?RA)7YSJ?D6"J
M)$7!(0H*C)60UD&1<T[(*JX(ZH=!)JMSE=3*W%X9?-)?ET"&W?5(F6(=X%?G
M\DN.IH)Q<MW=0XN,Z8_M5 G"E01QHU\[Z9%QJ;\.<_Z2!C0.7R@5/AV,75=&
MU+N$]A4WN8^YEYXT\T!]]/;DU*G@,I*X&3X>U6-W^H_NK''_C#JSCTO!86PN
MUS<A7>)H%FR,I@%TQ1%:^$6*:)62,B Y<#C#S OL2T,H%CI8]2X)P7PZ<-49
M..ECZ$Z9\)Y4>7'O%58J(#.DNC(]?H99 Q9V+>0C*:Y/0Q]/4668WL05V)=Y
MPYIBU> 9?WS>NF((O,6+.\H54ZP!+XKS51I\X#J2,%Z+9)PY@[,G*K/;I.[H
M<DIE ?96U+$YT%="/_71$TO">&][ZH'O8%_-:?W9+/*)OH87OG"_%RQL25^R
M,4R?;^G/K<S2:%KQ3SV)15Y8552MCFEQ22AZJ.V%'Q?P7KK15%7&&[C=;9PG
M)N2Z^6/2T%CU"4V@YJ%M#ZX9]Z!Z@XHA301667$OZ8HP[X[P:$:2G.O)+.W
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M?/=2$X,;V&)B/!,[/4<!YK;Y(M@.)=I9:9M-4.F8Q.4*YHV>OLW2,=CV-5?
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MRLP/NO'L>RYH4A=:YLXF;O#LV\3+KA!V8?A7&O?;<> NZ)+\^?\ 4$L#!!0
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M1U+\1(5[!>MC1[!$3$!#YB%YBK"'';)^<'R4;[-DMKNX_ !VNV!F5+#;Q6Q
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MEGA1JP4@K'GM=;,^:VZX@@9)[?2''=T$+O91S>W[&)H9GW:Z@C""S:B)'?E
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M3QJNAQ?]CM*.1WG/H[+K4:7OPPWRPPWRCB?$AQODAQOD;_L&N:%</KO+A30
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M:4A,K7R+?_O R&'O$OW;_P=02P,$%     @ VX-J4E:69>61J   VUT) !4
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M=4YWF1F+TG G]*-%?H>.5&.Q]>2($$-= 2C"P997F >&MX,W\3.>0LCD'2L
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M7?>QQ4#"1RX= TQV.\B93OP_[Y\])H/-(8=B,W";I0\ =0*AQ0,-6#F*"G9
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M)IK6$"J96,X2'NANGZ1>^B;VEH*337T;J.&_'PS'*DS9D6VC#V9Q"S$CJ'T
M*,&*TTME*!M] L0RUC*0(9W-N);087F.,8)$3_NP.<$8@&$FAUAN[9OY(@X>
M7$:SUG=DF80-H\> 0QFY+4DG[_;L8W#'@'@;)S%B>.SJA$ W?I,#5\=P3&,W
M/)TTC=R1<]9@-MP[8;58Z3Q>:4<[8@GZ@Y5F*+X%=)Y&5-KO3$ZD.?UN':5:
M+/0?H[I!'%'^GN-3UWA\,^@_9:AM8>XSDV$Q2&MNCBZCR;LP+NQCGK01XSJ0
MPSFIJS_.S8R]ES)6+P=/L"(ACN^Y=_W]3;2C<;Q4#_&R@](,7=PW==*A*E>3
M)5$8\&-G!<13\XMR#FS 9,J3I;FD..R_CI6&_0EJMP10JSFHR-EL%2F6#Y#!
M<R0#>_!EU6HH>Z!GMK"+*=XPPE2:*%#4:@A:J,P$_H,C:CVD7%XO!3WGWI[;
MR4T8TVOVT_$3=FMH-[2RA[DNI=2 HNMD)UVF*EDH88F%_ %X"$<T2"7W^=,K
M5[CW/Q;J!G_Y^YVHKW7%OI&JG!6C(CK TGXNTEZ9>9Q[N?_\>;\._A<; ]1"
MQPJ.Y&,2A-O0Y^X<+#-6K<&+S;JL>B\L3#"+A::<Q9R"Q#_ W'PN' W197CO
MH L$6&!1>HX7=EP1^,PD8SBR+0,N"C>SS<LV27>\MGOR&(5/HOG*XQMA4\09
MW/C 7G_/8$.P\*<D"2 "G]'T)?1%VY:J>%]8\D2\B@;VMY27N7H74/&O;^'E
M6%D5+Z5^\A1#=(PP.HA?"8/X((VSPYYXE3P$"WY9.G G2>4[4K M:&"[>NA"
M"QUE*._)+B!K2K?$V^\C!LP6R.]X\UW-6!)F54/;#"3 1/.4O- TYE\_*N-[
M.9/8LY?#\,<D?R;A;I_ <";,HH!&6;265SR$5YI ?"F(,R;AX."#[+C@Q1>2
M1+HBCX><Q D4O=V%0&:>L!.,%\'Y^ "ET7@$_LP+@N(5*7WUV2>;I^2(:C'!
MU?H"AL#,I*HN^;M<79)4LY-Z>L+G)Y_WI*: /"2DQ"<303;;"O6R1UY<V=XP
M2X\S6BBRW*1)4]S2@0*0ET4GFYZ#=,=XY(*/.@:4A1Z/!^,5>%13TE$$L01
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M2@(&\=:*J18CJ7[)&@?57< U6R%[GWB:PR/=6=DRV+BR,@5>_L;*CK+V"5S
M2V^L8==4WU-Q'.A+T%@N3W\1:B6(7,?^ 6IW7QP@E;L0T";E#3J\J/COA]2+
M,[B*:[U.FA OCCU/)A#9SD<C7=S^)Z)841J^E25%2M1$X":E[V +6(&^^I,T
M 8['F$LN^@0L.:$8,R3)=T>\75T0Y@<FW)+S#X?\4Y+_.^4[$^T1W10<*]!H
MQUXSIF@&BQ ^M"%,L944[S5E^-I6'P\YL\J<O%&QE<8QQY$L&I0N@LB.=]03
MCH_PBEXTD;X*^(@'XU=>F/[F18?F2\H[FH<IY-.4-R%72:I\<EF\MSR2VJ28
M$1Z'3RN4ZDGX-&AQ'H)/27O+/  Y>0'L8!^I0-I\X1+&=>(#/W'JGL(4;W(!
M("X6\[Q>%;.%'WO/+[;?2K$UGG47,X 4+F6Q:=^!%S,A/.M>4+,:BI+6(K+2
M++R]T29]\N+PG]Q&SZM+  AAQL$M^S"E_6ZVQ>'2B^ZKZX&>^,=$N'%V59,*
M1MYR38)X\?W8A%2W&WE(N/GVY()F?AKRAX9@,1\.61C3#/'^:13W%V'F1TG&
M]G</]#7_$.F+3$T_S0G:3H>X)C,CQ1RG95%:!CJ-:T4:$W%;DZ<"8ZLF(_5L
MI)Z._ $3$CXC4N 307!N>J6B&6D8/]TR&?C]-2>[ ' \13\+LLWK1R]NO7VD
M*"ZU=SLOY87.[\.G.-R&/API:CRD1(289E$3UN:O;_$R!49*LK!BK9%C802Y
M?(J%!5EM9>S60 ><_#CV9K4U3=3KO.[N_D+7<*Q[XDM.O>)HO+,U-$+TRIZY
M*D)E#HH3A;*E3W%=3 *Z#>-0[!3*KA +1X5&LW$3^M"7G&]U)&2,I?532M55
M#1=<FOQG&APB'J=1,YJQ[1]<66E^EJZQL@?X/CK',\-$2$O>;")K+(^3S[+\
M4CH3"^UUJ9A(1$HE7$2>BUL@F^W,UPV1KY)AL88IL=;IKU)VR_FU!S;!9BO1
MMWX-=<]@-&-QO$LGX;*#4 Y<W,8[J&CGS[.QO"&5I#6E7GE:30*$B(K4MCA/
M;60?Z>Z1IAHQ66-!"AL,8[812[!#L7R 80A]+55N^,:UT&&]"@M42"O)# SW
M&^U%LO/">)#9:HZ!_YVASVA<[*89(XV]=+65_O&O'[TW!OLWI3F.PH1P/!S'
M='54'(8&Y]@XAE9EK?I(.G_YC?.75R(3A>N+F<F',,FI_\R?4G]'WA5__I:(
M1UQL6O+C7U<$YE[X*#JI:$INR^/I6G\\_?&OI,"(Y,JFY][@4(Z85SE^QW\3
MQI0GJ^MRY":= BD_<P8Q-7(X)\2_?)[GY,2W<T&G.RW"5.+Y!](F:0%QW=&,
M,NU^/O(W(*K*!^M\SR1">*'I8X(NAI/TO.:I)E88W/*;A@DB%N#.>#WS[ 2M
M4W,K5V,\HP/L$-L+F3,WQM<NYVVJ;-J:L;Y,DVX0'']BPH;L0+K&+^XQ^HGI
M2N7^2#V X$ND6WK4MT[UP+BC29UK42> $[K4YZDD99*@'%AA1C(SUC)TR2#-
M0CUL6_J1]YF"VZ9[ZA_2KA;1@S!@)(4,8K).#+$"1TH.&4!C.T%DO7 JR!1$
M'Q=-XYN2&@^I$3E5:U##;.]Q: @F9^H*FC+=4TVP#XT+-03-:#2N'*A5:@=6
MMFFY=]V6/W@1O)"[?Z8TOQ,5!,R/&Z; .!9KQYILI&:0B]NE#5DM92R "8?F
M'?J2&/=<(A=SDUFS.*;8H<"O,VC*IJ[88!\\:L5!,^*ZRPXVM=2M(\\$O$YI
MA)HC4!G;:EY_QD%Y,5K&M<SRX\=@0S@:C6>^.B8-1X5S9!I+KZ/Y]9.S-7?L
M=Z19KA\9)<PI!!L_3QYIRO#\I,]5F@*KPV;:+PQK<]6C=-ML^^A6Y#:%&=GQ
M$5!9.H;FIDD*1:B%^OLM]:\RH:J\)Z^<E$BS.NH K 6D<01KE2,@:Y4D,-.=
MEA;+W/[QU^2%IC$@O4V3I]335GGM'8W@S_J)K_R4?BB._^FCIZ4?\??>L@[
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MP12E2^[ 3@S]SL ,GR.NP(98&T=P]Q6Y@5$R.A*$:S[ ,&YB!NN259M$4DP
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MD[RA\G%06+R,\GBKQYP^)2GO<1G3D!>2\#+R3*/@+$_.F(L$?&\D9CX@3SU
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M;PCY1F2;:G96JG9&_>^>DI?O>7&,]$UH=_$?Q\I=_/GOZ\]'[,@_+*NV;9)
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M>5G%<TMEWA8J/1A)D@Y\@#K]$I$8I,1.=([UCY'Y#%+VJ/1BM.42>()BE=
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MH.[QQL:SNVV'),UAH]JK0K*2@OPJ:9"\IJ\.Y8U"GI =%V;#?8D$R7;+%<F
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MZ&+CBZNXJ6MW(#L/#]S*14 79[MJ>:QQ!>];4W'3^.8CDS^]O2*2M2\N.<@
M6J_V1!$^/C@T&,2_*/1^0><>Q9B/B$?V)7K\Y,'B(T*.S+)]33[]O@M38_"+
M*R5"N%$_I72PD1L93JA1']E,<9-\"V,9523?4+Y72$0P(P.6?/I1H9:P<6 B
M<0'?#1W$]*<0.\G:8_I)$:]82EA,1;).<69%7^>NR#/*<C8PX?O"A%0<$ *7
M1JG6!3*RB$R<R+$P.$Y\FAFX-5C$EE'"1H S W>K4)^!S:UGGX&[1&F>5;>'
M'N$GCCC(V_WW(@VS51C P/XB:B09].^DPAE/CLK4!U4'R>PCRTD>0SKUA4X>
M7R<DOTI2I+.)$0IYAJV+WT/3YL;2WB-DK2O0":S0V ]<K21QAU6@04355CV^
MTBW[* K0]=&^3N716&HJTSFB*A(_QM6Q/,ZC"PC)KY(4"54G5>C*KM%\;E.&
M-%O7'L>-<)RB7=2Z#QRVF'W(MW5OCB''72/TDQ7BVS_6XMUA5-_$D+XP?/%M
MS7#;D7VMB\@CQ&^HT@GXMVCIUES$<5],W&(G61NLCGS^X4M>M?;5G>U.STKA
MD6^8;^HLS?WP"NOUDW'!@'FU-DR--E>PG=OZD3OV* /U^EN<\M\\Q^$?XB+Q
M@\QVFWWZ'>IF0TBQ,$-VS]*<+^7X+YZ23[_3+52YYLT?&%<MSAZ2*/HL36"<
MD$_=+=:J;1YS'JX#3]LGPLIR#H5:UG_U;N'FIMZQ6 6675\1W;E"JHQ4W8.O
MEP+(C-A2!/(K"$&4%&A+84^,NV3/82S,)<K+Q<*85-^:%77;PS662KR-B)4&
M4QD,;6R-@TP=PM<!Q=!T=ARPRM$8849G/8F?[5@:)JM/L35<NI\"'V@D@OUH
M#MX /K#G^]$32O^8TS0_B?R5;QNT0'?:,HHKX[O^(H+KV,_<7>ZY6=)[81S>
M]C[)0EOEBFE8>P4'@\SB@!V]^/H"- .$=D<E"#-4H7>:O4QZ)3H@L@=!HOO
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MI@*225.HBUS^<)OX)!^C26=4-7_I\_&#(6<JE+3IKLK4$J9WD6"E2G>3R^0
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M)=[3/;R.;C^OZTF+L2;OJ5BU1'<D1%JQ]Y*NN63(27H8PAG&ZR3=RO&U.RA
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M.&:[BY(]8]=)G!51#HM!OB[\&*8L@ ,UL6R4$Z:M.%1_)A@!-4-5K4)M^G)
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M,XAAB&WKN0WF/@AK/<(R=[ Z)SPY+9<Y>X8X>VP'Q%3S2*E?U.;Y_E]_*XH
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M2)F &R<&"S2@/XG,F,JBN6*9$Y?CRY.Q7G!P"JM)RMRT6K*0? ]\\/G="?\
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M 46!77\V1(CAJ&D,#B0K[JXL,#=J#)TMJ&=F@C^.FF5>G(PO3TYT'Q';R4\
M"0W4FV7;IEQ_H(9QN),@_-R018\-0BT\'.DWR&SG:D.,X$$(_#X)?1BC P[V
M34;G[@1UQR%ZCFJV@J MZ3;&F'L$3@26@3=[6*W#X#W-9\B,(\6H82%@VE)M
M5N 7Q?N-QX8L*<T5C4-.7YM/-@?V"D4DBH0H@D@EX]#34MP"N*'3;=:F1=);
M(==-5DEJT 6(#A<2::+/'B!B]6=9]"3R/95KM+="DIJW%X=*.=1U7]40%L8T
M/?<$Z#>W]"KV8DN8:EFK(ON*UA"T//ANL (;6S?_!66'%O<0:RV98J/G25'!
M4[!5+#(<L+24<15%C>0KW8.=:7<B0;N!, &55Q13YY-X:XDZDYP(.)-D7=<]
MH,B[/SB5J-J#8\X7,N?E<B]^U? H7Z2-\LPZ13/K:*CN)=WI[O$!13;8W-\?
MC?09L1JQ:9D1G<^]>C?$5FT8)^ON$MLQ.DOAB(UIW?+%9+7V@D\ KH$/YK#)
MQY5=R6HT=6"!C1<8&1O0IF\.HHC0<P^:@IBQ*^T3?$18H-0:K2FVV8./A@.B
M.-L\LF%37W@OX") NM(SL2:8I(\'*GSE>,)#K;07L&G! ED/, S<XW C9[]!
MTPHOYTJLP7U&K,C/ S>!YZ5N2NG%RB-TR1.F10A2NY60>>6B&I\B[VA4ZHE8
M4K*^1IO.),?GYJ9Q,UY6K.XNK>E]EU,8\3NX"D/'7X \P"2.4$3Y^15]BM#P
M$9FU^=35=62,XI$$H_K'/TJY-8!G0L*(QGY4DWF!%0P?]-JRQN"J9S!44<C/
M'G,3M%>YY-0SANEA*-B*<1#BEV3-WD<"[=I?NW1<_*_>T%8D\,%LXL8!(A*U
M<T)W9.[>JG$ D@&"'?.S(BYIAUK[!Y'3,)@E;CP)7T#XCKA >>A:5\PXP/2^
M: EQIK<75")RQPS)!AY1'\)2RQJ# "%!U,J/DSBSW$IIL=]>OYV,Q_2UHOA[
MF<JS\>7QI781<LIB1[<W4C4,V2V="+S^#*[S*U*DDZ WF4_C!5NF'/6,D36?
MO';EVY;"00123ZE#14 KP3=4M$'R;4@T*^AY^]7Z&>]0*%NSS6_&"%GK?HS-
M#L;EK89-&!EK[=3>^=48T39SN$8:_>KFOH27I5R@BJ_TNWD"Y%*_?'0,68AI
MH@.Z$(N_#UF(C70H6"I[C]CUX@+?08J\*5I7L9PQ0M6Z:O*SAN'7HF$%S8?[
MPX_6P(5S"&;T>%ZTLL9 0$P2.Q(4HDZ[RJ8<@^[\&$'H&?PS@6@,KP'.3@/]
M!+P&WYT_P-3YI$=F$*YOEMB%Q+=S0.I,M78XR+EXDZ P'QN".,CLPA@ :K_U
M5<Y5I>YTLFQ_3PF>H)/Y+7@'7I#&X8$>B.+ WTSB.J7'4\\XK"D7^8Z.;,VD
M09@/KQ:+D#S\OUKA&)!,,FM?*@G4+W/I7'_NL;ZAU)E99IDE:9":S6 ZKHR4
MR9L'%T2NK\%]$*Y 6+I&GSIA[-?OREHV=0":1+[9&$0I=^= ["],P>P)(64#
MQZRSSXAKSR 1DT /'N3?@G<0^GC0TQ '4%X)/L7_6O45WS8YRMN4[!)>'33+
MY9M56HKRKW90YVC-*FK,5.)D[T;IBM!CHS-S&A_DU?FX2N(E&0K#F[F^L.FR
MIPNTJ@X%*#37([E*!#,P-JVX,7)M(1P>R3*H'(3ST.0=-^]$]]#'>8\9=M+Z
MD@.0+T-$.WI<@$2SA*MJRC\Y*U9R!'H%8V"A1)TSJ30W[4$](8)J?5O%&!FW
M%!2OI >CXB4]14KP+M>#CH\80<0WF<^A6^]TQ%>IS+N+\>7)V$2D<"T4'2@V
M"RW4MT;OP$_ 2Y"$M4\[Z@L9(^$.^EZ ,@Z?0%DVU=* :G4UK9A9,N%C+$L:
M#*H&<>'RLG(\[SJ)H ^BZ,'W@W?"_-QX]BUT6&E'^&L;+'>&"'<DWY%<[=X)
MW$8RFO= 4W&SI-Q!XXK2J#1*DKQ5E&$1CYX!?K,$*U&"1:J:+G^V$"MZOCW-
M9NVJ))_4,/%Y,O>F(UJQK"WH$"?2K%"-0NJ!+&J4_3:]O"VB;D>HC7?4*;F-
M$W^WF"U $**OG]U #U?0M^!-,$#99?72&3>B-XH[(:,I!EE383W)&][B!Q^-
M(-FD*&.,>J=D&9I?$33/]!JXV&(HIV3@HZ:WF\J^W^\8(BT>&6RE)T8;A^SD
M> [H>H"C489BDMB1H!!UIMHTRNA]!NO,\="?A-=@'H3@'H91?.7[$%^O.N$G
MW<C5LBFSP" DU)W]KTP&# POUR#^"8"?$3A[ 6[@S[J@AJ]!Z['3@0W:'_B*
M(>AJCGKJCAM6,]:C19AX!0=P'=O_OR-&XGW7,WZC0?=XV2UF#![:;R6%2.-P
M;M'D@UH</M.EI5K0."%RB8(M09/WD7($/@WABI#*=$S9*66TJ+F4MPAAEDBZ
MK-,8VKE:T#AYM]?/G,1QN*9HTM!E AI=#VG%#1>I@+X6HE#[7*;LQ5]!N'H,
M'/\&C0#&FW#(]%TWLX+APFV0T<X66YQ2[4)6,=,?&^)C4$J7&71Y>7ER:A(4
MVJMN-H6]!4L2EBH>]V2>@OG><7&&H<\L2-AU$(;!3^@O;IPU^B7^I(A:I(D2
M=[Z.QY?'FF.%BTBQBH'.I/>3&KMG2 7^ FM)S%H:9 I%;(-$$VDJ3MM<)C7\
M&-Q= OR%XWED6T/B5C1;T6@U+1%=5XJ5NJL(Y^CCPP(J&RT#;S8%H8N%M  3
M?Y+$B%SR2@Z7?@VNP7>T*XK1_\#L*KIQ(NS"@_]S]\\$OCL>JAAE:< Y0"2[
M2XO1UPNKE'K9J($MWGA/0KB /I'K/0!;#C4CD%7;7C )4VUCRM$R2ZZ="$8O
MB!QG-O&+QKHCKM,,O;HE*))"MJQ,I'*VMESJY=X+@A!3U*Q+-D4M$;DPB9EX
M+\S0$ESB17H/!K/)/,_>/?&]3U8\1?[:]H) F.H,%U\'B(MI"'T7KAT/[:,*
M&=X%\<%JQ7Z<"%.?X>5R2'@)<\<*]&D%DY7()I11N<R?(\2?"UO0(4AT;A8;
M#P@5A2"-&VHGX7,'J(BV:"]^I' B!Y4:8ZNF@\V&!Q$./TLUN.X6LP0J0N3E
M\E?SBE"3_+\YT(\>@R@"T<2_^XBAOTA@M"03A 6(QGJ6(:0=O3ED##'MJK"%
MW -0>PW04-HR>(A0F8/"$,.I"E#\\)U5$,;P3S###\XP*[(U]@GP 879@M7@
M$:<\!Y1BBVM/[UV+%Z"B;U^/:]^^?AGA-K\@\E:CV>$QK)PI?N.$X2=:!064
M?[E*&<K'X\N3<_V3N,WS6 ZRK''A2@=[#WU\*W@31''$4NBUI0<M=WZ*NCZ3
MNDQ%[I,$(3-U#Z6N7#=,4I+R[!!H^\)A7*BM-T#A=J/-DI=.G7RN!B%F;C)D
MN36@S8YGC+MM;DK'UW'D8?J,:D@4;V# :.A(I )7![.P<C>? Q<GA>D EYHV
MK$0,+YT*'!MZ.Z ] B<"T>;5@M#Y#/&A$ILH;0]]V#2I]W"6T<<^E.T6TK)@
M@R@"J3AN0>2&D*"(%:&(4<.XZ5@OAM(R+DB-H9&*O@$<!FV]A*[C-44KVBUK
MH-3$9+*5JCB=ALD3+'9'3H]>1"MKC#S%I;$C22$*C;"-1+G<(^#^N@C>?XOB
M=8A:/_I*/GW!GXHR1]_]X^9J5[KIMV;)44@6!3DR:#%"8JJ6T,>&AXD-M8P1
M?G>EW(5BI0%W9?G?Y*F<)VN ,U_Z"T+C9B=:9P-KJ%+FQ0GBA>:+J3:RVS&-
MM2'9K-0+<M3%"W 3DCD,K(,(TLX&.Z4L X0(E6:I $D82)#:1*Q+(X_3(% J
M9"L"FHGD"#K29RSE]$SY.X"+90QF5^](FRW2+[$Y&,<6SV[;2=0=0<-&Y>)Y
M8]C(.QPY:8\CPK81N8QV_-EHEO4Z0LH5'(P?7 ,M+T4[(GT&>'N;_XAE2WN5
M)=J,@5.YR4PBA42EJ[DF3<YD3%$39,;<-A"J:<8V"/&2V,]FH+=5Y#N:-JMD
M1?[(7Z>(+ADGU"4C:SU;*7+/Y,/:T&)B/T+G#4=5@2#:R"EI<KH2::*,]DL3
MSOMB$[H%>3:N!^FNN)XUGP7&/*$9_?H3>._@>^#'2[:52+PYX^#4&2PT>Y(D
MWNPS%O\3..'KSZ C!+-6#LCC8XFDG0S:/KT%-9 ['P#D4,?L2V:!=@ZPXV6*
M)$_# 0/O/DAH$9U%FSG CI,GDKPA!XJZCF@[H*R!%[+\)PN^MF;OWG[XN;T7
MS.X^7%24^7ZF55M[CSHAQG3UQJQ]IZ$=A!3."!D\/O<!2"*DRPI999*VHM!_
MDX0AK]5[M](>PX;%@:Z!K0:E:)X"WVT#H6V]/491 Q.41KPZ[_TNA?R+GU(^
M^/,@7)&&1>]23JEW*>3#R$7-C^"V_<-=2HO)C67$-9MQP1)R+Y'V.CT>UKT(
ME0BE%N>3WJ??2[)>>\23S_&R:,\O2P"ZS,8SZFPL=C9Z2WL;1;B[P^QL== ,
M0NY0$K3B YRI0J3T,U]U*N9G[)(QF?^(P!4Z%?/IZ)TZ!H) 0,1-NIR'6$DP
M(?ZP\+V*E L#D;)YY#.9IR$MH.--"0$!CG$&_ B^>6A?RKGNMVY]K]#7D2TV
MNE6K-D)8!RDN:A5?&&K*#L5FA&2-UK[Y_<*?')UF54#$?@QC]B*K@6"E26;,
M4FU;3JC2;FUZV#L8RM%Q:M+9F*7C.MPRV@LD%BBZWB@:YEU#X8 J[77067(9
MTD\&GMX,W#BCX;T7_.Q@T#ZG&K1QXZ,Y:OU@O^ZH)BB)DMB%R_@]&E^>?-4]
MH<5NF9B$V&^YCIX1\7<?:Z22 #V0,+/.X"' 0X\USR=O@M4*Q@3R.-ELX&,V
M +1" <'WDT?56(*%MLG+^E+K>G4RBVS>^SO!-O1$$8ZBTL"8\0AK"QLWG5N)
MKAQPF)M.LX+:W1 /VA"Q"!V#G16@Q">L*V:<% 6$L)6@$'5FR>X9K)/0718#
M->U20@U0R%W7&"D+":HLWV[$:H^$1XEL]G\!]JV939<..I)\!SB UXZ@:<6,
MDFDWX6P%+42L=IE*""O[X@+?07JG*:1LL9PQDN^LL_G)8^RK=421S8;[PX_6
MP(5S"&;T*+*TLL:(44P2.Q(4HD[[C*5HX9?$Q8^/YHGG?=Z"=^ %:[*%7*U
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MXZMJ(R*ZD*[T4;NFJ BU[W:>$GPB1(S>6!!O',\#L^O/W(R8%11ZZLK?JF7
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M2'/3:PEPLEO'*0[I7<SR<OU9_(6Q./ W8!QL^EX[.K+*W$#5Q>$SUY=J0>-
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MPF&E4=2LG3']K3.,[@\S1@N'%3A(ULR8?EW"=O)U_?!A+.S^==K@_K7M(W,
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M\Q-3]@W.FSQU2[,(_5>[7YV@E;P]D9;8P"M$?PN#B-=KJ;Z2<9AH+V3Z9;X
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MM8(A@T4)+-=DMR0A/A_U-"6:9=@:$YU5S;124;,-@10(:*-@O$7!'(@D/G7
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M#>^<Z]W"A:1,E]BK7R2VY0O4>.LW7@#;@J/9=0[X(.2 Y-F*JP"G[MG26'1
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MM#NQMX"METW12-M 5MSME/:F0<9EH]E,3"NS7CM=3<:3--4.W]FX&Y/\E,9
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MFCPHD:1&#_J=4?C6'X8,UL])X&)1S=[.HY<YCVVO;9#&<!HCJ M-;H0A$KE
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M2#Q;WZAKHG'H^-9<*Q@2HF\&T 5P8/$ "@VRMAHO>D63)7/E5;-?$Q4W%MI
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M*W=VR^^!"NZIM;1B>ZH;.564^U6)&M4*\?#- ;PR4?D,0RXV3;@S67NLO!1
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MEO-@4OUMC5)0;O[6_3\C_P=_0!(F(I9H1V;H -(/SSI=WH"$3F:!)5D;DIW
MAGFZR(-9"Y^2CE$<TG65U#>]#:<+K-[*=<\BE$]HY+U<L:H%<Y03JKC(-%VF
M@+O1R\VIN8]ZKX1RG&.*Z07&8Q9KKS!UQ;>%-]:Z14<6IQ\MVN8T<P 3ZO41
M<V^SQM#HH^SV[Q_4CU<!Y<=L5^/XWI ;1V!:/#J>%G][)E9- [Q0E_GV+7/G
M[41]O#*"2%@O]4(>7RNR7D-0,&0T60PB@V5$&@-)C<#GJ!%E#?*]UDC%B8B1
M.= T3#7,.7P>$!VTH2G\P?& _1/U3LI@J!CKSLFFIP6UP2@>V^C,GJI!]7F(
M[+>7;^IGEY]5ZD B2H@&+B"AX%.P9[(S/;,%FLVFS$YY:NRV9_1X2<]?X60/
M.,^MQ'CIMF,\.-M2XE-?O/]OU;S D*(7WFCIDS3 ,%WXS7K;8>09AFA!@>TO
M]G%>**=2J&GE\*O=>I2=/SE4"(BGBPKB/=CX/"5MFYIGN*+M+Y^PG3WE7#6%
M&3UTU"(O,EBVFN(%GN^,7A%RU0R=;EZ+(LS'P&_->J0-?Q !?L?0\",]D".B
MIFV585]+!B"X #[XB&(\U84]/[$)JI%^(#>"UF9%9/BK,?(OM6P@ ;]80Y#K
M9_CKRIW('_#), >(.)XTCCAC$_7P;Y9%N6/1?4S/7'2>JK9_<T#2?Z&+,^3(
M'^0>W0.83L"+!A-(%;K)OQ[>B<83/,S?BMP?B3]<T7$C#+Y^@BPNG:]R@FG/
MMN'(U@L548;JBJZWKV8U9LQ,JP2=4FM4-DZDU$HN(3;N/O [^<!G5!\A'X)>
M5UP7Z@K0(/AMTS]?0%M& ,QIEI$"RA]$R9^WS8BNN%YZ]\@H[)ZQ[SJ?1(Y-
M,/*T=3\CA[4B?Z ?Z3])BGS8AI:*OTS'0LMT/L4XK$>^57?@_/>K]'B/T8C/
M@5KOZ;%J$GRNJ!@*/^TL:+',K*K1V3V6#8\>/UX5_;(:OTU3_:1-@\\"$5&2
MH*:BT^AE'[(H8S..?@NC7 ,[^H.C0Q6';[$W7@-"6H><6/Y$?AP^#GH[-.Y1
M!";5<W>\^?D!>G3@C\W/$/UTVD&:BWHG2/S/YT;H_TS\N;GLU0N>']_F0N3!
M@XN?&>OFRH,<EB '&+G)8O=#DH?]K@@B1@(F3N'"@)(&0G1 TP(C4D,!Q*1H
ME!E2XA!_TFW0XQF"2&$U @=+G78:-9=,<HUC"^)(?,DF+6[4PDDU7;8KN<PT
M@2>/+8CKYA*Y0K;>**@YD.F55I-9IVHEC_4ZY&B/R67)+L9WL#1&V)-A-J6-
MX)74XRLK@[)%]K@YV@6\Y2Z;G%X&_>2QI7/)#A:O-_,%1ZVERLRB4M/D!H?Z
M)YZ\W2UY?:JBI98\EG4*LSR&FQDJ*42W5YZK?^*3FR-(_ '_RN5P-[<UR8G=
MB/0#?>?Z9W.=I!Z(.]@_G>W, T'>N7X^KI^AH>A5LQ].3IS/P%X[?:^:LFLG
M\#6C$5[ZWK@YV>55\=D)U.=V<"JC'"?HB-_E,>LO_&0F=-KX9A+?D%@?3:5#
MI:IOICYY%JE>7$5?F?GW,Z)/$'/H%/KY+J5G^?!*PY%?G_-!@ HV(]->7FKQ
MJ#]'E@Y>LNTR<Z/*6"9HPV"5.M%U[53*GO"-8"'#RY-E1^H_9]IE\!:L5OR&
MK!:W+IEM5F,%=;/->BV_(A8Z$_9:0^$I-NP+MPM=ZZS/^)3G0#(<9ZNSM#6C
MM5I^&N<5QU@UXB70S;-SJ+/4FX#ZVM3S*VM"K]HJ'[=LC/6X>>PMIVJ%R<!=
M'TM":/;8P^+_W=Y=W-YM.)[S&9Y>LWIK]TRBI+NRV9!9137S"P;,!W4%305\
MHMV[M47$9VT0&+XPO8<6TY_80X=:!_R& 1A6HF8ZUXQXSGIJ$ YT?7;$D6V,
M3=M_E[9$+Y\K\-7PM1$#<L%$LWV0HWZ8:HB&I(@:FDE$F["ABYW@7%DG@G9P
M4>07ESU3?XB'C4@'4WW'N_..3_5_A8(M=ON/KT^]V.L"T#KQX5!7LV5\V9+$
M14/))5=$\I*Z=:O3]5_;=A,TV@4SW&B9'9K1%ET7H%V*D,I 4*-=:R$5XLAO
M/MMLK! 1'0>&FNBKS4PV& Z!WSJ"8E#T);I301TE!M0B!%+;U")HDF!/N7:3
MZ_XBP>WJB"@>W=LU@!/M@0@?B]46&ECZW7M_$+$(_\"A8R-I,HZV&/@O(GQ'
M9;#P8J!!!=I3X:%BZ^NN' N^6T070:WWV\YE?\2B)RMN,*Z'U]MP/E4W"]+0
M3J+QF79R)Z6L)H[VM).(N?5"<S"NLZ I1DNNH[:[UM$>G7.>#7#%JN#WM3AC
MH&D;'Q3YX[GU!\_V;FS:2?][4M_UE]MW#I%[$#?YV,&+O)#+% ICUO-*<2JI
MD]-4[J+8"8UE/W,O]=L:L="R0W$T@J!$J-7]177K=;(;K,W,( (Q(9JA\/S^
M9[^W:HA:A.%MSN;21ZV&H@6#E84"$0:T9>3_!-C+^GU^T-*BP]M]:/D'V7-!
MA.,?94]Y:J'3INL:7UKPU5)'4UN2!4W-_N%;AJ?+IBL#";Y ^Q%!YW=!KL4/
M49MTA-I0B L4OD9IW>FP<ZK:5UC0+M>,3M88*!!FD> QSM\_L-A3S-9]8Y[5
M3'&_)5$317DTT6F,3<\J,T;KM[.K# Q&XE'\@=[ ;4/M/Q$H2 V1+?KL*GJ;
M38<H?'WLUL_(0$3QGV<A]P>Y*6FFXW,>$@9]AB+YZ]&1P-8+*0]70@:. WD5
MX\C3'Y#-T#P9"@OURVTE#H<2(\F?\%)HB*!3.B++K>>5UBNK#Y&PWL[(=GY&
M9,6&/M2TG;4SWZ!#7M\P-C7H9IV'"#KF \:NENFL7R8#Z#%UQ?!CXL!.BOOW
MK+%D[)YX!&[0JQ[CZ..KH+/50= ;>YYWH.1@W7Z[][ _E"#^'L"0!+)'\5N*
MS3DRZ@3^;^3W==,^\HZCK [6I*VYA)8?^#!!:<4ZQE@WZOM<_V6BEV_>'M#T
M>.LIM/'L5ECH;_^ZG;B"Q.2U^T[C3X [9[T1[J93V0>:,S8];9T_#0#26O@<
M;]V8O$W$UI*"?M&_$>91#J+;]$- ^ B_.]J<H[;.]<#\D,I8__T3/6GWM21N
M4K3U=\&(T!>[*!-=:)F0J\I1J^8O?Q#=@]&@INUUB!FL#8$7K4/*0(B; -3G
MZ^$#'R)?9/,A^.;HGQ-M\EIB@I!ICA:T.2[A\3F1E"6NTATJR5/,,G[,+),"
M&4=FF1 ,3!5YEM$:?"E?CM'326E!Y!O[9KE0S1Y9_>$SV-_I@?-'6/-</U.&
M^K!GJ.>S2I)-,'23]91X;U9.X8W"!,864>IG D_\I/#$4VN],X9'M/-PBXGM
MSA)[FTU Z?M/^!DQ=T,*3'\6#&Q/M)=K12'COJ(09X?"!4X<R=32?(6MMKA(
MH9JN->NU9K+%9B*I7J3)9MDF6TVSOR/G.UWI;:BNHW0N:,A^QJINVK:A2:O#
MR&09\?>I]?5^L[+IR%U(.I'U0;J1"@!^- 3?P>UYM9\'Z\,<;^" J0?6M1G?
MXB!;AK0.WK<U WO+PY##W,;T>R<]_1$T>7-L.FCH1LNWH-[N]A)?VQP;#.'3
M#0G] M]9%VTW.-ZF4-BN+0E2RPCG6R^? <Z6 7,8GNQ(V V23?L66A-=/W\1
MT?X!>PN_H.-P@\0&0"*>Y_TS)ZQN3A\-O$9P!.G#&3.[39/T9G)@[RNT AY]
M#GJR@RLHM$0_XD O($<V"^F#*_P;COQ\YEZASVM@>L-,R790LN)8FKA<;Q'P
MMA'N5_]/'2)^^A"#!0SD #!Q4HH+DH0GA"@^$ 5&E!)HN\>$&$W$AS*Q:<U?
MMT[N=81*&L0FFA@9/]ZD@7Z@T"'(E^@*?6W+BG/VB?ZO_SEIYX@]/@3R(GW%
M&0%LW5_KZ_UO49M#(["908*J$=_N(+'5"@KI2_0A2O\[LOMSMYO$WFC08H<]
M_AZL=R!P?]>EPR4/FR]?:?,-)(FT%SI:M+IB;[N-*/% 7TJPCYP5A>_\K!@9
MVR@4^E>KEGZIS/'65ZX_H@=!!85AF7:PB4[PU1[@$'-13.BO48'F.[U>;+);
M."?N0^@Y33F4VS%Q?/Y9BZ]%,R<?#/<E)T6^-GH_^<S6FI6@/(ACI<C!.?2/
M-KM=PPQ),WRTM)*I,HN.+$W7JBT47UZ"[R>U%;R_D2#<F^2>V@0 #2KSE<<A
MOUQ?_Y0VCP3U$+_L <+AYT'L(9KX]Z.P^)6X]V*G+)_+VL/0Y>A&9R=M+Q@&
MO=A&#/5DLU40$E0B&B-"$#J@X00N\TG0<,5J]XF*]BE$OZ\Q_H-<N#8=^W0
MW&%_A_W7PW[K6@HNT(E-.[<0)P@B1H; Q:!A!7G.P[7[F+#S>C.B#_ YC.H=
MO17M3#851\V*_DR[0,?B#!X&U.QI:/+&5#2<#$>#B@2CNC%5)9E;T=44;]@
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MI)N##_T(/K_\LX+/?\;XX[AS[\+30\Y+#^JMPY 5Q]+$)02.$1R??/*8-,4
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M0W.)MG5KH,F;@DO(I!]&T889D<L6ARFYR,P>HRVWI#(2,0W_7%JG>9-C(&B
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M^:OD,$EGA5F=IF-Q0 ;Q0P;.PJ9HW-3J]7Z%SQ[T3]"5IFHV<0NP+4WRV1!
MOR\F(K,L4]"5%C)[<%DH%#4DEGCO'I<E^37> =PR%0V S&<!FHVP#]V$\]=2
M1(9]*1!84*7:#L<<E#(4>7@6$$@>&[H(DVWK[':)>2S)2)YTUA5R9_0A8W],
M-X\];7K(!.492R4YE[8<W(9<VW+DK;K/C,NC*UCP;&=+7)LY0B"CX=DA.SQ.
MYQ:[>?0_[KRP#"LZ#>(*7S-IFT_:P^&2TX"3"8]:!2RL88TGU1?1P?&Q$FQ2
M"T.5!!;),N;V)K-UTM' 7=VQD4%//7<5_X"U0_%$7O)1B O_T,6.Y4,OQ*N
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M_OX?#^_>>QR1Q"2-<*4*.ZK73A-C _W#6<)_Z)9%DPLA_O]NNW0)>%(/.&#
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M0.O)_^O*7_/J-QL#:!WZ*TO7V(&TQ7TG;7&_^?'DGY%Z\XSH&/O/I]>GND]
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M&$67A5?J@1 SR,;E:_&#8/EX)_4>VMZ9Z&;RV7":Z+P6NDWNBQ+?>]%$M1Y
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M.&'.7<Y*J90:;S0Z&%K%"J+)+?)S<$H#HLJY*OX8G;0 ==(IT-P$!V:WF1Y
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MW]N')9J@$023R ^X?.U:YSL[$<1(9WE)$!"3M]704$"UTKS)I\J,',S6-=1
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M5%J^.7J5#*?^C99L64]A%1?DH- _Q68G?[O%'Y3]%+>CM3WPQ L1)-WX?J5
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MI=H:/7WAY CCJ0Z"^4AYC.T"Q!-<0CT+?R]D(L*V) 2_>0$,K.!M!:]3N.9
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M C-5$E;0=-G7EM_Y=I_?V>=W_D3YG<MJQ[;N?/:AWH@/=9V^]#!"(@H46)W
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MD&KPM$7QB?N4\$<%GK:5<6?;]S6N& LH7K7:4""T9UZF@: DGR6&Y-$!0W+
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M$=W/\08RYM8AY0!Z;CLPDM^49KEPG4&PK366_59Z\?2E9.&]LKK@&SKQY:(
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MC\7S5&Z0*,6EQAB&OJ;FWR;US[72RI>,O<+'>];Y. KO@<"G'##Q,P)5/CN
M*@^@RGL!JKRO"):$1Y-%[47V#WPQ9^MLDR\STI4KVYUO\II/D3ZX#K)YU&-U
MA&N*,K@A=Y!X(<%$&@5IG8*OHJ85$'*N457R&*"HY)0,^*8!C@>]R(K3(D)J
M$PDMD0:*V!OS1:S-?<Y&WTE^2\^L+!MKG?4B;12+;B!FM%ATVTP@#,&/B?)O
MW + +87:-42+4OTLNJL4F2F?@O%B8.!D>SXUX($CH 7$8ZP5.(UO%7\T(%",
M N8ER-OS>B-4JQ2YA)_&R7$3,3:X<!L ,?LB5#RV3">PJ<*IJP=A.LGO@$KT
MP ^MNL<'9<A(";K*JTG(1\*"!2 C6-&'V,6[Z](S0;A('>:;4X1[9);H(WI\
M3"]M;CI?1KFV'*S2L!NWRJNF7X-^7K'-2F7P3)S_JZ+NTD2)*"B(U$5.S[4L
M@!'CNL!<)SN6,9"K5!S%H/),U9#+8@OB'5$39YXS$U6!^H-\/<PJDZEEY> R
MB7(9E!.Q^7C'ZV>Y[( H9"W2K[Y/CXF*I*K15N%#ZL,1.PQ-@5!L5.XUI.$P
MW/6+O[YXT_SY>/9&G_?ZDHQ#TT ?B#1UD%FB^H;U.>[2P@NXCND!,!C(&.SF
M,9=%3Q*6"=!2!H"*P1.UP=)J:;F;3KJ>5)K-]!HRN4<O"^RW(S,^0GDQW"\#
M XCVMDK/\R_A$PS8)DSC8A'\HT@82WR2:M=U:R=\MZZQ2M:_@1EH)E;=>@7!
M, AK^G?,AJ_9Y*:*,F4@XLR*2;A#WJF?P-'01H1IU*477.%X"-Y'@*9&34V=
MAYK.P2'&L?)2;0-9=:Q[#\-<U&'_IDH_8_ ]&MP^WEX'>P*H.@JX%[&4OIV^
MCS!P$T![Z9BF[C$*7+M"S4"%;Y!^['E1C=+,2PMD69G*G=.^"Y,4_G!94 =$
MHK!K*H]Z.+RG#%.;;N*L:5 \B\BXJ.(YNGCO'!K^*P<OLW[3N*1YT,3(\F:C
MTXR[E.7;Q[/G@PO; >B6&W')A0M>7))*61B_CL,/[FANM;D$>D/$Z$V?#FXY
M5'* H@8O(QF6V$*S8^_2^5;D=H":F^6<\](UT7I^/'!RF6+@/'D(BC]&>9+?
MD'39[('[]^FP="HLR<46)1<O["JG,)3;V5RP:T]P>VX<VOGC94105(G#4+<5
MH2[*)':R0+?%5244\K&N),!W#B<Z4D%JB9>.?GSSW[WTT"[F?=0Q+NIPAEYF
MZQ5W U,'[G?5-8GE"%_G56YP<"'ZX\XB&6W63>]O2_(&XI$N&Y&]-_T$TU!7
M=7K5&.UDXZ_+"51(U47ZRK&Q?*%N"'3NT#T=I2\SZBABCV%H (:N>>5.M&@>
M4E9!TL&BJ,(6)#F 3(=/I*<9(I6\'ME]5 (?F#4I]G.+TKW1R,8HC?17C9Z4
MW/ZQ6A,K/FW:=+!X,81'K)@?C_\E4==XIT@JP<*BC;M*<,TB#]Q'XLGJ<BM%
M>/RUM:UA*A;;(><5,SRG/1GG.R.IK#PL21_.]P;RUI+N-?W ,811T4*OZY&(
MMM?%)9005YY)TQS;G+3,E+7(A,,Q#-N*W#+,@HI=\&/1P%$^B:HGZ%!IE3CD
M]B?&V% [9O)DN.&Q45@OLYX 7&Q))'UY]DEI5Y1,1QU&@V$N6:,BDPM3W' A
M_._GA?U:SR9XK%<%C"3U/L%_+B>68U\?W,.J$Y9A')Z]_L@H;2'LX%S-S6<C
M!-VP,T)4T;.Y3NQZ.>^U<*F\2FQA837A?/F[>T(\OC&;)H?3V"@:+0=7%.W\
MX&'0DV4$&.6EE'',])03A-*2,R(EG9,Q$2+6&ME<>2:<Z=Z"IEX/8+U1?$%T
MGEAMB)J(@GGE+K*8_/K0SE9A/$G"L#%%B? (E7A!'@,V,C#:^]KGI&5VDW&?
MQ"4C)3UGA\'('80%9-\ZG&,ARRC/F9-^<D$J5;>"U(CZ!,B%'I!AG9V33W8Q
MMSO-9<:B)L,-JA>#UTC%.A *-^ZUA,B+QA/B%*Z9<$IBXE:=?;U<)HB\DQ'C
M9YZ2$QAY]!7G\CY+>M2')X="VJ&0]@<JI$T[' [>)X%?+/*S]+H%B:#U(PIG
M99@6-@,XAWUS-FYYF(B)">A2C1CJF$5VUZO#*(+Q!X=@M(1\L']SANCC"89*
M.G(SO0WSN3&F9\E!PYC)C+Q2!#SSL#-@C<-)@J K6N;^D2XOWM*G6\W2AW-W
M&T78(E5^YMQJ_^:KJAX]R9SMAZ=PF_=Y!Q$@;1L:C]H1%9]+^#JC-)]X[,-S
M:FZT&B1Q4#)1/[N:7!2$+T$)+Q*HG3[NDE%P!Z:^ZN@"LIQ_TN=]AVGKU^,O
MI^"LL>)4XF./3;*)^H8A5>S+RKN%B1\B]1#O-X4XC+Z\J[KH-_67Z4K0^WL<
M$6FOY'8:+2YP88,AP*3U7I:LG.7]*>Q+<CW7Z^.9%/70VS[NUEUS DK8-U N
MB5*&HP$+[<KT?8YGWX=M65TQV\J.X=-XKKR%2H(LIYX7.FZ[+ 0QU%U"#)()
MATZ_[" -#)"<(#(7IGDA7X@' H2 &0VCI(?":'0]\:HM%>P1=T9$GT6DD#Q8
M5^?AK<?3A2#6???7HW">8()AB)25 I%\M42*+!SJ1Q"H#AOL!8V-HB >//5U
M:%3A"JI[9^L=E4(V.>_2$!MS:HOHKZGBH>%F>.<-0<:T92EIF@KOIMR@//'$
M:6%FAY-QJZ+>Y"J"*8_"TB!Y7;.Y#]>NPMAL*8N2+1LUBL'@74#+Z8H^4/^Y
ME_Y90F,&;2WI#-W7R/[%B,'@I#<E7]K+78S:<!"I= BG7DK'K5)U+<ECSL5S
M-QJCX(FL"ZCTQIRTF ='G21<+$R;K%D17FY6-K1GI;0 NOW# X!%"78@[#(^
M3OQJ\%(B=UWBL.>76 ^$N#:RPDV#S!PGJC@85L+,7%F2J0E0!GL&ZE?"#&'U
MV60$.S U1&13M1J=8'C] I!9MAA5YW*RR$"3W&^\W)<.TB;&WH+HA^Q[EDB;
M/AEY$[6X$P.K?1;>^W*WI4N3?2&J7*7$3=Z(;&?Z(M4YM0B(2[52^=O)UZ*G
M13!K^KKPGA9M9.="V3P6$>!8!FNV9GP..Q^XJ:9'.>\^YN))]9[>7CY%B=7<
M*O<R;H[PU6?A9,AC:2*2]$H6=)TO8S+<W T6R(K7G)#FNT-WJ2=BBKF2GL')
M!3SH?+^.":Z*4W)N(R;2R]P>V"R0E"$9F2,_?KWA1D$O>K0^:Y:3\I+PIIMK
MZU1ZP/5+HNPCO@2?HJ72Z\8\D[E&\]D%43,)U&2XF.CJ)G1#D9BK.[:>Y']\
M9#2GCWK0$7!LAL*C/S>4/RR:2^_#RS[R5V>_;W$)BO"C)<44P;<B8QGEK3@]
MZ4MJ[*<\'/@I-4N&MHR;F84(#PQ)BKSQI4!?MF)M-FKMKI><?691MNO+G/P"
M<D5X4!KHQS>Y]<MY&[K8A2C\F!C61W+A,%=\7#4CC ?8OIK\!H=X;%)=CH9
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MV X5MG_:"ILV6HG.+/"K.,Q$[<BW_\"PXA,>U/+BQ]<-"T'FBX[ZL84'QC$
M#*FE2ZYIT7D*[I@H]72365:& !:3T@.>2 $,]R7I!#XB*1EH>8[C,(X$![G,
MU_!E!(O.=1X.)Z&3$.(!B=(S9\MA),EB-Y,FFP]L.CU):L%(! =2)867SBB
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MO3=U8AKZ^Z;RK_;4;WZ\%K]-N,39EFX1N?"^H@B,C'W1SKKM9;[F9=@;AC
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M")(0O C@.632\6JKMNX\OXX_.&,!0BU08\>$DO!B*>?R\(2T1/A38VW"VXF
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MKDOR9UU751S%*W]_O 4;$^8=O41BW.@)?(IS8Z_>OI3<6$Q<AJZ[ ;]>8A8
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M"QJ+=!FHU3S GW+V=B[]C:EC9+)8EQ4310 M/V!-K-JA;A122D8#(%!GAKT
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M#;17^PG4Z(M)^(@+!#']GGD(>U=V\R;)$.WEC@86TDD17T9;2>IHJ:X!O:%
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M>*XK,Z5D)8)_T)CI:B?:NK%HZTN?S'4)++QTU^(BRN7O9Y2+L=UM5W1_:1*
MQ@-<(J:;VNG26-L=B8I:72<0#<,BB[++3 RMM(8)>+.-)Q9%^)1YKE)\*K7'
MC-"='M7=VX=WZ2Z\1" :6\^(C]=.JI,/Y@RX!).PU?)"DJL:6XV]'[@2=LWB
MI2*-E*J4FC'X_#((*#?:BW!;P:#>L!%#VWN@0.I0KHG=?%H)M+"]K"SH.KW!
M)  WUQE1]*Q&E[S"XPYG!#>FN6C4%W*)3CV 5#L2ENV*M+7+!5JY1HN,TSCY
MMHY*2*= [=Y9-\:^JE(LUJ"A$KOX%*=SSW'A">E8V.Q8A:>7^V_%.NBBP;8Z
MXMH(71/!+)4UVXW,R,#W0$R6)X89=P57!4VKV^6M5Q!H7XB*45!75H4M("B7
MR[CK(F^VOPO"N6%F(=AGP,U3>2\!16CFK(+L.E&YGJ04KB]-!GX"E@&PA 2]
ME^$A FGMDJH=&I:%:@"K+O!<4_>RX&E!MZ=V(Z>8PST(/ 3%OV"DQ"HGAQ;%
ML@H9\EVY!>&4@ZZ[E+A&1]+UY?*6B=]17QB7M(^*;P5H)Y @?2@?F5CRYT%_
MMX:NU&K0!=]]]6QG?R5W+)IM&)0,@=;@<HCE*DF+S<UXI/!-0I W4(7"QSL9
MK1]J[%NW90+82:FV(4N69GN/)CP#V89$_:1.%S-\"#9/OL@ZFD*6.N/?SE-+
MA56K$=+>;S"%BA%( %N@DJZEU9P'Q.O!PFX#4@"1LWI*7@3?E.3:+&_4!GA2
MWMB7,,;L'X!A"3\1?[YA^I]T2D!R!VHC%@M=0IL)_RZ,):"@"-@0_&7I@U2D
M++9(ER\3\34&2&'ON-Y*_F@W.,.*C?UG6EZV!8UBGWQ"-P]A$\Y$L"&J8BO>
M**%R?X.(=@GKPSS[V\*AW%A%HOTISFQ6H)*S%J9W+JQ#8Y+*M;!4/<GV>T+?
MHM4(UQ0")ESPTW4O!JJ%F6^*N#4XC UPQ-V68N:MW\ + TT<E;P3,=O0'=*7
ME;W%=@M0Z(*X <H%<9GF8@'%G!A>Z7FI>W)#.YSN1H=+"-0@9A!;)X5%SA+&
M@&0%NP];V.8G=>4_WX#JHBGMP+.M[C2  ;G.XDCA(='PSA<]$6POT9LDFI!#
M")H!56=-JREZ#1G*.88B'046 L&(6Z4H*R?Y05"Q;$ILNSO<-@H7)<F]U/92
MNT5J;Y1-C%]W\J](HQ8Q,US26F2X%[U>]'8P 3H;2#OX>RSW/85\-C ==Q!M
MQ9T4=IY2Z28;NI?>7GHW26^*I7V.B,*'$K?<R9CH $6[,,G,,57U;09Z<;M9
MW$+C3[QRX<^H.7\"YJ<."B,A146P;!^WHL:M%##'RK)-/<Z"5FLA&)4H[EST
M;IOP/C8<TGF/0^IQ2 \"A]2K_2]<[;=8K-%7$R[LH#]C #> Z'^JP0AMD@))
M\]995:22H9'[)+&&]QQ;EDZ$]-FU2FR1G%'&R.&];QQ3#'?)-9#J)ES+)6.X
M1M9,2A,YA[31:%B"TIC&JQT4RR>HX8A!5DBHJB_U<JBR]2!Y*JB?N9!<NIS?
MO\-T&"<!>UNM/[3;8BJ>7@[DV($ _2F*< LH],>5U8ZII D.$+Q!S&43&E.Y
M9/X]\Y^:O.?P12Y$TP'/4$]^"D]^0"(]["7Z(4FT9B9W )R/ )D\PBY4;RX1
M;!-@FY']SJ[ =%H7B"-9W]!H0'A3.B W'5P&]T68<D,2?A*\,,RWOT[+]V7T
MVO.FOVP6CSZG7A]OH-='])=O)WM PK8=LCG^GY;V[1!9[%3"/4P /8XQ<"R)
M5)V;N16%8;C)%481%YYH'$ JP!84\MG"&C&F"J)"ID!#)9N:>T8;H+H+RLIV
M*3KH6HSYHH;HJ.)FAY+1-ENM7I,&B;M#2>^T;5_][2<PW?Z19#4 \D9Q-!Z.
MSAP,_0<S)3Z"0_S+>,CDHUAH"*AS,-\V]J-I3FEBJFO8[:^/!D>G.*FOQ\>#
MDV/8*H)(.HPWLFSA,YCMR,Z2^Y$Y3BS^"YB1(6^#*V@4-&$ZK2&%C:H#$,76
M ,X 363W$(HD92T=OAK&G<^!E@NEL\X:W0PZA8S8U=S+5%7ELS"<4P'.WK\R
MCGSK()!M/T HZT?&GHRIFNF#T@Z^N=Q!C[1:ZB^B.<-W =Q8EZ43+:LSN>P#
M-$_T$WU,:DN19V)1&G(3\!MVU,^R#&+WKW'_[P>X= NL$F!S"1[_W64ZLT<2
MK_ZS\?#PZ<,N&?BGESO>3P(*TXD2NATJVN"Z =]\RCJ$<+\17,ES,>P=6?7F
MQB$R_$F=L FJ&T]^[4^PASDE3NL'+8.\^J$SXE?(TVU,3;/?E&J_=1-K11)2
MFM_($.Y8P6^@S]V3"7(;_@NL52%> 5*"(1T=^U24T2/-(:A(0N]F9'H!K,=J
MLZM&IRXI6L?%SM::32]@PB)8W#0H@&L^'$D5FN2ZHE\=T'YJE/Y<P3NQZB)I
MUEL#HTIWI[5]'S+>%*$7BX,B[3>,83P:'DG5Q)NDF"16Z@Y>?EA84QH*MY^H
MCWT3,ZET!EC9A#<%T#"*>HB[T+F]S939U=R)C;O,968)7&PE/A9J)+ADG6JU
M%0J?(6/.V+\VR?N,:.P4K2A#--50A?=C]U$%!7XIEPQ16\'Y(D]P]O^HK?(Y
M'*(E- *#3/K.87.Z')L[)%B&^/7I<#@81E82%D0B5(=$1@H-+KT+IQB:P_YL
MJ=444JBE:>Q!SY2N#/^/[8,JVG'50,'M'KP9 -C6UIRY4JCHS8_/':?JW&Z8
M_1XT!8HX)=LT'$?6"F*0(!1:Q<PYU'3F9'\5[7EAJ)FB<GR!I"1%)G6P_C6Z
M8+>INVX-&[:DL1=[)==DA@: :J@XK?#*PG03:_%50$Q9KP)N&:D]NH2*9)%M
M^+R?7>@<V[MO/N?<IJ\-% $53:G,4\<'0\UW_7,AU&6EY<+HOH)25E7"9/#W
MBCQ)-?:!%V%O* *EK.VF+*5'&WP&S=M\6F.Y-BJP@'.&+7(Z(DB)Q9\Q,UH/
M)#*F>E^M*8/*!4]V3,5D./Z9>I[5EZ8,;BUW7,"CF*6.MCA!@8=@86)]>2AZ
M^X%Z#B&!BA_@A@,L)\6Q;4)_ NFDU:D7/U+U(?*7JZ=EZ&:3UJ5SR:I)$9+:
MOQ65!V;L_G+HTR)ZC.I:6F_U)5M=AL'NKVHT,4^S2^LTM(J8$P@X$?:>+T%J
MVM9FP\RE65BSENM1,H(<#_M,?)^)?Q"9^(?O$F'_4\A/(/&^H2I%*:8%W<"Y
M7<[TPE7T7)K>/;^$8%&Q=I9YQ4_XP2[!-75:8^)?(0"Q]UF]I'1IP/*04.$_
MT<-)<*TN/3LJN"K<HBYT1CU_@_X,.[1:'3INYGERE2-14O1O:V],N;LC#\L-
M@IF2A?UDE@+].98?Y]"(VA")GZLUW[L;!1N9+ U21K'O7J&/NW5WGW#<['GX
MH1?Z0\*=\L=$0:[:3?(@:4P*L93>3)(6W4$K)K%VQF/W1A^K<5Q>AX?1$_@;
M3S+\B$R+G&5:N3B:HA\$(/5,&,6"CHXP5&$XPR9J.%'L \GQ !#EQF!X3HT.
MW*!%^/MHO?)3^5EH'#>;2>+5A\NDZ$NIB&YZF7/PB-;4%?HKEI-$GQ$?\_%G
M9%)0>(I[0,!I:9P1ZDZ!/=BA4:X[2OKLZ+X*6,-NS9 +B5LEUV6-/#3//"(;
M5@-X(KB?)A+48?*;P^.;YP:F$G$AL[&X39!=Q:\BZVEB%W'2(H6N8C8%8=">
M!\?4RC*?$NL(J@N(ERVN7-Z<HX6IE!7KW;RG.OF[37(AI:!BC)#PT6520*Q
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MD-8-=/.2(XM&PZ_)FE=G.":XM-@'OGNY-*N?)U,VP? :$D9KA.[B0'6--E6
M8#(*^=JH5:C]]0=8!GKGTJ[>I330!*IA?Z?0W 0JE5PEZ8(,ZDR1B2">5^P5
MNNPPD":P[?! GLX.CR<3\^YDE)AW1\/ST;MD:O\U.3+):'8\'IZ>MP_DX2]
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M\:](QV"M^-=820N];JUG>GATY.*FNU&;N8/1(A?[:$JPT_&J20EVO_?H-II
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M>B)Y,2(B^F WHE2X&A]VX!(4:UQB002Q:T"&;YJND/>",-[MT3K&O1PP0E0
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MGHQ.CLZ/S;MC<W[T[NAT?F)OIN3T79+,1D>CH^F9SY?Z0W;ZJ^,;*7^@-@@
M'<QFS[)DL2[3\MW9W<)L-L_V\P#2G YV/6*_MNGR_0Z@ARE[ /+GS^%SQ[,*
MGWGMZQY>NKH'',*-TOXP;#"UWES3]) 9H]+-P_[J;_\WKR%Z0B4>R8Q#X1*G
MFH6;FZC-W42DN[&PQ6JG"PH;N;##5 /W.DMR=:51EE>8+\),TLW]3(B:7LV
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M8>5 4M40*)8!R1+%T:1FBA2AN\!5F:Z!5V!1,R4"\\303YB;M!M5$67E*PA
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MF,II5]8ZL>[: EL%U(LI>LA8< <5A=[&^]V;G3#?YT5^Z9G4FD-[KD9&-;6
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MV+%U+A!>!7$TB*MP=Q7^Y6R=)1!](+Q5X[?.D623P\Q\]Y<DM!G]P*XQM;,
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MA$U2C?)@[=!LG=9VX":OT<BP3[TR&?Y 6":[<@NJD,Y]HQ7IV2 7HBH6<^+
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MV'"]'W$)L&]4+(T[W?/$0>'&CLX2=1_02VP0WCB(GB<K.(R<":*= 9O.6OH
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M@-PXD'2W+E8YB[3( 'K&NTH!81N%OPQ39/AFPP90]ZM1^3:SKVZ"&=;))<A
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M-ZAB]CW!E\E[XXL]=:L+76T:H,B1J%Z:A/(W:!GL4Q-5.@!#APR RA\M*'V
M4V! 8N*@*(QA%?!.3F4@"7E++2';7V3_7\8W\PH:8%*U=6=/3.49JJ2=$\<U
M)X*<4Z@DFAK0='P9,)4=GX_#075F&7R\(XR%X&'">EF7@61F$U?&C\83UI/B
M!QG,Q0D?_)4,E3HCF&"<+3(5#K%HWU=YQIILP V$G6&G ?+B(LG$V@.'IT&>
MTN*+61%X!VL4<L\X>.,@P=@)-USS^'?G9:F.4 ZD>Q>5$HHEO%GG<8BU(X0:
M;XVAQJ$P"H^.ML]5I3,PDMMM!8  3@S*YG# !WYQG.E79W[:SE1T2^79%925
MZ&JF[2R!I@[15^&D0Z&3S''LVE8A.L]^Q?Z,;%FR,G+JYD5BYU)C;,1=/57*
MA)_9&LG&E,AL>*.K9:G6*YB/':WU+N!- ,;&(H8EX,U6"^,&V4FB)<E:7UNS
MN2ZKH2J0'D0M5""*W8M%QKX6M8.&J*VD#C+8K2![#"_;;^VI;^?((85Z"3KK
MOW",ZBU @W:";$8ZHW+,=B4>!I3:C\ZJTI3 PF7K%DRS*9ETXJ"@.9W452Z_
M(%L:?Q.8W$/O\O-GVCY-5<C ^(4C#ERX>$ CU$#N$3_E^'PPM#Z#<B(;T0-E
M;ZKG@S#-[?)+_UCY&2G@OR,'Y=JNTXV.@0K2N(\FDS)?U)6Y9X>@&PZ)'X3X
MS&X]<I5CUPS#;%CV3?&=\6 \ZC?B 6S$:'!TU&_$0]B(X6 X[G?B >Q$KYL>
MR$;TNNFA;$2OFQ[(3O2ZZ8%L1*^;'LA&G _.^XVXPXW 9&^( _A#+O6GF_79
MJJ,N;-=EN%>M_+C68)HOX)=__>KLJUNNQ^'9X/1(<K,."+7Z$&&Q5B19WWM<
ML+-MF6M^R21X25@(^G^AD/9';(O4X@FA?_SEVXE:MO[4/,!3<]9:@FU;3MO:
M_M]PH_7Y&-_V?(RL]7#RJ,\'$+*T%J87@R]/#$;GO1C\<3$X/'OL8G#6>1\V
M+._A!KLT6,?1T"UD8Y[]3?M0S]9VI. #796;7/C'OBKN1)W>VHX_'=SOV?FC
MBN?)#Y".+IC//Z_+))N5WSPZT_QY@&'H:)>!9.;CIP&5OC#G/QK]L%GN/Z/C
M'DSRZ[L8]DVQ]SM74XB]T'B4PP#D'>R<'C:@<7#@7_TM.AS'A^?'C^T&ZR7T
M"Y+087PX[B7TBY#0FW($#U) 1T?QX?"HM7<=YDR[K&8Z-68^;Y;=/1X[Y]5O
M!^='AUT[_[%S_;R.ZUW-?@_G^"'-_E%>6./#^/"XK0_ZH]$?C2_^: SC\W%_
M-/JC<9^S?Y1&Y/'X<!<+\O$:BF]_/A@/A[W_]CF?X"_B#COO@Q&],'\VPAP?
MC;;98[TX?Z'B_"B-J-%)/ *XTQ<:B1L?'O<^5>]3]>$&ESH:G?:QAOY<].>B
M<2[XSNC/1G\V^CC<;D?C<XO%C?I8W.=]BK^(B^SXJ.WM]<+<"_.C%.;QV5DO
MS+TP?Q9FU'@8'QWME-%\-)&X7YOM!Z)\8D?&7.XYLKTB6Z=N0 "][S)3]"Y6
M[V+UX8<^_-"?C?YL]&?C04C'%WTV'J5->3S<*;7[D4NQ#U/RU0UTV(XEFB-W
MO3_X.1_J+^)>&YW%1\=MA["7YUZ>'Z4\'\6CDW$OSKTX?Q:FU7E\=MB&RCSF
M:-W/U%80&U>%[;0D&UJ8=#FIB])0QZ',5+VW=;_>UAZ)L]JK(RQA]QZ V/>L
MMZB*7=7#DU%\='KV31^4Z(])?TRV'9/1L#\D_2&YMX#=OB=]%V=D'(\/.T[)
M(\#7O<TK:N"WO8-;[PW>_AP?6I&>Y36TM=O+0;Y#EJV]3^R.7<33H_AX>-)'
M/'H9_WQE_.0X'@[[('4OXYM,KL<OXL?G\='YAE#?M]A0]L&(Y9X:HX,=!_VF
M=^K6>YTNH"WRM#!)::!9_36WKC=EN:F==II5>00=ZH%U';HCNU1P5:3) CI#
M?UAAX/+21%D-+4V@:WF>7>1!;W'Y=#*[PN[E>H#)M$JOTBJUK[.^AWT /.L?
M25:6)HM^2:<8 85W/ _@BL_LP#D>*D^%271DIJ5S-,T&FQ2'[<9A8O ":#*<
M9K7QS;,/PN;9@^@M?CN?XIK-X1NP9#!7^4P<I;"!Z1R[MJ]R:%L,#:D[5I??
M*4]H=9YN+%^4&7AO8N<&#= GT%4=>EO7=H-R^\MD!6VPH?=UB4VN%VN**5N9
MPZ;>69E>F4%DY6:9K.W#KF!7:W#RH*6WW8?+U%S!0*S,O3<X)/=(:2G>,0OJ
MKKW@%8$/<?=R^V[K/N8%].SF=9LD=)BHM?UTJK[4\608YL1NS7QNL*7\9 TR
M9JR/6D;0J3XO@D[VP?K9)R1QU/P1>K97*;5L;_2[3U8\-NJ"+@.U*UW89;<K
M1TW>07SLBL)7\GG<M?QES N(>XLOX_;QC>?R LQKZ'MNAV9G!JW+K3K0"V+%
M=@YO76.C='H)MRUW^X0]T1,0P7I185]T;AT/VM^^:6;L";9C-CC\6<U'B.1O
MN5H8_)&VC;=CHSYQI\D. !O2XZKD]M\)*!L0=Q@ :IL+DQG[+CA 5P8.UKS(
ME]R$W4_7#Z9,['CM +"#_":Q&$0O;Q@?]6>')2CK"?:9M^.;7B;9A8P C@3H
M O@O:4)C=ZZ&H=)+T[P@E80=ZJ^2=(%K:=]J_VYW[2X[M]./\*#O4NNVI],V
M2__F6^!G7&+2%\]F=H_3LBJPJ5STHVC^3W9%-<:3A.-Q-Y$]%Z7]-6SQRA1E
MGF5F0=)GS\EBD6/?>#CA<%124RJ%DEOA*?R32"U5)9#7VXV?V^-D90F4NBFN
M[-41Z(>%552+.+JL[43]3MI7VC]7-.#I-*\SU'S^ ? '5"U.9.T?%PM4C_9/
M7EGB* ?1JW!*>K96OI,BA8=.[#+-4YY46>73]P<3>RW3>;1SPS-AC[5;C:[%
M"Y:AP+L4!X3*GF[$N5I&6 M _G,9@)E>9ODBO[ *;V;L!.W,W$%,EE9MR\F4
M+*1?_[)>K18I'$5OA, 1D_O3_MLN>ZTV"M7=:F6?RC<$?=(^<&5(&Y5P$%7[
M0-4/<;JP1QV,X$N6-6?C@LS=1T/$C?TCQD?>CN43"-B*L.GA__Y?03?'5ER5
MS7$U+>YE,T;+_,(<4+/(9&[?_%VRN$[6)4_S]!RZ9Y"E_YVSZ ]1*0P'A\?_
M$ZE_PWJT%G.9?#A02\:.P,'"S*OO^&ORNX):6_(O;VA:R3M3Y:OOQJ/!">@%
M^R-/[&A$JN)^FU?BIAPJ+R.)+@LS_^M7?WK[\GG#L+\KC9W!@5H$&IM_I60(
M%A>BLGB'V#/Y/(<36I7.A4C^MH/DA_O6V@ZUW*/1X/A^'-;F]9-$*^MBIE/4
M6_;:UOK6'7X<HD$KP7RPNDM4Y[RVQI<A$R1%?76=5I=145MCDO(4\"DVL5!%
MY&@*16]^?,[&6%X:^66&GT'M;%4/71SF U_[5HU9-].:"Z!]U ? 2+#WT\S,
M8.2EM8Q@&#)R^-T55%(5- <RY3HO&AS/!5]^X(!<FF36=0OR+?%0[(<7H-WL
M%*,7F=T'LS=OUHTCQ7'(-8=;GLK?[&'(X,[(Z!))2NMMP?]&YC]U:@TX.%.Q
MNI7QO/G=CED&T#]:6B,/+ESRXNSN6$\ ?"=^%VRS6:;U,KP+T=H$%[-&S]4Z
MTWA1W].R;3]['6V>M@J!6N0?!:R]WQ"&&X^8&)V[;DV3_"*SKW [O\CM[00N
MC;5<)M7';6NPG>!DV%LN)=T1S8W19F9:EC7J [%-R42D/4?;*@45(#66\.T[
M/=CW*0J_Y.!Z9]&/$.:(7AM7*#J/?K!KNF_)D.%A%,9*@!H>;'D@*"O_9[Q5
M6IMB?TAG4;T"J]=>%!W/; O58SG2+U%2^3S'=E#WO76G6R?P4OMGB%3T6V5/
MIOVB'0&Z^$M0H8%M8'T3.[7,7]H7UI.A\[BPXL!'4[Z05F9Y]V[X;I?F:PRT
MH/"]]/[+0[G2GX,I9K4@Z2B[(61+8?MIT]U^.H+>N[B\U'W53H0O3_9A*+6
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M^ZN__9).4>N"0GV>+Q:)/7:DCU^;*Y/5YNZ'K_7F^)#.S.8)Z %.@P$6-$"
MR5M- O?)U^,S=<EC,ZNOAX.Q_\V-5\OH/+(F$SSGY".^-1X.HK>7?B3V']'B
MQG%?)V6T*E([=;N,T<S^)MBLMDJ=X__9-;%#M)^K5[.DPG?!Z)*E_6A5PFB-
MO6@K'/:\KNK"1'8?KNQP2OOJ99+"-02SG)AH90K[L:6=D7V-H6GRAO\CR<K2
M9-%F 7EV41@#)$NQG6 !]W">@4JUD^&%@!?E=1'EUHQ(%HMH6B]K.LCP9KD=
MK:X 0V!A*K85X"L\LB2;V@],K(*A=\[J AZZ;2M@-+5]VBRZ3JM+^T-6I7:Y
M9\$C838SL[ C*=;P2K="?AWR["*'=WW$0MQ&"G8S=Q9E#L\%8VN&'T^7UA-"
M>JMD5ZFQ,S('E3V:>A^2V;_KLD*J+%2R\/B<!&JULJ-/9%-DO%:Z\HL,U3)(
M;S9-[5J#V"T6^35*EOWNK\F:#E-BGSP3(B[XRT>LIOU\ J.:U5-#UIX;Q&0=
M?7WNC_I A!:6'S:\@+59YK-T+C.PXEDO8'8IV*?!'L&P[#>L'3J56;&$@(D
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M\PLMXKKA3O<,!U1C/91*P8A9 WK@&/0(2!\4-I0K? T4A L.'/ASL*L(@FK
M,/D>3!4 %ED5A7 .4%])8)X*TB0D*=V$](I\&VFB6#?CU^?7^WE9%(7S/I*?
M3$F:/3YK:A1YH%.T?H!!?,.FA4G"*7+T.^*"3J!D] "6",4C#.D:>CP@?(*'
M4)GC;C]7"J5H0_!?&  T2P0XU^_\ L"':B0MM-1@ Q)($5\?TRW,AY_=[;I
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MGWXCJ:FD%$ISSP 23GMB2K1JNF#\A9YO^)F&Z+^R*,\(0/=L="415X\>53M
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M,E.T'GR5H"$$+JSGFHH'$&<->!K5<$3UZB*4G\;;%#J2H1R)>L7+98? $LL
M^5S_;+Y(^/3O9:B!4+#M)FR*9M0#,!8--"(6,1:+Q%(?9.B2K^$?R=4C'09
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MLT<9N:GS"UQ"IJ- -['884:E]-K#C-0&@N#',T<9]>N3EQQ63'J2,$^,JTJ
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M6WI6 ^E9BXGH6>FI5!,4EVT75]_4+DX83,N6GFG+[.VD9Z9PFY I"]H8B]A
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M&?1:,4_O?HQ[)^+=F7\PSKO?[*MQ!1:00:_.;N/7K?3P>']'Z@]GCG$F56M
M W(&$>[?CXZ-[Z7;P]8^:73EX^/.^<4=C)I%A%J^<[_;E-2[LYW]_.X9+*&V
M#]O*(,*!W7S:^U[UKYO&D9W?.;:OAS]5&#6#"'\5.S\>\MW:+G#!_=//;P<'
MS8HYPD>GB- XK@POM,XWK96_Z5M[SH]AB=S HQE$>"'=U^6SQU]64ZY?^[=[
M2D-3\A?XZ-2HM4KOV_Y0NC'$,_UH^,.OJZ?C.JPU@[*:^?/B5;VR5VN5:^6!
M5CMT'M4C&#6#LK[O%"_WAIU#D,:*?UEI_W@:[Z$&RA!O#]72K\OS<MV[&_NF
MHO[Z9GKBL-Y6,HCP^.ZXY#7UO1OQZ.?A7KU[6!D.-7@T@UR^B\K><>/,/&W*
MFBV=WW1ZE@)K53+(I?VS?7^XW^KG[QH-\F >E?JV<]AK*Y/DTE:(7BT3H+B.
M+G;:Q8JNM54"?\GP@RJ*15VL*2]_8X*!%GMG6D+U?M1VO(O!::MQ[UZ<GUUV
M]IZZH,@S")F,>^;CH'M;O"/':K>U0Y0?=VT 308A[SU6*T;EN+K?*G\[//(-
MZWHX;,.H&81\Y-R?W]=4_6?35^RC_<[3TT5]!T;-H,ZJ9:KJN.Q6FU?BMROG
MZ#+O7SLP:@;)Z2?MJWW2+]^WU)L[7?&+X\OF+Q@U@^0.OO=OSG9NOSTV_>+^
MZ;7D[QSF3^OXZ)2$\HSJ\*CX>-]IG8WJ1W?M^_M>JSS"1T,)M:R&2X$_2/U*
MU??L\ OF5-)OWKDG4T4L%*7UZ!WRDNXP"]6)2QS\6C8]]F5[E@O*1]NR5"A]
MM!V+A=J:-,7AA,T)>[F$7=W,/;^PA]<:Z:9J5@CP@_'T,F  MA)^^=]/I4^O
MA4>E(%>FFH$-'S>G%5B8!\P"O(H41'I?VAV,L\J[L\K+6OXQM$[_.]7A+V(*
M^;5,(<F%8GFCF8(=O'<X&?PN&50WG RDVK."</KP6-,(Z7;_7CL).;<CJ.N2
MV>T^7[K'=34?7B?XE[7[%7L'*][\^WC \TODKQ$\."M\W,VOVF?>,B^YX3L.
M9G"K5(=]W02C[3T;E&P5#WY0K</I]^/2[R:KBLUPCJ)TX3+3)WBG/BJ1@'?!
M'E23)8-R>W!;[,'/V^WL"$HJ U[XQWB$)5I[CJK1^U.^97B7F'B-%VC;5\'5
MQW;K:K>M^'<'-]\KYV;KZ+%U>G1CWEUKP]XG6E$9)J1OU=WV61>3[!2IC<&R
M=DO[7GVJM:US<3 \N/0KY[O&Z*C^2=")9@Q4T_WOI[SR"2]-#53OOY^,1^^K
MY0]TVPM^_R18Z@# X;OYGJH.OR(+UBT=_].,^:_N-53'P<8>WU73)Y\$%U "
M;\'(0?*$]-B]N[?*>W=W9ZU+LW=VV[K?:=7;)<Q)D:1*3BE5__DK#0KNY7&N
M7BMEO"Y<+=7:^[OWG>[.S][EW=G%F7G[L"M7_>K%NW/UT5FI]K-W<7-QY]^.
M>B</C;-;XP23MLN?_E64G"B6YS#UNCNP$\;'B>K<D2##*ZH0P%V"=14X']&E
MW7#;(N:PN 1'$$+*D#W?\GGWQTTI?WAWOVMZWRS=W<UW1FV: BU5J[EB25K(
MHN#L^G'9E1L-OV$TO(Q=_8/+_GZG5Y?$LV'K]LP@^_O--MZP E-!$L6<*,UC
MUVV)8%P2UW,,6D"'QC#R@L8@QGV=[?%UUFGSW";Y/9LD9EATCF:+-^6DU1[U
MR$^UV1CL[^T?7>P^B&?U-KTZ)8D\M,'9?8L.L->%W9=OTRS*[JV.=77N7O<?
MFN3I6[4Q^*Z,2RJR>_D9=M^PH,<ET8CQ0(,>M+ /O<36L5DU9-J8$&NTTB,9
M&!&WRP[[P; )BTWC0V/N>&VQ].(VR?O:)+L^V0-FO&0,=@[\-=?S,D_TX_T3
M[U83U1/??RP]-'<E==2NHFDBYXKRO!@MYU;.K=RD^"V3XH7<6G_8ZQK=XVI9
MW/]VI#ZY)SNEZY\]X%:P+,JY2JGT,:(DA-9:I&52R0,Q[2$M!>NICUCP%/[$
M;AI.9)QP=XJ[4SQZLGZ6RH&EV0-RK3X2-_8DLK)#NN>'QZ5;S1'O;\S#G_N'
MNSU%&K5K-'J2$ZM%'D#A'/\Q RBTS8/\]\9&$,X=,E0-+)8^))8;]%2P:9EV
M+74]@#L=+^#/%=[=7 L8,,6\:BALK^(.N+;)F+9NZ6?(L>PNZFS?I3DHBX/:
MY4V]152[=N17[^R]FQ[6G%30>9$K%1YJX%S_NZ&(54-A7;A^^:&*UW']MQ_[
M@_Y>\]QO$G=_IU,S)-+;O4"N+W_ZMY0KR;6M#EG0O@+8,M=3S05,&NZD<">%
MAR56:]T\)]'N?^AR([\_NF^JW_?+[=OCHM*\[6%!;+!C%*F4*\]-;.?,SIE]
MBR,2&V;4/,?L/?WIR+FX=\Z;Y-8JZM6J4Q*?:/5[S.4HEG+*2S-3U\I.F75S
M1<@+L*$YV:<?0D1]!$G$K8O57V,YC5@M0P*1[^.C^ZO\SE/3V'5N](OS4_+C
MEC;5H!D:X-/RL EGV VR$!8YL]@,+Y\>8& 72V],#RZPYL20]46U"+^TP4U^
M[M^OH08.6?;<5"VO;NG-D&M/29;^/3JJVC_W^Y52:]#S+ON5LR=S#YNI*2S]
MH%B6N;//.9\[^QO@[+^0\\\NZB?E8O.DVU)+GMWT3D\JM3SE?/3]<^7JAGO^
MT]=-N<_/70AN<;SQ-=&YWKY]7QO=CJODH267C-U+I_SCJ;[;PPZ68&T42]S7
MYXS*#81WNN YEU'/][L=N]0]*=WE3ZR]^^;WI[N]>]IJMOP<HVYRO.,,#"C5
M@SD$DZ@N$2@!Y.UNWH</['(G]WZX]\/C'NMGA42L>XR<>XF;.^NV7$*/0#,D
MW/?^V&L7O9\7K:O3\\=CY_2VX\HC[)"-IDBNMJ QPEF?LSX/?*S6KGDIZU^<
M-<C]37UPTRS;-WF[>?>S?M:K(^O3>Z9B<5[,<P,B'[ND2\"PT^F546JU<#>*
M9YIO[_V2J2-73N2<R/EUBM56?@AT4'0+FJ4B9A]%C*\D:Z=75%IWXZ'RRQJ?
M=8O=JXNVQ IDYHJ*LJ7Q!G9Q@EV8X)&%MW4OTKRN *_KMH]YH2L1>>_1Z6/E
M.UX7\?96MRBR"D[]M _<?%&4[O8/?AYHMZ5'\QMF5--BF(I<S!7+O-D'Y_PW
MCB6L?,?KPOEO=:4B@_,?1Z-1KZ&=?&OM[PT>FR?.SNG]8QTY'XV84C%7D^9=
M =^ N,+<7LW'ADK9W C*7%QYMG;7A]^(XU('K?*W@!DIWEC8E";F:^&H;&)D
M=././E:R;4Z_V[+'E0?P?V?;F^P_ATV6S5CY9'9:YL8T/Z7;^ /Z]8+'"ECA
M__XCE<6_V;^<SK?V-'K)RFRM=-9$@<"ZI@'&/%<8JN-9M7S7GR\_@E69&;79
M.!6RZ5'7@%W.&;?,KFNQU[G^=GAP]B#>^2>W3Z?R('_Z7:O#FF@4-B=6YE42
MYZRWG:S'<ZQ^)^RY*.OUSN3;_,-H/R\>?:\?51H')_N5Z@A9KXP%'2JUK<P=
MGRS\RZ D>/:,KD$+M C:8$-]G<S9CV[+<X/C][H-7=N+=B]I[<BN577$TY9Z
MU]NIV>+X^\T C Z)E;*I*/PJ/>?[#^+#;[BU\R*^_[9/JCL[OZZ:K2.K9&O5
M\Y_#ICU"OJ?9:_+<$AJ;%[!P?)+9T2 (8?!>!MLLH;@!\LZWVF@1\K3O5;?T
M@ T3.1<9<JFTJ_T\>]AMR<W]BMAZJE:U2K7::\NTM)Y4S15KBV6B<>;]N,S+
MK8C?N9?V&\Q[Y]W4O8O'AT[SZ.3I6_7LX,=5IT69%XT*.:>4/T(<);K)YI '
M8OED,FX"G^=4].&>%/>D> 1EM09,PV:MT6\,K]_P70 V<4+)-Y[M4W7.O?W#
M.U&[:AGB[MWCTZ#O7!V ^&-E"8NYXH+ME+@(X"* !U-6:P:]4@14]W[56]_+
M7K5)#H^'[;-VO]&]I"( +:!*KJ+,<U\V+*XR67@H3&A\QL+Y$%*,7V_^ '?X
M-\RL29<<64":6:>_KO,GWQN'S<:-Z,G'=OWA[OZB+1>#.LNE>8WB.,-SAN?U
M#-:HQM "#/\HU8W#@]&!*@Y,KWCP37?NM>((&9Z="I7F=5';_/A-9F?(Q#4-
M[JQQ9XW':];/L$E$I6?+-MG52NW\6&PVSWY*G1WSZ69D#< U8[43Q9Q<G%<[
MGC,\9W@>G5D7PV8AAJ_*ETW?O+N_%.\/6K<_'HK=2T^Z0(8'8T8IY8IS>\*N
M>RP&QCRVK5[>(\X P-B9W>#J0\BECR!^-MZLX#4/.9%R5;AD50A*X!ITP"ZH
M@ PEZ)P[NSWG46TWQ]IMZ:*FE\^_H1*D50IKN4JMN(T>_6)9&/-;*W$[G]OY
M6^?8S]' G-XYO7._=HVS#N;V/CH^N6[:W]K6L*G^Z-R.:C_Z5N-AU)9I(3]9
M 46_R1<ZGDDVX#T2N6NQ"=IWP\+J,XX/Y\HA63X5;]62>]VZ_ZY8ET;^[&;P
MO=>6JZQ#44GD[1(YSW(+XKV/_.<W..T:G9_.V:_=UN"@63G>:9T='^J49\%V
M*.5JY1<V5=Z8& &]Z\(/^%=4TWSS\YW>M/7!QTV$>J,;J8E#P[GB\%"_)4_R
M_HY[U^B>[+NG<O?XM%5ORS6:]2CS+ $N-=8#.!N7/CD5?5SWN$-V9N S!L.'
MX'#NN_!XPQNF\66HY;ZT_^OJN'3BBOYAO],=7N^.+L5Z6Z'E,8O%7'5NR1K.
MGIP]>6AA64EW63W$E(/28:/TH]7R3Y_&_9]2M^S]ZB%[EC_]6\'>Y-O:#[%A
M#P:&-R!8$ALK2R%.8$9B:=A6Z,NI[1%!DO[D7@(_<]W*'(/U@@=GA8^[^95K
M^-^!Q[K[PC!F5GL\0MOC938P^A"<^Q$8](.J)$Z_'Y=^MTJ/;(8K-=F.P DS
MN%U4.SGA\WQ_>==X,'1"O66WKSK$;9,#FTA-Z?MA2RX_U.5&_WQO4+GX;:?Y
MX'3O!5YSM VJ/,]5Y\P!S]XC^G?5],DY<:YPL9%#+3*'^E1UG'9_I_]3>RJV
M!\V;BWW[H:N/;BR]#I!_<S@L%-M[-SCL[__<5W_4]_5FOGTMC91?1W=/AZ-/
M_XH%/.#(.H^;^ (S_H4'G">W:- E %U[][+W6+'[1V)Y)-5U[>KDMFO45TI"
M%$YNW??ZM@-<I&>"3)1'BNN?*H>M\9AT?C;&_>&^^"SI_/[NWYQP%MK]Z9ZZ
M9_2>BH-6?L_=W2WIK5]'S8M/_TIB#@@&_[\ S3 8"&HTU=_K23MYEV@(P9'M
MZ"ZQ%@'?@>OZ,T#G*M\EM]EJ[#2-GO'S833P_3.KMZ:$L]RM'Q1+_D-'[[;O
M_+O:_=E]_>[0[H&8L>S%J<6@P[,"\[[G(E@P99D'/'C 8RMC?Q-'&BG8('?F
MC<<\ \S7;_0_[;NF<GUV\ZMS=->H5)J/ ^WXZ+I[,?EN )8@A>&W5L\^XK
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M3.#6YK TWB]F%9&K+]\9Q3[1X"QK\G[[RHZCJP>5[6Q%@]H8"\+$)Q,T-7F
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MJARO6!P_\SUZ/=MX8BG9UQ.2979&?7/B;BPSY/51">=92^BS8&AF63%1);B
MKN],'K,"8;+M-4@\'9K95](1;;/2U&+.KLD-NK$D(AQ))G!"7H?AR)M,I&9@
M5O;FF%D>YD8Q,4;)T,QF*25%IV3:7XKU$5O"]]96+PHZ&)H]V&9O7^[,NEV$
M7"X[["B<>,M1,O2$%@SV143=CM<,%\<#L](E9OU:.0)#,Q,(T.I^L%"502)9
MMH;HF]J"8].G9B;@[*11(YB'2T[;=8V)'>N<$B7+.J%;]I ;)'["N"-JR,1E
MZD.[S.+)4T_HEKH?<"3%:(2I^:79EA9[JR#1+>*$;MG3%=.K+FR,VQ9#3HZI
MSD) DZ$G=*M!]L;J-#0]A/<(5YL,=0=/3!QQ0@N6<W+IKE;A0*P<*'14'@]6
M<ED'0S.>8'LXX9&N4"V9X5A:$V6N,@N$=&C&%9Q94<LK+CE.U+8<,C=$;ME.
M)(LXX=WJ/+E?\%VFR[6[BWG14<0EE\ ;<4)AG.5@6O(W^E ,^PLQM":CG9Q
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M!L 8F!*N]>LIA'$\+(Z'_<GNZC_.R'HQOV!0+Y]='A;GA6HAHS6=BZZCW59
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MGEBV>%3P*WQH D@IM3>13:<SX:,&;(73A0>X3@*SC(@28!>X$4#] 0HD]C6
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M/9?HP-&%JYP;/#L)4/TL&_=ES!D\.&N+@H8XNZB#\:T[T@Y :4&[*_QZ. _
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M2LR>$J7946$?U^%1HL1BE"@9'>1)<G^5\'Y0[R8>S8-UH7<%=2ER""@!?DY
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M@T0U?DW@^ROM[NP6_\,2Z\32^"LS/.%NH]$&A?Q.J;2N[[/DFI&>CQ8+(JB
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M6#/G)SM:5O$MTJ8IQ3E%>1P31_LI_@ARGW_ '3;\3Q6WL/S8[!YE45,*,Q_
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M7Q0P?6KLL&GZLK$K=[5*KYS0^)2'!A/XUU JP_=+;NIH:M;,W\]#,P'6P46
M*?V0GQO(VM.#,'W(?LZAWF*"LVGLO:FYLTENVP/X#;!L%"6,N#YE?6^^??QU
M#G>(C?3MZV^87;=ER<ME3^R2"$+6[B*FFS'@$^"ECN%UW2V2;J\-'%7X4/K<
M7:.KK=6_EW8%WO,I\RK?90\2K9+'$ZUV]^)VMX;WH.2YQNE1RL)4I+UD;2B%
M-LP"?]Z?GLKGODA\WR9U;Z3Y.+'@Q=*_R9'P?I+FP/U*L 3UR18)=7/W2N'N
M^+3ZNS<YFA+WYHOMB[,(=BWP*I!  ,/:AE 1WI+:B3!X7M@?$L:C=I=A-@"P
M'0&V+CO<ZQUE')9:F]C!R\WA*9OL[?5Z$74OA8 4]B^%F]P3[0\O3*"I+ZN[
M2Q[;I=L835M@WC2DV=Y^VNN9&8+;TYR;Y=@SE;:7=#<\TEQM6XSWM4Q\<?5?
MB*FSE^GX.AEZA^1A5N2FP:NV:Z&Z15U8YBZ<27 !OHA A9Y>$DK?_EIM9ML^
MRWVY-/M..M3+I\KWPO/5, T0!Q=EFZVGF;M>LX<@M:=_T*[8),1NJ+OBK>W\
M]H;(VQ<I8&*(]V*+?Z+C'ES#3T4DNHMZ/RCXF,)FJ<60316E\2AYIH21S[EV
MV$C'TIU!T> T;,"4DC.C*VFPC<2[F3] '/<OF;UL,?YT^VF_9<13XG',Z^O&
M09-CN]RN+"I#I$"T_&HFX'IB#O;S3CVB[S+\N&O]9 *\:XD]7=[:ND)@FPNO
MLNV0%GI'6R1[\DJ>KU^^]HTVI1J>T.-+J80;\V[KB!T"DW,'HKH+2N5W-1NV
M?VQ XV+[Y7I&]>?##%?4?6K>6'>'%H'UOGX"?"HAQ3IB4LHL>@);F0Z%Y6B\
M="<RK$?U7E1S;X\<?V(W>MGF^] CWY:^.'#%ORAN$=Z97[?RN]S.?*)4L!.@
M-=Y:%AUY-))TC&RJR7*K-$W^06[?"7;F='\LYL8=.XTD]61QQ"W[?$L!.S/R
MB)UE8S[[P5!\G_52>;R2DIE4AX$PUPMEHCENEA2ZY07OWV<]N-;^\E;[JVM%
MSUC[<+DCGNB@Q1ED<$5J>%M!J#&B:>U*@^,$M9F[8BYYS99#YQ:N?V.\F^YX
MFF,F1UD^+QL(1J78%6T5.BU8F8Q^+SWC,TBUOQ.]+/[^%*0R]U[S:=M_?8,4
M/N BLHG?I6@V!KGQ<EPD:7T^F2@<7F@5N,5I1?-H3FT'_.O"J$P)@)ZRT&S?
M;89QCJ-26,&:MJQGE1;2T9S9P!FBLTX.)GA\X,A^*'GOMZ)%F3V+\"N53EZ6
M=_E,?MKC9\M\1A1G/^.8F"4W*9!\C697N$$-G%*K-V7?L\?>J,IY:L_$&0CY
M2K'0'>@5I3.HLG:F(,E RNKVH9#M>R/'/(QMP^-GA/O84+]HNX]/> [TU3P'
M^H6,?O5ZP0D M^(.]$Y@RF6=8FFWE.ZKF+6Z:DRO2:SG]64QF](5$JO(J=3$
MH@FP'^/(!ZEN$8WIG8C77\F07XRG@;"J#4N(LBS[K<E \=+J'U_Y^O,@7KOC
M+C.-O,<5R@4BUS%FR! FQ (.OY^1\WYYIX]WK3NI&H#%50/BJ@%1J!H@A#K-
M*YB("00N\AB*"3Q!IF2>(5&$QT@)E5$)%3!)^+%YZN8;78F74F2?['0K =>8
M3!7/&C8PK=."@/EZY)3FJ88O+K)(LLA*"ILK(EH7CD31UT/G@6.YTYJ]TN>S
M@ E8=X+CK1:/'4ZJ=WMJ?]8H8ZP_F"0S8LFP<5P%(P\G+914OU ;SRFDD!WA
M:X%LX+:0!LX2\GKD@.!RK8Z4G.E^%1/G1$O@\SX<>?#XOI^;EJ?U4DTWE1;E
MS3.31897P4CR]<A*9U1*$:Q39E<J3KO,:MU>B"TPDGX]<EF6*L8RFQQRVBB?
MJ^41SVYDX9R')/FF6>>+UJ* K'P,Z_87K<R<:_'$(4E.8*P7_%)JLT)C8%#K
MJIGD;94G#T<:T]YRV"]-6:0RK[)84<BJ_CP-1AX0;P>YE5+7%Q+2:-9-UYN;
MMM</P,@#XN>C&IIUBZ6%7AFWK(5'63FIW0(C#XBO2 I*%!M6GJV0_,JJ#9V)
MY,+W/"3>JCF3MI<JXFS2P,<C<\SS.*?RU"%)Y"(H<4RS7>=\G SX5J]7HO
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MS3K@Z,/F!YC&>;)M]\P&V._1OJ'O\-\#:D^F %<6BS]1D$U]E-C^NBQBWK#
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M2"P#IG7B_M+O539$:5*NXX8HL!33R+K.T)]AM30$%EC:D'J@\??J-]\JLL1
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MAM596-UZ6NX;ZYO=28;,#!.-?@O,.X-64HRK5&_5AD@2)Y-GD$0'Q@+ 7U9
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MURVX+2;8V-F97M'D;-P:^TO:"W;X*1 L&31$N".$=X;[>N1K<_98E3BLZ$G
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M@CC=/?T4NMQ/[.P9I\&XST('83PMYX]_0J6]_N)(6/B"&,LHQ[.*?E:X>4"
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M*H@_)VFO=?I;FYWO4L*O7"-QE(;#\KW4-CU2FX2R*+6M9#,GK2OT=1H<>#H
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MX6U)'8R'C'-))T9U^1V[;(":<P$\P^VX51RZ2F<Z,]S/PIM%&/&%59#( D/
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MH U7DN$M.-C(W:@/_ ZBV_XFIZ0WPS9AI^M-8-KM9K^V9PL2'[ %.^[XHAS
MKHV3L+%ZW5RO9J1YAFN(7.>U/*W)K_0?_U#QTR48$"HFFA2'1L X3;YQ>V43
MS7S')#1&;??WI_-PQFZ2DN#LQ;<:,9#WV[P;#G!M9#A2D1 D F] X7M-S""3
M"U#WS68P?%!N?A*:*#( +ZND\IH"3@)S)+.I2G>QFL\K2K%?H].B5&I 8*;2
M+]0I6*(;N_&EN'/,=NX.AAH9S6A+$=B.#<)2(F78H][G4?SM2R%K6KM')Y/%
M.5DISAO58F:H]N"E)*C3" XQVW!71=,\X+('/HNC&1)[7E#$/,/2)NQXY_\J
MXO^-Y&5KU9 -<C*O- ?T*ED?%PEZ?>C<W_=E?ZD_U=,IT%  TW>BXO\%93\\
M\<'E[/E_3M-F-!4)L6C*U/$ ,Y?\@P0+I2VZ;M2('_EVT?+^/"]N _#H,,/2
MG?Y$$('Q6#" <[M]N7[]\8,?T[P^$[+Y"I^QZR9VL  -2H!J#3<):C7X2@5W
MRH[C/$8ZTJY#_U\W'8B =0RL4K30T#O)Q(YX-/5'UB#0P9DQ""!/)2H=UI[-
MK>0PN6I,YGHK3]_(3 @$88C(Y6C=[IOHC^]$A)\[S""1CL2>O=L/,.-.PPRH
MV!,0#P (*#Q23T \ B"BD2=%/ (@GJSI00#Q9$V/ HAHA'Q"XHJ0^&#WD#?5
MUA_9QO8R%_ZFK2?CGVT]2:8BT8LT^*BM)7^I@?,3\V\$Z/>#]5R$\:C%[!7:
MJY*15.I;MU>]8N_=WQL-[ENA_NMH<*MVNK=GB!]#"S\,ZX3-G1&\R(7K#4K'
M+<S_.D<3UVOF\9.TA:O7KU^VH[[[0(QK7]<;CICG=3U)[TEZMR*]RXZ&;WU?
MW\#VZ;N!V; 7F-4!"F_OLJ%0B/8[*+>/48W\%<1_[T-^M;1\HT[X0F; N\O#
M#E,1!4M'R26'N3_[*8@>Z= .Y;0]PL%_1&IQ-) 35!\O6V:'%BEBN>Y7%HFH
MU1^WUG_\$XM0AZ6S3M+9D^:>-'=',7DMHKM0;GA[HK/(KETK)A<EEISQE0QG
MUI1IIO7'/]3;1/=]S/=WR/2][*J?;!K\#KK_.SO]?EOC^'V<YYXEY!_I"G*1
M>WDN,^0Q<VND3PWZF:OT>#GM=[=,HS\5!:,A9(S7]2B.BBTA>(XSBF\ZZ.=)
MXS^1QA]2O;AG"X2O)O)"NS]C>"JY(D!G*RH<!5[K# V)//$VD7^'_D#W* :M
MNM6"=LT="G@FF3N;T7JB;)4J\^R&D :#9G\SYULW2N;^>(\5)P\>ER0YB=J6
M K\ %S2"90RX<USR;R.D0(58L137?^-V5W?+)_%'7A&EC9+L-3%T%,=WJIO^
M1/4/4\TRX#>-?__UPS/%4]3E]IC/C*<OR\9,II^ > ! 1)^ >!! $$_6=,=D
MS+<DPQ<G8 Q1U2.CHAT$RQ[/9EQ<F?W^Z"PD*OVMLY"<R8>WR4.Z.14<DS[4
M0J.W]63<&-4?W)/QY:?_OYN>YPTI^;/Z%[_+4?FQ_L67#&AW]H21LT =;JB[
M1NVK:QKJCW.BUW'%W"02G#[NS*VA69#K^6Q"ZZ!N8S%(U->=LWH?MD1^!T'[
M$('+W^*03\[S)9P':;[=M7:"X:@Q.AF+U<@M"S+1<6%)F 9/H@:##L.)IS_&
M<+Z1@A1[*D@_2$%ZI-,_F=K7,;6I?G*H5R-+- F)2V6)?J-;UK;3XCJ]IIW.
MS>1+E#QNCOW-]"CJJ4?]9%[T9#D/RW+RFJ6?X#@%;I2,,K6AP))+,$Z$E5QQ
MM*"=5)-4^GABP4]1H^)/->JI1OT6:M31@+GW*PKGSG@'DNU.@0[P9*6G!O$1
M,KSWT-YW)K9]BLCN?;8K$^&U.- ]J%,S.3DD6J:E@S/I2$]Y^Y2WOX6\_:$V
MQ G;(6N)TW2[U>ZPC?(ZQ\3&Q1C#KT<I9#LD7XCD!ZV'QV=S>V@?W-A"!SC+
M!L$?_H?N]*^0I"PL9R* ,R'MFOV#OB/%?W_]Y5X>DGM?P@7NAS#^SY_$\EC5
M*YX# K/AX:-.DLVIJ/=VFJ8+A:DVE]K58:FLVRTRLQZE<9G.2S2:..)___ZI
M"F 3,C@T0&7%R18>EOK4!9^ZX%,7_&:,\0Q+/,'ZJ TYRK9ZS3!C,['->JCD
MV49_@@8R0MX7?TE_- #_^!SN8[H?;^DZXH<+3<> AQSQ<.J47Y3SU N?>N%3
M+WQ<]I=U:/D$%U2(98+,E]-#)F$PR4)XI)=%-#HZZFB U DN^&,UP,8Y]A8*
MA^ %N SQJ?G=5O/;YP@QR!$$#0W3N@]?_(+T[[L?^+?3!NL^,9_@B.%I*3R/
M:;/</&QMEZU!']28$9Z3#3DB]1)_.Q/<JVI_%&H]**Z_?54[O.NL9IAG*M<+
M\^F,!,/%G,B*2Z+9FM2%,O<8E>L=:[&0\1Q53G:%  \/$I)4!^40RDM&8,[;
M;U9PGDA'$L^Q,U<LZWS.__GN@'C._WD40$0CL<03$@\ "3)"1)^ > ! /'G3
MHP "\J8G)*X(B8]W*;^LMSXG-#WXR(,KS"9+1M*Q;]TJP^NB$I@=?^4Q9D\B
M^9TZQZ2I;TT.5QUC=EEC_::\\I>0XSG<[''8Y&%D"CDEG_V2?U"_Y-N&F=[R
MC'SW,-)GXQ97B2JA2,>),)*H,M'HIA.3B*RHOL:6HW&F8*Z=]A[1E^3%S/);
M$/1]!=R3H*]-T _5^_S&!!U-!PD:_L90(Z,9;2D"V[%!6$JD#'O4:]V6H!<Y
M6GJUPTV!4$;Q=7A1'"],:@().H$).DV^-RS\FS4[7YB3C1,3SG RI_*@,P7
M1!WF9<VP=' F2JPE.H-)!_12;$>6H\NBUD^IQ9:#)I)J 8$V+SPW0H]%'R^F
M/':N(&2@._C1867B0W'E5"3Q4?\H\720WB9X$_MH!^TG)&X5O?EH//,)B=M
M JK/'\VV>(+B1D21>D+B02#Q9$\/ HEH)$T^07''\/);ZNN/C)Q=UA._:<CD
M\^'E5"0=_=8A$WIOL%8H%GWYM7#RDRA^IW!R+!+_WH-(KAA.?DM)_=%H0*6^
M.1J\(W!\7[Z7_A#T=[%C[(0UKC=TZ;X*P!=5:E\V<G[&(=]R;WQ%J?4]8'MC
M+OT0L/TM$/@M _BA$?B&1?1WU\'#!N##TB;L7,)?1?R_T59)#[+CH2FP_6R^
MK%5Y\-JIMPZ_ZY[<51E^:8/.KVA9>#^ZPLE[!J/[40"\*.YU(NT*0SVLB6$+
M_L(9!M@UQ+MY#L/W%+=7S. XRD?\V:T!')E\]Q/_+KT!VNAP#9$U (WH^D3^
M1VLZRR1IK282"IEM<[6.,&@0+6>P"?62CE]J"W +@OB.RLN3'7P^XPMI.'<_
M\:.P@VAZ5,@MQV+F==*>-UH->;#*D2DK=:T<L+?907]);C9#OLFR9*M<"!?F
M1GQ007..$G_\DW@AJ#?3P7ZI>]S=%;N?X4Y]A$/^'A;:U[@8[GW*;RF4G_AZ
M-X_"TX'P.0="G565]2A>YHE"JS'-;3:3<;Q(/[X#(=A1T&\G^/0@?)W)\(,L
M@KL[[7^4_?^.5JGS&5L:I4>]Y5S)K@UC,IT06GT]2ISOE/IT #RI^:'TC4>A
MYEN;[^^@YC#3C/?KK[T<L2QT.G8[K%7%+@VI&9=SD?'CR1<_RGX_K5>)8GV4
M$0@KP5ATILD6RY-)M;'^7GI5L%/S6ZK5;Z%!7<&W^OLUIS\5?GFH[O0_4_NZ
MV)FY'58FQ=*VS3 248[7B%:OEENV1LGW-&9^^G2>-/^9&,OO2_-?IJ-=I/E"
MI3=H$GU%9_M)0LLJ;35<J4T@S2?PD)Y$]+;CW;^9_F;7Z8;4SLXADV:V_%+O
MOFKJY.'\8F='#SDS>,]-&9* \726/>/KSW2;GZ3PG9I)V5R2@]::XXGE)-8%
MVM@V^Z.6,Y/WK;EL3S_;DQ$\$VV^HQ9X@A$,AL:&KA79#)$0JI25*"9BK?P$
M,H($&LY-1I.?[;AT]#NN_ T4-/-0\] 1KDR]YC@>)J [OT5%\]F2)9+:0=N%
M>#I]6+7\/_]OKQS[B!9<I T<RZT#)S'^3D#8J?;F1/CFOSAYS=F&-X>-B!!^
M8=]?/N*CBPBE$7<(X1^C1"06Q_=Q=)FH]U#@RO9Z"[E?VV\OA)=]L^C<!8RI
M+?XBHQ'4ZTB!O[KGHJ).6Z;;%I]CF,1V@/DO%YKJB(;^M]O(GJI&_6(W*6ZM
MA8IZLQIN_;33G[E@X?LYQ-\'VREP<)A41\(8I--CD!@!4HR.**@^C#A 0O;!
MB3R1CE$):AS_PWDKYQ%W+-^)JFVEGF"6MD"71^')AJBN48.QPR>C<\'<Q-)%
MFDA8B4EMW%9:6G\RPO.X]I]L@M1H/#5C"\8RC&0E0X?)49N&3R8.GS1L<3(.
MEVH)0FH5<SG2#EMKDQ[%1L3AD[Q15(AN-+EE"C4Y+8_:=E-OK$?4\9.MVF"9
M:6>L&=L(DWQV0582KQ)*$#XZD;#5.O5Z5MLPE9C.$EVYQ^H]E#OHW1+D3VZ?
M,[<YF-,3;3G1INW8. G89;$]&\@LP6[5M=OK[.RW+G9(<YAA\&L/H]+<OB%=
MEC.F>5E;EW9]V-[L2\<*U;(BSF8T2_*U3@8L"M4)_8#3RWAXMA#JYG&G+G-?
M/9DL&:&>0V=VR]ZS@1SYT68T3T#< A#1YXBX!P$$&4D]2>(1(/'D30\"B"=O
M>A1 / >)7A<2'^T6\Y;>^B.[9%WFPK];Z[B8XP1[X*9()R:/_7I_N"?F?YO&
M8+\BY.^=3_-5?."7;(-OW3#MBF/8R =(P'IPA'D2U7N5VF]-5+_:A?#FTO5C
MH@:YVD,+#MZ^J.DA3M$LU31"DLK+%M(JL",:A!3 (=<[<F&CL-51_M?U>A?>
M5P/]0D[QTP_YEF_MH5N_/1'XB<!?,VOS&_8NO(-]N*LKVX5/+0/*I[%]F)9L
MW#;[^#N2]_62#K^<[F^=7'QG&?63YZ\V.1OIB\:I@K&8F0\7X[$)D4TUJ^O<
M:V)<C]).R[[H2YJZ5#SR).HG43^VW/[),U@O$'5'&N64)6C;;".AUX85?9/8
M"A.G\5[T)96Z-%CY.\QAO4?F6%.7H%5N:M@(YP1M@1$(6N!T)QM*4>0+_D-6
M4^ N;;3G:/)O(X1*]D)@LP JM-+7G!'ZOQNC8&H/!5.C%ML:U;9:)L4VK,["
MZM;3<M]8[Z%@_-,H:+3A\1CG=/5 "\B$@XEU3M='DWHZOEPI@QE+&HLZGTPM
M)F-S#?$P<ERD$H* E-&E( <(O$['U6ZCR K8BZPX?XA%7T+HD)%0^_":=<!K
M$Q6"6@C!Y3B(+SJ'.U/+D@I"8\Z0C! *R&*@F4!7$"31SXX_!0(AQ/&\IB-N
M)=M[L,5KZV@WZ$-!$D4 H<S#58&Y!D!U]&(,^(5+HG@]]+2[+0]U]K #[IJ#
M8(&KZ7!M_">_9T/$H<^C--1;Y7]ZX(9'5B03GX%6A2Q^]P0>5@)&( OT* &4
MR!5,RJ3I 6,EM\F9VDF5P_-;)8 >>=+.T_ %]]N9@LNZ9H)0-!H)P?\"EX$!
MNG<=(=_M=@_F5')\@QA?.=V&F&#I!DYK'UL&Q'C#V$=A[&M%OD7(S[B)#H!S
M*G/*F2&%LSVG8PAM0%$E$0I]C+,+74,L6E.-2*@)7V%Q$$OA&H;%3P,+[;_,
M6=!9")+2%%YW:,KIB@RWA2\2(3TB.'7W/D@!"TXW;<P)()I!7@-?@DD-4K2.
M-FAA.H%6)WK7T1<CH8ZF (^J=_L.K2&+@80%(>FMBWFZABA0A\] XU74-05^
M).G>)ASV!,\,[]E R_*(^;WLO]F](KR^-X$[A*M%?"8#@>.1/I8BWH5%0EWD
MV>4VDF(IH86&LH,E3G9]P.AQT3(AI>T82O!^(;#AC8X1=UE:$KH4>"*%FP,H
M6P3G[<;>%4#>IVHFO'9W3U#4.SOP5IPB7B0;FH,GV/<,ESP\:0!QUI(Y#4GP
M!P&^GS<UW0&L)L*'$:+YB.5N<6__@:7M2XMP$TY2#3/H[-XMC& '$#;HD('[
M5RRAA&G.M R$,Y#05G EQ&AW;X"?[W;I"'?1DB%J(L9L8B:.+LDT'5S+0CT3
MHJ0J<?#:]84&F2R4&=QZ__YX*/C0[KC=BUR-8.]$WF?P5)!;(Q&RT&2)A[C;
MU4("7'F?CA!4$-Q\W(<B&_(.E,BN&2;>ODM)<$.&A6X2G]HT98BQ,B<I2"[*
MG.E@R"GDW8%T_T!C($M@Y=TWOB0.WNV*DRV/QHQ+JR&4@YB&- I\ ]Y1H(R%
MH@"1ONT'/%S9']+&4*7G',*[(F.](!V.8W2XG$@R(=#Y8SGSQS]5,($':NH:
M-(^0IH"DP'VUU"#04"&#R\!<<,MXOZ[B*4!IK$MCA-= U@XPV->?# =&D!M@
MP#B,WF&'WJHNG6#4@%P5\CXL/%QDX3";19M!)5.(#8UQ^01" X=6X:]0(ADF
MQ(XC3N0@R XIQI@P\;,FQCQW><2 )*3H03J:@+^AD%E#?-5?0I(($6WW#3>(
MAI_">X+4@5DDA#QZ']PB_I;IOQG'W!#J0L[L\N/@(E FB'M4ZG'5X_,'3KN
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M1 U52+ P=[6SQRNZQ;L[L_YMT26)7A!W DD7!6YQ\8Y3:FMJ+Q>_O'83P54
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M*H[YIU#L7R'7+0K.>V'A/=><5CM<*XE)7+N5U#AMU$J66'AC^X+].>:-K]&
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MB5,)O*?A<U>&CP='Z)=55B7SKO3>T_PY,2U \!18"N:(ZET1PAW)@YLW@'*
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M\(W4ALVEG"ZA'-K*\QBU8+'DI)J>T;4_9O./])\_ Y-ORAN#%/U-LJ%W]WZ
M]4TD+?<;:G?&-?*,S9OQH1BU(,X^"?O^ :OETFQ_:=ZXC!J\)0;Y.*XGH/,=
M7$_P&T<(5A6MS89\8R5%98JQ5D+K<-<P&+L^&7CP;\E\FTVYDU?0E,P9MB7T
M1*\6Y>QNJ<_/:\Z8T=PFJQ=AZPD:B PZ1C/A#D9/.G]HQ781 *W3&Z]0L^&.
MDFNWZ*K*%Y9\N=!6E>; &/^Q2HN2U]%IVT01[QYDJ\6H+7-KI$R/L$8BC\AR
M61TKJ7JNGH &+(K\^(7%CBFQ.[A#>=-N_CXO0=Z7/T^O,N15?A5?^UI.I@<+
M;^4":/^,J5O6 5NS/9F6',OIQ3F1D>WTQ,9%E7*%.'0S@8N)4R_$@=Z$]WFQ
M\SMO\O9UZTD9]H[X]6L.XI]S[$G]1>M3#/M)GY&-U\FTRL3'7!++%7!]-B$T
MO0;XV/<92?Q,//SD@*]RP.D%TET?QY7ON+\/_.]72.Y^;I+>M\0W+:(.VN+/
M.Z&;MMZA!?#7-S#98=.AG&4YTA"\&FR@K\K]EDW>'P-BW6CS4*=PV&92(J?D
M<,94D49N+!59)9HR!1;V.04F.18G7C"<"2GSO[_9Q<\)9/,=A] >+_[]M/]?
MA<)778"E5>AWQPO-XE>CHL.-<Z6%&_<$!_ !Z!@1?XQKH^_"/+<J#[_SP=ZE
M$W)7=RNG6?P=71  _3&2Y+N](KB\DWS]0M*GMR)9]6T7;F^89Z>D-Z1\P/C@
MVGJ&8=J(B&0R%<)PY@NBKKL"BGI>"TV^D%0X!'G0:WD(Y^0A%---FE5/G^0S
M/DG \H[Y9:^DH^=$:93%Z\ILC)4=9U[G;=<3#,'-Q,>RV6[?2/VN#'/E13[&
M23Z"?+]O_^)&[T/.4%F#(<_*FJ_?HNS[+3CP6X:Z _O(WX#C<NG2&V#/\(,6
MLXX+6A69&;FZ0U=3LENX8E;41TIO<DVK0BPH75?FVBA'.P6;54D6K@KX,L0+
M13 O*/:QI*@[OH+YQD&W9^W-:6MO/L3G]U%[4S?%Q*A?G6A*@6VS>GM2J7<X
M%Z[4=U<8^C%N41Z)0SY>?/-A=_U"Q3<MR8*DK0VYI2'!8%U3AQ]]OB8'W3)
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M8,!6-BW[)0)6 ^0H9'O9''KB S[6:P:IR4#H6*(IOQ*$+XNAS_/>.4/MI\%
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MK'K+X3BE8=,5R5#ZW;QQ-!GR3 ! G)><!A,H3<?+8*S8$\EL3D3-+]6QRGK
M)GY4YVW:9',@8+52?=!=8S4EN:#Z3FXNDA-E+%"P.A:CF1>""4,U/1GJ9K7K
MOQY0#O@E) +?2&TD@933)91#6WD>HQ8LEIQ4TS.Z=A5)\)'*KPO*@<T=;W"I
MX<7Z8*AO"R5V0$2TQSQ"U#MK0TEBO79TV$E+HQ(L82<A,,5.A[(# N*>'>:,
MG[S_S9R3BR"1WY7\^(H=\=%L[L\(DQ7+K91E,6OQC48Y@R1YCI\J-VE6^"7
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MCY"B/DKQ8.>P/;A;S9)@TR%]('MP[Q[(\#L(K6^ACL.MD([BJ ;?>H76?(D
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M3P=G =<] $\590V\%Q"1O5LF!([< M(FPAM@BZ#EK4H>\8#5>GL ]GY?VHE
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M1ULR'F/N5(!]$HGLANRN"W9 N!6[ZS::A)!$#,'O&@G]S%U"GDQRIC._S<8
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M6)5/<OTF9L]#6#<WF1QPMFJ2NPEPGJS,Y!GR?(8\;U ?W5JVVW6M*6\WAM)
M]^,H/\&")%.5->GJ><[W:( ].>%NXU.WRPCW:-L],T+OSZ+S:GB>9</?S3K[
MQJKGP6VMAS"IGN3[30VDA["#'L'<^7:1K4W1S#.R]8QL/=-T[C"O;W,5'W#R
MQ]-UNOD>.*%TDT;F73G.-$K#?)(>"R@*\_K0%SP>;GSXG8.#UQ89]VBO/HS(
MN$#^[[G3^3XL)][- YX:I3J;<^D:ET0[^(SMY-JE40T*#*_'\H6;M]_E7?<S
M4/H0*7Z7$!=G[L;\Y^*"QM;M7)*UVXA$9J=<5E.6;-,3%W$@+N+QW[95ONU
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MJ4M(IAN(JKY%_X0C4@$1VC)\YA'15*3QW+K*N D>0W))6>)4%JVY @4-7^1
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M"O@5@= ZAVL$A<DVN5*AWV+I)\N3/S$.SPF@B0P=Y#2X;80Q6^VO%IZ)-7^
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M=6OJF+ITBNBNZ '0INH*: W]T5 )P SD[]W#2%_'5.IB&T(#E^@5>IX[G+9
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M?A\([FRA[#59T['11BO-PN5]_$O\Y9*+_1Z7\\ZELJR<]Y1D[*@PI2@S1D2
M$8*0$EA%Q"AP@JE$1!C!5"(JG& J$1%&,)78<=W<[QS7O:P)NECY8UHX-_W3
M\H"2DN+%6)<'W'3A7*8DL:F6^4?+4(Q58*W5<AGKX\7Z-9;(9:R/&>LW51=W
M!VM>N4=3!*[%]3Q;;0,'CD[VN9;:V>S6E]TZA3O>^_(=#-N_3?4SN1X_FU/_
MPQS.R7#^#?(#W1D]H^BW*:]BL:9B?TO<UGHQWWC2NFY)*29S5]U2YJK]?EF?
MV'ER63I;8>_)'\XFWT7"Y<[9F&)]W@P^SN3K2_ZI!,\KQHT"P2ONHBW^^BTG
M,K*2$,39*FY[IL%;.'=_>(HYLUDS&HII61>*F34^A:(X<-Y@_3%3S%1:T5/,
M6^^B_E%]33]VX+/Q<,97+LJJAK=5R+]^2XF,(B32HL 4DRGFGQ]#BX9B/@']
MI'C?[SFU:OU\4.KWS\26'<$5L_2BI.O"APYJUU?]W.LP6;MM]OI(,3-8,86L
MDI#E18H9@Z!5(>2L<WU@VX!L=(L^+(U$]8W#LR@[]<%+E@N?J(SZEN2TG2VE
M+2E?+;[?W G5N^IK4G_,1\^2?)P\=J2"6^[R</#^U,@^\6_%)J[=B'QO,9%-
M\PF>7\[W9GK(]'#7+O>L'K9/[OJG@VQ5['ABYKE;&]8SG[=WT=/#KC[TQ*O;
M^T'GNG5?*5M61L[=8CV4F1XR/8R;ASVKAQ>6TK_)-L^OBU7P\NB]-<\'?#>"
MD#=? U[E^O+#Y0O&P]W5!3#<C\<[6HQ\&3V,<\S\'CJNK:MXYSUUN[%0SO6Y
M8PSG6:3\8+WTL7P3Y(_GY-Q7:[Z%>E,>!_*U9!F\-WRX?+!J5[</V0A:J*)\
M?99^$*6G&NBW^#O-_GCO9?"Y).RQRW(B+2\JB\-TF.EPG#W\Q3K\TG<^G\X>
MQ">^VGLY.WUUK\#@/8(Z_)Q[:EP5O<^;SO5I\3)[=O%1MN^P#F-O'T?OE-ER
M+DR'F0[O!SI8K,,E54MWW_F[&[YP=_=44Y-%X_PQ@C'X:W S>'E\DY]KF=K-
MY=5[QP%G9@OI,$(*LH!T>$[GL5A%X(O52L4_S,OB#''9!18Y2Q.=O3&!?;FZ
M>'U5U4*3!_S+2;%9'92;]0A&!!N?MCQL"+D;_KJ1XU_SM=Q)Y1%7P,1^/D[P
M+>?F,S5E:AIUIWZ>FC8JWL7@[FU@\=ULR2KQS[>#UDD$$VBO@IS3>- 6._#L
MO=]]U]/U]P)64^3*RWQ"S#(U96JZ'W[[/#7M%"]N^49!.RL^O3;XES0HR.I'
M!+WULGQ7%QZ$VSZ?*8'2Q^UI,7MV[Y>(3XL)05I4'CZV0?VI?C@/E@N,/8LC
M;&U[7I2+&^[>J_^^3'(T[,!C]>+4;F??.\5SP3#E_$OU4\O@"ES(J\XF,EDA
M(0ALKSG3F6AT4XF&SGQ<]4Z*"O]6JW5OFIK]<LT/O3S6&>3B9DA.7,S.5A?>
M2YUAFA,)K_?[FKK1T)R;1NO^M53//A:[JEH[N1.;@[.3/BW)G4E(N5R"%[]M
M8K*KLKL_*R(R5<$R,E!TTX4;25+#4UTD.V8K;VKWN$@,U/*(I1]$FDYU1S4L
MQYM7FK&O=7OMGFVU.^?@5GW)6,_PNKFITHPS9W^_+O*)]W%Q0C;UU>'IB4ES
MA,Z[J$5:-KE;,.2R09E/MPTYK+# ''*@A^CZ 34.<(;>U?'F)AMJ'K54NHEM
MA JYGH$$"C2;$'V.9D)^-$"6PH7&<%G[UD.LK3=>3GHWO":9Q?/WBOB>O[@I
M5EY:7U@W"?N=OL"-7I=?O:?L7:]\7SO7*N<W +QF^M+*_01Z;FMPC.P3/@8.
M6A#9+!^\GP '7B+2X/3;R7""@15$A)$12XI4.DO MNOG90L\9D$>\MV39/$1
M7A6SM=;=K]_";)KZW[CP:X@!6!6%[#\.!_T!X$9&D!1AU4T\#=R*%5U.B8_>
M!-<Y*0[7F!TQ"XE#,L2L/G!(_U8#XA\UAN0F$-W5?[P#$<DU[MT#M@MM_"FF
M+KHGQL"<"IPV!P<]] ,=31Z.:LE^*1Q]:$/N_RPI"KB$O.1U+I\>LQ6C=CVH
ME:Z?C,Z#VENS)"33*RQR$[PNH'6K!9T1NS,A;I\.+]_<JW*]5M,_+\Z3%_U^
M[KK:^O6;3TDS[.:0?AOH18)SO 8N >R7^T5_,,V1FZ.V*>UL:A#QB?R1*#@0
M]PDS52H/#6C"INYBOCJNDYI;U'T7YN4GR\UZQCE1>C8W-?!D;AWK8D26Y]$P
M--U!^C;$3/?K]RX])D,WX:CH\)*N#;^\:T.K>-<%-2.K DC7FTT ZS(0U7JN
M*:-7DIC)-;(2$-)!->_8=2#([7<'@N!#UH(@)BT(+EW8S:&ERD1+E6X"W.;$
M 2T;PBY^9E]WVWE51?+HZ]NF;5E@FW23F)H&]N$G3/)8B[-B;[+BSJ3";)!G
MQ*6?Y1@F)=(K6N&'\FI1-2"?Z-@)PDOS!-TY3'B.4AZO^ Z'/"'_+?&>T0_.
M,+M4Y MP8]PSJBZTC45\FG>3]A:O[LO:_5VX'"6T^J7"JTY#;J0S#3%7E[,J
M@J1"KEEO"#E8AP!DH*3FQ*PXV14#*Z9M&0YB1L6V5.35XN"+E!9X,;=6=5D!
M3NZ5,E$$G,N'52H@.E&!,=G7B8Q#X]41DM'5!?0N?@##;R2"3+4V4D2"04;C
M[(W&N4WEO 4F<@^P/4D@%(5< (K:O!ZTL5Y:U.X02X._Z $<1=5[H]E8GLT5
MVCIL<L4!5&EKD7*SJ:OH3G]5$,3!%QNS7_Y-[DM_.392<WXY\^7?":Z-0">D
M1/5A*Z0Q@P\$71PG&-?WE.;^0G?2$-HQ(<;!W+UG0(=*E""!I)#^"_Y-W^+?
M"6DM_-&87,6!2NPTLKXNFA@9P/S>)RD. W\-6VHR[ G)6&[,B84T7T15TN<%
MW=7O\>*V@;LLG1;-B>+*$0<X=%>*X(%CF<1! 0ZZ.<&7!D*:1FI[(:JH+3^3
M(],G@5#8FH0U<Q2[ :;I(7[:L&?9+D=B(\B?-W$@A?*-PU6SN>:(\_1*Y P@
M /\[M2FJ9U.S-2!W!H$G1B:F9L2AC 2^.R(MISN(2$[/,M$0#4C"3]#!D7[=
M:0=.5!<@.J/_R7L-OF.SLSSI$UAY'$]%!A3:7?S :8/#^;:F28VB;V;0N_D6
M)L5-SB%!>R9IM '4CTQ# L\"!]QP@-:<,DM?VM>E24!BC2.CI]HZ^IT.. >Z
MF.!H:4&46*P,E\&C_*4]B3]HV<3^G]F@"_N6W<%"SOTE\H+T-R*SXXT#DKB*
MC>ZZD&"E*N:V14+E9;L%3/W3[V/ES_4!62X-(63Z*P<O@B&SC0-C(?J,6;31
M:5&C'Y+;.69\>7;@H&W(7D_8=FZT5&U1*:-K+A[:^K3=U2ST!--R?;7#05.T
MYKG8;!"1",SS_/B[#5NZ@QB%.-?SD)E1.3"&;$T=60AT!;")-B_-T10W9[7P
MQX&9C4?K>(TWQ'$<^ V/=JPA*PZSY]F.AV GOJ%-S)@_XW'FEIB<D>D:JQ.5
M6>1B(J6<R!+A,K&VA=N_(E4SAB&!GYZ5CF^"6).GK+D?+8EG"#UP I^\7J?\
M+O+VH^9BK(),0N&%%5R)'8'QAS;V,\?-"DV+4\?C7\T"4J.I(D'%$J[1Q"DQ
ML9;CHNMPD!;]$&=E1KDK\AOR>)R0M/T$BY\O0P8:K;!VR.T=<H;>P7E+)-0S
M/TBL-MZ)&(0,,FE!E91Z4VWFZG)&S=1SLI"I2U!*-W$ 0DT+$S&(,E(Q^]*D
M&2J2YN(%.2.P\,/ZP@\GX? #H3<7(G@$XE<1R2_Y(IR!::""M%17M0R/!%I1
MZXH,Q7I3DWD>B7!:D=,Q3=[@;:M;2]YD<RGIB]P-3;*PY,W!)V_J%T8GS2N"
M*&9E96)=J.3O'RXO+^L92<[D^,TN!XM:(DQ;+3PN:E?1Z$)F ]M;@3_5T?+L
M6K8S0K@^B'70NB;*BL36M;6M:P(?7M=&E$_,1A?09R2^8-G(9<'QD7/LRV!'
M!NYL]4/( Z(W./PR@N0-:%A]NC5-'R_0R--Z]W0["!@@7*'C/!W^UU2#*9$O
MD0%!7B@.99(6V21\BL,Y.B%&Q;8&0ZZ*H!5%Z<CU:Z K=0.&8NC58@$[K,CG
M,R'=OD2^PK="N%L((,TMA,15Q1$+?-*KC9B%Z$PN1C\71)[R2$/+ 4?6ANF]
M5]1_';?E7MB5>V-P_ULV/?E./="L'@E (2G2B&$\\1R=!)P*-#I%\22:ONI0
M;QST>@;&F1C3&@:GC074\L62_&2TEVTZ5-8;I1G@2*"M4+AL_/W8*?>_I]OB
MEADIDB)DGET:/L)/[<,&LM8D4-[O]U,(\;J@99D(;R.BJ2G5ZNZ4&1B5F&2#
MF(.4PVG2 $$H2> K"Y%P&O\:6XQTBD]C@F 83C]1DM>AD :.E: ?:KYZ$-C4
M!SK!/4BAD!6A$0!G%'S4G:6HC'034QD_@P1;P]H]2?=$D*% ?HV-[X;O@NPS
MO=;I055OZE@.&]8'V1&7P+0@NC7 Z_24L8 (Y_G/]?<=DD@(EHX2<#3PSIT;
M5@,K-+ [$"$_]"MD$0@QN (&H.B6D_&+,>'"1B,1\&#>'">SU*J: 1+,U=5F
M1JG+Z4:FKF@ UH6F C*"(D( FA.> %E9A9%1Q^$8:#K^=FQ%EJ4T6U37MZ@*
MX45UO)*&J;[+( M;&.<LC+YFP28/(#[Z(C:D;%V69*FNX*V'<D[+(->SV10U
M95:S1#\D.BSW3332MMZKIZ6LG FTBIPL&0%$>N0(R:L!>@X\#EZ,8=ZO;TH6
M$8XCY/7UZ::LN*GS2E^H]D0X-(0-Z;-#NB&FYIWJBLY0 TYR(U82!(<8 )#L
MG9"MTS2S1KXG:\LX-D_>^D=2PL*++G&1G(8*/$T<.6*&('*&0%-%T%3QL211
MRB%# !IUH/)JG4^KO*CE%!4"8=802+Z@$!' .4<D/TY=2"N2(K(5=GTKK#2Q
M&\Q7S@FB3VCB@PW0NDLDS<>Q =3E+M&T\?$4N$L@RW0QT$5\K&Q&%Q4MG04
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M- [^L,H&J\ 2D<&20X(ETRW3!3XJ98R7@R5"ABN^>XCA4V!D!#D<C#E(0_0
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M\P-8XM_39LADKY%)-;F,#W60ZW+DP G9OB5FQ:4VG1PDRR(&4%CR)#8@)<=
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M[$'T!UUU#UL(J4 ;:ES%:QBZRN55%5WJ(I)S9SHN9<9 "P,M;$EDH&5?^<I
MRP$PF8&6 V R RV;!"TK)]T/QO^++VB)3 V!,6BIV+H*^P I4]OR'%BPK!ZT
M'89<&')AZR)#+HRO#+D<%I,9<CD )C/DLCGD(K-T2Y21"\4F_ZI>GI?R#[7[
M8K6N2)*4BP HJ5A]:&-(DD>B89MPR/VEFZKA:0ARZ&ADZ%+@>C;D>J#E-^]
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M_H9NC6?LSBT="'OFAH&(=-5"O$BM8?!?CQT'OI3C@44Y^,JTH>Q0]4S6(8\
M?PCA;;+EJZU'0)E<<I16O!)CRU.R.A?K/6U9=#705XIPFG 3AF[WE89UYUZM
MN;^LE[@C07@$B&"!00K?>]7Q5&)0?" Y>9*R&#-FQ2JN>6A\/\!/"U\(*P)7
MUX(7N_@IR]+=FBC'+@J_G<5)NJBW"F ^893W-QZ3>AO4T@SKYG("T^.Q1G6Z
MBBG"ZOJZL0RRX"*'A-941K/\3JFB#V@V 8-;O(QOYH.3MZ#(HA]0H1\!Z2'
MY;2'%N+C-]3WT-H/=X^ B^UF;]#XOLQ]7=Z,KNXR4H9 -!^%# 1$'.O,NLHE
M7VJ0_>6>>5/HO*Z>9U;JF\*Z!W_X0N#/YG_%V;0@^-!Y5#-H7:*'D-E8.S=5
M@E_<,+.\'\7G8YUP@APWML?6DCW$(*:^:<X\/!H9W8\Y^@CH *2=/[._/7L$
M3&?]#).3IC33,7K;$4/=_A$ #PG\(M9Z-/((T O_]AS]P8_Q$> +O+G0&Z.X
MY240PYS_O1^B,=+]=:-968P' FOH)M#<BAUT=M^\:"EKZ"V1M;;\Y'[UAR5-
M^]3+3>\W1"]Y;$-ZAY*/K>1_VN0<^)/K J>07:70^!?>A-H2%4'[)O52MCD3
MR$EO-^ &!I:?B].5;"R6K'893'SU[_:AR*Z*<(MN)ZI^!/S.78['%6'.3 55
M3:ZN[6DIF;\ MW4@SYQ.[L*]@ZQ*^83++;QM6/><O*,I4F6U;4IW(UT4O_(C
M8 4@?P-?=W_]"-@;_8LV(;WU6CX?A*NKKP5DLW>#G"OP6)@$.L_H:>CC>O.[
MU<?M2HBE)PP29<P\F40SY>E)R%.=>(L> ;^-J-S)(9.F&\]MC6I3!'5\G8"G
MC280TI,3QNUO;%1'T'R2063!!W^#,]P2]=*)YY9;XZAD<1C31$EJGUWWPX1-
M20U2@]X-@G%#R]NUF=DYS$XLH62HZS'@[T(K$Z.OF-_O@F]>H)EP-*4](U8=
MKR3)LA]%(X@KN9<FG>?C_&0A;EK-JW*N%[,BM,"( AHJ&6+:5>]OJDL]W'%.
M-W@':'43EII;=])KBPRA-1%=;V"0K^>/+D/59#0'I4NK.G%75Z5R2&Z<? _H
M*_A/XU&CG804\NTP*ZK?S_]SJO?1&NZUEY+57(M_;6)!>:QA@W>,47O_680+
M?:H_D4=!Z]]ZTPT-?V:UEZ\UDVU/S'H=78CL>WY!O=1P\W=J%\C1R*&9/Q/[
MNZC)S[W4&Y9XIDV$U^@WHFII1Z@F3-G[V0&!/,?^]Z5%S5.N$.5.N[-$%E!R
M:)B*8^C'SXM&XUXWW 5B3[Z\*-HKL*SL)NOE;&R[I,50D"&'?,]+]YEW+]4R
M[;<XE#VNZ,;W#8,XYF65:,W"^0D)Q8KGQ]]%I\Q2E>A+I]G7-\D:XB&40GU0
M#&)@3_OHUFWYV^P0LKC"9FAZUNMH;K^:-"12=J"%,/:\29^:TJ.OVT)V]0G=
M*OV'5(NN2"W_0)$[38*RKU9I?TD%X9\$'6OVCK5T0U>?L+F@I[5EM%\)UAV5
M:DFRJD<(-9_ "P=WD7./C53MK9:&1%>EDV2N[@MJ ;SXWW==M_H2_J5NF5%#
MH7AO4^M\;>3EZY/KL&H,^OEPY?".AA<L728$1)E-]K_K&X7*P;O4"$+O_TM!
M_=LU$M4?O,$=U/J;T2Z2,.J\O"-9+]KAPM"7U[F-*+_;/7L+JQ@136Z#D;D+
M%3>47109*U*$J6NIUYF[@7>S5&LW44G"T&.$0-;2DD;C6;_!O@-@V!O-,^<_
M.]2,FF]RLN<N4O-L70EL&?C-T,\">UAF=M(4U1*O9*R];UWJ_40I% #1.D)#
M ]JDVJ6P8MQ_<ZX%Y,QL?AJ]?&)I_FY_S1H2D9A5XDN-<%<=JYY'X*$'!9KX
MAG3]MJ^B+O9O@S[IW.OH)#W%$TQ?]S?0?<?(P+WL[]<(9HO.]JW2E"[_%N]E
M)(HY^8>2-.3%=M-"@3JF(N*(O3,"2,F=;OO?)C@U3_6/* AWH4H]F5!'[<1X
M-M.LT-GPR4E3"G?8VVMR^\*'"87L3K*(@HL6PZ'KVM1X GDKKX7ZMXPGEF"T
M?()/K;!L5ZE;:AK?&C=6DZFF46"1PVB 4N#(2G3T+)WF]44(N]#M$W#%NCO?
M.&3Q&/;CYOZ^16"'.U0WX7BIN/7J1E*WRO ;Y7F+D7:6$9/8-3\"I-]U8;\X
M4X]2M0@VH+N6K3=XRGM1&OX[C78;LKP7=*)JBO]V)#B_SQ;;7W?$^-:8>/"7
M"BY[$RE_Y_^'JSTMS R\8-GDC_N<TO6>+Q /DGTP9\$D$-/.4>UO+_X@H0)&
M\0ZX7/;0X@74R[A;?B>D?8M.>)<6_ A@#\UL$OXFHOS@]P2\:>OWZOC)=&]"
M..G8\#X(]"#?#4SH4=0%]Q7P*2$""Q9<_[O@,&!4W/<WWQOUQ2[QT#>6AZY>
M(/5JZ^<UFM*1GS<F/O;+NX?&?[@'7FS?7*!LWN$ C8Q;HT_T-QUCU,$S-CP=
M\(M(Z]'T#PU^@N/C]?[,%UFX@G6Y_UO9&<_ ]FON0FU+M_@C/@GRZ&>2:=_*
MY8 ,4_&_A36ATKVR1:3._'DN4/VC8F(!CE79I*O:(;F.Y2:C+,Q&2UM#)(6(
M0'&K@N066:&E5[;7ZT1_ALM5EE03"(W&XH\]*JG.[VY41WZG4'&L#6>BTW)_
M"C/"1V=:\419_<(]H# [^HM3J@E*Z_DS6R1:MM<;KY=\#WWV,O@FBS^/RSO:
MA>$/Z''8!$'1((7K?<P'_BSB7X1(D?YF.7"H__X.0J'=#,-P$,_Z2'_KWDJM
MY5/PB(2(M<^3B<-^BESQ!77+:Q7:?;K2!B#,\H>20R732$"(,R@!8 8>UW[K
M_,-TI]AR4JO<(X!4I6T3/9RY:ERN*.?N9EE9:TU_3(N_'^U4F&^5.JQA%[)V
M^7-Y<8K6X:!BW:= _#U72R(LI8,WSQ6>_!Q4<,_ %-XF6;[: _<,S0X/#?Z"
MUJ8'B%&U.%,U)K;LDMWFN[N!(<J81,: AJ@!30,T>L_H1MO^-9P]V<J6&CR(
MNOJF4!B0K!^W::24(.OH^ZF2WV>QY<'Q99VP]OYGH9QP^00E;6W7C:UUI1"5
MZD!A%(XH!)BZA"V:]5+MT$< 7X6AIW7>$+_.[C.=H"TUW6*Y!8(CH5CFW^;+
MF&OYD';2\5FK 0B%-41^MD1@VJ3I4JSA8I%M:R!M&,3;6JV: Y5%%PCQ"""K
M>>]-@5#0[6S/&/-2ONDS2"WB8E?E1$OX=[)(8SI\F=-/4'5H"%,]4M;W I<?
M<U<\5E5)1:")I[OD&(,2NWB#D?C"^8B.&HP;\'=NM)6[5U:(].S;DV,KBUTU
M&QK=KK^7!GW57U9)_(5C:YG"@WU[PO^LZ/[6LU"+Z'4K+/',QZ/U._7K9-._
M:S_$/[H/ROXK]U-?^KMAMN#]O\G0\!^0WU]2\5\+8SZ8I74"K^&6@=.J#ZKS
MZL(KLC@64W7/@CY_,@[LUZU?V].%\:@OZ'$UI=GW >F*NSB4YREJEIW1+3\"
M"O1+S-7"CJDHVZA3)T6-'P&.K73MA*&V& ?A]SUW^3./@ 7[@8^!HW)__!?V
MXRY$M7*M\!7^:=8?ZP%_7?T&7XS_CR^XOB]*A_VU<?;<\B)X,5JP6^_#FJ^*
M#?"0>^/YD\R4BD= _7(L/O%MV+4"E$7>C_OB/Y8 YFCGO]]6_&,)@.L_F,9;
M UU;Z73_]R#^!^,"+NXK[=-TZ/\6QGI94;5)LA!]U 1I,2=,4W2#+A8>R*;%
M[_X*0[;CE"2<PBUC&VS/4)*VA*I)>#V(%3Y-VV?"GGJL@B"Q^#OA90><>U^O
MG1?OM7@KC+NVJ+M^'D*@@E>H,(BR[>MVB_)PEX]R3YZ7KN1!_!S5EP P,(=V
MR;%_NC,L94W8G8T6U1W$P -7PO^VXXF]@OY3K5E":=5/4:NZTS#]!@5'VW(P
M-KMS_O&?GH2HU376![JJ*F](#[!'/'V^ITN9^\[0V/4RR5J8R3;'_76OGY/7
M[1<7>G1SRH0J8?/(JT;3<FW>(6PHLE5>X162FM'NC06W5G/+0<^#EGDWUJ92
MN!RSW+S7=6YQ0.LHR=5):"*[0Y-7Z(&">Z4M8R4U3P(W%U.R>,5A8N.WQ9\\
M?R >7Z\)G"SN"\9>QE$S)6UQ>NHLUI95.,3Q0%(Q+G#->+ >M.$6%%P5\1PI
M<J3%J#;'AW!\A^Q4&6X^"J4Z[KH#50J_Q:/'NM '=D#&Y>U!MDE8788E066:
MV;#$EC0'/831%-"(2)2P6TZ*>EK0^2B1"1;!F'X7SS4N*[_7'2\HT@Z!WW&[
M-^HIGVH:TL+2;@A7@3L]7>MA5MV3T]*EDG E:ZUQL:J**$V26D.*K*?[G_<E
M<J6H<JO+@SM0R.:@"#P9JR$]!;V^P"$YELFCA""?Z@TG6@TK$+FQ*D \;V%/
MO6A9G4_Z4 P^<BK[Z3BF(WM>.F$PY F8UUJ=/^",'9IZ4I4S#,_W+7RUNVCC
M@2W1L^2:OCQI=[8;(;#!A=7 ),_HVPQYVZUCA1>0S!?0I+/0S>".&BO^L:^O
MY&'Y]8VZV"I]PUK:JZI@=3_^IK"H@??0 (0VP:!N;7!GLI?E.FVS28A20[Y-
M&60E%#)ROIE(FU$3GRR9FY,(^BA$N/B!/ ,Z^=UYYE>G.5"6=_;"+A;75;04
MWH?@?G)[BSH"(EF-B=R&T3+9FIJ+KM$10_;R.*4#?+)U'NI<9_#66.^-D=':
M:CVE6J?L%[H_9:^/&WQA8(Q3!8VV>A/';"1\C'DXE*)XZJWHP'O MKH[M29J
MZ.XH/)])9I*HM);KCGQ>Q!>?XKK:SR@TZXR,E.>9+LKZG-@;^42;2PLS+HTD
M:FYR<M*-ULQM3A!6JG=%;/.=*=#Y,BG)$L^>>7"I=%=Z/=E!@B"1"8XQ:W<N
MX#+'JE*G\K#*N?]:!NI-EPK+KE=@0IX>97?W\F5P1TD0\>>PP'W/#SZ\.P>Z
M$:/[4R8QFF]VB&-::=OD7[GDES0+YVEY^N$S?TK5AF5X!#"G]_,02S/!8IPN
M6+I[603>K#JZXR.H:<H\ IZ"@;>?%Y= *3761TLHNK^VHPA;K[]]&:KTDL#4
MR3'Y1MW<-EU#2^H3OOB3ZG2&S_,J%U 4:\<YNK#MI+5!-L=Q#:?/%V/NO$8=
M*OKF]/0Z<[6L7ESN2J4IG&IQQU0V8LV'Y8'>GQ=IX>LOZ^OV4\]3@?C[47E:
MZ K3SV>7&O&!3W>FJHJ_S%96LKK"+,:P'D+PC*R\\'#KH)VS.,B1,&?CFC4!
M5*PG0P4SP>$2Y;F-!<@TG7C<1(+83KFC%%@&+GI?3?44.;J;KZ)4Z^@LY+RE
M>98>38]O'+%S:.UYC@]78VU6^5F6.55]\_9Z>/\"-LH'LF-S[X!M-BZ>)#H.
M$#E.0D#<$_+6]^<&+/E?;:)U__TF^K]W1OQ_WE1W_!$PV3I5JBH#>,%#\B[U
MPBXGAO7AQL?RO/=VYR+O"X08AL(OKU?1A^$E0@G4B\1: !\,Q><P_^%")M[3
MWJ8];W^H^>27]F_?_KC8F"^,TEZ%W&NDPXV*80 4?W$IXQ_E33P"Z'Q8/]WX
MR)_^S4*XF\U'@ M0RX<%6&I_)7'Q-TN%-\H? 6YIKQX!<9WW<P"_*X6J\2Q-
M9B;RMS@'2ENX0K'06INQ7"-,-[#+)$$.BSJ7-U/,89_?6,)2JD7H,4V:S2'T
MECX5IAN9$N#WN4\IMHKVE/(8CF<50XI3F1U1@I77ZZA6E*5/I"FR<O,[G5E*
M8F7SR68ZP_(U$+2,GPM(38*/NUSE(3>;PQUF\Z$/&<NIF8P[Z\*^8I_M=G4E
M4#O 1Y74@UR':N<=LO5H,#,=@VD.(LA3"+?FLU/PW(7 O>M^E65N9%)LV5VZ
MH]QE"KK!>K[*Y@Y\MDW7?7"?FX(:=^H2@', ,Z*L PSB\%RKQ7:?MN;L'EIX
M%N='CE88>H[_<:N,-Y/1:/Y%M&)=K/^XF)=1!3;;>@&KG].^$X9S=&IJ=;'8
M\-C2*GZ32WU=I$FP2(.NG @FH_.-RA/#%6HL==3%830)%"3(@&$I**+ ^@IO
MWT:QA0C]PKA*]12E4ZEL-,^0,Z<WXIZ&=<+O,328O'(PM_#24LP9A_RQW:TA
MXKZ<\<?A5S0ARXG[T-E*F]5,V$\?N#];FI>W2_1I3=WZ'+HFS.3[>N-4SA&4
M&0(S/$<HU[-JB,S-*A#6A)@77??N6K7QE#\H-WA*TSAR-4;"1924Y%U310G]
MAXVZ>#6/(WN)F;$Q"Y%Z(Z@&_/ZMY+4\>1&Y=N>Q@M)!//8&Q$(VJ7WZX8?Y
M_/X2]GYG#.X0M\+"*R=(HW-4?Q(_]C/SDWQ;++5QEYVYW4,I9M]9@O8\)UR5
ME'3DD]"GR6/E.N<?J((W,1*Q-<D=8TVWQ:1TXM(8:EN?(B=J,CL25F',];P@
M,)\6N%5S[;I4U.A*="MR9,R.>L&<=H"\2DERUOH-W*J)!*O$_+9\Q#PGDP0O
M&TR-F)FRQX8^[R$5[R/GHY-OPE% +5\48DUS.VQ?UD'>'.34CV]:XN8:1V7#
MD+B1>"D:-.Q,<[-H=IC5QQJ%HB*QMH'/C ),6CJ,BA[ L/7@89[:> HC,U5C
MC;>U)K5Y3!^6O9#05D:['<^.&EE]:\-D@FD]B#^W(8J7S+H?">>ZX\,+ V3C
M)VD](3 CS^M:JQM-4.6BL)7VJK?HGB+<?2OBW(CCYL9*- R72]7MSUU@I^O3
M-T;X@NXGAT,KO#Z9-.\GL.?#K] 0U39D(]"=DH2\[ $W['G(#F:8HZ(X@CQ"
M)KX[A#OW%8AP7BR,5)6U>QDH143O/1;I"=*-E:;MD:>.LH:ZBM:P>"9P1EK?
M\''A6HD-VP9-A&2K! LIY1P4*3XF^2(3\K.\ 1VNO:U!]:U*%9G(F]<]/ 33
M*2*,0Y]B35WBZV09AVIN)/7,#%YZ(KR1AS;.WXI6L&(/.F\:.<#OC]LP?K]?
MD?#A:;:3V[F=5ZHC&%JAHLYF#5<!9I'>(++:R>RKR@*_E>1^(DF#P>JG[WGZ
M=S2XSY9MQF6[ZOWV9?BOI\-M,L(7\3NB6'BA@AFP!6&S4CUL,RSS7$&<NT-?
MU!.MM&)[+W6>#3F<+HD94&CZSE(@+K,;1KZ (C= WH*:JQ,0""K0WXW6DV?H
MBWR9H65VVF;"_TEG%9S:W2EH;/MM)+C4M71(C"]&%,.RJ^I!ILHUP01?I_D)
M)PJ.-Q',1<D%,ZGD?'< L#;.X]$JK_%?U]Z4],2<27C24ST"ZNC?1!6^P52!
M"'TC)^X,IN8LAJ&$\\]&][WWQMP8/ *TEJ5] /\K79V(_\1($[A"5QED%HF^
M;UA>+,$_5P]< HYT/0*NSJ=M3_0?))"8;TZ(;_#5G@9E]A9V^G#4R=IC)E.9
MT6.=MKE!D359SHIPN2E7^MGTWF_=W<D_ H"RQ,V/@+2@1\#13JG?6<<TC4V2
MO%MS\"DQ%]<,.1W_(70$ZT6NEH?>J:5]9@/5[$$)WC8D% )@'YYG2]"SJ!FQ
M^17S/Q&,WHY<?TM[>$@<BQ>96/&.C1J=F >8XA(S>;EO'7]_IX(U-2B>V3XH
MZ9;_-'L+O]SSZ]HTQOWH;2[WD?#6*O#VQN)/4';;#U@3G)Z&<T48:'&0ZH;A
M\:6P3E9#O7Y':^,EAR4S.@(E9-72*IBSV^ZO%R =:/409M1!O>S_!"#L^0@0
M1G\$+(]K*5KP)4^9'?)+L'Q-7H=\OO<V.:U-U?^XM/:$H<C(C<-(X=4'(=$[
MC1%IW^W[<>RKM+,3X?M[#M^S!U]J\&-];JWP"N&G\(,09^B*?GN4E !5!XF&
MQ?$%\QV%10NMV-B\N5)&:=$()#LEE<@(>#CR<"W!+U>OEO]-D=F'=O<O)34\
M5&S7XYZ,J.$P*';.PU93.5\/7@Q?6C"JEHX1T$L"GFO;K18BF9:C6#$_TZ/F
M_06;@I4AS8.,>FWVC<^.N$SI#<,\N$.BP&Q]RR#\Q?8*$PIR.#5H4+.?Q97$
M8<R_S"3^H:]USOAKJJMQ2T<I-U(?$1-7(KV#X"Q> 9!\CKSQ"I*/'#QU]:14
MH"8>0;]]S;NW$2PX%Q=#U#2DSB_7'P'_[BRCZK@]<<PZI*C"IF(Q)W-3<'ZF
M%F&7[ZDUM5)Y_*L)\\HD(A,FE<@OM^,Z);-/G%H0T_[,M*Q_ZERMO"%:B?YO
MJL<%\RIH(OP[?QDQ@GP&_U^D;DXF2 7KQ9_VX?\,P-BH!!T2Z;\K86F1%0L3
M\2M B@-^??+_%C\MF@T1$^I_2U-&#*?T_^?AL]-LV($?]84,RU2/J<.%%JND
M)M<A3\3)$AJE!>_W!G9PG?T0U)1C#=MA<UTF(M%SL\-S\\OXCXG#A98WMF^:
MW]H#NMB)HE%$'Z;/REZ6XHIUSR8[A814(=)D9HO\Z#M_S&(^[ _:*%<6$#KB
MTN\1Y7QUESY-3,6AMG($O>NE4,,.$A4#9B[%1*;7-5"IO612P23G(7B([6UC
MQ%8=3U*IBCU86.2..68W06.1-A;.X4?<RM+5T9R9Y:CRM$:VT@<\76PK(*^O
MJP_&A2)%HVLVK$CU<M2SL:%^_PJI6%-'3EL6P>R39F2F3:U(C\,,_1!>H8[D
M6V5Y!$<TK1AG2XIHK@6T?JI]$IQM6 OP(,!O*S[P"!AYUEA>%]-S&P@PO"C(
MUA:'R-: -X[0>&H]0CV^'FP=&SQ*'N#*[?ENMOJ#POV8JF.S-_*72TA"/NP8
M@4< P\,K=3[K9@HT(=7G&UF\!*P"D-\]NVJLA"-BHGHA(^:X>N?.%(OKTR E
M^-/7B"ST4I@32X],+;T\_C@4Y$;W-MWH%/IB >/00)!]R/%$(RXR.ZY;"WJ2
M)/)U$588)(:!IC$OB0GR/0P"S(B,(V1R'SGNX<R!U$,X15.KRQC-7CN).O<J
M/X1/F27IP:NI55YWR 3%TY/$K1*7Z^I;0J[5)USF"?O,6"O/32U9!BLT0%XN
M1Z 8\#P'?:8EAB158:+@\-("YVR?SG@=VT1(;Q5VI<?CHHR^/F!-9DJ2'(1
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M8F4(WDB$)$RJ22QX0N41TJ7(+.3Q+ZRN>J $!#;XP$Q^/B*7XOCR&7.E\RL
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M\U3+LA5!TKNL=>E<FN986OX"A)WVHLV@UZ-/T+O<$D$I1E?87"=Z.KU-?6R
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M@W;R#B;M = L<FO\ /"7</@1J/\V_'@K<VXC@..[%G?*^M.G32)PWEEC.ID
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M.@<6?7H<WMI&,OGB9U21G[N:#G9FO$D;>)\2*&$5='S?3X [4W3OHKD)XQX
M"#8/@"WXYDNT!\#4\,_=R>09%?5%<=TJ[W5KIC=A/MD6I.]5,C_.B)-]?.(P
M>R% #'45*3$MMT=O!-7TZ-G4/@!.8;1NX1X >\8_=\WZUX.68](CQ>N3F,"=
ML<HO?8T2_)V*SP9M=J_ESEEND*<%RQ[]S,,:HGNO@@> -__=H\OYAXY+E@1M
MY5 '>OG;/OPOE>8BB! MI$?H;KCNOM\1%_\"#]T-VQ'9 *DKZ]&CG?.\ABRY
MAWX G+.,7U;NU-YW_,Y=;L946ZD;A2,O_3WFZ@-@",/SD/P!4);Q4Z^$)3U<
M#ZEE+VWJ#$\KF+'' 5=]6QA;I?28Y@88KFZ!4R)84QMP,$_N(P0BQXN)7D/1
M8IU46UK$[D]51S"+-2JUZWT 6%\#![)@S-H'[!5*T&8I<HN*=1IJQ)8B]8,Z
M%:(/3577.']Z]?)IT9TOYTIN._1B=,<S!L#W9V4XG_@GV6\RKD<?UVH[SWK^
MHC^'_/EE#M36GYCP?Z7]1\&N7[5LL0N1B90?P1H 7WG5G4IE,$PLF0IYK!#P
MI9YW[07?>(%*_4(TJQO$TZB^&'PQO%4.G9$D"W?A(O=W%Q-6IZ%O$"R49P?B
M4+@S8X>CJ;JSXD5I["*'UNRWI:2Q5)N2XE8Z;_:.B2*!J;!C:]6 ZY5X/E_W
MO/F7 QDVL/'0J"*0K4CS UD2;)Z#J@7D_G0/@ J6 OLZ[X3NYSW$W$1AM46\
M"UDWC6+[M[)69T54>*QR1FZ(81V3FS!2C"U=)[E5GIABF<[9S_B,5V_0(WU&
MM->Q3WM.LXWO4>M&K5AZUNK].Q+$"]%1&EP&,<P4#DO'JUR*C2)Y@F@_)]=>
M^3JRN,4=(]NNXQ%AF.+Z*<8.ORQ?F%<7]^X%1:839MF!I,<4&LT4)^PE"3:3
M"U6U>&5>/FT11PN)(??A7V!5DSITGT@TTAW6:)^<L.W>V4/J4NH4^#93;#KS
MJJ#0Q *F8[XF<9/F8QI2!V 39\?X0\VHSDW-,8M]07PQ[IOK+/^=8HZJ<,O%
MDH'%D<J=4#^ELH:[;&HR68X;#FVQBW[-PH4-*[ONII]6H)[1A6$>+%LKX@3C
M^ZE/REDH2?N6ZVI7BC4=5E?8^_R[8YY;DNJO-F9K;&8G<58:3 I:"*R5?+B%
MQDD:#M?[1V8$43MH,,NN@.7E0C6P&Z0E!#:*CQM@+EZZ94(XV>EW?&^/9H33
MF$,B9ENB2)V(^C!:++6SG AR0,P=G%F1$:2B'2*OI2$+IG?3U!.V[*LCVM@#
M6:EY2<2*R9DR(G3A2#MA^2GT(I#-)XH#+=P0T03RN#AO6 1T=.)">4ZOM,)+
M8%E;23];U.%$7^=UT">_T%W0.^"56HT2]&_IW,R4(/B,Y:BX;62V/K>H+O1*
M6U8\@ .P&N*FP!V,K5V=((&GO'#-_32$@@1)RD"[O]*W=@DB"7?I=AH.]NL'
MW\@3>Q:X+$5$,NLO>B_";"2FKX*COI[R$DDF9X5)]'$;\^R"7@(1WD;;KW%C
MMNM-V:D_ ("ZRN;VGR(=T\EV,H;@P'7#/'U)$L0]/6V$)H5[EW/MJ]F2K$^2
M.U._V53*"!DK_YX#]QZ"'* _')($?_H-RAG/.%QA7'?SFR "$G@CW>Z]DGZO
M.-7>Q*5#EFF"8_2QEG@?]!2C6NFZ^UW%MD81 44QG$3\W')T77(KD"+O^?_D
MV38]1T^:ZJ$=0;P-[RJ^DEH4A?KBT(XFR:8\G^GRM$//0IU!,*AEARE_RC>5
MH3IJ,$;/4OU6"8C@<_*$OU4^O*O(SO921 YUQZ:S^Q ]?,\_L7@2N?0:B?%R
M=$A$_(-TQD?HSKW\>)Y"%BEL/F:?VFY^?S(^BA$Z=2$K1UQ%1:HBO%PR2-$>
M3638L*9Q?SKO?"TSL;P^"WSN$M+(M!,(*F"BK>A2E#@/>RZ"F3V*2",KCB7>
M)I%-A@%1'KZ,/F["T66-V/-6HWIYD"A(47E$1 $1 M9QN(M7%,/4ZOFVXH7/
MB$2AN(K<QZE<PYO44CP!OHVZ8'Z$G??;<=9BZ![Z">Z-];>KWU(A_-D> *\G
M+;.GNOMQI:U(=)>>GK^0%=#<;]D()AZ;*SMR\!^/GI3[5J-\@ LC&_9UC3#5
MHN<6%J,,YJRHXV,CT,!,-^MVP!>JV&X4F[6S.>!,Z$6[K"'"=);,LR_"D?AG
ML&6$9PTYVW&*?-C@"6CEXGE]?<6()H**D*C)E-900(-.L<E,4C]&YOJ:PIQ"
MACZWN_ 2$U^,G,H1;VP$63B?PPAV2Y"@MI5V!@T$X(R#YT@%3#1\)J'AM%]3
MUOM\]FE0[)*H(!28<4B.50--WN1,U,(B XQWM932;P)@W*..].VYR2!298&R
M=PZ6N)&I9M=JPH&&UF5Z(CH?@K:?-#JK,8JAH^?H;>@W]Z*E)42/=C0LH\A.
M41/[<Z!L&.<*2,+Y(/1+]/P'W^:YW901$#W<8F-L 70'%O7:5,0\Z0EBTK5^
M<O,ABE"$J86Z<WZ/3IC$NSG,VC!,X6<X&IN Y0 ;1:5V5;FY/LCY<";B]29A
MJ/6;*7/MR#E(LW@^G+%7U)35D2_1!&H''388Y;7%3J'"N$?$TDRMIT0L:)Y6
MGQ.91JO#0G_%9GO"Y7MBER).X[45U>%*VD+3>NEBT[51@3UGX"XL\I4O/I.0
M9A@QD6\V8 [=%R$$+<1H?0D_A#"@#B7-M'XQT*)ZAHQ/P5>04)^HD?8V<*+:
MZC.O._?N$X['Y5,L8)[DRFN=L6%[))BX@3VL(3OTK3)>VCEHUG'?HJ$LN:&L
MAF^Z7^&1_IH83W 4=3XS!0H'<DTNK"7<M2*^)G:CY#NR2 G:L@:)%.9]-1D;
MWUX'FJ?7<OL?V'.%LK>M68P)YP\04SB6^&S.TKM9N7C)%8/EA]/'@%<H]9C:
M:UY>#FO>78UOP:]&".<WL8QT&601I;"C1N&%I=S]98.%&VH/>1)X>HEKS9S\
M"%H"7%I6JP1<D!I=+ AGH:NGM@A(DM^64^ OUR-OOL85Z>!B %+R38C&Q*.\
MI5,N7R6UG%O3=\RJ/:*+@8E6>K/&]=5_Y6F(!(#;"PYJ;I(_P]E.KFK<W)*.
MA%"=7>[KUY% <QYM)+<DH(06\LZ,O;4$0:%=S[D+[0(I!82MV+.H[_RSV3\
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M _BW,)LOKJ7OJ>K%*3;CK#?C[!(? 'ZP;42G"%HW=X].-H;(+3'?H^N8JOH
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M]W-1I&=6^!PU!SE(8BD'X.%,L#A#E3(&;-H0=%79:1VF. ??>XS>W^9<*CP
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MNE&BLP[/UG*=$;HUT HG*8,8-"TS6:_\/A0OHUQ.H%5F=6UMJ$079 8C2NW
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M20+!&>E>SW=!QF2^HL66XU[/4+E@X^7*OO1XPS*]UKX(J 5T;&J^?Z]%$C)
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M8"-HQ@0@!V&KN@7W88+,AC^(S^<.M-],@$0N5/LOF%"%IB=%"1=?)[Z8^X'
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MUX6GW^F.%U!9[1!NBUIK'_9&7!JG,&D66C=%^S*(W$5BFV1E'S'5E85'<6C
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M7W'>^G.(SBRR<'P_'R\;A2(+%H:VI>T3060%J6FD!9"U3<TH^]WM#YQ0]<3
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MI7UU=13&$^K=4WN-N5)K?4.0+_Y0N"BL"RZV5)<7ZN>N!#E9_LM)6 A_M6"
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ML5X# SE.5CE9AD3BKYJO/YSD1;!IZEOF'6AXO$E@JLX]DFT0?DN$&N8H52)
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MM4!UE<J"+P"_3!\1J7)_1BK^:]QW_AYP-8[D%:X%W&ODD >^_D/D_ Z]-NW
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M.7B0HJRZGW&?\/V$NN\7,F+\'0+),YL;%<2"*K V80F!^^T+Z_<38]6BXB\
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MR&,\J@+/X3D0SQXKI ]&G&EHC"WKG6>@+M'1@@F DA_V&"@VNK,5;4K]$.5
M8JX\^KV-+K:!_6+OR]>\ ;/W XT.F\>HB"7B(!5<OM56HY$ &.=)3U;6SY 4
MR>&BHS='^DI!AY_,C05= =Z!L(PX;NCI7LVT7'+.6ZJ8C0""C=;5!@(][WUQ
M11WY2A]0"42&0$@PV'PP5DAQ8/^<6WGK6R_;X</)L4SAL-8T1Q$0)W$^;.,=
M &!)G,E>XDK)DLV<[97U 1#7%,=1_II4+?"EFK4V8Y9#@J'X7<QBU!MTKJX!
M8%^\)A8P09;3TY1L6T:ZJ(S44!-V0-/"!)A13$N=IY$X$)QBCSW0I:K=X<G)
MW&OO'MB1?#?AN<L-5S^D1K ^HV"GR52W&;L3,T/QN07DL][#3$*/('*ZCL56
M/XRD@4I> [9EMHQ!^7=A(B1:>C2H("*WVXM 4SI],HKZ>^9A*]* SGG)8+;0
MNZ*P%?NL>^ZRC\<_)6FW,3 XWG<4="X8?T'?8'Y,;SH'*'6VT1G,:"YM4ZNQ
M(;(8B8=WY/\N+XBYJ^N+^1\T3<WL.="6U>F\4[L+0!<*M_0%(&CS\D"WP04@
MQ9**34]!1Z;M4#% I,>= !=#7CP 63OHJ"M%:R?6@*&]*O9F7W95(VLC]#,Y
MG/*6EE^@_?*9GA5[3F@P9?V(<MN[AS,KS+LO8N,/]MHMJ0;&PJEN^SBKS)$^
M&XC=3DZ7$5*0[5?4(7!<F9GGF1BV+#O32Q+7<K))#]-3,C.E9+EAOI/.@>Q'
M$MT7: /8VH31OX(QAFTHO1+9-*$OX]C+$U#1?R /P>M[U.KB@L*7Z&YD^F--
MTZ]PJR&^#1.J[-R-]G%.9@<=LU'2)D/T44E5@<^;F-U\)1%:28'8XL^9KR)C
M2F'LXE(2(2,4CQF?4.CR!*T.YMAC?Q1B,0YCLX2OTH#VD[[[MNY4)>_D^T<)
MCSD]?IS3W-HAJ89D:8:!@G=C9@RS14'KE7[2NX0@4=G0FY8GLBNZ=/YTB)@C
M(W6Y^19A'_E2MJ]'(?4JS:22_;Z^SUCIX>'B7<O/5Q E#O62>AZM $[5#R\=
MX4V9M?625])SI2 331$@(XE8YB?6!;HGK[)0?DW R*-_X\1YT/8$#^.#K@K)
M+(^TT4P;G6]$8O#(23\UAZ>1M[7(XS7LQ9JO-,@.Q4!?IQD5!^[O#&\*:JJ#
M'YWV&F!LD^93!!@V1*Y_4'Z^8O+XE!LS?)X[X@)@B5$>CTY+!WJ]C5Y]/CE,
M,G#0.I4[%[!![-'\GI.7[N7*#+>XDBDEA^C'2B<4@+B0CJ*::G-"20*/A:H$
M#>OM^[HNO$"1G@Q;YU/9BH%BFGVR?&S%5OZ<,F$,V\X<@.4G><4\Q^%<[5.&
M5CO2AF6/$+^SJEU%'/O4+*N9+-URU^QU2M<1.FNS:-? S\W:ZR,N7)%T(-F*
MD-=]:QO*PD\+2X?G!;L5=[)Y.:?.A8RZ?MG>^"\V7'(MQ!"6/-J@L:$"76)0
M(WZC82O[LL]LKCJ&&JL%8!U@\VI*\QTZ%=N@3)S/F.K*"/ #>E208V%!'J4T
M$D7<ZZ+.>_4F/!6]XR*$8U&E2C8NKVL/!0X:C98C;\4D<W\W0'I85B\."G_/
MRV+7*)1NJR'6MR'1WH!!J>6IGZPSP;LE;*"8JYO_76G8MQJ'8YTIWJ4V\Z7E
M]CM6(A@FVMZJ<HF]QQY!=%AD;)#!K33*(D_"J.?,Y'G&[Q6VV;M4]>U-.B(C
M'</2&4(('_"I16S<7C+D9:T?,0VBDS#".LY^HA,F;(W<A4-]PQ<SAD@]R"!;
M]4BI*G]Z6X_,@E65WI-_O"UZULIZY*X8B;M.\)C(N]7[),8ZH6;FD1E@]ST5
MWY(RA[<HHQ:)+:U^3GU$!*,O%&<5NY\G^J$@N]"(R@3K8<[P/E-1$Y1@F$%O
MHURZGS?494>-BIK7[MK,/K!L/3A0DLHK*'5J.>KS\)@.!S4517?,EDZX(B8U
ME%&I+?P"$)C!0=T;2Z?PJF>]*$K6S&C!3K?4>>?Y(EAV+X'AN0SDL6TI7(A7
M$E[&+H=(W7."4?#JD!/(^GKTLX/W(ZJ/]775<I&:1/ID&2U7C:HYLZF>FPP_
M!]X3^':8VO#95=_G G G6R=S\91!\O6I%SNN)ZBD<.L@S7Y;#Q<7\Y'T[OT[
ML^"78V5=QHQF.684_@T'WVX/Z]!]XZRMG7,R=.#E&FD:7I\*?,!=6)#?(4X4
M6Y3]C,)N?(W+_0@_33IE^416:$$(6[_GU;=H#_IQR;*%"HK;<.JMW?LY%76"
MP5Q;Q78\N EI$2A9V.]$PGKRY3L/A=^![Q:;3Z]SS1M_"/IJ['*_H*769=9-
M8#'-GIY/QWQW:HE%A/K,_FMYR6)OV_CD*$=.WL-Z,Q2X*V6B<+B&J3]6&P#K
M0<=TLS%D1K_DCIZYP1RJV_3PG BW*W6><DZ:K?;+G@WG;C/DSRYU506LGTA\
M0QIQ<%F8+54(#;Q\DL.PK1U\@+XT/";+RK%WW\ Q>M&(XNA(7:B!*28I(R-H
M"7?O,T97E;]Y+ZF1PE=7-_DJ'];1_[+V?MUCSF\=]I$/L4+;V*2%I!]=.=-O
M6XW*?RN[J+?^]/8[4%!^@*'(.\E@0(DBM*3QWFUU,<PO6?LR<"-NCH&=95E+
M*+VQ D/(L,/<J=2]+.T9-,)1\2B_-K,#J5?;8X]$_+0YR3^GVH:UR5;@+ /[
M'G*9^:[?__0P+Y-DYDMQ&V>'3\9*./.QC!K;7>W5 DKSP^ICSAPG(])1 LQP
M_TE]8^W32@SHW3N5S]*SF7#$>)2YG")M/"%E/H(9M?B:=/0&-F@SN#W"^>GG
MD48:19RLCM/NVG<GZSB7:(@[FF#3]!MFQ1Q%.50JQS-B)+/ML<\:<LF-D2H'
M!Y>53VY(FN6NE+R?:+<@HL,-TW5J%$#=/XS'#M";,4U+5QE7'JFG#U)AP:&\
M0]AAA":XK>"38T) 2!&YP\ZK3/4QK\2HZ"@2YDB?*X>CXH'D/:=#4#V%U\V#
MK]D*2SD,(],VGZBGWKKA1C\6( +'8L*'=K%(GMTTVTJZ_I(GF^A6KF'1!IYF
MV0X_1Z:X 'P3O@#<_</K/A<-AL+8%K&&2A\[L999WI-PJ8_Q)J.%!AW,^^U6
M#VP'&W=>Y)'$]CP&>*E R *5-_.J&!)7GDT:5^0'B!VUZ?@/[2/G&"72ZZ?#
M@'*: (X;KC1\BV$7@#K=6::36X@XZN(/QX9>?P.N6$KQ*8SM=!Z]JM*] /!_
M!V\]J*D+_.6M^C4,.?20I_"_8LYEWJF3_@+PH:U)8^]>R 4 B?",EC /[ZAJ
MY"5%03#VB 7U\&?KTT4BA>P>%B^9;"29)P+$^KAT&[;-[NS^<K:9/>SEL;J1
M$@6@<DV1//:-?2_M)(,*I]K(CJ;;%-IMY "C]V7;*DDO#5+2%2(=-4F7E*6;
MSXH^ZFT!EZT627'#X921!GNA%X"/V>EG^E9\.-9?B3FW.CY!ESN8S@&04-N-
MF.W7FY*])MF#KSP&;H<]:9)A=?7;RP)OE6Z"E[!0S\_!TW)+KV?D0=H#^GE4
M%P"/&D01Q1\!WER^4I+9!+2+"O/T!%H7_B7B/%M2*;$J"HYSOGA^0_,"4)-V
M1O.'$;P?ZD<:]B/IOM=<&QIXI'(8MW?''0Z/VTH:>L7[_]'\VVCVM!%5&:+R
MJ>NM[#QSF_X=,,T& =@"O0+<$%TH7^[[&]0%(%X'?+B' "'=*MJX "SA8U[J
M7LAM,4U:7?L"@/9Z$^[Z\0(PV7OI)]?A<=!B8X3L L\8N&M.;@E> *"21]*_
MPBLRVM\JO@"0,0C"JY,1);B$KGXD/-!DNIV7JI\^:+;8CPM_\-TC86'6Z%,%
MA,-C,U((B_28#.-IA293/-ALE"%Y5BAS>^MKV.VY!P2(E3#;&EU4;^W3I!2C
MB@;IFA ;-HF'4_,S@?C&#KL*^^<:$OU%X@X,? N$OED^;QX(8=W2(7,30]Z8
M0A[X(M+('0^>P[WB3'[ZR+NDEZU+_RGSRS/6M-;V?3(I5 'HP8N!/.5!-1/R
M(Q9\F;GT (T#%^I8VMP$)ZN,)8*W25;<@MBX'\2L;D Q!<A0BW54SP15FB 5
M7?1Z=-]8SH;.&B41K/---<_'4$V^?;J^B\&\["=U:[S(6M9HQ#[/.]>*,\C/
M.RAB7$X[N,$26#F3HK?5>*1Q/"=V8I-[:W2&K&#\0.U6*_JD0RLWZ_ZWC)2C
M.',V2<)E*>QW<H%/]L >.,2=HOFZ1FCOXRP;RLZR0*\0%6"IT@7@/>F<D6?O
M5]#X\@'SR+GG8PBSQ]N/B\0>KVNPWHJIRW>OAXDT+6((&-M'6R!4FDK9@"5.
M(=U.^/U!?>872LRR=<52C1UNA%'LKS+M INH&[Z_"18#=>=(SW%:*]2:932S
MI<T8Y[#\L'30IG4#MD6[V+N8OZRUR-_V[O!\ !U@;Q#@JVPTR[7VV\^CK#KR
M,'>P,J"O<%1AB&X!3;QK][MAN]ZN]@?KL_ZG9I.-R\L%VR4]4K:![MWSNG(
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M<NN<)2GMM=-CJNW<()19E?QR786APSO(>$&%?KC+ [XH'0&P^:A&-$0=&GX
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M4(X"K3R.U%#@7VF=@WQ6O<4J52TRK\S"*D.HJ.A+YC' YOM[B*,9"U 'KS%
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M>D'Q[83WJYWBEF3LR*8"'>X4#'"1$)H+ LLJV8L$EN^?F/D8K:?&B^[#^QW
M.(0W!FK\&EK[88&PY9USI>4,.]VPPYQ\"[]][UF]DB1>[O*FB<<QT-""T:$1
M&MO6DH>):6B#2.78U4NPG26\DV/(M(Z'3M>HT>%ZAG> 8L1#_O-XLKOL/?D#
M3L4:]?G&/!JI?#$A!,GG\PVU7[YZG06"5P45#% 8C &ZG0QU?GY#^_'/U5:K
MY5B3ABTA7\/)T<"*@);4F\Q1.D8 ^LX\.-)QXK:8#_UEQ$7&L4AO\Z<7Q2^6
M"UZXZT=B.()XM59\_/1KY)<8T>%^:+54!_>K;G%IX?'52^'9!A-MSBQD_HG
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MW:C?;MEAS:]K='$GJ!>H?.&4_%8[=I!(X7JNUZ6$QZ5K9*V6;?H/61\]P8_
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M,!,M)V%1K/,(]DO"V\&/;^G*8/R[6^Y\J-U*S^=)QXL]?<;/X[<1J>!J05Z
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M[[KZ"0-0=_:(@RA !9XQD&+&FA%[(_VNH9"CREDZE>C(E_N9S#F_G<(IA&$
M^LO??I5+\+NBCM9?P2N@#$1-.'J720WK>KY\TO!-L,I?O1S:=(DEN_[,.>9-
MH1>ESWR<S:TMK^,:^ :(45O%Q1J)O_\LJ"KT<FQ.:LJ#DGSWW6Z16RC'K]6U
M+!?H3(?+ ;&J3F'ZS>+G@CDQ(52BF64X8IW?[D;<U=XS;+KI)RHC5G1.,/"-
MJZZ=Q*?375& XH6K.W'!NTCQ .&K482^\R6<5R4X4U(C]YO>B(TW1N;S[3<E
M80"HZP./M5^PX)]W(1UY37CQU9[D=G>Z4C+$V@[<F)WE7T;5I^1S =@9Y"]?
MGFY;QCNGE/07$'6^$[@B0"+,WY^'9_00BHVF\*.0/=T)]@8#_WN8F'U[N$'1
MY$@I=&<,-LF.XDP0N79]X:P\<Z1O5]JW?>G'9[/ [*BY?>/D'CKN_H"FJG!&
M_X#C.HM>K%OQG0OR$NU"0O;FKQE.1OV)U?WUFUH*S;P)$W,("MEW,OQEY&7.
M)OK$G#O./?U!&NM+E@EJJ( UQ!B%9XY==+6A!VE+D(GZ&1+[,MDQ^FE%.]MT
MYA]W87*@PU'!YC'&;/,\,LI2K2N-UNVL.:;UU,L7CVY"7][?GPJS0/8;KN8:
M#WY+)#I/W%SFU$J^)0YCD+8<#& C*V2ZM>6V!<;[MVL!Q+?#SS!(=\OC7HF_
ML,R1&O5PX,J+K)'1I:Y&GB 3:1QRY^M(W7[R)@WT8!'8OQE]Z+*94QF1YB#Q
MN%N.T<;LX341\1-N\S"-9%MP?08E\]]]A^[TS@V=*WHZVPFTWA&^ [QMN"I9
M^T7Y&:YZ'!WI3/ED+%=/8%%\']YE-=;/$8FZ=06ZDM!O1*A6++7&VC[,)*_Q
M=#19^,%$VPT[NOYTFSM8=K1%)[9#UWAZS.-#903WM,FD"<@^4FE;W2)9N)EP
M\R*C$EO%/8FP5;N1WY/<#<L0/V8)H9?F4M'M'CEB6#>P5#(8(O"U+S$HU_.X
MP<1J[2,2T04NR-6^VXM\;GNLO*R,Y%:@+OH1)VY@(L8*OAS_]E(U/.IT3R#]
MAST!+I6DP]W7)TUH'?K7(!89A1W@TF&GV(/28Z;^VIB ]KE=OT9P.'(SQ?71
M7E;"N1CM)XL+?K-9.\TN364Y<<VHQVNP<=B2=KJFM6.EGR*I>0\J\SS<YR4M
M\*"DFB,C?;QAO.XWU_RMZ'T]4Y'YRG%IY'JVQ1%!9X_SA:=,W%Q5*LSAW5>G
MBIACN#5#O2A/K?[?O'NHTY<10RRPK)\><9V,S<I'<CGJ//Y^@5%]6>J">BF[
M[A9Q?>4E?I-AQ\<HQ 0IUNY1C=B@5C:+IMT+)?&WQJH7\>YC%UO$=E)\]G:;
ME^]C"%8U,K8MA3#QRO2(]DQ++5-R6#P*;,7;2U:P 2WJZK>[7'^:%ZK]^;5'
MCC/C/U^U4V"M%K1H?PJA U.^;([D<S-EP;1'&DPV!?W8PJS?W>U054-+;Y_@
M[>228H!<T^2<D5>0X>V=(9C8!PBR!$G@C]?E_]NVCK:PZ>EABRKVG=R]N)R.
M!AY.)[<Y2UU6)I8[?KU&X<[VW1I&[0O-U0I,?HI5:G.:/1?^<9$0*RD+UMP>
M>>())H6JIA0OLL:-\L<37GW%93MZY+J-@A=FV#4M,>')ZVIU9;<(#37_NM<*
M"OZU0C(JVS89^__4!5?U'MC,@!IR%0-T%/83LZ,E+,%AG:CE$Y'RN?)?M]_^
MS<+1Z2";<06QY0MC<OAQ.E2*1%@+*S=''F]RV+R+.O-)8>-R-LI!)FLY:6L#
M<G+/=$'5DYJ&Y\!-9I&'UEE3<)X=/I!G<+-K6)8F3"#K;-ZOB@$<KKE[#A8I
MESKJ2M1+FN\D]*0FW'DLHQR@9R>AD,'[VU72?V[8(AJ@_T:\P "FQ!@@=:0X
M]^<WLGX><N9M'I.8Q%2B2>JVJ2]\@MFNA6I#7TS(Q<O+RM6U<,14@>!R:2AE
M/^V<:T6+17D0>_*9?.]X$VL:+R>QMAN+U/ADBBH<C)'R]=CE%LPN]_M-J'L4
M2T03JVG,X'=HQ^586&,CY=1]E@Y[2?OIN6ET^RVIY>::XH0_?'8^O\/ <@6+
M_5%84E.I??[)8\/PM-%?>IY,!F_/<BGNMJPI6KS*B._D%VMF9F <]@)<EZ*-
MEY=]JP>X>2"U3Z_<OE8>/,;O_7$Z(![2V$RUE# <*U\6/SP58Y2I$-+JLAO2
M:GSB>[R7&4Y&4:J/V[XHM_0LF)*R271M38H"/BATT-/A7"\490GA"9OUM0CM
M_O&@RO!4Z*!BS+D+"N2N%#JW'V+=^I.?<_C;V^.#U/X9O<%O)ZY3$IVI%SKV
MT^?5SB-EL?=AE.>R_U/%?=/$I=)'0Q]DJ=BS.:YGD^J0<V7IT &4\/_X!BZM
MUQ]7C=-^/X>@A5T$8JQ?O36/QA6N>.67,P)2&$#1O"CVK0CI2/DS.%_Z<,-M
MEF&ZCH%*]]EW),W/W6,FQSHW!].^QI)CO8W?\+)R8JBL*3OIF5,R&<>;:!%'
M]MZ7Y$]K$+A%+QW;AUHS5%A/^*DV_A>\?>,O^'3'_CULT 9][T&6'71KA?W$
M$[:@MU33S'L:]9F"LSXQ/NWPS,NYA24*">+L7WW8^OSAC9>C**X]/3!Z1G+^
M>@@M"O5$OM#R(RGW!5]2&E@0M1DQ3H%@28:YP+D6E+T#Y' K$%U1N)U+?GH:
M*2H@:QFVM?;-\_1R(N @ =T88% '[3$P8_3BUW+M?WRM6_ >Y.C<$FQO<Q+)
MFZO\X8>G?^K,/=G.6A+4L*4PKT3KV)8TP6!),"\$O?#9QP_W53^ORYP(&;YX
MD,83U+N/4Q<?4JXMY'OXYGD)+(FX#E>HQ <]_@6.<TWTQ*%3<AA&1FF#'BDS
M;](M5Q57$)SV)C(WIM@YASR82;!5@'>K&[Q*:#M;8?+A95^+! TV-%_MVST_
M7+^_.&65].= ^]?=T_^J"_#_R4OQH1Q8)#^&<4/V'P]7)A-S_<U7</QA3<O?
M6]GK,;?3WTJ3(2CT!]\4/-VLBM//.9C<FH&"U*B748_Q_'Y@4<?O#]/!/ZWP
MXFKT@<1.0)'+B(Y"G1M5ERK-7F='2^-P!34I]&F!RZ-11M9T>&H8=UL/9.,J
MU0F7\G^],7$MJXG[6O6.VG3JOVQ^/.9U9R8"M5^@5U_0F6U$9;5E\#S[2MD6
MQ4.ZZMDU[*7.C'N&SSKI7[OMIXD07J1L$HS_U PQG/-X><\(1FK4S+M?XDY*
M,[I&FO6XR6)9GZ,>;\;%U!['\[G&?_[@7O>_^0,$_TK3I#84ZSI+LE_2/.JY
M$0*QW7[07GST$KT/,U6>R/110CQHG QS;H8F2KZV=0+UI*A ]]V)*X[O=B4_
MKMJFADK]MO0S_E@NR[VY^_,AJ.]OR2KZN@[$AP*M90X[WH]0J\Z2MO?.7+WA
M).'/;1A+7HS]JWZR,I\W4IG1M*+;B!* W-.CM,7_.$J;U\X[=],[O?2M0$<'
MU7,+G!.'6Z_'7.Z>GGGCJCE >7>"$5K'/'<2U@PZQ#ID3F;,X>[W]YET_CA(
MJ\[VW_PK'!8.R,3V\%PY.S.8JWC1NP@5_;@&IPC\SR2F/47WQ?*$:2QX"T/3
M7IA-#![@3N&Y7*=I0;HN&5'/J#C=@T]2+L1W3,C;]>#RU'-).:7% WO8$NX1
M7'G4;WP'*BRNO*8;#OC_FKOR<*C:OW_&-I:*!Y-]FHIH2%FS1F09LDUCK,F6
ML0TR=LD@BAAK0M8LV8;L6Z)DR;[+3I2=2)9L;_543\_S^[W/\GNO][W>ZSK?
M_^[SW>[[NYUSKL\9;Q5JXQ24B^'%QSB<9U^2%JLGD=#G>>3S'[]%^;N(Q?\)
M37U%?4-_17V#_M:/QG"$?#YIW^L[F?1AS-^$</LS@A/7#!&D2B2*P[V^5YL:
M9ZW[&$'H>KN3/J8))Z\&,3(ZXK9]T)G_/.'^HPSSE0@63H&)8JW!%'(D(.X>
M[J"((.#MQZJ8C/(BO$I_Y</[#JPSEOZD-UL='' ][#,BH@6N6.FE>.35S,)Q
M>#,:F]JJW82&!4.W/J$7H]\W/T\+9"?X1['BY-FRT K7N3DA9!9X\1;5:JVG
M8@^)9,TF,L\BO'*5Q#C->B!E/V.]#-0=_;5 G?__5:!($M/]+.9U?94!JE:N
MT(S)IEW>L/(^^YI)#LK":R"F^.OE@7I-/--\GHU:\Z.UFWEC-FYY)P346!%L
MSCJ:M?L4808OCM/=#;M$T>FC..)ABH<E\.=!H&,S3<@*^/MEF2SF3"F9\-1+
MS-,KD=S,'>U]:;?F<D</^\[.OIP 1R7M+&62J@=E43S&X!CIZ\XY)00UR$J%
M1RB5R??GJL+E&1 GR158++@!:L +HN7,ZUI">"<CJIS6WD\X9=]Y*"AN[(UD
M)KVE;K&=8)JOX(4 /->O)3??U=/>C/8ACB=$*#C1\98OGD]+>[HZ0!QY0B_-
M)"S3_R[T,:G/QYSO>5DG^M,06PPQ+8HJ?2>P-^E],@TCZIBMWY+W]0\RWF4N
M(] DH_O2WW**]@/-$L] 8X2\*N7H";QZE^Q1R^R-@2=7'^C&EG&/H>72;I%I
M?PN#- MJ*DY (A+5HUT4,9A';]P%'KR/=!S#FW%_%E&,0F\*7+W$Z5_&?Z,)
MYC=[<0[9^6N*AFB)\.KQ2_F'K7#ZK(6E$9+9C<-_R@YIW$"2"O%("MDF!?D'
MM&95Z2L&;@ZAIF2:'\,A"M?!\=0"86!-D$9(XSG:^)"Y77<T)Z#MZ1K3[LG@
MSX4-]->?WO]9'0,9_7NDJ)]@XE!OGAH<.V(P4HR%$4:/],[?TJIM ZRU4$LE
M/'GI(2?1VV\$S3>>/P>/BSCBJ>$9*3?YS@0WL%P'UH./2+=[4!.PZF(K]'TH
MX6"0>+@.L+[0NT,-U/RH8A#DQIYMZ_&4^[N-5%'L_)X1EB2C$(VEA;TTOJ>Q
M%WETE149=VCU*WX;)2!JSL# FKX[?<"E,78\J9?XH_ZM$4-5LC I9 ,(%G81
M_/@$GO\W"S'>-@V'^[=.:11-K0#G9S+ 6YT4(1!T^^:2&J<]@P*?N9TB[",+
M>U#)3Q(2/'.X$FKOOERIM8#Y/!=C!N=/Z@/3&$:@^$=!0MGG3Q?!]J)>L5S7
M;)Z@1S0 PB"/(/")GW)G]KEYQ(V;&UT\)P3E!9S!)_.8\B0M\K^:#?[;S0"O
M$O(3G:;X&9YCF\/H$LQA^C9'NA$89T*6P[R@N@;02<Z&/3$_M*!A3GE<X;#$
M\DX>@YU2GN<>N9V*[J5ZS2HS?S+<=M_911O[E5'O"532KO:QUQLU'[H7#@"2
MM"\(["3%H@.-"CO<D=/-[:@"!X?<EQ$"BS;Z//T\W<+,VB#9=9)"KF[P\-)+
M>]=IDZ?CZP\6"))]^8N>U[;GG \ 'Z3W*@J4\@5KP<S ^]8/KOL-I?M[ _OD
MG^M.O2:%OU:?61SV@F[R[>;E*MD1"NGMC#^N;_QI/3D-46+9)DE"3 ^JW"5/
M51JC"YV >NST;\VUF2FDD7J)A2_OXIE:#@"56T]GMI[=Q^Q AW<VKVU!N \
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MIR++;#@%L?LZH;%N#\G%BXIQ8B MHBE9SS/:6,JMEM56R_14LHV/J9^381]
M-;.H)-[QTYM+L2JH%U;%T!',8IG( B[4Z -J1Z='!NGV76,9BAVI8@1&)-8
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M@PY<O]YQ+89C9,_Z1LJ<KTCH8F"!R3ER\9,F\[QR04#3O3I6J?-=8UPQ'Z:
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MKUNNK<GA0N-^(_2M#>(NGIHXRI\IVOQ/Z' \<!VIJ2-&CO-YC1I7J%)..V$
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MG<ER*U45D=(?1>I>YV$71LH3/0IUBNC,F6AQ=YIR"-4-&$BDR75:5_S&>K%
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M?F'2C)PAGTFHDC/]DYLND;'A<NOK& /'J*A*P0 *?@HMJ)8H'Q_<V![A[\.
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MVM\"OL; P L7RD.OP2>;MX W54*72.;@LQ787-'!P+,7@]%M-U [ &X!DMW
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M]26J#S8E-;%YL56.'WL]^,>DA0@QHD-:$,"'3Y'4K[4LTFVMAE/@Y^O_9P9
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MBH(?C![DS0FLU<V4-L=E*KP]Z*>=5>/1I13),^?%SST$%=WGBR/"Y<_A+RE
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M,_AJZ 0:W3Q%\T66&KEFGLNBID?H0W1Y2%SGPVX6Y^QGMMHLAH2)ATW'#S.
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M8?#W_-A%S26C+9=MIYG,>+#ADL;?8J7\_)7=$TI\3@O]-XI8-^-/ 'C7F"<
MO\*N.D>DA+>8TM1TO7?&BAT#$ZK[04K89G>S7FLB1JWLL.T=%5TRTK%W40L2
M>>9?&<>ZF0FSK)]X*V8>,<PT[C'HWS/2R_GFNE8&$JM=99>= 9 6VV;^=]TF
MNC<>:)Q0>U.M*[>/67^6?_?8*!G>:#R\N+M[7[YJ5*^&'R70A0E!E7:>JUC#
M!)X&_SO3E5[BA?,>ANG;%EA#"(C'?-X^\<@KC!/9=SQG^@H@<O<NBU@)!XEL
M8\E_]I&\)U^0O#\12K=8L71M]O9K:W8B>@/5MYOQ@:1.6@AS;M#&A2'T@TYA
MT@FOX>6M_[.Z_HZT9#"G@)@&*.7VD$)TZ(W2QX%/<.T>1UJ?W*/5IUAL45+G
M2\48R:KBI6*^9OXPZYB(G],B\/T;O5413IJN)ZP;GJ5[!I%J]TQYJ<94)%-G
MR&JP-7H5:);\M&<_4%#<%O_#PD+KJ!-"NZ'W>[9>DG:"$;9E9A@MTF1OV02Z
M==,,*B3/BFE.)%)MA&*8H@XC,(%*;&&]U0)%4SQ*+WZ7^G>O<Q%8#04M\B7X
M9P#Q 6QX<?;"GF83.9E=5;WEBQ;C7<=4T4,>?C=J4GT<%=\2*'W_0?8[>!;,
M)_4$R* ]*R[G5RC47Z9"3XY.DHI2>+GU3@#%>MR5J.C+/V%R?_?0AN\YASQ*
M_G]C!;MQ\3G'7*A_<^75G/"J;0FX?V.[0_R%X4 $VK_JX\ GC.5;/![IOZGX
M 5LOA.&5T+_S7WY+UX*J:O WH:!SKO1_*X8D#^T'9\>3':BTDV'@G^@X>G]_
MK*,F&O+ZC\1T_Z_8*"/%= \ZUW$D WGLFO0)?4FO4=@$@V;_C6**+O1,;WME
M)U\G46;\,(_UP#Z,^(0F>W<[/8IJZ490D'&Z!,T4B]<5$\'DYXM^.VD3%//V
M;\1.9/]_5J[2\-HRT==YOYAH[>][<;XE=ODOC+8E\'ZZQD1?_+E?KS3=SG_R
MB>[_$U\I;A6K2,<<ZB?.2\3$87K], W50BH]VCI;1Z@')YL>B.#D^85_!+6O
M!F'+3*#-HN!K7]W?V$9A?5A^4[4J029>U.AS#W6$H0D4D?]"/?U_X9^D__')
MB__"IXWGW*WDJ]ID4MT'^IHZRT\4:5=QWGV:J%)F_1JW)R.UZOQ AX^6^3AZ
M(/E\41P7QO)X AP^@MI][SAAZ+(06I\ E^9G3X#YHJ(L!*]__]$Q7U1L#JG
M]Y#REFLA)_](&-.CXW!\YPE0*YOC1W4F4.PU:OE1>0PZ]:%H]4B6F-X<8O&A
MV$WE^1O\):FM#=";LLW+\7OAPF+Q>1^@.YXB30=AGH<-^F,^$'DEIU[Z$GS9
MS:"#PC]DH3FQUACQT^ZT52*<CG+JW=2JL6CN3N\IQ8D'*1=D;86'&" ;;*%+
M^M1-^V"WWJI@].N8:P<%EUL:JL7",T4@T-LU;FVE^:@ICXK-I"I.FK0'S=ML
M6U"[-C*WU78BI3U/ZF4R+5EP6>\Y"Y<LFF68!XZ:8B421-).O0^HS#4.UL,7
M'3##%Q<#3KV^'6^YW2(>-)WG_9@(#XI2MN%2JYEA,:NNC])<&"<+2OYR>EG!
M&ETNGG?M>3ORWL,D%%A7;1P-[<1N)/38?,B3/^JE9%_=U[E^UU4]?I3Q2ITQ
MI+'YIB.\8::T(JX224]^VH8<3CEY4':$G0 K2M*'L6ZT#O\R-XG)(9&$H+5V
M2G8F1J!+P;8J,A&6(NFB$Q_'3O3G>;-/_2SFUU!D]0,BLM>'K%3U[*/Y+N!>
MM&./SGI!,=$;Q*\W;IAVZM\DR&AUK<BDP?7:6K'9O-1HLY%43, .VW]O5RL"
M66^/@$_U ./B >XW$?BUFX]/ S2^7A<:;Q*&7J(@O/K8O/W#64Y%PUUPLF!1
M9T62HM82@QL.<"I,-&MQ,[%U"Q:K?]GB=DH[H9RS'.3D78%!Y%CK#S(J8(#G
M\-91:*_*6!GAF1B9')P;@35^!Z3<ZW9]&\2BD/\"B0CZM<U#K:$A?W6_!^?F
M6STJN1@2'L"C&K\@7GO0=LU[(\[6.(]@.U!-+HO3P(>9%OC#H^STW:AE3 T>
M-Z5!;SF%9]/QR##S:4Z8M36 0 TIC,D?PD.)[!NAH-UZ&+Y9+*1<!Y_N\[D3
MT#.KT^E%#\ 3PY_3-/-G2NO>@;GN-5^@*;0H$V.RYXS,@3W+.1O,S;Q4C0L[
MM!!"U!V;HP(7P^3@>; PS'^C8?1?;=Y.Q1-E^@A=E4C_8_TU8@Q"'/\R;[0.
MP&QT'=NSJU(5/+/,Q2@?R2(O*#)[J]ZQ+N%=!)4^Z[S8[R)C5<1,T1Y )^MK
M&N^G9FL_QT\R[?NMV;I9/APF;X1 O)_/$_F29+HP;B(BT],-"4F<QKMHM(X,
M-XS]Z+>R';N_8YIK(E-IR-=Y51H05X?M=R+S%Q;Q26AJFJ9 0.MR#2=942[N
MK[N9$T56!'*;*_,*-E;$1ZWHG^\X(B"#*8,[UZ[N#_+!_C=JZ883,8IF,6FA
MS>$Z69/,Q?ZIP\71Y_NM>CZ-O(4%\I^7FAV]3]09:L 7<T">7://9U#D%=J$
M'_TX.*B5PZ25A)&>%]&>FS0]O3D@_P@H?_2++42Z+/"%5WD"]3,(H#RA/ 89
M!0(%)/C]6F;2EM;^A5Q)'/*?E"3N"DK5$L 7+#_@D3#^^(&KXT'L'J+.$6N6
MZZ@H:QJB3V;)XK[ZA*Y8?"05?=-U/W&WO=--U3>7C2359*,V%VYB(]*7Y\6Q
M*X2:(!GO=Y+1<J_PW\;B; NDDD:J?:KPQ#,8;)(BNX)-:!)"7NDVL>&3/14W
M<7!6[Z8:D>JU/@MKVX1KC!9Q@)(*,U9+WAS9EKWO,EHH^-;42!U1;$AAZ)FV
MBY.9?^!ZVQJ'9+Y]NL$G6R:H+CC=TU@E$]X[@;,H%]7].#'/1SSR^FQII[D2
M>4Z\P-UUU5A':_.,:H''Z FP7U)586TG?,=5\>/X>"?RX,SKX/1B-]\#1+-<
M-[>%^G+E?>L1]<3&R]1L(J^<_#C5CWN>0^]7CV9GWY'CP3&T5(\68FNRN/XH
MU9$LE2S$])H-'U[.C-?@WBEL:M4Q#?)J^#2P+M&99M9T62F4M">I.85:W&%2
MUZRS6#1"[$?E'U5(I38L8+=P)ED?YZ2[H-5ZIWN*,/+%%UG)H&G93NX75[LI
M2$7>J;-N!1Z5KZJB=#Y84>@63<^H4&:NX#M"#%1]A[.3GACOB7-F'IYJ8+-R
ME!\F%UW<)#L7# ]3QQF9?WF4U_:>(U[;66_([YSD@K<OUKM7_99HH_4(M_L)
ML$[9Q :TX1L9NXG)9B8X7W(8(VDJ)X6#UU!OC*+;B#.F?&"83QWTD81V7A8/
M<0(M-74:9C0.<^Y$&K'H8@2X"_C$=U_G'@$W/J[5(E.U@U[].&RDBKN=(4*Q
M?R1I3O\ 4Q-:9E/C<QX8SWP[;M#T/;1,.^E(-N\;]> [[KSUT&[FX'*;(HX-
M"E4Q^H^)CS1X(T*\F\='AUDGU'ENTEQ:%MN3KCYN *.#*,OJB5PY*-G&;T\
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M=+.@,37%,Y,\IRX3:^;-KTXTRP+X!F-P KAYMC6HH$;84YA>"$!HZ9IHOKJ
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M@CY3WP]U>_7ANSHL-8@($PIJ*VT7YCL5=LMLP^"NZ2;+BA.H(<(#'NXW&W\
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M%W[=DZX;@SM22+CZ:5]Q-S6-YOUB+,;D\<P?S58+/!VR-;9&1).H$XBD@.\
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M60$[_*1T8;SK=0YB;ZY-.Y/]+K2LDT:F6?A4:RE9T>B^V7O.V>PUSPEG=_2
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MH)[)\=,36NC=:2F3=.SZ#8BNJ:5[J_+V<W8(NQN!>2"'%)?0A7J&R_J276;
M/GFK.!E6ZIFZ'\D57"PMQQ^R^E#Y958WCNK:M8P5S0"QHAX L6T/;-2D;#-
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MJ<O/<K;,E0ZLTD#]^3<@.$'1^,+J4F*:2_@W((!J[O8W@"4V;F-R*-49LG]
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M(K:Z0:2%@1[2-H*VV.@U^L6I,,(X',JGV.J-?GEG6^6;M;@+/SGP8S(\=WI
MNH%/J;7!.IB_U"FI^*L>M-CZTH8,P@ET( 1O$'"A: E8I>2X<PS=VO*/:MX5
M[OC-6[VG]?V3J6L-698"X866A1]:RAQDT=V@8,VTGB_K8]>GL_8:C00_/HIS
M3D _X?VH"]>"/FT(MDG1(4E#.<;>"?(KP6PM+2&&_\VT_J.ICZ;.6O!PTP,K
MJL&!NDH7F_W?HNDED@Z.HN%PC89Z(\8P)1D!P$9O'H&:WA\&:DQ)TKF(["ZG
MNM$#JV8L=]PE^:+55^XEEY]3@O9W6L(G5PXG5&CO<.Z_H;T>ISGIMHP\B)N+
M!A!IDPSUV0GE\G3/UUAX05(T^F[$3J'PJR$ 0_-;A=31<N5='$IZALQ%SE/>
MFR'1'_?\BN\@T<1U&T<M2P(=2_9_&"<4K%:.=#EU@J_XP3XSZ66\X>BT"0<0
M:&P$O=[-W.3YHM68490S8BG?F@)BHZ4)B9NKGUIRF^*?+F6M"[J^%F6<0XC;
MBN/U"U'SU6#WT8*-9/X#'UO,UM8+=3_NE^Y4NO$3PP7$*%RL53#*^+)RQQ8A
M*&=]GC !L%E,!^6SWA+O%K6^SAPBFP4QOE*BR34@XS'"GR)Y;K@S/]&^GGKM
M=^G@CI="Y>ED13N5&[:W2Q+Q&X"C6/\AOPG\D"3UR:?IQN_N+F!Q<'+"$-:X
M.K%I&:W.[X^BUJNN;MS<39^P^<6ZL2/T;7,:C8*XJ3*8]L PV[A94VSQQ_N+
M.@H#'M%1"1W,][=;Z0B/^I\I(-":)C?7:9U5V&:H[^=DHB>SB49PLDO1]M0Q
MD 7WK)1,R=5TK3C&9!8'Y?0 [^KJ,'&SC]"X\%TF,QA'*HUXG:TEP0X7 F5N
M5-WM&J-G?2%RKQ0P6_]B*Z;_\U6EEZ2R7NA6,F.8#"-G!OEO &53)<2A?+6T
M$:3IY7:PY^<6E]3%?T<)6"BM<W0E4D'FI1*3+DDIKJM'O@L3D? 0Z=MY8+<[
M-VC7^HEH"U (C/>NT#!_")0\6.9VO2ZMX9A^OK*RWI5#ND2F7X3SI+_M5MM?
M5<+($M8,K=+X#8",Q C*=[C1>B8".<F$AX' 3^$#BQ_MW"5F-%V9.S!\K=_D
MORS#>CMW_%:6>GX2?[#FVB-BO5ILV^,N!G5OD,N]_7TLY1Z'=L,G*!X4/% I
M/B0W5AKIGJ_[5P1>YI4_T%GL;PJ ^'_5')1?/3\;>3P+^$=*%(D3IU4]@O2\
MP09O,O54]1&A]!L@!QI=UT9,4JH)C5->D >K+9<(H$RM.<AM ^>*U7U  <Q<
M>T1"+3)D2PA0QV?&]E:80GL61CZ-OY(;TS;5(RKB$=Y6M&$;3\,<<RWHC7IL
MT?-EFRK(R^P-_LI82KA :+X%GO2[ CK:Q>8F13(TK$?"**!XLN#\K.2$&:CM
M@?? <&-FD:F-0'SDAA![+6H_-.X14:YDWVH\F/II)BVNSTN B-.2Q?/P4)QV
MXM'+_4>'W>QO0-,7U7#;J<X'Z)%1DY(]&H:$0+=?5L"OZ*^C]DJ7,\!<]\V!
MC) 6J#*%3(J2F CMR.(N\2DI;_GW'RYCBTO\P,=CA4?=H5TTM/-A_ZRO"LW-
MR6-VX_8*4B8'S?!OI6X-[_(H#5I;?+I:?6N_OM7EO35"EB1^.L#OM?_X4MWB
M9>:U6Q!X_^7W2:<9Q=YQ,:8W%BG+F@RG'\;JRC&,\^9/A)4UI4SL^"66B$)H
ME$\QW:3U@:__9_GV_^5"_R<C*/R[6I__5Y9,1HW=]V,]C=XU[6NCP!/G_ _Y
MWZ]K<V:R %.+7$RM#?K8$Y]'&NFN^D9I88Z0#MF*97)F9K00[0JZ<,.? N&U
M (/6N=D]D GUR"_Q,P-JG)M*VQ9^D=7]<:1!\3 >=F63#-UE%F H5D9E+ZYK
M_F)E8*4X='JL_&X>&0CO<>WJS'Q" 69GD^['E,Y@@5_*%&UP$?]SP-6_S5$'
MI/GKS;[ZQ] K-MXL("MJC9 ZQLG@B"4PL"/T)*9:$AY=J^A'"5-EY!E/6.M[
MT'34LPSA3?UT7K,MK"]8-;I7VR:J\V5Z-ZL%6O90M58<$(WF^O7%1PQ\LT%N
M>S2I3^H@>H[,/(?=7Q<]^@GA!P;#[S=!-O&V[GQCMI>_ 5%MHJ.U,:QH3S1?
MCE,&QK$'3>/E.24,UZ$,;Z=(LZ\2$V8!_[LJ<ITUY*< !Z[:?JP8 V1_65$(
MVT&635VR+9?3]I=G3!LY*8[?2DJI6='8MV9-)+0=W!C77.K%^&E"<LZ-S^V-
M8'DOHQGUD';I;$K3=T7+8TO&UK)T<?5/5R.F67*UMAI&7CCK_V+NE'[(<U.5
M]6EU6M:"'N4%<I1VQ&@?M]%'"J0-@ R8?GT<X@E"0.ZWXH+_RF A*7?PV;JT
M0>0.1C0I'$A U2AP&.,+].. G4BOR"S/%ED',;^4='0>](O.)4LF)6]%-Y.@
MB_ ;AVT)G67CG>%K1-I0 QY07RL]M2>-S@TPI01"5I4ES)JN'7"P9RKEQ'9(
M6 M!FK'6JX$'L&9]30%>9YA5)GD#<X]46&Q$@K;&S [DEPQ2H%X ZR95DX<C
M>8TWYS'-8_GP3K'ZP/#.(O?=^]$V3HFNDGVNKXFE7F_G]!12W93QX9L-4_AD
MN.3M D;>R*&2=-)C(F\30XOX\CC"H_S^JI^P,?7JD9P#C]6!ADW;EB3.J"\2
MT 2.LA.-EK:80VDA')(Y)A>:@HU'>!W_AQ;X0FUDK.0\$5B"^X@5#Y>!A\YN
MB8*BA/0.T9W)_2[+/=G:DO2;R#)QSL[-]*9IU(9/:;F[\581[%+CG/D09(SX
MIFYL18^-ATV.E;> !VM!:MR]NA.;])S3Y.^OG?-HH'M^8)J8[ #Q8OZ"PI+M
MR)]ZT_#Y=<J7/L$!,B(EO'HB*]?3'?/? #%N4M$7DZ2_ <"PNSN0%7HC/,BT
M29BSLJ.2"M4GZ$.62Y2+2XE%R:AUGKKRWC2K[:KR]] \CN:;BJ O+J[XY3D]
M]K@=X],B5T6;5O$P?%L0OKBZ,U<(/(N6SVT;PEZ_&W ]Z<-0878$],[E&_3S
MH>+C&3&4V,JWJEYVU-B:VF5ANPF[+K 9\Q+*5?D_<H3-V:ROGG/O_SZ^;V+^
ME4WS/">#G$1;9O@#@ 3X=> Z_7D1I_"31+9W:C-)V7U#_(G ADJ326B%L3HY
M!KTMMW9K%>^!D7HQ:(7D#>\KB46*1UJ>EHL"Q8RWBLZ28P,-6E9VK$VW=A;2
M0-DM<7ZO7:?TL5>[T?=-NZ<_IM5&'C_U4)9]HP,%KY\Z;'\XL9D6U?!B7"^G
MM*UP3E?AZ><RU/P-<%B;6MTG'P;ZHWBXDIC(<\:<3S>R2;0Q$:94?07ZW#,M
M5D/<!1K "N8<791\+_!DT)\^.-9D2:XXW-2_D[M8NZV>QH#J.5(:+ RNS155
MFJ#36?\&>,WG?Z8$9/P,PZFMBS*IW8V03V:RIB[Y+B,9,%?7*8N?M_$9/-90
MX6"=P& @2[&?J/:Q\L#(2-@G1:'*$/0ZVB,XBO?E[0(U2&G^C#GO%:<Z53)&
M5&9,33#W4R71?0&4145VS2?J%&,\(U(+S 9SF[X"1[XE #$Z_40@0L7B_Z.J
M_\_4?MJDV2%E;ORLP-*?,]?Y@=/;'/6T;4CY[9(*)+N[<<$UMY:EI<7FU8=.
M_+#8? TO8I2/56:"N7D_O]MZ&W^F-:0+RIS46;R2E.M?"YJ$=(:4J6:$5/%A
MH;55>GW+/FZ>NU @PS[&*G/3WLQY)+$R:DGYI9K"\9:_>[9-@D:V %O0IR,,
MS8OZ;J4_&D9C;#E\45G+TMXR,SE4T+>GP">%R0.8$BD[-(2:=GUP1(E@)N#6
MMHA[TN#W8E7INI"?>*91?/]TQS)$]$$:V-G9^9YL\>,>C7,K^JM?7*N+:Q$[
MC6MKR.EP)FX>][A*0.)^8G^CU1P")VC<AKGFF:(S'51,R <E!\![9@2_ND2L
M*1T$+\37AQ_*H.<OT48 G&+^28+^*_OS+X_;Z:8SYUYK< <1F71(#;D@OAH%
MI\LKINB3,UH[6&PX(5WR=%#&/<3_=,WE>*_%4FXL H=FJY[K6% \VJGV(WTT
M7:/SGN+;VQ)43$R1HRS P;\WGOI_,23_F!6IK ;8=]EL=:4V%ELEB9,9MOWL
MN\]X7D5XZ)\#I$+.M\2_9&$]6<"<N000+&5].X4/MOZ/VJX#&LYMW\^,EF@1
MT6OT$D0/H@S1>X_1HC-ZKQ$M(83!:#&$T>L(P:@1O?<:#*(D6I0@'(0\R3GG
MGOON/??=<]];;ZWY_FNOM6?M_>WO^]9__]O^_291KU.AS*F AP1C85M$HO0T
MT[Q,1S,+K,0J;(T'7AKXW<3I)5L>2YWPC%EDHA;B1/2<0NA]!"Q%HW;^_:?P
M91&N"O4T?%BTJSPM ;##>@GE+7I)#^-Z@'ED9H8MEU@>]13O=,IV/U9:71N=
MY[TOUS_:O7 +VGMV5(1TM*=V^\PGJ>1'OFA&:"(K&YL4=DIXZ>,<9R>E.SYQ
M#GG>\K1WI]).4*:IYZV#UO)&4=:7H<'2-,=<Y1[UDEX9X\8Y;[<0J*]9W;RB
M#I[5C=<?%=I[>/GJ2F;G5*SLX="N59/R38;U.4&O4(D/^NBS[A*B+&0Y7SIS
MQ&!D4+$HR2P@HD?*R<Z->&XP#9B?+#EQ@50N(J(]BU%N%B<)W[1KKJ]/_2@J
M_(8!? 1Z@:Q2I/8Q$3\JJ1#!DEA:MGF.Q'\:*OMHN& _5J@3D?;*W>X[0#TA
M>%2<T-/_*PKB75]PCFL6]?XYU^4T@.Y2/Y7&&#IS3U=)^!D?JV" RQA59J9N
M/?5$7_%68.U.+6IOUK):04P?NTDT<+V.$:4]ZL;G4G[DY+X=O<L!J90^IOL.
M^+KM>BX+._B,Z?&2*J]H8N//_OIBPQ&X_,)[P@7%U(!@1_OZV^D=<G&POPA3
M,IK9$SZ/TV ^#1<6:,_QU&\!2J\CA*74]"ZGU:#/CJ;'<WC9AAIB\PB]Q>@8
M'+\]H:B^N5 ^/B3>B&]C+R.Z/!;5HN@8+"-'X6>UY;2=46(@RI12KW,)SMW
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M'A?<TY52Y,2*#9HUA#R9+3:;7;I..X!)CZ ^#?2AZBEP4"FO345YT+W^U*1
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M<D).!&;M+BX5DE- :3O:ZG 'ZD>J,VZZ?;8--7ZUI*<N[H^R-('SL/23LN^
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M3TY"24%.0D9&1<-$2_7@"349&1WGXR?/F-G8V"AIN?FY6/B86-E8K@=!PL#
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MP &IA#GT6P0$S@98,,)/%5?(2W! 0^HE'1S@DVD!!PA6@7=6X0#, _JQW>5
MBE(W>JT7?:!6BI./.._BZ2XE"RJD8M5,UQV2(KX._F7_7/_'^3N+)<RE+\*(
MCCW#9&T'\D&KSOOF(^-O1BH(#V0;D6B>W\:X^,8O2M$57?>)M>9Z *O?!@#.
MF8W# 7U,NA?GP,^5W8'(;BZ%C *=[@^'6%UL-SVVC%;"9T)8&!Y2Q3X/': U
M^F LC!_BS;4R&$M ;TG Q3H _K%_\*FFZLPA5A0,%KQ;R!<G4U]>+NVW6?#
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M^W]'C8J(\D+:?]]B6$:UMZ5A3.VM4Z9AOXM,E>JDEQB_O;:1P@AX$<L-@3Y
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M\>,XXN60EB1)#!\5662(G>X$J7IR9<G!"T&/:3.=!JGAWRD>^(/]9AN=A5T
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M\W"(:F5LN',Q']"PR"R3)TR6F/BY1/Z!R2A;B,Y$SFI3.J#QJQ$<8,*8N(2
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M-K&<'EA0,[LV2N,ON0U>!$N*1+_#1R6)"41I2E:MZ1 GZE,Y:_GK9*[^5"$
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M@+B8>\Q\XL),4=O;D;RRC=3IQMM4WP#0#MJ&5&E.J%Y_FY2D1)+ZRGK\NS=
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M&L;,_6'\IJ\X<,<-ZESAC<29=+U<"_/>OM/8\.DA$C)P+T "Z\?7L')M1I!
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M>$B;^F\.M:4MRF?HXU1NK] W[?I5G@:2#D>\X>%<BUZ8[A%J0O/TX!\+?@,
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MS]N.MU0_6LPB_5D2@H>^9&AH5=Q+3&ITZMRTS[(_M6?IC!L)_844*U9V#^&
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M_#U?#37<OKNX=!!T'*XH[\1>TKY/FA2U:9P;8?^]\TX<<"-8$&GL3XC\;P9
M8AWN_%BJ]B&P.J,,?[X0&\OQ?+FN![%$2Z=WDDZB-.65::/6H@C%8YT+38 >
M^5#D6-F1EI>_)TZ\#(E,*J4J*>L@#J ,H CH0@!H<+Z^F\YZE8D"R>#$>T*T
M&7I1W7T+4A[)@ 57%)?/X\?UA*M90KRYY<><K1()C(4L3(@>;P!U$1H:$M,
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M!4Z^4]>^ND?V/G?O<T_M.CWU^V?>KJY^>LUZNM=;/2^_7]8!KY7D%.4 "(@
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M>UNJ7GM+ R5?#VQT8 Q9>R[%M3(E?''@<AQ#H*=1 ISL5R+:A0JNTD!/ZE\
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M8@YO4HAC"-:%;_R*%RT+)"R55__YEKKC"/@!+AG:D(V"[<'GA9RD??G9?U6
M3/34)H,:EY0/87':$*=D"Y<(Y(MGXZJ."YK<>9IYGSRF8+A%?^N=<5/!%?(L
M$ &AIGB>?12!C44/L_]UIAZA/:3J')S:\(L-N+I6QUW07V\:QX%ID3':,K>R
MD$D/2F& 6B?[)_% $D*!O6OG,: +(T/6=JZ;70SM>%0_MY[U*;22:</&N@KW
M>(C&K$UY?93$ANVS+HB+#$.([#- )BX VF+WVEL93ARPN<2%.[QQ(J%XYC?7
MW/G-?.W66P.M1%/3H/X,3& D%[=,A/HAJHFUR1X'57[#\ 40W6Z"^[U=D*F,
M0<(K&"/.=G#39Q^I(+=E=(U \07PZH?!:J)54ZT:_<6OM7IN,U0>A'WU @>#
MHOX7 *'5,^/L%685-BCWYMY-MDG#,>_/U@Y<BKI&UK[6O6I  V10OD!-71-]
MIN[,Q.NY:A@7J_C5)G6H>XOJB*+O!8#?KKEI@K%R!/,+9C=F<_W\1G!\5]@X
M!Y>K2D7C'W))^K*I#ZE%ZCI:DU4:ZA0H1K6!\:>&+E@"D3CR8G/09R:X,]SZ
MX@70*UG$[BI\D;'6N @?AIP^F$N&0CH KE>ZB>ZZF[KAWJ8@+X?".SME[?J$
MT5C5XM9XCX/'NJS$U3M+G39HO4(55[EOGV-_&,>M[6_Y;^L:J -$>[ 70%2[
M:GZ4V>E:7Z/C0:M3(J^J^]#%9\LW[VE,#(IRGC[ )1KR%L%L&V5O"I='Z"VB
MK],^H#1N5XZYW.;@JN8VB[X 0AU7W#/;13=L),0_/N.U[NRD#&#)K/B;9\2*
M:(+@&& N OF-OXMX,'W0U"3TR!ZK\C781+,YB/;J1(IJAVC/F!:^%E9OQ>]U
MURYLR91:-#&-_K7]BX<4X!2S.OJY@3IPZP5  "8W3B\7##Z>5>Z(94ZE.A*+
M^[[DJ/N9ZF\(9ZPJ12'4$@WGAC!#)YD]_N--^DMSLXRGU:?-5N!21%R!LD,A
M!'L DMQ*&/\^=&_%7X@F"&"8VS[98X+/WT5\%WVK+$*4V*I7#4Q%V>(F8SZ-
M"A3'+?#\"B#437-/W^0*%9/<HN#"Y0PTY5W[#IVA@&IH6YYY_\V1"J5L?'X.
MWD&H+P5<(,KNRT+98T2$<@)/TE9@HB&N)^#*FFU<S Y. SP/"66OWYDZKC3K
M=&R<H1C\Z!#3+D#I0C7^[?==S "244WMO#,%J8UMX L@WV"5KU,?,^.UID,:
MX+BXBG7!E^DN3VIJS:#UO"/^]_TX/FJG*3U@0)IM9]V2NJ&JT+UK(#FB2%DP
MA!U_22.2#Q_B_7<[L<=^K(F6J$=8TS0VW:@*,_@;(S%+MPWH%/L;+S(5MX^8
MT,\ (49?-3^E_2\+WMJK].VS'%=&_)O!7 +"QO<_JX4QXW;@0\)'4E0N1#N>
M-/TQ1'<AP+GZ="[L@VS0;,A9^[AL;_:M>O+X-W?!3<I5U@2MV6Q5957K[FJP
MTUON1AS>+C*(VAS"JJ8Q,._)*+'=8I423IR(D\IT$RV\U<Q#WRS4S2A/-(?M
M94+-FJ[NP]D-J@E@A@4MD5Q,RM19\/9L\2',:QI2KA%>L;1K4J=QE8^GAM9-
M&/6';TFRJ+9'HPF?&?430)P0U3'1HF6QRD4#I? U90D!_U;H_O"V4@Z5H+TS
M?CX@J^__\O'W2-G]CTOC,^T&([H^8$W\J&9#^"X:,F&<]*!7C,R9%$%ZA%O]
MY5A-NJO1TO"]4MKY6KC Z->_OUMTZU]$SLXNGUP,Z1!B1CHX1S>@869T4<SS
M#$T1 *"J'T-LK CBC_48Z]6Y*U5!_5F<3#]+PILBTJBYU_G.]%/A@%U?IE58
MW_F"5KR^!D/CCKGP8W\TMV&V_U5;&5<@-,P[$OF6FV?PS\\15&ZC2#^L)Q%R
M/*'.]F""GTUM[1ZY-.>H##J-31L1V+XP"G )YV8P/@9CQ6BOT$%FOB4APC:Y
MUN3Y"V SN"Y'ALS+QM C:4B$MP9Y:Q_35QMT<P1ZE,?\PE"N8^V?+1U^#3F/
M3N#\9>['[CCL9DX6C;ZJ8PFX'A9+.-/K.B]M%^)/* N9&\SQ7/;I-+J[FO#4
M0,/<4K"ME) $<2^N1"B.Y]JD]#,L#3\30-N,V'J(C8GFKG&)#CU_M":5;J1/
MQB':4#@TZ#)\N7JR'CCK?0'@FAQ)PBZ'2])? !NI=CM8>5.4YVR6QN>-V9O*
M%%ZB]YQ/*:0BH;;&/ J#F*\]!A'V.@#N)OWN7#OUL^V*Q &E2T:+RQYU1F.A
M1+GL"MO<XG/.!\8EY4<.[A'KUZ<E!&\OC]V$:'J7O_BZ=)3>*:M!G5FNO!;M
MC*=%@EKM)\3) D9Q*\R7O-G/=[(B.&-L83]U\!OW@KCR,?R,0\19D 9.N,1D
M"[Q9JE/S27Q),\?<H-.%PT2OR"@@0O3\QZ[P_;@GZHX7P ]OEMGH5.X8-.93
M 4<?L+K\.4[0KP,WD:_E;CQZRTR0IN9FD!;U" 2Q&/;$<7Z2E.U0!!LNZ;-T
MR.8A/=O1%CY\AR-\($7M=]X-4CVW>!8'2RY>J-#'1B^E /QX6#F4E>"ZO7<S
M1^IS6@;G>4,!%94X2B5[_HZ 20=H![W*G>E&)IMZ\^S)1BOX[<U]TLR*Z*!]
M3\B(FDB CN2&\;ZJ"^&,3Z->KL\!B&.IH36K^X/:,DX?I09:TI'MU)/7U'79
M/+?^JNSK8$54@$3(+%EEUU;#&.8YU)TJ(,EC$X_Y(\1^GZUYP5LP_RY&7< @
M,U<5CU0KDL>KY!"WN3S=+L03B^3F-B%B](#C<KOBS^PR*XU&I0*J_[LGQL+Q
MKQM<*+^MW[; >89JG6)']M#.^7OOLJ7G.HG<4QN,L,E5T;021K/6)-F_021#
MQ,6;J\RA8HQ%1V[0!3?>-0ACTT-!4YO[3[]N[2U8 ^?5$? 1M:8M5-UVA"A)
M/5WH(.,/"T*:[E/ B>11^ N %>Z'WO^@?H)949CWV,)YVXZU;(<FSK9L&L2Q
MKF!.^D&C%/U$G_SV1[T?OH>JGZWW70J?V^N::&W:;5,(G;\8Y"9PX"0IH!"8
M>3MC3!7:7CW4S9\.+URUXN-"71*UR1(,%C#C#<:,?'8YA%D&.(MS:8G$1F^>
MWMH.9#VX9L;ZU1IF^!*AA3Y3[E.S=0([@">UK;%#9:Z'H?(N&O;8 -X>3[6Z
M(FOR^H>*LR7\'9LQ_.-7[XJE*>15OGQ:([FSE(6K95)%M[!Q%/OT?%@UWCT9
M!X/2OHFH_G"U5Q2+*Y++THGK.LL;UX1S!?%5$?\NR*H@C/\03:7B2/A9OGG7
M7^P%T+=*,=>.!D<=59QM(#L3D_3#^K&DU!_ZZJ.<I)H7-"1"2PU>%/JMOK'M
MN[BD0H:AT= ,0C+2#Q.M(?Z% U^BV:L4YFATNR^@A%&>2><+A;)(4[V,F-X6
MK7.9'FR/FZ*Z-H^F^Z"LDPF@\/!>&N"*U%B8-FJ#MG\$ V\J>OZO!1(]B;@8
MD>C,G<Q%K/!(B]EV>>C&_WX*\GRRE\>N!0YB#(;B28D#2,O9N%! KKJ"O.6P
M'X,[&$K))/%*D;B/[ Y2U/J;JK;JQ$_4S="OD:4,FOV_VA1PQ^3GS/+^5J!M
M+X#%,G7@!TMN2,>T/*/WK'&JQ_E6WT(K=F<8G5%A-JIK']%LSK<7@!?:[A-8
MIN\9?U:,OZ@C* 1F,!U K=I_PEHL+H7E3CV'D' .>YCQ"WYPKE$*%EJ'[4DZ
M!P1FC[3?;HB7+_CAM>N6+6T?#(*(#'V@#!GF%U6R"1M%(1&3VYA'"D7"\:LS
M\(VPKG4,J8K0=JX"V+Z\7&U0><6K00[*_C6CT<!L3\"E':&W^%]+2.[QM*W+
M1R!N^_K:O4"-7 J=UG)A]NCO#OU*3,9K4UQ2JWGNUT75F^;7(^)ZK)=&E8$Y
M^G>N?<<Z'XWX:+<QPV ?.[MKUKT^17 PC:HUMV;-H(2=9H^E% _N=I,]^>?@
MDMT5O  8$WI-3K-WP7-B/B\ .NJ&%X#QN/Y#TU];Q3DR:#U,AFC&PW',8TT4
MQ+IN/;;.*Z)T>Z'D$V'4<1[\!PVR&*Y&(FW^W)?OA.T&_<4B-I(R*R;/TT[!
MXAXV-C+CZ4X6M98!V2D9EP9==5/T?6G-S,PG9PE'%Q6NQ))8WI*%!UJ@I(^'
ML08JTE9;73^Q'IT&O1[FN[">)*>>Z$5'\WUJ:;>3HDXSI\-.M3,L5_V%N&"H
MJ_ K&[I-/K>Z[\=BCQX8[_Y.XYF\O:'M?##3 4S'A[KX3OM<0G/ R@@&7#,8
MMG'!4$4.Q*4,QZB^16T!V@6G8<?7NSH>)D%W%I\GL9]*B!6'[Q$&Q8N1"+;P
M@9/G;1^]WE"\25$X(5W/<G0_NJ[@0E1_?2=9.+S+.5#S+>/J<1Z:R:QNPWX0
M/();_?/B>8*>0N#!O) M8]:7PHI<;:[>1MIFO@G3HB/NUY-&AOEY#CJ_$%0=
M<3"Z1=<J *V9A\,C.H9QTE^"!2Q!^9T'^M!T9N-/26*&(PG0TZT&9Y'5P%':
M-8Q&/0@U7W^RL37&@ZB<T L5"OZH3^7'Y'BOL!-_.D)/R"M6;HATJ,[P.(46
M!Q(8MGR4I["ZK&43C\B6DE7="KKPLU)%]'BE!WL5RWV0>?+,OPHY+^N+ TO"
M#A^R;T*>;@4OSNAGA0^ U'3GOE&;H3FJ:BN9)[_Y/@[N,+P7)W6"^5.5M?XM
M(*1_<6XTC[Z!-"6!1WP9_(9MSXL>"SLLY<\'@L/HE9&3G4;DD)/=L'E9KE#"
M:+UTF(K.V_I:.ROY@8-SQG#%M[2=L:27?U;=GUB0*K-.5^=S]7?U8)9X@^@[
M*3=$>Q*"<4_R_,\I:<1YQ4L#MN=]XKEO/B4&8&>.B7@W=';AU)NZ8<\U&=1?
M=+M]L)S[FF!Z329&/C7UQ%ATY\$9/P*^:)+T5G6]^/Q0J8ZVK(&6Z?UJH<!&
MX+%/L"VO=3:?D=Z73./FZ5)_[?4+8+O5'?AG]@^XJ_K.:*-#T$ADONGF^UK=
M&4CU^$?-[5[<B5S>/V9>6<T/;)PSOE9\R[64CR*YLA=PE8-=1>(W5%#JMX!:
MB73S-S_B_;C^^"K^89MJ,,'1/R)G!>EJ&?ND2B%#'/=/ 9"Q[NW'O0J-<T@
MG\DK8G+))?JH6I6/1J*%ZC[Y6Q)7"#L&'V:\1>\Z2O</R=BOG3FL 4,ZPDN0
M-MTZ]6\<8MQ.KTCI8._7SH@8GO-GC._ 2G/\;>)FNTL^)SETS)-2/O*>-64@
M>["(=Y(NOB'#1RSN[Q91-=?&5DC=$O@@SX$K$B<]H\T9JD\&FTN?[Q? EVU5
M&R8?9)RP)UX 3+(^D9J-63]<B 9!+P ,,>$"AK"B\3(8>Y%3*#^9!O>UD-B"
M>JY5DB_-[/. &>-%4RIZTOOC,<]X2((4J1^!WW86F.:ZIRNNW"X08_*\=D![
M(]40Z:QY ;C)A?7;/7?XVS5)ZVNL'=IFJ\"].ANQF J9C6PTD#%>0,Y,%*Q;
M#OGC<GMXEY0:VH84M>ZYJ\#,\YN[//5.ZD]'HPSA53TN7',^CMB\6RI<Y>Z/
MO6D6&6[&WS>^NQ@F]DADLLTW=*%:M5YOZS9I#!-MR[,Y@=\&&Z<,7O<,D'-]
MOS+"N0$>N3.DW4@A&1DI6213!RPQ8  &[TH+?$D/E3Q#I203>=</,,^;Y!G\
MD544Q3LM*D/Z.XEFVW4MDM+2C3PPU#YB!H=*^'747][-4TEN/$<5[#OMW\0?
M<B^JM*GXV23LD.T72;*(_ZW?/>#XPNTF>8=5-"$-RLE!E^:NH<%\F'V.0*&-
M-EW-\XC^KO-8;XD@)K^K,L9W"OD7 %+D9\36="Y,/= #8:L8@8E/DG1]<JNK
M"W5X_[8O45C!$]OY:O@"1Y% @>T"JXX6U95_H]?UT9D4)7./WSW-D^D+P(C@
MOL'KHS%PV/4FC(</7NPFY:'A XZJO5/=Z!#9!!T7S%<4INSJT\U]U?$K04M;
MG?)^6WCG"DPMCQH==W1B;Q+$9A/<[$\#7%2%PU>4X7Z]BE]%>AQMLD?C$NRU
M6EJCKR:Q5SE>  .Z]?!M_04;WAOTYVWVCNH.'CEL3^*2\\F^AXG:M(8C:RXO
MFH<6E*O T1MC7\VK,I$]?S[<UPT_TW[PUM]8$Y/-N.K+B1M2)DA1@^##7_Q(
MW!7-$D9C1S9,;$^*V"9$%_+<WZ_>RE1WD)]L#O,/'%CMT-NE8!23(A7Q S7O
M=#?&#;P\JK;G.1F;2,.VYQ@9Q7LF33P[0.OB3#,/J^?+A\GXP(S!)MT+I5*_
M%3-9@*,?C>1VMN ?%Y-=MJ9SDZ<P ZX_'K(O@!R,P %JM.DGTYW*JINF*!*K
M<+;D*%SA80U[]0XK*Q&4HA!G^%=SQE&I9@Q.9I!2P!0B).!$BEK^_.J5A/!=
MK? KW7B0D?2IH&Z)@4A3-#]M/J5^+XXHU>2G!C_ OL%$=6O[]#)PK33Q4;:@
M[_VV5R(]?X'EQA$;%0^8E'R=?41'<6S,XENDY=CCXNTXP)TSY&]!Q^[+ Q^8
M#.8TB[YX30IAD'X:&!I"ON)?>2+-ENFL[>SX3AQA'"_S)Z=V2+_),L,R1]S!
MB"GJ?$%JRL5B[IA"0[E(."[M1@[?KQW]OHO<R5O@_'RADK_,N:VNHYDTL8(S
MZ_6:1CZN7P7 :97VG*@HZHG7-T"3GX6KDASF**S5#L^6@>QH2^"!6P=_E5L;
MZ+01<#RG8MFWM=QG(/Z>O%O(M:(FJ3E?S]!7]=RT6-W</=BY;XMKSB#0-9OY
MEC//-)<;\/'463M>ZIT>UI9D:@Z6AS=FWFBY'[BF[7D*M\,6I<].^L^49Y X
M1$V]PCGGLUDX"R#WWQ_$X 8WCN@X)S$ A?^/]_F63C=$<1L=OOK.P$8HXPM
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M&NO/P^[,P$N8NAI7S;L+5%G82E(5V!ZCLXDF%WA?M-]-?GEP9?=Z!?PPOVR
MU7C.L]11*U9C$]O7M=-MBV1+!:Z:O:;2&O8J.B]OG*G+Y3-3:!_<0QG&CLKQ
MV@L''( GKNU"WSIFT=;-G#(TM,V$V\15A.%.";AA81'<71/]!J4-S]E5<1A,
MKX,M,)N'RBG\_7YDN.S;@\,6^#(=.)_T42K#^(]%2KNG1N('RWYJ8,2.X58
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MQZF%I'#')=&VT#JQ^:0:BBZ\LJUL7\"U2<30E0?=4D'/\.SPF!"O_A%J&U3
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M-#(!JJA8JHHM%DNRG2"!8L8.SAXTT/0W:?"MB8WIJZ>NYFJ5(YJS-#F.7H>
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MZ_/ C:_;L_N"C;4$._JKH\A(M8-%"/+5B&VB94/L>;CVCX092/79.]K>XK^
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M$J#^HEXV<H/P10X[CKTOCZ.$I0.^S?QTRU*S]9A\%E\ ]:;!Z[@JX9=<*-(
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MW%$:4VV2*GQYQC7SN9&-EAT):*HBB6:(6%^((LT>O7[0=6+*33/[^Z-Y -!
M-;^.8NC;<MUIR247IYM*L[R*GF_X!Z<77JS=Z#:OMD4WTVU7,*J/$I?"[@$U
MCA9Q&V\%*E_[Z[U)+^:N7V-N]=XI+$"3H^<M[.=&GY]X[O>QR:NX>U1-51;1
M1DVH:,>Q&TX$Z?LS^VMY>7G*?K\T9HZ/3BG^U^L\G"F3(/]^UY&>/P047_S
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MJDF1V0KE,&E&Z*SO.K-FV:G8N4G0'<\NE,$6%W>LY=_[NU^-4W</B:P%=AH
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M;&?Y/3$#>T^%6[+-VGWT(%[$3 )2:YP661P]5LZ/FUTN1#%'Y* L0 FWLD>
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MAJI,8BXRDY:\)+HC7:L2VC_6DL2?*]):81ZA$P/5)9FF=_-K0H8X1&<MV%M
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MU4*'4S'H^*VL*1X9E"^CKW^>ZL>@_>V;B=7:\L/MUEBS>G#8>BRWI_#6V2#
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M6_;\H"4H290, @*2<\X@2)8HDJ. ),E1<LY!R1F4+#0Y9R0)2),;:7)00MM
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MLLZ^X;PHFZ[:5-ZK3#Y\R]/M.<=L>I9.A 7CRS_F.K;LVBS%G/K,K#LX4]A
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M(0$^G7I<1!0!7M>SM_<XI9A+&!A I.)UP/8_2W"0&P%[L-(2;=0H7TD=1DL
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M\='QDINRW.%9S]-%'Y7 :VU@V4<?K&>TM9!].(UI%2#9ONFTR@<JXD'MZ%'
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M22BI>:?../C2KP\,(+3XMXN%? /6F<1^@#_<:*'4)B-A2RO:A4Z5SN]%6=+
M)SPMH>_,8E[;.\./VYNKHB$M<=SC Y=K1M(.:UC5OK;"2R,EF[#@:.]SEK0[
M@S;ZP1!A9^_C/)SF-N6R4P^=7!5D5 &,LBPY:/]A<@3G7'7GJ-?+[+UO!Y_(
M'%LFW7!N*=+7)]=NS%W,517@]51*&]HU)/&-H.Y*04T/WFN8*1BB'-R-":,,
ML:1LTSI.+=+;/'/EYW?Z'O;H3G[S !C0B^67+4UPCS&?+"FQM\^K#2QN3J>)
M]#MH[B) X7.\8LKM%7ZOBA'^C<BCQ2=(.<%_^.,R!9Z]TU&19ZL,4K;1Y^7X
M4645;*[K4: 9\*/FH(?"=5F#OF9B?NM^P7A'335:2\/3E_(GA!)/!49.U3"$
M:Z61I&".A\W"#-&N*8Q(1>&<$+.6C)TVCI7&\>+VCF9]\_:.V8UH@XA!@XLN
M$V=GESX#2K*)^ B5%CLS@7X)5H4Z<UP)(V%HW\\6,O4@9U;Z<Q(J*T:I^U_.
MK@A0B, E_B]U^08C%U!Z"*\H]FX?0U@@RTBCLI7*>^RY:R1KJ2JMF9#:SL=)
MD9$KJD4\ZN+5JQ*W#>=UX'<7;:$"U#RC!(KBHZVD#VJ#O%^V>"O34.%[OEB3
MGIJ$U*O=ND\(V8R?I\Y='7BV*TE6NQ7M =:%\]_O:R88X,*@T103]G*)!]M-
M&TJH-DQ\IZFIBY&[I52O!59#D9=_H,)D&X?LC(@/KS@L+8R%P10:LBA0+P/%
MN&; @#;2OGA5""JS-\&\L#7Q.E%_!+HB$<)1W0V/JETQOF]UQ36^\X*KL'T^
M76E. =#&EL65\V/!'>W3/O%C>MXR85[3V7B^6<!M(.E519V5/*#J!4>T,15T
MKRJT/7Y0$SV[AMG+CD$J-% I9H6Z&&KJ4F1M;>G"_?D%'6W\SOJR'PBT!V:^
ML=H2&UC&EE:9B-0^B_"[N0LAP<'C$A^%U][%I^YGNRH!HQX$,ODQV"GBR>M5
MGAT(/BQ+LA!82F3I)S9[<'%(>4K<$H>!Z\9,/6#/$,7GC^T9_)V26[Z"-W/6
M8W:)YBN-6'+3I6UC\V3'7/G6&23;A4B-("WX+9U<%K8'A#F&3 -^1=4\=E0B
MVAMZ44U+W1O9C>8K2&T):SQ<$)Y3F%RY428=9YX,9=>+ +9Q&6D7-[0L<;?/
M@P0F@<T0-$#9@".J"$E42A&]LM57N)/.D;'7>=&&[;M4A+?Q%.D>NQJKA]SE
M!5O-ZNM)?^NF,*-Y27$Q,'987%1E,>5:^BZ%?QHZZ[=@$YX2'^ T)Q(AH0CD
M=E]Q3%YH%X_8NJ#.VD2?M[8* =CDS93Y8%<RW)0S_I0&'*X409URNGTI=XS%
M_/@>/0._AXD&1-67S6,,Z77F>,@3L!? ^+YT.^R[=:UO"%[=V_K;WQ7Z_7'K
M4"@K2V+91T>M%MXT0"WZ:4>15*]6VZ#*]@>JTW1[&[WD5NRNPQL+=E[$7*C^
M(<AN4KAJJL[,Q2-OCT+XFP4XS.=<9T'N+J6*''4<SR B)WFR[UWWJBKV:)XM
MIF6HN/PWTP3D-8 %FNW4 [X>+H55^=M^#E:>[.AJ5'"Q]D7IC4+!L 3-'55J
M/X>]\T5GQB)GY(4+@MG>T*F7/$<M5T-Y3.W&JTV\IGI/(MS-EUX!/P=J" ]P
M#V:7[5)8]H!+WO6LU432+9J=6A/:\PXJJ=KQ\[A0D<S-! <)];D0$WE1];()
MVL"T,DTZJ,-DB-U3K4#W,.?! Z*N$HK0R;;G_MZK;]AY7[^J)W$O1\9PCX(H
MT+%O0Y;2KOAF9D^?*=0A<?I;"5NBAT/O]+(#5*K&7@!X>1>[9V7.NS$*RB+M
M":>=>Z(@_\G 1%OY9]% /W!I1;)]HJC]T [M?#MAY,>-.?H\I-C1M\R5N;EA
M$C+KE9BF)Z1F@5\\^+X2+7(T1ZLW8CQ+U1@[DB4ZZ.-%,Z]-OE*'B,G?S.8$
MN$>+2BE#^(6_ \ZWMR7RRN!EY?$*%:G&!RTOLXM]^!K)0O;DBK;ZNX8W]+;O
M4BB00-SWA.!Q]3-%<:*/5^"Q> 8! @FK8E]=DC&8-<\070QP0_1<4[O"+](6
MUB1QF)K,)8<$*.:.7#*$.",+[4GB=I\'L;V#=MR[!@51 ^@K\/H$*.FFWEON
M'0;!#IZF?DY9&.6)<Q3#I/Z6OKI VR></7\6EUZ>R>)->$ =B'%_V7Q'/%M&
M1]E J<R:^.Y0;&G[>['+#Y3NG!HJPN;W,"8"A!(ODY'$RL3N+?;9=JN9NF_F
M]8VE;K_@21:E"#9<"O41( HE.,#2MU6HD+>FKB>)5#VG!?UXWN3#5]B]>ONH
MKSX>,<GXC'Z\BVIFL?YGYK*P+'/T>UE\E1E"QHE4+%)P]&L&\+*ZU-]BMKR?
MWA%"R\H5 O$S^\XRO./&DK:SOI?;JV.6J=K^"F;#M9<N1I"3%\?IN]W; JU?
M4<I<(._E-(1GF+]3Z) /P$>'2.-R"[N.*FZG2D?W+I(GRLR8\6 :6R4GO91Y
M0$(Y>[P1!905>5*I3M8O4%X#*BG6H6EOZ@Z>6K#'A$H%*0C>VB"<UR1R=]31
MD[&U#Z2)E2JA#"K.0PV2W+:JX.@W>N2 >QHLS4$NUMZ5SM6*]>VB%84A</#&
M$U9&\SG<5]1;ZW$J\677L+>SZ(>'=)UW@E]:M7B$7#BPMB":<N:>F3.]-D_D
M]<["-DVBH)QF3UQMA>_>3VF:H*^9HIE[\!F$7?-QX,[V8]H@!0G%[ZP^#(76
M5]2MT.7&YZW-72^( 4=A/"/A,5 ;2[Z_J1673EQ@^L=KP)7KDW&/X']&"K7U
MOJKGW"3S_;WR<Z+=)^KQ"Z/5@H3&?0(G&9;A%96L[ZP+(ST('J?,+8%F"+^F
M&#&W7$TUAI^K*#^3GNH?U+*Z,VC)M 61:(\[1''?>-;<T)'Y<>GNBFX=? L+
M9EQ\IR KE*&$MLBWK&C2!\>T&*[W?"&D5B6EY$=3B@M3-TOH($,<\^FX=F\'
M1:+L#+C;ROCE?O.CQS]TJ#2 46@+"PN+KSB$14FGU['WW7.Y0D#G?538MYW%
MH8=L-\9K\9OQ@@[R;I<%(F66(BO7O'-Q:WJ<BIX^;4B@M#1R/S>)>UV U(I>
M;9?3R-68=,NW=# G1(#'?&JQ4>>:-MIU&J$:&WJ3]N!"V8Z4!?$%JQ!+6\ C
M]\3+CQ<E?F73AW8MN@<\;'Y\MNJ3ZNYG*C4PGIH/&M5#M+&\CP7U')]Y J^]
MXS >)Z@PV?EP%>J=!FT8Q$&Y?!W?&2GG.?*<'4 ;?H;1^>67K>>4Z]8%6!_3
M(JH^8?"B/.L]RX:DYBNP97E7&)\X\9C9<&WJPYIN^PA]D*&#64;SF99LGH7@
M<:2MH2\^T9BE*F*B@_+%X\P;6E'2!!WH3!1VV2G0 D_(A4:E!^I=!<0I$OO)
M"#NR/XSP2DV\DD=>='@Y>M)64Y !@WLGP0X5*ME.XH66);JZS;;D1ZSLJ,[\
ME)QRZM!VX;(OL_I;4+59V)/JQW<03]0#T'3R4-^\$<[2F"%>O=G_"X1?2.>7
M]8X2=B73DGY,Y^0/8X@K4$/#N]NWJGK?YEG?^^WXPJ*<=*OCBPGE*= 5!+-<
M/5_)OVQV6]B^V,YRE71YSMN"W:<LNY/%'J!P/02+$?=IP\(CLXLG+*H[ C!W
MV:[V$FC\% AB@@_P$S=9WNU= T&LO,I&)UKN @(G&CRWZ3:&-5SJ?1E1ET(N
M)*X!S)V4X[D7\9^3"[FD%.*X!^C8G?H<?M8HCU]E4['C[T-K>V61':/$0?Z"
MCH+'VS*^M.3"L,1HRXB\N:TJL"A#K# 97?^EWPNQKL%*SBJD\IP-%"JGD?A\
M[,CA3=U8<L*$@3GZ6C4!2L$B)90VPY"C+Z-DBC=6:K8P0>Z'<EU>C)U8.$.A
M[MY 2"4'[?C.^A2"CTT<HIDS= VPLM_!=1>@" Y<;-AM$^*($16S*[*9& 'I
MS0?R,,'L\9V%XT:Z*QKZ^^>4:Z(F( 1AF*DV--@ (VH?@:: @/NQ4_A-Q"LE
M%80(4$!(WJ=,WL@X3J_T[#_^)O+ 9DU6"?VA!FTPRUF#1'B41U2=,='B=B-9
M43J8W(KU(U]]37R*$3IBWF6Q0M_V[H)GU,1JOZ9WY'N9C@85>9P3G6N@=71#
MDJ).3VI;+R6V5-^F^LMIS>I\9@E7V@ZA2_:R$QS",N;#E8>#"O%$DI%'^D"C
M6+_'+*,2B\7QG$Z1404=+A!KMT\GD596Y(J_ROIA>SE]^,#+:T;ASX^+:$S5
MZXO13,T;#==P;1;&KPN5U?=[;O1D0(H>3O&*J;_:L7O;0_<V\IX,[=L82BL
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M,3(S,7@Q,&LP,3,N:G!G[7EU4%Q/M.80$ER".P0+)$CPX!(<@@88G!"<"<X
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MG@(?^6Y:<[A'Q>[UVS>X0DUKK4%PYB??MG(E'^'06U%$+^]5J,?Z<G%5L5I
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M5\A]'[,>3_3[\TP ,D933# Z\'==0HD8\[1Z%0HX)<9R$$_-6%.]!ZQPPZ?
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MG0.SYWQ:3%'" 1_&A_8;$G9:C%79M/BLAH!2?9*K35(RJXC/A\*$(F1V3I)
M'M>>@C>O\ZD -5+?! +K,0XF@:F&M_(HYU8&.U9E9V'DFT-[GCNMA?*"U[^
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MVH=5,8?LFA[UGCWJWL=GJDV3[UOC5D]G5L+?S^!73\N-BLA)C?CNE>82Z5H
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MC70UN ?@>DKX%66:[VH..3M-"@T%ETC^72QPZ]%@ZB)\CD]'YP?ZJX;+7>C
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M+6/H1TJDI4,I4:!H*^ZO'_5B1TK:%4F]#6@%Z.UX).^>>^YT&OYB&),D(DG
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MRUE&4?1$R"N H<3:+$,E6R6X1<P+N!1B159F-9K3DE#"8?QY!G.I*K\;JAJ
MHEPTPAB7$2KPG JI;?[FJ_-_&OG/</'+]?C'U=<J+ B4H"NPK9!R)19EA82W
MP4,09IBLI4Q@2.0T87CY=IZK5%*GIUT^J7S7;68]IFH')&+QUX4B?I*#=F.O
M67P^L77L'@"Q=_&QWZ9N1<^ZU,,..&<+-")J^+\:;$Y=E<\>)$]Z=7=ZT36]
M=[U(*NJ1M@VK7?7,=6-==>J#OP%02P,$%     @ VX-J4N-EK;;4 P  M@H
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M,XR%Q.FZ6W7L9MO2*UFSXXW_ 5!+ P04    " #;@VI2<5V1<"4)   )+
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M"V=$LL2H"NA<%"]P5_)L[1!PRW<V!4\W)<=*P4[703#CIUGW)&GF@?A:0?L
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M7\3![G[_R=[>P9\;(_KW T)71J=WQ8.&_)5J]!UMS_\/4$L! A0#%     @
MVX-J4D'O1ZZP&@  N"L! !$              ( !     '!T9W@M,C R,#$R
M,S$N>'-D4$L! A0#%     @ VX-J4J42JA/"%   83H! !4
M ( !WQH  '!T9W@M,C R,#$R,S%?8V%L+GAM;%!+ 0(4 Q0    ( -N#:E*1
M&FIZ53D  "O? P 5              "  =0O  !P=&=X+3(P,C Q,C,Q7V1E
M9BYX;6Q02P$"% ,4    " #;@VI25I9EY9&H  #;70D %0
M@ %<:0  <'1G>"TR,#(P,3(S,5]L86(N>&UL4$L! A0#%     @ VX-J4B>M
MN'L]:0  "L\' !4              ( !(!(! '!T9W@M,C R,#$R,S%?<')E
M+GAM;%!+ 0(4 Q0    ( -N#:E)6M$SB'38$  =(*0 5              "
M 9![ 0!P=&=X+3(P,C Q,C,Q>#$P:RYH=&U02P$"% ,4    " #;@VI2\<:T
M78"M  "HW   &               @ '@L04 <'1G>"TR,#(P,3(S,7@Q,&LP
M,#8N:G!G4$L! A0#%     @ VX-J4@_5,0S4?   5*@  !@
M ( !EE\& '!T9W@M,C R,#$R,S%X,3!K,# W+FIP9U!+ 0(4 Q0    ( -N#
M:E(\BB'>WU8   AW   8              "  :#<!@!P=&=X+3(P,C Q,C,Q
M>#$P:S P."YJ<&=02P$"% ,4    " #;@VI2R-:*I9UT  "GDP  &
M        @ &U,P< <'1G>"TR,#(P,3(S,7@Q,&LP,#DN:G!G4$L! A0#%
M  @ VX-J4I_T^N-GG0  ![   !@              ( !B*@' '!T9W@M,C R
M,#$R,S%X,3!K,#$P+FIP9U!+ 0(4 Q0    ( -N#:E*CQXZ0^XT  (BO   8
M              "  25&" !P=&=X+3(P,C Q,C,Q>#$P:S Q,2YJ<&=02P$"
M% ,4    " #;@VI2 P5J@\RB  " O0  &               @ %6U @ <'1G
M>"TR,#(P,3(S,7@Q,&LP,3(N:G!G4$L! A0#%     @ VX-J4E%<EYZ6-0
M,#T  !@              ( !6'<) '!T9W@M,C R,#$R,S%X,3!K,#$S+FIP
M9U!+ 0(4 Q0    ( -N#:E(U'*G[I@,  %@-   8              "  22M
M"0!P=&=X+3(P,C Q,C,Q>&5X,C%D,2YH=&U02P$"% ,4    " #;@VI29V[+
M.Q $  !\#   &               @ $ L0D <'1G>"TR,#(P,3(S,7AE>#(S
M9#$N:'1M4$L! A0#%     @ VX-J4N-EK;;4 P  M@H  !@
M ( !1K4) '!T9W@M,C R,#$R,S%X97@R,V0R+FAT;5!+ 0(4 Q0    ( -N#
M:E)Q79%P)0D   DL   8              "  5"Y"0!P=&=X+3(P,C Q,C,Q
M>&5X,S%D,2YH=&U02P$"% ,4    " #;@VI21/J^210)  #G*P  &
M        @ &KP@D <'1G>"TR,#(P,3(S,7AE>#,Q9#(N:'1M4$L! A0#%
M  @ VX-J4JD;V:VD!@  NR<  !@              ( !]<L) '!T9W@M,C R
M,#$R,S%X97@S,F0Q+FAT;5!+ 0(4 Q0    ( -N#:E)$+0CG>1(  '9.   7
M              "  <_2"0!P=&=X+3(P,C Q,C,Q>&5X-&0W+FAT;5!+!08
1    %0 5 *<%  !]Y0D    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
